Final Program N

Home , Fibrolase, Hemotympanum, Hotel Arbez, Moroctocog alfa

XXII Congress The International Society on Thrombosis and Haemostasis B July 11-16 2009 O

55th Annual Meeting S of the Scientific and Standardization Committee of the ISTH T O Final Program N

Boston - July 11-16 2009 XXII Congress of the International Society on Thrombosis and Haemostasis 2009 Table ISTH of Contents Venue and Contacts 2 Wednesday 209 Welcome Messages 3 – Plenary Lectures 210 Committees 7 – State of the Art Lectures 210 Congress Awards and Grants 15 – Abstract Symposia Lectures 212 Other Meetings 19 – Oral Communications 219 – Posters 239 ISTH Information 20 Program Overview 21 Thursday 305 SSC Meetings and – Plenary Lectures 306 Educational Sessions 43 – State of the Art Lectures 306 – Abstract Symposia Lectures 309 Scientific Program 89 – Oral Communications 316 Monday 90 – Posters 331 – Plenary Lectures 90 Nursing Program 383 – State of the Art Lectures 90 Special Symposia 389 – Abstract Symposia Lectures 92 Satellite Symposia 401 – Oral Communications 100 – Posters 118 Technical Symposia Sessions 411 Exhibition and Sponsors 415 Tuesday 185 – Plenary Lectures 186 Exhibitor and Sponsor Profiles 423 – State of the Art Lectures 186 Congress Information 445 – Abstract Symposia Lectures 188 Map of BCEC 446 – Oral Communications 196 Hotel and Transportation Information 447 ISTH 2009 Congress Information 452 Boston Information 458 Social Events 463 Excursions 465 Authors’ Index 477

1 Venue & Contacts

Venue Boston Convention & Exhibition Center 415 Summer Street - Boston, Massachusetts 02210 - USA Phone: +1 617 954 2800 - Fax: +1 617 954 3326 The BCEC is only about 10 minutes by taxi from Boston Logan International Airport. The 2009 Exhibition is located in Hall A and B of the Exhibit Level of the BCEC, along with posters and catering. Meeting rooms for oral presentations and symposia are located on the 1st and 2nd floors. For further information about the BCEC, please visit www.massconvention.com/bcec.html

Contacts Sponsorship & Exhibit Sales, Industry Relations MCI Suisse is the official Congress Organizer for Requests about sales opportunities or the XXII Congress of the ISTH. questions by industry partners should be directed to: For further information contact: Margo Price, ISTH Director of Corporate Relations ISTH 2009 Congress Organizer Local Number: +1 919 600 4095 MCI Suisse SA Email: [email protected] Rue de Lyon 75 1211 Geneva 13, Switzerland Exhibition & Sponsorship Logistics Local Number: +1 617 954 3360 and Management Phone: +41 22 33 99 587 MCI Suisse SA Local Fax: +1 617 954 3379 Christophe de Rham Fax: +41 22 33 99 601 Email: [email protected] Email: [email protected] Website: www.isth2009.com ISTH Headquarters 610 Jones Ferry Road, Suite 205 Registration and Hotel Accommodation Carrboro, NC 27510, USA MCI Suisse SA Phone: +1 919 929 3807 Local Number: +1 617 954 3368 Fax: +1 919 929 3935 Phone: +41 22 33 99 587 Website: www.isth.org Local Fax: +1 617 954 3379 Email: [email protected] Fax: +41 22 33 99 601 Email: [email protected] General Society Information Requests for information about ISTH and its mission may be directed to:

Cathy Cole, ISTH Executive Secretary Email: [email protected] Robert Cary Clark, SSC Coordinator Email: [email protected] Sharon Overcash, ISTH Membership Secretary Email: [email protected]

2 Message from the Congress Presidents

Dear Colleagues and Friends, On behalf of the Local Organizing Committee, it is our great pleasure to welcome you to Boston and the XXII Congress of the ISTH. This biennial event is one of the highlights of our professional activities, and we are confident that you will find the meeting enlightening and enjoyable. We have worked to develop an array of topics, lectures and poster presentations that will be of interest to a broad spectrum of physicians and scientists in our field, from students to seasoned practitioners, and covering topics in both basic and clinical science. A new Education Program, special opportunities for trainees, grants to young scientists and attendees from developing countries, and geographic-specific programs, among other initiatives, are all intended to make this an inclusive meeting that embraces the great diversity of our field within the context of an international meeting. We have had the privilege of working with a dedicated Local Organizing Committee and Program Committee, and we can’t thank them enough for their generous commitment of time and energy to this event. This Congress is the result of their efforts, as well as the efforts of countless others, who have shaped the program and tended to the myriad of arrangements that make up a successful meeting. Thank you for joining us. We invite you to take advantage of the full range of program offerings, as well as the exciting social events and opportunities to meet or reconnect with colleagues from around the world.

BRUCE FURIE President XXII Congress of the ISTH

BARBARA C. FURIE President XXII Congress of the ISTH

3 Message from the Council Chairman

Dear Colleagues and Friends,

Nearly 150 years ago, Boston was already renowned as a place of learning in the United States, when Mark Twain remarked that in Boston someone was judged on what he knew, rather than on what he was worth or who his parents were. It is therefore most appropriate that in 2009 Boston is our place of learning, as it hosts our XXII Congress.

Our biennial Congress is an important event for the advancement of our field, and I am delighted that you are participating. It is here that professional colleagues from all over the world can come together to hear the latest developments in clinical medicine and basic science, as well as have time to meet informally to share ideas and build relationships.

The Society is extremely grateful to the Congress Presidents, Barbara and Bruce Furie, and their team, for taking on the task of organizing all aspects of this meeting. Their commitment and efforts are of great benefit to all of us.

The ISTH 2009 program is filled with topics important to us all, from basic scientists to clinicians. I look forward to seeing you during the course of the Congress.

F. R. ROSENDAAL MD PhD Chairman of Council, ISTH

4 Message from the Executive Director of ISTH

Dear Colleagues and Friends,

For the first time since the Washington Congress in 1999, the ISTH returns to the United States – to Boston, the site of our 2002 SSC meeting – for our XXII Congress and for the 55th SSC meeting. Congress Presidents Bruce and Barbara Furie and their organizing committee have worked hard and have developed an outstanding and unique program, including for the first time an educational component aimed at students, trainees, clinicians and basic scientists interested in our field. As always, the scientific program will feature invited speakers and the latest in our science and medicine. The new convention center set on Boston's Inner Harbor provides a beautiful site for the meeting. The social program showcases the remarkable history and culture of the city. It promises to be a memorable Congress.

New England is a beautiful place in the summer. From the sand bea- ches of Cape Cod and the maritime islands, Nantucket, Martha's Vineyard, and the Elizabeth Islands, to the Berkshire region in western Massachusetts, to Casco Bay and the dramatic coast of Maine and Acadia National Park, to the Allagash Wilderness in the North Woods, to the White Mountains of New Hampshire, to the crystal waters of Lake Champlain, it is a great place to explore before or after the meeting.

Take advantage of the excellent science offered here and become part of the tradition of the International Society on Thrombosis and Haemostasis.

GILBERT C. WHITE II Executive Director ISTH

5 Message from the Scientific Program Committee Chairpersons Dear Colleagues and Friends, We are very pleased to present to you the ISTH 2009 Scientific Program - a full array of lectures and programmatic elements that address the varied interests of basic and clinical scientists. Our dedicated committee, with essential input from the distinguished International Scientific Advisory Board, has worked hard to ensure that each of our six core disciplines is well- represented and includes new voices and ground-breaking science. The XXII Congress program includes several innovations. An Education Pro- gram has been developed in conjunction with the SSC meetings on Saturday and Sunday, to provide a basic introduction to key topics. In addition to the traditional Oral Communications, we have organized Abstract Symposia sessions where an invited speaker is paired with the presentation of several abstracts on a related theme, and some of the most outstanding abstracts will be showcased in a special Presidential Plenary Abstract session on Tuesday afternoon. We will of course also hear from some exciting Plenary and State of the Art speakers throughout the Congress as well. The success of each ISTH Congress is measured first and foremost by the quality of the scientific program, and we are confident that you will find the XXII ISTH Congress outstanding in this regard. We are enormously grateful to our wonderful Scientific Program Committee, International Scientific Advisory Board, Abstract Reviewers and Congress Organizers for all the hard work that went into making this program a reality. Welcome. We look forward to your participation in ISTH 2009.

KENNETH A. BAUER Congress Vice President and Chair, Education Program Co-Chair Scientific Program Committee (Clinical Sciences)

PAULA B. TRACY Co-Chair Scientific Program Committee (Basic Sciences)

6 Committees

୵ Local Organizing Committee From left to right Standing: R. Handin, B. Furie, K. Bauer, K. Mann, R. Flaumenhaft, K. Plazak Seated: D. Wagner, P. Tracy, B. Furie, M. Price

Congress Committees Paula B. Tracy PhD Local Organizing Committee Co-Chair, Scientific Program Committee (Basic Sciences) Bruce Furie MD Robert Flaumenhaft MD PhD Barbara C. Furie PhD Editor, State of the Art Book Presidents Denisa D. Wagner PhD Kenneth A. Bauer MD Secretary Senior Vice President Chair, Educational Program Kenneth G. Mann PhD Co-Chair, Scientific Program Treasurer Committee (Clinical Sciences) Margo Price MA Robert I. Handin MD ISTH Director of Corporate Relations Vice President Kathryn F. Plazak MBA Liaison to SSC and Satellite Symposia ISTH 2009 Congress Executive Director

International Members Ian Peake XIX Congress President, 2003 Colin Chesterman XX Congress President, 2005 Henri Bounameaux XXI Congress President, 2007 Yasuo Ikeda XXIII Congress President, 2011 Gilbert C. White II ISTH Executive Director

7 Committees

୵ Scientific Program Committee

From left to right Standing: S. Krishnaswamy, L. Brass, N. Key, R. Silverstein Seated: C. Abrams, P. Tracy, M. Cushman, K. Bauer

Scientific Program Committee Platelets (Basic) Vascular Biology Lawrence Brass, Chair (US) Roy L. Silverstein, Chair (US) Joel S. Bennett (US) William Aird (US) Joseph E. Italiano (US) Kari Alitalo (FI) Shaun Jackson (AU) Yugiro Asada (JP) Athan Kuliopulos (US) Lena Claesson-Welsh (SE) Satya P. Kunapuli (US) Stefanie Dimmeler (DE) Jose A. Lopez (US) Harold Dvorak (US) Peter J. Newman (US) Timothy Hla (US) Bernhardt Nieswandt (DE) Klaus Ley (US) Yukio Ozaki (JP) Keith R. McCrae (US) Mortimer Poncz (US) Michael Mendelsohn (US) Zaverio Ruggeri (US) William Sessa (US) Sanford J. Shattil (US) Susan Smyth (US) Stephen Watson (UK) Mervin Yoder (US) Donna Woulfe (US) Thrombotic Disorders Coagulation and Fibrinolysis Mary Cushman, Chair (US) Sriram Krishnaswamy, Chair (US) Trevor Baglin (UK) Jay L. Degen (US) Sabine Eichinger (AT) Naomi L. Esmon (US) Samuel Z. Goldhaber (US) Gary Gilbert (US) Gerhard J. Johnson (US) Tilman Hackeng (NL) Susan Kahn (CA) Katherine Hajjar (US) Ajay Kakkar (UK) James A. Huntington (UK) Vicky Ploplis (US) Wolfram Ruf (US) Guido Tans (NL) 8 Committees

Tetsuhito Kojima (JP) Marilyn J. Manco-Johnson (US) Saskia Middeldorp (NL) Paul Monagle (AU) Paul Ridker (US) Jeffrey Weitz (CA) Neil Zakai (US) Jeffrey Zwicker (US)

Hemorrhagic Disorders Nigel S. Key, Chair (US) Andra H. James (US) David Lillicrap (CA) Pete Lollar (US) ISTH Committees Michael Makris (UK) Council of ISTH Catherine Manno (US) Chairman of Council Pier Mannucci (IT) (2008-2010) Ellis Neufeld (US) Frits R. Rosendaal (NL) Johannes Oldenburg (DE) Secretary/Chairman-Elect Alok Srivastava (IN) (2008-2010) Edward G. D. Tuddenham (UK) Henri Bounameaux (CH) Akira Yoshioka (JP) ISTH Executive Director Platelets (Clinical) Gilbert C. White, II (US) Charles Abrams, Chair (US) Presidents of XXII Congress James B. Bussell (US) Bruce Furie and Barbara Furie (US) Doug Cines (US) Senior Vice President, XXII Congress Jorge Di Paola (US) Kenneth A. Bauer (US) Jane Freedman (US) Chairman, Scientific and Andreas Greinacher (DE) Standardization Committee David Kuter (US) Gerhard J. Johnson (US) Alan Michelson (US) Co-Editors, Journal of Thrombosis Adrian Newland (UK) and Haemostasis Alan T. Nurden (FR) Mike Greaves (UK) Chris Van Geet (BE) David Lane (UK) David Varon (IL) Council Class of 2010 Ph. G. de Groot (NL) David Lane (UK) Ian Peake (UK) Uri Seligsohn (IL) Denisa Wagner (US)

Committees

Council Class of 2012 Members Michael Berndt (AU) SSC Class of 2009 Henri Bounameaux (CH) Paquita Nurden (FR) Trevor Baglin (UK) Bjarne Østerud (NO) Joel S. Bennett (US) P.H. Reitsma (NL) Beng Hock Chong (AU) Council Class of 2014 Osamu Matsuo (JP) Nuala Ann Booth (UK) SSC Class of 2010 Jean-Marie Freyssinet (FR) Nigel S. Key (US) Dermot Kenny (IE) Robert R. Montgomery (US) Claude Negrier (FR) Hugo Ten Cate (NL) Edward G. D. Tuddenham (UK) Ton van den Besselaar (NL) Scientific and Standardization Committee Officers SSC Scientific Subcommittee Chairman (2008-2010) Chairmen Gerhard J. Johnson (US) Trevor Baglin (UK) Secretary/Chairman-Elect Marco Cattaneo (IT) (2008-2010) Moniek de Maat (NL) Anna Falanga (IT) Jean-Marie Freyssinet (FR) Special Assistant to the Chairman David Gailani (US) (2008-2010) Andreas Greinacher (DE) Nuala A. Booth (UK) Johan Heemskerk (NL) Anthony Hubbard (UK) Executive Director Andra James (US) Gilbert C. White II (US) Gili Kenet (IL) David Lillicrap (CA) Colin Longstaff (UK) Gordon Lowe (UK) Mary Ann McLane (US) John McVey (UK) Tim Nichols (US) Vittorio Pengo (IT) Martin Prins (NL) Cheng-Hock Toh (UK) Alok Srivastava (IN) Herb Winna (US)

10 Committees

Congress Francis J Castellino (US) William Fay (US) International Jean-Pierre Cazenave (FR) Philip Fay (US) Advisory Board Alessandro Celi (IT) Garrett A Fitzgerald (US) Giancarlo Agnelli (IT) Anthony Chan (CA) Charles Francis (US) Jan Willem Akkerman (NL) Israel Charo (US) Paul Frenette (US) Lorenzo Alberio (CH) Frank C Church (US) Jean-Marie Freyssinet (FR) Jack Ansell (US) Ken Clemetson (CH) Karen Furie (US) Valder Arruda (US) Barry Coller (US) Martha Furie (US) Wadie Bahou (US) Peter Collins (UK) Christian Gachet (FR) Lazlo Bajzar (CA) John Cooke (US) David Gailani (US) Carlo Balduini (IT) Shaun Coughlin (US) J.G.N. (Skip) Garcia (US) Shannon Bates (CA) Mark Crowther (CA) Pablo Garcia (ES) Victoria Bautch (US) Ola E Dahl (NO) Jonathan Gibbins (UK) Wolfgang Bergmeier (US) Bjorn Dahlback (SE) Mark Ginsberg (US) Brad Berk (US) Patricia D’Amore (US) David Ginsburg (US) Francesco Bernardi (IT) Raimondo De Cristofaro (IT) Alison Helena Goodall (UK) Rogier Bertina (NL) Philip de Moerloose (CH) Anne Goodeve (UK) Joyce Bischoff (US) Hans Deckmyn (BE) Shinya Goto (JP) Mark Blostein (CA) Cécile Denis (FR) Eric Grabowski (US) Paul E Bock (US) Michael Detmar (CH) Mike Greaves (UK) Susan Bock (US) Thomas Deuel (US) Paolo Gresele (IT) Annie Borel-Derlon (FR) Scott Diamond (US) John Griffin (US) Beth Bouchard (US) Enrico DiCera (US) Peter Gross (CA) Edwin Bovill (US) Françoise Dignat-George (FR) Tilo Grosser (US) Paul Bray (US) Donna DiMichele (US) Yves Gruel (FR) Benjamin Brenner (IL) Maria Benedetta Donati (IT) Paul Gurbel (US) George Broze (US) Jing-Fei Dong (US) Stephen Hanson (US) Kathleen Brummel-Ziedins (US) Xiaoping Du (US) John Hartwig (US) Harry Büller (NL) Christophe Dubois (FR) Johan W.M. Heemskerk (NL) Tatiana Byzova (US) Bernd Engelmann (DE) John Heit (US) Marina Camera (IT) Gines Escolar (ES) Coen Hemker (NL) Rodney Camire (US) Anna Falanga (IT) Ruth-Ann Henriksen (US) Alan Cantor (US) Richard Farndale (UK) Stanley Heptinstall (UK)

11 Committees

Congress John Lawler (US) David Motto (US) International Dan Lawrence (US) William Muller (US) Advisory Board Jeff Lawson (US) Claude Negrier (FR) (continued) Bernard LeBonniec (FR) Gary Nelsestuen (US) Kathy High (US) Agnes Lee (CA) Debra Newman (US) Maureane Hoffman (US) Peter J. Lenting (NL) William Nichols (US) Phil Hogg (AU) Jack Levin (US) Tim Nichols (US) Keith Hoots (US) Mark Levine (CA) Diane Nugent (US) Marc Hoylaerts (BE) Howard Liebman (US) Doyeun Oh (KR) Mingdong Huang (US) Judith Lin (US) Ann-Kristin Ohlin (SE) Beverly Hunt (UK) Roberto Lorenzet (IT) John Olson (US) Licia Iacoviello (IT) Gordon Lowe (UK) Steven Olson (US) Yasuo Ikeda (JP) Alice Ma (US) Tom Ortel (US) Luisa Iruela-Arispe (US) Nigel Mackman (US) Susanne Osanto (NL) Mukesh Jain (US) Patricia Maguire (IE) Bjarne Østerud (NO) Martine Jandrot-Perrus (FR) Elaine Majerus (US) Willem H Ouwehand (UK) Nancy Jenny (US) Aaron Marcus (US) Ingrid Pabinger (AT) Walter Kahr (CA) Ida Martinelli (IT) Joseph Palumbo (US) Michael Kalafatis (US) Muriel Maurer (US) Leslie Parise (US) Raghu Kalluri (US) John McVey (UK) Carlo Patrono (US) Cécile Kaplan (FR) Koen Mertens (NL) Cam Patterson (US) Simon Karpatkin (US) Dominique Meyer (FR) Bernard Payrastre (FR) Ken Kaushansky (US) Diego Mezzano (CL) Ian Peake (UK) Beate Kehrel (DE) Tadashi Mitsuru (JP) Ellinor Peerschke (US) Craig Kessler (US) Stephan Moll (US) Raul Perez-Bianco (AR) Benjamin Kile (AU) Paul Monahan (US) Egon Perrson (SE) Wolfgang Koenig (DE) Manuel Monreal (ES) Petro Petrides (DE) Barbara Konkle (US) McDougald Monroe (US) David Phillips (US) Thomas Kühne (CH) Robson Monteiro (BR) Rob Pike (AU) Thomas Kunicki (US) Bob Montgomery (US) Steven Pipe (US) Paul Kyrle (AT) Jim Morrissey (US) Edward Plow (US) David A Lane (UK) Michael Mosesson (US) Kathy Ponder (US) Francois Lanza (FR) Laurent Mosnier (US)/(NL) Alistair Poole (UK)

12 Committees

Congress International Stephanie Smith (US) State of the Advisory Board Martha Sola-Visner (US) Art Book Associate (continued) Steve Sommer (US) Editors Henrik Sørensen (DK) Paolo Prandoni (IT) William Aird (US) Alex Spyropoulos (US) Klaus Preissner (DE) Tatiana Byzova (US) Darrel Stafford (US) Ed Pryzdial (CA) Beth Bouchard (US) Svetla Stoilova-McPhie (UK) Bruce Psaty (US) Kevin Croce (US) Alison Street (AU) Margaret Ragni (US) Peter Gross (CA) Dudley Strickland (US) Koneti Rao (US) Jonathon Gibbins (UK) Katsuo Sueishi (JP) Katya Ravid (US) John Heit (US) Mark Taubman (US) Mark Reding (US) Joseph Italiano (US) Hugo Ten Cate (NL) Armin Reininger (DE) Howard Leibman (US) Douglas Tollefsen (US) Pieter Reitsma (NL) Jose Lopez (US) (US) Mauro Torti (IT) Thomas Renne (DE) Nigel Mackman (US) Russell Tracy (US) Fred Rickles (US) Flora Peyvandi (IT) JoAnn Trejo (US) George Rivard (CA) Denisa Wagner (US) Elena Tremoli (IT) Simon Robson (US) Ted Warkentin (CA) Han-Mou Tsai (US) Francesco Rodeghiero (IT) Hartmut Weiler (US) Dimitrios Tsakiris (CH) Elliot Rosen (US) Jeffrey Zwicker (US) Frits R Rosendaal (NL) Alexander Turpie (CA) Jan Rosing (NL) Tetsumei Urano (JP) Evan Sadler (US) Elizabeth van Cott (US) Hatem Salem (AU) Doug Vaughan (US) Charles - Marc Samama (FR) Carla Vossen (DE) Michel Samama (FR) Thomas Wakefield (US) Andrew Schafer (US) Ulrich Walter (DE) Barbara Schick (US) Chris M Ward (AU) Alvin Schmaier (US) Ted Warkentin (CA) Uri Seligsohn (IL) Christian Weber (DE) Sam Schulman (CA) Hartmut Weiler (US) Don Siegel (US) Phil Wells (CA) Paolo Simioni (IT) Andy Weyrich (US) Daniel Simon (US) Richard H White (US) Nicholas Smith (US) Sidney (Wally) Whiteheart (US) C. Wayne Smith (US) Ariella Zivelin (IL)

Committees

Presidents of Past Congresses

I 1970 Fritz Koller, Montreux, Switzerland II 1971 Paul A. Owren, Oslo, Norway III 1972 Kenneth M. Brinkhous, Washington, DC, United States IV 1973 Erwin Deutsch, Vienna, Austria V 1975 Jean-Pierre Soulier, Paris, France VI 1977 Sol Sherry, Philadelphia, PA, United States VII 1979 Gustav V. R. Born, London, United Kingdom VIII 1981 J. Fraser Mustard, Toronto, Canada IX 1983 Birger Blomback, Stockholm, Sweden X 1985 Russel F. Doolittle, San Diego, CA, United States XI 1987 Marc Verstraete, Brussels, Belgium XII 1989 Takeshi Abe, Tokyo, Japan XIII 1991 Jan Sixma, Amsterdam, The Netherlands XIV 1993 Yale Nemerson, New York, NY, United States XV 1995 Uri Seligsohn, Jeruslem, Israel XVI 1997 Pier M. Mannucci, Florence, Italy XVII 1999 Victor J. Marder, Washington, DC, United States XVIII 2001 Dominique Meyer, Paris, France XIX 2003 Ian R. Peake, Birmingham, United Kingdom XX 2005 Colin Chesterman, Sydney, Australia XXI 2007 Henri Bounameaux, Geneva, Switzerland

Presidents of Future Congresses

XXIII 2011 Yasuo Ikeda, Kyoto, Japan XXIV 2013 Frits R. Rosendaal, Amsterdam, The Netherlands XXV 2015 Sam Schulman, Toronto, Canada

14 Congress Awards and Grants

ISTH AWARDS 2009 Robert P. Grant Medal Biennial Awards for The highest award of the Society will Contributions to Hemostasis: be presented at the XXII Congress Investigator Recognition Opening Ceremony on Sunday, July 12 Anna Falanga at 6:00 PM in the Grand Ballroom. Jean-Marie Freyssinet Katherine High Marion I. Barnhart Memorial Clive Kearon Lecturer Gordon Lowe Shaun Jackson To be presented during the Awards Wednesday, July 15 at 5:15 PM Presentation Ceremony on Tuesday, July 14 at 4:00 PM Brinkhous Memorial Lecturer Evan Sadler Biennial Awards for Thursday, July 16 at 9:45 AM Contributions to Hemostasis: Distinguished Career ISTH Congress Plenary Lecturer Henri Bounameaux Made possible by a grant from the Désiré H Roger Lijnen Collen Foundation Michael Nesheim Rudolph Jaenisch Pieter Reitsma Thursday, July 16 at 5:15 PM Sam Schulman To be presented during the Awards Pia Glas-Greenwalt Memorial Presentation Ceremony on Tuesday, Lecturer July 14 at 4:00 PM Andreas Greinacher Wednesday, July 15 at 9:45 AM Roberts Medal for Distinguished Service to the SSC Shirley P. Johnson Memorial This medal will be presented at the Lecturer Awards Presentation Cermony on Helen Hobbs Tuesday, July 14 at 4:00 PM. Monday, July 13 at 9:45 AM 2008 Journal of Thrombosis and Oscar Ratnoff Memorial Lecturer Haemostasis, Pier M. Mannucci This new award has been established Young Investigator Awards through the generosity of Dr. Hidehiko Michiel Coppens Saito, President of the 23rd Annual Meeting Adriana Franco Paes Leme of the Japanese Society on Thrombosis Jonathan George Tardos and Hemostasis. Xiao-lin Zang Philip Hogg Tuesday, July 14 at 9:45 AM sanofi-aventis/ISTH Research Fellowship Awards Sol Sherry Memorial Lecturer Awardees will be announced at the William Geerts Awards Presentation Cermony on Monday, July 13 at 5:15 PM Tuesday, July 14 at 4:00 PM.

15 Congress Awards and Grants

Young Investigator Awards The Young Investigator Awards were provided in the form of travel grants to medical trainees and young scientists (under 35 years of age as of July 11, 2009) who have been chosen to present their highly rated abstracts at the Congress. These awards are part of the ISTH’s Reach the World initiative and have been made possible thanks to ISTH, the XXII Congress of the ISTH, and the following corporate sponsors: Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, GlaxoSmithKline, Novo Nordisk, Wyeth.

Frédéric Adam (FR) Sheryl R. Bowley (US) Olav R. de Peuter (NL) Helena M. Andersson (UK) Karlien Buelens (BE) Sandrine Delignat (FR) Guillemette Antoni (FR) Sharene D. Bungay (CA) Mieke Delvaeye (BE) Cihan Ay (AT) Laurent Burnier (CH) Ingrid den Uijl (NL) Bani M. Azari (US) Yamini S. Bynagari (US) Francesco Dentali (IT) Jennie Bäck (SE) Robert A. Campbell (US) Sukhdeep S. Dhadwar (CA) Behnaz Bayat (DE) James E. Campbell (US) Leonardo Di Gennaro (IT) Markus Bender (DE) Jessica Cardenas (US) Renee A. Douma (NL) Florieke J. Berfelo (NL) Sofia U. Carlsson (SE) Connie Duckers (NL) Heike Bernhard (AT) Caterina Casari (IT) Daniel Duerschmied (US) Michelle A. Berny (US) Luca Cecchetti (IT) Ammon M. Fager (US) Gerald Bertrand (FR) Francesca Cesari (IT) Neychelle L. Fernandes (US) Irene D. Bezemer (NL) Kan Chen (US) Hendrik B. Feys (BE) Wiebke Bielenberg (DE) Elim Y. Cheung (NL) Jonathan D. Finn (US) Ruben Bierings (UK) Robert B. Conley (US) Linda E. Flinterman (NL) Marc Blondon (CH) Gregory C. Connolly (US) Jonathan H. Foley (CA) Anita N. Böing (NL) Judith Cosemans (NL) Daniel Frith (UK) Elodie Boissier (FR) Mitali Das (US) Christian Furlan-Freguia (US) Knut H. Borch (NO) Rebecca L. Davis-Harrison (US) Kathryn C. Gersh (US) Keren S. Borensztajn (NL) Pavel Davizon-Castillo (US) Nadine S. Gibson (NL) Julian I. Borissoff (NL) Rens de Goot (UK) Karen Gilio (NL) Yacine Boulaftali (FR) Bas de Laat (NL) Mia Golder (CA) Claire Bouvard (FR) Simon F. de Meyer (BE) Evelyn Groot (NL) 16 Congress Awards and Grants

Paul Gueguen (FR) Meadhbh McCall (IE) Jaapjan D. Snoep (NL) Ina Hagedorn (DE) Mirjam E. Meltzer (NL) Francesco Sofi (IT) Justin R. Hamilton (AU) Xi Mo (US) Timothy J. Stalker (US) Daniel J. Hampshire (UK) Felicitas Mueller (DE) Brian M. Steele (IE) Ellen Hanson (SE) Eric S. Mullins (US) Katharina N. Steinitz (AT) Nicholas Hickson (UK) Keith B. Neeves (US) Catherine Strassel (FR) Lisa-Marie Holbrook (UK) Reyhan Nergiz-nal, (NL) Min K. ten Kate (US) Gregor Hron (AT) Chris Oschatz (DE) Jonathan N. Thon (US) Vera Ignjatovic (AU) Cecilia Oslakovic (SE) Ynse I. G. V. Tichelaar (NL) Miriam E. Jaax (DE) Elena Osto (IT) Lisa J. Toltl (CA) Ewa Jablonska (DE) Michael J. Page (US) Erik Tournoij (NL) Indu Jagannathan (US) Marta Palomo (ES) Rolf T. Urbanus (NL) Shashank Jain (US) Peter R. Panizzi (US) Yascha W. van den Berg (NL) Reema Jasuja (US) Ronan Pendu (FR) Maartje van den Biggelaar (NL) Sheng-Yu Jin (US) Nicolas S. Petrera (CA) Lisa van den Hengel (NL) Matthew L. Jones (UK) Irina Pleines (DE) Frederiek F. van Doormaal (NL) Roman Kanz (AT) Narcis I. Popescu (US) Markus van Geffen (NL) Anuja Khan (US) Ginta Pordes (AT) Pauline M. van Helden (AT) Paul Y. Kim (CA) Wouter Pos (NL) Vielg Astrid van Hylckama (NL) Jenny Klintman (SE) Nicola Pozzi (IT) Gwendolyn van Os (NL) Frederikus A. Klok (NL) Cynthia M. Pruss (CA) Inge M. van Schouwenburg (NL) Iris L. H. Knottnerus (NL) Christoph Reinhardt (SE) Geerte L. van Sluis (NL) Jorine S. Koenderman (NL) Goran Rudez (NL) Rainer Vormittag (AT) Suzanne J. A. Korporaal (NL) François Saller (CH) Natalya M. Vorobyeva (RU) Krystin Krauel (DE) Francesca Santilli (IT) J. W. Wang (NL) Colin A. Kretz (CA) Steven L. Schadinger (CA) Jian-Guo Wang (US) Michele P. Lambert (US) Marc Schindewolf (DE) Xiang Xu (US) Danila Leontyev (CA) Alec A. Schmaier (US) Yuwna Yakura (JP) Willem M. Lijfering (NL) Marcel Schouten (NL) Takayuki Yamada (JP) Luca A. Lotta (IT) Joerg Schuettrumpf (DE) Hong Yin (US) Ester C. Lowenberg (NL) Sol Schulman (US) Yuana Yuana (NL) Brenda M. Luken (UK) Hansjorg Schwertz (US) Melec G. Zeadin (CA) Coen Maas (NL) Olivier Segers (NL) Erin Zekas (US) Bakhtawar K. Mahmoodi (NL) Stefanie Seifert (DE) Wenhua Zhou (US) David A. Manly (US) Ruchira Sengupta (CA) Xiao-Juan Zhu (CN) Nicola Martinelli (IT) Bob Siegerink (NL) Majida Zidane (NL) Irene Martínez-Martíez (ES) Kerrie A. Smith (UK) Andreas C. Mauer (US) 17 Congress Awards and Grants

Developing World Scientist Awards The Developing World Scientist Awards provided travel grants to scientists from developing countries to support participation at the Congress. These awards are part of the ISTH’s Reach the World initiative and have been made possible thanks to ISTH, the XXII Congress of the ISTH and the following corporate sponsors: AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, GlaxoSmithKline, Novo Nordisk.

Yolanda P. Adamczuk (AR) Luci MS. Dusse (BR) Ghasem Rastegarlari (IR) Firdos Ahmad (IN) Hejer Elmahmoudi (TN) Shirin Ravanbod (IR) Dalila Aïtchafa Tadlaoui (DZ) Fernanda Faria (BR) Maria A. Romaniuk (AR) Silvia Albanez (YE) Ana P. Fernandes (BR) Anna Rusanova (RU) Maha Aly Aldeen Abd Adriana Georgescu (RO) Izabela Sacewicz (PL) Elbasset Aly Mohamed (EG) Francisco J. Goico (DO) Andrey Santos (BR) Samina T. Amanat (PK) Lyubov Gorbacheva (RU) Mirta Schattner (AR) Angchaisuksiri Pantep (TH) Elena M. Gupalo (RU) Tahereh Shashaani (IR) Rumjana Apostolovska (MK) Mohammad Bagher Ene Siigur (EE) Omolade A. Awodu (NG) Hashemi Soteh (IR) Janaina B. J. Silva (BR) Xia Bai (CN) Hu Hu (CN) Elena I. Sinauridze (RU) Bernát J. Béres (HU) Baolai Hua (CN) Olga V. Sirotkina (RU) Arijit Biswas (IN) Maria B. Irigoyen (AR) Olga A. Smirnova (RU) Mariana Bonduel (AR) Mehrez M. Jadaon (KW) Svetlana Strukova (RU) Wangwei Cai (CN) Ekaterina V. Kiseleva (RU) Ayadurai Thiruchelvam (MY) Jose M. Ceresetto (AR) Grace W. Kitonyi (KE) Anettab Undas (PL) Qiong Chen (CN) Yeling Lu (CN) Nadezda A. Vorobyeva (RU) Yingyong Chinthammitr (TH) Eduard V. Lugovskoy (UA) Xuefeng Wang (CN) Ana M. Chudzinski-Tavassi (BR) Andrea Manzino (UY) Zhaoyue Wang (CN) Czeslaw S. Cierniewski (PL) Yulia A. Mikheeva (RU) Adriana I. Woods (AR) Punsaldulam Dashnyam (MN) Marija Milos (HR) Shilong Xiong (CN) Gabriela F. de Larrañaga (AR) Robson Q. Monteiro (BR) Erkan Yilmaz (TR) Kai-yang Ding (CN) Elena G. Oganova (BY) Tingting Yu (CN) Qiulan Ding (CN) Olga Panes (CL) Ziqiang Yu (CN) Valentina J. Djordjevic (RS) Mikhail A. Panteleev (RU) Teresa B. Domagala (PL) Alfredo Perez Cuadra (MX) Olena Dotsenko (UA) Marlien Pieters (ZA)

18 Other Meetings

Saturday July 11 SSC Members Meeting 6:30 PM - 9:30 PM Westin Boston Waterfront Hotel - Douglas and Alcott Rooms

Sunday July 12 APSTH Council Meeting 12:00 PM - 1:00 PM Room 155 ISFP Council Meeting 2:00 PM - 5:00 PM Room 155

Monday July 13 MLTD Councilors Meeting 11:00 AM - 12:30 PM Room 259B MLTD General Assembly 12:30 PM - 2:00 PM Room 259B JTH Editorial Board Luncheon 12:30 PM - 2:15 PM Westin Boston Waterfront Hotel - Douglas Room MLTD Foundation Meeting 2:00 PM - 3:30 PM Room 259B MLTD 21st Milan Congress Presentation 3:30 PM - 4:30 PM Room 259B ISTH Council Meeting 6:00 PM - 11:00 PM Westin Boston Waterfront Hotel, Douglas and Alcott Rooms

Tuesday July 14 ISTH General Membership Assembly 3:00 PM - 3:15 PM Grand Ballroom

Wednesday July 15 SSC Annual Business Meeting 1:00 PM - 3:30 PM Room 256

Thursday July 16 Industry Liaison Meeting 12:00 PM - 2:00 PM Room 256

19 ISTH Information

The International Society on Thrombosis and Haemostasis, Inc. is organized and operated exclusively for scientific and educational purposes. Its objectives are to foster and advance science relating to the important medical problems of thrombosis and abnormalities of hemostasis and vascular biology; to provide a forum for discussion of these problems; to encourage research on these problems by scientists of the relevant disciplines; to foster the diffusion and exchange of ideas through scientific meetings and publications; to standardize nomenclature and methods as appropriate and timely.

˿ ISTH Headquarters 610 Jones Ferry Road - Suite 205 - Carrboro, NC 27510 - USA Phone: +1 919 929 3807 - Fax: 1 919 929 3935 Website: www.isth.org ˿ For information about sponsorships and industry participation in meetings, please contact: Margo Price, ISTH Director of Corporate Relations Direct line: +1 919 929 2381 Email: [email protected]

˿ For membership questions, please contact: Sharon Overcash, ISTH Membership Secretary Email: [email protected]

˿ For the ISTH website and SSC Information, please contact: Robert Cary Clark, ISTH Information Services Email: [email protected]

˿ For general information about the ISTH, please contact: Cathy Cole, ISTH Executive Secretary Email: [email protected]

ISTH Membership If you are not yet a member of the ISTH and wish to join, you may apply online at http://www.isth.org/Membership or contact the Membership Secretary at [email protected]. Membership is by application and payment of annual dues, which are for the calendar year January through December. Membership dues for 2009 are $160. 20 ISTH2009

Program Overview

21 SSC Meetings and Educational Sessions

Room Room Room Room 104 ABC 107 ABC 153 ABC 156 ABC

8:00 - 12:00 P. 55 8:00 - 9:30 P. 46 8:00 - 11:00 P. 53 8:00 - 9:30 P. 49

Hemostasis and Predictive Variables Malignancy Platelet Immunology in Cardiovascular Factor VIII & IX Disease

9:30 - 12:00 P.46 9:30 - 12:00 P.50

Hemostasis and Predictive Variables Malignancy in Cardiovascular Disease 11:00 - 12:00 P. 54 Platelet Immunology

12:15 - 1:45 P. 57 12:15 - 1:45 P. 58 12:15 - 1:45 P. 59 12:15 - 1:15 P. 60

APSTH / ISTH Genomics 101 In silico Drug Design The Illusion of Symposium Disclosure

2:00 - 4:30 P. 68 2:00 - 3:00 P. 71 2:00 - 3:30 P. 64 2:00 - 3:00 P. 61

Biorheology Factor VIII and IX Fibrinogen and Animal Models Factor XIII

3:00 - 6:00 P. 71 3:00 - 6:00 P. 62

Biorheology 3:30 - 6:00 P. 65 Fibrinogen and Factor XIII 4:30 - 6:00 P. 69 Factor VIII and IX Animal Models

22 Saturday, July 11, 2009

Room Room Room Room 160 ABC 204 AB 102 AB 109 AB SSC & Educational 8:00 - 9:30 P. 47 8:00 - 10:30 P. 50

Vascular Biology Women's Health in Thrombosis & Haemostasis

9:30 - 12:00 P.48

Vascular Biology

10:30 - 12:000 P. 51 Women's Health in Thrombosis & Haemostasis

12:00 - 2:00 P. 385

12:15 - 1:45 P. 60

Translating evidence Nurses Meeting into practice

2:00 - 4:30 P. 69 2:00 - 3:30 P. 66 2:00 - 4:30 P. 63

Lupus Anticoagulant / Perinatal/Pediatric Plasma Coagulation Phospholipid- Hemostasis Inhibitors Dependent Antibodies

3:30 - 6:00 P. 67

4:30 - 6:00 P. 70 Perinatal/Pediatric 4:30 - 6:00 P. 63 Hemostasis Lupus Anticoagulant / Plasma Coagulation Phospholipid- Inhibitors Dependent Antibodies

23 Educational SCC Sessions Meetings SSC Meetings and Educational Sessions

Room Room Room Room Room 205 ABC 253 ABC 258 ABC 104 ABC 107 ABC

8:00 - 10:30 P. 77 8:00 - 9:30 P. 73

Disease-Specific Control of Molecular Anticoagulation Mechanisms in Disseminated Intravascular Coagulation (DIC)

9:30 - 12:00 P. 74

Disease-Specific Molecular 10:30 - 12:00 P. 79 Mechanisms in Disseminated Control of Intravascular Anticoagulation Coagulation (DIC)

12:30 - 2:30 P. 391 12:30 - 2:30 P. 392 12:30 - 2:30 P. 392

Scienta Healthcare Bayer sanofi-aventis Education® Healthcare US (Baxter)

3:15 - 5:15 P. 393 3:15 - 5:15 P. 394

Octapharma AG Medscape LLC (CH) (sanofi-aventis)

Sunday, July 12, 2009

Room Room Room Room Room 153 ABC 156 ABC 160 ABC 102 AB 109 AB SSC & Educational 8:00 - 11:00 P. 83 8:00 - 11:00 P. 82 8:00 - 10:30 P. 85 8:00 - 9:30 P. 75

8:30 - 10:30 P. 80 Plasma Platelet Registry of von Willebrand Kallikrein-Kinin Physiology Exogenous Factor (VWD) System Hemostatic Fibrinoloysis Factors

9:30 - 12:00 P. 76

von Willebrand Factor (VWD) 10:30 - 12:00 P. 81 10:30 - 12:00 P. 85 Registry of Fibrinoloysis 11:00 - 12:00 P. 84 11:00 - 12:00 P. 82 Exogenous Hemostatic Factors Plasma Platelet Kallikrein-Kinin Physiology System

The Opening Ceremony will take place on Sunday, July 12 at 6:00 PM in the BCEC's Grand Ballroom. For more information, please see page 87.

25 Special Educational SCC Symposia Sessions Meetings Program Overview

Grand Ballroom Ballroom Room 210 ABC 205 ABC A B

8:00 - 9:30 P. 117 8:00 - 9:30 P. 100 8:00 - 9:30 P. 100 Risk Factors for Resistance to Late Breaking Abstracts Session Venous Thrombosis I Antiplatelet Therapy

9:45 - 10:30 P. 90

Cardiovascular genetics - H. Hobbs

10:30 - 11:00 COFFEE BREAK

11:00 - 12:30 P. 90 11:00 - 12:30 P. 91 11:00 - 12:30 P. 91 11:00 - 12:30 P. 92 Pulmonary Von Willebrand Novel Approaches Endothelial and Embolism, 2009 Disease - New to Understanding Vascular Signaling Developments Hemostasis

12:30 - 2:15 LUNCH / POSTERS ATTENDED

2:15 - 3:45 P. 93 2:15 - 3:45 P. 93

Thrombophilia: Interventions Clinical Applications for Venous Thromboembolism

3:45 - 4:00 COFFEE BREAK

4:00 - 5:00 P. 109 4:00 - 5:00 P. 109

Venous Thrombosis: Pre-clinical Studies Clinical Course of Novel Factor IX Concentrates

5.15 - 6:00 P. 90 Thromboprophylaxis as a key patient safety priority: Current approaches and future directions - W. Geerts

6:30 - 8:00 P. 395

Scienta Healthcare Education® (Baxter)

26 Monday, July 13, 2009

Room Room Room Room Room 253 ABC 258 ABC 157 ABC 104 ABC 107 ABC am Overview ogr

8:00 - 9:30 P. 101 8:00 - 9:30 P. 102 8:00 - 9:30 P. 103 8:00 - 9:30 P. 103 8:00 - 9:30 P. 103 Pr Cancer and Genetics Antiphospholid Hemophilia: Diagnosis of Thrombosis: of Venous Syndrome: Clinical I Pulmonary Clinical Aspects Thrombosis I Basic and Clinical Embolus Aspects

10:30 - 11:00 COFFEE BREAK

11:00 -12:30 P. 92 11:00 - 12:30 P. 91 Inherited Platelet Inflammation Disorders and Coagulation

12:30 - 2:15 LUNCH / POSTERS ATTENDED

2:15 - 3:45 P. 94 2:15 - 3:45 P. 94 2:15 - 3:45 P. 95 2:15 - 3:45 P. 95 2:15 - 3:45 P. 96

Biology Biology of von Serpins- Women and Platelets of ADAMTS13 Willebrand Factor Inhibitors Bleeding Disorders and Cancer

3:45 - 4:00 COFFEE BREAK

4:00 - 5:00 P. 110 4:00 - 5:00 P. 111 4:00 - 5:00 P. 111 4:00 - 5:00 P. 112 4:00 - 5:00 P. 112

Hormone Therapy Thrombosis in Anticoagulant Novel Mechanisms Factor XI/XIa in Women Cancer: Clinical Reactions of of Antiplatelet Course Activated Protein C Therapy

6:30 - 8:00 P. 399 6:30 - 8:00 P. 396 6:30 - 8:00 P. 397 6:30 - 8:00 P. 397 Network for Potomac Center for ACCELMED® Continuing Medical Medical Education (Daiichi Sankyo, CSL Behring Education (Novo (Bohringer Inc. and Lilly USA, GmbH Nordisk) Ingelheim) LLC) Ģ 27 Plenary Oral State-of-the-Art Abstract Symposia Special Lectures Communications Lectures Lectures Symposia Program Overview

Room Room Room Room Room 153 ABC 156 ABC 160 ABC 204 AB 102 AB

8:00 - 9:30 P. 105 8:00 - 9:30 P. 106 8:00 - 9:30 P. 106 8:00 - 9:30 P. 107 Mechanisms of Hospitalization Regulation of Factors V Platelet Activation I and the Initiation of and VIII Venous Thrombosis Coagulation

10:30 - 11:00 COFFEE BREAK

12:30 - 2:15 P. 385 12:30 - 2:15 LUNCH / POSTERS ATTENDED Nurses Meeting

2:15 - 3:45 P. 96 2:15 - 3:45 P. 97 2:15 - 3:45 P. 97

Novel Approaches Extrinsic Pathways Platelet Adhesion to Understanding of Coagulation and Cohesion Platelet Biology

3:45 - 4:00 COFFEE BREAK

4:00 - 5:00 P. 113 4:00 - 5:00 P. 113 4:00 - 5:00 P. 114 4:00 - 5:00 P. 114

Mechanisms Antiphospholipid Fibrinolysis: Factor V of Platelet Syndrome: Beta 2 Biochemistry Activation II Glycoprotein 1

6:30 - 8:00 P. 399 6:30 - 8:00 P. 395 6:30 - 8:00 P. 398 6:30 - 8:00 P. 400 Bayer HealthCare Stago AG and Ortho- Grifols Wyeth McNeil Pharmaceuticals Pharmaceuticals

28 Monday, July 13, 2009

Room Room Room Room Room 109 AB 151 AB 162 AB 252 AB 257 AB am Overview ogr

8:00 - 9:30 P. 108 4:00 - 5:00 P. 108 Pr Endothelial Cell Fibrin Clot Signaling Structure

10:30 - 11:00 COFFEE BREAK

12:30 - 2:15 LUNCH / POSTERS ATTENDED

2:15 - 3:45 P. 98 2:15 - 3:45 P. 98 2:15 - 3:45 P. 99

Platelet Inflammation and Angiogenesis Transfusions and Vascular Polymorphisms Pathobiology

3:45 - 4:00 COFFEE BREAK

4:00 - 5:00 P. 115 4:00 - 5:00 P. 115 4:00 - 5:00 P. 116 4:00 - 5:00 P. 116

Atherosclerosis: Endothelial P2Y12 Immune-mediated Plaque Dysfunction: Thrombocytopenia Composition Vascular Signaling

29 Plenary Oral State-of-the-Art Abstract Symposia Special Lectures Communications Lectures Lectures Symposia Program Overview

Grand Ballroom Ballroom Room 210 ABC 205 ABC A B

8:00 - 9:30 P. 196 8:00 - 9:30 P. 196 Risk Factors for Diagnosis of Venous Venous Thrombosis II Thromboembolism

9:45 - 10:30 P. 186 Contibution of allosteric disulfide bonds to regulation of hemostasis - P. Hogg

10:30 - 11:00 COFFEE BREAK

11:00 - 12:30 P. 188 11:00 - 12:30 P. 187 11:00 - 12:30 P. 187 11:00 - 12:30 P. 186 Genomics and Vascular Blood Coagulation- Burning Questions in Platelet Activation Disease: What Have Systemic Effects Hemophilia Inhibitors We Learned About Thrombosis?

12:30 - 1:15 LUNCH

1:15 - 2:45 P. 188 1:15 - 2:45 P. 189 Immunology and Post-thrombotic Treatment of ITP Syndrome and other Outcomes of Venous Thrombosis

2:45 - 3:00 COFFEE BREAK

P. 195 3:00 - 3:15 ISTH General Membership Assembly 3:15 - 4:00 Presidential Plenary Abstracts 4:00 - 4:15 Awards Presentation 4:15 - 4:30 Presidential Plenary Abstracts

30 Tuesday, July 14, 2009

Room Room Room Room Room 253 ABC 258 ABC 157 ABC 104 ABC 107 ABC am Overview ogr

8:00 - 9:30 P. 197 8:00 - 9:30 P. 198 8:00 - 9:30 P. 199 8:00 - 9:30 P. 199 8:00 - 9:30 P. 200 Pr Risk of Thrombosis Thrombo- Platelets and Genetics of Antiphospholipid in Cancer prophylaxis Systemic Disorders Coagulation Syndrome: Basic in Surgery Apspects

10:30 - 11:00 COFFEE BREAK

11:00 -12:30 P. 186 11:00 - 12:30 P. 187 Inflammation and Immune Atherosclerosis: Thrombocytopenia Plaque Progression and Regression

12:30 - 1:15 LUNCH

1:15 - 2:45 P. 189 1:15 - 2:45 P. 190 1:15 - 2:45 P. 190 1:15 - 2:45 P. 191 1:15 - 2:45 P. 191 Update on Gene Cofactors Regulation of Platelets and Intracranial Therapy in Coagulation Systemic Disorders Hemorrhage Hemophilia

2:45 - 3:00 COFFEE BREAK

6:30 - 8:00 P. 413 6:30 - 8:00 P. 414 Rovi Network for Continuing Medical Education (Novo Nordisk) Ģ 31 Plenary Oral State-of-the-Art Abstract Symposia Technical Lectures Communications Lectures Lectures Sessions Program Overview

Room Room Room Room Room 153 ABC 156 ABC 160 ABC 204 AB 102 AB

8:00 - 9:30 P. 201 8:00 - 9:30 P. 201 8:00 - 9:30 P. 202 8:00 - 9:30 P. 203 8:00 - 9:30 P. 204 Novel Assays in Platelet Biology I Atherosclerosis: Microparticles Venous Thrombosis Hemophilia and Mouse Models in Pediatrics von Willebrand Disease

10:30 - 11:00 COFFEE BREAK

12:30 - 1:15 LUNCH 12:30 - 2:15 P. 386 1:15 - 2:45 P. 192 1:15 - 2:45 P. 192 1:15 - 2:45 P. 193 1:15 - 2:45 P. 193 Nurses Meeting Mechanisms of Inflammation Platelets and Pediatric Platelet Activation Myleoproliferative Thrombosis Syndromes

2:45 - 3:00 COFFEE BREAK

32 Tuesday, July 14, 2009

Room Room Room Room Room 109 AB 151 AB 162 AB 252 AB 257 AB am Overview ogr

8:00 - 9:30 P. 204 8:00 - 9:30 P. 205 8:00 - 9:30 P. 206 8:00 - 9:30 P. 207 Pr Genotypes of Serpin Structure Endothelial Membrane Hemophilia and and Function Dysfunction and Binding and von Willebrand Biomarkers I Funcion in Disease Coagulation

10:30 - 11:00 COFFEE BREAK

12:30 - 1:15 LUNCH

1:15 - 2:45 P. 194 Regulation of Gene Expression in Vascular Cells

2:45- 3:00 COFFEE BREAK

33 Plenary Oral State-of-the-Art Abstract Symposia Technical Lectures Communications Lectures Lectures Sessions Program Overview

Grand Ballroom Ballroom Room 210 ABC 205 ABC A B

8:00 - 9:30 P. 219 8:00 - 9:30 P. 219 Clinical Trials: Factor Xa Thrombotic Inhibitors Thrombocytopenic Purpura I

9:45 - 10:30 P. 210

Heparin- induced thrombocytoperia A. Greinacher

10:30 - 11:00 COFFEE BREAK

11:00 - 12:30 P. 212 11:00 - 12:30 P. 211 11:00 - 12:30 P. 210 11:00 - 12:30 P. 211 Thrombopoietin Inflammation and Integrin Biology Cues to Create A Mature Receptor Agonists Atherosclerosis: Vasculature A Paradigm Shift?

12:30 - 2:15 LUNCH / POSTERS ATTENDED

2:15 - 3:45 P. 212 2:15 - 3:45 P. 213 Hemophilia Stroke

3:30 - 4:00 COFFEE BREAK

4:00 - 5:00 P. 231 Genetics of Venous Thrombosis II

5.15 - 6:00 P. 210

Modern concepts of platelet activation during thrombus development S. Jackson

6:30 - 8:00 P. 407 Institute for Medical Studies (CME Provider), (Lundbeck)

34 Wednesday, July 15, 2009

Room Room Room Room Room 253 ABC 258 ABC 157 ABC 104 ABC 107 ABC am Overview ogr

8:00 - 9:30 P. 220 8:00 - 9:30 P. 221 8:00 - 9:30 P. 222 8:00 - 9:30 P. 222 8:00 - 9:30 P. 223 Pr Risk Factors for Hemostasis and Cell Biology of the Arterial Disease Experimental Venous Thrombosis Cancer Extrinsic Pathway Risk Markers I Studies in III Thrombosis

10:30 - 11:00 COFFEE BREAK

11:00 -12:30 P. 210 11:00 - 12:30 P. 211 Fibrinogen/ Factor XI Fibrinolysis in the Revisited Brain

12:30 - 2:15 LUNCH / POSTERS ATTENDED

2:15 - 3:45 P. 213 2:15 - 3:45 P. 214 2:15 - 3:45 P. 214 2:15 - 3:45 P. 215 2:15 - 3:45 P. 215 TTP and Microparticles Obstetric Megakaryocytes Platelet Biology ADAMTS13 Complications and Thrombopoiesis

3:30 - 4:00 COFFEE BREAK

4:00 - 5:00 P. 231 4:00 - 5:00 P. 232 4:00 - 5:00 P. 232 4:00 - 5:00 P. 233 4:00 - 5:00 P. 233 Vascular Disease Cancer Treatment Fibrinolysis: Cell Stroke Hemophilia: Prevention Effects on Biology Clinical II Hemostasis and Thrombosis

6:30 - 8:00 P. 408 6:30 - 8:00 P. 403 6:30 - 8:00 P. 406 6:30 - 8:00 P. 406 Octapharma AG, CMEducation CSL Loyola University (CH) Resources, LLC Behring GmbH Chicago (BMS) Ģ 35 Plenary Oral State-of-the-Art Abstract Symposia Satellite Lectures Communications Lectures Lectures Symposia Program Overview

Room Room Room Room Room 153 ABC 156 ABC 160 ABC 204 AB 102 AB

8:00 - 9:30 P. 224 8:00 - 9:30 P. 225 8:00 - 9:30 P. 225 8:00 - 9:30 P. 226 Mechanisms of Novel Approaches Bypassing Hemophilia: Platelet Activation to Understanding Therapies Basic Science III Platelet Function

10:30 - 11:00 COFFEE BREAK

12:30 - 2:15 P. 387 12:30 - 2:15 LUNCH / POSTERS ATTENDED Nurses Meeting

2:15 - 3:45 P. 216 2:15 - 3:45 P. 216 2:15 - 3:45 P. 217 von Willebrand Intrinsic Pathway Fibrinogen and Factor: Structure of Coagulation Fibrinolysis and Function

2:45 - 3:00 COFFEE BREAK

4:00 - 5:00 P. 234 4:00 - 5:00 P. 234 4:00 - 5:00 P. 235 4:00 - 5:00 P. 236 4:00 - 5:00 P. 236 Platelet Biology II Inflammation and Thrombotic von Willebrand Atherosclerosis: Cell Trafficking I Thrombocytopenic Disease Risk factors I Purpura II

6:30 - 8:00 P. 403 6:30 - 8:00 P. 408 6:30 - 8:00 P. 404 6:30 - 8:00 P. 409

Biomerieux Siemens CMEducation Wyeth Resources, LLC Pharmaceuticals (Eisai)

36 Wednesday, July 15, 2009

Room Room Room Room Room 109 AB 151 AB 162 AB 252 AB 257 AB am Overview ogr

8:00 - 9:30 P. 227 8:00 - 9:30 P. 228 8:00 - 9:30 P. 228 8:00 - 9:30 P. 229 8:00 - 9:30 P. 230 Pr Angiogenesis and Vitamin K Cycle Proteases: Endothelial Pediatric Vascular Structure and Dysfunciton and Thrombosis Development Function Biomarkers II

10:30 - 11:00 COFFEE BREAK

12:30 - 2:15 LUNCH / POSTERS ATTENDED

2:15 - 3:45 P. 217 2:15 - 3:45 P. 218 Blood Vessel Atherosclerosis Development

2:45 - 3:00 COFFEE BREAK

4:00 - 5:00 P. 237 4:00 - 5:00 P. 237 4:00 - 5:00 P. 238 Cell Biology of the Fibrinogen Megakaryocytes Activated Protein C Structure and and Pathway Function Thrombopoiesisa

37 Plenary Oral State-of-the-Art Abstract Symposia Special Lectures Communications Lectures Lectures Symposia Program Overview

Grand Ballroom Ballroom Room 210 ABC 205 ABC A B

8:00 - 9:30 P. 316 8:00 - 9:30 P. 316 Risk Factors for Clinical Trials: Recurrent Venous Anticoagulation Thrombosis

9:45 - 10:30 P. 306

Willebrand factors assembly and secretion J. Sadler

10:30 - 11:00 COFFEE BREAK

11:00 - 12:30 P. 306 11:00 - 12:30 P. 307 11:00 - 12:30 P. 308 11:00 - 12:30 P. 307 Anticoagulation Duration after Idiopathic Acquired Bleeding Platelet Physiology/- Endothelial Progenitor Venous Thrombosis - the Disorders Pathophysiology Cell Biology Swinging Pendulum

12:30 - 2:15 LUNCH / POSTERS ATTENDED

2:15 - 3:45 P. 309 2:15 - 3:45 P. 309 Estrogens and Vascular Pathophysiology of Disease Heparin-Induced Thrombocytopenia

2:45 - 3:00 COFFEE BREAK

4:00 - 5:00 P. 325 Health Services and Outcomes

5.15 - 6:00 P. 306

Stem cells, pluripotency, and nuclear reprogramming R. Jaenisch

38 Thursday, July 16, 2009

Room Room Room Room Room 253 ABC 258 ABC 157 ABC 104 ABC 107 ABC am Overview ogr

8:00 - 9:30 P. 317 8:00 - 9:30 P. 318 8:00 - 9:30 P. 319 8:00 - 9:30 P. 320 Pr Health Services, Heparin-induced Artierial Disease Experimental Outcomes and Thrombocytoperia I Risk Markers II Studies in Patient Education Thrombosis: Animal Models

10:30 - 11:00 COFFEE BREAK

11:00 -12:30 P. 307 11:00 - 12:30 P. 308 Platelet Novel Regulatory Inhibition Reactions in Coagulation

12:30 - 2:15 LUNCH / POSTERS ATTENDED

2:15 - 3:45 P. 310 2:15 - 3:45 P. 310 2:15 - 3:45 P. 311 2:15 - 3:45 P. 311 2:15 - 3:45 P. 312 New Products in Signal Transduction Platelets as Drug Treatment of Deep Platelet Function Hemophilia in Vascular Cells Targets Vein Thrombosis Tests

2:45 - 3:00 COFFEE BREAK

4:00 - 5:00 P. 325 4:00 - 5:00 P. 326 4:00 - 5:00 P. 326 4:00 - 5:00 P. 327 Arterial Disease Pregnancy Hemophilia: Gene Inflammation Mechanisms Complications Therapy and Cell Trafficking II

Ģ 39 Plenary Oral State-of-the-Art Abstract Symposia Lectures Communications Lectures Lectures

Program Overview

Room Room Room Room Room 153 ABC 156 ABC 160 ABC 204 AB 102 AB

8:00 - 9:30 P. 320 8:00 - 9:30 P. 321 8:00 - 9:30 P. 322 8:00 - 9:30 P. 323 8:00 - 9:30 P. 323 Platelet Vascular Inhibitors of Antithrombtic - Coagulation and Biology III Progenitors and Factor VIII and Systemic Effects Infection Stem Cells Factor IX

10:30 - 11:00 COFFEE BREAK

12:30 - 2:15 LUNCH / POSTERS ATTENDED

2:15 - 3:45 P. 313 2:15 - 3:45 P. 313 2:15 - 3:45 P. 314 2:15 - 3:45 P. 314 Contact Pathway Genetics of Protease: Neonatal/ Pediatric Platelet Disorders Structure-Function Hemostasis

2:45 - 3:00 COFFEE BREAK

4:00 - 5:00 P. 327 4:00 - 5:00 P. 328 4:00 - 5:00 P. 328 4:00 - 5:00 P. 329 Mechanisms of Platelet Biology IV Heparin-induced Inhibitors of Platelet Activation Thrombocytopenia Coagulation and IV II Fibrinolysis

40 Thursday, July 16, 2009

Room Room Room Room Room 109 AB 151 AB 162 AB 252 AB 257 AB am Overview ogr

8:00 - 9:30 P. 324 Pr Trauma, Sepsis and Disseminated Intravascular Coagulationvon

10:30 - 11:00 COFFEE BREAK

12:30 - 2:15 LUNCH / POSTERS ATTENDED

2:15 - 3:45 P. 315 Shear-induced Signaling

2:45 - 3:00 COFFEE BREAK

4:00 - 5:00 P. 329 4:00 - 5:00 P. 330 4:00 - 5:00 P. 330 Regulation of Thrombin Acti- Atherosclerosis: Coagulation & vatable Fibrinolysis Risk factors II Fribrinolysis1 Inhibitor (TAFI)

41 Plenary Oral State-of- Abstract Session Communications the-Art Symposia NOTES ISTH2009

SSC Meetings and Educational Sessions

43 55th Annual Meeting of the Scientific and Standardization Committee and Educational Program

The SSC Annual Meeting will be held on Saturday July 11 from 8:00 AM - 6:00 PM and on Sunday July 12 from 8:00 AM - 12:00 Noon.

An Education Program, sponsored jointly by the Congress and the SSC, will be a part of individual SSC scientific subcommittee sessions, and will supplement topics not addressed in the main ISTH program. Speakers will provide attendees with an introduction to, and fundamentals of, a given subject. Additional education sessions will be held between 12:00 Noon and 2:00 PM on Saturday July 11. Coffee Breaks Coffee will be served near the SSC Meeting Rooms. It will be possible to purchase coffee at various outlets throughout the BCEC as well. Name Badges Name Badges can be picked up at the Registration Desk beginning on Friday, July 10 from 3:00 PM to 6:00 PM Name Badges must be worn at all times throughout the BCEC. SSC Speakers Preview Room SSC and Education Program Speakers are asked to bring their formatted PowerPoint presentations to the Speaker's Preview Room (Room 251) at least two hours before their session. Files from key drives or CD-ROMs can be transferred to the Congress servers at that time. All conference rooms contain state-of-the-art technical equipment. Speaker Preview Room Hours: Friday July 10, 2009 3:00 PM - 6:00 PM Saturday, July 11, 2009 7:30 AM - 7:00 PM Sunday July 12, 2009 7:30 AM - 7:00 PM Scientific and Standardization Committee See Page 9 for committee list

44 Best wishesforapr SSC meetings.Iamconfidentthatyouwillbenefitfrom theexperience. meetings willbeoneofthehighlightsISTH2009.So, pleasejoinusforthe cussed inSubcommitteebusinessmeetings.Itismyexpectation thattheSSC complement thewiderangeofcurrent basicandclinicalscienceissuesdis- Bauer andDr. RobertHandin.Theseeducationalopportunitieseffectively the SSCSubcommitteesandISTHCongr tanding educationalpr Subcommittees willhaveeducationalsessions.Thesecarefully planned,outs- the firsttimeatanSSCmeetingheldwithISTHCongress, 19 devoted totheactivitiesandprojects intheirrespective areas. Inaddition,for Each ofthe20SSCSubcommitteesandWorking Groups willhavemeetings SSC SubcommitteemeetingsonSaturday July11thandSunday12th. As theChairmanofSSC,itismypleasure toinviteyouparticipateinthe scientific meetings. Local OrganizingCommittee,tobethebestinalongsequenceofoutstanding Presidents Dr. BarbaraFurieandDr. BruceFurie,withtheassistanceoftheir tional component,andtheXXIICongress hasbeenmeticulouslyplannedby the XXIIISTHCongress. TheSSCAnnualMeetinghasavaluableneweduca- the ISTHScientificandStandardization Committee(SSC)andcontinueswith the fieldofhemostasisandthrombosis. ItbeginswiththeAnnualMeetingof gest andmostcomprehensive gatheringofinvestigatorsandpractitionersin Welcome toBoston!You havetheprivilegeofparticipatinginworld'slar- Dear ColleaguesandFriends: Message from theSSCChairman oductive andenjoyablevisit! esentations ar ISTH Scientific andStandardization Committee Chairman Gerhar e ther esult ofclosecollaborationbetween d J.Johnson,M.D. ess V ice Pr esidents, Dr . Kenneth 45

SSC & Educational

SATURDAY, JULY 11, 2009 Hemostasis and Malignancy Chairperson: Martin H Prins (NL) Co-Chairpersons: Giancarlo Agnelli (IT), Dominique Claire Farge (FR), Charles W Francis (US), Alok A. Khorana (US), Agnes Y. Y. Lee (CA)

Educational Session 8:00 AM - 9:30 AM Room 107 ABC

Moderator: Martin H. Prins (NL) Coagulation as a biological target for cancer therapy Frederick R. Rickles (US) 8:00 - 8:30 AM Predicting cancer patients at risk for venous thromboembolism: Strategies for prophylaxis Alok A. Khorana (US) 8:30 - 9:00 AM Diagnosis and management of cancer-associated thrombosis Agnes Y. Y. Lee (CA) 9:00 - 9:30 AM This session will discuss the relationship between cancer and coagulation. Thrombosis is not only a common complication of cancer but coagulation might also play a role as a biological target for cancer therapy. Experimental and clinical evidence for the role of anticoagulants in cancer therapy will be discussed. While it is clear that cancer patients who have surgery should receive prophylaxis, it is unclear which cancer patient (if at all) deserves prophylaxis in the absence of surgery. Hence, it might be important to identify cancer patients at risk for venous thromboembolism to improve research in strategies for prophylaxis. Finally, the issues specific to cancer patients in the diagnosis and management of their thrombosis will be discussed.

SSC Business Session 9:30 AM - 12:00 PM Room 107 ABC

Program unavailable at time of printing. Go to www.isth.org for the most current program.

46 SATURDAY, JULY 11, 2009 Vascular Biology Chairperson: Jean-Marie Freyssinet (FR) Co-chairpersons: Michael C. Berndt (IE), Françoise Dignat-George (FR), John H. Griffin (US), Peter J. Newman (US) SSC & Educational

Educational Session 8:00 AM - 9:30 AM Room 160 ABC

Shed proteins/receptors as clinical biomarkers of vascular disease Moderator: Peter J. Newman (US) Exploring the platelet sheddome Lawrence Brass (US) 8:00 - 8:30 AM Translating the mechanism of GPVI shedding: Soluble GPVI as a clinical biomarker Michael Berndt (IE) 8:30 - 9:00 AM Platelet aging and ectodomain shedding Simone Schoenwaelder (AU) 9:00 - 9:30 AM There is growing realization that certain cell surface receptors are shed from the surface of blood and vascular cells as a result of their activation - perhaps as a mechanism to dampen the adhesive properties of the cell. A second consequence of platelet activation is the secretion of the contents of specialized granules, some of which have the potential to support endothelial cell growth, stem cell differentiation, and tumorigenesis. This 90 minute session will highlight recent progress in the identification and characterization of the so-called platelet sheddome and platelet secretome, with an emphasis on how such fluid-phase proteins can both affect vascular physiology and report vascular disease.

SATURDAY, JULY 11, 2009

SSC Business Session 9:40 AM - 12:00 PM Room 160 ABC

Characterization of circulating endothelial progenitors Chairpersons: Françoise Dignat-George (FR) and John Griffin (US) Identification criteria of endothelial progenitor cells Mervin Yoder (US) 9:40 - 9:55 AM Standardization of late endothelial progenitor cells culture from human blood David Smadja (FR) 9:55 - 10:10 AM Determination and characterization of circulating microparticles Chairpersons: Jean-Marie Freyssinet (FR) and Nigel Key (US) Megakaryocyte-derived microparticles Joseph Italiano (US) 10:15 - 10:30 AM The plasmin generation capacity of microparticles Romaric Lacroix (FR) 10:30 - 10:45 AM Determination of microparticles by dynamic light scattering Paul Harrison (UK) 10:45 - 11:00 AM Determination of microparticles by atomic force microscopy Yuana Yuana (NL) and Susanne Osanto (NL) 11:15 - 11:30 AM Standardization off flow cytometry measurement, analysis, and reporting: Considerations for quantification of cell-derived membrane vesicles John Nolan (US) 11:30 - 11:45 AM Progress on the standardization of microparticle enumeration by flow cytometry Françoise Dignat-George (FR) and Nigel Key (US) 11:45 - 12:00 PM

guidelines, andinr diseases, andapplyittoeveryday clinicalpractice. critically appraisenewinformation onclinicalriskmanagementofthrombotic in everydayclinicalpractice clinical/laboratory predictorsofvenousandarterialthromboembolism Predictive hemostaticvariables:Auser'sguidetoapplying Alberto Tosetto (IT) Co-Chairpersons: Chairperson: Predictive Variables inCardiovascular Disease studies, theirinterpr associations ofclinicalandlaboratorypr application toclinicalpractice.Thefirstpresentation considersanalysisofthe laboratory predictors ofvenousandarterialthromboembolism, andtheir This educationalprogram reviews thestagesindevelopmentofclinicaland Henri Bounameaux(CH) for primetime? When isaClinicalPracticeGuideliner Interpreting clinical-laboratoryprediction rules: Marc A.Rodger(CA) How dowegetthere? rule forrecurrent venousthromboembolism: Developing aclinical-laboratorydecision Mark W outcomes: Whatdoeshavingariskfactorreally mean? Interpreting studiesofpredictor variablesandclinical Moderators: final pr using pr pr Educational Session 2009 SATURDAY, JULY 11, esentation r esentation addr oodward (US) ediction ofr Gordon Lowe(UK)andJamesDouketis(CA) Gordon D.Lowe(UK) eviews thedevelopmentofdecisionrulesfr James Douketis(CA),Veikko Salomaa(FI), outine clinicalcare. Thissessionwillenableparticipants to etation, andpotentialforriskstratification.Thesecond ecurr esses theapplicationofsuch rulesinclinicalpractice ent venousthr :0A :0A Room156ABC 8:00 AM-9:30 edictors withoutcomesinpr omboembolism asanexample.The eady om suchinformation, 9:00 -9:30AM 8:30 -9:00AM 8:00 -8:30AM ospective 49

SSC & Educational

SATURDAY, JULY 11, 2009

SSC Business Session 10:00 AM - 12:00 PM Room 156 ABC

Predictive Variables: Update Chairpersons: Veikko Salomaa (FI) and Alberto Tosetto (IT) Thrombophilias and recurrent venous thromboembolism Trevor Baglin (UK) 10:00 - 10:30 AM Factor IX and venous thromboembolism Frits Rosendaal (NL) 10:30 - 11:00 AM D-dimer and recurrent venous thromboembolism Alberto Tosetto (IT) 11:00 - 11:30 AM

Women's Health in Thrombosis and Hemostasis Chairperson: Andra H. James (US) Co-Chairpersons: Margareta Blomback (SE), Benjamin Brenner (IL), Jacqueline Conard (FR), Sabine Eichinger (AT), Barbara A. Konkle (US), Claire McLintock (NZ), Claire S. Philipp (US)

SSC Business Session 8:00 AM - 10:30 AM Room 102 AB

Introduction and Overview Chairperson: Andra H. James (US) Welcome Purpose and function of SCC's What constitutes issues in women's health in thrombosis and hemostasis Introduction of co-chairs and their comments 8:00 - 8:15 AM Educational Activities Chairperson: Benjamin Brenner (IL) Report on the Women's Health Issues in Thrombosis and Haemostasis Symposia 8:15 - 8:30 AM Report on publications 8:30 - 8:45 AM Update on registries

complications -anticoagulation? (Yes) Ron Hoffman(IL) disorders Corpus luteumbleedinginwomenwith Rezan Kadir(UK) disorders Mirena IUDformenorrhagiainwomenwithbleeding heart valves Pregnancy outcomein women withmechanical Marc A.Rodger (CA) complications -anticoagulation?(No) Inherited thrombophilia andpregnancy Anticoagulation duringpregnancy/ Debate: Benjamin Brenner(IL) Inherited thr Anticoagulation duringpregnancy/ Debate: Claire S.Philipp(US) evaluation Identifying womenwithmenorrhagiaforhemostatic Moderator: Br Margareta Blombäck(SE) Laboratory analysesinhabitualabortion TIPPS Anne McLeod(CA) HEPRIN a historyofpoorpr 2 randomizedtrialsofanticoagulationinwomenwith Other newandproposed projects includingregistries Flora Peyvandi(IT) Menorrhagia inwomenaffected bybleedingdisorders collaborations Update onongoinginternational Educational Session 2009 SATURDAY, JULY 11, eak Andra H.James(US ombophilia andpregnancy egnancy 10:30 AM-12:00PMRoom102AB ) 11:30 -12:00 PM 11:00 -11:30AM 10:30 -11:00AM 10:00 -10:30AM 9:50 -10:00AM 8:45 -8:55AM 9:40 -9:50AM 9:30 -9:40AM 9:15 -9:25AM 9:05 -9:15AM 8:55 -9:05AM 51

SSC & Educational

SATURDAY, JULY 11, 2009

Dr. Philipp will discuss her experience developing a screening tool for stratifying women with unexplained menorrhagia for hemostatic testing for underlying bleeding disorders. Recently, she and her colleagues completed a study of 146 women with a physician diagnosis of menorrhagia who underwent comprehensive hemostatic testing for the diagnosis of bleeding disorders, including von Willebrand disease, platelet dysfunction, and coagulation factor deficiencies. Bleeding symptoms with high predictive values for laboratory hemostatic abnormalities were combined and used as single variables to calculate sensitivity, specificity, and positive and negative predictive values in order to develop a short screening tool. Dr. Phillip will discuss the results of the study. A combination of 8 questions in 4 categories resulted in a sensitivity of 82% (95%CI 75-90) for bleeding disorders. Adding a pictorial blood assessment chart score > 100 increased the sensitivity of the screening tool to 95% (95%CI 91-99). Adding the PFA-100 did not increase the sensitivity for bleeding disorders overall, though sensitivity for VWD was increased.

Dr. Brenner will present one side of the debate: Inherited thrombophilia and pregnancy complications - anticoagulation? (Yes) Inherited thrombophilias are associated with gestational vascular complications including three or more first trimester losses, two or more second trimester losses, or any stillbirth; early, severe or recurrent preeclampsia and severe intrauterine growth restriction. Furthermore, low-molecular-weight heparin is safe and effective in preventing pregnancy loss and decreasing the recurrence of placental-mediated complications in women with both acquired and inherited thrombophilia.

Dr. Rodger will present one side of the debate: Inherited thrombophilia and pregnancy complications - anticoagulation? (No) Inherited thrombophilias are not yet established as a cause of placenta-mediated pregnancy complications, such as fetal growth restriction, preeclampsia, abruption, and pregnancy loss. An inherited thrombophilia is only one of many factors that lead to development of these diseases and is unlikely to be the unique factor that should drive management in subsequent pregnancies. The paucity of evidence for benefit, coupled with a small potential for harm, suggests that low molecular weight heparin should be considered an experimental drug for these indications until data from controlled trials are published. At present, women with a history of placenta-mediated pregnancy complications, with or without a thrombophilia, should be followed closely without routine prophylactic low molecular weight heparin other than for prevention of venous thromboembolism in limited circumstances.

for plateletautoantibody testing? Andreas Greinacher (DE) Welcome Hartmut Kroll(DE),TheodoreWarkentin (CA) Co-Chairpersons: Chairperson: Platelet Immunology Br Discussion GPIIbIIIa andGPIbIXglycopr Discussion Donald Arnold(CA) of patientswithITP Platelet antibodiesinwell-definedpopulations could beanswered bythePARC study? the PlateletImmunologySubcommitteewhich Discussion: Are there specific questionsof Paul Imbach(CH)andT Update: P Subcommittee agree withtheconsensus? Discussion: DoesthePlateletImmunology Francesco Rodeghiero(IT) what ar On whichtopicshasaconsensusbeenreached and Standar Chairpersons: Autoimmune thrombocytopenia PART 1. and followingITPadultpediatricpatients questions arisingfrom systematicallycollecting SSC BusinessSession 2009 SATURDAY, JULY 11, eak e theopenissues dization ofterminologyanddefinitionsinITP: ARC studynewlessonslear Andreas Greinacher(DE) Beng Chong(AU)andHartmutKroll(DE) Beng H.Chong(AU),Yves Gruel(FR),Volker Kiefel(DE), . Kühne(CH) oteins suf :0A 10 M Room153ABC 8:00 AM-11:00 ned, new ficient 9:25 -9:35AM 9:20 -9:25AM 9:10 -9:20AM 9:05 -9:10AM 8:55 -9:05AM 8:45 -8:55AM 8:30 -8:45AM 8:20 -8:30AM 8:05 -8:20AM 8:00 -8:05AM 53

SSC & Educational

SATURDAY, JULY 11, 2009

Discussion for a Statement of the Platelet Immunology Subcommittee on the role of platelet antibody testing in the time of new therapeutic options for ITP: Is there a role for platelet autoantibody testing in patients with ITP? Discussion 9:35 - 10:00 AM Statement for the SSC chair Volker Kiefel (DE) 10:00 - 10:05 AM PART 2. 10:05 - 10:45 AM Heparin-induced thrombocytopenia Chairpersons: Yves Gruel (FR) and Theodore Warkentin (CA) How to improve the clinical use of antigen assays in HIT Combining quantitative interpretation of PF4-dependent EIA's and high heparin Karina Althaus (DE) 10:05 - 10:20 AM Towards genetics in HIT Yves Gruel (FR) 10:20 - 10:35 AM Last Minute Contributions 10:35 - 11:00 AM

Educational Session 11:00 AM - 12:00 PM Room 153 ABC

Moderator: Volker Kiefel (DE) Laboratory testing for heparin-induced thrombocytopenia Theodore E. Warkentin (CA) 11:00 - 11:30 AM Drug-induced immune thrombocytopenias Richard Aster (US) 11:30 - 12:00 PM The educational session will focus on two important issues related to drug- induced immune reactions towards platelets. Heparin-induced thrombocytopenia is by far the most frequent drug induced antibody response, and the lecture will provide a comprehensive overview on the different assays currently available and an appraisal of their role in clinical practice. Drug-induced immune thrombocytopenias are less frequent but can be associated with severe bleeding. Recent data provide new concepts on the understanding of the pathogenesis of the immune response. Both speakers are internationally respected experts in these topics.

Program, willbeheldonSaturday2:00-6:00PM. Note: AnadditionalFactorVIIIandIXSSCBusinessSession,Educational Co-Chairpersons: Chairperson: Factor VIIIandIX General discussion /Futur Kim Jacobsen(DK) Recombinant FXIII:Early data Clive Dash(UK) A newFactorXconcentrate: Clinicalissues Waander vanHeerde(NL) Thrombin GenerationinRBDs Steven Kitchen(UK) Standar Amy Shapiro(US) North AmericanRegistryofRare BleedingDisorders Flora Peyvandi(IT) European NetworkofRare Bleeding Disorders (ENRBDs) Flora Peyvandi(IT)andChristineA.Lee(UK) Overview Chairpersons: Rare bleedingdisorders Alok Srivastava(IN) Completed/Submitted reports andrecommendations Alok Srivastava(IN) Welcome andIntroduction Part 1 (BE), EdwardGDTuddenham (UK) (FR), JohannesOldenburg(DE),FloraPeyvandi(IT),Jean-MarieSaint-Remy SSC BusinessSession 2009 SATURDAY, JULY 11, dization ofassays:FVIIandFXI Alok Srivastava(IN) Flora Peyvandi(IT)andChristineA.Lee(UK) Charles Hay(UK),ChristineLeeClaudeG.Negrier e directions :0A 20 M Room104ABC 8:00 AM-12:00PM 9:45 -9:55AM 9:30 -9:45AM 9:15 -9:30AM 9:00 -9:15AM 8:45 -9:00AM 8:30 -8:45AM 8:15 -8:30AM 8:10 -8:15AM 8:05 -8:10AM 8:00 -8:05AM 55

SSC & Educational

SATURDAY, JULY 11, 2009

Break 9:55 - 10:00 AM Factor VIII/IX: Clinical issues- I (Assay / EQA / Phenotype) Chairpersons: Claude Negrier (FR) and Alok Srivastava (IN) Overview: Tests of global hemostasis Claude Negrier (FR) and Alok Srivastava (IN) 10:10 - 10:15 AM Systematic approach to the assay discrepancies between one and two-stage assays Johannes Oldenburg (DE) 10:15 - 10:30 AM Factor VIII assay - A new paradigm Edward Gomperts (US) and Kenneth Mann (US) 10:30 - 10:45 AM Assays for global hemostasis in hemophilia: Correlation with adjuvant therapeutic options Benny Sorensen (UK) 10:45 - 11:00 AM Comparison of TEG / TGT / Wave form analysis in clinical samples of hereditary bleeding disorders Sukesh C. Nair (IN) 11:00 - 11:15 AM Global hemostasis tests in hemophilia - Early data and a systematic study plan Claude Negrier (FR) 11:15 - 11:30 AM General discussion 11:30 - 11:40 AM The agenda of the SSC: What are the priorities? General discussion 11:40 - 12:00 PM

blood coagulationmechanism Use ofAsiansnakevenominhibitorsinstudies Pantep Angchaisuksiri(TH) Coagulopathy inMalaria Moderator: APSTH-ISTH Symposium coagulopahty prevalent intheFarEast. induced bysnakebitesand itsmanagement,andgeneticdisorders related to venom inhibitorsinstudies ofbloodcoagulationmechanism,coagulopathy comprehensive introduction oncoagulopathyinmalaria,use ofAsiansnake symposium attheBostonISTHConference willdelivertotheaudience thr Geneva ISTHConference in2007,focusingonthediseasesrelated to symposium washeldattheSydneyISTHConfer r has contributedimmenselytothedevelopmentofresearch andclinicalstudies founded 11yearsago,andwiththehelpofar The Asian-PacificSocietyonThr Toshiyuki Miyata(JP) in theFarEast Genetic disorders related tocoagulopathyprevalent Geoff Isbister(AT) management Coagulopathy inducedbysnakebitesandits Takashi Morita(JP) of APSTH: Conference ofAPSTHwillbeheldinIndonesia2010.Pleasevisitthewebsite Confer Philippines, Singapor Australia, Cambodia,China,India,Indonesia,Japan,Korea, Malaysia,Mongol, countries. TheAPSTHhasthemembershipofmor Educational Session 2009 SATURDAY, JULY 11, elated tothr ombosis andhemostasispr ences inTaiwan, Korea, Thailand,China,andSingapore, andthe6th Yukio Ozaki(JP) ombosis andhemostasisinAsian-Pacific http://www e, T aiwan, Thailand,andV .jsth.org/apsth/index.html 21 M-14 M Room104ABC 12:15 PM-1:45 evalent intheAsian-Pacificar ombosis andHemostasis(APSTH)was dent activitiesofitsmembers,it ietnam. W e than350membersfr ence in2005,andatthe The APSTH-ISTHjoint e havehad5APSTH 12:15 -12:40PM 12:40 -1:05PM 1:25 -1:45PM 1:05 -1:25PM ea. Thejoint om 57

SSC & Educational

SATURDAY, JULY 11, 2009 Genomics 101

Educational Session 12:15 PM - 1:45 PM Room 107 ABC Moderator: Willem Ouwehand (UK) The genetic architecture of thrombosis and bleeding: Rare mutations and common SNP's Pieter H. Reitsma (NL) 12:15 - 12:45 PM The architecture of genome-wide SNP studies: New examples including fibrinogen, vWD, FVII and VFII Andrew Johnson US) 12:45 - 1:15 PM Small steps in a long journay: The discovery of risk loci for cardiovascular disease Willem Owehand (UK) 1:15 - 1:45 PM A large number of common diseases have a substantial heritability. It has however until recently not been possible to identify loci which contribute to disease risk. The sequencing of the human genome, and the cataloguing of sequence variation within and between populations, has provided the information which was needed for the design of genome-wide typing arrays. These high density arrays have been used to test large numbers of DNA samples from cases with disease and healthy controls for common sequence variation. Three distinguished speakers will review the results of the first Genome-Wide Association Studies (GWAS) and how this type of study has lead to the discovery of novel loci implicated in cardiovascular disease, hemostasis and thrombosis. In a stepwise process you will be familiarized with the principle categories and extent of common sequence variation, the design of GWAS and the statistical approach used for the analysis of large scale genotyping results. Finally, we will show how these results have altered our insight in disease pathophysiology of thrombosis and hemostasis.

Gerr chemistry research: From virtualproteins towetprotein Application ofinsilicomethodsbloodcoagulation Moderator: In silicoDrugDesign will bediscussed. considerations thatare ofimportancetothisrapidlydevelopingfieldscience academia andinindustry systems havemadethesetechniquespossiblefor r protein-ligand interactions.Advancesincalculationpowerofcomputer established themselvesasnovelcomputationaltechniques thatcanpr techniques suchasmoleculardockingandvirtualligand scr bind specificallyandtightlytoabindingsiteonprotein target.Insilico A majorapplicationofstructuralbioinformaticsisthedesignligandsthat discovery pipeline. Structural bioinformaticsmeanwhileplayarole across theentire drug Xavier Morelli(FR) undruggable targets? Protein-Protein complexes:Druggableor Bruno V and chemicalbiology Methods andapplicationsfordrugdiscovery In silicoscreening ofcompoundcollections: Educational Session 2009 SATURDAY, JULY 11, y AFNicolaes(NL) illoutreix (FR) Gerry AFNicolaes(NL) Gerry . Duringthissession,thebasicrulesand 21 M-14 M Room153ABC 12:15 PM-1:45 esear 12:15 -12:45PM eening (VLS)have 12:45 -1:15PM 1:15 -1:45PM chers, bothin edict 59

SSC & Educational

SATURDAY, JULY 11, 2009 Translating Evidence into Practice

Educational Session 12:15 PM - 1:45PM Room 160 ABC

Moderators: Gerhard J. Johnson (US) and James Douketis (CA) Developing Clinical Practice Guidelines - GRADE system experiences Roman Jaeschke (CA) 12:15 - 1:00 PM Incorporating practice guidelines into the realm of arterial and venous thromboembolism predictors: What do we have? What is missing? Gordon Lowe (UK) 1:00 - 1:45 PM The session on 'translating evidence into practice' begins with a general overview of how evidence from clinical trials and observational studies is incorporated into clinical practice guidelines. This discussion will focus on the practical aspects of developing practice guidelines, including how grades of evidence are established and how guideline committees work to interpret available evidence, especially controversial evidence, in formulating simple and easy-to-use practice guidelines. The session ends with a discussion of how clinical practice guidelines have been applied to the area of clinical predictors of venous and arterial thromboembolism. This discussion will focus on currently used predictors and the evidence for their recommended use as well as gaps in knowledge and future research.

The Illusion of Disclosure

Educational Session 12:15 PM - 1:15 PM Room 156 ABC

Moderator: Bruce Furie (US) The illusion of disclosure- Conflict of interests in clinical investigation: Perspectives of a journal editor Robert S. Schwartz, Deputy Editor, New England Journal of Medicine (US) 12:15 - 1:15 PM This session will discuss the conflict of interest in medical publishing from an editor's point of view, the recent Institute of Medicine report on conflict of interest, and some new questions about the tension between conflict of interest and ethical conduct of clinical trials.

and dif Newer applicationsincludeitsuseasamatrixfordrugdelivery, cellmigration is commonlyusedasasealanttostembleedingandpromote woundhealing. polymerization canbemodulatedtopr engineering. Fibrinishighlyextensiblewithnon-linearelasticity, and them wellsuitedfornumer Moderator: Co-Chairpersons: Chairperson: Fibrinogen andFactorXIII pr underlying theseef angiogenesis andwoundrepair aswellthemolecularmechanisms processes thatinvolveangiogenesis.Inthisreview therole ofFXIIIin hemostasis FXIIIhasarole inwoundhealingandembryoimplantation- link formationbetweenfibrinchainstostabilizetheclot. Besideitsfunctionin Inbal: W Aida Inbal(IL) Non-coagulation activitiesofFactorXIII John Weisel (US) Fibrin gelsandbioengineering/clinicalapplications Marguerite Neerman-Arbez(CH),RainerSeitz(DE),JohnW. Weisel (US) (CH), JaapKoopman(NL),MurielMaurer(US),LeonidMedved Educational Session 2009 SATURDAY, JULY 11, otein disulfideisomerase(PDI)willbedescribed. eisel: fer Factor XIII(FXIII)isaplasmatransglutaminasethatcatalyzes thecross Fibrin gelshaveuniquestructuralandrheologicalpr entiation, tissueengineering,andpatter Moniek deMaat(NL) Moniek P. M.deMaat (NL) Robert ASAriens(UK),AidaInbal(IL),HansP. Kohler fects willbediscussed.Finally ous biomaterialsapplicationsinmedicineand :0P :0P Room156ABC 2:00 PM-3:00 oduce avarietyofsoftsubstrates.Fibrin ning. , anovelactivityofFXIII- operties thatmake 2:30 -3:00PM 2:00 -2:30PM 61

SSC & Educational

SATURDAY, JULY 11, 2009

SSC Business Session 3:00 PM - 6:00 PM Room 156 ABC

Factors XIII Diagnosis of factor XIII deficiency; Outline of a position paper Laszlo Muszbek (HU) and Hans P. Kohler (CH) 3:00 - 3:20 PM FXIII values in patients with heterozygous deficiency Vytautas Ivaskevicius (DE), Arijit Biswas (DE) and Johannes Oldenburg (DE) 3:20 - 3:40 PM Measurement of Factor XIII activation peptide (FXIII-AP) in patients with acute ischemic stroke using a new FXIII-AP ELISA Verena Schroeder (UK), Elisabeth Ortner (CH) and Hans P. Kohler (CH) 3:40 - 4:00 PM Measuring the B-unit in standards Robert Ariens (UK) 4:00 - 4:20 PM Break 4:20 - 4:40 PM Fibrinogen PT-derived and Clauss assay and dysfibrinogens Wolfgang Miesbach (DE) 4:40 - 5:00 PM Update Characterization Marguerite Neerman-Arbez (CH) 5:00 - 5:20 PM Fibrin Structure Marlien Pieters (ZA) 5:20 - 5:40 PM 2nd International Standard Fibrinogen Plasma (98/612) - replacement Sanj Raut (UK) 5:40 - 5:50 PM 1st International Standard Fibrinogen Concentrate (98/614) - replacement Sanj Raut (UK) 5:50 - 6:00 PM

advantages/disadvantages of testsemployingdif the standardization oflaboratorytestsforinvestigation ofthrombophilia. The r coagulation inhibitortesting Proposal forascoringsystemoftheanalyticalperformance quality assessmentprogram oftheECAT Foundation Differences inprotein Sactivityassayoutcomesintheexternal Report from theWorking PartyonThrombin GenerationTests Co-chairpersons: Chairperson: Plasma CoagulationInhibitors anticoagulant pr protease inhibitors.Dr. Castoldiwilladdress therole ofprotein S,amajor polysaccharides suchasheparininfluencetheirfunction asimportantserine antithr The firstpresentation byDr. Baglinwillfocusonhowthestructure of Steven Kitchen(UK) Laboratory investigationofthr Elisabetta Castoldi(NL) in protein Sdeficiency Molecular mechanismsofthrombosis risk T and function Antithr Moderator: Laurent O.Mosnier(US) Hackeng (NL),StevenKitchen(UK),RichardMarlar(US),PietMeijer tissue factorpathwayinhibitor involving several hundred laboratories. illustrated using genuinecasesanddata fr antithrombin assaysemployingthrombin orfactorXa.The issueswillbe including clotting/chromogenic PCassays,protein Sactivity assays,and Educational Session SSC BusinessSession 2009 SATURDAY, JULY 11, esult ofcongenitalprotein Sdeficiencywillbereviewed. Dr. Kitchen willcover revor Baglin(UK) ombin andheparin-cofactorIItheirinteractions withsulphated ombin andheparinCo-factorII:Structur Elaine Gray(UK) Herbert C.Whinna(US) otein thatactsasacofactorofbothactivatedpr Francesco Bernardi(IT),ElaineGray(UK),Tilman M. . Theincr 4:30 PM-6:00 ombophilia :0P :0P Room109AB 2:00 PM-4:30 eased riskofvenousthr om exter ferent principlesofanalysis e nal qualityassessment Room 109AB 5:30 -6:00PM 5:00 -5:30PM 4:30 -5:00PM ombosis asa otein Cand 63

SSC & Educational

SATURDAY, JULY 11, 2009 Factor VIII and IX Chairperson: Alok Srivastava (IN) Co-Chairpersons: Charles Hay (UK), Christine Lee (UK), Claude G. Negrier (FR), Johannes Oldenburg (DE), Flora Peyvandi (IT), Jean-Marie Saint-Remy (BE), Edward G D Tuddenham (UK)

Educational Session 2:00 PM - 3.30 PM Room 153 ABC Moderator: Alok Srivastava (IN) Management of hemophilia and assessment of outcomes Kathelijn Fischer (NL) 2:00 - 2:30 PM Factor concentrates for hemophilia - Current products and newer technologies Edward G D Tuddenham (UK) 2:30 - 3:00 PM Gene therapy of hemophilia B: Overview and new possibilities Arun Srivastava (US) 3:00 - 3:30 PM This program will review three important aspects of the management of hemophilia. First, Dr. Fischer will discuss the different approaches to prophylactic factor replacement therapy, describe the assessment of musculoskeletal outcome after such therapy and tell us if we are anywhere near defining an optimal protocol. Dr. Tuddenham will then review the current options of products for replacement therapy and discuss their advantages and potential drawbacks. He will also mention some of the newer products and how they may impact care of people with hemophilia. Finally, Dr. Srivastava will look at the possibility of cure from this condition. He will review the possibilities for gene therapy of hemophilia, describe the experience so far and discuss some of the ways to move this field forward.

Recommendations of an International groupRecommendations ofanInternational ITIstudy:Update International Charles Hay(UK)andJean-MarieSaint-Remy(BE) Overview Chairpersons: Therapies) Factor VIII/IX:Clinicalissues-II(Inhibitors/ProphylaxisNovel Alok Srivastava (IN) Closing remarks General discussion/Future directions Pradeep Poonnoose(IN) outcome inhemophilia Standardizing assessmentofmusculoskeletal Koen Mertens(NL) Standar Sanj Raut(UK) 8th Inter Anthony Hubbard(UK) Standard6th International fortheFVIII/VWFplasma Edward Tuddenham (UK)andJohannesOldenburg(D Overview Chairpersons: Factor VIII/IX:Standardizationissues General discussion/Futur Michele Calos(US) therapy withplasmidDNA A simple,safestrategyforhemophiliagene V What studiesdoweneedtostandardize practice Prophylactic factorreplacement inhemophilia- Angela Huth-Kuhne(DE) Diagnosis andtr Donna DiMichele(US) SSC BusinessSession 2009 SATURDAY, JULY 11, ictor Blanchette(CA) dizing theFVIIIinhibitorassay:Canitbedone? national Standar Edward T Charles Hay(UK)andJean-MarieSaint-Remy(BE) eatment ofacquired hemophiliaA: uddenham (UK)andJohannesOldenburg(DE) d forFVIIIConcentrate e dir :0P .0P Room153ABC 3:30 PM-6.00 ections ) 4:45-4:50PM E) 5:55 -6:00PM 5:50 -5:55PM 5:35 -5:50PM 5:20 -5:35PM 5:05 -5:20PM 4:50 -5:05PM 4:35 -4:45PM 4:20 -4:35PM 4:05 -4:20PM 3:50 -4:05PM 3:35 -3:50PM 3:30 -3:35PM 65

SSC & Educational

SATURDAY, JULY 11, 2009 Perinatal/Pediatric Hemostasis Chairperson: Gili Kenet (IL) Co-chairpersons: Janna M. Journeycake (US), Prasad Mathew (US), Paul Monagle (AU), Wolgang Muntean (AT), Ulrike Nowak-Gottl (DE), Nicole Schlegel (FR)

Educational Session 2:00 PM - 3:30 PM Room 102 AB Moderator: Gili Kenet (IL) Developmental Hemostasis Gili Kenet (IL) 2:00 - 2:30 PM Pediatric venous thromboembolism and thrombophilia Ulrike Nowak-Gottl (DE) 2:30 - 3:00 PM Anticoagulant therapy in children Paul Monagle (AU) 3:00 - 3:30 PM Kenet: Hemostasis is a dynamic process, which begins in-utero. The procoagulant capacity of new-borns is reduced. This fact, theoretically increasing the risk of bleeding, is balanced by the protective physiologic deficiencies of coagulation inhibitors, as well as by decreased fibrinolytic capacity. The variations in levels and activity of hemostatic components affecting the clinical settings in neonates will be highlightened. Nowak-Gottl: The annual incidence of venous thromboembolism (VTE) in children was estimated as 0.07 to 0.14 per 10,000 children, 5.3 per 10,000 hospital admissions, and 24 per 10,000 admissions of neonates. VTE in children often occurs as a complication of a severe underlying medical condition. The potential role of inherited thrombophilias as risk factors, also affecting recurrence rates in children, will be presented.

Monagle: The current standard anti-thrombotic therapy in children consists of initial short-term intravenous administration of either un-fractionated heparin (UFH) or LMWH, followed by long-term oral anticoagulants or continued LMWH. New drugs deserve attention, yet data regarding their pharmacokinetics, efficacy and safety in paediatric patients are to be elucidated. The difficulties and controversies regarding “tailoring” of anticoagulant treatment in children will be discussed.

anticoagulant drugsforuseinchildren Trial designandoutcomesforevaluationof Aisha Bruce(CA)andFionaNewall(AU) anticoagulant therapy Quality ofLifetoolforchildren receiving Chairpersons: Anticoagulant trials Mahendranath Moharir(CA) Neonatal CSVT Suzan W Neonatal PortalVein Thrombosis Keith Lau(CA) Neonatal RenalVein Thrombosis Chairpersons: Neonatal Thrombosis Monika Stoll(DE) and stroke Genetic associationstudiesforjuvenilethr N Goldberg(US) Kids -DOTTtrial N Goldberg(US) A validatedpediatricPTSoutcomeinstrument Lesley Mitchell(CA) thrombosis studies Limitations anddefinitionsinpediatric Chairpersons: definitions andtrials Pediatric thrombosis andstroke -Suggestions, Break Christoph Male(AT) SSC BusinessSession 2009 SATURDAY, JULY 11, illiams (CA) Anthony K.Chan(CA)andMarianaBonduel(AR) Janna Journeycake(US)andGuyYoung (US) Patricia Massicote(CA)andWolfgang Munteau(AT) :0P :0P Room102AB 3:30 PM-6:00 ombosis 5:30 -5:45PM 5:15 -5:30PM 5:00 -5:15PM 4:50 -5:00PM 4:40 -4:50PM 4:40 -PM 4:20 -4:40PM 4:05 -4:20PM 3:45 -4:05PM 3:30 -3:45PM 67

SSC & Educational

SATURDAY, JULY 11, 2009 Animal Models Chairperson: Timothy Charles Nichols (US) Co-chairpersons: Edward M. Conway (BE), Shaun Coughlin (US), Jay L. Degen (US), Nigel Mackman (US), Eva-Maria Muchitsch (AT), Susan Smyth (US), Hugo Ten Cate (NL), Hartmut Weiler (US)

SSC Business Session 2:00 PM - 4:30 PM Room 104 ABC Moderators: Nigel Mackman (US), Hartmut Weiler (US), Timothy C. Nichols (US) Human gamma fibrinogen in mouse coagulation Hartmut Weiler (US) 2:00 - 2:15 PM Coagulation protease-inhibitor effects in models of cardiovascular disease Hugo Ten Cate (NL) 2:15 - 2:30 PM Intra-articular factor IX protects hemophilia B mice from developing hemophilic synovitis Paul Monahan (US) 2:30 - 2:45 PM Tissue factor and tissue-specific hemostasis Nigel Mackman (US) 2:45 - 3:00 PM Novel ultrasound methods to monitor hemostasis Caterina Gallippi (US) 3:00 - 3:30 PM Hemophilia A in sheep Graca Almeida-Porada (US) 3:30 - 3:45 PM Canine hemophilia A and B Timothy C. Nichols (US) 3:45 - 4:00 PM Break 4:00 - 4:30 PM

in developingnewdrugsandobtainingapproval Key questionsforanimalmodelsofhemostasis Thomas G.Diacovo(US) platelet therapies domain forinvivoassessmentofhuman Modifying murinevonWillebrandfactorA1 Moderators: Silvia Pierangeli (US),GuidoReber(CH) Katrien Devreese (BE),EmmanuelFavaloro (AU),ElaineGray(UK), antibodies: Problems andpossiblesolutions Standard reference material fordetectingantiphospholipid Chairperson: Round T V Opening (US), GuidoReber(CH),ArmandoTripodi (IT) Co-chairpersons: Chairperson: Phospholipid-Dependent Antibodies Lupus Anticoagulant/ differences betweenmurineandhumanhemophilia. approval forusewillbediscussedbyDr. Muchitsch.Dr. Ponczwilldiscuss key utilization ofanimalmodelsindevelopingnewhemostaticagentsandobtaining platelets willbediscussedbyDr. Diacovo.Issuestobeconsidered inthe The approach tocross speciesinteractionsofmurineVWFandhuman discuss thestrengths andlimitationsofanimalmodelsinhemostasisresearch. The focusofthisAnimalModelsSubcommittieeeducationalsessionisto Mortimer Poncz(US) When miceare notsmallpeople Stressing thelimitsofmicemodelshemophilia: Eva-Marie Muchitsch(A SSC BusinessSession Educational Session 2009 SATURDAY, JULY 11, ittorio Pengo(IT) able Hartmut Weiler (US)andTimothy C.Nichols(US) Armando Tripodi (IT) V ittorio Pengo(IT) Ph GDeGroot(NL),ThomasOrtel(US),JacobH.Rand T) :0P :0P Room104ABC 4:30 PM-6:00 :0P :0P Room160ABC R 2:00 PM-4:30 2:15 -3:00PM 2:00 -2:15PM 5:30 -6:00PM 5:00 -5:30PM 4:30 -5:00PM 69

SSC & Educational

SATURDAY, JULY 11, 2009

Laboratory diagnosis: Coagulation assays (new guidelines) Armando Tripodi (IT) 3:00 - 3:30 PM Detection of antibodies against domain I of beta2- glycoprotein I improves the diagnosis of APS: An international multicenter study Bas de Laat (NL) 3:30 - 3:45 PM Predictive value of the Antiphospholipid Score Tatsuya Atsumi (JP) 3:45 - 4:00 PM Break 4:00 - 4:30 PM

Educational Session 4:30 PM - 6:00 PM Room 160 ABC Moderator: Vittorio Pengo (IT) Antiphospholipid antibodies: Historical background Thomas Ortel (US) 4:30 - 4:50 PM Mechanism of action of antiphospholipid antibodies Jacob H. Rand (US) 4:50 - 5:10 PM Laboratory diagnosis Ph. G. de Groot (NL) 5:10 - 5 :30 PM Clinical features Vittorio Pengo (IT) 5:30 - 6:00 PM Four speakers will cover all the relevant aspects of the antiphospholipid syndrome. An Historical background will initially be given by Dr. Ortel starting from the discovery of antiphospholipid antibodies at the beginning of past century. To follow Dr. Rand will describe the current hypotheses on the pathogenesis of the syndrome. Dr. de Groot will then discuss the very important issue on the laboratory diagnosis of the syndrome and finally Dr. Pengo will describe the clinical features to diagnose the disease as well the infrequent associated clinical manifestations.

Rheological principlesandcriticalparameters Adhesion ofplateletsandleukocytestothevesselwall: Moderator: Co-chairpersons: Chairperson: Biorheology Lawrence Brass (US) to explore new ideasaboutplatelet activation Using flow-dependentmodels invitro andinvivo Beatrice Hechler(FR)andPierre Mangin(FR) Comparison ofinvivoand invitro thrombosis models Shaun Jackson(AU) Novel molecularinteractions inthrombus formation Chairpersons: translation. Howtouseflow-dependentthrombosis models? Section 1. thrombus formationcanbemeasured inbothvivoandvitro assays. chambers, capillarysystems)are developed.Itwillbediscussedhow formation exvivoorinvitro, varioustypesofflow-baseddevices(flow provoke thrombus formationexperimentally. To studyhumanthrombus dependent thrombus formation.Invivo,different procedures are usedto The secondlecture overviewsrecent literature onthevariousstagesofflow- blood flowdeterminesadhesionofplateletsandleukocytestothevesselwall. stress andshearrate.Subsequently, anoverviewwillbegivenofhowthe and quantitativeparametersofrheology, including(arterialandvenous)shear The firstlecture discusseskeyprinciplesofbloodflow-dependentprocesses Johan W to measure this Thrombus formationandthedifferent ways Gerard B.Nash(UK) (US), GerardB.Nash(UK),J.Zwaginga(NL) SSC BusinessSession Educational Session 2009 SATURDAY, JULY 11, .M. Heemskerk(NL) Flow-dependent experimentalthrombosis modelsand Johan W.M. Heemskerk(NL) Johan W.M. Heemskerk(NL) Marc Hoylaerts(BE)andJohanHeemskerk(NL) Thomas Diacovo(US),MarcHoylaerts(BE),MichaelKing 2:00 PM-3:00Room107ABC :0P :0P Room107ABC 3:00 PM-6:00 3:30 -3:45PM 3:15 -3:30PM 3:00 -3:15PM 2:30 -3:00PM 2:00 -2:30PM 71

SSC & Educational

SATURDAY, JULY 11, 2009

Limitations of animal thrombosis models: The need for alternatives Marc Hoylaerts (BE) 3:45 - 4:00 PM Break 4:00 - 4:25 PM Section 2. Determination of flow-dependent molecular interactions. Processes relying on flow Chairpersons: Michael King (US) and Thomas Diacovo (US) Platelet-fibrin-thrombus formation in arterial flow requires high and low shear regions Armin Reininger (DE) 4:25 - 4:40 PM Flow-based measurement of VWF binding to collagen Birte Fuchs (DE) 4:40 - 4:55 PM Flow-dependent function of VWF after gene therapy Karen Vanhoorelbeke (BE) 4:40 - 5:10 PM Section 3. Standardization of thrombus formation under flow. How to use flow devices? Chairpersons: J.J. Zwaginga (NL) and Gerald Nash (UK) Measurement of thrombus formation on (ruptured) atherosclerotic plaques Judith Cosemans (NL) 5:10 - 5:25 PM Use of quantitative flow assays to study unknown bleeding disorders Mark Roest (NL) 5:25 - 5:40 PM The analysis of shear-dependent thrombus deposition on synthetic collagen surfaces Richard Farndale (UK) 5:40 - 5:55 PM

Moderator: Co-chairpersons: Chairperson: Disseminated IntravascularCoagulation(DIC) Disease-Specific MolecularMechanismsin specific. Thissessionisfocusedonunderstandingthese dif the molecularpathogenesisofDICcanbedifferent andcanbedisease- stratification ofpatientmanagement.However, theemergingevidenceisthat recognizing DIC,irrespective ofitsaetiology, hasclinicalvalueintheimproved diagnostic criteriathathasnowbeenwell-validated.Studies haveshownthat ISTH ScientificandStandardization Sub-CommitteehasdevelopedaDIC coagulopathy. Intranslatingthisintoastandardized formatofrecognition, the outcome ofanyprimarydiseasestateisworsenedbythedevelopmenta Fr Katherine A.Hajjar(US) of coagulopathy Acute Promyelocytic Leukemia:Mechanisms Karim Brohi(UK) New conceptsintraumainducedcoagulopathy Peter A.Ward (US) Role ofIL-17inSepsis Nielsen (DK),HideoWada (JP) physiologically importantandclinically-relevant targets. mechanisms, pr specific therapy. Exampleswillbedescribedofwhere complement-mediated to enablethenextstageoftranslationalmedicine,i.e. infacilitatingpathway- Educational Session 2009 SUNDAY, JULY 12, om theearliestclinicalobservations,ithaslongbeenrecognized thatthe Cheng-Hock Toh (UK) Cheng-Hock Toh (UK) o oranticoagulantpathwaysandfibrinolyticsystems may be Nigel S.Key(US),HyunKyungKim(KR),JornDalsgaard 8:00 AM-9:30 Room 107ABC fer 9:00 -9:30AM 8:30 -9:00AM 8:00 -8:30AM ences inor der 73

SSC & Educational

SUNDAY, JULY 12, 2009

SSC Business Session 9:30 AM - 12:00 PM Room 107 ABC

Chairman's report Cheng-Hock Toh (UK) 10:00 - 10:15 AM A. STANDARDIZATION Evaluation of non-overt DIC criteria Hideo Wada (JP) 10:15 - 10:30 AM Experience of evolving scores of hemostatic dysfunction in critical care Gary Kinasewitz (US) 10:30 - 10:45 AM Impact of the ISTH DIC score in children with critical illness Robinder Khemani (US) 10:45 - 11:00 AM Impact of method for platelet count determination in DIC Hyun K. Kim (KR) 11:00 - 11:15 AM B. COLLABORATIONS

With SSC in plasma coagulation inhibitors and UK NEQAS on Protein C and Antithrombin measurements Tina Dutt (UK) With SSC in vascular biology on procoagulant microparticles Nigel Key (US) Summation and Closing 11:45 - 12:00 PM

discuss ther Co-chairpersons: Chairperson: D von WillebrandFactor(VWD) qualitative abnormalitiesofvonW review theappropriate hemostasistestingstrategytoevaluatequantitativeand evaluation oftheclinicalsymptomsmanifestinVWD.Dr. Montgomerywillthen these diagnosticareas. Dr. Rodeghiero willdiscussanoptimalapproach tothe factor. Inthiseducationalsession,expertsinthefieldwilladdress eachof demonstrating quantitativeand/orqualitativeabnormalities ofvonWillebrand bleeding, afamilyhistoryofthediseaseandset oflaboratorytests the diagnosticdefinition:apersonalhistoryofexcessive mucocutaneous disease (VWD),isoftencomplicated.Intheory, there are three components to The diagnosisofthemostcommoninheritedbleedingdisorder, vonWillebrand Anne Goodeve(UK) Genetic analysisasanaidinVWDdiagnosis (US) Robert R.Montgomery in VWD Laboratory testingofthehemostatisphenotype Francesco Rodeghiero(IT) Clinical aspectsofVWDdiagnosis Moderator: Schneppenheim (DE) J Favaloro(AU),AnneGoodeve(UK),BernhardLämmle(CH),Reinhard Castaman (IT),JorgeDiPaola(US),JeroenC.J.Eikenboom(NL),Emmanuel Educational Session 2009 SUNDAY, JULY 12, David Lillicrap(CA) ole ofmoleculargeneticanalysisinmakingadiagnosis of(VWD). avid Lillicrap(CA) Thomas Abshire(US),ImreBodo(HU),Giancarlo :0A :0A Room109AB 8:00 AM-9:30 illebrand factor . Finally , Dr. Goodeve will 9:00 -9:30AM 8:30 -9:00AM 8:00 -8:30AM 75

SSC & Educational

SUNDAY, JULY 12, 2009

SSC Business Session 9:30 AM - 12:00 PM Room 109 AB

1. VWF Assays for VWD Diagnosis Chairperson: Emmanuel Favaloro (AU) Standardization of ristocetin-based VWF assays RIPA Augusto Federici (IT) 9:30 - 9:40 AM Automated VWF: RCo Andreas Hillarp (SE) 9:40 - 9:50 AM Alternative functional assays - GPIb binding assays: Robert Montgomery (US) 9:50 - 10:00 AM Hans Deckmyn (BE) 10:00 - 10:10 AM Discussion 10:10 - 10:15 AM 2. VWF Propeptide Studies Chairperson: Jeroen Eikenboom (NL) Standardization and Clinical utility Robert Montgomery (US) 10:15 - 10:25 AM Bas De Laat (NL) 10:25 - 10:35 AM Discussion 10:35 - 10:40 AM 3. Standarized Bleeding Scores (joint session with Pediatric SSC) Chairperson: Tom Abshire (US) Bleeding scores Adult Francesco Rodeghiero (IT) 10:40 - 10:50 AM Pediatric Paula James (CA) 10:50 - 11:00 AM Discussion 11:00 - 11:10 AM

Chairperson: 5. ADAMTS13 Discussion Tony Hubbard(UK) Discussant Chairperson: 4. VWFPlasmaandConcentrateStandards Walter Ageno (IT) Registry Report -Splanchnicveinthrombosis Trevor Baglin(UK) of progress ofWorking Partiesandfuture plans Introduction andupdateonactivitiesoftheSSC includingoverview Chairpersons: (CA), A.M.H.P. vandenBesselaar(NL) Aharon Lubetsky(IL),JohnOlson(US),GualtieroPalareti (IT),SamSchulman Co-chairpersons: Chairperson: Contr Discussion Anne Goodeve(UK) VWD registry Discussant Chairperson: 6. VWFandVWDRegistries Discussion Bas DeLaat(NL) ADAMTS13 antibodyassays Koichi Kokame(JP) ADAMTS13 assays SSC BusinessSession 2009 SUNDAY, JULY 12, ol ofAnticoagulation Trevor PatrickBaglin(UK) Imre Bodo(HU) Bernhard Laemmle(CH) Anne Goodeve(UK) Trevor Baglin(UK)andSamSchulman (CA) Walter Ageno(IT),JobHarenberg(DE),CliveKearon(CA), :0A 03 M Room104 ABC 8:00 AM-10:30 11:30 -11:40AM 11:10 -11:15AM 11:50 -11:55AM 11:45 -11:50AM 11:40 -11:45AM 11:20 -11:30AM 11:15 -11:20AM 8:10 -8:20AM 8:00 -8:10AM 77

SSC & Educational

SUNDAY, JULY 12, 2009

Discussion / Potential registry - Cerebral Vein Thrombosis - duration of anticoagulation Walter Ageno (IT) 8:20 - 8:30 AM Working Party Report - Recommendation for requirements on biosimilar Anticoagulants / Working Party Report - Standardization of methods to determine direct factor Xa inhibitors Job Harenberg (DE) 8:30 - 8:40 AM Working Party Report - Results of international collaborative study for calibration of two candidates for International Standard for thromboplastin, human, plain Ton Van Den Besselaar (NL) 8:40 - 8:50 AM Working Party Report - Variability of INR in stabilized patients and requirements for INR analytical precision Ton Van Den Besselaar (NL) 8:50 - 9:00 AM Discussion / New Working Party - Reporting INRs in liver disease Armando Tripodi (IT) 9:00 - 9:10 AM New Oral Anticoagulants Introduction to the Working Party: General and specific aims Trevor Baglin (UK) 9:10 - 9:20 AM Overview of drug development programs Harry Buller (NL) 9:20 - 9:35 AM Monitoring, bleeding and reversal Jeffrey Weitz (CA) 9:35 - 9:50 AM Patient education, concordance and compliance (role of thrombosis centres / anticoagulation clinics) Jack Ansell (US) 9:50 - 10:00 AM What to recommend for phase IV studies in collaboration between companies and anticoagulation clinics Gualtiero Palareti (IT) 10:00 - 10:10 AM Break 10:10 - 10:30 AM

therapy (for) Interruption oforalVKAtherapyrequires bridging Elaine Hylek(US) Which drugandwhen? Atrial fibrillationandantithrombotic therapy: Moderators: provide guidance. r relevant toroutine clinicalpracticethatallthree might be encountered in interrupted. Whatistheclinicalevidence?Theseissues are socommonand debate whetherheparinbridgingisevernecessarywhen oralVKAtherapyis therapy. Isthere evidenceofaddedvalue?Dr. KeelingandDr. Kearon will debate whetherpharmacogenetictestinghasarole wheninitiatingoralVKA translate intotr fibrillation intermsofwhichdrugandwhen.How do clinicaltrialresults Hylek willconsidertheissueofantithrombotic therapyinpatientswithatrial atrial fibrillation;howtoinitiatetherapy;andwhen bridge withheparin.Dr encountered inclinicalpractice:whentogivevitaminKantagoniststherapyfor This educationalsymposiumfocusesonthree controversies frequently David AGarcia(US) testing (against) Warfarin dosingandpharmacogenetic Brian Gage(US) Warfarin dosingandpharmacogenetictesting(for) Clive Kearon(CA) therapy (against) Interruption oforalVKAtherapyrequires bridging David Keeling(UK) Educational Session 2009 SUNDAY, JULY 12, elation toasinglepatient.Itishopedthatthesession willbringclarityand Trevor Baglin(UK)andSamSchulman(CA) eatment ofindividualpatients?Dr 03 M-1:0P Room104ABC 10:30 AM-12:00PM . GageandDr 11:30 -12:00PM 11:15 -11:30AM 11:00 -11:15AM 10:45 -11:00AM 10:30 -10:45AM . Garcia will 79 .

SSC & Educational

SUNDAY, JULY 12, 2009 Fibrinolysis Chairperson: Colin Longstaff (UK) Co-chairpersons: Carl-Erik H. Dempfle (DE), Ann Gils (BE), Dirk Hendriks (BE), Osamu Matsuo (JP), Michael E. Nesheim (CA), Tetsumei Urano (JP)

SSC Business Session 8:00 AM - 10:30 AM Room 153 ABC

WHO International Standards Report on a new WHO International Standard for Streptodornase Colin Longstaff (UK) 8:30 - 8:40 AM Update on standardization of PAI-1 antigen determinations in plasma Colin Longstaff (UK) 8:40 - 8:50 AM Approaches to dual labeling of International Standards for enzymes and inhibitors Craig Thelwell (UK) 8:50 - 9:00 AM TAFI/CPU Update on the functional assay for plasma TAFIa Michael Nesheim (CA) 9:00 - 9:25 AM Determination of CPU/TAFIa in plasma samples Evelien Heylen (BE) and Dirk Hendriks (BE) 9:25 - 9:45 AM D-dimer Update on the NEQAS EQA for D-dimer Ian Jennings (UK) 9:45 - 10:00 AM General Discussion and Break 10:00 - 10:30 AM

Wolfgang Korte(CH setting Fibrin generationmarkersintheperioperative Carl-Eric Dempfle(US) thromboembolism exclusion,aorticdissection) D-dimer intheemergencyroom (venous Moderator: assay systemsfrom apracticalperspective. session willfocusontheprimaryclinicalapplications of D-dimerandrelated monitoring ofpregnancy complications,andincancer. Theeducational as aprognostic toolinsecondaryprevention ofvenousthromboembolism, for to thromboembolic complications.Finally, D-dimermeasurement hasemerged generation mayidentifypatientswithhighclinicalrisk,including patientsprone chest pain.Intheperioperativesetting,D-dimerandothermarkersoffibrin venous thrombosis orpulmonaryembolism,differential diagnosisofacute conditions withoutintravascularfibrinformation.Examplesare exclusionof discriminate conditionsassociatedwithintravascularfibrinformationfrom patient assays.Quantitativeassaysare thecurrent standard. D-dimermay high throughput laboratoryinstrumentation,aswellpointofcare ornear activation. Various assaysystemsare available,includingautomatedassaysfor D-dimer currently isthemostprevalent markerfordetectionofcoagulation Saskia Middledorp(NL) thromboemolism, pregnancy andcancer D-dimer asprognostic parameterinvenous Educational Session 2009 SUNDAY, JULY 12, Carl-Erik H.Dempfle(DE) 11:00-11:30AM ) 03 M-1:0P Room153ABC 10:30 AM-12:00PM 11:30 -12:00PM 10:30 -11:00AM 81

SSC & Educational

SUNDAY, JULY 12, 2009 Platelet Physiology Chairperson: Marco Cattaneo (IT) Co-chairpersons: Joel S. Bennett (US), Paul Harrison (UK), Catherine P. M. Hayward (CA), Dermot Kenny (IE), Alan D. Michelson (US), Diane Nugent (US), Steve Watson (UK)

SSC Business Session 8:00 AM - 11:00 AM Room 160 ABC Chairpersons: Marco Cattaneo (IT) and Alan D. Michelson (US) Discussion of the Consensus of Experts on LTA Standardization Marco Cattaneo (IT), Chiara Cerletti (IT), Paul Harrison (UK), Catherine P.M. Hayward (CA), Dermot Kenny (IE), Alan D. Michelson (US), Diane Nugent (US), Paquita Nurden (FR), Koneti A. Rao (US), Alvin Schmeier (US), Steve Watson (UK) 8:00 - 9:45 AM Proposal on formation of an SSC Working Party on Diagnosis of Platelet Function Disorders Marco Cattaneo (IT) 9:45 - 10:00 AM Break 10:00 - 10:30 AM Chairperson: Marco Cattaneo (IT) New BCSH (British Committee for Standards in Haematology) guidelines for platelet function testing Paul Harrison (UK) 10:30 - 11:00 AM

Educational Session 11:00 AM - 12:00 PM Room 160 ABC Moderator: Marco Cattaneo (IT) Platelet function as a guide to thrombotic risk Alan D. Michelson (US) 11:00 - 11:30 AM Recent advances in the understanding and diagnosis of inherited platelet function disorders Catherine P. M. Hayward (CA) 11:30 - 12:00 PM Platelets play an important role in hemostasis, because both inherited and acquired abnormalities of their number and/or function are associated with excessive bleeding. Platelets also play an important pathogenic role in

in heparin thrombosis. available plateletfunctiontestsintheidentificationofpatientsatrisk platelet functiondefects;2)toreview theclinicalusefulnessofcurrently update onthediagnosticwork-upofpatientswithclinicalsuspicioninherited SocietyonThrombosisInternational andHaemostasisare thefollowing:1)to Subcommittee oftheScientificandStandardization Committeeofthe are available.AimsoftheEducationalSessionPlateletPhysiology thrombosis. Severallaboratorymethodsfortheevaluationofplateletfunction showed thatdrugsinhibitingplateletfunctionreduce theriskofarterial thrombosis, asshownbythe results ofseveralrandomizedclinicaltrials,which Cornelius Kluft (NL) Assays forover José Govers-Riemslag(NL) Contact activationinarterial thr Br Andras Gruber(US) of pathologiccoagulation Targeting factorXIinprimateandmurinemodels Owen McCarty(US) to platelets The plateletApoER2'receptor andfactorXIbinding Alvin Davis(US) The pathophysiologyofhereditary angioedema David Gailani(US) to "PlasmaContactActivationSystem"Subcommittee Business issue-ChangingthenameofSubcommittee Introduction. Descriptionofthemeetingorganization. Co-chairpersons: Chairperson: Plasma Kallikrein-Kinin system An updateonclinicalstudies SSC BusinessSession 2009 SUNDAY, JULY 12, eak David Gailani(US) -sulfated chondr Keith RMcCrae(US),ThomasRenné(SE),AlvinSchmaier(US) :0A 10 M Room156ABC 8:00 AM-11:00 ombosis - oitin sulfate 10:30 -11:00 AM 10:00 -10:30AM 9:45 -10:00AM 9:15 -9:45AM 8:45 -9:15AM 8:15 -8:45AM 8:00 -8:15AM 83

SSC & Educational

SUNDAY, JULY 12, 2009

Educational Session 11:00 AM - 12:00 PM Room 156 ABC Moderator: David Gailani (US) Misfolded proteins as a trigger for contact activation Martijn F.B.G. Gebbink (NL) 11:00 - 11:30 AM Role of leukocytes and platelets in contact system activation Thomas Renne (SE) 11:30 - 12:00 PM The term Contact Activation describes the conversion of the plasma protease zymogens factor XII, factor XI and prekallikrein (PK) to their active forms (factor XIIa, factor XIa and _-kallikrein, respectively) in the presence of an activating surface and the plasma protein high molecular weight kininogen (HK). This process can trigger activation of several host defense mechanisms including vasoactive kinin formation and blood coagulation. Contact activation initiates thrombin generation and fibrin formation in the classic cascade/waterfall models of coagulation, and in the partial thromboplastin time assay used to screen for plasma coagulation defects in the clinical setting. However, for many years, the importance of this process has been considered minimal because of the absence of bleeding or other clinical disorders in patients with complete deficiency of factor XII, PK or HK. This school of thought is reflected in the decision of the ISTH SSC on Contact Activation to change its name several years ago to the SSC on The Plasma Kallikrein-Kinin System. However, recent studies with genetically engineered mice demonstrate that factor XII, while not required for normal hemostasis, makes important contributions to pathologic coagulation in a number of vascular injury/thrombosis models. Similar results with factor XI deficient mice raise the distinct possibility that a process similar to classic contact activation is operating in these models. The nature of the trigger for factor XII activation in vivo is an area of active research. Traditional plasma assays typically use purified earths such as kaolin or celite to trigger contact activation. A number of physiologically relevant compounds including collagen, RNA, and polyphosphates from platelet granules have been implicated as triggers of factor XII activation at sites of vascular injuries. It is the goal of this educational session to further explore biologically relevant mechanisms for factor XII activation. Our first speaker, Dr. Gebbink of the University Medical Center in Utrecht will discuss the role of misfolded proteins, such as occur in amyloidosis, in activation of factor XII and prekallikrein. Then, Dr. Renné of the Karolinska Institute will speak on the role of platelets and leukocytes in initiating contact activation, and the implications for vascular thrombosis.

(25th Anniversary),Boston2009 on ExogenousFactorsAffecting Thrombosis andHemostasis Progress reportConference andplanningfor4thInternational Recor Welcome Francis S.MarklandJr. (US),Takashi Morita(JP) Co-Chairpersons: Chairperson: Registry ofExogenousHemostaticFactors Francis S.Markland, Jr A longandwinding road Fibrolase anditsevolutiontoclinicaltrials: Ivo Francischetti(US) glands from hematophagousarthropods T Moderator: Manjunatha Kini(SG) Metallopr Future projects fortheRegistry: Nomenclature ofVenom Netherlands 6/29-7/4/2013) Next EFATH meeting (ISTH schedule:Amsterdam, Cairo Egypt5/22-5/25/2010) Next Registrymeeting(ISTHschedule: Mar Interaction ofdisintegrinswithnaturalkillercellactivity Kenneth Clemetson(CH)andT of C-typelectins Final Reportonclassificationandnomenclatur Mar Educational Session SSC BusinessSession 2009 SUNDAY, JULY 12, ranscriptomics andfunctional genomicsofsalivary y AnnMcLane(US) y AnnMcLane(US) d oflastmeeting(Vienna, 3July2008) oteases Mary AnnMcLane(US) Mary Mary AnnMcLane(US) Mary Kenneth J.Clemetson(CH),ManjunathaR.Kini,(SG), . (US) akashi Morita(JP) 10:30 AM-12:00PM :0A 03 M Room102AB 8:00 AM-10:30 e 11:15 -12:00 PM 10:30 -11:15AM Room 102AB 85

SSC & Educational

SUNDAY, JULY 12, 2009

Francischette: Transcriptome and proteomic studies of the salivary gland from blood sucking arthropods have provided new insights in our understanding of saliva pharmacopea. Currently available sialomes from mosquitoes, sand flies, bugs, soft and hard ticks indicate that protein families such as Kunitz inhibitors are common to most hard ticks, while lipocalins are the most abundant proteins in soft ticks. Several proteins with unique sequences have also been found in distinct genera, and their functions have now been identified. Ixolaris inhibits the initiation of the coagulation cascade through inhibition of tissue factor in a FX/FXa-dependent manner, while RPAI-1 binds with high affinity to ADP and inhibits platelet aggregation. In addition, mosquito aegyptin specifically binds to the collagen sequence that mediates its interaction with von Willebrand factor (vWf). These molecules are being tested in vivo for inhibition of thrombus formation, cancer and metastasis. Markland: Fibrolase is a direct-acting fibrinolytic enzyme from southern copperhead (Agkistrodon contortrix contortrix) snake venom. The enzyme has no thrombin-like activity, does not activate protein C or platelets, does not activate nor degrade plasminogen, and has no hemorrhagic or hemolytic activity. Alfimeprase is the recombinant form of fibrolase made in yeast that is virtually identical to fibrolase with respect to enzymatic activity. However, the altered amino acid sequence stabilizes the structure of alfimeprase for prolonged shelf-life. In an acute carotid arterial thrombosis model, administration of alfimeprase produced significantly more rapid clot lysis than urokinase (UK) in rats, piglets or dogs. In a porcine model of peripheral arterial occlusion of the carotid artery, alfimeprase (but not(UK)) achieved close to complete thrombus resolution and flow restoration within 30 min. However, in clinical trials for peripheral arterial occlusion, alfimeprase did not meet target end points and further clinical development was ended in 2008.

McLane: Naturally occurring animal venoms from snakes, leeches, spiders, caterpillars, ticks and scorpions have been recognized for centuries as significant modulators of thrombosis and hemostasis. It is only within the past 40 years, however, that research techniques have allowed definitive insights into structure-function relationships of molecules from these sources, and their adaptation for clinical use. This session will highlight recent advances in molecular analyses and translational opportunities for proteins isolated from the southern copperhead viper (Agkistrodon contortrix contortrix) and blood sucking arthropods (mosquitoes, sand flies, ticks).

86 Opening Ceremony

You are cordially invited to attend the XXII Congress' Opening Ceremony on Sunday, July 12 at 6:00 PM in the BCEC's Grand Ballroom, followed by the Welcome Reception, which will take you through the sights, sounds and tastes of Boston's historic 'Freedom Trail'.

Welcome by Barbara and Bruce Furie Presidents of the XXII Congress of the ISTH

Remarks by Gilbert C. White II Executive Director of ISTH

Remarks and Presentation of the Grant Medal by Frits Rosendaal Chairman of the ISTH Council

Closing Remarks by Barbara and Bruce Furie Presidents of the XXII Congress of the ISTH

Boston through Its Music Entertainment by: Patriot Fife and Drum Duo Draw the Line Aaron Goldberg Trio PALS Children's Chorus

87 NOTES

ISTH2009

Scientific Program

Monday, July 13, 2009

MONDAY, JULY 13, 2009

Plenary Lecture 9:45 AM – 10:30 AM

Shirley Johnson Memorial Lecture Grand Ballroom Chairperson: Roy Silverstein (US) Cardiovascular genetics PL-MO-001 Helen H. Hobbs (US) 9:45 – 10:30 AM

Plenary Lecture 5:15 PM – 6:00 PM

Sol Sherry Memorial Lecture Grand Ballroom Chairperson: Mary Cushman (US) Thromboprophylaxis as a key patient safety priority: Current approaches and future directions PL-MO-002 William H. Geerts (CA) 5:15 - 6:00 PM

State of the Art Lectures 11:00 AM - 12:30 PM

Pulmonary Embolism, 2009 Grand Ballroom A Chairpersons: Phillip Wells (CA) and Samuel Goldhaber (US) Short term prognosis of pulmonary embolism SA-MO-001 Drahomir Aujesky (CH) 11:00 - 11:30 AM Treatment strategies including thrombolysis and embolectomy SA-MO-002 Samuel Goldhaber (US) 11:30 - 12:00 PM Diagnostic management of pulmonary embolism SA-MO-003 Menno Huisman (NL) 12:00 - 12:30 PM

atu elr(S 12:00-12:30PM 11:30-12:00PM Hartmut Weiler (US) Wolfram Ruf(US) Selective sortingofplatelet?-granulecontents Systems biologyofplateletsandcoagulation in hemostasis Empirical andtheoretical phenotypicdiscrimination Chairpersons: KennethKanushansky(US)andJosephItaliano nhn oln U) 11:00-11:30AM 12:00-12:30PM 11:30-12:00PM Modulation ofsepsiswith activatedprotein Cvariants Dendritic cellsandP Anthony Dorling(UK) inflammation Critical roles forthrombin inacute andchronic Chairpersons: CharlesEsmon(US)andHartmutWeiler (US) 11:00-11:30AM 12:00-12:30PM David Lillicrap(CA) disease: Istheglasshalffullorempty? 11:30-12:00PM Genotype/phenotype associationinvonWillebrand Cécile Denis(FR) Mouse modelsofvonWillebranddisease Giancarlo Castaman(IT) and clinicalrelevance Willebrand disease:Pathophysiological Reduced vonWillebrandfactorsurvivalin (US)andCécileDennis(FR) Chairpersons: RobertMontgomery 11:00-11:30AM Joseph Italiano(US) Scott Diamond(US) Kathleen Brummel-Ziedins(US) Inflammation andCoagulation GrandBallroom B Von WillebrandDisease-NewDevelopments Ballroom 210ABC Novel Approaches toUnderstandingHemostasis 2009 MONDAY, JULY 13, AR signalinginInflammation Room 258ABC SA-MO-012 SA-MO-011 SA-MO-010 SA-MO-009 SA-MO-008 SA-MO-007 SA-MO-006 SA-MO-005 SA-MO-004 91

Monday Science

MONDAY, JULY 13, 2009

Inherited Platelet Disorders Room 253 ABC Chairpersons: Christel Van Geet (BE) and Charles Abrams (US) Altered megakaryopoiesis in Type IIb von Willebrand disease SA-MO-013 Alan Nurden (FR) 11:00 - 11:30 AM Regulation of platelets biogenesis SA-MO-014 Ramesh Shivdasani (US) 11:30 - 12:00 PM Lesions in platelet signaling SA-MO-015 Christel Van Geet (BE) 12:00 - 12:30 PM

Endothelial and Vascular Signaling Room 205 ABC Chairpersons: William Aird (US) and Susan Smyth (US) Systems approach to inflammation resolution: Identification of novel anti-inflammatory and pro-resolving lipid mediators SA-MO-016 Charles N. Serhan (US) 11:00 - 11:30 AM Molecular control of angiogenesis and remodeling SA-MO-017 William Sessa (US) 11:30 - 12:00 PM Regulation of vascular cell function by bioactive l ysolipids SA-MO-018 Susan Smyth (US) 12:00 - 12:30 PM

Abstract Symposia 2:15 PM - 3:45 PM

Abstract Symposia consist of an invited speaker and four highly rated abstracts presented on a related general theme.

SM-0 2:45-3:00PM 2:15-2:45PM ANTITHROMBIN ASYMPTOMATIC SUBJECTSWITHHEREDITARY DEFICIENCIESOFPROTEINS,COR A PROSPECTIVECOHORT STUDYONTHEABSOLUTERISKOFVENOUSTHROMBOEMBOLISMIN AS-MO-002 Saskia Middeldorp(NL) More harmthangood? Thrombophilia testinginasymptomaticfamilymembers: Chairperson: SaskiaMiddeldorp(NL) J. N.Lozier*(US),R. Chang EXTREMITY DVT CLINICAL SAFETY, EFFICACY&PHARMACOKINETICS OFINTRA-CLOTTPA FORLOWER AS-MO-010 F. Piovella*(IT),A.M.D’Armini,Barone, V. Emmi,C.Beltrametti,M.Viganò HYPERTENSION (CTEPH) ENDARTERECTOMY (PEA)INPATIENTS WITHCHRONICTHROMBOEMBOLIC PULMONARY THE PAVIA ENDARTERECTOMY PROGRAMFORTHEMANAGEMENTOFPULMONARY AS-MO-009 M. Jørgensen*(DK),S.Just,R.Br THROMBOLYSIS ILIOFEMORAL VENOUSTHROMBOSISSUCCESSFULLY TREATED WITHCATHETER-DIRECTED AS-MO-008 3:00-3:15PM T. R. Enden* (NO),C.E.Slagsvold,N.Kløw, P. M.Sandset RANDOMIZED CONTROLLEDTRIAL THROMBOSIS; SHOR ADDITIONAL CATHETER-DIRECTED VENOUSTHROMBOLYSIS INILIOFEMORALDEEPVEIN AS-MO-007 Thomas W Aggressive therapiesforDVT Chairperson: ThomasWakefield (US) I. D.Bezemer*(NL),C.J.M.Doggen,S.LeCessie,P MULTIPLE SNPTESTINGTOPREDICTRISKOFFIRSTVENOUSTHROMBOSIS AS-MO-005 G. Hron* (AT), L.Eischer, S.Eichinger, P. A.Kyrle FIRST UNPROVOKEDVENOUSTHROMBOEMBOLISM(VTE) RISK OFRECURRENCEAMONGHETEROZYGOUSCARRIERSFACTOR II(FII)G20210AAND A AS-MO-004 Kaider, F. R.Rosendaal I. Pabinger*(AT), C.Y. Vossen, J.Lang,Conard, C.García-Dabrio, W. Miesbach,G.Palareti, P. Svensson,A. PROSPECTIVE COHOR MORTALITY INTHROMBOPHILIA:ACONTROLLEDEVALUATION FROMTHEEUROPEAN AS-MO-003 B. K.Mahmoodi*(NL),J.Brouwer, M.tenKate,W. Lijfering,N.Veeger, H.Kluin-Nelemans,J.vanderMeer Interventions forV Room210ABC Thrombophilia: ClinicalApplications 2009 MONDAY, JULY 13, akefield (US) T-TERM RESULTS FROMTHECAVENT STUDY, AMULTICENTER, T ONTHROMBOPHILIA(EPCOT) enous Thr oholm, N.Bækgaar omboembolism . H.Reitsma,L.A.Bar d, L.Panduro e, F. R.Rosendaal Room 205ABC 2:15 -2:45PM AS-MO-001 AS-MO-006 3:30 -3:45PM 3:15 -3:30PM 3:00 -3:15PM 2:45 -3:00PM 3:30 -3:45PM 3:15- 3:30PM 93

Monday Science

MONDAY, JULY 13, 2009

Biology of ADAMTS13 Room 253 ABC Chairperson: Jo’se Lo’pez (US) ADAMTS13, TTP and related disorders AS-MO-011 Jo’se Lo’pez (US) 2:15 - 2:45 PM AS-MO-012 2:45 - 3:00 PM CRYSTAL STRUCTURE OF THE EXOSITES-CONTAINING FRAGMENT OF ADAMTS13 M. Akiyama* (JP), S. Takeda, K. Kokame, J. Takagi, T. Miyata AS-MO-013 3:00 - 3:15 PM MOLECULAR MODELLING OF ADAMTS-13 METALLOPROTEINASE DOMAIN R. de Cristofaro* (IT), S. Lancellotti, N. Pozzi, V. de Filippis AS-MO-014 3:15 - 3:30 PM UNPRODUCTIVE BINDING OF ADAMTS13 TO VON WILLEBRAND FACTOR H. B. Feys* (BE), P. J. Anderson, K. Vanhoorelbeke, J. E. Sadler AS-MO-015 3:30 - 3:45 PM AMINO ACID RESIDUES R660, R661 AND Y662 WITHIN THE SPACER DOMAIN OF ADAMTS13 ARE ESSENTIAL FOR RECOGNITION AND CLEAVAGE OF VON WILLEBRAND FACTOR S. Jin* (US), X. Zheng

Biology of von Willebrand Factor Room 258 ABC Chairperson: Peter Lenting (NL) Biology of von Willebrand factor AS-MO-016 Peter Lenting (NL) 2:15 - 2:45 PM AS-MO-017 2:45 - 3:00 PM CLEARANCE OF VON WILLEBRAND FACTOR (VWF) IN TYPE 2 VON WILLEBRAND DISEASE (VWD): THE IMPLICATIONS OF VWF PROPEPTIDE (VWFPP) AND VWF:AG LEVELS S. L. Haberichter* (US), G. Castaman, P. D. James, P. A. Christopherson, F. Roheghiero, D. Lillicrap, R. R. Montgomery, for Canadian Vicenza and ZPMCB-VWD Study Groups AS-MO-018 3:00 - 3:15 PM EXPRESSION OF HUMAN TYPE 2B VON WILLEBRAND DISEASE MUTANTS IN THE VWF KO MOUSE MODEL M. Golder* (CA), C. M. Pruss, C. Hegadorn, K. Laverty, K. Sponagle, D. Lillicrap AS-MO-019 3:15 - 3:30 PM ASSOCIATIONS BETWEEN THE VON WILLEBRAND FACTOR GENE (VWF) VARIANT C.2771G>A (P.R924Q), VON WILLEBRAND FACTOR ANTIGEN (VWF:AG) AND FVIII ACTIVITY (FVIII:C) LEVELS AND ITS ROLE AS A RISK FACTOR FOR TYPE 1 VON WILLEBRAND DISEASE (VWD) N. Hickson* (UK), D. J. Hampshire, P. R. Winship, P. D. James, I. R. Peake, A. C. Goodeve, on behalf of the EU- VWD and ZPMCB-VWD Study Groups AS-MO-020 3:30 - 3:45 PM THE IMPACT OF VON WILLEBRAND FACTOR SEQUENCE CHANGES THAT AFFECT ADAMTS13- MEDIATED CLEAVAGE IN THE VWF KNOCKOUT MOUSE MODEL C. M. Pruss* (CA), M. Golder, C. Hegadorn, K. Laverty, K. Sponagle, C. Notley, Y. Chirinian, D. Lillicrap

ereBoe(S 2:15-2:45PM PHOSPHOLIPID SURFACES CRYSTAL STRUCTURESSHOWHOWPROTEINZCATALYSES ZPIINHIBITIONOFFXaON AS-MO-023 L. J.Toltl* (CA),R.C.Austin,P. C.Y. Liaw ENDOPLASMIC RETICULUM(ER)STRESS ACTIVATED PROTEIN C(APC)INHIBITSINFLAMMATION ANDAPOPTOSISBYREGULATING AS-MO-022 George Broze (US) Protein ZandZPI:Anupdate Chairperson: GeorgeBroze(US) Kamphuisen, S.Middeldorp S. Roshani*(NL),D.M.Cohn,A.Stehouwer, S.Hamers,H.Wolf, J.M.vanderPost,H.R.Büller, P. W. MOLECULAR-WEIGHT HEP RISK OFPOSTPARTUM HEMORRHAGE INWOMENRECEIVINGTHERAPEUTICDOSESOFLOW- AS-MO-030 G. Castaman*(IT),A.T WILLEBRAND FACTOR MUTATIONS PREGNANCY ANDDELIVERY INWOMENWITHVONWILLEBRANDDISEASEANDDIFFERENT AS-MO-029 M. Menegatti*(IT),R.Palla,S.Siboni,Benedik-Dolnicar DATABASE): PRELIMINARY RESULTS ON190PATIENTS ESTABLISHMENT OFAEUROPEANNETWORKRAREBLEEDINGDISORDERS (EN-RBD AS-MO-028 A. C.Mauer*(US),E.M.Barbour HISTORY PHENOTYPINGINSTRUMENTINNORMALINDIVIDUALS INITIAL DEPLOYMENTOFACOMPREHENSIVE,ONTOLOGY-BACKED, WEB-BASEDBLEEDING AS-MO-027 Rezan Kadir(UK) Women andbleedingdisorders: Newperspectives Chairperson: RezanKadir(UK) W MECHANISMS OFCOFACTOR-ASSISTED PROTEASEINHIBITIONBYPROTEINCINHIBITOR AS-MO-025 S. A.Maroney* (US),J.P. Ferrel, B.C.Cooley, A.E.Mast FIBRIN DEPOSITIONINMOUSETISSUESANDLIMITSTHROMBUSGROWTH PLATELET TISSUEFACTOR PATHWAY INHIBITOR(TFPI)PREVENTSHEPATIC ANDCEREBRAL AS-MO-024 Z. Wei, Y. Yan, A.Zhou*(UK) Gilmore, J.Ingerslev, K.Peerlink,H.Pergantou,F. Suzan,M.Spreafico, R.Waha, P. Lanzi,F. Peyvandi W Room157ABC Serpins -Inhibitors 2009 MONDAY, JULY 13, . Li*(UK),J.A.Huntington omen andBleedingDisor osetto, F ARIN . Rodeghier , N.A.Khazanov o ders , N.Levenkova,S.A.Mollah,B.Coller , C.Bidlingmaier , T . Celkan,P Room 104ABC 2:15 -2:45PM AS-MO-021 AS-MO-026 . Giangrande,R. 3:00 -3:15PM 3:30 -3:45PM 3:15 -3:30PM 3:00 -3:15PM 2:45 -3:00PM 2:45 -3:00PM 3:30 -3:45PM 3:15 -3:30PM 95

Monday Science

MONDAY, JULY 13, 2009

Platelets and Cancer Room 107 ABC Chairperson: Jerry Ware (US) The platelet paradigm in cancer AS-MO-031 Jerry Ware (US) 2:15 - 2:45 PM

AS-MO-032 2:45 - 3:00 PM THE EFFECT OF P2Y-MEDIATED ACTIVATION ON VEGF AND ENDOSTATIN RELEASE FROM PLATELETS N. M. Bambace* (US), J. E. Levis, C. E. Holmes AS-MO-033 3:00 - 3:15 PM AN ASSOCIATION BETWEEN ANTI-PLATELET DRUG USE AND REDUCED CANCER PREVALENCE IN DIABETIC PATIENTS: RESULTS FROM THE VERMONT DIABETES INFORMATION SYSTEM C. E. Holmes* (US), M. E. Ramos-Nino, B. Littenberg AS-MO-034 3:15 - 3:30 PM GENETIC VARIANTS OF PLATELET FUNCTION AND CANCER MORTALITY: A FOLLOW-UP STUDY J. D. Snoep* (NL), C. E. Holmes, F. R. Rosendaal, J. G. van der Bom AS-MO-035 3:30 - 3:45 PM PLASMA LEVELS OF MICROPARTICLE ASSOCIATED TISSUE FACTOR ACTIVITY IN PATIENTS WITH CLINICALLY SUSPECTED PULMONARY EMBOLISM WITH OR WITHOUT CANCER P. Garcia Rodriguez* (NL), H. C. J. Eikenboom, M. E. T. Tesselaar, M. V. Huisman, M. Nijkeuter, S. Osanto, R. M. Bertina

Novel Approaches to Understanding Platelet Biology Room 153 ABC Chairperson: Angel Garcia (ES) Novel strategies in platelet research: The proteomics approach AS-MO-036 Angel Garcia, (ES) 2:15 - 2:45 PM

AS-MO-037 2:45 - 3:00 PM DEFINING THE FUNCTION OF NOVEL PLATELET GENES USING A LASER THROMBOSIS MODEL IN DANIO RERIO I. I. Salles* (BE), M. N. O’Connor, A. Cvejic, N. A. Watkins, P. Burns, A. Walker, S. F. Garner, C. I. Jones, I. C. Macaulay, M. Steward, J. Zwaginga, S. L. Bray, F. Dudbridge, B. de Bono, A. H. Goodall, H. Deckmyn, D. L. Stemple, W. H. Ouwehand, on behalf of the Bloodomics consortium AS-MO-038 3:00 - 3:15 PM THE IDENTIFICATION OF ABI-1 AS NEW VASP EVH1 DOMAIN INTERACTING PARTNER IN HUMAN PLATELETS BASED ON THE “PLATELETWEB” KNOWLEDGE BASE M. Dittrich, V. Strassberger, T. Jarchau, P. Tas, U. Lewandrowski, T. Dandekar, U. Walter, I. Birschmann* (DE) AS-MO-039 3:15 - 3:30 PM STUDY OF BIMOLECULAR INTEGRIN-FIBRINOGEN INTERACTIONS UNDER A CONSTANT UNBINDING FORCE R. I. Litvinov* (US), H. Shuman, J. W. Weisel, J. S. Bennett AS-MO-040 3:30 - 3:45 PM RAPID ADHESION KINETICS OF PLATELETS UNDER VERY HIGH SHEAR D. N. Ku* (US), A. N. Para, D. L. Bark

FORMATION INLIVINGMICESUBJECTEDTOLASERINJURY ENDOTHELIAL TISSUEFACTOR CONTRIBUTESTOFIBRINGENERATION DURINGTHROMBUS AS-MO-043 R. Pawlinski*(US),N.Mackman IN ENDOTOXEMICMICE CELLULAR SOURCESOFTISSUEFACTOR THAT CONTRIBUTETOACTIVATION OFCOAGULATION AS-MO-042 Diego Mezzano(CL) Regulation ofplatelet-expressed tissuefactor Chairperson: DiegoMezzano(CL) SM-4 3:15-3:30PM U. J.H.Sachs,S.Jessen,B.Kehr GI24R: ANOVELMEMBEROFIMMUNOGLOBULIN RECEPTORONPLATELETS AS-MO-050 Z. M.Ruggeri*(US),J.N.Orje,B.Molins,S.Harvey TARGETING ONGOINGARTERIAL THROMBOSISWITHPLATELET-SPECIFIC MICROPARTICLES AS-MO-049 D.J.Kenny E. Dunne*(IE),M.C.Berndt, CADHERIN 6MODULA AS-MO-048 D. Duerschmied*(US),M.Canault,Lievens,A.Brill,S.Cifuni,Bader, D.Wagner ALPHA-CONVER SEROTONIN STIMULATES PLATELET RECEPTORSHEDDINGBYTUMORNECROSIS FACTOR- AS-MO-047 Mark Ginsberg(US) Dynamic regulation ofcell-celladhesion Chairperson: MarkGinsberg(US) N. I.Popescu*(US),C.Lupu,F COAGULATION THROUGHPHOSPHATIDYLSERINE EXPOSURE INHIBITION OFPROTEINDISULPHIDEISOMERASEONENDOTHELIALCELLSENHANCES AS-MO-045 J. Wang* (US),D.Manly, D.Kirchhofer, R.Pawlinski,N.Mackman ACTIV LEVELS OFMICROPARTICLE TISSUEFACTOR ACTIVITYCORRELATE WITHCOAGULATION AS-MO-044 V. M.Chen*(US),T. H.David,G.Merrill-Skoloff, N.Mackman, S. R.Coughlin,B.C.Furie,Furie ltltAhso n oein Room160ABC Platelet AdhesionandCohesion Room156ABC Extrinsic PathwayofCoagulation 2009 MONDAY, JULY 13, ATION INENDOTOXEMICMICE TING ENZYME(ADAM17) TES PLATELET FUNCTIONTHROUGHINTEGRIN . Lupu el, K.Clemetson,S.Santoso*(DE) , S.Mitragorti,J.Smith α IIB β 3 2:15 -2:45PM 2:15 -2:45PM AS-MO-041 AS-MO-046 3:30 -3:45PM 3:30 -3:45PM 3:00 -3:15PM 2:45 -3:00PM 3:00 -3:15PM 2:45 -3:00PM 3:15 -3:30PM 97

Monday Science

MONDAY, JULY 13, 2009

Platelet Transfusions and Polymorphisms Room 109 AB Chairperson: Sherrill Slichter (US) Current advances in platelet transfusion therapy AS-MO-051 Sherrill Slichter (US) 2:15 - 2:45 PM AS-MO-052 2:45 - 3:00 PM MODIFIED MONOCLONAL PLATELET ANTIBODIES PREVENT ANTIBODY-MEDIATED CLEARANCE OF HUMAN PLATELETS IN AN IN VIVO MODEL OF IMMUNE THROMBOCYTOPENIA T. Bakchoul* (DE), B. Boylan, G. Bein, S. Santoso, P. J. Newman AS-MO-053 3:00 - 3:15 PM THE ALPHA2 INTEGRIN (GPIA) POLYMORPHISM: THE NEW PLATELET ALLOANTIGEN CABA AND 6 NEW MUTATIONS G. Bertrand* (FR), V. Jallu, D. Saillant, D. Kervran, C. Martageix, C. Kaplan AS-MO-054 3:15 - 3:30 PM ASSESSMENT OF GENOTYPE-PHENOTYPE RELATIONSHIP FOR SIX COMMON PLATELET POLYMORPHISMS IN 286 HEALTHY SUBJECTS C. Martínez, A. I. Antón, J. Corral, T. Quiroga, O. Panes, M. L. Lozano, R. González-Conejero, R. Teruel, L. Navarro-Núñez, J. Pereira, N. Navarro, D. Mezzano, V. Vicente, J. Rivera* (ES) AS-MO-055 3:30 - 3:45 PM A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (RAISE) OF ELTROMBOPAG FOR THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) G. Cheng, M. N. Saleh, J. B. Bussel* (US), C. Marcher, S. Vasey, B. Mayer, M. Aivado, M. Arning, N. L. Stone

Inflammation and Vascular Pathobiology Room 252 AB Chairperson: Ulrich Von Adrian (US) Mechanisms and consequences of dendritic AS-MO-056 cell migration Ulrich Von Adrian (US) 2:15 - 2:45 PM AS-MO-057 2:45 - 3:00 PM PECAM-1 POLYMORPHISM IN IG DOMAIN 6 (S536N) PLAYS A ROLE IN TRANSENDOTHELIAL MIGRATION OF NEUTROPHILS B. Bayat* (DE), S. Werth, C. Andrei-Selmer, P. Newman, S. Santoso AS-MO-058 3:00 - 3:15 PM A ROLE OF THE ENDOTHELIAL P2Y1 RECEPTOR IN MONOCYTE ADHESION TO AND TRANSMIGRATION ACROSS MURINE MICROVASCULAR ENDOTHELIAL CELLS IN VITRO M. Zerr-Fouineau* (FR), B. Hechler, I. Lanois, J. Cazenave, C. Gachet AS-MO-059 3:15 - 3:30 PM HYPERCOAGULABILITY PROMOTES PLAQUE STABILITY DURING ATHEROGENESIS BY INHIBITING MONOCYTE MIGRATION THROUGH A PAR-1, PLC-BETA, PI3K, AND NO-DEPENDENT MECHANISM K. Shahzad, S. Seehaus, I. Vinnikov, H. Wang, M. Kashif, M. Thati, P. P. Nawroth, B. Isermann* (DE) AS-MO-060 3:30 - 3:45 PM CD146 AND ITS SOLUBLE FORM REGULATE MONOCYTE TRANSENDOTHELIAL MIGRATION N. Bardin* (FR), M. Blot-Chabaud, N. Despoix, A. Kebir, K. Harhouri, F. Vely, F. Dignat George

ogrGrad U) 2:15-2:45PM LIGA ALTERNATIVELY SPLICEDTISSUEFACTOR PROMOTESANGIOGENESISTHROUGH INTEGRIN AS-MO-063 J. W VITRONECTIN PROMOTESISCHEMIA-INDUCEDANGIOGENESIS AS-MO-062 Holger Gerhardt (UK) Molecular control ofangiogenicsprouting Chairperson: HolgerGerhardt(UK) M. Turu* (ES),L.Badimon,A.Luque,M.Baldellou,N.Rovira,J.Krupinski,Slevin HUMAN ADVANCED ATHEROSCLEROTIC PLAQUESUSINGLASER-CAPTUREMICROSCOPE IDENTIFICATION OFUPREGULATED PROANGIOGENICGENESININTIMALNEOVESSELSFROM AS-MO-065 M. Chrzanowska-Wodnicka* (US) VASCULAR ENDOTHELIALGROWTHFACTOR RECEPTOR2ANDINTEGRINALPHAV/BETA3 ANGIOGENIC SIGNALINGBYRAP1BINENDOTHELIALCELLSINVOLVES ACTIVATION OF AS-MO-064 Reitsma, H.Versteeg Y. W. vandenBerg*(NL),L.G.Hengel,H.R.Myers,O.Ayachi, K.(JO)ova,W. Ruf,A.C.Spek,P. H. nignss Room257AB Angiogenesis 2009 MONDAY, JULY 13, u* (US),W. P. Fay TION AS-MO-061 2:45 -3:00PM 3:15 -3:30PM 3:00 -3:15PM 3:30 -3:45PM 99

Monday Science

ORAL COMMUNICATIONS

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

* Presenting Author

Risk Factors for Venous Thrombosis I Ballroom 210 ABC

Chairpersons: Thomas Ortel (US) and Bakhtawar Mahmoodi (NL) OC-MO-001 8:00 AM - 8:15 AM MICROALBUMINURIA: A NOVEL RISK MARKER FOR VENOUS THROMBOEMBOLISM B. K. Mahmoodi* (NL), R. Gansevoort, N. Veeger, A. Matthews, G. Navis, H. Hillege, J. van der Meer OC-MO-002 8:15 AM - 8:30 AM UNIQUE WHOLE BLOOD GENE EXPRESSION PROFILES DISTINQUISH DIFFERENT CLINICAL PHENOTYPES OF VENOUS THROMBOEMBOLISM D. A. Lewis* (US), G. Stashenko, O. M. Akay, L. Price, A. Metjian, J. Chi, T. L. Ortel OC-MO-003 8:30 AM - 8:45 AM FACTOR Xa GENERATION IN ADULT INDIVIDUALS K. Brummel-Ziedins* (US), T. Ashikaga, T. Orfeo, M. Gissel, K. G. Mann, F. R. Rosendaal OC-MO-004 8:45 AM - 9:00 AM PROS1 GENE DELETIONS ARE RARE IN A POPULATION-BASED STUDY ON VENOUS THROMBOSIS M. C. Pintao* (NL), A. A. Garcia, M. C. H. de Visser, C. J. M. Doggen, P. H. Reitsma, F. R. Rosendaal OC-MO-005 9:00 AM - 9:15 AM TYPE III PROTEIN S DEFICIENCY IS ASSOCIATED WITH A HYPERCOAGULABLE STATE AND AN INCREASED RISK OF VENOUS THROMBOSIS E. Castoldi* (NL), L. F. Maurissen, D. Tormene, L. Spiezia, S. Gavasso, C. Radu, T. M. Hackeng, J. Rosing, P. Simioni OC-MO-006 9:15 AM - 9:30 AM HETEROGENEOUS PRESENTATION OF FV IN FV LEIDEN HETEROZYGOTES M. F. Whelihan* (US), M. Cushman, K. G. Mann

Resistance to Antiplatelet Therapy Room 205 ABC

Chairpersons: Koneti Rao (US) and Carlo Patrono (IT) OC-MO-007 8:00 AM - 8:15 AM IMPACT OF THE CYP2C19*17 ALLELE ON PLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS SUFFERING FROM NON–ST ELEVATION ACUTE CORONARY SYNDROME C. Frere* (FR), T. Cuisset, P. Morange, L. Camoin-Jau, J. Bonnet, M. Alessi, J. Hulot OC-MO-008 8:15 AM - 8:30 AM THE RELATIVE CONTRIBUTION OF THE CYP2C19*2 POLYMORPHISM IN THE LOW RESPONSIVENESS TO CLOPIDOGREL IN THE VASP02 STUDY B. Aleil, L. Jacquemin, F. de Poli, M. Zaehringer, J. P. Collet, G. Montalescot, C. Léon, J. P. Cazenave, M. C. Dickele, J. P. Monassier, C. Gachet* (FR)

100 OC-MO-010 8:45 AM - 9:00 AM - 8:45AM 8:45 AM - 8:30AM OC-MO-010 OC-MO-009 ORAL COMMUNICATIONS OC-MO-016 8:45 AM - 9:00 AM - 8:45AM 8:45 AM - 8:30AM 8:30 AM - 8:15AM OC-MO-017 9:30 AM - 9:15AM OC-MO-016 9:15 AM - 9:00AM OC-MO-015 OC-MO-014 OC-MO-013 OC-MO-012 OC-MO-011 acradTrmoi:Ciia set Room253ABC Cancer andThrombosis: ClinicalAspects 2009 MONDAY, JULY 13, ANTICOAGULANT A. Y. Lee*(CA),L.Elit, J.Julian,P. Hoskins,D.Julian,S.Parpia,M.Levine STUDY PHASEIIRANDOMIZED DIAGNOSEDOVARIAN CANCER: A NEWLY THE EFFECTOFLOWMOLECULAR WEIGHTHEPARIN DALTEPARIN IN A. Y. Lee*(CA),S. Parpia, J.Julian,F. Rickles,M.Prins,Levine RISK F P. Prandoni V. Pengo*(IT),F. Noventa,U.Gallo, A. Grion,G.Denas,S.Padayattil, BASED STUDY POPULATION- CHRONIC WARFARIN USE AND INCIDENTCANCER: A F. F. vanDoormaal*(NL),J.M.B.Otten VENOUS THROMBOSIS.THETROUSSEAUINVESTIGA SCREENING FORMALIGNANCY J. Douketis*(CA),C.Gu, A. Piccioli, A. Ghirarduzzi,V. Pengo,P. Prandoni FIRSTEPISODEOF VENOUS THROMBOEMBOLISM? A WHA Chairpersons: PaoloSimioni(IT)and R. F. Storey S. B.G.Patil*(UK),H.M.Judge,R.J.Buckland, A. Jakubowski, BLOCKADE RIF C. BalDitSollier, N.Berge,B.Boval,L.Drouet*(FR) CLOPIDOGREL OFPLATELET RESPONSETO VARIABILITY MONITORING FUNCTIONAL OFTHEVARIOUS EXVIVOTESTS SENSITIVITY DIFFERENTIAL F. Sofi*(IT),B.Giusti, A. Gori,R. Marcucci,R. Abbate, G.Gensini META-ANALYSIS A RECURRENCES INP CYTOCHROME P4502C19 POLYMORPHISM AND CARDIOVASCULAR P. Harrison*(UK),L.Silver, H.Segal, A. Syed,Z.Mehta,P. Rothwell A AFTER ACUTE VASCULAR EVENTS: AND PLATELET REACTIVITY LONG TERMPROGNOSTICVALUE OF ASPIRIN NON-RESPONSIVENESS POPULATION-BASE COHORTSTUDY AMPICIN INCREASESTHEEXTENTOFP2Y12RECEPT T ISTHELONG-TERMRISKFORNEWCANCERINP ACT ORS FORRECURRENTTHROMBOSIS CIVDB LPDGE ADMINISTRATION CLOPIDOGREL ACHIEVED BY -RELA TET NE LPDGE TREATMENT: ATIENTS UNDERCLOPIDOGREL TED BLEEDINGINCANCERPATIENTS IN P Agnes Lee(CA) A TIENTS WITHIDIOP AND T ORS ATIENTS WITH A OR THIC 8:00 AM -9:30 AM 9:00 AM -9:15 AM 8:00 AM -8:15 AM 101

Monday Orals

ORAL COMMUNICATIONS

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

OC-MO-018 9:15 AM - 9:30 AM PREVENTION OF THROMBOEMBOLIC EVENTS IN ADVANCED LUNG CANCER PATIENTS RECEIVING CHEMOTHERAPY: A COMBINED ANALYSIS FROM PROTECHT AND TOPIC-2 STUDIES M. Verso* (IT), G. Agnelli, G. Gussoni

Genetics of Venous Thrombosis I Room 258 ABC

Chairpersons: Pierre Morange (FR) and Astrid van Hylckama (NL) OC-MO-019 8:00 AM - 8:15 AM PROTEIN S DEFICIENCY IN A LARGE PANEL OF SMALL THROMBOPHILIA FAMILIES (GIFT STUDY) M. C. Pintao, J. Veth, R. van Minkelen, H. L. Vos, P. H. Reitsma, R. M. Bertina, M. C. H. de Visser* (NL) OC-MO-020 8:15 AM - 8:30 AM SINGLE NUCLEOTIDE POLYMORPHISMS IN AKT3 ARE ASSOCIATED WITH DEEP VEIN THROMBOSIS L. A. Bare* (US), I. D. Bezemer, A. R. Arellano, C. H. Tong, P. H. Reitsma, J. J. Devlin, F. R. Rosendaal OC-MO-021 8:30 AM - 8:45 AM A MULTI-STAGE / MULTI-DESIGN STRATEGY IDENTIFIES A NEW QTL FOR VON WILLEBRAND FACTOR ON CHROMOSOME 6–A POSSIBLE LINK WITH VTE? G. Antoni* (FR), N. Saut, Y. Luo, G. Burgos, S. Heath, C. Perret, M. Desuremain, C. Biron-Andreani, J. Schved, G. Pernod, P. Galan, D. Zelenika, I. Juhan-Vague, M. Alessi, L. Drouet, S. Visvikis-Siest, M. Lathrop, P. S. Wells, J. Emmerich, F. Gagnon, P. Morange, D. Tregouet OC-MO-022 8:45 AM - 9:00 AM FIBRINOGEN MUTATIONS SPECIFIC TO CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION T. A. Morris* (US), J. J. Marsh, P. G. Chiles, N. Liang, V. L. Woods OC-MO-023 9:00 AM - 9:15 AM GENETIC VARIATIONS AND ELEVATED LEVELS OF FIBRINOGEN AND THE RISK OF VENOUS THROMBOSIS A. van Hylckama Vlieg* (NL), R. G. J. van der Voort, C. J. M. Doggen, F. R. Rosendaal OC-MO-024 9:15 AM - 9:30 AM GENE DISCOVERY FOR VENOUS THROMBOSIS IN A LARGE PROTEIN C DEFICIENT FAMILY C. Y. Vossen* (NL), S. J. Hasstedt, P. W. Callas, C. C. Elbers, B. P. C. Koeleman, F. R. Rosendaal, E. G. Bovill

102 OC-MO-026 8:15 AM - 8:30 AM - 8:15AM 8:15 AM - 8:00AM OC-MO-026 OC-MO-025 ORAL COMMUNICATIONS OC-MO-032 8:15 AM - 8:30 AM - 8:15AM 9:30 AM - 9:15AM 9:15 AM - 9:00AM OC-MO-032 9:00 AM - 8:45AM OC-MO-031 8:45 AM - 8:30AM OC-MO-030 OC-MO-029 OC-MO-028 OC-MO-027 eohla lnclI Room104ABC Hemophilia: ClinicalI Room157ABC Antiphospholid Syndrome: BasicandClinicalAspects 2009 MONDAY, JULY 13, F. G.H.Hill J. W. Ironside* (UK), A. Peden,M.W. Head,D.M.Keeling,C.Millar, PATIENT INTHEUK DETECTION OFPRPSCINTHESPLEEN OF AN ADULT HAEMOPHILIC C. L.Madeira,R.Layman,M.E.Devera, P. A. Fontes,M.V. Ragni*(US) FVIII PRODUCTION Chairpersons: JorgenIngerslev(DK)andThomas Abshire (US) P G. M. A. vanOs*(NL),J.C. M.Meijers,R. T. Urbanus,R.H.W. M.Derksen, ANTICOAGULANT DEPENDENT TO DISTINGUISHBETWEENBETA2-GLYCOPROTEIN RAPID I ASSAY A C. Selton-Suty, J.Bruntz,V. Regnault, T. Lecompte,D.Wahl S. Zuily*(FR),P. Dotto,C.Perret-Guillaume, E.Bodé-Dotto,deMaistre, STUDIES META-ANALYSISERYTHEMATOSUS: OFECHOCARDIOGRAPHIC A ANTIPHOSPHOLIPID THE RISKOFHEARTVALVE DISEASE ASSOCIATED WITH E. Bison, A. Banzato,S.Padayattil,D.Barcellona, A. Ruffatti V. Pengo*(IT),C.Legnani,F. Marongiu,P. Gresele,S. Testa, G.Denas, LABORA ANTIPHOSPHOLIPID SYNDROME(APS) AND TRIPLEPOSITIVE COURSEOFPATIENTS WITH LONG-TERM CLINICAL R. Vormittag* (AT), S.Panzer, C. Ay, P. Quehenberger, S.Koder, I.Pabinger THROMBOSIS INPATIENTS WITHTHELUPUS ANTICOAGULANT (LAC) HIGH LEVELSOFSERUMIMMUNOGLOBULINGPREDICTTHERISK T. Shilagard,E.Papalardo,G.Vargas, K.Hajjar S. Pierangeli*(US),Z.Romay-Penabad,G.Montiel-Manzano, MICE AMELIORATEDDEFICIENT (ABS) ARE IN ANNEXINA2 P D. T. Le,D.Ho,J.O.Olsen,B.Østerud*(NO) FOR THROMBOSIS POSSIBLERISKFACTOR LUPUS ANTICOAGULANT - A INDUCED BY INMONOCYTESOFWHOLEBLOOD TISSUE FACTOR ACTIVITY Chairpersons: OO IE NOANRA RECIPIENT NORMAL DONOR LIVERINTO A . G.deGroot ATHOGENIC EFFECTSOF ANTIPHOSPHOLIPID (APL) ANTIBODIES T R TESTS ORY AND PROTHROMBINDEPENDENTLUPUS Armando Tripodi (IT)andVittorio Pengo(IT) FE RNPATTO FAHEMOPHILIA AFTER TRANSPLANTATION OF A ANTIBODIES INP A TIENTS WITHSYSTEMICLUPUS 8:00 AM -9:30 AM 8:00 AM -8:15 AM 103

Monday Orals

ORAL COMMUNICATIONS

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

OC-MO-033 8:30 AM - 8:45 AM EXTENT OF EXPOSURE TO AND RISK STRATIFICATION OF UK PATIENTS REATED WITH PLASMA CONCENTRATES WITH CONTRIBUTION FROM A DONOR WHO DEVELOPED VCJD F. G. H. Hill* (UK), A. Zaman, N. Connor, C. Millar, J. Ironside, N. Gill OC-MO-034 8:45 AM - 9:00 AM PRIMARY AND SECONDARY PROPHYLAXIS IN CHILDREN WITH HAEMOPHILIA A REDUCES BLEEDING FREQUENCY AND ARTHROPATHY DEVELOPMENT COMPARED TO ON-DEMAND TREATMENT: A 10-YEAR, RANDOMIZED, CLINICAL TRIAL A. Gringeri* (IT), B. Lundin, S. von Mackensen, L. G. Mantovani, P. M. Mannucci OC-MO-035 9:00 AM - 9:15 AM PLASMA DERIVED (PD) AND RECOMBINANT (R) FACTOR VIII (FVIII) CONCENTRATES INDUCE A DIFFERENT RATE OF INHIBITOR DEVELOPMENT IN HEMOPHILIA A PATIENTS. A SYSTEMATIC REVIEW OF THE LITERATURE A. Iorio* (IT), M. Marcucci, E. Marchesini, P. Mannucci OC-MO-036 9:15 AM - 9:30 AM A CASE-CONTROLLED DANISH-RUSSIAN COMPARATIVE STUDY OF CLINICAL OUTCOMES IN YOUNGER SEVERE HAEMOPHILIA PATIENTS TREATED WITH PROPHYLAXIS COMPARED TO THOSE MANAGED WITH ON-DEMAND TREATMENT J. Ingerslev* (DK), S. Lethagen, L. Hvitfeldt Poulsen, E. Lopatina, I. Tentsova, O. Yastrubinetskaya, O. P. Plyushch

Diagnosis of Pulmonary Embolus Room 107 ABC

Chairpersons: Menno Huisman (NL) and Marc Righini (CH) OC-MO-037 8:00 AM - 8:15 AM THE SAFETY OF EXCLUDING ACUTE PULMONARY EMBOLISM BASED ON AN UNLIKELY CLINICAL PROBABILITY BY THE WELLS RULE AND A NORMAL D-DIMER CONCENTRATION F. A. Klok* (NL), J. D. Snoep, S. M. Pasha, I. C. M. Mos, S. Siragusa, R. J. Goekoop, M. A. Rodger, M. V. Huisman OC-MO-038 8:15 AM - 8:30 AM COMPARISON OF THE UNSTRUCTURED CLINICIAN GESTALT, THE WELLS SCORE AND THE REVISED GENEVA SCORE TO ESTIMATE THE PRETEST PROBABILITY FOR SUSPECTED PULMONARY EMBOLISM P. Roy* (FR), C. Coroller-Bec, S. Dambrine, M. Righini, J. Callahan, A. Perrier, H. Bounameaux, G. Le Gal OC-MO-039 8:30 AM - 8:45 AM IMPLEMENTATION OF A DECISION RULE AND A D-DIMER ASSAY IN THE DIAGNOSIS OF PULMONARY EMBOLISM N. S. Gibson* (NL), R. A. Douma, M. Sohne, A. Squizzqato, H. R. Buller, V. E. A. Gerdes

104 OC-MO-041 9:00 AM - 9:15 AM - 9:00AM 9:00 AM - 8:45AM OC-MO-041 OC-MO-040 ORAL COMMUNICATIONS OC-MO-048 9:15 AM - 9:30 AM - 9:15AM 8:45 AM - 8:30AM 8:30 AM - 8:15AM 8:15 AM - 8:00AM OC-MO-048 OC-MO-047 9:30 AM - 9:15AM OC-MO-046 OC-MO-045 OC-MO-044 OC-MO-043 OC-MO-042 ehnsso ltltAtvto Room153ABC Mechanisms ofPlateletActivationI 2009 MONDAY, JULY 13, CYT ACTIVATION Scherrer, M.F. Hoylaerts,P. Carmeliet, J.W. M.Heemskerk K. Bledzka*(US), Y. Q.Ma,J.Qin,E. F. Plow INTERACTIONS OFKINDLIN-2 M. Das*(US),S.Ithychanda,J.Qin,E. F THE MIGFILIN-FILAMININTERACTION REGULA U. P JUNCTIONAL M. L.Jones*(UK), PROTEIN TYROSINEPHOSPHATASE PTP1B SIGNALLING PATHWAY FROMINTEGRINTO GPVIINVOLVING THE GPVI-INDUCED PLA ENHANCE PARADOXICALLY ANTAGONISTS OFINTEGRINGPIIB/IIIA J. M.E.Cosemans*(NL),I.C. ACTIVATION AND THROMBUSSTABILIZATION: INVOLVEMENT OF AKT HUMAN GAS6CONTRIBUTESTO LATE INTEGRIN ALPHAIIBBETA3 S. Kim*(US),J.Belcher, B.NagyJr, K.Bhavaraju,F. F. Safadi THROUGH INTEGRIN-MEDIA REGULATES PLATELET FUNCTION OSTEOACTIVIN POSITIVELY Chairpersons: WolfgangBergmeier(US)andJonathanN.Thon F. W. G.Leebeek,H.R.Buller G. L.vanSluis*(NL),R. A. Douma,M.Sohne,P. W. Kamphuisen, UTILITY INCREASE THECLINICAL TO EMBOLISM INCANCERPATIENTS: AN EXPLORATIVE STUDY TO RULEOUTPULMONARY PROBABILITY D-DIMER AND CLINICAL L. Bressollette,G.Meyer, A. Perrier, H.Bounameaux M. Righini*(CH),G.LeGal,D. Aujesky, P. Roy, O.Sanchez,F. Verschurren, EMBOLISM SUSPECTED PULMONARY COMPLETE VENOUSUL J. Kjærgaard,U.S.Kristoffersen, A. Kjær J. Mortensen*(DK),H.Gutte,C.V. Jensen,P. V. D.Recke,C.L.Petersen, LOW ORVENTILATION/PERFUSION SPECTCOMBINEDWITH ANGIOGRAPHY MDCT- EMBOLISMWITHPULMONARY DETECTION OFPULMONARY IN PLATELETS 3-DEPENDENTCONTRACTILE SIGNALING IIBBETA INTEGRIN ALPHA . Naik*(US),M.U.Naik OPLASMIC T -DOSE CT ADHESION MOLECULE-A AILS EE CIAIN EELN FEEDBACK TELET ACTIVATION,A REVEALING T . Harper TRASOUND INOUTPATIENTS WITH TED SIGNALING , E.W AND T A. Munnix,L.J.Schurgers, . Aitken, A. W. Poole ALIN WITHINTEGRINBET . Plow NEGA TIVEL TES INTEGRIN REGULATES Y A. Angelillo- 8:00 AM -9:30 AM A 9:00 AM -9:15 AM 8:45 AM -9:00 AM 105

Monday Orals

ORAL COMMUNICATIONS

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

Hospitalization and Venous Thrombosis Room 156 ABC

Chairpersons: Patrick Mismetti (FR) and Alex Spyropoulos (US) OC-MO-049 8:00 AM - 8:15 AM A RISK ASSESSMENT MODEL FOR THE IDENTIFICATION OF HOSPITALIZED MEDICAL PATIENTS AT RISK OF VENOUS THROMBOEMBOLISM S. Barbar, D. Tormene, M. Perlati, B. Brandolin, P. Simioni, A. Pagnan, P. Prandoni* (IT) OC-MO-050 8:15 AM - 8:30 AM BIOLOGICAL AND CLINICAL PREDICTORS OF BLEEDING IN 999 PATIENTS TREATED WITH FONDAPARINUX AFTER MAJOR ORTHOPAEDIC SURGERY: THE POP-A-RIX STUDY FROM THE GETHCAM INVESTIGATORS P. Mismetti* (FR), E. Presles, X. Delavenne, P. Zufferey, J. Barré, P. Nguyen, J. Borg, N. Rosencher, S. Laporte OC-MO-051 8:30 AM - 8:45 AM ALIGNMENT TO PROPHYLAXIS GUIDELINES AND OCCURRENCE OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP AND KNEE REPLACEMENT R. Selby* (CA), B. Borah, H. McDonald, J. Henk, M. Crowther, P. Wells OC-MO-052 8:45 AM - 9:00 AM VENOUS THROMBOEMBOLISM RISK FACTORS IN ACUTELY ILL HOSPITALIZED MEDICAL PATIENTS: FINDINGS FROM THE IMPROVE REGISTRY A. C. Spyropoulos* (US), F. A. Anderson, G. Fitzgerald, H. Decousus, V. Tapson OC-MO-053 9:00 AM - 9:15 AM PREDICTORS OF VENOUS THROMBOEMBOLISM (VTE) AND BLEEDING IN 3600 ACUTELY ILL MEDICAL PATIENTS RECEIVING THROMBO- PROPHYLAXIS S. Laporte* (FR), G. F. Pineo, C. Chapelle, J. Liotier, F. Kleber, P. Mismetti OC-MO-054 9:15 AM - 9:30 AM IMPACT OF AGE, BODY MASS INDEX, AND RENAL IMPAIRMENT ON VENOUS THROMBOEMBOLISM RISK AND PROPHYLAXIS PRACTICES IN THE ACUTE HOSPITAL CARE SETTING: A SUBANALYSIS OF THE ENDORSE SURVEY F. Anderson* (US), A. Cohen, V. Tapson, J. Bergmann, S. Goldhaber, A. Kakkar

Regulation of the Initiation of Coagulation Room 160 ABC

Chairpersons: Bjarne Østerud(NO)and Christian Furlan-Freguia (US) OC-MO-055 8:00 AM - 8:15 AM ZINC-CONTAINING PROTEIN S INHIBITS EXTRINSIC FACTOR X ACTIVATING COMPLEX INDEPENDENTLY OF TISSUE FACTOR PATHWAY INHIBITOR N. L. Fernandes* (US), M. J. Heeb

106 OC-MO-057 8:30 AM - 8:45 AM - 8:30AM 8:30 AM - 8:15AM OC-MO-058 OC-MO-057 OC-MO-056 ORAL COMMUNICATIONS OC-MO-064 8:45 AM - 9:00 AM - 8:45AM 8:45 AM - 8:30AM OC-MO-065 OC-MO-064 9:15 AM - 9:00AM OC-MO-063 OC-MO-062 OC-MO-061 OC-MO-060 OC-MO-059 atrVadFco IIRoom102AB Factor VandVIII 2009 MONDAY, JULY 13, LIMITING ITSCOFACTOR EFFICIENCY T INTRACELLULAR PROCESSINGOFVWF THE ROLEOFN- LINKED GLYCANS INTHE EXPRESSION AND Y. Meslier*(FR),S. André, M. Teyssandier, S.V. Kaveri,S.Lacroix-Desmazes REDUCTION OFTHE S. CHAIN OFCOAGULA APC-MEDIATED CLEAVAGE SITESFOUNDINTHE HEAVYNOVEL C. Négrier J. Plantier*(FR),V. Rolli,C.Ducasse, Y. Dargaud,N.Enjolras, H.Boukerche, ACTIV P A PROTHROMBINASE INTHE ACTIVATION OFPRETHROMBIN-1CANBE DIFFERENCESBETWEENHUMAN AND BOVINE FUNCTIONAL Chairpersons: KoenMertens(NL)andLaurentBurnier(CH) (FR) P. Gueguen,I.Badirou,G.Cherel,R.Pendu,C.V. Denis,O.D.Christophe* DETERMINE ITSHALF-LIFEINVIVO TWO RESIDUESINTHE A. Puchta*(CA),B.J.Clarke,W REPEATED ACTIVATION SITE A ANNEXIN VVIA FACTOR VIIRETAINS FUNCTIONWHENFUSEDTO ALBUMIN OR C. Øie*(NO),E.Brodin,I.Hilden,R. Appa, B.Smedsrød,J.Hansen RAT MODEL FACTOR PATHWAY INHIBITOR IN A ELIMINATION OFHUMANRECOMBINANTMAMMALIANTISSUE J. Cho*(US),D.R.Kennedy, G.Merrill-Skoloff, B.C.Furie,Furie LASER-INDUCED V EXTRACELLULAR PROTEINDISULFIDEISOMERASEFOLLOWING BETA3 INTEGRINS ARE REQUIREDFORTHE ACCUMULATION OF T DISULFIDE BOND REDOX PROPERTIESOFTHETISSUEFACTOR MEMBRANE-PROXIMAL TRANSFER OF ANTI-FACTOR VIIIIGG IN FACTOR VIII-DEFICIENTMICEFOLLOWINGMATERNO-FETAL . . M.Brophy*(AU),H.P. Liang,P. J.Hogg . TTRIBUTED T A. J.McKinnon*(UK), Y T . Kim*(CA),R.Manuel,M.E.Nesheim ran* (SE),B.Dahlback A TED FACTOR XCLEAVES FACTOR VIII AT ARGININE 562 O THECOOH-TERMINUSOFF SUA NUYINLIVEMICE ASCULAR INJURY TION F NIFCO IIHMRLIMMUNE RESPONSE ANTI-FACTOR VIIIHUMORAL A. C.K.Chion,G. Birdsey ACTIV ACT . P A TION PEPTIDEOFF OR V . Shef a field ACT , M. OR V A. Laf ACTOR X a HEA fan VY 8:00 AM -9:30 AM CHAIN 8:45 AM -9:00 AM 9:00 8:15 8:00 9:15 AM -9:15 AM -8:30 AM -8:15 AM AM -9:30 AM AM AM 107

Monday Orals

ORAL COMMUNICATIONS

MONDAY, JULY 13, 2009 8:00 AM - 9:30 AM

OC-MO-066 9:15 AM - 9:30 AM THE ACTIVATED PLATELET MEMBRANE DIRECTS PROTHROMBIN ACTIVATION THROUGH A PATHWAY DISTINCT FROM THAT ON PHOSPHOLIPID VESICLES J. P. Wood* (US), J. R. Silveira, P. B. Tracy

Endothelial Cell Signaling Room 252 AB

Chairpersons: Meghna Naik (US) and Magdalena Chrzanowska-Wolnicka (US) OC-MO-067 8:00 AM - 8:15 AM ROLE OF THE SMALL GTPASE RAB27A IN EXOCYTOSIS OF WEIBEL- PALADE BODIES FROM ENDOTHELIAL CELLS R. Bierings* (UK), B. Patel, L. Knipe, L. Hewlett, T. Carter, M. J. Hannah OC-MO-068 8:15 AM - 8:30 AM DIFFERENTIAL VASP PHOSPHORYLATION CONTROLS ACTIN CYTOSKELETON REMODELING S. Seifert* (DE), P. M. Benz, C. Blume, S. Wilhelm, J. Waschke, K. Schuh, T. Muenzel, F. B. Gertler, T. Renné OC-MO-069 8:30 AM - 8:45 AM A ROLE FOR THE ENDOTHELIAL TETRASPANIN TSPAN18 IN CALCIUM SIGNALLING D. Colombo, V. L. Heath, J. M. J. Herbert, R. Bicknell, S. P. Watson, M. G. Tomlinson* (UK) OC-MO-070 8:45 AM - 9:00 AM PHOSPHOLIPASE D, BUT NOT CALCIUM OR CYCLIC AMP, IS REQUIRED FOR REGULATED SECRETION OF VWF INDUCED BY B5 SUBUNITS OF SHIGA-LIKE TOXIN TYPE 2 J. Huang* (US), F. Liu, E. Sadler OC-MO-071 9:00 AM - 9:15 AM JAM-A NEGATIVELY REGULATES VASCULAR PERMEABILITY: ENHANCED VASCULAR PERMEABILITY IN JAM-A NULL MICE IS VEGF-DEPENDENT M. U. Naik* (US), U. P. Naik OC-MO-072 9:15 AM - 9:30 AM ANTI-DENGUE NS1 ANTIBODY INDUCES HEME OXYGENASE- 1 GENE EXPRESSION IN ENDOTHELIAL CELLS P. Rahayu, S. Naidu, A. Rachman, S. Immenschuh, S. Santoso* (DE)

Fibrin Clot Structure Room 257 AB

Chairpersons: Susan Lord (US) and Rusten Litvinov (US) OC-MO-073 8:00 AM - 8:15 AM THE PROCOAGULANT PHENOTYPE OF THE CELL DICTATES FIBRIN CLOT STRUCTURE R. A. Campbell* (US), K. A. Overmyer, A. S. Wolberg OC-MO-074 8:15 AM - 8:30 AM SELECTIVE DETECTION OF FREE PLASMIN USING A CHROMOGENIC SUBSTRATE BOUND TO AGAROSE BEADS T. A. Mewhort-Buist* (CA), L. R. Berry, A. K. C. Chan

108 OC-MO-077 9:00 AM - 9:15 AM - 9:00AM 9:00 AM - 8:45AM 8:45 AM - 8:30AM OC-MO-077 OC-MO-076 OC-MO-075 ORAL COMMUNICATIONS CM-8 4:45PM-5:00 4:30PM-4:45 4:15PM-4:30 4:00PM-4:15 OC-MO-083 9:30 AM - 9:15AM OC-MO-082 OC-MO-081 OC-MO-080 OC-MO-079 OC-MO-078 Pr Ballroom 210ABC Venous Thrombosis: ClinicalCourse 2009 MONDAY, JULY 13, e-clinical StudiesofNovelFactor IXConcentrates R. M.Bertina,P G. CHARACTERIZATION OFFACTOR IX-FC MONOMER BIOCHEMICAL Chairpersons: PaulMonahan(US)and JennyGoudemand(FR) N. J.G.M.Veeger, M.Visser, W. Lijfering,J.vanderMeer I. M.vanSchouwenburg*(NL),B.K.Mahmoodi,R. THROMBOSIS INSUBJECTSWITHPREVIOUSVENOUS ONTHERISKOF ARTERIAL POPULATION BASEDCOHORTSTUDY I. Martinelli*(IT),P. Bucciarelli, S.Passamonti, T. Battaglioli,P. M. Mannucci PROSPECTIVECOHORTSTUDY THROMBOSIS: A VEIN COURSEOFCEREBRAL THE LONG-TERMCLINICAL R. H.White*(US),B.Danielsen UNPROVOKED VTE SURGER RECURRENT VENOUSTHROMBOEMBOLISM(RVTE) AFTER F. R.Rosendaal L. E.Flinterman*(NL), MORT Chairpersons: MarcRodger(CA)andLindaFlinterman(NL) E. OUTCOME REACTION ORCLINICAL CARDIOVASCULAR DISEASES,BUTNOTWITH ACUTE PHASE ELEV S. M.Nordstrom*(US),B.C.Sos, T. S.Fong,E.J.Weiss THROMBOSIS INSTAT5-DEFICIENT MICE TO INCREASED FIBRINCLOTFORMATION AND SUSCEPTIBILITY N. J.Mutch*(UK),S.UittedeW THE RESISTANCE OFCLOTSTO FIBRINOLYSIS POLYPHOSPHATE MODIFIES FIBRIN STRUCTURE AND INCREASES C. Longstaf ACTIVATION INFIBRINMATRICES OFVARYING ARCHITECTURE PLASMINOGEN KINETICS OFFIBRINDISSOLUTIONINITIATED BY THROMBOSIS Y T . Cheung*(NL),H.L.V oby* (US),R. TDFBIOE AM’RATIO IS ASSOCIATEDATED WITH FIBRINOGENGAMMA’ ALITY Y -ASSOCIA f* (UK),L.Szabó,K.Kolev AND RECURRENCE T . deMaat . Peters, A. J.Bitonti TED VTE:COMP A. vanHylckamaVlieg,S.C.Cannegieter os, M.J.Kruip,H.denHertog,P illige, R.Engel,H.Philippou, A. S. Ariens AFTER A FIRST VENOUS FIRST AFTER A ARISON WITHR T . Gansevoort, VTE AFTER . J.Koudstaal, , 4:00 PM-5:00 4:00 PM-4:15 Room 205ABC 109

Monday Orals

ORAL COMMUNICATIONS

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

OC-MO-084 4:15 PM - 4:30 PM DOSE RESPONSE AND PROLONGED EFFECT OF 40K PEG-FIX ON BLEEDING IN HEMOPHILIA B MICE T. Elm* (DK), H. Oestergaard, M. Tranholm OC-MO-085 4:30 PM - 4:45 PM THE PHARMACOKINETICS OF A LONG-ACTING FACTOR IX (40K PEG-RFIX) IN MINIPIGS SUGGESTS AT LEAST A ONCE-WEEKLY DOSING REGIME L. Hansen, H. Ostergaard, M. Tranholm, H. Agersoe* (DK) OC-MO-086 4:45 PM - 5:00 PM IB1001, A NEW RECOMBINANT FACTOR IX PREPARATION: INITIAL SAFETY AND CHARACTERIZATION E. D. Gomperts* (US), M. Lee, T. Nichols, M. Griffith

Hormone Therapy in Women Room 253 ABC

Chairpersons: Cornelis Kluft (NL) and Catherine Bagot (UK) OC-MO-087 4:00 PM - 4:15 PM SHOULD WE CLASSIFY WOMEN WHO DEVELOP VENOUS THROMBOSIS ON ESTROGEN AS HAVING PROVOKED OR UNPROVOKED VENOUS THROMBOEMBOLISM? RESULTS FROM THE REVERSE STUDY G. Le Gal* (FR), M. Carrier, M. Rodger OC-MO-088 4:15 PM - 4:30 PM THROMBIN GENERATION IS INCREASED IN POST MENOPAUSAL WOMEN USING HORMONE REPLACEMENT THERAPY ADMINISTERED BY THE ORAL BUT NOT THE TRANSDERMAL ROUTE C. N. Bagot* (UK), M. S. Marsh, M. Whitehead, R. Sherwood, L. Roberts, R. K. Patel, R. Arya OC-MO-089 4:30 PM - 4:45 PM PEAK THROMBIN GENERATION CORRELATES WITH ESTRADIOL LEVELS IN WOMEN WHO USE HORMONE REPLACEMENT THERAPY ADMINISTERED BY THE ORAL BUT NOT THE TRANSDERMAL ROUTE C. N. Bagot* (UK), M. S. Marsh, M. Whitehead, R. Sherwood, L. Roberts, R. K. Patel, R. Arya OC-MO-090 4:45 PM - 5:00 PM THE EFFECT OF MONOPHASIC ORAL CONTRACEPTIVE REGIMENS ON FACTOR VII-ACTIVATING PROTEASE - A RANDOMIZED MULTICENTRE STUDY J. J. Sidelmann* (DK), S. O. Skouby, C. Kluft, U. Winkler, F. Vitzthum, H. Schwarz, J. Jespersen

110 CM-9 4:15PM-4:30 4:00PM-4:15 OC-MO-092 OC-MO-091 ORAL COMMUNICATIONS CM-9 4:45PM-5:00 4:00PM-4:15 4:45PM-5:00 OC-MO-098 4:30PM-4:45 OC-MO-097 OC-MO-096 OC-MO-095 OC-MO-094 OC-MO-093 niogln ecin fAtvtdPoenCRoom157ABC Anticoagulant ReactionsofActivatedProtein C Room258ABC Thrombosis inCancer:ClinicalCourse 2009 MONDAY, JULY 13, E. A. Norstrom*(SE), Y. Sun,B.Dahlback GLA-DOMAIN MUT G. Salvagno*(IT),Lippi,M.Franchini, G.Guidi,B.Dahlback SYSTEM INTHROMBINGENERATION ASSAY ANTICOAGULANT ACTIVITY GLA B. Dahlbäck M. J.Krisinger*(SE),L.Guo,G.Salvagno,C.Guidi,Lippi, MEMBRANE MOUSE RECOMBINANTPROTEINCVARIANTS WITHENHANCED P. Y. Kim*(CA),M.E.Nesheim ACTIVATION PROTEIN CMEASUREDINREAL-TIMEDURINGPROTHROMBIN ACTIVATED BY DOWN REGULATION OFPROTHROMBINASE ACTIVITY Chairpersons: GuidoTans (NL)andLaurentMosnier(US) L. diGennaro*(IT),R.Marfisi,Marchioli,Landolfi POL THROMBOTIC DIATHESIS AND VASCULAR RISKFACTORS IN S. M.Siragusa*(IT) OF THELOWERLIMBSINCANCERPATIENTS VEINTHROMBOSIS DURATION OF ANTICOAGULANTS AFTER DEEP VEINTHROMBOSISFOR ASSESSING THEOPTIMAL RESIDUAL M. GiorgiPierfranceschi,G. Agnelli, S.Siragusa,W. Ageno F. Dentali*(IT),J.Vitale, C.Nitti,D.Imberti,Becattini, A. Malato, A. Salvi, PATIENTS PROGNOSTIC RELEV H. R.Büller R. A. Douma*(NL),M.G.Kok,L.Verberne, P. W. Kamphuisen, PATIENTS: PREVALENCE AND CONSEQUENCE ASYMPTOMATIC VENOUSTHROMBOEMBOLISMINCANCER Chairpersons: CharlesFrancis(US)andFrancescoDentali(IT) MOUSE PLASMA ANTICOAGULANT YCYTHEMIA DOMAIN-MUT AFFINITY VERA: GENDERRELATED DIFFERENCES A A ACTIVITY TED HUMANPROTEINSCEXHIBITENHANCED TED ANCE OF ASYMPTOMATIC VTEINCANCER AND HYPER-ANTICOAGULANT ACTIV ON PLA ATED PROTEINCEXHIBITSENHANCED TELET SURFACES ACTIVITY 4:00 PM-5:00 IN 4:30 PM-4:45 4:15 PM-4:30 111

Monday Orals

ORAL COMMUNICATIONS

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

Novel Mechanisms of Antiplatelet Therapy Room 104 ABC

Chairperson: Athan Kuliopulos (US) and Pamela Couley (US) OC-MO-099 4:00 PM - 4:15 PM THE NEW TYROSINE-KINASE INHIBITOR AND ANTI-CANCER DRUG DASATINIB REVERSIBLY AFFECTS PLATELET ACTIVATION IN VITRO AND IN VIVO B. Payrastre, M. Gratacap* (FR), V. Martin, M. Valéra, S. Allart, C. Garcia, P. Sié, C. Recher OC-MO-100 4:15 PM - 4:30 PM EP3 RECEPTOR BLOCKADE AND PLATELET FUNCTION IN MAN S. Heptinstall* (UK), S. C. Fox, J. A. May, D. Hermann, D. Streiter, D. Hartman OC-MO-101 4:30 PM - 4:45 PM THE LECTIN-LIKE DOMAIN OF THROMBOMODULIN AND GRP78 COMPLEX EXHIBITS NOVEL ANTI-THROMBOTIC PROPERTIES A. Sharma* (AU), X. Zhang, A. Samudra, S. Dezfouli, C. Selan, B. Michell, B. Kemp, A. D’Apice, P. Cowan, H. Nandurkar OC-MO-102 4:45 PM - 5:00 PM THE MECHANISM OF IVIG TREATMENT FOR IMMUNE-MEDIATED PLATELET DESTRUCTION IS THROUGH INDUCTION OF INTERLEUKIN-11 D. Leontyev* (CA), Y. Katsman, D. R. Branch

Factor XI/XIa Room 107 ABC

Chairpersons: Uri Seligsohn (US) and Coen Mass (NL) OC-MO-103 4:00 PM - 4:15 PM STRUCTURAL ANALYSIS OF APPLE DOMAIN MISSENSE MUTATIONS RELATED TO FACTOR XI DEFICIENCY P. A. McEwan, D. V. Kravtsov, M. Sun, D. Gailani, J. Emsley* (UK) OC-MO-104 4:15 PM - 4:30 PM FACTOR XI ACTIVATION IN PLASMA IN THE ABSENCE OF FACTOR XIIA D. Gailani* (US), A. Matafonov, D. V. Kravtsov, E. I. Tucker, M. Sun, A. Gruber OC-MO-105 4:30 PM - 4:45 PM DIMERIZATION OF HUMAN FACTOR XI IS NOT A PREREQUISITE FOR ITS SECRETION OR ACTIVATION M. Zucker* (IL), A. Zivelin, M. Landau, N. Rosenberg, U. Seligsohn OC-MO-106 4:45 PM - 5:00 PM REGULATION OF CONTACT ACTIVATION BY ANTITHROMBIN (AT) AND C1 INHIBITOR (C1INH) J. Bäck* (SE), G. Elgue, J. Sanchez, K. Nilsson Ekdahl, B. Nilsson

112 CM-0 4:15PM-4:30 4:00PM-4:15 OC-MO-108 OC-MO-107 ORAL COMMUNICATIONS CM-1 4:30PM-4:45 4:15PM-4:30 4:45PM-5:00 OC-MO-1 OC-MO-113 OC-MO-112 OC-MO-1 OC-MO-110 OC-MO-109 nihshlpdSnrm:Bt lcpoen1Room156ABC Antiphospholipid Syndrome: Beta2Glycoprotein 1 Room153ABC Mechanisms ofPlateletActivationII 2009 MONDAY, JULY 13, 1 14 1 I (BET ON THROMBOGENICEFFECTSOF K. Mertens,M.Gebbink,C.Maas T. Shilagard,R.Derksen,P. deGroot,S.Pierangeli*(US) Z. Romay-Penabad,R.Urbanus,M.Pennings, E.Papalardo,G.Vargas, IN VIVOINVOL V N. Pozzi*(IT), A. Banzato,E. Bison,S.Olivieri, A. Ruffatti, V. Pengo, IMPLICA PROPERTIES OFDOMAINI(1-64)BETA2-GLYCOPROTEIN I: SYNTHESIS, CHARACTERIZATION AND ANTIBODY-BINDING B. deLaat*(NL),C.Zappelli,M.vanBerkel,Siregar DEPENDENT ONPROTEINCONFORMATION IMMUNE RESPONSES AGAINST DOMAINIOFBETA2GPI ARE M. Boon-Spijker LAC DOMAIN IOFBETA2-GLYCOPROTEINACTIVITY IDISPLAY P Chairpersons: PhilipdeGroot(NL)andBasLaat R. K. M. Al-Tamimi* (AU),J.R.Hamilton,S.P. Jackson, A. Ludwig,M. C.Berndt, RECEPTOR SHEDDING SHEARRATES INCREASELEVELSOFPLATELETPATHOLOGICAL J. E.B.Fox*(US), Y. Zhang,K.Bialkowska ALPHAIIBBETA3 ACCORDINGLY MODULATES ANDOUTSIDE-INSIGNALS ACROSS 14-3-3 AVAILABILITY CONDITIONS AND PLATELET GPIBSENSESENVIRONMENTAL L. Bellido-Martin*(US),G.Merrill-Skoloff, B.Furie,C.Furie P COLLAGENINDUCED ROLE OFPDIINTHROMBUSFORMATION IN A K. Chen*(US),W. Li,M.Febbraio,R.Silverstein STATE PROTHROMBOTIC ANDA HYPERLIPIDEMIA VAV GUANINENUCLEOTIDEEXCHANGEFACTORS LINK Chairpersons: B. deLaat,R.Derksen . deFilippis A ATHWAY TIENT Andrews, E.Gardiner A2GPI) TION FORTHE DRVDMNCOA ANTIBODIESDIRECTED TOWARDS -DERIVED MONOCLONAL AND OF Yukio Ozaki(JP)andTimothy J.Stalker(US) VEMENT OF APOLIPOPROTEIN ERECEPTOR (APOER2’) , I.Dienava*(NL),P ANTIPHOSPHOLIPID (APL) ANTIBODIES ANTIPHOSPHOLIPID SYNDROME(APS) . deGroot,J.Voorberg, K. Mertens, A DIMER OFBET , P A2GL . deGroot, YCOPROTEIN 4:00 PM-5:00 4:30 PM-4:45 4:00 PM-4:15 4:45 PM-5:00 113

Monday Orals

ORAL COMMUNICATIONS

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

Fibrinolysis: Biochemistry Room 160 ABC

Chairpersons: John Weisel (US) and Oleg Gorkun (US) OC-MO-115 4:00 PM - 4:15 PM THE ROLE OF THE FIBRINOGEN ALPHA CHAIN IN ENHANCING FXIII ACTIVATION K. A. Smith* (UK), P. J. Adamson, R. J. Pease, A. J. Balmforth, R. A. S. Ariens, H. Philippou, P. J. Grant OC-MO-116 4:15 PM - 4:30 PM THE RELATIVE IMPORTANCE OF FINGER AND KRINGLE DOMAINS IN THE REGULATION OF TPA ACTIVITY S. Williams* (UK), C. Thelwell, C. Longstaff OC-MO-117 4:30 PM - 4:45 PM PLASMIN-CATALYZED LYSIS IS ENHANCED IN FIBRIN VARIANTS WITH WEAKENED HOLE “B” B. A. Holliday* (US), S. R. Bowley, S. T. Lord OC-MO-118 4:45 PM - 5:00 PM COAGULATION FACTOR Xa DERIVATIVE, Xa33/13, ENHANCES PLASMINOGEN ACTIVATION AND CLOT LYSIS K. Talbot, S. C. Meixner, E. L. G. Pryzdial* (CA)

Factor V Room 204 AB

Chairpersons: Francesco Bernardi (IT) and Beth Bouchard (US) OC-MO-119 4:00 PM - 4:15 PM THROMBIN GENERATION IN PATIENTS WITH SEVERE FACTOR V DEFICIENCY RELIES ON PLATELET FACTOR V C. Duckers* (NL), P. Simioni, C. Radu, L. Spiezia, S. Gavasso, J. Rosing, E. Castoldi OC-MO-120 4:15 PM - 4:30 PM THE PLATELET FACTOR V/Va POOL REMAINING TWO WEEKS SUBSEQUENT TO FFP ADMINISTRATION CORRECTS TOTAL PLASMA FACTOR V DEFICIENCY B. A. Bouchard* (US), K. E. Brummel-Ziedins, J. P. Wood, P. B. Tracy OC-MO-121 4:30 PM - 4:45 PM DIRECT CORRELATION BETWEEN PLATELET AND PLASMA FACTOR V LEVELS IN HOMOZYGOUS AND HETEROZYGOUS FACTOR V DEFICIENT SUBJECTS L. Spiezia* (IT), C. Radu, G. Tognin, C. Bulato, M. Florean, P. Pradella, S. Gavasso, G. Barillari, V. de Angelis, P. Simioni OC-MO-122 4:45 PM - 5:00 PM A DATABASE OF MUTATIONS AND POLYMORPHISMS IN AND AROUND THE FACTOR V GENE; AN UPDATE H. L. Vos* (NL)

114 CM-2 4:15PM-4:30 4:00PM-4:15 OC-MO-124 OC-MO-123 ORAL COMMUNICATIONS CM-3 4:45PM-5:00 4:15PM-4:30 4:00PM-4:15 4:45PM-5:00 OC-MO-130 4:30PM-4:45 OC-MO-129 OC-MO-128 OC-MO-127 OC-MO-126 OC-MO-125 Endothelial Dysfunction:V Room109AB Atherosclerosis: PlaqueComposition 2009 MONDAY, JULY 13, J. Barrenetxe,Martinez-Gonzalez, J.C.Reverter, J. A. Paramo J. Orbe*(ES), A. Rodriguez,C. S. MartinezdeLizarrondo, MA J. Madon,W. Ruf,S.Valsami, M.Leikauf, A. Kaech,L.M. Asmis* (CH) AND TISSUEF EXPRESSION AND SECRETIONOFTISSUEFACTOR DIFFERENTIAL X. G. N. PROTHROMBOTIC HYPERTENSIVE AND PROLYLCARBOXYPEPTIDASE MURINEHYPOMORPHS ARE S. Robson, A. D’Apice,P. Cowan,H.Nandurkar X. Zhang*(AU),S.Crikis,Dezfouli,K.Dwyer THROMBOSIS AND PROLONGSCARDIACXENOGRAFTSURVIVAL THROMBOMODULIN OVER-EXPRESSIONPREVENTSVENOUS Chairpersons: Tatiana Byzkova(US)andMiekeDelvaeya(NL) Y G. H.Heine*(DE),K.S.Rogacev, C.Ulrich,L.Blömer, K.Oster, M.Ziegelin, ATHEROSCLEROSIS MONOCYTE HETEROGENEITY M. Daemen,H.tenCate,Spronk J. I.Borissoff* (NL),S.Heeneman, P. Kassak,R.vanOerle,K.Hamulyák, POSSIBLEROLEFORFXII A THE PROTHROMBOTICSTATE OF ATHEROSCLEROTIC LESIONS: R. Farndale,C.Gachet,Brandl,W. Siess A. J.Reininger*(DE),I.Bernlochner, S.Penz,C.Ravanat,P. Smethurst, ATHEROSCLEROTIC PLAQUES HUMAN STEPSOFTHROMBUSFORMATION INDUCEDBY THE INITIAL P. G.deGroot,J.R.Lindner, O.McCarty R. B.Conley*(US),W. Shentu, A. Xie, Y. Qi, Y. Zhao,C.Carr, T. Belcik, WILLEBRAND FACTOR TARGETED MOLECULARIMAGINGOF ACTIVATED VON VIA NON-INVASIVE IDENTIFICATION OF ATHEROSCLERTOTIC PLAQUES Chairpersons: WITH ENHANCEDTHROMBINGENERATION CELLS AND INCREASEDINPATIENTS THROMBIN INENDOTHELIAL THROMBORESIST . Grenner Yu, F. Mahdi,Z.Shariat-Madar, L. D’Alecy, Y. Okada, A. H.Schmaier TRIX MET Adams* (US), , J.Geisel, ALLOPROTEINASE-10 (MMP-10)IS UP-REGULA Armin J.Reininger(DE)andJulianI.Borissoff(NL) ACT ANCE INVITRO OR P ascular Signaling Y . Zhou,G.Larusch,M.Nieman,B.Hoit,Jacobs, A. Schlitt,H.Köhler TWYINHIBITOR MODULATEATHWAY ENDOTHELIAL IN OBESITY , M.Girndt,D.Flliser AND SUBCLINICAL , L.Murray-Segal,E.Salvaris, TED BY 4:00 PM-5:00 4:30 PM-4:45 Room 151AB 115

Monday Orals

ORAL COMMUNICATIONS

MONDAY, JULY 13, 2009 4:00 PM - 5:00 PM

P2Y12 Room 252 AB

Chairpersons: Jane Freedman (US) and David Varon (IL) OC-MO-131 4:00 PM - 4:15 PM IDENTIFICATION OF TWO NOVEL P2Y12 ADP RECEPTOR GENE DEFECTS IN PATIENTS WITH TYPE 1 VON WILLEBRAND DISEASE M. E. Daly* (UK), B. B. Dawood, W. A. Lester, A. B. Federici, A. Artoni, I. R. Peake, A. D. Mumford, S. P. Watson, S. J. Mundell, on behalf of the EU-VWD Study Group OC-MO-132 4:15 PM - 4:30 PM REPRODUCIBILITY OVER TIME OF PLATELET FUNCTION TESTS TO EVALUATE ASPIRIN AND CLOPIDOGREL RESPONSIVENESS: INSIGHT FROM THE ADRIE STUDY ON STABLE CARDIOVASCULAR PATIENTS J. L. Reny* (FR), I. Barazer, C. Castelli, S. Nolli, P. Berdague, P. Fabbro- Peray, J. Schved, H. Bounameaux, F. Mach, P. de Moerloose, P. Fontana OC-MO-133 4:30 PM - 4:45 PM COMMON VARIATION IN THE PLATELET RECEPTOR P2RY12 GENE IS ASSOCIATED WITH RESIDUAL ON-CLOPIDOGREL PLATELET REACTIVITY IN PATIENTS UNDERGOING ELECTIVE PCI G. Rudez* (NL), H. J. Bouman, J. W. van Werkum, F. W. G. Leebeek, A. Kruit, H. J. T. Ruven, J. M. ten Berg, M. P. M. de Maat, C. M. Hackeng OC-MO-134 4:45 PM - 5:00 PM THE INTERPRETATION OF LIGHT TRANSMITTANCE PLATELET AGGREGATION IS INCONSISTENT – RESULTS FROM AN INTERNATIONAL CHALLENGE K. A. Moffat* (CA), E. Plumhoff, E. Reyes, S. Hoffman, S. Israels, P. Meijer, C. P. M. Hayward OC-MO-135 5:00 PM - 5:15 PM WHICH PLATELET FUNCTION TEST IS THE MOST SENSITIVE FOR THE IN VIVO EFFECTS OF CLOPIDOGREL? A PHARMACOKINETIC ANALYSIS H. J. Bouman* (NL), J. W. van Werkum, N. J. Breet, C. M. Hackeng, J. M. ten Berg, D. Taubert

Immune-mediated Thrombocytopenia Room 257 AB

Chairpersons: Ming Hou (CN) and Samuel Machin (UK) OC-MO-136 4:00 PM - 4:15 PM THE EFFECT OF BAFF AND BAFF-R-FC FUSION PROTEIN IN CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA X. Zhu, Y. Shi, J. Sun, J. Peng, C. Guo, P. Qing, X. Zhang* (CN), X. Ji, L. Wang, M. Hou OC-MO-137 4:15 PM - 4:30 PM MESENCHYMAL STEM CELL-MODULATED DENDRITIC CELLS INDUCE PLATELET-SPECIFIC T CELL-ANERGY IN IDIOPATHIC THROMBOCYTOPENIC PURPURA X. Zhang* (CN), J. Peng, Y. Shi, C. Guo, J. Sun, M. Hou

116 CM-3 4:45PM-5:00 4:30PM-4:45 OC-MO-139 OC-MO-138 ORAL COMMUNICATIONS BM-0 9:00 AM –9:15 AM 8:45 AM –9:00 AM 8:30 AM –8:45 AM 8:15 AM –8:30 AM LB-MO-005 8:00 AM –8:15PM LB-MO-004 LB-MO-003 LB-MO-002 LB-MO-001 Late Br 2009 MONDAY, JULY 13, aigAsrcsGrandBallroom eaking Abstracts Chairperson: KenBauer(US) STUDY) (THECANBESURE ORPELVIC SURGERY GOING CANCER ABDOMINAL M. R.Lassen*(DK), A. S.Gallus,G.F. Pineo,G.E.Raskob DOMIZED DOUBLE-BLINDTRIAL RAN- TRIAL:THE ADVANCE -2STUDY: LATEA BREAKINGCLINICAL H. R.Buller*(NL),M.Prins TORS) WITH CANCER: INPATIENTSLAR-WEIGHT HEPARIN NADROPARIN ONTHESURVIVAL TRIAL:THEEFFECTOFLOW-MOLECU- LATE BREAKINGCLINICAL Deutschinoff, J.Stieler, P. Reizig,H.Oettle H. B.Riess*(DE),U.Pelzer, B.Opitz, A. Hilbig,M.Strauch,S.Hahnfeld,G. ATIC CANCERPATIENTS LAR WEIGHTHEP WITH AND WITHOUTTHELOWMOLECU- OFCHEMOTHERAPY TRIAL PROSPECTIVE,RANDOMIZED TRIAL: A LATE BREAKINGCLINICAL V. V. Kakkar*(UK),J.Balibrea,Martinez-Gonzalez,P. Prandoni THE THROMBOPROPHYLAXISWITHBEMIP OFPROLONGING ANDSAFETY TO EVALUATE THEEFFICACY TRIAL RANDOMISEDDOUBLEBLIND TRIAL: A LATE BREAKINGCLINICAL Y ANTAGONISTS: WARFARIN VERSUSPHENPROCOUMON WITHTWOVITAMIN K OF ANTICOAGULANT THERAPY THE QUALITY RANDOMISEDCOMPARISON OF TRIAL: A LATE BREAKINGCLINICAL P (FNIT) AND FNITTHERAPY IMMUNE THROMBOCYTOPENIA ANDNEONATAL FCRECEPTOR (FCRN)INFETAL ROLE OFNEONATAL V (AITTP) THROMBOTIC THROMBOCYTOPENIC PURPURA THE PHARMACOKINETICSOFRITUXIMABIN ACUTE IDIOPATHIC Rosendaal MENT KNEEREPLACE- PARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL . vanLeeuwen*(NL),E.P . Chen,G.Zhu,J.Freedman,H.Ni*(CA) . McDonald*(UK),I.J.Mackie,K.Manns,S.Machin,M. A. Scully A ARIN (LMWH)ENOXAP RANDOMIZED TRIAL . A. Gebuis,F. J.M.vanderMeer, F. R. COMP ARING (FOR THEINP ARIN IN ARIN INP APIXABAN WITHENOXA ADV A ANCED P ACT INVESTIGA TIENTS UNDER 4:00 PM-5:00 ANCRE- - - - 117

Monday Orals

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

* Presenting Author

Mechanisms of Platelet Activation I

PP-MO-001 FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) ANALYSIS OF ACTIVATED PLATELET INTEGRIN ALPHA IIB BETA 3 VARIANTS EXPRESSED IN HEK293 CELLS R. E. Scharf, A. El Khattouti* (DE), V. R. Stoldt, M. Gyenes PP-MO-002 MODULATION OF PLATELET ADHESION BY DIFFERENTIAL PHOSPHORYLATION OF MULTIPLE GLYCOPROTEIN IB ALPHA SERINE AND THREONINE RESIDUES A. D. Munday* (US), R. A. Penkala, W. E. Thomas, J. A. Lopez PP-MO-003 DO HUMAN PLATELETS HAVE A PERIMEMBRANE, EXTRACELLULAR CA2+ SOURCE WHICH CAN BE MOBILISED UPON THROMBIN STIMULATION? A. G. S. Harper* (UK), S. O. Sage PP-MO-004 PLATELET SURFACE BINDING ENHANCES IMMUNE COMPLEX-INDUCED PLATELET AGGREGATION M. L. Hatfield, J. Meyer, L. Robles-Carillo, A. Amirkhosravi* (US), T. Meyer, J. Francis PP-MO-005 FRACTALKINE PROMOTES PLATELET ACTIVATION AND VASCULAR DYSFUNCTION IN CHRONIC HEART FAILURE: A LINK TO IMPAIRED CLOPIDOGREL RESPONSIVENESS A. Schaefer* (DE), C. Schulz, D. Fraccarollo, S. Massberg, J. Bauersachs PP-MO-006 LIPID RAFTS REGULATE PAR-1 SIGNALING LEADING TO PLATELET ACTIVATION AND PLATELET-INDUCED MONOCYTE ACTIVATION A. E. Schade* (US), E. Shick PP-MO-007 INDUCTION OF INSULIN RESISTANCE BY ADIPOKINES IN HUMAN MEGAKARYOCYTES A. J. Gerrits* (NL), E. Gitz, C. A. Koekman, F. L. Visseren, J. W. N. Akkerman PP-MO-008 THE PLAQUE LIPID LYSOPHOSPHATIDIC ACID STIMULATES HUMAN MEGAKARYOCYTIC CELLS VIA THE LPA5 RECEPTOR A. L. Khandoga* (DE), P. Goyal, W. Siess PP-MO-009 BINDING OF PLASMA FACTOR XIII TO THROMBIN-RECEPTOR ACTIVATED HUMAN PLATELETS B. Nagy* (HU), Z. Simon, Z. Bagoly, L. Muszbek, J. Kappelmayer PP-MO-010 STREPTOCOCCUS PYOGENES BACTERIA INDUCE PLATELET ACTIVATION AND AGGREGATION VIA A FIBRINOGEN-DEPENDENT MECHANISM C. Liu* (TW), Y. Chen, L. Chang PP-MO-011 PLATELET KAINIC ACID RECEPTOR SIGNALING PROMOTES THROMBOSIS BY STIMULATING CYCLOOXYGENASE ACTIVATION IN A MAPK DEPENDENT MANNER H. Sun, A. Swaim, C. N. Morrell* (US) PP-MO-012 CD40L PRIMES PLATELETS AND ENHANCES AGONIST-INDUCED ACTIVATION AND AGGREGATION TROUGH CD40-MEDIATED SHAPE CHANGE AND FILOPODIA FORMATION D. Yacoub* (CA), A. Hachem, J. F. Théorêt, M. Tabrizian, W. Mourad, Y. Merhi PP-MO-013 HEMATOCRIT AND ERYTHROCYTE DEFORMABILITY AFFECT ADP PLATELET REACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROMES ON DUAL ANTIPLATELET THERAPY E. Cecchi* (IT), R. Marcucci, R. Paniccia, B. Bandinelli, S. Valente, C. Giglioli, C. Lazzeri, G. Gensini, R. Abbate, L. Mannini

118 POSTER PRESENTATIONS

MONDAY, JULY 13, 2009 s oster PP-MO-014 IDENTIFICATION OF G PROTEIN-COUPLED RECEPTORS (GPCRS) IN HUMAN PLATELETS BY GENE EXPRESSION PROFILING A. Hansen, B. Spath, C. Bokemeyer, B. Eifrig, F. Langer* (DE) PP-MO-015 THROMBOXANE AND PROSTACYCLIN BIOSYNTHESIS IN HEART FAILURE OF ISCHEMIC ORIGIN: EFFECTS OF DISEASE SEVERITY AND ASPIRIN TREATMENT Monday P F. Santilli* (IT), G. Davi, S. Basili, S. Lattanzio, A. Cavoni, G. Guizzardi, L. de Feudis, G. Traisci, C. Pettinella, P. Minuz, A. Meneguzzi, G. Ciabattoni, C. Patrono PP-MO-016 POSTPRANDIAL HYPERGLYCEMIA IS AN IMPORTANT DETERMINANT OF PLATELET ACTIVATION. EVIDENCE FROM BIOCHEMICAL MEASUREMENTS AND PHARMACOLOGICAL INTERVENTION WITH ACARBOSE F. Santilli* (IT), G. Formoso, P. Sbraccia, M. Averna, R. Miccoli, P. di Fulvio, A. Ganci, N. Pulizzi, S. Lattanzio, G. Ciabattoni, A. Consoli, R. Lauro, C. Patrono, G. Davi PP-MO-017 CROSS ACTIVATION OF PAR-1 AND -4 BY PAR-1 AND -4 AGONIST PEPTIDES L. L. Dewar, Y. Song, S. J. Craven, F. A. Ofosu* (CA) PP-MO-018 A NOVEL SINERGISM BETWEEN EPINEPHRINE AND ADP STIMULATES PROTEIN KINASE C AND RAP1B ACTIVATION P. Lova, G. F. Guidetti* (IT), I. Canobbio, C. Balduini, M. Torti PP-MO-019 INCREASED PLASMA PHOSPHOLIPID AND PLATELET MICROPARTICLES IN ACUTE STROKE G. Gilmore* (AU), J. Thom, G. Hankey, J. Eikelboom, R. Baker PP-MO-020 DO YOUNG PLATELETS HAVE AN ENHANCED CAPACITY TO EXPOSE PROCOAGULANT PHOSPHATIDYLSERINE (PS) UPON ACTIVATION? M. L. Rand* (CA), H. Wang, K. W. Annie Bang, J. Freedman PP-MO-021 PLATELET PAI-1 RELEASE IS DEPENDENT ON BOTH THROMBIN RECEPTOR PAR1 AND PAR4 M. Nylander* (SE), E. Löfgren, M. Grenegård, T. L. Lindahl PP-MO-022 PROLACTIN DOES NOT AFFECT HUMAN PLATELET AGGREGATION OR SECRETION A. Q. Reuwer, R. Nieuwland* (NL), I. Fernandez, V. Goffin, C. M. van Tiel, M. C. L. Schaap, R. Berckmans, J. J. P. Kastelein, M. Twickler

Platelet Biology I

PP-MO-023 NITRIC OXIDE INDUCES VASODILATOR-STIMULATED PHOSPHOPROTEIN PHOSPHORYLATION BY PROTEIN KINASE G-DEPENDENT AND INDEPENDENT MECHANISMS: ROLE OF PROTEIN KINASE C A. A. Aburima* (UK), R. Riba, K. M. Naseem PP-MO-024 REGULATION OF COLLAGEN MEDIATED PLATELET ADHESION AND AGGREGATION UNDER CONDITIONS OF FLOW BY PROSTACYCLIN A. Michno* (UK), W. Roberts, S. Homer-Vanniasinkam, K. M. Naseem PP-MO-025 PLATELET-ACTIVE SUBSTANCES IN THE VENOM OF BOTHROPS MOOJENI SNAKE – AN EVALUATION USING WHOLE BLOOD AGGREGOMETRY C. Demler, B. Buehler, A. M. Perchuc* (DE) PP-MO-026 THE PLASMA MEMBRANE CALCIUM ATPASE REGULATES CALCIUM HOMEOSTASIS AND FUNCTION IN PLATELETS A. B. Solomon* (UK), S. Jones, D. Sanz-Rosa, M. Emerson PP-MO-027 PLATELET RECEPTORS AND SIGNAL TRANSDUCTION MECHANISMS INVOLVED IN ERYTHROCYTE-AMPLIFIED PLATELET REACTIVITY A. Moscardo* (ES), J. Valles, M. A. Dasi, A. Latorre, M. T. Santos

119

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-028 CURCUMIN INHIBITS GPVI-MEDIATED PLATELET ACTIVATION BY INTERFERING WITH THE KINASE ACTIVITY OF SYK AND THE SUBSEQUENT ACTIVATION OF PLCGAMMA2 A. Mayanglambam* (US), J. L. Daniel, C. A. Dangelmaier, C. D. Reddy, D. Thomas, S. P. Kunapuli PP-MO-029 HUMAN PLATELET GRANULE SECRETION INDUCED BY THROMBIN AND COLLAGEN IS DIFFERENTIALLY MODULATED BY INTEGRINS: PLATELET FUNCTION OF A PATIENT WITH LAD-1V/LAD-III SYNDROME K. Jurk, A. S. Schulz, W. Friedrich, H. Schulze, H. Omran, R. Henschler, J. S. Scheele, B. E. Kehrel* (DE), B. Zieger PP-MO-030 THE EXTRACELLULAR ADHERENCE PROTEIN (EAP) OF STAPHYLOCOCCUS AUREUS ACTIVATES PLATELETS VIA THE ATP-GATED P2X1 CATION CHANNEL AND FCGAMMA RIIA S. Niemann, M. Hussain, S. Pohl, T. Schifferdecker, A. Schulte, A. Bertling, C. Heilmann, B. E. Kehrel* (DE) PP-MO-031 THE FUNGAL METABOLITE GLIOTOXIN INHIBITS PLATELET FUNCTION IN VITRO A. Bertling, S. Niemann, A. Uekötter, C. Lass-Flörl, C. von Eiff, B. E. Kehrel* (DE) PP-MO-032 A STRUCTURAL BASIS FOR THE INHIBITION OF SRC-FAMILY KINASE ACTIVITY BY DIETARY FLAVONOIDS B. Wright* (UK), J. A. Lovegrove, J. M. Gibbins PP-MO-033 SEQUENCE DIFFERENCES IN THE N-TERMINAL REGION OF MOUSE GPIB? CHANGE PROTEASE SPECIFICITY AND PREVENT THROMBIN BINDING C. Ravanat* (FR), V. Wurtz, C. Strassel, R. K. Andrews, S. Schuhler, C. Gachet, F. Lanza PP-MO-034 PHOSPHOTYROSINE PROTEINS IN PLATELETS FROM PATIENTS WITH STICKY PLATELET SYNDROME D. M. Fries* (BR), C. S. S. S. Silva, V. Oliveira, L. Lopes, F. E. V. Barros, V. Debbas, M. L. Santoro, E. A. D’Amico, T. J. C. Neiva, T. R. F. Rocha PP-MO-035 EFFECT OF GLYCOPROTEIN IBALPHA CLUSTERING ON PLATELET CLEARANCE IN VIVO D. E. van der Wal* (NL), S. Verhoef, J. W. N. Akkerman PP-MO-036 ROLE OF GLYCOPROTEIN IBALPHA MOBILITY IN PLATELET FUNCTION D. E. van der Wal* (NL), S. Verhoef, R. E. G. Schutgens, M. P. Peters, J. W. N. Akkerman PP-MO-037 INTERRELATION BETWEEN PERIPHERAL PLATELET COUNT AND PLATELET ACTIVATION DURING AND AFTER LIVER SURGERY IN PIGS A. H. Hussein, S. A. Kishta, E. A. A. Khaled* (EG) PP-MO-038 EFFECT OF NYTROXYL AND NITRIC OXIDE ON THE OXIDATIVE STATUS IN NORMAL PLATELETS E. Bermejo* (AR), M. F. Alberto, D. Saenz, S. Bari, M. A. Lazzari, R. Rosenstein PP-MO-039 HUMAN FIBRINOGEN SUPPORTS NORMAL HEMOSTATIC FUNCTION IN A MOUSE PLATELET SYSTEM E. S. Krystofiak* (US), J. A. Oliver PP-MO-040 ACCURATE QUANTIFICATION OF MICROPARTICLES BY FLOW CYTOMETRY : IMPORTANT ISSUES F. Mullier* (BE), J. M. Dogné, N. Bailly, Y. Cornet, S. Robert, B. Chatelain PP-MO-041 A ROLE FOR ADAP IN REGULATING INTEGRIN ALPHA2BETA1 IN PLATELETS G. E. Jarvis* (UK), S. Hamaia, D. Bihan, C. E. Rudd, R. W. Farndale PP-MO-042 PLATELET PROTEIN DISULFIDE ISOMERASE IS RESTRICTED TO THE DENSE TUBULAR SYSTEM AND NOT ASSOCIATED WITH THE CELL SURFACE H. E. van Nispen Tot Pannerden, S. M. van Dijk, V. Du, H. F. G. Heijnen* (NL)

120 PM-4 UCINLPO OFP2Y12RECEPTORS EXPOSEDUPONPLATELET POOL FUNCTIONAL A PP-MO-045 PP-MO-044 IIB INTHEINTEGRIN ALPHA REPLACEMENTOFPHE992 AND PHE993WITH ALA PP-MO-043 POSTER PRESENTATIONS PM-5 NIIOYEFFECTOFQUERCETINONPLATELET SPREADING ONCOLLAGEN AND INHIBITORY PP-MO-055 ACTIVATION REPRESSOROFGPIIB-IIIA CD9TETRASPANIN IS A PP-MO-054 PP-MO-053 OESTROGENIC AND ANDROGENIC MODULATION OFITGA2PROMOTER ACTIVITY PP-MO-052 STREPTOCOCCUS NOVEL SUPPORTS ADHESION TO A PLATELET GPIIB/IIIA PP-MO-051 INTERACTORS SLAP-2 AND RHOGDI- INFLUENCEOFTHENOVEL PP-MO-050 1DUETO 2BETA DIFFERENTBINDINGCHARACTERISTICSOFTHEINTEGRIN ALPHA PP-MO-049 VON FLOWCONDITIONSTO A PLATELET ADHESION UNDER ARTERIAL PP-MO-048 PLATELET ADHESION TO PROTEINSINMICROPLATES: FROMEXPERIMENTAL PP-MO-047 AMYLOIDPRECURSORPROTEINPROTEOLYSIS INHUMANPLATELETS IS PP-MO-046 Platelet AdhesionandCohesionI 2009 MONDAY, JULY 13, FIBRINOGEN AND ONMULTIPLE PLATELET KINASES THROMBOGENIC SURFACES INHIBITOR DIRECT ACTING, REVERSIBLEP2Y12 ELINOGREL, A CAN BEBLOCKEDBY ACTIVATION PERSISTSINMICETREATED WITHHIGHDOSECLOPIDOGREL, AND COMPARISON OFMETHODS MOTIF: A REGULATORY PROTEIN INTERACTIONSWITHTHEINTEGRIN ALPHA TO ITSINTERACTORS CYTOPLASMIC MOTIFCHANGES THEBINDING AFFINITY PLA AND INTEGRIN GORDONII SURFACE PROTEIN I-DOMAIN MUTATIONS WILLEBRAND F EVALUATION OFPLATELET FUNCTION RESEARCH TO CLINICAL CALMODULIN REGULATED BY L. Navarro-Núñez* (ES),M.Lozano,C.Martínez,V. Vicente, J.Castillo,Rivera J. Kotha*(US),S.N.Hill,Grgurevich, S.Cholera,L.K.Jennings I. Lopez-V F. M. Al-Zahrani* (UK),M.E.Daly, P. R. Winship C. Keane*(IE),H.Petersen,M.Vickerman, D.Cox,H.F. Jenkinson,S.W. Kerrigan Deckmyn B. F α B. F B. D.Maddox*(UK),G.E.Jarvis,R.W. Farndale A. C.Eriksson*(SE),P. A. Whiss I. Canobbio*(IT),S.Catricalà,L.Cipolla,C.Balduini,M. Torti Conley H. Haberstock-Debic*(US),P. Andre, S.M.Delaney, S.Mills, Y. Pak,D.R.Phillips,P. B. H. Daxecker*(IE),M.Raab,R.J.Edwards,D.Murphy M. Raab,R.Moriarty H. Deckmyn Escolar 2 β . Iserbyt*(BE),S.Katsutani,Staelens,N.V . Iserbyt*(BE),S.Staelens,G.R.vandeW 1 BINDING TELET ilchez* (ES), ASSOCIA ALPHA ACT , L.Parthasarathi,S. Allen, N.Moran,H.Daxecker*(IE) OR-BINDING PEPTIDESEQUENCEPRESENTINCOLLAGENIII TED TISSUEF A. M.Galan,F 2 EXPRESSIONLEVEL ACT . Navalon,L.Brunso,P. Molina,M.Diaz-Ricart,G. OR ENHANCESTHROMBUSFORMATION ON alle, I.S.Salles,Pareyn,K.V andeputte, I.Pareyn,K.V , A. Treumann, N.Moran α ON INTEGRIN anhoorelbeke, H. anhoorelbeke, 121

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-056 RELEASE OF PENTRAXIN-3 FROM ACTIVATED NEUTROPHIL MODULATES PLATELET- NEUTROPHIL CROSS-TALK N. Maugeri* (IT), R. Patrizia, D. Andrea, B. Barbara, C. Domenico, M. Attilio, M. Alberto, A. A. Manfredi

Novel Approaches to Understanding Platelet Biology I

PP-MO-057 THE PECULIAR PLATELET BEHAVIOR IN THE ARABIAN CAMEL (CAMEL DROMEDARIUS) A. M. Abdelgadir* (SA), A. K. Al Ghomlas, A. Al Haidari, M. F. Husain, J. White PP-MO-058 STRATEGY FOR THE USE OF SINGLE MOLECULE FORCE SPECTROSCOPY TO INVESTIGATE BINDING OF INTEGRIN ALPHA(2)BETA(1) AND COLLAGEN A. M. C. Simpson* (UK), S. J. Attwood, D. Bihan, S. W. Hamaia, M. E. Welland, R. W. Farndale PP-MO-059 POSSIBLE ROLE OF GNAS1 IMPRINTING IN A PROTHROMBOTIC PHENOTYPE: NESP55 HYPERMETHYLATION IN ISCHEMIC STROKE AT YOUNG AGE B. Izzi* (BE), R. Bouillon, K. Devriendt, C. van Geet, K. Freson PP-MO-060 SOLUBLE AGONISTS AND SHEAR FORCES DIFFERENTIALLY ALTER THE LIQUID ORDER OF PLATELET MEMBRANES: QUANTITATIVE MEASURES AND PLATELET SUBPOPULATION DETECTION B. Labarthe* (CA), A. Maguy, P. Theroux, A. Bonnefoy PP-MO-061 ATORVASTATIN TREATMENT INCREASES THE LIQUID ORDER OF PLATELET MEMBRANES B. Labarthe* (CA), A. Maguy, R. Gallo, P. Theroux, A. Bonnefoy PP-MO-062 REAL-TIME MEASUREMENT OF NON-LETHAL PLATELET THROMBOEMBOLIC RESPONSES IN THE ANAESTHASIZED MICE C. Tymvios* (UK), C. Moore, M. Emerson PP-MO-063 OPTIMIZATION OF INTRACELLULAR NITRIC OXIDE ASSESSMENT IN MONOCYTES BY FLOW CYTOMETRY N. C. C. Schachnik, V. Peruhype-Magalhães, F. Lucas-Junior, G. M. M. Paula, V. M. Freitas, O. A. Martins-Filho, L. M. S. Dusse* (BR) PP-MO-064 TYPE OF AGONIST DETERMINES THE ROLE OF PLATELETS IN FIBRINOLYSIS. ASSEMBLY OF LRP-1, UPA, UPAR AND PAI-1 COMPLEX IN STIMULATED PLATELETS O. Panes* (CL), D. Flores, V. Matus, J. Pereira, D. Mezzano PP-MO-065 MITOCHONDRIAL CONTROL OF PLATELET APOPTOSIS: ROLE OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE V. Leytin* (CA), A. Mutlu, D. J. Allen, A. V. Gyulkhandanyan, S. Mykhaylov, J. Freedman

Platelets and Systemic Disorders I

PP-MO-066 PLATELET TRANSFUSION INDEPENDENCE ACHIEVED WITH USE OF A THROMBOPOIETIN RECEPTOR (TPO-R) AGONIST IN REFRACTORY SEVERE APLASTIC ANEMIA (SAA) E. M. Bloch, A. Giermasz* (US), J. Knoche, P. F. Fogarty PP-MO-067 THE D1424N AND R1933X MUTATIONS OF MYH9 RESULT IN AN ALTERED PROPLATELET FORMATION BY HUMAN MEGAKARYOCYTES A. Pecci, A. Malara, S. Badalucco, V. Bozzi, C. L. Balduini, A. Balduini* (IT) PP-MO-068 LACK OF ASPIRIN RESISTANCE IN PREGNANT WOMEN A. Duncan* (US), A. Winkler, A. Ingle

122 PM-7 DOESHEMODIALYSIS CAUSEBLOODPLATELETS APOPTOSIS? PP-MO-071 TISSUEFACTOR EXPRESSIONONRECIPIENTPLATELETS AND PBMCSISTHEKEY PP-MO-070 –THEPLATELET OFPREECLAMPSIA ONTHEPATHOPHYSIOLOGY STUDY A PP-MO-069 POSTER PRESENTATIONS PM-8 GATA-1,G208S MACROTHROMBOCYTES LACK TALIN PP-MO-081 PRESENCEOFPLATELET-ASSOCIATED ANTI-GPVI AUTOANTIBODIES AND PP-MO-080 NEWPOLYMORPHISM, IN A+, INVOLVED IN NEONATAL IIBCARRIES A ALPHA PP-MO-079 PP-MO-078 PATIENT HETEROZYGOUSFOR GVIDEFECTIN A FIRSTCASEOFCONSTITUTIONAL PP-MO-077 PATIENT HOMOZYGOUSP2Y12MUTATION WITH A IN A NOVEL IDENTIFICATION OF A PP-MO-076 MOLECULARGENETIC BASISOFINHERITEDTHROMBOCYTOPENIA PP-MO-075 PP-MO-074 INCHILDRENWITHTHERAPY IMMUNETHROMBOCYTOPENIC PURPURA PP-MO-073 SELECTIVESEROTONIN REUPTAKE INHIBITORS INFLUENCE AGONIST-INDUCED PP-MO-072 Mechanisms ofInheritedandAcquired DefectsofPlateletNumberandFunctionI 2009 MONDAY, JULY 13, RESTORATION OFGPVIEXPRESSIONINPATIENTS WITHGPVIDEFICIENCY TRANSPLANTATION F SERIES OF3CASES DYSFUNCTION. A THROMBOCYT TARGET OFRUNX1 DIRECTTRANSCRIPTIONAL MYL9 IS A PLA TWO GPVIMUTATIONS MILD PLA MEGAKAR GRANULELOCALIZATION OFOSTEOPROTEGERIN(OPG)INPLATELETS AND ALPHA STUDIES FROM MODALITIES DEPRESSION AND CARDIOVASCULAR DISEASESTUDY OF RESULTSPLATELET FROMCOMORBIDITY AGGREGATION. PRELIMINARY J. G.White*(US), S. M.Burris,B.R.Crowe M. V G. S.Jalagadugula*(US),Kaur, G.Mao,D.Dhanasekaran, A. K.Rao Grandchamp, M.Jandrot-Perrus B. Dumont*(FR),D.Lasne,C.Rothschild,M.Bouabdelli,V. Ollivier, N. Ajzenberg, B. B. Dawood*(UK),M.Daly A. O. Al-Marwani* (UK),D. Pearson, B.Wagner, A. C.Ong,M.Makris,E.Daly M. E.Chollet*(FR),J.P H. Sen G. Aydogan* (TR),M.Celik,D. Tugcu, Z.Salcioglu,F. Akici, A. Kiyak, A. Akcay, N.Canpolat, E. Litinas*(US),J.Fareed,O.Iqbal A. Sobol,M.Kaminska,Stasiak,J.Szymanski,B.Walkowiak* (PL) Dorling* (US),D.K.C.Cooper C. Lin,B.Ekser, B.Gridelli,C.Long,G.Echeverri,H.Hara,M.Ezzelarab,D. Ayares, A. Nicolescu, I.V M. Onisai,R.Vladareanu, Bellucci Tomiyama ACTOR INCOAGULATION DYSFUNCTIONINPIG-TO-PRIMATE LIVER . Jallu,M.Dusseaux,D.Granier, C.Kaplan,G.Bertrand*(FR) Akiyama, H.Kashiwagi*(JP),K. EE YSNLGTCAN(Y9 EIINYINRUNX1HAPLODEFICIENCY: TELET MYOSINLIGHTCHAIN(MYL9)DEFICIENCY TELET YOCYTES. EVALUATION OFMYELOFIBROSIS oican OPENIA -BASED BLEEDINGDISORDER AIN IHAGA PLATELET SYNDROME:EVIDENCEFOR AN GRAY PATIENT WITH A A . Brouland,C.BalDitSollier A. Vladareanu*(RO),H.Bumbea,S.Radesi,M.Ciorascu, A. , M.Makris, A. Mumford,S. Watson, J.Wilde T odo, M.Moroi,C.Berndt,H.Kojima, Y. Kanakura, Y. , M.Lebret,F . Bauduer , L.Drouet,S. 123

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-082 VISUALIZING THE VON WILLEBRAND FACTOR/GLYCOPROTEIN IB-IX AXIS IN PLATELET-TYPE VON WILLEBRAND DISEASE J. A. Guerrero* (US), S. Russell, T. K. Gartner, B. Storrie, J. Ware PP-MO-083 A CASE OF SEVERE THROMBOCYTOPENIA ASSOCIATED WITH PENTAMIDINE- DEPENDENT ANTIBODY SPECIFIC FOR GLYCPROTEIN IIB K. S. Heidinger* (DE), A. Giptner, R. Fischer, S. Santoso, G. Bein, U. Sachs PP-MO-084 A POTENTIAL HOT SPOT FOR UNEQUAL HOMOLOGOUS RECOMBINATION WITHIN EXON 24 OF THE MYH9 GENE K. Miyazaki* (JP), S. Kunishima, W. Fujii, M. Higashihara PP-MO-085 DOMINANT INHERITANCE OF A NOVEL INTEGRIN BETA3 MUTATION ASSOCIATED WITH HEREDITARY MACROTHROMBOCYTOPENIA AND PLATELET DYSFUNCTION P. Gresele, E. Falcinelli, L. Bury* (IT), S. Giannini, P. D’Adamo, A. D’Eustacchio, T. Corazzi, A. Mezzasoma, F. di Bari, G. Guglielmini, L. Cecchetti, P. Noris, C. Balduini, A. Savoia PP-MO-086 DOSE-DEPENDENT EFFECTS OF ASPIRIN ON PLATELET FUNCTION M. Sobieraj-Teague* (CA), J. J. I. Weitz, J. J. S. Ginsberg, D. D. Sloane, S. S. Anand, J. J. W. Eikelboom

Basic Biology of ADAMTS13 I

PP-MO-087 DEPLETION OF NEUTRALIZING ANTI-ADAMTS13 ANTIBODY FROM ACQUIRED TTP PATIENT PLASMA BY ADAMTS13-SPECIFIC AFFINITY ADSORPTION B. Plaimauer* (AT), S. Skalicky, M. Schmidt, M. Hasslacher, F. Scheiflinger PP-MO-088 IN VITRO AND IN VIVO ACTIVITY OF TRUNCATED MURINE ADAMTS13 MUTANTS B. de Maeyer* (BE), S. F. de Meyer, H. B. Feys, H. Deckmyn, K. Vanhoorelbeke PP-MO-089 STABILISATION OF THE VWF A2 DOMAIN BY INTRODUCTION OF A DISULPHIDE BOND PREVENTS BINDING TO AND CLEAVAGE BY ADAMTS13 B. M. Luken* (UK), L. Y. N. Winn, J. Emsley, D. A. Lane, J. T. B. Crawley PP-MO-090 VON WILLEBRAND FACTOR IS A MAJOR DETERMINANT OF ADAMTS-13 DECREASE DURING MOUSE SEPSIS INDUCED BY CECUM LIGATION AND PUNCTURE C. Dunois-Larde* (FR), N. Lerolle, I. Badirou, D. G. Motto, G. Hill, P. Bruneval, J. L. Diehl, C. V. Denis, D. Baruch PP-MO-091 GLOBULAR VWF INTERACTION WITH C-TERMINAL DOMAINS OF ADAMTS13 SUGGESTS A TWO SITE INTERACTION MECHANISM LEADING TO PROTEOLYSIS S. Zanardelli, C. K. W. Chion, P. J. Lenting, E. Groot, D. A. Lane* (UK) PP-MO-092 INTRAPLATELET LOCALIZATION OF ADAMTS13 I. Garagiola, R. Lombardi, A. Artoni, R. de Cristofaro, M. Cattaneo, F. Peyvandi* (IT) PP-MO-093 IMAGING ANALYSIS OF PLATELET THROMBUS FORMATION IN ADAMTS13-MUTANT MICE F. Banno* (JP), A. K. Chauhan, K. Kokame, J. Yang, S. Miyata, D. D. Wagner, T. Miyata PP-MO-094 THE ADAMTS13 S119F MUTATION DECREASES ENZYME ACTIVITY BY ALTERING SUBSITE ORIENTATION H. B. Feys* (BE), I. Pareyn, R. Vancraenenbroeck, H. Deckmyn, M. de Maeyer, C. van Geet, K. Vanhoorelbeke

124 PM-9 H FET FMJRI IOMTBLTSO RSGE ONHUMAN THEEFFECTSOFMAJORINVIVOMETABOLITES OFPRASUGREL PP-MO-096 PP-MO-095 POSTER PRESENTATIONS PM-0 P2Y12 ANTAGONISM INHIBITSSERUMTHROMBOXANEGENERATION: IMPLICATIONS PP-MO-106 PP-MO-105 PP-MO-104 PP-MO-103 GLUCOSAMINE SUPPRESSIONOFPLATELET AGGREGATION CAUSEDBY PP-MO-102 EP3 HARNESSINGTHE ANTIPLATELET EFFECTSOFPROSTAGLANDIN E2BY PP-MO-101 SIMULTANEOUS DIRECTFACTOR XaINHIBITION AND ACTIVATED PLATELET PP-MO-100 INPULMONARY OFEPOPROSTENOL CELLULARBASESFORTHEEFFICACY PP-MO-099 PP-MO-098 ON ANDPLATELET CHOLESTEROL OXLDL THEEFFECTOFPLATELET AND PLASMA PP-MO-097 Novel MechanismsofAntiplateletTherapyI 2009 MONDAY, JULY 13, O OBNTO HRP WITH ASPIRIN FOR COMBINATION THERAPY PROLONGA PLATELET AGGREGATION VIVO CANINEMODEL WITH ONGOING TREATMENT WITHCANGRELOR,BUTNOTTICAGRELOR,IS ASSOCIATED I THEINHIBITIONOF AKT PHOSPHORYLATION VIA THROMBOSIS PLATELET INHIBITS ACTIVATION ANDARTERIAL SALVIANOLICA ACID ACTIONONPLATELET FUNCTION DEPENDENT INHIBITORY PLA STUDY SUPPLEMENT RECEPT BLOCKAGE HYPERTENSION INHIBITION OFPLA ACETYLATION IN ATORVASTATIN-TREATED HYPERCHOLESTEROLEMICPATIENTS THE ASA-MEDIATED BLOODPLATELET INHIBITION AND PLATELET PROTEIN LARGE ARTERIES AND VEINS LARGE ARTERIESAND K. Bhavaraju*(US),S.Kim, Y. Mao,J.Jin,S.Kunapuli H. Hu*(CN),L.Zhu,Z.Huang, Y. Zhao,N.Li E. D. L.McGlasson*(US),G.Patino,B.J.Rubal, A. D.Shah D. L.McGlasson*(US),G. D. Iyu*(UK),S.Heptinstall Ahrens, C.Bode,K.Peter C. E.Hagemeyer*(AU),S.U.Eisenhardt,N.Bassler, P. Stoll,M.Schwarz, Y. C.Chen,I. Cerletti* (IT) M. Crescente,C. Tamburrelli, M.Barisciano,W. Zamboni,M.B.Donati,G.deGaetano,C. B. C.Cooley*(US) B. Luzak*(PL),M.Boncler, J.Rywaniak,R.Wilk,L.Stanczyk,Rysz,C.Watala Kurihara Hagihara, A. A. Sugidachi*(JP), Y. Niitsu, T. Ogawa,J. A. Jakubowski,M.Hasegawa,Hashimoto,K. Giezen A. Ravnefjord*(SE),P ANGIOGRAPHY T rifiro’, A. Borgognone,D.di Pietrantonio,D.Reale,F. M.Pulcinelli*(IT) TELET MRP4OVEREXPRESSIONISRESPONSIBLEFORREDUCEDCAMP- INFCN EUTO NTEEFCC FCOIORLIN AN EX- OFCLOPIDOGREL SIGNIFICANTREDUCTIONINTHEEFFICACY A OF PLA OR BLOCKADE TION ALLOWS SUPERIOR TELET TELET AGGREGATION AUGMENTS FIBRINCLOTFORMATION IN . Delavaux,J. Tornvall, J.Weilitz, B.M.Emanuelsson,J.van ACTIVITY A. Fritsma IN ROUTINE ANTICOAGULA AND ACUTE CORONOARY AND ACUTE TION WITHOUTBLEEDINGTIME 125

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

Extrinsic Pathway of Coagulation I

PP-MO-107 FUNCTIONAL BLOOD COAGULATION ASSAYS BASED ON THE LOCI® TECHNOLOGY A. Kappel* (DE), G. Christ PP-MO-108 ALIMENTARY LIPEMIA IS ASSOCIATED WITH INCREASED PLASMA VIIaAT CONCENTRATION AND THROMBIN GENERATION A. Silveira* (SE), A. Carlo, B. J. Woodhams, A. Hamsten PP-MO-109 HUMAN ALTERNATIVELY SPLICED TISSUE FACTOR IS NOT SECRETED AND DOES NOT TRIGGER COAGULATION A. N. Böing* (NL), C. M. Hau, A. Sturk, R. Nieuwland PP-MO-110 INR IN LIVER DISEASE: AN ISI DERIVED FROM LIVER DISEASE PATIENTS IMPROVES AGREEMENT BETWEEN INRS WITH DIFFERENT REAGENTS A. M. Sermon* (UK), J. M. Smith, R. Maclean, S. Kitchen PP-MO-111 DISTURBED BLOOD FLOW INDUCES EROSIVE INJURY OF TISSUE FACTOR-RICH INTIMA AND PROMOTES THROMBUS FORMATION T. Sumi, A. Yamashita* (JP), S. Matsuda, K. Nishihira, E. Furukoji, H. Sugimura, T. Imamura, K. Kitamura, S. Goto, Y. Asada PP-MO-112 HOW TO OVERCOME THE INNER FILTER EFFECT IN FLUORESCENT SUBSTRATE ACTIVITY ASSAYS? A. Carlo* (FR), C. Vauthier, E. Lebra, T. Fürle, M. Clabon, D. Drilhole, S. Kerdélo, G. Quentin, M. Gonidec, E. Arnaud, B. J. Woodhams PP-MO-113 NMR STUDIES OF TISSUE FACTOR: SAMPLE PREPARATION AND PARTIAL CHEMICAL SHIFT ASSIGNMENTS J. M. Boettcher, B. D. Lahood, J. H. Morrissey, C. M. Rienstra* (US) PP-MO-114 HYPERCOAGULABILITY IS INDEPENDENTLY ASSOCIATED WITH KYNURENINE PATHWAY ACTIVATION IN DIALYZED URAEMIC PATIENTS D. Pawlak* (PL), M. Mysliwiec, K. Pawlak PP-MO-115 PRACTICE IN POINT OF CARE INR TESTING-REVIEW OF QUESTIONNAIRES FROM 2001, 2004 AND 2007 OF UK NEQAS PARTICIPANTS D. P. Kitchen* (UK), S. Munroe, S. Kitchen, I. Jennings, T. Woods, I. Walker PP-MO-116 ESTABLISHMENT OF AN EXTERNAL QUALITY ASSESSMENT PROGRAMME FOR USERS OF ACTIVATED CLOTTING TIME D. P. Kitchen* (UK), S. Munroe, S. Kitchen, I. Jennings, T. Woods, I. Walker PP-MO-117 EPITOPE LOCALISATION AND FUNCTIONAL IMPACT OF A MONOCLONAL ANTIBODY RECOGNISING V158D/E296V/M298Q-FACTOR VIIa E. Persson* (DK) PP-MO-118 SIGNIFICANCE OF COMPLETE GAMMA-CARBOXYLATION FOR DEVELOPMENT OF A LONG-ACTING GLYCOPEGYLATED COAGULATION FACTOR IX VARIANT J. R. Bjelke* (DK), P. K. Holm, M. B. Hermit, A. A. Pedersen, J. M. Petersen, B. Kjær, T. N. Krogh, M. Nielsen, K. Vinther, H. Ostergaard PP-MO-119 PREPARATION OF RECOMBINANT BOVINE TISSUE FACTOR EXPRESSED AS AN INTEGRAL MEMBRANE PROTEIN IN SILKWORM USING A BACULOVIRUS EXPRESSION SYSTEM, AND ITS APPLICATION IN AN OWREN-TYPE (II-VII-X, BOVINE COMBINED) REAGENT M. Okuda* (JP), T. Taniguchi, K. Kishi, Y. Hamaguchi, H. Nagaya, S. Murayama, A. Usami PP-MO-120 ANTICOAGULATION OF A PATIENT WITH HYPERTROPHIC CARDIOMYOPATHY AND FACTOR VII DEFICIENCY S. J. Davidson* (UK), N. Turner, L. Tillyer

126 PM-2 INHIBITIONOFFACTOR XIREDUCESTHROMBUSFORMATION INRABBIT JUGULAR PP-MO-123 PP-MO-122 CLEARANCEOF ACTIVATED RECOMBINANTHUMANCOAGULATION FACTOR VII PP-MO-121 POSTER PRESENTATIONS PM-3 LSAPEIUINWT DIINO ELTDPAM NAPT-REAGENT IN A PREDILUTION WITH ADDITION OFDEPLETEDPLASMA PLASMA PP-MO-133 THERATIO BETWEENTHE ACTIVITIES OFCOAGULATION FACTOR XII AND C1 PP-MO-132 PP-MO-131 DUETO MISSENSE MUTATIONS INTHECOAGULATION ANGIOEDEMA HEREDITARY PP-MO-130 VARIABLES ONINTRINSICFACTOR IMPACT OF ASSAYSANALYTICAL RESULTS: PP-MO-129 PP-MO-128 PP-MO-127 MODULATES FACTOR IXa-MEDIATED GLYCOPROTEIN FACTOR IB-ALPHA Xa- PP-MO-126 CONTINUOUSINFUSIONINTHEMANAGEMENTOFSEVEREBLEEDINGEPISODES PP-MO-125 PP-MO-124 Anticoagulant PathwaysI Intrinsic PathwayofCoagulationI 2009 MONDAY, JULY 13, IMPROVES THE AGREEMENT BETWEENDIFFERENT PROTHROMBIN TIMEMETHODS ESTERASE INHIBIT ENUDRCNIIN FEDTEILDENUDATION AND/OR BLOODSTASIS VEIN UNDERCONDITIONSOFENDOTHELIAL INRODENTMODELS TUBULES OFTHEKIDNEY PROXIMAL REABSORPTION OFRECOMBINANT ACTIVATED VII(RFVIIa)INRENAL (RFVIIa) INRAT AND MOUSELIVER PHOSPHA F TESTINGFROM2003-2007 (NASCOLA) PROFICIENCY ASSOCIATION COAGULATION LABORATORY NORTH AMERICAN SPECIAL FOUR NOVEL THROMBIN GENERATION UNDERLOWSHEARCONDITIONS FACTOR VIIICONTRIBUTESTO PLATELET-FIBRIN THROMBUSFORMATION VIA GENERATION ONTHE ACTIVATED PLATELET SURFACE CHILDREN A HAEMOPHILIA OFTHECHICKENWHITELEGHORN WHOLE BLOODSAMPLES,BUTNOTINPLASMA INCITRATED THROMBELASTOGRAPHIC DETECTIONOFFACTOR XII-LIKE ACTIVITY A. Osman*(SE), T. L.Lindahl G. Moessmer*(DE) G. E.Gilbert*(US),J.Shi,C.Bai,Lu, T. Rasmussen,C.W. Heegaard E. Aygören Pürsün*(DE),G.Dewald,E.Rusicke,I. Martinez-Saguer, W. Kreuz D. Castellone*(US),E.I.B.Peerschke Zieger C. Geisen*(DE),J.Farac,D.Delev, M.Compes,B.Just,J.G.Kadar, A. Siegemund,B. Soeda, C. Sugita*(JP), A. Yamashita, S.Moriguchi-Goto,E.Furukoji,M. Takahashi, A. Harada, T. C. W Roussel B. PautardMuchemble,Pautard*(FR),V. Li Thiao Te, T. Tinot, J.NotheauxMicheli,B. B. C.Prezoto*(BR),S.Silva,M.Rocha,G.Motta, T. R.F. Rocha Kitazawa, K.Hattori, Y. Asada A. Yamashita* (JP),M. Takahashi, S.Moriguchi-Goto,C.Sugita,Matsuda, Y. Sato, T. T T PREKALLIKREIN DEFICIENCY . SeestedJohansen*(DK),E.I.Christensen,C.Jacobsen,R.S. Appa . SeestedJohansen*(DK),H.M.Nielsen,E.I.Christensen,R.S. Appa ACT eeterings* (NL),P RXIGN HE OE CASES OR XIIGENE-THREENOVEL , E.Seifried,J.Oldenburg T . Kitazawa,K.Hattori,S. TIDYLSERINE-INDEPENDENT PLA KLKB1 MUT RMYB RISKPREDICTOR FOR ANGIOEDEMA BE A OR MAY . G.deGroot, A TIONS INSEVENFAMILIES WITHSEVERE T amura, Y. Asada T. Lisman TELET BINDINGSITESFORF ACT OR VIII 127

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-134 SEVERE BIOCHEMICAL AND FUNCTIONAL EFFECTS IN ANTITHROMBIN CAUSED BY ACROLEIN A. Ordóñez* (ES), S. Pedersen, J. A. Guerrero, A. Miñano, R. Teruel, C. Martínez, L. Velázquez, S. R. Kristensen, V. Vicente, J. Corral, I. Martínez-Martínez PP-MO-135 THE INFLUENCE OF CYP2C9 GENETIC POLYMORPHISMS ON ORAL ANTICOAGULANT DOSE REQUIREMENTS IN THE LEBANESE POPULATION N. Zgheib, M. Esmerian, Z. Mitri, G. Zaatari, S. Alam, H. Skouri, R. Mahfouz, A. Taher* (LB) PP-MO-136 ASSAY DEPENDENT VARIATIONS IN THE USP POTENCY STANDARDIZED UNFRACTIONATED HEPARINS A. Gray* (US), D. Hoppensteadt, L. Myers, O. Iqbal, C. Adiguzel, J. Fareed PP-MO-137 COMPARISON OF A NOVEL ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (UPLC-MS/MS) METHOD WITH THE ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) AND PROTHROMBIN TIME (PT) A. M. Winkler* (US), M. L. Synder, A. Duncan, R. J. Molinaro PP-MO-138 DOWN-REGULATION OF PROTEIN S EXPRESSION BY 17BETA-ESTRADIOL IN HEPG2 CELLS A. Suzuki* (JP), N. Sanda, K. Makita, Y. Miyawaki, Y. Fujimori, T. Yamada, A. Takagi, T. Murate, H. Saito, T. Kojima PP-MO-139 DIFFERENTIAL THROMBIN GENERATION INHIBITION BY BRANDED AND GENERIC LOW MOLECULAR WEIGHT HEPARINS (LMWHS) AS STUDIED BY USING FLUORESCENCE SUBSTRATE BASED KINETIC METHOD C. Adiguzel* (US), E. Litinas, J. Cunanan, D. Hoppensteadt, J. M. Walenga, J. Fareed PP-MO-140 GENERIC VERSIONS OF ARGATROBAN CAN BE DIFFERENTIATED FROM BRANDED ARGATROBAN IN THE THROMBIN GENERATION ASSAYS (TGA) C. Adiguzel* (US), E. Litinas, O. Iqbal, J. Cunanan, W. Jeske, D. Hoppensteadt, J. Walenga, J. Fareed PP-MO-141 TESTSTRIP-BASED GENOTYPING TO ASSIST IN THE PREDICTION OF ANTICOAGULANT DOSE REQUIREMENT H. Puehringer, G. Klose, B. Schreyer, W. Krugluger, R. M. Loreth, C. Oberkanins* (AT) PP-MO-142 VITAMIN K DEFICIENCY IN INJECTING DRUG USERS D. Dawson* (UK) PP-MO-143 ACTIVATION OF PREKALLIKREIN BY CONTAMINATED HEPARINS, ISOLATED CONTAMINANT AND RELATED HYPERSULFATED CHONDROITIN SULFATE PREPARATIONS: PHARMACOLOGIC IMPLICATIONS D. Hoppensteadt* (US), O. Iqbal, H. Messmore, C. Adiguzel, V. Bansal, J. Fareed PP-MO-144 FIRST TYPE II ANTITHROMBIN DEFICIENCY CAUSED BY A LARGE INSERTION. STRUCTURAL AND FUNCTIONAL RELEVANCE I. Martínez-Martínez* (ES), T. Sevivas, N. Gómez, A. Ordóñez, A. Miñano, A. I. Antón, J. Padilla, M. E. de La Morena, R. González-Conejero, V. Vicente, J. Corral PP-MO-145 ENCAPSULATION OF HEPARIN IN POLYMERIC NANOPATICLES C. Pazzini, P. D. Marcato, N. Durán, S. A. L. Montalvão, N. F. Höehr, J. M. Annichino- Bizzacchi* (BR)

128 PM-4 AINSWT NACDCO OUIIYIN ACID CONDITIONSREQUIRE PATIENTS WITHENHANCEDCLOTSOLUBILITY PP-MO-148 PURIFYING METHODOFTHROMBIN-LIKEENZYME INDUSTRIAL PP-MO-147 PP-MO-146 POSTER PRESENTATIONS PM-5 EUNEI H IS NRNO XI SUBUNIT GENEISINVOLVED IN SEQUENCE INTHEFIRSTINTRONOFFXIII A PP-MO-159 PP-MO-158 PP-MO-157 PP-MO-156 ROLEOFTHEINTERACTION BETWEENTHEFACTOR VIII A1 DOMAINCA2+ BINDING PP-MO-155 COMPARATIVE IMMUNOGENICPOTENTIALSOFCRUDE AND PURIFIEDBOVINE PP-MO-154 BOVINETHROMBINPREPARATIONS OFIMPROVEDTOPICAL RELATIVE PURITY PP-MO-153 OF RABBIT ANTI-BOVINE THROMBINIGGSWITHHUMAN A- CROSS-REACTIVITY PP-MO-152 PP-MO-151 RECOMBINANTHUMANCOAGULATION FACTOR IX(RFIX):INFLUENCEOFSERINE PP-MO-150 SNAKEVENOM LEBETINA HAEMOSTASIS AFFECTING PROTEASES FROMVIPERA PP-MO-149 Cofactors andProteases I 2009 MONDAY, JULY 13, EUAIGTEEPESO FFIIASUBUNIT GENE REGULATING THEEXPRESSION OFFXIII A FURTHER EVALUATE THETHROMBOSIS RISK MOUSE MODELSTO CHARACTERIZETHECLOTTINGFUNCTION INVIVO AND AN ENGINEEREDCOAGULATION FACTOR IXWITH AUGMENTED ACTIVITY: USING RTAEPPIOE N NIIOYANTIBODIESTO FACTOR XIII PROTEASE PEPSINOGENI AND INHIBITORY LEVELSOFTHE ASPARTIC DIFFERENTIATION BETWEENRAISEDPLASMA USING ENZYMEELECTROPHORESISMETHOD THE INVESTIGATION OFPROTEIN-PROTEININTERACTIONSINHEMOSTATIC SYSTEM ACTIVATION OFFACTOR VIII THROMBIN CLEA DEFINITION OFTHETHROMBIN-BINDINGSITEONHUMANF ANDSTABILITY SITE AND C2DOMAINON ACTIVITY THROMBIN PREP TM) RECOMBINANTVERSIONOFHUMANTHROMBIN(RECOTHROM THROMBIN AND A VARIATION AND CONSERVATION INTHEB-DOMAINOFFACTOR V PHOSPHOR PROPERTIES INFIX-KNOCK-OUTMICE W. Cai* (CN), L.H.Huang,X.Liu,G. L.Li (TW) C. Y. Kao,C.N.Lin, I.S. Yu, S.R.Lin,M.H. Tao, H.L.Wu, G. Y. Shi,C.Fang,S.W. Lin* J. L.Newell*(US),P J. C.Lin*(US),Schuman,S.M.Nakaya,K.P. Pratt H. W H. Zhu*(US),D.Hoppensteadt,O.Iqbal,R.Wahi, J.Fareed H. Zhu*(US),D.Hoppensteadt,R.Wahi, J.Fareed H. Zhu*(US),D.Hoppensteadt,R.Wahi, J.Fareed H. L.V Reiter, F. Scheiflinger E. Böhm*(AT), M.Dockal,Hasslacher, C.Konetschny, A. Mitterer, E.M.Muchitsch, Siigur E. Siigur*Estonia,K. Tonismagi, M.Samel,H.Vija, K. Trummal, A. Aaspollu, J.Subbi, E. M.Duncan*(AU),B.Dale,J.V. Lloyd B. Jonj*(MN), T. P. Buhan A. I.Zhukova*(MN),Krasnobrysha,O.M.Savchuk,G.L.Volkov DOMAIN akabayashi* (US), os* (NL), YLATION AND TYROSINESULFATION ONPHARMACOKINETIC A. vanW V ARA G TAG69IFUNE EV CHAINCLEAVAGEAGE AT DURING ARG1689 INFLUENCESHEAVY . J.Fay TIONS A. E.Grif ijngaarden fiths, P . J.Fay ACT OR VIIIC2 129

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

Inhibitors of Coagulation I

PP-MO-160 INHIBITORS IN CHILDREN DURING SECONDARY PROPHYLAXIS FOR HEMOPHILIA IN A DEVELOPING COUNTRY A. Linares* Colombia, M. Aristizabal, I. Sarmiento, S. Castaño, M. Cortes PP-MO-161 THE COMPLETE ISOLATED N-TERMINAL EXTENSION OF HEPARIN COFACTOR II IS REQUIRED FOR MAXIMAL THROMBIN BINDING A. J. Boyle* (CA), V. Bhakta, W. P. Sheffield PP-MO-162 MONITORING OF RIVAROXABAN: SUITABILITY OF A WELL-ESTABLISHED CHROMOGENIC ANTI-FACTOR Xa ASSAY A. Karst* (DE), B. Bakowski-Enzian, E. Perzborn PP-MO-163 LOW INHIBITOR INCIDENCE IN PREVIOUSLY UNTREATED HAEMOPHILIA A PATIENTS TREATED WITH OCTANATE A. Klukowska* (PL), P. Laguna, M. Jansen PP-MO-164 CAN PROTEIN C AND PROTEIN S DEFICIENT PATIENTS BE IDENTIFIED DURING ORAL ANTICOAGULANT TREATMENT? A. B. Münster* (DK), J. J. Sidelmann, J. Gram, J. Jespersen PP-MO-165 HEPARIN SULFATE FROM HUMAN FOLLICULAR FLUID CONTAINS ABUNDANT 3-O- SULFATED CHAINS WITH HIGH ANTICOAGULANT ACTIVITY A. I. de Agostini* (CH), A. Fischer, N. W. Shworak, L. Zhang, R. J. Linhardt PP-MO-166 SUCCESSFUL MANAGEMENT OF MAJOR SURGERY WITH IVIG IN A PATIENT WITH A PROGRESSIVE ACQUIRED VON WILLEBRAND FACTOR INHIBITOR ON THE BACKGROUND OF HEREDITARY TYPE 1 VON WILLEBRAND’S DISEASE B. Madan* (UK), G. W. Moore, P. Earnshaw, D. A. Gurney PP-MO-167 RISK OF BLEEDING WITH DABIGATRAN ETEXILATE IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY IS NOT INCREASED BY CONCOMITANT USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS OR ACETYLSALICYLIC ACID B. I. Eriksson* (SE), A. A. Kurth, R. J. Friedman, J. M. Schnee, A. Clemens, H. Noack, J. A. Caprini PP-MO-168 RESULTS OF THE ECAT WORKSHOP ON THE DETECTION OF COAGULATION INHIBITORS B. Verbruggen* (NL), P. Meijer PP-MO-169 NON-PARALLELISM IN THE ONE-STAGE FACTOR ASSAYS IS A PHENOMENON OF LUPUS ANTICOAGULANTS AND NOT OF PARTICULAR FACTOR INHIBITORS J. Ruinemans-Koerts, B. Verbruggen* (NL), I. Peterse-Stienissen PP-MO-170 COMPARISON OF DIFFERENT MONITORING METHODS FOR DIRECT THROMBIN INHIBITOR, LEPIRUDIN B. Salmela* Finland, L. Joutsi-Korhonen, R. Lassila PP-MO-171 ACQUIRED HAEMOPHILIA A IN CHINA:REVIEW AND META-ANALYSIS FOCUSED ON CLINICAL CHARACTERS AND MANAGEMENT C. Zheng* (CN), J. Wu, K. Ding, W. Zhu, X. Cai PP-MO-172 NANIPROIN, A NOVEL PROTHROMBINASE COMPLEX INHIBITOR FROM NAJA NIGRICOLLIS VENOM C. Y. Koh* (SG), B. H. See, R. Kini PP-MO-173 HEREDITARY ANTITHROMBIN DEFICIENCY CAUSED BY HETEROZYGOUS CAMBRIDGE II MUTATION IN COMBINATION WITH A LARGE GENE DELETION C. Orlando* (BE), K. Jochmans, W. Lissens, I. Liebaers, M. de Waele

130 PM-7 UNFRACTIONATED HEPARIN PROMOTESELIMINATION OFHUMANRECOMBINANT PP-MO-177 ANTICOAGULANTS:DABIGATRAN ISMORE ENHANCEMENTOFCLOTLYSIS BY PP-MO-176 PP-MO-175 IDENTIFICATION OFLARGEGENEDELETIONSINTHE ANTITHROMBIN GENEBY PP-MO-174 POSTER PRESENTATIONS PM-8 OPNNSO AIBLT OFTHEEFFECT ACTIVATED PARTIAL COMPONENTS OFVARIABILITY PP-MO-188 POTENTANTIDOTE VARIANTANTITHROMBIN RECOMBINANT ASA OF A DESIGN PP-MO-187 PP-MO-186 PP-MO-185 RIVAROXABAN, AN BY PP-MO-184 INHIBITIONOFTHROMBINGENERATION INHUMANPLASMA PROTHROMBINCOMPLEX CONCENTRATE REVERSESTHEEFFECTSOFHIGH-DOSE PP-MO-183 OFMOLECULARDESIGN AND NEWTHROMBININHIBITORS: STRATEGY PP-MO-182 PROTEASENEXIN2 MECHANISMSOFINHIBITIONFACTOR XIa AND TRYPSIN BY PP-MO-181 CHILD IN A ACQUIREDFACTOR XIIIDEFICIENCY PP-MO-180 DIRECTLOW-MOLECULAR FXa- AND/OR FIIa-INHIBITORS HAVE NORISKFORHIT PP-MO-179 SOLUBLEEPCRINHIBITSTHEPROCOAGULANT ACTIVITIES OFFACTOR VIIa: AN PP-MO-178 ODY UY1,2009 MONDAY, JULY 13, DOSE ADJUSTMENTS THROMBOPLASTIN TIMEVS. FOR FONDAPARINUX AND OTHERHEPARIN DERIVATIVES AMLA FII RAT MODEL MAMMALIAN TFPIIN A THANHEPARIN EQUAL INDIRECT FACTOR XaINHIBITOR ANTICOAGULANT ACTIVITIES OFEP42675,SYNTHETICDIRECTTHROMBIN AND MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION LOW PLASMA ASSESSMENT OFF ORAL, DIRECTF RIVAROXABAN INRATS TESTING EXPERIMENTAL AND BASICP RIV TYPE II:EFFECTSOFPF4ONTHROMBINGENERATION INHIBITEDBY EXPLANATION FORITSROLEINTHROMBOSIS F. Guerrero*(FR), A. Faucher, V. Diemert, S.Voisin, P. Sié, A. BuraRivière E. P. Bianchini*(FR),V. Picard,J.Fazavana,D.Borgel E. Castoldi*(NL),P. Simioni,D. Tormene, J.Rosing, T. M.Hackeng E. Perzborn*(DE),M.Hardwardt,Samama E. Perzborn*(DE),M.Harwardt E. Perzborn*(DE),H. Tinel V E. I.Sinauridze*(RU), A. N. Romanov, I.V. Gribkova,O. A. Kondakova, A. S.Gorbatenko, Y. D. Navaneetham*(US),Sinha,P. N.Walsh C. Y. Hu,R.Saksena,Ricafort,D.Manwani*(US) D. Pillitteri*(DE), T. Scholz,D.Westrup, M.Krause,C.Kirchmaier C. Puy*(ES),J.Lopez-Sagaseta,Hermida,R.Montes C. Øie*(NO),E.Brodin,I.Hilden,R. Appa, B.Smedsrød,J.Hansen C. T. Ammollo* (IT),F. Semeraro,C.Carrieri,R.Galasso,N.M.Colucci C. BalDitSollier*(FR),E.Neuhart,Krezel,M.Petitou,L.Drouet C. Orlando*(BE),K.Jochmans,W INHIBIT PHARMACODYNAMICS OFRIVAROXABAN – AN ORAL,DIRECTFACTOR Xa TYPE IPROTEINS-DEFICIENTINDIVIDUALS . Kuznetsov, A. A. Bogolyubov, M. Y. Manakov, V. B.Sulimov, F. I. Ataullakhanov AROXABAN, DABIGA OR ANCREA LEVELS OFFULL-LENGTHTISSUE F ACT ACT OR XaINHIBITOR TIC TR OR XaCHROMOGENIC TRAN YPSIN INHIBIT ANTI-FACTOR XaONUNFRACTIONATED HEPARIN AND NEWDUAL . Lissens,I.Liebaers,M.deWaele OR ASSA FIIA/FXa-INHIBITORS ACT YS FORMEASURINGTHE OR P A THW A Y INHIBITOR IN 131

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-189 PHOSPHOINOSITIDES INTERACT WITH PROTEIN C INHIBITOR (PCI) F. Wahlmüller* (AT), M. Furtmüller, B. Sokolikova, B. R. Binder, M. Geiger PP-MO-190 NEBULIZED RECOMBINANT HUMAN TFPI ATTENUATES PULMONARY COAGULOPATHY DURING STREPTOCOCCUS PNEUMONIAE PNEUMONIA F. E. van den Boogaard* (NL), J. H. Hofstra, C. van ‘t Veer, J. J. T. H. Roelofs, M. M. Levi, T. van der Poll, M. J. Schultz PP-MO-191 NEBULIZED RECOMBINANT HUMAN TFPI ATTENUATES COAGULATION AND LIMITS BACTERIAL OUTGROWTH IN A RAT MODEL OF GRAM–NEGATIVE PNEUMONIA F. E. van den Boogaard* (NL), J. J. H. Hofstra, C. van ‘t Veer, J. J. T. H. Roelofs, M. M. Levi, T. van der Poll, M. J. Schultz PP-MO-192 IDENTIFICATION OF MUTATIONS IN THE PROTEIN C GENE ASSOCIATED WITH THE RISK OF VENOUS TROMBOSIS P. Medina, S. Navarro, A. Vayá, F. Ferrando, M. T. Contreras, A. Estellés, F. Espana* (ES) PP-MO-193 INFLUENCE OF THE HAPLOTYPE 1 OF THE ENDOTHELIAL PROTEIN C RECEPTOR GENE ON THE CIRCULATING ACTIVATED PROTEIN C LEVELS DURING ORAL ANTICOAGULANT THERAPY S. Navarro, P. Medina, F. Ferrando, A. Vayá, M. T. Contreras, A. Estelles, F. Espana* (ES) PP-MO-194 ANTI-FIBROGENIC EFFECTS OF THE DIRECT THROMBIN INHIBITOR DABIGATRAN IN LUNG FIBROBLASTS G. S. Bogatkevich* (US), R. M. Silver PP-MO-195 A C.-39C>T NOVEL POINT MUTATION IN THE 5’-UT REGION OF PROS-1 GENE ASSOCIATED WITH PS DEFICIENCY S. Labrouche, C. Vergnes, G. Freyburger* (FR) PP-MO-196 MLPA SCREENING OF THE PROS1 GENE: FINDING OF A NEW LARGE DELETION IN THREE PATIENTS WITH PROTEIN S DEFICIENCY S. Labrouche, C. Vergnes, C. Conri, J. Constans, G. F. Freyburger* (FR) PP-MO-197 COMPARISON OF RECOMBINANT AND PLASMA-DERIVED ANTITHROMBIN BIODISTRIBUTION IN VIVO L. R. Berry, B. Thong, H. M. Atkinson* (CA), A. K. C. Chan PP-MO-198 EFFECT OF FOOD ON DISPOSITION OF DU-176B: PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS IN CAUCASIAN AND JAPANESE HEALTHY VOLUNTEERS J. Mendell* (US), M. Tachibana, M. Shi, S. Kunitada PP-MO-199 RESISTANCE TO HEPARINS IN A SUBJECT WITH ANTITHROMBIN BUDAPEST III P. C. Cooper, K. P. Hickey* (UK), R. Jones, R. Krishna, S. Kitchen, R. M. Maclean, A. Goodeve, K. K. Hampton, J. van Veen, M. Makris PP-MO-200 A CHROMOGENIC SCREENING ASSAY IDENTIFIES THROMBOBOTIC RISK FACTORS IN PRE-SURGERY PATIENTS M. Johnston* (CA), M. Rupwate, J. McGrath, M. Smirnov, O. Safa, M. Triscott PP-MO-201 SYNERGISTIC EFFECT OF TAK-442, A DIRECT FACTOR Xa INHIBITOR, AND ANTIPLATELET AGENTS ON WHOLE BLOOD COAGULATION AND ARTERIAL THROMBOSIS IN RATS N. Konishi, K. Hiroe, E. Shinozawa, Y. Imaeda, K. Kubo, M. Kawamura* (US) PP-MO-202 EFFECT OF A LOW MOLECULAR WEIGHT HEPARIN ON VASCULAR CELL TISSUE FACTOR EXPRESSION E. Napoleone, A. Cutrone, G. Colavecchia, F. Calanni, G. de Gaetano, M. B. Donati, R. Lorenzet* (IT)

132 PM-0 ATRXI NCRBOPNLFLUID FACTOR XIIIINCEREBROSPINAL PP-MO-205 (CF) AND RHEUMATOID ARTHRITIS (RA) SEVEREBLEEDING,CRYOFIBRINOGENAEMIA PP-MO-204 THEPREVALENCE AND GENETICBACKGROUND OFFACTOR VIIIINHIBITORS IN PP-MO-203 POSTER PRESENTATIONS PM-1 XRSINO RTOYI N NIGNCFCOSI NOERA CELL EXPRESSIONOFPROTEOLYTIC AND ANGIOGENIC FACTORS INENDOMETRIAL PP-MO-215 MONOCLONAL OFPLASMINOGENBY INDUCTIONOFCATALYTIC ACTIVITY PP-MO-214 WITHGAMMA DYSFIBRINOGENEMIA FIBRINOGEN YECHEON :CONGENITAL PP-MO-213 LATERAL THEROLEOFFRAGMENT BBETA121-138 INFIBRINPROTOFIBRIL PP-MO-212 PP-MO-21 PP-MO-210 PP-MO-209 FIBRINOGENPOLYMORPHISMS AND THERISKOF ACUTE ONSETISCHEMICSTROKE PP-MO-208 FIBRINCLOTPROPERTIES EFFECTOFCIGARETTESMOKINGONPLASMA PP-MO-207 NOVEL HETEROZYGOUSCASEOF A FIBRINOGENKRAKOW: A PP-MO-206 Fibrinolysis I Fibrinogen I 2009 MONDAY, JULY 13, 1 UTR RMEDMTISS NLEC FPRTNA FLUID CULTURE FROMENDOMETRIOSIS.INFLUENCE OFPERITONEAL A5E10INTHEPRESENCEOFPLASMINOGEN ACTIVATORS ANTIBODY Aixalá, S.Meschengieser, M.Lazzari HNS EOHLAAPATIENTS A CHINESE HEMOPHILIA METHIONINE-310 ASSOCIATION FINDINGS FEATURES AND LABORATORY CENTRE: CLINICAL RETROSPECTIVE EV FIBRINOGEN IN YOUNGINDIANS ASIAN FUNCTION AND FIBRIN ARCHITECTURE (GASN325ILE)AFFECTING HYPODYSFIBRINOGENEMIA THESE LEVELS? CARDIOVASCULAR RISKFACTORS? LIFESTYLEMODIFICATION CANMODULATE Chirivella, A. Estelles*(ES) R. Cosin,J.Gilabert-Estelles, L. A. Ramon,M. Gomez-Lechon,F. España,J.Gilabert,M. A. Maleki*(IR),M. E. Park*(KR),G.Park,R.H.Kim,S.Lee, E. V D. K.Galanakis*(US),J.Koo,B.Kudryk,M.Rafailovich C. Santoro*(IT), C. A. Villaverde* (ES),J.Rodriguez,C.Fernandez,D.Bleda,E.Peña A. Biswas*(IN),R.Ranjan, A. Meena,M.S. Akhter, B.K. Yadav, M.Behari,R.Saxena A. Undas*(PL),E.Stepien,R. Topor-Madry, T. Miszalski-Jamka,W. Tracz, M.Pasowicz Neerman-Arbez A. Undas*(PL),J.Zdziarska, T. Iwaniec,E.Stepien, A. Skotnicki,P. deMoerloose,M. A. Csapó*(HU),É.Katona,G.Szucs,Haramura,L.Muszbek X. W ALPHA-C DOMAIN ADSORPTION-INDUCED FIBRINOGENSELF-ASSEMBL Komisarenko Mazzucconi A. N.Blanco*(AR),S.Grosso,L. . Lugovskoy*(UA),P ang* (CN),Q.Ding,R. Yang, Y. Zhao,J.Wu, J.Sun,X.Zhang,H.Wang AND CHOLESTEROL A. Leporace,F Akrami, M.Mirshahi, AND «A»KNOBROLES TO THREONINESUBSTITUTION ALUA . G.Gritsenko,I.N.Kolesnikova,E.Lugovskaya,S.V TION OFDYSFIBRINOGENAEMICP . Biondo,R. A. Bastos,J.Speroni, A. SanchezLuceros,F. Alberto, M. PLASMATIC LEVELS ARE INDEPENDENT A. Pourfathollah Asselta, S.Duga,M.Menegatti,Platè, Y . Cha Y : EVIDENCEOFESSENTIAL A INSI SINGLE TIENTS IN A . 133

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-216 ALTERED FIBRIN CLOT STRUCTURE/FUNCTION IN PATIENTS WITH IDIOPATHIC VENOUS THROMBOEMBOLISM A. Undas* (PL), K. Zawilska, M. Ciesla-Dul, A. Lehmann-Kopydlowska, A. Skubiszak, K. Ciepluch, W. Tracz PP-MO-217 A HYPOFIBRINOLYTIC STATE IS ASSOCIATED WITH RETINAL VEIN OCCLUSION A. Cellai* (IT), S. Fedi, D. Lami, B. Giambene, A. Sodi, U. Menchini, R. Marcucci, R. Abbate, G. Gensini, D. Prisco PP-MO-218 RATIO BETWEEN TIME OF XIIa-DEPENDENT FYBRINOLYSIS (FS) AND ANTITHROMBIN III (AT) ACTIVITY AS A MARKER OF SEVERITY OF SEPSIS A. V. Krechetova* (RU), G. M. Galstyan, E. B. Orel, S. A. Vasiliev, M. G. Alexanyan, V. M. Gorodetsky PP-MO-219 CHARACTERIZATION AND APPLICATION OF MONOCLONAL ANTIBODIES TOWARD MOUSE PAI-1 B. van de Craen* (BE), H. R. Lijnen, I. Scroyen, P. J. Declerck, A. Gils PP-MO-220 DIAGNOSIS OF HYPERFIBRINOLYSIS : WHICH TEST(S) SHOULD BE USED ? S. Eeckhoudt, D. Latinne, C. Lambert* (BE), C. Hermans PP-MO-221 THE EFFECTS OF HYPERGLYCAEMIA ON THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR C. J. N. Verkleij* (NL), M. Nieuwdorp, V. E. A. Gerdes, M. Mörgelin, J. C. M. Meijers, P. F. Marx PP-MO-222 PLASMA LEVELS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 AND VITRONECTIN IN CHILDREN WITH SOLID TUMORS D. Tugcu, O. Devecioglu, A. Unuvar* (TR), O. B. Ekmekci, H. Ekmekci, A. Karatas, Z. Karakas, G. Ozturk, S. Anak, L. Agaoglu PP-MO-223 EVALUATION OF THE INNOVANCE D-DIMER ANALYTICAL PERFORMANCE D. Coen Herak* (HR), M. Milos, R. Zadro PP-MO-224 IMPAIRED FIBRINOLYSIS AS A RISK FACTOR FOR BUDD-CHIARI SYNDROME J. Hoekstra, F. W. Leebeek, A. H. Guimaraes, S. D. Murad, J. J. Malfliet, A. Plessier, P. Langlet, E. Elias, J. Trebicka, M. Primignani, J. Garcia-Pagán, D. C. Valla, H. L. Janssen, D. C. Rijken* (NL) PP-MO-225 IDENTIFICATION OF MONOCLONAL ANTIBODIES THAT IMPAIR THE ACTIVATION OF BOTH MOUSE AND HUMAN TAFI THROUGH DIFFERENT MECHANISMS E. Vercauteren* (BE), M. Peeters, P. J. Declerck, A. Gils PP-MO-226 DERIVATION OF A CLINICAL PREDICTION RULE THAT INCLUDES D-DIMER TO IDENTIFY HIGH-RISK PATIENTS WITH PULMONARY EMBOLISM: FINDINGS FROM THE RIETE REGISTRY E. Grau* (ES), J. Tenias, J. Ferrer, M. Guil, R. Sanchez, A. Riera, J. Sahuquillo, B. Vasco PP-MO-227 D-DIMER AND SHORT-TERM CLINICAL OUTCOME OF PULMONARY EMBOLISM: ROLE OF PULMONARY ARTERY CLOT LOAD E. Grau* (ES), M. Santos, R. Garcia, J. Ferrer, S. Isarria, J. Sanchez, S. Selfa, R. Molina, J. Tenias PP-MO-228 FACTOR XIII LEVELS IN PATIENTS WITH DIFFERENT STAGES OF ALCOHOLIC LIVER CIRRHOSIS É. Katona* (HU), B. Garai, I. Tornai, É. Csák, L. Muszbek PP-MO-229 PROCARBOXYPEPTIDASE U (TAFI) CONSUMPTION IN ACUTE ISCHEMIC STROKE CORRELATES WITH STROKE SEVERITY, EVOLUTION AND OUTCOME E. Heylen* (BE), R. Brouns, J. Willemse, P. de Deyn, D. Hendriks

134 PM-3 H OEO APIN THEGENEEXPRESSIONOFPLASMINOGEN ACTIVATOR THEROLEOFCAMP PP-MO-232 O-LINKEDGLYCOSYLATION OFVWFIS AN IMPORTANT MODULATOR OF ADAMTS13 PP-MO-231 THROMBOLYTIC TREATMENT ALTERS THEPROCARBOXYPEPTIDASEU(TAFI) PP-MO-230 POSTER PRESENTATIONS PP-MO-243 PROTEINSDEFICIENCY PLATELET PROTEINS ANTIGEN LEVELSINCONGENITAL PP-MO-242 PP-MO-241 PP-MO-240 PP-MO-239 PP-MO-238 FACTOR VTO THROMBIN PLATELETAND FACTOR 4(CXCL4)SHIELDSPLASMA PP-MO-237 COAGULATION ESTROGENRECEPTORS MEDIATE CHANGESINMOUSEPLASMA PP-MO-236 FUNCTIONSOFPOSITIVEFEEDBACKSFACTORS V AND VII REGULATORY PP-MO-235 ANGIOTENSIN-(1-9)ENHANCESVENOUSTHROMBOSISDEVELOPMENT INRAT BY PP-MO-234 OFD-DIMERLEVELS USINGTWODIFFERENTIMMUNOTURBIDOMETRIC STUDY PP-MO-233 Regulation ofCoagulationandFibrinolysisI 2009 MONDAY, JULY 13, DECREASED LEVELS OFPLA COAGULOPATHY OFDILUTIONAL MODEL COAGULATION AND CLOTFIRMNESSIN A ON THE EFFECTOF ADDITION OF FXIII TO FRESHFROZENPLASMA WITH WARFARIN INHIBITOR-1 AND TISSUEFACTOR IN ADIPOCYTE PROTEOL CONSUMPTION PROFILEINISCHEMICSTROKEPATIENTS PLASMA ANDS/D- INLYOPHILIZEDCOMPARISON PLASMA OFCLOTTINGFACTOR STABILITY STAT1 MEDIATED MECHANISM OCCURSTHROUGH A GAMMA INHIBITION OFGAMMA NA RET ETHINYLESTRADIOL F ACTIVATION INBLOODCLOTTINGINITIATION INHIBITING FIBRINOLYTIC ACTIVITY ASSA HRPUI OEEOAAI:ARANDOMIZED,DOUBLE-BLINDSTUDY THERAPEUTIC DOSEENOXAPARIN: A ACTIVATION EMBOLISM TREATED WITH AND FIBRINOLYSIS IN ACUTE PULMONARY EFFECT OFDROTRECOGIN C. Bulato*(IT),Radu, S.Gavasso,G. Tognin, L.Spiezia,P. Zerbinati,P. Simioni C. Radu*(IT),L.Spiezia,D. Tormene, C.Bulato,S.Gavasso,M.Perlati, M.Fadin,P. Simioni C. vonHeymann*(DE),Rosenthal, M.K.Keller, M.Schuster, C.Spies Rosenthal, C.Spies C. vonHeymann*(DE),M.K.Keller, A. Pruss,M.Sander, H.Schoenefeld,U.Kalus,C. C. M.Rein*(US),D.H.Farrell C. H.Dempfle*(DE), A. Link, E.Elmas,N.Suvajac,V. Liebe, J.Janes,M.Borggrefe A. A. Amelot, M. Tagzirt, J.Libraire,B.F. LeBonniec*(FR) A. C. A. Cleuren*(NL),I.K.vanderLinden,P. H.Reitsma,B.J.M.vanVlijmen A. N.Balandina*(RU),M. A. Panteleev, A. M.Shibeko,I.Shmirev, F. I. Ataullakhanov A. Mogielnicki*(PL),K.Kramkowski,D.Pawlak,J.M.Hermanowicz,W. Buczko Blesingk, I.Robertson,D.Seaton, T. Brain A. A. Khalafallah*(AU),M.Morse, A. Dennis,J.Bates, G.Bates,L.Smith,Mishra,N. A. Hayashi*(JP),N.Ono, A. Tomita, H. Takeya A. A. Nowak*(UK),G. Angus, M. A. Laffan, T. A. J.McKinnon E. Heylen*(BE),R.Brouns,J.W CO EESADHPTCTASRP EESIDCDB ORAL ACTOR LEVELS AND HEPATIC TRANSCRIPTLEVELSINDUCEDBY TURAL ARDS YS AT DIFFERENTSTAGES OFPREGNANCY ST YSIS AND BINDINGTO GPIB ACTIV COURSE OFENDOGENOUSPLASMA ORED FOR6DA A TION A N AM’FBIOE YTEI YINTERFERON- FIBRINOGENSYNTHESISBY AND GAMMA’ YS LA(ACTIVATED) ONMARKERSOFCOAGULATIONALFA TELET PROTEINS INP illemse, P. deDeyn,D.Hendriks A T 4 °C ACTIV A TIENTS UNDERTREA A TED PROTEINCLEVELS TMENT AND 135

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-244 THE NOVEL ANTICOAGULANT SOLULIN PROMOTES REPERFUSION AND REDUCES INFARCT VOLUME IN A THROMBOTIC MODEL OF STROKE E. J. Su* (US), M. Geyer, M. Wahl, M. Warnock, K. Mann, H. Brohmann, K. Petersen, D. A. Lawrence PP-MO-245 THE NOVEL DIRECT THROMBIN INHIBITOR DABIGATRAN ACCELERATES PLASMA FIBRINOLYSIS THROUGH TAFI-DEPENDENT AND -INDEPENDENT MECHANISMS F. Semeraro* (IT), C. T. Ammollo, N. Semeraro, M. Colucci PP-MO-246 QUENCHING OF THROMBIN GENERATION BY ANTITHROMBIN III (AT-III) AS MEASURED BY THROMBINOSCOPE IN NORMAL AND ALTERED CLOTTING PROCESSES F. Carmassi* (IT), F. de Negri, F. Mori, I. Nardini PP-MO-247 BLEEDING CONCERNS DRIVE PRACTICES OF ORTHOPEDIC SURGEONS IN PREVENTION OF VENOUS THROMBOEMBOLISM IN PRIMARY HIP AND KNEE ARTHROPLASTY F. A. Anderson* (US), D. Ayers, C. Colwell, F. Cushner, R. Friedman, M. Huo, G. Fitzgerald, L. Kwong PP-MO-248 PRACTICES IN PREVENTION OF VENOUS THROMBOEMBOLISM IN PRIMARY HIP AND KNEE ARTHROPLASTY VARY WITH SURGEON OPERATIVE VOLUME: FINDINGS FROM A SURVEY OF US ORTHOPEDIC SURGEONS F. A. Anderson* (US), J. Lieberman, V. D. Pellegrini, A. C. Spyropoulos, A. G. Turpie, G. Westrich, P. Franklin, D. Warwick PP-MO-249 A QUANTITATIVE MODEL FOR THE HUMORAL COAGULATION NETWORK G. K. Isbister* (AU), T. Wajima, S. B. Duffull PP-MO-250 THE ROLE OF BARRELS 1 AND 2 IN ENZYMATIC ACTIVITY OF FACTOR XIIIa E. L. Smith, P. J. Adamson, R. A. S. Ariëns, M. C. Maurer, P. J. Grant, H. Philippou* (UK) PP-MO-251 CALIBRATED THROMBIN GENERATION FROM A SINGLE MEASURING WELL H. C. Hemker* (NL), R. Al Dieri, P. W. Hemker PP-MO-252 INTRACELLULAR CYCLIC AMP UP-REGULATES EXPRESSION OF THROMBIN- ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) IN CULTURED HUMAN HEPATOMA HEPG2 CELLS H. Ishii* (JP), Y. Masuda, K. Takada, K. Sugimoto PP-MO-253 ACTIVATION OF FIBRINOLYSIS AND BLEEDING HISTORY IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS H. Seidel* (DE), H. J. Hertfelder, K. Alfter, U. W. Kolck, I. von Kügelgen, J. Homann, J. Oldenburg, G. J. Molderings PP-MO-254 THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR GENETIC POLYMORPHISMS AS MARKERS OF THE TYPE OF ACUTE CORONARY SYNDROME D. Tassies, M. Roque, J. Monteagudo, T. Martorell, A. Sionis, D. Arzamendi, M. Heras, J. C. Reverter* (ES) PP-MO-255 PROCOAGULANT EFFECT OF PLASMIN DEPENDENT ON FACTOR V AND FACTOR VIII DURING THE BLOOD COAGULATION PROCESS K. Ogiwara* (JP), K. Nogami, K. Nishiya, M. Takeyama, M. Shima PP-MO-256 OXYTOCIN INFLUENCE ON HAEMOSTASIS SYSTEM AND BEHAVIORAL REACTION IN WHITE RAT BY NORMAL AND STRESSOGENIC CONDITION M. Golubeva* (RU), M. Grigorjeva, O. Voscresenskaya PP-MO-257 EFFECT OF, UMBILICAL CORD, BLOOD CELLS IN THE “EXPRESSION” OF PLATELET GLYCOPROTEIN RECEPTORS M. P. Makris* (GR), M. Moshou, D. Vasileiadou, G. Koliakos, P. E. Makris

136 PM-6 THEPARAMETERS OFIMMUNEINFLAMMATION AND HAEMOSTASIS INPATIENTS PP-MO-260 INPATIENTS WITHPOSITIVE ANTIPHOSPOLIPID LONG-TERMFOLLOW-UP PP-MO-259 II-DETECTSUBCLINICAL VITAMIN K ABSENCE -PIVKA CANPROTEINSINDUCEDBY PP-MO-258 POSTER PRESENTATIONS PM-7 REILTHROMBOSISINPATIENTS WITH ANTIPHOSHOLIPID SYNDROME ARTERIAL PP-MO-271 AND VARIANTS ANDIIB/IIIA OFPLATELET GLYCOPROTEINS IA/IIA FUNCTIONAL PP-MO-270 PP-MO-269 OUTCOMESINPATIENTS WITHSYSTEMICLUPUS ANALYSIS OFLETHAL PP-MO-268 PP-MO-267 PP-MO-266 PREPARED LYOPHILIZED LUPUS ANTICOAGULANT NEGATIVE CONTROL A PP-MO-265 PP-MO-264 THELUPUSRATIO TESTSIMPROVETHEDIAGNOSISOFLUPUS ANTICOAGULANTS PP-MO-263 THELIPOPROTEINDISTRIBUTIONOFBETA-2-GLYCOPROTEIN I(APOLIPOPROTEIN PP-MO-262 PP-MO-261 Antiphospholipid AntibodiesandSyndr 2009 MONDAY, JULY 13, REILTHROMBOSISINPATIENTS WITH ANTIPHOSHOLIPID SYNDROME ARTERIAL V Musial THROMBOSIS ORSTROKEIN ANTI-PHOSPHOLIPID SYNDROME SYNDROME (APS) AND WITHOUT APS WITH SYSTEMICLUPUSERYTHEMATOSUS (SLE)WITH ANTIPHOSPHOLIPID ANTIBODIES –SINGLECENTREEXPERIENCE VITAMIN KDEFICITINMAJORSURGERY? (SIL-2R) LEVELSINPATIENTS WITH ANTIPHOSPHOLIPID SYNDROME TUMOUR NECROSISF LONG-TERM FOLLOW-UP ERYTHEMATOSUS (SLE) AND ANTIPHOSPHOLIPID SYNDROME(APS)BASEDON IF APTT ISNORMAL? IS LUPUS ANTICOAGULANT TESTINGUSEFUL CEREBRAL RECOMMENDATIONS ACCORDING TO ISTHLA LABORA H) WITHTHEBMS(DADEBEHRINGSIEMENS)SYSTEM PLASMA (ETP) ANALYSIS OFLUPUS ANTICOAGULANT ENDOGENOUS THROMBINPOTENTIAL J. Swadzba*(PL), J. Swadzba*(PL), J. Swadzba*(PL), T. Iwaniec,J. Musial E. V T. M. Reshetnyak, I.B.Shtivelband*(RU),E.N. Alexandrova, E.S.Mach,L.V. Kondratyeva, A. Mameli,D.Barcellona,L.Fenu,M.V D. Barcellona, A. Mameli,S. Cornacchini,L.Casciu,M.Piga,F. Marongiu*(IT) D. Sanchez*(US),C.Cueto,J.V C. Nougier*(FR), Y. Chevalier, F. Sobas,C.Negrier C. Nougier*(FR),F. Sobas,G.Baud,C.Negrier C. Agar* (NL),P. G.deGroot,J.H.M.Levels, A. Marquart,J.C.M.Meijers A. D’Angelo*(IT),P. DellaValle, E.Pattarini,L.Crippa, A. Fattorini A. V. Arshinov* (RU),V. I.Emanuylov, N.V. Zubova A. Bulikova*(CZ),D.Harustiakova,J.Zavrelova,L.Dusek,M.Penka U. Schott*(SE),P ALINE/LEUCINE247 POL . Ostryakova, T R IGOI FLPSATCAUAT O AYTESTS? DIAGNOSISOFLUPUS ANTICOAGULANT: HOWMANY ORY MR AND SPECT . Anveden, K.Strandberg,P. Flisberg,M.Engström, A. Hillarp A. A. Matyja-Bednarczyk, A. Matyja-Bednarczyk,M.Sanak,S.Dziedzina, T. Iwaniec, A. Bulikova,J. A. Novikov, E.L.Nasonov CO LH ANDSOLUBLE INTERLEUKIN2RECEPTOR ACTOR ALPHA YMORPHISM OFBET ABNORMALITIES INP asquez, R.Bottenus,M. ome I annini, F T. Iwaniec, A. Bulikova,J.Musial . Marongiu*(IT) -GYORTI N RISKOF 2-GLYCOPROTEIN I AND A A TET IHDE VEIN ATIENTS WITHDEEP T riscott 137

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-272 EVALUATION OF A NEW ENZYME IMMUNO ASSAY FOR DETECT AND QUANTIFICATION OF HUMAN ANTICARDIOLIPIN ANTIBODIES J. Needham* (UK), S. Knight, S. Rangarajan PP-MO-273 PROSPECTIVE STUDY OF THE CLINICAL AND SEROLOGICAL CHARACTERISTICS AND LONG-TERM EVOLUTION OF THE ANTIPHOSPHOLIPID SYNDROME AT THE AMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTER L. Bazzi* (LB), A. Taher, R. Mahfouz, I. Uthman PP-MO-274 B2 GLYCOPROTEIN I (B2GPI) CONTAINING IGM IMMUNE-COMPLEXES (B2GPI-IGM IC) IN PATIENTS WITH IGM ANTICARDIOLIPIN ANTIBODIES (ACL IGM) M. F. Alberto* (AR), A. Sanchez Luceros, S. Meschengieser, M. A. Lazzari PP-MO-275 THE IMPORTANCE OF APPROPRIATED CRITERIA FOR LUPUS ANTICOAGULANT (LA) DIAGNOSIS M. E. Martinuzzo* (AR), G. Cerrato, M. Iglesias Varela, Y. Adamczuk, R. Forastiero PP-MO-276 LUPUS ANTICOAGULANT IN NIGERIAN WOMEN WITH POOR OBSTETRICS HISTORY O. A. Awodu* (NG), A. O. Ejele, W. A. Shokunbi

Risk Factors and Epidemiology of Venous Thrombosis I

PP-MO-277 THROMBOPHILIC GENE MUTATION IN RECURRENT MISCARRIAGE Z. Mostafa* (EG), N. Abulata, S. Sahlab, A. Shams Eldin PP-MO-278 HEMOSTASIS AND HEMATOLOGICAL THROMBOTIC RISK FACTORS IN YOUNG NIGERIAN SEMI VEGETARIANS A. A. Adeyemi* (NG), O. A. Omolade, Y. O. Makinde, O. I. Ajayi, O. A. Awodu, A. A. Famodu PP-MO-279 JAK2 MUTATIONS OTHER THAN JAK2 V617F MAY BE ABSENT IN PATIENTS WITH UNUSUAL SITE THROMBOSIS A. H. Tabares* (AR), A. L. Basquiera, N. Soria, M. Salguero, R. Ryser, J. J. García PP-MO-280 DIFFERENCES IN VENOUS THROMBOEMBOLISM MANAGEMENT IN THREE EUROPEAN COUNTRIES: RESULTS FROM THE RIETE REGISTRY J. P. Cambou, N. Hassairi, A. Bura* (FR) PP-MO-281 VENOUS THROMBOEMBOLIC DISEASE IN MEN AND WOMEN: DATA FROM THE RIETE REGISTRY A. Bura* (FR), J. Ben Cheik, J. P. Cambou PP-MO-282 VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OF PROVOKED VENOUS THROMBOSIS DUE TO A TRANSIENT RISK FACTOR. A SYSTEMATIC REVIEW OF THE LITERATURE A. Iorio* (IT), C. Kearon, E. Filippucci, M. Marcucci, V. Pengo, G. Agnelli, G. Palareti PP-MO-283 FAVORABLE OUTCOMES WITH ONCE DAILY FONDAPARINUX 2.5MG VS. ENOXAPARIN 40MG FOR THROMBOPROPHYLAXIS AFTER ABDOMINAL OR MAJOR ORTHOPEDIC SURGERY A. F. Shorr* (US), R. V. Horblyuk, O. E. Lunacsek, L. A. Menditto, M. A. Franklin PP-MO-284 ROLE OF LIPID LOWERING THERAPY (LLT) ON VENOUS THROMBOEMBOLISM (VTE) RISK: A POPULATION-BASED CASE-CONTROL STUDY A. A. Ashrani* (US), J. A. Heit, M. K. Barsoum, C. L. Leibson, T. M. Petterson, K. R. Bailey, L. J. Melton PP-MO-285 THE RISK OF VENOUS THROMBOEMBOLIC EVENTS AFTER SPLENECTOMY. PROSPECTIVE OBSERVATIONAL COHORT STUDY IN 412 CONSECUTIVE PATIENTS A. Ghirarduzzi* (IT), F. Landini, S. Corradini, M. Iotti, I. Barbieri, F. Biolchini

138 PM-8 NIHSHLPDATBDE NWMNWT ITR OFPREGNANCY- HISTORY ANTIPHOSPHOLIPID ANTIBODIES INWOMENWITH A PP-MO-288 PP-MO-287 INFLUENCEOFEXOGENOUSRISKFACTORS TO THEFACTOR VLEIDENPARADOX PP-MO-286 POSTER PRESENTATIONS PM-9 VLAINO HOBSSGNTCPEIPSTO NSOMGE ISLAND EVALUATION OFTHROMBOSISGENETICPREDISPOSITIONINSÃOMIGUEL PP-MO-297 PP-MO-296 CYTOMEGALOVIRUS INFECTIONIS ASSOCIATED WITHVENOUS PP-MO-295 PP-MO-294 THEEFFECTOFLEVOTHYROXINE ONCOAGULATION AND FIBRINOLYSIS IN PP-MO-293 PRO-THROMBOTICSTATE INPATIENTS PRESENCEOF A WITHCUSHING’S PP-MO-292 PP-MO-291 EPISODE FIRST RECURRENCE AFTERA FACTORSFOR RISK D-DIMERANDAGEAS PP-MO-290 THROMBOPHILIA,HYPERCOAGULABILITY, AND ENVIRONMENT, AND THERISK OF PP-MO-289 ODY UY1,2009 MONDAY, JULY 13, ELH POPULATION HEALTHY ADAMTS13 FORQUANTITATION OF PERFORMANCE CHARACTERISTICS OF AN ELISA STUDY POPULATION-BASED CASE-CONTROL RELATED VENOUSTHROMBOSIS(VT)- A ANDRISKOFTHROMBOSIS PROTEIN CDEFICIENCY COHORT RETROSPECTIVETHROMBOPHILICFAMILYIN MEN AND WOMEN–RESULTS FROM A HOBEBLS AECNRLSTUDY CASE-CONTROL THROMBOEMBOLISM - A EMBOLISM RISK FACTORS FORPULMONARY CONTROLLED TRIAL SINGLEBLINDEDCROSSOVERRANDOMISED VOLUNTEERS: A HEALTHY HYPERCORTISOLISM ONHEMOSTASIS AND VENOUSTHROMBOSIS SYSTEMATIC REVIEWONTHEINFLUENCEOFENDOGENOUS SYNDROME: A PROLONG STUDY OFTHE OF VENOUSTHROMBOEMBOLISMINTHEEXTENDEDFOLLOW-UP D-DIMER PROLONG STUDY OFTHE OF VENOUSTHROMBOEMBOLISMINTHEEXTENDEDFOLLOW-UP VENOUS THROMBO-EMBOLISM(THE-VTESTUDY) C. Branco*(PT), T. Pereirinha,P. R.Pacheco,Cabral,L.Mota-Vieira C. J.Hoecke*(US),H.L.Fryer, E.Guinto,R.S.Greenfield Schambeck* (DE) S. Schimanski,B.Linnemann,Luxembourg,J.Rochon,E.Seifried,Lindhoff-Last, C.M. B. Milli*(IT), E. A. Gerdes,S.C.Cannegieter, D.P. M.Brandjes B. vanZaane*(NL), A. Squizzato, J.Debeij,O.M.Dekkers,C.Meijers,H.R.Buller, V. B. vanZaane*(NL),E.Nur A. Tripodi, G.Palareti B. Cosmi*(IT),C.Legnani,V A. B. Cosmi*(IT),C.Legnani,V. Pengo, A. Ghirarduzzi,S. Testa, A. Alatri, P. Domenico,D.Poli, A. vanHylckamaVlieg*(NL),F. R.Rosendaal,C. A. Baglin,R.Luddington, T. P. Baglin A. Bergrem*(NO),E.M.Jacobsen,F. E.Skjeldestad, A. F. Jacobsen,P. M.Sandset A. Cafolla*(IT),E.Baldacci,N. Angelosanto, P. Pignoloni,F. Biondo,M.Mazzucconi A. B.U.Mäkelburg*(NL),W A. Gerdes,H.R.Buller, D. P. M.Brandjes H. Prins,R.Büller, J.vanderMeer T ripodi, G.Palareti N E SRS ATR O EURNEATRAFIRSTEPISODE AND SEX AS RISKFACTORS FORRECURRENCE AFTER A AUTOANTIBODIES INHUMANPLASMA A. Rocci,M.Riccò,Lombardi,R.Quintavalla , A. Squizzato,O.M.Dekkers, T. H.B. Twickler, E.Fliers,V. E. . M.Lijfering,N.J.G.V . Pengo, A. T osetto, A. Ghirarduzzi, eeger, S.Middeldorp,K.Hamulyak,M. A. Alatri, D.Prisco,Poli, 139

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-298 VENOUS THROMBOSIS IS ASSOCIATED WITH HYPERGLYCEMIA AT DIAGNOSIS: A CASE-CONTROL STUDY D. M. Cohn* (NL), J. Hermanides, J. H. Devries, P. W. Kamphuisen, R. Huijgen, J. C. M. Meijers, J. B. L. Hoekstra, H. R. Büller PP-MO-299 SIMPLIFICATION OF THE PULMONARY EMBOLISM SEVERITY INDEX FOR PROGNOSTICATING PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM D. Jiménez* (ES), D. Aujesky, L. Moores, D. Marti, J. Lobo, F. Uresandi, R. Otero, M. Monreal, R. Yusen PP-MO-300 PROTHROMBIN LEVELS ARE INCREASED IN TYPE II DIABETICS D. L. Sauls* (US), R. McFarland, A. Brogden, M. Hoffman PP-MO-301 METABOLIC SYNDROME IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM IN KOREAN POPULATION D. Oh* (KR), M. Jang, W. Choi, S. Bang, T. Lee, Y. Kim, W. Ageno PP-MO-302 IS THERE FAMILIAL CLUSTERING OF ELEVATED FACTOR VIII? E. Vagdatli* (GR), K. Mitsopoulou, F. Tsikopoulou, E. Pantziarela, O. Serafimidou, E. Protonotariou, E. Kazantzidou PP-MO-303 HYPERHOMOCYSTEINEMIA AND RISK OF VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OF PULMONARY EMBOLISM E. Grifoni* (IT), G. Ciuti, D. Poli, E. Antonucci, R. Marcucci, C. Arcangeli, M. Miniati, G. Gensini, R. Abbate, D. Prisco PP-MO-304 OBESITY AS A POSSIBLE RISK FACTOR FOR INCOMPLETE RESTORATION OF PULMONARY PERFUSION AFTER PULMONARY EMBOLISM (PE) E. Grifoni* (IT), D. Poli, E. Antonucci, G. Ciuti, R. Marcucci, C. Arcangeli, G. Gensini, R. Abbate, D. Prisco, M. Miniati PP-MO-305 TYPE AND LOCATION OF VENOUS THROMBOEMBOLISM IN FV LEIDEN CARRIERS; EXPERIENCE FROM A SINGLE CENTER E. Papadakis* (GR), A. Spyrou, S. Efraimidou, K. Loukidhs, H. Kartsios, M. Topalidou, I. Korantzis PP-MO-306 HEMORRHAGE IN ACUTE CARE SETTING IS A RISK FACTOR FOR LATER VENOUS THROMBOEMBOLISM IN REHABILITATION UNIT E. Tincani* (IT), A. Bernardini, M. A. Crowther, M. Foroni PP-MO-307 A GENOME WIDE ASSOCIATION STUDY TO IDENTIFY CANDIDATE GENES FOR HIGH FACTOR VIII LEVELS IN VENOUS THROMBOEMBOLISM: DO ABO- GLYCOSYLTRANSFERASES PLAY AN IMPORTANT ROLE? F. Thieme* (DE), A. Fiebig, T. Lu, B. Luxembourg, H. von Eller-Eberstein, B. Flesch, M. Spannagl, E. Lindhoff-Last, S. Schreiber, C. M. Schambeck PP-MO-308 NATURAL HISTORY OF MESENTERIC VENOUS THROMBOSIS IN PATIENTS TREATED WITH ORAL ANTICOAGULANTS F. Dentali* (IT), W. Ageno, D. Witt, A. Malato, N. Clark, D. Garcia, K. McCool, S. Siragusa, M. Crowther PP-MO-309 JAK2V617F MUTATION FOR THE EARLY DIAGNOSIS OF PH- MYELOPROLIFERATIVE NEOPLASMS IN PATIENTS WITH VENOUS THROMBOEMBOLISM. A META-ANALYSIS F. Dentali* (IT), A. Squizzato, L. Brivio, L. Appio, L. Campiotti, M. Crowther, A. M. Grandi, W. Ageno PP-MO-310 ELEVATED THROMBIN GENERATION IN RELATIVES OF PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM AND NO DETECTABLE THROMBOPHILIA F. Couturaud* (FR), J. Duchemin, G. Quere, C. Kearon, J. Ginsberg, C. Leroyer, D. Mottier, J. Abgrall

140 PM-1 TSU ATRATVT OFBLOODMONONUCLEARCELLS,BUTNOTPLASMA TISSUEFACTOR ACTIVITY PP-MO-314 HIGHLEVELSOFVONWILLEBRANDFACTOR ANTIGEN AND FACTOR VIIIIN PP-MO-313 PP-MO-312 OF THEINCIDENCEOFVENOUSTHROMBOEMBOLISM ALONG THE CHRONOLOGY PP-MO-311 POSTER PRESENTATIONS PM-2 RECURRENTTHROMBOSISINNORTH INDIANPATIENTS AND THEROLEOF PP-MO-324 MELTING MUTATION SCREENINGFORTHEC46TVARIANT INTHEF12GENEBY PP-MO-323 FACTOR VLEIDENMUTATION INCREASESTHERISKFORVENOUS PP-MO-322 VEINTHROMBOSIS LIVINGNEARMAJORTRAFFIC ROADS AND RISKOFDEEP PP-MO-321 PP-MO-320 PP-MO-319 PP-MO-318 PP-MO-317 DISEASE AND RISKOFVENOUSTHROMBOSIS KIDNEY PP-MO-316 DATA VENOUSTHROMBOEMBOLISMINTHEELDERLY: EPIDEMIOLOGICAL PP-MO-315 ODY UY1,2009 MONDAY, JULY 13, THROMBOPHILIC RISKFACTORS DETECTION OFTHEV RESULTS,POINT ANALYSIS WITHTHELIGHTCYCLER SYSTEM: ATYPICAL NIE,I NRAE FE OA KNEE ARTHROPLASTY ANTIGEN, ISINCREASED AFTER TOTAL PATIENTS WITHCHRONICPOSTTRAUMATIC STRESSDISORDER RESULTS “IPER”:PRELIMINARY EMBOLISMREGISTRY THE ITALIAN PULMONARY PATIENTS FEMURFRACTUREINELDERLY FIRST THREEMONTHS AFTER PROXIMAL THROMBOEMBOLISM INP REFERENCE RANGESINTHROMBOPHILIA THROMBOEMBOLISM ROLEINVENOUS A PLAY SUGGEST ADAMTS13 MAY AUTOANTIBODY OF ADAMTS13 PRESENCE THE AND ANTIGEN ANDACTIVITY LOW ADAMTS13 DIFFERENT DECISIONSUPPORTSYSTEMS MULTISITE COMPARISON OF REPORTOF PATIENTSA (IMPART): PRELIMINARY ADEQUACY GROUP CONTROL HEALTHY OFTHROMBOEMBOLISMORRECURRENTPREGNANTLOSSVS. A HISTORY AND A INCIDENCE OFTHROMBOPHILICDISORDERSINWOMENCHILDBEARING OVERVIEW BASEDON THE 2149-PATIENTS PROSPECTIVEOPTIMEVCOHORT J. I. Mannhalter I. Pabinger*(AT), D.Dunkler, R. Vormittag, C. Ay, C.Marosi,R.Simanek,Zielinski, C. I. Martinelli*(IT), A. Baccarelli, V. Pegoraro,P. A. Bertazzi,J.Schwartz,P. M.Mannucci I. Jennings*(UK),D.P. Kitchen, S.Kitchen, T. A. L.Woods, I.D.Walker H. J.L.Fryer*(US),C.Hoecke,R.W Bounameaux* (CH) M. R.Nendaz,P. Chopard,C.Lovis,J.Doerffler, N.Kucher, L. Asmis, D.Spirk,H. H. Schinzel*(DE),E.Rolfes,L.W F G. Ocak*(NL),C. Y. Vossen, M.Verduijn, K.J.vanStralen,F. W. Dekker, C.J.M.Doggen, G. Pernod*(FR),J.Bosson,M.Sevestre,Labarere G. J.Johnson*(US),L. A. Leis,R.Bach B. Makhoul,O.Rubichek,E.Klein,Brenner, G.Sarig*(IL) Bongarzoni, P C. Becattini,F. Casazza*(IT), A. Rubboli, L.Roncon,P. Zonzin,C.D’Agostino, A. A. B.C.Machado,M.L.Sobreira,G.J.Pereira,E.Corrente,F . R.Rosendaal T Ahluwalia* (IN),R. Das, P irado* (ES),I.Coll,E.Martínez-Sánchez, OF VENOUSTHROMBOPROPHYLAXISIN . Favretto,G. Agnelli ARIANT G47A . Malhotra,N.V A TIENTS WITHMALIGNANCY alter , A. V u, E.Guinto,R.S.Greenfield arma, S.V iertel, D.Peetz A. Santamaría,E.Martí,J.Fontcuberta SCREENING arma ACUTEL Y . H. A. Maffei* (BR) ILL MEDICAL AGE 141

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-325 PERSISTENT HIGH FACTOR VIII ACTIVITY LEADING TO INCREASED THROMBIN GENERATION J. K. Ryland* (UK), A. S. Lawrie, S. J. Machin, I. J. Mackie PP-MO-326 VENOUS THROMBOEMBOLISM IN THE EMERGENCY DEPARTMENT: INCIDENCE, DIAGNOSIS AND CLINICAL CHARACTERISTICS OF PATIENTS K. Hitos* (AU), A. Singh, N. Gunja, J. P. Fletcher PP-MO-327 INFLUENCE OF PROCARBOXYPEPTIDASE U LEVEL AND THR325ILE POLYMORPHISM ON CLINICAL EXPRESSION OF THROMBOPHILIA IN CARRIERS OF FV LEIDEN OR FII 20210A MUTATION P. S. Miljic* (RS), E. Heylen, J. L. Willemse, V. Djordjevic, M. Colovic, I. Elezovic, D. F. Hendriks PP-MO-328 THROMBOTIC RISK FACTORS IN PATIENTS WITH LIVER CIRRHOSIS: CORRELATION WITH MELD SCORING SYSTEM AND PORTAL VEIN THROMBOSIS DEVELOPMENT R. de Cristofaro* (IT), M. Zocco, E. di Stasio, S. Lancellotti, M. Pompili, G. Rapaccini, R. Landolfi, A. Gasbarrini PP-MO-329 A COMMON GENETIC VARIANT OF FACTOR XIII A SUBUNIT VAL34LEU PREDISPOSES TO VENOUS THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME M. Sanak, T. Iwaniec* (PL), S. Dziedzina, J. Musial PP-MO-330 ASSOCIATION BETWEEN FACTOR XII C46T POLYMORPHISM AND THROMBOTIC DISEASES IN TAIWAN AND ITS PARTICULAR ROLE IN MALE PATIENTS Y. B. Yu* (TW), J. P. Gau, C. C. Chen, J. Y. You, H. C. Hsu, Y. C. Hong, C. Y. Liu, P. M. Chen, T. S. Lee, C. H. Tzeng

Arterial Vascular Diseases I

PP-MO-331 ASSESSMENT OF PULMONARY HYPERTENSION IN PATIENTS AFFECTED BY PULMONARY EMBOLISM (PE) A. Barchitta* (IT), L. Ruzza, F. Tosato, A. C. Pessina, V. Pengo PP-MO-332 CARDIOVASCULAR AND THROMBO-EMBOLIC RISK FACTORS AND ANTECEDENTS IN IDIOPATHIC SUDDEN SENSORINEURAL HEARING LOSS: THE ACOBRUSK STUDY A. Stepanian* (FR), I. Mosnier, F. Defay, G. Baron, F. Tankere, C. Bodenez, A. Robier, P. Bertholon, B. Fraysse, B. Meyer, O. Sterkers, D. de Prost PP-MO-333 ABO BLOOD GROUP POLYMORPHISMS IN BRAZILIAN PATIENTS WITH VASCULAR ARTERIAL DISEASE A. P. Fernandes* (BR), A. P. Sabino, D. D. Ribeiro, G. G. Lages, M. S. Santos, T. Gadelha, L. S. Dusse, M. Carvalho PP-MO-334 PLASMINOGEN ACTIVATOR INHIBITOR -1 (PAI-1) 4G5G POLYMORPHISM AND PAI-1 ENZYME ACTIVITY IN YOUNG PATIENTS WITH ISCHEMIC STROKE M. S. Santos, A. P. Sabino, M. G. Carvalho, D. D. Ribeiro, T. Gadelha, L. S. Dusse, A. P. Fernandes* (BR) PP-MO-335 EVALUATION OF POLYMORPHISMS IN APOLIPOPROTEIN B GENE AND THE RISK OF ISCHEMIC STROKE IN YOUNG PATIENTS A. P. Fernandes* (BR), C. G. M. Santos, M. Carvalho, A. P. Sabino, D. D. Ribeiro, T. Gadelha, M. O. Sousa, K. B. Gomes PP-MO-336 IMPACT OF THROMBOPHILIA IN YOUNG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION A. Guida* (IT), A. Tufano, M. N. D. di Minno, M. di Capua, A. M. de Gregorio, G. Quintavalle, A. Russolillo, A. Coppola, E. Cimino, A. M. Cerbone, G. di Minno

142 PM-3 EEATRS FBEDN NARA FIBRILLATION PATIENTS RELEVANT RISKOFBLEEDINGIN ATRIAL ONWARFARIN PP-MO-339 COAGULATION MARKERSLEVELSMEASUREDDURING ACUTE INFECTIONMAY PP-MO-338 OUTCOME AFTER ACUTE MARKEROFCLINICAL THROMBINGENERATION IS A PP-MO-337 POSTER PRESENTATIONS PM-4 INCREASED FACTORS VIII AND VONWILLEBRAND IN TYPE2DIABETESWOMEN PP-MO-349 DECREASEFACTOR VIIa/ANTITHROMBIN COMPLEXESINCHILDRENWITHISCHEMIC PP-MO-348 PP-MO-347 PP-MO-346 FIBRINPOLYMERIZATION CARDIOVASCULAR RISKFACTOR RATE AND (FPR) AS A PP-MO-345 PP-MO-344 ASSOCIATION BETWEENGENETICVARIATION AT THE ADAMTS13 LOCUS AND PP-MO-343 PP-MO-342 FIBRILLATION PATIENTS STROKERISKIN ATRIAL ONWARFARIN: PREDICTIVE PP-MO-341 FIBRILLATION ANTICOAGULATION IN ATRIAL BLEEDINGRISKDURINGORAL PP-MO-340 ODY UY1,2009 MONDAY, JULY 13, AND THEIR ASSOCIATION TO MACROVASCULAR DISEASE EXTENT STROKE YOUNG PATIENTS PLA WAITING FORELECTIVECARDIOVERSION EVENTS INELDERLY PREDICT THEDEVELOPMENTOFLONGTERMCARDIO- INFARCTION MYOCARDIAL EFFECT OFTHEDIRECTTHROMBIN INHIBIT ANAL CORONAR THROMBOSIS PEDIATRIC ARTERY PATIENT WITH ACUTE STROKEDUETOA CEREBRAL ISCHEMIC STROKE AND CARDIOV DISEASE ELEVATED ARTERY D-DIMERLEVELS ARE ASSOCIATED WITHCORONARY PREVENTION ANDSECONDARY OFRISKSTRATIFICATION SCHEMESFOR PRIMARY ABILITY PATIENTS OLDERTHAN80 YEARS Fernandes, M. G.Carvalho*(BR), M.O.Sousa, A. Borges, P. W. Rosario,G.F. G.Lages, A. L. Spiezia*(IT),V. Rossetto,S.Gavasso,G. Tognin, B.Brandolin,Woodhams, P. Simioni J. vanRyn*(DE), T. Dietze,I.Kuritsch,M.Kink-Eiband,W. Wienen Sabino, T.Gadelha F. F. Coelho*(BR), A. P. Fernandes,K.B.Gomes,C.G.Miranda,M.Carvalho, A. P. A. E.Ramirez,Cortina*(MX),R. A. Izaguirre E. Turkkan* (TR),F. Pekun,D. Yalcin Atay E. Hanson*(SE),K.Jood,S.Nilsson,C.Blomstrand,Jern Busti, L. Annarumma, R.Corrocher, O.Olivieri D. Girelli*(IT),N.Martinelli, A. Castagna,N.Campostrini,P. Guarini,S.Friso,F. Pizzolo,F. Abbate, D.Prisco D. Poli*(IT),E. Antonucci, E.Grifoni,G.Ciuti,R.Marcucci,L.Mannini,F. Gensini,R. Prisco D. Poli*(IT),E. Antonucci, E.Grifoni,R.Marcucci,L.Mannini, Abbate, G.F. Gensini,D. Prisco D. Poli*(IT),E. Antonucci, E.Grifoni,G.Ciuti,R.Marcucci,S.Fedi,Gensini, Abbate, D. A. Winder*(IL), T. Bruzgol,I.Lichman, A. Herman,E.Leibovitz,Rachmilewitz,D.Gavish J. Rosing,M.H.Prins,W A. W FLOW MODEL THROMBOSIS WHENGIVENINCOMBINA EE LCPOENIBII GENE AND THERISKOFISCHEMICSTROKEIN TELET GLYCOPROTEIN IIB/IIIA . J.H.Dielis*(NL),M.Smid,Spronk,R.vanOerle,Winkens,K.Hamulyak, YSIS OFTHE Y A. Soares RISK PREDICT ASCULAR DEA IN ANESTHETISED PIGS IN ANESTHETISED ASSOCIA altenberger OR TION BETWEENTHEPOL TH IN AN , H.tenCate ANGIOGRAPHICALL INWT SII AA NACYCLIC TION WITH ASPIRIN (ASA)IN A OR, DABIGATRAN, ON ARTERIAL YMORPHISM PLA1/A2OFTHE AND CEREBRO-VASCULAR Y -STUDIED POPULATION 143

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-350 ASSOCIATION OF HAEMOSTATIC AND INFLAMMATORY MARKERS WITH FUTURE ISCHEMIC CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE - INITIAL LABORATORY RESULTS OF THE PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE (PID M. Bedencic* (SI), A. Blinc, M. Bozic Mijovski, M. Stegnar, M. Kozak, M. Sabovic, P. Poredos, A. Kravos, B. Barbic-Zagar, M. Pohar-Perme, J. Stare PP-MO-351 THROMBOPHILIC RISK FACTORS AND PERIPHERAL ARTERIAL DISEASE SEVERITY M. Sartori* (IT), E. Favaretto, C. Legnani, A. Amato, M. Cini, A. Caniato, M. Filippini, G. Palareti PP-MO-352 PLASMA LEVELS OF FIBRINOLYTIC PROTEINS AND THE RISK OF MYOCARDIAL INFARCTION IN MEN M. E. Meltzer* (NL), C. J. M. Doggen, J. C. M. Meijers, P. G. de Groot, F. R. Rosendaal, T. Lisman PP-MO-353 POLYMORPHISMS OF TUMOR NECROSIS FACTOR-ALPHA AND HYPOXIA INDUCIBLE FACTOR 1ALPHA GENES ARE ASSOCIATED WITH PLASMA HOMOCYSTEINE LEVEL AND SUSCEPTIBILITY TO ISCHEMIC STROKE AND SILENT BRAIN INFARCTION (SBI) N. Kim* (KR), J. Lee, O. Kim, J. Choi, D. Rim, S. Lee, D. Oh PP-MO-354 ACTIVATION OF COAGULATION SYSTEM AND ENDOTHELIAL MICROPARTICLES IN CHILDREN WITH HENOCH SCHONLEIN PURPURA N. Sirachainan* (TH), W. Reakatanan, A. Chunharas, P. Kardkasam, N. Porntrasertsud, Tapaneya-Olarn, S. Treepongkarune, A. Chuansumrit PP-MO-355 IMPROVEMENT OF PARAOXONASE 1 ACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROMES R. Januszek* (PL), T. B. Domagala, M. Rzeszutko, S. Dziedzina, M. Kaczor, A. Szczeklik PP-MO-356 PREGNANCY-ASSOCIATED ISCHEMIC STROKE: PREVALENCE AND RISK OF RECURRENT STROKE COMPARED TO NON-PREGNANT WOMEN WITH ISCHEMIC STROKE R. H. White* (US), A. Cheema, P. Verro PP-MO-357 INFLUENCE OF THROMBOPHILIC RISK FACTORS ON PATENCY OF PERIPHERAL ARTERIAL BYPASSES IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE – A PROSPECTIVE STUDY R. Klamroth* (DE), S. Gottstein, C. Kubicek, M. Orlovic, I. Fritsche, H. Landgraf PP-MO-358 PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCY ENHANCES NEOINTIMA FORMATION IN A MURINE MODEL OF VEIN GRAFT DISEASE Y. Ji* (US), W. P. Fay PP-MO-359 STEM CELL THERAPY IN THE TREATMENT OF BUERGER’S DISEASE: A NEW AND PROSPECTIVE APPROACH Z. Boda* (HU), K. Rázsó, M. Szarvas, M. Udvardy, Z. Oláh, P. Ilonczai, J. Tóth, L. Jámbor, T. Sipos, G. Kovács, J. Kappelmayer, K. Farkas, Z. Veréb, É. Rajnavölgyi

Hormones, Pregnancy and Women’s Issues I

PP-MO-360 PREVENTION OF RECURRENT PREECLAMPSIA IN WOMEN WITH THROMBOPHILIA A. D. Makatsariya* (RU), V. O. Bitsadze, S. M. Baimuradova, S. V. Akinshina PP-MO-361 PREGNANCY MANAGEMENT IN WOMEN WITH HISTORY OF OBSTERIC COMPLICATIONS AND THROMBOPHILIA A. D. Makatsariya* (RU), V. O. Bitsadze, S. M. Baimuradova, S. V. Akinshina PP-MO-362 FACTOR VIIIC AS CARDIOVASCULAR RISK IN DM2 SUBJECTS AND CORONARY HEART DISEASE A. Perez Cuadra* (MX), E. Cortina, R. A. Izaguirre 144 PM-6 IFRN EHD FTRMI EEAINA PARAMETER TO MONITOR DIFFERENTMETHODSOFTHROMBINGENERATION AS A PP-MO-365 PP-MO-364 POLYMORPHISM (4G/5G)INTHEPLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI1) PP-MO-363 POSTER PRESENTATIONS PM-7 EA N AENLTRMOHLAINIUGR WITHORWITHOUTMATERNAL THROMBOPHILIA ANDMATERNAL FETAL PP-MO-375 PP-MO-374 ACTIVATED THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFIA) LEVELSIN PP-MO-373 LOW-MOLECULAR-WEIGHT HEPARIN FORPREVENTIONOFOBSTETRIC PP-MO-372 PP-MO-371 RESULTS OFBASELINETHROMBINGENERATION AND FIBRINOLYSIS PRELIMINARY PP-MO-370 PP-MO-369 VARIATIONS INTHROMBOMODULIN,TISSUEFACTOR AND PROCOAGULANT PP-MO-368 CAUSE FORRESISTANCE INPROTEINC “NON-SPECIFIC ABNORMALITIES” - A PP-MO-367 LOSS: OPPOSINGTRENDSINTHROMBOPHILIA-INDUCEDRECURRENTPREGNANCY PP-MO-366 ODY UY1,2009 MONDAY, JULY 13, FERTILIZA HYPERTENSIVE DISEASE CHANGES INVONWILLEBRANDF AINSWT HOBPII ANDPREGNANCY PATIENTS WITHTHROMBOPHILIA WOMEN USINGHORMONEREPLACEMENTTHERAPY ABO BLOODGROUP, D-DIMER AND FACTOR VIIILEVELSINPOSTMENOPAUSAL WOMEN UNDERORAL LEVELSIN WITHTHEPAI-1 PLASMA PROMOTER GENE AND ITSRELATIONSHIP HIGH PREGNANCY MUT COMPLICATIONS INWOMEN,CARRIERSOFFACTOR VLEIDENORPT–G20210A TINZAP REDUCED COMP THROMBIN GENERATION APPEARS INCREASED AND FIBRINOLYTIC ACTIVITY IN WOMENWITHPREVIOUSPREGNANCY FOR PRE-ECLAMPSIA? MARKERS ANDPROCOAGULANTPHOSPHOLIPIDS:NEW AND USEFUL ACTIVITY ELEV PHOSPHOLIPID PATHWAY INMALAYSIAN WOMENWITHRECURRENTFAILED PREGNANCIES INCAUCASIANS, ACQUIRED IN ASIANS CONGENITAL E. Biguzzi*(IT),F. Franchi, P. Pileri,P. Antonazzo, I.Cetin,P. Mannucci Blombäck, A.Antovic M. E. Westerlund* (SE),P. Henriksson,H.Wallén, O.Hovatta,K.Persdotter Eberg,F. Mobarrez, D. Peetz*(DE),Dickemann,C.Interthal, E.Rolfes,H.Schinzel Rossi, C.Legnani, A. Tosetto, P. Simioni D. C. J.Rea*(UK),S.Rangarajan,B.Hunt B. Myers*(UK),N.Brook,R.Kirby A. Rousseau,R.Favier, P. vanDreden*(FR),B.J.Woodhams P. VanDreden* (FR), A. Rousseau,B.J.Woodhams, R.Favier A. Thiruchelvam* (MY),M. Sekaran, A. FaraizahKarim,S.Z.Omar A. Thiruchelvam* (MY),M. Sekaran,K.FaraizahKarim,S.ZOmar A. Siegemund*(DE), T. Siegemund,I.Wittig,U.Scholz R. M.Franco,G.S. Teixeira, L.M.S.Dusse,Carvalho, A. Fernandes*(BR) D. A. M.Guimarães,S.Santos,D.R. A. Rios,S.G. Paiva,J.E.Cardoso,K.B.Gomes, D. R. M.Franco,G.S. Teixeira, M.O.Sousa,L.S.Dusse,Carvalho, A. Fernandes*(BR) A. M.Guimarães,S.Santos,D.R. Tormene* (IT),E.Grandone,V. de Stefano,G.Palareti,Castaman,M.Margaglione,E. A A TION, WITHPREVIOUSEARL TED CIRCULA ARIN THROMBOPROPHYLAXISFORPROSTHETICV TION ACTIVITY RDT ELH FEMALECONTROLS ARED TO HEALTHY TING SOLUBLETHROMBOMODULIN OMN ELCMN HRP (HRT) HORMONE REPLACEMENTTHERAPY NERYADLT NXLIE EA LOSS ANDLATE UNEXPLAINEDFETAL IN EARLY ACTOR AND ADAMTS-13 DURINGIN VITRO Y OR LA A. Rios, A. P. Sabino,J.E.Cardoso,K.B.Gomes, -ASSOCIA TE OBSTETRICCOMPLICA TED VENOUSTHROMBOSIS: ACTIVITY AL VES INPREGNANCY , TISSUEF TIONS ACTOR 145

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-376 TREATMENT OF VENOUS THROMBOEMBOLISM DURING PREGNANCY WITH A ONCE- DAILY REGIMEN OF LMWH F. Parent* (FR), P. Deruelle, X. Jaïs, M. Wolf, F. Jilwan, O. Sanchez, G. Meyer, G. Simonneau PP-MO-377 MENORRHAGIA IS COMMON IN PATIENTS ON ORAL ANTICOAGULATION WITH VITAMIN-K-ANTAGONIST PHENPROCOUMON H. Rott* (DE), G. Kappert, S. Halimeh PP-MO-378 FOLATE DEFICIENCY STATE AND HYPERHOMOCYSTEINEMIA AS CAUSE OF ANTENATAL FETAL DEATH I. N. Talalaeva* (RU), A. D. Makatsaria, L. N. Kiss PP-MO-379 PREDICTIVE VALUE OF THROMBOPATH DETERMINATION IN WOMEN WITH PREGNANCY COMPLICATIONS P. Ferroni* (IT), F. La Farina, R. Palmirotta, F. Martini, V. Raparelli, C. Nigro, S. Riondino, M. Proietti, M. Rampini, S. Basili, F. Guadagni PP-MO-380 TNF-ALPHA GENE POLYMORPHISMS AND SUSCEPTIBILITY TO RECURRENT PREGNANCY LOSS IN ITALIAN WOMEN R. Palmirotta, F. La Farina, P. Ferroni* (IT), G. Ludovici, C. Nigro, A. Savonarola, V. Raparelli, B. Leone, M. R. Rampini, F. Guadagni, S. Basili PP-MO-381 ALTERED REFERENCE RANGES FOR PROTEIN C AND PROTEIN S DURING EARLY PREGNANCY: IMPLICATIONS FOR DIAGNOSIS OF THEIR DEFICIENCY DURING PREGNANCY J. M. Said, V. Ignjatovic* (AU), P. Monagle, S. P. Walker, J. R. Higgins, S. P. Brennecke

Animal and Experimental Models I

PP-MO-382 S 35972, A NOVEL ORALLY ACTIVE THROMBIN INHIBITOR : IN VITRO AND EX VIVO ANTICOAGULANT ACTIVITY A. Rupin* (FR), P. Mennecier, M. O. Vallez, P. Gloanec, G. de Nanteuil, T. J. Verbeuren PP-MO-383 COAGULATION FACTOR CONCENTRATIONS ARE NOT HIGHER IN THE HEPATIC VEINS THAN IN THE PERIPHERAL CIRCULATION A. P. A. Gadisseur* (BE), J. Schouten, S. Franque, I. Vangenechten, M. van der Planken, P. Michielsen PP-MO-384 HYPOXIA MAY BE A STIMULUS FOR VENOUS THROMBUS RESOLUTION C. E. Evans, J. Humphries, A. Wadoodi, M. Waltham, K. Burnand, A. Smith* (UK) PP-MO-385 THE USE OF MRI TO FOLLOW THE FIRST 3 HOURS OF THROMBUS DEVELOPMENT IN AR-H067637 TREATED RATS A. Ravnefjord* (SE), S. Pehrsson, A. W. Bidar, F. Risse, P. D. Hockings, M. Elg PP-MO-386 HAEMOSTATIC RESPONSE TO IN VITRO ADDITION OF RECOMBINANT FACTOR VIIa, PROTHROMBIN COMPLEX CONCENTRATE, OR CONCENTRATE OF FACTOR IX/X IN BLOOD SPIKED WITH A DIRECT Xa INHIBITOR J. B. Olesen, K. Christiansen, J. Ingerslev, B. Sørensen, A. Hvas* (DK) PP-MO-387 PERMISSIVE HYPOTENSION AND DESMOPRESSIN ENHANCE CLOT FORMATION J. B. Rezende-Neto, M. V. Andrade, J. R. Cunha-Melo, D. D. Ribeiro* (BR), T. A. Lisboa, E. R. Camargos, P. Martins, S. B. Rizoli PP-MO-388 ENOXAPARIN DOES NOT DECREASE TOTAL MICROPARTICLES TISSUE FACTOR ACTIVITY IN AN EXPERIMENTAL MODEL OF EARLY VENOUS THROMBOSIS IN MICE E. Ramacciotti* (US), J. A. Diaz, A. E. Hawley, D. M. Farris, N. E. Ballard, S. K. Wrobleski, D. D. Myers Jr, P. K. Henke, T. W. Wakefield

146 PM-9 FIAYADSFT OFPROTHROMBINCOMPLEXCONCENTRATE AND ANDSAFETY EFFICACY PP-MO-391 PP-MO-390 PLATELET UPREGULATION INMICEEXPOSEDTO AMBIENT PARTICULATE MATTER PP-MO-389 POSTER PRESENTATIONS PM-0 EIAINO OE FORPREDICTINGTHE WARFARIN MAINTENANCEDOSEIN MODEL DERIVATION OF A PP-MO-403 DURING IDIOPATHIC PULMONARY HIGHLIGHTINGINVITROHYPERCOAGULABILITY PP-MO-402 OF EFFECTSOF7kDaSTREPTOKINASE FRAGMENT: THERABBITMODEL PP-MO-401 THROMBOGENESISWITH CONTINUOUSBLOODFLOWINTHEINFERIORVENA PP-MO-400 OFLOWMOLECULARWEIGHTHEPARINS AND BIOSIMILARS IMMUNOGENICITY PP-MO-399 PARTICULATE MATTER INDUCELUNGINFLAMMATION URBAN AND DIESEL BUT PP-MO-398 MORERELIABLEMEASURE OFHEPARIN ISTHE APTT OR ANTI-Xa A PP-MO-397 PP-MO-396 THROMBIN INHIBITOR S35972IS ANTITHROMBOTIC INTHE THEDIRECTORAL PP-MO-395 SYSTEMIC ADMINISTRATION OF ANKAFERD BLOODSTOPPER HASNO ORAL PP-MO-394 ISCHEMIA MICE ARE VULNERABLETO CEREBRAL NDRG4-NULL PP-MO-393 MURINEHEMOSTASIS MODEL:STUDIESONRECOMBINANTFACTOR VIIa NOVEL A PP-MO-392 Clinical Trials I 2009 MONDAY, JULY 13, STANDARDIZED INITIATION NOMOGRAM PATIENTS WITHVENOUS THROMBOEMBOLISMBASEDON THERESPONSETO A DYSFUNCTION HYPERTENSIONWITHENDOTHELIAL ARTERIAL TDE NAIA MODELSOFBLEEDING AND THROMBOSIS STUDIED IN ANIMAL EOIUIN LEIGADTRMOI:ABLINDSTUDY HEMODILUTION, BLEEDING AND THROMBOSIS: A OF RECOMBINANT RABBITMODEL ACTIVATED FACTOR VIIVERSUSPLACEBOIN A ACYLHYDRAZONE DERIV PHARMACOLOGIC CHARACTARIZATION OFTHE ANTIHEMOSTATIC EFFECTSOF HAEMOSTASIS SYSTEM CA HEMOSTASIS ACTIVATIONPOOR SECONDARY INMICE ANTICOAGULATION INTHE ACUTE PHASERESPONSE? PHARMACOEQUIV MICROVASCULATURE OFMICE MODEL IN AN INVIVORABBITEXPERIMENTAL SHORT-TERM TOXICITY AND NN1731 A. Lazo-Langner*(CA), K.Monkman,M.J.Kovacs A. Brunette*(FR),J.Max,V. Regnault, A. Benetos, T. Lecompte,D.Wahl, F. Chabot S. P J. A. Diaz*(US), A. E.Hawley, A. M.Berguer, S.K.Wrobleski, B.R.Lucchesi,D.MyersJr J. M.W J. Emmerechts*(BE),B.Nemery, M.Hoylaerts J. Uprichard*(UK),R. J. Kuziej*(US),W. Jeske,D.Hoppensteadt,E.Litinas,McGeehan,J.Fareed,R.Kennedy I. Marx*(FR),M.O.V Goker, I.C.Haznedaroglu*(TR) H. Bilgili,O.Captug, H. Yamamoto* (JP),K.Kokame,H. Yanamoto, T. Okuda, Y. Nakajo,S.Miyamoto, T. Miyata H. C.Whinna*(US),D.M.Monroe Samama F. LeSache*(FR),B.Bonniec,Dizier, A. Godier, C.Bachelot-Loza,J.Emmerich,M. F. S.Frattani*(BR),E.O.Coriolano,L.M.Lima,C. A. M.Fraga,E.J.Barreiro,R.B.Zingali F. Tablin* (US),J.W. Norris,M.Pombo,H. Auh, M.W. Lame,D.W. Wilson V . Gavrylyuk*(UA),O.M.Savchuk,G. L.V A: A alenga* (US),D.Hoppensteadt,J.Cunanan,W NOVEL MOUSE MODEL ALENCE OFENOXAP A. Kosar allez, J.Paysant,G.deNanteuil, A. Manning, A. Hann,M. A. Laffan ATIVES , M.Kurt,Kekilli, ARIN olkov AND CONT A. Shorbagi,O.K.Kurt,Ozdemir , L.I.Ostapchenko . P. Jeske,C. Adiguzel, M.Bakhos A. Rupin, AMINA T . J.V TED ENOXAPARIN AS erbeuren , H. 147

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-404 QUALITY OF TELEPHONE-BASED MANAGEMENT OF ORAL ANTICOAGULATION TREATMENT M. Gubensek, A. Mavri* (SI) PP-MO-405 URINARY PROTHROMBIN FRAGMENT 1.2 (UF1.2) LEVELS IN PREGNANCIES COMPLICATED BY PREECLAMPSIA A. S. Andersen* (DK), T. Bergholt, C. Sørensen, I. Deltour, J. G. Berthelsen, M. R. Lassen PP-MO-406 EFFICACY OF 3-MG WARFARIN LOADING DOSE ON TIME TO THERAPEUTIC INR IN ADULT THAI PATIENTS B. Suwanawiboon* (TH), P. Kongtim, Y. Chinthammitr, T. Ruchutrakool, W. Wanachiwanawin PP-MO-407 EFFECTS OF AGE AND GENDER ON THE SINGLE-DOSE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF APIXABAN C. E. Frost* (US), S. Nepal, Y. Barrett, F. Lacreta PP-MO-408 LONG-TERM TREATMENT WITH AN ORAL DIRECT THROMBIN INHIBITOR CHANGES THE PATTERN OF INFLAMMATORY MARKERS IN PATIENTS WITH MYOCARDIAL INFARCTION C. Christersson* (SE), J. Oldgren, L. Wallentin, A. Siegbahn PP-MO-409 HOW USEFUL IS DETERMINATION OF ANTI FACTOR Xa ACTIVITY TO GUIDE BRIDGING THERAPY WITH ENOXAPARIN? A PILOT STUDY C. Hammerstingl* (DE), H. Omran, B. Pötzsch PP-MO-410 AN EVALUATION OF THROMBOTIC CHANGES IN BEREAVEMENT M. C. Morel-Kopp, T. Buckley, Q. Chen, G. Tofler, S. McKinley, R. Bartrop, C. M. Ward* (AU) PP-MO-411 LONG TERM EFFECT OF TOMATO JUICE AND FISH OIL ON PLATELET FUNCTION AND THROMBUS FORMATION M. C. Morel-Kopp, B. McEwen, Q. Chen, C. M. Ward* (AU) PP-MO-412 ANTI-HUMAN, ANTI-BOVINE THROMBIN ANTI-BODIES AND FACTOR V/Va ANTI- BODIES IN NORMAL HUMAN SUBJECTS C. Paterson* (US), J. Fareed PP-MO-413 EFFICACY AND SAFETY OF LONG TERM ADMINISTRATION OF BEMIPARIN IN PATIENTS WHO NEED CRONIC ANTICOAGULATION AND HAVE SUFFERED SEVERE AND RECURRENT GASTROINTESTINAL BLEEDING E. Marti* (ES), J. Mateo, A. Santamaria, J. C. Souto, C. Alvarez, C. Villanueva, J. Fontcuberta PP-MO-414 SUPERVISED PATIENT SELF-TESTING OF WARFARIN THERAPY USING AN INTERNET BASED EXPERT SYSTEM - A FOLLOW UP STUDY F. Ryan, S. Byrne, S. Oshea* (IE) PP-MO-415 FONDAPARINUX VERSUS LEPIRUDIN IN THE MANAGEMENT OF PATIENTS WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) WITH OR WITHOUT THROMBOSIS (ON BEHALF OF THE FLHIT STUDY INVESTIGATORS) F. Piovella* (IT), M. Barone, C. Beltrametti, C. Piovella, S. Barco, M. de Amici, A. D’Angelo PP-MO-416 LIMITED UTILITY OF PLATELET-THROMBIN ACTIVATION MARKERS IN THE ASSESSMENT OF PATIENTS WITH CHEST PAIN OR SUSPICION OF VENOUS THROMBOEMBOLISM S. El Ghannudi, S. Gayol, T. Kirchgesner, M. L. Wiesel, O. Morel, L. Calvel, P. Bareiss, J. Kopferschmitt, J. P. Cazenave, P. Ohlmann, C. Gachet, F. Lanza* (FR) PP-MO-417 EFFICACY AND SAFETY OF FONDAPARINUX IN THE INITIAL TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH MODERATE RENAL IMPAIRMENT (MRI) H. R. Buller* (NL)

148 PM-2 IDENTIFICATION OFCOAGULATION PARAMETERS WHICHDETERMINETHE PP-MO-420 PP-MO-419 OFTHE ANTI- ASSESSINGIMMUNERESPONSE AFTER REPEATED AVIDIN REVERSAL PP-MO-418 POSTER PRESENTATIONS PP-MO-431 CELLULOSE TIMEMEASURMENTSOFCOAGULATION ONBACTERIAL REAL PP-MO-430 PP-MO-429 IMMOBILIZATION OFCORN TRYPSIN INHIBITOR REDUCESTHEINVITRO PP-MO-428 PP-MO-427 RETRIEVABLE INFERIOR GUNTHERTULIP FILTER FRACTURE AND MIGRATION OF A PP-MO-426 TERTIARY FILTER INSERTION–5 YEAR EXPERIENCEIN A CAVAL INFERIORVENA PP-MO-425 VEINOCCLUSION ANTITHROMBOTICTREATMENT INRETINAL OFEARLY EFFICACY PP-MO-424 BYPASS SURGERY ARTERY CORONARY INVIVOTAFI ACTIVATION INOFF-PUMP PP-MO-423 PROSPECTIVE, PREVENTIONOFVENOUSTHROMBOSISINCANCERPATIENTS: A PP-MO-422 HEMORRHAGICRISK TEST BETTERREFLECTSTHEPOTENTIAL WHICHBIOLOGICAL PP-MO-421 Intravascular DevicesandInterventionsI 2009 MONDAY, JULY 13, CORONAR PROGNOSTIC ROLEOFHYPERHOMOCYSTEINEMIA TILFIBRILLATION ATRIAL PHENPROCOUMON INPATIENTS UNDERGOINGCARDIOVERSIONFORRECENT COMBINED EFFECTOFLOW-MOLECULAR-WEIGHT HEPARIN CERTOPARIN AND NEW ASSAYS FORMEASURINGDIRECTTHROMBININHIBITORS ONPLASMA OFIDRABIOTAPARINUX (BIOTINYLATED IDRAPARINUX)Xa ACTIVITY IMP PROCOAGULANT PROPERTIESOFCA ARTERIOVENOUS (A PEDIATRIC FILTER PATIENT: CASEREPORT 22DAYS CAVA AFTER IN A A VENA CARE HOSPITAL (OPCAB): EFFECTOFDIFFERENTHEP LOW-MOLECULAR WEIGHTHEPARIN COMPARING TWODIFFERENTDOSAGESOF RANDOMIZED, DOUBLE-BLINDSTUDY STACKENOX STUDY ASSOCIATED WITHSTACK-ON UNFRACTIONATED HEPARIN: RESULTS FROMTHE O. A. Smirnova* (RU),V. M.Shmeleva,L.P. Papayan,S. A. Boldueva L. Faxälv*(SE),H.Fink,B.Risberg,P. Gatenholm, T. L.Lindahl, A. Sellborn K. Komukai*(JP), J. W J. I.Varughese* (US),M.Sandhu,S.Sachdev, S.Palekar, A. Cohen, A. Eisenberger J. Y. K. Yang* (CA), A. K.C.Chan,L.R.Brandao,S.Williams J. Saour*(SA),M.ElSherif, A. Donà,M. T. Sartori,S.Piermarocchi,E.Pilotto,L.Pasetto, A. Pagnan,P. Prandoni*(IT) Semeraro M. Colucci*(IT),F L. Traby* (AT), A. Kaider, R.Schmid, A. Kranz,P. Quehenberger, P. A. Kyrle,S.Eichinger L. Drouet*(FR),C.BalDitSollier, J.Martin J. Harenberg*(DE),Wierdak,C.Giese,Weiss, C. Abletshauser, U. Tebbe J. Amiral* (FR), A. M.Vissac, M.Peyrafitte I. Paty*(FR),P THROMBIN AND PLASMINGENERATION M. Mizukoshi, T. Imanishi, T. Akasaka PIA OEEC OORPYSTUDY COHERENCE TOMOGRAPHY OPTICAL ACT OFINVIVOPLA . Y au* (CA), Y STENT IMPLANT . Cortez,M. Trellu, E.Sultan A. R.Staf . Semeraro,C. T. Ammollo, D.Paparella,G.Scrascia,C.Fondacone,N. A. Tanaka, H.Kitabata, T. Tanimoto, S. Takarada, N.Nakamura, K.Hirata, V) FISTULA TELET ford, J.C.Fredenburgh,L.Brash,I.W A. Al Harthi,E.Bakhsh,L.Mammo A TION ACTIVITY THROMBOSIS AND THROMBOPHILIA THROMBOSIS AND THETERS ARIN DOSAGES NSBLNCLSTENTTHROMBOSIS: AN ON SUBCLINICAL IN PATIENTS UNDERGOING AND CORRELATION WITH eitz 149

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-432 HAEMOPHILIA AND INVASIVE CORONARY PROCEDURES R. Santoro* (IT), S. Prejanò, P. Iannaccaro, G. Muleo PP-MO-433 A HISTORY OF LATE STENT THROMBOSIS IS NOT ASSOCIATED WITH INCREASED ACTIVATION OF THE CONTACT PHASE SYSTEM V. Pönitz* (NO), J. W. P. Govers-Riemslag, H. ten Cate, R. van Oerle, P. Næsgaard, H. Grundt, D. Pritchard, A. Larsen, D. W. T. Nilsen

Pediatric Thrombosis I

PP-MO-434 INCREASED LEVELS OF VON WILLEBRAND FACTOR MULTIMERS AND VWF- CLEAVING PROTEASE (ADAMTS-13) IN TERM AND PRETERM NEONATES T. Strauss, A. Zivelin, B. Ravid, A. Lubetsky* (IL), I. Morag, J. Kuint, G. Kenet PP-MO-435 DEVELOPMENT OF A PEDIATRIC QUALITY OF LIFE INVENTORY FOR CHILDREN REQUIRING LONG-TERM ANTICOAGULATION A. A. K. Bruce* (CA), M. E. Bauman, A. S. Newton, M. Bauman, L. Bajzar, K. Black, L. Legge, M. Massicotte PP-MO-436 INCIDENCE OF THROMBOTIC AND BLEEDING COMPLICATIONS DURING CARDIAC CATHETERIZATION IN CHILDREN (HEARTCAT-STUDY) A. Hanslik* (AT), E. Kitzmüller, M. Haumer, H. Karapetian, K. Thom, U. Salzer-Muhar, I. Michel-Behnke, C. Male PP-MO-437 THROMBIN GENERATION IN CHILDREN ON ORAL ANTICOAGULANTS A. Greenway* (AU), V. Ignjatovic, R. Summerhayes, F. Newall, J. Burgess, L. Derosa, P. Monagle PP-MO-438 EVALUATION OF POINT OF CARE INR IN CHILDREN A. L. Greenway* (AU), V. Ignjatovic, R. Summerhayes, F. Newall, J. Burgess, L. Derosa, P. T. Monagle PP-MO-439 EFFECTS OF L-ASPARAGINASE THERAPY ON THROMBIN GENERATION IN CHILDREN WITH ACUTE LEUKEMIA A. Yamashita* (JP), C. Nagae, T. Shoji, S. Muto, M. Asahara, M. Morimoto, K. Kondo, A. Kinoshita, S. Yamazaki, S. Takayama, M. Taki PP-MO-440 THROMBOCYTOPENIA ASSOCIATED MULTIPLE ORGAN FAILURE IN AN INFANT - A CHALLENGING CASE A. Unuvar* (TR), D. Demirkol, A. Nayir, M. Karabocuoglu, D. Yanni, O. Devecioglu PP-MO-441 EVALUATION OF THROMBOTIC EFFECTS OF ASPARAGINASE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) C. Pawlik* (BE), A. Demulder, P. Lê, A. Ferster PP-MO-442 CONCURRENT PAS AND CSVT IN THE NEWBORN D. Telega, S. Ong, O. O. Zaidat, C. Amlie-Lefond* (US) PP-MO-443 MAJOR BLEEDING COMPLICATIONS IN PEDIATRIC MECHANICAL VALVE PATIENTS DURING BRIDGING ANTICOAGULATION THERAPY C. I. Segbefia* (CA), S. Williams, L. Brandao PP-MO-444 CATHETER-RELATED THROMBOSIS AND INFECTION IN CHILDREN WITH LONG-TERM TOTAL PARENTERAL NUTRITION I. L. Vegting, M. M. Tabbers, M. A. Benninga, C. H. van Ommen* (NL) PP-MO-445 A CLINICAL CASE OF HEMOGLOBIN C DISEASE, PROTEIN S DEFICIENCY AND LEUKEMIA D. Aïtchafa Tadlaoui* (DZ), C. Touchrift, Z. Guechi

150 PM-4 AGE-RELATED DIFFERENCESINVIVOUFHRESPONSECHILDREN PP-MO-449 INPEDIATRIC PROTEINCREPLACEMENTDURINGFEBRILENEUTROPENIA PP-MO-448 PP-MO-447 ISDECREASEDINCHILDRENWITHBETA-THALASSEMIA ADAMTS-13 ACTIVITY PP-MO-446 POSTER PRESENTATIONS PP-MO-462 GENERAL BY ANTICOAGULANTTHERAPY STRUCTUREDMANAGEMENTOFORAL PP-MO-461 CURRICULUMDEVELOPMENTINTHROMBOSISMEDICINE PP-MO-460 OUTCOMEINPARENTS OFCHILDRENWITHHAEMOPHILIA PSYCHOSOCIAL PP-MO-459 PP-MO-458 MONITORING WITHPOINTOFCARE DEVICE BY COMPUTER ASSISTED VKA PP-MO-457 INCHILDREN:UFH CHALLENGESOF ANTICOAGULATION THERAPY PP-MO-456 PP-MO-455 EMPOWARMENT: EDMONTON PEDIATRIC WARFARIN SELF-MANAGEMENTSTUDY PP-MO-454 INCHILDREN THROMBOPHILIA PP-MO-453 PAEDIATRIC THROMBOSISINKENYA PP-MO-452 CORRELATION OFUFHMEASURESEFFECTWITHPROTAMINE TITRATION IN PP-MO-451 ANTI-Xa:ANTI-IIaRATIO VARIES WITH AGE AND UFHCONCENTRATION INCHILDREN PP-MO-450 Health ServiceandOutcomesI 2009 MONDAY, JULY 13, ANTICOAGULATION THERAPY EV PRACTITIONERS PATIENTS WITHCANCER MUL VENOUS STASIS ULCERINPAEDIATRIC POSTPHLEBITICSYNDROME- PROSPECTIVE PRACTITIONERS GENERAL CENTRAL CONTAMINATION OFENOXAPARIN ANTI XaLEVELSWHENDRAWN THROUGH A ENOXAP CHILDREN D. M.Witt*(US), T. Delate, N.P. Clark,M. A. Crowther, D. A. Garcia, W. Ageno, E.M.Hylek C. Manotti*(IT),Pattacini,R.Emanuele C. Gonsalves*(CA),P S. W A. Iorio*(IT),E.Filippucci,M.Basileo,S.Iaboni,Paccamiccio,Vecchioli, G. Agnelli M. Basileo,E.Filippucci,S.Iaboni,P. Grilli,M.Vecchioli, G. Agnelli, A. Iorio*(IT) M. P. Massicotte*(CA),M.E.Bauman, M.L.Bauman,K.Black,Bajzar M. P. Massicotte*(CA),M.E.Bauman,K.L.Black,Bajzar M. E.Bauman*(CA),K.L.Black,Bauman,S.Kuhle,Bajzar L. Lokar*(SI),V G. W. Kitonyi*(KE),J.W. Githanga,J. A. Rajab,W. O.Mwanda F. H.Newall*(AU),V. Ignjatovic,L.Johnston,G.Lane,R.Summerhayes,P. Monagle F. H.Newall*(AU),V. Ignjatovic,L.Johnston,G.Lane,R.Summerhayes,P. Monagle F. H.Newall*(AU),V. Ignjatovic,L.Johnston,G.Lane,R.Summerhayes,P. Monagle Arcamone, N.Santoro,F.A. Badainah*(IT) P. Giordano,V. Cecinati,M.Grassi,L.P. Brescia,G.C.DelVecchio, F. deLeonardis,G. D. Castle*(CA),L.Brandao,S.Williams D. Sosothikul*(TH),P. Kuwatjanakul, Y. Kittikalayawong,C.Bubpachart,P. Seksarn PRIMAR ALUA IICPIAYMNGMN FACHRONICCONDITION MANAGEMENTOF A TIDISCIPLINARY iedebusch, B.Siegmund*(DE),H.Pollmann, F. Muthny Y IGTEFAIIIYOFLESS FREQUENTINRTESTINGDURING CHRONIC TING THEFEASIBILITY ARIN MONIT CARE COMPUTER ASSISTED MANAGEMENTMODEL LINE . Urlep?alinoviæ,O.Krajnc,L.?olman ASSESSMENT OFCLINICAL . W ORING: CHALLENGESOFCENTRAL ells, A. Karovitch,L.Varpio, M.Marks,Rodger ENDPOINTS OFVKA LINE BLOODSAMPLES , M.P TREA . Massicotte TMENT IN A 151

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-463 INCIDENCE AND PREDICTORS OF SERIOUS BLEEDING FOLLOWING POLYPECTOMY IN PATIENTS RECEIVING AND NOT RECEIVING ORAL ANTICOAGULATION THERAPY D. M. Witt* (US), T. Delate, K. H. McCool, M. Dowd, N. P. Clark, M. A. Crowther, D. A. Garcia, W. Ageno, F. Dentali, E. M. Hylek, W. G. Rector PP-MO-464 QUALITY OF ORAL ANTICOAGULATION MANAGEMENT IN PHARMACIST VS NURSE MANAGED MODELS OF CARE E. A. Nutescu, A. Bautista* (US), W. Gao, T. Stamos, W. Galanter, J. Garofalo, J. Bauman PP-MO-465 ENOXAPARIN IS COST-SAVING COMPARED WITH UNFRACTIONATED HEPARIN (UFH) FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH ACUTE ISCHEMIC STROKE: AN ANALYSIS OF HOSPITAL COSTS FROM THE PREVAIL TRIAL G. Pineo* (CA), J. Lin, L. Stern, T. Subrahmanian PP-MO-466 ENOXAPARIN FOR VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS IN PATIENTS WITH ACUTE ISCHEMIC STROKE IS ASSOCIATED WITH LOWER COSTS TO THE PAYERS THAN UNFRACTIONATED HEPARIN (UFH): ANALYSIS FROM THE PREVAIL TRIAL G. Pineo* (CA), J. Lin, L. Stern, T. Subrahmanian PP-MO-467 PERFORMANCE OF A LOW-VOLUME COAGULATION ANALYZER WITH EXPANDED TEST MENU M. Sonnek, H. Su, G. A. Cutsforth* (US) PP-MO-468 ECONOMIC COMPARISON OF RIVAROXABAN WITH ENOXAPARIN IN CANADIAN PATIENTS UNDERGOING TOTAL HIP AND TOTAL KNEE REPLACEMENT P. Wells, A. Diamantopoulos, H. McDonald* (CA), F. Forster, M. Lees PP-MO-469 INTERIM ANALYSIS OF TRIPLE INTERVENTION TO IMPROVE INR CONTROL IN WARFARIN-TREATED PATIENTS H. I. Bussey* (US), M. B. Walker, K. L. Bussey Smith, C. Frei PP-MO-470 INFREQUENT USE OF EMPIRIC ANTICOAGULATION OR FIBRINOLYSIS FOR SEVERE ACUTE PULMONARY EMBOLISM J. A. Kline* (US), B. Hiestand, D. Slattery, D. Schreibner, D. Schreibner, R. Pendleton PP-MO-471 ARNICA MONTANA HAS NO EFFECT ON COAGULATION AND BLEEDING TIME IN VIVO J. N. Mahlangu* (ZA), J. N. Mahlangu, B. Saunders, A. Reaves, T. Nkujani, M. Basson PP-MO-472 MAINTAINED IMPACT OF AN ELECTRONIC ALERT SYSTEM FOR VENOUS THROMBOEMBOLISM PREVENTION AMONG HOSPITALIZED PATIENTS: 3-YEAR EXPERIENCE R. Lecumberri, M. Marqués, E. Panizo, P. Rodríguez-Otero, C. Pegenaute, A. García-Mouriz, J. A. Páramo* (ES) PP-MO-473 REAL-WORLD PATTERNS OF ARGATROBAN OR LEPIRUDIN USE IN PATIENTS WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA A. F. Shorr, R. V. Horblyuk* (US), A. Basu, M. D. Zilberberg

Cancer and Thrombosis I

PP-MO-474 DIC AND THROMBOPHILIA PROPHYLAXIS DURING CHEMOTHERAPY IN GYNECOLOGIC CANCER PATIENTS A. Vorobev* (RU), A. Makatsaria PP-MO-475 TICK INHIBITORS MODULATING BLOOD CLOTTING AND CELL PROLIFERATION A. M. Chudzinski-Tavassi* (BR), P. L. De-Sá-Júnior, S. M. Simons, D. G. L. Oliveira, J. S. Ventura, F. Faria, I. F. C. Batista, E. M. Reis

152 PM-7 EFFECTOFPOST-OPERATIVE PROPHYLAXISWITHENOXAPARIN ON PP-MO-478 PP-MO-477 HEMOSTATIC VARIABLES INCANCERPATIENTS RECEIVINGLOW-MOLECULAR- PP-MO-476 POSTER PRESENTATIONS PM-8 MECHANISMFOR THROMBIN-DEPENDENTLUNGMETASTASIS INPATIENTS A WITH PP-MO-489 VENOUSTHROMBOEMBOLISM(VTE)INHOSPITALIZED CANCER PATIENTS: PP-MO-488 LOWRISKFORSYMPTOMATIC VENOUSTHROMBOEMBOLICEVENTS(VTE)DURING PP-MO-487 PP-MO-486 CANCERCELL-DERIVED MICROPARTICLES ACCELERATE THROMBUSFORMATION PP-MO-485 VERSUS MALIGNANTCOLONTISSUE COAGULATION PROTEINSINHEALTHY PP-MO-484 PROBABILISTICCOST-EFFECTIVENESS ANALYSIS FORDEEP-VEINTHROMBOSIS A PP-MO-483 PP-MO-482 PP-MO-481 GENETICPOLYMORPHISMS INCLOTTINGFACTORS AND THERISKOFCOLORECTAL PP-MO-480 LOWMOLECULARWEIGHTHEPARIN DOWNREGULATES TISSUEFACTOR PP-MO-479 ODY UY1,2009 MONDAY, JULY 13, OSTEOSARCOMA PROPHYLAXIS FAILURE ORFAILURE TO PROPHYLAX! CYT CIIY(PCA)OFTUMORCELLS ACTIVITY FORIDENTIFICATION AND CHARACTERIZATION OFTHEPROCOAGULANT ASSAY THOMBOELASTOGRPHIC PROFILEOFPATIENTS WITHLUNGCANCER RESECTION AND ENOXAPARIN PROPHYLAXIS SURGICAL REVERSED BY INCREASED THROMBINGENERATION INLUNGCANCERPATIENTS ISPARTIALLY THE PROTECHTTRIAL IN WEIGHT HEPARIN (LMWH)NADROPARIN ORPLACEBODURINGCHEMOTHERAPY MOLECULAR P IN VIVO INBRAZIL FOLLOWING SURGERY PROPHYLAXIS ENOXAP CALIBRA LINEMCF7 CELL LEPTIN ENHANCESTISSUEF CANCER INVASION INVITRO EXPRESSION AND SUPPRESSESPANCREATIC CANCERCELL CANCER CELL-DERIVEDMICROPARTICLES INVIVO K. S.Borensztajn* (NL), H. H. N. Abdel-Razeq, F. A. Badainh*(JO),I.M. Treish, A. H.Mansour Hogan, M. A. Gertz,D. A. Gastineau,M. A. Elliott,G.S.Nowakowski,K.Kumar H. V Dubois G. M. Thomas* (FR),C.Dubois,R.Lacroix,F. Dignat-George,D.Lombardo,L.Panicot- G. M. Otten G. L.vanSluis*(NL),H.M.Spronk,R.Oerle,J.W E. deMeis*(BR),L.Schluckebier E. Diani*(IT),M.Marchetti,Cantalino,H.tenCate, A. Falanga Gaetano, M.B.Donati,R.Lorenzet E. Napoleone*(IT), C. Y. Vossen* (NL),M.Hoffmeister, J.Chang-Claude,F. R.Rosendaal,H.Brenner C. Ettelaie*(UK), A. Maraveyas,M.E.W. Collier C. Papageorgiou*(FR),E.Marret, Y. Ynineb, F. Bonnet,G. T. Gerotziafas,I.Elalamy C. Papageorgiou*(FR),E.Marret, Y. Ynineb, F. Bonnet,I.Elalamy, G. T. Gerotziafas A. Falanga*(IT), inhn,adtePOEH StudyGroup Bianchini, andthePROTECHT . K.Naina*(US),R.Pruthi,D.J.Inwards, M.R.Litzow, S.M. Ansell, D. Angela, W. J. OKINE Thomas* (FR),L.Panicot-Dubois,D.Lombardo,C.Dubois TED DIITAINFRPRPEA LO TMCL MOBILIZATION BLOODSTEMCELL ADMINISTRATION FORPERIPHERAL AUT A A. V THW OMA A. Cutrone,F ignoli, M.Marchetti,Mandalà,L.Russo,Kauling,G. Agnelli, C. A YS INVOL TED THROMBOGRAM(CA ARIN VERSUSNOINTER Aberson, A. P. Groot,M.P. Peppelenbosch, A. Spek ACT . Zurlo,G.Colavecchia,M.Latella,L.Iacoviello,de , R. A. Fernandes,E.Bernardina, R. A. Levy, F. F. Quintella VED INTHROMBUSFORMATION INDUCEDBY OR SYNTHESISINTHEHUMANBREASTCANCER T) IS VENTION INONCOLOGY esterga, H.tenCate,J.M.B. SUITABLEUSEFUL AND A PATIENTS 153

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-490 THE CHEMOTHERAPEUTIC METABOLITE ACROLEIN MODULATES PRO- AND ANTICOAGULANT PATHWAYS ON ENDOTHELIAL AND SMOOTH MUSCLE CELLS L. L. Swystun* (CA), P. C. Liaw PP-MO-491 EFFECT OF L-ASPARAGINASE ADMINISTRATION ON TISSUE FACTOR,THROMBOMODULIN ACTIVITY AND PROCOAGULANT PHOSPHOLIPIDS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) A. Rousseau, P. Schneider, P. Vandreden, J. Vannier, B. J. Woodhams, M. Vasse* (FR) PP-MO-492 VENOUS THROMBOEMBOLISM AND BLEEDING IN CANCER PATIENTS ON BEVACIZUMAB THERAPY: A META-ANALYSIS N. M. Kuderer* (US), T. L. Ortel, C. W. Francis, A. A. Khorana, M. S. Poniewierski, G. H. Lyman PP-MO-493 VENOUS THROMBOEMBOLISM COMPLICATING MALIGNANCY:EFFECT OF TUMOUR SUBTYPE AND THROMBOTIC LOAD ON SURVIVAL T. Prestidge, S. Lee, L. Young, P. Harper, P. A. Ockelford* (NZ) PP-MO-494 ELEVATED LEVELS OF FVIIa-AT FOLLOWING PREDNISONE MONOTHERAPY IN CHILDREN WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA U. Athale* (CA), T. Nayiager, J. McGrath, A. Moghrabi, A. Chan PP-MO-495 PREVALENCE OF HYPERHOMOCYSTEINEMIA IN PATIENTS WITH MULTIPLE MYELOMA V. M. Shmeleva* (RU), L. P. Papayan, K. M. Abdulkadirov

Venous Thrombosis: Diagnosis I

PP-MO-496 USEFULNESS OF VENOMETER TEST IN OUTPATIENT WITH CLINICAL SUSPICION OF DEEP VEIN THROMBOSIS A. Alatri* (IT), O. Paoletti, L. Bassi, A. Zimmermann, E. Spotti, N. Delpero, S. Testa PP-MO-497 CUT-OFF LEVEL OF SOLUBLE FIBRIN FOR DIAGNOSING VENOUS THROMBOEMBOLISM USING NANOPIA®SF A. Suzuki* (JP), H. Yago, H. Wada, T. Matsumoto, N. Yamada, A. Sudo, T. Nobori PP-MO-498 COMPARISON OF THE WELLS SCORE WITH THE SIMPLIFIED REVISED GENEVA SCORE FOR ASSESSING PRETEST PROBABILITY OF PULMONARY A. Penaloza* (BE), C. Melot, S. Motte PP-MO-499 “COCKADE THROMBUS”, A NEW ULTRASOUND DIAGNOSIS M. Maufus, G. Le Gal, P. Quehe, A. Delluc* (FR), L. Bressollette PP-MO-500 ”COCKADE” THROMBOSIS OF LOWER LIMBS IS ASSOCIATED WITH REDUCED OCCURRENCE OF SYMPTOMATIC PULMONARY EMBOLISM A. Delluc* (FR), P. Quehe, E. Plat, M. Maufus, G. Le Gal, K. Lacut, E. Oger, D. Mottier, L. Bressollette PP-MO-501 PERFORMANCE OF FIVE D-DIMER ASSAYS IN THE DIAGNOSIS OF SYMPTOMATIC DISTAL LEG VEIN THROMBOSIS B. Luxembourg* (DE), J. Schwonberg, C. Hecking, M. Schindewolf, D. Zgouras, S. Lehmeyer, E. Lindhoff-Last PP-MO-502 PERFORMANCE CHARACTERISTICS OF A NEW AUTOMATED LATEX IMMUNOTURBIDIMETRIC ASSAY FOR DETERMINING D-DIMER CONCENTRATIONS IN HUMAN PLASMA C. Silverstrim* (US), C. J. Hoecke, R. S. Greenfield, E. A. Lazarski, H. J. L. Fryer

154 PM-0 RDCINRLSFRPLOAYEBLS:AMETA-ANALYSIS EMBOLISM: A PREDICTIONRULESFORPULMONARY PP-MO-505 PP-MO-504 D-DIMER(DD) OF A ANDDIAGNOSTICUTILITY IMPROVEMENTOFTHESPECIFICITY PP-MO-503 POSTER PRESENTATIONS PM-1 EAIEIMNTRIOERCDDMRA STAND-ALONE TEST NEGATIVE IMMUNOTURBIDOMETRICD-DIMER AS A A PP-MO-515 EVALUATION OFTHECOMBINATION OFD-DIMER AND SOLUBLEFIBRIN PP-MO-514 INDIAGNOSTICS GAP ANTITHROMBINDEFICIENCY: A PP-MO-513 ANTICOAGULATION PRIORTO DIAGNOSTICCONFIRMATION INPATIENTS WITH PP-MO-512 PP-MO-51 PRO275SERHOMOZYGOUS MUTATION OFPROCGENECAUSESTYPEIIINHERITED PP-MO-510 NON-IMPLEMENTATION OFGUIDELINERECOMMENDATIONS FORDIAGNOSISOF PP-MO-509 EVALUATION OFVENTILATION AND PERFUSION LUNGSPECT(SINGLEPHOTON PP-MO-508 USEOFCARDIACMRIIN ANDPOTENTIAL RIGHTVENTRICULARREMODELINGBY PP-MO-507 SUSPECTED OFD-DIMERTESTING INPATIENTS WITHCLINICALLY UTILITY PP-MO-506 ODY UY1,2009 MONDAY, JULY 13, 1 XLDSPLOAYEMBOLISM EXCLUDES PULMONARY DETERMINA THROMBOEMBOLISM (VTE) SUSPECTED VENOUS INPATIENTS WITHCLINICALLY DIMER ASSAY SENSITIVELATEX NEWQUANTITATIVEMULTICENTER D- EVALUATION HIGHLY OF A LEVELS VEINTHROMBOSIS(DVT) EXCLUSIONUSINGDIFFERENTCUT-OFF TEST FORDEEP SUSPECTED PULMONAR PROTEIN CDEFICIENCY VENOUSTHROMBOSISINGERMANY DEEP RESULTS BASEDON100CASES EMBOLISM: PRELIMINARY EMISSION COMPUTEDT EMBOLISM OFPATIENTS WITH ACUTE PULMONARY FOLLOW-UP THE CLINICAL FUNCTION EMBOLISM AND IMPAIRED RENAL PULMONARY QUANTITATIVE AND QUALITATIVE PROTEINSDEFICIENCY Parpia, J.S.Ginsberg S. M.Bates*(CA),C.Kearon,J. A. Julian,J.Douketis,S.Schulman, B.MacKinnon,S. Varin, J.Chidiac,M.Grimaux,C.Parry, B.J. Woodhams, J.Soria S. Mirshahi*(FR),C.Soria,B.Kouchakji, G.Kierzek,J.Borg,L.Drouet,D.Elkharrat,R. Oldenburg, B.Kemkes,Matthes R. Fischer*(DE),K.Heidinger, A. Huth,Kühne,P. Staritz,R. Zimmermann, A. Pavlova,J. M. R.Marchick*(US),D.Courtney J. J. Wang* (CN),J.Dai,Q.Fu, T. Yu, X.Wang, H.Wang S. Eberle,R.M.Bauersachs H. E.Gerlach*(DE),S.M.Schellong,V. Hach-Wunderle, E.Rabe,H.B.Riess,Carnarius, Leroyer S. Querellou,P F. A. Klok*(NL),S.Romeih,J. M.Westenberg, L.J.M.Kroft, A. deRoos,M.V. Huisman F. A. Klok*(NL),R.Karami-Djurabi, J.Kooiman,S.I.Velthuis, M.Nijkeuter, M.V. Huisman Righini E. Ceriani*(CH),C.Combescure,G.LeGal, T. Perneger, H.Bounameaux, A. Perrier, M. C. Legnani*(IT),M.Cini,D.Scarvelis,P. Toulon, J.Wu, G.Palareti Palareti C. Legnani*(IT),M.Cini,Poggi, COMPOUND HETEROZYGOUSMUT Y amanouchi* (JP), , D.Mottier ACCORDING TO AGE AND GENDER TIONS INP . Guillo,F. Couturaud,P. Salaun,G.LeGal*(FR),K.Lacut,E.Oger, C. , A. LeDuc-Pennec T. Hato, H.Fujiwara, Y. Yakushijin, M. Yasukawa ATIENTS WITHSUSPECTEDVENOUS THROMBO-EMBOLISM OMOGRAPHY) INTHEDIAGNOSISOFPULMONAR Y EMBOLISM , C.Kabrhel,L.Moore,K.E.Nordenholz,J. A. Kline A Abate, E.Favaretto,L.Piscitelli,G.Guazzaloca, TIONS INTHEPROS1GENERESPONSIBLEFOR Y 155

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-516 PREOPERATIVE SCREENING USING VENOUS DUPLEX SCANNING DOES NOT ALTER THE OUTCOME IN PATIENTS AT HIGH RISK OF POSTOPERATIVE VENOUS THROMBOEMBOLISM T. Yamaki* (JP), H. Sakurai, K. Soejima, T. Kono, A. Hamahata

Hemophilia I

PP-MO-517 FATAL POST SPLENECTOMY PULMONARY EMBOLISM IN MILD HAEMOPHILIA. A REPORT OF A CASE A. Davoodabadi* (IR), B. Keleidari PP-MO-518 FUNCTIONAL MRI TECHNIQUES AS EARLY DIAGNOSTIC MARKERS IN HEMOPHILIC ARTHROPATHY A. Amirabadi* (CA), E. Miller, H. Gahunia, S. A. F. Peel, A. Zhong, R. Weiss, G. Detzler, A. S. Doria PP-MO-519 BONE QUALITY IN PATIENTS WITH HAEMOPHILIA EVALUATED BY QUANTITATIVE ULTRASOUND A. Boban* (HR), D. Kastelan, S. Zupancic-Salek PP-MO-520 ALLELIC VARIANTS OF HUMAN FACTOR VIII IN BRAZILIAN PATIENTS WITH SEVERE HEMOPHILIA A AND CORRELATION WITH THE RISK OF INHIBITOR A. Santos* (BR), G. Damian, L. H. Siqueira, E. V. de Paula, J. M. Annichino-Bizzacchi, M. C. Ozelo PP-MO-521 LOWER INCIDENCE OF IGGS SUBCLASSES OF ANTI-FVIII ANTIBODIES THAT RECOGNIZE AN INTERMEDIATE-PURITY PLASMA DERIVED FACTOR VIII PRODUCT IN SEVERE HEMOPHILIA A INHIBITOR POSITIVE PATIENTS A. Santos* (BR), S. A. L. Montalvão, L. H. Siqueira, G. B. Damian, S. Thomas, M. Veiga, D. E. Fujimoto, A. Streva, E. V. de Paula, J. M. Anicchino-Bizzacchi, M. C. Ozelo PP-MO-522 CARDIOVASCULAR DISEASE IN PATIENTS WITH HEMOPHILIA B A. A. Sharathkumar* (US), M. Soucie, B. Trawinski, A. Griest, A. Shapiro PP-MO-523 INHERITED BLEEDING DISORDERS: THE EMILIA ROMAGNA REGION REGISTRY, 2008 UPDATE A. Tagliaferri* (IT), G. Rivolta, C. di Perna, C. Biasoli, L. Valdrè, G. Rodorigo, M. D’Incà, M. Serino, S. Macchi, D. Vincenzi, P. Pedrazzi, M. Arbasi, F. Riccardi, C. Pattacini PP-MO-524 COMPARISON OF THREE DIFFERENT THROMBIN GENERATION ASSAYS IN PATIENTS WITH HAEMOPHILIA S. Aghighi, A. F. Riddell* (UK), P. Chowdary, A. Gatt PP-MO-525 MANAGEMENT OF ACUTE CORONARY SYNDROMES IN HAEMOPHILIACS: A NEW CHALLENGE BETWEEN HAEMORRHAGIC AND THROMBOTIC RISK A. Coppola* (IT), G. F. Rivolta, M. Lapecorella, A. C. Molinari, C. Santoro, M. di Capua, M. N. D. di Minno, L. Banov, C. di Perna, E. Zanon, P. Schinco, R. Santoro, A. Tagliaferri PP-MO-526 MULTIDISCIPLINARY APPROACH FOR OPTIMIZATION OF HAEMOPHILIA CARE IN VENEZUELA A. Ruiz-Saez* (VE), A. Boadas, A. Arguello, N. de Bosch, A. Luque, C. Garrido PP-MO-527 VARIABLE IMMUNE RESPONSE IN TWO BROTHERS WITH MILD/MODERATE HEMOPHILIA A CARRYING THE ARG2150HIS SUBSTITUTION B. Fimbel* (FR), S. Regina, C. Pouplard, G. Lavigne-Lissalde, R. D’Oiron, Y. Gruel PP-MO-528 SPORADIC VERSUS FAMILIAR SEVERE HAEMOPHILIA A RATIO IN A NEONATE COHORT C. Altisent* (ES), F. Vidal, L. Ramirez, M. Martorell, I. Corrales, R. Parra

156 PM-3 ARE N RNTLDANSSO EMPII INCHINESEPEDIGREE DIAGNOSISOFHEAMOPHILIA CARRIER AND PRENATAL PP-MO-531 PP-MO-530 A HAEMOHILIA DUPLICATION OFEXONS1TO 22OFTHEF8GENE:ÀPROPOS A PP-MO-529 POSTER PRESENTATIONS PM-4 OPRSNO H AE FJITATRPAT INPATIENTS COMPARISON WITHSEVERE OFTHERATES OFJOINT ARTHROPLASTY PP-MO-542 PHARMACOKINETICSTUDY: IMPACT ONTHROMBINGENERATION OFTWO A PP-MO-541 IMPACT ONTHROMBINGENERATION OFDIFFERENTFACTOR VIIICONCENTRATES PP-MO-540 BPATIENTS FACTOR IXMUTATIONS IDENTIFIEDINIRANIANHAEMOPHILIA 12NOVEL PP-MO-539 FACTOR DEFICIENCIESPRESENTINGWITH BLEEDING AT SERIES OFHEREDITARY A PP-MO-538 PP-MO-537 INMURCIA,SPAIN A MOLECULAR ANALYSIS OFHEMOPHILIA PP-MO-536 PATIENTS WITHINHIBITORS HEMOPHILIA PATTERNS OFBLEEDINGINCONGENITAL PP-MO-535 SCHEMEFORINHERITEDBLEEDINGDISORDERS THEUKNEQASGENETICSQA PP-MO-534 EFFECT OFPROPHYLACTICORONDEMANDTREATMENT REGIMES DIFFERENTIAL PP-MO-533 OFLIFEIN MULTICENTRIC SELF-ASSESSMENTOFHEALTH-RELATED QUALITY PP-MO-532 ODY UY1,2009 MONDAY, JULY 13, THE TWOCOAGULA OF SEVERITY FACTOR VIII AND IXDEFICIENCY: AN INDEXOFDIFFERENTCLINICAL A RECOMBINANT FACTOR VIIICONCENTRATES INSUBJECTSWITH HAEMOPHILIA PHARMACISTS, PHYSICIANS,PATIENTS ASSOCIATION, HEALTH AUTHORITIES AND MANAGEMENTOFSUPPL SURVEILLANCE OFCOAGULATION FACTORS FORLONG-TERMNATIONAL TOOL DATABASE (MDSRAPPRO): AN EFFECTIVE THE FRENCHBLOODPRODUCTSSUPPLY PATIENT IN P A ACTIVE LIFEOF14PATIENTS WITHHEMOPHILIAC ARTHROPATHY SCORE AND BETWEENFACTOR LEVELSRADIOLOGICAL THE RELATIONSHIP AND VER PATIENTS ONTAFI ACTIVATION A IN HEMOPHILIA ROMANIAN HAEMOPHILIACS,USINGEQ-5D Solimeno, P M. Mazzucconi,G. Pasta,P. Radossi,G.Rodorigo, C.Santoro,R.Sartori, A. Scaraggi,L. G. Tagariello* (IT), A. Iorio,E.Santagostino,M.Morfini, R.Bisson,M.Innocenti,Mancuso, G. Salvagno*(IT),J. Berntorp G. Salvagno*(IT),J. Astermark, M.Gunnarsson,Franchini,G.Poli,Guidi,Lippi,E. G. Rastegarlari*(IR),M.Rassoulzadegan,S.Ravanbod,Hejazi,Enayat, F. A. Ala F. Pekun, E. Turkkan* (TR),S.Guler, G.Korkmaz S. Guler, F. Pekun,E. Turkkan* (TR), G.Korkmaz A. Morales F. GarcíaCandel*(ES),E. Tizzano, M.Moreno,E.Salido,Majado,J.Moraleda,C.Funes, E. J.Neufeld*(US),D.L.Cooper D. J.Perry*(UK), D. Mikovic*(RS),M.Holmström,B.J.Woodhams, J. Antovic G. Olteanu, A. Lacatusu,E.Ursu,W. Schramm,M.Serban D. Lighezan*(RO),M.Mihailov, L.Pop,Ritli,C.Jinca,P. Stancu, A. Cucuianu,D.Baghiu, D. Jing*(CN), Y. Lu,Q.Ding,H.Wang, X.Wang Ferré, B.Worms, J.Vernois, C.Vigneron, P. Arnaud, F. Suzan,C.Ratignier*(FR) P. Chocarne,M.Gensbittel,V. Chamouard,C.Rothschild,J.Goudemand,S.Clayessens,N. C. Costa*(FR),E.Bieth,P HOBSSRSAC OIT (HTRS) REGISTRY THROMBOSIS RESEARCHSOCIETY Berntorp PEDIA A TIENTS WITH TRIC HEMA Y . Mannucci FREQUENT BLEEDING: T . Cumming,S.Kitchen,I.Jennings, A. Goodeve,M.Hill,I.Walker ACQUIRED HAEMOPHILIA Astermark, M.Ekman,Franchini,G. Guidi,G.Lippi,R.Janco,E. T TION DISORDERS LG UNIT OLOGY . Boisseau,S.Letourneau,F. Dastot,E.Girodon,M.Goossens HRAE COORDINATIONBETWEEN SHORTAGES A Y ANAL YSIS FROMTHEHEMOPHILIA AND 157

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-543 HEPATITIS C IN HAEMOPHILIA – PREDICTIVE VALUES OF COAGULATION FACTOR ACTIVITIES IN PREDICTION OF FIBROSCAN VERIFIED CIRRHOSIS G. Thomson* (UK), S. Trenchfield, D. Bevan, G. Moore, J. Ingerslev, S. Rangarajan, B. Sørensen PP-MO-544 THROMBIN GENERATION: A COMPARISON OF ASSAYS USING PLATELET-POOR AND –RICH PLASMA SAMPLES FROM HEALTHY CONTROLS AND PATIENTS WITH HEMOPHILIA G. R. Lischetzki* (DE), H. Topf, M. Rauh PP-MO-545 PRELIMINARY EVALUATION OF DAILY QOL ASSESSMENTS IN CONGENTIAL HEMOPHILIA PATIENTS WITH ALLOANTIBODY INHIBITORS G. A. Young* (US), C. T. Wilke, D. L. Cooper, A. Pickard PP-MO-546 IDENTIFICATION AND CHARACTERIZATION OF A NOVEL ADENINE TO GUANINE TRANSITION IN INTRON 10 OF THE FACTOR VIII GENE AS A CANDIDATE CAUSATIVE MUTATION OF MILD HEMOPHILIA A H. Inaba* (JP), T. Koyama, K. Shinozawa, K. Fukutake PP-MO-547 SUCCESSFUL LIVER TRANSPLANTATION IN A PATIENT WITH MILD HAEMOPHILIA A AND LOW-TITRE OF FACTOR VIII INHIBITOR TREATED WITH RECOMBINANT FACTOR VIIa: THE FIRST ARGENTINIAN CASE STUDIED H. A. Guglielmone* (AR), S. Minoldo, G. Jarchum PP-MO-548 ALL ROUND UTILITY OF FACTOR VIII DEFICIENT PLASMA WITH VWF J. Xia* (US), H. Patel, C. Kung, M. Triscott PP-MO-549 UTILITY OF THROMBIN GENERATION IN SCREENING PATIENTS WITH HEMOPHILIA FACTOR DEFICIENCIES J. R. Wu* (US), T. S. Smith, B. Bai PP-MO-550 THE ROLE OF FIBROSCAN IN THE INVESTIGATION OF LIVER FIBROSIS IN HAEMOPHILIACS WITH CHRONIC HEPATITIS C VIRUS S. Green, J. Vowles, D. Sheridan, M. L. Schmid, K. L. Talks* (UK) PP-MO-551 FIRST EXPERIENCES WITH THE MEASUREMENT OF THROMBIN GENERATION(TGA) ON THE CEVERON®ALPHA IN THE ROUTINE LAB L. Wagner* (AT), R. Luddington, A. Grigorov, L. Wiens, I. Hrachovinova, B. R. Binder PP-MO-552 PREVALENCE AND MANAGEMENT OF INHERITED BLEEDING DISORDERS IN IRAN M. Lak* (IR), R. A. Sharifian, M. R. Baghaiepour, H. Mansouritorghabeh PP-MO-553 HEALTH-RELATED QUALITY OF LIFE IN RUSSIAN PATIENTS WITH HEREDITARY COAGULOPATHIES P. A. Vorobyev, O. V. Borisenko, U. A. Zhulev, N. I. Zozulya* (RU), K. G. Kopylov, E. A. Telnova, A. A. Tonoyan PP-MO-554 SAFETY AND EFFICACY OF RECOMBINANT FACTOR VIII FOR THE TREATMENT OF PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A IN CHINA R. Yang* (CN), Y. Zhao, J. Sun, J. Wu, X. Wang, M. Yu PP-MO-555 GENETIC DEFECT ANALYSIS OF 104 HEMOPHILIA A PATIENTS IN TAIWAN Y. Chen* (TW), T. Chao, S. Hu, S. Cheng

Hemophilia Therapy I

PP-MO-556 PRION REDUCTION BY THE MANUFACTURING PROCESS OF A VWF/FVIII PRODUCT DEMONSTRATED BY BIOASSAY AND BIOCHEMICAL ASSAY A. Gröner* (DE), A. Buschmann, S. Rehberg, M. Groschup, W. Schäfer

158 PM-6 OTNOSIFSO RCIEI 2HEOHLACOMPREHENSIVECARE CONTINUOUSINFUSIONPRACTICEIN22HAEMOPHILIA PP-MO-560 CHARACTERIZATION OFGLYCOPEGYLATED RECOMBINANTHUMAN BIOPHYSICAL PP-MO-559 PP-MO-558 MANUFACTURING PROCESSESOFPLASMA-DERIVED PRODUCTSREMOVEPRIONS PP-MO-557 POSTER PRESENTATIONS PM-7 HRAOIEI P)ADPAMCDNMC(D RPRISO NEW PHARMACOKINETIC(PK) AND PHARMACODYNAMIC(PD)PROPERTIES OF A PP-MO-570 PP-MO-569 PP-MO-568 PP-MO-567 PROPHYLAXISWITHRFVIIaINHEMOPHILIAC EVALUATION OFSECONDARY PP-MO-566 NEWRECOMBINANTFVIII(N8) PURIFICATION AND CHARACTERISATION OF A PP-MO-565 GLYCOPEGYLATED LONG ACTING RFVIIaREDUCESBLEEDINGINHEMOPHILIC A PP-MO-564 PP-MO-563 IN A EFFECTIVEHAEMOSTASIS WITHOUTFACTOR VIII-MAJORCARDIACSURGERY PP-MO-562 ARTERIO-VENOUSSHUNTSFORVENOUS ACCESS INCHILDRENWITH PERIPHERAL PP-MO-561 ODY UY1,2009 MONDAY, JULY 13, EOBNN VI N)I EOHLAADOGS A RECOMBINANT FVIII(N8)INHEMOPHILIA ADMINISTRATION OFDIFFERENTDOSE LEVELSTO FVIIIKNOCK-OUT MICE CENTRES IN16EUROPEANCOUNTRIES FVIIa MONOCLONAL NEWRECOMBINANTFVIII(N8)WITH ANTI-FVIII CHARACTERIZATION OF A PHARMACOKINETIC (PK)EV FURTHER CLINICAL THE USEOFFEIBA PATIENTS WITHINHIBITORS RABBITS INCHILDREN FACTOR VIII ADVATE ® FOUR OFINHIBITOR DEVELOPMENT HISTORY AND A A PATIENT WITHMILDHAEMOPHILIA HAEMOPHILIA NIIOS PAEFO H UFITRAINLREGISTRY INHIBITORS: UPDATE FROMTHESURFINTERNATIONAL A. Raymer, T. C.Nichols,M.Ezban D. M.Karpf*(DK),Kjalke,H.Pelzer, L. Thim, H. Agerso, E.P. Merricks,H.G.Franck,R. D. M.Karpf*(DK),Kjalke, T. D.Steenstrup,H.Pelzer, H. Agerso C. H.Dash*(UK),E.W. Gascoigne, K.R.Gillanders T C. Negrier*(FR),R.Fleury, J.HaNoh,F. Baghaei,S.Claeyssens, T. Yee, H.Gajek,D. I. Soto,F C. Sedano*(ES), Altisent, F. Garcia-Candel,F. Gimenez,E.Mingot,R.Nuñez,M.Paloma, Steenstrup J. M.Petersen,L.B.Johnsen,G.Bolt,P. L.Nørby, J.Hansen,K.Kjaergaard, T. D. I. Thim, B.S.Vandahl* (DK),J.Karlsson,N.K.Klausen,Pedersen, T. N.Krogh,M.Kjalke, B. Lauritzen*(DK),M. Tranholm, M.Ezban B. Blazek*(CZ),H.Ptoszkova, T. Kuhn B. Sørensen*(UK),S.Rangarajan,McCorkell,Ferris,M.Mitchell,D.Bevan B. Raubal*(AT), K. Thom, T. Hölzenbein,N.Jones,K.Zwiauer, G.Endres,C.Male Altisent, M.Lopez-Fernández A. Batorova*(SK),P. Holme, A. Gringeri,K.Fijnvandraat,M.Richards,C.Hermans, A. D.Nielsen*(DK),C.Rischel A. Gröner*(DE),W. Schäfer A. Gruhler*(DK),B.Vandahl, M.Kjalke olenaar YEARS OFEXPERIENCEWITH , D.Stephens . V elasco, ANTIBODIES (MAB) A. Cid,M.López-Fernandez,V UIGSREISI EOHLAPATIENTS WITH DURING SURGERIESINHEMOPHILIA EXPERIENCE WITH ALUA TION OF ADMINISTRATION OFTHERECOMBINANT A F A ACTOR XICONCENTRATE NEW RFVIII(N8) . Jimenez,M.Prieto AFTER I.V . 159

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-571 A PHASE IV CLINICAL STUDY IN HAEMOPHILIA B PATIENTS USING AN ULTRAPURE FACTOR IX (FIX) PLASMA PRODUCT E. P. Mauser-Bunschoten, I. Kleine Budde* (NL), F. J. M. van der Meer, I. R. O. Nováková, P. Ypma, P. W. G. van der Linden, P. F. W. Strengers PP-MO-572 EFFECTIVE INTRACRANIAL HAEMORRHAGE MANAGEMENT WITH CONTINUOUS INFUSION OF HIGHLY PURIFIED VWF/FVIII COMPLEX CONCENTRATE IN AN ADULT WITH SEVERE A HAEMOPHILIA F. Daniele* (IT), V. Rossi, C. Santoro PP-MO-573 PROLONGED HAEMOSTATIC EFFECT OF 40K PEG-RFIX COMPARED TO RFIX IN A FECL3 INDUCED INJURY MODEL IN HEMOPHILIA B MICE F. Moeller* (DK), H. Oestergaard, M. Tranholm PP-MO-574 CHARACTERISTICS OF THE FIRST HUMAN CELL LINE RECOMBINANT HUMAN FACTOR VIII (HUMAN-CL RHFVIII) H. Sandberg* (SE), I. Agerkvist, C. Kannicht, M. Ramström, P. Stenlund, M. Dadaian PP-MO-575 PROLONGED IN VIVO HALF-LIFE AND RETAINED ACTIVITY OF FACTOR IX GLYCOPEGYLATED IN THE ACTIVATION PEPTIDE P. K. Holm, L. C. Petersen, J. R. Bjelke, A. A. Pedersen, L. Hansen, M. B. Hermit, J. M. Petersen, T. N. Krogh, M. D. Andersen, M. Tranholm, S. E. Bjørn, H. Østergaard* (DK) PP-MO-576 BENEFIT ANALYSIS OF A 750 IU RECOMBINANT FACTOR VIII POTENCY FOR THE TREATMENT OF HEMOPHILIA A PATIENTS J. D. Epstein* (US), J. H. Kwon PP-MO-577 POSTMARKETING EXPERIENCE WITH SUCROSE-FORMULATED RECOMBINANT FACTOR VIII IN PATIENTS WITH HEMOPHILIA A K. Fukutake* (JP), R. Musso, J. Yong, C. Norenberg PP-MO-578 GLYCOPEGYLATED HUMAN RECOMBINANT FACTOR IX SHOWED PROLONGED HAEMOSTATIC ACTIVITY IN CYNOMOLGUS MONKEYS H. Offenberg, K. Abel, C. Sommer, H. Oestergaard, M. Tranholm* (DK), W. Beck, P. K. Holm PP-MO-579 RESCUE IMMUNOTOLERANCE IN HAEMOPHILIAC PATIENTS TO A SERIOUS WITH A HIGH M. Quintana* (ES), J. Romero, M. Alvarez, P. Baltar, V. Jimenez, F. Navarro PP-MO-580 IN VITRO ACTIVITY OF N8, A NEW RECOMBINANT FVIII COMPOUND M. Kjalke* (DK), A. Bagger-Sørensen, L. F. Larsen, J. K. Rasmussen, N. K. Klausen, M. Ezban PP-MO-581 CLINICAL USE OF WHOLE BLOOD THROMBELASTOGRAHY IN TAILORING MANAGEMENT OF BYPASSING AGENTS IN HAEMOPHILIACS WITH INHIBITORS P. A. Holme* (NO), B. Sørensen PP-MO-582 COMPARISON OF THE HAEMOSTATIC AND PROTHROMBOTIC ACTIVITIES OF DIFFERENT FACTOR IX PREPARATIONS BY MEANS OF THE THROMBIN GENERATION TEST R. Al Dieri* (NL), H. C. Hemker PP-MO-583 HIV POSITIVE PATIENT WITH SEVERE HEMOPHILIA A AND MALIGNANT LYMPHOMA: PROPHYLAXIS WITH RECOMBINANT FVIII V. Geierova* (CZ), V. Pohlreichova, S. Rittich, K. Benesova, I. V. Hrachovinova, P. Cetkovsky, P. Salaj PP-MO-584 DOES THERAPY OF HEMOPHILIA CHANGE IN THE ELDERLY ? W. Miesbach* (DE), S. Krekeler, G. Asmelash, B. Llugaliu, S. Alesci

160 PM-8 MUETLRNEI AINSWT EOHLAAANDLONGSTANDING A IMMUNETOLERANCE INPATIENTS WITHHEMOPHILIA PP-MO-587 VWF/FVIIICONCENTRATES INHIGH-RISKIMMUNOTOLERANCE: THERESIST PP-MO-586 PP-MO-585 POSTER PRESENTATIONS PP-MO-597 PP-MO-596 PP-MO-595 POOR PATIENTS WITHINHIBITORS AND A A ITIEXPERIENCEINHEMOPHILIA PP-MO-594 LOWINCIDENCEOFFACTOR VIIIINHIBITOR DEVELOPMENTINTHEDUBLIN PP-MO-593 CORRELATION OFITICOURSE TO EPITOPE LOCATION ONFACTOR VIII- AN INTERIM PP-MO-592 IMMUNETOLERANCE OUTCOME AND ECONOMICS RETROSPECTIVEREGISTRY PP-MO-591 PATIENTS A FVIIIINHIBITOR EPITOPE MAPPINGINHAEMOPHILIA PP-MO-590 PP-MO-589 ROLEOFTHESPLEENININITIATION OFTHEIMMUNERESPONSETO PP-MO-588 Inhibitors: Pathogenesis,Prevention andTreatment I 2009 MONDAY, JULY 13, OEAEHMPII A MODERATE HEMOPHILIA ARG593CYS ARE RISK FACTORS FORFACTOR VIIIINHIBITORS INMILD AND INTENSIVE PERI-OPERA ETHNICITY TO PATIENTS: FACTOR VIIIMUTATIONS RELATIONSHIP INU.S.HEMOPHILIA NOVEL INHIBITORS STUDIES UNRESPONSIVE T OFBLEEDS COMBINEDBYPASS THERAPY OFSEQUENTIAL ANDEFFICACY SAFETY SUCCESSFUL PROGNOSIS HAEMOPHILIA ANALYSIS FROMTHEOBSITISTUDY (HA) AND FACTOR VIIIINHIBITORS A (ITER-STUDY) OFPATIENTS WITHHAEMOPHILIA HAEMOPHILIA SEVERE WEEKIN A HIGH-DOSE IMMUNOTOLERANCE TREATMENT THREETIMES A A THERAPEUTIC FACTOR VIIIINHEMOPHILIA A Kamphuisen, M.Peters, K.Fijnvandraat C. L.Eckhardt*(NL), L. A. Menke,C.H.vanOmmen, J.H.vanderLee,R.B.Geskus, P. W. M. Wicklund,J.Manco-Johnson, A. L.Dunn,C.Knoll,M.Creary, J.M.Soucie Bockenstedt, D.B.Brettler, J.diPaola,G.Massey, A. T. Neff, A. D.Shapiro,M. Tarantino, B. C. H.Miller*(US),Hooper, J.Benson,D.Ellingsen,Driggers, T. C. Abshire, P. L. C. M.Potthoff* (DE),S.Weinspach, B.Boxnick,H.Laws C. Berger*(FR),S. T. Thouvenin, J.R.Reynaud,C.L.Latour, J.L.S.Stephan O’Donnell C. L.Bacon*(IE),E.Singleton,B.White,Nolan,R.Gilmore,V. Jenkins,B.Brady, J. C. Heller, W. Kreuz C. Königs*(DE),Kessel,Escuriola-Ettinghausen,K.Becker-Peters, Klich,F. Vorpahl, A. Rocino*(IT), A. Gringeri, T. Lambert,R.Klamroth,M.Lopez-FernàndezF, M.Diniz Gutierrez, V. Cortina,B.Galmes,M.Canaro,J. A. Aznar F A. Moret*(ES),S.Haya,M.Quintana,V S. Haya, A. R.Cid*(ES), A. Moret,M.C.Carreras,P. Casaña,M. A. Dasi,J. A. Aznar Teyssandier, S.Kaveri,Lacroix-Desmazes A. Navarrete*(FR),S.Dasgupta,Delignat, Y. Repesse,S. Andre, Y. Meslier, M. A. L.Dunn*(US),S.Meeks,R.Chapman,C.Kempton A. Gringeri*(IT),N.Ewing,M. A. Heisel-Kurth,K.Hoots,C.Negrier A. Gringeri*(IT),K.Fischer, A. Karafoulidou,M.López-Fernández . Lopez,F HIGH RESPONDINGINHIBIT . Gimenez,J.Malcorra,M.Paloma,Prieto,C.Sedano,I.Soto, AND INHIBITOR HISTORY IMMUNE T A PATIENT A POPULA O A SINGLE BYPASSING SINGLE AGENT O A TIVE USEOFF OLERANCE INDUCTIONIN TION FOLLOWINGFVIIIPRODUCTSWITCH OR USINGMOROCT . Jimenez-Yuste, C. Altisent, R.Parra,Perez,M. ACT OR VIII AND THEMISSENSEMUTATION OCOG ALFA A YOUNG HEMOPHILIAC A WITH 161

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-598 THE EFFICACY AND SAFETY OF RECOMBINANT FACTOR VIIa (RFVIIa) IN ADULT PATIENTS: THE EXPERIENCE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY (2004-2008) C. M. Kessler* (US), D. L. Cooper, M. E. Carr PP-MO-599 SUCCESSFUL TREATMENT OF INTRACRANIAL HAEMORRHAGE IN TWO PATIENTS WITH HAEMOPHILIA A AND INHIBITORS D. A. Antic* (RS), I. Elezovic, L. Davidovic, P. Djoric, P. Miljic PP-MO-600 SAFETY OF HIGHER DOSES OF RECOMBINANT FACTOR VIIa (RFVIIa) >=250 MCG/KG IN PATIENTS WITH CONGENITAL HEMOPHILIA COMPLICATED BY INHIBITORS (CHWI): THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY EXPERIENCE (2004-2008) E. J. Neufeld* (US), C. M. Kessler, J. C. Gill, C. T. Wilke, D. L. Cooper PP-MO-601 PRIMARY PROPHYLAXIS WITH RECOMBINANT FACTOR VIIa (RFVIIa) IN ELEVEN HAEMOPHILIA A PATIENTS WITH INHIBITORS YOUNGER THAN 3 YEARS OLD F. López Fernández* (ES), V. Jiménez Yuste, C. Altisent, F. Garcia Candel, C. Sedano, M. Prieto, A. Cid, E. Mingot, R. Nuñez, M. Paloma, I. Soto PP-MO-602 PROSPECTIVE ADVATE IMMUNE TOLERANCE INDUCTION REGISTRY (PAIR): COLLECTING REAL-WORLD EXPERIENCE WITH PLASMA/ALBUMIN-FREE RECOMBINANT FVIII G. Spotts* (US), H. Luu, D. Stephens, B. Ewenstein PP-MO-603 PROSPECTIVE STUDY OF INHIBITOR INCIDENCE WITH CONTINUOUS INFUSION OF FACTOR CONCENTRATES DURING AND AFTER SURGICAL PROCEDURES IN PATIENTS WITH HAEMOPHILIA A, B, OR VON WILLEBRAND DISEASE G. Auerswald* (DE), A. Bade, J. Johne, K. Haubold, S. Masurat, C. Moorthi, D. Overberg PP-MO-604 IDENTIFYING NONRESPONSIVE BLEEDING EPISODES IN PATIENTS WITH HEMOPHILIA AND INHIBITORS: A CONSENSUS DEFINITION G. Young* (US), E. Berntorp, P. Collins, R. D’Oiron, N. Ewing, A. Gringeri, C. Négrier PP-MO-605 GENERATION AND PHENOTYPIC CHARACTERIZATION OF A FACTOR VIII–SPECIFIC HUMAN BCR TRANSGENIC C57BL/6 MOUSE A. Benhida, L. A. Vanderelst, F. G. Ectors, V. A. Carlier, J. G. Gilles* (BE), M. G. Jacquemin, J. R. Saint-Remy PP-MO-606 THE VALUE OF EARLY TREATMENT IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS K. Kavakli* (TR), A. Yesilipek, B. Antmen, S. Aksu, C. Balkan, D. Yilmaz, A. Kupesiz, I. Sasmaz, P. Lindgren, J. Mesterton PP-MO-607 INFLUENCE OF FACTOR VIII PRODUCTS, VIRAL INACTIVATION AND DOSAGE REGIMENS ON MEANINGFUL INHIBITOR DEVELOPMENT IN CHILDREN WITH SEVERE HEMOPHILIA A: RESULTS OF A NON-CONCURRENT COHORT STUDY C. Bidlingmaier, D. Manner, S. Halimeh, S. Holzhauer, K. Kurnik, M. Olivieri* (DE), U. Nowak- Gottl PP-MO-608 RADIOSYNOVECTOMY IN CHILDREN WITH SEVERE HEMOPHILIA AND FACTOR VIII OR IX INHIBITOR P. Laguna* (PL), P. Zbikowski, J. Cwikla, A. Klukowska, M. Matysiak PP-MO-609 FIRST LINE IMMUNOSUPPRESSIVE TREATMENT FOR ACQUIRED FACTOR VIII ANTIBODIES: RESULTS OF THE EUROPEAN ACQUIRED HAEMOPHILIA REGISTRY (EACH2) P. Collins* (UK), F. Baudo, A. Huth-Kuhne, P. Knobl, H. Levesque, P. Marco, L. Nemes, K. Peerlinck, L. Tengborn

162 PM-1 LOWREQUIREMENTOFVONWILLEBRANDFACTOR (VWF)THERAPEUTIC PP-MO-611 PP-MO-610 POSTER PRESENTATIONS PM-2 VLAINO NEWCOLLAGENBINDING ASSAY EVALUATION OF A PP-MO-621 IMPORTANCE OFMULTIMER SIZEFORVONWILLEBRANDFACTOR FUNCTION PP-MO-620 VONWILLEBRANDFACTOR CONCENTRATE WITH A OF A ANDSAFETY EFFICACY PP-MO-619 PP-MO-618 PP-MO-617 PP-MO-616 FORVWF_FVIIICONCENTRATES IMPROVED AUTOMATED AND VWF:RCO ASSAY PP-MO-615 SEGREGATION OFTYPE1,3, AND TYPE2NVONWILLEBRANDDISEASEIN PP-MO-614 PP-MO-613 INCONSECUTIVE PATIENTS PROSPECTIVE ASSESSMENT OFBLEEDINGSEVERITY PP-MO-612 von WillebrandDiseaseI 2009 MONDAY, JULY 13, NE LO LW–CMAIO FCMECAL AVAILABLEUNDER BLOODFLOW–COMPARISON PRODUCTS OFCOMMERCIALLY Chatelanaz, F. Bridey ILBADFCO OCNRT IHALOW FACTOR VIIICONTENT WILLEBRAND FACTOR CONCENTRATE WITH A RESPONSE INFLAMMATORY INDUCEDSYSTEMIC FUSIONSURGERY TYPE 2MPATIENT WITHPOSTSPINAL VONWILLEBRANDDISEASE(VWD) CONCENTRATE FORTHEMANAGEMENTOF A EXON 28 RESULTS INTHE ANALYSIS OF GENOTYPIC DIAGNOSISOFVWD:PRELIMINARY LOW FVIIICONTENTINCHILDRENWITHVONWILLEBRANDDISEASE (VWD) FROM FOCUS ONLONGTERMPROPHYLAXISINVONWILLEBRANDDISEASE (VWD):DATA DISEASE (VWD)UNDERGOINGREDOCARDIACSURGERY HIGHL PURIFIED VONWILLEBRANDFACTOR CONCENTRATE WITH A THROMBOPHILIA VWD AND HEREDITARY PATIENT WITH2A ELDERLY SUCCESSFUL PERFORMANCE P REAGENTS,COMPOSITION AND ADJUSTMENTOF ASSAY SAMPLESBY PLASMA THREE GENERA RESPONSEIN VONWILLEBRANDDISEASE DESMOPRESSIN BIOLOGICAL F REFERRED FORHEMOSTATIC EVALUATION B. vanHaren*(NL),S.Gijsen,Verbruggen A. J.Reininger*(DE),I. Marketing StudyGroup,C.Henriet,F A. Borel-Derlon*(FR),J.Goudemand,M.Bertrand,P. Sié,C.Boyer-Neumann,Post A. C.Demulder*(BE),D.Rans,Noubouossié, A. Efira, A. Jeandriens,P. vanderLinden A. C.Molinari*(IT),P M. Stadler A. M.Guilliatt*(UK),B.D. Theophilus, M.S.Enayat,D.Williams A. Sanchez-Luceros*(AR), A. I.Woods, S.Meschengieser, S.Grosso,M. A. Lazzari A. Tosetto* (IT),G.Castaman,F. Rodeghiero,J.Eikenboom Clavert, M.Giacomelli A. Faradji*(FR),N.Salhi,L.Marcoux,C.Bopp,Grunebaum,D.Desprez,Caron,J. Palomino, M.Lazzari A. I.Woods* (AR), A. C.Kempfer, L.Keller, J.C.Calderazzo, A. Sanchez-Luceros,J.Paiva- A. Borel-Derlon*(FR),S. Aronis, H.Platokouki,P. Maes,PostMarketingStudyGroup,C. CO IIADVNWLERN CIIYAESRNL RELATED TO THE ARESTRONGLY ACTOR VIII AND VONWILLEBRAND ACTIVITY Y A PURIFIED VWF FRENCH CLINICAL , A. Hillarp*(SE),C.Haderer AAEETO OA NERPAEETSREYIN AN KNEEREPLACEMENTSURGERY MANAGEMENT OFTOTAL TIONS OF ARAMETERS . Perutelli,P CO O H AAEETO VONWILLEBRAND ACTOR FORTHEMANAGEMENTOF A Angerer AN POST AFFECTED F . Marino,U.V , M.Napoleone,Spannagl,F -MARKETING SUR . Bridey , C.Zapfl,K.Pock,J.Weinberger, J.Roemisch , C.Chatelanaz AMIL iesti, G.Barberis, Y VEY FAHG-UIYVON HIGH-PURITY OF A A. Camera,L.Banov . Schneider 163

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-622 PHARMACOKINETICS AND PHARMACODYNAMICS OF THE APTAMER ARC1779, A SPECIFIC INHIBITOR OF VON WILLEBRAND FACTOR A1 DOMAINS. A PILOT STUDY IN PATIENTS WITH TYPE 2B VON WILLEBRAND DISEASE S. Schranz, B. Jilma* (AT), C. Firbas, J. C. Gilbert, R. Hutabarat, P. Knöbl PP-MO-623 IDENTIFICATION OF A PSEUDOGENE CONVERSION IN THE VON WILLEBRAND FACTOR GENE AS THE CAUSE OF TYPE 3 VON WILLEBRAND DISEASE B. D. Theophilus* (UK), A. M. Guilliatt, D. Chandra, M. D. Williams PP-MO-624 THE SPECTRUM OF VWD TYPE 2 PHENOTYPES ASSOCIATED WITH A1 DOMAIN MUTATIONS C. M. Millar* (UK), A. F. Riddell, G. Mellors, T. T. Yee PP-MO-625 VON WILLEBRAND DISEASE TREATMENT PATTERNS IN THE UNITED STATES C. Leissinger* (US), D. Nugent PP-MO-626 AN ACCURATE AND ROUTINELY ADAPTED ENZYME-LINKED IMMUNOSORBENT ASSAY FOR TYPE 2N VON WILLEBRAND DISEASE DIAGNOSIS C. Caron* (FR), C. Ternisien, M. Wolf, E. Fressinaud, J. Goudemand, A. Veyradier PP-MO-627 COST EFFECTIVENESS STRATEGY TO PREDICT POSTOPERATIVE BLEEDING IN VON WILLEBRAND DISEASE DEFINED BY VWF:RCO <30 IU/ML D. Delitto* (US), K. J. Smith, M. V. Ragni PP-MO-628 A NOVEL MUTATION IN THE VWF A1 DOMAIN CAUSING TYPE 2B VWD WITH SEVERE CHRONIC THROMBOCYTOPENIA D. H. Bevan* (UK), J. Cutler, M. Hadonou, M. J. Mitchell PP-MO-629 LABORATORY CHARACTERISTICS OF AN AUTOMATED VON WILLEBRAND FACTOR ACTIVITY (VWF) ASSAY J. I. Tange, D. Chen* (US), R. K. Pruthi, W. L. Nichols, J. A. Heit PP-MO-630 CASE SERIES OF PATIENTS WITH INHERITED HEMORRHAGIC DISORDERS AND RECURRENT SEVERE GASTROINTESTINAL BLEEDINGS – IMPORTANCE OF CAPSULE ENDOSCOPY D. Pulanic* (HR), S. Zupancic Salek, R. Pulanic, A. Boban, B. Labar PP-MO-631 AN UNUSUAL CASE OF TYPE 2N VWD E. G. Merriman* (NZ), A. Laurie, M. Smith PP-MO-632 ACQUIRED VON WILLEBRAND SYNDROME WITH A TYPE 2B PHENOTYPE: DIAGNOSTIC AND THERAPEUTIC DILEMMAS E. Scepansky* (US), M. Othman, H. Smith PP-MO-633 BLEEDING SEVERITY AND QUALITY OF LIFE IN VON WILLEBRAND DISEASE E. M. de Wee* (NL), E. P. Mauser-Bunschoten, J. G. van der Bom, M. E. L. Degenaar- Dujardin, H. C. J. Eikenboom, K. Fijnvandraat, A. de Goede-Bolder, K. Meijer, I. Nováková, F. W. G. Leebeek PP-MO-634 A PROSPECTIVE STUDY ABOUT VON WILLEBRAND DISEASE IN WOMEN WITH OBSTETRIC AND GYNAECOLOGICAL PROBLEMS F. Gagliano* (IT), R. Amodeo, A. Martorana, R. Guido, G. Dantona PP-MO-635 MONOZYGOTIC TWINS MONOCORIAL CHILDBIRTH IN A PRIMIPARA PATIENT SUFFERING FROM VON WILLEBRAND DISEASE. FOLLOW UP DURING PREGNANCY AND PROPHYLAXIS OF SURGICAL CAESAREAN F. Gagliano* (IT), A. Maiorana, R. Amodeo, R. Guido, G. Dantona PP-MO-636 VWF:CB AND VWF:RCO. ASSAY TO DIFFERENTIATE BETWEEN TYPE 1 AND TYPE 2 VON WILLEBRAND DISEASE IN NATIONAL BLOOD CENTRE F. Md. Afandi* (MY), S. Che Nordin, F. Abd.Karim, Y. Ayob, N. Asidin

164 PM-3 XADDPEOYEGNTP ORLTOSI PAEDIATRIC EXPANDED POPULATION PHENOTYPE-GENOTYPECORRELATIONS IN A PP-MO-639 MUTATION SPECTRUM AND MOLECULARSTUDIESOFTYPE2VONWILLEBRAND PP-MO-638 WITHMULTIPLE ELECTRODES(MEA) OFTHEIMPEDANCE AGGREGOMETRY UTILITY PP-MO-637 POSTER PRESENTATIONS PP-MO-650 PP-MO-649 PP-MO-648 DISORDERSOFFIBRINOGEN–EFFECTIVE SYMPTOMATIC CONGENITAL PP-MO-647 FACTOR VGENEMUTATIONS ASSOCIATED FIVENOVEL WITHINHERITEDFACTOR V PP-MO-646 PP-MO-645 USEOF ACTIVATED RECOMBINANTFACTOR VIIINTHECEREBRAL SUCCESSFUL PP-MO-644 PP-MO-643 WITHBLEEDINGTENDENCY FAMILY ALPHA1-ANTITRYPSIN PITTSBURGHIN A PP-MO-642 INHERITEDCOAGULATION DISORDERSINTHEPUBLICREFERENCEHEMOSTASIS PP-MO-641 OF ADAMTS13-MEDIATED PROTEOLYSIS OF SPECIES-DEPENDENTVARIABILITY PP-MO-640 Other InheritedCoagulationDisorders I 2009 MONDAY, JULY 13, DEFICIENCY MOLECULAR CHARACTERIZA INTWOTUNISIANPATIENTS FACTOR V AND VIIIDEFICIENCY ANDONERECURRENTMISSENSEMUTATIONS CAUSINGCOMBINED TWO NOVEL WITH TYPE1VONWILLEBRANDDISEASE DISEASE IN DIAGNOSISOFVONWILLEBRANDDISEASE(VWD) DEFICIENCY MOLECULAR CHARACTERIZA TREA DEFICIENCY FACTOR VDEFICIENCY ASSOCIATED WITHCONGENITAL MUTATIONS INCOAGULATIONIDENTIFICATION FACTOR OFFOURNOVEL VGENE DEFICIENCY OPERA COMPLICATIONS PATIENTS WITHTHROMBOTIC HOW SHOULDWETREAT AFIBRINOGENAEMIA INURUGUAY LABORATORY HUMAN RECOMBINANTVWF H. Elmahmoudi,M. Ben Amor, E.Gouider* (TN),R.Horchani, A. Ben Ammar Elgaaied H. Elmahmoudi, A. Jlizi,M.Ben Amor, E.Gouider*(TN),B.Meddeb, A. Ben Ammar Elgaaied E. M.Paraboschi*(IT),I.Guella,S.Duga, F D. Overberg*(DE),W D. Huang*(CN),X.Wang, Q.Ding,H.Wang, G.Xu, H.Chen,J.Dai, Y. Lu, T. Yu M. Fretigny, V. Broyer, L.Rugeri, V. Guerin,P. deMoerloose,C.Negrier, C.Vinciguerra* (FR) I. Sasmaz,B. Antmen* (TR), Y. Kilinc,G.Leblebisatan,B.S.Karagun, T. Erman B. Brand*(CH), T. Pfammatter, B. Amann-Vesti, E.Bachli B. Hua*(CN),L.Fan, A. Manzino*(UY),L.Varela, I.M.Queijo (AT), H.J.Ehrlich,P. Schwarz K. Varadi, H.Rottensteiner, S.Vejda, E.M.Muchitsch, A. Weber, H.Gritsch,P. L. Turecek* J. D.Robertson*(AU),P. R. Yenson, M.L.Rand,V. S.Blanchette,D.Lillicrap,P. D.James Saxena F. Ahmad* (IN),R.Schneppenheim, U.Budde,F. Oyen, T. Obser, I.Hasan,M.Kannan,R. Pinto PregodeFaria,J.Batlle F . LopezFernandez*(ES),F. Miras,M. Albors, L.GarciaIglesias, A. Vale Lopez,M.Costa TMENT WITHFIBRINOGENCONCENTRATE TION FORINTRACEREBRAL . Eberl, Y . Liang, A. Bade,K.Haubold,J.Johne,C.Moorthi,G. Y. Zhao,E.G.D. Tuddenham TION OF11 TUNISIANFAMILIES WITHINHERITEDFXIII TION OF9GENETICDEFECTSRESPONSIBLE FORFV HEMORRHAGE IN . Peyvandi,P. M.Mannucci,R. Asselta A PATIENT WITHFACTOR VII Auerswald 165

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-651 CONGENITAL FACTOR V DEFICIENCY: MALAYSIA EXPERIENCE F. Abdul Karim* (MY) PP-MO-652 LOW PLASMA CONCENTRATION OF FIBRINOGEN AND FACTOR XIII ACTIVITY ARE SYNERGISTICALLY ASSOCIATED WITH INCREASED BLEEDING AFTER CARDIAC SURGERY F. Baghaei* (SE), L. Ternström, V. Radulovic, M. Karlsson, M. Hyllner, A. Jeppsson PP-MO-653 T33P SUBSTITUTION AND W519X MUTATION IN TWO TURKISH PATIENTS WITH FXI DEFICIENCY H. Caglayan* (TR), S. Usluer, Y. Pekcelen, E. Berber, S. Aksu PP-MO-654 MANAGEMENT OF KIDNEY TRANSPLANTATION IN A FACTOR VII-DEFICIENT PATIENT M. Lapecorella* (IT), M. Napolitano, A. Lucchesi, F. Pisani, P. di Cocco, V. Rizza, A. Famulari, C. Mazzotta, L. Aloisio, F. Bernardi, M. Pinotti, P. Ferraresi, G. Mariani PP-MO-655 FREQUENCY OF INTRACRANIAL HEMORRHAGE AMONG IRANIAN PATIENTS WITH RARE BLEEDING DISORDERS M. Karimi* (IR), N. Cohan, M. Yavarian, Y. Ardeshiri, A. Vafafar PP-MO-656 IMPACT OF THE C.-65G>C VARIANT ON THE F7 TRANSCRIPTIONAL REGULATION M. Giansily-Blaizot* (FR), E. Lopez, J. Tapon-Bretaudière, O. Chafa, M. Claustres, M. C. Romey-Chatelain PP-MO-657 NEW SEQUENCE VARIATIONS IN FACTOR VII GENE FOUND IN APPARENTLY HEALTHY ADULTS PRESENTING WITH TYPE 1 FACTOR VII DEFICIENCY N. I. Kolaitis* (GR), M. Giansily-Blaizot, P. Koliou, G. Vartholomatos, J. Schved PP-MO-658 THROMBIN GENERATION TEST AND CLINICAL BLEEDING RISK IN FACTOR XI DEFICIENCY L. Rugeri, J. Bordet, H. Simpson, B. Chatard, C. Negrier, Y. Dargaud* (FR)

Acquired Coagulation Disorders and DIC I

PP-MO-659 THE EFFECT OF THYROID AUTOANTIBODIES ON WARFARIN STABILITY: RETROSPECTIVE INCEPTION COHORT STUDY A. Squizzato* (IT), E. Rancan, B. van Zaane, V. Gerdes, W. Ageno, F. Dentali PP-MO-660 HUMAN PROTEIN C CONCENTRATE IN THE TREATMENT OF PURPURA FULMINANS: SAFETY AND OUTCOME IN 94 PATIENTS A. Veldman* (AU), D. Fischer, B. Eberspaecher, U. Mansmann, R. Schosser PP-MO-661 COAGULOPATHY SECONDARY TO NIACIN THERAPY A. Ahmed, B. McJunkin, S. J. Jubelirer* (US) PP-MO-662 SUCCESSFUL INHIBITOR-ELIMINATION WITH RITUXIMAB IN ONE PATIENT WITH A CARRIER STATE FOR HEMOPHILIA A, 9 PATIENTS WITH ACQUIRED HEMOPHILIA A AND ONE PATIENT WITH POSTPARTAL HEMOPHILIA A A. Huth-Kuehne* (DE), P. Staritz, P. Lages, M. Krause, R. Zimmermann PP-MO-663 ACQUIRED INHIBITORS OF BLOOD COAGULATION: THE VENEZUELAN NATIONAL HEMOPHILIA CENTER EXPERIENCE A. Boadas* (VE), C. Reyes, M. Mijares, N. de Bosch, M. Echenagucia, A. Torres, R. Borges, A. Ruiz-Saez PP-MO-664 COMPARATIVE STUDY OF COAGULATION IN THE PORTAL AND SYSTEMIC CIRCULATIONS OF CIRRHOTIC PATIENTS B. Delahousse* (FR), V. Labat, B. Hammamy, J. Perarnau, Y. Gruel

166 PM-6 THEUSEOFPROTHROMBINCOMPLEXCONCENTRATE INPATIENTS UNDERORAL PP-MO-667 WITH ANAPHYLAXIS AND CASEOFSEVERE ACQUIRED FACTOR VIIDEFICIENCY A PP-MO-666 FORMONITORING HAEMOSTATIC APPLICATION OFTHROMBELASTOGRAPHY® PP-MO-665 POSTER PRESENTATIONS PM-7 NXLIE EORAI ANDHEMOSTATIC EVALUATION UNEXPLAINEDMENORRHAGIA IN PP-MO-677 HEMOSTATIC MANAGEMENTINJEHOVAH’S WITNESSPATIENT UNDERGOING PP-MO-676 PP-MO-675 INHUMAN THESIGNIFICANCEOFSNAKEVENOM AND ANTIVENOM SPECIFICITY PP-MO-674 PP-MO-673 OF ANAPHYLATOXIN KINETICSINMAN FORTHESTUDY AUTOLOGOUS PLASMA PP-MO-672 ARETEGPATTERN INTERPRETATIONS RELIABLE PP-MO-671 PP-MO-670 FORTHEDIAGNOSISOFDIC PROGRESSREPORTONTHEPROSPECTIVESTUDY A PP-MO-669 OFHIGHDOSES ANTITHROMBIM III(AT) ANDSAFETY EFFICACY CLINICAL PP-MO-668 Consultative HemostasisI 2009 MONDAY, JULY 13, GYNAECOLOGICAL PRACTICE, A RETROSPECTIVE STUDY RETROSPECTIVE PRACTICE,A GYNAECOLOGICAL COMPLEX CARDIACSURGER ANTICOAGULATION PROSPECTIVESTUDY ORWITHHEPATIC FAILURE: A DIFFERENT FACTOR VIICONCENTRATES DISSEMINA INTRA CHANGE INRATS WITHLIPOPOLYSACCHARIDE-INDUCED DISSEMINATED GENETIC DETERMINANTSOFRESPONSET PLASMA INRLIVER FORTHECALCULATION OFTHEMELDSCORE TO IMPLEMENTTHE NORMALIZED RATIO FORCIRRHOSIS(INRLIVER)CANHELP POINT-OF-CARE COAGULATION MONITORS CALIBRATED FORTHEINTERNATIONAL INMAJORSURGERY COAGULOPATHY WITH DILUTIONAL IMP THROMBOCYTOPENIC PATIENTS (PTS) TREATMENT OFSEVERESEPSIS AND SEPTICSHOCKINNEUTROPENIC H. M.Knol*(NL),D.Bogchelman, K. Meijer, A. G.J.vanderZee, J.vanderMeer D. Bolliger*(US),G.Sreeram,R.J.Molinaro, F. Szlam,E.P. Chen,K. A. Tanaka A. V. Pathare*(OM),S. Alkindi, S. Alzadjali, R.Misquith,Krishnamoorthi S. Buschek,V Iannuzzi, F. Salerno,P. M.Mannucci V U. Schott*(SE),R.Norda T. Exner*(AU),K.Parsi Hamulyák, H.tenCate,J.W S. E.M.Schols*(NL),D.Lancé, T H. Wada* (JP),K.Kawasugi,S.Kushimoto,H. Tsuyoshi, T. Uchiyama, Y. Seki,K.Okamoto, Gorodetsky G. M.Galstyan*(RU),E.B.Orel, A. V. Krechetova,S. A. Vasiliev, M.G. Alexanyan, V. M. F. Campos*(PT),E.Cruz,C.Lau,R.Matos,N.Pinho,M.Miranda,S.Morais, Campos D. Lechner*(AT), S.Machherndl-Spandl,P. Knoebl H. . Okamura,S.Madoiwa,Gando . Chantarangkul*(IT), T AIRED THROMBINGENERATION AND FIBRINCLOTFORMATION INPATIENTS sai, M.Liao,W. Liaw, C.Wu* (TW) VASCULAR COAGULATION TED INTRAVASCULAR COAGULATION FOLLOWING ADMINISTRATION OF . Ignjatovic*(AU),R.Summerhayes,Lowe A. T ripodi, M.Primignani, A. Dell’Era, M.Clerici,Cazzaniga,F. . M.Heemskerk,E.C.vanPampus Y A. H.Feijge,J.Damoiseaux,M. A. Marcus,K. O W ARF ARIN INOMANIP A TIENTS 167

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-678 DIVERSE COAGULATION LABORATORY CHARACTERISTICS OF EDTA- VS. CITRATE- ANTICOAGULATED PLASMA SAMPLES AND A SIMPLE METHOD TO DIFFERENTIATE THEM L. K. Cardel* (US), D. Chen, R. K. Pruthi, W. L. Nichols, J. A. Heit PP-MO-679 COMBINATION OF RFVIIa AND FXIII IN AML PATIENTS WITH BLEEDING AND THROMBOCYTOPENIA P. A. Kotsi* (GR), A. Kouramba, M. Gavalaki, G. Georgiou, G. Kanellopoulou, K. Markakis, A. Karafoulidou PP-MO-680 CLINICAL USE OF RECOMBINANT FACTOR VIIa: A SINGLE CENTRE EXPERIENCE P. Greaves* (UK), M. Madhani, S. Hallam, P. McCallum

Hemorrhagic Disorders in Children

PP-MO-681 TRANSFUSION REQUIREMENT IN CHILDREN WITH DENGUE VIRUS INFECTION A. Chuansumrit* (TH), K. Tangnararatchakit, P. Kitpoka, R. Udomchaisakun, S. Yoksan, S. Kitjakornpa PP-MO-682 IS COAGULATION WORK-UP REALLY NECESSARY IN CHILDREN BEFORE ADENOIDECTOMY AND TONSILLECTOMY A. Samkova* (CZ), P. Dulicek, E. Parizkova PP-MO-683 COMPARISON OF THE CLASSICAL AND THE MODIFIED TURKISH MODEL IN THE CIRCUMCISION OF PEOPLE WITH HEMORRHAGIC DIATHESIS B. Zulfikar* (TR), I. Karaman, F. Bezgal, F. Ovali PP-MO-684 SCREENING CLOTTING TIMES AND COAGULOPATHIES IN CHILDREN WITH RECURRENT TONSILLITIS G. Gamba* (IT), N. Montani, A. Trinchero, F. Pagella, M. Benazzo PP-MO-685 CLOT FORMATION OF NEONATES TESTED BY THROMBOELASTOGRAPHY CORRELATES WITH GESTATIONAL AGE T. Strauss, Y. Levy-Shraga, B. Ravid, I. Eisen-Schuchan, A. Maayan-Metzger, J. Kuint, G. Kenet* (IL) PP-MO-686 THE USE OF THE PLATELET FUNCTION ASSAY (PFA) TO ASSESS BLEEDING RISK IN A PEDIATRIC POPULATION H. Henry* (CA), J. Berman, E. McBride, D. Barnard, L. Dickey, J. Gao, V. Price PP-MO-687 LUPUS ANTICOAGULANT HYPOPROTHROMBINEMIA SYNDROME (LAHPS) AND ANTIPHOSPHOLIPID ANTIBODIES: REPORT OF FOUR CHILDREN WITH LONG TERM FOLLOW-UP G. Pieroni, M. Hepner* (AR), S. E. Annetta, G. Sciuccati, A. Feliú-Torres, M. Castañon, J. Frontroth, M. Bonduel PP-MO-688 INTRACRANIAL BLEEDINGS IN CHILDREN WITH ITP A. V. Ageenkova, V. Y. Petrov, T. G. Plachuta, G. I. Soskov, P. V. Svirin* (RU

Immunology and Treatment of ITP I

PP-MO-689 RITUXIMAB TREATMENT FOR REFRACTORY CHRONIC AUTOIMMUNE THROMBOPENIA – SINGLE CENTRE EXPERIENCE A. Hlusi* (CZ), T. Papajik, J. Vondrakova, V. Krcova, L. Starostova, R. Zborilova PP-MO-690 DIAGNOSTIC REVIEW OF CHILDREN WITH PRESUMED IMMUNE THROMBOCYTOPENIC PURPURA IN THE GREATER MANCHESTER AND LANCASHIRE REGION (UK E. J. Searle* (UK), A. M. Will, J. D. Grainger

168 PM-9 NTRLHSOYADEOOI UDNO T INGERMANY ANDECONOMIC BURDENOFITP HISTORY NATURAL PP-MO-694 AFTERELTROMBOPAG PLATELET FUNCTIONINPATIENTS TREATMENT WITHITP PP-MO-693 PP-MO-692 MICE ROLEOFTLR7/BAFF/BAFFRECEPTORS PATHWAY INITP PP-MO-691 POSTER PRESENTATIONS PP-MO-705 PP-MO-704 PP-MO-703 HOWTO MEASURELEPIRUDINCONCENTRATION: DIFFERENCESBETWEEN ASSAYS PP-MO-702 FORHITIMMUNOASSAYS SPECIFITY CANWEIMPROVECLINICAL PP-MO-701 TYPEII(HITII) AN AUTOIMMUNE ISHEPARIN-INDUCED THROMBOCYTOPENIA PP-MO-700 SCORESYSTEMFOR HEPARIN-INDUCED THROMBOCYTOPENIA NEW CLINICAL A PP-MO-699 PP-MO-698 PSEUDO-HIT ASSOCIATED WITH ANTIBODIES TO PROTAMINE SULFATE PP-MO-697 WITH COSTOFTREATING PATIENTS WITHIMMUNETHROMBOCYTOPENIC PURPURA PP-MO-696 HIGHDOSEDEXAMETHASONEREGULATES INTERLEUKIN-18 AND INTERLEUKIN-18 PP-MO-695 Pathophysiology andT 2009 MONDAY, JULY 13, THROMBOCYTOPENIA HEP THROMBOCYT ONPREVALENCE AND TREATMENT OFIMMUNE SURVEY NATIONAL HEPARIN-INDUCED THROMBOCYTOPENIA RE-EXPOSURE TO HEPARIN INUREMICPATIENTS REQUIRINGHEMODIALYISIS WITH ANTIBODIES INHITPATIENTS COMP DISEASE (HIT) DIAGNOSIS (HIT) INDUCED THROMBOCYTOPENIA RELIABILITY RETROSPECTIVE DATABASE ANALYSIS OFOUTPATIENT CLAIMS ANTI-D IMMUNEGLOBULIN AND INTRAVENOUS IMMUNEGLOBULIN: A BINDING PROTEININIDIOPATHIC THROMBOCYTOPENIC PURPURA Ludwig, E.Lindhoff-Last M. Schindewolf*(DE),H.Kroll,J.Garbaraviciene, R.Kaufmann,W. H.Boehncke,R.J. Y. Nakajima K. Wanaka* (JP), T. Matsuo,M.C. Kaneko,K.Miyashita,R. Asada, H.Matsushima, J. P. Antovic* (SE),J.Fareed,D.Hoppensteadt,M.Prechel,E.Norberg,Sten-Linder J. vanV J. Amiral* (FR), A. M.Vissac G. Nowak*(DE), D. R.G.Junqueira*(BR),E.Perini,M.Carvalho D. R.G.Junqueira*(BR),M.Carvalho,E.Perini J. P. O.Bonnet*(US),D.Dobler N. Shan,X.Zhu,C.Wang, P. Qin, J.Peng,M.Hou*(CN) M. Krych*(DE), A. Baumann,B. Ackermann, R.Shlaen, K.Berger, H.Ostermann M. vonDepka*(DE),Rieke, T. Hoebbel-Schnell,K.Lennemann, A. Czwalinna Chojnowski, J.W K. M.Zawilska*(PL)onbehalfofHaemostasisGroupPHiT, M.Podolak-Dawidziak, K. Y. Qing,W. Bo, Y. Lei,P. Jun,M.Daoxin,H.Ming*(CN) ARIN-INDUCED SKINLESIONS:RARE Amiral, RSNO MUOOIA ASSAYS FORDETECTIONOFHEPARIN/PF4 ARISON OFIMMUNOLOGICAL een* (UK),B.J.Hopkins,C.W A. M.V N CUAYOF4T’SSYSTEMFORTHEDIAGNOSISHEPARIN- AND ACCURACY r eatment ofHITI PNCPRUAINPOLAND–PLATE PROJECT OPENIC PURPURA indyga, J.Zdziarska T . Kaden,J.Hentrich issac* (FR) atson ASSOCIA TION WITHHEPARIN-INDUCED 169

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-706 SIMULTANEOUS OCCURRENCE OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) AND DELAYED-TYPE HYPERSENSITIVITY (DTH) TO HEPARIN M. Schindewolf* (DE), H. Kroll, M. Wolter, W. H. Boehncke, R. J. Ludwig, E. Lindhoff-Last PP-MO-707 A FIVE-YEAR EXPERIENCE FROM 848 PATIENTS TESTED FOR HIT, IN A LARGE GREEK HOSPITAL T. Theodoridis* (GR), C. Kalpodimou, M. El-Ali, D. Cokkinos, V. Christopoulou-Cokkinou

Pathophysiology and Clinical Studies of TTP I

PP-MO-708 HUMAN IMMUNODEFICIENCY VIRUS (HIV) RELATED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) – FAVOURABLE OUTCOME WITH PLASMA EXCHANGE AND PROMPT INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) D. P. Hart* (UK), V. Macdonald, R. Sayer, S. J. Machin, M. Scully PP-MO-709 A RAPID, SENSITIVE FRET ACTIVITY ASSAY USING ALEXA488/VWF84, A NOVEL SUBSTRATE FOR QUANTIFICATION OF ADAMTS13 IN PLASMA E. R. Guinto* (US), M. Smirnov, H. J. L. Fryer, C. J. Hoecke, R. S. Greenfield PP-MO-710 SEVERE MALARIA IS ASSOCIATED WITH A DEFICIENCY OF VON WILLEBRAND FACTOR CLEAVING PROTEASE, ADAMTS13 E. C. Lowenberg* (NL), P. Charunwatthana, S. Cohen, B. van den Born, J. C. M. Meijers, E. B. Yunus, M. U. Hassan, G. Hoque, R. J. Maude, F. Nuchsongsin, M. Levi, A. M. Dondorp PP-MO-711 ADAMTS13 ACTIVITY, ADAMTS13 AND VWF ANTIGEN CONCENTRATION AND THE RISK OF MYOCARDIAL INFARCTION H. Vetr* (AT), S. Geiter, M. Graf, B. Laemmle, M. Redondo, B. R. Binder PP-MO-712 EXISTENCE OF LINEAR RELATIONSHIP BETWEEN ADAMTS13 AND PLATELET DYNAMICS EVEN BEFORE SEVERE THROMBOCYTOPENIA J. Song* (KR), R. Park, K. Lee, J. Choi PP-MO-713 EVALUATION OF AN ADAMTS13 ACTIVITY ELISA J. Butler* (AU), J. J. Butler, E. Malan, J. Clifford, M. Wheeler, E. Gan PP-MO-714 SUCCESSFUL PREGNANCY OUTCOME IN UPSHAW-SCHULMAN SYNDROME (USS) J. Windyga* (PL), B. Baran, E. Stefanska-Windyga, K. Bykowska, J. Kremer Hovinga PP-MO-715 FOLLOW UP OF TTP PATIENTS AND RESULTS OF SPLENECTOMY IN RELAPSING CASES. EXPERIENCE OF ONE CENTRE K. Markakis* (GR), G. Kanellopoulou, I. Anastasopoulou, A. Marinaki, T. Adraktas, P. Kotsi, O. Katsarou, I. Karavokiros, A. Karafoulidou PP-MO-716 EPISTATIC INTERACTION AMONG SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) WITH PRO-INFLAMMATORY FUNCTIONS IN PREDICTING RECURRENCE OF THROMBOTIC THROMBOCYTOPENIC PURPURA L. Beretta* (IT), R. Palla, M. Spreafico, C. Cristofalo, M. Pizzuti, P. Mannucci, F. Peyvandi PP-MO-717 NATIONAL QUESTIONNAIRE SURVEY OF TMA N. Ito* (JP), H. Wada, M. Sugita, M. Matsumoto, Y. Fujimura, M. Murata, Y. Ikeda

Platelet Function Tests I

PP-MO-718 TIME-DEPENDENT ACTIVATION OF SHEAR-DEPENDENT PLATELET FUNCTION AND COAGULATION AFTER SINGLE-DOSE OF GRANULOCYTE COLONY-STIMULATING FACTOR IN HEALTHY VOLUNTEERS A. O. Spiel* (AT), J. Siller-Matula, C. Firbas, J. Leitner, G. Russmüller, B. Jilma

170 PM-2 MEASUREMENTOFPROCOAGULANTPLATELET SUBPOPULATIONS INWHOLE PP-MO-721 THEPERFORMANCEOFPLATELET FUNCTION ANALYZER ISINSUFFICIENTTO PP-MO-720 NON- VARIATION OFCLOPIDOGREL ANDINTRA-INDIVIDUAL THEFREQUENCY PP-MO-719 POSTER PRESENTATIONS PM-3 USEOFTHEVERIFYNOW(TM)P2Y12POINT-OF-CARE DEVICETO MONITOR PP-MO-733 INPATIENTS COMPARISON OFFOURTESTSTO ASSESS PLATELET REACTIVITY PP-MO-732 PP-MO-731 PP-MO-730 IMAGINGOFLIVINGPLATELET ARCHITECTURE AND FUNCTION INREAL OPTICAL PP-MO-729 PREDICTINGRESPONSETO ANTIPLATELET DRUGSWITHTHEMULTPLATE® PP-MO-727 ANDGENETICVARIATIONS ASSOCIATION IN BETWEENPLATELET REACTIVITY PP-MO-726 PP-MO-725 ASSESSMENTPROGRAMFORTHEPFA-100 QUALITY ANEXTERNAL PP-MO-724 RESPONSEINPATIENTS EVALUATION TREATED WITH OFTHEBIOLOGICAL PP-MO-723 STENOTICTUBESUSINGWHOLEBLOOD THROMBUSFORMATION INHIGHLY PP-MO-722 ODY UY1,2009 MONDAY, JULY 13, ANALYSIS ANDCLOPIDOGREL: AN INTEGRATED PLATELET FUNCTIONWITHPRASUGREL LO:DVLPETO NASYFORPOPULATION-BASED STUDIES BLOOD: DEVELOPMENTOF AN ASSAY ADULT PATIENTS RELIABL ST VERIFYNOWINPATIENTS WITH RESPONSIVENESS OVERTIME AS MEASUREDBY UNDER DUAL EV NOT NECESSAR TRANSMITTANCE AGGREGOMETRY: AN ADJUSTMENT FOR PLATELET COUNTIS ASSESSMENT OFRESPONSIVENESST TIME ANALYZER JAP MAXIMAL AND ASPIRIN. CONCORDANCEBETWEEN3TECHNIQUES CLOPIDOGREL Luo, K.J.W J. A. Jakubowski*(US), Y. G.Li,D.S.Small,C.Payne,E.Salazar, M.E. Tomlin, J. Vicente, M.Valdés, J.Rivera*(ES) L. Navarro-Núñez,F. Pastor, M.Lozano,F. Marín, J.Hurtado,V. Roldán,C.Martínez, V. J. Lee*(CN), J. Schwonberg*(DE),B.Linnemann,S.Prochnow, H.Mani,E.Lindhoff-Last I. Vasilenko* (RU),V. Metelin,V. Tychinsky, T. Vishenskaya S. Park,H.Chi*(KR),Min,M.Choi,Jang,C.Park H. Okada*(JP), T. Sakata, Y. Kokubo, T. Okamura, T. Miyata E. V. dePaula*(BR), T. F. G.S.Machado,M.Pereira,F. Orsi,J.M. Annichino-Bizzacchi E. J.Favaloro*(AU),R.Bonar A. Munier, J.Charniot,E.Martinod,F. Cymbalista,E.Mazoyer*(FR) A. N.Para,M. T. J.Hurwitz,D.N.Ku*(US) Wildes, A. K.Paradis,E.Brummel-Ziedins,B. A. Bouchard*(US) A. K.Stroobants*(NL),N.Dors,E.J.vandenDool,derNeut,P. W. Kamphuisen A. Pettersen*(NO),H. RCOIORLINTAKE OR CLOPIDOGREL AGGREGATION REPORTS BECRNR HEARTDISEASE ABLE CORONARY ALUA ANESE GENERAL TION OFPLA IGOEA NRAE LEIGTNEC INCHILDREN AND DIAGNOSE AN INCREASEDBLEEDINGTENDENCY Y AGGREGA inters Y . L.Cong ANTIPLA Y TION ORSLOPE:WHICHONESHOULDBEUSEDINPLATELET Arnesen, I.U.Njerve,M. TELET FUNCTIONTESTSINHEAL POPULA TELET THERAPY , K.Marsden TION O ANTIPLA T. Kase,I.Seljeflot EE HRP YLIGHT BY TELET THERAPY TH SUBJECTSWITH ASPIRIN 171

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-734 CLINICAL APPLICATION OF ADP-COATED BEAD COLUMNS FOR CLOPIDOGREL MONITORING K. Satoh* (JP), I. Fukasawa, Y. Ozaki PP-MO-735 REDUCING INTRAINDIVIDUAL VARIATION IN PLATELET AGGREGATION: IMPLICATIONS FOR PLATELET FUNCTION TESTING A. J. Peace, K. Egan* (IE), G. F. Kavanagh, A. F. Tedesco, D. P. Foley, P. Dicker, M. C. Berndt, D. Kenny PP-MO-736 DIAGNOSTIC VALUE OF PLATELET FLOW-CYTOMETRIC ANALYSIS IN PATIENTS WITH CLINICALLY RELEVANT BLEEDING DIATHESIS AND UNREVEALING LABORATORY WORK-UP T. Conte, M. Pavicic, M. Reusser, G. Barizzi, P. Keller, L. Alberio* (CH) PP-MO-737 THE APPLICATION OF THROMBOELASTGRAPHY (TEG) IN THE STUDY OF HAEMOSTATIC DISORDERS M. Echenagucia* (VE), A. Boadas, A. Arguello, A. Quijada, M. Hernandez, J. Becerra, C. Reyes, N. Blumenfeld de Bosch, A. Ruiz-Saez PP-MO-738 ASPIRIN RESISTANCE; AN INVESTIGATION AND EXPLANATION M. McCall* (IE), A. F. Tedesco, A. Peace, D. Foley, D. Cox PP-MO-739 PLATELET REACTIVITY TO ADENOSINE DIPHOSPHATE AND LONG-TERM ISCHEMIC EVENT P. A. Gurbel* (US), M. J. Antonino, K. P. Bliden, J. Dichiara, T. A. Suarez, A. Singla, U. S. Tantry PP-MO-740 DETERMINATION AND DIFFERENTIATION OF ASPIRIN AND CLOPIDOGREL EFFECTIVENESS BY 96-WELL PLATE AGGREGOMETRY AND MEASUREMENT OF THROMBI ADHESION P. C. J. Armstrong* (UK), A. A. Dhanji, N. J. Truss, Z. N. M. Zain, A. T. Tucker, J. A. Mitchell, T. D. Warner PP-MO-741 URINARY 11-DEHYDRO-THROMBOXANE B2 AS A MARKER OF THE ANTI-PLATELET EFFECTS OF CLOPIDOGREL OR ASPIRIN THERAPY IN HEALTHY MALE VOLUNTEERS P. C. J. Armstrong* (UK), A. A. Dhanji, A. T. Tucker, J. A. Mitchell, T. D. Warner PP-MO-742 COMPARISON OF SOLUBLE GLYCOPROTEIN V (SGPV) AND SOLUBLE CD40 LIGAND (SCD40L) AS PLASMA MARKERS OF PLATELET ACTIVATION K. Javela, P. Mustonen* Finland PP-MO-743 MONITORING PLATELET FUNCTION IN CORONARY HEART DISEASE PATIENTS ON CLOPIDOGREL THERAPY: WHOLE BLOOD MULTIPLATE IMPEDANCE AGGREGOMETER COMPARED TO CLASSICAL AND NEW PLATELET FUNCTION METHODS R. Paniccia* (IT), E. Antonucci, N. Maggini, M. Miranda, R. Marcucci, A. M. Gori, I. Romagnuolo, D. Prisco, R. Abbate, G. F. Gensini PP-MO-744 ASSOCIATION BETWEEN ASPIRIN RESISTANCE AND PLATELET FUNCTION TESTS S. Genc* (TR), B. Saka, H. Eroglu, B. Omer, N. Erten, C. Tascıoglu

Diagnosis and Treatment of Inherited and Acquired Platelet Disorders I

PP-MO-745 PLATELET-FREE HEMOTHERAPY IN PATIENTS WITH BERNARD SOULIER SYNDROME (BSS): SUCCESSFUL BLEEDING PROPHYLAXIS WITH RECOMBINANT FACTOR VIIa (RFVIIa) FOR DENTAL EXTRACTION R. E. Scharf, B. Bomke* (DE), T. Hoffmann

172 PM-4 PLATELET DISORDERSINPATIENTS WITHLOWESYNDROME:EFFECTOF PP-MO-748 ASSOCIATED WITHREBOUND ANDNEUTROPENIA THROMBOCYTOPENIA CYCLICAL PP-MO-747 GLANZMANNPATIENT WITH A COMPOUNDHETEROZYGOUSTHROMBASTHENIA A PP-MO-746 POSTER PRESENTATIONS PM-5 THEINFLUENCEOFMICROPARTICLES ONCLOTFORMATION INFRESH-FROZEN PP-MO-759 PP-MO-758 PP-MO-757 MANAGEMENTWITH ACQUIREDBERNARDSOULIER SYNDROME:SUCCESSFUL PP-MO-756 RISKFACTOR DISEASE: THROMBOCYTOSISA ASSOCIATED WITHINFLAMMATORY PP-MO-755 MUTATION INTHEKINDLIN-3GENE ASSOCIATED WITHCOMBINEDLEUKOCYTE A PP-MO-754 ONPLATELET FUNCTION:SELECTIVEENHANCEMENTOF THEEFFECTOFDDAVP PP-MO-753 PP-MO-752 THROMBINGENERATION (TG)ISDECREASEDINSCOTTSYNDROMEDOGS PP-MO-751 MEANPLATELET VOLUME AND PLATELET AGGREGATION: SCREENINGTESTS FOR PP-MO-750 PATIENT WITHSLE IN A ANTI-GPIIBIIIA-INDUCED ACQUIRED THROMBASTHENIA PP-MO-749 irprilsI Microparticles 2009 MONDAY, JULY 13, LSAA SESDB TWOFLUOROGENIC THROMBINGENERATION TESTS AS ASSESSED BY PLASMA ANGIOTENSIN IIINDUCESTHEEXPRESSION OFPROCOAGULANTMICROP YHUMAN MONOCYTES/MACROPHAGES BY HGPDOMAIN RHOGAP PI(4,5)P25-PHOSPHATASE WITH A GENECODINGFOR A MUTATIONS INTHEOCRL THROMBOCYT FRAMESHIFTMUTATIONMISSENSE MUTATION INTHEGPIIIA-SUBUNIT AND A EFFICACY PLASMAPHERESIS INTHEPERI-OPERA FOR THROMBOEMBOLICDISEASE AND PLATELET DYSFUNCTION PLA THROMBOCYTHEMIA PATIENTS WITHESSENTIAL INFLUENCE OFLOW WISKOTT-ALDRICH SYNDROME PLATELET ABNORMALITIES RELEVANCE INBLEEDINGPATIENTS A. S.Lawrie*(UK),P C. Cordazzo, A. Mahaldar S. Nagalla*(US),P. Singh,G. Pullen, J.H.Herman,P. F. Bray Amico P. L.Junqueira, A. K.Zeinad,E.Okazaki,P. R.Villaca* (BR),D. A. F. Chamone,E. A. D’ M. K.Boudreaux*(US),J.Wardrop, V. Kiklevich,P. Felsburg T. Conte,M.Pavicic,C. Thuerlemann, G.Colucci,P. Keller, L. Alberio* (CH) M. Tybura, J. Trelinski, P. Smolewski,K.Chojnowski*(PL) J. L.Catalfamo*(US),M.B.Brooks, F. Gagliano,M.Diquattro,S.Ditta,G.Mancuso*(IT) D. Blickstein*(IL),R.Dardik,E.Rosenthal,J.Lahav, Y. Molad,O.Shpilberg, A. Inbal T. Mirault,G.Baujat,R.Salomon,F. Grelac,J.Lunardi,C.Bachelot-Loza,D.Lasne*(FR) D. E.Connor*(AU),J.Joseph Kirchmaier D. W TELET PROCOAGULANT estrup* (DE), A. Pilgrimm,R.Klamroth, T. Scholz,D.Pillitteri,M.Krause,C. OF WHOLEBLOODIMPEDANCE , Y T. Neri,M.Iorio, Y. Carmazzi, R.Vanacore, R.Pedrinelli, A. Celi*(IT) . Shen*(US),K.Matevosyan,C.Burke,E.Frenkel,R.Sarode SS–ACASEREPORT OSIS – A . Harrison,R. -DOSE ASPIRIN ONLEUKOCYTE-PLATELET INTERACTIONIN ACTIVITY A. Cardigan,S.J.Machin,I.Mackie A. Bryon TIVE SETTING AGGREGOMETR Y (WBIA) INIDENTIFYING ARTICLES 173

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-760 ASSAY OF PROCOAGULANT MICROPARTICLES WITH A CALIBRATED AUTOMATED THROMBOGRAM B. A. Owen* (US), J. A. Heit PP-MO-761 REDUCED EXPRESSION OF TISSUE FACTOR ON PLATELET DERIVED MICROPARTICLES DURING ATORVASTATIN TREATMENT IN PATIENTS WITH PERIPHERAL ARTERY DISEASE F. Mobarrez* (SE), A. Antovic, A. Bröijersén, B. Wiklund, H. Wallén PP-MO-762 A MULTICOLOR FLOW CYTOMETRIC ASSAY FOR THE DETECTION OF PLATELET DERIVED MICROPARTICLES F. Mobarrez* (SE), J. Antovic, N. Egberg, M. Hansson, H. Wallén PP-MO-763 PHOSPHOLIPID-DEPENDENT CLOTTING TIME IS ABLE TO IDENTIFY CANCER PATIENTS WITH HIGH LEVELS OF CIRCULATING MICROPARTICLES F. F. van Doormaal* (NL), A. Kleinjan, H. R. Buller, P. Kamphuisen, R. J. Berckmans, R. Nieuwland PP-MO-764 PLATELET-RELEASED PROTEIN DISULFIDE ISOMERASE ENHANCES TF PROCOAGULANT ACTIVITY ON ENDOTHELIAL CELL-DERIVED MICROVESICLES IN A REDOX INDEPENDENT MANNER L. G. van den Hengel* (NL), P. H. Reitsma, H. H. Versteeg PP-MO-765 MICROPARTICLES PLASMA LEVELS IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND CANCER E. Campello, L. Spiezia* (IT), M. Castelli, C. Radu, S. Gavasso, P. Simioni PP-MO-766 SENSITIVITY OF 2 FUNCTIONAL HAEMOSTASIS ASSAYS TO PLATELET-DERIVED MICROPARTICLES (PMP M. Gonzalez* (FR), A. Carlo, P. Poncelet, D. Boulay-Moine, F. Nicham, E. Arnaud, G. Contant, B. J. Woodhams PP-MO-767 THE PROTECTIVE EFFECTS OF FRESH THAWED PLASMA (FFP) ON ENDOTHELIAL PERMEABILITY ARE CORRELATED WITH CHANGES IN THROMBOSPONDIN-1 MICROPARTICLES N. Matijevic* (US), J. F. Dong, E. Hartwell, S. Pati, J. B. Holcomb PP-MO-768 ACTIVATION OF COAGULATION IN SICKLE CELL TRAIT; POSSIBLE ROLE FOR CIRCULATING MICROPARTICLE TISSUE FACTOR N. S. Key* (US), C. Amin, J. Y. Chang, S. Adam, A. Kutlar, B. Hulkower, D. Esserman, N. Mackman, K. I. Ataga PP-MO-769 MEASURING THE REAL CONTRIBUTION OF MICROPARTICLE-EXPOSED PROCOAGULANT PHOSPHOLIPIDS TO COAGULATION: A NEW ASSAY R. J. Berckmans* (NL), E. J. van Beers, J. M. van den Goor, F. F. van Doormaal, J. M. Tushuizen, M. Diamant, B. J. Biemond, A. Sturk, R. Nieuwland

Patient-oriented Studies of Antiplatelet Therapy I

PP-MO-770 MINOR BLEEDING IN CHD PATIENTS RECEIVING DUAL ANTIPLATELET THERAPY A. B. Sumarokov* (RU), L. I. Buryachkovskaya, I. A. Uchitel, T. E. Shirokova PP-MO-771 THE RELATION BETWEEN PLATELET REACTIVITY AND HBA1C IN DIABETIC PATIENTS WITH CARDIOVASCULAR DISEASE ON MAINTENANCE ASPIRIN AND CLOPIDOGREL THERAPY A. Singla* (US), M. Antonino, L. Lawal, S. Kotev, K. Bliden, P. A. Gurbel, U. Tantry PP-MO-772 PLATELET ALPHA-2 ADRENERGIC RECEPTOR HAS A ROLE IN THIENOPYRIDINE- RESISTANCE OF STABLE CORONARY ARTERY DISEASE PATIENTS ON CONVENTIONAL DUAL ANTIPLATELET THERAPY B. J. Béres* (HU), E. Tóth-Zsámboki, K. Vargová, I. Préda, R. Kiss 174 PM-7 OPRSNO EIYO-21 ETADFO YOER FOR COMPARISON OFVERIFYNOW-P2Y12 TEST AND FLOWCYTOMETRY PP-MO-775 PP-MO-774 TREATMENTPOST OFADP-INDUCEDAGGREGATIONVASP AND PREDICTIVEABILITY PP-MO-773 POSTER PRESENTATIONS PP-MO-783 PP-MO-782 PP-MO-781 CANGRELORINCREASES THEMAGNITUDEOFPLATELET INHIBITION AND REDUCES PP-MO-780 PP-MO-779 PP-MO-778 INHIBITTHROMBINGENERATION IN TREATMENT WITH ASPIRIN AND CLOPIDOGREL PP-MO-777 CANWEREVERSECLOPIDOGREL-INDUCEDPLATELET DYSFUNCTION PP-MO-776 ODY UY1,2009 MONDAY, JULY 13, ANALYSIS ON14PROSPECTIVESTUDIES META- NON-RESPONSIVENESSINCARDIOVASCULAR PATIENTS: A BIOLOGICAL AGE MODULA HYPERTENSIVE SUBJECTS: A THROMBIN GENERATION ASSOCIATED WITHINCREASEDTHROMBINGENERATION. EVALUATION OF Gerotziafas* (FR) LPDGE THERAPY CLOPIDOGREL CUT-OFF VALUE FORIDENTIFYINGPATIENTS WHO ARE LOWRESPONDERSTO PLATELET RESPONSETO CLOPIDOGREL.WHAT ISTHE MONITORING INDIVIDUAL GLYCEMIC CONTROL BUTNOTTO RELATED TO FIBRINOGENLEVEL ISINDEPENDENTLY CLOPIDOGREL REDUCED PLATELET INHIBITIONINDIABETICPATIENTS TREATED WITH CLOPIDOGREL-TREA SYNDROMEIN INDEX ONSTENTTHROMBOSIS AFTER ACUTE CORONARY DIFFERENTIAL THE INFLUENCEOFV INCLOPIDOGREL-PRETREATED SUBJECTS VARIABILITY INTERINDIVIDUAL WITH REPEATED POINTOFCAREMONITORING WITHMULTIPLATE ANALYSER PROSPECTIVESTUDY INTERVENTION. A TIME AFTER PERCUTANEOUS CORONARY PHARMACOLOGICAL AND CLOPIDOGREL DISEASE(CAD)RECEIVING ASPIRIN IN PATIENTS ARTERY WITHSTABLE CORONARY P ANTAGONIST CANGRELOR MAGNITUDE OFINVITROPLATELET INHIBITIONWITHTHEDIRECTP2Y12 Fabbro-Peray, J.L.Reny* (FR) C. Combescure,P. Fontana,N.Mallouk,P. Berdague,C.Labruyere,I.Barazer, J. Gris,P. Huisman J. D.Snoep*(NL),M.C.Hovens, S. M.Pasha,Frölich,H.Pijl,J. T. Tamsma, M.V. H. J.Bouman*(NL),W H. J.Bouman*(NL),W A. Banti,L.Mosialos,J.Zarifis,I.Kaprinis,C.V Katsamouris, I.Elalamy A. Bandi,L.Mosialos,N.Katsiki,C.Vassara, J.Zarifis,I.Kaprinis,D.Kiskinis, A. T. Gerotziafas*(FR) A. Bandi,L.Mosialos,N.Katsiki,J.Zarifis,C.Vassara, I.Kaprinis,D.Kiskinis,Elalamy, G. F. Szlam*(US),K. A. Tanaka, D.Bolliger, B.Rumph,J.H.Levy Cera, A. Chieffo, A. Castelli, A. Maseri,Z.Ruggeri, A. Colombo C. Godino*(IT),L.Mendolicchio,F. Figini, A. Latib, A. Sharp,J.Cosgrave,G.Calori,M. C. Frere*(FR),B.Gaborit, T. Cuisset,P. E.Morange,L.Camoin, A. Dutour, M.C. Alessi Alessi C. Frere*(FR), Hackeng, J.M.tenBerg,P A AEIGO LSARNNATVT,CRIO ANDCATECHOLAMINESWAKENING IN ONPLASMA-RENIN ACTIVITY, CORTISOL TIENTS WITHST E H EE FCIIA RISK ASSOCIATED WITHCLODIPOGREL OFCLINICAL TES THELEVEL T . Cuisset,J.Quilici,B.Gaborit,R.Poyet,L.Bali,P. Morange,J.Bonnet,M. EFFECTS OFLOW-DOSE ASPIRIN TAKEN AT BEDTIMEVERSUSON ABLE CORONAR PHARMACOLOGICAL E AINS PROSPECTIVE STUDY TED PATIENTS: A , G. ARIA EITNET LPDGE (PRC)STATUS ISMODIFIEDIN RESISTANCE TO CLOPIDOGREL . vanW . vanW T. Gerotziafas*(FR) TION INTHEP2Y12RECEPT . M.deMaat,H.J. RANDOMIZEDCROSSOVERTRIAL A erkum, G.Rude?,F erkum, C.M.Hackeng,N.Clappers,J.tenBerg REYDISEASE ARTERY Y RESPONSE T assara, D.Kiskinis,I.Elalamy T . Ruven . W . G.Leebeek, OR GENEONTHE O CLOPIDOGREL A. Kruit,C.M. , G. IS T . 175

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-784 A SURPLUS ANTIPLATELET ACTION OF CLOPIDOGREL IN CORONARY ARTERY DISEASE PATIENTS TREATED WITH ASPIRIN J. Dropinski* (PL), M. Sanak, B. Jakiela, W. Wegrzyn, J. Musial, A. Szczeklik PP-MO-785 TAILORED CLOPIDOGREL LOADING DOSE ACCORDING TO PLATELET REACTIVITY MONITORING TO PREVENT ACUTE AND SUBACUTE STENT THROMBOSIS L. Camoin-Jau* (FR), L. Bonello, S. Armero, O. Com, P. Barragan, F. Paganelli, F. Dignat George PP-MO-786 IN VIVO IMAGING OF FIBROSIS USING A COLLAGEN TRACER MIMICKING PLATELET GPVI L. Sarda-Mantel, J. Muzard, S. Loyau, A. Meulemans, L. Louedec, J. Michel, D. Le Guludec, P. Billiald, M. Jandrot-Perrus* (FR) PP-MO-787 COMPARISON OF A NOVEL ELISA-BASED VASP WHOLE BLOOD (WB) ASSAY WITH THE FLOW CYTOMETRIC (FC) TECHNIQUE J. A. Jakubowski, D. Boulay-Moine, N. Bourguet, A. Sugidachi, P. Barragan, M. Moulard* (FR) PP-MO-788 THE EFFECT OF PLATELET REACTIVITY ON INFARCT RELATED ARTERY PATENCY IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION N. J. Breet* (NL), C. A. C. Pittens, H. J. Bouman, J. W. van Werkum, J. M. ten Berg, C. M. Hackeng PP-MO-789 THE ANTI-PLATELET EFFECT OF ASPIRIN DOES NOT DECREASE AFTER 2-YEAR INTERVAL T. Ikeda* (JP), R. Taniguchi, H. Horiuchi

Atherosclerosis I

PP-MO-790 RESTORATION OF BLOOD FLOW IN UNILATERAL RENAL ARTERY STENOSIS REDUCES AORTIC INFLAMMATION, LIPID DEPOSITION AND ATHEROMA FORMATION A. S. Pathak* (US), M. Rojas, D. Fox, G. Stouffer PP-MO-791 A 9p21 GENOMIC VARIANT ASSOCIATED WITH PREMATURE CORONARY ARTERY DISEASE IN ASIAN INDIANS A. Maitra* (IN), D. Dash, S. John, P. R. Sannappa, J. Shanker, V. S. Rao, H. Sridhara, V. V. Kakkar PP-MO-792 ASSOCIATION OF THE GENETIC POLYMORPHISMS OF THE PITUITARY GROWTH HORMONE AND ITS RECEPTOR WITH PREMATURE CORONARY ARTERY DISEASE IN ASIAN INDIANS A. Maitra* (IN), D. Dash, S. John, P. R. Sannappa, S. Nagaraj, J. Shanker, V. S. Rao, H. Sridhara, V. V. Kakkar PP-MO-793 UNDERSTANDING THE ROLE OF TOLL-LIKE RECEPTORS IN CORONARY ARTERY DISEASE IN ASIAN INDIANS: IMPLICATIONS FOR DISEASE ETIOPATHOLOGY AND PREVENTION A. Maitra* (IN), D. Dash, P. R. Sannappa, S. Nagaraj, S. John, J. Shanker, V. S. Rao, H. Sridhara, V. V. Kakkar PP-MO-794 LIPOPROTEIN (A) AS A PREDICTOR OF FURTHER CLINICAL EVENTS IN PATIENTS WITH CORONARY DISEASE A. de la Peña* (MX), M. Baños, M. Peña, G. Cardoso, A. Bahena, B. Valente, E. Angles- Cano PP-MO-795 ANTIINFLAMMATORY AND ANTIATHEROGENIC EFFECTS OF DIETARY SUPPLEMENTATION WITH A COMBINATION OF MARINE OIL AND EXTRA VIRGIN OLIVE OIL IN APO-E-DEFICIENT MICE FED AN ATHEROGENOUS DIET K. Eilertsen, E. Elvevoll, J. Olsen, M. Hoylaerts, B. Østerud* (NO)

176 PM-9 FIBRINCLOTSTRUCTUREIS ASSOCIATED WITHOXIDIZEDLOW-DENSITY PP-MO-798 THEPROTEOMIC APPROACH OFOXIDATION AND INFLAMATION PROCESSON PP-MO-797 DENDRITICCELLS(DCS)DIFFERENTIATED FROMCIRCULATING HEMATOPOIETIC PP-MO-796 POSTER PRESENTATIONS PM-0 H EAINHPBETWEENTFPI AND TFEXPRESSIONINCIRCULATING THERELATIONSHIP PP-MO-808 PP-MO-807 PP-MO-806 PP-MO-805 PP-MO-804 RICHINCIS-9, PRODUCT(PECORINOCHEESE)NATURALLY DIARY EFFECTOF A PP-MO-803 SELECTED A EFFECTOFSHORT-TERM CONSUMPTIONOFBREAD OBTAINED BY PP-MO-802 BEVERAGES AND DRINKINGPATTERN ON INFLUENCEOF ALCOHOL PP-MO-801 MODIFICATIONS OFRETICULOCYTES AND RETICULATED PLATELETS IN PP-MO-800 DIFFERENTPATTERN OFMODIFICATIONS FORHAEMATOPOIETIC AND PP-MO-799 ODY UY1,2009 MONDAY, JULY 13, OPOOIA COMPOSITION MORPHOLOGICAL MONOCYTES AND WITHINCAROTID ATHEROSCLEROTIC PLAQUESWITHDIFFERENT ATHEROSCLEROSIS AND STROKEINHIGH RISKPATIENTS ONPROGRESSIONOFCORONARY INTENSIVE LIPIDLOWERINGTHERAPY A IORTI EESI AINSWT OOAYATR DISEASE ARTERY LIPOPROTEIN LEVELSINPATIENTS WITHCORONARY INVITRO V INHIBITION OFREGULA CD4+TCELLSISRESPONSIBLEFOR PROGENITOR CELLS(HPCS), INDUCEDBY COLONY ARTERIAL ACE D/-240THAPLOTYPEMODULA HEMORHEOLOGICAL VARIABLES: AN INTERVENTION STUDY HAEMORHEOLOGICAL TRANS-1 VARIABLES: AN INTERVENTION STUDY HAEMORHEOLOGICAL AND ONLIPID,INFLAMMATORY “HEALTHY” ITALIAN GRAINVARIETY HOMOCYSTEINE CONCENTRA MEN AFTER AN ACUTE EPISODEOFSTRENUOUSEXERCISE HEALTHY SEDENTARY MEN HEALTHY SEDENTARY STRENUOUSEXERCISEIN PROGENITOR CELLS AFTER A ENDOTHELIAL F. X.Gruber, B. Østerud,J.Hansen G. B.Manjunath*(NO), M.Sovershaev, E.Egorina,V. Bogdanov, J. T. Fallon,N.Seredkina, G. Corinaldesi*(IT),C.Corinaldesi E. L.Soboleva,G.N.Potapova*(RU), S.P Pratesi, R. Abbate, G.Gensini C. Fatini,E.Sticchi, A. Abdihakim, F. Sofi*(IT),I.Romagnuolo,G.Pratesi,R.Pulli,C. F. Sofi* (IT),F. Cesari,L.Mannini,G.Pratesi,R.Pulli,C. Abbate, G.Gensini Abbate, G.Gensini F. Sofi* (IT), A. Gori,F. Cesari,L.Mannini, A. Buccioni,M. Antongiovanni, A. Casini,R. Vecchio, R. Abbate, G.Gensini F. Sofi*(IT),F. Cesari, A. Gori,L.Mannini,Evangelisti,Ghiselli,S.Benedettelli,V. Gensini F. Sofi*(IT),F. Cesari,R.Marcucci, A. Gori,S.Fedi,I.Lapini, A. Casini,R. Abbate, G. F. Cesari*(IT),F. Sofi, A. Capalbo,N.Pucci, A. Gori,R.Caporale, Abbate, G.Gensini Gensini F. Cesari*(IT),F. Sofi, A. Capalbo,N.Pucci,R.Caporale, A. Gori,S.Califano,R. Abbate, G. E. Stepien*(PL), A. Undas,B.Kapelak,G. Tylko, J.Sadowski D. F. OzelDemiralp*(TR),C.Gumustekin,N. Yazihan D. Chen*(UK),X.Lu,V THEROSCLEROSIS OF -FORMING UNITSOFMEGAKAR OJGTDLNLI CDO II,IFAMTR AND 1 CONJUGATED LINOLEIC ACID ONLIPID,INFLAMMATORY ASCULAR MODEL DISEASE . Kakkar PROFILE INPERIPHERAL OYTCELLS(TREGS)IN ATHEROSCLEROSIS TORY AORTA TIONS TES THEPREDISPOSITIONT . Veselova YOCYTES ININTIMA REILDISEASEPATIENTS ARTERIAL IN MANWITH O PERIPHERAL 177

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-809 ENDOGENOUS CHOLESTEROL SYNTHESIS, BUT NOT CHOLESTEROL ABSORPTION IS ASSOCIATED WITH EARLY ATHEROSCLEROSIS G. H. Heine* (DE), O. Weingärtner, D. Lütjohann, K. S. Rogacev, L. Blömer, Y. Grenner, S. Gräber, C. K. Ulrich, M. Girndt, M. Böhm, D. Fliser, U. Laufs PP-MO-810 SIGNIFICANCE OF SERUM INFLAMMATORY CYTOKINE AND BLOOD CLOTTING FACTOR IN PATIENTS WITH ACUTE CEREBRAL INFARCTION H. Gu* (CN), Y. Zhang, J. Gu PP-MO-811 GENETIC ANALYSIS OF APOA1-APOC3-APOA5 GENE CLUSTER IN RELATION TO LIPIDS AND CORONARY ARTERY DISEASE IN THE ASIAN INDIAN POPULATION J. Shanker* (IN), V. S. Rao, S. John, S. Hebbagodi, B. Dhanakshmi, V. V. Kakkar PP-MO-812 DISSECTION OF METABOLIC SYNDROME TRAIT IN ASIAN INDIAN FAMILIES WITH STRONG HISTORY OF CORONARY ARTERY DISEASE J. Shanker* (IN), K. Sibi, S. Hebbagodi, V. S. Rao, B. Dhanalakshmi, A. Mani, V. V. Kakkar PP-MO-813 THE APOLIPOPROTEIN CI CONTENT OF VERY LOW DENSITY LIPOPROTEINS IS A KEY REGULATOR OF FASTING TRIGLYCERIDES AND POSTPRANDIAL LIPEMIA IN HUMANS J. B. Hansen* (NO), J. Fernandez, A. With Notø, H. Deguchi, J. Bjorkegren, E. Mathiesen PP-MO-814 TISSUE FACTOR PATHWAY INHIBITOR-2 GENE METHYLATION IN CAROTID ATHEROSCLEROTIC PLAQUES C. Zawadzki, J. Breyne* (FR), N. Chatelain, M. Delestre, S. Susen, B. Quesnel, F. Juthier, E. Jeanpierre, R. Azzaoui, D. Corseaux, G. Torpier, B. Staels, E. van Belle, B. Jude PP-MO-815 POTENTIAL ROLE OF TISSUE FACTOR IN HUMAN AORTIC VALVE STENOSIS DEVELOPMENT J. Breyne* (FR), F. Juthier, S. Maréchaux, D. Corseaux, C. Zawadzki, E. Jeanpierre, A. Vincentelli, T. Le Tourneau, B. Jude PP-MO-816 FREQUENCY OF THE APOLIPOPROTEIN A5 -1131T> C POLYMORPHISM IN DYSLIPIDEMIC SUBJECTS FROM MINAS GERAIS STATE - BRAZIL K. B. Gomes* (BR), C. N. Ferreira, P. S. Pinheiro, K. F. Rodrigues, A. P. Fernandes, M. G. Carvalho, M. O. Sousa PP-MO-817 IN VITRO MODEL FOR THE EVALUATION OF THE EFFICACY OF PUTATIVE VACCINES AGAINST ATHEROSCLEROSIS L. A. Mundkur* (IN), K. Kumar, M. Varma, X. Lu, V. V. Kakkar PP-MO-818 PLATELET REACTIVITY IN STABLE ATHEROSCLEROTIC DISEASE PATIENTS ON CHRONIC ANTIPLATELET TREATMENT R. Paniccia* (IT), E. Antonucci, N. Maggini, E. Romano, L. Lucarini, L. Rossi, C. Saracini, E. Sticchi, G. F. Gensini, R. Abbate

Regulation of Gene Expression in Vascular Cells

PP-MO-819 THE MOUSE SAPHENOUS VEIN: MORPHOLOGICAL CHARACTERISTICS OF VENOUS ENDOTHELIUM B. Hemmeryckx* (BE), E. Bovill, E. Conway, M. Hoylaerts, R. Lijnen PP-MO-820 MICROARRAY ANALYSIS OF GENE EXPRESSION IN GLUCOCORTICOID-INDUCED OSTEONECROSIS USING A RAT MODEL: NEW INSIGHTS IN THE PATHOGENESIS OF OSTEONECROSIS M. A. Kerachian, D. Cournoyer, E. J. Harvey, T. Y. Chow, L. R. Bégin, A. Nahal, C. Séguin* (CA) PP-MO-821 INFLUENCE OF GENETIC VARIATIONS IN P-SELECTIN ON P-SELECTIN EXPRESSION AND SECRETION H. Ponniahpillai Subramanian, B. Subbarayal, C. Mannhalter* (AT) 178 PM-2 ITRCINO FWT NOHLA CELLS INTERACTIONOFTFWITHENDOTHELIAL PP-MO-824 TISSUEFACTOR PROMOTERD/DHAPLOTYPE AMPLIFIES INFLAMMATORY PP-MO-823 BETWEENHAEMOSTASIS AND ANGIOGENESIS FACTORS RELATIONSHIP IN PP-MO-822 POSTER PRESENTATIONS PM-3 AGOEI FETO LENTVL SPLICED ANGIOGENICEFFECTOF AND FULL-LENGTHTISSUE ALTERNATIVELY PP-MO-834 PP-MO-833 PP-MO-832 PP-MO-831 VECTOR-MEDIATED TRANSFEROFENDOSTATIN INTO LEUKEMIC RETROVIRAL PP-MO-830 MEMBEROFTHEINTERLEUKIN-1FAMILY, ISUP NOVEL INTERLEUKIN-33, A PP-MO-829 TOWARDS AN UNDERSTANDING OFDIABETICVASCULOPATHY: MECHANISMSOF PP-MO-828 ANDEXPRESSIONINTHEVASCULAR SYSTEM RNASE ACTIVITY PP-MO-827 VENOUS ANALYSIS OFTHEGENETICEXPRESSIONFROM ACUTE DEEP PP-MO-826 MEDIATORS ANALYSIS FROM OFTHEGENETICEXPRESSIONINFLAMMATORY PP-MO-825 Angiogenesis I 2009 MONDAY, JULY 13, ATR NIIINB TFPI FACTOR. INHIBITIONBY PRODUCTFORSTROKE THERAPY PROGENITOR CELLS AS CELL TRANSPLANTED LATE OUTGROWTH ENDOTHELIAL RNCITOA ANDPROTEINLEVELSIN HUVEC TRANSCRIPTIONAL CELLS(HMVEC MICROVASCULAR ENDOTHELIAL RESPONSE VIA VASCULARPLACENTAE COMPLICATIONS FROMGESTATIONAL VWF/ PROGESTERONE GROWTH CELLS AND ITSEFFECTONCELL CELLS INVITRO CYTOKINES INHUMANSMOOTHMUSCLE PROINFLAMMATORY REGULATED BY HYPEROSMOLARITY THROMBOSIS VENOUSTHROMBOSISPATIENTS DEEP C. Giannarelli*(US), M. George, P C. Moubarik,B.Guillet*(FR),J.Codaccioni, F. Sabatier, M.Piercecchi-Marti, F. Dignat- L. Keller, M. A. Lazzari Y. P. Powazniak*(AR), A. C.Kempfer, J.C.Calderazzo,H.PaivaPalomino,V. A. Zapata, Palomino, L.Keller Y. P. Powazniak*(AR), A. C.Kempfer, J.C.Calderazzo,M. A. Carrivale,J.H.Paiva X. Bai*(CN),J.Fu,Xie,Z.W S. Demyanets*(A R. Madonna,E.Montebello,G.Lazzerini,deCaterina*(IT) M. Nishio*(JP),S.Fischer Annichino-Bizzacchi M. S.Rubin*(BR), A. C.Deckmann,M.F. Carazzolle,L.P. Parizzi,G. A. G.Pereira,J.M. Annichino-Bizzacchi M. S.Rubin*(BR), A. C.Deckmann,M.F. Carazolle,L.P. Parizzi,G. A. G.Pereira,J.M. S. Albrecht, M.Grosser*(DE),G.B.Baretton J. S.Buzby*(US), A. Williams,K.L.Imfeld,D.J.Nugent Cappucci, M.Margaglione,E.Grandone*(IT) E. Chinni,D.Colaizzo,G. Maurer, K.Huber, J.Wojta ADAMTS13 SYSTEMREGULA . Pisano 3-AKI ENTLCOMPARED TO ADULTP38-MAPK INNEONATAL HUMAN T), C.Kaun,K.Katsaros,Rychli,R.Hintenberger , M. AND HIST -RELA A. Lazzari Tiscia, D.Pisanelli,M. Tomaiuolo, G.Vecchione, P. Vergura, F. , S.Dadkhahi, Turu, G.Cimmino,V. Fuster, J.Badimon TED HYPERGL AMINE EXERT ang, C.Ruan TION BY T. Koyama,K. T. Preissner YCAEMIC DAMAGE AN OPPOSITEEFFECTONVWF/ADAMTS13 ESTRADIOL AND HIST , S.Pfaf AMINE fenberger, G. 179

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-835 ENDOTHELIAL PROGENITOR CELLS ARE SELECTIVELY MOBILIZED IMMEDIATELY AFTER CORONARY ARTERY BYPASS GRAFTING OR VALVE SURGERY D. M. Smadja* (FR), A. Godier, R. R. Packard, J. Fabiani, M. Aiach, P. Gaussem PP-MO-836 BALANCE BETWEEN CIRCULATING ENDOTHELIAL PROGENITOR CELLS (EPCS) AND MATURE CIRCULATING ENDOTHELIAL CELLS (CECS) IN RELATION TO THE SEVERITY OF PERIPHERAL ARTERIAL DISEASE F. Cesari* (IT), F. Sofi, A. Gori, R. Caporale, G. Pratesi, R. Pulli, C. Pratesi, R. Abbate, G. Gensini PP-MO-837 ROLE OF THROMBOMODULIN IN MONOCYTE ADHERENCE TO ENDOTHELIUM F. Rendu* (FR), P. Chieng Yane, B. Le Bonniec, M. David-Dufilho PP-MO-838 GROWTH FACTOR INDUCED ENDOTHELIAL CELL MIGRATION REQUIRES UROKINASE RECEPTOR (UPAR) DEPENDENT INTEGRIN REDISTRIBUTION G. W. Prager* (AT), M. Unseld, J. Breuss, J. Mihaly, C. C. Zielinski, B. R. Binder PP-MO-839 DNAZYMES TO MOUSE BETA1 INTEGRIN MRNA IN VIVO - TARGETING THE TUMOR VASCULATURE I. Sacewicz* (PL), M. Wiktorska, T. Wysocki, C. S. Cierniewski, J. Niewiarowska PP-MO-840 A NOVEL COMPOUND, NP-184, INHIBITS THE VASCULAR ENDOTHELIAL GROWTH FACTOR INDUCED ANGIOGENESIS K. Lin* (TW), C. Chung, T. Huang PP-MO-841 THE EFFECT OF THE RATIO BETWEEN ANGIOGENIC AND ANTIANGIOGENIC FACTORS ON PATIENTS’ SURVIVAL IN ADVANCED NONSMALL CELL LUNG CANCER V. Demir, M. Demir* (TR), I. Cicin, G. E. Pamuk, E. Ozturk, E. Tekgunduz, T. Caglar PP-MO-842 NICKED BETA2-GLYCOPROTEIN I, BUT NOT INTACT BETA2-GLYCOPROTEIN I, BINDS PLASMINOGEN PROTEOLYSIS PRODUCT ANGIOSTATIN4.5 AND REDUCE ITS PHYSIOLOGICAL PROPERTIES S. Yasuda* (JP), H. Nakagawa, E. Matsuura, K. Kobayashi, M. Ieko, H. Kataoka, T. Horita, T. Atsumi, T. Koike PP-MO-843 DOWNREGULATION OF MMP-7 BY SIRNA IN CANCER CELLS RESULTS IN RETARDATION OF TUMOR GROWTH AND NEW BLOOD VESSELS FORMATION IN VITRO AND IN VIVO T. Wysocki* (PL), M. Wiktorska, I. Saczewicz, C. S. Cierniewski, J. Niewiarowska PP-MO-844 A NOVEL YC-1 DERIVATIVE, P95WU25, INHIBITED ANGIOGENESIS INDUCED BY VASCULAR ENDOTHELIAL GROWTH FACTOR Y. Chen* (TW), T. Huang

Extracellular Matrix and Cell-Matrix Interactions

PP-MO-845 CARDIOPROTECTIVE EFFECT OF ROSUVASTATIN IN WILD TYPE AND APOE MICE FED WITH HIGH FAT DIET-ROLE OF MATRIX METALLOPROTEINASE AND ITS INHIBITORS A. Siddiqui* (SE), T. Gustafsson, H. Fischer, M. Crisby PP-MO-846 THE INTEGRIN ALPHA2BETA1 AS A NEW ANTI-ANGIOGENESIS TARGET FOR REGULATING TUMOR ANGIOGENESIS BY AGGRETIN C-TERMINAL C. Chung* (TW), C. Chang, T. Huang PP-MO-847 ADHESION, PROLIFERATION AND MIGRATION OF HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS ON FIBRINOGEN GAMMA A AND GAMMA’ E. Y. Cheung* (NL), E. M. Weijers, P. Koolwijk, M. P. de Maat

180 PM-5 XRSINO NERNAPAIBBT3I RMR HUMANTROPHOBLASTS EXPRESSIONOFINTEGRIN ALPHA(IIB)BETA3 INPRIMARY PP-MO-850 PP-MO-849 PAI-1 INDUCESMALIGNANTPHENOTYPEMODULATING EXPRESSION AND ACTIVITY PP-MO-848 POSTER PRESENTATIONS PM-6 UPREGULATION OFINTEGRINEXPRESSIONINHUVECSTRANSDUCED WITH AD- PP-MO-861 FROMCHRONICCOCAINECONSUMERS INDUCES ACTIVATION OF PLASMA PP-MO-860 EXPRESSIONOF ANNEXIN IIINPATIENTS WITHHEMATOLOGIC MALIGNANCIES PP-MO-859 HEMOSTATIC CHANGESINCYANOTIC HEART AND ACYANOTIC CONGENITAL PP-MO-858 DYSFUNCTIONINDEPRESSION:FACTORS INFLAMMATION AND ENDOTHELIAL PP-MO-857 AND CELLSINHYPOXIA OFCULTURED ACTIVATION ENDOTHELIAL AND INJURY PP-MO-856 ANDPLATELET MICROPARTICLES ELEVATION INPATIENTS OFENDOTHELIAL WITH PP-MO-855 PP-MO-854 SERPIN,MASPIN, THENON-INHIBITORY INHIBITIONOFVSMCMIGRATION BY PP-MO-853 HYDROPHOBICINTERACTIONS BY 2-I-DOMAIN AFFINITY REGULATION OF ALPHA PP-MO-852 VONWILLEBRANDFACTOR-DEPENDENT PLATELET ADHESION FROMTHE ASPECT PP-MO-851 Endothelial DysfunctionI 2009 MONDAY, JULY 13, CELL NUMBEROF VEGF-D IS ASSOCIATED WITHSIGNIFICANT DOWNREGULATION OF A ENDOTHELIAL N IL.PSIL NOVMN FFBI SAMATRIX LIGAND AND VILLI.POSSIBLEINVOLVEMENT OFFIBRIN AS A REMODELING ANDEXTRACELLULAR MATRIX SURVIVAL CELL ON VASCULAR ENDOTHELIAL PROTHROMBIN ACTIVATOR BELONGINGTO THELIPOCALINFAMILYTHE ROLEOF A PHOSPHATASES (DUSP) ACTIVITY OF MAPKPATHWAY REGULATOR DUAL DISEASES CONTRIBUTING TO CARDIOVASCULAR DISEASECO-MORBIDITY REOXYGENA CHRONIC VENOUSINSUFFICIENCY VON WILLEBRANDFACTOR A3 DOMAINUNDERHIGHSHEARFLOW PLA INVOLVES DIRECTINTERACTIONSWITH?1INTEGRINS MORPHOLOGY WALL OF HUMAN ARTERY C. S.Cierniewski* (PL), I.Papiewska-Pajak Pallavicini, J.Pereira C. G.Sáez*(CL),P. Olivares,P. Hidalgo,S.Belmont,D.Mezzano, T. Massardo,J. M. Jiang,L.Zhang,Zhu,X.Bai,C.Ruan*(CN) A. Ayaz Ozkul*(TR), A. Selime,U.Sevde,E.Murat, A. Hatemi,E.Kansiz,B.Guney A. Halaris*(US),J.Fareed,Piletz,E.Litinas,O.Iqbal,D.Hoppensteadt, E. Tobin O. Zamfir A. Georgescu*(RO),N. Alexandru, D.Popov, M. Amuzescu, E. Andrei, M.Nemecz,C. Y. Zhao*(CN), T. Zhang,F. Shen,X.Bai, Y. He,C.Ruan R. Bass,L.W S. W. Hamaia*(UK),D.G.Bihan,R.James,V. Bolanos-Garcia,R.W. Farndale N. Wohner* (HU),E.Komorowicz, Z.Keresztes,R.Machovich,K.Kolev N. Lanir*(IL),B.Brenner, B.Paz, A. Snir L. C.Carrijo-Carvalho*(BR),J.S.Ventura, L.Wlian, A. M.Chudzinski-Tavassi J. Mihaly*(A A. Antonova, S. A. Loktionova, Y. A. Romanov, O.N.Shustova, A. V. Mazurov*(RU) TELET , MEMBRANE PROTEINS A. Badila,M.Simionescu DEINT AII SIHBTDB OOLNLATBD TO ANTIBODY MONOCLONAL ADHESION TO LAMININ ISINHIBITEDBY T), V. A. Carroll,J.M.Breuss,N.Geetha,G.W. Prager, B.R.Binder agstaf TION. EFFECTSOFEXTRACELLULARPH CELLS f, L.Ravenhill,V . Ellis*(UK) 181

Monday Posters

POSTER PRESENTATIONS MONDAY, JULY 13, 2009

PP-MO-862 COAGULATION ACTIVATION AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA. BENEFICIAL EFFECT OF ECULIZUMAB TREATMENT D. Helley* (FR), R. Peffault de Latour, R. Porcher, C. A. Rodrigues, J. Matheron, I. Galy- Fauroux, A. Duval, G. Socié, A. M. Fischer PP-MO-863 ASSESSMENT OF ENDOTHELIAL DYSFUNCTION IN PATIENTS OF DIFFERENT AGE WITH CHRONICAL RENAL FAILURE E. Vlasova* (RU), I. Vasilenko, V. Samoylenko, V. Suslov, I. Vaschuk PP-MO-864 INHIBITION OF PAI-1 PRODUCTION BY TREATMENT OF HERBAL MEDICINE IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS G. Atsumi* (JP), N. Ohkura, A. Kurata, S. Kanai, T. Fukuda, J. Matsuda PP-MO-865 NITRIC OXIDE PRODUCTION AND ANTIOXIDANT EFFECT OF A PROPANOLAMINOESTROGEN DERIVATIVE G. Gonzalez* (MX), M. Flores, V. Gomez-Vidales, L. Del Valle, J. Fernandez-G, E. Pinzon, I. Torres, A. de La Peña PP-MO-866 A RELIABLE MARKER OF ENDOTHELIAL CELL DYSFUNCTION AND VASCULAR DAMAGE: LEGEND OR REALITY G. Corinaldesi* (IT), C. Corinaldesi PP-MO-867 NITRIC OXIDE AND SOLUBLE PLASMA SELECTINS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV G. Cella* (IT), F. Vianello, M. Marchetti, A. Vignoli, M. Panova, T. Barbui, A. Falanga PP-MO-868 SOLUBLE THROMBOMODULIN LEVEL IS NOT A MARKER OF ENDOTHELIAL INJURY IN DIABETIC PATIENTS J. Kloczko* (PL), A. Blaszkowski, M. Galar, J. Sokolowski PP-MO-869 ARECOLINE INDUCED CYTOTOXICITY, IL-8 PRODUCTION AND GENE EXPRESSION IN HUMAN ENDOTHELIAL CELLS J. H. Jeng* (TW), M. C. Chang PP-MO-870 CIRCULATING ENDOTHELIAL CELLS IN DEEP VENOUS THROMBOSIS A. M. Alessio, F. L. A. Orsi, L. F. Bittar, M. P. Beltrame, F. G. Pereira, E. V. de Paula, I. Lorand-Metze, J. M. Annichino-Bizzacchi* (BR) PP-MO-871 NITRIC OXIDE ASSESSEMENT IN PREECLAMPSIA L. M. S. Dusse* (BR), L. C. Godoi, H. S. Madeira, B. A. Lwaleed, M. G. Carvalho PP-MO-872 DIFFERENTIAL ROLES OF PAR-1 AND PAR-3 IN VASCULAR ENDOTHELIAL CELLS M. V. Skok* (UA), O. M. Kalashnyk, A. I. Zhukova, L. I. Mikhalovska, S. V. Mikhalovsky PP-MO-873 ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH PULMONARY DISEASES N. V. Yahorava* (BY), I. S. Karpova, H. L. Hurevich PP-MO-874 CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH PULMONARY DISEASES N. V. Yahorava* (BY), I. S. Karpova, H. L. Hurevich

Inflammation and Cell Trafficking I

PP-MO-875 ACTIVATED PROTEIN C INHIBITS HISTAMINE RELEASE AND ACTIVATION OF NF-KB IN MAST CELL FROM RATS UNDER NORMAL CONDITIONS AND ACUTE INFLAMMATION A. Rusanova* (RU), S. Ishiwata, S. Strukova

182 PP-MO-877 FUNCTION,C-REACTIVEPROTEIN AND CARDIOVASCULAR RISKIN PULMONARY PP-MO-876 POSTER PRESENTATIONS PM-8 YOPI EUAE H LSAKALLIKREIN-KININSYSTEMFUNCTIONON DYNORPHINREGULATES THE PLASMA PP-MO-885 THROMBIN-THROMBOMODULIN INVASCULAR SYSTEMBOUNDS AND ENDOTHELIAL PP-MO-884 PP-MO-883 ACTIVATED PROTEINC(APC)PROMOTESPROLIFERATION OFRAT KERATINOCYTES PP-MO-882 PP-MO-881 ACTIVATED PROTEINC BY OFINNATE IMMUNITY CONTROL PP-MO-880 DISINTEGRIN,RHODOSTOMIN, INHIBITS ACTIVITIES OFLPS-TREATED A PP-MO-879 RESPONSEINMACROPHAGE INDUCED MECHANISMOFINFLAMMATORY NOVEL A PP-MO-878 ODY UY1,2009 MONDAY, JULY 13, HUMAN NEUTROPHILS ACTIVATING IN PROTEINPHOSPHATASESUPEROXIDE ANION RELEASEBY 2A INDUCED DIHYDRONAPHTHO [2,3-B][1,4]DIAZEPIN-2-ONE(ND700C),INHIBITSFMLP BENZODIAZEPINESDERIVEDCOMPOUND,4-(3-CHLOROPHENYL)-1,3- A THE MOLI-SANIPOPULATION ASTROCYTES CLEA ARSENIC TRIOXIDEINHIBITSINV PROTEIN CRECEPTOR (EPCR ACTIVATION OFPROTEASE-ACTIVATEDVIA RECEPTOR1 (PAR1) AND ENDOTHELIAL EFFICACY ALPHAVBETA3 INTEGRIN MONOCYTES VIA SNAKEVENOMC-TYPELECTINPROTEIN, AGGRETIN A BY REGULATION OF ANNEXIN 2 J. Mallela*(US), I. Maruyama*(JP), H. Bao*(CN),J.Ruan,M.Jiang,C.Ruan E. V. Kiseleva*(RU),L.R.Gorbacheva,O.N.Davydova,S.Ishiwata,M.Strukova H. Grif E. J.Kerschen*(US),I.Hernandez,M.Zogg,B.C.Cooley, J. A. Fernández,L.O.Mosnier, J. Mosnier E. J.Kerschen*(US),I.Hernandez,M.Zogg,S.Jia,Hessner, J. A. Fernández,L.O. C. Hsu*(TW), T. Huang C. Chang*(TW),Chung, T. Huang C. Liao*(TW), Tseng, Y. Day, C.Chang,S.Kuo,Lin L. Iacoviello Giuseppe, L.Rago, A. COAGULATION Arcari* (IT),D.Barbato,S.Costanzo,F. Bracone, A. deCurtis,M.Persichillo,R.di VES HMGB1, fin, F. J.Castellino,H.Weiler , J.H.Grif OF ACTIVATED PROTEINCVARIANTS INMURINESEPSIS MODELS fin, F Yang, Z.Shariat-Madar T A. diCastelnuovo,F AND PREVENTSSYSTEMICINFLAMMA . Ito,K.Kawahara, . J.Castellino,H.W ASIVE POTENTIAL T. Hashiguchi . Zito,H.J.Schunemann,G.deGaetano,M.Donati, eiler OF NB4CELLSTHROUGHDOWN TION AND INTRAVASCULAR 183

Monday Posters NOTES

ISTH2009

Scientific Program

Tuesday, July 14, 2009

185

TUESDAY, JULY 14, 2009

Plenary Lecture 9:45 AM – 10:30 AM

Oscar Ratnoff Memorial Lecture Grand Ballroom Chairperson: Paula Tracy (US) Contribution of allosteric disulfide bonds to regulation of hemostasis PL-TU-001 Philip Hogg (AU) 9:45 - 10:30 AM

State of the Art Lectures 11:00 AM - 12:30 PM

Platelet Activation Room 205 ABC Chairpersons: Edward Plow (US) and Joseph Italiano (US) Novel molecules in calcium signaling in platelets SA-TU-001 Wolfgang Bergmeier (US) 11:00 - 11:30 AM The Y's that bind: Negative regulators of platelet activation SA-TU-002 Debra Newman (US) 11:30 - 12:00 PM Novel interactions in platelet biology SA-TU-003 Yukio Ozaki (JP) 12:00 - 12:30 PM

Immune Thrombocytopenia Room 253 ABC Chairpersons: Carlo Balduini (IT) and Mortimer Poncz (US) Fetal and neonatal alloimmune thrombocytopenia SA-TU-004 James Bussel (US) 11:00 - 11:30 AM New insight into the mechanism of action of IV immunoglobulin SA-TU-005 Alan Lazarus (CA) 11:30 - 12:00 PM Pathogenesis of heparin-induced thrombocytopenia: Clinical implications SA-TU-006 Mortimer Poncz (US) 12:00 - 12:30 PM

186 TUESDAY, JULY 14, 2009

Blood Coagulation: Systemic Effects Grand Ballroom B Chairpersons: David Lane (US) and Francis Castellino (US) The role of the protein C system in pathologic processes SA-TU-007 Francis Castellino (US) 11:00 - 11:30 AM Modifier genes for disorders of thrombosis and hemostasis SA-TU-008 David Ginsburg (US) 11:30 - 12:00 PM The many faces of tissue factor SA-TU-009 Nigel Mackman (US) 12:00 - 12:30 PM

Inflammation and Atherosclerosis: Room 258 ABC uesday Science T Plaque Progression and Regression Chairpersons: Yujiro Asada (JP) and Gwendalyn Randolph (US) Dysfunctional HDL - Lipoprotein at the crossroads of inflammation, oxidant stress and reverse cholesterol transport SA-TU-0010 Stanley Hazen (US) 11:00 - 11:30 AM Dendritic cell and macrophage emigration from atheromatous plaque SA-TU-00011 Gwendalyn Randolph (US) 11:30 - 12:00 PM Progenitor cell trafficking to the vessel wall SA-TU-0012 Christian Weber (DE) 12:00 - 12:30 PM

Burning Questions in Hemophilia Inhibitors Ballroom 210 ABC Chairpersons: Marc Jacquemin (BE) and Birgit Reipert (AT) The role of regulatory T cells in tolerance to coagulation factors SA-TU-0013 Roland Herzog (US) 11:00 - 11:30 AM Opportunities and limitations of mouse models humanized for HLA class II antigens SA-TU-0014 Birgit Reipert (AT) 11:30 - 12:00 PM Clinical prediction models for inhibitor development SA-TU-0015 Marijke van den Berg (NL) 12:00 - 12:30 PM

187

TUESDAY, JULY 14, 2009

Genomics and Vascular Disease: Grand Ballroom A What Have We Learned About Thrombosis? Chairpersons: Russell Tracy (US) and Willem Ouwehand (UK) The discovery of genes implicated in myocardial infarction SA-TU-0016 Willem Ouwehand (UK) 11:00 - 11:30 AM Genome wide association studies: Atherosclerosis and risk factors SA-TU-0017 Bruce Psaty (US) 11:30 - 12:00 PM Genetics of venous thrombosis SA-TU-0018 Frits Rosendaal (NL) 12:00 - 12:30 PM

Abstract Symposia 1:15 - 2:45 PM

Abstract Symposia consist of an invited speaker and four highly rated abstracts presented on a related general theme.

Immunology and Treatment of ITP Room 210 ABC Chairperson: Douglas Cines (US) Controversies in ITP AS-TU-001 Douglas Cines (US) 1:15 - 1:45 PM AS-TU-002 1:45 - 2:00 PM ORAL ELTROMBOPAG REDUCES THE NEED FOR CONCOMITANT MEDICATIONS IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) P. Fogarty, J. B. Bussel* (US), G. Cheng, M. N. Saleh, B. Meddeb, C. Bailey, A. Brainsky AS-TU-003 2:00 - 2:15 PM SAFETY OF ALTERNATIVE TREATMENTS FOR ITP: META-ANALYSIS N. Cooper* (UK), M. D. Tarantino AS-TU-004 2:15 - 2:30 PM PLATELET VOLUME, PLATELET DIAMETER AND THROMBOPOIETIN LEVEL FOR DIFFERENTIATING INHERITED THROMBOCYTOPENIAS FROM IDIOPATHIC THROMBOCYTOPENIC PURPURA P. Noris* (IT), A. Pecci, L. Arcaini, V. Bozzi, A. di Cesare Merlone, F. Passamonti, F. Melazzini, M. Zecca, C. Balduini AS-TU-005 2:30 - 2:45 PM STORE-OPERATED CALCIUM ENTRY IS ESSENTIAL FOR FC GAMMA RECEPTOR ACTIVATION AND AUTOIMMUNE THROMBOCYTOPENIA D. Stegner* (DE), A. Braun, S. N. Syed, S. Konrad, A. Berna-Erro, D. Varga-Szabo, J. E. Gessner, B. Nieswandt

188

SYNDROME RISK F AS-TU-007 Susan Kahn(US) and management The post-thrombotic syndrome: Epidemiology Chairperson: SusanKahn(US) B. E.Hof IMMUNE RESPONSES TOF SUBSTANTIAL IMPACT OF THEGENETICMUTATION ANDTHEGENE TRANSFERPROTOCOLON AS-TU-015 M. C.Ozelo*(CA),H.Matsui,McMurray, L.Harpell,S.Powell,C.Hough,D.Lillicrap C.Hegadorn, OF DOGSRESUL IMPLANTING GENETICALLY ENGINEERED ENDOTHELIALPROGENITORCELLSINTHEOMENTUM AS-TU-014 J. D.Finn*(US),E.Sabatino,M.C. Ozelo, S.Zhou,D.Lillicrap,H.Kazazian,T MEDIATED EXPRESSIONOFCFVIIIIN HEMOPHILIA ADOGSWITHINHIBITORANTIBODIES INDUCTION OFIMMUNOTOLERANCETOCANINEFVIII(CFVIII)USING LIVERDIRECTED,AAV AS-TU-013 R. Sengupta*(CA),H.Matsui,J.W FOR HEMOPHILIAA ENCAPSULATED FETAL MOUSEMYOBLASTSSECRETINGFVIIIASAGENE THERAPYSTRATEGY AS-TU-012 Amit Nathwani(UK) Gene therapyforhaemophiliaB Chairperson: AmitNathwani(UK) F. A.Klok*(NL),N.vanderBijl,deRoos,L.J.M.Kroft, M.V. Huisman PATIENTS WITHACUTEPULMONARY EMBOLISM-THEPROBESTUDY SYNCHRONIZED MUL RIGHT VENTRICULAREJECTIONFRACTIONMEASUREDBYELECTROCARDIOGRAPHY- AS-TU-010 A. Perrier, C.Lorut,B.Tardy, M.Benoit,G.Chatellier, G.Meyer*(FR) O. Sanchez,L.T STUDY. THEPREPSTUDY PROGNOSTIC FACTORS OFPULMONARY EMBOLISM.APROSPECTIVEMULTICENTER COHORT AS-TU-009 M. Menahem,Weintraub, (IL) S.Revel-Vilk* TREATEDSURVIVORS WITHHICKMANCATHETERS MILD SIGNSOFPOST-THROMBOTIC SYNDROMEARENOTRAREINCHILDHOODCANCER AS-TU-008 M. Cushman*(US),P. W. Callas,M.H.Criqui,J.O.Denenberg,E.G.Bovill paeo eeTeayi eohlaRoom253ABC Update onGeneTherapyinHemophilia Room205ABC of Venous Thrombosis Post-thrombotic Syndrome andOtherOutcomes 2009 TUESDAY, JULY 14, ACTORS FORVENOUSINSUFFICIENCYTHAT RESEMBLESPOST-THROMBOTIC fman* (US),O.Cao, B.Moghimi,S.Nayak,M.Cooper rinquart, V TS INPERSISTENTFVIIIEXPRESSION ANDCELLVIABILITY TI-DETECTOR ROWCTANGIOGRAPHYPREDICTSCLINICALOUTCOMEIN . Caille,F ACTOR IXINAA en, D.Lillicrap,G.Hortelano . Couturaud,G.Pacouret, N.Meneveau,F. Verschuren, P. Roy, F. Parent, V-BASED THERAPYFORHEMOPHILIAB , S.Zhou,H.Ertl,K. A.High,R.W . C.Nichols,V. R.Arruda 1:15 -1:45PM 1:15 -1:45PM AS-TU-006 AS-TU-011 2:30 -2:45PM 2:15 -2:30PM 1:45 -2:00PM 1:45 -2:00PM 2:00 -2:15PM 2:30 -2:45PM 2:15 -2:30PM 2:00 -2:15PM . Herzog 189

Tuesday Science

TUESDAY, JULY 14, 2009

Cofactors Room 258 ABC Chairperson: Pete Lollar (US) The immune response to factor VIII AS-TU-016 Pete Lollar (US) 1:15 - 1:45 PM AS-TU-017 1:45 - 2:00 PM FACTOR V IS A COFACTOR FOR ACTIVATION OF FACTOR XI BY THROMBIN C. Maas* (NL), J. C. M. Meijers, C. Weeterings, P. G. de Groot, R. T. Urbanus AS-TU-018 2:00 - 2:15 PM NOVEL ROLE FOR CONNEXIN37 IN FVIII SECRETION AND COAGULATION L. Burnier* (CH), A. Pfenniger, R. Sugamele, I. Roth, M. Delmar, P. Fontana, B. R. Kwak, A. Angelillo-Scherrer AS-TU-019 2:15 - 2:30 PM ACTIVATED PROTEIN C COFACTOR FUNCTION OF PROTEIN S: A CRITICAL ROLE FOR THE EGF1- LIKE DOMAIN H. M. Andersson* (UK), M. J. Arantes, J. T. B. Crawley, B. M. Luken, D. A. Lane, S. M. Rezende AS-TU-020 2:30 - 2:45 PM PLG-RKT, A NOVEL, STRUCTURALLY UNIQUE, AND DEVELOPMENTALLY REGULATED TRANSMEMBRANE RECEPTOR FOR PLASMINOGEN L. A. Miles* (US), N. M. Andronicos, E. I. Chen, N. Baik, H. Bai, M. P. Kamps, J. R. Yates Iii, R. J. Parmer

Regulation of Coagulation Room 157 ABC Chairperson: Bernd Engelmann (DE) Activation of tissue factor-triggered coagulation by proteindisulfide isomerase AS-TU-021 Bernd Engelmann (DE) 1:15 - 1:45 PM AS-TU-022 1:45 - 2:00 PM PLATELET INDEPENDENT ENDOTHELIUM-DERIVED PROTEIN DISULFIDE ISOMERASE IS REQUIRED FOR FIBRIN GENERATION DURING THROMBUS FORMATION IN VIVO R. Jasuja* (US), G. Merrill-Skoloff, B. Furie, B. C. Furie AS-TU-023 2:00 - 2:15 PM ENDOTHELIAL CELL REGULATION OF BLOOD COAGULATION: A MODEL FOR VENOUS STASIS J. E. Campbell* (US), M. F. Whelihan, K. E. Brummel-Zeidens, T. Orfeo, J. Krudysz-Amblo, S. Butenas, K. G. Mann AS-TU-024 2:15 - 2:30 PM ANTITHROMBOTIC AND ANTIFIBRINOLYTIC EFFECTS OF PLATELET PROTEASE NEXIN-1 Y. Boulaftali* (FR), F. Adam, L. Venisse, S. Loyau, V. Ollivier, M. Alessi, M. Bryckaert, R. Favier, V. Arocas, M. Jandrot-Perrus, M. Bouton AS-TU-025 2:30 - 2:45 PM CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF VITAMIN K EPOXIDE REDUCTASE W. Li* (US), S. Schulman, R. Dutton, D. Boyd, J. Beckwith, T. Rapoport

190

DISORDERS (RBDS) ai hlis(S 1:15-1:45PM DEVELOPMENT OFATHEROSCLEROSIS HYPERSENSITIVITY INDYSLIPIDEMIAANDCONFERSPROTECTIONAGAINSTTHE GENETIC DELETIONOFSEMAPHORIN4D(SEMA4D)AMELIORATES PLATELET AS-TU-028 H. Yin* (US),J.Lu,Z.Wang, X.Du IB-IX-14-3-3 INTERCTIONANDITSTHERAPEUTICACTIONINENDOTOXEMICMOUSEMODELS IN VIVOANTI-THROMBOTICEFFECTOFANINHIBITORPLATELET GLYCOPROTEIN AS-TU-027 David Phillips(US) New directions inantithrombotic drugdiscovery Chairperson: DavidPhillips(US) K. Bakhtiari*(NL),M. D.I.Vergouwen, N.vanGeloven, M.Vermeulen, Y. B. W. E.Roos,J.C.M.Meijers SERIAL CHANGES INVONWILLEBRANDF AS-TU-035 A. Majeed,Y. Kim,M.Holmström, S.Schulman*(CA) WHEN SHOULDWARFARIN BERESTARTED AFTERINTRACRANIALHEMORRHAGE? AS-TU-034 F. Peyvandi*(IT) S. M.Siboni,E.Zanon,G.Sottilotta,D. Mikovic,A.Iorio,G.Castaman,M.Mazzucconi,P. M.Mannucci, CENTRAL NER AS-TU-033 A. Dragani,Giuf E. Zanon*(IT),L.Spiezia,Santagostino,A.Coppola,Tagliaferri, G.Rossetti,A.Iorio,R.Santoro, SUR INTRACRANIAL HAEMORRHAGEINHAEMOPHILIAAANDB:ANITALIAN RETROSPECTIVE AS-TU-032 Thorsten Steiner(DE) Intracranial hemorrhage:Threats andchances Chairperson: ThorstenSteiner(DE) C. Li*(CA),S.Piran,P. Chen,G.Zhu,S.Lang,J.Ware, Z.Ruggeri,J.Freedman, H.Ni NEONATAL FCRECEPTOR MISCARRIAGE THAT CANBEPREVENTEDBYBOTHIVIGANDANTIBODIESAGAINSTTHE MATERNAL IMMUNERESPONSETOFETAL PLATELET GPIBALPHACAUSESMOREFREQUENT AS-TU-030 J. W. M.Heemskerk,J.E.Kuijpers R. Nergiz-Unal*(NL),J.M.E.Cosemans,P AND ISRESTRICTEDTOHIGHSHEARFLOWCONDITIONS THROMBUS STABILIZATION BYP2Y12RECEPTORSCONTRIBUTESTOATHEROTHROMBOSIS AS-TU-029 A. Kumanongoh,E.Pure, S. L.Diamond,F. Brass T. J.Stalker*(US),L.Zhu,K.P. Fong,H.Jiang,A.Tran, I.Crichton,E.K.Lee,B.Neeves,S.F. Maloney, WITHOUT DELAYED CEREBRAL ISCHEMIAAFTERANEURYSMAL SUBARACHNOIDHEMORRHAGE nrcailHmrhg Room107ABC Intracranial Hemorrhage Room104ABC Platelets andSystemicDisorders 2009 TUESDAY, JULY 14, VEY VOUS SYSTEM(CNS)BLEEDINGINP frida, R.Musso,G.Mancuso,Castaman,Gamba,Mazzucconi,M.Lapecor . J.E.vanderMeijden,M.A.H.Feijge,G.OudeEgbrink, ACTOR ANDADAMTS13 INP A TIENTS WITHRAREBLEEDING ATIENTS WITHAND 1:15 -1:45PM AS-TU-026 AS-TU-031 2:00 -2:15PM 2:30 -2:45PM 2:15 -2:30PM 2:15 -2:30PM 1:45 -2:00PM 2:00 -2:15PM 1:45 -2:00PM 2:30 -2:45PM ella 191

Tuesday Science

TUESDAY, JULY 14, 2009

Mechanisms of Platelet Activation Room 153 ABC Chairperson: Stephen Watson (UK) Comparison of the proximal events in glycoprotein receptor signaling in platelets AS-TU-036 Stephen Watson (UK) 1:15 - 1:45 PM AS-TU-037 1:45 - 2:00 PM ROLE OF PLATELET ORAI1 AND STIM1 IN GPVI-DEPENDENT AND GPVI-INDEPENDENT THROMBUS FORMATION AND PROCOAGULANT ACTIVITY K. Gilio, R. van Kruchten* (NL), A. Braun, M. Elvers, P. E. J. van der Meijden, M. A. H. Feijge, M. J. E. Kuijpers, D. Stegner, J. W. M. Heemskerk, B. Nieswandt AS-TU-038 2:00 - 2:15 PM SIGNAL ACCELERATION BY THE GLYCOPROTEIN VI PROLINE-RICH DOMAIN ENABLES AN IMMUNE-TYPE RECEPTOR TO ADOPT A HEMOSTATIC ROLE A. A. Schmaier* (US), Z. Zou, K. B. Neeves, S. F. Maloney, K. P. Fong, A. Kazlauskas, S. L. Diamond, K. Saksela, M. L. Kahn AS-TU-039 2:15 - 2:30 PM TRAF4 (TNF-RECEPTOR ASSOCIATED FACTOR 4): A NOVEL LINK BETWEEN GLYCOPROTEIN IB AND GLYCOPROTEIN VI AND REDOX-DEPENDENT SIGNALING PATHWAYS IN HUMAN PLATELETS J. F. Arthur* (AU), Y. Shen, E. E. Gardiner, D. Kenny, R. K. Andrews, M. C. Berndt AS-TU-040 2:30 - 2:45 PM STIM1, BUT NOT STIM2 REGULATES CALCIUM STORE CONTENT IN PLATELETS A. Braun* (DE), D. Varga-Szabó, A. Berna-Erro, I. Hagedorn, B. Nieswandt

Inflammation Room 156 ABC Chairperson: Paul Fox (US) Post-transcriptional regulation of inflammatory gene expression AS-TU-041 Paul Fox (US) 1:15 - 1:45 PM AS-TU-042 1:45 - 2:00 PM GLYCOGEN SYNTHASE KINASE-3 NEGATIVELY REGULATES TISSUE FACTOR GENE EXPRESSION IN MONOCYTES INTERACTING WITH ACTIVATED PLATELETS. A NOVEL MECHANISM LINKING THROMBOTIC RISK AND METABOLIC DISORDERS A. di Santo, C. Amore, S. Manarini, V. Evangelista* (IT) AS-TU-043 2:00 - 2:15 PM VASCULAR AND INNATE IMMUNE CELL SIGNALING CONTRIBUTE TO LETHALITY PROTECTION BY ACTIVATED PROTEIN C IN MURINE SEPSIS MODELS C. Furlan-Freguia* (US), F. Niessen, J. A. Fernández, L. O. Mosnier, F. J. Castellino, H. Rosen, H. Weiler, J. H. Griffin, W. Ruf AS-TU-044 2:15 - 2:30 PM CONTRIBUTION OF EGFR TO LPS-INDUCED INFLAMMATION AND COAGULATION R. Pawlinski* (US), N. Mackman AS-TU-045 2:30 - 2:45 PM REDUCTION OF PROTHROMBIN IN MICE ATTENUATES THE DEVELOPMENT OF PARALYSIS ASSOCIATED WITH EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS E. S. Mullins* (US), K. W. Kombrinck, M. J. Flick, J. S. Palumbo, K. E. Talmage, M. A. Shaw, K. Akassaglou, J. L. Degen

192

neoplasms lsadoVnuci(T 1:15-1:45PM C. Strassel*(FR),P. Mangin,M.Freund, J.Cazenave,R.Skoda,G.Chrisitian,F. Lanza MOUSE MODEL EV AS-TU-047 Alessandro Vannucchi (IT) Mechanisms ofthrombosis inmyeloproliferative Chairperson: AlessandroVannucchi (IT) L. J.Raffini* (US),Y. Huang,C.Witmer, C.Feudtner THE UNITEDSTATES FROM2001TO2007 A SIGNIFICANTINCREASEINVENOUS THROMBOEMBOLISMINHOSPITALIZED CHILDRENIN AS-TU-055 U. NowakGöttl,K.Dietrich,N.Eldin,Y AS-TU-054 U. Nowak-Gottl,A.Huge,S.Thedieck,M.Stoll*(DE) ASSOCIA GENETIC VARIATION INTHEC-REACTIVEPROTEINGENEANDIL4-IL13CLUSTER IS AS-TU-053 Y. Berkun,M.Simchen,T. Strauss,S.Menashku,Padeh,G.Kenet* (IL) V ANTIPHOSPHOLIPID ANTIBODIESOFINF AS-TU-052 Neil Goldenberg(US) Neonatal andchildhoodarterialischemicstroke Chairperson: NeilGoldenberg(US) A. Falanga (IT),M.Marchetti,A. Vignoli* L.Russo,M.Panova-Noeva,S.Salmoiraghi,T. Barbui,A.Rambaldi,H.tenCate, POLYCYTHEMIA VERA(PV)PATIENTS ISINFLUENCEDBYJAK2V617FMUTATIONAL LOAD MONOCYTE (MNC)HEMOSTATIC PROFILEINESSENTIALTHROMBOCYTHEMIA(ET)OR AS-TU-050 D. Mattoscio,R.deCristofar F. Santilli*(IT),M.Romano,A.Recchiuti,Dragani,Falco,G.Lessiani,F. Fioritoni,S.Lattanzio, BIOSYNTHESIS INLOW-DOSEASPIRIN-TREATED POLYCYTHEMIA VERAPATIENTS CIRCULATING ENDOTHELIALPROGENITORCELLSANDRESIDUALINVIVOTHROMBOXANE AS-TU-049 M. Panova-Noeva*(IT),Mar ESSENTIAL THROMBOCYTHEMIA(ET)ANDPOLYCYTHEMIA VERA(PV)PATIENTS CHARACTERIZATION OFTHETHROMBINGENERATION (TG)POTENTIALOFPLATELETS FROM AS-TU-048 VKORC1 ORCYP2CPGENOTYPES IN PEDIATRIC PATIENTS, AGEHASMOREIMPACT ONORALANTICOAGULANTDOSETHAN Pediatric Thr Room160ABC Platelets andMyeloproliferative Syndromes 2009 TUESDAY, JULY 14, ARIANT OFANTIPHOSPHOLIPIDSYNDROME? ALUATION OFHAEMOSTASIS ANDTHROMBOSISRESPONSESINATHROMBOCYTOSIS TED WITHV ombosis ASCULAR STROKEINCHILDREN o, B.Rocca,G.Davì chetti, H.Spronk, G.Finazzi, A.Rambaldi,T. Barbui,H.tenCate,A.Falanga . Y asui, C.Geissen,L.G.Mitchell*(CA) ANTS WITHCEREBRALEVENTS-AUNIQUEENTITYOR Room 102AB 1:15 -1:45PM AS-TU-046 AS-TU-051 2:30 -2:45PM 2:30 -2:45PM 1:45 -2:00PM 2:15 -2:30PM 2:00 -2:15PM 1:45 -2:00PM 2:15 -2:30PM 2:00 -2:15PM 193

Tuesday Science

TUESDAY, JULY 14, 2009

Regulation of Gene Expression in Vascular Cells Room 109 AB Chairperson: Philip Marsden (CA) Regulation of vascular endothilial gene expression: The role of epigenetics AS-TU-056 Philip Marsden (CA) 1:15 - 1:45 PM AS-TU-057 1:45 - 2:00 PM MIRNA-DEPENDENT REGULATION OF SMOOTH MUSCLE CELL FUNCTION W. Bielenberg* (DE), A. Prock, H. Tillmanns, D. G. Sedding AS-TU-058 2:00 - 2:15 PM THE TRANSCRIPTIONAL MACHINERY RESPONSIBLE FOR THE TISSUE-SPECIFIC EXPRESSION OF THE MURINE MVWF1 GENE IS CONSERVED IN ZEBRAFISH Y. Kalish* (US), J. Johnsen, D. Ginsburg AS-TU-059 2:15 - 2:30 PM BIO-MECHANICAL REGULATION OF MICRORNA EXPRESSION AND ENDOTHELIAL CELL PHENOTYPE IN VITRO A. Murphy* (IE), M. Britto, P. Fitzpatrick, N. Barron, D. O'Gorman, N. Moyna, P. Cummins, R. P. Murphy AS-TU-060 2:30 - 2:45 PM GAS6 REGULATES DIFFERENT INFLAMMATORY RESPONSES TO TNF AND LPS IN ENDOTHELIAL CELLS L. Bellido-Martin* (ES), P. Garcia de Frutos

194 E. M.Conway VIA IMP V. Arruda (FACTOR IXPADUA) EXAMINATION OFTHEFINALSTAGES OFPLATELET PRODUCTION PL-TU-002 Introducer: KennethKaushansky(US) Slagboom, J.Houwing-Duistermaat,R.M.Bertina M. C.H.deV SUSCEPTIBILITY REGIONFORVENOUSTHROMBOEMBOLISM GENOME-WIDE SCANINAFFECTEDSIBLINGPAIRS (GIFTSTUDY)IDENTIFIESANOVEL PL-TU-001 Introducer: EdwinBovill(US) M. Delvaeye*(BE),Noris,A.deV THROMBOMODULIN MUT PL-TU-006 Introducer: HartmutWeiler (US) E. Plow, S.Shurin T. V. Byzova*(US),N.Malinin,J.Choi,A.Ciocea,L.Zhang,E.Podrez, M.Tosi, D.Lennon,A.Caplan, KINDLIN3 ININTEGRINACTIVATION PL-TU-005 Introducer: MarkGinsberg(US) P F EVIDENCE OFTHEFIRSTX-LINKEDTHROMBOPHILIADUETOANOVEL MUTATION INCLOTTING PL-TU-004 Introducer: PeteLollar(US) N. Mackman,T. Renné J.W.H. M.Spronk* (NL),S. Wilhelm, M.Heemskerk,H.tenCate,L.Knetsch,D.Gailani,R.Pawlinski, FEEDBACK ACTIVATION OFFACTOR XIBYTHROMBINISESSENTIALFORHAEMOSTASIS INVIVO PL-TU-003 Introducer: GeorgeBroze(US) J. N.Thon*(US),A.Montalvo,S.R.Patel,L.Richardson, J.H.Hartwig,E.Italiano rsdnilPeayAsrcs 4:15PM-5:00 4:00PM-4:15 Presidential PlenaryAbstracts ISTH 2009Awards Presentation 3:15PM-5:00 Presidential PlenaryAbstracts 2009 TUESDAY, JULY 14, . Simioni*(IT),D.T ACTOR IXGENERESUL AIRED COMPLEMENTREGULATION isser* (NL),R.vanMinkelen,V. vanMarion,M.denHeijer, J.C.Eikenboom,H.L.Vos, P. E. ormene, G.T TING INHYPERFUNCTIONALFIX:F ATIONS PREDISPOSETOATYPICAL HEMOLYTIC-UREMIC SYNDROME ognin, S.Gavasso,C.Bulato,N.Iacobellis,J.Finn,L.Spiezia,Radu, riese, C.T. Esmon,N.L.D.Lambrechts, G.Remuzzi, ACTOR IXARGININE338LEUCINE 3:35 -3:45PM 4:35 -4:45PM 3:20 -3:30PM 4:50 -5:00PM 4:20 -4:30PM 3:50 -4:00PM 195

Tuesday Science ORAL COMMUNICATIONS

TUESDAY, JULY 14, 2009 08:00 - 09:30

* Presenting Author

Risk Factors for Venous Thrombosis II Ball Room 210 ABC

Chairpersons: Peter MacCallum (UK) and Mirjam Meltzer (NL)

OC-TU-001 8:00 AM - 8:15 AM HYPOFIBRINOLYSIS AS A RISK FACTOR FOR THROMBOSIS AND LINKAGE ANALYSIS OF CLOT LYSIS TIME IN A PROTEIN C DEFICIENT KINDRED M. E. Meltzer* (NL), S. J. Hasstedt, C. J. M. Doggen, P. G. de Groot, F. R. Rosendaal, T. Lisman, E. G. Bovill OC-TU-002 8:15 AM - 8:30 AM AIR TRAVEL AND RISK OF VENOUS THROMBOEMBOLISM: A COMMUNITY-BASED STUDY P. K. MacCallum* (UK), S. Mt-Isa, K. Whyte, L. Letley, J. Martin, M. R. Vickers, E. M. Hennessy, D. Ashby OC-TU-003 8:30 AM - 8:45 AM EVALUATING THROMBIN GENERATION IN A FAMILY WITH PROTEIN C DEFICIENCY K. Brummel-Ziedins* (US), P. W. Callas, T. Orfeo, M. Gissel, M. F. Hockin, K. G. Mann, E. G. Bovill OC-TU-004 8:45 AM - 9:00 AM PROSPECTIVE STUDY OF BODY MASS INDEX AND THE RISK OF PULMONARY EMBOLISM IN WOMEN C. Kabrhel* (US), R. Varraso, S. Z. Goldhaber, E. Rimm, C. A. Camargo OC-TU-005 9:00 AM - 9:15 AM TALLER MEN HAVE INCREASED RISK OF VENOUS THROMBOEMBOLISM – THE TROMSO STUDY K. H. Borch* (NO), S. Kufaas-Braekkan, E. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer, J. Hansen OC-TU-006 9:15 AM - 9:30 AM HDL CHOLESTEROL AND FUTURE RISK OF VENOUS THROMBOEMBOLISM – THE TROMSO STUDY K. H. Borch* (NO), S. Kufaas-Braekkan, E. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer, J. Hansen

Diagnosis of Venous Thromboembolism Room 205 ABC

Chairpersons: Gregoire LeGal (FR) and Nadine Gibson (NL) OC-TU-007 8:00 AM - 8:15 AM PROSPECTIVE MULTI-CENTER ASSESSMENT OF INTEROBSERVER AGREEMENT FOR RADIOLOGIST INTERPRETATION OF 64-CHANNEL CT ANGIOGRAPHY FOR PULMONARY EMBOLISM D. M. Courtney* (US), N. T. Klekowski, C. D. Miller, H. A. Smithline, M. M. Hogg, J. A. Kline

196 ORAL COMMUNICATIONS

TUESDAY, JULY 14, 2009 08:00 - 09:30

OC-TU-008 8:15 AM - 8:30 AM AN ALTERNATIVE DIAGNOSTIC STRATEGY WITH LOWER RADIATION RISK IN YOUNG WOMEN WITH SUSPECTED PULMONARY EMBOLISM R. A. Douma* (NL), P. W. Kamphuisen, A. J. M. Rijnders, B. Hendrickx, M. ten Wolde, H. R. Büller OC-TU-009 8:30 AM - 8:45 AM DETECTION OF PULMONARY EMBOLI WITH 99MTC-LABELED ANTI- FIBRIN FAB’ FRAGMENTS (THROMBOVIEW): PHASE II STUDY T. A. Morris* (US), M. Gerometta, R. H. White, R. D. Yusen, J. D. Douketis, S. S. Kaatz, J. S. Ginsberg

OC-TU-010 8:45 AM - 9:00 AM als SAFETY AND SENSITIVITY OF TWO ULTRASOUND STRATEGIES IN PATIENTS WITH CLINICALLY SUSPECTED DEEP VENOUS THROMBOSIS; A PROSPECTIVE MANAGEMENT STUDY N. S. Gibson* (NL), S. M. Schellong, D. Y. El Kheir, J. Beyer, A. S. Gallus,

S. McRae, R. E. G. Schutgens, F. Piovella, V. E. A. Gerdes, H. R. Buller uesday Or T OC-TU-011 9:00 AM - 9:15 AM VALIDATION OF A DIAGNOSTIC APPROACH TO EXCLUDE RECURRENT VENOUS THROMBOEMBOLISM G. Le Gal* (FR), M. J. Kovacs, M. Carrier, K. Do, S. R. Kahn, P. S. Wells, D. A. Anderson, I. Chagnon, S. Solymoss, M. Crowther, M. Righini, A. Perrier, R. H. White, L. Vickars, M. Rodger OC-TU-012 9:15 AM - 9:30 AM COMMON ALTERNATIVE DIAGNOSES AFTER EXCLUSION OF DEEP VENOUS THROMBOSIS IN SYMPTOMATIC PATIENTS IN GENERAL PRACTICE A. J. ten Cate-Hoek* (NL), H. R. Büller, A. W. Hoes, K. M. G. Moons, R. Oudega, D. B. Toll, E. van der Velde, H. van Weert, M. H. Prins, H. E. J. H. Stoffers

Risk of Thrombosis in Cancer Room 253 ABC

Chairpersons: Alok A. Khorana (US) and Richard White (US) OC-TU-013 8:00 AM - 8:15 AM ELEVATED C-REACTIVE PROTEIN (CRP) LEVELS ARE ASSOCIATED WITH RISK OF OCCURRENCE OF VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS – RESULTS FROM THE VIENNA CANCER AND THROMBOSIS STUDY (CATS) R. Kanz* (AT), T. Vukovich, C. Ay, D. Dunkler, R. Vormittag, J. Haselboeck, C. Zielinski, I. Pabinger OC-TU-014 8:15 AM - 8:30 AM INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH LYMPHOMA S. J. Conlon* (US), R. H. White, H. K. Chew, T. Wun OC-TU-015 8:30 AM - 8:45 AM PREDICTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS BY MEASURING THROMBIN GENERATION - RESULTS FROM THE VIENNA CANCER AND THROMBOSIS STUDY (CATS) C. Ay* (AT), R. Simanek, D. Dunkler, J. Thaler, S. Koder, O. Wagner, C. Zielinski, I. Pabinger

197 ORAL COMMUNICATIONS

TUESDAY, JULY 14, 2009 08:00 - 09:30

OC-TU-016 8:45 AM - 9:00 AM BIOMARKERS IMPROVE THE RISK SCORING MODEL FOR PREDICTION OF CANCER-ASSOCIATED THROMBOSIS C. Ay* (AT), A. L. Chiriac, D. Dunkler, R. Vormittag, R. Simanek, P. Quehenberger, C. Zielinski, I. Pabinger OC-TU-017 9:00 AM - 9:15 AM INCREASED MICROPARTICLE TISSUE FACTOR ACTIVITY IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM D. A. Manly* (US), J. Wang, R. Kasthuri, H. Liebman, N. S. Key, N. Mackman OC-TU-018 9:15 AM - 9:30 AM LEUKOCYTOSIS, THROMBOSIS AND MORTALITY IN CANCER G. C. Connolly* (US), N. M. Kuderer, E. Culakova, C. W. Francis, G. H. Lyman, A. A. Khorana

Thromboprophylaxis in Surgery Room 258 ABC

Chairpersons: David Bergqvist (SE) and Cecilia Becattini (IT) OC-TU-019 8:00 AM - 8:15 AM EVALUATION OF DURATION OF THROMBOEMBOLIC PROPHYLAXIS AFTER MAJOR ORTHOPEDIC SURGERY: THE ETHOS REGISTRY D. Bergqvist* (SE), J. Arcelus, P. Felicissimo OC-TU-020 8:15 AM - 8:30 AM BURDEN OF ILLNESS OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP AND KNEE REPLACEMENT IN CANADA R. Selby* (CA), D. Becker, H. McDonald, S. Cartier, M. Crowther, P. Wells OC-TU-021 8:30 AM - 8:45 AM VARIATION IN MAJOR BLEEDING DEFINITIONS IN PHASE III ORTHOPEDIC VTE PROPHYLAXIS TRIALS AND THE IMPACT ON MAJOR BLEEDING FREQUENCY R. D. Hull* (CA), R. D. Yusen, D. Bergvist OC-TU-022 8:45 AM - 9:00 AM ULTRASOUND SCREENING OF DEEP VENOUS THROMBOSIS (DVT) AND DURATION OF THROMBOPROPHYLAXIS AFTER TOTAL KNEE ARTHROPLASTY (TKA): THE RANDOMIZED MULTICENTER PROTHEGE STUDY ON 878 PATIENTS M. T. Barrellier* (FR), B. Lebel, P. Mismetti, J. Parienti, J. Dutheil, C. H. Vielpeau OC-TU-023 9:00 AM - 9:15 AM AN ASSESSMENT OF SURGICAL THROMBOPROPHYLAXIS IN A TERTIARY CARE CENTER C. Robinson-Cohen* (US), V. Tagalakis, M. Dubois, D. Pilon OC-TU-024 9:15 AM - 9:30 AM ANTITHROMBOTIC PROPHYLAXIS FOR LAPAROSCOPIC CHOLECYSTECTOMY: A META-ANALYSIS C. Becattini* (IT), F. Rondelli, G. Manina, G. Noya, G. Agnelli

198 OC-TU-026 8:15 AM - 8:30 AM - 8:15AM 8:15 AM - 8:00AM OC-TU-026 OC-TU-025 ORAL COMMUNICATIONS OC-TU-032 8:15 AM - 8:30 AM - 8:15AM 9:30 AM - 9:15AM 9:00 AM - 8:45AM OC-TU-032 OC-TU-031 8:45 AM - 8:30AM OC-TU-030 OC-TU-029 OC-TU-028 OC-TU-027 eeiso oglto Room104ABC Genetics ofCoagulation Room157ABC Platelets andSystemicDisorders 2009 TUESDAY, JULY 14, F. L. Moll, S.Schulte-Merker PROTEIN CRECEPT B. Saposnik,P. Gaussem, A. Lokajczyk, J.L.Reny, M. Aiach, S.Gandrille*(FR) INFLUENCE OFTHEGENETICST E. D.Rosen*(US) DEFICIENT MICE IDENTIFICATION OFHEMOSTATIC MODIFIER GENESRESCUINGFVII Chairpersons: KatherineHigh(US)andRandalW E. COMPONENTFORTHROMBUSFORMATION ESSENTIAL ISEXPRESSED INZEBRAFISHTHROMBOCYTES AND AN MLCK1A A. H.Goodall*(UK) J. R.Wright, P. Ellis,C.Landford, N. A. Watkins, W. H.Ouwehand, INCREASE INMRNA C. Licht*(CA),F. G.Pluthero,P. F. Zipfel,W. H. A. Kahr INDIVIDUALS HUS AND PATIENTS WITH ATYPICAL PLATELET-ASSOCIATED COMPLEMENTFACTOR HINNORMAL A. R.L.Gear, J.Linden R. K.Polanowska-Grabowska*(US),Wallace, R.Figler, L.Chen, DISEASE IN THENY1DDTRANSGENICMOUSEMODEL POLYMORPHONUCLEAR NEUTROPHILS ACTIVATES OXIDATIVE BURST PLATELET ACTIVATIONTO INCREASED ADHESION AND R. Rettig,U.Völker, A. Greinacher S. Gebhard*(DE),L.Steil,M.Gesell-Salazar, B.Kuttler, J.Peters, STATUS IN ANGIOTENSIN-II-INDUCED HYPERTENSION FORTHEBLOODPRESSURE MEMORY PLATELET PROTEINS AS A E. Tremoli, M.Camera*(IT) K. Gertow, G.Marenzi,Colombo,M.Brambilla,L.Ruggiero,deMetrio, SYNDROME NON-ST ELEVATION ACUTE CORONARY AND PLATELET TRANSCRIPTOME PROFILINGINSTABLE ANGINA Chairpersons: NATRA THROMBUS AN ARTERIAL BLOOD MONONUCLEAR CELLS(PBMC), (SEPCR) LEVELS T ournoij* (NL),G.J.W Alison H.Goodall(UK)andKanChen(US) R(PR RAFORMSFROMPERIPHERAL OR (EPCR)MRNA LEVELS OFPLA eber , J.N. TSO NOHLA CELL ATUS ONENDOTHELIAL Akkerman, P TELET-SPECIFIC GENES WITHIN AND ONSOLUBLE EPCR . G.deGroot,L.I.Zon, OF SICKLECELL estrick (US) 08:00 -09:30 8:00 9:00 AM -8:15 AM AM -9:15 AM 199

Tuesday Orals ORAL COMMUNICATIONS

TUESDAY, JULY 14, 2009 08:00 - 09:30

OC-TU-033 8:30 AM - 8:45 AM TWO SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) IN THE ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) GENE ARE ASSOCIATED WITH LOWER SOLUBLE EPCR (SEPCR), LOW COMPLEMENT C4 AND THROMBOTIC RISK IN PATIENTS WITH LUPUS (SLE) J. T. Merrill* (US), S. Kamp, K. Thomas, B. J. Woodhams, N. L. Esmon OC-TU-034 8:45 AM - 9:00 AM GENOME-WIDE ASSOCIATION STUDY REVEALS MULTIPLE NOVEL GENETIC LOCI WITH PLASMA LEVELS OF COAGULATION FACTOR VII, FACTOR VIII, AND VON WILLEBRAND FACTOR: THE COHORTS FOR HEART AND AGING RESEARCH IN GENOME EPIDEMIOLOGY (CHARGE) CONSORTIUM N. L. Smith* (US), W. Tang, M. de Maat, W. L. McArdle, M. Chen, A. Peters, W. Koenig, E. G. Bovill, S. Basu, J. C. M. Witteman, D. Strachan, C. J. O’Donnell OC-TU-035 9:00 AM - 9:15 AM ANNEXIN V GENE INVOLVEMENT IN THE OCCURRENCE OF GESTATIONAL VASCULAR DISORDERS G. L. Tiscia, D. Colaizzo, E. Chinni, D. Pisanelli, N. Scianname’, G. Favuzzi, M. Margaglione, E. Grandone* (IT) OC-TU-036 9:15 AM - 9:30 AM FINE MAPPING OF MOUSE CHROMOSOME 11 THROMBOSIS MODIFIERS USING CONGENIC MOUSE STRAINS Q. Sa* (US), J. L. Hoover-Plow

Antiphospholipid Syndrome: Basic Aspects Room 107 ABC

Chairpersons: Nathalie Satta-Poschung (CH) and Jacob Rand (US) OC-TU-037 8:00 AM - 8:15 AM ANTIPHOSPHOLIPID ANTIBODIES STIMULATE HUMAN CELLS VIA TLR2 AND CD14 N. Satta* (CH), S. Dunoyer-Geindre, F. Boehlen, G. Reber, E. K. O. Kruithof, P. de Moerloose OC-TU-038 8:15 AM - 8:30 AM INDUCTION OF PATHOGENIC ANTIPHOSPHOLIPID ANTIBODIES IN VIVO ARE DEPENDENT ON EXPRESSION OF MHC-II GENES S. S. Pierangeli* (US), E. Papalardo, Z. Romay-Penabad, A. Ibarra, P. Christadoss OC-TU-039 8:30 AM - 8:45 AM ASSOCIATION OF ANTI-B2GPI DOMAIN I IGG AND RESISTANCE TO ANNEXIN A5 WITH OBSTETRICAL ANTIPHOSPHOLIPID SYNDROME: EVIDENCE FOR A SPECIFIC MECHANISM IN A PATIENT SUBSET B. J. Hunt* (UK), X. Wu, B. de Laat, A. A. Arslan, K. Parmar, S. Stuart-Smith, J. H. Rand OC-TU-040 8:45 AM - 9:00 AM ANTI- BETA2- GLYCOPROTEIN I ANTIBODIES DIRECTED TO DOMAIN I IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS) AND TRIPLE LABORATORY POSITIVITY A. Banzato* (IT), N. Pozzi, V. Defilippis, E. Bison, M. Tonello, A. Ruffatti, V. Pengo

200 OC-TU-042 9:15 AM - 9:30 AM - 9:15AM 9:15 AM - 9:00AM OC-TU-042 OC-TU-041 ORAL COMMUNICATIONS OC-TU-049 8:00 AM - 8:15 AM - 8:00AM 9:00 AM - 8:45AM 8:45 AM - 8:30AM OC-TU-049 8:30 AM - 8:15AM 8:15 AM - 8:00AM OC-TU-048 OC-TU-047 OC-TU-046 OC-TU-045 OC-TU-044 OC-TU-043 teoceoi: os oesRoom156ABC Atherosclerosis: MouseModels Room153ABC Platelet BiologyI 2009 TUESDAY, JULY 14, IOHNRA SIGNALING MITOCHONDRIAL F. Lanza C. Strassel*(FR),B.Hechler, A. Bull,M.Freund,J.Cazenave,C. Gachet, IN THEGPIBBET A Chairpersons: V S. M.Jobe*(US),W. Clemmons ACCELERA L. Cecchetti*(IT),N. MEGAKAR X. Mo*(US),N.Nguyen,H.Fan,M.C.Berndt,R.Li GLYCOPROTEIN IB-ALPHA TRANS-SUBUNIT REGULATION OFECTODOMAIN SHEDDINGOF D. Wagner A. Brill*(US), F P38KINASE-DEPENDENT SHEDDINGIN A INDUCES GPIB-ALPHA OXIDATIVE STRESS ACTIVATES ADAM17 (TACE) INPLATELETS AND A. Zampolli*(US),J.R.Roberts,P. Marchese,Z.M.Ruggeri GL PLATELET THROMBINMODULATION INVIVOBY FUNCTIONAL P. A. McEwan,X.Zheng,R.Li,J.Emsley*(UK) ECTODOMAIN STRUCTURE OFTHEGLYCOPROTEIN IB-BETA Chairpersons: JoelBennett(US)andMatthewJones(UK) K. L. ANTIPHOSPHOLIPID ANTIBODIES MODULATION OFKLF2 AND KLF4BY T GL ASSOCIATED DIMERS COVALENTLY AND MULTIMERS OFB2- N YTEIEMPTM AIYMEMBERS FAMILY AND SYNTHESIZEMMP/TIMP . Matsui*(JP), A. Hayashi, Y. Yakura, S.Matsumoto,H. Takeya ASHION THEROSCLEROTIC LESIONSDEVELOPMENT ISNOTPREVENTED YCOPROTEIN IB YCOPROTEIN I Allen* (US),D.Kawanami,M.K.Jain,R.McCrae YOCYTES TED THROMBOSISIN A. K.Chauhan,M.Canault, ictoria A. Ploplis(US)andPeterPanizzi (US) A-/-APOE-/- DOUBLEKNOCKOUTMICE T olley, A. S.Weyrich, P. Gresele AND PLA TELETS DIFFERENTIALL A MOUSE MODEL T. Walsh, W. Bergmeier, WITH IMP EXPRESS Y AIRED 08:00 -09:30 9:15 AM -9:30 AM 9:00 AM -9:15 AM 201

Tuesday Orals ORAL COMMUNICATIONS

TUESDAY, JULY 14, 2009 08:00 - 09:30

OC-TU-050 8:15 AM - 8:30 AM A PLASMINOGEN DEFICIENCY ATTENUATES ATHEROSCLEROSIS AS A RESULT OF ALTERED LIPOPROTEIN PROCESSING T. Iwaki, D. L. Donahue, M. J. Sandoval-Cooper, F. J. Castellino, V. A. Ploplis* (US) OC-TU-051 8:30 AM - 8:45 AM A SYNERGISTIC ROLE OF COMBINATION OF APOB AND HHSP60 EPITOPES IN REGRESSION OF ATHEROSCLEROTIC LESION X. Lu* (UK), V. Endresz, M. Xia, D. Chen, G. Qi, I. Faludi, K. Burián, A. Csanadi, A. Miczák, E. Gonczol, V. Kakkar OC-TU-052 8:45 AM - 9:00 AM ALPHA-LINOLENIC ACID DIMINISHES ATHEROTHROMBOSIS, REDUCES RED CELL ARACHIDONIC ACID AND ENDOTHELIAL TISSUE FACTOR EXPRESSION C. M. Matter, C. Lohmann, F. C. Tanner, E. W. Holy, E. K. Richter, F. Leiber, T. F. Lüscher, M. Forestier* (CH), J. H. Beer OC-TU-053 9:00 AM - 9:15 AM WARFARIN INDUCES VASCULAR CALCIFICATION AS AN UNWANTED SIDE-EFFECT L. J. Schurgers* (NL), R. Westenfeld, T. Krueger, S. Oelenberg, C. Vermeer, C. P. Reutelingsperger OC-TU-054 9:15 AM - 9:30 AM TISSUE TRANSGLUTAMINASE IS NOT ESSENTIAL FOR ARTERIAL CALCIFICATION IN THE APOLIPOPROTEIN E KNOCKOUT MOUSE R. J. Pease* (UK), H. Williams, R. M. Graham, C. L. Jackson, P. J. Grant

Microparticles Room 160 ABC

Chairpersons: Benjamin Brenner (IL) and Rienk Nieuwland (NL) OC-TU-055 8:00 AM - 8:15 AM CASPASE 3 IS SORTED INTO MICROPARTICLES FROM MCF-7 CELLS A. N. Böing* (NL), G. B. Afink, C. Ris, A. Sturk, R. Nieuwland OC-TU-056 8:15 AM - 8:30 AM APPLICATION OF DYNAMIC LIGHT SCATTERING TO THE MEASUREMENT OF MICROPARTICLES P. Harrison* (UK), R. Dragovic, A. Albanyan, A. S. Lawrie, M. Murphy, I. Sargent OC-TU-057 8:30 AM - 8:45 AM THE ROLE OF MICROPARTICLES (MPS) IN DIABETIC VASCULAR COMPLICATIONS A. Aharon* (IL), G. Tsimerman, A. Rugin, E. Melamed, A. Bachar, B. Brenner OC-TU-058 8:45 AM - 9:00 AM MICROPARTICLES AFFECT ANGIOGENESIS AND INFLAMMATION BALANCE– IN HEALTHY PREGNANCIES AND GESTATIONAL VASCULAR COMPLICATIONS A. Aharon* (IL), E. Shomer, S. Katzenell, B. Brenner

202 OC-TU-059 9:00 AM - 9:15 AM - 9:00AM OC-TU-060 OC-TU-059 ORAL COMMUNICATIONS OC-TU-063 8:30 AM - 8:45 AM - 8:30AM 8:30 AM - 8:15AM OC-TU-066 OC-TU-065 OC-TU-064 OC-TU-063 OC-TU-062 OC-TU-061 eosTrmoi nPdarc Room204AB Venous Thrombosis inPediatrics 2009 TUESDAY, JULY 14, K. L.Black,M.E.Bauman,S.Kuhle, L. Bajzar, M.P. Massicotte*(CA) CONSERVATIVE APPROACH OF A ASSESSMENT INCHILDREN: INDUCEDCOAGULOPATHY WARFARIN THERAPY S. J.Hanson*(US),R.C.Punzalan,N. S.Ghanayem,P. L.Havens IN CRITICALL INCIDENCE AND RISKFACTORS FORVENOUSTHROMBOEMBOLISM A. Feliú-Torres, M.Castañon,J.Frontroth M. Bonduel*(AR),Hepner, G.Sciuccati,Pieroni,S.E. Annetta, WITH VENOUSTHROMBOEMBOLISM ANTIPHOSPHOLIPID SYNDROME(APS)IN C. vanOmmen F. J.Berfelo* (NL), T. R.deHaan,F. Groenendaal,L.S.deVries, P. Govaert, NEONA R. Mesters,U.Nowak-Göttl S. Holzhauer*(DE),M.Stoll, Thedieck, A. Huge,G.de Angelis, D.Manner, INDEX CASES: THROMBOEMBOLISM INFIRSTDEGREERELATIVES OFPEDIATRIC ANDINCIDENCEOFSYMPTOMATIC PREVALENCE OFTHROMBOPHILIA O. Kretschmar, S.Kroiss,M.Schmugge,Hug M. Albisetti* (CH),B.Brotschi,D.Neuhaus,C.Bürki,Latal,W. Knirsch, THROMBOSIS INCHILDREN INCIDENCE AND RISKFACTORS OFCATHETER-RELATED ARTERIAL Chairpersons: MarilynManco-Johnson(US)andSusanneHolzhauer(DE) J. R.Strahler, P. C. Andrew, P. K.Henke, T. W. Wakefield E. Ramacciotti*(US), A. E.Hawley, S.K.Wrobleski, D.MyersJr, THROMBOSIS VENOUS PROTEOMICS OFHUMANMICROPARTICLES AFTER DEEP A. Sturk,F. F. vanDoormaal,J.C.M.Meijers,B.Biemond E. J.vanBeers*(NL),M.C.L.Schaap,R.Berckmans,Nieuwland, DISEASE ASSOCIA CIRCULATING ERYTHROCYTE-DERIVED MICROPARTICLES ARE RISKFACTORS, IMAGING RESULTS, OUTCOME T AL TED WITHCOAGULATION ACTIVATION INSICKLECELL SINOVENOUS THROMBOSIS:CLINICAL Y A L CHILDRENWITHCARDIACDISEASE ILL PROSPECTIVE COHORTSTUDY A PEDIA TRIC COHORT PRESENTATION, 08:00 -09:30 9:15 AM -9:30 AM 9:15 AM -9:30 AM 9:00 8:45 8:00 AM -9:15 AM -9:00 AM -8:15 AM AM AM 203

Tuesday Orals ORAL COMMUNICATIONS

TUESDAY, JULY 14, 2009 08:00 - 09:30

Novel Assays in Hemophilia and von Willebrand Disease Room 102 AB

Chairpersons: Michael Makris (UK) and Evelyn Groot (NL) OC-TU-067 8:00 AM - 8:15 AM QUANTIFICATION OF LOW LEVELS OF FUNCTIONAL FACTOR VIII IN PLASMA BY TURBIDITY P. Y. Kim* (CA), A. C. Ma, V. A. Ward, M. E. Nesheim OC-TU-068 8:15 AM - 8:30 AM DOES HETEROGENEITY IN MEASURED CALIBRATED THROMBIN GENERATION ASSAY OR FVIII ACTIVITY (<1%) EXPLAIN CLINICAL HETEROGENEITY IN SEVERE HEMOPHILIA A? G. D. Sinclair* (CA), V. Blanchette, R. T. Card, A. K. C. Chan, S. Israels, D. Lillicrap, G. Rivard, S. Robinson, L. Vickars, Z. Williams, J. K. M. Wu, M. Poon OC-TU-069 8:30 AM - 8:45 AM TAFI ACTIVATION IN THE WHOLE BLOOD OF PATIENTS WITH HEMOPHILIA A J. H. Foley* (CA), M. E. Nesheim, G. E. Rivard, K. E. Brummel-Ziedins OC-TU-070 8:45 AM - 9:00 AM PREDICTED FREQUENCY OF JOINT BLEEDS BASED ON RESIDUAL CLOTTING FACTOR LEVELS I. E. M. den Uijl* (NL), K. Fischer, J. G. van der Bom, D. E. Grobbee, F. R. Rosendaal, I. Plug OC-TU-071 9:00 AM - 9:15 AM FUNCTIONAL ASSAYS FOR THE DISCRIMINATION OF TYPE 2 VWD VARIANTS V. H. Flood* (US), P. A. Morateck, P. A. Christopherson, J. C. Gill, K. D. Friedman, R. R. Montgomery OC-TU-072 9:15 AM - 9:30 AM NANOBODY AU/VWF-A11: AN ADDITIONAL TOOL FOR A BETTER CHARACTERIZATION OF DIFFERENT TYPES OF VON WILLEBRAND DISEASE E. Groot* (NL), A. B. Federici, M. Solimando, M. Punzo, P. J. Lenting, F. Rezzonico, L. Baronciani, P. G. de Groot

Genotypes of Hemophilia and von Willebrand Disease Room 109 AB

Chairpersons: David Lillicrap (CA) and Daniel Hampshire (UK) OC-TU-073 8:00 AM - 8:15 AM STUDY OF 7 LARGE DELETIONS OF BEGINNING OR END OF F8 GENE IN SEVERE HEMOPHILIA A PATIENTS R. Chatelain, M. Fretigny, H. Chambost, J. Goudemand, C. Zawadzki, B. Guillet, Y. Gruel, T. Lambert, C. Negrier, C. Vinciguerra* (FR) OC-TU-074 8:15 AM - 8:30 AM FVIII MRNA ANALYSIS IN MILD HEMOPHILIA A PATIENTS WITH SPLICE SITE CHANGES OR WITHOUT GENOMIC MUTATIONS S. Sanna, S. Giacomelli, M. Mancuso, E. Santagostino, P. Mannucci, F. Rodeghiero, G. Castaman* (IT)

204 OC-TU-076 8:45 AM - 9:00 AM - 8:45AM 8:45 AM - 8:30AM OC-TU-076 OC-TU-075 ORAL COMMUNICATIONS OC-TU-081 8:30 AM - 8:45 AM - 8:30AM 8:15 AM - 8:00AM 9:30 AM - 9:15AM OC-TU-081 9:15 AM - 9:00AM OC-TU-080 OC-TU-079 OC-TU-078 OC-TU-077 epnSrcueadFnto Room151AB Serpin Structure andFunction 2009 TUESDAY, JULY 14, WITH HIGH-RESPONDINGINHIBIT M. Furtmüller*(A INHIBITOR (PCI) INTRACELLULAR INTERACTIONPARTNERS OFPROTEINC V. Vicente, J.Corral A. Ordóñez*(ES),F. J.Corrales,I.Martínez-Martínez,C.Miqueo, A. Miñano, CONFORMA AND CHARACTERIZATION AND CORRELATION WITHFUNCTIONAL CITRULLINA N. Birch,P L. Young, N.vandeWater, P. Ockelford, A. Horvath,P. Coughlin,P. Browett, FUNCTION IMPAIR INHIBITORY POINT MUT Chairpersons: BernardLeBonniec(FR)andDanielJohnson(UK) D. J.Bowen,P. W. Collins,C.R.M.Hay, A. Will,S.Keeney*(UK) M. S.Sutherland, A. M.Cumming,Bowman,P. H.B.Bolton-Maggs, RECURRENTDELETIONMUTATION NOVEL WITH A TYPE 1 AND TYPE3VONWILLEBRANDDISEASE ASSOCIATED Group A. C.Goodeve,D.J.Hampshire*(UK),onbehalfoftheEU-VWDStudy G. J.Burghel,C.Eikenboom,R.Schneppenheim,U.Budde,I.Peake, (MCMDM-1VWD) MARKERS FORTHEDIAGNOSIS ENROLLED INTHEEUROPEANSTUDY, MOLECULAR AND CLINICAL MUTATIONS INPATIENTSIDENTIFICATION OFTHREE ADDITIONAL S. N.Waddington, A. H.Baker, D.Lillicrap M. Othman*(CA), Y. Chirinian,C.Brown,Notely, S.Buckley, WILLEBRAND DISEASE (-1255 DEL)INTHEVWFGENEPROMOTERCAUSINGTYPE1VON DELETIONMUTATION CHARACTERISATION OF13-BP FUNCTIONAL E. Zanon,R.Musso,G.Mancuso,diMinno,P. Mannucci A. Tagliaferri, G.Castaman,M.Messina,E.Mancuso, A. Iorio,P. Schinco, A. Coppola*(IT),M.Margaglione,E.Santagostino, IMMUNE T FACTOR PREDICTOR OFOUTCOMEIN VIIIGENE(F8)MUTATIONS AS A B. Binder, M.Geiger . L.Harper*(NZ) LRNEIDCIN(T)I EOHLAAPATIENTS A OLERANCE INDUCTION(ITI)INHEMOPHILIA ATIONS INPROTEINZDEPENDENTPROTEASEINHIBITOR INLEFFECTS TIONAL TION OF T), B.Sokolikova,F ANTITHROMBIN: PROTEOMIC AND MANAGEMENTOFTYPE1VWD . W ORS ahlmüller , J.Schmid,H.Linder A. Rocino,F. Scaraggi, , 08:00 -09:30 8:15 AM -8:30 AM 205

Tuesday Orals ORAL COMMUNICATIONS

TUESDAY, JULY 14, 2009 08:00 - 09:30

OC-TU-082 8:45 AM - 9:00 AM ANTITHROMBIN MURCIA (K241E) REVEALS A NEW MECHANISM FOR ANTITHROMBIN DEFICIENCY INDIRECTLY AFFECTING GLYCOSYLATION I. Martínez-Martínez* (ES), A. Ordóñez, J. Navarro-Fernández, Á. Pérez-Lara, R. Gutiérrez-Gallego, R. Giraldo, C. Martínez, E. Llop, V. Vicente, J. Corral OC-TU-083 9:00 AM - 9:15 AM SURFACE EXPOSED LYSINE RESIDUES, BUT NOT ARGININE RESIDUES, CONTRIBUTE TO LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN INTERACTION M. van den Biggelaar* (NL), J. W. T. M. Klein Gebbinck, K. Mertens, A. B. Meijer OC-TU-084 9:15 AM - 9:30 AM LYSINE RESIDUES IN THE ANTIPLASMIN C-TERMINUS MEDIATE ONLY A PART OF THE INTERACTION WITH PLASMIN B. Lu, T. Sofian, P. B. Coughlin* (AU), A. Horvath

Endothelial Dysfunction and Biomarkers I Room 252 AB

Chairpersons: Francoise Dignat-George (FR) and Michael Tomlinson (UK) OC-TU-085 8:00 AM - 8:15 AM MARKERS OF ENDOTHELIAL FUNCTION IN LACUNAR STROKE I. L. H. Knottnerus* (NL), H. ten Cate, J. W. P. Govers-Riemslag, R. van Oerle, R. P. W. Rouhl, J. Staals, H. M. H. Spronk, J. Lodder, R. van Oostenbrugge OC-TU-086 8:15 AM - 8:30 AM THROMBIN GENERATION AND MICROPARTICLES PLASMA LEVELS IN PATIENTS WITH VASCULITIS M. Castelli, L. Spiezia* (IT), V. Rossetto, V. Carraro, C. Radu, F. Schiavon, S. Todesco, A. Pagnan, P. Simioni OC-TU-087 8:30 AM - 8:45 AM INCREASED LEVELS OF MICROPARTICLES ORIGINATING FROM ENDOTHELIUM, PLATELET AND ERYTHROCYTE IN SUBJECTS WITH METABOLIC SYNDROME: RELATIONSHIP WITH OXIDATIVE STRESS O. Helal, C. Defoort, S. Robert, C. Marin, N. Lesavre, J. Lopez-Miranda, U. Riserus, S. Basu, J. Lovegrove, J. McMonagle, F. Sabatier, H. Roche, D. Lairon, F. Dignat-George* (FR) OC-TU-088 8:45 AM - 9:00 AM DECREASED PLASMA SOLUBLE RAGE IN PATIENTS WITH HYPERCHOLESTEROLEMIA: EFFECTS OF STATINS N. Vazzana* (IT), F. Santilli, L. G. Bucciarelli, D. Noto, A. B. Cefalù, V. Davì, E. Ferrante, C. Pettinella, M. Averna, G. Ciabattoni, G. Davì OC-TU-089 9:00 AM - 9:15 AM IMPACT OF IMMUNOSUPPRESSIVE TREATMENT ON ENDOTHELIAL BIOMARKERS AFTER KIDNEY TRANSPLANTATION L. Camoin-Jau* (FR), H. Vacher Coponat, P. Paul, L. Arnaud, S. Robert, Y. Berland, F. Dignat George

206 OC-TU-091 8:00 AM - 8:15 AM - 8:00AM 9:30 AM - 9:15AM OC-TU-091 OC-TU-090 ORAL COMMUNICATIONS OC-TU-094 8:45 AM - 9:00 AM - 8:45AM 8:30 AM - 8:15AM OC-TU-096 OC-TU-095 OC-TU-094 OC-TU-093 OC-TU-092 ebaeBnigadFnto nCauain Room257AB Membrane BindingandFunctioninCoagulation 2009 TUESDAY, JULY 14, C. Ehnholm,B.Dahlbäck C. Oslakovic*(SE),M.J.Krisinger LIPOPROTEINS PROPERTIES WHENINCORPORATED INTO HIGH-DENSITY ANIONIC PHOSPHOLIPIDSLOSETHEIRPROCOAGULANT D. Pantazatos*(US),C.R.Gessner MEMBRANE BINDING DYNAMICS OFFACTOR VIII C2DOMAININRELATION TO E. Tajkhorshid* (US), Y. Z.Ohkubo FORMA VIEWOFMEMBRANEBINDING AND COMPLEX DYNAMICAL S. H.Qureshi*(US),L. Yang, C.Manithody, A. R.Rezaie PROTHROMBINASE COMPLEX NEW INSIGHTINT A. M.Fager*(US),P ASSEMBLED ONTHE ACTIVATED PLATELET MEMBRANE MODELSOFPROTHROMBINASE UNIQUE STRUCTURAL S. G.Sligar, C.M.Rienstra,J.H.Morrissey R. L.Davis-Harrison*(US),J.M.Boettcher, A. J.Nieuwkoop, A. Z.Kijac, BILAYERS USINGISOTOPICALLY-LABELED PHOSPHATIDYLSERINE SOLID-STATE NMRSTUDIESOFNANOSCALEPHOSPHOLIPID Chairpersons: GaryGilbert(US)andRinkuMajumder D. M.Smadja*(FR),L.Mauge,Israel-Biet,P HYPERTENSION PROGENIT CELLS AND IMBALANCE BETWEENCIRCULATING ENDOTHELIAL TION OFHUMANTISSUEFACTOR AND FACTOR VIIa ORS INPRIMITIVE AND POSTEMBOLICPULMONARY O THEROLEOFMEMBRANEIN . B. T racy , S.J.Everse , A. , V Andersson, M.Jauhiainen, . L.W oods, G.E.Gilbert . Gaussem,O.Sanchez 08:00 -09:30 9:15 9:00 8:30 AM -9:30 AM AM -9:15 AM -8:45 AM AM 207

Tuesday Orals NOTES

ISTH2009

Scientific Program

Wednesday, July 15, 2009

209

WEDNESDAY, JULY 15, 2009

Plenary Lecture 9:45 AM – 10:30 AM

Pia Glas-Greenwalt Memorial Lecture Grand Ballroom Chairperson: Nigel Key (US) Heparin-induced thrombocytopenia PL-WE-001 Andreas Greinacher (DE) 9:45 - 10:30

Plenary Lecture 5:15 AM – 6:00 AM

Marion Barnhart Memorial Lecture Grand Ballroom Chairperson: Lawrence Brass (US) Modern concepts of platelet activation during thrombus development PL-WE-002 Shaun Jackson (AU) 5:15 - 6:00

State of the Art Lectures 11:00 AM - 12:30 PM

Fibrinogen/Fibrinolysis in the Brain Room 253 ABC Chairpersons: Jay Degen (US) and Katerina Akassoglou (US) Fibrinogen signal transduction in the nervous system SA-WE-001 Katerina Akassoglou (US) 11:00 - 11:30 AM tPA and neurovascular coupling in stroke SA-WE-002 Daniel Lawrence (US) 11:30 - 12:00 PM The role of fibrin in Alzheimer's Disease SA-WE-003 Sidney Strickland (US) 12:00 - 12:30 PM

Integrin Biology Ballroom 210 ABC Chairpersons: Sanford Shattil (US) and Shaun Jackson (US) Integrin structure SA-WE-004 Joel S Bennett (US) 11:00 - 11:30 AM Integrins in platelet activation SA-WE-005 Bernhardt Nieswandt (DE) 11:30 - 12:00 PM Platelets and integrin signaling SA-WE-006 Sanford Shattil (US) 12:00 - 12:30 PM

210

Inflammation andatherosclerosis: Pathophysiology John Danesh(UK) heart disease Epidemiology ofinflammationandcoronary Chairpersons: GordonLowe(UK)andPaulRidker, (US) hmsRné(E 11:30-12:00PM Uri Seligsohn(IL) Factor XIdeficiencyinhumans Thomas Renné(DE) Factor XIdeficiencyinanimalmodels 11:00-11:30AM David Gailani(US) Structural andfunctionalfeatures offactorXI 12:00-12:30PM Chairpersons: PaulBock(US)andThomasRenné(DE) 11:30-12:30PM Brant W Signaling pathwaysr Dean Li(US) Guidance signalsthatpromote vascularstability Anne Eichman(FR) Receptors involvedinguidingvascularcells Chairpersons: HaroldDvorak(US)andAnneEichman Paul Ridker(US) Clinical interventionsforinflammation Goran Hansson(SE) atrX eiie Room258ABC Factor XIRevisited Room205ABC Cues toCreate AMature Vasculature GrandBallroom B A ParadigmShift? Inflammation andAtherosclerosis: 2009 WEDNESDAY, JULY 15, isen(S 12:00-12:30PM einstein (US) egulating angiogenesis 11:00 -11:30AM 12:00 -12:30PM 11:00 -11:30AM 11:30 -12:00PM SA-WE-015 SA-WE-014 SA-WE-013 SA-WE-012 SA-WE-011 SA-WE-010 SA-WE-009 SA-WE-008 SA-WE-007 211

Wednesday Science

WEDNESDAY, JULY 15, 2009

Thrombopoietin Receptor Agonists Grand Ballroom A Chairpersons: Diana Beardsley (US) and Yasuo Ikeda (JP) Development of thrombopoietin receptor agonists for clinical use SA-WE-016 Yasuo Ikeda (JP) 11:00 - 11:30 AM Molecular mechanisms of thrombopoietin signaling SA-WE-017 Kenneth Kaushansky (US) 11:30 - 12:00 PM Regulation of megakaryocyte maturation and platelet formation SA-WE-018 William Vainchenker (FR) 12:00 - 12:30 PM

Abstract Symposia 2:15 PM - 3:45 PM

Abstract Symposia consist of an invited speaker and four highly rated abstracts presented on a related general theme.

Hemophilia Room 210 ABC

Chairperson: Alok Srivastava (IN) Hemophilia and rare bleeding disorders AS-WE-001 Alok Srivastava (IN) 2:15 - 2:45 PM

AS-WE-002 2:45 - 3:00 PM FVIII ASSAY DISCREPANCY - HEMOPHILIA A VARIANTS ESCAPING THE TWO-STAGE ASSAY H. Brondke* (DE), U. Herbiniaux, J. Oldenburg AS-WE-003 3:00 - 3:15 PM LONG TERM (10 YEAR) RESULTS FROM THE CANADIAN HEMOPHILIA PRIMARY PROPHYLAXIS STUDY V. S. Blanchette* (CA), P. Babyn, A. Chan, R. Card, C. Demers, K. Gill, S. Israels, R. Klaassen, N. Laferriere, D. Lillicrap, K. Luke, M. McLimont, M. Pai, M. C. Poon, V. Price, G. E. Rivard, S. Robinson, M. Steele, J. K. M. Wu, B. M. Feldman AS-WE-004 3:15 - 3:30 PM CONTRIBUTION OF POLYMORPHISMS IN THE IL-10, TNF-ALPHA, CTLA-4 GENES AND HLA CLASS II MOLECULES TO THE RISK OF INHIBITOR DEVELOPMENT: A CASE-CONTROL STUDY ON 260 PATIENTS WITH SEVERE HAEMOPHILIA A A. Pavlova* (DE), D. Delev, M. Mende, R. Fimmers, R. Schwaab, J. Oldenburg AS-WE-005 3:30 - 3:45 PM TYPE OF FVIII PRODUCT AND INHIBITOR RISK IN PATIENTS WITH SEVERE HEMOPHILIA A AND NULL MUTATIONS IN THE FACTOR VIII GENE E. Santagostino* (IT), M. E. Mancuso, A. Rocino, A. Tagliaferri, M. Margaglione, P. Mannucci

212

ACQUIRED TTP 2:15-2:45PM C. Lodigiani*(IT),D.Mari,P. Ferrazzi,M.Minaudo,L.Librè,E.Morenghi, L.Rota YOUNG PATIENTS WITHSTROKE,PFO(PATENT FORAMENOVALE) ANDTHROMBOPHILIA AS-WE-007 Shunichi Homma(US) foramen ovale Paradoxical embolusandtreatment ofpatent Chairperson: ShunichiHomma(US) B. Plaimauer*(AT), S.Skalicky, M.Hasslacher, M.Wolfsegger, F. Scheiflinger AUTOANTIBODY IN ACQUIREDTTPP INHIBITINGANTI-ADAMTS13 RECOMBINANT ADAMTS13EFFICACY TOOVERWHELM AS-WE-015 B. Jilma,P. Jilma,J.C.Gilbert, R.Hutabarat,J.Siller, A.Spiel,M.Gorczyca, P. Knoebl*(AT) 2:15-2:45PM AS-WE-014 W ANTIGENIC COREREQUIREDFORBINDINGOFANTI-ADAMTS13ANTIBODIES INP RESIDUES ARG660,TYR661ANDTYR665INTHESPACER DOMAINPROVIDE ACOMMON AS-WE-013 B. M.Luken*(UK),W. Pos,J.Voorberg, J.T. B.Crawley, D.A.Lane TTP AUTOANTIBODIESDEFINEAVWFBINDINGSITEINTHEADAMTS13 SP AS-WE-012 Flora Peyvandi(IT) Congenital andacquir Chairperson: FloraPeyvandi(IT) J. Malloy, S.G.Ellis,J.P. Kane,J.Devlin,W. Lalouschek,C.Mannhalter*(AT) M. Luke,K.Berger, C.M.Rowland,J.Catanese,H.Tong, D.A.Ross,V. Garcia, C.R.Pullinger, M. STUDIES POLYMORPHISMS ASSOCIATED WITHNONCARDIOEMBOLICSTROKEINTHREECASE-CONTROL AS-WE-010 Nickerson, M.Cushman N. A.Zakai*(US),P. Reiner, L.A.Lang,W. T. Longstreth, E.O'Meara,J.Kelley, D.A. M.Fornage, WITH ISCHEMICSTROKE:THECARDIOVASCULAR HEALTH STUDY ASSOCIATION OFCOAGULATION ANDINFLAMMATION RELATED GENESANDFACTOR 7LEVELS AS-WE-009 R. T STROKE INYOUNGWOMEN ANTIPHOSPHOLIPID ANTIBODIESANDTHERISKOFMYOCARDIALINFARCTION ANDISCHEMIC AS-WE-008 PURPURA (TTP) FACTOR APTAMER ARC1779INPATIENTS WITHACUTETHROMBOTIC THROMBOCYTOPENIC SAFETY T n DMS3 Room253ABC TTP andADAMTS13 Room205ABC Stroke 2009 WEDNESDAY, JULY 15, . Pos*(NL),E.A.M.T . Urbanus*(NL),B.Siegerink,M.Roest,F. R.Rosendaal,P. G.deGroot, A.Algra , PHARMACOKINETICSANDPHARMACODYNAMICS OFTHEANTIVONWILLEBRAND ur enhout, B.deLaat,R.Fijnheer ed TTP A TIENT PLASMA , J.V oorberg ACER DOMAIN AS-WE-006 AS-WE-011 A TIENTS WITH 3:30 -3:45PM 2:45 -3:00PM 3:30 -3:45PM 2:45 -3:00PM 3:15 -3:30PM 3:00 -3:15PM 3:15 -3:30PM 3:00 -3:15PM 213

Wednesday Science

WEDNESDAY, JULY 15, 2009

Microparticles Room 258 ABC Chairperson: Shosaku Nomura (JP) New outlook on the clinical significance AS-WE-016 of microparticles Shosaku Nomura (JP) 2:15 - 2:45 PM

AS-WE-017 2:45 - 3:00 PM TISSUE FACTOR AND PROTEIN DISULFIDE ISOMERASE CO-LOCALIZE IN NON-CAVEOLAR RAFTS IN MICROPARTICLES A. N. Böing* (NL), C. M. Hau, A. Sturk, R. Nieuwland AS-WE-018 3:00 - 3:15 PM PROTEOMIC ANALYSIS OF MICROPARTICLES/MICROVESICLES FROM HUMAN B (LG2) CELLS INFECTED WITH VIRUS N. de Bosch, A. Becerra, K. J. Martin, M. Woda, K. J. Xhaja, I. Bosch* (US) AS-WE-019 3:15 - 3:30 PM THE DETECTION OF NANOSIZED BLOOD MICROPARTICLES BY ATOMIC FORCE MICROSCOPY Y. Yuana* (NL), T. H. Oosterkamp, S. Bahatyrova, B. Ashcroft, P. Garcia Rodriguez, R. M. Bertina, S. Osanto AS-WE-020 3:30 - 3:45 PM LARGER VON WILLEBRAND FACTOR MULTIMERS PLAY A ROLE IN GENERATING PLATELET MICROPARTICLES A. Artoni* (IT), A. Lecchi, M. Mancuso, E. Santagostino, A. B. Federici, P. Mannucci

Obstetric Complications Room 157 ABC Chairperson: Ananth Karumanchi (US) Pathogenesis of pre-eclampsia AS-WE-021 Ananth Karumanchi (US) 2:15 - 2:45 PM

AS-WE-022 2:45 - 3:00 PM THE ASSOCIATION OF FVL AND PGM AND PLACENTA MEDIATED PREGNANCY COMPLICATIONS. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE COHORT STUDIES M. A. Rodger* (CA), M. Betancourt, M. Carrier AS-WE-023 3:00 - 3:15 PM LOW-MOLECULAR-WEIGHT HEPARIN FOR PREVENTION OF OBSTETRIC COMPLICATIONS IN CARRIERS OF FACTOR V LEIDEN OR PT-G20210A MUTATION D. Tormene* (IT), E. Grandone, V. de Stefano, G. Palareti, G. Castaman, M. Margaglione, A. Ciminello, L. Valdre, A. Tosetto, P. Simioni AS-WE-024 3:15 - 3:30 PM INCREASED THROMBOXANE PRODUCTION IN PREECLAMPSIA - INFLUENCE OF ASPIRIN TREATMENT C. Perneby* (SE), K. Bremme, M. Vahter, M. Daleskog, P. Hjemdahl AS-WE-025 3:30 - 3:45 PM SEARCH FOR AN ASSOCIATION BETWEEN V249I AND T280M CX3CR1 GENETIC POLYMORPHISMS, ENDOTHELIAL INJURY AND PREECLAMPSIA: THE ECLAXIR STUDY A. Stepanian* (FR), S. Benchenni, T. Beillat-Lucas, S. Omnes, F. Defay, E. Peynaud-

214

PROCOAGULANT FUNCTION onHrwg(S 2:15-2:45PM M. P. Lambert*(US),Y. Wang, K.Bdeir, Y. Nguyen,M.A.Kowalska,Poncz F EXPRESSED DURINGMEGAKARYOPOIESIS ANDISTHERECEPTORBYWHICHPLATELET LOW DENSITYLIPOPROTEINRECEPTORRELATED PROTEIN-1(LRP1)ISTRANSIENTLY AS-WE-027 John Hartwig(US) Megakarycytes andthrombopoiesis Chairperson: JohnHartwig(US) B. M.Steele*(IE),I.C.Macaulay, M.T. Harper, R.Habas,A.Poole,D.J.Fitzgerald, P. B.Maguire CANONICAL WNTSIGNALLINGIN PLATELETS NEGATIVELY REGULATES THEIRFUNCTION AS-WE-035 F. Mueller*(DE),N.J.MutchMueller, W. A.Schenk,W. A.Gahl,J.H.Morrissey, T. Renné CONT PLA AS-WE-034 2:15-2:45PM Y. A.Senis*(UK),M.G.Tomlinson, S.Ellison,A.Mazharian,Y. Zhao,N.Kalia,J.Zhu,A.Weiss, S.P. Watson CRITICAL ROLEFORCD148INHAEMOSTASIS ANDPLATELET FORMATION IN VIVO AS-WE-033 K. D.Mason,L.A.O'Reilly S. M.Schoenwaelder*(AU),Y. Yuan, E.C.Josefsson,M.J.White,Gardiner, R.Andrews, M.Hua,Y. Yao, TWO DISTINCTP AS-WE-032 Donna Woulfe (US) Arr Chairperson: DonnaW N. Debili,C.Gachet,Brakebusch,B.Nieswandt I. Pleines*(DE),M.Elvers,Rhomdhane,A.Eckly, M.Bender, I.Hagedorn, X.Wu, A.Chrostek, G.Krohne, FORMATION INVITROANDVIVO MEGAKARYOCYTE-SPECIFIC DELETIONOFRAC1ANDCDC42ABROGATES PROPLATELET AS-WE-030 G.Krohne,M. Bender*(DE),Elvers,I.Pleines,C.Gurniak, W. B.Nieswandt Witke, ADF /N-COFILIN-DEPENDENTACTINTURNOVERISESSENTIALFORPLATELET FORMATION AS-WE-029 H. Schwertz*(US),S.Koster, W. H.A.Kahr, L.W. Kraiss,G.A.Zimmerman,S.Weyrich ANUCLEA AS-WE-028 Salem, B.T ltltBooyRoom107ABC Platelet Biology Room104ABC Megakaryocytes andThrombopoiesis 2009 WEDNESDAY, JULY 15, ACTOR 4(PF4)INHIBITSMEGAKARYOCYTE DEVELOPMENT TELET estin-2: Regulatingplateletresponses toagonist ACT ACTIVATION INVIVO TE PLATELETS GENERATE FUNCTIONALPROGENY -POLYPHOSPHATES AREPRO-COAGULANTANDPRO-INFLAMMATORY BYPLASMA . Kile,S.P. Jackson A THW A , K.J.Henley YS REGULATE PLATELET PHOSPHATIDYLSERINE EXPOSUREAND oulfe (US) , A.Ono,S.Hsiao,W illcox, A.W . Roberts,D.C.S.Huang,H. AS-WE-026 AS-WE-031 3:30 -3:45PM 3:00 -3:15PM 3:30 -3:45PM 2:45 -3:00PM 3:15 -3:30PM 2:45 -3:00PM 3:15 -3:30PM 3:00 -3:15PM 215

Wednesday Science

WEDNESDAY, JULY 15, 2009

von Willebrand Factor: Structure and Function Room 153 ABC Chairperson: Zaverio Ruggeri (US) Structure and function of von Willebrand factor: AS-WE-036 Facts and myths Zaverio Ruggeri (US) 2:15 - 2:45 PM

AS-WE-037 2:45 - 3:00 PM TRANSITION FROM LATENT TO ACTIVE CONFORMATION OF VON WILLEBRAND FACTOR OCCURS UPON EXOCYTOSIS E. Groot* (NL), R. Fijnheer, S. Sebastian, P. J. Lenting, P. G. de Groot AS-WE-038 3:00 - 3:15 PM HOMOZYGOUS AND HETEROZYGOUS EXPRESSION OF TYPE 2A VON WILLEBRAND DISEASE (VWD) VARIANTS: NEGATIVE IMPACT ON MECHANISMS CRITICAL FOR VON WILLEBRAND FACTOR (VWF) PROCESSING AND SECRETION P. M. Jacobi* (US), J. C. Gill, K. D. Friedman, R. R. Montgomery, S. L. Haberichter AS-WE-039 3:15 - 3:30 PM CELLULAR MODELS OF A DOMINANT-NEGATIVE VWF GENE DELETION: A BREAKPOINT SPECIFIC RNAI RESTORES SECRETION OF FUNCTIONAL VWF C. Casari* (IT), M. Pinotti, A. Casonato, S. Calzavarini, D. Gemmati, F. Bernardi AS-WE-040 3:30 - 3:45 PM INTRACELLULAR STORAGE AND REGULATED SECRETION OF VON WILLEBRAND FACTOR IN QUANTITATIVE VON WILLEBRAND FACTOR DEFECTS J. W. Wang* (NL), H. C. de Boer, K. M. Valentijn, R. J. Dirven, P. H. Reitsma, H. C. J. Eikenboom

Intrinsic Pathway of Coagulation Room 156 ABC Chairperson: Jacky Chi Ki Ngo (HK) Crystal structure of B-domain deleted factor VIII and AS-WE-041 implications for the formation of the tenase complex Jacky Chi Ki Ngo (HK) 2:15 - 2:45 PM

AS-WE-042 2:45 - 3:00 PM LOSS OF FACTOR IX BINDING TO COLLAGEN IV RESULTS IN ABNORMAL IN VIVO HEMOSTASIS AND THROMBOSIS P. E. Monahan* (US), T. Gui, A. Reheman, H. Ni, P. L. Gross, F. Yin, D. M. Monroe, D. W. Stafford AS-WE-043 3:00 - 3:15 PM INHIBITION OF MITOCHONDRIAL PERMEABILITY TRANSITION IMPROVES SECRETION OF COAGULATION FACTOR VIII J. D. Malhotra* (US), H. Miao, S. W. Pipe, R. J. Kaufman AS-WE-044 3:15 - 3:30 PM HETEROGENEOUS LOCALIZATION OF COAGULATION FACTORS IN AN EX VIVO MODEL OF THROMBUS FORMATION M. A. Berny* (US), I. C. A. Munnix, S. E. M. Schols, P. E. Bock, O. J. McCarty, J. W. M. Heemskerk AS-WE-045 3:30 - 3:45 PM IDENTIFICATION OF CRITICAL RESIDUES IN THE 558-LOOP OF FACTOR VIIIA A2 SUBUNIT IN THE INTERACTION WITH FACTOR IXA I. Jagannathan* (US), H. Ichikawa, S. Chadha, T. Kruger, P. Fay

216

ahrn ajr(S 2:15-2:45PM X. Xu*(US),H.Går FORM ANDINCOMPLEXWITHITSLIGANDUPA CRYSTAL STRUCTURESOFASOLUBLEUROKINASERECEPTORMUTANT INITSLIGAND-FREE AS-WE-047 Katherine Hajjar(US) Implications forhealthanddisease Fibrinolysis andcellularfunctions: Chairperson: KatherineHajjar(US) G. Arderiu, E.Peña,L.Badimon*(ES) CAPILLARIES TISSUE FACTOR PROMOTESANDSTABILIZES THEVASCULAR PHENOTYPEOFNEWLY FORM AS-WE-055 C. Reinhardt* (SE),G.Östergren-Ludén, F. Schaffner, W. Ruf,F. Bäckhed THE GUTMICROBESTRIGGERSMALL INTESTINALMICROVESSELFORMA AS-WE-054 M. Kashif,A.Hellweg,Thati,K.Shahzad,P. P. Nawroth, B.Isermann*(DE) AUTONOMOUSL CROSS-COUPLING OFTHETRANSCRIPTIONF AS-WE-053 A. Dhanji*(UK),F. Y. Ali,L.S.Harrington,A.Shipolini,J.Mitchell, T. D.Warner SMOOTH MUSCLECELLS MAKING ANTI-THROMBOTICBYPASS VESSELSFROMSELECTEDPOPULATIONS OFVASCULAR AS-WE-052 V Integrating cellularpr Chairperson: Victoria Bautch(US) Camoin-Jau, V. Gurewich, E.Angles-Cano,F. Dignat-George R. Lacroix* (FR),F. Sabatier, A.Mialhe,Basire, R.Pannell,H.Borghi,S.Robert,E.Lamy, L.Plawinski, ENDOTHELIUM PROTEOLYTIC ACTIVITIES ENDOTHELIAL MICROPARTICLES PLASMINGENERATION: ANEWMECHANISMREGULATING AS-WE-050 M. W PROTEIN, PAM PLASMINOGEN INCOMPLEXWITHAPEPTIDEDERIVEDFROMTHESTREPTOCOCCALSURFACE STRUCTURAL ANDDYNAMICPROPERTIES OFTHEKRINGLE2DOMAINHUMAN AS-WE-049 I. N.Cher VISUALIZATION OFSTRUCTURESEARLY INFIBRINPOLYMERIZATION AS-WE-048 CYTOPLASMIC TAIL-DEPENDENT TISSUE FACTOR SIGNALING lo eslDvlpet Room252AB Blood Vessel Development Room160ABC Fibrinogen andFibrinolysis 2009 WEDNESDAY, JULY 15, ictoria Bautch(US) ang, J.Zajicek,M.Pr nysh, C.Nagaswami,J.W. Weisel* (US) Y TROPHOBLASTSYNCYTIUMFORMA dsvoll, M.Ploug,Huang orok* (US),F. J.Castellino ocesses tomakeabloodvessel ACTORS NF-E2ANDAP-1REGULATES CELL- TION ANDPLACENT TION VIA AL V 2:15 -2:45PM ASCULARISA AS-WE-046 AS-WE-051 3:30 -3:45PM 3:15 -3:30PM 3:30 -3:45PM 2:45 -3:00PM 3:00 -3:15PM 2:45 -3:00PM 3:15 -3:30PM 3:00 -3:15PM TION 217

Wednesday Science

WEDNESDAY, JULY 15, 2009

Atherosclerosis Room 257 AB Chairperson: Timothy Hla (US) Vascular cell signaling by sphingosine-1-phosphate: AS-WE-056 Implications for atherosclerosis Timothy Hla (US) 2:15 - 2:45 PM

AS-WE-057 2:45 - 3:00 PM ATHEROSCLEROSIS-ASSOCIATED LY-6CHI BLOOD MONOCYTOSIS IMPAIRS WOUND HEALING IN MICE WITH MYOCARDIAL INFARCTION P. R. Panizzi* (US), F. K. Swirski, J. Figueiredo, P. Waterman, D. E. Sosnovik, E. Aikawa, P. Libby, M. Pittet, R. Weissleder, M. Nahrendorf AS-WE-058 3:00 - 3:15 PM GENETICALLY ALTERED LEVELS OF THROMBIN GENERATION DEMONSTRATE AN IMPACT ON ATHEROSCLEROTIC PROGRESSION IN APOE-NULL MICE J. I. Borissoff* (NL), S. Heeneman, P. Leenders, R. van Oerle, H. Weiler, J. Degen, M. Marchetti, K. Hamulyák, M. Daemen, H. ten Cate, H. Spronk AS-WE-059 3:15 - 3:30 PM EVALUATION OF SPLA2 TYPE IIA AS A MARKER OF CORONARY ARTERY DISEASE AND ITS PREDICTIVE VALUE FOR FUTURE CORONARY EVENTS AMONG ASIAN INDIANS V. S. Rao, B. K. Natesha, H. Sridhara, J. Shibu, V. V. Kakkar* (IN) AS-WE-060 3:30 - 3:45 PM ELEVATED FIBRINOGEN LEVELS AND SUBCLINICAL CARDIOVASCULAR DISEASE IN MIDDLE- AGE: THE CARDIA STUDY D. Green* (US), C. Chan, J. Kang, K. Liu, P. J. Schreiner, N. S. Jenny, R. P. Tracy

218 OC-WE-001 8:00 AM - 8:15 AM - 8:00AM OC-WE-001 * Presenting Author ORAL COMMUNICATIONS OC-WE-004 8:45 AM - 9:00 AM - 8:45AM OC-WE-007 8:30 AM - 8:15AM OC-WE-006 OC-WE-005 OC-WE-004 OC-WE-003 OC-WE-002 hobtcTrmoyoei upr Room205ABC Thrombotic Thrombocytopenic PurpuraI BallRoom210ABC Clinical Trials: FactorXaInhibitors 2009 WEDNESDAY, JULY 15, N LPDGE THERAPY AND CLOPIDOGREL J. Gilbert,R.Schaub,F D. A1 DOMAIN ANTI-THROMBOTIC EFFECTSOF AN ANTI-VON WILLEBRANDFACTOR Chairpersons: T I. Paty*(FR),M. PATIENTS SUBJECTSAND HEALTHY IDRABIOT OF THE ANTICOAGULANT ACTIVITY OF REVERSIBILITY F. Rasul, M.Lees P. Wells* (CA), A. Diamantopoulos,H.McDonald,F. Forster, C.Lereun, REPLACEMENT HIP CANADIAN PATIENTS UNDERGOINGTOTAL ECONOMIC COMP A. G. ON SYMPT POOLED ANALYSIS OFFOURRIVAROXABAN STUDIES:EFFECTS J. Mendell,E. Antman, D.Salazar R. Giugliano*(US),S.Rohatagi,H.Kastrissios,M.Green, FIBRILLATIONBLEEDING EVENTS(BE)INPATIENTS (AF) WITH ATRIAL DU-176B PHARMACOKINETICS(PK) FACTOR Xa(FXa)INHIBITOR BETWEENORAL THE RELATIONSHIP B. Deygas,E.Presles,S.Laporte P. Mismetti*(FR),N.Rosencher, C.Samama,Vielpeau, P. Nguyen, THE PROPICESTUDY IMPAIRMENT UNDERGOINGMAJORORTHOPEDICSURGERY: RENAL FONDAPARINUX 1.5MGINPATIENTS WITHMODERATE TO SEVERE H. R.Buller*(NL) AGED 75 YEARS OR ABOVE TREATMENT OFVENOUSTHROMBOEMBOLISM(VTE)INPATIENTS OFFONDAPARINUX INTHEINITIAL ANDSAFETY EFFICACY Chairpersons: SamSchulman(CA)andRobertGiugliano(US) Arzamendi* (CA),F T urpie* (CA),M.R.Lassen, AP OMATIC EVENTS AND BLEEDING APT ARINUX (BIOTINYLA oshiyuki Miyata(JP)andX.LongZheng (US) T AMER INBLOODFROMP rellu, J.Destors,P. Cortez,E. Boëlle, G.Sanderink ARISON OFRIV . Dandachli,G.Ducroq,J.F. Théorêt, W. Mourad, . T anguay , Y.Merhi E DAAIU)B AVIDIN IN TED IDRAPARINUX) BY AROXABAN WITHDABIGA A. K.Kakkar AND THEPROBABILITY A TIENTS UNDER , B.I.Eriksson,M.Gent T. J.Carrothers, ASPIRIN TRAN IN 8:00 AM -9:30 AM OF 8:00 9:15 9:00 8:30 AM -8:15 AM -9:30 AM -9:15 AM -8:45 AM AM AM AM 219

Wednesday Orals ORAL COMMUNICATIONS

WEDNESDAY, JULY 15, 2009 8:00 AM - 9:30 AM

OC-WE-008 8:15 AM - 8:30 AM IDENTIFICATION OF 41 JAPANESE PATIENTS WITH UPSHAW-SHULMAN SYNDROME, WITH SPECIAL REFERENCE TO ITS GENOTYPE- PHENOTYPE ANALYSIS Y. Fujimura* (JP), K. Kokame, M. Matsumoto, A. Isonishi, S. Kato, H. Hiura, T. Miyata OC-WE-009 8:30 AM - 8:45 AM ADAMTS13 ACTIVITY, RACE, AND AGE AS PREDICTORS OF EXACERBATION IN PATIENTS WITH IDIOPATHIC TTP S. R. Cataland* (US), S. Yang, L. Witkoff, E. H. Kraut, S. Lin, J. N. George, H. M. Wu OC-WE-010 8:45 AM - 9:00 AM RESPONSIVENESS OF VON WILLEBRAND FACTOR (VWF) TO SHEAR STRESS MAY AFFECT THE THROMBOTIC PHENOTYPE OF ADAMTS13 DEFICIENCY W. Zhou* (US), H. Tsai OC-WE-011 9:00 AM - 9:15 AM THE ANTI VON WILLEBRAND FACTOR APTAMER ARC1779 INCREASES PLATELET COUNTS IN A PATIENT WITH FAMILIAL THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) C. Firbas, B. Jilma* (AT), J. C. Gilbert, S. Schranz, P. Knöbl OC-WE-012 9:15 AM - 9:30 AM ECULIZUMAB IN CONGENITAL RELAPSING AHUS/TTP R. A. Gruppo* (US), V. Fremeaux-Bacchi, R. P. Rother

Risk Factors for Venous Thrombosis III Room 253 ABC

Chairpersons: Pieter Kamphuisen (NL) and Suzanne Cannegieter (NL) OC-WE-013 8:00 AM - 8:15 AM INCREASED LEVELS OF THYROXIN INCREASE THE RISK OF VENOUS THROMBOSIS S. C. Cannegieter* (NL), J. Debeij, O. M. Dekkers, S. C. Christiansen, I. Naess, B. O. Asvold, J. Hammerstrom, F. R. Rosendaal OC-WE-014 8:15 AM - 8:30 AM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS INCREASE THE RISK OF PULMONARY EMBOLISM S. Rafi* (NL), M. di Nisio, E. Porreca, A. de Boer, P. C. Souverein, H. R. Buller, P. W. Kamphuisen OC-WE-015 8:30 AM - 8:45 AM COAGULATION FACTORS AND BLOOD GROUP AS RISK FACTORS FOR VENOUS THROMBOSIS OF THE UPPER EXTREMITY L. E. Flinterman* (NL), A. van Hylckama Vlieg, F. R. Rosendaal, C. J. M. Doggen OC-WE-016 8:45 AM - 9:00 AM PLASMA LEVELS OF FIBRINOLYTIC PROTEINS AND THE RISK OF VENOUS THROMBOSIS M. E. Meltzer* (NL), T. Lisman, J. C. M. Meijers, P. G. de Groot, C. J. M. Doggen, F. R. Rosendaal

220 OC-WE-018 9:15 AM - 9:30 AM - 9:15AM 9:15 AM - 9:00AM OC-WE-018 OC-WE-017 ORAL COMMUNICATIONS OC-WE-024 9:15 AM - 9:30 AM - 9:15AM 9:15 AM - 9:00AM 9:00 AM - 8:45AM 8:30 AM - 8:15AM OC-WE-024 8:15 AM - 8:00AM OC-WE-023 OC-WE-022 OC-WE-021 OC-WE-020 OC-WE-019 eotssadCne Room258ABC Hemostasis andCancer 2009 WEDNESDAY, JULY 15, M. F. Scully, G.Dawson, C.Goodwin, T. Razzaq, A. K.Kakkar*(UK) FOLLOWING TREATMENT OFBREAST CANCERCELLSWITHHEPARIN GENES DOWN REGULATION OFTHEEXPRESSION OFKEY G. L. Figueiredo-Pontes,F. P. Saggioro,C.L. A. Silva,P. S.Scheucher, M. C.Pintao*(BR),B. PROMYELOCYTIC LEUKEMICMICEMODEL COAGULATION ACTIVATIONINFLAMMATION ANDINA R. D.Balsara, A. Carmony, H. Menchen, F. J.Castellino V. A. Ploplis*(US),H. Tipton, S.Chapman,M.J.Sandoval-Cooper, ADENOMA FAMILIAL OF MODEL A IN GROWTHAND ANGIOGENESIS ADENOMA ENHANCES TISSUEPLASMINOGEN ACTIVATOR DEFICIENCY A C. Prévost,H. MIGRATION AND INVASION ANDMEDIATES TUMORCELL ASSEMBLY MDA-9/SYNTENIN PROMOTES ACTIVE TISSUE-FACTOR/FVIIa COMPLEX S. Jain*(US),Russell,J.W METASTASIS PLATELET GLYCOPROTEIN VI FACILITATES MURINEEXPERIMENTAL D. J.Richel,H.R.Buller, C.J.F. vanNoorden,C. A. Spek G. L.vanSluis*(NL), T. M.H.Niers,W. Tigchelaar Gutter, C. T. Esmon, PROTECTION BARRIER RECEPTOR-1 MEDIATED VASCULAR ENDOTHELIAL METASTASIS THROUGHSPHINGOSINE1-PHOSPHATEEXPERIMENTAL ENDOGENOUS ACTIVATED PROTEINCPROTECTS AGAINST Chairpersons: ChrisHolmes(US)and Ajay Kakkarand(UK) S. Deitelzweig*(US),J.Lin,B.H.Johnson,K.L.Schulman AND FUTURE PREV K. Guillot,M.V J. Emmerich*(FR), VENOUS THROMBOEMBOLISM VACCINATION WITHREDUCEDRISKOF ASSOCIATION OFINFLUENZA P. B.Fisher, H.Boukerche,Boukerche*(FR) A. S.Santos,M.Baggio, A. B.Garcia, A. A. Garcia,E.M.Rego ALENCE OFVENOUSTHROMBOEMBOLISMINTHEUSA:NOW T OUS POL Aissaoui, J.C.Bordet,L.Plantier ergnes, P. Scarabin T. Zhu,L.Carcaillon,I.Martinez,J.Cambou,X.Kyndt, A. YPOSIS A. Santana-Lemos,F. G.Mangolini, are , Y . Dargaud,C.Negrier, 8:00 AM -9:30 AM 8:30 AM -8:45 AM 221

Wednesday Orals ORAL COMMUNICATIONS

WEDNESDAY, JULY 15, 2009 8:00 AM - 9:30 AM

Cell Biology of the Extrinsic Pathway Room 157 ABC

Chairpersons: Wolfram Ruf (US) and Vivien Chen (US) OC-WE-025 8:00 AM - 8:15 AM TISSUE FACTOR (TF) LOCALIZATION AND ACTIVITIES IN BLOOD CELLS: MONOCYTES THE ONLY CELL POSSESSING TF ACTIVITY AND ANTIGEN AND MICROPARTICLES ARE FREE OF TF B. Osterud* (NO), J. Olsen OC-WE-026 8:15 AM - 8:30 AM ACTIVATION OF TISSUE FACTOR-DEPENDENT CLOTTING PATHWAY IN HUMAN PLATELETS IS AGONIST-SPECIFIC, USES SRC-LYN SIGNALING PATHWAY, IS NOT INHIBITED BY TFPI AND IS NOT INDUCED BY PKC-SIGNALING AGONISTS D. Mezzano* (CL), G. Valenzuela, V. Matus, J. Pereira, O. Panes OC-WE-027 8:30 AM - 8:45 AM HIGH MOBILITY GROUP BOX 1 PROTEIN INDUCES TISSUE FACTOR EXPRESSION IN VASCULAR ENDOTHELIAL CELLS VIA ACTIVATION OF NFB AND EGR-1 F. Chen* (CN), B. Lv, H. Wang, Y. Tang, X. Xiao OC-WE-028 8:45 AM - 9:00 AM DYNAMIN2- MEDIATED CAVEOLAE INTERNALIZATION CONTROLS THE CELL SURFACE ACTIVITY OF TISSUE FACTOR PATHWAY INHIBITOR IN ENDOTHELIAL CELLS C. Lupu* (US), N. I. Popescu, R. Silasi-Mansat, H. Zhu, F. Lupu OC-WE-029 9:00 AM - 9:15 AM ROLE OF THE RENIN ANGIOTENSIN SYSTEM IN THE MODULATION OF TISSUE FACTOR EXPRESSION BY TNF-ALPHA-STIMULATED HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS A. Del Fiorentino, S. Cianchetti, C. Armani, R. Pedrinelli, A. Celi* (IT) OC-WE-030 9:15 AM - 9:30 AM ASSEMBLY OF THE PROTHROMBINASE COMPLEX IN THE PRESENCE OF TSP1 ON THE FIBROBLAST SURFACE INDUCES UPREGULATION OF CTGF BY TWO SEPARATE SIGNALING PATHWAYS M. C. Rico* (US), J. J. Rough, J. M. Manns, S. P. Kunapuli, R. A. Dela Cadena

Arterial Disease Risk Markers I Room 104 ABC

Chairpersons: Nancy Jenny (US) and Francesco Sofi (IT) OC-WE-031 8:00 AM - 8:15 AM HOMOCYSTEINE, B-GROUP VITAMINS (VITAMIN B6 AND FOLIC ACID) AND RHEOLOGICAL PARAMETERS AS INDEPENDENT RISK FACTORS FOR RETINAL VEIN OCCLUSION F. Sofi* (IT), R. Marcucci, L. Mannini, B. Giambene, A. Sodi, U. Menchini, R. Abbate, G. Gensini, D. Prisco

222 OC-WE-033 8:30 AM - 8:45 AM - 8:30AM 8:30 AM - 8:15AM OC-WE-033 OC-WE-032 ORAL COMMUNICATIONS OC-WE-040 8:45 AM - 9:00 AM - 8:45AM 8:45 AM - 8:30AM 8:30 AM - 8:15AM 9:30 AM - 9:15AM OC-WE-040 OC-WE-039 9:00 AM - 8:45AM OC-WE-038 OC-WE-037 OC-WE-036 OC-WE-035 OC-WE-034 Experimental StudiesinThr 2009 WEDNESDAY, JULY 15, K. V S. F. deMeyer*(BE),C. Kleinschnitz, T. Schwarz,M. Austinat, DEFICIENCY R. J.W FOR FACTOR VLEIDEN-DEPENDENTTHROMBOSISINTHE MOUSE MODIFIER GENES SENSITIZEDSUPPRESSORSCREENTO IDENTIFY A C. N.D’Alessandro-Gabazza,M. Toda, A. Fujiwara, Y. Takei, O. Taguchi T INJURY DIRECT EFFECTSOFPROTEINSIN AMELIORATING ACUTE LUNG A. Angelillo-Scherrer F. Saller* (CH), A. C.Brisset,M. Azevedo, R.Chrast,M.Schapira, S-DEFICIENT MICE GENERATION AND PHENOTYPIC ANALYSIS OFPROTEIN Chairpersons: DavidMotto(US)andRogerLijnen(BE) B. Siegerink*(NL),J.W THROMBOSISIN YOUNG WOMEN THE RISKOF ARTERIAL ACTIVATION OFTHEINTRINSICCOAGULATION PROTEINS AND H. R.Büller, P. W. Kamphuisen O. R.dePeuter*(NL),P. C.Souverein,O.H.Klungel, A. deBoer, IN P NON-SELECTIVE BET M. Arnold, H.P. Mattle,V. Schroeder*(CH) E. Ortner, H.P. Kohler, M.Mono, A. Galimanis,N.Meier, O.Findling, IN PATIENTS WITH ACUTE ISCHAEMICSTROKE FACTOR XIII ACTIVATION PEPTIDE AND SUBUNIT ANTIGEN LEVELS I. Ford,N.Sattar, R.Westendorp, T. deCraen A. Rumley*(UK),G.Lowe,D.Stott,P. Welsh, M.Robertson,H.Murray, COHORT PROSPER STUDY CARDIOVASCULAR AT EVENTS RISK: AND DEATH INTHEELDERLY COAGULA R. F INCREASED RISKOFRETINAL HIGH LIPOPROTEIN(A)LEVELS ARE ASSOCIATED WITH AN A. Algra ISCHEMIC STROKE . Takagi* (JP),E.C.Gabazza,J.Morser, S. Aoki, H.Fujimoto, . Sofi*(IT),R.Marcucci,S.Fedi,B.Giambene, A. Sodi,U.Menchini, Abbate, G.Gensini,D.Prisco anhoorelbeke, B.Nieswandt, H.Deckmyn,G.Stoll A TIENTS WITHHEARTF estrick* (US),S.L.Manning,G.Zhu, D. R.Siemieniak,Ginsburg TION ACTIVATIONARE ASSOCIATEDMARKERS WITH OF VONWILLEBRANDF ombosis A-BLOCKERS DECREASETHROMBOTICEVENTS . P . Govers-Riemslag,F AILURE VEIN OCCLUSION ACTOR PROTECTSMICEFROM . R.Rosendaal,H.tenCate, 8:00 AM -9:30 AM 8:00 AM -8:15 AM 9:00 AM -9:15 AM Room 107ABC 223

Wednesday Orals ORAL COMMUNICATIONS

WEDNESDAY, JULY 15, 2009 8:00 AM - 9:30 AM

OC-WE-041 9:00 AM - 9:15 AM SCANNING ELECTRON MICROSCOPY STUDY OF ENDOTHELIAL INJURY AND THROMBUS FORMATION IN WT AND VWF-DEFICIENT MICE J. D. Barr* (US), D. G. Motto OC-WE-042 9:15 AM - 9:30 AM A MURINE MODEL TO TEST ANTITHROMBOTIC DRUGS TARGETING HUMAN VON WILLEBRAND FACTOR R. Pendu* (FR), I. Marx, P. J. Lenting, O. D. Christophe, C. V. Denis

Mechanisms of Platelet Activation III Room 153 ABC

Chairpersons: Satya Kunapuli (US) and Yotis Senis (UK) OC-WE-043 8:00 AM - 8:15 AM THE MITOGEN-ACTIVATED PROTEIN KINASE JNK1 IS INVOLVED IN PLATELET FUNCTION AND THROMBUS GROWTH F. Adam* (FR), A. Kauskot, E. Sulpice, M. F. Hoylaerts, R. J. Davis, J. Rosa, M. Bryckaert OC-WE-044 8:15 AM - 8:30 AM THE CONTRIBUTION OF THROMBIN-INDUCED PLATELET ACTIVATION TO THROMBOSIS IS DEPENDENT ON BLOOD SHEAR RATE J. R. Hamilton* (AU), H. Lee, S. A. Sturgeon, A. Ono, H. H. Salem, S. P. Jackson OC-WE-045 8:30 AM - 8:45 AM A ROLE FOR MICRO-RNA IN THE REGULATION OF HUMAN VAMP8 EXPRESSION AND PLATELET REACTIVITY A. Kondkar* (US), S. Nagalla, M. Bray, C. Shaw, S. Leal, Y. Jin, S. Whiteheart, P. F. Bray OC-WE-046 8:45 AM - 9:00 AM THE HDL RECEPTOR SR-BI MODULATES PLATELET FUNCTION AND SUSCEPTIBILITY TO THROMBOSIS IN VIVO S. J. A. Korporaal* (NL), I. Meurs, M. Vergeer, A. Hauer, R. B. Hildebrand, D. Praticò, J. N. Akkerman, T. J. C. van Berkel, J. Kuiper, J. A. Kuivenhoven, M. van Eck OC-WE-047 9:00 AM - 9:15 AM STREPTOCOCCUS PNEUMONIAE TRIGGERS PLATELET ACTIVATION VIA TOLL LIKE RECEPTOR 2 A. Cunningham, C. Keane, D. Cox, A. Kadioglu, H. F. Jenkinson, S. W. Kerrigan* (IE) OC-WE-048 9:15 AM - 9:30 AM THE ROLE OF FIBROUS COLLAGEN STRUCTURE IN DETERMINING ITS ABILITY TO BIND AND ACTIVATE PLATELETS R. W. Farndale* (UK), A. B. Herr

224 OC-WE-050 8:15 AM - 8:30 AM - 8:15AM 8:15 AM - 8:00AM OC-WE-050 OC-WE-049 ORAL COMMUNICATIONS OC-WE-056 8:15 AM - 8:30 AM - 8:15AM 8:15 AM - 8:00AM 9:15 AM - 9:00AM 9:00 AM - 8:45AM OC-WE-056 8:45 AM - 8:30AM OC-WE-055 OC-WE-054 OC-WE-053 OC-WE-052 OC-WE-051 yasn hrpe Room160ABC Bypassing Therapies Room156ABC Novel Approaches toUnderstandingPlateletFunction 2009 WEDNESDAY, JULY 15, IN HEAL GLYCOPEGYLATED FIRSTHUMANDOSETRIAL RFVIIaDERIVATIVE: A H. L.Holmberg*(DK), HAEMOPHILIC MICECOMPARED WITH RFVIIa LONG ACTING RFVIIaONBLEEDING IN PROLONGED EFFECTOF A J. Møss*(DK), A. Rosholm, A. Laurén SAFETY Chairpersons: ElenaSantagostino(IT)andOlivierChristophe(FR) T. Urano* (JP),M.Rybaltowski, T. Hayashi, Y. Suzuki,H.Mogami MICROSCOPY CONFOCAL ON PLATELET THROMBUSUSINGINTRA-VITAL REALTIME IMAGING ANALYSIS OFPHOSPHATIDYLSERINE EXPOSURE K. B.Neeves*(US),S.L.Diamond PLATELET AGONISTS INTO FLOWINGBLOOD MICROFLUIDICMETHODFORCONTROLLINGTHEFLUXOF A V. Kulkarni*(US),S.Kim,L.Zafreen,P. Jagadeeswaran COUPLED RECEPTORS (GPCRS) THROMBOCYTES IMMUNOSELECTION OFZEBRAFISH YOUNG AND MATURE A. J.Reininger*(DE),I. UNDER SHEARSTRESS DETERMINE PLATELET TETHER AND MICROPARTICLE FORMATION STRUCTURE ANDCYTOSKELETAL MEMBRANE ELASTICITY S. Neelamegham*(US),I.Singh,L.Porcar, E. Themistou FLUIDSHEAR WILLEBRAND FACTOR INDUCEDBY CONFORMATION CHANGEINHUMANBLOODPROTEINVON S. F. Maloney*(US),S.L.Diamond THROMBUS FORMATION AND STABILITY PLATFORM PROVIDES TOA INVESTIGATE DRUGRESPONSEREGIMESON MODEL INJURY MICROFLUIDIC-BASEDFOCAL A Chairpersons: ScottDiamond(US)andDanilaLeontyev(CA) H SUBJECTS THY AND PHARMACOKINETICSOF AND IDENTIFICA T. Elm,M. Tranholm, M.Ezban Angerer, M.Napoleone, A. Kern,M.F. Schneider TION OFNOVEL LONG-ACTING A G-PROTEIN 8:00 AM -9:30 AM 9:15 AM -9:30 AM 225

Wednesday Orals ORAL COMMUNICATIONS

WEDNESDAY, JULY 15, 2009 8:00 AM - 9:30 AM

OC-WE-057 8:30 AM - 8:45 AM ENHANCED AND PROLONGED EFFICACY OF A NOVEL RECOMBINANT FVIIa VARIANT (BAY86-6150) FOR ACUTE AND PROPHYLACTIC TREATMENTS IN HEMOPHILIA A (HEMA) MICE T. Liu, X. Zhang, J. Pan, D. Sim, K. McLean, Z. Cui, J. M. Sommer, J. Haaning, X. Zhao, J. E. Murphy, G. F. Pierce, H. Jiang* (US) OC-WE-058 8:45 AM - 9:00 AM HEMOSTATIC THERAPY IN ACQUIRED HAEMOPHILIA: DATA FROM THE EUROPEAN ACQUIRED HAEMOPHILIA (EACH2) REGISTRY F. Baudo* (IT), P. Collins, A. Huth-Kühne, P. Knoebl, H. Lévesque, M. Pascual, L. Nemes, K. Peerlinck, L. Tengborn OC-WE-059 9:00 AM - 9:15 AM BINDING TO ACTIVATED PLATELETS AND ENHANCED CLOTTING PROPERTIES OF THE RECOMBINANT FVIIa ANALOGUE BAY7 J. Pan* (US), J. Kim, D. Zhu, E. Blank, X. Zhang, T. Liu, J. Wu, D. Schneider, K. McLean, X. Zhao, D. Sim, H. Jiang, H. Apeler, J. E. Murphy, J. Haaning, G. F. Pierce, J. M. Sommer OC-WE-060 9:15 AM - 9:30 AM THROMBIN GENERATION TEST OPTIMIZED TO MEASURE TREATMENT OF FACTOR VIII DEFICIENCY WITH RECOMBINANT FACTOR VIIa P. L. A. Giesen* (NL), R. van Oerle, H. M. H. Spronk

Hemophilia: Basic Science Room 102 AB

Chairpersons: Steven Pipe (US) and Pauline van Helden (AT) OC-WE-061 8:00 AM - 8:15 AM WOUND HEALING IN HEMOPHILIA: PROGRESSIVE IMPROVEMENT WITH LONGER TREATMENT D. M. Monroe* (US), M. Hoffman, J. Brock, M. Ezban, H. R. Roberts, U. Hedner OC-WE-062 8:15 AM - 8:30 AM TRANSGENIC MURINE MODEL FOR EVALUATING THE IMMUNOGENICITY OF BIOENGINEERED FACTOR VIII VARIANTS H. Z. Miao, C. H. Miao, R. J. Kaufman, S. W. Pipe* (US) OC-WE-063 8:30 AM - 8:45 AM TOWARDS A NEW HEMOPHILIC MOUSE MODEL FOR THE DETECTION OF NEO-ANTIGEN FORMATION IN HUMAN FACTOR VIII P. M. van Helden* (AT), S. Unterthurner, M. Schuster, G. Antoine, R. U. Ahmad, C. Hermann, E. M. Muchitsch, H. J. Ehrlich, H. Schwarz, B. M. Reipert OC-WE-064 8:45 AM - 9:00 AM TNF-ALPHA ANTAGONISTS AUGMENT FACTOR REPLACEMENT TO PREVENT ARTHROPATHY IN HEMOPHILIC MICE J. Sun* (US), G. Hu, P. E. Monahan

226 OC-WE-065 9:00 AM - 9:15 AM - 9:00AM OC-WE-066 OC-WE-065 ORAL COMMUNICATIONS OC-WE-071 9:00 AM - 9:15 AM - 9:00AM 8:45 AM - 8:30AM 8:30 AM - 8:15AM OC-WE-072 OC-WE-071 OC-WE-070 OC-WE-069 OC-WE-068 OC-WE-067 nignssadVsua eeomn Room109AB Angiogenesis andVascular Development 2009 WEDNESDAY, JULY 15, SOITDWT NIA YEPAI POST-TRANSPLANTATION HYPERPLASIA ASSOCIATED WITHINTIMAL K. Berkner, B.C.Furie,D.Ginsburg M. Bronstein*(US),H.Sun,G.Merrill-Skoloff, M.Rishavy, B.Furie, AND HEART WALL TO THELIVERLEADSTO MINERALIZATION INBLOODVESSEL CARBOXYLASEEXPRESSION RESTRICTION OFGAMMA-GLUTAMYL R. Madonna,D.Schiavone,deCaterina* (IT) ENDOTHELIAL INSULIN-INDUCED CD36EXPRESSIONINHUMANMICROVASCULAR ACIDDOCOSAHEXAENOATE ATTENUATESTHE OMEGA-3FATTY M. Jandrot-Perrus V. Arocas* (FR),F. Azibani, S.Iatmanen, Y. Boulaftali,M.Bouton, OF ITS PROTEASE NEXIN-1IS ANTI-ANGIOGENIC INVITROINDEPENDENTLY G. W. Prager*(AT) K. Braemswig,M.Poettler, M. Cabaravbic,B.Binder, C.Zielinski, CARCINOEMBR THEHUMAN FORMATION IS AFFECTED BY TUMOR BLOODVESSEL S. Yang, B.Zhou,Z.Han P INRABBITCAROTIDS PROTECTION AFTER BALLOON ANGIOPLASTY STEMCELLS CONFERVASCULAR ALLOGENEIC MESENCHYMAL D. Chen*(UK),J.M. Abrahams, J.H.McVey, A. Dorling PROGENIT EXPRESSION OFTF AND PARS ONSMOOTHMUSCLEVASCULAR Chairpersons: RaffaeledeCaterina(IT)andBernardBinetruy(FR) Y. Meslier, M. Teyssandier, S.Kaveri,Lacroix-Desmazes S. Delignat*(FR), A. Navarrete,S.Dasgupta, Y. Repesse, S. André, ZONE OFTHESPLEENFACTOR VIII-DEFICIENTMICE ACCUMULATION OFTHERAPEUTICFACTOR VIIIINTHEMARGINAL H. P. Schwarz,B.M.Reipert K. N.Steinitz*(A THA BINDING WEAK AGREEMENT BETWEENCOMPUTERSIMULATION AND INVITRO . Liu,L.Zhang*(CN),W T BINDTO THEMHC-CLASS IIHAPLOTYPEHLA-DRB1*1501 ANTI-PROTEASE ASSAYS FORIDENTIFYINGFACTOR VIII15MERPEPTIDES ORS DEFINES CELLS T), P. M.vanHelden,Wolfsegger, H.Ehrlich, YONIC ANTIGEN (CEA) . Liao,W ACTIVITY A P A TTERN OFCD34+MOBILISA . Du,D.Gu,M.Liu,J.Xu,S.Lu,W. Xing, TION 8:00 AM -9:30 AM 9:15 AM -9:30 AM 9:15 AM -9:30 AM 8:45 AM -9:00 AM 8:00 AM -8:15 AM 227

Wednesday Orals ORAL COMMUNICATIONS

WEDNESDAY, JULY 15, 2009 8:00 AM - 9:30 AM

Vitamin K Cycle Room 151 AB

Chairpersons: Darrel Stafford (US) and Weikai Li (US) OC-WE-073 8:00 AM - 8:15 AM GAMMA-GLUTAMYL CARBOXYLASE IS A CARGO RECEPTOR FOR VITAMIN K-DEPENDENT PROTEINS M. Souri* (JP), H. Iwata, W. Zhang, T. Nakagaki, A. Ichinose OC-WE-074 8:15 AM - 8:30 AM IN VITRO RECONSTITUTION OF VKOR-DEPENDENT DISULFIDE BRIDGE FORMATION S. Schulman* (US), W. Li, R. Dutton, D. Boyd, J. Beckwith, T. Rapoport OC-WE-075 8:30 AM - 8:45 AM INVESTIGATION OF RESIDUES L394, Y395, AND W399 ROLES IN LINKAGE AMONG THE GAMMA-GLUTAMYL CARBOXYLASE (GGCX) SUBSTRATE BINDING SITES V. P. Mutucumarana* (US), S. L. Higgins-Gruber, D. W. Stafford, D. L. Straight OC-WE-076 8:45 AM - 9:00 AM PHENOTYPE OF VKORC1 KNOCKOUT-MICE G. Spohn* (DE), A. Kleinridders, M. Watzka, F. T. Wunderlich, F. Zaucke, K. Blumbach, C. Geisen, E. Seifried, C. Müller-Reible, M. Paulsson, J. C. Brüning, J. Oldenburg OC-WE-077 9:00 AM - 9:15 AM HEREDITARY WARFARIN RESISTANCE IN 16 PATIENTS DUE TO NINE NOVEL AND THREE KNOWN VKORC1 MUTATIONS C. Geisen* (DE), M. Watzka, K. Sittinger, G. Spohn, D. M. Dimichele, H. Haubelt, M. Heistinger, J. G. Kadar, B. Kemkes-Matthes, R. Klamroth, P. Lages, E. Lindhoff-Last, B. Luxembourg, B. Mansouri Taleghani, H. Pollmann, M. Spannagl, S. Struve, R. Zimmermann, E. Seifried, J. Oldenburg OC-WE-078 9:15 AM - 9:30 AM THE VITAMIN K-DEPENDENT CARBOXYLASE ACHIEVES EFFICIENT COUPLING OF VITAMIN K EPOXIDATION AND GLUTAMATE CARBOXYLATION USING A CONCERTED MECHANISM OF CARBANION- AND GAMMA-CARBOXYLATED GLUTAMATE FORMATION M. A. Rishavy* (US), K. L. Berkner

Proteases: Structure and Function Room 162 AB

Chairpersons: James Huntington (UK) and Neychelle Fernandes (US) OC-WE-079 8:00 AM - 8:15 AM EXOSITE 2-DIRECTED LIGANDS MODULATE THE FUNCTION OF EXOSITE 1 ON THROMBIN N. S. Petrera* (CA), A. R. Stafford, B. A. Leslie, J. C. Fredenburgh, J. I. Weitz OC-WE-080 8:15 AM - 8:30 AM FLUORESCENCE RESONANCE ENERGY TRANSFER STUDIES OF PROTHROMBIN RECOGNITION BY PROTHROMBINASE E. Zekas* (US), S. Krishnaswamy

228 OC-WE-083 9:00 AM - 9:15 AM - 9:00AM 9:00 AM - 8:45AM 8:45 AM - 8:30AM OC-WE-083 OC-WE-082 OC-WE-081 ORAL COMMUNICATIONS OC-WE-085 8:00 AM - 8:15 AM - 8:00AM OC-WE-088 9:30 AM - 9:15AM OC-WE-087 OC-WE-086 OC-WE-085 OC-WE-084 nohla yfnto n imresI Room252AB Endothelial DysfunctionandBiomarkersII 2009 WEDNESDAY, JULY 15, O. Iqbal,J.Fareed,G.Cella E. Osto*(IT),F. Vianello, F. Tona, F. Cozzi,H.Marotta, G.Saggiorato, CONNECTIVE TISSUEDISEASES:EFFECT OFBOSENTAN HYPERTENSIONRELATED TO PULMONARY WITH SECONDARY ACTIVATION INPATIENTS CELL MARKERSOFENDOTHELIAL PLASMA L. Malincarne,P S. Giannini*(IT),D.Francisci,F. Baldelli,M.Leone,B.Belfiori,G.Guglielmini, HUMAN IMMUNODEFICIENCY J. C.Quintana,D.Mezzano O. Panes,P. Hidalgo, T. Massardo,J.Pallavicini,R.Jaimovich, J. Pereira*(CL),C.G.Sáez,P. Olivares,N.Moreno,M.J.Cabrera, WITH BRAINPERFUSIONDEFECTS DYSFUNCTION INCHRONICCOCAINECONSUMERS: ASSOCIATION ACTIVATION OFTHEHEMOSTATIC SYSTEM AND ENDOTHELIAL A. Bura*(FR),S.Labro,N.Vaysse, D. Thomas, J.P. Cambou THE DILA FUNCTION: ENDOTHELIAL DISCOTHEQUES ONEMPLOYEES’ IMP Chairpersons: ChristopherJackson(AU)andDavidSmadja(FR) F. Stavenuiter*(NL),E.Sellink,H.J.M.Brinkman, A. B.Meijer, K.Mertens FACTOR VII? F M. J.Page*(US),E.diCera ACTIVITY FRAGMENT-BASED ENZYMEDESIGNOFCOAGULATION FACTOR H. K.Kroh*(US),P. E.Bock VONWILLEBRANDFACTOR-BINDING PROTEIN BY LABELING T CONTRIBUTION OFPROTHROMBINDOMAINS AND ACTIVE SITE R. Frasson*(IT),N.Pozzi,D.J.Johnson, ST EFFECT OFGLYCOSYLATION ON THROMBINSTRUCTURE, NOHLA DYSFUNCTION ENDOTHELIAL THERAPY, INDUCES ACTIVE ANTIRETROVIRAL SHORT-TERM HIGHLY ACTOR VII-ACTIVATING PROTEASE (FSAP):DOESIT ACTIVATE BLT ANDFUNCTION ABILITY ACT OFSMOKINGPROHIBITIONINBARS,REST TER STUDY OFRAINLACTIVATION OFPROTHROMBIN O CONFORMATIONAL . Gresele VIRUS TYPE1INFECTION, A. Huntington,V. deFilippis AURANTS AND AND NOT 8:00 AM -9:30 AM 8:45 AM -9:00 AM 8:30 8:15 AM -8:45 AM -8:30 AM AM 229

Wednesday Orals ORAL COMMUNICATIONS

WEDNESDAY, JULY 15, 2009 8:00 AM - 9:30 AM

OC-WE-089 9:00 AM - 9:15 AM CIRCULATING ENDOTHELIAL CELLS ARE A NEW CANDIDATE BIOMARKER OF IRREVERSIBLE PULMONARY HYPERTENSION SECONDARY TO CONGENITAL HEART DISEASE D. M. Smadja* (FR), P. Gaussem, L. Mauge, F. Dignat-George, D. Bonnet, M. Levy OC-WE-090 9:15 AM - 9:30 AM INCREASED LEVELS OF CIRCULATING ENDOTHELIAL CELLS IN PATIENTS WITH MAJOR DEPRESSION C. G. Sáez* (CL), J. Pereira, L. Risco, P. Olivares, O. Panes, V. Araya, T. Galleguillos, T. Massardo, C. Liberman

Pediatric Thrombosis Room 257 AB

Chairpersons: Paul Monagle (AU) and Sharene Bungay (CA) OC-WE-091 8:00 AM - 8:15 AM COAGULATION ABNORMALITIES IN LEGG-CALVÉ-PERTHES DISEASE J. S. Koenderman* (NL), A. Vosmaer, R. Rodrigues Pereira, F. R. Rosendaal, S. C. Cannegieter OC-WE-092 8:15 AM - 8:30 AM OVERWEIGHT YOUTH HAVE A DECREASED FIBRINOLYTIC CAPACITY: A POTENTIAL NOVEL RISK FACTOR FOR CARDIOVASCULAR DISEASE IN CHILDREN G. Ball, K. Dietrich, S. Qayyum, L. G. Mitchell* (CA) OC-WE-093 8:30 AM - 8:45 AM DOSING OF LMWH (ENOXAPARIN) THERAPY IN CHILDREN V. Ignjatovic* (AU), S. Najid, F. Newall, R. Summerhayes, P. Monagle OC-WE-094 8:45 AM - 9:00 AM ENOXAPARIN POPULATION- PHARMACOKINETIC MODELLING [POP-PK] IN CHILDREN – PRELIMINARY RESULTS L. Mitchell* (CA), A. Krumpel, J. Barett, U. Nowak-Gottl OC-WE-095 9:00 AM - 9:15 AM MODELLING THROMBIN GENERATION IN DEVELOPMENTAL HEMOSTASIS S. D. Bungay* (CA), A. K. Chan OC-WE-096 9:15 AM - 9:30 AM DECREASED GLOBAL FIBRINOLYTIC CAPACITY IN CHILDREN POST CARDIOPULMONARY BYPASS SURGERY FOR REPAIR OF CONGENITAL HEART DEFECTS: A PROSPECTIVE COHORT STUDY L. G. Mitchell* (CA), K. Dietrich, I. Rebeyka, D. Ross, S. Qayyum

230 CW-9 4:15PM-4:30 4:00PM-4:15 OC-WE-098 OC-WE-097 ORAL COMMUNICATIONS CW-0 4:45PM-5:00 4:30PM-4:45 4:00PM-4:15 OC-WE-104 OC-WE-103 4:30PM-4:45 OC-WE-102 OC-WE-101 OC-WE-100 OC-WE-099 aclrDsaePeeto Room253ABC Vascular DiseasePrevention Room205ABC Genetics ofVenous Thrombosis II 2009 WEDNESDAY, JULY 15, TYPE 1DIABETES M. H.Prins,R.Büller, J. vanderMeer P. Henriksson, H.Wallén, G.Jörneskog S. Tehrani* (SE), F. Mobarrez, A. Antovic, P. Santesson,P. Lins,U. Adamson, EFFECTS OF M. Cushman*(US),L. A. McClure,S.G.Lakoski,N.Jenny POPULATIONSAMPLE GENERAL INA CRITERIA INDIVIDUALS ELIGIBLEFORLIPID LOWERINGUSINGTHEJUPITER RATES OF PREVALENCE, CHARACTERISTICS AND MORTALITY G. F. Gensini, R. Abbate, D.Prisco D. Poli*(IT),E. Antonucci, E. Grifoni,G.Ciuti,R.Marcucci,L.Mannini, P GENDER DIFFERENCESINSTROKERISKOF H. Billett*(US),E.R.Giannattasio,B. A. Scorizello,H.W. Cohen FIBRILLATION LMWH BRIDGINGIN ATRIAL Chairpersons: HennyBillett(US)andGunJorneskog(SE) W LEIDEN AND PROTHROMBING20210A CARRIERS, AND DOUBLEHETEROZYGOUSCARRIERSOFFACTOR V RISK OFRECURRENTVENOUSTHROMBOSISINHOMOZYGOUS P. E.Morange C. BalDitSollier, L.Drouet,I.JuhanVague, J.C.Gris,M. Alessi, G. LavigneLissalde*(FR),C.Castelli,Sanchez,S. Alonso, E.Mazoyer, GENERA OF VENOUSTHROMBOSISCONTRIBUTEBOTHT CARRIERSTHEGENETICMUTATION AND THEHISTORY IN PTG20210A D. J.Johnson, A. Huntington,J.Ott,vanderMeer R. Mulder, C.Wijmenga, A. B.Mulder, H.C.Kluin-Nelemans, M. K.tenKate*(US),C.He,I.vanSchouwenburg,G.derSteege, PROTHROMBINMUTATION NOVEL GENES IDENTIFIES A GENOMEWIDELINKAGESCANFORTHROMBOSISSUSCEPTIBILITY A O. Segers*(NL),R.vanOerle,H.tenCate,J.Rosing,E.Castoldi THROMBOGRAPHY POLYMORPHISMS USINGCALIBRATED AUTOMATED ANALYSIS OFCOMMONHAEMOSTATIC GENE FUNCTIONAL Chairpersons: T A . M.Lijfering*(NL),N.J.G.V INSO RLANTICOAGULANTTREATMENT TIENTS ONORAL TION INDEPENDENTL ATORVASTATIN ONHAEMOSTASIS INPATIENTS WITH etsuhito Kojima(JP)andNeilZakai(US) Y eeger, S.Middeldorp,K.Hamulyák, OF FIIPLASMA A TRIAL LEVELS O THROMBIN FIBRILLATION 4:00 PM-5:00 4:15 PM-4:30 4:45 PM-5:00 231

Wednesday Orals ORAL COMMUNICATIONS

WEDNESDAY, JULY 15, 2009 4:00 PM - 5:00 PM

Cancer Treatment Effects on Hemostasis and Thrombosis Room 258 ABC

Chairpersons: Javier Corral (ES) and Ulrike Nowak-Gottl (DE) OC-WE-105 4:00 PM - 4:15 PM A PIVOTAL ROLE OF PROTEASE-ACTIVATED RECEPTOR-2 IN BLEOMYCIN-INDUCED PULMONARY FIBROSIS K. S. Borensztajn* (NL), P. Bresser, J. von der Thusen, B. van den Blink, A. P. Groot, J. Daalhuisen, M. P. Peppelenbosch, A. Spek OC-WE-106 4:15 PM - 4:30 PM A PREDICTIVE MODEL FOR INDENTIFYING CHILDREN AT RISK FOR SYMPTOMATIC THROMBOEMBOLISM DURING ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT – RESULTS OF A MULTICENTER COHORT STUDY S. Flege, L. Mitchell, G. Kenet, M. Fruhwald, R. Schobess, U. Nowak-Gottl* (DE) OC-WE-107 4:30 PM - 4:45 PM DEXAMETHASONE INDUCES A HEAT-STRESS RESPONSE THAT AMELIORATES THE CONFORMATIONAL CONSEQUENCES ON ANTITHROMBIN OF L-ASPARAGINASE TREATMENT AND HELPS TO EXPLAIN THE REDUCED RISK OF THROMBOSIS D. Hernández-Espinosa, A. Miñano, A. Ordóñez, R. Mota, I. Martínez-Martínez, V. Vicente, J. Corral* (ES) OC-WE-108 4:45 PM - 5:00 PM DEFIBROTIDE BLUNTS THE PRO-THROMBOTIC EFFECT OF THALIDOMIDE ON ENDOTHELIAL CELLS C. Echart, S. Somaini, P. G. Richardson, J. Fareed* (US), M. Iacobelli

Fibrinolysis: Cell Biology Room 157 ABC

Chairpersons: Edward Pryzdial (CA) and Eric Mullins (US) OC-WE-109 4:00 PM - 4:15 PM REGULATION OF MOUSE THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR GENE EXPRESSION BY INFLAMMATORY CYTOKINES M. Garand* (CA), N. Jiang, C. E. Hill, M. L. Koschinsky, M. B. Boffa OC-WE-110 4:15 PM - 4:30 PM EPIGENETIC CONTROL OF TISSUE-TYPE PLASMINOGEN ACTIVATOR EXPRESSION BY HUMAN ENDOTHELIAL CELLS S. Dunoyer-Geindre* (CH), E. K. O. Kruithof OC-WE-111 4:30 PM - 4:45 PM PLASMIN FORMATION ON NEURONS STIMULATES THE RELEASE OF NEURON-DERIVED MICROPARTICLES BEARING PROTEOLYTIC ACTIVITY L. Doeuvre* (FR), L. Plawinski, O. Nicole, D. Goux, F. Toti, E. Anglés-Cano

232 CW-1 4:00PM-4:15 4:45PM-5:00 OC-WE-113 OC-WE-112 ORAL COMMUNICATIONS CW-1 4:15PM-4:30 4:00PM-4:15 4:45PM-5:00 4:30PM-4:45 OC-WE-118 4:15PM-4:30 OC-WE-117 OC-WE-116 OC-WE-115 OC-WE-114 eohla lnclI Room107ABC Hemophilia: ClinicalII Str 2009 WEDNESDAY, JULY 15, k Room104ABC oke K. Berger*(DE),D.Eheberg,W. Schramm CAREINTIMESOFLIMITEDRESOURCES OPTIMAL PATIENTS WITHINHIBITORS: MANAGEMENT OFHAEMOPHILIA U. Nowak-Goettl N. Goldenberg,S.Holzhauer, G.Kenet,K.Kurnik,D.Manner, S. Halimeh*(DE),C.Bindlingmaier PRODUCTS: TREATED WITHRECOMBINANT FACTOR VIII A SEVERE HEMOPHILIA EVIDENCE FORINCREASEDINHIBITOR INCIDENCEINCHILDRENWITH Chairpersons: WolfgangSchramm(DE)andBarbaraKonkle(US) N. Sattar, R.Westendorp, T. J.M.deCraen,Shepherd G. D.O.Lowe*(UK),J.Stott, DECLINE INOLDERPEOPLE? IS COAGULA E. Hanson*(SE),K.Jood,P. Redfors,S.Nilsson,C.Blomstrand,Jern SUBTYPES OFISCHEMICSTROKE LEVELSOFVONWILLEBRANDFACTOR INETIOLOGICAL PLASMA C. Byrne,P. J.Grant A. M.Carter*(UK),D.Kirby, N. A. Englyst,R. A. Ajjan, J.M.Bamford, AND POST-STROKE MORTALITY FIBRIN STRUCTURE/FUNCTIONINRELATION TO STROKESUB-TYPES E. Fourn,Pasquier, A. Delluc* (FR),L.Bressollette,deSaintMartin THREE YEARS PROSPECTIVECOHORTSTUDY POSITIVE PERSONS: A THICKNESS AMONG HIV DETERMINANTS OFCAROTIDINTIMA-MEDIA Chairpersons: PeterGrant(UK)andChristinaJern(SE) K. C.Gersh*(US),S.Zaitsev PROP RBC-BOUND PLASMINOGEN ACTIVATORS INITIATE AND AGATE EFFICIENTFIBRINOLYSIS A TION SYSTEMA CIAINARISKFACTOR FORCOGNITIVE ACTIVATION A TIC REVIEW&MET , D.B.Cines,V. Muzykantov, J.W. Weisel A. Rumley, P. Welsh, M.Robertson,I.Ford, , C.EscuriolaEttinghausen, A-ANAL YSIS 4:00 PM-5:00 233

Wednesday Orals ORAL COMMUNICATIONS

WEDNESDAY, JULY 15, 2009 4:00 PM - 5:00 PM

OC-WE-119 4:30 PM - 4:45 PM THE EUROPEAN STUDY OF CLINICAL, HEALTH ECONOMIC AND QUALITY OF LIFE OUTCOMES IN 1,426 HAEMOPHILIA PATIENTS W. Schramm* (DE), K. Berger, B. Bullinger, A. Crispin, P. Giangrande, A. Giebl, A. Gringeri, R. Ljung, L. Nemes, S. von Mackensen, L. Mantovani, M. Serban OC-WE-120 4:45 PM - 5:00 PM IMPROVED CONCEPT OF FACTOR IX ALBUMIN FUSION PROTEINS H. J. Metzner* (DE), T. Weimer, U. Kronthaler, W. Lang, S. Schulte

Platelet Biology II Room 153 ABC

Chairpersons: Peter Newman (US) and Steven W. Kerrigan (IE) OC-WE-121 4:00 PM - 4:15 PM FIBRINOGEN-BETA3 INTEGRIN INTERACTION IS REQUIRED FOR MAINTENANCE OF PLATELET P-SELECTIN EXPRESSION H. Yang, S. Lang* (CA), Z. Zhai, L. Li, W. H. A. Kahr, P. Chen, J. Brkic, C. M. Spring, M. J. Flick, J. L. Degen, J. Freedman, H. Ni OC-WE-122 4:15 PM - 4:30 PM THE ROLE OF PI 3-KBETA IN GLYCOPROTEIN VI-MEDIATED AKT ACTIVATION IN PLATELETS S. Kim* (US), P. Mangin, C. Dangelmaier, R. Lillian, S. P. Jackson, J. L. Daniel, S. P. Kunapuli OC-WE-123 4:30 PM - 4:45 PM DIVERGENT ROLES OF CONVENTIONAL AND NOVEL PKC ISOFORMS IN PLATELET ACTIVATION TOWARDS THROMBUS FORMATION K. Gilio* (NL), M. T. Harper, J. M. E. M. Cosemans, K. J. Hall, O. Konopatskaya, I. C. A. Munnix, J. D. Molkentin, M. Leitges, J. W. M. Heemskerk, A. W. Poole OC-WE-124 4:45 PM - 5:00 PM IDENTIFICATION OF A RHEOLOGICAL-DEPENDENT MECHANISM STABILIZING DISCOID PLATELET AGGREGATION INDEPENDENT OF SOLUBLE AGONISTS E. Westein* (AU), W. S. Nesbitt, F. Jia, S. P. Jackson

Inflammation and Cell Trafficking I Room 156 ABC

Chairpersons: Sandip Kanse (DE) and Virgilio Evangelista (IT) OC-WE-125 4:00 PM - 4:15 PM FXIIIa ADOPTS A PERINUCLEAR DISTRIBUTION IN MONOCYTIC-CELLS AND TRANSFECTED COS CELLS P. A. Cordell* (UK), P. J. Grant, R. J. Pease

234 CW-2 4:15PM-4:30 OC-WE-127 OC-WE-126 ORAL COMMUNICATIONS CW-3 4:30PM-4:45 4:15PM-4:30 4:45PM-5:00 OC-WE-132 OC-WE-131 OC-WE-130 OC-WE-129 OC-WE-128 hobtcTrmoyoei upr IRoom160ABC Thrombotic Thrombocytopenic PurpuraII 2009 WEDNESDAY, JULY 15, A. Gurgey L. A. Lotta*(IT),I.Garagiola,R.Palla, A. Cairo,R.Klaassen, A. Metin, CONGENIT INFLUENCE OF ADAMTS13 GENOTYPEONTHE AGE OFONSET R. Palla*(IT),C.Valsecchi, M.Spreafico, T. Bajetta,F. Peyvandi MEASUREMENT ACTIVITY ON ADAMTS13 INFLUENCE OFTHEVONWILLEBRANDFACTOR (VWF)SUBSTRATE S. ACTIVITY AND OF ADAMTS13 ANTIGEN PERFORMANCES LONGITUDINAL H. M.Wu S. R.Cataland*(US),J.Paskavitz,P. Maruff, L.Witkoff, M.Jin,J.C.Gilbert, PURPURA PATIENTS WITHIDIOPATHIC THROMBOTICTHROMBOCYTOPENIC TITLE: OBJECTIVEDOCUMENT Chairpersons: J.EvanSadler(US)andLucaLotta(IT) A. Erdogan,S.Kanse*(DE) M. Parahuleva,R.Maj, DISEASE COAGULATION CROSS-TALK ARTERY INPATIENTS WITHCORONARY FACTOR SEVEN ACTIVATING PROTEASE (FSAP)–INFLAMMATION AND A. Maseri, A. A. Manfredi N. Maugeri*(IT),P. Rovere-Querini, A. Capobianco,L. Totani, V. Evangelista, CLEARANCEPROGRAM CELL PHOSPHATIDYLSERINE, P-SELECTIN AND ß2INTEGRIN-DEPENDENT NEUTROPHILS PHAGOCYTOSE ACTIVATED PLATELETS INVIVO: A W. H.Ouwehand, A. H.Goodall*(UK) J. R.W ANTITHROMBOTIC EXPRESSION PROFILETHA MONOCYTEGENE PLATELET SOLUBLEMEDIATORS INDUCE A Yang, M.Jin,S.Lin,R.Cataland,H.Wu* (US) right, U.Krishnan,R.Farrugia,N. A. Watkins, P. Ellis,C.Langford, , F. Peyvandi OVER THECOURSEOFIDIOP AL (TTP) HOBTCTRMOYOEI UPR (TTP) THROMBOTIC THROMBOCYTOPENIC PURPURA AND PRO-ANGIOGENIC A. Staubitz,H.Hoelscherman, Tillmanns, T IS ANTI-INFLAMMATORY, A TION OFNEUROLOGICINJUR A THIC TTP 4:00 PM-5:00 YIN 4:30 PM-4:45 4:45 PM-5:00 4:00 PM-4:15 235

Wednesday Orals ORAL COMMUNICATIONS

WEDNESDAY, JULY 15, 2009 4:00 PM - 5:00 PM

von Willebrand Disease Room 204 AB

Chairperson: Emmanuel Favaloro (AU) and Augusto Federici (T) OC-WE-133 4:00 PM - 4:15 PM REDUCED VWF SURVIVAL IN TWO LARGE COHORTS OF TYPE 1 VWD PATIENTS FROM THE CANADIAN TYPE 1 VWD AND US VWD (ZPMCB-VWD) STUDIES S. L. Haberichter* (US), P. D. James, P. A. Christopherson, D. Lillicrap, R. R. Montgomery, for the Canadian Type 1 VWD and ZPMCB-VWD Study OC-WE-134 4:15 PM - 4:30 PM CANADIAN PLATELET-TYPE VON WILLEBRAND DISEASE (PT-VWD) PROJECT: PROGRESS AND UPDATE M. Othman* (CA), M. C. Ozelo, H. Brown, J. Leggo, C. Notley, E. J. Favaloro, S. Enayat, J. P. Frontroth, A. Angelillo, H. Smith, J. Olson, D. Lillicrap OC-WE-135 4:30 PM - 4:45 PM USE OF IN SILICO AND IN VITRO ANALYSIS TO IDENTIFY VWF 5’ REGULATORY ELEMENTS D. J. Hampshire* (UK), P. R. Winship, D. Lillicrap, I. R. Peake, A. C. Goodeve, on behalf of the EU-VWD and ZPMCB-VWD Study Groups OC-WE-136 4:45 PM - 5:00 PM HOMOZYGOUS R854W VON WILLEBRAND FACTOR IS POORLY SECRETED AND CAUSES A SEVERE VON WILLEBRAND DISEASE PHENOTYPE G. Castaman* (IT), S. Giacomelli, T. Obser, U. Budde, R. Schneppenheim, F. Rodeghiero

Atherosclerosis: Risk factors I Room 102 AB

Chairpersons: John-Bjarne Hansen (NO) and David Green (US) OC-WE-137 4:00 PM - 4:15 PM IMPACT OF SERUM OSTEOPROTEGERIN AND SRANKL ON CAROTID ATHEROSCLEROTIC PLAQUE FORMATION AND GROWTH IN A GENERAL POPULATION – THE TROMSØ STUDY A. Vik, E. Mathiesen, S. Johnsen, J. Brox, T. Wilsgaard, I. Njølstad, J. Hansen* (NO) OC-WE-138 4:15 PM - 4:30 PM ENDOGENOUS THROMBIN POTENTIAL IS ASSOCIATED WITH CAROTID INTIMA MEDIA THICKNESS IN SUBJECTS YOUNGER THAN 45 YEARS H. Bernhard* (AT), P. Wipfler, B. Leschnik, J. Kraus, M. Novak, G. Pilz, G. Ladurner, W. Muntean OC-WE-139 4:30 PM - 4:45 PM INTERLEUKIN-6 GENE POLYMORPHISMS IN ASIAN INDIAN FAMILIES WITH PREMATURE CORONARY ARTERY DISEASE A. Maitra* (IN), J. Shanker, D. Dash, S. John, P. R. Sannappa, V. S. Rao, V. V. Kakkar

236 CW-4 4:45PM-5:00 OC-WE-141 OC-WE-140 ORAL COMMUNICATIONS CW-4 4:30PM-4:45 4:15PM-4:30 4:00PM-4:15 OC-WE-147 4:15PM-4:30 OC-WE-146 OC-WE-145 OC-WE-144 OC-WE-143 OC-WE-142 Fibrinogen Structur Room151AB Cell BiologyoftheActivatedProtein CPathway 2009 WEDNESDAY, JULY 15, GLUTAMATE- AND THROMBIN-INDUCEDTOXICITY O. V MOLECULE DREGIONOF THE UNFOLDINGINTHEDISTAL ACCOMPANIED BY KNOB-HOLE INTERACTIONIS FORCED RUPTUREOFFIBRIN‘A-A’ A. E.X.Brown,R.I.Litvinov SIGNIFICANCE CLINICAL ITS POTENTIAL PROPERTIES AND BASISFORFIBRINMECHANICAL STRUCTURAL S. R.Bowley*(US),N.Okumura, T. Lord DUE T IMPAIRED POLYMERIZATION OFFIBRINOGENGAMMA-N308KIS Chairpersons: MargaretaBlomback(SE)andSherylBowley(US) Veer, C. T. Esmon,M.Levi, T.M. Schouten*(NL),C.van‘T vanderPoll INFLAMMA PROTEIN CDEPLETIONENHANCESBACTERIAL G. Reiser S. Strukova*(RU),L.Gorbacheva,I.Savinkova,V. Pinelis,S.Ishiwata, ACTIV L. O.Mosnier*(US) PROTEIN CRECEPT CELL USINGGPI-LINKEDENDOTHELIAL CELLULARTHERAPY BY MODULATION OF ACTIVATED PROTEINCCYTOPROTECTIVE EFFECTS S. U.Carlsson*(SE),B.Dahlbäck PROTEIN -?-CHAIN IMPORTANCE OFPROTEINSFOREXPRESSIONTHEC4B-BINDING Chairpersons: BjornDahlback(SE)andJasimuddin Ahamed (US) J. Hansen*(NO) A. V THE TROMSØSTUDY INTIMA RELATIONS BETWEENSERUMOSTEOPROTEGERIN AND CAROTID ik, E.Mathiesen,S.Johnsen,J.Brox, T. I.Njølstad, Wilsgaard, . Gorkun*(US),L.E. A O TED PROTEINCPREVENTSTHENF-KB ACTIVATION AT EI HCNS NAGNRLPOPULATION – GENERAL THICKNESSIN A MEDIA AL TION INMURINEE.COLIPERIT TERED D:D e andFunction OR AND “A:A”INTERACTIONS Averett, B. Akhremitchev, M.H.Schoenfisch , D.E.Discher , P . K.Purihit,J.W ONITIS OUTGROWTH . W eisel* (US) 4:00 PM-5:00 AND 4:00 PM-4:15 4:45 PM-5:00 4:30 PM-4:45 Room 162AB 237

Wednesday Orals ORAL COMMUNICATIONS

WEDNESDAY, JULY 15, 2009 4:00 PM - 5:00 PM

OC-WE-148 4:45 PM - 5:00 PM FIBRINOGEN SHAPE IN SOLUTION: A MULTI-RESOLUTION STUDY B. Cardinali* (IT), C. Rosano, A. Profumo, O. Byron, M. Roessle, N. Volkmann, M. Rocco

Megakaryocytes and Thrombopoiesis Room 257 AB

Chairperson: Hansjorg Schwertz (US) and Anna Kowalska (US) OC-WE-149 4:00 PM - 4:15 PM DYNAMIC UPREGULATION OF HUMAN PLATELET PRODUCTION BY HIGH SHEAR RATES C. Dunois-Larde, C. Capron, S. Fichelson, E. Cramer-Borde, D. Baruch* (FR) OC-WE-150 4:15 PM - 4:30 PM ABNORMAL MEGAKARYOCYTE AND PROPLATELET FORMATION IN MEGAKARYOCYTE-RESTRICTED MYH9 INACTIVATION A. Eckly, C. Strassel, M. Freund, J. Cazenave, F. Lanza, C. Gachet, C. Léon* (FR) OC-WE-151 4:30 PM - 4:45 PM CLINICAL IMPLICATIONS OF THE NEGATIVE PARACRINE EFFECT OF PLATELET FACTOR 4 (PF4) ON THROMBOPOIETIN (TPO) TREATMENT IN RADIATION-INDUCED THROMBOCYTOPENIA (RIT) M. P. Lambert* (US), Y. Nguyen, M. A. Kowalska, M. Poncz OC-WE-152 4:45 PM - 5:00 PM GENE EXPRESSION DIFFERENCES BETWEEN FETAL LIVER AND ADULT BONE MARROW-DERIVED MURINE MEGAKARYOCYTE PROGENITORS: IMPLICATIONS FOR DOWN SYNDROME MEGAKARYOBLASTIC LEUKEMIA K. Wieland, A. B. Cantor* (US)

238

PW-0 EIUAE LTLT N LTLTRATVT NRNLTRASPLANT INRENAL RETICULATED PLATELETS AND PLATELET REACTIVITY PP-WE-002 IMMUNECOMPLEXES PLATELET ANTI-CD40L ACTIVATION AND THROMBOSISBY PP-WE-001 * POSTER PRESENTATIONS PP-WE-013 REGULATION OFPLATELET THROMBOXANEGENERATION DOWNSTREAMOF PP-WE-012 RESIDUESCOOPERATIVELY AND-DISTAL INTEGRIN3MEMBRANE-PROXIMAL PP-WE-011 ALPHAIIBBETA3 POST-ACTIVATION NECESSITATES PDI-MEDIATED SIGNALINGBY PP-WE-010 STENTIMPLANTATION ONPLATELET INFLUENCEOFCORNARY ACTIVATION PP-WE-009 PP-WE-008 THEROLE AND REGULATION OF MTOR INHUMANPLATELETS PP-WE-007 REGULATE PLATELET ACTIN DIFFERENTIALLY RHOGTPASES RAC1 AND RHOA PP-WE-006 STUDY AREPLATELETS PHAGOCYTESORCOVERCYTES? AN ULTRASTRUCTURAL PP-WE-005 DIRECTINTERACTIONBETWEENGALPHA13 AND INTEGRINBETA3 SUBUNIT PP-WE-004 ENOSLOCUSINNON-TYPE2 ISMODULATED BY PLATELET AGGREGABILITY PP-WE-003 Mechanisms ofPlateletActivationII 2009 WEDNESDAY, JULY 15, Presenting Author CONFORMATION HINDERING ADOPTION OFTHEBENT (ALPHA)IIB(BETA)3 RECEPTOR BY AFFINITY HIGH S527FMUTATION INTHEINTEGRINBETA3 CHAININDUCES A THE NOVEL RECIPIENTS ON ANTIPLATELET THERAPY G12/13 PATHWAYS ADHESION KINASE THROUGHFOCAL ACTIVATIONREGULATE TALIN-MEDIATED IIB3 DISULFIDE EXCHANGE CYT RAPID PROCOAGULANTPHOSPHA REORGANIZATION, SECRETION AND AGGREGATION AND HUMANPLA BACTERIUM OF INTERACTIONBETWEENPORPHYROMONASGINGIVALIS, AN ORAL MEDIATES INTEGRINOUTSIDE-INSIGNALLING SYNDROME DIABETIC PATIENTS WITH ACUTE CORONARY Pradier, P. Fondu,N. Kieffer, T. A. Springer, H.Deckmyn K. Vanhoorelbeke* (BE),S.F. deMeyer, I.Pareyn, C.Melchior, S.Plançon, C. Margue,O. K. Bhavaraju*(US),P. Lakhani,R.Dorsam,J.Jin, A. Sanjay, S.Kunapuli J. O. Romanenko,V. Sheptovitsky, R.MorCohen,N.Rosenberg,J.Lahav*(IL) J. Gu*(CN),X.Gu,H.L.Wang A. Arachiche, D.Kerbiriou-Nabias, I.Garcin, T. Letellier, J. Dachary-Prigent*(FR) R. W. Hunter, I.Hers*(UK) H. H. Suzuki*(JP),X.Li,Nakamura, Y. Inoue, Y. Chen,M.Umeda, T. Iwai H. Gong*(US),P. Flevaris,C.Chow, S.Lam, T. Voyno-Yasenetskaya, T. Kozasa,X.Du Gensini, R. Abbate C. Fatini,E.Sticchi,F. Sofi*(IT),P. Bolli,R.Marcucci,B.Giusti,Paniccia, A. Gori,G. Salvadori, G.Gensini,R. Abbate, M.Zanazzi F. Cesari*(IT),R.Marcucci, A. Gori, F. Sofi,R.Caporale,Paniccia,E. Antonucci, M. Francis L. Robles, Y Akbar* (US),K.Funk,R.Perveen,X.Shang, amanouchi* (JP), SLCCLIMRTE HNO IOHNRA DEPOLARIZATION OSOLIC CALCIUMRATHER THANONMITOCHONDRIAL A. Amirkhosravi* (US), T. Meyer, H.Desai,M.Davila,F. Langer, M. Amaya, J. TELETS T . Hato,H.Fujiwara, TIDYLSERINE EXPOSURERELIESONHIGH Y. Yakushijin,M. Yasukawa Y . Zheng 239

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-014 PLATELET THROMBIN RECEPTORS PAR1 AND PAR4 ACT IN A SYNERGISTIC MANNER K. V. Öberg* (SE), S. Kulsum, N. Boknäs, S. Ramström, T. L. Lindahl PP-WE-015 AN INHIBITORY ROLE OF PLATELET CD109 IN PLATELET FUNCTION K. Matsumoto* (JP), Y. Matsubara, H. Hoshino, K. Yokoyama, G. Watanabe, T. Shibano, N. Suzuki, Y. Ikeda, M. Murata PP-WE-016 CALDAG-GEFI: AT THE NEXUS OF CALCIUM-DEPENDENT PLATELET ACTIVATION L. Stefanini* (US), R. C. Roden, W. Bergmeier PP-WE-017 EVALUATION OF DIFFERENT BLOOD DRAWING TECHNIQUES ON THE RESULTS OF PLATELET FUNCTION TESTS M. D. Lance* (NL), Y. M. C. Henskens, H. M. S. Theunissen, R. van Oerle, K. Hamulyak, H. ten Cate, M. A. E. Marcus PP-WE-018 COOPERATIVE CALCIUM SIGNALING ELICITED BY GLICOPROTEINS (GP)IB-IX-V, GPVI AND INTEGRIN ALPHA2BETA1 DURING PLATELET ADHESION TO COLLAGEN UNDER FLOW M. R. Cozzi, M. Battiston, M. Mazzucato, M. Jandrot Perrus, Z. M. Ruggeri, L. de Marco* (IT) PP-WE-019 A ROLE FOR SHIP1 IN PLATELET INTERNAL CONTRACTION VIA THE CONTROL OF ACTOMYOSIN AND MICROTUBULE DYNAMICS M. Gratacap* (FR), S. Severin, G. Chicanne, V. Martin, S. Allart, A. Eckly, M. Plantavid, B. Payrastre PP-WE-020 PKC ALPHA REGULATES GPVI-DEPENDENT CALCIUM SIGNALLING AND PHOSPHATIDYLSERINE EXPOSURE IN PLATELETS M. T. Harper* (UK), A. W. Poole PP-WE-021 PRE-OPERATIVE PLATELET CD40 LIGAND EXPRESSION PREDICTS ADVERSE CARDIAC EVENTS AFTER ORTHOPAEDIC SURGERY M. J. Ray* (AU), D. Walters, S. Crawford, D. Enever, L. Calabro, T. Sirisena, R. Crawford PP-WE-022 EFFECTS OF THE 5-HT4 RECEPTOR AGONIST, TEGASEROD, ON IN VITRO HUMAN PLATELET AGGREGATION V. L. Serebruany, M. El Mouelhi* (US), H. Pfannkuche, K. Rose, M. Marro, D. J. Angiolillo

Platelet Biology II

PP-WE-023 PROTEIN KINASE A PHOSPHORYLATES MULTIPLE GPIB ALPHA; CYTOPLASMIC RESIDUES: IMPLICATIONS RECEPTOR REGULATION A. D. Munday* (US), J. A. Lopez PP-WE-024 TISSUE FACTOR PRE-MRNA SPLICING IN PLATELETS FROM HEALTHY SUBJECTS AND TYPE 2 DIABETES MELLITUS PATIENTS A. J. Gerrits* (NL), C. A. Koekman, J. W. N. Akkerman PP-WE-025 USE OF THE PLATELET INDICES FOR DIFFERENTIAL DIAGNOSIS OF PEDIATRIC IMMUNE THROMBOCYTOPENIC PURPURA ( ITP H. Nakadate* (JP), M. Kaida, S. Furukawa, M. Ishii, M. Higashihara PP-WE-026 LEVELS OF VON WILLEBRAND FACTOR AS MEASURE OF ENDOTHELIAL DYSFUNCTION ARE INCREASED IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION I. Seljeflot* (NO), S. Ulimoen, S. Enger, H. Arnesen, A. Tveit PP-WE-027 EFFECTS OF ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE POLYMORPHISMS AND PLATELET-DERIVED NITRIC OXIDE ON PLATELET AGGREGATION J. Kim* (KR), S. Park, E. Park, Y. Koo, J. Kim, I. Kim, S. Yoon, H. Yun-Choi, S. Park

240 PW-3 DIMINISHEDSYKPHOSPHORYLATION INPLATELETS UNDERLIESIMPAIRED PP-WE-030 PP-WE-029 POTENTINHIBITOR OFPLATELET PLATELET PROTEIN AND A NOVEL MMP-13: A PP-WE-028 POSTER PRESENTATIONS PW-4 PROTEOMICS OFPLATELET SECRETOME INPATIENTS STORAGE POOL WITHDELTA PP-WE-041 AGONISTS15D-PGJ2,ROSIGLITAZONE AND CIGLITAZONE PPAR-GAMMA ENGAGEIN PP-WE-040 PP-WE-039 PP-WE-038 TIMECOURSEOF ASPIRIN EFFECTONPLATELET FUNCTIONEXAMINEDBY PP-WE-037 PP-WE-036 MODULATOR OFPLATELET ROLE OFGALECTIN-8 ACTIVATIONAS A PP-WE-035 OFMODIFIED C-REACTIVEPROTEININTHEMODULATION OFPLATELET EFFICACY PP-WE-034 FLAVONOIDS: TO THROMBINBY MODULATION OFPLATELET REACTIVITY PP-WE-033 SRC AND PI3-KINASETRANSMITSIGNALSLEADINGTO CK2 ACTIVATION INPAR1- PP-WE-032 SHEDDING: ASSOCIATION EFFECTOF ASPIRIN ADMINISTRATION ONGPIB ALPHA PP-WE-031 ENSA,JL 5 2009 WEDNESDAY, JULY 15, DISEASE IN PP NON-GENOMIC SIGNALLINGPATHWAYS THAT INHIBITHUMANPLATELET FUNCTION 4D THROMBUS GROWTHINRESPONSETO COLLAGENINMICELACKINGSEMAPHORIN CENTRAL THE CHAIN ISENHANCEDBY PLATELET RECEPTOR GLYCOPROTEIN IB ALPHA BOTROCETIN-DEPENDENT BINDINGOFVONWILLEBRANDFACTOR TO THE AGGREGATION WILLEBRAND DISEASE MUL BLEEDING TIME,PFA-100 AND WHOLEBLOOD AGGREGOMETRY THROMBOGENIC MUT COMPONENTS USINGTHROMBOELASTOGRAPHY POTENTIAL: INVITRO ASSESSMENT OFFRESHVERSUSSTORED BLOOD STORAGE OFBLOODCOMPONENTSDOESNOTDECREASETHEIRHEMOSTATIOC CONDITIONS FUNCTION UNDERDIFFERENTEXPERIMENTAL INTERFERENCE ONP AP-STIMULATED PLATELETS TO ASPIRIN WITHPLATELET SENSITIVITY OF GLYCOCALICIN LEVEL M. diMichele*(BE), C. M. Spyridon*(UK),L. S. Lison, K. vonPape,C.Jambor M. Kannan*(IN),B.K. Yadav, F. Ahmad, J.Fareed,R.Saxena M. H.Ellis*(IL),G.Bartfeld, M. M. Boncler*(PL),J.Rywaniak,B.Rychlik,C.Watala Rivera L. Navarro-Núñez*(ES),M.Lozano,J.Guerrero,C.Martínez,V. Vicente, J.Castillo, K. Nakanishi*(JP),M.Ido, Y. Komada, T. Hayashi,K.Suzuki K. Yamaji* (JP), Y. Matsubara,H.Hoshino,N.Suzuki, Y. Ikeda,M.Murata Neeves, S.Maloney, A. Kumanogoh,D.Hammer, S.L.Diamond,F. Brass K. M.Wannemacher* (US),L.Zhu,H.Jiang,K.Fong, T. J.Stalker, D.Lee, A. Tran, K. T. K.Biswas,J.L.Miller*(US) J. Howes*(UK),N.Pugh,R.W Geet, K.Freson A. Romaniuk*(AR),M.V TIPLE ELECTRODEPLA RGMA-DEPENDENTMECHANISMS AR-GAMMA A. Dick, MACROGLYCOPEPTIDE REGIONOFTHERECEPTOR A. Giebl, A. Moraes,W AR1 Thys, W , M.Spannagl*(DE),H.W A TIONS INGLANZMANN’STHROMBASTHENIA T. Kauke, A. Perchuc,M.Spannagl*(DE) . A. Lubetzky AND PAR4 SIGNALING Tribulatti, V. Cattaneo,J.Etulain, O.Campetella,M.Schattner TELET . Farndale . D’Hertog,E.W . J.Kaiser AGGREGOMETR , V . Yahalom, G.Kenet , C.I.Jones,J.M.Gibbins aelkens, R.deV eisser FORTHEEVALUATION OFVON Y os, K.Peerlinck,C. van PATIENTS 241

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-042 EXTRACELLULAR ACIDOSIS PROMOTES PLATELET-MEDIATED INFLAMMATORY RESPONSES M. Schattner* (AR), M. A. Romaniuk, J. Etulain, L. P. D´atri, E. Malaver, S. Negrotto, R. Pozner PP-WE-043 DARK CHOCOLATE EFFECT ON PLATELET ACTIVITY, C-REACTIVE PROTEIN AND LIPID PROFILE:A PILOT STUDY M. Hamed* (US), S. Gambert, K. Bliden, O. Bailon, A. Singla, M. Antonino, F. Hamed, U. Tantry, P. A. Gurbel PP-WE-044 SHEAR INDUCED PLATELET ADHESION STIMULATES CORTACTIN TYROSINE PHOSPHORYLATION N. Savion* (IL), I. Budnik, B. Shenkman PP-WE-045 DETECTION OF P2Y14 RECEPTOR PROTEIN ON PLATELETS AND INVESTIGATION OF THE ROLE OF P2Y14 IN PLATELET FUNCTION N. Dovlatova* (UK), Y. D. Wijeyeratne, S. C. Fox, P. Manolopoulos, A. J. Johnson, A. E. White, L. Latif, V. Ralevic, S. Heptinstall PP-WE-046 CONVERSION OF LYMPHOCYTES CHROMATINE AND NEUTROPHILES UNDER CONDITIONS OF THE HEAT SHOCK IN VITRO: POSSIBLE CONNECTION WITH PLATELETS MORPHOLOGY N. G. Kruchynsky* (BY), S. Vishnevskaya

Platelet Adhesion and Cohesion II

PP-WE-047 FINE MAPPING THE VWF A1 DOMAIN BY PHAGE DISPLAY A. Yee* (US), F. Tan, D. Ginsburg PP-WE-048 PLATELET ACTIVATION AND PLATELET-LEUKOCYTE MIXED CONJUGATES IN PATIENTS WITH ATRIAL FIBRILLATION S. Alberti, G. Angeloni, C. Tamburrelli, A. Pampuch, B. Izzi, L. Messano, Q. Parisi, M. Santamaria, M. B. Donati, G. de Gaetano, C. Cerletti* (IT) PP-WE-049 EFFECT OF COATING CONDITIONS ON COLLAGEN MATRIX FORMATION AND TO THE VON WILLEBRAND FACTOR AND PLATELET BINDING TO IT S. Mendelboum Raviv, K. Szekeres-Csiki, A. Jenei, J. Nagy, B. Shenkman, N. Savion, J. Harsfalvi* (HU) PP-WE-050 PROTEASE-ACTIVATED RECEPTORS 1 AND 2 ACTIVATION INDUCES TISSUE FACTOR THROUGH MITOCHONDRIAL REACTIVE OXYGEN SPECIES C. Banfi, M. Brioschi, S. S. Barbieri, S. Eligini, S. Barcella, E. Tremoli, S. Colli, L. Mussoni* (IT) PP-WE-051 FECL3-INDUCED THROMBUS FORMATION IN THE INFERIOR VENA CAVA OF MICE REQUIRES PLATELETS, GLYCOPROTEIN IB-IX, AND VON WILLEBRAND FACTOR M. Joglekar* (US), J. Ware, T. K. Gartner PP-WE-052 INVESTIGATION OF THE EFFECT OF DIFFERENTIAL PLATELET RECEPTOR ENGAGEMENT ON THROMBUS FORMATION USING COLLAGEN PEPTIDES N. Pugh* (UK), D. G. Bihan, R. W. Farndale PP-WE-053 CIB1 CONTROLS INTEGRIN ALPHA IIB BETA 3-DEPENDENT PLATELET SPREADING BY REGULATING FAK ACTIVATION U. P. Naik* (US), M. U. Naik PP-WE-054 ENHANCED SHEAR-INDUCED ADHESION ACTIVITY AND DECREASED MICROMOBILITY OF PLATELETS RELATED TO THE ALPHA2 807TT VARIANT OF INTEGRIN ALPHA2 BETA1 R. E. Scharf, V. R. Stoldt* (DE)

242 PW-5 C3I XRSE N YTEIE YHUMANPLATELETS CD3ISEXPRESSED AND SYNTHESIZEDBY PP-WE-057 PP-WE-056 FLOW MODULATES PLATELET THROMBUSFORMATION UNDER ARTERIAL CD40L PP-WE-055 POSTER PRESENTATIONS PP-WE-068 IN THEROLEOFCHEMOKINES,GROWTH FACTORS AND ELECTRONMICROSCOPY PP-WE-067 PP-WE-066 PROMOTEPLATELET TLT-1 ENDOTHELIAL INDUCTIONDURINGDENGUEFEVERMAY PP-WE-065 PP-WE-064 PP-WE-063 THEROLEOF ANTIPHOSOLIPID AND ANTIPLATELET ANTIBODIES INPLATELET PP-WE-062 PP-WE-061 PP-WE-060 PLATELET-ADHESION INFLOWINGBLOOD ANALYSIS OFINITIAL NOVEL A PP-WE-059 TO PHAGOCYTOSIS DEPENDSONTHEIRFUNCTIONAL PLATELETS ABILITY PP-WE-058 Platelets andSystemicDisorders II Novel Approaches toUnderstandingPlateletBiologyII 2009 WEDNESDAY, JULY 15, PLA DIAGNOSIS OFDIABETICNEPHROP ENHANCED BINDINGOFPLATELETS UNDERFLOWCONDITIONS ROLE OFTHED’D3SUBUNITVONWILLEBRANDFACTOR INTHESHEAR CONDITIONS AMONG 15UNRELATED PATIENTS WITHBERNARDSOULIERSYNDROMEINBRAZIL FIVE NOVEL INTERACTION CELL PLA FORFAST AND EFFICIENTEVALUATION FLOWCYTOMETRY OF MULTIPLE ANTIBODY MODELING COMPUTATIONAL PLA DYSFUNCTION: COMPUTER-AIDEDVISUALIZATION HIGH RESOLUTIONEM-T HEMOSTASISTHROMBOSIS AND DEVELOPMENT AND CHARACTERIZATION OFNEWREAGENTSFORRESEARCH IN ANTIBODIES: MONOCLONAL GPIBALPHA MOUSEANTI-MOUSE NOVEL ANDGPIIB/IIIA ACTIVITY J. Maly*(CZ),P. Bradna,Z.Hrncir, T. Soukup, P. Dulicek,M.Pecka,R. Maly E. A. A. Khaled* (EG), A. H.Hussein,E. A. Waked, S. A. Badr, K. A. Younis Paula, J.Maria L. H.Siqueira*(BR), A. Santos, M.PerlingeiroBeltrame,V. OliveiraDuarte,E.Vinícius de W J. Morales*(PR),K.Vila, J.Gattis,K.Colon,Lubkowski,P. Sanabria,R.Hunter, A. J. vanVelzen* (NL),W. L.vanHeerde,J.Boezeman J. E.Purvis*(US),M.S.Chatterjee,R.Radhakrishnan,L.F. Brass,S.L.Diamond I. V H. E.vanNispen Tot Pannerden,F. deHaas,H.F. G.Heijnen*(NL) G. Zhu*(CA),S.Lang,C.Li, A. Reheman,P. Chen,J.Ware, Z.Ruggeri,J.Freedman,H.Ni Lee, B.D.MacCraith,Kenny G. R.Meade*(IE),B.Lincoln, A. J.Ricco,N.Kent,L.Basabe-Desmonts,S.O’Brien,P. E. M.Gupalo*(RU),L.I.Buryachkovskaya, C. G.Sáez*(CL),V. Matus,O.Panes,J.Pereira,D.Mezzano R. R. E.Scharf,Reif ashington A. Penkala*(US), A. Tu, A. D.Munday, P. Lenting,H.Deckmyn,J. A. Lopez,W. Thomas asilenko* (RU),I.Kastrikina,V TELET FUNCTIONS INSYSTEMICLUPUSER TELET SURF TELET CALCIUM MUTATIONS IDENTIFIEDINTHEGLICOPROTEINSIBA,IBB AND 9GENES Annichino-Bizzacchi, M.CastroOzelo ACE f, V. R.Stoldt*(DE) AND PHOSPHOINOSITIDESIGNALINGTHROUGH ANTIGENS OMOGRAPHY . Metelin, AND ATHY ACTIV OF A VITRIFIED PLATELET VITRIFIED OF A T . Reshetnyak A. A. B.Sumarokov ATION MARKERS YTHEMATOSUS (SLE 243

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-069 RISK FACTORS FOR THROMBOTIC OR HEMORRHAGIC COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA (ET) PATIENTS (PTS J. Park* (KR), B. Kim, H. Kim, S. Bang, I. Kim, S. Yoon, D. Lee, J. Lee, S. Park, B. Kim PP-WE-070 SERIOUS CONGENITAL DEFICIENCY OF FVII AND ACQUIRED ITP - THE RARE COMBINATION OF TWO BLEEDING DISORDERS J. Slechtova* (CZ), Z. Hajsmanova PP-WE-071 PLATELET SECRETION CONTRIBUTES TO THE DEVELOPMENT OF ATHEROSCLEROSIS J. M. Patton* (US), R. A. McNamee, S. M. King, H. Mehta, G. L. Reed PP-WE-072 A CASE CONTROL STUDY ON PLATELET RESPONSE TO ANTIPLATELET THERAPY IN SURVIVORS OF LATE STENT THROMBOSIS K. Winckers* (NL), V. Poenitz, R. van Oerle, K. Noordermeer, H. ten Cate, D. W. T. Nilsen PP-WE-073 EVALUATION OF A NEW KIT FOR QUANTITATION OF PLATELET ASSOCIATED IMMUNOGLOBULINS L. Le Flem* (FR), F. Ballon, S. Aguilar PP-WE-074 EVALUATION OF THE INCIDENCE, MATERNAL AND NEONATAL COMPLICATIONS OF THE HELLP SYNDROME AND ITS RISK FACTORS M. Kashanian* (IR), N. Sohrabi, E. Rafiee Khoshnood PP-WE-075 PLATELETS AGGREGATION CHANGES IN PATIENTS WITH RENDU OSLER DISEASE – BRIEF REPORT V. I. Popov* (RO), C. Socoliuc, H. Bumbea, M. Onisai, A. Vladareanu, T. Savopol, E. Kovacs

Megakaryocytes and Thrombopoiesis I

PP-WE-076 MEGAKARYOCYTE MIGRATION AND THROMBOPOIESIS ARE REGULATED BY SRC KINASES AND PLCGAMMA2, BUT NOT BY THE GPVI-FCRGAMMA-CHAIN A. Mazharian* (UK), T. S. Dhanjal, Y. Zhao, C. D. Buckley, S. P. Watson PP-WE-077 DIFFERENTIAL ROLES OF CAMP AND CGMP IN MEGAKARYOCYTE MATURATION AND PLATELET FORMATION A. Jurak Begonja* (US), S. Gambaryan, H. Schulze, S. Patel Hett, J. E. Italiano, J. H. Hartwig, U. Walter PP-WE-078 ROLE OF THE HSP40 DNAJC10 IN ALPHAIIB-BETA3 BIOGENESIS A. Chen, M. Yazdani-Abyaneh, B. Mitchell* (US) PP-WE-079 DISABLED-2 IS A KEY REGULATOR DURING MESODERMAL DIFFERENTIATION AND MEGAKARYOPOIESIS OF MURINE EMBRYONIC STEM CELLS C. Huang* (TW), J. Cheng, C. Lin, C. Tseng PP-WE-080 SYNTHESIS OF PROTEIN S BY HUMAN MEGAKARYOCYTES C. Radu* (IT), C. Bulato, L. Spiezia, S. Gavasso, G. Tognin, M. Fadin, P. Simioni PP-WE-081 IN VITRO ADHESION CULTURES OF HUMAN MEGAKARYOCYTES AS A TOOL FOR STUDYING MEGAKARYOCYTIC DEVELOPMENT AND PROPLATELETS FORMATION C. Radu* (IT), P. Simioni PP-WE-082 DIRECTED DIFFERENTIATION OF THE MEGAKARYOCYTE LINEAGE FROM HUMAN ES CELLS D. L. French* (US), M. Jirouskova, B. S. Coller, M. Kennedy, G. Keller PP-WE-083 MEGAKARYOCYTOPOIESIS IN C-MPL KNOCKOUT NEONATAL VS. ADULT MICE F. Ferrer-Marin* (US), Z. Hu, Z. Liu, W. Slayton, M. Bailey, R. K. Gutti, M. Sola-Visner

244 PP-WE-085 HUMANPLATELETS PRODUCEDINNOD/SCIDMICEUPONTRANSPLANTATION OF PP-WE-084 POSTER PRESENTATIONS PP-WE-095 PP-WE-094 PP-WE-093 PP-WE-092 PP-WE-091 OFISCHEMICSTROKE MOUSE-MODEL OF ADAMTS13 IN A PROTECTIVEPROPERTY PP-WE-090 SPECTRUMOF ADAMTS13 GENEMUTATIONS IN19PATIENTS WITH ADAMTS13 PP-WE-089 ANTI-VONWILLEBRANDFACTOR ANTIBODY-SZ-34 INHIBITS MONOCLONAL PP-WE-088 VON-WILLEBRAND-FACTOR COMMERCIAL IN ANDANTIGEN ADAMTS-13ACTIVITY PP-WE-087 PROTEOLYSIS OF ADAMTS13 IN ACUTE PHASETHROMBOTICTHROMBOCYTOPENIC PP-WE-086 Novel MechanismsofAntiplatelet TherapyII Basic BiologyofADAMTS13II 2009 WEDNESDAY, JULY 15, MEDIA R AIYKINASEINHIBITION SRC FAMILY THE PROTEINTYROSINEKINASEINHIBIT THROMBOPOIESIS THROMBOPOIETIC EFFECTOFVPAC1 INHIBITIONINMURINE AND HUMAN FLOW MODEL ACTIVEIN AN EXVIVO HUMAN CORDBLOODCD34+CELLS ARE FUNCTIONALLY ENDOTHELIAL TIMEQUANTITATIVE PCROF ADAMTS 13INPLATELETS REAL AND HUMAN STUDY HEMODIALYSIS WITH AND WITHOUTTHROMBOTICCOMPLICATIONS ADAMTS13 AND VWF ANTIGENS ASSESSMENT INPATIENTS UNDERGOING PLA DEFICIENCY ADAMTS13UNDERSHEARSTRESS PROTEOLYTIC CLEAVAGE OFVWFBY (VWF) CONCENTRATES PURPURA A. E.Schade*(US), E.Shick A. Lazzari M. A. Carrivale*(AR), A. C.Kempfer, Y. P. Powazniak, A. Sánchez Luceros,V. A. Zapata,M. Lazzari M. A. Carrivale*(AR),V. A. Zapata,L.Keller, A. SánchezLuceros, A. C.Kempfer, M. A. M. S.Dusse*(BR) D. R. A. Rios,M.G.Carvalho, D. A. Guimarães, A. C.S. Silva,E.M.Lima,R. A. Souza,L. L. I.Buryachkovskaya*(RU),N.E.Dovlatova, A. Uchitel, A. B.Sumarokov, E.Limonov Miyata, K. Nishio*(JP),M.Fujioka,Hayakawa,Mishima,Fujiwara,F. Banno,K. Kokame, T. J. C.Calderzzo*(AR), J. Zhang*(CN),N.Dong,Z.Ma,C.Ruan I. Scharrer*(DE), H. B.Feys*(BE),N.Vandeputte, K.Peerlinck,F. Peyvandi,K.Vanhoorelbeke K. Peeters*(BE),I.Salles,M.F. Hoylaerts,H.Deckmyn,C.vanGeet,K.Freson Deckmyn I. Salles*(BE), RADAMS13 Powazniak, M. A. Lazzari TELET FUNCTION TED PLA Y OF . Shida,M.Sugimoto, ADAMTS13 ISOFORMSINHUVEC OF THROMBOSIS TELET CELLS T T. Vigh, M.Böhm-Weigert . Thijs, C.Brunaud,S.F. deMeyer, J. Thys, K.Vanhoorelbeke, H. A. C.Kempfer ACTIV AND THEVONWILLEBRANDF A T TION . Ueyama,H.Fukushima,K.Okuchi , L.Keller AND GRANULERELEASEINDEPENDENTL OR DASATINIB INHIBITSP2Y12 AND PAR-1 , A. SánchezLuceros, A. I.Woods, Y. P. ACTOR PROTEOLYSIS BY YOF 245

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-096 SIMVASTATIN INHIBITS TXA2 SYNTHESIS IN PLATELETS REGULATING CPLA2 PHOSPHORYLATION AND CALCIUM MOVEMENTS A. Moscardo* (ES), M. T. Santos, B. Cortina, A. Latorre, J. Valles PP-WE-097 MODERATE PHARMACOLOGICAL PLATELET COUNT REDUCTION PREVENTS ACUTE THROMBOTIC VASCULAR GRAFT OCCLUSION IN PRIMATES E. I. Tucker* (US), U. M. Marzec, S. Hurst, A. Gruber, S. R. Hanson PP-WE-098 PRODUCTION OF A RECOMBINANT PUTATIVE INHIBITOR OF PLATELET AGGREGATION FROM HAEMENTERIA DEPRESSA LEECH F. Faria* (BR), J. Lacerda-Alves, A. M. Chudzisnki-Tavassi PP-WE-099 CONSTRUCTION AND CHARACTERIZATION OF A CHIMERIC ANTI-PLATELET GLYCOPROTEIN IB ALPHA MONOCLONAL ANTIBODY J. Yang* (CN), S. Ji, N. Dong, C. Ruan PP-WE-100 BLEEDING RESPONSE INDUCED BY ANTI-THROMBOTIC DOSES OF PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR IN MICE J. E. Bird* (US), P. L. Smith, J. S. Bostwick, W. A. Schumacher PP-WE-101 P2RY1 GENE POLYMORPHISMS ARE ASSOCIATED WITH ASPIRIN RESISTANCE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION P. P. Aung, G. Murugesan, L. Zhang, J. Barnard, Y. Hu, Q. Wang, K. Kottke-Marchant* (US) PP-WE-102 BRIEF ANTECEDENT ‘PRECONDITIONING’ ISCHEMIA ATTENUATES RECURRENT PLATELET-MEDIATED THROMBOSIS: LOSS OF EFFICACY IN AGING RATS K. Przyklenk* (US), P. Whittaker PP-WE-103 DISPERSAL OF PLATELET AGGREGATES BY P2Y12 ANTAGONIST ARC-69931MX H. E. Speich, J. D. Caughran, L. T. Lands, L. K. Jennings* (US) PP-WE-105 VITAMIN C INFUSION BLUNTS CD40L UP-REGULATION IN PATIENTS UNDERGOING CORONARY STENT P. Pignatelli* (IT), S. Basili, G. Tanzilli, R. Carnevale, S. di Santo, L. Loffredo, A. Celestini, E. Mangieri, F. Violi PP-WE-106 A SMALL MOLECULE INHIBITOR OF P2Y1 BLOCKS ADP-INDUCED AGGREGATION BUT DOES NOT SHAPE CHANGE VIA AN ALLOSTERIC MECHANISM R. Mairuhu* (US), L. Dowal, J. R. Dilks, P. Blair, R. Flaumenhaft

Extrinsic Pathway of Coagulation II

PP-WE-107 FIBRIN PRESENCE AND TISSUE FACTOR EXPRESSION IN AORTIC VALVES IN PATIENTS WITH AORTIC STENOSIS AND AORTIC INSUFFICIENCY: ASSOCIATION WITH PLASMA MARKERS OF FIBRIN TURNOVER AND THROMBIN GENERATION A. Undas* (PL), J. Natorska, G. Marek, M. Hlawaty, J. Sadowski, W. Tracz PP-WE-108 DETECTION OF TISSUE FACTOR ACTIVITY IN WHOLE BLOOD BY A FLUOROGENIC THROMBIN GENERATION ASSAY E. Coll* (US), A. Amirkhosravi, J. Francis PP-WE-109 INTRACELLULAR PROCESSING AND SECRETION OF COAGULATION FACTOR VII STUDIED BY PULSE-CHASE ANALYSIS G. Bolt* (DK), T. D. Steenstrup, C. Kristensen PP-WE-110 IMPACT OF ANTICOAGULANTS ON PLATELET-MONOCYTE COMPLEX FORMATION AND REGULATION OF PROCOAGULANT FUNCTION OF MONOCYTES ISOLATED FROM HUMAN BLOOD G. B. Manjunath* (NO), F. X. Gruber, M. Sovershaev, B. Østerud, J. Hansen

246 PW-1 VLAINO H NOEOSTRMI OETA (ETP) ASSAY EVALUATION OFTHEENDOGENOUSTHROMBINPOTENTIAL PP-WE-114 METFORMINDECREASESFACTOR VIIEXPRESSION PP-WE-113 PP-WE-1 NEW AUTOMATED EVALUATION ANALYSER OF FORHAEMOSTASISA AND PP-WE-111 POSTER PRESENTATIONS PW-2 THROMBINGENERATION: CORNTRYPSIN INHIBITOR CHANGESRELATIONSHIPS PP-WE-125 VOLUMEONINTERNATIONAL THEIMPACT OF COLLECTIONTUBEFILL PP-WE-124 F12-4C>TPOLYMORPHISM COUPLEDWITHLOW THE COMMON AND FUNCTIONAL PP-WE-123 PP-WE-122 ANDPLATELET CHOLESTEROL INVERSECORRELATION BETWEENPLASMA PP-WE-121 VERSUSFACTOR IXa-BETA FACTOR FACTOR IXa-ALPHA VII ACTIVATION BY PP-WE-120 ANIONICLIPIDDOMAINFORMATION ONTHENANOMETERSCALE PP-WE-119 METHODFOR NOVEL AS A ENDOGENOUSTHROMBINPOTENTIAL PP-WE-118 LIQUIDHUMAN HIGH-SENSITIVITY EVALUATIONS OF ANDLABORATORY A CLINICAL PP-WE-117 POSITIVE PREDICTOR OFRENAL APTT BIPHASICWAVE FORMIS AN EARLY A PP-WE-116 ONINR PROTHROMBINTIMEVARIABILITY MEANNORMAL THEIMPACT OFLOCAL PP-WE-115 Intrinsic PathwayofCoagulationII 2009 WEDNESDAY, JULY 15, 2 OA ANESTHETICS ATTENUATE TISSUEFACTOR LOCAL EXPRESSIONIN ACTIVATED 12 EWE OMLANDTHROMBOTIC SAMPLES BETWEEN NORMAL NORMALISED RATIO Vicente, D.Mezzano OOYE I FK-EITDIHBTO FMN SYNTHESIS NF-KB-MEDIATED INHIBITIONOFMRNA MONOCYTES VIA THROMBOSIS ANALYSIS PROLONGED APTT, AND LESSTHROMBINGENERATION FXII LEVELSSIGNIFICANTL SCANNING ELECTRONMICROSCOPY DETECTING TISSUEF ACTIVITY CONCENTRATION WITHPLATELET TISSUEFACTOR-DEPENDENT CLOTTING CHARACTERISATION OFPROCOAGULANTSNAKEVENOMS THROMBOPLASTIN FORUSEWITH IMPAIRMENT INPATIENTS ONTHEINTENSIVECAREUNIT NEWSETOFCERTIFIEDPLASMAS ISICALIBRATION WITH A LOCAL WITH LESSRESPONSIVETHROMBOPLASTINREAGENTS AS DEMONSTRATED BY J. K.Ryland*(UK), A. S.Lawrie,J.Machin, I.J.Mackie J. Potgieter*(ZA),R.Pool,E.M.D. Botha, A. Prinsloo,S.Olorunju J. Corral*(ES), V. Strogolov*(US),L.G.Westrick, J. A. Oliver O. Panes*(CL),V M. L.Morgret*(US),J.H.Morrissey M. A. McLean*(US),I.G.Denisov, S.G.Sligar L. F K. M.Cawthern*(US),R.Bottenus,J.Vasquez, D.Diaz,M.X. Triscott K. Sullivan*(UK),J. Thachil, C.Downey, T. Dutt,J.Harper, C.H. Toh J. Hammelburger*(US),R.Bottenus,M. Triscott, M.Johnston,Lauzon J. P. Antovic* (SE), A. Kallner, N.M.H.Soutari,Sten-Linder J. A. Carew*(US),K.R.Cronin J. Kim*(KR),K.Kim,Han,H.Kim J. Needham*(UK),H.Lewis,S.Rangarajan, . Lincz*(AU),D.W A. I. . Matus,M. Antón, oods, S. ACT T. Quiroga,R.González-Conejero,J.Pereira, V. Roldán,V. RPSTV EL NAMIXEDPOPULATION BY OR-POSITIVE CELLSIN A Y Acevedo, J.Pereira,D.Mezzano Alley ASSOCIA , M. AUT A. O’Leary TED WITHREDUCEDFVIIC OMA A. Roy TED COAGULATION ANALYZERS , M.Seldon,G.Isbister AND FIXCLEVELS, 247

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-126 CHANGES OF INHIBITORY COMPLEXES OF THE PLASMA KALLIKREIN-KININ SYSTEM FOLLOWING PERCUTANEOUS CORONARY INTERVENTION OR THROMBOLYTIC THERAPY WITH TENECTEPLASE J. W. P. Govers-Riemslag* (NL), V. Pönitz, T. Brügger-Andersen, H. Grundt, H. ten Cate, D. W. T. Nilsen PP-WE-127 DOES FACTOR XI ACTIVITY CORRELATE WITH THROMBIN GENERATION L. Elreda* (US), O. U. Ogbata, M. Drejka, A. J. Cohen PP-WE-128 TOTAL LAB AUTOMATION AND COAGULATION TESTING M. Deckers* (NL), G. Bulut, T. Hofman, J. de Kok PP-WE-129 BIOLOGICAL EVALUATION OF SYNTHETIC LINEAR ANALOGUE PEPTIDES OF 1811- 1818 LOOP OF THE A3 SUBUNIT OF THE LIGHT CHAIN A3-C1-C2 OF FVIII BLOOD COAGULATION M. P. Makris* (GR), K. Patsialas, C. Koutsas, M. Liakopulu, P. E. Makris PP-WE-130 INSIGHTS INTO THE MECHANISM UNDERLYING POLYPHOSPHATE STIMULATED AUTOACTIVATION OF FACTOR XII R. Engel, R. A. S. Ariens, H. Philippou, N. J. Mutch* (UK) PP-WE-131 GENETIC POLYMORPHISM OF BLOOD COAGULATION FACTOR IX GENE IN GREEK PATIENTS WITH THROMBOPHILIA M. S. Iskas, R. M. Papi, G. E. Mimikakou, D. A. Kyriakidis, P. E. Makris* (GR) PP-WE-132 FACTOR VIII LEVELS DURING AND AFTER ORAL ANTICOAGULANT THERAPY S. Passamonti, I. Martinelli, P. Bucciarelli* (IT), P. M. Mannucci PP-WE-133 STANDARDIZATION OF THROMBIN GENERATION TEST – II. WHICH REFERENCE PLASMA FOR TGT? : AN INTERNATIONAL MULTICENTER STUDY Y. Dargaud* (FR), R. Luddington, E. Gray, V. Regnault, T. Siegemund, T. Baglin, J. Hogwood, T. Lecompte, A. Siegemund, C. Negrier

Anticoagulant Pathways II

PP-WE-134 INHIBITION OF THROMBIN VERSUS FACTOR Xa FOR VENOUS THROMBUS REDUCTION B. C. Cooley* (US) PP-WE-135 EFFECT OF LMWH OF FIRST AND SECOND GENERATION ON THE THROMBIN GENERATION (TG) PARAMETERS C. L. Duboscq* (AR), J. J. Ceresetto, C. Shanley, G. Stemmelin, O. Rabinovich, C. Doti, N. Cazap, E. Bullorsky PP-WE-136 ENDOTHELIAL PROTEIN C RECEPTOR GENE SILENCING AFFECTS MDA-MB-231 BREAST CANCER CELL INVASIVENESS G. Fontana, C. Razzari, S. Ferrero, E. M. Faioni* (IT) PP-WE-137 MONITORING OF LOW MOLECULAR WEIGHT HEPARIN IN PATIENTS WITH CHRONIC RENAL FAILURE BY USING CPM E. Vlasova* (RU), I. Vasilenko, V. Suslov PP-WE-138 INFLUENCE LOW MOLECULAR WEIGHT HEPARIN ON PLATELETS E. Vlasova* (RU), I. Vasilenko, V. Samoylenko, V. Suslov PP-WE-139 A NOVEL METHOD TO ANALYZE ENDOTHELIAL CELL PROTEIN C RECEPTOR EXPRESSION IN VITRO E. Ducros* (FR), S. Mirshahi, C. Bermot, M. Mirshahi

248 PW-4 MLCLRADFNTOA EEOEET INCONTAMINANTS ISOLATED HETEROGENEITY MOLECULAR AND FUNCTIONAL PP-WE-143 MONITORING OFDABIGATRAN DURINGORTHOPEDIC SURGERY LABORATORY PP-WE-142 PP-WE-141 THEEFFECTSOFPHOSPHOLIPID AND TISSUEFACTOR CONCENTRATIONS ONTHE PP-WE-140 POSTER PRESENTATIONS PW-5 MAPPINGFACTOR VIIIC1DOMAIN AMINO ACIDS THAT COOPERATE WITHEPITOPES PP-WE-153 PP-WE-152 SELECTEDMODIFICATION OFTHE ADENOVIRUS TYPE5HEXONMODULATES PP-WE-151 AD5 AND BY INFLUENCE OFFACTOR XONINVITRO AND IN VIVO GENEDELIVERY PP-WE-150 PP-WE-149 OFNATTOKINASE OFITS : APPLICATION TO SUBSTRATE THE ASSAY SPECIFICITY PP-WE-148 THROMBINGENERATION INCARRIERSOFINHERITEDCLOTTINGINHIBITORS PP-WE-147 OFNORMAL GROUP OFVKORC1POLYMORPHISM C1173T IN A FREQUENCY PP-WE-146 C1173T POLYMORPHISM INTHEVKORC1GENE AND WARFARIN SENSITIVITY PP-WE-145 FORFACTOR QUANTITATIVE VLEIDEN(FVL ASSAY NOVEL EVALUATION OF A PP-WE-144 Cofactors andProteases II 2009 WEDNESDAY, JULY 15, OF THEC2DOMAININMEMBRANE BINDING THE INFLUENCEOFGLYCOSYLATION ONTISSUEFACTOR ACTIVITY ADVERSE REACTIONS FROM RECALLEDHEPARIN. IMPACT ON ANTICOAGULATION AND POTENTIAL ANTITHROMBIN ANDPOSSIBLEGAINOFFUNCTIONP1MUTANTS OF INFECTIVITY GENERATION THROMBIN ASSAY A IN APC ANTICOAGULANTACTIVITY IN VIVO INTERACTION WITHCOAGULATION FACTOR X AND HEPATOCYTE TRANSDUCTION AD35 VECTORS FERMENT POTENCY DEFECTS INDIVIDUALS J. Lu*(US),S.W J. Krudysz-Amblo*(US),K.G.Mann, S.Butenas J. Goudsmit,N.vanRooijen,D.H.Barouch, J.H.McV R. Alba, A. C.Bradshaw, A. L.Parker, D.Bhella,S. A. Nicklin,S.N.Waddington, J.Custers, Custers, J.Goudsmit,S. A. Nicklin,J.H.McVey* (UK), A. H.Baker J. H. Sumi*(JP),M.Imai, Y. Yanagisawa H. Sumi*(JP),C. Simioni V L. A. Bastos*(AR), A. N.Blanco,S.Meschengieser, M. A. Lazzari L. A. Bastos*(AR), A. N.Blanco,S.Meschengieser, M. A. Lazzari K. P. Hickey*(UK),P. C.Cooper, S.Kitchen J. Fareed*(US),D.Hoppensteadt,W. Jeske,C. Adiguzel, O.Iqbal,J.Walenga J. Ulehlova*(CZ),L.Slavik,V. Krcova,J.Prochazkova, A. Hlusi,L.Cech Martínez, R.Lecumberri,H.Cano,C.deCos,V. Vicente, J.Corral I. Martínez-Martínez*(ES), G. Salvagno*(IT),Lippi,M.Franchini,Guidi,B.Dahlback AND VITAMIN K2CONTENT . Rossetto*(IT),L.Spiezia,G.Sabrina,P A. Greig,S.N.W A TION OFROY AND P . Pipe,H.Z.Miao, M. G.Jacquemin,E.Gilbert Y atagai, S.Naito, addington, S.M.K.Buckley A TIENTS UNDER ANTICOAGULANT TREATMENT IN ARGENTINA AL A. Ordóñez, A. Miñano,L.Velázquez, R. Teruel, J.Padilla,C. JELL ANDBEEPOLLEN:NATTOKINASE FIBRINOLYSIS Y T . Ohsugi,J.Saito . Dabrilli,C. , A. L.Parker, D.Bhella,R.Pink, T. Morita,J. Abalotti, S.Barbar ey* (UK), A. H.Baker , D. T ormene, P. 249

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-154 EFFECT OF ANTITHROMBIN (AT) COMPLEX FORMATION ON THE PHARMACOKINETICS OF RECOMBINANT FACTOR VIIa (RFVII) AND NN1731 IN BEAGLE DOGS L. C. Petersen* (DK), D. M. Karpf, H. Pelzer, M. B. Hermit, M. Ezban PP-WE-155 ENDOTHELIAL PROTEIN C RECEPTOR AND PROTEASE ACTIVATED RECEPTOR 1 ARE REQUIRED FOR NEUROPROTECTIVE ACTION OF ACTIVATED PROTEIN C L. Gorbacheva* (RU), O. Davidova, V. Pinelis, G. Reiser, S. Strukova PP-WE-156 THROMBIN RESIDUES IN THE BETA-INSERTION LOOP AND THE S2 POCKET CONTRIBUTE TO RECOGNIZING FACTOR XIII ACTIVATION PEPTIDES M. A. Jadhav* (US), R. C. Lucas, M. C. Maurer PP-WE-157 IDENTIFICATION AND CHARACTERISATION OF FACTOR VIII-MEMBRANE INTERACTION INHIBITORS M. Kulharia* (FR), O. Sperandio, J. Voorberg, S. Wielders, J. Rosing, B. O. Villoutreix, G. A. F. Nicolaes PP-WE-158 CONFORMATIONAL CHANGES THAT OCCUR WHEN THROMBIN BINDS EXOSITE- DIRECTED LIGANDS IN SOLUTION M. V. Malovichko* (US), T. M. Sabo, M. C. Maurer PP-WE-159 SUBSTRATE SPECIFICITY OF VKORC1 M. Marinova* (DE), M. Watzka, P. Westhofen, M. Hass, D. Luetjohann, J. Oldenburg PP-WE-160 ADHESIVES PROPERTIES OF A HEMOLIN FROM LONOMIA OBLIQUA CATERPILLAR BRISTLES AND MECHANISMS OF ACTIVATION OF HUMAN FACTOR X M. P. Flores* (BR), O. H. Ramos, A. M. Chudzinski-Tavassi PP-WE-161 TRANSCRIPTIONAL REGULATION OF PROTEIN Z M. Ben-Hasan* (UK), P. R. Winship, A. J. Hall PP-WE-162 BINDING OF THE C2 DOMAIN OF FACTOR V AND FACTOR VIII TO ANIONIC PHOSPHOLIPID BILAYERS Y. Z. Ohkubo* (US), E. Tajkhorshid

Inhibitors of Coagulation II

PP-WE-163 NATURAL ANTICOAGULANTS CAN BE USEFUL PREDICTORS OF SEVERITY IN CHRONIC LIVER DISEASE A. M. Abdelgadir* (SA), A. A. Abdo, F. M. Al Sania, N. Azzam, K. Al Sawat, M. Al Duhgyal, A. K. Al Ghumlas, A. Hersi PP-WE-164 THE USE OF POLYBRENE FOR HEPARIN NEUTRALISATION IN THE THROMBIN GENERATION TEST A. Carlo* (FR), E. Arnaud, B. J. Woodhams PP-WE-165 VENOUS THROMBOSIS RELATED TO RESISTANCE TO TISSUE FACTOR PATHWAY INHIBITOR B. Tardy- Poncet* (FR), M. Piot, C. Chapelle, P. Morange, J. Reynaud, K. Rivron-Guillot, O. Garraud, L. Campos, H. Decousus, P. Mismetti, B. Tardy PP-WE-166 INCREASED LEVELS OF ANAPHYLATOXIN (C5A) AND BRADYKININ IN END-STAGE RENAL DISEASE PATIENTS ON MAINTENANCE HEMODIALYSIS. POTENTIAL RELEVANCE TO HEPARIN MEDIATED HEMODYNAMIC RESPONSES C. Adiguzel* (US), V. Bansal, E. Litinas, D. Hoppensteadt, J. Fareed PP-WE-167 INHIBITORY POWERS MOLECULES OF SPECIFICS SITES IN THE HAEMOSTATIC SYSTEM FROM SALIVARY GLANDS LEECH HAEMENTERIA VIZOTTOI (VIZOTTO, 1967 D. G. L. Oliveira* (BR), A. Miranda, A. M. Chudzinski-Tavassi

250 PW-7 THROMBINGENERATION INPATIENTS (PTS)WITHSEVERESEPSIS AND SEPTIC PP-WE-170 PP-WE-169 EFFECTOFNU172 AND BIVALIRUDIN ONECARINCLOTTINGTIMEINHUMAN PP-WE-168 POSTER PRESENTATIONS PP-WE-181 PP-WE-180 SUBJECTS 24HOURS THEFACTOR XaINHIBITOR DU-176BISSAFEINHEALTHY PP-WE-179 LOWMOLECULARWEIGHT ULTRA NOVEL OF A PHARMACOKINETICS AND SAFETY PP-WE-178 PP-WE-177 LOW MOLECULARWEIGHTHEPARIN INHIBITSTUMOR ASSOCIATED ANGIOGENESIS PP-WE-176 PATIENT NEWMISSENSEVARIANT IDENTIFIEDIN A ANTITHROMBIN ALA383PRO: A PP-WE-175 PP-WE-174 PP-WE-173 THEORAL EXPOSUREDEPENDENTEFFECTSONCOAGULATION ASSAYS BY PP-WE-172 ASSAY INTHEBETHESDA USEOF ALBUMIN TO REPLACEFVIIIDEFICIENT PLASMA PP-WE-171 ENSA,JL 5 2009 WEDNESDAY, JULY 15, HUMAN THROMBIN AND APIXABAN INVITRO: COMPARISON OFDABIGATRAN WITH RIVAROXABAN THROMBOGENICITY EFFECTS OFDIRECT THROMBINORF IN-VITRO CHARACTERISA POST W SHOCK DURINGTHETREATMENT WITHHIGHDOSESOF ANTITHROMBIN III (AT ADJUSTMENTS (APTT) VS. ANTI-FACTOR Xa (AXa)ONUNFRACTIONATED HEPARIN (UFH)DOSE THROMBOPLASTINTIME OF ACTIVATED PARTIAL COMPONENTS OFVARIABILITY ANDWHOLEBLOOD PLASMA SINGLE ASCENDING DOSESTUDY HEP FXa INTHEPROTHROMBINASECOMPLEX COV IN VIVO WITH VENOUSTHROMBOSIS NOVEL ANTICOAGULANT MECHANISMSOF RESULTS FROMTWOPHASEIISTUDIES DIRECT THROMBININHIBITOR FIBRILLATION.AZD0837 INPATIENTS WITH ATRIAL ASSAYFOR FACTOR VIIIINHIBITORS: COMPARISON TO THENIJMEGENBETHESDA WEIGHT FORMATION SELECTSFORDERMATAN SULFATE WITHHIGHERMOLECULAR J. vanRyn*(DE),M. Kink-Eiband,I.Kuritsch,W J. Müller*(DE),B.Wulffen, G.Mayer, B.Pötzsch J. Mendell*(US),R.Noveck,I.Rubets, R.Luo,M.Shi,D.Salazar Gonzalez* (ES),M.J.Barbanoj R. M. Antonijoan, S.Rico,M. Puntes,M.Borrell,J.Fontcuberta,Monreal,Martinez- I. Stevic*(CA), T. A. Kentner, L.R.Berry, A. K.C.Chan I. M.C.Debergh*(BE),N.vanDamme,P I. Tirado* (ES),M.Borrell,D. Llobet,I.Coll,C.Vallvé, P. Fuentes,J.Mateo,Fontcuberta H. W. Chan*(CA),D.L.French,R.Berry, A. K.C.Chan H. M. Atkinson* (CA), T. A. Mewhort-Buist,L.R.Berry, A. K.C.Chan P G. Y. H.Lip*(UK),B.Olsson,L.Rasmussen, A. Tveit, E.Jensen,U.G.Eriksson,M.Elg, G. W. Kershaw*(AU),D.Jayakodi, A. Belin,S.Dunkley, D.Joshua VasilievS. A. G. M.Galstyan*(RU), A. V. Krechetova,M.G. Alexanyan, E.I.Sinauridze,V. M.Gorodetsky, F. Guerrero*(FR), A. Faure,V. Diemert, S.Voisin, P. Sié, A. BuraRivière E. K.W . W ARIN (RO-14)INHEAL eissman, K.Wåhlander ALENTL aters* (US),J.Richardson,R.G.Schaub,C.Kurz HEP ARF ARIN COF RNTETET RANDOMIZED,DOUBLE-BLIND STUDY ARIN TREATMENT: A Y LINKING ANTITHROMBIN TO HEPARIN ENHANCESTHEINHIBITIONOF ACT OR II-DERMA THY TION OF VOLUNTEERS – BIVALENT FUSION APTAMER TARGETING A NIHOBNHPRNSUIDB TEG ANTITHROMBIN-HEPARIN STUDIEDBY . Pattyn,M.Peeters,W ACT T AN SULFATE COVALENT COMPLEX OR XaINHIBITION ONCLOT . Wienen A FIRST TIMEINHUMAN(FTIH) . P . Ceelen 251

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-182 ATTITUDES TOWARDS TREATMENT WITH VITAMIN-K ANTAGONISTS IN RELATION TO PERSONALITY TRAITS IN PATIENTS ON STABLE ORAL ANTICOAGULANT THERAPY M. Felten, J. Harenberg* (DE), L. Frölich, C. Weiss PP-WE-183 GENETIC POLYMORPHISMS OF VKORC1 AND CYP2C9 CONTRIBUTES TO STEADY- STATE DOSE REQUIREMENTS OF PATIENTS ON PHENPROCOUMON J. Harenberg* (DE), W. Wu, C. Weiss, S. Stehle, J. Kirchheiner, U. Fuhr, C. Gleiter PP-WE-184 FUCOSYLATED CHONDROITIN SULFATE INHIBITS PLASMA THROMBIN GENERATION VIA TARGETING OF THE FACTOR IXa HEPARIN-BINDING EXOSITE J. P. Sheehan* (US), Y. Buyue PP-WE-185 ECT MEASUREMENT AFTER DIFFERENT STORAGE CONDITIONS OF AR-H067637, THE ACTIVE METABOLITE OF AZD0837, IN WHOLE BLOOD AND PLASMA K. Wåhlander* (SE), F. Wågberg, M. Elg PP-WE-186 EFFECTS OF CYTOCHROME P450 2C9 (CYP2C9) AND VITAMIN K EPOXIDE REDUCTASE (VKORC1) GENOTYPES ON FLUINDIONE ANTICOAGULATION STATUS K. Lacut* (FR), C. Verstuyft, L. Gourhant, E. Poulhazan, L. Becquemont, D. Mottier PP-WE-187 PROTAMINE INHIBITS PROPAGATION OF THROMBIN GENERATION K. A. Tanaka* (US), D. Bolliger, J. H. Levy, F. Szlam PP-WE-188 ASSOCIATION OF THE SINGLE NUCLEOTIDE POLYMORPHISM RS2227589 IN THE SERPINC1 GENE WITH INHERITED ANTITHROMBIN DEFICIENCY K. Jochmans* (BE), C. Orlando, W. Lissens, I. Liebaers, M. de Waele PP-WE-189 ANTIDOTE REVERSAL OF A NOVEL PROTHROMBIN APTAMER ANTICOAGULANT K. M. Bompiani* (US), S. Oney, F. C. Church, B. A. Sullenger PP-WE-190 COMPARISON OF DABIGATRAN, UNFRACTIONATED HEPARIN AND LOW- MOLECULAR-WEIGHT HEPARIN IN PREVENTING THROMBUS FORMATION ON MECHANICAL HEART VALVES: RESULTS OF AN IN VITRO STUDY L. Maegdefessel* (DE), T. Linde, F. Krapiec, U. Steinseifer, J. van Ryn, B. Hauroeder, U. Raaz, M. Buerke, K. Werdan, A. Schlitt PP-WE-191 MECHANISM UNDERLYING PROTEIN C DEFICIENCY IN A PATIENT WITH AN ALA267THR MUTATION L. Tjeldhorn* (NO), N. Iversen, P. Sandset, G. Skretting PP-WE-192 WHAT IS THE BEST WAY TO MONITOR TINZAPARIN TREATMENT? A COMPARISON BETWEEN ASSAYS L. Lanning* (UK), A. Riddell, A. Griffioen, S. Brooks, P. Chowdary, A. Gatt PP-WE-193 COVALENT LINKAGE OF HEPARIN TO ANTITHROMBIN INCREASES LUNG CELL PROLIFERATION L. R. Berry* (CA), I. Tseu, M. Post, A. K. C. Chan PP-WE-194 EFFECT OF SUBSTRATE AND ANTICOAGULANT ON THE FLUOROGENIC DETECTION OF DYNAMIC THROMBIN ACTIVITY IN WHOLE BLOOD M. S. Chatterjee* (US), S. L. Diamond PP-WE-195 PERFORMANCE OF A NEW KCT ASSAY AND COMPARISON TO THE DRVVT FOR DETECTION OF LA M. D. Goldford* (US), S. R. Raval PP-WE-196 RANDOMIZED, PARALLEL GROUP, WARFARIN CONTROL, MULTICENTER PHASE II STUDY EVALUATING SAFETY OF DU-176B IN JAPANESE SUBJECTS WITH NON- VALVULAR ATRIAL FIBRILLATION (NVAF M. Yasaka* (JP), H. Inoue, Y. Kawai, T. Yamaguchi, S. Uchiyama, M. Matsumoto, S. Ogawa, Y. Koretsune, T. Yamashita

252 PW-0 EFCSO H RLDRC HOBNIHBTRAD87ADVAONFIBRIN DIRECTTHROMBININHIBITOR AZD0837 AND VKA EFFECTSOFTHEORAL PP-WE-200 OFCHROMOGENIC ANTI-FACTOR XaMETHODSTO MEASURE SUITABILITY PP-WE-199 PP-WE-198 AND VENOUSTHROMBOEMBOLISMPROPHYLAXISMETHODSINTHETRAUMA PP-WE-197 POSTER PRESENTATIONS PW-0 GENETIC VARIANTS UNDERLAYING FIBRINOGENLEVELS:FROMLINKAGE PP-WE-209 LEVELS SEX-SPECIFIC GENETICDETERMINATION OFFIBRINOGENPLASMA PP-WE-208 OFDIRECTTHROMBININHIBITOR CONCENTRATIONS WITH INTER-RELATIONSHIP PP-WE-207 PP-WE-206 FORTHEPREVENTIONOFVENOUS DABIGATRAN ETEXILATE 150 MGONCEDAILY PP-WE-205 ININITIATING PROPHYLACTICTREATMENT WITHDABIGATRAN DELAY ETEXILATE PP-WE-204 PROPHYLACTICTREATMENT WITHRECOMBINANT ACTIVATED FACTOR VIIIN PP-WE-203 PREDICTOR OF PP-WE-202 ROLEOFTISSUEFACTOR PATHWAY INHIBITOR (TFPI) AS A THEORAL DOSE-DEPENDENTINHIBITIONOFEXVIVOFIBRINFORMATION BY PP-WE-201 Fibrinogen II 2009 WEDNESDAY, JULY 15, ANALYSIS TO FINEMAPPINGONCHROMOSOME 12Q24 SEPSIS SYNDROME Eriksson IHARA FIBRILLATION WITH ATRIAL OFTHROMBOSISINPATIENTS PERFUSIONCHAMBERMODEL FORMATION IN A RIVAROXABAN INHUMANPLASMA COAGULATION ASSAYS NOVEL,ORAL,DIRECTFACTOR XaINHIBITOR, ON EFFECTS OFRIVAROXABAN, A INTENSIVECAREUNITPATIENTS SURGERY EMERGENCY THROMBIN CONCENTRA PROSPECTIVERANDOMIZEDPILOTSTUDY BYPASS SURGERY: A ARTERY PROPHYLACTIC FIBRINOGENINFUSIONREDUCESBLEEDING ELDERL INTHE REPLACEMENTSURGERY KNEEORHIP THROMBOEMBOLISM AFTER TOTAL EFFICACY. POOLED ANALYSIS OFTWOEUROPEANPHASEIIITRIALS DIDNOT AFFECT ORKNEEREPLACEMENTSURGERY HIP FOLLOWING TOTAL P DISSEMINA DIRECT THROMBININHIBITOR FIBRILLATIONAZD0837 INPATIENTS WITH ATRIAL Almasy, J.Soria*(ES) I. (ES) M. Sabater-Lleal,I. Arbesú, A. Buil,J.Souto,Blangero,Fontcuberta,L. Almasy, J.Soria* J. B.Callahan*(US),K.Distasio,H.Lin, M.Doyle, F. Baghaei* (SE),M.Karlsson,L. Ternström, M.Hyllner, A. Flinck,S.Skrtic, A. Jeppsson Eriksson O. E.Dahl*(NO), A. A. Kurth,N.Rosencher, A. Clemens,M.Feuring,H.Noack,B.I. O. E.Dahl*(NO), M. A. Cermelj*(AR), A. M.Ferro, S.M.Ouvina,J. A. Pollola,G.B.Paoloski M. M. Wolzt* (AT), S.Kapiotis,K.Schützer, M.Holmberg,U.Eriksson,K.Wahlander M. Wolzt* (AT), S.Kapiotis,K.Schützer, M.Holmberg,U.Eriksson,K.Wahlander M. Samama*(FR),L.Flem,C.Guinet,E.Perzborn,J. Amiral, F. Depasse M. Samama*(FR),L.Fem,C.Guinet,E.Perzborn,J.Martinoli,F M. Kurtoglu*(TR),K.Serin,H. AEDIA Arbesú, M.Sabater-Lleal, A. Buil,J.Souto,S. Lopez, L.Rib,J.Blangero,Fontcuberta, L. A. F . Ragab*(EG),F. M.Hafez TRIC P Y AND THOSEWITHMODERA TED INTRA A TIENTS WITHHAEMOPHILIA A. A. Kurth,N.Rosencher V ASCULAR COAGULOP TION Yanar, Y.Ozdenkaya AND CLAUSSFIBRINOGENLEVELS TE RENAL , J.M.Schnee, A. Clemens, S.Hantel,B.I. A TY(DIC) AMONG CHILDRENWITH ATHY AND INHIBIT IMPAIRMENT Triscott ORS AFTER CORONARY . Depasse 253

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-210 GENETIC, LABORATORY AND CLINICAL CHARACTERIZATION OF 45 FAMILIES WITH CONGENITAL DYSFIBRINOGENEMIA K. Sittinger* (DE), W. Miesbach, C. Heller, D. Weiss, A. Lauricella, M. Vega-Ostertag, C. Bidlingmaier, U. Harbrecht, C. Sucker, B. Zieger, E. Seifried, J. Oldenburg, C. Geisen PP-WE-211 IMPAIRED THROMBIN SCAVENGING MAY LEAD TO THROMBOEMBOLIC COMPLICATIONS IN AFIBRINOGENEMIA: A CASE REPORT K. Peter* (CH), S. Gretener, B. Laemmle, F. Demarmels Biasiutti, L. Alberio PP-WE-212 ALA312THR POLYMORPHISM IS NOT ASSOCIATED WITH CHANGES IN CLOT STRUCTURE IN A RECOMBINANT SYSTEM: PITFALLS IN ANALYZING PLASMA- PURIFIED PROTEIN K. F. Standeven* (UK), S. Dolling, F. P. Phoenix, K. Gersh, J. W. Weisel, R. A. S. Ariens, R. A. Ajjan PP-WE-213 FUNCTIONAL CHARACTERIZATION OF FIBRINOGEN POZNAN: A PREMATURE TRUNCATING MUTATION IN FGG ASSOCIATED WITH HYPOFIBRINOGENEMIA AND MILD BLEEDING TENDENCY K. Zawilska* (PL), A. Undas, L. Malendowicz-Portala, P. de Moerloose, R. Fish, M. Neerman-Arbez PP-WE-214 GENETIC MUTATIONS ASSOCIATED WITH DYSFIBRINOGENEMIA IN A UK COHORT M. Hill* (UK), R. C. Tait, M. Williams, G. Dolan PP-WE-215 FIBRINOGEN BIRMINGHAM II - A NOVEL VARIANT ASSOCIATED WITH HYPODYSFIBRINOGENEMIA, DUE TO COMPOUND HETEROZYGOSITY FOR TRP334CYS AND ASN335TYR IN THE FIBRINOGEN A ALPHA CHAIN M. Hill* (UK), N. Thompson, B. Gordon, R. Ajjan, R. A. S. Ariens, M. Williams, G. Dolan PP-WE-216 FIBRIN IN BLOOD CLOTS FORMS NATURAL AMYLOID B. Bouma, C. Maas, L. M. J. Kroon-Batenburg, O. Kranenburg, Y. Wu, M. F. B. G. Gebbink* (NL)

Fibrinolysis II

PP-WE-217 EVALUATION OF MARKERS OF INFLAMMATION, HEMOSTASIS AND FIBRINOLYSIS IN OBESE ASTHMATIC ADOLESCENTS F. Huang* (MX), B. Del-Rio-Navarro, J. Perez-Ontiveros, S. Torres-Alcantara, Toussaint- Martinez de Castro PP-WE-218 REPROGRAMMED STREPTOKINASES DEVELOP FIBRIN-TARGETING AND DISSOLVE BLOOD CLOTS WITH MORE POTENCY THAN TISSUE PLASMINOGEN ACTIVATOR I. Y. Sazonova* (US), R. A. McNamee, A. K. Houng, S. M. King, L. Hedstrom, G. L. Reed PP-WE-219 MARKERS OF FIBRINOLYSIS IN FIRST-EVER LACUNAR STROKE I. L. H. Knottnerus* (NL), J. W. P. Govers-Riemslag, K. Hamulyak, R. van Oerle, R. P. W. Rouhl, H. M. H. Spronk, J. Staals, H. ten Cate, J. Lodder, R. J. van Oostenbrugge PP-WE-220 THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR IN PATIENTS WITH DIABETES MELLITUS TYPE 2 J. Stasko* (SK), P. Chud?, P. Holl?, P. Galajda, P. Kubisz PP-WE-221 ABNORMALITIES IN FIBRINOLYTIC FACTORS CONTRIBUTE TO HYPERCOAGULABLE STATES AND ARE QUANTIFIABLE UTILIZING THE OVERALL HAEMOSTATIC POTENTIAL (OHP) ASSAY J. L. Curnow* (AU), M. C. Morel-Kopp, C. M. Ward PP-WE-222 NORMALIZATION OF CYTOKINES IN PULMONARY HYPERTENSION IN MICE DEFICIENT IN THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR J. Morser* (JP), P. Gil Bernabe, S. Aoki, L. Qin, D. Boveda Ruiz, T. Takagi, C. N. D’Alessandro-Gabazza, O. Taguchi, Y. Takei, E. C. Gabazza

254 PW-2 IRNLSSADAGORPIAL OUETDCRNR ARTERY CORONARY DOCUMENTED FIBRINOLYSIS ANDANGIOGRAPHICALLY PP-WE-226 UPAR SRUCTURAL OFHUMANC4.4A, A CRYSTALLOGRAPHIC STUDY PRELIMINARY PP-WE-225 PP-WE-224 FAILURE HYPERFIBRINOLYSIS AND KYNURENINEPATHWAY INCHRONICRENAL PP-WE-223 POSTER PRESENTATIONS PW-3 UCPIIIYADCIIA INVOLVEMENT OF4G/5GPOLYMORPHISM OF ANDCLINICAL SUSCEPTIBILITY PP-WE-236 STANDARD ASSAYS TO COMPARISONA OFTWOCHROMOGENICFVIII ACTIVITY PP-WE-235 HAEMOSTATIC FACTOR PROFILEDURINGORTHOPAEDIC REPLACEMENTSURGERY PP-WE-234 PP-WE-233 PP-WE-232 THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) DURING ON THEINFLUENCEOF ALPHA-2-ANTIPLASMIN POLYMORPHISM ARG6TRP PP-WE-231 CHARACTERIZATION OF ANTIBODIES TO TISSUE-TYPEPLASMINOGEN ACTIVATOR PP-WE-230 PLASMININHIBITOR AND PAI-1 INHIBITIONKINETICSINFIBRINCLOTS PP-WE-229 DOSE, AS SINGLEMODERATE ETHANOL FOLLOWING A FIBRINOLYTIC CAPACITY PP-WE-228 LEVELS ASSESSMENT INDYSLIPIDEMICSUBJECTSMINASGERAIS TAFI PLASMA PP-WE-227 Regulation ofCoagulationandFibrinolysisII 2009 WEDNESDAY, JULY 15, PLASMINOGEN CLOT ER DIFFERENT THROMBINGENERATION ASSAYS INPATIENTS WITHTHROMBOPHILIA LINK DISEASE (CAD):ISTHERE A HOMOLOGUE PATIENTS WITHHYPERTENSION INELDERLY URINE FIBRINOLYTIC ACTIVITY PATIENTS IN THE INFLUENCEOFDIRECTF BYPASS CARDIOPULMONARY STUDY FIBRINOLYSIS; THELEEDSFAMILY RECOMBINANT PROTEIN (T ASSAYS FIBRINOLYTIC ACT, CAPACITY PAI-1 TPA ACT AND TWOGLOBAL MEASURED BY STATE, BRAZIL Rijken Barreira, A. Álvarez, A. Eimon Álvarez, A. Barreira, A. G. F. deLarrañaga*(AR), S.PerésWingeyer, A. Allievi, S.Muñoz,R. Trobo, A. Orden,J. D. L.McGlasson*(US),G. A. Fritsma C. Altisent* (ES),M.Colomina,J.Massons,C.Fernández,Melado, R.Parra A. Siegemund*(DE), S. J.Davidson*(UK),D. Ariëns S. UittedeW M. Cugno*(IT),R.Castelli,G.Bisiani, A. Calini,P. M.Mannucci M. Silva*(UK),C. Thelwell, K.Kolev, C.Longstaff M. Pieters*(ZA),H.V M. G.Carvalho*(BR),O.Sousa, A. P. Fernandes,C.N.Ferreira A. B.Fernandes,L.M.Lima,O.Sousa,V. P. C. Toledo, M. G.Carvalho*(BR) L. Lin*(US),H.Gardsvoll,B.Jacobsen,M.Ploug,Huang L. V. Podorolskaya*(RU),L. A. Alekseeva, E.L.Chumakova K. Pawlak*(PL), -P A YTHEMA A) INP HEAL BSDFIIATVT ASSAY -BASED FVIII ACTIVITY THY A T TIENTS WITH illige* (UK), A. M.Carter, K.F. Standeven, H.Philippou,P. J.Grant,R. A. S. OSUS (SLE).PRELIMINAR POPULA A. Buraczewska-Buczko,M.Mysliwiec,D.Pawlak ACTIV T. Siegemund, U.Scholz ATOR INHIBITOR-1 (4G/5GPAI-1) GENEINSYSTEMICLUPUS orster A. Lindsey TION ACUTE MYOCARDIAL , J.C.Jerling,S.V , L. ACT T illyer, B.J.Woodhams Y OR XaINHIBITOR RIVAROXABAN ONTWO EUT FAMULTICENTRE STUDY RESULTS OF A enter INFARCTION TREATED WITHTHE , R.C.M.Kotze,J.Malfliet,D. 255

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-237 REDISTRIBUTION OF RECOMBINANT ACTIVATED FACTOR VII INTO PLATELETS AND THE VASCULAR BED: IMPLICATIONS ON HEMOSTATIC MECHANISMS I. Lopez-Vilchez* (ES), J. Tusell, U. Hedner, C. Altisent, G. Escolar, A. M. Galan PP-WE-238 PROFIBRINOLYTIC EFFECT OF THROMBIN FORMATION DURING FIBRINOLYSIS J. R. Ha* (CA), A. Klompas, P. Massicotte, M. Bauman, P. L. Swanson, L. Bajzar PP-WE-239 APO(A) INCREASES CLOT STABILITY IN TRANSGENIC MICE J. L. Hoover-Plow* (US), E. Hart, J. Saraniti PP-WE-240 EFFECT OF IN-VITRO CRYSTALLOID DILUTION ON COAGULATION IN HEALTHY VOLUNTEERS AND PATIENTS WITH A HISTORY OF VENOUS THROMBOSIS OR HEPATIC CIRRHOSIS USING THROMBOELASTOGRAPY (TEG J. Kaur* (UK), N. Jones, A. Riddell, C. Melikian, S. Mallett PP-WE-241 IDENTIFICATION OF HUMAN THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR IN VARIOUS VASCULAR CELL TYPES J. H. Lin* (CA), M. Garand, S. Schadinger, M. B. Boffa, M. L. Koschinsky PP-WE-242 DIAGNOSIS OF NONOVERT, PRECLINICAL DIC USING CRITERIA FROM THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HEMOSTASIS J. Lee* (KR), J. Song PP-WE-243 PLEIOTROPIC EFFECTS IN THROMBOTIC-RELATED TRAITS USING BIVARIATE VARIANCE COMPONENTS MODELS A. Buil, Á. Martínez, J. Souto, J. Blangero, L. Rib, M. Borrell, J. Fontcuberta, L. Almasy, J. Soria* (ES) PP-WE-244 COAGULATION FACTORS DURING LIVER REGENERATION IN MICE K. Tatsumi* (JP), K. Ohashi, Y. Sakurai, T. Okano, M. Shima PP-WE-245 REGULATION OF PLASMA THROMBIN GENERATION BY VASCULAR ENDOTHELIAL CELLS L. Pepler* (CA), P. C. Liaw PP-WE-246 GENETIC REGULATION OF INFLAMMATION-MEDIATED HAEMOSTASIS ACTIVATION: A FAMILY-BASED APPROACH L. Iacoviello* (IT), B. Vohnout, F. Gianfagna, A. di Castelnuovo, L. Nanni, E. Napoleone, M. Crescente, A. de Curtis, A. Cutrone, C. Tamburrelli, F. Zurlo, R. Lorenzet, C. Cerletti, M. Arca, G. de Gaetano, M. B. Donati PP-WE-247 WHOLE BLOOD THROMBOELASTOMETRY PROFILE IN FACTOR V LEIDEN SUBJECTS AFTER IN VITRO ADDITION OF HUMAN ACTIVATED PROTEIN C L. Spiezia* (IT), D. Bertini, D. Tormene, C. Radu, V. Rossetto, M. Perlati, F. Dalla Valle, P. Simioni PP-WE-248 WHOLE BLOOD THROMBOELASTOMETRY IN HUMAN AND CYNOMOLGUS MONKEYS L. Spiezia* (IT), D. Bertini, M. Boldrin, S. Gavasso, C. Radu, P. Zerbinati, C. Bulato, E. Ancona, E. Cozzi, P. Simioni PP-WE-249 TAFI-DEPENDENT INHIBITION OF FIBRINOLYSIS BY PLATELETS EVALUATED IN WHOLE BLOOD BY THROMBOELASTOGRAPHY M. Colucci* (IT), C. Carrieri, R. Galasso, F. Semeraro, C. T. Ammollo, F. Incampo, N. Semeraro PP-WE-250 ANTI-A2 MONOCLONAL ANTIBODY ENHANCING THROMBIN (AND FACTOR Xa)- CATALYZED FACTOR VIII ACTIVITY M. Takeyama* (JP), K. Nogami, T. Soeda, K. Ogiwara, K. Nishiya, M. Shima PP-WE-251 CYP2C9 GENOTYPES AND RESPONSE TO WARFARIN DURING INITIAL ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION M. Bedencic* (SI), E. Zemljic, M. Bozic, P. Peternel, M. Stegnar

256 PW-5 OE LOOERCASYOFSIMULTANEOUS THROMBIN FLUOROMETRIC AND PLASMIN ASSAY NOVEL A PP-WE-255 IN ADOLESCENT ANTICOAGULANTTHERAPY IMPORTANCE OFLIFELONGORAL PP-WE-254 PP-WE-253 ESTIMATION OFTHROMBINPRODUCTIONINDIFFERENTSUBJECTS PP-WE-252 POSTER PRESENTATIONS PW-6 LNCLMANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROMEINOBSTETRIC CLINICAL PP-WE-265 PP-WE-264 MODULATED LEVELSOFVEGF, PLGF AND SDF-1 ARE DIFFERENTLY PLASMA PP-WE-263 IN VIVONEUTRALIZATION OFHEPARIN AND LOWMOLECULARWEIGHTHEPARIN BY PP-WE-262 DISEASE AND ENDSTAGE RENAL FIBRINOKINETICDEFICITINCHRONICKIDNEY PP-WE-261 NEWROLEOFPLATELETS ININDUCINGFIBRIN FORMATION UNDERFLOW PP-WE-260 THEEFFECTOFBLOODCOAGULATION FACTOR XIIIONFIBRINCLOTSTRUCTURE PP-WE-259 PP-WE-258 EVALUATION OFSOMEHEMOSTATIC PARAMETERS INPATIENTS WITHEND-STAGE PP-WE-257 BETWEEN PHOSPHATIDYLSERINE AND OTHERPHOSPHOLIPIDSIN SYNERGY PP-WE-256 Antiphospholipid AntibodiesandSyndr 2009 WEDNESDAY, JULY 15, PRACTICE AUT EERLVENOUSTHROMBOSIS CEREBRAL EEAINDTCSANRA COAGULATION AND FIBRINOLYSISGENERATION INPLASMA DETECTS ABNORMAL THROMBOPHILLIA WITH CONGENITAL THE ROLEOFF TASK-ORIENTED MODULAR ANALYSIS OFTHEBLOODCOAGULATION NETWORK: DURING THE ANTIPHOSPHOLIPID SYNDROME A DISEASE PATIENTS CONTRIBUTESTO THEHEMOSTATIC ABNORMALITIES AND FUNCTION DURING THEIRLIFETIME PLASMA ANDHEMODIALYSIS THERAPY DISEASE:RELATION TO DYSLIPIDEMIA RENAL BLOOD COAGULATION J. Khizroeva*(RU), G. N.Cesarman-Maus*(MX),F D. M.Smadja*(FR),P J. Kuziej,E.Litinas,W. P. Jeske*(US),D.Hoppensteadt,J.M.Walenga, J.Fareed V. Bansal*(US),C. Adiguzel, J.Cunanan,D.Hoppensteadt, O.Iqbal,J.Fareed Deckmyn, J.W S. E.M.Schols*(NL), A. Berny, J.M.E.Cosemans,K.Gilio, A. H.Feijge, (UK) S. Ariëns* E. L.Smith,R.H. Abou-Saleh, S.D.Connell,K.F. Standeven,P. J.Grant,H.Philippou,R. A. P. A. Cordell*(UK),B. T. Kile,P. J.Grant,R.Pease N. K.H. N. Tavoosi* (US),R.L.Davis-Harrison,J.H.Morrrissey H. A. Hathaway, M.J.Manco-Johnson M. L.Grunzke*(US),N. A. Goldenberg,W. E.Hathaway, L.J.Jacobson,C.G.Bombardier, M. Jovic*(RS),D.Redzic,O.Serbic, Aleksic, D.Djokic M. A. Panteleev*(RU), A. N. Balandina,M.V. Ovanesov, E.N.Lipets,F. I. Ataullakhanov M. Makris*(GR),P. Makris K. A. Hajjar, C.Cantu-Brito NOVEL OANTIBODIES A. F SALICYLAMIDE DERIVATIVE Y CO II EESAENTMITIE YCIRCULATING PLATELETS LEVELS ARE NOTMAINTAINED BY ACTOR XIIIA . R. . M.Heemskerk A. T. Abousamra, T. S.Selim,N.K. Abousamra* (EG),S.M.Elshaarawy ACTOR VFEEDBACK ACTIVATION INTRIGGERINGCLOTFORMATION A. AGAINST THEFIBRINOLYTIC RECEPTOR, ANNEXIN A2, IN . Gaussem, A. D.Makatsaria . Barinagarrementería,R.Villa, E.García-Latorre,Reyes, A. Fischer ome II , J.Emmerich,L.Darnige 257

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-266 ANTICARDIOLIPIN ANTIBODIES AND LUPUS ANTICOAGULANT IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS - THE NORTH INDIAN EXPERIENCE J. Ahluwalia* (IN), S. Singh, S. Naseem, D. Suri PP-WE-267 CLINICAL PERFORMANCE OF NEW AND QUANTITATIVE ASSAYS FOR THE DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME (APS) ON A FULLY AUTOMATED, CHEMILUMINESCENT ANALYZER J. Serra* (ES), R. G. Barry, K. A. Morin, C. V. Manion, J. Musial, J. Arnout, M. van Russelt, P. de Moerloose, G. Reber, N. Ruiz, J. Puig PP-WE-268 CALIBRATED AUTOMATED THROMBOGRAPHY IN QUANTITATION OF LUPUS ANTICOAGULANTS IN THE DIAGNOSIS OF THE ANTIPHOSPHOLIPID SYNDROME K. M. J. Devreese* (BE), K. Peerlinck, M. F. Hoylaerts PP-WE-269 THE P38 MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) PATHWAY MEDIATES THE INDUCTION OF TISSUE FACTOR AND ADHESION MOLECULE EXPRESSIONS ON ENDOTHELIAL CELLS K. Oku* (JP), T. Atsumi, O. Amengual, E. Miyamoto, Y. Fujieda, K. Otomo, M. Kato, H. Kataoka, T. Horita, S. Yasuda, T. Koike PP-WE-270 ANALYTICAL PERFORMANCE OF NEW AND QUANTITATIVE ASSAYS FOR THE DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME ON A FULLY AUTOMATED, CHEMILUMINESCENT ANALYZER K. A. Morin* (US), R. G. Barry, J. F. Guasch, N. Ruiz, J. Puig, J. Musial, J. Arnout, G. Reber, P. de Moerloose PP-WE-271 PREDICTIVE VALUE OF THE ANTIPHOSPHOLIPID SCORE (APL-S) FOR THROMBOTIC EVENTS IN PATIENTS WITH AUTOIMMUNE DISEASES K. Otomo* (JP), T. Atsumi, Y. Fujieda, M. Kato, E. Miyamoto, K. Oku, O. Amengual, H. Kataoka, T. Horita, S. Yasuda, T. Koike PP-WE-272 RELAPSING CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME ASSOCIATED WITH EARLY ONSET HELLP SYNDROME AND LIVER INFARCTIONS L. Schliamser* (IL), R. Gonen, M. Carlebach, E. Schiff, D. Attias PP-WE-273 THE EFFECT OF LUPUS ANTI-COAGULANTS ON ANTI-COAGULANT THERAPY MONITORING L. Slavik* (CZ), J. Ulehlova, V. Krcova, A. Hlusi, J. Prochazkova PP-WE-274 DRUG-INDUCED ANTIPHOSPHOLIPID ANTIBODY SYNDROME - TIME TO RESOLUTION M. Kennedy* (US), J. S. Dlott PP-WE-275 MONOCLONAL IGM PARAPROTEIN WITH LUPUS ANTICOAGULANT ACTIVITY – INFLUENCE ON COAGULATION TESTING M. Milos* (HR), D. Coen Herak, D. Matisic, R. Zadro PP-WE-276 CLINICAL AND LABORATORY PICTURE OF APS IN A NATIONAL REGISTRY M. Puurunen* Finland, P. Makkonen, P. Mustonen PP-WE-277 SIGNIFICANCE OF DELTA TIME VALUE IN THE LAB BY HEXAGONAL ASSAY FOR ANTIPHOSPHOLIPID SYNDROME M. Samonte* (US), O. Tcherniantchouk PP-WE-278 COMBINED ANTIPLATELET AGENTS MIGHT HELP PREVENT ARTERIAL THROMBOSES IN ANTIPHOSPHOLIPID SYNDROME M. Yamazaki* (JP), Y. Kadohira, M. Maekawa, T. Hayashi, E. Morishita, H. Asakura, S. Nakao PP-WE-279 A SERIOUS PROBLEM IN NEW REAGENT LOTS OF BETA(2)- GLYCOPROTEIN I IGG ASSAY K. Javela, P. Mustonen* Finland

258 PW-8 H VI EPOET IS EINLEVALUATION OFVENOUS FIRSTREGIONAL MEPROJECT: THE AVAIL A PP-WE-281 CASEOFCATASTROPHIC TREATMENTANTIPHOSPHOLIPID OF A SUCCESSFUL PP-WE-280 POSTER PRESENTATIONS PW-9 AA N IOOYACAIESIUAE OOULA ELTISSUE ANDLIPOPOLYSACCHARIDE-STIMULATED MONONUCLEAR CELL BASAL PP-WE-292 SCREENING PATIENTS WITHFACTOR V LEIDENMUTATION AND PROTEINS PP-WE-291 ROLEOFP16INK4A-MEDIATED CELLULARSENESCENCEINIDIOPATHIC, AGE- PP-WE-290 PP-WE-289 THROMBOSIS ININFANTS AND CHILDREN:LITERATURE REVIEW RIGHT ATRIAL PP-WE-288 PP-WE-287 PRESENTATION OFVENOUSTHROMBOEMBOLISMPREDICT DOESTHECLINICAL PP-WE-286 SAUDI ARABIAN AND THOSEWITH INNORMAL INHERITEDTHROMBOPHILIA PP-WE-285 LARGE STATUS AND OUTCOMESOF DEMOGRAPHICFEATURES,A FUNCTIONAL PP-WE-284 PP-WE-283 VENOUSTHROMBOSIS SCREENINGINTHE ACUTE PHASEOFDEEP PP-WE-282 THROMBOPHILIA Risk FactorsandEpidemiologyofV 2009 WEDNESDAY, JULY 15, THROMBOEMBOLISM INPATIENTS WITHPRIOR VENOUS FACTOR PROCOAGULANT ACTIVITY MEASURINGTHROMBINGENERATION BY ANDPROTEINCDEFICIENCY DEFICIENCY Pendleton Poli, C. THROMBOEMBOLISM (VTE)RISK SYNDROME WITH AUTOLOGOUS BONEMARROWTRANSPLANTATION RELA OF THEFACTOR VIIIa A1 DOMAIN THE ROLEOFP4-P3’ FROM 1981TO 2008 THROMBOPHLEBITIS–WHICHCASES ARE MORERISKY SUPERFICIAL THE RISKFOR AND TYPEOFTHROMBOSISRECURRENCE T (S- TROMBOPHILIA VENOUS THROMBOSIS-THESAUDITHROMBOSIS AND FAMILIAL DEPARTMENTS INTHEUNITEDSTATES EMBOLISMINEMERGENCY SAMPLE OFPATIENTS DIAGNOSEDWITHPULMONARY HYPERTENSION(CTPH) THROMBOEMBOLIC PULMONARY EMBOLISM(PE)FORTHEDETECTIONOFCHRONIC PULMONARY FIRSTEPISODEOF IN PATIENTS WITH A TRANSTHORACIC ECHOCARDIOGRAPHY A. Xue,J. A. Heit*(US),R.Miller, J. Larson, T. M.Petterson,W. G. Owen J. R.W J. Cardenas*(US),N.Sharpless,H.Whinna, F J. P. Deangelis*(US),F. Varfaj, H.Wakabayashi, P. J.Fay J. J. Hirmerova*(CZ),Seidlerova,I.Subrt J. Douketis*(CA), J. Saour*(SA), A. Sheereen, T. Saour, M.Shoukri,L.Mammo J. Hernandez*(US),C.V Arcangeli D. Poli*(IT),E. A. B.Münster*(DK),J.Sidelmann,Gram Sultanaliev, S. Tuganbekova, A. Vasheghani, R.Vardosanidze, T. Charkviani,J. Aoun A. Alfahim, S.Haggag,N.Shahrour, A. Khoury, M. Aghili, A. Aldeshev, M.Begaliyev, T. A. Taher* (LB),P. Salameh,G.Dabar, M.Waked, G.Chaar, M.Itani,E.Elias,R. Abdelkarim, T . M.Owaidah*(SA),F. Al Mohareeb, A. Al Harthi,H. Al Zahrani AFT) REGISTR Y . K. TED VENOUSTHROMBOSIS u* (US),B.Bai, Yang* (CA),S.Williams,L.R.Brandao, A. K.C.Chan Tait,Tosetto A. Antonucci, E.Grifoni,G.Ciuti,M.Miniati,Gensini,D.Prisco,R. Abbate, C. Y A. Iorio,M.Marcucci, RESIDUES INFACILITATING ACTIVATED PROTEINCCLEAVAGE T . S.Smith . Pollack,J. enous Thrombosis II AND PROPHYLAXISPRACTICE A. Kline,B.Hiestand,D.Slattery T . Baglin,M.Cushman,S.Eichinger . Church , D.Schrieber, R. , G.Palareti,D. 259

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-293 RELATIONSHIP BETWEEN THE PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) 4G/5G POLYMORPHISM AND CEREBRAL VENOUS THROMBOSIS (CVT). ANOTHER BRICK IN THE WALL J. M. Ceresetto* (AR), C. Duboscq, C. Doti, F. Bottaro, O. Rabinovich, C. Shanley, G. Stemmelin, E. Bullorsky PP-WE-294 MOLECULAR CHANGES IN VWF AND ADAMTS13 GENES AND THEIR CORRELATION WITH PLASMA LEVELS OF FVIII AND VWF IN PATIENTS WITH DEEP VENOUS THROMBOSIS L. F. Bittar, L. H. Siqueira, E. V. de Paula, F. L. A. Orsi, J. M. Annichino-Bizzacchi* (BR) PP-WE-295 INCREASED ACTIVITY OF COAGULATION FACTORS FVII AND FIX ASSOCIATED WITH RECURRENT THROMBOSIS T. M. Melo, F. A. Orsi, E. V. de Paula, M. C. Ozelo, J. M. Annichino-Bizzacchi* (BR) PP-WE-296 THE FACTOR VIII D1241E POLYMORPHISM, LEVELS OF FACTOR VIII AND RISK OF DEEP VENOUS THROMBOSIS IN A BRAZILIAN POPULATION T. B. T. Mello, L. H. S. Siqueira, S. A. L. Montavão, D. S. P. Paixão, J. M. Annichino- Bizzacchi* (BR) PP-WE-297 ANTITHROMBIN (AT) DEFICIENCY: EFFECT OF PERIOPERATIVE THROMBOPROPHYLACTIC APPROACH ON VENOUS THROMBOEMBOLIC EVENT (VTE) RATE T. Sooriyakumar, S. Bretherton, J. K. Phillips* (NZ) PP-WE-298 A PROSPECTIVE STUDY OF QUANTITATIVE D-DIMER AND ENDOGENOUS THROMBIN POTENTIAL MEASUREMENTS IN INDIVIDUALS STOPPING ORAL ANTICOAGULANTS FOR ACUTE VENOUS THROMBOEMBOLISM; ROLE IN PREDICTING RISK OF RECURRENT THROMBOTIC EVENTS S. P. Green, E. Hynes, K. Knaggs, J. Hanley, P. Kesteven, K. L. Talks* (UK) PP-WE-299 USE OF CALIBRATED AUTOMATED THROMBOGRAPHY TO DETECT HYPERCOAGULABILITY K. R. Machlus* (US), E. A. Colby, J. R. Wu, G. G. Koch, N. S. Key, A. S. Wolberg PP-WE-300 BLEEDING COMPLICATIONS WITH PHARMACOLOGICAL PROPHYLAXIS FOLLOWING GYNAECOLOGICAL ONCOLOGY SURGERY K. Hitos* (AU), G. V. Wain, J. P. Fletcher PP-WE-301 VENOUS THROMBOEMBOLISM PROPHYLAXIS FOLLOWING LAPAROSCOPIC SURGERY K. Hitos* (AU), J. P. Fletcher PP-WE-302 THERE IS NO INCREASE IN THROMBIN GENERATION IN PATIENTS WITH IDIOPATHIC INTRACRANIAL HYPERTENSION K. Hickey* (UK), S. Dhungana, B. Sharrack, P. C. Cooper, M. Makris PP-WE-303 THE EFFECT OF AGING ON VENOUS VALVES K. van Langevelde* (NL), A. Srámek,ˇ A. de Roos, J. H. C. Reiber, F. R. Rosendaal PP-WE-304 PHYSICAL ACTIVITY AND RISK OF VENOUS THROMBOEMBOLISM -THE TROMSO STUDY K. H. Borch* (NO), S. Kufaas-Braekkan, E. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer, J. Hansen PP-WE-305 ANTHROPOMETRIC MEASURES OF OBESITY AND RISK OF VTE - THE TROMSO STUDY K. H. Borch* (NO), S. Kufaas-Braekkan, E. Mathiesen, I. Njolstad, T. Wilsgaard, J. Stormer, J. Hansen

260 PW-0 RISKOFRECURRENTVENOUSTHROMBOEMBOLISM–EFFECT AGE PP-WE-309 INPATIENTS WITHTHROMBOEMBOLICDISEASE INHERITEDTHROMBOPHILIA PP-WE-308 PP-WE-307 ANDVENOUS ELEVATED RISKFACTOR FOR ARTERIAL FACTOR IXLEVELS AS A PP-WE-306 POSTER PRESENTATIONS PW-1 AEO EEEIHRTDHPROOYTIEI NAYOUNGMALE IN A CASEOFSEVEREINHERITED HYPERHOMOCYSTEINEMIA A PP-WE-319 PP-WE-318 PRO-BRAINNATRIURETIC PEPTIDECORRELATES WITHTHE N-TERMINAL PP-WE-317 PP-WE-316 DANISHFOLLOW-UP ANDVENOUSTHROMBOEMBOLISM: A ANTHROPOMETRY PP-WE-315 VEINTHROMBOSIS(RVO) AND THROMBOPHILIA RETINAL PP-WE-314 INCIDENCEOFCARDIOVASCULAR EVENTS AFTER VENOUSTHROMBOEMBOLISM. A PP-WE-313 PP-WE-312 OBESITY, POORMUSCLESTRENGTH AND THERISKOFVENOUS PP-WE-311 ROLEOFGENETICMUTATIONS INVASCULAR ACCESS THROMBOSIS AMONG PP-WE-310 ENSA,JL 5 2009 WEDNESDAY, JULY 15, TREATED WITHVITAMIN B6 AND B9 HAVING VENOUSTHROMBOEMBOLISM AND CLAUDICATION SUCCESSFULLY AFO RXMLLCLZTO FDE VEINTHROMBOSIS LOCALIZATION OFDEEP CALF ORPROXIMAL Tromp, M.H.Prins,D.Biesma UMNR EMBOLISM PULMONARY MYELOPROLIFERATIVE SYNDROME FEATURE OF VEINTHROMBOSIS AS THEFIRSTCLINICAL ABDOMINAL THROMBOSIS RISK STRA PERCENT PREV STUDY SYSTEMA RISK-ASSESSMENT OFVENOUSTHROMBOEMBOLISMINHOSPIT THROMBOEMBOLISM INOLDERPERSONS:THEINCHIANTISTUDY HEMODIALYSIS PATIENTS M. Prins, D.H.Biesma M. J. Agterof* (NL),E.R.vanBladel,G.Schutgens,J.Snijder, E. A. M. Tromp, M.H. M. J. M. Horellou*(FR),J.Conard,V M. T. Severinsen*(DK),S.R.Kristensen, S.P. Johnsen,K.Overvad Theodosiadis M. S.Bellia*(GR), A. J.Gafou, E.Nomikou,V. Tsevrenis, C.Zafiri,G. Apergis, G. M. C.Vedovati* (IT),C.Becattini,W. Ageno, F. Dentali,G. Agnelli M. Debastos*(BR),J.Caiafa, T. Bogutchi,S.Barreto,Rezende F M. diNisio*(IT), A. diIorio,E.Porreca,M. Abate, S.Bandinelli, J.Guralnik,R.Molino-Lova, M. S.Dusse*(BR) D. R. A. Rios,D. A. Guimarães,K.B.Gomes, A. P. Fernandes,D.Reis,M.G.Carvalho, L. L. Eischer*(AT), S.Eichinger, P. A. Kyrle L. Lokar*(SI),V. Urlep K. M.Zawilska*(PL),Jamrozek-Jedlinska, K. J.Smock*(US),R. RLMNR EUT RMALARGEPROSPECTIVESTUDY RESULTS FROM A PRELIMINARY PULSE RATE AND D-DIMERCONCENTRATION . Cuccurullo,L.Ferrucci Andersen* (DK),J. Dalsgaard,S.Stender Agterof* (NL),R.E.G.Schutgens,J.F ALENCE OFTHROMBOPHILIA AGE OFPULMONAR TIC REVIEW TIFICA TION OFP A. Crist,K.Murphy, A. R.Wilson,G.M.Rodgers Salinoviæ, B.Bizjak,MajcenVivod, I.Maraèiè,E.Kava? ˇ AND MET A . Olié,C.Flaujac,M.Fontenay TIENTS WITHPULMONAR Y A-ANAL V ASCULAR OBSTRUCTIONINP IN COHORTOF2607WOMEN: IMPACT OFTHE A YSIS . V erzijlbergen, M.C.vanBuul,E. A. M.Grzywacz Y , G.Plu-Bureau EMBOLISM BASEDON A TIENTS WITH ACUTE ALIZED P ATIENTS: A. M. 261

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-320 THE METABOLIC SYNDROME AND THE RISK OF IDIOPATHIC VENOUS THROMBOEMBOLISM M. N. D. di Minno* (IT), A. Guida, A. Tufano, A. Coppola, A. M. de Gregorio, M. di Capua, E. Cimino, A. M. Cerbone, G. di Minno PP-WE-321 LACK OF CHANGE IN INSULIN LEVELS AS A BIOLOGICAL MARKER OF PAI-1 LOWERING IN 60 GROWTH HORMONE (GH) DEFICIENT ADULTS ON RECOMBINANT HUMAN GH (R-HGH) REPLACEMENT THERAPY: A PROSPECTIVE STUDY M. N. D. di Minno* (IT), V. Palmieri, G. Lombardi, S. Pezzullo, F. Cirillo, A. Meola, C. di Somma, P. Beck-Peccoz, G. di Minno PP-WE-322 SAFETY OF VITAMIN K ANTAGONISTS IN PULMONARY ARTERIAL HYPERTENSION M. V. Huisman* (NL), T. A. Hazenoot, I. R. Henkens, H. W. Vliegen, A. Boonstra, P. E. Postmus, A. Vonk Noordegraaf PP-WE-323 DECREASED HEME OXYGENASE-1 EXPRESSION IN PATIENTS WITH PULMONARY HYPERTENSION FOLLOWING PULMONARY EMBOLISM M. R. Marchick* (US), J. A. Kline PP-WE-324 A COMPARISON OF THE PREVALENCE OF HEREDITARY NATURAL ANTICOAGULANT PATHWAY DEFECTS BETWEEN PATIENTS WITH DVT, PE AND THROMBOSIS AT UNUSUAL SITES M. Ahmadinejad* (IR), D. Bashash, T. Ahmadinejad, S. Zolfaghari, M. Tabatabaii, K. Atarodi, L. Seyed Mortaz, S. Baluch PP-WE-325 CORONARY ARTERY DISEASE AND-OR CEREBRAL NON-FATAL ISCHEMIC STROKE FOLLOWING RETINAL VEIN OCCLUSION: A 8-YEAR FOLLOW-UP M. di Capua* (IT), M. N. D. di Minno, A. Guida, A. M. de Gregorio, C. Cuccaro, M. Loffredo, A. Tufano, E. Ciminno, A. Coppola, A. M. Cerbone, G. di Minno PP-WE-326 STATIN USE IN PATIENTS WITH NEPHROTIC SYNDROME IS ASSOCIATED WITH RISK REDUCTION OF VENOUS THROMBOEMBOLISM M. Resh* (NL), B. Mahmoodi, G. Navis, N. Veeger, W. Lijfering, J. van der Meer PP-WE-327 ENOS POLYMORPHISMS MAY BE A RISK FACTOR FOR DEEP VEIN THROMBOSIS IN INDIAN ASIAN POPULATION M. S. Akhter* (IN), A. Biswas, R. Ranjan, A. Meena, A. Sharma, S. Kumar, R. Saxena PP-WE-328 EPIDEMIOLOGY OF AND RISK FACTORS FOR UPPER EXTREMITY VENOUS THROMBOSIS IN THE POPULATION-BASED MALMO TROMBOPHILIA STUDY, (MATS) N. Isma* (SE), P. J. Svensson, A. Gottsäter, B. Lindblad PP-WE-329 PHYSICIAN COMPLIANCE WITH ADVANCED NON-INTERRUPTIVE ELECTRONIC ALERTS FOR PREVENTING VENOUS THROMBOEMBOLISM AMONG HOSPITALIZED MEDICAL PATIENTS N. Kucher* (CH), M. Puck, D. Spirk, G. Bucklar, E. Eschmann, T. F. Lüscher PP-WE-330 ANTHROPOMETRIC AND HAEMOSTATIC CARDIOVASCULAR RISK IN YOUNG NIGERIAN SEMI VEGETARIANS O. A. Awodu* (NG), A. A. Adeyemi, O. A. Omolade, Y. O. Makinde, O. I. Ajayi, A. A. Famodu PP-WE-332 RISK ASSESSMENT AND MANIFESTATION OF VENOUS THROMBOSIS (VT) IN PREGNANCY AMONG CARRIERS OF THE FACTOR V LEIDEN AND THE PROTHROMBIN GENE 20210GA MUTATIONS – A POPULATION-BASED CASE- CONTROL STUDY A. F. Jacobsen, F. E. Skjeldestad, A. Bergrem, P. M. Sandset* (NO) PP-WE-333 PERFORMANCE OF THE HEMOSIL THROMBOPATH ASSAY IN THE SCREENING FOR PROTEIN C PATHWAY ABNORMALITIES. PRELIMINARY RESULTS IN 352 UNSELECTED PATIENTS WITH A HISTORY OF THROMBOSIS P. A. Toulon* (FR), I. Martin Toutain, A. Ankri

262 PP-WE-335 FACTOR VLEIDEN AND THROMBINGENERATION AND RISKOFRECURRENT PP-WE-334 POSTER PRESENTATIONS PW-4 VONWILLEBRANDFACTOR DOESNOTPREDICTOUTCOME INUNSTABLE ANGINA PP-WE-346 PROCOAGULANTSTATE INTHELEFT ATRIUM OFPATIENTS LOCAL WITHNON- PP-WE-345 PP-WE-344 PP-WE-343 HAVE BEENINVOLVED INTHEREDUCTIONOF MAY STATIN THERAPY PP-WE-342 CARDIOVASCULAR EVENTSINPATIENTS RISKOF AFTER ARTERIAL ACUTE PP-WE-341 JAK2V617FMUTATION THROMBOSISINTHE ABSENCE INPATIENTS WITH ARTERIAL PP-WE-340 INCREASED ACTIVE VONWILLEBRANDFACTOR IN YOUNG WOMENWITH ACUTE PP-WE-339 AGEISMOREIMPORTANT TO PREDICTCAROTIDSTENOSIS AMENABLE OF PP-WE-338 HAEMOSTATIC BIOMARKERSINCHRONICHEARTFAILURE AND INFLAMMATORY PP-WE-337 THEHEMOSTATIC SYSTEMINPATIENTS WITHTYPE2DIABETES AND PP-WE-336 Arterial Vascular DiseasesII 2009 WEDNESDAY, JULY 15, AVLRARA FIBRILLATIONVALVULAR ATRIAL Kautzner FOLLOW-UP DISEASE:THERESULTS OF4 YEARS PATIENTS ARTERY WITHSTABLE CORONARY HAEMOSTATIC GENEFACTORS AND RISKOFVASCULAR EVENTSINRUSSIAN THROMBOEMBOLISM. THELISTSTUDY PATIENT COHORTWITHVENOUS THROMBOTIC EPISODESIN A PREDICTION OFCARDIOV HEARTDISEASE CORONARY METHYLENETETRAHYDROFOLATE REDUCTASE GENEINPATIENTS WITH PREV PRODUCTION SUPPRESSIONOFENHANCEDTHROMBOXANE CARDIOVASCULAR EVENTSVIA EMBOLISM PULMONARY OF OVERTMYELOPROLIFERA MYOCARDIAL SYMPTOMS NEUROLOGICAL CORRECTIONTHANFOCAL SURGICAL WITHOUT CARDIOVASCULAR DISEASE J. E.vanLoon*(NL), J.W I. V T S. Park,H.Chi*(KR),Min,Jang,C.Park H. Omori*(JP),K.Murasaki, Huisman F F. Dentali* (IT), A. Squizzato,L. Appio, L.Brivio,W. Ageno Merlini, P. J.Lenting,P. M.Mannucci F. Peyvandi*(IT),M.J.Hollestelle,R.Palla,F. M.deRooij,H.Feys,D. Ardissino, P. Andreozzi F. Verlato* (IT),G.Verlato, M.Marzolo,G.Camporese,F. Rosso,F. Busonera,M.Nardi,G. E. G.Oganova*(BY),S.F C. J.N.Verkleij* (NL),V. E. A. Gerdes,R.deBruijn,J.C. M.Meijers,P. F. Marx Panchenko A. L.Komarov*(RU),O.Shakhmatova,D.Rebrikov, I.Kofiady, D.Stambolsky, A. Deev, E. R. Chaireti,C.Jennersjö, . Weiss, I.Seljeflot*(NO),E.B.Furenes,H. Arnesen . A. Klok*(NL),I.C.M.Mos,L.Broek,J. . Hrachovinová*(CZ),P ALENCE OFC677T AND A1298C POLYMORPHISMS IN INF ARCTION T . Jukema,F. W. G.Leebeek, M.P. M.deMaat . Zolotukhina,S.M.Komissarova,O. A. Petruk . . L.Lindahl*(SE) Sulc, M.Zemanova,V ˇ ASCULAR EVENTSBY Y . Uetsuka,N.Hagiwara TIVE DISEASE T . T amsma, F . Melenovsk?,D.W M- NEDRYMEN MMP-9 INELDERLY . R.Rosendaal, A. deRoos, M.V. ichterle, G. Y. H.Lip,J. 263

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-347 FREQUENCY OF THE POLYMORPHISM -1131T> C IN APOLIPOPROTEIN A5 (APOA5) GENE IN SUBJECTS IN MINAS GERAIS STATE - BRAZIL K. B. Gomes* (BR), A. P. Fernandes, N. G. Cruz, F. F. Coelho, I. R. Santos, K. F. Rodrigues, P. S. Pinheiro, D. A. Guimarães, M. O. Sousa PP-WE-348 A POSSIBLE MECHANISM OF FASTER ONSET OF PRASUGREL - THE INTESTINE AS AN IMPORTANT CONTRIBUTOR TO THE ACTIVE METABOLITE FORMATION IN VIVO - K. Hagihara* (JP), M. Kazui, H. Ikenaga, T. Nanba, K. Fusegawa, A. Kurihara, O. Okazaki PP-WE-349 COULD D-DIMER IN THE TYPE 2 DIABETIC PATIENTS BE A MARKER OF THE MACROVASCULAR COMPLICATIONS K. Yokoyama* (JP), Y. Tsukada, Y. Matsubara, T. Kawai, Y. Oikawa, A. Shimada, H. Itoh, M. Murata, Y. Ikeda PP-WE-350 FACTOR XIII A SUBUNIT VAL34LEU POLYMORPHISM IN PATIENTS SURVIVING OR NOT SURVIVING ISCHEMIC STROKE L. Muszbek* (HU), A. H. Shemirani, B. Antalfi, E. Pongrácz, R. Ádány PP-WE-351 LOOKING FOR EARLY SIGNS OF ATHEROSCLEROTIC ALTERATIONS IN CARRIERS OF INHERITED THROMBOPHILIA L. Valdre* (IT), C. Legnani, B. Cosmi, M. Cini, E. Favaretto, G. Palareti PP-WE-352 DETERMINANTS OF THROMBIN GENERATION IN ACUTE MYOCARDIAL INFARCTION M. Smid* (NL), A. W. J. H. Dielis, R. van Oerle, J. W. P. Govers-Riemslag, H. M. H. Spronk, K. Hamulyák, M. Prins, J. Rosing, J. Waltenberger, H. ten Cate PP-WE-353 REDUCED THROMBIN GENERATION IS ASSOCIATED WITH MYOCARDIAL INFARCTION IN THE GLASGOW MYOCARDIAL INFARCTION STUDY (GLAMIS M. Smid* (NL), M. Woodward, R. van Oerle, H. M. H. Spronk, A. Rumley, H. ten Cate, G. Lowe PP-WE-354 PLASMA GLUTATHIONE PEROXIDASE (GPX-3) AND APOLIPOPROTEIN (A) (APOA) IN YOUNG PATIENTS WITH NON-EMBOLIC ISCHEMIC STROKE (IS): A SUB-GROUP ANALYSIS M. F. Alberto* (AR), P. Casais, L. Jones, G. Campregher, S. Meschengieser, M. A. Lazzari PP-WE-355 ENDOTHELIAL CELL ACTIVATION MEASURED BY VON WILLEBRAND FACTOR PROPEPTIDE IN ISCHEMIC STROKE PATIENTS M. C. van Schie* (NL), M. P. M. de Maat, A. A. Hyseni, D. W. J. Dippel, P. J. Lenting, P. G. de Groot, F. W. G. Leebeek, M. J. Hollestelle PP-WE-356 PLATELET BEHAVIOUR IN PATIENTS WITH DRUG-ELUTING STENTS AFTER THIENOPYRIDINE TREATMENT DISCONTINUATION M. Camera* (IT), D. Trabattoni, D. Villa, A. Bartorelli, P. Bogani, M. Brambilla, E. Tremoli PP-WE-357 INCREASED INNATE AND ADAPTIVE IMMUNE CELL CONCENTRATIONS IN BLOOD PREDICT AN INCREASED CARDIOVASCULAR DISEASE INCIDENCE M. Roest* (NL), H. B. Bueno-De-Mesquita PP-WE-358 PLASMA FACTOR AND INHIBITOR COMPOSITION CONTRIBUTES TO THROMBIN GENERATION DYNAMICS IN ACUTE CEREBROVASCULAR EVENTS M. Gissel* (US), A. Undas, A. Slowik, K. G. Mann, K. Brummel-Ziedins PP-WE-359 THROMBOPHILIC RISK FACTORS AND OUTCOME IN PATIENTS UNDERGOING ENDOVASCULAR INTERVENTION FOR PERIPHERAL ARTERIAL DISEASE M. Sartori* (IT), E. Conti, E. Favaretto, C. Legnani, G. Guazzaloca, L. Valdre’, C. Pili, G. Palareti PP-WE-360 MAJOR BLEEDING EVENTS IN STABLE OUTPATIENTS WITH CORONARY, CEREBROVASCULAR OR PERIPHERAL ARTERY DISEASE. FINDINGS FROM THE FRENA REGISTRY T. Gadelha, J. Bisbe, J. Toril, J. N. Alcalá Pedrajas, C. Sanclemente, T. Pascual, M. Manuel* (ES) 264 PW-6 ODPRNXFRAPENN OA IHDE VEINTHROMBOSIS AND PREGNANTWOMANWITHDEEP FONDAPARINOX FOR A PP-WE-363 PP-WE-362 DISEASE ARTERY MOLECULARGENETICS ANALYSIS INCORONARY PP-WE-361 POSTER PRESENTATIONS PW-7 EDGNU HOBNPTNIL RFLSI OMLPENNYAND PREGNANCY ENDOGENOUSTHROMBINPOTENTIAL: PROFILESINNORMAL PP-WE-372 PP-WE-371 REFERENCERANGESFORTHEDETERMINATION OFD-DIMERSINPREGNANCY PP-WE-370 INPREGNANTWOMENRECEIVINGLOW LEVEL PREDICTIONOF ANTI Xa ACTIVITY PP-WE-369 LOCALISATION AND PERIODOFVENOUSTHROMBOSISOCCURRENCEIN PP-WE-368 NESTED LOSS: JAK2V617FMUTATIONA ISNOT ASSOCIATED WITHPREGNANCY PP-WE-367 SPORADICMUTATIONS WITHINTHEEXON8OFPROTEINZ ARE SIGNIFICANTLY PP-WE-366 LIPIDS AND APOLIPOPROTEINS (APOB/APO A-I RATIO) INPOST-MENOPAUSAL PP-WE-365 GENOTYPING AND VENOUSTHROMBOSISINBRAZILIAN ABOBLOODGROUP PP-WE-364 Hormones, Pregnancy andWomen’s IssuesII 2009 WEDNESDAY, JULY 15, PRO-THROMBOTIC PREGNANTWOMEN (UK) HEPARIN ALLERGY DISEASES AND INFLAMMATORY INPATIENTSFACTOR XIa WITHCARDIOVASCULARAND TISSUE FACTOR ACTIVITY THROMBIN SUPPORT VECT NETWORK AND NEURAL MOLECULAR WEIGHTHEPARIN USING ARTIFICIAL THROMBOEMBOLIC DISEASE ANDPUERPERIUMRELATED VENOUS THROMBOPHILIC WOMENWITHPREGNANCY STUDY CASE-CONTROL LOSS ASSOCIATED WITHTHEOCCURRENCEOFFETAL WOMEN UNDERHORMONEREPLACEMENTTHERAPY WOMEN USINGESTROGEN E. Hynes,K.Knaggs, S.McCourt,C.Bomken, Reverter* (ES) D. Tassies, M. A. Martinez,J.Monteagudo,C.Freire,Pijoan,F. Carmona, J.Balasch,C. G. Kappert*(DE),S.Halimeh,H.Rott Jelicic G. Mitic*(RS),M.Scekic,D.Jurisic,L.Povazan,R. Tesic, M.Petkovic,B.Jakovljevic,Z.D. Novakov Mikic G. Mitic*(RS),M.Kovac,L.Povazan,V D. Colaizzo,P G. Favuzzi,D.Colaizzo,V Carvalho, A. Fernandes*(BR),M.O.Sousa D. A. M.Guimarães,D.Diniz,K.B.Gomes,S.Santos,R.Franco,G. Teixeira, M. K. B.Gomes,L.M.S.Dusse, A. P. Fernandes*(BR) M. S.Santos,D. A. M.Guimarães,S.G.Paiva, A. P. Sabino,M.G.Carvalho,D.Ribeiro, A. M. Almomen* (SA), A. M. Abdel Gader S. Butenas*(US), Papayan O. A. Smirnova*(RU),V. M.Shmeleva,S.I.Kapustin,N. A. Klenkova,M.N.Blinov, L.P. Santacroce, M.Margaglione,E.Grandone*(IT) atnli .D Andrea,M.Margaglione,E.Grandone*(IT) Martinelli, G.D’ IHPECAPI N/RITATRN EA GROWTHRESTRICTION AND/ORINTRAUTERINEFETAL WITH PREECLAMPSIA POL YMORPHISMS AND CLOTLYSIS TIME IN PREGNANTPATIENTS: RELATIONSHIP ACTIV . V ergura, G.Favuzzi,V OR MACHINES A. Undas,M.Gissel,K.G.Mann ATABLE FIBRINOLYSIS INHIBITOR (TAFI) LEVELS,TAFI GENE . deStefano,E.Rossi,D.Pisanelli,F . Djordjevic,Z.Magic,I.Salatic,N. Antonijevic, A. ecchione, A. D.Loughney A. Iannaccone,L.Greco,Mazzarelli,P. , P. Kesteven, J.P. Hanley* . Cappucci, T. Za,R. 265

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-373 EFFECT OF GENISTEIN VERSUS OESTROGEN ON HAEMOSTATIC GENE EXPRESSION IN OVARIECTOMISED RATS L. A. Kelly* (IE), W. Wuttke, J. J. O’Leary, L. A. Norris PP-WE-374 GESTATIONAL VASCULAR COMPLICATIONS: SCREENING FOR CONGENITAL THROMBOPHILIA S. Morais, C. Laranjeira, S. Faria, L. Lima, R. Lopes, M. Pereira, L. Moreira, F. Oliveira, E. Valente, A. Cunha, J. Braga, M. Campos* (PT) PP-WE-375 THROMBOPROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN AFTER CAESAREAN SECTION: A DECISION ANALYSIS M. Blondon* (CH), M. Righini, A. Perrier, M. Nendaz, F. Boehlen, M. Boulvain, P. de Moerloose PP-WE-376 ALTERNATIVE ANTICOAGULATION WITH FONDAPARINUX IN PREGNANT PATIENTS WITH HEPARIN-INTOLERANCE M. Schindewolf* (DE), B. Linnemann, B. Luxembourg, E. Lindhoff-Last PP-WE-377 PREDICTORS OF CARDIOVASCULAR DISEASE IN PRE-ECLAMPSIA M. G. Macey* (UK), S. Bevan, S. Alam, L. Verghese, S. G. Agrawal, S. Beski, R. Thuraisingham, P. K. MacCallum PP-WE-378 THE SIGNIFICANCE OF ENDOTHELIAL MARKERS ACTIVATION IN THE PREDICTION OF SUBSEQUENT DEVELOPMENT OF PREECLAMPSIA M. Procházka* (CZ), J. Procházková, R. Pilka, L. Slavík, J. Úlehlová, A. Mechurová, O. Simetka,ˇ A. Hlusíˇ PP-WE-379 THROMBOPHILIA PRESENCE AMONG WOMEN WITH PREGNANCY-ASSOCIATED COMPLICATIONS: FETAL LOSS OR PREGNANCY RELATED VENOUS THROMBOEMBOLISM M. Kovac* (RS), G. Mitic, Z. Mikovic, V. Djordjevic, V. Mandic, L. Rakicevic, D. Mikovic, D. Radojkovic PP-WE-380 HAEMOLYTIC URAEMIC SYNDROME (HUS) WITHIN TWO HOURS POSTPARTUM M. M. Tea* (AT), R. Kroiss, D. Bikas, T. Wagner PP-WE-381 VIRAL INFECTIONS, INFLAMMATION, PATHOLOGY OF HEMOSTASIS AND PLACENTAL FAILURE N. V. Dolgushina* (RU), A. Makatsaria PP-WE-382 ROLE OF ACTIVATED RECOMBINANT FACTOR VII IN MASSIVE POSTPARTUM HEMORRHAGE N. Hossain* (PK), T. Shamsi, S. Haider, N. Khan, E. Triche, C. Lockwood, M. Paidas PP-WE-383 GESTATION AGE SPECIFIC REFERENCE INTERVALS FOR COAGULATION TESTS DURING UNCOMPLICATED PREGNANCY DELIVERY AND EARLY POSTPARTUM PERIOD P. B. Szecsi* (DK), M. Jørgensen, A. Klajnbard, N. P. Colov, M. R. Andersen, A. Barfoed, K. Haahr, B. Bjørngaard, S. Stender

Animal and Experimental Models II

PP-WE-384 IMMUNOLOGICAL CHARACTERIZATION AND ANALYSIS OF SEQUENCE ALIGNMENT OF THE COAGULATION PROTEINS IN PRIMATES AND PIGS C. Bulato* (IT), C. Radu, G. Cozza, M. Boldrin, L. Spiezia, S. Gavasso, E. Cozzi, P. Simioni PP-WE-385 INCREASED ANTITHROMBOTIC AND BLEEDING EFFECTS OF CONTAMINATED HEPARINS; HEMATOLOGICAL IMPLICATIONS E. Litinas* (US), C. Adiguzel, W. Jeske, D. Hoppensteadt, H. Messmore, J. Walenga, J. Fareed

266 PW-8 H OEO H W 1DMI NMRN OESO T ANDHEMOSTASIS THEROLEOFVWF A1 DOMAININMURINEMODELSOFTTP PP-WE-389 DISTRIBUTION OF IDRAPARINUX AND IDRABIOTAPARINUX INRATS BODY PP-WE-388 PP-WE-387 OF DOGMODEL EVALUATION OFBOTH ANTI- AND PRO-THROMBOTICEFFECTSIN A PP-WE-386 POSTER PRESENTATIONS PW-0 EETO FCNN OTDPAEESB THREECOLORFLOWCYTOMETRY DETECTIONOFCANINECOATED PLATELETS BY PP-WE-401 FACTOR XaINHIBITOR, IN ORAL NOVEL ANTITHROMBOTIC PROFILESOFTAK-442, A PP-WE-400 EFFECTSOF ACTIVATED RECOMBINANTFACTOR VII(RFVIIa)ONCOAGULATION PP-WE-399 PP-WE-398 PP-WE-397 ACTIVETHROMBIN NEWORALLY ANTITHROMBOTICPROPERTIESOFS35972, A PP-WE-396 CONTAIN ANTIBODIES THAT SPECIMENSMAY FALSE-POSITIVE HIT-ELISA PP-WE-395 LIMITCLOT GROWING?-FIBRINPOLYMERIZATION MAY DOTHROMBISTOP WHY PP-WE-394 PP-WE-393 PORCINEMODEL HEPARINS IN A OFORAL ANTITHROMBOTIC ACTIVITY PP-WE-392 ERYTHROCYTE HEMOLYSIS AND HEMOGLOBINOXIDATION PROMOTEFERRIC PP-WE-391 COMPARISON OFTHE ANTITHROMBOTIC AND BLEEDINGEFFECTSOFTHEDIRECT PP-WE-390 ENSA,JL 5 2009 WEDNESDAY, JULY 15, VENOUS PARAMETERS INHEMORRHAGED ACIDOTIC AND PHCORRECTEDSWINE ENOXAPARINS FIBRIN CLOTFORMATION DIFFERSINTHEPRESENCEOFBRANDED AND GENERIC THROMBOSIS,MODIFIEDFOLTS MODEL ARTERIAL PLA DIRECTFACTOR XaINHIBITOR, AND FONDAPARINUXEFFECTS OFTAK-442, ON A THE PREVENTIONOFEXPERIMENT INHIBITOR RECOGNIZE NON-SPECIFICHEP GROWTH TRANSPORT OFHEP CHLORIDE INDUCEDVASCULAR INJURY IN RATS THROMBIN INHIBITOR, DABIGATRAN, WITHENOXAPARIN, HEPARIN AND WARFARIN ACTIVE TRANSPORT T Kubo, M.Kawamura N. Konishi*(JP),K.Hiroe,E.Shinozawa, K.Shofuda,Matsuda, Y. Imaeda, T. Fujimoto,K. M. A. Dubick*(US),D.N.Darlington,M.R.Scherer, W. Z.Martini,B.S.Kheirabadi N. Konishi,H.Katsuhiko, Y. Imaeda, T. Fujimoto,K.Kubo,M.Kawamura*(US) M. Grigorjeva*(RU), T. Obergan M. O.V M. Prechel*(US),V. Escalante,J.M.Walenga M. Kamocka*(US),Z.Xu,J.Mu,X.Liu, Alber, D. Chen, E.D.Rosen B. Moazed,L.M.Hiebert*(CA) L. M.Hiebert*(CA), K. J.Woollard* (AU),S.Sturgeon, J.Chin-Dusting,H.Salem,S.P. Jackson J. vanRyn*(DE),I.Kuritsch,M.Kink-Eiband,H.Priepke,W. Wienen J. Y. Barr*(US),D.G.Motto J. Herault*(FR),F. Hurbin,M.Pasdelou,B.Remandet, Trellu J. M.W J. Björkman*(SE), RATS INFLUENCE OFPRO-GLY-PRO-ARG . Knudsen*(DK),M. Kjalke,M. Tranholm, A. L. Jensen, A. T. Kristensen TELET allez* (FR),P alenga* (US),C. Adiguzel, O.Iqbal,D.Hoppensteadt,J.Cunanan,M.Bakhos AND -ASSOCIA ARTERIAL A. Bulhak,H.Zachrisson T . Gloanec,G.deNanteuil, . Ping,S.M.W TED PROTHROMBINASEINTHEBALLOONINJURED ARINS ACROSS RAT GASTRICMUCOSA:DOESITDEPENDON THROMBOSIS MODELS ARIN-BOUND CA ice AL THROMBUS FORMATION UNDERTHE A. Rupin, TIONIC PEPTIDES T. J.Verbeuren ARTER Y OF 267

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-402 EFFECTS OF SHORT-TERM GLUCOCORTICOIDS ON VON WILLEBRAND FACTOR IN MICE. PRELIMINARY RESULTS V. A. Zapata* (AR), A. C. Kempfer, J. H. Paiva Palomino, O. G. Astudillo, H. Costa, M. A. Lazzari, A. Sánchez Luceros

Clinical Trials II

PP-WE-403 A RANDOMIZED, PROSPECTIVE, OPEN-LABEL STUDY ON DISTAL VEIN THROMBOSIS (LOW-MOLECULAR-WEIGHT HEPARIN VERSUS WARFARIN FOR SIX WEEKS): THE TODI STUDY A. Ghirarduzzi* (IT), G. Camporese, S. Siragusa, D. Imberti, E. Bucherini, F. Landini, W. Ageno, P. Prandoni PP-WE-404 POOLED ANALYSIS OF FOUR RIVAROXABAN STUDIES: NSAIDS, ASA AND PLATELET INHIBITORS B. I. Eriksson* (SE), A. G. G. Turpie, M. R. Lassen, A. K. Kakkar, M. Gent PP-WE-405 A POOLED EFFICACY AND SAFETY ANALYSIS OF THE USE OF ANTITHROMBIN (RECOMBINANT) IN HEREDITARY AT DEFICIENT PATIENTS IN HIGH-RISK SITUATIONS C. Tait* (UK), M. J. Paidas, J. Frieling PP-WE-406 LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS) FOR PROPHYLAXIS OF VTE IN PATIENTS WITH SEVERE RENAL INSUFFICIENCY: AN ANALYSIS OF RECENT CLINICAL TRIALS E. Nutescu* (US), A. C. Spyropoulos PP-WE-407 BUNGEE JUMPING LEADS TO ACTIVATION OF COAGULATION AND VASCULAR ENDOTHELIUM E. C. Lowenberg* (NL), D. J. van Westerloo, G. Choi, A. F. de Vos, J. C. M. Meijers, T. van der Poll, M. Levi PP-WE-408 SMOKING INDUCES AN EPIGENETIC MODIFICATION OF PLATELET SEROTONIN CATABOLISM F. Rendu* (FR), M. Del Pino, G. Chironi, J. Callebert, K. Peoc’H, A. Simon, J. Launay PP-WE-409 VENOUS THROMBOEMBOLISM PROPHYLAXIS GUIDELINE IMPLEMENTATION IS IMPROVED BY A DEDICATED NURSE PRACTITIONER IN MEDICAL PATIENTS H. Gibbs* (AU), J. Fletcher, P. Blombery, R. Collins, T. Glennane PP-WE-410 FONDAPARINUX 2.5 MG FOR THE TREATMENT OF SYMPTOMATIC, ISOLATED SUPERFICIAL THROMBOPHLEBITIS (ST): PRELIMINARY DATA FROM THE RANDOMIZED PLACEBO-CONTROLLED CALISTO TRIAL (ON BEHALF OF THE CALISTO INVESTIGATORS H. Décousus* (FR), A. Leizorovicz, P. Prandoni PP-WE-411 DETERMINATION OF PT-INR BY NEW PORTABLE DEVICE (COAGUCHECK XS H. Iwahashi* (JP), T. Tashiro, N. Morishige, K. Tacheuchi, M. Nishimi, Y. Hayashida, N. Ito, G. Kuwahara PP-WE-412 IMPROVING ANTICOAGULATION CONTROL IN HOSPITALIZED ELDERLY PATIENTS ON WARFARIN I. Gouin-Thibault* (FR), C. Levy, E. Pautas, J. Cambus, L. Drouet, I. Mahé, C. Bal Dit Sollier, M. Horellou, J. Golmard, V. Siguret PP-WE-413 NO INTERACTION OF IDRAPARINUX AND ASPIRIN WHEN CO-ADMINISTERED TO HEALTHY SUBJECTS I. Paty* (FR), M. Trellu PP-WE-414 COMBINED USE OF D-DIMER AND THE EXHALED CO2/O2 EXCLUDE PULMONARY EMBOLISM J. A. Kline* (US), D. M. Courtney, C. D. Miller, H. A. Smithline, R. Lanier, M. M. Hogg 268 PW-1 CUAYADPEIINO NAI E EEAINO POINTOF NEWGENERATION OF A ANDPRECISIONOFINRATIO 2- A ACCURACY PP-WE-417 PP-WE-416 OFBEMIPARIN AFTER MULTIPLE PHARMACOKINETICS AND SAFETY PP-WE-415 POSTER PRESENTATIONS PW-2 UVYO URN AAEETO SLTDDSA EPVEIN DEEP OFCURRENTMANAGEMENTISOLATED DISTAL SURVEY PP-WE-427 MONITORING OFHEPARINEMY LABORATORY PP-WE-426 PP-WE-425 VEINTHROMBOSISMANAGEMENTINCANDIDATES FORLIVER PORTAL PP-WE-424 SINGLE ADMINISTRATION OFIDRABIOTAPARINUX HASNOEFFECTONDIGOXIN PP-WE-423 OF POLYUNSATURATED ACIDS,VITAMIN E, AND COENZYMEQ10INTHERAPY FATTY PP-WE-422 POOLED ANALYSIS FUNCTIONIN A EFFECTSOF AGE, WEIGHT, GENDER AND RENAL PP-WE-421 PP-WE-420 DURINGTHEFIRSTTHREEMONTHS AFTER DECREASINGWARFARIN SENSITIVITY PP-WE-419 STRONGPREDICTOR FORFUTURE PLATELET COX-2EXPRESSIONIS A PP-WE-418 ENSA,JL 5 2009 WEDNESDAY, JULY 15, THROMBOSIS WITH DIC CARE COAGULOMETER UNDERGOINGPCI INPATIENTS WITHSTABLE ANGINA PHASE 1STUDY MULTIPLE DOSE ANTI-THROMBOTIC:FIRSTRESULTS OF A NOVEL ALX-0081 A HEAL PROPHYLACTIC AND SINGLETHERAPEUTICDOSESIN YOUNG AND ELDERLY AND EMBOLISM(PE) VENOUSTHROMBOSIS(DVT),PULMONARY PATIENTS WITHDEEP ANTICOAGULANT IDRAPARINUX (IDRA)VS.VITAMIN K ANTAGONIST (VKA)IN CONVENIENCE OF TRANSPLANTATION (LT) PHARMACOKINETICS INHEAL METABOLIC SYNDROME OF FOURRIV INCREASED LEVELSOFPLA HEART VALVE SURGERY: IMPLICATIONS FORDOSING CARDIOVASCULAR SYNDROME EVENTSINPATIENTS WITH ACUTE CORONARY N. Blest,R.Fitridge,S.J.McRae*(AU) Useini, I.Nikoloska R. M. H.Prins*(NL),P. Leguet,H. Gilet,B. Arnould M. M. Trellu* (FR),S.Cartot-Cotton, D.Ibghi,I.Paty, G.Sanderink L. V. Lyutova* (RU),V. M.Panchenko,G.S.Simowchenko, A. A. Ershov, V. A. Isaev K. A. Bauer*(US), A. G. Turpie, M.R.Lassen, A. K.Kakkar, B.I.Eriksson,M.Gent K. Kawasugi*(JP),R.Shirasaki,H. K. Meijer*(CA), Y. Kim,S.Schulman K. M.Murasaki*(JP),H.Omori, A. Kobayashi, Y. Uetsuka, N.Hagiwara J. Engelsen*(DK),DalsgaardNielsen J. Holz*(BE),Bartunek,E.Barbato,K.Vercruysse, S.Pullan,G.Heyndrickxs J. Martinez-Gonzalez,M.Barbanoj S. Rico,R.M. Apostolovska* (MK),S.Kostovska,V T . Sartori*(IT),C.Ferronato,P A H VOLUNTEERS–NONEEDFORDOSE ADJUSTMENT THY TRIAL FIBRILLA AROXABAN STUDIES Antonijoan, J.Martinez-Colomer AND SATISFACTION WITHTHE NEWLONG-ACTING TION (AF TELET H SUBJECTS THY . Boccagni,D.Gasparini,U.Cillo,M.Senzolo T ashiro, N.Shirafuji,C.Shimazu, Y. Miyazawa -DERIVED MICROP . Dejanova,V , M.Borrell,J.Fontcuberta*(ES),Monreal, . Neceva, T. Balkanov, S. Atanasova, S. ARTICLES INSEPTICPATIENTS 269

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

Patient Education and Knowledge Transfer

PP-WE-428 SURVEY ON PHYSICIANS’ ADHERENCE TO DEEP VENOUS THROMBOSIS PROPHYLAXIS GUIDELINES IN A TERTIARY HOSPITAL G. V. Alemany* (PH), C. C. Budhrani, A. P. Bautista, E. B. Madronio, E. C. Santos PP-WE-429 BARRIERS TO AND POTENTIAL SOLUTIONS TOWARD OPTIMAL PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS FOR HOSPITALIZED MEDICAL PATIENTS: A SURVEY OF HEALTHCARE PROFESSIONALS N. S. Lloyd* (CA), J. D. Douketis, J. Cheng, H. J. Schunemann, D. J. Cook, L. Thabane, M. Pai, F. A. Spencer, R. Haynes PP-WE-430 PATIENTS AT HIGHEST RISK FOR VENOUS THROMBOEMBOLISM ARE NOT RECEIVING SPECIFIC DISCHARGE INSTRUCTIONS WARNING FOR SIGNS AND SYMPTOMS OF VTE: A DOUBLE SETBACK O. Dabbagh* (US), W. A. Parker, M. A. Philpot, M. B. Keegan, J. P. Bosanquet PP-WE-431 DEVELOPMENT OF FACTOR V LEIDEN BROCHURE R. E. Goldsmith* (CA), A. K. C. Chan, W. M. Seroski, L. Wizowski PP-WE-432 AN EXPLORATION OF THE LIVED EXPERIENCES OF PATIENTS LIVING WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA V. Ragoonanan* (UK) PP-WE-433 INFLUENCE OF PUBLIC AWARENESS ABOUT DVT SYMPTOMS AND BURDEN ON THE RATE OF CONFIRMED DVT EVENTS W. Z. Tomkowski* (PL), P. Andziak, M. Dybowska, A. Jawien, P. Kuca, K. Ziaja, G. Malek, M. Gorska PP-WE-434 SELF ADMINISTRATION OF C1-INHIBITOR-CONCENTRATE IN PATIENTS WITH HEREDITARY ANGIODEMA (HAE) W. Kreuz* (DE), E. Rusicke, I. Martinez-Saguer, C. Heller, E. Aygören-Pürsün, T. Klingebiel

Pediatric Thrombosis II

PP-WE-435 ASSOCIATION BETWEEN C-REACTIVE PROTEIN AND ARTERIAL ISCHEMIC STROKE IN CHILDREN D. Coen Herak* (HR), M. Milos, J. Lenicek Krleza, R. Zrinski Topic, S. Dodig, V. Duranovic, R. Zadro PP-WE-436 D-DIMER CONCENTRATIONS IN UMBILICAL CORD BLOOD OF NORMAL NEONATES E. Grau* (ES), P. Correcher, J. Tenias, R. Garcia, M. Santos, E. Monteagudo, F. Calvo PP-WE-437 DO BOLUS DOSES OF UFH CONTRIBUTE TO INCREASED BLEEDING RISKS IN CHILDREN F. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, P. Monagle PP-WE-438 UNFRACTIONATED HEPARIN HAS AN AGE-DEPENDENT PHARMACOKINETIC PROFILE IN CHILDREN F. H. Newall* (AU), V. Ignjatovic, L. Johnston, G. Lane, R. Summerhayes, N. Cranswick, P. Monagle PP-WE-439 THE ROLE OF THROMBIN GENERATION IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE H. Bernhard* (AT), A. Deutschmann, B. Leschnik, M. Novak, A. Hauer, H. Haidl, A. Rosenkranz, W. Muntean PP-WE-440 PRESUMED PERINATAL ISCHAEMIC STROKE H. Platokouki* (GR), H. Pergantou, A. Komitopoulou, P. Xafaki, S. Aronis

270 PW-4 EVALUATION OFVONWILLEBRANDFACTOR AND ADAMTS13 INCHILDRENWITH PP-WE-444 SINUSVENOUS THROMBOSISINPAEDIATRIC ACUTE LYMPHOBLASTIC CEREBRAL PP-WE-443 PP-WE-442 VEINTHROMBOSISWITHCONTINUOUSINTRAVENOUS TREATMENT OFDEEP PP-WE-441 POSTER PRESENTATIONS PP-WE-453 ADMINISTRATION OF ANTITHROMBIN CONCENTRATE AND EFFECTON PP-WE-452 PP-WE-451 ANAESTHETICMAXILENEONENOXAPARIN THEEFFECTOFTOPICAL PP-WE-450 LACKOF ASSOCIATION OFPROTHROMBIN20112A, FACTOR VLEIDEN,LP(A)OR PP-WE-449 COMPARISON OFHEMOCLOTTO STANDARD COAGULATION ASSAYS FOR PP-WE-448 THEIMPACT OFPROPHYLACTICCRYOPRECIPITATE AND FRESHFROZENPLASMA PP-WE-447 THROMBOSESIN ARTERIAL ADVERSEOUTCOMESFOLLOWINGNON-CEREBRAL PP-WE-446 SYSTEMATIC LITERATURE REVIEWOFILIACVEINCOMPRESSIONSYNDROMEIN PP-WE-445 ENSA,JL 5 2009 WEDNESDAY, JULY 15, MANAGEMENT OFSUBCUT ANTICOAGULA SEVERE PROTEINCDEFICIENCY L DURINGINDUCTIONTHERAPY ALL SINGLE CENTRE EXPERIENCE LEUKAEMIA: A CASEREPORT MULTIPLE PROTHROMBOTICRISKFACTORS - A WITH FAMILY ANDHYPOFIBRINOLYSIS IN A THROMBOPHILIA HEREDITARY INFUSION OFLMWHINCHILDREN– AN UPDATE DEVELOPMENT PEAK ANTI-Xa LEVELS METABOLISM AS MEASUREDBY OF CONGENIT FORCORRECTION VIII:C WITHTHROMBOSISINCHILDRENUNDERGOINGSURGERY P MONITORING THEDIRECT THROMBININHIBITOR (DABIGATRAN) INPEDIATRIC L ON THEINCIDENCEOFCNSTHROMBOSESINCHILDRENWITH ACUTE NEONA PEDIATRIC PATIENTS ANTICOAGULATED CHILDREN FOR HANDOUT AND PERFORMANCE EVALUATION TOOL EDUCATIONAL Nowak-Göttl, M.Sigl-Kraetzig,K.Kurnik M. Olivieri*(DE),C.Bidlingmaier, W. Behnisch,I.Engelsberger, A. Kienast, A. Krümpel,U. M. E.Bauman*(CA),L.Bauman, K. L.Black,Bajzar M. E.Bauman*(CA),G.Mack, M. E.Bauman*(CA),S.Duncan,L.Ray L. G.Mitchell*(CA),K.Dietrich,I.Rebeyka,D.Ross,S.Qayyum L. G.Mitchell*(CA),K.Dietrich,Stang,W. Etches,S.Qayyum Fitzgerald, D.Dix,J.N.Berman V. Price,L.S. Abbott* (CA),M.Deveeska,D.R.Barnard,C.V. Fernandez,M. Yhap, C. J. Franco,S.Williams,G.Chaudry, B.Connonly, D.Castle,L.R.Brandao*(CA) B. H.L. Tam, A. K.Chan,S.Williams,L.Brandao*(CA) F. Chamone J. D. A. Carneiro*(BR),E. A. D’Amico, T. R.F. Rocha,C.S. S.Silva,V. Odone-Filho,D. A. J. D.Robertson*(AU),C.Ryan,Castle,S.Williams,L.Brandao J. LenicekKrleza*(HR),G.Jakovljevic,D.CoenHerak, J. Blatny*(CZ),V YMPHOBLASTIC LEUKEMIA A TIENTS: TES: AN INVITROSTUDY A AL CASE-SERIES REPORT TION . Fiamoli AND V HEART DISEASE ALIDA ANEOUS PROTEINCSUBSTITUTION INCHILDRENWITH TION OF A. Bruce,K.L.Black,M.P (ALL) RECEIVING , L.Bajzar A OPEETR ALTERNATIVECOMPLEMENTARY MEDICINE , S.Kuhle,M.P ASP ARAGINASE A. Bronic,R.Zadro,M.Nakic . Massicotte , M.P. Massicotte . Massicotte 271

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-454 POOLED ANALYSIS OF TWO RANDOMIZED STUDIES COMPARING FONDAPARINUX 2.5MG AND ENOXAPARIN 40MG FOR PREVENTING VENOUS THROMBOEMBOLISM (VTE) IN HIP SURGERY USING NEW STUDY ENDPOINTS M. R. Lassen* (DK) PP-WE-455 THROMBOTIC RISK IN THALASSEMIC PATIENTS N. Dhouib, N. Ben Romdhane* (TN), F. Mallouli, S. Mahjoub, H. Kallel, R. Ellouze, M. Bejaoui PP-WE-456 STUDY OF INHERITED AND ACQUIRED PROTHROMBOTIC RISK FACTORS IN PEDIATRIC PATIENTS WITH THROMBOSIS J. Ahluwalia, S. Naseem* (IN), R. Das, P. Singhi, B. Thapa, S. Singh, N. Varma

Post-thrombotic Syndrome

PP-WE-457 INCIDENCE OF PTS AFTER INDIVIDUALLY TAILORED DURATION OF ELASTIC COMPRESSION THERAPY A. J. ten Cate-Hoek* (NL), H. ten Cate, J. Tordoir, K. Hamulyák, M. H. Prins PP-WE-458 VENOUS THROMBOSIS RISK FACTORS ARE ASSOCIATED WITH RISK OF VENOUS INSUFFICIENCY M. Cushman* (US), P. W. Callas, M. H. Criqui, J. O. Denenberg, E. G. Bovill PP-WE-459 FREQUENCY OF HEREDITARY THROMBOPHILIC RISK FACTORS IN IRANIAN PATIENTS WITH DEEP VEIN THROMBOSIS M. Karimi* (IR), M. Yavarian, M. Ramzi, M. Zakernia, M. Dehgani, A. Afrasiabi, H. Nourani Khojaste PP-WE-460 THROMBOPHILIA DOES NOT INCREASE THE RISK OF THE POST-THROMBOTIC SYNDROME. A PROSPECTIVE COHORT STUDY L. Spiezia, E. Campello, E. Giolo, D. Tormene, P. Simioni, S. Villalta, P. Prandoni* (IT) PP-WE-461 MEASUREMENT PROPERTIES OF THE VILLALTA SCALE TO DEFINE AND CLASSIFY THE SEVERITY OF THE POST-THROMBOTIC SYNDROME S. R. Kahn* (CA) PP-WE-462 FEASIBILITY OF RECRUITMENT AND RETENTION IN AN UNBLINDED RANDOMIZED CONTROLLED TRIAL OF EXERCISE TRAINING FOR THE POST-THROMBOTIC SYNDROME S. R. Kahn* (CA), A. Houweling, S. Shapiro, A. Muladzanov, I. Shrier, A. M. Hirsch, R. Reid, C. Kearon, M. A. Rodger, M. J. Kovacs, D. Anderson, P. S. Wells PP-WE-463 INCREASED CALF MUSCLE DEOXYGENATION DURING LIGHT-INTENSITY EXERCISE SUGGESTS INCREASED VENOUS REFLUX FLOW IN ADVANCED HUMAN CHRONIC VENOUS DISEASE T. Yamaki* (JP), M. Nozaki, H. Sakurai, K. Soejima, A. Hamahata, K. Kim

Health Service and Outcomes II

PP-WE-464 USE OF WARFARIN AND DRUGS WITH POTENTIAL INTERACTION IN A HEALTH MAINTENANCE ORGANIZATION (HMO) FROM CÓRDOBA, ARGENTINA A. H. Tabares* (AR), A. I. Casanegra PP-WE-465 APPROPRIATE VTE PROPHYLAXIS, COMPARED WITH PARTIAL VTE PROPHYLAXIS, LEADS TO LOWER VTE RECURRENCE AND COST IN US MEDICAL PATIENTS A. N. Amin* (US), M. Hussein, D. Battleman, J. Lin, S. Stemkowski, G. J. Merli PP-WE-466 REAL-WORLD EFFECTIVENESS OF ANTITHROMBOTIC AGENTS FOR INTPATIENT TREATMENT OF VENOUS THROMBOEMBOLISM A. F. Shorr* (US), M. M. Bonafede, B. H. Johnson, R. V. Horblyuk

272 PW-6 OTEFCIEESO AIARNEEIAE10GI AAAFORTHE COST-EFFECTIVENESS OFDABIGATRAN ETEXILATE 150MGINCANADA PP-WE-469 SCREENINGPANELS: AN APPARENT OVERUTILIZATION OFTHROMBOPHILIA PP-WE-468 LARGENATIONWIDE ADMISSIONSFROM A CHARACTERISTICSOFHOSPITAL PP-WE-467 POSTER PRESENTATIONS PW-7 EA DYSFUNCTIONINOLDERPATIENTS IS ASSOCIATED WITHREDUCED RENAL PP-WE-479 IMPACT OFVENOUSTHROMBOEMOLISMINUSMEDICARE PATIENTS UNDERGOING PP-WE-478 PP-WE-477 PP-WE-476 TREATMENT PERIOD INTHEINITIAL OF ANTICOAGULANT THERAPY THEQUALITY PP-WE-475 PP-WE-474 COST-EFFECTIVENESS OFRIVAROXABAN FORPREVENTIONOFVENOUS PP-WE-473 PP-WE-472 FORTHEPRIMARY COST-EFFECTIVENESS OFDABIGATRAN ETEXILATE IN CANADA PP-WE-471 FORTHEPRIMARY COST-EFFECTIVENESS OFDABIGATRAN ETEXILATE INCANADA PP-WE-470 ENSA,JL 5 2009 WEDNESDAY, JULY 15, RETROSPECTIVE CHARTREVIEW OF 2,138P WARFARIN MAINTENANCEDOSE AND DECREASED ANTIOCOAGULATION STABILITY KNEEREPLACEMENTSURGERY AND TOTAL HIP TOTAL FUNCTION THAT HAVE MODERATE IMPAIRMENT ARTHROPLASTY OFRENAL KNEE ORHIP PREVENTION OFVENOUSTHROMBOEMBOLISMINPATIENTS UNDERGOINGTOTAL CENTER ANAL PREV EMBOLISMPATIENTS INTHEUNITEDSTATES:SAMPLE OFPULMONARY THROMBOPROPHYLAXIS WITHDAL ANTICOAGULATION CLINICINBRAZIL UNIVERSITY PORTABLE MONITOR OFPROTHROMBINTIMEIN A PERFORMANCE OF A OF P ANALYZER NEWHIGHTHROUGHPUTHEMOSTASIS EVALUATION OFCLOTTINGTESTSUSING A IN THEUS ORKNEEREPLACEMENT(THR,TKR) HIP THROMBOEMBOLISM (VTE) AFTER TOTAL SWEDEN ECONOMIC COMPARISON OFRIVAROXABAN WITHENOXAPARIN INTHEUK AND PREVENTION OFVENOUSTHROMBOEMBOLISM(VTE)INP REPLACEMENTSURGERY HIP PREVENTION OFVENOUSTHROMBOEMBOLISMINPATIENTS UNDERGOINGTOTAL OA NERPAEETSREY(TKR) KNEEREPLACEMENTSURGERY TOTAL P. Whittaker* (US),C.L.Garwood,M.E.Kleinow, K.Curtis,J.L.Clemente O. Baser*(US),D.Supina,N.Sengupta, L.Wang, L.M.Kwong M. Snyder*(US) Bizzacchi M. Fiusa,S.Pereira*(BR),E.V. dePaula,F. A. Orsi,S.Custodio,J.M. Annichino- Schutgens, D.H.Biesma M. J. Agterof* (NL),E.R.van Bladel,B.Frijling,R.vanderGriend,M.H.Prins,E.G. M. McInerney*(IE),N.Kelly, E.Kearney, J.Landowska,Grace L. Kwong*(US), L. Ryttberg*(SE),I.Bjorholt, A. Diamantopoulos,L.Gilmour, M.Lees C. Bradley-Kennedy, S.E.Wolowacz, N.S.Roskell,J.M.Plumb*(DE) C. Bradley-Kennedy, S.E.Wolowacz, N.S.Roskell,J.M.Plumb*(DE) C. Bradley-Kennedy, S.E.Wolowacz, N.S.Roskell, A. Clemens,J.M.Plumb*(DE) K. P. Patel,J.Somma,H.Rose,I.Sussman,Rand*(US) D. M.Courtney*(US),R.K.Khare A ALENCE, OUTCOME, AND CHARGES YSIS OFPHYSICIANORDERINGPATTERNS AT AN URBAN ACADEMIC MEDICAL TIENTS WITHPULMONAR A. Duran, A. Diamantopoulos,N.Sengupta,M.Lees EMBOLISM Y TEPARIN INBARIATRIC SURGERY: A ATIENTS A TIENTS UNDERGOING 273

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-480 DEVELOPMENTAL DIFFERENCES IN PROCOAGULANT PHOSHOLIPID/MICROPARTICLE CONCENTRATION R. Summerhayes* (AU), V. Ignjatovic, P. Monagle

Cancer and Thrombosis II

PP-WE-481 AVE5026: A NEW HEMISYNTHETIC ULTRA LOW MOLECULAR WEIGHT HEPARIN WITH ENRICHED ANTI-Xa ACTIVITY AND ENHANCED ANTITHROMBOTIC ACTIVITY FOR MANAGEMENT OF CANCER ASSOCIATED THROMBOSIS A. Gray* (US), D. Hoppensteadt, W. Jeske, J. M. Walenga, J. Fareed PP-WE-482 UPREGULATION OF PROCALCITONIN IN CANCER PATIENTS WITH VENOUS THROMBOSIS D. Hoppensteadt* (US), O. Iqbal, C. Adiguzel, J. Cunanan, J. Fareed PP-WE-483 STANDARDS, OPTIONS : RECOMMENDATIONS 2008 THROMBOEMBOLIC EVENTS TREATMENT IN CANCER PATIENTS D. Farge Bancel* (FR), L. Bosquet, P. Mismetti, I. Mahe, F. Cajfinger, H. Desmurs Clavel, G. Meyer, C. Grange, H. Hocini, J. Renaudin, H. Levesque, P. Debourdeau PP-WE-484 PROTEIN C PATHWAY VALUES, HOMOCYSTEINE AND ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOPROLIFERATIVE DISORDERS E. Papadakis* (GR), S. Efraimidou, K. Loukidhs, K. Kokoviadou, M. Speletas, I. Korantzis, M. Sion PP-WE-485 ROLE OF TISSUE FACTOR (TF) IN LEUKEMIA-ASSOCIATED COAGULATION ACTIVATION AND VEGF EXPRESSION B. Spath, A. Amirkhosravi, J. L. Francis, C. Bokemeyer, B. Eifrig, F. Langer* (DE) PP-WE-486 INCREASED ACQUIRED ACTIVATED PROTEIN C RESISTANCE IN UNSELECTED PATIENTS WITH HEMATOLOGIC MALIGNANCIES H. F. S. Negaard* (NO), P. O. Iversen, B. Østenstad, M. Mowinckel, P. M. Sandset PP-WE-487 REGULATORS OF EXTRACELLULAR MATRIX TURNOVER ARE NOT STRONGLY CORRELATED WITH HEMOSTATIC PARAMETERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES H. F. S. Negaard* (NO), K. Svennevig, S. O. Kolset, P. O. Iversen, B. Østenstad, N. Iversen, P. M. Sandset PP-WE-488 SUCCESSFUL THERAPY OF AN EXTENSIVE VENA CAVA SUPERIOR THROMBOSIS WITH INTRAVENOUS LOW MOLECULAR WEIGHT HEPARIN (DALTEPARIN) H. Schinzel* (DE), S. Schadmand-Fischer, T. Achenbach, D. Peetz, K. Fruth PP-WE-489 APIXABAN IN PATIENTS WITH METASTATIC CANCER: A RANDOMIZED PHASE II FEASIBILITY STUDY H. Liebman* (US), M. N. Levine, D. Deitchman, J. Julian, C. P. Escalante, M. C. O’Brien, L. M. Ramirez, L. Weise-Kelly, S. Solymoss PP-WE-490 ALTERATION OF THE LMWHS INHIBITORY EFFECT ON THROMBIN GENERATION BY DIFFERENT HISTOLOGICAL TYPES OF CANCER CELLS. AN IN VITRO STUDY V. Galea, M. Mbemba, A. Khaterchi, C. Prengel, J. Bernaudin, M. Hatmi, I. Elalamy* (FR), G. T. Gerotziafas PP-WE-491 PROTEIN C, THROMBOMODULIN AND ENDOTHELIAL PROTEIN C RECEPTOR IN ACUTE MYELOBLASTIC LEUKAEMIA M. Galar, J. Sokolowski, K. Mazgajska-Barczyk, J. Kloczko* (PL) PP-WE-492 PROTEIN Z IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA J. Oleksiuk, E. Luksza, J. Kloczko* (PL), M. Galar

274 PW-9 YECAUAINI AINNYLCLZDB THROMBOELASTOGRAPHY LOCALIZEDBY HYPERCOAGULATION INMALIGNANCY PP-WE-495 PP-WE-494 PROCOAGULANTPROPERTIESOFCANCERCELLS PP-WE-493 POSTER PRESENTATIONS PP-WE-506 PP-WE-505 PP-WE-504 SPLANCHNICTHROMBOSISINCANCERPATIENTS INCIDENTAL PP-WE-503 INHIBITSTISSUEFACTOR EXPRESSIONINHUMANCANCER AND EPOPROSTENOL PP-WE-502 ANTINEOPLASTICDRUGSFORMULTIPLE ACTIVATION OFCOAGULATION BY PP-WE-501 EVALUATING RISKFORRECURRENTVENOUSTHROMBOEMBOLISM(VTE) PP-WE-500 PP-WE-499 PP-WE-498 MICROPARTICLE-ASSOCIATED TISSUEFACTOR ACTIVITY, VENOUS PP-WE-497 VENOUSTHROMBOEMBOLISMINGASTRICCANCER:INCIDENCE AND CLINICAL PP-WE-496 ENSA,JL 5 2009 WEDNESDAY, JULY 15, OF POTENTHEPARANASE INHIBITORS DEVELOPMENT OF THROMBOSIS INCANCERP PREDICTOR OF USEFUL CLINICALLY SOLUBLEFIBRINLEVEL, A PLASMA ANALYSIS CANCER PATIENTS INTERVENTION STUDIES PHASEOFCOAGULATION TO THEHUMORAL ANDCANCER IMMUNOTHERAPY AND DIAPEDESIS ADHERENCETO THE ROLEOFSOLUBLEFIBRININLYMPHOCYTE AND LAKCELL VENOUS THROMBOEMBOLISM(VTE)RISKSTRA TUMOR-ASSOCIATED HOSTCELLS MYELOMA ASSOCIA CHARACTERISTICSINPATIENTS WITHCANCER- ACCORDING TO MALIGNANCY (PV)PATIENTS VERA (ET) AND POLYCYTHEMIA THROMBOCYTHEMIA JAK2 V617F THROMBOTIC COMPLICA INPANCREATIC CANCERPATIENTSTHROMBOEMBOLISM AND POORSURVIVAL CHARACTERISTICS S. Alban* (DE),S.Schiemann B. J.Woodhams, J.Soria S. Mirshahi*(FR),C.Soria,J.Chidiac, R.Varin, K.Khalfi,E.Pujade-Lauraine,M.Mirshahi, S. B.Hijjawi*(JO),G.Jallad, S. M.Ramasamy*(UK),G.Bozas, Avery, A. Maraveyas Lorenzet* (IT) A. Cutrone,E.Napoleone,G.Colavecchia,W M. Nishio*(JP), A. Hoshi,J. Chung, A. Matsumoto, T. Koyama M. L.Louzada*(CA),H.Majeed,V M. Marchetti*(IT),E.Castoldi,L.Russo, A. Vignoli, J.Rosing,H.tenCate, A. Falanga V Osanto M. E. T. Tesselaar* (NL),F. Romijn,P. Garcia-Rodrigues,I.vanderLinden, R.Bertina,S. K. Lee*(KR),S.Bang, Y. Kim,J.H.D.Park,Lee Puttarajappa K. A. Schwartz*(US),S.Nagpal,E. A. Faber, D.Estrada,Schwartz, A. Cziffer, C. J. P J. C.Bordet*(FR),K.Villaume, J. Y. Scoazec,C.Negrier M. B.Donati*(IT) . Caruso, . Biggerstaff* (US),B.L.Weidow TED-THROMBOSIS: A. diCastelnuovo,V. C.Lein,G.deGaetano,M. A. Lazzari,S.Storti,L.Iacoviello, ALLELE BURDEN COSEDTEILCELLS:IMPLICATIONS FOR ACROSS ENDOTHELIAL A NOVEL TIONS IN A A TIENTS HEP AND HEMOST YTMTCRVE FOSRAINLAND SYSTEMATIC REVIEWOFOBSERVATIONAL A. ARANASE ACTIVITY ASSAY AND IDENTIFICATION AND ASSAY ARANASE ACTIVITY Ababneh, H.N. Abdel-Razeq ADUL . V. D.Dao,P. P. W. Wells T PATIENTS META- WITHLYMPHOMA: A . Zamboni,G.deGaetano,M.B.Donati,R. A TIC PROFILEOFESSENTIAL TIFICA TION INHOSPITALIZED 275

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-507 PRODUCTION OF VWF MAY MEDIATE LYMPHOBLAST INDUCED THROMBIN ACTIVATION IN CHILDREN WITH NEWLY DIAGNOSED ALL U. Athale* (CA), A. Moghrabi, T. Nayiger, D. Yves-Line, L. Thabane, A. Chan

Venous Thrombosis: Diagnosis II

PP-WE-508 IS COCKADE DEEP VEIN THROMBOSIS OF THE LOWER LIMBS ASSOCIATED WITH AN INCREASED FIBRINOLYTIC POTENTIAL A. Delluc* (FR), A. Rousseau, P. Quehe, G. Le Gal, K. Lacut, E. Oger, P. vanDreden, D. Mottier, L. Bressollette PP-WE-509 D-DIMER (DD) LEVELS AT DIAGNOSIS IN RELATION TO THE SITE AND EXTENSION OF LEG DEEP VEIN THROMBOSIS (DVT) C. Legnani* (IT), M. Cini, K. Cavallaroni, G. Rodorigo, S. Cavazza, L. Valdrè, A. Amato, G. Palareti PP-WE-510 VALIDITY OF ANGULAR SUM AS PLANAR EXTRACTION TECHNIQUE OF LUNG VENTILATION-PERFUSION SPECT DATA P. Cambefort, A. Le Duc-Pennec, P. Guillo, F. Couturaud, S. Querellou, R. Abgral, G. Le Gal* (FR), D. Mottier, C. Leroyer, P. Salaun PP-WE-511 ILEO-FEMORAL THROMBOSIS IN A PATIENT WITH ELEVATED HOMOCYSTEINE DUE TO THREE POLYMORPHISMS IN THE MTHFR GENE H. A. Guglielmone* (AR), S. Minoldo, G. Jarchum PP-WE-512 SAFETY OF RULING OUT ACUTE PULMONARY EMBOLISM BY NEGATIVE CT PULMONARY ANGIOGRAPHY IN PATIENTS WITH A STRICT INDICATION FOR CT: SYSTEMATIC REVIEW AND META-ANALYSIS I. C. M. Mos* (NL), F. A. Klok, L. J. M. Kroft, A. de Roos, O. M. Dekkers, M. V. Huisman PP-WE-513 CONTRAST INDUCED NEPHROPATHY FOLLOWING CT-PULMONARY ANGIOGRAPHY FOR CLINICALLY SUSPECTED PULMONARY EMBOLISM J. Kooiman* (NL), F. A. Klok, I. C. M. Mos, J. T. Tamsma, Y. W. J. Sijpkens, M. V. Huisman PP-WE-514 CLINICAL EVALUATION OF NEW QUANTITATIVE D-DIMER ASSAYS FOR EXCLUSION OF DEEP VEIN THROMBOSIS J. L. Elf* (SE), K. Strandberg, P. J. Svensson PP-WE-515 DIAGNOSTIC PERFORMANCE OF AQT90 FLEX D-DIMER IN PATIENTS SUSPECTED FOR DEEP VENOUS THROMBOSIS - COMPARISON WITH FOUR WELL-ESTABLISHED D-DIMER TESTS J. J. Sidelmann* (DK), J. Gram, J. Jespersen PP-WE-516 DEEP VENOUS THROMBOEMBOLISM IN A PATIENT OF FACTOR V DEFICIENCY K. Nishiya* (JP), K. Nogami, Y. Kikukawa, K. Shinozawa, H. Yada, K. Fukutake, M. Shima PP-WE-517 PROTEIN C AND S LEVELS CAN BE ACCURATELY MEASURED DURING AN ACUTE VENOUS THROMBOEMBOLISM (VTE) L. Minuk, A. Lazo-Langner* (CA), M. Kovacs PP-WE-518 FREQUENCY OF FACTOR V LEIDEN AND PROTHROMBIM 20210A AS THROMBOTIC AND GENETIC RISK FACTORS FOR PREECLAMPSIA IN THE SOUTH IRANIAN PROVINCE M. Yavarian* (IR), S. Karimi, L. Ahmadian, M. Karimi PP-WE-519 EVALUATION OF PRECISION, ACCURACY AND SUITABILITY OF EDTA PLASMA FOR A NEW ROCHE D-DIMER ASSAY A. Busse Grawitz, M. Mueller, G. Honauer, H. Maier, M. Wilmer* (CH), A. Hubbuch

276 PW-2 H TLT N ESBLT FSREIGFRDE VENOUSTHROMBOSISIN OFSCREENINGFORDEEP ANDFEASIBILITY THEUTILITY PP-WE-522 PP-WE-521 OF ANDSPECIFICITY IMPROVETHESENSITIVITY FIBRINMONOMER:DOESITHELP PP-WE-520 POSTER PRESENTATIONS PW-3 NSA INTRON1INVERSIONWITHCONCOMITANT LARGE DUPLICATION WITHIN UNUSUAL PP-WE-533 PP-WE-532 PP-WE-531 SELF- A:COMPARISON OF LIMITATIONSA INHEMOPHILIA FUNCTIONAL PP-WE-530 META-ANALYSIS PATIENTS: A INHEMOPHILIA DENSITY BONEMINERAL PP-WE-529 MALEPREDOMINANCEINCHILDHOODSTROKE AND VENOUSTHROMBOEMBOLISM PP-WE-528 PP-WE-527 TO ONEMONTH ACCELERATES PROLONGATION OFENOXAPARIN THERAPY PP-WE-526 ADAPTEDTO NEWTURBIDIMETRICD-DIMER ASSAY PERFORMANCEOF A PP-WE-525 VENOUS THROMBOSISRISKFACTORS AND INCIDENCEOFJAK2V617F CEREBRAL PP-WE-524 CAREPHYSICIANSWHENREFERRING FACTORS WHICHINFLUENCEPRIMARY PP-WE-523 Hemophilia II 2009 WEDNESDAY, JULY 15, V H 8GN NASVR EOHLAAPATIENT A SEVEREHEMOPHILIA THE F8GENEIN A DETECTION OFLARGEREARRANGEMENTS BY RMR CAREPRACTICE PRIMARY THROMBOSIS VEIN RECURRENT DEEP RESULTS INTHEDIAGNOSISOFIPSILATERAL HIGH PERCENTAGE OFNON-DIAGNOSTICCOMPRESSIONULTRASONOGRAPHY FORIDENTIFICATION OFVENOUSTHROMBOEMBOLISM THE D-DIMER ASSAY AMPII A HAEMOPHILIA THROMBIN GENERA ANDJOINTROM ASSESSMENT TOOL REVISITED: THE V VEINTHROMBOSIS RECANALIZATION OFDEEP AUT MUTATION OUTPATIENT DVTSCREENINGSERVICE HOSPITAL PATIENTS TO A PATIENTS EMBOLISM OF PULMONARY M. Badoz,D.Pellechia,Fretigny N. Lannoy Monagle A. Greenway*(AU),V. Ignjatovic,R.Summerhayes,C.Barnes,J.Furmedge,Ekert,P. A. Zakarija*(US),J.Brewer M. Marcucci,G.Fabbriciani,Brozzetti, A. Iorio*(IT) Deveber R. Pesavento,G.deConti,I.Minotto,F. Maurizi,M.Mongiat, A. Pagnan,P. Prandoni*(IT) N. M.V B. Arza, T. Sánchez,L.Del Toro, M.Sales*(ES),J. Arnout M. Ko M. D.Creagh*(UK),H.Bond,S.Gupta, A. McSorley M. D.Creagh*(UK),P. Carson,S.Herbert,M.Kazi, A. McSorley M. Tan* (NL),S.I.Velthuis, C.J.vanRooden,R.E.Westerbeek, M.V. Huisman M. Johnston*(CA),E. inciguerra* (FR) OMA stál* (CZ),P. Dulís ˇ ALUE OF64-DETECT orobyeva* (RU),E.P TED COAGULOMETERS , I. Abinet, C.Lambert*(BE),Vermylen, K.Dahan,C.Hermans U. Nowak-Gottl*(DE),S.Normann,M.Fobker, C.Langer, R.Strater, G. TION AND FIBRINOLYSIS PARAMETERS INBOYSWITHSEVERE Ali, N.McEwen,S.Bates ˇ ek, J.Maly , S.Harris,D.Green . Panchenko, OR ROWCOMPUTEDT ’, D.Krajís , V . Roussel-Robert,N.Stieltjes,C.Negrier, C. A. B.Dobrovolsky ˇ ková MLP OMOGRAPHY NSVR EOHLAA INSEVEREHEMOPHILIA A , A. I.Kirienko, FOR THEDIAGNOSIS T . V. Balakhonova 277

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-534 EVALUATING THERAPY IN HEMOPHILIA: DEVELOPMENT OF AN MRI PROTOCOL I. E. M. den Uijl* (NL), A. M. A. de Schepper, D. E. Grobbee, K. Fischer PP-WE-535 PROSPECTIVE EVALUATION OF SAFETY AND EFFICACY OF RADIOSYNOVIORTHESIS WITH HYDROXYAPATITE-YTTRIUM IN CHRONIC SYNOVITIS IN HEMOPHILIA: PRELIMINARY RESULTS J. B. J. Silva* (BR), J. M. Annichino-Bizzacchi, R. G. Pagnano, H. Hong, M. A. P. Matta, A. L. A. Sambo, R. G. Roveri, E. Bortoletto, J. Mengatti, C. D. Ramos, A. O. Santos, M. C. Ozelo, E. V. de Paula PP-WE-536 ANALYSIS OF INTRON 1 AND INTRON 22 INVERSION IN FACTOR VIII GENE IN PATIENTS WITH HAEMOPHILIA A J. Wu* (CN), T. Li, J. Dai, Q. Ding, X. Wang, K. Ding, C. Zheng PP-WE-537 THE RELATIVE BURDEN OF HEMOPHILIA ON HEALTH RELATED QUALITY OF LIFE J. D. Epstein* (US), J. M. Li-McLeod, A. S. Yarlas, G. C. Hammond PP-WE-538 THE IMPACT OF TARGET JOINT DEVELOPMENT ON HEALTH RELATED QUALITY OF LIFE FOR ADULT HEMOPHILIA A PATIENTS: RESULTS FROM THE PASS STUDY J. D. Epstein* (US), J. M. Li-McLeod, A. S. Yarlas PP-WE-539 INCIDENCE OF PORT INFECTIONS IN A COHORT OF BOYS WITH HAEMOPHILIA – IMPACT OF RIGOROUS ANTISEPTIC TECHNIQUE TRAINING IN THE HOME J. Mitchell* (UK), D. Bevan, S. Rangarajan, B. Sørensen PP-WE-540 HIGHER CD4+CD25HIGH TREG CELLS IN HAEMOPHILIA PATIENTS WITH FVIII INHIBITOR K. Ding* (CN), J. Wu, T. Li, Y. Sheng PP-WE-541 LONG-TERM BLEEDING HISTORY AS A TOOL FOR HEMOPHILIA MANAGEMENT K. L. Strike, A. K. C. Chan, T. M. Almonte, K. P. Decker* (CA), R. E. Goldsmith Rn, I. Walker, M. J. Wright PP-WE-542 RESOURCE CONSUMPTION IN HAEMOPHILIA CARE - THE ESCHQOL STUDY (EUROPEAN STUDY OF CLINICAL, HEALTH ECONOMIC AND QUALITY OF LIFE OUTCOMES IN HAEMOPHILIA TREATMENT K. Berger* (DE), M. Bullinger, P. Giangrande, A. Giebl, A. Gringeri, R. Ljung, L. Nemes, S. von Mackensen, L. Mantovani, M. Serban, M. Shlaen, W. Schramm PP-WE-543 SKEW RATIOS OF FEMALE HEMOPHILIA PATIENTS IN KOREA K. Y. Yoo* (KR), S. Kwon, M. Lee PP-WE-544 GENETIC MUTATIONS IN MILD HAEMOPHILIA A FAMILIES IN SOUTH AUSTRALIA L. H. Tay* (AU), S. Rodgers, S. McRae, Z. Rudzki, E. Duncan, J. Lloyd PP-WE-545 SEVERE HEMOPHILIA B DUE TO AN APPROXIMATELY 100 KB FACTOR IX GENE DELETION INVOLVING THREE DISTAL EXONS L. Kokabee* (IR), N. Karimi, S. Zeinali, M. Karimipoor PP-WE-546 HYPERMOBILITY AND ARTHROPATHY IN HEMOPHILIA: A RETROSPECTIVE EVALUATION OF JOINT HYPERMOBILITY AS A RISK FACTOR FOR ARTHROPATHY IN SEVERE AND MODERATE HEMOPHILIA L. A. Skeith* (CA), S. C. Jackson, J. Brooks, M. Poon PP-WE-547 HAEMOPHILIA A PATIENTS WITH DISCORDANT FVIII LEVELS BY 1-STAGE & CHROMOGENIC ASSAYS SHOW REDUCED THROMBIN GENERATION & INCREASED BLEEDING L. T. Khoo* (AU), G. W. Kershaw, J. Curnow, M. Morel-Kopp, S. Matthews, C. Waite, S. Dunkley

278 PW-5 NERLASSMN FFML EOHLACARRIERS ASSESSMENTOFFEMALEHEMOPHILIA INTEGRAL PP-WE-550 OFCAREIN EXPRESSIONOFTHEQUALITY LOCOMOTOR STATUS –CLINICAL PP-WE-549 ANDCARDIOVASCULAR THEINVERSE ASSOCIATION BETWEEN HEMOPHILIA PP-WE-548 POSTER PRESENTATIONS PP-WE-561 PP-WE-560 PP-WE-559 MARKERSINHEMOPHILIA CARRIERDETECTIONUSINGTHREEPOLYMORPHIC DNA PP-WE-558 THROMBINGENERATION TESTINFVIII-DEFICIENTMOUSEPLASMA A PP-WE-557 PP-WE-556 PP-WE-555 CASESERIES ANDCARDIOVASCULAR EVENTS: A A HEMOPHILIA PP-WE-554 IN YOUNG BOYSWITHSEVERE RISKFACTORS OFBLEEDINGSEVERITY PP-WE-553 INSTRUMENTINSELF-ASSESSMENTOF ACTIVITIESLIST-USEFUL HAEMOPHILIA PP-WE-552 HEMOPHILIACPATIENT SERUMBANK:EVALUATION OFTHEINFLUENCE PP-WE-551 ENSA,JL 5 2009 WEDNESDAY, JULY 15, DATA EPIDEMIOLOGY HAEMOPHILIA AFIBRINOGENAEMIA; RMTECNDA EOHLAPIAYPROPHYLAXISSTUDY PRIMARY FROM THECANADIANHEMOPHILIA HEMOPHILIA PROFILE DIFFERENCESINCARDIOVASCULAR RISK ISNOTEXPLAINEDBY MORTALITY FAMILIES FROMMAZANDARAN,NORTHERNPROVINCEOFIRAN A THE DIFFERENTIAL DIFFERENTIA HEMOPHILIA FUNCTIONINROMANIANHEMOPHILIACS MUSCULOSKELETAL AFTERTWO YEARS FOLLOW-UP THERAPY EMERGING PATHOGENS AND INFECTIOUSRISKS ASSOCIATED TO REPLACEMENT CIIY ASSETOER APPROACH SPECTROMETRY MASS ACTIVITY: A I. Zozulya*(RU) P. A. Vorobyev, O.V. Borisenko,U. A. Zhulev, K.G.Kopylov, E. A. Telnova, A. A. Tonoyan, N. Jimenez, F. Hernandez M. Martin-Salces*(ES), Alvarez, I.Fernandez,N.Butta,Muñoz, M.Garcia,I.Rivas,V. M. R.Baghaipour*(IR) Zadeh, R.ZakiZadeh M. HashemiSoteh*(IR),Z.HosseiniKhah,Bagherian,R.Mohseni,E.Siami, F M. Dockal*(A M. W W. L.vanHeerde M. vanGef M. Zwiers*(NL),W. M.Lijfering,K.Meijer, J.D.Lefrandt, A. J.Smit,vanderMeer Pai, M.Poon,V. Price,G.E.Rivard,S.Robinson,M.Steele,J.K.Wu, B.Feldman Demers, K.Gill,S.Israels,R.Klaassen,N.Laferriere,D.Lillicrap,Luke,M.McLimont, M. X.Hang*(CA),V Ursu, W. Schramm,M.Serban M. Mihailov*(RO),L.Pop,R.Ladislau,G.Miculschi,C.Jinca,D.Lighezan, A. Lacatusu,E. M. E.Mingot*(ES),García,J. A. Fernández, A. Palomo, A. Heiniger, J.Camacho M. E.Mingot*(ES), A. Palomo, A. Heiniger Uscatescu, E.Ursu, A. Lacatusu,L.Barna,D.Poenaru,W. Schramm M. Serban*(RO),L.Pop,Ritli,P. Stancu,H.Ionita,D.Mihailov, D.Baghiu, A. Cucuianu,V. M. AMPII ANDBDEPENDANTONTISSUEFACTOR A HAEMOPHILIA Scheiflinger A. Baarslag*(NL),S.Rafi,M.J.H. . Besser*(UK),R.Luddington, fen* (NL),B.Verbruggen, M. E.Mancuso,B.Laros-Vangorkom, E.Santagostino, T), R.Hartmann,M.Fries,E.Panholzer A TION OFP - MULTICENTRIC STUDY A ON TAILORED PROPHYLAXIS:LONG-TERM(10-YEAR)RESULTS OF HEREDIT IN FEMALEPATIENTS . S.Blanchette,E.Pullenayegum,P. Babyn,R.Card, A. Chan,C. PREDICTIVE V AN IRANIANEXPERIENCE TET IHSVR EOHLAAB FACTOR VIII BY A ATIENTS WITHSEVEREHEMOPHILIA AR Y T COAGULOPATHIES INRUSSIA: PATIENT-REPORTED . Baglin ALUE OFTHROMBINGENERA A. Kruip,M.Peters,P. W. Kamphuisen , A. Schiviz,E.M.Muchitsch,F TION IN . V . ali 279

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-562 CASE OF AN INFANT WITH A SEVERE HEMOPHILIA A DIAGNOSED DUE TO THE DEVELOPMENT OF SPINAL EPIDURAL HEMATOMA S. Muto* (JP), C. Nagae, T. Shoji, A. Yamashita, J. Hiramoto, S. Yamazaki, M. Taki PP-WE-563 LINGUISTIC VALIDATION OF THE HAEMO-QOL AND HAEM-A-QOL IN RUSSIAN AND BULGARIAN FOR USE IN A PHASE III CLINICAL TRIAL I. Gil-Campos, P. O. Bonnet, S. von Mackensen* (DE) PP-WE-564 TITRE : EVALUATION OF THE OCCURRENCE INCIDENCE OF ANTI-F VIII INHIBITORS IN HAEMOPHILIA : ALGERIAN STUDY T. K. Taouli* (DZ), B. K. Bendedouche, A. S. Ayad, M. N. Mesli PP-WE-565 HEMOPHILIA B PATIENT, TRAUMA OR SPONTANEOUS BLEEDING V. V. Jovanoska* (MK), I. I. J. Jovanoski PP-WE-566 THE PROMINENT MUTATION OF INVERSION INTRON 22 AMONG SPORADIC HEMOPHILIA: IS IT WORTH FOR ANTENATAL SCREENING W. Sasanakul* (TH), A. Chuansumrit

Hemophilia Therapy II

PP-WE-567 PROPHYLAXIS VS ON-DEMAND THERAPY THROUGH ECONOMIC REPORT (P.O.T.T.E.R.) STUDY A. Tagliaferri* (IT), G. Rivolta, A. Coppola, G. Feola, E. Boeri, C. Santoro, G. Mancuso, R. Musso, M. Mancuso, E. Zanon, L. Valdrè, G. Piseddu PP-WE-568 EFFECTIVITY OF INTRAARTICULAR HYALURONIC ACID IN HEMOPHILIC ARTROPATHY B. Zulfikar* (TR), O. Taser, O. Kilicoglu, F. Dikici, A. Atalar, F. Bezgal PP-WE-569 A NON-HUMAN PRIMATE MODEL OF HEMOPHILIA A E. K. Waters* (US), J. L. Parker, J. R. Preiss, J. C. Kurz, K. McGinness, J. Chung, R. M. Hutabarat, R. G. Schaub PP-WE-570 A PROSPECTIVE, RANDOMIZED TRIAL OF DAILY PROPHYLAXIS IN HEMOPHILIA E. Berntorp* (SE), K. Lindvall, J. Astermark, L. Kampf, K. Steen Carlsson, R. Ljung, S. Björkman PP-WE-571 THE COMPREHENSIVE, MULTIDISCIPLINARY TEAM FOR THE TREATMENT OF HAEMOPHILIA: ISTANBUL EXPERIENCE G. Aydogan* (TR), M. Altun, Z. Salcioglu, F. Pekun, E. Turkkan, H. Sen, T. Ozulker, C. Timur, Y. Yildirmak, N. Sarper, T. Sahin, A. Akcay, D. Yalcin Atay, F. Akici, D. Tugcu PP-WE-572 GENERATION OF RECOMBINANT FVIII PURIFICATION ANTIBODY FOR MANUFACTURING OF N8 J. J. Hansen* (DK), G. Bolt, K. Kjærgaard, C. Kristensen, T. D. Steenstrup PP-WE-573 A CASE OF PERICARDIOCENTESIS FOR HEMOPHILIA A PATIENT WITH TUBERCULOUS PERICARDIAL EFFUSION J. Park* (KR), Y. Park, S. Lee PP-WE-574 POST-AUTHORIZATION SAFETY SURVEILLANCE (PASS) FOR RAHF-PFM: FINAL EU AND US SAFETY AND EFFICACY RESULTS J. Oldenburg* (DE), H. Luu, G. Spotts, H. Gajek, A. Kriukov, D. Stephens, R. Berg, K. Barker, B. Ewenstein PP-WE-575 FACTOR IX PRODUCTION STEPS EFFECTIVELY REMOVE A TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY (TSE) MODEL AGENT J. M. Diez, S. Caballero, F. Belda, M. Otegui, R. Gajardo, J. I. Jorquera* (ES)

280 PW-7 INHIBITOR FORMATION WITHSUCROSE-FORMULATED RECOMBINANTFACTOR VIII PP-WE-579 TREATMENT OFHCVINFECTED YOUNG HAEMOPHILIACS– AN UPDATE ANTIVIRAL PP-WE-578 PP-WE-577 AGENTDURINGFVIII/VWFPURIFICATION TSE-MODEL OF A EFFECTIVEREMOVAL PP-WE-576 POSTER PRESENTATIONS PP-WE-590 NEWRECOMBINANTFVIII(N8) CHARACTERIZATION OF A FUNCTIONAL PP-WE-589 PATIENTS WITH INHIBITORS A PROPHYLATIC TREATMENT OFHAEMOPHILIA PP-WE-588 PP-WE-587 USEDFORGLYCOPEGYLATED ANALYSES OF40KPOLYETHYLENE GLYCOL PP-WE-586 ANALYSIS AND CHARACTERIZATION OFGLYCOPEGYLATED RECOMBINANTHUMAN PP-WE-585 FACTOR VIIIPROPHYLAXISFOR A: ADULT PATIENTS WITHSEVEREHEMOPHILIA PP-WE-584 PP-WE-583 ACTIVATION NEWRECOMBINANTFVIII(N8) AND INACTIVATIONARE RATES OF A PP-WE-582 THEEFFECTOFN8 AND RFVIIIONNEEDLEINDUCEDHEMARTHROSISIN PP-WE-581 SOURCE FOR HUMANHEPATOCYTE FORCELL PROPAGATION INMICE:POTENTIAL PP-WE-580 ENSA,JL 5 2009 WEDNESDAY, JULY 15, HOBEATGAH (TEG® THROMBOELASTOGRAPHY EFFECT OF40KPEG-RFIXINBLOOD FROMHEMOPHILIA SURVEILLANCE STUDIES A:RESULTS FROMPOSTMARKETING IN PATIENTS WITHHEMOPHILIA OF 16 YEARS EXPERIENCE HEMOPHILIA SYNOVECT BREAKAGES AFTER RADIOISOTOPE LONG-TERM EVALUATION OFCHROMOSOMAL RELA RECOMBINANT HUMANFVIIa FVIIa OF ATTITUDES AND PRACTICES USSURVEY RESULTS OF A INHIBITORS ASSESSING THEBENEFITS LENGTHMOLECULE SIMILAR TO FVIIIEXPRESSED AS FULL HEMOPHILIA COAGULATION FACTOR DEFICIENCIES IDMDRT EOHLAA MILD/MODERATE HEMOPHILIA M. L.S.Christiansen*(DK),B.Sorensen, D.Viuff, H.Ostergaard, S.Segel,Lethagen Sørensen, D.Viuff, S.Segel,M.Ezban,Lethagen, T. D.Steenstrup M. Kjalke*(DK),S.Christiansen,K. W. Balling,L.F. Larsen,E.Persson, I.Hilden,B. M. B. M. E.Seary L. Palm*(DK), T. S.Hoeg,J.Ström, J.Malmstrom,W. Chen, A. D.Nielsen L. Palm*(DK), T. Jepsen,S.F. Garmer, J.Malmstrom, A. D.Nielsen,W. Chen,S.Valentin C. E.W L. A. Valentino* (US) K. W K. Øvlisen*(DK),M.Kjalke, Tranholm K. Ohashi*(JP), Tatsumi, C. Tateno, K. Yoshizato, M.Shima, T. Okano K. Fukutake*(JP),R.Musso,J. Young, C.Norenberg K. Koehler-Vajta* (DE),G.Froesner, R.Zachoval K. Kavakli*(TR),O.Cogulu,S. S. Caballero,F. Belda,M.Otegui,J.Diez,R.Gajardo,I.Jorquera*(ES) . Balling*(DK),M.Kjalke Antunes* (PT), TIONSHIP alsh, L. A. Valentino* (US) , D.Feldman, M FORTREATMENT OFTARGET JOINTSINPATIENTSOMY WITH A MICE BETWEEN GENETICMUT A. Santos,M.Diniz A. M.Stain,D.Carcao*(CA) APCC PROPHYLAXISINHEMOPHILIA Aydogdu, H.Ozkilic,B.Durmaz, C.Balkan,D. Yilmaz, Y. Ay A TION N DV RESPONSIVENESSIN AND DDAVP B P A TIENTS USING P A TIENTS WITH 281

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-591 EFFECT OF A NEW RFVIII COMPOUND N8 USING BLOOD FROM HEMOPHILIA A (HA) PATIENTS EVALUATED BY THROMBOELASTOGRAPHY (TEG® M. L. S. Christiansen* (DK), B. B. Sorensen, D. Viuff, M. Kjalke, M. Ezban, S. Segel, S. Lethagen PP-WE-592 SUCCESSFUL NEUROSURGERY OF A MALIGNANT GLIONEURONAL TUMOR (MGT) UNDER RECOMBINANT ACTIVATED FACTOR VII (RFVIIa) COVER IN A SEVERE HEMOPHILIA A PATIENT WITH A HIGH TITER INHIBITOR (SHHI A. Aouba, E. Dezamis, C. Rothschild, M. Torchet* (FR) PP-WE-593 THE FIRST 2 YEARS OF A MOBILE ELECTRONIC PATIENT DIARY IN HEMOPHILIA – INSIGHTS FROM ADOPTION RATES AND USAGE DATA W. Mondorf, R. Klamroth, B. Siegmund, M. Westfeld* (DE), M. Kosch, J. Tuischer, H. Pollmann PP-WE-594 A PHARMACOVIGILANCE EVALUATION OF B-DOMAIN DELETED RECOMBINANT FACTOR VIII – INTERIM RESULTS AFTER NINE YEARS H. Pollmann, M. Westfeld* (DE), B. Eifrig, R. Klamroth, W. Kreuz, H. Lenk, J. Oldenburg, I. Pabinger, W. Schramm, T. Schwarz, N. Zavazava, R. Zimmermann PP-WE-595 THE STUDY ON THE POTENCY TEST FOR HUMAN BLOOD COAGULATION FACTOR VIII S. Y. Kang* (KR), N. Lee, S. N. Kim, H. J. Oh, D. J. Shin

Inhibitors: Pathogenesis, Prevention and Treatment II

PP-WE-596 FACTOR XI INHIBITOR ASSOCIATED WITH AUTOIMMUNE HEPATITIS AND ULCERATIVE COLITIS-CASE REPORT A. Bulikova* (CZ), L. Husova, J. Zavrelova, M. Penka PP-WE-597 MODELING COSTS AND OUTCOMES OF GUIDELINES ADHERENCE IN THE TREATMENT OF PROBLEM BLEEDS IN PATIENTS WITH SEVERE HAEMOPHILIA A AND HIGH-TITRE INHIBITORS A. Gringeri* (IT), E. Gomperts, C. Leissinger, R. D’Oiron, J. Teitel, G. Young, B. Ewenstein, P. O. Bonnet, E. Berntorp PP-WE-598 IMMUNE TOLERANCE INDUCTION WITH FVIII/VWF CONCENTRATE IN AN ELDERLY SEVERE HAEMOPHILIA A PATIENT WITH HIGH-RESPONDING INHIBITOR A. Tagliaferri* (IT), G. Rivolta, C. di Perna, F. Riccardi, L. Ippolito, M. Lombardi, M. Franchini PP-WE-599 ITALIAN EXPERIENCE OF IMMUNE TOLERANCE INDUCTION (ITI) WITH A FVIII CONCENTRATE AT HIGH VWF CONTENT IN HAEMOPHILIACS WITH PREVIOUS UNSUCCESSFUL ITI AND/OR NEGATIVE PREDICTORS OF ITI RESPONSE A. Coppola* (IT), C. Biasoli, G. Mancuso, A. Tagliaferri, M. Schiavulli, M. Morfini, E. Santagostino, F. A. Scaraggi PP-WE-600 A SINGLE CAUSATIVE MUTATION IN THE PROMOTER REGION OF F8 GENE ASSOCIATED WITH FVIII INHIBITOR DEVELOPMENT C. Costa* (FR), Y. Repesse, P. Gautier, M. Goossens, A. Borel-Derlon PP-WE-601 THE USEFULNESS OF REGISTRY DATA FOR UNDERSTANDING TREATMENT PRACTICES AND CLINICAL OUTCOMES IN HEMOPHILIA: THE EXPERIENCE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY (2004-2008 C. M. Kessler* (US), J. C. Gill, D. L. Cooper PP-WE-602 DOSING AND EFFECTIVENESS OF RECOMBINANT FVIIa (RFVIIa) IN CONGENITAL HEMOPHILIA WITH INHIBITORS BY BLEED TYPE AND LOCATION: THE EXPERIENCE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY (2004-2008 G. A. Young* (US), D. L. Cooper, R. Gut

282 PW-0 VLAINO IRNCO OMDFO VI-ELTDPAM WITH EVALUATION OFFIBRINCLOTFORMEDFROMFVIII-DEPLETEDPLASMA PP-WE-605 PP-WE-604 THEONEREGISTRY: DESIGN AND BASELINEDATA PP-WE-603 POSTER PRESENTATIONS PP-WE-616 PP-WE-615 PP-WE-614 INHIBITOR SURVEILLANCE AND MUTATION BPATIENTS ANALYSIS INHEMOPHILIA PP-WE-613 PP-WE-612 APCCINCOMBINATION WITHFVIIIPOTENTIATE INVITRO THROMBINPRODUCTION PP-WE-611 HUMANBCR-TRANSGENEMOUSESPECIFICTO OF A REACTIVITY FUNCTIONAL PP-WE-610 ANDINHIBITORS ON A OFLIFE INPATIENTS WITHSEVEREHAEMOPHILIA QUALITY PP-WE-609 OFFACTOR VIIaFORMULATED SAFETY, WITH PHARMACOKINETICS AND EFFICACY PP-WE-608 PATIENT A HEMOPHILIA OPERATION AND CIRCUMCISIONIN A HERNIA INGUINAL PP-WE-607 OFPATIENTS THEJAPANESE GUIDELINEFORTHEHEMOSTATIC WITH THERAPY PP-WE-606 ENSA,JL 5 2009 WEDNESDAY, JULY 15, AINSWT EEEHEOHLAANDINHIBITORS PATIENTS WITHSEVEREHAEMOPHILIA ST A Kaveri, S.Lacroix-Desmazes NIIOYANTIBODY INHIBITORY STRUCTUREDREVIEW OFTHEPHARMACOECONOMICLITERATURE A FVIIa/FX MIXTURE HAEMOPHILIA OFTHEEUROPEAN ACQUIRED ACQUIRED HAEMOPHILIA:DESCRIPTIVEDATA PHYSICOCHEMICAL APCC VERSUSRFVIIaINTREA IN INHIBITOR PLASMA F PDFVIII VIII PEGYLA WITH INHIBITOR ANDINHIBITORS HEMOPHILIA CONGENITAL L. Dai*(UK),S.Rangarajan, D.Bevan,B.Sorensen,M. Mitchell K. A. Breen*(IE),M.Kavanagh,I.Kelly, B.Nolan,I.Regan,C.McMahon J. D.Dimitrov*(FR),L. J. M.Soucie*(US),Creary J. W. Hay*(US),Z.Zhou J. Klintman*(SE), W. K.Hoots,S. Y. Grailly, V. A. Carlier, M.G.Jacquemin,J.Gilles*(BE), J.R.Saint-Remy D. Furby, A. Phillott, A. Roy, S.Rangarajan, J. Alamelu* (UK) M. Baru,J.Spira*(IL),O.Plyushch,N.Zozulya,R. I. Sasmaz*(TR),B. Antmen, G.Leblebisatan, Y. Kilinc, A. Aridogan Yoshioka, M.Shima H. Takedani, H.Hanabusa,S.Higasa,K.Fukutake, T. Fujii, T. Matsushita,J.Mimaya, A. I. Tanaka* (JP),K. Amano, M. Taki, T. Oka,M.Sakai, A. Shirahata,N. Takata, J. Takamatsu, Tsuji, E.Kusumoto, A. Takaki, T. Hamamoto, T. Nakagaki H. Miyazaki*(JP),K. Tomokiyo, S.Nishimura, Y. Nakatomi, T. Nakashima,E. Takami, M. T H. Levesque*(FR),P. Collins,F. Baudo, A. Huth-Kuhne,P. Knoebl,P. Marco,L.Nemes, H. Chambost*(FR)fortheSteeringCommitteeofONERegistry Dunn, C.Knoll,S.J.Platt,Driggers,D.Ellingsen,Benson,Hooper, C.H.Miller Massey, A. T. Neff, A. D.Shapiro,M. Tarantino, B.M.Wicklund,J.Manco-Johnson, A. L. engborn ACT SINGLE CENTREEXPERIENCEOF PROPHYLACTICRFVIIaINP ABILIZA OR VIII TED LIPOSOMESINHEMOPHILIA TION OFFIBRINCLOTS BY EITY(EACH2) REGISTRY Astermark, M.Ekman,E.Berntorp CHARACTERIZA T . Roumenina,B.P. Atanasov, M.Jacquemin,J.Saint-Remy, S.V. , T . C. TMENT OFHEMOPHILIA Abshire, D.B.Brettler INO ATRVI ETAIAINB AN TION OFFACTOR VIIINEUTRALIZATION BY FEIBA PATIENTS WITHINHIBITORS TO FACTOR A N X INFVIIIINHIBITOR PLASMA AND TXA Yatuv, I.Dayan,M.Robinson , P P . L.Bockenstedt,J.diPaola,G. ATIENTS WITHINHIBITORS: AEDIATRIC 283

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-617 UNDERSTANDING REAL-WORLD EXPERIENCE WITH INHIBITOR BY-PASS THERAPY: FEIBA NF POST-AUTHORIZATION SAFETY SURVEILLANCE (PASS) M. Pirck* (AT), G. Spotts, H. Gajek, B. Ewenstein PP-WE-618 A FLOW CYTOMETRY EVALUATION OF ANTI-FVIII ANTIBODIES: CORRELATION WITH ELISA AND BETHESDA ASSAYS M. B. Irigoyen* (AR), L. Primiani, M. Felippo, M. Candela, R. Perez Bianco, M. E de Bracco, N. Galassi PP-WE-619 NEW ASSAY FOR QUANTIFYING FUNCTIONAL DOMAIN-SPECIFIC INHIBITORS AGAINST HUMAN VWF IN PLASMA K. Varadi, G. Schrenk, S. Langlet, N. Martineau, E. Arnaud, H. Rottensteiner, P. L. Turecek* (AT), H. J. Ehrlich, H. P. Schwarz PP-WE-620 IMPROVED VENOUS ACCESS AND BLEEDING MANAGEMENT IN AN EIGHT-YEAR OLD BOY WITH LONG-LASTING INHIBITOR AGAINST FACTOR VIII S. Gottstein, A. Hinrichs, S. Seibt, R. Klamroth* (DE) PP-WE-621 INHIBITOR DEVELOPMENT IN TWO PATIENTS WITH MILD HAEMOPHILIA A S. E. Reitter* (AT), K. Lechner, R. Sunder-Plassmann, I. Pabinger-Fasching, C. Mannhalter PP-WE-622 THE USE OF FVIII PREPARATIONS IN THE BETHESDA INHIBITOR ASSAY – A PITFALL T. Siegemund* (DE), U. Scholz, A. Siegemund

von Willebrand Disease II

PP-WE-623 SUCCESSFUL MANAGEMENT OF PREGNANCIES IN THREE SISTERS WITH VARYING PHENOTYPES OF VON WILLEBRAND’S DISEASE B. Madan* (UK), C. Rea, A. Dunkerley, D. Holloway, L. Chappell PP-WE-624 VON WILLEBRAND FACTOR FUNCTION UNDER PHYSIOLOGICAL FLOW CONDITIONS: COMPARISON OF FIVE VWF-CONTAINING CONCENTRATES IN AN IN VITRO FLOW- CHAMBER MODEL B. Fuchs* (DE), C. Fisseau, L. Trawnicek, R. Kuhelj, C. Kannicht PP-WE-625 CONGENITAL AND ACQUIRED DEFECTS OF FVIII BINDING TO VON WILLEBRAND FACTOR: RESULTS OF A COHORT STUDY ON 48 ITALIAN PATIENTS M. T. Canciani, G. Cozzi, S. La Marca, V. Rubini, F. Rezzonico* (IT), L. Baronciani, P. M. Mannucci, A. B. Federici PP-WE-626 PLATELET VON WILLEBRAND FACTOR (VWF) MRNA ANALYSIS IN PATIENTS WITH VON WILLEBRAND DISEASE (VWD) AND NULL MUTATIONS IN VWF GENE S. Giacomelli, F. Rodeghiero, G. Castaman* (IT) PP-WE-627 A NOVEL MUTATION AT THE PHYSIOLOGICAL TERMINATION CODON OF VON WILLEBRAND FACTOR (VWF) GENE PRODUCES A LONGER VWF PROTEIN G. Castaman* (IT), S. Giacomelli, F. Rodeghiero PP-WE-628 THE COMPLEX RELATIONSHIP BETWEEN PHENOTYPE AND GENOTYPE IN VON WILLEBRAND DISEASE: COEXISTENCE IN THE SAME FAMILY OF SEEMINGLY HOMOZYGOUS P1266Q/L VON WILLEBRAND FACTOR GENE MUTATIONS G. Castaman* (IT), S. Giacomelli, F. Rodeghiero PP-WE-629 CHARACTERISATION OF TWO NOVEL VON WILLEBRAND FACTOR (VWF) MUTATIONS (C2190Y AND R2663C) WITH LOSS OR GAIN OF CYSTEINE RESIDUES IN VWF G. Castaman* (IT), S. Giacomelli, T. Obser, U. Budde, R. Schneppenheim, F. Rodeghiero PP-WE-630 TRANSIENT EXPRESSION OF TWO NOVEL VON WILLEBRAND FACTOR MUTATIONS (I1343V AND A1716P) IN THE COLLAGEN BINDING DOMAINS OF THE PROTEIN G. Castaman* (IT), S. Giacomelli, T. Obser, U. Budde, R. Schneppenheim, F. Rodeghiero

284 PW-3 PAEO FIAYADTLRBLT FANEWGENERATION VWF/FVIII OF A ANDTOLERABILITY UPDATE ONEFFICACY PP-WE-633 OFHAEMORRHAGIC DISORDERSINNORTHEASTERNIRAN FREQUENCY PP-WE-632 MOLECULAR ASSESSMENT OFFVIIIBINDINGSITEINVONWILLEBRANDFACTOR PP-WE-631 POSTER PRESENTATIONS PW-4 AAEETO EISRIA HAEMOSTASIS INVWDPATIENTS –CLINICAL MANAGEMENT OFPERI-SURGICAL PP-WE-644 ANDINTHEPOST-PARTUM TREATMENT PERIODOFWOMEN WITH AT DELIVERY PP-WE-643 PP-WE-642 PP-WE-641 VON WILLEBRANDFACTOR LEVELSINHUMANS: OFPLASMA GENETICCONTROL PP-WE-640 SEVEREBLEEDINGUSINGLOW HAEMOSTATIC MANAGEMENTOFPOSTSURGICAL PP-WE-639 NEWVWF:CBKITFORQUANTITATIVE THEEVALUATION DETERMINATION OF OF A PP-WE-638 USEOFLOW-DOSE RISTOCETIN INDUCEDPLATELET AGGREGATION (RIPA) AS A PP-WE-637 QUANTITATIVE TRAITLOCI(QTL)FORVONWILLEBRANDFACTOR (VWF)LEVELSIN PP-WE-636 FRAMESHIFTMUTATION INTHEVWF REPEAT NOVEL THEIDENTIFICATION OF A PP-WE-635 ACQUIREDVONWILLEBRANDSYNDROMEINPATIENTS WITHMULTIPLE MYELOMA PP-WE-634 ENSA,JL 5 2009 WEDNESDAY, JULY 15, CONCENTRA DOUBLEVIRUS-INACTIVATED VWF/FVIII- HIGH-PURITY EXPERIENCE WITH A VON WILLEBRANDSDISEASE Trossaërt* (FR) Bizzacchi, M.Ozelo MARKETING SURVEILLANCE PROSPECTIVEPOST- CONCENTRATE INVONWILLEBRAND’SDISEASEFROM A GENE INSUSPECTSPATIENTS OFVONWILLEBRANDDISEASETYPE2N UNIP 2 VONWILLEBRANDDISEASE THE CONTRIBUTIONOF THE GENES AND BLOODCLOTTINGSTUDY DOSES OFFVIII/VWFCONCENTRA INTHEDIAGNOSISOFVWD VWF ACTIVITY AND PLA INTHEDIAGNOSISOFTYPE2BVON WILLEBRAND SCREENINGTOOL FIRST-STEP A GENE WITH AN UNPREDICTEDEFFECT M. vonDepkaProndzinski* (DE), T. Hoebbel-Schnell, S.Doepke,M.Rieke M. Holmström*(SE),D.Näslin,Bruzelius, E.Nord,K.Bremme M. Fouassier Bertomoro, L. Gallinaro*(IT),M.G.Cattini,E.Pontara,F. Sartorello,V. Daidone,R.Padrini, A. K. C.Desch*(US),J.Li,E.Metzger K. W. Chennoukh*(DZ),S. Nekkal,M. Adjali, S.Bourada,N.Zidani,M.Belhani K. Sukhu*(UK),V. Heath,J.Beavis,D.Keeling J. P. Frontroth*(AR),M.D.Hepner, G.Sciuccati,Pieroni, A. Feliu-Torres, M.Bonduel J. diPaola*(US),D. Abbott, K.Wang, J.Hinckley, J.Murray, B.Nixon, T. L.Burns, A. Shapiro J. A. Cutler*(UK),M.Hadonou,B.Madan,Laffan, M.J.Mitchell I. S.Djunic*(RS),Elezovic,N.MilosevicJovcic,V. Ilic,D. Antic, A. Vidovic, D. Tomin Feddern I. Scharrer*(DE),S.Halimeh,J.Kadar, U.Nowak-Göttl,M.vonDepkaProndzinski,J. H. Mansouritorghabeh*(IR),L.Manavifar G. B.Damian*(BR), EHNS O CASEOFVONWILLEBRANDDISEASETYPE3 MECHANISM FOR A LARGE PEDIGREEWITHVONWILLEBRANDDISEASE(VWD) ARENT TELET A. Pagnan, AL , P TE . Boisseau, ISODISOMY -TYPE VONWILLEBRANDDISEASEINCHILDREN A. Santos,C.OliveiradiMigueli,L.Siqueira, A. Prezoti,E.diPaula,J. A. Casonato EUE O ILBADFCO UVVLINTYPE REDUCEDVONWILLEBRAND FACTOR SURVIVAL A A. Lefrançois,C. Thomas, M.Sigaud,C. Ternisien, S.Bezieau,M. FCRMSM 2 OE ANDORIGINAL NOVEL OF CHROMOSOME12: A TE INTYPE3VONWILLEBRANDDISEASE , D.Siemieniak,Ginsburg , A. Mobalegh , A. 285

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-645 VON WILLEBRAND FACTOR PROPEPTIDE RATIO FOR EVALUATING VWF SURVIVAL AND CHARACTERIZING TYPE 1 AND TYPE 2 VON WILLEBRAND DISEASE M. Sztukowska* (IT), L. Gallinaro, M. G. Cattini, E. Pontara, F. Sartorello, V. Daidone, A. Pagnan, A. Casonato PP-WE-646 ESTABLISHMENT OF A CLINICAL ROUTINE ASSAY, WHICH CAN DETECT MILD DEFECTS IN COAGULATION FACTOR VIII – VON WILLEBRAND FACTOR BINDING M. Karlman* (SE), B. Wiman PP-WE-647 DUODENAL AND GASTRIC DIEULAFOY’S LESIONS IN TWO UNRELATED PATIENTS WITH TYPE 2A VON WILLEBRAND’S DISEASE: IS THIS A CASUAL ASSOCIATION R. de Cristofaro* (IT), M. Riccioni, M. Basso, S. Lancellotti, A. Federici, C. Spada, G. Costamagna, R. Landolfi PP-WE-648 RECOVERY STUDY IN A CHILD WITH VWD TYPE 3 ON PROPHYLAXIS S. I. Heine* (DE), T. Krenn, N. Graf PP-WE-649 MONITORING VON WILLEBRAND FACTOR REPLACEMENT THERAPY IN THE SETTING OF ORTHOTOPIC LIVER TRANSPLANTATION USING A RAPID LATEX VWF ACTIVITY ASSAY S. V. Brooks* (UK), L. Lanning, S. Unadkat, A. Condez, J. O’Beirne, A. Gatt, P. Chowdary PP-WE-650 MUTATIONS IN TYPE 2 VON WILLEBRAND DISEASE IN SOUTH AFRICA S. M. Mothabeng* (ZA), A. de Kock, M. Meiring PP-WE-651 STRONG BLEEDING TENDENCY IN A FAMILY WITH MODERATE THROMBOCYTOPENIA - LABORATORY DIAGNOSTIC WORK-UP OF SEVEN FAMILY MEMBERS J. Zdziarska, T. Iwaniec* (PL), A. B. Skotnicki, R. Schneppenheim, K. Kentouche, U. Budde PP-WE-652 PK COMPARABILITY OF VWF/FVIII CONCENTRATES AFTER REPEATED DOSING U. Kronthaler* (DE), M. Stockschlaeder PP-WE-653 TREATMENT OF PAEDIATRIC VON WILLEBRAND’S DISEASE PATIENTS WITH HIGH PURITY DOUBLE VIRUS INACTIVATED VWF/FVIII CONCENTRATE – EXPERIENCE FROM CLINICAL STUDIES U. Nowak-Göttl* (DE), S. Halimeh, A. Russo, I. Scharrer, M. Sigl-Kraetzig, J. Feddern PP-WE-654 PARALLEL DECREASES OF INTRAPLATELET VON WILLEBRAND FACTOR (VWF) AND PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) MAY DETERMINE THE BLEEDING PHENOTYPE OF TYPE 1 VON WILLEBRAND DISEASE (VWD) V. Matus* (CL), O. Panes, S. Acuña, J. Pereira, D. Mezzano

Other Inherited Coagulation Disorders II

PP-WE-655 VALUE OF A PROTHROMBIN COMPLEX CONCENTRATE IN THE MANAGEMENT OF PERIOPERATIVE HAEMORRHAGIC RISK IN A FACTOR X-DEFICIENT WOMAN A. Faradji* (FR), E. Baulon-Thaveau, J. P. Mole, L. Grunebaum, D. Deprez, J. L. Poplavsky PP-WE-656 MANAGEMENT OF 118 SURGERIES IN CONGENITAL FVII DEFICIENCY. A SINGLE CENTRE EXPERIENCE A. Batorova* (SK), V. Cupanik, B. Steno, M. Borovsky, D. Horvathova, D. Jankovicova PP-WE-657 MUTATIONAL SCREENING OF 25 UNRELATED FV-DEFICIENT PATIENTS FROM 6 COUNTRIES I. Guella* (IT), E. M. Paraboschi, S. Duga, F. Peyvandi, D. Gemmati, N. Ciavarella, P. M. Mannucci, R. Asselta

286 PW-6 OEUA N EEI NLSSO RTRMI-HNHA DOUBLE MOLECULAR AND GENETIC ANALYSIS OFPROTHROMBIN-CHUNGHWA: A PP-WE-661 OFONEFAMILY STUDY – A FACTOR XIDEFICIENCY PP-WE-660 NEWCLASSIFICATION OFMISSENSEMUTATIONS INFVIIUSINGSTRUCTURE AND PP-WE-659 ANTIBODIES AGAINST FACTOR VII:CINFACTOR VIIDEFICIENCY. INHIBITORY 2009 PP-WE-658 POSTER PRESENTATIONS PW-7 OE OOYOSMSES UAINI H MN EEI JAPANESE HOMOZYGOUS MISSENSEMUTATION INTHELMAN1GENE A NOVEL A PP-WE-671 OFPATIENTS WITHINHERITEDFIBRINOGEN DEFICIENCY PROPHYLACTIC THERAPY PP-WE-670 PP-WE-669 GYNECOLOGIC AND OBSTETRICPATHOLOGIES INWOMENWITHSEVEREBLEEDING PP-WE-668 INFIFTEENFAMILIES FROMCHINA: MOCULARBASISOFFACTOR XIDEFICIENCY PP-WE-667 A CAUSEDBY OFBLEEDINGSYMPTOMS INFACTOR VDEFICIENCY THESEVERITY PP-WE-666 HIGHERTHANEXPECTEDPREVALENCE OFRARECOAGULATION DISORDERSIN PP-WE-665 PP-WE-664 OFPLASMINOGEN ACTIVATOR INHIBITOR TYPE1(PAI-1) DEFICIENCY AND ALPHA2- PP-WE-663 FACTOR XCONCENTRATE HIGHPURITY CHARACTERISTICSOF A PP-WE-662 ENSA,JL 5 2009 WEDNESDAY, JULY 15, PATIENT WITHCOMBINEDFACTORS V AND VIIIDEFICIENCY Mesa, A. Cabello, A. Oliva,M.Rios,N.Hernan HETEROZYGOTE MUTATION SEQUENCE THE SEVENTREA OF FACILITY LABORATORY ANALYSISINTERIM DATA REPORTFROMTHECENTRAL WITH HAEMOCOMPLET LONG TERMNRECOMBINANTF DISORDERS: EXPERIENCE MUTATIONS FOUR NOVEL COMPOUNDHETEROZYGOUSMUTATION (P1618R AND IVS7+5G>C) NOVEL ISLANDS,SPAIN) THE ISLEOFTENERIFE(CANARY SHOULD WESCREENCOAGULA UNKNOWN ORIGIN OF BLEEDINGTENDENCY INPATIENTS WITH A ANTIPLASMIN (APL) ACTIVITY Saito, T.Kojima T. Yamada* (JP), Y. Fujimori, A. Suzuki, Y. Miyawaki, A. Takagi, M.Sano, T. Matsushita, H. S. Halimeh*(DE),R.Eisert,H.Rott,B. Siegmund, A. Tiede, H.Pollmann S. Halimeh*(DE),H.Rott,G.Kappert L. Abad-Franch* (ES), A. R.Cid,S.Haya,P. Casaña,N.Cabrera, A. Moret,J. A. Aznar L. Dong*(CN),X.Wang H. Inaba,K.Fukutake K. Shinozawa*(JP),D.Imanishi, Amano, Y. Miyazaki,M. Tomonaga, T. Suzuki, A. Tanaka, J. Garcia-T S. M.Djukic,N. Andjelkovic, P. Djurdjevic, A. Djukic,J. Antovic* (SE) J. Haselböck*(A J. Lloyd*(UK),R.Mead,E.John J. Young* (TW),J.Lin J. Windyga*(PL), A. Pavlova,B.Baran, A. Buczma,J.Oldenburg J. L.Pellequer*(FR),M.Giansily-Blaizot,S.W. Chen J. Ingerslev*(DK),L.Norengaard,K.Christiansen,B.Sørensen,G.Mariani I EIINYANDBLEEDINGINTHEFIRST TRIMESTER VII DEFICIENCY alavera* (ES),C.Marrero, ANALYSES T), C.Laczkovics, MN VLAINRGSR (STER) TMENT EVALUATION REGISTRY AN P/RIAST A REFERENCECOAGULOPATHIES UNITINSPAIN T A ACT TION INWOMENWITHMENORRHAGIA A. Leon,S.Jover A AP OR VIIaINPREGNANA y , R.Simanek,P. Quehenberger, I.Pabinger , T . Bello,M. T WOMENWITHF Trujillo, M.Herrera, ACT OR 287

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

Acquired Coagulation Disorders and DIC II

PP-WE-672 EVALUATION OF AN AUTOMATED ASSAY FOR SOLUBLE FIBRIN MONOMERS A. Duncan* (US), A. Winkler, A. Ingle, K. Hostetler PP-WE-673 THROMBOELASTROGRAPHY (TEG) IN ORTHOTOPIC LIVER TRANSPLANTATION (OLT) S. Roullet, J. Pillot, P. Revel, A. Quinart, F. Sztark, S. Labrouche, G. Freyburger* (FR) PP-WE-674 DAUNORUBICIN ENHANCES PROCOAGULANT ACTIVITY OF RBC J. Zhou, Y. Zheng, H. Li, Y. Fu, W. Li, X. Zhang, J. Hou, G. E. Gilbert, J. Shi* (US) PP-WE-675 AN EXPERIMENTAL MODEL TO STUDY DISSAMINATED INTRAVACULAR COAGULATION IN SHEEP J. M. Siller-Matula* (AT), R. Plasenzotti, B. Jilma PP-WE-676 COST-EFFECTIVENESS OF PROTHROMBIN COMPLEX CONCENTRATE COMPARED TO FRESH FROZEN PLASMA IN EMERGENCY WARFARIN REVERSAL IN THE UK J. F. Guest, H. G. Watson* (UK), S. Limaye PP-WE-677 DEVELOPMENT OF A LABORATORY MODEL OF POST CARDIAC COAGULOPATHY M. Tang* (DK), K. Christiansen, J. Ingerslev, V. Hjortdal, B. Sørensen PP-WE-678 DISSEMINATED INTRAVASCULAR COAGULATION SYNDROME IN SEVERE BURNS M. V. Presnyakova* (RU), A. N. Sidorkina, V. G. Sidorkin PP-WE-679 ROLE OF GENETIC MONITORING OF HAEMOSTASIS IN SEVERE DIC SYNDROME N. A. Vorobyeva* (RU) PP-WE-680 OFF LABEL USE OF RECOMBINANT FACTOR VIIa IN THE HEMATOLOGY WARD N. V. Rajic, N. V. Rajic* (RS), S. Popovic, A. Savic, I. Savic, I. Urosevic, B. Zeravica, N. Vlaisavljevic, D. Agic, I. Percic PP-WE-681 ASSESSING THE FUNCTION OF CLOTTING SYSTEM AND SEARCHING FOR PROGNOSTIC TESTS IN LIVER CIRRHOSIS N. I. Kolaitis* (GR), A. Oikonomou, G. Vartholomatos, G. Baltayiannis, E. V. Tsianos PP-WE-682 PROLONGED COAGULOPATHY RELATED TO ANTICOAGULANT SUPERWARFARIN RODENTICIDES OVERDOSE O. Paoletti* (IT), A. Alatri, L. Bassi, A. Zimmermann, M. Stramezzi, A. Cogrossi, S. Testa PP-WE-683 THE PROCOAGULANT EFFECT OF VITAMIN-K ANTAGONISTS IN PATIENTS WITH ATRIAL FIBRILLATION, ATHEROSCLEROSIS AND DEEP VENOUS THROMBOSIS R. Al Dieri* (NL), A. J. ten Cate-Hoek, H. ten Cate, H. C. Hemker PP-WE-684 ASSOCIATION OF VASOPRESSIN INDUCED IMPAIRMENT OF MICROCIRCULATION WITH A DROP-OFF IN ADAMTS13 ACTIVITY IN PATIENTS WITH SEPTIC SHOCK R. A. Claus* (DE), S. Klinzing, P. Reuken, C. L. Bockmeyer, T. Schuerholz, K. Reinhart, G. Marx, W. Losche, M. Bauer PP-WE-685 DIFFERING EFFECTS OF THREE PROTHROMBIN COMPLEX CONCENTRATES ON ANTICOAGULATED PLASMA AS MEASURED BY CALIBRATED AUTOMATED THROMBOGRAPHY R. M. Gilmore* (IE), S. Harmon, G. Keane, C. Gannon, M. Byrne, B. White, J. S. O’Donnell PP-WE-686 USE OF RECOMBINANT ACTIVATED FACTOR VII IN PEDIATRIC PATIENTS WITHOUT HEMOPHILIA S. A. Muwakkit* (LB), M. M. Majdalani, K. M. Musallem, R. Saab, M. Abboud

288 PP-WE-688 DISSEMINATED FIBRINOLYTIC INTRAVASCULAR PHENOTYPE COAGULATION WITH A PP-WE-687 POSTER PRESENTATIONS PW-9 MEIT EESLO RLATCAUAINI SEVERE ANTICOAGULATION IN A OFORAL IMMEDIATE REVERSAL PP-WE-699 COAGULOPATHY MECHANISMS OFDILUTIONAL PP-WE-698 PASTEURISED NANOFILTRATED OF A ANDLONG-TERMSAFETY EFFICACY PP-WE-697 PP-WE-696 PP-WE-695 PREVALENCE OFSUSPECTEDCOLLAGENDISORDERSINTHE ADULT BLEEDING PP-WE-694 PP-WE-693 THE FORASSESSING TOOL (ROTEM)ASA THROMBOELASTOGRAPHY ROTATIONAL PP-WE-692 DOWEEVALUATE PT AND APTT BEFOREDELIVERY WHY PP-WE-691 WEB-BASEDRESOURCEFORLABORATORY PRACTICAL-HAEMOSTASIS.COM -: A PP-WE-690 TEST(THROMBOELASTOGRAPHY) REFLECTSTHECONVENTIONAL GLOBAL A PP-WE-689 Innovative TherapiesforHemorrhagicDisorders I Consultative HemostasisII 2009 WEDNESDAY, JULY 15, REPORT OFFOUR CASES COMPARTIMENTSYNDROME: A ABDOMINAL BLEEDINGAND RETROPERITONEAL P/N PROTHROMBIN COMPLEXCENCENTRATE (BERIPLEX® CATHETERIZATION HEMORRHAGIC ORVASCULAR COMPLICATIONS ASSOCIATED WITHCARDIAC DESIGN AND RESULTSDESIGN AND INUMBRIA:STUDY USEOFFRESH-FROZEN PLASMA AUDIT OFTHECLINICAL PREDICTS MORT MODIFIED THROUGHFIBRINOGENOLYSIS PHASEOFTRAUMA AT AN EARLY IS ROUTINESCREENINGFORCOAGULA DISORDER CLINIC THROMBOCYT SURGERY RESCUE RFVIIa ADMINISTRATION FORINTRACTABLE BLEEDINGINCARDIAC RESPONSETO HEMOSTATIC AGENTS INBLEEDINGDISORDERS CLINICAL HAEMOSTASIS COAGULOGRAM AND PLATELET COUNTBEFORELIVERTRANSPLANTATION EXTRACTION NEEDED M. Quintana*(ES), M.SánchezCasado,S.Martinez, Fabra C. Fenger-Eriksen*(DK),E. A. A. Hanke*(DE),L.Rodewald,C.Joch,K.Görlinger S. Revel-V S. C.Jackson*(CA),R. T. Card, M.Brown,C.Spitzer, M.Poon P Kotsi, K.Markakis,C.Charitos, O. Katsarou*(GR),V. Panagiotakopoulos, A. Koumarianou, A. Kouraba, T. Sakellaridis,P. Reyes, N.BlumenfelddeBosch, M. Echenagucia*(VE), A. Boadas, A. Arguello, A. Quijada,M.Hernandez,J.Becerra,C. E. Biguzzi*(IT),F. Franchi,B.Ibrahim, Acaia, T. Radaelli,P. Bucciarelli,P. Mannucci D. J.Perry*(UK), D. Ribeiro*(BR), A. S.Lima,M.D.Faria,C.Caram Iorio* (IT) M. Basileo,Marchesi,E.Marchesini,Materazzi, A. Germani,L.Rocchetti,C.Silvani, A. S. Gando*(JP), . V idwan* (US),J.Bumgarner ilk* (IL), OPENIA A. Sawamura,M.Hayakawa,N.Kubota,Sugano, T. Todd ALITY Y. Schejter-Dinur, A. Revel DOES NOTINCREASETHERISKOFPERI-PROCEDURAL T onnesen, J.Ingerslev, B.Sorensen , C.Stalls,J.Rossi,G.Stouf A. Karafoulidou A. Ruiz-Saez TION ABNORMALITIES PRIORTO OVA fer T. Wada, K.Katabami 289

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-700 OFF-LABEL USE OF RECOMBINANT ACTIVATED FACTOR VII IN INTRACTABLE HAEMORRHAGE AFTER CARDIOVASCULAR SURGERY: AN OBSERVATIONAL STUDY OF FRENCH PRACTICES (2005-2007) M. Hacquard* (FR), M. Durand, T. Lecompte, J. Carteaux, on behalf of the French Societies on CV Surgery Anesthesiology and IC T&H/Haematology PP-WE-701 THE USE OF ACTIVATED FACTOR VII IN HAEMORRHAGIC DISEASES- THE STUDY OF 09 CASES N. Mesli* (DZ), S. Bereksi Reguig, K. Taouli, H. Hemche PP-WE-702 THE COMBINATION OF RECOMBINANT FACTOR VIIa AND FIBRINOGEN CORRECTS COAGULATION IN A MODEL OF WHOLE BLOOD THROMBOCYTOPENIA O. H. Larsen* (DK), J. Ingerslev, B. Sørensen PP-WE-703 KERATIN HYDROGEL HEMOSTASIS - CELLULAR AND MOLECULAR MECHANISMS C. Orebaugh, M. Bahawdory, M. C. Stahle, J. Rouse, L. Burnett, M. van Dyke, R. R. Hantgan* (US)

Immunology and Treatment of ITP II

PP-WE-704 VARIABLE PLATELET RESPONSIVENESS TO SEQUENTIAL THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) ADMINISTRATION IN CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP P. Olszynski* (US), C. Cromwell, M. P. Russin, L. M. Aledort, P. F. Fogarty PP-WE-705 IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) IN TWO MEMBERS OF A FAMILY: FAMILIAL ITP OR COINCIDENCE P. L. Junqueira, E. Okazaki, A. K. Zeinad, P. R. Villaca* (BR), D. A. F. Chamone, E. A. D’ Amico PP-WE-706 PLASMA APRIL LEVELS IN CHINESE PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA D. Gu, W. Du, J. Ge, Z. Chen, H. Zhao, L. Zhang, R. Yang* (CN) PP-WE-707 THE ROLE OF TIM-3 POLYMORPHISMS IN IDIOPATHIC THROMBOCYTOPENIC PURPURA W. Du, D. Wang, H. Zhao, J. Xu, D. Gu, F. Xue, J. Ge, R. Yang* (CN) PP-WE-708 PARAOXONASE-1 L/M 55 GENE POLYMORPHISM IN THE CASES OF IDIOPATHIC THROMBOCYTOPENIC PURPURA O. Cakici, S. Akarsu* (TR), D. Erol, B. Ustundag, H. Yuce PP-WE-709 ENOS GLU298ASP GENE POLYMORPHISM IN THE CASES OF IDIOPATHIC THROMBOCYTOPENIC PURPURA F. Arslan, S. Akarsu* (TR), M. Kara, B. Ustundag, H. Yuce PP-WE-710 SUCCESSFUL USE OF CYCLOSPORINE AS AN ADJUNCTIVE IMMUNOSUPPRESSIVE AGENT IN AN INFANTILE EVANS SYNDROME: A CASE REPORT AND LITERATURE REVIEW S. Hutspardol* (TH), S. Soonsawad, S. Wattanatittan, P. Siripattanapong PP-WE-711 IMMUNOMODULATORY THERAPY FOR REFRACTORY ITP WITH ALL-TRANS RETINOIC ACID Z. Wang* (CN), W. Liu, X. Bai, L. Cao, C. Ruan

290 PW-1 PERFORMANCEOF ANTI-HEPARIN/PLATELET FACTOR 4-ASSAYS INTHEDIAGNOSIS PP-WE-714 DETECTIONOF ANTI PLATELET FACTOR 4/HEPARIN ANTIBODIES USING PP-WE-713 PP-WE-712 POSTER PRESENTATIONS PP-WE-724 PP-WE-723 PP-WE-722 PP-WE-721 PP-WE-720 TO DIAGNOSE PF4-DEPENDENTENZYMEIMMUNOASSAY OF A THEUTILITY PP-WE-719 AND CASEOFSPONTANEOUS HEPARIN INDUCEDTHROMBOCYTOPENIA A PP-WE-718 PP-WE-717 PP-WE-716 ASSAYS FORDETECTIONOFIGG ANTI- PERFORMANCEOFTWONEWEIA PP-WE-715 Pathophysiology andClinicalStudiesofTTPII Pathophysiology andTreatment ofHITII 2009 WEDNESDAY, JULY 15, DETERMINA MOBILIZATION BLOODSTEMCELL (TMA)DURINGPERIPHERAL THROMBOTIC MICROANGIOPATHY THROMBOCYTOPENIC DISORDERSINKUWAIT ANDOTHER PATIENTS WITHTHROMBOTICTHROMBOCYTOPENIC PURPURA OAINLTRMOLSOER ANDAPTT THROMBOELASTOMETRY ROTATIONAL THROMBOCYT CARDIOVASCULAR DISEASEPATIENTS WITHHEPARIN-INDUCED CRITERIA CLINICAL (HIT)DEFINEDBY OF HEPARIN-INDUCED THROMBOCYTOPENIA ASSAYS ELISA COMMERCIAL GEL-P HEPARIN-INDUCED THROMBOCYTOPENIA: COMPARISON BETWEENTHESTANDARD FAMILIES CONGENIT AN EV ARGA INCHILDREN HEPARIN-INDUCED THROMBOCYTOPENIA THROMBOSIS TESTING SYSTEMID-H/PF4-P THERAPID RESULTS OBTAINED OF BY ANTI-PF4/HEPARIN ANTIBODY VARIABILITY COAGULATION) PARTICIPANTS THROMBOCYT TESTINGFORHEPARIN INDUCED ASSESSMENT AND LABORATORY CLINICAL (HIT INDUCED THROMBOCYTOPENIA PF4/HEPARIN ANTIBODIES (ABS)INPATIENTS SUSPECTEDOFHAVING HEPARIN- M. Jadaon*(KW), A. M. Al-Awadhi, H. A. Al-Jafar, H.J. Al-Wazzan H. V. K.Naina*(US),M. A. Gertz,M. A. Elliott A. Klukowska*(PL),E.Niewiadomska, U.Budde,F U. Schott*(SE),M.Rundgren,Engström S. Miyata*(JP),H. Yamamoto, Y. Ohkita,N. Yamada, T. Shimokawa,K.Myojin,H. Tomoike P. R. Yenson* (CA), A. K.Chan,S.Williams,L.R.Brandao M. T. Desancho*(US),K.S.Carlson, A. Mallik G. Colucci,S.Schneiter, I.Sulzer, G.Barizzi,B.Laemmle, L. Alberio* (CH) I. Jennings*(UK),D.P. Kitchen,S. T. A. L.Woods, D.Keeling,I.Walker C. Legnani*(IT),M.Cini,Frascaro,O.Boggian,F. Bettini,M.Poggi,B.Cosmi, G.Palareti N. Schwarz,B.Luxembourg*(DE),H.Kroll,M.Schindewolf,E.Lindhoff-Last A. F. Riddell*(UK),S.Brooks, A. Davenport,P. Chowdary A. Tomer* (IL),G. Abslander, S.Fleisher TROBAN RIL SA N H UCINLFLOWCYTOMETRIC ASSAY ANDTHEFUNCTIONAL ARTICLE ASSAY ALUA AL TION OFMONIT TION OF ADAMTS-13 AND VWF ANTIGEN AND ACTIVITY LEVELS IN LEVELS VWF ANTIGENANDACTIVITY AND OF ADAMTS-13 TION THROMBOTIC THROMBOCYT OPENIA PEI (HIT);CURRENTPRACTICE AMONGST UKNEQAS(BLOOD OPAENIA ANTICOAGULANT THERAPY ORING POSSIBILITIESOF AGIA PNCPRUAIN TWO POLISH OPENIC PURPURA WITH LOWINITIAL . Oyen,R.Schneppenheim ARGA TROBAN USING DOSAGE IN 291

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-725 PREDICTIVE VALUE OF PATIENT CHARACTERISTICS IN THE DIAGNOSIS OF CLINICALLY-SUSPECTED TTP M. J. Bentley* (US), A. R. Wilson, G. M. Rodgers PP-WE-726 ADAMTS13 LEVELS IN HIV INFECTED PATIENTS WITH AND WITHOUT TTP M. Meiring* (ZA), B. van Staden, K. van Hoorelbeke, H. Deckmyn, P. Badenhorst PP-WE-727 MATERNAL DEATHS DUE TO ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN LONDON, ENGLAND 2003-7 R. R. Thomas-Dewing* (UK), S. B. Lucas, B. J. Hunt PP-WE-728 CLINICAL ANALYSIS OF INTRACRANIAL HEMORRHAGE IN THE FIRST EPISODE IDIOPATHIC THROMBOCYTOPENIC PURPURA CHILDREN R. Wu* (CN), H. Ma PP-WE-729 SUB-CLINICAL CARDIAC AND RENAL COMPLICATIONS IN PATIENTS WITH MULTIPLE RELAPSES OF THROMBOTIC THROMBOCYTOPENIC PUPURA DURING LONG-TERM FOLLOW-UP S. Viswanathan* (US), B. H. Rovin, G. B. Shidham, S. V. Raman, J. N. George, H. M. Wu, S. R. Cataland PP-WE-730 ADAMTS13 IN THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) EVALUATION OF 11 CASES REVEALS 2 NEW MUTATIONS T. Fidalgo* (PT), P. Martinho, R. Salvado, T. Sevivas, C. Silva Pinto, D. Marques, E. Gonçalves, N. Martins, M. Ribeiro PP-WE-731 ELEVATED INTERLUKIN-21 AND IFN-R IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA X. Zhu, D. Ma, J. Zhang, J. Peng, M. Hou* (CN) PP-WE-732 THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC UREMIC SYNDROME IN PREGNANCY: A REPORT OF FIVE CASES Y. He* (CN), Y. Zhang, Y. Zhao, J. Hu, J. Zu, J. Yan, W. Yang

Platelet Function Tests II

PP-WE-733 MONITORING OF ANTIPLATELET AGENTS – NECESSARY IN PATIENTS WITH CARDIOVASCULAR DISEASES A. Siegemund* (DE), I. Körner, U. Scholz PP-WE-734 IN VITRO ASSAY FOR THE DETECTION OF NON CLASSICAL PLATELET DISORDERS AND FOR MONITORING THE EFFECT OF RECOMBINANT FACTOR VIIa K. Jurk, M. F. Brodde, S. Niemann, B. E. Kehrel* (DE) PP-WE-735 TEN YEAR EXPERIENCE WITH WHOLE BLOOD AGGREGOMETRY IN THE DIAGNOSIS OF THROMBOCYTOPATHY T. de Boer, R. Polenewen, I. Novakova, B. Verbruggen* (NL) PP-WE-736 EFFECTS OF DIFFERENT WAVELENGTH ULTRAVIOLET IRRADIATION ON PLATELET FUNCTION C. Terada* (JP), H. Okazaki, Y. Tani, M. Satake, K. Tadokoro PP-WE-737 THE CLINICAL SIGNIFICANCE OF HEPARIN/PLATELET FACTOR 4 ANTIBODIES AFTER CARDIAC SURGERY D. C. Filipescu* (RO), A. Calugareanu, M. Luchian, O. Ghenu, S. Marin, L. Dima, V. Uscatescu, H. Ghomchi, L. Iliuta, V. Iliescu

292 PW-4 TRDPAEE OL OETERAIIYTO FACILITATE STORED PLATELET POOLSLOSETHEIR AGGREGATIONABILITY BUT PP-WE-740 PP-WE-739 LOW-DOSE ASPIRIN ISNOT PLATELET CYCLOOXYGENASEINHIBITIONBY PP-WE-738 POSTER PRESENTATIONS PP-WE-749 COMPARISON WITH OF WHOLEBLOODMULTIPLATE IMPEDANCE AGGREGOMETRY PP-WE-748 MULTIPLE ELECTRODEWHOLEBLOOD PLATELET FUNCTION ASSESSMENT BY PP-WE-747 PP-WE-746 EFFECTONLIGHTTRANSMITTANCE AGGREGATION OF ADJUSTMENT OFPLATELET PP-WE-745 COHORTOF750STABLE IN A PLATELET REACTIVITY DETERMINANTSOFRESIDUAL PP-WE-744 PP-WE-743 THECONE-AND-PLATE(LET) ANALYZER FORTHEMONITORING OFCLOPIDOGREL PP-WE-742 AND CHARACTERISTICS,LABORATORY THEINFLUENCEOFCLINICAL PP-WE-741 ENSA,JL 5 2009 WEDNESDAY, JULY 15, PLA PLATELET REACTIVITY PLATELET FUNCTIONTESTSTO ASSESS RESIDUAL PIA AGGREGOMETRY OPTICAL RGTETDPTET IHCRNCPRCRILEFFUSION DRUG TREATED PATIENTS WITHCHRONICPERICARDIAL WHOLE BLOODTHROMBOCYTOPENIA OF MAINTAIN THEIRSUPPORTOFCLOTFORMATION MODEL AS EVALUATED IN A VOLUNTEERS CARDIOVASCULAR DISEASESINCOMPARISON TO HEALTHY PREVALENCE AND PROFILEOF ASPIRIN RESISTANCE INPATIENTS WITH ASPIRIN ‘RESIST PLATELET FUNCTION ASSAYS. IMPLICATIONS FOR BY REFLECTED CONSISTENTLY ANTIPLA DISEASE ON ARTERY INHIGHRISKPATIENTS WITHCORONARY AGGREGOMETRY ANTICOAGULANT PLATELET AGGREGATION INWHOLEBLOOD:SODIUMCITRATE ORHIRUDIN AS COUNT INPLA INSIGHT FROMTHE CARDIOVASCULAR PATIENTS TREATED WITH ASPIRIN AND/OR CLOPIDOGREL: PLA THERAPY MEASURED WITHDIFFERENTPLATELET FUNCTIONTESTS MARKERSON“HIGHON-TREATMENT PLATELET REACTIVITY” INFLAMMATORY AS S. F. Stein*(US), A. Rice, K.Lindstrom,C.H.Miller R. Paniccia*(IT),E. R. Paniccia*(IT),E. D. Prisco,R. Abbate, G.F. Gensini R. Paniccia*(IT),E. Antonucci, N.Maggini,E.Romano, A. Abdullahi Said,F. Sofi,L.Rossi, G. F. Gensini, R. Abbate R. Paniccia*(IT),E. Antonucci, E.Romano,N.Maggini, A. M.Gori,P. Bolli,D.Lami,I.Lapini, H. Bounameaux,F. Mach,P. deMoerloose,J.Reny P. Fontana*(CH),I.Barazer, C.Castelli,S.Nolli,P. Berdagué, P. Fabbro-Peray, J.Schved, N. V. Lomakin*(RU), A. Gruzdev, D.Privalov ten Berg,C.M.Hackeng N. J.Breet*(NL),W. vanWerkum, H.J.Bouman,E. A. M.Elsenberg,S.Postma,J. A. Verheugt, J.M.tenBerg,C.Hackeng N. J.Breet*(NL),W. vanWerkum, R.M. A. vandeWal, C. A. Zomer, H.J.Bouman,F. W. M. Andersen* (DK),J.Ingerslev, B.Sørensen,Møller T. Kaden,J.Hentrich,G.Nowak*(DE) Pettinella, A. Recchiuti,E.Ferrante,G.Ciabattoni,Davi,C.Patrono F DEMONSTRATE HIGH FALSE-POSITIVE RATES WITH MULTIPLE INSTRUMENTS D. Prisco,G.F. Gensini,R. Abbate Prisco, R. . Santilli*(IT),B.Rocca,R.deCristofaro,S.Lattanzio,L.Pietrangelo, TELET TELET CYCLOOXYGENASE-1 TELET THERAPY Abbate, G.F. Gensini : A AGGREGA COMP TELET ANCE’ Antonucci, N.Maggini,M.Miranda,R. Marcucci, Antonucci, N.Maggini,E.Romano,R. Marcucci,F. Cesari, A. M.Gori, D. RSNWT H LWYOERCVS SA AND ASSAY ARISON WITHTHEFLOWCYTOMETRIC VASP ADRIE STUDY -RICH PLASMA INADAPRELEASESTUDIESINDRUG-FREE NORMALS TION AND ATP ACTIVITY ON STABLE CARDIOVASCULAR PATIENTS IN P TET NDA ANTIPLATELET THERAPY ATIENTS ONDUAL IN NONSTEROIDAL ANTI INFLAMMA A. M.Gori, A. Vestrini, A. Habib,C. TORY 293

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-750 ASSESSMENT OF PLATELET FUNCTION IN NORMAL ADULTS: GENDER AND RACE DIFFERENCES IN PLATELET AGGREGATION AND ATP RELEASE S. F. Stein* (US), A. Rice, K. Lindstrom, C. H. Miller PP-WE-751 SPONTANEOUS THROMBOLYTIC ACTIVITY IN CORONARY ARTERY DISEASE S. Saraf, S. Sharma* (UK), D. Gorog PP-WE-752 UNIVERSAL NORMAL RANGES FOR LIGHT TRANSMITTANCE AGGREGOMETRY AND PLATELET FUNCTION ANALYZER (PFA-100 S. Nagalla* (US), J. F. Dong, P. F. Bray PP-WE-753 PFA100: A RELIABLE TOOL TO EVALUATE PATIENTS COMPLIANCE TO ASPIRIN THERAPY S. Basili* (IT), P. Pignatelli, R. Carnevale, S. di Santo, L. Loffredo, F. Violi PP-WE-754 PLATELET FUNCTION DETERMINATION IN PLATELET CONCENTRATES FOR TRANSFUSION S. Thomas* (UK) PP-WE-755 ASSESSMENT OF CLOPIDOGREL AND ASPIRIN THERAPY USING REMOTE PLATELET TESTING S. C. Fox* (UK), J. A. May, A. Shah, U. Neubert, S. Heptinstall PP-WE-756 MULTIPLATE WHOLE BLOOD IMPEDANCE AGGREGOMETRY: REFERENCE VALUES IN HEALTHY INFANTS, CHILDREN AND ADOLESCENTS S. Halimeh* (DE), G. Deangelis, C. Edelbusch, S. Thedieck, U. Nowak-Gottl PP-WE-757 PLATELET FUNCTION IN PATIENTS UNDERGOING AORTO-CORONARY ARTERY BYPASS SURGERY T. A. Suarez* (US), K. P. Bliden, M. J. Antonino, E. Mahla, A. Sequeria, P. W. Cho, U. S. Tantry, P. A. Gurbel PP-WE-758 PROTHROMBIN COMPLEX CONCENTRATE AND EFFECTS ON THE CONE AND PLATE ANALYSER U. Schott* (SE), L. Jirgård, K. Strandberg, A. Hillarp PP-WE-759 PLATELET REACTIVITY BEFORE AND AFTER ASPIRIN TREATMENT Y. Lee* (KR), H. Kim, H. Kang

Diagnosis and Treatment of Inherited and Acquired Platelet Disorders II

PP-WE-760 PREGNANCY-RELATED COMPLICATIONS IN WOMEN WITH RARE PRODUCTION- DEFECT THROMBOCYTOPENIAS B. Myers* (UK), D. Elliott, S. Pavord PP-WE-761 MINIMALLY-INVASIVE PARATHYROIDECTOMY WITH RECOMBINANT ACTIVATED FVII IN GLANZMANN´S THROMBASTHENIA C. Altisent* (ES), J. Baena, J. Ayats, J. Escoll, N. Purroy, M. Martorell, R. Parra PP-WE-762 JAK2V617F MUTATION IS ASSOCIATED WITH SPEEDED THROMBIN GENERATION A. Bauters, N. Cambier, N. Trillot, E. Jeanpierre, C. Caron* (FR), B. Jude, A. Renneville, C. Preudhomme PP-WE-763 THREE UNRELATED THROMBASTHENIA GLANZMANN PATIENTS WITH A SPLICING DONOR SIDE MUTATION OF GPIIB EXON 29 D. Westrup* (DE), R. Eisert, T. Scholz, D. Pillitteri, M. Krause, C. M. Kirchmaier

294 PW-6 NIC2 SATRAIET PEETM INPATIENTS ANTI-CD20 AS ALTERNATIVE WITHREFRACTORY TO SPLENECTOMY PP-WE-765 MUTATIONS INGPIX CHARACTERIZATION OFNOVEL MOLECULAR AND FUNCTIONAL PP-WE-764 POSTER PRESENTATIONS PP-WE-775 PP-WE-774 PP-WE-773 EFFECTOFHELICOBACTERPYLORIERADICATION INTHAI ADULT PATIENTS WITH PP-WE-772 SEVEREVONWILLEBRANDFACTOR/ADAMTS13 DYSBALANCE DEVELOPMENTOF A PP-WE-771 MUTATIONS AMONG TENUNRELATED IDENTIFICATION CHINESE OFEIGHTNOVEL PP-WE-770 PATIENT WITHBERNARDSOULIERSYNDROME:CASE OUTCOMEIN A FATAL PP-WE-769 NEW AUTOMATED CHEMILUMINESCENT ANTI-HEPARIN/PF4 IMMUNOASSAY: PP-WE-768 IN RECOMBINANTFACTOR VIIaISEFFECTIVEFORBLEEDING AND SURGERY PP-WE-767 INPATIENTS WITH BLEEDING DUETO ANGIODYSPLASIA GASTROINTESTINAL PP-WE-766 Micr 2009 WEDNESDAY, JULY 15, prilsII oparticles CD1 ADOACLREET NPTET IHCRNR REYDISEASE CARDIOVASCULAR ARTERY EVENTSINPATIENTS WITH CORONARY AND PROTEINDIAGNOSTICS IMMUNE THROMBOCYTOPENIC PURPURA.TWO YEARS FOLLOW-UP MISDIAGNOSED WITHIDIOP A AND BETA3 INTEGRINGIVINGRISETO BERNARD-SOULIERSYNDROME AND TO AN V TRANSPLANTATION STEM CELL PHASEOFHEMATOPOIETIC OF HEMORRHAGEINTHEEARLY STUDY CLINICAL IDIOP DURING LIVERTRANSPLANT PATIENTS WITHGLANZMANNTHROMBASTHENIA REPORT ANAL PATIENTS WITHGLANZMANNTHROMBASTHENIA INHERITED PLATELET FUNCTIONDISORDERS Alessi D. Faille,C.Frere*(FR), T. Cuisset,J.Quilici,P. Morange,I.Juhan-Vague, J. Bonnet,M. Z. Bagoly*(HU),F Y. Han*(CN),D.Wu, A. Sun,Z.Wang, C.Ruan W Y. Chinthammitr*(TH),N. Thongtanyong, Y. Nakkinkun, T. Ruchutrakool,B.Suwanawiboon, (NL) I. T. A. Pereboom,J. Adelmeijer, Y. vanLeeuwen,H.G.D.Hendriks,R.J.Porte, T. Lisman* T. Yu* (CN),X.Wang, Q.Ding,J.Dai, Y. Lu,X.Xi,H.Wang S. Stankovic*(MK),L.B.Hadzi-Pecova, S. Faraudo, A. Martinez,S.Morcillo,F. Robert, A. Katerchi,R.G.Barry*(US),I.Elalamy R. J.Nuñez*(ES),Perez-Garrido Makris N. R.Farquharson*(UK),Maclean,K.Hampton,M.McAlindon,J.vanVeen, M. F. Hernandez M. Alvarez* (ES),V. Jimenez,M.Martin,I.Fernandez,N.Butta,Muñoz,Rivas,Garcia, Roldán, V. Vicente, J.Rivera* (ES) A. Antón, L.Navarro-Núñez,M.Lozano,C.González-Manchón, A. Jayo,C.Martínez,V. Dukovski, S. Trajkova ARIANT TYPEGLANZMANNTHROMBASTHENIA:MOLECULARGENETIC, PRENA YIA GLANZMANN’STHROMBASTHENIA-LIKE SYNDROMEINTWOPATIENTS TYPICAL . Wanachiwanawin 1B-POSITIVE MICROP A YTICAL THIC THROMBOCYT PERFORMANCE INHITSUSPECTEDP . Fazakas, A. Marosi,J. Tóth, J.Kappelmayer, L.Muszbek ARTICLES ARE AN INDEPENDENTPREDICTOR OF OPENIC PURPURA A ATION THIC THROMBOCYTOPENIC PURPU T . Smilevska,L.Cevreska, A TIENTS T . Sotirova, A. Ljatifi,D. T AL 295

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-776 PHOSPHOLIPID-DEPENDENT PROCOAGULANT ACTIVITY OF PLATELET-DERIVED MICROPARTICLES IS RESTRICTED TO THE ANNEXIN V BINDING SUBPOPULATION D. E. Connor* (AU), T. Exner, D. D. F. Ma, J. E. Joseph PP-WE-777 THROMBOGENIC FUNCTION OF CIRCULATING MICROPARTICLES DOES NOT CORRELATE WITH MICROPARTICLE NUMBER H. Vetr* (AT), T. Perkmann, M. Graf, S. Geiter, V. Kaufmann, J. Mager, C. J. Binder, B. R. Binder PP-WE-778 A SHIFT FROM LOW NUMBERS OF CELLULAR MICROPARTICLES WITH HIGH SPECIFIC PROCOAGULANT ACTIVITY TO HIGH NUMBERS WITH LOW SPECIFIC PROCUAGULANT ACTIVITY DURING CHEMOTHERAPEUTIC LEUKEMIA TREATMENT: BEHAVIOUR OF BLAST-DERIVED MICROPARTICLES IN A PHOSPHOLIPID- A M. C. Trappenburg, M. van Schilfgaarde* (NL), P. J. Molenaar, W. E. Terpstra, A. Leyte PP-WE-779 ELEVATED LEVELS AND DIFFERENT SUBSETS OF PROCOAGULANT MICROPARTICLES IN BREAST CANCER PATIENTS USING HORMONAL THERAPY M. C. Trappenburg, M. van Schilfgaarde* (NL), H. M. Spronk, H. ten Cate, A. Leyte, W. E. Terpstra PP-WE-780 STANDARDIZED METHODOLOGY FOR IDENTIFICATION AND CHARACTERIZATION OF MICROVESICLES M. Jayachandran* (US), V. M. Miller, W. G. Owen PP-WE-781 ADIPONECTIN-DEPENDENT EFFECTS OF PITAVASTATIN ON PLATELET-DERIVED MICROPARTICLES, SOLUBLE CD40 LIGAND AND MCP-1 IN HYPERLIPIDEMIC PATIENTS N. Inami* (JP), S. Nomura, A. Shouzu, S. Omoto, T. Shimazu, D. Satoh, T. Kajiura, K. Yamada, T. Iwasaka PP-WE-782 PROTEOMIC ANALYSIS OF MICROPARTICLES DERIVED FROM HUMAN B CELLS INFECTED WITH DENGUE VIRUS N. de Bosch* (US), J. Evans, A. Becerra, K. Giaya, K. Green, K. J. Martin, I. Bosch PP-WE-783 MICROPARTICLES WITH PROCOAGULANT POTENTIAL IN THE ASPIRATE FROM THE CULPRIT CORONARY ARTERY OF PATIENTS WITH ACUTE MYOCARDIAL INFRACTION P. Min* (KR), S. Kang, H. Doh, S. Hong, H. Mun, J. Kim, E. Choi, B. Lee, Y. Yoon, B. Hong, S. Rim, K. Chung, H. Kwon PP-WE-784 FEMALE STEROID HORMONES AND ENDOTHELIAL FUNCTION IN IVF/ICSI PATIENTS B. Toth, A. Rank, U. Jeschke, K. Friese, C. Thaler, R. Nieuwland* (NL) PP-WE-785 STANDARDIZATION OF FLOW CYTOMETRY-BASED ENUMERATION OF PLATELET MICROPARTICLES USING CALIBRATED BEADS: RESULTS OF INSTRUMENT QUALIFICATION R. Lacroix* (FR), P. Poncelet, S. Robert, N. S. Key, F. Dignat-George, on behalf of the ISTH SSC Workshop PP-WE-786 EFFECT OF NEEDLE GAUGE, SHEAR RATE AND ANTICOAGULANT ON PLATELET ACTIVATION IN BLOOD COLLECTION T. Exner* (AU), K. Parsi PP-WE-787 INCREASED LEVELS OF CIRCULATING MICROPARTICLES IN AUTOIMMUNE DISEASES AND RELATION TO DISEASE ACTIVITY V. Proulle* (FR), J. Sellam, A. Jungel, M. Ittah, C. Miceli-Richard, J. Gottenberg, F. Toti, J. Benessiano, S. Gay, J. Freyssinet, X. Mariette

296 PW-9 CROCODILESMILE:BENEFIT AND RISKSOFCOMBINED ANTICOAGULANT AND PP-WE-790 PERSISTENTTHROMBOXANE-A2PRODUCTIONINTYPE1 AND TYPE2DIABETIC PP-WE-789 PP-WE-788 POSTER PRESENTATIONS PW-0 URINE11DEHYDRO-THROMBOXANEB2 CONCENTRATIONS ARE HIGHER POSTCABG PP-WE-800 TREATMENT ON PLATELET FUNCTION AND EFFECT OF LONG-TERMCLOPIDOGREL PP-WE-799 EFFECTOFEPTIFIBATIDE ADDED TO BIVALIRUDIN ONPERIPROCEDURAL PP-WE-798 COX-1SPECIFIC AND COX-1NON- ASPIRINRESPONSIVENESSMEASUREDBY PP-WE-797 PP-WE-796 COMBINEDWITHORAL ANTIPLATELET THERAPY COMPLICATIONS OFDUAL PP-WE-795 INDIABETICPATIENTS THE ANTIPLATELET RESPONSE TO CLOPIDOGREL PP-WE-794 PP-WE-793 PP-WE-792 TIMEEVALUATION OF REAL DETECTEDBY RESISTANCE TO CLOPIDOGREL PP-WE-791 Patient-oriented StudiesofAntiplateletTherapyII 2009 WEDNESDAY, JULY 15, OPRDWT ELH CONTROLS COMPARED WITHHEALTHY STENTING INFLAMMATION ARTERIAL INPATIENTS UNDERGOING CORONARY RAE AINSWT CT YCRILINFARCTIONTREATED PATIENTS WITH ACUTE MYOCARDIAL TYPE-2 DIABETESMELLITUS INCVD ANTIPLATELET THERAPY PATIENTS UNDERCHRONIC ASPIRIN TREATMENT ARTER REDUCED PLATELET RESPONSETO ASPIRIN INPATIENTS WITHCORONARY INFLAMMA «RESISTANCE» SUBJECTS:CLARIFYINGTHEDEBATE ON ASPIRIN SPECIFIC METHODSINHEALTHY A ANTICOGULATION SYNDROMES INPATIENTS POST ACUTE CORONARY STENTING UNDERGOING ELECTIVECORONARY EV PROSPECTIVE STUDY OCCLUSIVEDISEASE- A ARTERIAL TREATMENT INPATIENTS WITHPERIPHERAL PLATELET FUNCTIONDESPITECLOPIDOGREL OFRESIDUAL VARIABILITY PLATELET THROMBUSFORMATION N. C.Raju*(CA),M. Teague, H.Jung,J.Sun,S. Anand, J.Eikelboom M. J. Antonino* (US),E.Mahla,K.Bliden,U.S. Tantry, P. A. Gurbel Gesheff, S. Yadav, U.S. Tantry, P. A. Gurbel M. J. Antonino* (US),K.P. Bliden, T. A. Suarez,W. R.Herzog, A. K.Bassi,M. S. Hamed, T. M. J. M. M. Banaszewski*(PL),J.Stepinska F. Saucedo, P. A. Gurbel K. P K. Takano* (JP), Y. Kimura,K.Sato, Aida, T. Kobayashi, Y. Ozaki J. Schwonberg*(DE),B.Linnemann,S.W Presbitero, L.Rota,Z.M.Ruggeri G. L.Mendolicchio*(IT),D.Zavalloni,E.Corrada,M.Rossi,Marconi,Bacci,P. G. Corinaldesi*(IT),C.Corinaldesi D. Pitocco,F. Crea F. M.Pulcinelli*(IT),L.Biasucci,S.Riondino,Giubilato, A. Leo,L.diRenzo,E. Trifiro’, S. B.Mortensen,Larsen,E.L.Grove,D.Kristensen, A. Hvas*(DK) Lawal, S.Kotev, U.S. Tantry, P. Gurbel T ORVASTATIN REDUCESPERSISTENTPLATELET TXA2SYNTHESISIN ASPIRIN- ALUA T. Santos* (ES),M.P. Fuset,M.Ruano, A. Moscardó,J.Valles . Bliden*(US),L.Lawal, Antonino* (US),K.P DISEASE AND TYPE2DIABETESMELLITUS Y TION OF TION AND PLATELET FUNCTIONINELECTIVE STENTING ASPIRIN RESIST . Bliden,R.Coppolecchia,M.Geshef A. Singla,S. Yadav, J.Dichiara, M. J. Antonino, U.S. Tantry, J. ANCE IN . T oennes, H.Mani,E.Lindhof ASPIRIN-FREE PATIENTS WITHSEVERE f, P. A. Gurbel, A. Singla,L. f-Last 297

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-801 THE ANTIPLATELET EFFECT OF A NEW, DIRECT ACTING, REVERSIBLE P2Y12 INHIBITOR, ELINOGREL (PRT060128) IN PATIENTS WITH HIGH PLATELET REACTIVITY DURING CLOPIDOGREL THERAPY P. A. Gurbel* (US), K. Bliden, M. Antonino, P. Andre, G. Stephens, D. Gretler, M. Jurek, A. Hutchaleelaha, A. Singla, T. Suarez, P. Conely, U. Tantry PP-WE-802 CYTOCHROME P450 2C19 GENOTYPE IS A MAJOR DETERMINANT OF CLOPIDOGREL RESPONSE AND A PREDICTOR OF POST-STENTING ISCHEMIC EVENT OCCURRENCE P. A. Gurbel* (US), K. Bliden, K. Ryan, W. Herzog, M. Antonino, U. Tantry, A. Shuldiner PP-WE-803 PA32520 (SINGLE-TABLET OF IMMEDIATE-RELEASE OMEPRAZOLE 20 MG + ENTERIC-COATED ASPIRIN 325 MG): SAFER ASPIRIN THERAPY WITH GREATER THROMBOXANE SUPPRESSION P. A. Gurbel* (US), J. G. Fort, E. Orlemans, J. Planchetka PP-WE-804 COMPARISON OF THE DIFFERENT METHODS OF MONITORING THE EFFECT OF ASPIRIN AND CLOPIDOGREL IN PATIENTS WITH PERCUTANEOUS CORONARY INTERVENTION P. Smejkal* (CZ), P. Kala, J. Zavrelova, M. Poloczek, J. Spinar, M. Penka PP-WE-805 ENDOTHELIN-1 DUAL RECEPTOR ANTAGONIST AND THE EFFECT ON PLATELET FUNCTION IN PULMONARY ARTERIAL HYPERTENSION S. J. Davidson* (UK), S. J. Wort, L. A. Parfitt, T. J. Corte, J. Park, C. Harries, M. Gatzoulis PP-WE-806 IMMUNE THROMBOCYTOPENIC PURPURA-RELATED HEMOTYMPANUM PRESENTING WITH HEARING LOSS T. Fisgin* (TR), S. Atmaca, F. Duru, E. Ozyurek, R. Cetin, D. Albayrak

Atherosclerosis II

PP-WE-807 MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: A BURNING QUESTION G. Corinaldesi* (IT), C. Corinaldesi PP-WE-808 MATRIX GLA-PROTEIN: A RISK MARKER FOR VASCULAR CALCIFICATION THAT CAN BE MODIFIED BY VITAMIN K L. J. Schurgers* (NL), E. C. M. Cranenburg, C. Vermeer PP-WE-809 THE NUCLEAR RECEPTOR FXR AS A NOVEL REGULATOR OF PLATELET FUNCTION L. A. Moraes* (UK), M. Spyridon, D. Bishop-Bailey, J. M. Gibbins PP-WE-810 FBM PIGS: HUMAN-SIZED PIGS WITH HUMAN-LIKE ATHEROSCLEROSIS C. Bal Dit Sollier, T. Thim, M. Bonneau, C. Kang, J. Brouland, N. Berge, M. Beauchaton- Piallat, C. Chaabane, E. Falk, L. Drouet* (FR) PP-WE-811 ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS (SNP) IN METHIONINE SYNTHASE (MTR) AND BETAINE-HOMOCYSTEINE METHYL TRANSFERASE (BHMT) GENES WITH CORONARY ARTERY DISEASE (CAD): ROLE OF DIETARY FACTORS ON HOMOCYSTEINE M. S. Mukherjee* (IN), P. R. Singh, K. R. Shetty PP-WE-812 LIPID PENTAD INDEX IN NORMOLIPIDEMIC PATIENTS UNDERGOING CORONARY ANGIOGRAPHY L. M. Lima, M. Carvalho* (BR), M. O. Sousa PP-WE-813 IDENTIFICATION OF BIOMARKERS FOR VULNERABLE PLAQUE M. P. Brennan* (IE), J. Padickakudi, G. Kirwan, C. L. Jackson, D. Cox PP-WE-814 POLYMORPHISM -1131T> C IN THE APOLIPOPROTEIN A5 (APOA5) GENE IN YOUNG SUBJECTS WITH DYSLIPIDEMIAS IN MINAS GERAIS STATE, BRAZIL M. O. Sousa* (BR), D. D. V. Brito, F. F. Coelho, N. G. Cruz, I. R. Santos, A. P. Fernandes, K. B. Gomes 298 PW-1 THEEFFECTOFLEPTINONVASCULAR CALCIFICATION IN APOLIPOPROTEIN E- PP-WE-817 PP-WE-816 IN LEVEL EFFECTSOF APOLIPOPROTEIN EPOLYMORPHISMS ONLIPIDPLASMA PP-WE-815 POSTER PRESENTATIONS PW-2 THEVALUE OFD-DIMER AND FIBRINMONOMER AS PROGNOSTICMARKERS OF PP-WE-829 DISEASEIN ARTERY IDENTIFICATION AND PREDICTIONOFRISKFORCORONARY PP-WE-828 PP-WE-827 WITHINSULIN ASSOCIATION OFFACTOR VIIHYPERCOAGULANT ACTIVITY PP-WE-826 PP-WE-825 GROWTHFACTOR GENE POLYMORPHISMS AND VASCULAR ENDOTHELIAL PP-WE-824 HUMAN ATHEROSCLEROTIC PLAQUESPOTENTIATE PLATELET AGGREGATION: PP-WE-823 PP-WE-822 BETWEENVARIANTS INGAS6-TAM GENES AND ASSOCIATIONATHEROMA STUDY PP-WE-821 PP-WE-820 ASSOCIATION OFBLOODCELLULARMARKERSWITHCAROTIDPLAQUESIZE AND PP-WE-819 PLATELET-DEPENDENT FLOW LYMPHOCYTE ADHESION UNDER ARTERIAL PP-WE-818 ENSA,JL 5 2009 WEDNESDAY, JULY 15, MICROPARTICLES AND ANGIOPOIETIN-2 INPATIENTS WITHTYPE2DIABETES OOAYSYNDROME CORONARY DEA PREDISPOSED ASIAN INDIANFAMILIES DEFICIENT MICE P LEVELSINDYSLIPIDEMIC AND/OR ISCHEMIC LIPID- LIPOPROTEINPLASMA EFFECTS OF APOLIPOPROTEIN EC.471T>C AND C.609C>TPOLYMORPHISMS ON CHILDREN AND TEENAGERSINMINASGERAISSTATE, BRAZIL EICOSAPENT RESIST OBESEHYPERTENSIVES ABDOMINALLY F MICROVASCULAR HYPERTENSION COMPLICATIONS INPATIENTS WITHESSENTIAL ROLE OFMMP-2 PROTEIN S CAROTID PLAQUE HIGH-RISK COMPOSITION CONDITIONS: EVIDENCEFROMINVITRO AND INVIVOSTUDIES T. Brügger-Andersen*(NO), V. Pönitz,H.Staines, Grundt, D.Nilsen S. Hebbagodi*(IN),V. S.Rao,K.Sibi,John,J.Shanker, V. V. Kakkar S. Nomura*(JP),N.Inami,Omoto, A. Shouzu, T. Ueba R. A. Karatela*(IN),G.Sainani R. A. Karatela*(IN),G.Sainani M. Proietti, R. Palmirotta,P. Ferroni*(IT),G. Ludovici,F. Martini, A. Savonarola,M.Ciancia,V. Raparelli, P B. Hurtado,X.Muñoz,N.Garcia,J.Krupinski,Sala,P. GarciadeFrutos*(ES) B. Hurtado,N. N. V. Akulich* (BY),N.G.Kruchinsky Sharrett N. Matijevic*(US),K.Wu, A. G.Howard,B.Wasserman, W. Wang, A. R.Folsom, L. Zhu,H.Hu,Q.Ji,N.Li*(SE) M. G.Zeadin*(CA),Butcher, G.H.Werstuck, M.I.Khan,C.K. Yee, S.G.Shaughnessy M. O.Sousa*(BR),P. Alía, M.Navarro,E.Corbella,X.Pintó M. O.Sousa*(BR),D.V IFRNIL ESPRESSEDINCAROTID ATHEROSCLEROTIC PLAQUES DIFFERENTIALY . Gresele*(IT),M.Pompili,Lenti,E.Falcinelli,G.Giordano, T. Corazzi,P. Cao CO I YECAUATATVT N YELPIEI AMONG ANDHYPERLEPTINEMIA ACTOR VIIHYPERCOAGULANT ACTIVITY ATIENTS HA 0DY OLWU INCHEST PAINTH PATIENTSAT 30DAYS WITHSUSPECTED ACUTE FOLLOW-UP ANCE INCORONAR A. Scarno,S.Riondino,Basili,F A AND TYROSINEKINASERECEPT THEROSCLEROSIS OFMOGILEVSCHOOLCHILDREN AENOIC Abasolo, X.Muñoz,N.Garcia,J.Krupinski,P ACID IMPROVES . Brito,K.B.Gomes, A. P. Sabino,J.E.Cardoso, A. P. Fernandes Y HEART DISEASE ADIPONECTIN, ENDOTHELIAL . Guadagni ORS TYRO3, . GarciadeFrutos*(ES),N.Sala AXL AND MERTK CELL-DERIVED ARE 299

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-830 WOULD THE USE OF N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE AS A PROGNOSTIC MARKER HAVE CHANGED OUR CLINICAL JUDGEMENT T. Brügger-Andersen* (NO), H. Aarsetøy, H. Grundt, D. W. T. Nilsen PP-WE-831 EVALUATION OF PLAQUE DESTABILIZATION BY PREGNANCY-ASSOCIATED PLASMA PROTEIN A (PAPPA) AND COAGULANT ACTIVITY DID NOT PREDICT RECCURENT TROPONIN-T POSITIVE CARDIAC EVENTS FOLLOWING AN ACUTE MYOCARDIAL INFARCTION T. Brügger-Andersen* (NO), H. Aarsetøy, H. Grundt, D. W. T. Nilsen PP-WE-832 USEFULNESS OF C-REACTIVE PROTEIN AS A MARKER FOR PREDICTION OF FUTURE CORONARY EVENTS IN THE ASIAN INDIAN POPULATION V. S. Rao, B. K. Natesha, H. Sridhara, J. Shibu, V. V. Kakkar* (UK) PP-WE-833 ASSOCIATION OF SOLUBLE TWEAK WITH CORONARY ARTERY DISEASE IN THE ASIAN INDIAN POPULATION V. S. Rao, B. K. Natesha, S. Niladri, H. Sridhara, J. Shibu, V. V. Kakkar* (UK) PP-WE-834 UTILITY OF CYTOMETRIC BEAD ASSAY FOR SIMULTANEOUS DETECTION OF MULTIPLE INFLAMMATORY MARKERS IN URINE SAMPLES: THE INDIAN ATHEROSCLEROSIS RESEARCH STUDY V. S. Rao, B. K. Natesha, U. Balakrishnan, V. V. Kakkar* (UK) PP-WE-835 DEPLETION OF ANTIOXIDANT CAPACITY IN HYPERHOMOCYSTEINEMIC PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE V. M. Shmeleva* (RU), L. P. Rybakova PP-WE-836 IMMUNE RESPONSE IN BALB/C MICE BY USING A MULTIFUNCTIONAL EPITOPES INTRODUCED INTO A DENDROASPIN PROTEIN SCAFFOLD X. Lu* (UK), V. Endresz, M. Xia, G. Qi, D. Chen, I. Faludi, K. Burián, A. Csanadi, A. Miczák, E. Gonczol, V. Kakkar

Signal Transduction in Vascular Cells

PP-WE-837 SERINE 253 REGULATES THE INCORPORATION OF TISSUE FACTOR AND RELEASE AS MICROPARTICLES C. Ettelaie* (UK), M. E. W. Collier PP-WE-838 RAP1 REGULATES VASCULAR SMOOTH MUSCLE CELL ADHESION, SPREADING AND PROLIFERATION, MIGRATION AND RESPONSE TO THROMBIN: IMPLICATION FOR NEOINTIMAL FORMATION J. Huang* (US), G. A. Stouffer PP-WE-839 FXa-INDUCED INTRACELLULAR SIGNALING LINKS COAGULATION TO NEOANGIOGENESIS: POTENTIAL IMPLICATIONS FOR FIBROSIS K. S. Borensztajn* (NL), H. Aberson, M. Peppelenbosch, A. Spek PP-WE-840 EXOGENOUS TISSUE FACTOR STIMULATES VASCULAR ENDOTHELIAL CELL PROLIFERATION THROUGH ACTIVATION OF THE ERK1/2 PATHWAY M. E. W. Collier* (UK), C. Ettelaie PP-WE-841 THE HYALURONIC ACID-BINDING PROTEASE HABP STIMULATES MMP-2 AND UPA ACTIVITY IN FIBROBLASTS, BUT INITIATES CELL INVASION IN AN UPA- INDEPENDENT WAY M. Etscheid* (DE), N. Beer, R. Seitz, J. Dodt PP-WE-842 “MODULATION OF UPAR SIGNALING TO ERK/MAPK BY ENDOCYTIC RECEPTORS OF THE LDLR FAMILY” N. Geetha* (AT), J. Mihaly, B. R. Binder

300 PW-4 INFLUENCEOF ANGIOTENSIN-(1-7) ONTHEEXPRESSIONOFTISSUEFACTOR PP-WE-846 THEFLAVONE CHRYSIN INHIBITS PDGF- AND OXIDATIVE STRESS-INDUCED PP-WE-845 PP-WE-844 MIGRATION REQUIRESUROKINASE CELL ENDOTHELIAL VEGF-INDUCEDINITIAL PP-WE-843 POSTER PRESENTATIONS PW-5 ACLGNCMMCYO CT EKMCBN ARWSRMLCELLS. OF ACUTE LEUKEMICBONE MARROWSTROMAL VASCULOGENIC MIMICRY PP-WE-855 REPAIR ANGIOTENSIN IIRECEPTOR BLOCKADEINCREASESENDOTHELIAL PP-WE-854 GROWTHFACTOR VASCULAR PATTERN ENDOTHELIAL OFCIRCULATORY PP-WE-853 ALTERED TRAFFICKING OFBONEMARROW-DERIVED CXCR4+PROGENITOR CELLS PP-WE-852 EFFECTSOF ASPIRIN ONCIRCULATING HEMATOPOIETIC STEMCELLS AND PP-WE-851 PP-WE-850 PP-WE-849 PP-WE-848 CELL-DRIVEN ANGIOGENESIS AND NEUROGENESIS AFTER STROKEISREGULATED PP-WE-847 Angiogenesis II 2009 WEDNESDAY, JULY 15, ROLE OFIGF-1 (PAD) POTENTIAL NUE YLSADISMCAIM NVSUA NOHLA CELLS LPS AND ITSMECHANISMSINVASCULAR ENDOTHELIAL INDUCED BY SIGNALING INVASCULAR SMOOTHMUSCLECELLS HYPERPLASIA ROLE OFCERAMIDE1-PHOSPHATE ONNEOINTIMAL RECEPTOR FORINTEGRIN REDISTRIBUTION L RECEPT FOLLOWING CARDIACSURGER ENDOTHELIAL HEMODIALYSIS PATIENTS PROGENIT SMOOTH MUSCLEPROGENIT SPECIFICSUBPOPULATION OF ON A INHIBITION OFTISSUEFACTOR ACTIVITY REGENERA TRANSPLANTATION SUBSET OFSMOOTHMUSCLEPROGENITOR CELLSFOUNDCIRCULATING POST- SPECIFIC CELLSINTRANSPLANT ARTERIOSCLEROSIS RESEMBLE A NEOINTIMAL PLATELET MICROPARTICLES BY Calandini, J.Marie, C.Soria,J.M.Mirshahi P C. M.Ferrario P. J.Levy*(US),W. B.Strawn,K.Brosnihan,L.C.Moore,J.Holbrook,Hansen, O. Elbaz*(EG), A. M.Eldemeri, M.S.Elashry O. Dotsenko*(UK),Q.Xiao,Xu,M.Jahangiri Rabelink, M.V. Huisman M. C.Hovens*(NL),H.deBoer, J.D.Snoep, T. Tamsma, A. vanZonneveld, T. J. N. Jourde-Chiche,L.Dou,F D. Chen*(UK),J.M. Abrahams, J.H.McVey, A. Dorling D. Chen*(UK),J.M. Abrahams, J.H.McVey, A. Dorling D. Varon* (IL), Y. Hayun, A. Brill,R.Leker X. He*(CN),J.Hu,H.Wang, X.Shen,S.He,Z.Wen W. Wu* (TW),H.Lo,M.Wu T. Kim*(KR), Y. Lim,H.Han,Lee,M.Song,Chung, Y. Kim,H. Yoo, Y. Yun R. RANDOMIZED CROSSOVERTRIAL YMPHOCYTIC LEUKEMIA . Mirshahi*(FR), A. Rafii,L.Vincent, A. Berthaut,R.Varin, G.Kalantar, C.Marzac,O. A. Alexander* (AT), J.M.Breuss,G.W. Prager, B.R.Binder R EF- N EF- NPTET IHBCL CHRONIC ORS (VEGFR-1 AND VEGFR-2)INPATIENTS WITHB-CELL OR CELLS TIVE REP NYUGRAUT IHSVR EIHRLATRA DISEASE ARTERIAL IN YOUNGER ADULTS WITHSEVEREPERIPHERAL PROGENIT I FE NOUIA NUYASSOCIATED WITH INJURY AIR AFTER ENDOLUMINAL ARE RELA . Sabatier OR CELLSINP ORS Y TED T WITH THEUSEOFCARDIOPULMONAR , R.Calaf,C.Cerini,P ACLRIJR ANDUREMICTOXINS IN O VASCULAR INJURY A TIENTS WITHTYPE2DIABETES: . Brunet,F . Dignat-George*(FR) BYPASS Y A 301

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-856 AGE-DEPENDENT IMPAIRMENT OF NUMBER AND ANGIOGENIC POTENTIAL OF ADIPOSE TISSUE – DERIVED PROGENITOR CELLS R. Madonna, F. Renna, C. Cellini, R. Cotellese, N. Picardi, P. Innocenti, R. de Caterina* (IT) PP-WE-857 CHANGES OF COAGULATION AND INFLAMMATION BY TRANSPLANTATION OF TF SILENCED HUMAN EPCS IN ENDOTOXEMIC MICE S. Xiong* (CN), Q. Wang, L. Zheng, J. Bao, X. Huang, J. Liu, F. Zeng, Y. Qiu PP-WE-858 THE PRESENCE OF BONE MARROW CELLS-DERIVED MICROPARTICLES IMPAIRS THE EFFICACY OF CARDIAC CELL THERAPY S. Susen* (FR), G. Lemesle, C. Charbonnel, C. Delhaye, D. Corseaux, T. Le Tourneau, O. Fabre, P. Marchetti, R. Nevière, E. vanBelle, B. Jude, F. Mouquet PP-WE-859 LINEAGE NEGATIVE MONONUCLEAR CELLS : A MAJOR SOURCE OF MURINE ENDOTHELIAL PROGENITOR CELLS V. Barbay* (FR), V. Richard, J. Borg, O. Boyer, C. Thuillez, E. Brakenhielm

Shear-induced Signaling

PP-WE-860 A MICROFLUDIC SYSTEM DESIGNED TO OBSERVE PLATELET BEHAVIOR UNDER CONTROLLED SHEAR IN REAL TIME C. G. Conant* (US), M. Schwartz, C. Ionescu-Zanetti PP-WE-861 PLATELET ADHERENCE TO PROTEINS UNDER SHEAR FLOW CONDITIONS J. L. Berry, R. R. Hantgan* (US), M. Guthold, D. C. Sane, P. J. Nelli, N. Wajih PP-WE-862 ENHANCED OUTSIDE-IN SIGNALING RELATED TO THE PRO33 (HPA-1B) VARIANT OF PLATELET INTEGRIN ALPHAIIB BETA3 R. E. Scharf, M. Gyenes* (DE), M. Hasse, V. R. Stoldt PP-WE-863 INTRAVENOUS OZON IN MULTI-DRUG RESISTANT PULMONARY TUBERCULOSIS N. V. Yahorava* (BY), H. L. Hurevich, A. M. Skrahina, E. E. Konstantinova, E. V. Mironova, D. A. Milyutina PP-WE-864 CORRECTION OF MICROCIRCULATORY AND RHEOLOGICAL DISORDERS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE N. V. Yahorava* (BY), E. E. Konstantinova, H. L. Hurevich, E. V. Mironova, D. A. Milyutina PP-WE-865 THE HPA-1B (PRO33) VARIANT OF INTEGRIN ALPHAIIB BETA3 INCREASES THE RESISTANCE OF ADHERENT PLATELETS UPON EXPOSURE TO SHEAR STRESS R. E. Scharf* (DE), V. R. Stoldt

Endothelial Dysfunction II

PP-WE-866 TADALAFIL IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR RISK FACTORS: EFFECTS ON PLATELETS AND ENDOTHELIUM E. de Bon, G. Bonanni, P. Bassi, G. Saggiorato, S. Imbergamo, C. Giuseppe* (IT), O. Iqbal, J. Fareed PP-WE-867 INCIDENCE, RISK FACTORS, COAGULATION DISTURBANCES AND OUTCOME OF PEDIATRIC PATIENTS WITH VOD AFTER SCT – A SINGLE CENTRE EXPERIENCE D. M. Jevtic* (RS), D. Vujic, Z. Zecevic, D. Veljkovic, S. Gazikalovic, I. Elezovic PP-WE-868 INFLAMMATORY CYTOKINES PRESENT IN SMOKERS’ SERUM MODULATE CYCLOOXYGENASE-2 EXPRESSION VIA NADPH-OXIDASE IN ENDOTHELIAL CELLS S. S. Barbieri, E. Zacchi, S. Gianellini, P. Amadio, B. B. Weksler, E. Tremoli* (IT)

302 PW-7 OTIUINO OHUEI ANDSUBSTITUTIVETHERAPIESINTHE CONTRIBUTIONOFBOTHUREMIA PP-WE-871 PP-WE-870 THROMBOMODULININPREECLAMPSIA PLASMA PP-WE-869 POSTER PRESENTATIONS PP-WE-882 PP-WE-881 EVALUATION OF HEMATOLOGIC CANDIDATES FACTORS IN YOUNG AND ELDERLY PP-WE-880 ISCHANGED AFTER CONTACT WITH CELL PROTEOMEOFENDOTHELIAL PP-WE-879 DYSFUNCTION AND ONENDOTHELIAL EFFECTSOFCHILDHOODOBESITY PP-WE-878 NITRICOXIDESYNTHASEGENEPOLYMORPHISMS (-786T>C,4A4B, ENDOTHELIAL PP-WE-877 LEVELS PROTEINCRECEPTOR AND HIGHSENSITIVECRP SOLUBLEENDOTHELIAL PP-WE-876 PP-WE-875 MOLECULARSTRUCTURE AND ANTIOXIDANT EFFECTOF A X-RAY PP-WE-874 RESULTS IN ALTERATIONS IN CELLSWITHCRP INCUBATION OFENDOTHELIAL PP-WE-873 GENETICPOLYMORPHISMS OFENDOTHELIN-RELATED GENES ASSOCIATED WITH PP-WE-872 ENSA,JL 5 2009 WEDNESDAY, JULY 15, NOHLA INFLAMMATION ENDOTHELIAL CELLS AND MODULATES TUMORNECROSISFACTOR-ALPHA-INDUCED GAP IN RESTENOSIS AFTER PCI LP(A) LIPOPROTEIN,ADHESIONMOLECULE FOR CORONAR FAILURE DYSFUNCTION INPATIENS WITHCHRONICRENAL DEVELOPMENT OFENDOTHELIAL PATIENTS THALASSEMIA IN HOMOZYGOUSBETA CYT ANDVASCULAR ENDOTHELIUM ABNORMAL HYPERCOGULABILITY THE PLASMA RIIILSURFACES OFBIOMATERIALS ARTIFICIAL COAGULATIVE ACTIVATIONCHILDREN ANDADOLESCENTS OBESE IN SPONT 894G>T) AND HAPLOTYPESINPATIENTS WITHIDIOPATHIC RECURRENT IN OBESITY PKC-MMP-14 BUTYLAMINOESTROGEN DERIV RIEXPRESSION SURFACE FCGAMMA HYPERTENSIVES TWENTY-FOUR HOURSBLOODPRESSUREVARIATIONS INJAPANESE VASCULAR COMPLICATIONS PRODUCTION: INVOLVEMENT OFSTIE-2INDIABETESMELLITUS-ASSOCIATED T S. M.Pantovic*(ME),E.Pejovic S. P M. F N. Kim*(KR),S.Shin,D.Choi,J.Lee,Shim,Oh B. Taskiran, S.Guldiken,M.Demir* (TR), T. Kilic-Okman M. Onimaru*(JP), Y. Murakami, Y. Ikeda, T. Ishibashi,K.Sueishi M. Flores*(MX),L.DelValle, B.Valente, L.Quintanar, J.Fernandez-G,V. Salgado, A. deLaPeña M. Shahidi*(UK),L.Powell,E.Oviedo-Orta,K.Bodman-Smith M. Banno*(JP),K.Kamide, T. Horio, T. Miyata, Y. Kawano M. Diaz-Ricart*(ES),Palomo, A. Cases,P. Molina,F. Navalon,G.Escolar Guido, R.Musso M. Musso*(IT),D.Cultrera, L. M.S.Dusse*(BR),C.Godoi,H.Madeira,B. A. Lwaleed,M.G.Carvalho Altomare, L.Piacente,Cavallo,D.deMattia . Okamoto*(JP), T. Hayashi,K.Suzuki . Komorowski*(PL),H.Jerczynska,Z.Pawlowska,B.W Ayaz* (TR), A. Aksöyek, U. Tutun, T. A. Ulus,S.B.Guney . Faienza,P KNS EES A INFLUENCETHEPROGRESSION OFTHEOSTEOPATHY RELEASEMAY OKINES’ JUNCTION PROTEIN, CONNEXIN32ISEXPRESSEDIN V ANEOUS AXIS REGULA . Giordano*(IT),V Y ABORTION (RSA) REYBYPASS GRAFTING ARTERY A. Cipolla,M.Rosso,G.Colletta,Ferro,B.Ximenes, TES ENDOTHELIAL . Cecinati,M.Grassi,Delvecchio,L.P A TIVE AND CYT SOLUBLE TIE-2(STIE-2) alkowiak OKIN:ROLE AND INTERACTION OKIN:ROLE AND ASCULAR ENDOTHELIAL . Brescia,M. 303

Wednesday Posters POSTER PRESENTATIONS WEDNESDAY, JULY 15, 2009

PP-WE-883 ENDOTHELIAL DYSFUNCTION AND TNF-ALPHA IN YOUNG MEN WITH MULTIPLE CARDIOVASCULAR RISK FACTORS T. B. Domagala* (PL), R. Januszek, K. Kotula-Horowitz, J. Dropinski, T. Iwaniec, A. Szczeklik PP-WE-884 IMPROVEMENT OF ENDOTHELIAL FUNCTION AND REDUCTION OF PROINFLAMMATORY MARKERS IN SIMVASTATIN TREATMENT T. B. Domagala* (PL), R. Januszek, K. Kotula-Horowitz, T. Iwaniec, M. Kaszuba, S. Polanski, A. Szczeklik PP-WE-885 HIGH LEVELS OF CIRCULATING ENDOTHELIAL CELLS IN HEART FAILURE V. Martínez-Sales* (ES), V. Vila, I. Sánchez-Lázaro, L. Almenar, T. Contreras, E. Reganon

Inflammation and Cell Trafficking II

PP-WE-886 ACE INHIBITION REDUCES MONOCYTE MFG-E8 AND MCP-1 EXPRESSION IN RATS WITH CHRONIC HEART FAILURE J. Pfrang* (DE), D. Fraccarollo, J. Bauersachs, A. Schaefer PP-WE-887 ACTIVE VON WILLEBRAND FACTOR (VWF) IN PLASMA OF SICKLE CELL PATIENTS IS AN INDICATOR OF DISEASE SEVERITY J. Chen* (US), W. Hobbs, J. Le, P. Lenting, P. G. de Groot, J. A. Lopez PP-WE-888 THROMBOSPONDIN-1 INDUCES TNF ALPHA AND IL-6 GENE EXPRESSION ON HUMAN FIBROBLASTS M. C. Rico* (US), J. J. Rough, F. E. Del Carpio-Cano, F. F. Safadi, S. P. Kunapuli, R. A. Dela Cadena PP-WE-889 THE RELATIONSHIPS BETWEEN VASCULAR ENDOTHELIAL GROWTH FACTORS, PARAMETERS OF INFLAMMATION AND PATIENTS’ SURVIVAL IN ADVANCED NONSMALL CELL LUNG CANCER V. Demir, M. Demir* (TR), I. Cicin, G. E. Pamuk, E. Ozturk, E. Tekgunduz, T. Caglar PP-WE-890 PLATELETS ENHANCE T HELPER CELL ACTIVATION N. Gerdes* (SE), M. Ersoy, G. K. Hansson, P. Hjemdahl, N. Li PP-WE-891 IMMATURE MYELOID DENDRITIC CELLS INTERACT WITH ACTIVATED PLATELETS IN SUSPENSION AND ON PREFORMED THROMBI UNDER REDUCED FLOW CONDITIONS B. Maître, P. Mangin* (FR), A. Eckly, V. Heim, J. Cazenave, D. Hanau, F. Lanza, C. Gachet PP-WE-892 DOMAIN SWAPPING OF CCR1 AND CCR5 REVEALS DEFINED FUNCTIONS OF THE EXTRACELLULAR REGIONS IN CELL RECRUITMENT R. R. Koenen* (DE), B. K. Kramp, A. Sarabi, S. Winkler, C. Weber PP-WE-893 METABOLIC ALTERATION OF GLYCOSYLATION IN LEUKOCYTE PSGL-1 AND REDUCTION IN SELECTIN BINDING FUNCTION USING ANALOGS OF NATURALLY OCCURRING MONOSACCHARIDES S. Neelamegham* (US), D. D. Marathe, A. Buffone, E. V. Chandrasekaran, J. Xue, M. Nasirikenari, J. T. Y. Lau, K. L. Matta PP-WE-894 INFLAMMATORY BIOMARKER CRP: ASSOCIATION WITH MICROVESSEL OCCLUSION IN PEDIATRIC SICKLE CELL DISEASE S. Krishnan* (US), Y. B. N. Setty, C. Dampier, A. Rao, S. Gayen-Betal, M. Stuart PP-WE-895 EFFECT OF A NOVEL ANTI-INFLAMMATORY COMPOUND, PCPC07F2, ON LPS- INDUCED CYTOKINES RELEASE OF MACROPHAGE T. Huang* (TW), T. Huang PP-WE-896 THE CONTRIBUTION OF PROTEASE-ACTIVATED RECEPTOR 4 TO PLATELET ACTIVATION AND INFLAMMATION DURING CEREBRAL ISCHEMIC/REPERFUSION Y. Mao* (US), M. Zhang, R. F. Tuma, S. P. Kunapuli

304

ISTH2009

Scientific Program

Thursday, July 16, 2009

305

THURSDAY, JULY 16, 2009

Plenary Lecture 9:45 AM – 10:30 AM

Brinkhous Memorial Lecture Grand Ballroom Chairperson: Sriram Krishnaswamy (US) von Willebrand factor assembly and secretion PL-TH-001 J. Evan Sadler (US) 9:45 - 10:30 AM

Plenary Lecture 5:15 PM – 6:00 PM

ISTH Congress Plenary Lecture, made possible Grand Ballroom by a grant from the Désiré Collen Foundation Chairperson: Charles Abrams (US) Stem cells, pluripotency, and nuclear reprogramming PL-TH-002 Rudolf Jaenisch (US) 5:15 - 6:00 PM

State of the Art Lectures 11:00 AM - 12:30 PM

Anticoagulation Duration after Idiopathic Grand Ballroom A Venous Thrombosis - the Swinging Pendulum Chairpersons: Henri Bounameaux (CH) and Trevor Baglin (US) What happens after venous thromboembolism? SA-TH-001 Trevor Baglin (UK) 11:00 - 11:30 AM Risk assessment to predict recurrence SA-TH-002 Sabine Eichinger (AT) 11:30 - 12:00 PM Balancing risks and benefits of extended anticoagulation SA-TH-003 Clive Kearon (US) 12:00 - 12:30 PM

306

al arn I) 12:00-12:30PM 11:30-12:00PM 11:00-11:30AM Carlo Patrono (IT) Aspirin: 110yearslater Marco Cattaneo(IT) New P2Y12antagonists Richard Becker(US) The evolutionofplatelet-directed pharmacotherapy Chairpersons: MarcoCattaneo(IT)andAlanMichelson(US) aclLv N) 12:00-12:30PM 11:00-11:30AM 12:00-12:30PM Marcel Levi(NL) in patientsusingvitamin Kantagonists Epidemiology andmanagement ofbleeding 11:30-12:00PM George Despotis(US) car Prediction andmanagementofbleedingafter Mark Crowther (CA) Management options Bleeding withthenewanticoagulants: Chairpersons: MichaelGreaves(UK)andMarcelLevi (NL) Marvin Yoder (US) progenitor cells Defining andcharacterizinghumanendothelial Shahin Rafii(US) Regulation ofstemcellnichebyendothelium Lena Claesson-W Properties andpotential Embryonic stemcell-derivedendothelialcells: Chairpersons: KeithMcCrae(US)andLenaClaesson-Welsh (SE) Acquir Room205ABC Room253ABC Endothelial Progenitor CellBiology Platelet Inhibition 2009 THURSDAY, JULY 16, diac surgery dBedn iodr Grand Ballroom B ed BleedingDisorders elsh (SE) 11:30 -12:00PM 11:00 -11:30AM SA-TH-0012 SA-TH-0011 SA-TH-0010 SA-TH-004 SA-TH-009 SA-TH-008 SA-TH-007 SA-TH-006 SA-TH-005 307

Thursday Science

THURSDAY, JULY 16, 2009

Platelet Physiology/Pathophysiology Ballroom 210 ABC Chairpersons: Bernhardt Nieswandt (DE) and Garret FitzGerald (US) Bioactive lipids and atherothrombosis SA-TH-013 Garret A FitzGerald (US) 11:00 - 11:30 AM The role of the intrinsic apoptosis pathway in platelet biogenesis, life and death SA-TH-014 Benjamin Kile (AU) 11:30 - 12:00 PM Platelet hyperreactivity, scavenger receptors and atherothrombosis SA-TH-0015 Eugene Podrez (US) 12:00 - 12:30 PM

Novel Regulatory Reactions in Coagulation Room 258 ABC Chairpersons: Kenneth Mann (US) and Tilman Hackeng (NL) Regulation of TFPI function by protein S SA-TH-0016 Tilman Hackeng (NL) 11:00 - 11:30 AM Protease allostery in hemostasis SA-TH-0017 James Huntington (UK) 11:30 - 12:00 PM Blood clotting reactions on nanoscale bilayers SA-TH-0018 James Morrissey (US) 12:00 - 12:30 PM

308

and riskofthrombosis Non-oral postmenopausalhormones Insights fr Tosetto Estrogens andvasculardisease: Chairperson: JosephEmmerich(FR) abstracts presented onarelated generalthemeperiod. Abstract Symposiaconsistofaninvitedspeakerandfourhighlyrated otaiAeal U) 2:15-2:45PM K. Krauel*(DE),C.Pötschke,B.Fürll,W. Keßler, J.Bagemühl,B.M.Bröker, A.Greinacher REACTING WITHPF4/HEPARIN PLATELET FACTOR 4BINDSTOGRAMPOSITIVEBACTERIAAND INDUCESANTIBODIESCROSS- AS-TH-007 Gowthami Arepally (US) Heparin-induced thrombocytopenia: Chairperson: GowthamiArepally(US) J. Douketis*(CA),A.Iorio,M.Mar RECURRENCE AFTERAFIRSTVENOUSTHROMBOEMBOLISM? DOES PATIENT SEXANDPRIORHORMONALTHERAPYPREDICTRISKFOR THROMBOSIS AS-TH-005 A. L.Eilertsen*(NO),E.Hoibraaten,C.M.Lofthus,Mowinckel,P SEX HORMONEBINDINGGLOBULIN(SHBG) DIFFERENTIAL IMPACT OFCONVENTIONALANDLOWDOSEORALHORMONETHERAPY(HT)ON 2:15-2:45PM AS-TH-004 M. Barsoum,J.A.Heit*(US),Ashrani,C.L.Leibson,T THROMBOEMBOLISM (VTE)?APOPULATION-BASED CASE-CONTROLSTUDY IS PROGESTERONEANINDEPENDENTRISKFACTOR FORINCIDENTVENOUS AS-TH-003 A. vanHylckamaVlieg*(NL),F CONTRACEPTIVES THE RISKOFVENOUSTHROMBOSISASSOCIATED WITHNON-ORALHORMONAL AS-TH-002 Joseph Emmerich(FR) Thr Pathophysiology ofHeparin-Induced Room210ABC 2:15PM-3:45 Estrogens andVascular Disease Abstract Symposia 2009 THURSDAY, JULY 16, ombocytopenia om murinemodels . M.Helmerhorst,J.P cucci, T . Baglin,M.Cushman,S.Eichinger . Vandenbroucke, C.J.M.Doggen,F. R.Rosendaal . M.Petterson,K.R.Bailey . M.Sandset , G.Palar eti, D.Poli,C.T Room 205ABC , L.J.MeltonIII AS-TH-001 AS-TH-006 2:45 -3:00PM 3:30 -3:45PM 3:15 -3:30PM 3:00 -3:15PM 2:45 -3:00PM ait, A. 309

Thursday Science

THURSDAY, JULY 16, 2009

AS-TH-008 3:00 - 3:15 PM A MODEL OF HOW PLATELET FACTOR 4 (PF4) CONTRIBUTES TO PHYSIOLOGIC AND PATHOLOGIC THROMBOSIS M. A. Kowalska* (US), T. Turoczi, J. Hirsch, L. Rauova, D. Cines, H. Weiler, R. Camire, S. Krishnaswamy, M. Poncz AS-TH-009 3:15 - 3:30 PM ANTIBODY-INDEPENDENT, ALPHAIIBBETA3-MEDIATED ACTIVATION OF HUMAN PLATELETS BY UNFRACTIONATED HEPARIN C. Gao* (US), B. Boylan, J. Fang, D. A. Wilcox, D. K. Newman, P. J. Newman AS-TH-010 3:30 - 3:45 PM SIGNIFICANCE OF HIGH CONCENTRATION OF HEPARIN-INDUCED PLATELET ANTIBODIES K. M. Javela, R. Kekomäki* Finland, S. Koskinen

New Products in Hemophilia Room 253 ABC Chairperson: Claude G. Negrier (FR) Can we improve upon nature to design products AS-TH-011 with enhanced efficacy for treating hemophilia and von Willebrand disease? Claude G. Negrier (FR) 2:15 - 2:45 PM

AS-TH-012 2:45 - 3:00 PM REPEAT ORAL ADMINISTRATION OF CHITOSAN FVIII DNA NANOPARTICLES RESULTS IN FVIII ANTIGEN IN BLOOD OF HEMOPHILIA A MICE S. S. Dhadwar* (CA), J. Wen, G. Hortelano AS-TH-013 3:00 - 3:15 PM ZYMOGEN-LIKE FACTOR Xa VARIANTS IMPROVE HEMOSTASIS IN HEMOPHILIA MICE L. Ivanciu* (US), R. Toso, A. Schlachterman, H. Downey, J. Liu, V. R. Arruda, R. M. Camire AS-TH-014 3:15 - 3:30 PM FACTOR IX VARIANTS WITH FACTOR VIII INHIBITOR BYPASSING ACTIVITY J. Schuettrumpf* (DE), P. Milanov, D. Abriss, T. Tonn, E. Seifried AS-TH-015 3:30 - 3:45 PM DEVELOPMENT OF A NOVEL TENASE-BYPASSING AGENT WITH A PROLONGED HALF-LIFE IN VIVO P. Gueguen* (FR), G. Cherel, L. Panicot-Dubois, R. Pendu, I. Badirou, C. Dubois, C. V. Denis, O. D. Christophe

Signal Transduction in Vascular Cells Room 258 ABC Chairperson: Michael Mendelsohn (US) Estrogen signaling in endothelium AS-TH-016 Michael Mendelsohn (US) 2:15 - 2:45 PM

AS-TH-017 2:45 - 3:00 PM ENDOGENOUS PROTEIN C IS ESSENTIAL FOR THE FUNCTIONAL INTEGRITY OF HUMAN ENDOTHELIAL CELLS M. Xue, N. Minhas, P. N. Sambrook, L. March, C. J. Jackson* (AU) AS-TH-018 3:00 - 3:15 PM VISCERAL STROMAL SECRETOME INDUCES ENDOTHELIAL DAMAGE AND ACTIVATION IN OBESITY M. Palomo* (ES), F. Hanzu, P. Molina, P. Gomez, M. Garaulet, G. Escolar, R. Gomis, M. Diaz-Ricart

310

for oldandnewdrugs R. A.Schuepbach,M.Riewald*(US) THE ENDOTHELIALPROTEINCRECEPTOR ACTIVATED FACTOR XCLEAVES PAR1 ANDMEDIATES SIGNALINGDEPENDENTONBINDINGTO AS-TH-020 Grant K. F MURINE MODEL MET AS-TH-019 uehVdnhm(S 2:15-2:45PM B. Hajduk*(PL),W. Z.Tomkowski, G.Malek,B.L.Davidson STUDY RISK INFULLY ANTICOAGULATED PATIENTS: APROSPECTIVE, OBSERVATIONAL CONTROLLED INFERIOR VENACAVA FILTER OCCLUSION ANDSYMPTOMATIC VENOUSTHROMBOEMBOLISM AS-TH-028 D. Bearelly* (US),N.Nagam,R.Chitima-Matsiga,S.Bearelly, O.Dabbagh RETRIEVABLE IVCFILTERS ARENOTBEINGRETRIEVED.WHEREISTHEGAP? AS-TH-027 Suresh Vedantham (US) Best useofvenacavafilters Chairperson: SureshV S. Dezfouli*(AU),X.Zhang,Crikis,K.Dwyer, C.Selan,S.Robson,A.D'Apice,P. Cowan,H.Nandurkar ANTI-INFLAMMATORY EFFECTS DEVELOPMENT OFRSOLCD39-PSGLASANOVELTHERAPEUTICWITH ANTI-THROMBOTICAND AS-TH-025 Roodt, P H. Ulrichts,A.Schoolmeester*(BE),S.Hoefman,M.Lauwereys, P. Casteels,P. Stanssens,J.Baumeister, J. AND SAFETYCOMP 2:15-2:45PM ANTI-THROMBOTIC DRUGCANDIDATE ALX-0081SHOWSSUPERIORPRECLINICALEFFICACY AS-TH-024 M. Dumas*(FR),F. Nadal-Wollbold, F. Grelac, M.Aiach,B.LeGrand,P. Gaussem,C.Bachelot-Loza ANTAGONIST IN VIVOANDVITROEFFECTOFANEWTHROMBINPROTEASE-ACTIVATED RECEPTOR(PAR-1) AS-TH-023 P. Andre* (US),F. Deguzman,S.Mills,Y. Pak,M.Inagaki,A.Pandey, S.Hollenbach,D.Phillips,P. Conley LEVELS ASSOCIATED WITHP2Y12INHIBITION CLOPIDOGREL ANDPRASUGRELPROLONGPRIMARY HEMOSTASIS INTHE MOUSEBEYOND AS-TH-022 Christian Gachet(FR) Purinergic andotherreceptors astargets Chairperson: ChristianGachet(FR) ramn fDe enTrmoi Room104ABC Treatment ofDeepVein Thrombosis Room157ABC Platelets asDrugTargets 2009 THURSDAY, JULY 16, . Standeven*(UK),K.A.Hess,N.Y. Yuldasheva, A.J.Balmforth,S.B.Wheatcroft, N.M.Hooper, P. J. ABOLIC ANDVASCULAR CONSEQUENCESOFNEPRILYSIN DEFICIENCY: STUDIESINA . P. T. deJaegere, J.Holz ARED TOCURRENTMARKETEDANTIPLA edantham (US) TELET DRUGS AS-TH-026 AS-TH-021 3:00 -3:15PM 2:45 -3:00PM 3:00 -3:15PM 2:45 -3:00PM 3:30 -3:45PM 3:15 -3:30PM 3:30 -3:45PM 3:15 -3:30PM 311

Thursday Science

THURSDAY, JULY 16, 2009

AS-TH-029 3:15 - 3:30 PM A PROSPECTIVE BLIND STUDY ON DIAGNOSIS AND CLINICAL RISK OF ISOLATED CALF DEEP VEIN THROMBOSIS IN SYMPTOMATIC OUTPATIENTS (THE CALTHRO STUDY; NCT00816920) G. Palareti* (IT), B. Cosmi, G. Lessiani, G. Rodorigo, G. Guazzaloca, C. Brusi, E. Conti, M. Filippini, M. Sartori, C. Legnani AS-TH-030 3:30 - 3:45 PM ABSENCE OF RESIDUAL VEIN THROMBOSIS AFTER AN EPISODE OF IDIOPATHIC DEEP VEIN THROMBOSIS: SHORT-TERM ANTICOAGULATION IS SAFE. THE “EXTENDED DACUS STUDY” S. M. Siragusa* (IT), A. Malato, G. Saccullo, G. Pizzo, D. Caramazza, L. Lo Coco, G. Baiardi, G. Milio, A. Pinto

Platelet Function Tests Room 107 ABC Chairperson: Catherine Hayward (CA) Platelet function tests in the assessment AS-TH-031 of bleeding problems Catherine Hayward (CA) 2:15 -2:45 PM

AS-TH-032 2:45 - 3:00 PM PREVALENCE AND CHARACTERISTICS OF DUAL NON RESPONSIVENESS TO ASPIRIN AND CLOPIDOGREL IN A COHORT OF 430 STABLE CARDIOVASCULAR PATIENTS. INSIGHT FROM THE ADRIE STUDY ON STABLE CARDIOVASCULAR PATIENTS P. Fontana* (CH), I. Barazer, C. Castelli, S. Nolli, P. Berdagué, P. Fabbro-Peray, J. Schved, H. Bounameaux, F. Mach, P. de Moerloose, J. Reny AS-TH-033 3:00 - 3:15 PM MEAN PLATELET VOLUME AS A PREDICTOR OF CARDIOVASCULAR RISK: A META-ANALYSIS S. G. Chu, R. C. Becker, P. B. Berger, D. L. Bhatt, J. W. Eikelboom, B. Konkle, E. R. Mohler, J. S. Berger* (US) AS-TH-034 3:15 - 3:30 PM CARDIOVASCULAR DEATH AND NONFATAL MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME PATIENTS ARE PREDICTED BY RESIDUAL PLATELET REACTIVITY TO ADP IN THE ABSENCE OF CYP2C19*2 ALLELE: BEYOND GENETIC SCREENING R. Marcucci* (IT), B. Giusti, A. Gori, R. Paniccia, C. Saracini, A. Vestrini, C. Nanna, A. Cordisco, E. Antonucci, G. Gensini, R. Abbate AS-TH-035 3:30 - 3:45 PM GENETIC VARIANTS OF PLATELET FUNCTION AND CARDIOVASCULAR EVENTS: RESULTS FROM THE SMILE-PLATELETS PROJECT J. D. Snoep* (NL), J. Emmerich, P. Gaussem, J. C. J. Eikenboom, J. J. Zwaginga, H. L. Vos, P. G. de Groot, F. R. Rosendaal, J. G. van der Bom

312 B. Royer, N.Djafari,C.Fagnou,H.Charlanne,P. Nurden, A.Nurden, N.Schlegel Modulation ofarterialthrombosis li cmir(S 2:15-2:45PM E. Jablonska*(DE),P. Markart,I.Henneke,T. Renné,A.Günther, K.T. Preissner, M.Wygrecka FACTOR XIIISANOVELMITOGENICFACTOR FOR LUNGFIBROBLASTSINFIBROSIS AS-TH-037 Alvin Schmaier(US) Animal modelsoftheplasmakallikrein/kinin system: Chairperson: AlvinSchmaier(US) M. Haywar A. Paterson,J.Rommens,B.Baraj,I. Wong, J.Blavignac*(CA), M. Diamandis,J.S.Waye, G.E.Rivard, C.P. INDIVIDUALS WITHQUEBECPLA AS-TH-045 G. S.Jalagadugula*(US),Kaur, G.Mao,D.Dhanasekaran,A.K. Rao THET 2:15-2:45PM RUNX1 REGULATES PLATELET/MEGAKARYOCYTE PKC-THETA :DECREASEDPLATELET PKC- AS-TH-044 B. Saposnik*(FR),S.Binar AND 3NEWEXONSAFFECTED MYH9-RELATED DISEASE(MYH9-RD),FROMONETHINGTOTHEOTHER: 11NOVELMUTATIONS AS-TH-043 Y MACROTHROMBOCYTOPENIA ANDABSENTALPHA-GRANULES DISRUPTION OFGATA-1/FOG-1 INTERACTIONWITHTHENURDCOMPLEXRESULTS INA AS-TH-042 Paul Bray(US) Pathways tovariationinplateletreactivity Chairperson: PaulBray(US) (DE),U.Kronthaler,I. Hagedorn* I.Pleines,C.Kleinschnitz,G.Stoll,B.Nieswandt THROMBOSIS ANDISCHEMICSTROKEWITHOUTIMPAIRING HEMOSTASIS RHA-INFESTIN, ACOAGULATION FACTOR XIIaINHIBITOR,PROTECTSMICEFROMARTERIAL AS-TH-040 A. Gruber*(US),E.I.Tucker, Q.Cheng,I.Sisler, A.Matafonov, M. Sun,T. Renné,D.Gailani FACTOR XIACTIVATION BYFACTOR XIIaINAMURINETHROMBOSISMODEL AS-TH-039 Hammarström, H.tenCate,P. G.deGroot, B.N.Bouma,M.F. B.G.Gebbink C. Maas*(NL),J.W FORMATION WITHOUTINITIATING COAGULATION MISFOLDED PROTEINSACTIVATE FACTOR XIIINHUMANS,LEADINGTOKALLIKREIN AS-TH-038 UROKINASE PLASMINOGENACTIVATOR GENE(PLAU) Genetics ofPlateletDisor Room153ABC Contact Pathway 2009 THURSDAY, JULY 16, . W ang* (US),A.Miccio,G.D.Gr A EXPRESSIONINHUMANRUNX1 HAPLODEFICIENCY d . P. Govers-Riemslag,B.Bouma,Schiks,P. C.Hazenberg,H.M.Lokhorst,P. d, S.Elbaz,C.T egory TELET DISORDERHA , W ders . Hong,G.A.Blobel,M.Poncz richet, C.Pouplar d, V VE AT . Roussel-Robert,V ANDEM DUPLICATION OFTHE . Leymarie,E.deMaistr Room 156ABC AS-TH-036 AS-TH-041 3:30 -3:45PM 3:15 -3:30PM 3:00 -3:15PM 2:45 -3:00PM 2:45 -3:00PM 3:30 -3:45PM 3:15 -3:30PM 3:00 -3:15PM e, 313

Thursday Science

THURSDAY, JULY 16, 2009

Protease Structure-Function Room 160 ABC Chairperson: Rodney Camire (US) Novel factor Xa Variant for improving Hemostasis AS-TH-046 in Hemophilia Rodney Camire (US) 2:15 - 2:45 PM AS-TH-047 2:45 - 3:00 PM SUBSTRATE GEOMETRY GOVERNS ACTIVE SITE DOCKING AND REGULATES THE ACTION OF PROTHROMBINASE ON THE TWO CLEAVAGE SITES IN PROTHROMBIN H. N. Bradford* (US), J. A. Micucci, S. Krishnaswamy AS-TH-048 3:00 - 3:15 PM IN-VITRO SELECTION AND CHARACTERISATION OF DNA-APTAMERS THAT SPECIFICALLY BIND TO HUMAN ACTIVATED PROTEIN C J. Müller* (DE), G. Mayer, B. Isermann, J. Oldenburg, B. Pötzsch AS-TH-049 3:15 - 3:30 PM THROMBIN CONTAINS A CRYPTIC LRP BINDING SITE D. J. D. Johnson* (UK), K. S. Larsen, H. Stennicke, J. A. Huntington AS-TH-050 3:30 - 3:45 PM CONFORMATIONAL ACTIVATION OF ZYMOGEN-LIKE THROMBIN VARIANTS BY TIGHT BINDING LIGANDS A. Khan* (US), P. Panizzi, H. K. Kroh, P. E. Bock, S. Krishnaswamy

Neonatal and Pediatric Hemostasis Room 204 AB Chairperson: Anthony Chan (CA) Neonates: Are they more prone to clotting or bleeding? AS-TH-051 Anthony Chan (CA) 2:15 - 2:45 PM

AS-TH-052 2:45 - 3:00 PM ROLE OF 18 FUNCTIONAL HEMOSTATIC POLYMORPHISMS IN MUCOCUTANEOUS BLEEDING A. Antón* (ES), R. González-Conejero, V. Roldán, T. Quiroga, C. Martínez, M. Lozano, L. Navarro-Núñez, B. Sánchez-Vega, J. Rivera, J. Corral, D. Mezzano, V. Vicente AS-TH-053 3:00 - 3:15 PM IDENTIFICATION OF CHILDREN WITH SIGNIFICANT MUCOCUTANEOUS BLEEDING: COMPARISON OF THE HOSPITAL FOR SICK CHILDREN (HSC) CRITERIA AND A QUANTITATIVE PEDIATRIC- SPECIFIC BLEEDING QUESTIONNAIRE (PBQ) T. T. Biss* (CA), V. S. Blanchette, D. S. Clark, C. D. Wakefield, D. Lillicrap, P. D. James, M. L. Rand AS-TH-054 3:15 - 3:30 PM MAJOR HAEMORRHAGE IN NEONATES WITH HAEMOPHILIA, FREQUENCY AND RISK FACTORS. A EUROPEAN COHORT STUDY M. Richards* (UK), K. Fijnvandraat, G. Lavigne-Lissalde AS-TH-055 3:30 - 3:45 PM EVALUATION OF FAMILY HISTORIES IN PEDIATRIC PATIENTS WITH HEREDITARY THROMBOCYTOPATHIES: RESULTS FROM THE THROMKID-STUDY R. Knoefler* (DE), M. Olivieri, S. Weickardt, W. Eberl, W. Streif

314 THURSDAY, JULY 16, 2009

Shear-induced Signaling Room 257 AB Chairperson: Martin A. Schwartz (US) Fluid shear stress signaling in endothelial cells: AS-TH-056 Role of integrins and extracellular matrix Martin A. Schwartz (US) 2:15 - 2:45 PM

AS-TH-057 2:45 - 3:00 PM VON WILLEBRAND FACTOR SELF-ASSEMBLY UNDER ELEVATED SHEAR STRESS FOSTERS ACTIVATION-INDEPENDENT PLATELET STRING FORMATION A. J. Reininger* (DE), J. I. Angerer, M. Fallah, M. F. Schneider AS-TH-058 3:00 - 3:15 PM FACTOR SEVEN ACTIVATING PROTEASE (FSAP); A KEY REGULATOR OF PERICELLULAR PROTEOLYSIS J. Daniel, O. Uslu, K. Hersemeyer, O. Rannou, L. Muhl, K. T. Preissner, D. Sedding, S. M. Kanse* (DE) AS-TH-059 3:15 - 3:30 PM PHOSPHODIESTERASE-TYPE IV-CAMP-PKA AXIS REGULATES SFK-PYK2 PATHWAY, PMN/ PLATELET ADHESION AND PMN ACCUMULATION AT THE SITE OF VASCULAR INJURY L. Totani, Z. Pamuklar, A. Piccoli, R. Pecce, L. Federico, N. Martelli, S. Manarini, V. Evangelista, S. S. Smyth* (US) AS-TH-060 3:30 - 3:45 PM CD40 LIGAND (CD40L) INCREASES PLATELET THROMBUS STABILITY AND OUTSIDE-IN SIGNALING THROUGH INTEGRIN ALPHAIIB BETA3 R. E. Scharf* (DE), M. Hasse, E. Reiff, M. Gyenes, V. R. Stoldt sday Science Thur

315

ORAL COMMUNICATIONS

THURSDAY, JULY 16, 2009 8:00 AM - 9:30 AM * Presenting Author

Risk Factors for Recurrent Venous Thrombosis Ball Room 210 ABC

Chairpersons: James Douketis (CA) and Gregor Hron (AT) OC-TH-001 8:00 AM - 8:15 AM INCREASING LEVELS OF THROMBIN GENERATION PRECEDE RECURRENT DVT A. J. ten Cate-Hoek* (NL), A. J. W. H. Dielis, H. M. H. Spronk, R. van Oerle, K. Hamulyák, M. H. Prins, H. ten Cate OC-TH-002 8:15 AM - 8:30 AM D-DIMER TO PREDICT THROMBOSIS RECURRENCE AFTER UNPROVOKED VENOUS THROMBOEMBOLISM: EFFECT OF PATIENT- AND D-DIMER-RELATED FACTORS ON RECURRENCE PREDICTION A. Iorio* (IT), J. Douketis, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto OC-TH-003 8:30 AM - 8:45 AM D-DIMER TIME COURSE AFTER STOPPING ANTICOAGULATION AFTER A FIRST EPISODE OF IDIOPATHIC VENOUS THROMBOEMBOLISM: THE PROLONG II PROSPECTIVE STUDY B. Cosmi* (IT), C. Legnani, A. Tosetto, V. Pengo, A. Ghirarduzzi, A. Alatri, S. Testa, D. Prisco, D. Poli, A. Tripodi, G. Palareti OC-TH-004 8:45 AM - 9:00 AM CLINICAL PREDICTION GUIDE TO PREDICT THROMBOSIS RECURRENCE AFTER A FIRST UNPROVOKED VENOUS THROMBOEMBOLISM A. Tosetto* (IT), A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, J. Douketis OC-TH-005 9:00 AM - 9:15 AM RISK FACTOR FOR THE PREDICTION OF RECURRENT VENOUS THROMBOEMBOLISM J. Emmerich* (FR), T. Zhu, L. Carcaillon, I. Martinez, V. Olie, V. Remones, F. Dali-Ali, P. Scarabin OC-TH-006 9:15 AM - 9:30 AM D-DIMER AND COMORBIDITIES AS RISK FACTORS FOR RECURRENCE AFTER A FIRST EPISODE OF VENOUS THROMBOEMBOLISM IN THE EXTENDED FOLLOW-UP OF THE PROLONG STUDY B. Cosmi* (IT), C. Legnani, V. Pengo, A. Ghirarduzzi, S. Testa, A. Alatri, D. Prisco, D. Poli, A. Tripodi, G. Palareti

Clinicial Trials: Anticoagulation Room 205 ABC

Chairpersons: Samuel Goldhaber (US) and Walter Ageno (IT) OC-TH-007 8:00 AM - 8:15 AM SINGLE-DOSE ADJUSTMENT VERSUS NO ADJUSTMENT OF WARFARIN IN STABLY ANTICOAGULATED PATIENTS WITH AN OCCASIONAL LEVEL OUT OF RANGE S. Schulman* (CA), A. Melinyshyn, D. Ennis, L. Rudd-Scott

316 ORAL COMMUNICATIONS

THURSDAY, JULY 16, 2009 8:00 AM - 9:30 AM

OC-TH-008 8:15 AM - 8:30 AM FREQUENCY OF MAJOR BLEEDING IN PATIENTS TREATED WITH LOW MOLECULAR WEIGHT HEPARIN FOR DEEP-VEIN THROMBOSIS OR PULMONARY EMBOLISM- A STUDY IN ROUTINE CLINICAL PRACTICE M. Zidane* (NL), E. P. C. Plompen, F. Cluitmans, F. J. M. van der Meer, E. V. Planken, M. V. Huisman OC-TH-009 8:30 AM - 8:45 AM LOW-INTENSITY ADJUSTED-DOSE WARFARIN FOR THE PREVENTION OF MECHANICAL MALFUNCTION OF DOUBLE-LUMEN HAEMODIALYSIS CATHETERS: A RANDOMIZED CONTROLLED TRIAL C. M. Clase, M. A. Crowther* (CA), T. J. Wilkieson, S. D. Soroka, R. Nagai, K. K. Jindal, A. J. Ingram OC-TH-010 8:45 AM - 9:00 AM BLEEDING RISK WITH FIXED DOSE SUBCUTANEOUS LOW MOLECULAR WEIGHT HEPARIN COMPARED TO INTRAVENOUS ADJUSTED DOSE UNFRACTIONATED HEPARIN: A METANALYSIS G. Podda* (IT), G. Costantino, E. Ceriani, A. Rusconi, G. Casazza, N. Montano, P. Duca, M. Cattaneo OC-TH-011 9:00 AM - 9:15 AM LMWH VS ASPIRIN FOR THE TREATMENT OF ACUTE RETINAL VEIN OCCLUSION W. Ageno* (IT), R. Cattaneo, E. Manfredi, A. Ghirarduzzi, E. Filippucci, G. Scannapieco, F. Rubbi, D. Imberti OC-TH-012 9:15 AM - 9:30 AM PREDICTION OF THE WARFARIN MAINTENANCE DOSE AFTER COMPLETION OF THE 10 MG INITIATION NOMOGRAM G. Le Gal* (FR), M. Carrier, S. Tierney, H. Majeed, M. Rodger, P. S. Wells

Health Services, Outcomes and Patient Education Room 258 ABC

Chairperson: Mark Crowther (CA) and Alex Spyropoulos (US) OC-TH-013 8:00 AM - 8:15 AM THE ROLE OF NEW EDUCATIONAL MATERIAL IN PATIENTS

KNOWLEDGE OF ANTICOAGULANT THERAPY als N. Ostasevski Fernandez* (SI), A. Kramaric, A. Mavri OC-TH-014 8:15 AM - 8:30 AM

MULTIDETECTOR COMPUTED TOMOGRAPHY TO ASSESS CLINICAL sday Or OUTCOME IN HEMODYNAMICALLY STABLE PATIENTS WITH ACUTE PULMONARY EMBOLISM C. Becattini* (IT), M. C. Vedovati, S. Grifoni, F. Casazza, R. Douma, Thur M. Bianchi, A. Salvi, S. Konstantinides, S. Vanni, W. Ageno, P. Kamphuisen, C. Nitti, R. Poggio, M. Duranti, G. Agnelli

317

ORAL COMMUNICATIONS

THURSDAY, JULY 16, 2009 8:00 AM - 9:30 AM

OC-TH-016 8:30 AM - 8:45 AM VENOUS THROMBOEMBOLISM PHARMACY INTERVENTION MANAGEMENT PROGRAM C. E. Mahan* (US), M. A. Hussein, A. N. Amin, A. C. Spyropoulos OC-TH-017 8:45 AM - 9:00 AM COST-EFFECTIVENESS OF RULING OUT DEEP VENOUS THROMBOSIS (DVT) IN PRIMARY CARE A. J. ten Cate-Hoek* (NL), H. E. J. H. Stoffers, E. van der Velde, H. C. van Weert, D. B. Toll, H. R. Büller, A. W. Hoes, K. G. M. Moons, R. Oudega, M. H. Prins, M. Joore OC-TH-018 9:00 AM - 9:15 AM EFFECT OF A COMPUTERIZED HANDHELD CLINICAL DECISION SUPPORT SYSTEM ON THE APPROPRIATENESS OF PULMONARY EMBOLISM DIAGNOSIS IN EMERGENCY DEPARTMENTS. A CLUSTER CONTROLLED CLINICAL TRIAL P. Roy* (FR), P. Durieux, F. Guillaizeau, C. Legall, A. Armand-Perroux, L. Martino, M. Hachelaf, A. Dubart, J. Schmidt, M. Cristiano, J. Chretien, A. Perrier, G. Meyer

Heparin-induced Thrombocytopenia I Room 157 ABC

Chairpersons: Raj Kasthuri (IN) and Christilla Bachelot-Loza (FR) OC-TH-019 8:00 AM - 8:15 AM A HIGHER PREVALENCE OF HIT ANTIBODIES IN HEMODIALYSIS PATIENTS MAY BE DUE TO CONTAMINATED HEPARIN J. M. Walenga* (US), D. Hoppensteadt, J. Cunanan, C. Adiguzel, O. Iqbal, J. Fareed OC-TH-020 8:15 AM - 8:30 AM HEPARIN ANTIBODY COMPLEXES ACTIVATE MONOCYTES AND INDUCE THE RELEASE OF TISSUE FACTOR POSITIVE MICROPARTICLES R. S. Kasthuri* (US), S. Glover, G. Arepally, N. Key, N. Mackman OC-TH-021 8:30 AM - 8:45 AM THROMBIN GENERATION RELATED TO HEPARIN-INDUCED THROMBOCYTOPENIA B. Tardy- Poncet* (FR), M. Piot, C. Chapelle, L. Campos, O. Garraud, H. Decousus, P. Mismetti, B. Tardy OC-TH-022 8:45 AM - 9:00 AM THE RISK OF HEPARIN-INDUCED THROMBOCYTOPENIA IS INCREASED IN PATIENTS HOMOZYGOUS FOR THE GNB3 825T ALLELE E. Boissier* (FR), D. Lasne, C. Pouplard, S. Gandrille, M. Alhenc-Gelas, F. Grelac, P. Gaussem, Y. Gruel, C. Bachelot-Loza OC-TH-023 9:00 AM - 9:15 AM ANTIBODIES OF PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA RECOGNIZE COMPLEXES FORMED BY PLATELET FACTOR 4 AND NUCLEIC ACIDS M. E. Jaax* (DE), K. Krauel, B. Fürll, T. Marschall, B. Appel, S. Müller, S. Fischer, K. T. Preissner, A. Greinacher

318 OC-TH-025 8:00 AM - 8:15 AM - 8:00AM 9:30 AM - 9:15AM OC-TH-025 OC-TH-024 ORAL COMMUNICATIONS OC-TH-030 9:15 AM - 9:30 AM - 9:15AM 9:15 AM - 9:00AM 9:00 AM - 8:45AM 8:45 AM - 8:30AM 8:30 AM - 8:15AM OC-TH-030 OC-TH-029 OC-TH-028 OC-TH-027 OC-TH-026 reilDsaeRs akr IRoom104ABC Arterial DiseaseRiskMarkersII 2009 THURSDAY, JULY 16, R. Corrocher, O.Olivieri N. Martinelli*(IT),D.Girelli,S.Friso, F. Pizzolo, P. Guarini, A. Bassi,G.Guidi, DISEASE ARTERY DEFINEDCORONARY ANGIOGRAPHICALLY CARDIOV AND APOLIPOPROTEINC-IIILEVELSPREDICTTOTAL HIGH PLASMA M. C.vanSchie*(NL),J.E.Loon,D.W HAPLOTYPEAPPROACH A WITH THERISKOFCARDIOVASCULAR DISEASES AT YOUNG AGE: VARIATION INTHEVONWILLEBRANDFACTOR GENEIS ASSOCIATED O. Olivieri,F N. Martinelli*(IT),B.Lunghi,D.Girelli,M.Pinotti,G.Marchetti,Bisi, DISEASE ARTERY AND IS ASSOCIATED WITHCORONARY LEVELS PREDICTOR OFFACTOR VIII ACTIVITY RECEPTOR GENEIS A A J. Corral*(ES) R. González-Conejero,J.Pineda, A. Estellés,J.Fontcuberta,V. Vicente, V THROMBOSIS IN ARTERIAL ANTITHROMBIN DEFICIENCY ROLEFOR ANTITHROMBIN CAMBRIDGEII(A384S)SUPPORTS A D. Tormene* (IT),M.Perlati,V. Ferri,M.Facchin,S.Gavasso,P. Simioni COHORT STUDY PROSPECTIVEFAMILY RESULTS FROM A INCREASED RISKOF COAGULATION( ANTITROMBIN, PROTEINCORS)CONFERS INHIBITORS OF OFNATURAL DEFICIENCY HEREDITARY J. G.vanderBom J. D.Snoep*(NL),M.Roest, A. Barendrecht,F. R.Rosendaal, INFARCTION IN YOUNG WOMEN ANDTHERISKOFMYOCARDIAL HIGH PLATELET REACTIVITY Chairpersons: HugoTen Cate(NL)andVeikko Salomaa(FI) K. PF4/HEP IMMUNOSORBENT OFTHE ANTI-PF4/HEPARIN ENZYME IMPROVING THECAPABILITY D. Poldermans,M.P. M.de Maat, F. W. G.Leebeek . Roldán, COMMON POL Althaus* (DE),U.Strobel,B.Fuerll, A. Greinacher ARIN ANTIBODIES SUA OTLT INPATIENTS WITH ASCULAR MORTALITY A. Ordóñez,F . Manzato,R.Corrocher, F. Bernardi YMORPHISM INLOW SA TO RULEOUTPLATELET ACTIVATINGASSAY ARTERIAL . Marín,E.Zorio,J.M.Soria, A. Miñano,F. España, THROMBOEMBOLIC EVENTS. -DENSITY . J.Dippel,W LIPOPROTEIN . Deckers, 8:00 AM -9:30 AM 319

Thursday Orals

ORAL COMMUNICATIONS

THURSDAY, JULY 16, 2009 8:00 AM - 9:30 AM

Experimental Studies in Thrombosis: Animal Models Room 107 ABC

Chairpersons: Beatrice Hechler (FR) and Pieter Rietsma (NL) OC-TH-031 8:00 AM - 8:15 AM EFFICACY OF FULL-LENGTH RECOMBINANT HUMAN PLASMIN IN A PORCINE MODEL OF ARTERIOVENOUS GRAFT THROMBOSIS I. Hoefer, E. S. G. Stroes, G. Pasterkamp, M. Levi, J. A. Reekers, H. J. M. Verhagen, J. C. Meijers, J. E. Humphries* (US), J. I. Rotmans OC-TH-032 8:15 AM - 8:30 AM BLOOD CELL-DERIVED MATRIX METALLOPROTEINASE TYPE 2 (MMP-2) PLAYS A ROLE IN ATHEROGENESIS S. Momi* (IT), S. Giannini, P. Gresele OC-TH-033 8:30 AM - 8:45 AM LOCALIZED ARTERIAL THROMBOSIS ON RUPTURED ATHEROSCLEROTIC PLAQUES OF APOE-/- MICE AFTER VASCULAR INJURY WITH ULTRASOUND B. Hechler* (FR), A. Eckly, S. Magnenat, M. Freund, J. P. Cazenave, F. Lanza, C. Gachet OC-TH-034 8:45 AM - 9:00 AM FURTHER PHARMACOLOGICAL AND HISTOLOGICAL CHARACTERIZATION OF A MODEL OF LASER-INDUCED LOCALIZED THROMBOSIS IN MESENTERIC ARTERIOLES WITH STANDARDIZED MODERATE AND SEVERE INJURIES B. Hechler* (FR), A. Eckly, C. Nonne, S. Magnenat, C. Ravanat, M. Freund, C. Denis, J. P. Cazenave, F. Lanza, C. Gachet OC-TH-035 9:00 AM - 9:15 AM HISTOLOGICAL CHARACTERIZATION OF MOUSE CAROTID ARTERY ALTERATION FOLLOWING FERRIC CHLORIDE-INDUCED INJURY A. Eckly* (FR), M. Freund, M. Zerr Fouineau, J. Cazenave, F. Lanza, B. Hechler, C. Gachet OC-TH-036 9:15 AM - 9:30 AM TLT-1 PROMOTES THROMBOSIS IN MICE L. Rivera* (PR), R. Hernández, O. González, J. Simon, A. Washington

Platelet Biology III Room 153 ABC

Chairpersons: Jonathan Gibbins (UK) and Michelle Lambert (US) OC-TH-037 8:00 AM - 8:15 AM CHARACTERISATION OF NOVEL PLATELET SURFACE THIOL ISOMERASE ENZYMES L. Holbrook* (UK), K. L. Jones, N. A. Watkins, C. I. Jones, W. H. Ouwehand, J. M. Gibbins OC-TH-038 8:15 AM - 8:30 AM CIB1 IS A KEY REGULATOR OF PLATELET INTEGRIN IIB3-DEPENDENT RETRACTILE SIGNALING M. U. Naik* (US), U. P. Naik

320 OC-TH-040 8:45 AM - 9:00 AM - 8:45AM 8:45 AM - 8:30AM OC-TH-040 OC-TH-039 ORAL COMMUNICATIONS OC-TH-045 8:30 AM - 8:45 AM - 8:30AM OC-TH-046 9:30 AM - 9:15AM 9:15 AM - 9:00AM OC-TH-045 OC-TH-044 OC-TH-043 OC-TH-042 OC-TH-041 aclrPoeiosadSe el Room156ABC Vascular Progenitors andStemCells 2009 THURSDAY, JULY 16, C. Boisson-Vidal, A. M.Fischer, D.Helley C. Bouvard*(FR),B.Gafsou,Dizier, I.Galy-Fauroux, A. Lokajczyk, CELLS PROGENITOR PROANGIOGENIC PROPERTIESOF ENDOTHELIAL MAJORROLEIN ALPHA-6 INTEGRINSUBUNITPLAYS A B. Binetruy*(FR) E. Barruet,F PROTEIN KINASE P38 MITOGEN-ACTIVATED LINEAGEBY INTO THEENDOTHELIAL COMMITMENT REGULATION OFMOUSEEMBRYONIC STEMCELL P. Baltopoulos,E.Goussetis I. Papassotiriou, MEDIATE TISSUEREPAIR EXERCISE ONCIRCULATING STEM/PROGENITOR CELLSTHAT EFFECT OF J. H.McV D. Chen*(UK),S.Shrivastava,J.Coe,Chai,M.Scott, INHIBITING TISSUEFACTOR ONVASCULAR PROGENITOR CELLS COMPLETE INHIBITIONOFTRANSPLANT Chairpersons: Anthony Dorling(UK)andChristophReinhardt(SE) H. Hauschner*(IL),N.Rosenberg,M.Landau,U.Seligsohn EFFECTS ONINTEGRINS SUBSTITUTIONS OFTHEUNIQUEBETA3-ARG261 HAVE DIFFERENT S. P. Watson, M.D.Williams A. D.Mumford*(UK),B.Dawood,M.E.Daly, J.C.Spalton,S.Mundell, RECEPTOR p.D304NVARIANT WITHREDUCEDLIGANDBINDING PLATELET THROMBOXANE A2 NOVEL IDENTIFICATION OF A S. P. Kunapuli,J.L.Daniel D. H. Thomas* (US),C. A. Dangelmaier, J.Jin, A. Y. Tsygankov, INTERACTION WITHTHEHISTIDINEPHOSPATASE TULA-2 AND SYK C-CBL M. Elvers*(DE),R.Pozgaj,D.V LEADS T GAMMA GAIN-OF-FUNCTIONMUTATION INTHEPHOSPHOLIPASE C A EAIEYRGLTSPAEE PISGAIGVAAN REGULATES PLATELETNEGATIVELY GPVISIGNALINGVIA 2 GENEENHANCESINTEGRINOUTSIDE-INSIGNALING AND PROTHROMBOTICPHENOTYPE INMICE O A ey , . Peiretti,O.Hadadeh,I.Juhan-V A. Dorling ACUTE INFLAMMA A. Spiropoulos,M. ALPHAIIB-BETA3ALPHAV-BETA3 AND arga-Szabo, F. May, P. Yu, B.Nieswandt TION INDUCEDBY T sironi, K.Skenderi*(GR), ARTERIOSCLEROSIS BY ague, M. Alessi, PROLONGED A. Margeli, 8:00 AM -9:30 AM 8:45 AM -9:00 AM 8:15 8:00 AM -8:30 AM AM -8:15 AM 321

Thursday Orals

ORAL COMMUNICATIONS

THURSDAY, JULY 16, 2009 8:00 AM - 9:30 AM

OC-TH-047 9:00 AM - 9:15 AM BONE MARROW-DERIVED PROGENITOR CELLS IN ISCHEMIC STROKE PATIENTS: RELATIONSHIP BETWEEN INFARCT SIZE, NEUROLOGICAL IMPAIRMENT AND DISCHARGE OUTCOME F. Cesari* (IT), A. Gori, R. Marcucci, F. Sofi, V. Palumbo, G. Pracucci, P. Nencini, D. Inzitari, G. Gensini, R. Abbate OC-TH-048 9:15 AM - 9:30 AM EX VIVO PRETREATMENT OF ENDOTHELIAL PROGENITOR CELLS WITH FUCOIDAN ENHANCES THEIR FUNCTIONAL ACTIVITY FOR CELL THERAPY C. Boisson-Vidal* (FR), F. Zemani, G. Sarlon, J. P. Duong, B. Dizier, A. Lokajczyk, I. Galy-Fauroux, P. Bruneval, S. Colliec-Jouault, A. M. Fischer, J. Emmerich

Inhibitors of Factor VIII and Factor IX Room 160 ABC

Chairperson: Jenny Klintman (SE) and Donna Dimichele (US) OC-TH-049 8:00 AM - 8:15 AM NOVEL TOLERANCE PROTOCOL FOR FACTOR VIII B. Moghimi* (US), B. Sack, S. Nayak, C. Mah, R. Herzog OC-TH-050 8:15 AM - 8:30 AM NON-INHIBITORY ANTIBODIES IN THE MIBS COHORT J. Klintman* (SE), A. Hillarp, E. Berntorp, J. Astermark OC-TH-051 8:30 AM - 8:45 AM INTRATHYMIC ADMINISTRATION OF FACTOR VIII RESULTS IN IMMUNE TOLERANCE BY INDUCTION OF FACTOR VIII-SPECIFIC REGULATORY T CELLS IN MURINE HEMOPHILIA A S. Madoiwa* (JP), T. Yamauchi, E. Kobayashi, Y. Kashiwakura, A. Ishiwata, T. Ohmori, J. Mimuro, Y. Sakata OC-TH-052 8:45 AM - 9:00 AM MAPPING THE FVIII BINDING SITE OF THE MONOCLONAL ANTI- FACTOR VIII ANTIBODY ESH-8 BY MASS SPECTROMETRY M. van Geffen* (NL), A. Loof, B. Verbruggen, W. van Heerde OC-TH-053 9:00 AM - 9:15 AM DISTINCT T CELL AND B CELL IMMUNE RESPONSES IN BALB/C AND C57BL/6 MICE INFLUENCE THE ANTI-FVIII ANTIBODY TITRE IN HEMOPHILIA A MICE M. Qadura, B. Waters* (CA), E. Burnett, R. Chegeni, M. Othman, D. Lillicrap OC-TH-054 9:15 AM - 9:30 AM THE RESIDENCE OF FVIII-SPECIFIC MEMORY B CELLS IN HEMOPHILIC MICE AFTER INTRAVENOUS APPLICATION OF FVIII G. Pordes* (AT), A. Trbic, C. Hausl, E. M. Muchitsch, R. U. Ahmad, H. J. Ehrlich, H. P. Schwarz, B. M. Reipert

322 OC-TH-056 8:15 AM - 8:30 AM - 8:15AM OC-TH-056 OC-TH-055 ORAL COMMUNICATIONS OC-TH-063 8:30 AM - 8:45 AM - 8:30AM 8:15 AM - 8:00AM 9:30 AM - 9:15AM 9:15 AM - 9:00AM OC-TH-063 9:00 AM - 8:45AM OC-TH-062 8:45 AM - 8:30AM OC-TH-061 OC-TH-060 OC-TH-059 OC-TH-058 OC-TH-057 Coagulation andInfection Room204AB Antithrombotics -SystemicEffects 2009 THURSDAY, JULY 16, X. Zheng,N.L.Esmon, C. M. J.Flick*(US), EXPRESSING THE THROMBIN ANTICOAGULANT MUTANT W215/E217A INFECTIONIN MICE FOLLOWING MICROBIAL PROLONGED SURVIVAL Veer, C. T. Esmon,M.Levi, T.M. Schouten*(NL),C.van‘T vanderPoll SEPSIS INMURINEPNEUMOCOCCAL INCREASES MORTALITY OUTGROWTH AND PROTEIN CDEPLETIONENHANCES BACTERIAL H. Sun*(US), REAGENTS ANTIMICROBIAL NOVEL COMPOUNDS AS SMALL STREPTOCOCCUS VIRULENCEBY A INHIBITION OFGROUP Chairpersons: DavidGinsburg(US)andMettineBos W M. L.Rand*(CA),P OF ANNEXINA5 HOMODIMER NOVEL A IN VITRO AND INVIVO ANTITHROMBOTIC EFFECTS OFDIANNEXIN, S. Hammerschmidt,W. Mueller-Esterl, T. Renné C. Oschatz*(DE),B.Lecher, T. Tradler, M.Paschke,R.Sedlmeier, S.Cichon, INITIA HEPARIN- BY MAST CELLSINCREASEVASCULAR PERMEABILITY C. Gerdes*(DE),M.Schumacher MODEL RAT ARTERIOLAR, LASER-INDUCEDINJURY FORMATION IN A RIVAROXABAN SUPPRESSESPLATELET-RICH THROMBUS M. Jacquemin T P. Verhamme* (BE),S.Pakola,Glazer, J.Stassen,G.Cahillane, VOLUNTEERS INTERACTIONS WITHRHFVIII,LMWH AND WARFARIN INHEALTHY HUMAN ANTI-FVIII ANTIBODY, AND OFITS EFFECT OFTB-402, A THROMBOGRAM ANALYSIS OFTHELONG-ACTING ANTICOAGULANT M. T. Nieman*(US), Y. Zhou,G.Larusch, Adams, A. H.Schmaier IN VITRO AND INVIVO THROMBOSTATIN COMPOUNDS-INHBITIONOFPROSTATE CANCER K. Gersh,J.W. Weisel, R. A. S. Ariens, M. T. Kearney, P. J.Grant R. A. Ajjan* (UK),K.F. Standeven,K.Naseem,M.Khanbhai,F. Phoenix, INDEPENDENT MODEOF ACTION ASPIRIN Chairpersons: JefferyW . J.Jensen,Saint-Remy . H.Kahr TED BRADYKININFORMA N ADOACLRDSAE CYCLOOXYGENASE- AND CARDIOVASCULAR DISEASE: A Y . Xu,M.Lapadatescu,S.Larsen,D.Ginsburg A. K.Chauhan,E. S. Mullins,J.Palumbo, . L.Gross,H.W eitz (CA)andIreneMartinez-Martinez(ES) T , E.Sonesson,P. Giessen,M.Hoylaerts, . Esmon,D.W TION INVIVO ang, A. C. agner Allison, F , J.L.Degen . G.Pluthero, Thornton, 8:00 AM -9:30 AM 8:00 AM -8:15 AM 8:15 AM -8:30 AM Room 102AB 323

Thursday Orals

ORAL COMMUNICATIONS

THURSDAY, JULY 16, 2009 8:00 AM - 9:30 AM

OC-TH-064 8:45 AM - 9:00 AM THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IS DEGRADED BY PLASMINOGEN ACTIVATOR PLA OF YERSINIA PESTIS M. Valls Serón* (NL), J. Haiko, P. F. Marx, T. K. Korhonen, P. G. de Groot, J. C. M. Meijers OC-TH-065 9:00 AM - 9:15 AM INTERACTIONS OF PLASMIN WITH TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IN A MOUSE MODEL OF ENDOTOXEMIA F. Lupu* (US), O. Herlea, N. I. Popescu, H. Tang, C. Lupu, C. T. Esmon, H. R. Lijnen OC-TH-066 9:15 AM - 9:30 AM PROTEIN C DEPLETION ENHANCES INFLAMMATION AND DELAYS MORTALITY IN MURINE LETHAL INFLUENZA A INFECTION M. Schouten* (NL), K. van der Sluijs, C. van ‘T Veer, C. T. Esmon, M. M. Levi, T. van der Poll

Trauma, Sepsis and Disseminated Intravascular Coagulation Room 109 AB

Chairpersons: Carl-Erik Dempfle (DE) and Daniel Frith (UK) OC-TH-067 8:00 AM - 8:15 AM ACUTE TRAUMATIC COAGULOPATHY IS DEPENDENT ON BOTH INJURY SEVERITY AND SHOCK: CLINICAL AND EXPERIMENTAL VALIDATION D. Frith* (UK), S. Stanworth, C. Gaarder, M. Maegele, C. Goslings, P. I. Johansson, S. Allard, M. J. Cohen, R. M. Pearse, C. Thiemermann, K. Brohi OC-TH-068 8:15 AM - 8:30 AM FACTOR V LEIDEN MUTATION ENHANCES FIBRIN FORMATION AND DISSOLUTION IN VIVO IN A HUMAN ENDOTOXEMIA MODEL C. H. Dempfle* (DE), N. Suvajac, E. Elmas, B. Jilma, H. Weiler, M. Borggrefe OC-TH-069 8:30 AM - 8:45 AM EFFICACY AND SAFETY OF RECOMBINANT ACTIVATED FACTOR VII IN THE MANAGEMENT OF HEMORRHAGIC SHOCK DUE TO TRAUMA C. J. Hauser, K. D. Boffard, R. P. Dutton* (US), G. R. Bernard, M. A. Croce, J. B. Holcomb, A. K. Leppaniemi, M. J. A. Parr, J. L. Vincent, B. J. Tortella, J. Dimsits, B. Bouillon, for the CONTROL Study Group OC-TH-070 8:45 AM - 9:00 AM EBOLA VIRUS INFECTION MODULATES THE BALANCE BETWEEN TISSUE FACTOR AND THROMBOMODULIN ON ENDOTHELIAL CELLS: RELEVANCE FOR DYSFUNCTIONAL HAEMOSTASIS IN VIRAL INFECTIONS A. Shibamiya, M. Schuemann, T. Schmidt-Woell, K. T. Preissner, E. Muehlberger, S. M. Kanse* (DE) OC-TH-071 9:00 AM - 9:15 AM TEMPORAL ASSOCIATION OF ALPHA-1-PROTEASE INHIBITOR INACTIVATION WITH INCREASED ELASTASE DURING EXPERIMENTAL SEPSIS J. A. Samis* (CA), K. A. Stewart, M. E. Nesheim, F. B. Taylor Jr OC-TH-072 9:15 AM - 9:30 AM TEMPORAL ASSOCIATION OF COAGULATION FACTOR INACTIVATION WITH INCREASED ELASTASE DURING EXPERIMENTAL SEPSIS J. A. Samis* (CA), K. A. Stewart, M. E. Nesheim, F. B. Taylor Jr

324 CT-7 4:15PM-4:30 4:00PM-4:15 OC-TH-074 OC-TH-073 ORAL COMMUNICATIONS CT-7 4:00PM-4:15 4:45PM-5:00 OC-TH-079 4:30PM-4:45 OC-TH-078 OC-TH-077 OC-TH-076 OC-TH-075 reilDsaeMcaim Room253ABC Arterial DiseaseMechanisms Room205ABC Health ServicesandOutcomes 2009 THURSDAY, JULY 16, G. Jörneskog A. STRUCTURE INTYPE1DIABETES ISOFMAJOR IMPORTANCE FORFIBRINCLOT GLYCEMIC CONTROL C. Ekman*(SE),D.Flondell, ANEURYSMS AORTIC ASMARKERSOFLARGE ABDOMINAL RECEPTOR AXL 6 (GAS6) AND THESOLUBLEFORMOFITSTYROSINEKINASE PLASMA L. W ANGIOTENSIN IIINFUSION AORTIC ANEURYSM INDUCEDBY DEVELOPMENT OF ABDOMINAL V Chairpersons: A. Nieland,P. Rose,S.Bacon,D.O’Shaughnessy R. Arya* (UK), A. McManus,S.Paneesha,N.Scriven, T. Nokes, T. Farren, VENOUS THROMBOEMBOLISMP INITIATIVES TO IMPROVE ASSESSING THEUPTAKE OFNATIONAL V. deMicheli,S. Testa, R.Frontoni,D.Prisco,S.Iliceto V. Pengo,U.Cucchini,G.Denas*(IT),N.Erba,Guazzaloca,L.LaRosa, COHORT MANAGEMENTSTUDY UNDERGOING INVASIVE PROCEDUREORSURGERY: AN INCEPTION ANTICOAGULANTS REGIMEN INOUTPATIENTS ONORAL STANDARDIZED LOWMOLECULARWEIGHTHEPARIN BRIDGING K. M.Shermock,B.L.Pinto,P. S.Kraus,M.B.Streiff* (US) NORMALIZEDRATIO (INR) MEASURES OFTHEINTERNATIONAL IMPORTANT DIFFERENCESBETWEENTWO EXTENT OFCLINICALLY N. Turck, J.Sanchez,N.Mensi, T. Perneger, D.Hochstrasser, M.Righini N. Vuilleumier* (CH),G.LeGal,F. Verschuren, A. Perrier, H.Bounameaux, MULTICENTER PROSPECTIVESTUDY EMBOLISM: A PULMONARY CARDIAC BIOMARKERSFORRISKSTRATIFICATION INNONMASSIVE Chairpersons: CliveKearon(CA)andMichaelStreiff(US) ASCULAR SMOOTHMUSCLE-DERIVEDTISSUEF Antovic* (SE),F. Mobarrez,S. Tehrani, P. Lins,U. Adamson, N.Wallen, ang* (US),D.L.Rateri,C.M.Miller CONCENTRA Aleksandra TIONS OFGROWTH Antovic (SE)andMarkT A. Gottsäter, B.Lindblad,Dahlbäck A TIENT CAREINTHEUK , A. Daugherty ARREST SPECIFICPROTEIN aubman (US) , M.B. ACT OR MEDIATES T aubman 4:00 PM-5:00 4:30 PM-4:45 4:15 PM-4:30 325

Thursday Orals

ORAL COMMUNICATIONS

THURSDAY, JULY 16, 2009 4:00 PM - 5:00 PM

OC-TH-080 4:45 PM - 5:00 PM ASSOCIATIONS OF THROMBIN GENERATION WITH RISK OF CARDIOVASCULAR DISEASE IN THE GLASGOW MONICA STUDY M. Smid* (NL), M. Woodward, A. Rumley, R. van Oerle, H. M. H. Spronk, H. ten Cate, G. Lowe

Pregnancy Complications Room 258 ABC

Chairpersons: Andra James (US) and Marc Blondon (CH) OC-TH-081 4:00 PM - 4:15 PM PATERNAL THROMBOPHILIA AS A RISK FACTOR FOR DEEP VEIN THROMBOSIS (DVT) DURING PREGNANCY AND POSTPARTUM: INFLUENCE OF THE PATERNAL A3 HAPLOTYPE OF THE EPCR GENE ON MATERNAL DVT OCCURRENCE J. Galanaud* (FR), E. Cochery-Nouvellon, S. Alonso, C. Chauleur, E. Mercier, G. Lissalde-Lavigne, P. Fabbro-Péray, P. Marés, J. Daurés, M. Dauzat, I. Quéré, J. Gris OC-TH-082 4:15 PM - 4:30 PM INCREASED LEVELS OF SOLUBLE ENDOTHELIAL CELL PROTEIN C RECEPTOR (SEPCR) IN WOMEN WITH PREECLAMPSIA: WITNESSES OF ENDOTHELIUM DAMAGE, OR NEW RISK FACTOR FOR PREECLAMPSIA? B. Saposnik* (FR), E. Peynaud-Debayle, A. Stepanian, S. Benchenni, M. Simansour, G. Baron, M. Fontenay, A. Le Querrec, L. Mandelbrot, D. de Prost, S. Gandrille, on behalf of the ECLAXIR Study OC-TH-083 4:30 PM - 4:45 PM HIGH-DOSE ANTITHROMBIN SUPPLEMENTATION IN EARLY PRE- ECLAMPSIA: A DOUBLE-BLIND, PLACEBO CONTROLLED STUDY (ON BEHALF OF THE ATIII-EPAS STUDY GROUP) L. Valsecchi, A. D’Angelo* (IT) OC-TH-084 4:45 PM - 5:00 PM MATERNAL TOBACCO SMOKE EXPOSURE IN WOMEN WITH PREECLAMP- SIA IS ASSOCIATED WITH HIGHER BIRTHWEIGHT FOR GESTATIONAL AGE S. R. Kahn* (CA), N. Almeida, G. Koren, M. Dahou, H. McNamara, R. Platt, M. S. Kramer

Hemophila: Gene Therapy Room 104 ABC

Chairpersons: Edward Tuddenham (UK) and Jonathan Finn (US) OC-TH-085 4:00 PM - 4:15 PM INTRAVENOUS INFUSION OF GENETICALLY-MODIFIED ENDOTHELIAL PROGENITOR CELLS FOR THE TREATMENT OF HEMOPHILIA A: INITIAL TRIALS IN THE HEMOPHILIA A DOG MODEL H. Matsui* (CA), M. Ozelo, A. Labelle, S. Powell, L. Harpell, C. Hegadorn, P. Thompson, C. Hough, D. Lillicrap OC-TH-086 4:15 PM - 4:30 PM REDUCED IMMUNOLOGICAL RESPONSE TO FACTOR VIII IN HEMOPHILIA A MICE ASSOCIATED WITH SUBCUTANEOUS IMPLANTATION OF LENTIVIRALLY-ENGINEERED ENDOTHELIAL PROGENITOR CELLS H. Matsui* (CA), A. Labelle, C. Hegadorn, P. Thompson, E. Burnett, C. Hough, D. Lillicrap 326 CT-8 4:45PM-5:00 4:30PM-4:45 OC-TH-088 OC-TH-087 ORAL COMMUNICATIONS CT-9 4:30PM-4:45 4:15PM-4:30 OC-TH-094 4:00PM-4:15 OC-TH-093 OC-TH-092 OC-TH-091 OC-TH-090 OC-TH-089 ehnsso ltltAtvto VRoom153ABC Mechanisms ofPlateletActivationIV Room107ABC Inflammation andCellTrafficking II 2009 THURSDAY, JULY 16, ATHEROSCLEROSIS CELLS(EC):ROLEINTHROMBOGENESIS AND ENDOTHELIAL Y. S.Bynagari* (US),B.Nagy, K.Bhavaraju,S.Kim, D.Woulfe, S.Kunapuli GENE KNOCKOUT STUDIES AND RESPONSES –PHARMACOLOGICAL PLATELET FUNCTIONAL ANDEPSILON IN ADP-INDUCED ROLE OFPKCISOFORMS ETA W. H.Ouwehand, A. H.Goodall,J.M.Gibbins C. I.Jones*(UK),S.F. Garner, L. A. Moraes,W. J.Kaiser, A. Rankin, FORMA PATHWAYS AND RESULTS INSIGNIFICANTREDUCTIONOFTHROMBUS CLUSTERING OFPECAM-1INHIBITS MULTIPLE PLATELET SIGNALING Chairpersons: JohanHeemskerk(NL)andJustinHamilton(AU) A. Babinska B. M. F1 G. W COMPLEXESINSEPSIS CRP-VLDL E. Peña,G. Arderiu, L.Badimon*(ES) REGULA HUMAN VASCULAR SMOOTHMUSCLECELLS AND ITSDOWN- TISSUE FACTOR LOCALIZESINTHELEADINGEDGEOFMIGRATING A. M.Carter V. Schroeder*(UK),V. Polkinghorne,K.F. Standeven,P. J.Grant, INFLAMMA LINKBETWEEN NOVEL INCORPORATED INTO FIBRINCLOTS– A SUBSTRATE FORFACTOR XIII AND IS COMPLEMENT C3IS A Chairpersons: LinaBadimon(ES)andElenaOsto(IT) H. Kurosaki,M.Oshimura, T. Doi,N.Komatsu,H. Takeya Y. Yakura* (JP),C.Ishihara, A. Hayashi, T. Matsui,S.Matsumoto, A OFHEMOPHILIA FOR GENETHERAPY DEVELOPMENT OFHUMAN P HEMOPHILIA IS ENHANCEDBY ADENO-ASSOCIATED VIRUSVECTOR EXPRESSIONOFLARGEGENES . E.Monahan*(US),J.Sun,C.D.LothropJr, R.J.Samulski 1R/JAM-A ang* (UK),S. Azari* (US),J.D.Marmur TION TION SIGNIFICANTL TION IS REQUIREDFORPLA A MICE AND DOGS MICEAND A AND THROMBOSIS Abrams, C.Dowsey PROTEASOME INHIBITORS AS MODELEDIN RIIILCHROMOSOMEVECTORS ARTIFICIAL Y , E.Kornecki, REDUCES MIGRATION TELET ADHESION TO INFLAMED , J. Thachil, C. Toh Y . H.Ehrlich,M.O.Salifu, 4:00 PM-5:00 4:15 PM-4:30 4:00 PM-4:15 4:45 PM-5:00 327

Thursday Orals

ORAL COMMUNICATIONS

THURSDAY, JULY 16, 2009 4:00 PM - 5:00 PM

OC-TH-095 4:30 PM - 4:45 PM THE ROLE OF PGRMC1 IN PLATELET FUNCTION Y. Jin* (US), W. Hong, D. Woulfe, D. Kenny, P. F. Bray OC-TH-096 4:45 PM - 5:00 PM MECHANISM OF THROMBIN BINDING TO PLATELET GLYCOPROTEIN IB A. Zarpellon* (US), A. Zampolli, R. A. McClintock, J. R. Roberts, Z. M. Ruggeri

Platelet Biology IV Room 156 ABC

Chairpersons: Paquita Nurden (FR) and Judith Cosemans (NL) OC-TH-097 4:00 PM - 4:15 PM THERE IS A HIGH MORTALITY RATE IN MICE WHEN PLATELET INTEGRIN ? IIB?3 IS LOCKED-IN ITS HIGH AFFINITY STATE D. A. Wilcox* (US), J. Fang, P. North, P. Nurden, A. T. Nurden, N. Valentin OC-TH-098 4:15 PM - 4:30 PM IMPAIRED ACTIVATION OF PLATELETS LACKING PROTEIN KINASE C THETA ISOFORM B. Nagy* (US), K. Bhavaraju, T. Getz, Y. B. Bynagari, S. Kim, S. P. Kunapuli OC-TH-099 4:30 PM - 4:45 PM A ROLE OF PLATELET MEMBRANE MICRODOMAINS IN CLEC-2- MEDIATED SIGNAL TRANSDUCTION K. Suzuki-Inoue* (JP), O. Inoue, Y. Ozaki OC-TH-100 4:45 PM - 5:00 PM A NOVEL ROLE OF GAB1-SHP2-PI3K COMPLEX ON PECAM-1 SIGNALLING IN PLATELETS L. A. Moraes* (UK), C. I. Jones, J. M. Gibbins

Heparin-induced Thrombocytopenia II Room 160 ABC

Chairpersons: Andreas Greinacher (DE) and Yves Gruel (FR) OC-TH-101 4:00 PM - 4:15 PM QUANTITATIVE INTERPRETATION OF OPTICAL DENSITY MEASUREMENTS OF IGG ANTIBODIES AGAINST HEPARIN/PF 4- COMPLEX IN COMPARISON WITH RESULTS OF OUR FUNCTIONAL ASSAY – IS THERE A BETTER CUTOFF VALUE? F. Bergmann* (DE), C. Bruns, C. Platzer, S. Krell, B. Arndt, A. Gröning OC-TH-102 4:15 PM - 4:30 PM FALSE POSITIVE TESTS FOR HEPARIN INDUCED THROMBOCYTOPENIA IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS R. Pauzner* (IL), A. Greinacher, K. Selleng, K. Althaus, B. Shenkman, U. Seligsohn OC-TH-103 4:30 PM - 4:45 PM BIOMARKER PROFILING OF PLASMA SAMPLES FROM SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS USING A PROTEIN CHIP ARRAY METHOD J. Fareed* (US), H. Zhu, J. Walenga, J. Cunanan, D. Hoppensteadt

328 CT-0 4:00PM-4:15 4:45PM-5:00 OC-TH-105 OC-TH-104 ORAL COMMUNICATIONS CT-1 4:45PM-5:00 4:15PM-4:30 4:00PM-4:15 4:45PM-5:00 OC-TH-112 4:30PM-4:45 OC-TH-1 4:15PM-4:30 OC-TH-110 OC-TH-109 OC-TH-108 OC-TH-107 OC-TH-106 euaino oglto n irnlss Room109AB Regulation ofCoagulationandFibrinolysis Room102AB Inhibitors ofCoagulationandFibrinolysis 2009 THURSDAY, JULY 16, 14:30PM-4:45 11 G. T. Kinasewitz, F. Lupu*(US) C. Lupu,G. A. Harris,R.Silasi-Mansat,L.Ivanciu, F. B. Taylor, EXPRESSION OFHEMOST A. Tanaka* (JP), Y. Suzuki, N.Kanayama, T. Urano THE CONT ACTIVATEDINACTIVATION ROLEIN FACTOR OFPAI-1 XII PLAYS BY A M. Etscheid*(DE),L.Muhl,D.Pons,K. T. Preissner, W. Ruf, W. Jukema,S.M.Kanse T PROTEASE (FSAP)PREVENTSFVII ACTIVATION, BUTCONTRIBUTES THE MARBURGIPOLYMORPHISM (G534E)OFFACTOR VII ACTIVATING M. S.Chatterjee*(US),W SPACE EXPERIMENTAL AND BLOODCOAGULA OFCOMBINEDPLATELET ACTIVATION MODEL SYSTEMS BIOLOGY Chairpersons: DennisGalanakis(US)andMaartjevandenBiggelaar(NL) A. R.MacLeod,B.P. Monia J. R.Crosby*(US),D.Gao,C.Zhao, A. Siwkowski,H.Zhang, OLIGONUCLEOTIDE INMICE FACTOR VII ANTISENSE ANTITHROMBOTIC EFFECTSOF A A. Hutchaleelaha,M.Inagaki,P. B.Conley, D.R.Phillips,U.Sinha G. Lu*(US),P FACTOR XaINHIBITORS REVERSE ANTICOAGULATION BY RECONSTRUCTED RECOMBINANTFACTOR Xa AS AN ANTIDOTE TO C. A. Kretz*(CA),K.Cuddy, A. R.Stafford, J.C.Fredenburgh, J.I.Weitz PROTHROMBIN ACTIVATION AND THROMBINFEEDBACK HD1 INHIBITSTHROMBINGENERA R. M.Kini C. CLASS OFTHROMBININHIBITORS NOVEL STRUCTURE-FUNCTION RELATIONSHIPS OFVARIEGIN: A Chairpersons: NaomiEsmon(US)andMichaelPage R. L.Levine*(US), THROMBOCYT DOCUMENT RISK DEPARTMENT PHYSICIANS DOEMERGENCY HOW FREQUENTLY V O THROMBOEMBOLICRISKDUET ASCULA Y. Koh*(SG),S.Kumar, K.Swaminathan,P. Uvaraj,P. Jagadeeswaran, TURE OFHEAL ACT PHASEDEPENDENTENHANCEMENT OFFIBRINOL . Luan,S.J.Hollenbach,K. OPENIA? ASSESSMENT FORHEPARIN-INDUCED T. Funk,G.W. Hergenroeder, M.J.Hursting TION TESTEDOVER . S.Denney, H.Jing,D.Jager, S.L.Diamond THY A TIC PROTEINSINTHEL AND SEPTICBABOONS INB ATTENUATING TION BY O FVIII ACTIVATION Abe, F. R.Deguzman,G.Siu, MULTIVARIATE A YMPHATIC 4:00 PM-5:00 YSIS 329

Thursday Orals

ORAL COMMUNICATIONS

THURSDAY, JULY 16, 2009 4:00 PM - 5:00 PM

Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Room 151 AB

Chairpersons: Michael Nesheim (CA) and Mary Prorok (US) OC-TH-113 4:00 PM - 4:15 PM IN VIVO AND IN VITRO PROFIBRINOLYTIC EFFECT OF MMP-10 MEDIATED BY TAFI: A NEW ROLE FOR MMPS ON FIBRINOLYSIS? J. Orbe* (ES), J. A. Rodriguez, C. Orset, J. Barrenetxe, R. Serrano, E. Angles-Cano, D. Vivien, M. Belzunce, J. A. Paramo OC-TH-114 4:15 PM - 4:30 PM STIMULATION OF THE INTRINSIC ENZYMATIC ACTIVITY OF TAFI ATTENUATES CLOT LYSIS K. Buelens* (BE), G. H. Hassanzadeh, S. Muyldermans, A. Gils, P. J. Declerck OC-TH-115 4:30 PM - 4:45 PM ACTIVE PLATELET-DERIVED TAFI ATTENUATES PLATELET-RICH THROMBUS LYSIS IN VITRO S. L. Schadinger* (CA), M. B. Boffa OC-TH-116 4:45 PM - 5:00 PM CARBOXYPEPTIDASE N: AN ANTIFIBRINOLYTIC CARBOXYPEPTIDASE? P. L. Swanson* (CA), T. Binette, P. Scott, C. Peterson, L. Bajzar

Atherosclerosis: Risk factors II Room 162 AB

Chairpersons: Gunnar Heine (DE) and V. V. Kakkar, (UK) OC-TH-117 4:00 PM - 4:15 PM ASSOCIATIONS OF CIRCULATING NATURAL KILLER CELLS WITH CARDIOVASCULAR DISEASE RISK FACTORS: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA) N. S. Jenny* (US), M. Doyle, R. Kronmal, S. Huber, B. M. Psaty, R. P. Tracy OC-TH-118 4:15 PM - 4:30 PM HIGH ANTIBODY LEVELS TO PATHOGENS, HEAT SHOCK PROTEINS AND THE RISK OF CORONARY ARTERY DISEASE IN INDIAN POPULATION V. S. Rao, L. A. Mundkur* (IN), J. Shanker, H. Sridhara, J. Shibhu, K. Sibi, K. Hemapriya, V. Ravi Kumar, B. Dhanalakshmi, A. Mani, V. V. Kakkar OC-TH-119 4:30 PM - 4:45 PM THE RHEUMATOID FACTOR MAY BE AN INDEPENDENT RISK FACTOR FOR CORONARY ARTERY DISEASE IN METABOLIC SYNDROME MEN G. Jong* (TW), T. Ma, L. Tien, M. Chang OC-TH-120 4:45 PM - 5:00 PM CALU A29809G POLYMORPHISM ROLE IN CORONARY ATHEROTHROMBOTIC PLAQUES AND PROGNOSTIC INVOLVEMENT V. Pérez Andreu* (ES), R. Gonzalez Conejero, J. Ruiz Nodar, D. Hernandez Romero, F. Marín, A. Tello Montoliu, A. Antón, V. Vicente, V. Roldan

330

PT-0 HOMOCYSTEINEINDUCESCHANGESINPLATELET CALCIUMMOBILIZATION AND PP-TH-003 FROM NITRICOXIDEINHIBITSPLATELET AGGREGATION INDEPENDENTLY PP-TH-002 THEEFFECTOFHYDROGENSULPHIDEONPLATELET ACTION PP-TH-001 * POSTER PRESENTATIONS PT-1 K EUAE EKAOITMDAE A1 CIAINVAAGSK-3 AKTREGULATES WEAK-AGONISTMEDIATED A RAP1B ACTIVATION VIA PP-TH-014 SPECIFICCYSTEINES INTHEEGFDOMAINSOFBETA3 AFFECT DIFFERENTLY PP-TH-013 THROMBOSPONDIN-1ENHANCESTHROMBUS OUTSIDE-INSIGNALINGINDUCEDBY PP-TH-012 PP-TH-01 14-3-3ISOFORMSINTERACTINGWITHTHE IDENTIFICATION OFFIVENOVEL PP-TH-010 PP-TH-009 CHARACTERIZATION OFPLATELET NITRICOXIDEPRODUCTIONTRIGGEREDBY PP-TH-008 PP-TH-007 DETERMINATION OFGLYCOPROTEIN OFTHERESISTANCE IN ASPIRIN, BY STUDY PP-TH-006 SOLUBLEELASTININHIBITSPLATELET ACTIVATION MEDIATED THROUGH PP-TH-005 DISTRIBUTIONOFCYTOSOLIC CALCIUMIONINPLATELET FORMING LOCAL PP-TH-004 Mechanisms ofPlateletActivationIII 2009 THURSDAY, JULY 16, Presenting Author 1 INDEPENDENT SIGNALLINGP ALPHA PROCOAGULANT ACTIVITY FUNCTION INTYPE2DIABETESMELLITUS FORMATION OFTHROMBOXANE A2 FORMATION: INVOLVEMENT OFCD36 PLATELET GPIB-IXCOMPLEX THE DYNAMICSOFPLATELET ACTIVATION INVIVO PLA INTEGRIN ON THEPLA GLYCOPROTEIN IB CONTROLLED BLOODFLOWCONDITION THROMBI ONCOLLAGENFIBRILS AND VONWILLEBRANDFACTOR UNDER J. Kaiser, J.M.Gibbins, Y. M.Patel R. N.Sumathipala*(UK),K.V. Patel,S.Rahman, Y. Nishino,I.G.Webb, S.Rangarajan,W. R. Mor-Cohen*(IL),N.Rosenberg,U. Seligsohn R. Nergiz-Ünal*(NL),M.J.E.Kuijpers, I.C. A. Munnix,J.F. Glatz,J. W. M.Heemskerk R. Chari*(US),S.Kim,Murugappan, A. Sanjay, J.L.Daniel,S.P. Kunapuli P P. L.Gross*(CA),R.Ni,B.Esposito, M.L.Rand,J.I.Weitz G. Guglielmini,M.Cozzi,Battiston,Mazzucato,P P. E.J.vanderMeijden*(NL),M. A. H.Feijge,K.Gilio,Hamulyak,J.W. M.Heemskerk P. E.Makris*(GR),M.Moshou,P. Makris,G.Koliakos O. Inoue*(JP),K.Suzuki-Inoue, Y. Ozaki N. Tamura* (JP),H.Ishida,S.Goto Rosado N. Alexandru* (RO),I.Jardín,D.Popov, M.Simionecu,J.García-Estañ,G.Salido, A. N. J. Truss* (UK),P. C.J. Armstrong, S.K.Shinhmar, T. D.Warner N. J. LTLTDNEGAUESCEINB PROTEINKINASEC-DELTA PLATELET DENSEGRANULESECRETIONBY REGULATION OF MOLECULAR MECHANISMSUNDERLYING THEDIFFERENTIAL . Mangin*(FR),N.Receveur TELET Truss* (UK),F. Y. Ali, P. C.J. Armstrong, T. D.Warner VBETA3 AND ALPHAIIBBETA3 RECEPTOR FUNCTION ALPHAIIBBET ADHESION UNDERFLOWUSINGIMAGESEQUENCE TELET MEMBRANE A3 OUTSIDE-INSIGNALINGVIA , V . Wurtz, C.Gachet,F. Lanza A HA INPLATELETS THWAY . Gresele*(IT),L.deMarco SYK INDUCESPLA ANAL YSIS TELET 331

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-015 INTEGRIN-LINKED KINASE ASSOCIATED WITH INTEGRIN ACTIVATION S. Honda* (JP), H. Shirotani-Ikejima, S. Tadokoro, Y. Maeda, T. Kinoshita, Y. Tomiyama, T. Miyata PP-TH-016 ELECTRON MICROSCOPY CHARACTERIZATION OF PLATELET INTERACTION WITH CARBON NANOMATERIALS S. H. Lacerda* (US), J. Semberova, O. Simakova, K. Holada, M. P. Gelderman, J. Simak PP-TH-017 PLATELETS INTERACTION WITH PHOSPHOLIPASE A2 PURIFIED FROM THE AGKISTRODON BLOMHOFFII USSURIENSIS SNAKE VENOM S. B. Otgontaij* (MN), E. E. Altantsetseg PP-TH-018 GPIB ALPHA IS A COFACTOR BINDING THROMBIN AND THUS FACILITATING PAR1 CLEAVAGE L. Faxälv, S. Nylander, R. Chaireti, F. Pettersson, T. L. Lindahl* (SE) PP-TH-019 FRACTALKINE DESENSITIZES PLATELETS TO PLATELET INHIBITION BY THE ENDOGENOUS PLATELET INHIBITOR PROSTACYCLIN U. Flierl* (DE), J. Bauersachs, A. Schaefer PP-TH-020 NITRIC-OXIDE MEDIATED INHIBITION OF PLATELET FUNCTION IS REVERSED BY THROMBOSPONDIN-1 W. Roberts* (UK), R. Riba, K. M. Naseem PP-TH-021 CD148 ENHANCES PLATELET RESPONSIVENESS TO COLLAGEN AND FIBRINOGEN BY MODULATING SRC FAMILY KINASE ACTIVITY S. Ellison, A. Barr, M. G. Tomlinson, J. Zhu, A. Weiss, S. P. Watson, Y. A. Senis* (UK) PP-TH-022 BF0801, A NOVEL PLATELET PHOSPHODIESTERASE INHIBITOR S. Zhang, Y. Zhang, X. Yu, K. Bhavaraju, L. Hu, J. Jin, H. Du, S. P. Kunapuli, Z. Ding* (CN)

Platelet Biology III

PP-TH-023 HEAT SHOCK IN VITRO MODEL: POSSIBLE RELATIONSHIP WITH PLATELETS MORPHOLOGY LYMPHOCYTES AND NEUTROPHILS LEUKOCYTES CHROMATIN REALIGNMENT N. G. Kruchynsky* (BY), S. Vishnevskaya PP-TH-024 PLATELET AGGREGATION AND SECRETION MEDIATED BY GPVI ACTIVATION ARE NOT ACCOMPANIED WITH INCREASE OF TISSUE FACTOR-DEPENDENT PROCOAGULANT ACTIVITY (PCA O. Panes* (CL), V. Matus, J. Pereira, D. Mezzano PP-TH-025 THE P2Y1, P2Y12, GPIIB AND GPIIIA GENE EXPRESSIONS IN PLATELETS OF HEALTHY DONORS AND PATIENTS WITH MYOCARDIAL INFARCTION O. V. Sirotkina* (RU), N. A. Bogankova, A. L. Schwarzman, T. V. Vavilova PP-TH-026 PLATELET REACTIVITY IN DIFFERENT ETHNICITIES AND GENDER (PRIDE G) PILOT TRIAL O. Bailon* (US), A. Singla, M. Antonino, J. Dichiara, K. Bliden, M. Hamed, T. Suarez, P. A. Gurbel, L. Lawal, U. S. Tantry PP-TH-027 ADP-MEDIATED AGGREGATION AS A PHARMACODYNAMIC ASSAY UNDERESTIMATES THE ANTITHROMBOTIC ACTIVITY OF ELINOGREL, A COMPETITIVE, REVERSIBLE P2Y12 INHIBITOR, RELATIVE TO CLOPIDOGREL P. B. Conley* (US), P. Andre, G. Stephens, H. Haberstock-Debic, M. Jurek, D. Gretler, D. R. Phillips PP-TH-028 CALPAIN CLEAVES ANTI-APOPTOTIC PROTEINS IN ACTIVATED PLATELETS P. A. Cordell* (UK), P. J. Grant, R. J. Pease

332 PT-3 PALMITOYLATION SUPPORTSTHE ASSOCIATION OFTETRASPANIN CD63WITHCD9 PP-TH-032 SYSTEMATIC IDENTIFICATION AND INTERPRETATION OFPLATELET PROTEIN PP-TH-031 PP-TH-030 PLATELET AGGREGATION INHIBITOR FROM AGKISTRODON BLOMHOFFII PP-TH-029 POSTER PRESENTATIONS PP-TH-042 PP-TH-041 PP-TH-040 PP-TH-039 PP-TH-038 PP-TH-037 USEOFMEMBRANE-PERMEABLEITAM-PEPTIDES TO INVESTIGATE THEINITIAL PP-TH-036 DIMERIC-SPECIFICCONFORMATION OFTHECOLLAGEN-RECEPTOR GLYCOPROTEIN PP-TH-035 MARKERSOFHUMANPLATELET ACTIVATION INHYPERHOMOCYSTEINAEMIC PP-TH-034 OF THEPLATELET REDOXPOTENTIAL ALTERATIONS INTHEEXTERNAL PP-TH-033 HRDY UY1,2009 THURSDAY, JULY 16, THE SELECTIVE P2Y12RECEPT NOVEL PROPERTIES OF ASP1645, A ANDPHARMACOLOGICAL BIOCHEMICAL COMPARED WITHCLOPIDOGREL NEEDN FISCTRIA PDZ-DOMAINBINDINGMOTIF INDEPENDENT OFITSC-TERMINAL HOMOPHILICINTERACTIONBETWEEN ADJACENT CELLS, A JUNCTIONSVIA CELL MONOCYTE UPA (THR)18 AND (SER)19PHOSPHORYLATIONS INPLATELETS AND WITHTHE ACTIN CYTOSKELETON INTHROMBIN-ACTIVATED PLATELETS LOCALISATION ACTIVEMETABOLITES ANDPRASUGREL BINDING OFCLOPIDOGREL REVERSIBLE BINDINGOFCANGRELORTO THEP2Y12RECEPTOR PREVENTSTHE USSURIENSIS VENOM DIFFERENTIAL FIBRINOL ENDOTHELIAL FACTOR XI PLATELET RECEPTOR FORCOAGULATION APOLIPOPROTEIN ERECEPTOR 2IS A COLLAGEN RECEPTOR GLYCOPROTEIN (GP)VI REACTIONS OFPLATELET ACTIVATION INDUCEDTHROUGHTHEPLATELET EVIDENCE PROVIDEDBY (GP) VICONTAINS THECOLLAGEN-BINDINGSITEOFNATIVE PLATELETS: DIRECT STATES ENVIRONMENT IMPACTS ONPLATELET REACTIVITY Ito, S.Mutoh T. Uemura*(JP), T. Kawasaki,C.Sakata, T. Shigenaga, Y. Moritani,J. Takasaki, Y. Koga,H. Ito, S.Mutoh T. Uemura*(JP), T. Kawasaki, Y. Moritani,C.Sakata,F. Takamura, J. Takasaki, Y. Koga,H. T T. de Jouvencel* (FR),L.Doeuvre,Plawinski,R.Lijnen,E. Angles-Cano T de Groot, T. C.White-Adams* (US),M. A. Berny, E.I. Tucker, J.Pang,D.Gailani,R. T. Urbanus,P. G. S. M.Jung*(JP),Moroi S. M.Jung*(JP),Moroi Mayne, P. B.Collins S. ONeill*(IE), S. ONeill*(IE),D.Murphy S. J.Israels*(CA),E.M.McMillan-Ward R. G.Stanley*(UK),B.Wright, W. J.Kaiser, J.M.Gibbins R. J.Buckland,H.M.Judge, P . M.Getz*(US),C.D.Dangelmaier . J.Stalker*(US),W . Dashnyam*(MN),B.Jugder, A. Nemekh ANTIPLA A. Gruber YTIC CROSS-T TELET EFFECTOF CELL ACTIV A. McGarrigle,N.Moran,I.G.Graham,M. , O.J. SPECIFIC TO N UCINLROLEOFMYOSINLIGHT CHAIN ATION AND FUNCTIONAL u, M.S.Chatterjee,L.Diamond,F ALK: PLA T . McCarty A A. Sugidachi,J. A. Jakubowski,R.F. Storey*(UK) OR RECOMBINANT F ANT ADHESION MOLECULE(ESAM)LOCALIZESTO CELL- ASP1645, TELET AGONIST , J.D.Daniel,S.P. K.Kunapuli -BOUND PLASMINOGENIS OE P2Y12 RECEPTOR ANTAGONIST, NOVEL A AB SPECIFICFORDIMERICGPVI T . Cooney . Brass , A. Monavari,P. ACTIVATED BY 333

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-043 HUMAN PLATELETS EXPRESS MRNA AND SYNTHESIZE UPAR, BUT NOT UPA V. Matus* (CL), O. Panes, E. Torres, C. G. Sáez, J. Pereira, D. Mezzano PP-TH-044 ABSOLUTE QUANTITATION OF VWF MRNA FROM HUMAN NORMAL PLATELETS V. A. Zapata* (AR), A. C. Kempfer, M. A. Carrivale, J. H. Paiva Palomino, A. Vellicce, Y. P. Powazniak, M. A. Lazzari PP-TH-045 BINDING OF PLATELET GLYCOPROTEIN IB-BETA THROUGH THE CONVEX SURFACE OF LEUCINE-RICH REPEATS DOMAIN OF GLYCOPROTEIN IX X. Mo* (US), N. X. Nguyen, P. A. McEwan, X. Zheng, J. A. López, J. Emsley, R. Li PP-TH-046 AN IN VITRO MODEL TO VISUALIZE AND QUANTIFY PHAGOCYTOSIS OF PLATELETS AND VWF Y. P. Wu* (NL), D. E. van der Wal, P. G. de Groot, J. W. N. Akkerman

Novel Approaches to Understanding Platelet Biology III

PP-TH-047 SEROTONIN IMPROVES CLOT FORMATION AND VISCOELASTIC PROPERTIES A. M. Galan* (ES), I. Lopez-Vilchez, F. Navalon, M. Pino, C. Gasto, G. Escolar PP-TH-048 HUMAN BLOOD PLATELET FUNCTION AND PROTEOME FOLLOWING CHRONIC INTAKE OF ORANGE JUICE A. Della Corte, S. Marcone, M. Crescente, L. Giordano, W. Coletta, C. Tamburrelli, M. Barisciano, A. de Curtis, L. Iacoviello, R. Lorenzet, G. de Gaetano, M. B. Donati, C. Cerletti* (IT), D. Rotilio PP-TH-049 A HIGH THROUGHPUT STUDY OF PLATELET CALCIUM RESPONSE TO PAIRWISE COMBINATION FROM A 6-DIMENSIONAL AGONIST SPACE ALLOWS TRAINING OF A SYSTEMS BIOLOGY NEURAL NETWORK “PLATELET BARCODE” M. S. Chatterjee* (US), J. E. Purvis, S. L. Diamond PP-TH-050 INHERITED HUMAN NOX2 DEFICIENCY IS ASSOCIATED WITH IMPAIRED ISOPROSTANE FORMATION AND REDUCED PLATELET RECRUITMENT P. Pignatelli* (IT), R. Carnevale, S. di Santo, S. Bartimoccia, V. Sanguigni, A. Plebani, S. Basili, F. Violi PP-TH-051 CLOCK REGULATES CIRCADIAN PLATELET ACTIVITY S. Horie* (JP), N. Ohkura, Y. Sudo, H. Hayashi, K. Shikata, N. Ishida, J. Matsuda, K. Oishi PP-TH-052 BLOOD VOLUME IS SIGNIFICANTLY REDUCED IN A NOVEL PARALLEL PLATE FLOW CHAMBER S. O’Brien* (IE), N. Kent, A. J. Ricco, D. Kenny, G. Meade PP-TH-053 CAPTURE AND ASSAY OF INDIVIDUAL ADHERING PLATELETS S. Ramstrom* (IE), L. Basabe-Desmonts, A. Lopez-Alonso, A. J. Ricco, J. O’Donnell, D. Kenny PP-TH-054 THE CHS-4 CHROMATIN INSULATOR SEQUENCE PROTECTS CLONAL DOMINANCE OF HEMATOPOIETIC STEM CELLS TRANSDUCED WITH A SELF-INACTIVATING SIV VECTOR IN PLATELET-DIRECTED GENE THERAPY T. Ohmori* (JP), S. Madoiwa, Y. Kashiwakura, A. Ishiwata, E. Akiba, M. Hasegawa, J. Mimuro, Y. Sakata PP-TH-055 DEVELOPMENT OF A MODEL TO STUDY PLATELET FUNCTION UNDER CONDITIONS OF FLOW V. X. Du* (NL), H. F. G. Heijnen, P. G. de Groot, A. Barendracht, M. Roest

334 PT-5 -RSLIHBT LTLTAGEAINADIDCSEDTEILCELL INHIBITSPLATELET AGGREGATION AND INDUCESENDOTHELIAL P-CRESOL PP-TH-058 LEVELSOFPLATELET-DERIVED MICROPARTICLES (PDMP)MIGHT PLASMA PP-TH-057 PP-TH-056 POSTER PRESENTATIONS PT-6 FETO LO LT NTEMGKROYI OETA OFTHAWED EFFECT OFBLOODCLOTSONTHEMEGAKARYOCYTIC POTENTIAL PP-TH-068 EXPRESSIONSIGNATURES ARE DIFFERENTINHUMANNEONATAL MICRORNA PP-TH-067 PP-TH-066 ON (ITP)PLASMA THEEFFECTOFIMMUNETHROMBOCYTOPENIC PURPURA PP-TH-065 PP-TH-064 ALTERATIONS OFPLATELET FUNCTIONINPATIENTS WITH CHRONICMYELOID PP-TH-063 VALIDATION OFRAPID AND AUTOMATED METHODFORMEASUREMENTOF PP-TH-062 PP-TH-061 PP-TH-060 OFMATRIXMETALLOPROTEINASE 9 ONTHE ACTIVITY EFFECTOFSOLUBLECD40L PP-TH-059 Megakaryocytes andThrombopoiesis II Platelets andSystemicDisorders III 2009 THURSDAY, JULY 16, CORD BLOODUNITS COMPARED TO ADULT MEGAKARYOCYTES CORD BLOODCUL NPLATE EXPANDS AND DIFFERENTIATES MEGAKARYOCYTIC CELLSINUMBILICAL THROUGH TLR2 AND IL1R IL-8 PRODUCTION ANTIPHOSPHOLIPID SYNDROME(APS) IN INDICATORFOR ANTIPLATELET THERAPY USEFUL COMPRISE A IMMUNOGLOBULIN G INPLATELET ADHESION TO AND ALPHAIIB BETA3 SYNERGY RIIA FC GAMMA DIAGNOSIS PLASMA MEGAKAR INFLAMMA LEUKEMIA AUTO AND ANTIBODIES ADAMTS-13 ACTIVITY INCIDENCE OFHAEMORRHAGICSTROKEINJAPAN RACIAL SYNDROME PLATELET AGGREGATION AND COAGULATION DISORDERSINEHLERS-DANLOS OF MEG-01CELLS S. Juutistenaho*Finland, S.Möttönen,M.Eskola,K. Aranko, R.Kekomäki R. K.Gutti*(US),H.Sallmon,M.Bailey, Z. Liu,M.C.Sola-Visner M. Chang*(US),P. A. Nakagawa,J.S.Buzby, D.J.Nugent M. Chang*(US),P. A. Nakagawa,S. A. Williams,K.L.Imfeld, J.S.Buzby, D.J.Nugent L. M.Beaulieu*(US),E.Lin,N.Mavrogiorgos,R.Ingalls,J.Freedman E. Kovacs V. Popov*(RO),H.Bumbea, A. Vladareanu,C.Saftoiu,S. Radesi, A. Nicolescu, T. Savopol, T S. Saraf,H.Ishii,J. Yamamoto, Y. Yamori, D.Gorog,S.Sharma*(UK) Garbiero, L.Roumeque,D.diPaolo P. Martinez*(AR),P. Martinez,H.Caferri,M.Facchini,P. Iommi,E. Agriello, M.Brandt,S. Hernandez N. Butta*(ES),E. Arias-Salgado, M. Alvarez, M.Martin, I.Fernandez,V. Jimenez-Yuste, F. M. C.Chang*(TW),J.H.Jeng M. Yamazaki* (JP), Y. Kadohira,M.Maekawa, T. Hayashi,E.Morishita,H. Asakura, S.Nakao M. P. Brennan*(IE),M. Thai Trung King,S.Kerrigan,D.Cox . M.Owaidah, DIFFERENCES INTHROMBOTICST YOCYT T R MODULATION OFMEGAKARYOCYTES AND THROMBOPOIESIS ORY Ahmed* (SA),R. Al Nounou,N.Rasheed OPOIESIS INVITRO:COMP TURES A ARISON OFPREVERSUSPOST TUS MA Y EXPLAIN THEINCREASED 335

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-069 HIGH GLUCOSE CONCENTRATIONS RAPIDLY UPREGULATE CYCLOOXYGENASE-2 (COX-2) EXPRESSION IN HUMAN MEGAKARYOCYTES (MK) T. Corazzi* (IT), P. Gresele, L. Bury, G. B. Bolli PP-TH-070 HEMATOPOIETIC STEM CELL STIMULATORS THROMBOPOIETIN , ARP AND FIBRONECTIN PROVIDE A NOVEL STRATEGY FOR EXPANSION OF EARLY HEMATOPOIETIC AND MEGAKARYOCYTE-PROGENITOR CELLS FROM CORD BLOOD V. R. Deutsch* (IL), E. Hubel, S. Kay, T. Ohayon, B. Katz, E. Naparstek, D. Grisaru PP-TH-071 APOPTOTIC PROCESS IS INVOLVED IN THE EARLY PHASE OF MEGAKARYOPOIESIS, BUT NOT IN PLATELET PRODUCTION FROM MEGAKARYOCYTES Y. Kozuma* (JP), H. Ninomiya, T. Kono, H. Y. Mukai, H. Kojima PP-TH-072 GSK-3 NEGATIVELY REGULATES THROMBOPOIESIS IN AN IN VITRO NORMAL HUMAN CD34-POSITIVE CELL-DERIVED DIFFERENTIATION SYSTEM M. Ono, Y. Matsubara* (JP), T. Shibano, Y. Ikeda, M. Murata PP-TH-073 THROMBOPOIETIN STIMULATES THE CYTOPLASMIC MATURATION OF LOW-PLOIDY NEONATAL MEGAKARYOCYTES THROUGH THE MTOR PATHWAY Z. Liu* (US), M. Bailley, R. Gutti, H. Sallmon, M. Sola-Visner

Mechanisms of Inherited and Acquired Defects of Platelet Number and Function II

PP-TH-074 GLANZMANN THROMBASTHENIA (GT): A SERIES OF 12 GENETIC VARIANTS - 11 NOVEL- IN ITGB3 AND ITGA2B GENES IN 16 INDIVIDUALS FROM FRANCE AND GERMANY B. Saposnik, M. Simansour, S. Binard, M. Hurtaud-Roux, V. Proulle, M. Gerard-Blanluet, D. de Prost, A. Nurden, U. Nowak Göttl And, N. Schlegel* (FR) PP-TH-075 STRUCTURAL ANALYSIS OF THE HUMAN PLATELET ANTIGENS N. Rosenberg* (IL), M. Landau PP-TH-076 ESTIMATION OF INCIDENCE OF THROMBOCYTOSIS-INDUCED BY HEPARIN IN 1861 MEDICAL PATIENTS M. Epinat, N. Moulin, E. Presles, T. Monatte, C. Guy, S. Laporte, P. Mismetti* (FR) PP-TH-077 RITUXIMAB FOR REFRACTORY AND RELAPSING THROMBOTIC THROMBOCYTOPENIC PURPURA P. N. Knoebl* (AT), P. Distelmaier, S. Koder, P. Schellongowski, P. Quehenberger PP-TH-078 DECREASED EXPRESSION OF MBD2 AND MBD4 GENE AND GENOMIC-WIDE HYPOMETHYLATION IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA Z. Chen, D. Gu, X. Chen, Z. Zhou, Z. Guo, J. Ge, H. Zhao, R. Yang* (CN) PP-TH-079 CONGENITAL OR ACQUIRED ADAMTS13 DEFICIENCY OR BOTH – THAT’S THE QUESTION S. C. Meyer* (CH), I. Sulzer, G. Mäder, J. N. George, B. Lämmle, J. A. Kremer Hovinga PP-TH-080 HETEROZYGOUS ADAMTS13 MUTATIONS IN IDIOPATHIC TTP WITH SEVERE ACQUIRED ADAMTS13 DEFICIENCY S. C. Meyer* (CH), S. Jin, W. Cao, W. Pos, J. Voorberg, X. L. Zheng, B. Lämmle, J. A. Kremer Hovinga PP-TH-081 A HETEROZYGOUS ITGA2B R995W MUTATION CAUSES CONSTITUTIVE ACTIVATION OF THE IIB 3 RECEPTOR AND RESULTS IN CONGENITAL MACROTHROMBOCYTOPENIA S. Kunishima* (JP), H. Kashiwagi, Y. Ito, Y. Fujimori, Y. Miyajima, Y. Takamatsu, J. Suzumiya, Y. Tomiyama, H. Saito

336 PT-8 OE UAINO IHYCNEVDRSDEANAPOFINTEGRIN CONSERVED RESIDUE ASN2ASP HIGHLY MUTATION OF A NOVEL A PP-TH-084 MANIFESTATIONS OFDISORDERS ASSOCIATED WITHMYH9MUTATIONS CLINICAL PP-TH-083 CASEOFSELECTIVEENZYMATIC DEFECTOFCYCLOOXYGENASE-1 NOVEL A PP-TH-082 POSTER PRESENTATIONS PP-TH-093 PP-TH-092 PP-TH-091 EXOSITEINTHE ADAMTS13 DISINTEGRIN-LIKE FUNCTIONAL IDENTIFICATION OF A PP-TH-090 PP-TH-089 ADAMTS13MISSENSE MUTATIONS INCHILDHOOD AND ADULT EIGHTNOVEL ONSET PP-TH-088 PP-TH-087 NECROSISIN A WITHSEVERE ARTERIAL THROMBOTICMICROANGIOPATHY RENAL PP-TH-086 FORMATION OFMETHIONINE-SULFOXIDE AT POSITION1606OFVONWILLEBRAND PP-TH-085 Basic BiologyofADAMTS13III 2009 THURSDAY, JULY 16, SN OE OOLNLANTIBODIESTO VWF MONOCLONAL USING NOVEL UNDERSHEARSTRESS INPLASMA ESTIMATION OFTHE ADAMTS13 ACTIVITY REGULATING ADAMTS13 ACTIVITY DURING INFLAMMATION DURING REGULATINGACTIVITY ADAMTS13 SPECIFICITY ALPHA-IIB CAUSESGLANZMANNTHROMBASTHENIA ASSOCIATED WITHHAEMORRHAGICDIATHESIS HYPOCHLOROUS IN VIVO DOMAIN ADAMTS13 MET TTP CONGENITAL STELLATE CELLS AND STIMULATION INENDOTHELIAL ADAMTS13 UNDERPROINFLAMMATORY DIFFERENTIAL SEPTIC PORCINE2-HITMODEL STRESS OXIDATIVE NEWPROTHROMBOTIC MECHANISMPROMOTEDBY INTERACTION: A F Z. Ma*(CN),N.Dong,J.Zhang, A. Wang, C.Ruan X. Fu*(US), S. F. de Meyer*(BE),U.Budde,H.Deckmyn,K.Vanhoorelbeke R. deGroot*(UK),N.Ramroop, R. deGroot*(UK),D. A. Lane, J. T. B.Crawley R. S.Camilleri*(UK),I.J.Mackie,Liesner R. Becker C. L.Bockmeyer, K.Kentouche,P. Reuken,S.Krause,C.Krusche,G.Marx,W. Losche,J. S. Rutella,P. Mannucci R. deCristofaro*(IT),S.Lancellotti,V W. Mansour*(IL),N.Rosenbreg,H.Haushner, A. Koren,U.Seligsohn S. Rittich*(CZ),D.Provaznikova,V Rocca S. Pascale*(IT), W. Losche,S.Friedman,M.Bauer CO NIISCEVG YADAMTS-13WITHOUT AFFECTING PLATELETACTOR INHIBITSCLEAVAGE BY A. Claus*(DE),F , R. ABSENCE OF ADAMTS13 DOESNOT ABROGATE VWF SIZEHETEROGENEITY A. Claus*(DE) Y . W TRANSCRIPTION OFMRNA A. Dragani,D.Mattoscio,E.Ferrante,L.Mucci,I.diMarzio,G.Davì,B. ALLOPROTEASE DOMAINSUBSITESCONTROL ang, J.Chen,M.Ling,D.Kulman, A. López,D.W. Chung ACID INACTIV . Conradi,C.L.Bockmeyer A. Bardhan,J. A . Geierova,D.Mikulenkova,I.Hrachovinova,P. Salaj TES . deFilippis,N.Pozzi,F. Peyvandi,R.Palla,B.Rocca, ADAMTS13: , W , K.Kentouche,M.W CODING THEVWF-CLEAVING PROTEASE T . J.Chen,K.Manns,S.Machin,M.Scully . B.Crawley, D. A. Lane AN OXIDATIVE MECHANISMFOR . Sieber CLEA V , P AGE SITE . Recknagel, 337

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

Novel Mechanisms of Antiplatelet Therapy III

PP-TH-094 GALLIC ACID COMPETES WITH ASPIRIN, RESVERATROL AND QUERCETIN FOR PLATELET COX-1: FUNCTIONAL AND MOLECULAR MODELLING STUDIES M. Crescente, S. Momi, G. Jessen, M. Leone, H. D. Höltje, P. Gresele, C. Cerletti* (IT), G. de Gaetano PP-TH-095 ANTI-DIABETIC SMALL MOLECULE 1,2,3,4,6-PENTA-O-GALLOYL-?-D- GLUCOPYRANOSE INHIBITS PLATELET ACTIVATION BY PREVENTING GI?2- MEDIATED SIGNAL TRANSDUCTION H. Akbar* (US), K. Funk, S. Wulf, R. Perveen, Y. Cao, X. Chen PP-TH-096 THROMBOXANE A2 RECEPTOR ANTAGONISM BY FLAVONOIDS: STRUCTURE- ACTIVITY RELATIONSHIPS L. Navarro-Núñez* (ES), J. Castillo, M. Lozano, C. Martínez, O. Benavente-García, V. Vicente, J. Rivera PP-TH-097 PLATELET AGGREGATION REVERSAL BY GPIIB-IIIA ANTAGONISTS: DEPENDENCE UPON AGONIST AND AGGREGATE AGE H. E. Speich, A. D. Earhart, S. N. Hill, T. J. Kueter, M. M. White, L. K. Jennings* (US) PP-TH-098 ANTIPLATELET EFFECTS OF PARTHENOLIDE, THE SESQUITERPENE LACTONE FROM FEVERFEW (THANACETUM PARTHENIUM) M. Helinska* (PL), M. Rozalski, B. Rychlik, C. Watala PP-TH-099 ARONIA MELANOCARPA EXTRACT MAY LEAD TO PLATELET ACTIVATION WHEN USED AT HIGH CONCENTRATIONS J. Golanski, M. Helinska* (PL), M. Rozalski, £. Kraszula, C. Watala PP-TH-100 AN “IN VITRO” STUDY ABOUT THE COMBINED ANTIPLATELET EFFECTS OF CILOSTAZOL AND ASPIRIN M. F. Alberto* (AR), S. Meschengieser, P. Pieczanski, J. Rodriguez Moncalvo, M. A. Lazzari PP-TH-101 ANTIPLATELET EFFECTS OF ASPIRIN WITH PHYTOSTEROLS: COMPARISON WITH NON-ENTERIC COATED ASPIRIN ALONE M. J. Antonino* (US), R. Coppolecchia, E. Mahla, K. P. Bliden, U. S. Tantry, P. A. Gurbel PP-TH-102 DEVELOPMENT OF FC-GAMMA-RIIA ANTAGONIST M. Thai Trung King* (IE), M. Adamo, M. Brennan, D. Cox PP-TH-103 EV-077-3201-2TBS, A REVERSIBLE DUAL THROMBOXANE RECEPTOR ANTAGONIST AND THROMBOXANE SYNTHASE INHIBITOR, IS MORE POTENT THAN ASPIRIN IN INHIBITING ARACHIDONIC ACID AND COLLAGEN-INDUCED HUMAN PLATELET AGGREGATION IN VITRO P. Alberts* (CH), P. Fontana, K. S. Sakariassen, H. Bounameaux, J. P. Meyer, A. Santana Sorensen PP-TH-104 THE REVERSIBLY BINDING P2Y₁₂ RECEPTOR ANTAGONIST TICAGRELOR REDUCES EFFECT OF NEWLY FORMED PLATELETS UNDER LAMINAR FLOW CONDITIONS R. Megens* (NL), M. Oude Egbrink, E. Nikookhesal, J. Heemskerk, J. J. J. van Giezen PP-TH-105 INTEGRIN PRIMING DYNAMICS R. R. Hantgan* (US), M. C. Stahle

338 PT-0 CODING AND PROMOTERREGION POLYMORPHISMS OFFACTOR VII(FVII)GENEIN PP-TH-108 PP-TH-107 PP-TH-106 POSTER PRESENTATIONS PT-1 EETO FEDGNU ISEFCO EESI LSAUSINGTHE DETECTIONOFENDOGENOUSTISSUEFACTOR LEVELSINPLASMA PP-TH-119 PP-TH-1 TISSUEFACTOR INDUCESPROMMP9RELEASE AND ACTIVATES PROMMP2IN PP-TH-117 CANINETISSUEFACTOR (TF)BINDSHUMAN AND CANINEFVIIWITHSIMILAR HIGH PP-TH-116 BYPASS FACTOR VIIa-ANTITHROMBINCOMPLEXESDURINGCARDIOPULMONARY PP-TH-115 PP-TH-1 COMPUTERMODELISATION OFTHEPROTHROMBINTIMETEST. CONCEPTION, PP-TH-113 PP-TH-1 INNIGERIANPRE- HAEMOSTATIC PROFILE AND DETERMINANTS OFRHEOLOGY PP-TH-111 TISSUEFACTOR AND GULFWAR-ASSOCIATED CHRONICCOAGULOPATHIES PP-TH-110 REGULATION OFTISSUEFACTOR-INITIATED THROMBINGENERATION INPLASMA PP-TH-109 Extrinsic PathwayofCoagulationIII 2009 THURSDAY, JULY 16, 8FEUNYANDGENDERDIFFERENCESOF POLYMORPHISMS INTHETF AND TFPI FREQUENCY 18 4EFFECTOFPUERARINONTHEEXPRESSIONTISSUEFACTOR INDUCEDBY 14 12 CALIBRATED AUTOMATEDTHROMBOGRAM ASSAY DISEASE GENES, WITH ACUTE CEREBROCARDIACTHROMBOTICDISEASES OOAYATR DISEASE(CAD) ARTERY CORONARY (FVII:C) AND FREQUENCIES, LINKAGEDISEQUILIBRIUM,FVIICOAGULANT ACTIVITY ASIAN INDIANSVIS-À-VISOTHERPOPULATIONS OFTHEWORLD: ALLELE THE EFFECTOFPLASMA-DILUTIONONTHROMBINGENERATION PRAGMATIC APPROACH FORTHEMEASUREMENTOFINRINLIVERPATIENTS A OSTEOSARCOMA CANINE FVII AFFINITY SURGER CELLS ANGIOTENSIN II AND ITSMECHANISMINVASCULAR ENDOTHELIAL V OBSER ECLAMPTICS FACTOR VII AND ACTIVATEDBY FACTOR VII Mackman V. Ollivier*(FR),D. A. Manly, J.Wang, K.R.Machlus, A. S.Wolberg, M.Jandrot-Perrus,N. T. B.Opstad*(NO), A. Pettersen,S.Åkra,H. Arnesen, I.Seljeflot T. Stokol* (US),J.L.Daddona,V. Rathnam T. Knudsen* (DK),B.Sørensen,H.R.Stennicke,L.C.Petersen, A. T. Kristensen S. J.Davidson*(UK),B.Woodhams S. He*(CN),H.Wang, J.Hu,X.Shen,He,Z.Wen S. Kerdelo*(FR),P R. Wang* (CN),L.Li,B.Z.Wen, D.Zhong, Y. T. Ma,P. Pen Ande B. O. A.Awodu, A. (NG), Anyanwu* R. A. R. Bach*(US),B.C.S.Slater M. V. Ovanesov*(US), T. K.Lee M. S.Mukherjee*(IN),C.Deshpande,Joshi,K.R.Shetty E. deSmedt*(NL),R.Wagenvoord, C.Hemker A. F ALIDA . Riddell*(UK),V. Calvaruso,E.G. Tuddenham, A. Burroughs, A. Gatt V TION SRLTDT HNTPSI AINSWT OOAYHEART AS RELATED TO PHENOTYPESINPATIENTS WITHCORONARY A Y TION ONTISSUEF HC OTAT H O FIIYFOR BINDINGOFHUMANTFTO WHICH CONTRASTSTHELOW AFFINITY AND POTENTIAL . Redou,J. Tisseau, J. Abgrall ACT OF OR EXPRESSIONOFMONOCYTESINPATIENTS APPLICA TION 339

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-120 VALIDATION OF THE INR CALIBRATION OF COAGUCHEK XS PT TEST STRIP MASTER LOTS AND ROUTINE PRODUCTION LOTS W. Plesch* (DE), B. Scheffler, P. Herbel, A. Jünschke, T. Wickert PP-TH-121 RFVIIa TREATMENT IN FACTOR VII DEFICIENCY : A SINGLE CENTRE EXPERIENCE Z. Salcioglu* (TR), G. Aydogan, F. Akici, A. Akcay, D. Tugcu, H. S. Sen, Z. Baslar

Intrinsic Pathway of Coagulation III

PP-TH-122 ACTIVATION OF THE INTRINSIC PATHWAY OF BLOOD COAGULATION BY PARTICULATE MATTER IN VITRO E. Kilinc* (NL), H. M. H. Spronk, I. Gosens, R. van Oerle, J. W. P. Govers-Riemslag, M. E. Gerlofs-Nijland, F. R. Cassee, H. ten Cate PP-TH-123 EVALUATION OF NORMAL PLASMA MIXING STUDIES ON PROLONGED ACTIVATED PARTIAL THROMBOPLASTIN TIME IN CHINESE J. Lin* (TW), S. Kuo, S. Yang, S. Chio, M. Shen PP-TH-124 DIFFERENT SEVERITY OF CLINICAL MANIFESTATION IN PATIENTS WITH SEVERE HEMOPHILIA A M. Faranoush* (IR), N. Danaie, R. Ghorbani, M. Rahmani, M. Jazebi, T. Shashaani, A. Mehrvar, A. Hedayatiasl, P. Vossough PP-TH-125 HEMODYNAMIC EFFECTS OF COAGULATION BETA-FXIIa IN CONSCIOUS RATS P. C. Papageorgiou* (CA), P. H. Backx, C. T. Chan, E. L. Yeo, J. S. Floras PP-TH-126 STUDY OF THE MOLECULAR MECHANISM OF THE COAGULATION FACTOR X DEFICIENCY IN THREE CHINESE PEDIGREES Q. Chen* (CN), Q. Ding, X. Wang PP-TH-127 CHARACTERIZATION OF TWO NOVEL MUTATIONS (VAL384ALA AND VAL384PHE) CAUSING FACTOR X DEFICIENCY IN TWO UNRELATED CHINESE FAMILIES Q. Ding* (CN), X. Wang, T. Yu, H. Wang PP-TH-128 FACTOR VIII AND VON WILLEBRAND FACTOR – THE CONFUSION OF THE 70’S PERSISTS TODAY R. R. Montgomery* (US), S. L. Haberichter, M. Jozwiak, S. Fahs, Q. Shi PP-TH-129 DEVELOPMENT OF NEW ASSAYS TO IDENTIFY THE CRP-VLDL COMPLEX S. T. Abrams* (UK), C. Downey, J. Thachil, G. Wang, C. H. Toh PP-TH-130 FACTOR XIIa INHIBITORS PREVENT FE(III)-CHLORIDE INDUCED THROMBOSIS IN MICE S. Schmidbauer* (DE), C. Nerlich, T. Weimer, U. Kronthaler, H. Metzner, S. Schulte PP-TH-131 THE PLASMA KALLIKREIN-KININ SYSTEM AND CLINICAL OUTCOME DURING FOLLOW-UP IN CHEST-PAIN PATIENTS V. Pönitz* (NO), J. W. P. Govers-Riemslag, J. Konings, T. Brügger-Andersen, H. Grundt, H. ten Cate, H. Staines, D. W. T. Nilsen PP-TH-132 GENETIC ANALYSIS OF A PEDIGREE WITH COMBINED FACTOR XII AND FACTRO XI DEFICIENCY X. Ye* (CN), Y. Feng PP-TH-133 MOLECULAR SIGNALING PATHWAY REGULATING PROLYLCARBOXYPEPTIDASE- DEPENDENT KININ GENERATING CASCADE IN INFLAMMATION Z. Shariat-Madar* (US), M. Ngo, D. Kolte, F. Mahdi

340 PT-3 VALIDATION OF FORMONITORING PLASMA AN AUTOMATED CLOTTING ASSAY PP-TH-136 COVALENT ANTITHROMBIN-HEPARIN AND THEPROTEINCPATHWAY PP-TH-135 PP-TH-134 POSTER PRESENTATIONS PT-4 H FET FTNHNN AONPLATELETS AND MEGAKARYOCYTES IN THEEFFECTSOFTANSHINONE 2A PP-TH-147 PP-TH-146 FORSUBSTITUTE ANTICOAGULANTS CALL CONTAMINANTS INHEPARIN! A PP-TH-145 PP-TH-144 PP-TH-143 ANTITHROMBIN AND ANTI-Xa AGENTS WITH DRUGINTERACTIONSOFORAL PP-TH-142 EFFECTSOFTHROMBIN-ORXa-INHIBITORS ONTHEENDPRODUCTOF PP-TH-141 ANTITHROMBINVARIANT DYSFUNCTIONAL CHARACTERIZATION OF A BIOPHYSICAL PP-TH-140 LARGEDUTCHFAMILY DETERMINANTSOFHIGHPROTEINCLEVELSIN A PP-TH-139 EFFECTSOFGENERIC ARGATROBANS ONWHOLEBLOOD DIFFERENTIAL PP-TH-138 EFFECTSOFGENERIC ARGATROBANS ONTHEPT/INR DIFFERENTIAL PP-TH-137 Anticoagulant PathwaysIII 2009 THURSDAY, JULY 16, IMMUNE VASCULITIS CELL ANGIOTENSIN II AND ITSMECHANISM INVASCULAR ENDOTHELIAL EFFECT OF ANGIOTENSIN(1-7) ONTHE EXPRESSIONOFE-SELECTININDUCEDBY METHOD (UPLC-MS/MS) TANDEM MASSSPECTROMETRY LIQUID CHROMATOGRAPHY ULTRA-PERFORMANCE NOVEL ARGATROBAN LEVELSINCOMPARISON WITH A THROMBIN CLOTTINGTIME MEASUREMENT OFTHEPHARMACODYNAMICEFFECTDABIGATRAN ETEXILATE: GROUPS OFP GENETIC INFLUENCEOFCYP2C9 AND VKORC1ONWARFARIN DOSEINTWO IDENTIFICA ANTICOAGULANTTREATED PATIENTSHEPARINIZED AND ORAL COAGULA ACTIV BOMLPROTEINC-TOTTORI ABNORMAL FIBRINOL X. Li*(CN),M.Zhou,Li, Yang X. H.Shen*(CN),Z.B.Wen, X.F. He,N. Li,S.L.He V Borg V. LeCam-Duchez*(FR),M.Fretigny, N.Cailleux, Y. Benhamou, V. Barbay, H.Levesque,J. T. Hayashi* (JP), Y. Tanaka, Y. Okuyama,K. Yoshida, T. Okamoto,K.Iijima,Suzuki S. Masood*(US),J.Cunanan,D.Hoppensteadt,van S. He,M.Blombäck*(SE),N.Bark,H.Jonhsson,Wallen S. Pedersen*(DK),M. Thomsen, S.R.Kristensen, A. Stensballe,D.E.Otzen W S. Roshani*(NL),M.C.Pintão,H.deVisser, C. Tieken, M.W. Tanck, H.R.Büller, I.M. O. Iqbal*(US),S.Masood,D.Hoppensteadt,J.Fareed O. Iqbal*(US),S.Masood, A. Gray, D.Hoppensteadt,J.Fareed M. L.Snyder*(US), A. M.Winkler, F. Brierre,R.J.Molinaro M. C.vanWalderveen* (CA),L.R.Berry, A. K.C.Chan J. Stangier, K.Wetzel, W. Wienen,J.vanRyn*(DE),K.Rathgen RVOSYDESCRIBED ALGORITHM FORLOWINRRANGE PREVIOUSLY . Bansal*(US),E.Litinas,D.Hoppensteadt, C. ichers, J.C.M.Meijers,S.Middeldorp,P. H.Reitsma ATION AND THROMBINGENERATION MARKERS YSIS TION: INCREASEDPOROSITY TION OFMUT A TIENTS WITHDIFFERENTINRT TO IEADFNTOA CHARACTERIZATION OF ATION SITE AND FUNCTIONAL OF THEFIBRINNETWORKCONTRIBUTEST Adiguzel, J.Fareed ARGET RANGES.(RELEV Thiel, J.Fareed ANCE OF A 341 O

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

Cofactors and Proteases III

PP-TH-148 MEASUREMENT OF THROMBIN-ALPHA-2-MACROGLOBULIN COMPLEXES GENERATED IN PLASMA H. Vetr* (AT), S. Geiter, M. Graf, S. Knapp, B. R. Binder PP-TH-149 CORRELATION BETWEEN PLASMA ACTIVITY OF ADAMTS-13 AND COAGULOPATHY, AND PROGNOSIS IN DISSEMINATED INTRAVASCULAR COAGULATION J. Kim* (KR), J. Hyun, S. Park, H. Cho, H. Kim PP-TH-150 CLEARANCE OF RECOMBINANT AND PLASMA DERIVED HUMAN FACTOR VIII IN A PERFUSED RAT LIVER MODEL R. Appa* (DK), C. Theill, L. Hansen PP-TH-151 INVESTIGATION OF CLEARANCE OF RECOMBINANT HUMAN FACTOR VIIa AND ITS VARIANTS IN A PERFUSED RAT LIVER MODEL R. Appa* (DK), L. Hansen, C. Theill PP-TH-152 THE DETECTION OF PROS1 DELETIONS, A COMMON CAUSE OF PROTEIN S DEFICIENCY R. B. Wheeler* (UK), J. Cutler, M. Mitchell PP-TH-153 FACTOR VII-ACTIVATING PROTEASE IS ACTIVATED IN SEPSIS S. Zeerleder* (NL), I. Bulder, F. Stephan, M. de Kruif, J. Hoogerwerf, T. van der Poll, L. Aarden PP-TH-154 REEVALUATION OF “NORMAL” FACTOR VIII CONCENTRATION IN PLASMA S. Butenas* (US), B. Parhami-Seren, A. Undas, K. G. Mann PP-TH-155 THROMBIN GENERATION IN A THIN LAYER OF WHOLE BLOOD S. Nijhuis* (NL), R. Apitz-Castro, C. H. Hemker PP-TH-156 EVOLUTION OF PRIMARY HEMOSTASIS: ROLE OF TRYPSINS IN GILL HEMOSTASIS S. Kim* (US), S. Rajpurohit, M. Carrillo, V. Kulkarni, P. Jagadeeswaran PP-TH-157 DETERMINATION OF RISTOCETIN COFACTOR ACTIVITY: EYES ON BOTH DIRECTIONS S. A. L. Montalvão* (BR), J. M. Annichino-Bizzacchi, M. S. Pereira, T. M. Machado, M. C. Ozelo, E. V. de Paula PP-TH-158 ANTI-INFLAMMATORY EFFECT OF THROMBOLYTIC PREPARATION LONGOLYTIN T. N. Serebryakova* (RU), T. S. Sharkova, L. V. Podorolskaya, I. S. Chromov PP-TH-159 MEMBRANE BINDING OF FACTOR VIII C2 DOMAIN INHIBITED BY PHYSIOLOGIC SALINE IMPLYING A PROCESSIVE BINDING MECHANISM V. A. Novakovic* (US), D. B. Cullinan, J. B. Baleja, G. E. Gilbert PP-TH-160 ISOLATION AND CHARACTERIZATION OF A NOVEL FIBRINO(GENO)LYTIC SERINE PROTEINASE FROM AGKISTRODON BLOMHOFFII USSURIENSIS SNAKE VENOM V. L. Karbovskyy* (UA), V. N. Skalka, A. N. Savchuk, G. L. Volkov PP-TH-161 MOUSE THROMBIN IS UNIQUELY INSENSITIVE TO SODIUM ION AMONG REPRESENTATIVES OF MAMMALIAN, AVIAN AND REPTILIAN THROMBINS N. Goli, W. G. Owen* (US) PP-TH-162 AGE-RELATED REFERENCE RANGES OF C1-INH ACTIVITY AND ANTIGEN ARE IMPORTANT FOR EARLY DIAGNOSIS IN PAEDIATRIC HAE PATIENTS W. Kreuz* (DE), E. Rusicke, I. Martinez-Saguer, E. Aygören-Pürsün, T. Klingebiel

342 PT-6 KNOCKDOWNOFTFPIEXPRESSIONINSUM102BREASTCANCERCELLSLEADSTO PP-TH-165 PP-TH-164 PP-TH-163 POSTER PRESENTATIONS PT-7 IAOAA ONRGLTSTECAUATATVT INDUCEDBY RIVAROXABAN DOWNREGULATES THECOAGULANT ACTIVITY PP-TH-174 ON THE APTT MIXINGTEST INTERFERENCEOFPLATELETS INPLASMA PP-TH-173 PP-TH-172 PP-TH-171 STANDARD DOSEOFDABIGATRAN ETEXILATE INPATIENTS UNDERGOINGTOTAL PP-TH-170 INPATIENTS PREDISPOSEDTO CARDIOVASCULAR EVENTS,STANDARD DOSESOF PP-TH-169 FACTOR XaINHIBITOR, AND EFFECTSOFTAK-442, A DIFFERENTIAL PP-TH-168 PROFILE OF ANDSAFETY DIDNOT AFFECT THEEFFICACY TYPEOF ANAESTHESIA PP-TH-167 DEFIBROTIDE AUGMENTS THE ANTICOAGULANT ACTIONS OFHEPARIN AND LOW PP-TH-166 Inhibitors ofCoagulationIII 2009 THURSDAY, JULY 16, ACTIVATED MONOCYTES.COMPARISON WITH FONDAPARINUX PRO-ANGIOGENIC PHENOTYPES STUDIESOFTHE5’UTR AND INTRON7SNPSOFTHETFPIGENE FUNCTIONAL META-ANALYSIS PROTEIN ZLEVELS AND THROMBOTICDISEASES– A HEMOPHILIA OF ANTI-FVIII ANTIBODIES INSIXCASESOFPOSTPARTUM ACQUIRED SPECIFICITY MUL ACTIVITIES OFTHEF EVALUATION OFCLOTTINGTIME ASSAYS FORMONITORING ANTITHROMBOTIC PROFILE OPERATIVE VENOUSTHROMBOEMBOLISM:EFFECTIVE AND GOODSAFETY WHO ARE PREDISPOSEDTO POST- ORKNEEREPLACEMENTSURGERY HIP PROFILE GOODSAFETY ANDWITH A THROMBOEMBOLISM EFFECTIVELY DABIGATRAN ETEXILATE PREVENTPOST-OPERATIVE VENOUS COAGULA THROMBININHIBITOR ONFACTOR V-MEDIATEDXIMELAGATRAN, FEEDBACKON A REPLACEMENT SURGER KNEEORHIP THROMBOEMBOLISM PREVENTIONFOLLOWINGTOTAL DABIGATRAN VENOUS ETEXILATE COMPARED WITHENOXAPARIN FORPRIMARY MOLECULAR WEIGHTHEPARINS Soria, R.V M. Laurent,U.Joimel, H.Li,S.Mirshahi,V. Lecam-Duchez, J.Borg,L.Cazin,Soria, C. R. Ikeda*(JP),C.Morikawa,H. Lissalde Polack, C.Rotschild,J.Schved,H.Levesque, S.Lacroix-Desmazes,C.Granier, G.Lavigne- P. Lapalud*(FR),S.Grosbrois, S. André, J.Borg,B.Guillet, Y. Gruel,M. Trossaert, B. P. C.Wong* (US),E.J.Crain,C. A. Watson A. Caprini O. E.Dahl*(NO),C.Francis, A. Kurth,N.Rosencher, M.Feuring,H.Noack,B.I.Eriksson,J. I. Eriksson,J. O. E.Dahl*(NO),C.Francis, A. Kurth,N.Rosencher, M. Feuring, A. Clemens,H.Noack,B. N. Konishi*(JP),K.Hiroe, N. Rosencher*(FR),H.Noack,M.Feuring, J. Fareed*(US),Cunanan,D.Hoppensteadt,O.Iqbal,C. Adiguzel B. Stavik,G.Skretting*(NO),M.Sletten,E.Frengen,P. Sandset,N.Iversen G. Skretting*(NO),B.Stavik,C.F. Myklebust,P. Sandset,N.Iversen F THE THROMBININHIBITOR DABIGATRAN INTHERABBIT . Sofi*(IT),F. Cesari,S.Fedi,G.Broze,R. Abbate, G.Gensini TIPLEXED arin* (FR) TION CASCADE AND BLEEDING A. Caprini ANALYSIS OFIMMUNOGLOBULINCLASS/SUBCLASS AND EPITOPE ACT Y Y OR XaINHIBIT . Imaeda, Y ago T . Fujimoto,K.Kubo,M.Kawamura ORS, A. Clemens,R.Friedman,B.I.Eriksson APIXABAN AND RIV AROXABAN, AND 343

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-175 MAMMALIAN CELL SURFACE DISPLAY OF A FUNCTIONAL THROMBIN-INHIBITORY SERPIN R. F. Gierczak* (CA), J. S. Sutherland, V. Bhakta, W. P. Sheffield PP-TH-176 IN CALIBRATED AUTOMATED THROMBINOSCOPY, A DIRECT THROMBIN INHIBITOR (AR-H067637) CAUSES A SPURIOUS INCREASE OF THROMBIN GENERATION, DUE TO A TRANSIENT ALPHA2-MACRO-GLOBULIN-THROMBIN PEAK R. J. Wagenvoord* (NL), J. Deinum, M. Elg, C. Hemker PP-TH-177 ASSESSMENT OF THE EFFECT OF AR-H067637 ON THE ETP AS OBTAINED BY CALIBRATED AUTOMATED THROMBINOSCOPY R. J. Wagenvoord* (NL), J. Deinum, M. Elg, C. Hemker PP-TH-178 EFFECTS OF OVERSULFATED AND FUCOSYLATED CHONDROITIN SULFATES ON COAGULATION. CHALLENGES IN STUDIES OF ANTICOAGULANT POLYSACCHARIDES R. J. C. Fonseca* (BR), S. M. C. G. Oliveira, V. H. Pomin, A. S. Mecawi, I. G. Araújo, P. A. S. Mourão PP-TH-179 BOTHROJARACIN A PROTHROMBIN INHIBITOR WITH POTENT ANTI-THROMBOTIC ACTIVITY R. B. Zingali* (BR), R. R. Q. Monteiro, F. F. S. Frattani, M. Assafim PP-TH-180 EVALUATION OF MIXING STUDIES INTERPRETATION CRITERIA AND LUPUS ANTICOAGULANTS (LA) CONFIRMATORY TEST IN PEDIATRIC PATIENTS S. Estelle* (US), M. Chitlur, L. Llanto, J. Thul, L. Kodali, M. Rajpurkar, J. M. Lusher PP-TH-181 THE ANTI-COAGULANTS ASIS OR APC DO NOT PROTECT AGAINST RENAL ISCHEMIA/ REPERFUSION INJURY S. T. B. G. Loubele* (NL), A. C. Spek, P. Leenders, K. Hamulyak, R. A. Matthijsen, W. A. Buurman, C. J. Peutz-Kootstra, H. M. H. Spronk, H. ten Cate PP-TH-182 EVALUATION OF A GENOTYPING TEST DETECTING VKORC1 AND CYP2C9 POLYMORPHISMS ASSOCIATED WITH COUMARIN-BASED ANTICOAGULANT SENSITIVITY IN PATIENTS S. Campbell* (US), T. Patno, W. Cork PP-TH-183 INFLUENCE OF A FLUOROGENIC SUBSTRATE ON THROMBIN GENERATION: WHEN IN SILICO SIMULATIONS PREDICT IN VITRO EXPERIMENTS A. Carlo, S. Kerdélo* (FR), M. Gonidec, E. Arnaud, B. J. Woodhams PP-TH-184 EFFECTS OF NOVEL FACTOR Xa INHIBITOR YM150 ON IN VITRO HUMAN PLATELET ACTIVATION AND AGGREGATION S. Kaku* (JP), K. Suzuki, M. Sasamata, K. Miyata PP-TH-185 PROTEIN Z/PROTEIN Z-DEPENDENT PROTEASE INHIBITOR COMPLEX IS A POOR INHIBITOR OF FACTOR Xa IN A PLASMA MILIEU S. Mirshahi* (FR), C. Soria, M. Adam, J. Soria, B. J. Woodhams PP-TH-186 EFFECTS ON FIBRIN NETWORK POROSITY OF ANTICOAGULANTS WITH DIFFERENT MODES OF ACTION S. He, M. Blombäck* (SE), N. Bark, H. Wallén, M. Elg PP-TH-187 EVALUATION OF A NEW ANTI-Xa HEPARIN ASSAY S. J. Davidson* (UK) PP-TH-188 THROMBIN GENERATION IN ACQUIRED AND INHERITED PROTEIN S DEFICIENCY A. Wong, S. Rodgers, T. Stanford, E. Duncan, B. Dale, R. Baker, S. J. McRae* (AU)

344 PT-9 MASSTRANSPORTPROPERTIESOF ANTITHROMBIN IIIISOFORMSSUGGEST PP-TH-191 PP-TH-190 PROTEINCRECEPTOR (EPCR)GENE CELL INFLUENCEOFTHEENDOTHELIAL PP-TH-189 POSTER PRESENTATIONS PT-0 THEPREVALENCE AND GENETICBACKGROUNDOFFACTOR VIIIINHIBITORS IN PP-TH-203 EVALUATION OFTHEDIRECTFACTOR XaINHIBITOR APIXABAN INRAT MODELSOF PP-TH-202 HEPARIN NOVEL A EXVIVONEUTRALIZATION OF ENOXAPARIN INPRIMATES BY PP-TH-201 NEWLIQUIDHEPARIN SITEEVALUATIONASSAY OF A CLINICAL PP-TH-200 PP-TH-199 DAMAGEWITHLESSBLEEDING ENOXAPARIN ATTENUATES ENDOTHELIAL PP-TH-198 EPCR AND ACTIVATED PROTEINCREGULATES CARDIOMYOCYTE FUNCTIONVIA PP-TH-197 MODELINGOFWARFARIN THERAPY COMPUTATIONAL PP-TH-196 PP-TH-195 PP-TH-194 HEPARINS SIMPLESCREENINGMETHODTO IDENTIFY PROTHROMBINTIME AS A PP-TH-193 FORDIRECTQUANTIFICATION OF FLUORESCENCEMICROPLATE ASSAY A PP-TH-192 HRDY UY1,2009 THURSDAY, JULY 16, HNS EOHLAAPATIENTS A CHINESE HEMOPHILIA HEMOSTASISTHROMBOSIS AND IHPESR OBECRUAOYSYSTEMS,WHICHREQUIRERAPID HIGH-PRESSURE DOUBLECIRCULATORY SWITCHTO TRANSITION WAS ADAPTIVE INTHECONTEXTOFEVOLUTIONARY INTRODUCTION OF ALPHA-ANTITHROMBIN AT THETELEOSTTO TETRAPOD A DEVELOPMENT INHEMOPHILIA EXPRESSEDGENES ASSOCIATED WITHINHIBITOR PROFILING OFDIFFERENTIALLY EXPRESSION (PROCR) ONPROTEINCDEFICIENCY ANT FACTOR X THROMBIN GENERA COMPARED TO UNFRACTIONATED HEPARIN INENDOTOXEMIC RATS P INHIBITION OFTHROMBINGENERA ACTIV CONTAMINATED WITHOSCS AND SIMILARCOMPOUNDS HEPARINS AND OTHERSULFATED CARBOHYDRATES FACTOR XaINHIBITOR DU-176BINVITRO X. W W. A. Schumacher* (US),J.S.Bostwick, A. B. Stewart,Xin,P. C.Wong W. P. Jeske*(US),E. Litinas,J.Emanuele,D.Hoppensteadt,E.McAllister V T. H. Tran* (CH),G.Favre, A. Marbet T T. Dutt* (UK),E.Dubuis,M.Perez-Casal,G.Wang, G.Hart,C. Toh T. Orfeo*(US),K.Brummel-Ziedins,M.Gissel,S.Butenas,G.Mann T. Furugohri*(JP),C.Kamisato-Matsumoto, Y. Morishima, T. Shibano T. Koide*(JP),H.Kawajiri,E.Ooe, Y. Shoya S. S. Alban* (DE),S.Lühn S. C.Bock*(US),B.Leng S. Hwang*(KR),H.C.Kim,Lee,K. Yoo, H.J.Kim, H.Kim Aiach, S.Gandrille*(FR) Dreyfus, J.Emmerich,M.Gouault-Heilman,B.Jude,C. B. Saposnik,M. . Iba*(JP) . Krougliak*(US),J.Gabbeta,C.Kung,M. AR1 Alban* (DE),S.Lühn AGONIST ang* (CN),Q.Ding, R. Yang, Y. Zhao, J.Wu, J.Sun,X.Zhang, H.Wang TO FATTRMI YTWOSITESMUTATIONS ATION OF ANTITHROMBIN BY Alhenc-Gelas, J.F. Abgrall, M.F. Aillaud, C.Boinot,P. deMoerloose,M. TION INTHE ASSESSMENT OFSUSPECTED ANTIBODIES TO TION INHUMANPLASMA T riscott T ernisien, B. Tardy, C.Vergnes, M. BY THE ORAL DIRECT 345

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-204 ACQUIRED FACTOR X DEFICIENCY: DIFFICULTIES TO ESTABLISH ETIOLOGIC DIAGNOSIS Z. Kaci* (DZ), H. Ahmidatou, N. Zidani, K. Chennoukh, Y. Berkouk, M. Belhani PP-TH-205 PROLONGATION OF THE APTT MAY DEPEND ON INHIBITION OF CONTACT FACTORS Z. Volovyk* (US), D. M. Monroe, M. Hoffman

Fibrinogen III

PP-TH-206 OBESITY INCREASES FIBRINOGEN LEVELS IN PREGNANCY M. P. Smrtka* (US), B. H. Thames, M. Beckman, P. Rawlins, A. H. James PP-TH-207 THE EFFICACY OF FIBRINOGEN CONCENTRATE IN TREATING EXCESSIVE BLEEDING IN AORTIC SURGERY N. Rahe-Meyer* (DE), K. Tanaka, C. Solomon, A. Osthaus, K. Goerlinger, S. Piepenbrock, M. Pichlmaier PP-TH-208 RECOVERY OF FIBRINOGEN PLASMA LEVEL AFTER ADMINISTRATION OF FIBRINOGEN CONCENTRATE FOR HEMOSTATIC THERAPY IN AORTIC SURGERY N. Rahe-Meyer* (DE), K. Tanaka, K. Goerlinger, M. Pichlmaier, A. Osthaus, S. Piepenbrock, C. Solomon PP-TH-209 EFFECTS OF ANTI-RETROVIRAL THERAPY ON HAEMOSTATIC AND HAEMORHEOLOGICAL PARAMETERS IN HIV/AIDS PATIENTS O. A. Awodu* (NG), A. O. Adebayo, A. A. Famodu PP-TH-210 IN VITRO PROPERTIES OF BLOOD BANK PRODUCED FIBRIN SEALANTS FROM SINGLE DONOR HUMAN PLASMA P. Eshghi* (IR), A. Hashemi, N. Amirizadeh, H. Abolghasemi PP-TH-211 DETERMINATION OF ACTIVATED FACTOR XIII IN PLASMA AS A MARKER OF ACTIVATION OF COAGULATION S. Mirshahi* (FR), C. Soria, J. Chidiac, G. Kierzek, R. Varin, R. Batista, L. Drouet, B. J. Woodhams, J. Soria PP-TH-212 ANALYSIS OF FIBRIN STRUCTURE AND FUNCTION IN MAN EXPOSED TO TRANSIENT DIESEL EXHAUST S. Metassan* (UK), M. N. Routledge, A. J. Lucking, J. A. Scott, N. L. Mills, D. E. Newby, R. A. S. Ariëns PP-TH-213 KINETICS OF FIBRINOPEPTIDES RELEASE FROM FIBRINOGEN ADSORBED ON A SURFACE T. Riedel* (CZ), E. Brynda, M. Houska, J. Suttnar, J. E. Dyr PP-TH-214 MOLECULAR SIMULATIONS OF FORCED UNFOLDING OF FIBRIN MONOMERS V. Barsegov* (US), R. Dima, J. W. Weisel, R. I. Litvinov, A. Zhmurov PP-TH-215 CRYPTIC HEPATOPATHY AND HYPOFIBRINOGENEMIA IN A PATIENT COMPOUND HETEROZYGOUS FOR A KNOWN MUTATION IN THE FIBRINOGEN GAMMA CHAIN (ARG375TRP) AND A NOVEL MUTATION IN THE FIBRINOGEN BETA CHAIN (PRO70SER W. A. Hassenpflug* (DE), K. Franke, E. Grabhorn, H. Schäfer, R. Schneppenheim, M. Meyer PP-TH-216 FACTOR XIII SUBUNITS IN NON-STIMULATED AND STIMULATED HUMAN TEARS AND IN TEARS PRODUCED FOLLOWING PENETRATING KERATOPLASTY Z. Z. Orosz* (HU), É. Katona, A. Facskó, A. Berta, L. Muszbek

346 PT-1 ROLEOFKRINGLESPLASMINOGEN(PG) AND PLASMIN-STAPHYLOKINASE PP-TH-219 FIBRINOLYSIS INPREECLAMPSIA PP-TH-218 PP-TH-217 POSTER PRESENTATIONS PT-3 INVITRO COMPARISON OFFIBRINOLYTIC PROPERTIES OFDIRECT PP-TH-230 UROKINASE-TYPEPLASMINOGEN ACTIVATOR INDUCESHEPATIC DIFFERENTIATION PP-TH-229 INFLUENCEOFHEAT-PROOF SUBSTANCE CONTAINED INNATTO ONBLOOD PP-TH-228 PP-TH-227 MECHANISMOFTHE ACTION OFTHEPLASMINOGENMODULATOR SMTP PP-TH-226 PP-TH-225 THEEXTREMEC-TERMINUSOF ANTIPLASMIN ISMOSTIMPORTANT IN PP-TH-224 UNFRACTIONATED PATIENTS HEPARIN ORFONDAPARINUX WITHNON- INELDERLY PP-TH-223 LEVELSOFTHROMBIN ACTIVATABLE FIBRINOLYSIS THEPLASMA INHIBITOR IN PP-TH-222 PP-TH-221 FIBRINOLYSIS DUETO TISSUEPLASMINOGEN ACTIVATOR SYSTEMICPRIMARY PP-TH-220 Fibrinolysis III 2009 THURSDAY, JULY 16, THROMBOLYTICS OF EMBRYONIC STEMCELL FORMATION ENZYME-SUBSTRATEACTIVATOR COMPLEX COMPLEX(PM-STA) INTERNARY WITHOUT THROMBOTICCOMPLICA FIBRINOLYTIC SYSTEM ASSESSMENT INHEMODIALYSIS PATIENTS WITH AND CIRCULA TISSUEPLASMINOGEN ACTIVATORACTIVATION (TPA) BY AND UROKINASE(UPA MECHANISM OFINHIBIT DOSE INTRACLOTINJECTIONSOFTPA TREA ACCELERATING THEPLASMIN-ANTIPLASMININTERACTION FIBRINOLYTIC STATUS 8 AT DAY SYNDROME:DIFFERENTEFFECTON ST-ELEVATION ACUTE CORONARY P INHIBIT ONTHROMBIN ACTIVATABLE FIBRINOLYSIS EFFECTOFOBESITY IS THERE ANY (TPA) PRODUCINGMETASTATIC BREASTCANCER V. Novokhatny* (US),J.Nixon,C.Li,Bromirski, J.Hunt,P. Scuderi,S.R.Petteway Harashima, T. Seki*(JP), Y. Hasebe, G.Watanabe, H.Nakashima,K.Sawada,S.Hanazawa, M. T V R. B. Aisina* (RU),L.Mukhametova, N.Prisyazhnaya,D.Gulin,K.Gershkovich,S. R. Narasaki*(JP),H.Koide,Shiraishi,K.Hasumi R. Chang,Chang*(US), T. Sofian, B.Lu,C.Hitchen, A. J.Horvath,P. B.Coughlin*(AU) O. Averkov* (RU),L.Skutnitskaya,Z.Kobalava N. Ermantas,S.Guldiken,M.Demir*(TR), B. Taskiran, S.Guldiken,M.Demir*(TR), T. Kilic-Okman,E. Arikan, B. Turgut, A. Tugrul H. V. K.Naina,M.Patnaik*(US),U. Ali, A. Behfar, C.Dong, A. A. Ashrani M. Y. Levashov*(RU),R. Aisina, R.Kramor, K.Gershkovich,S.Varfolomeyev L. C.Godoi,S.Dusse*(BR),H.Madeira,B. A. Lwaleed,M.G.Carvalho Lwaleed, M.G.Carvalho L. M.S.Dusse*(BR),D.R. A. Rios, A. C.SimõesESilva, V. Rodrigues, A. V. Santos,B. A. . Ohsugi*(JP),E.Sumida,H.Sumi TET IHPIAYHYPOTHYROIDISMBEFORE AND AFTER TREATMENT ATIENTS WITHPRIMARY arfolomeyev TMENT OFCENTRAL RLVL NPSMNPUA WOMEN OR LEVELSINPOSTMENOPAUSAL TION Y. Ito,N.Okumura, T. Ariga OR A. W CA Y ACTION OF . Kam,E.Chen,J.N.Lozier THETER RELA TIONS A. ANGIOST T ugrul TED VENOUSTHROMBOSISWITHLOW ATIN ONPLASMINOGEN(PG) , M.K.Horne 347

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-231 A UNIQUE RECOMBINANT PLASMIN MOLECULE LACKING KRINGLES 2-5 EXHIBITS COMPARABLE HEMOSTATIC SAFETY AND EFFICACY AS FULL-LENGTH, PLASMA- DERIVED PLASMIN V. J. Marder* (US), S. Manyak, T. Gruber, J. Hunt, J. Bromirski, A. Goyal, P. Scuderi, S. R. Petteway Jr, V. Novokhatny PP-TH-232 DOSE RESPONSE STUDY OF INTRA-ARTERIAL PLASMIN TO RECANALIZE THE THROMBO-OCCLUDED RABBIT MIDDLE CEREBRAL ARTERY R. Jahan, T. Gruber, A. Goyal, V. Arora, V. J. Marder* (US) PP-TH-233 DEVELOPMENT OF NOVEL TECHNOLOGY TO ANALYZE THE PROCESS OF INTRAVASCULAR THROMBOLYSIS Y. Magari* (JP)

Regulation of Coagulation and Fibrinolysis III

PP-TH-234 ROTEM® THROMBOELASTOMETRY IN LIVER TRANSPLANTATION: COULD IT PREDICT POSTRANSPLANTATION GRAFT PERFORMANCE A. F. Minou* (BY), A. M. Dzyadzko PP-TH-235 SELECTION OF A FLUOROGENIC MARKER FOR USE IN WHOLE BLOOD (WB) ENZYMATIC ASSAYS E. Lebra, A. Carlo* (FR), H. Apan, V. El Qacemi, G. Quentin, B. J. Woodhams, E. Arnaud PP-TH-236 TESTING OF LOW MOLECULAR WEIGHT HEPARIN DURING HEMODIALYSIS E. Vlasova* (RU), I. Vasilenko, V. Samoylenko, V. Suslov PP-TH-237 PIVOTAL ROLE OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) FOR LOCAL REGULATION OF TISSUE FACTOR (TF) -INDUCED THROMBIN GENERATION IN MONOCYTES ISOLATED FROM HUMAN BLOOD G. B. Manjunath* (NO), F. X. Gruber, M. Sovershaev, H. I. Appelbom, B. Østerud, L. C. Petersen, S. Pankiv, J. Hansen PP-TH-238 THE EFFECT OF THYROXINE AND THYROTROPIN (TSH) LEVELS ON THE COAGULATION SYSTEM J. Debeij* (NL), S. C. Cannegieter, B. van Zaane, J. W. A. Smit, N. P. M. van der Kley- Corssmit, F. R. Rosendaal, J. A. Romijn, O. M. Dekkers PP-TH-239 CARBON MONOXIDE RELEASING MOLECULE 3 (CORM-3) INHIBITS ARTERIAL THROMBOSIS IN RATS K. Kramkowski* (PL), A. Mogielnicki, R. Motterlini, S. Chlopicki, W. Buczko PP-TH-240 BIOLOGICAL VARIABILITY OF COAGULATION TESTS M. W. Besser* (UK), L. Figueiredo, T. Baglin, R. Luddington PP-TH-241 QUANTIFICATION OF PROTHROMBIN FRAGMENT 1+2 BY LOCI® TECHNOLOGY* M. Ehm* (DE), H. Althaus, B. Fischer, A. Muth, M. Pfeiff, S. Teigelkamp PP-TH-242 EFFECT OF IN-VITRO CRYSTALLOID DILUTION ON ENDOGENOUS THROMBIN POTENTIAL (ETP) IN HEALTHY VOLUNTEERS (HV) AND PATIENTS WITH A HISTORY OF VENOUS THROMBOSIS (VT) OR HEPATIC CIRRHOSIS (HC) N. Jones* (UK), J. Kaur, A. Riddell, C. Melikian, S. Mallett PP-TH-243 THROMBIN REDUCES TIME TO PEAK ON TISSUE FACTOR INDUCED THROMBIN GENERATION IN HUMAN AORTIC SMC VIA ACTIVATION OF PAR 3 AND 4 RECEPTORS P. Vidwan* (US), A. Pathak, S. Sheth, G. A. Stouffer PP-TH-244 FURTHER CHARACTERISATION OF AN ANDROGEN RESPONSE ELEMENT IN THE HUMAN PROTEIN C GENE PROMOTER K. Korfi, K. J. Cameron, P. R. Winship* (UK)

348 PT-4 HL LO RCAUATATVT NHATYVOLUNTEERSIS INHEALTHY WHOLEBLOODPROCOAGULANT ACTIVITY PP-TH-248 FAST QUANTITATIVE AND GLYCOMIC VARIATIONS OF ANTITHROMBIN AFTER BIRTH PP-TH-247 PP-TH-246 RESPONSESTO LOW-DOSE VITAMIN KTREATMENT FORWARFARIN OVERDOSE PP-TH-245 POSTER PRESENTATIONS PP-TH-259 LOW-MOLECULAR-WEIGHT HEPARIN AND TRANEXAMIC ACID FORCHRONICDICIN PP-TH-258 HEPARIN ACCELERATES FIBRINOLYTIC AND THROMBOLYTIC FUNCTION OF PP-TH-257 PP-TH-256 MASSONRESULTS OFCANINE EFFECTOFINVIVOREDUCTIONREDCELL PP-TH-255 THROMBINGENERATION INPATIENTS WITH SEPSIS PP-TH-254 IN (CAT) INPLATELET CALIBRATED POORPLASMA AUTOMATED THROMBOGRAPHY PP-TH-253 MOLECULE SMALL IDENTIFICATION AND CHARACTERIZATION OFHIGH AFFINITY PP-TH-252 DIAGNOSTICTECHNIQUESINTHE ASSESSMENT OF THEROLEOFINSTRUMENTAL PP-TH-251 PP-TH-250 POSSIBLECELLULARMARKEROF AS A WHOLEBLOODPROCOAGULANT ACTIVITY PP-TH-249 HRDY UY1,2009 THURSDAY, JULY 16, THE (GT)NLOCUSOFVONWILLEBRAND F CASEREPORT PROSTATE CANCER- A PREDICTS INCREASEDVWFLEVELS INRESPONSETO GLUCOCORTICOID EXCESS DECREASED FOLLOWINGORANGEJUICEINTAKE DETACHMENT DISORDER RETINAL FLUIDINPRIMARY INSUBRETINAL HIGH PROCOAGULANT ACTIVITY AND VKORC1SINGLENUCLEOTIDEPOLYMORPHISM (SNP) LONGOLYTIN DIFFERENTIAL WHOLE BLOODTHROMBOELAST ADUL INACTIBITORS OFPLASMINOGEN ACTIVATOR INHIBITOR-1 THE DEGREEOFHEMOST DEFICIENCY TYPES OFENERGY THE CARDIOVASCULAR RISK V. Daidone*(IT),F. Sartorello,M.Cattini,E.Pontara,L.Gallinaro, A. Pagnan, A. Casonato T. Vucemilo* (HR),D.S T S. A. Smith*(US),S.H.Choi, J.Huyck,H.Morrissey S. A. Smith*(US),M.McMichael, A. Galligan,K.Swanson,J.H.Morrissey S. Petros*(DE),P. Kliem, T. Siegemund,R.S.Kindler S. Petros*(DE), T. Schneider, T. Siegemund,R.Siegemund S. Li*(US),J.M.Cale,Warnock, C.Emal,D. A. Lawrence S. V. Sinkov*(RU),I.B.Zabolotskikh,S. A. Shaposhnikov S. V de Gaetano,M.B.Donati,R.Lorenzet*(IT) E. Napoleone, A. Cutrone,F. Zurlo, A. deCurtis,F. Gianfagna,B.Vohnout, L.Iacoviello,G. Curtis, L.Iacoviello,C.Cerletti,D.Rotilio,G.deGaetano,M.B.Donati,R.Lorenzet*(IT) E. Napoleone, A. Cutrone,F. Zurlo, G.Colavecchia, A. diCastelnuovo,L.Giordano, A. de Vicente, C.Martínez R. Teruel* (ES),J.Corral,I.Martínez-Martínez, A. Miñano, A. Ordóñez,B.Sánchez-Vega, V. R. R. Deoisares,P . S.Sharkova*(RU),L.V Al Dieri*(NL),L.J. A. G.Ricker, E.C.LaHeij, A. Kijlstra,H.C.Hemker . Sinkov*(RU),I.B.Zabolotskikh,K.D.Zybin,S.V ARTERIO-VENOUS DIFFERENCEOFHEMOST TS . Rojnuckarin*(TH) EFFECTS OFPOL ˇ turm, M.Banoviæ,G.Krajaèiæ,Karas . Podorolskaya, A TIC DYSFUNCTION YPHOSPHA OMETR T . N.Serebryakova Y TE ONBLOODCLOTTING ACT ASIS P . Grigoriev OR (VWF)GENEPROMOTER ARAMETERS INVARIOUS 349

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-260 PLASMIN-INDUCED THROMBIN FORMATION EXPLAINS MILD HAEMORRHAGE IN FIBRINOLYTIC DISORDERS W. L. van Heerde* (NL), S. Croockewit, P. Lap, A. Loof, K. Verbeek, J. Boezeman, I. Novakova, M. van Kraaij, B. Verbruggen PP-TH-261 FACTOR VA C1 AND C2 DOMAINS PARTICIPATE IN PHOSPHATIDYLETHANOLAMINE MEMBRANE BINDING X. Liang* (US), M. Quinn-Allen, W. H. Kane PP-TH-262 FURTHER STUDIES ON HEMOSTATIC ACTIVATION IN SICKLE CELL DISEASE : ROLE OF HEMOLYSIS AND TYPE-II PHOSPHATIDYLSERINE-POSITIVE ERYTHROCYTES Y. B. Setty* (US), N. S. Key, M. J. Stuart

Antiphospholipid Antibodies and Syndrome III

PP-TH-263 ANTICARDIOLIPIN AND ANTI-BETA 2 GLYCOPROTEIN 1 ANTIBODIES ARE REQUIRED FOR THE CLINICAL DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME C. Gardiner* (UK), J. Hills, S. J. Machin, H. Cohen PP-TH-264 PHOSPHOLIPID COMPOSITION IMPACT ON DILUTE THROMBOPLASTIN SENSITIVITY TO LUPUS ANTICOAGULANTS K. M. Cawthern* (US), R. Bottenus, D. Diaz, M. X. Triscott PP-TH-265 CATASTROPHIC ANTIPHOSPHOLIPID ANTIBODY SYNDROME (CAPS) IN CHILDREN: SUCCESSFUL MANAGEMENT WITH AGGRESSIVE DIRECT THROMBIN INHIBITION, PHARMACOMECHANICAL THROMBOLYSIS, AND IMMUNOMODULATORY THERAPY M. J. Manco-Johnson* (US), M. Wang, N. A. Goldenberg, J. Soep, E. Pounder, C. Knoll PP-TH-266 BIOPHYSICAL CHARACTERIZATION OF THE COMPLEXES BETWEEN B2GPI AND THE LIGAND-BINDING LA MODULES FROM THE LIPOPROTEIN RECEPTORS C. Lee, A. de Biasio, N. Beglova* (US) PP-TH-267 MARKERS OF INFLAMMATION AND ENDOTHELIAL CELLS ACTIVATION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME DEPENDING ON THROMBOSIS LOCALIZATION N. V. Seredavkina* (RU), T. M. Reshetnyak, E. N. Alexandrova, A. A. Novikov, E. S. Much, M. V. Cherkasova, E. L. Nasonov PP-TH-268 ASSOCIATION BETWEEN HOMOCYSTEINE, ANTICARDIOLIPIN AND ANTIBETA2 GLYCOPROTEIN-I ANTIBODIES IN PATIENTS WITH CORONARY ARTERY DISEASE O. A. Smirnova* (RU), V. M. Shmeleva, V. A. Kobilyanskaya, L. P. Papayan PP-TH-269 CLINICAL MANIFESTATIONS OF LUPUS ANTICOAGULANTS IN CHILDREN O. M. Serbic* (RS), M. Kuzmanovic, G. Vlahovic, D. Veljkovic, S. Pasic, D. Micic PP-TH-270 TISSUE FACTOR -603A/G POLYMORPHISM AND TISSUE FACTOR LEVELS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME R. Kahraman, V. Hancer, R. Diz-Kucukkaya* (TR) PP-TH-271 THE MANAGEMENT OF ELEVATED APL IN PREGNANCY R. Apostolovska* (MK), T. Balkanov, V. Dejanova, K. Dimitrovski, S. Atanasova, I. Nikoloska, L. Stojanovska-Trajkovska, V. Neceva PP-TH-272 LUPUS ANTICOAGULANT IN A CHILD WITH CELIAC DISEASE- AN UNCOMMON ASSOCIATION S. Naseem* (IN), J. Ahluwalia, D. Suri, S. Singh PP-TH-273 ANTI-BETA-2-GLYCOPROTEIN-I IGG ANTIBODIES AND ANTI-CARDIOLIPIN IGG ANTIBODIES DO NOT PREDICT THROMBOSIS IN PATIENTS WITH A PERSISTENT LUPUS ANTICOAGULANT S. Koder* (AT), R. Vormittag, C. Zoghlami, S. Panzer, P. Quehenberger, I. Pabinger

350 PT-7 SEVEREBLEEDINGDUETO ACQUIRED HYPOPROTHROMBINEMIA-LUPUS PP-TH-276 REPORTOF2 LUPUS ANTICOAGULANT –WITHHYPOPROTHROMBINAEMIA: A PP-TH-275 ROLEOFCALCIUMIONSINTHEBINDINGBETA2-GLYCOPROTEIN ITO PP-TH-274 POSTER PRESENTATIONS PT-8 UCINLCONSEQUENCESOFTHEPROTHROMBOTICSERPINC1 RS2227589 FUNCTIONAL PP-TH-287 HYPERTHYROIDISMIS ASSOCIATED WITH AN INCREASEDRISKOFVENOUS PP-TH-286 PP-TH-285 VENOUSTHROMBOEMBOLISMPROPHYLAXIS AFTER MAJORORTHOPEDIC PP-TH-284 PP-TH-283 PP-TH-282 THEEFFECTOFLUPUS ANTICOAGULANTS AND APC RESISTANCE ONPROTEINS PP-TH-281 ARTERIES CALCIUMSCORINGINPATIENTS WITH ANTIPHOSPHOLIPID CORONARY PP-TH-280 THICKNESSINPATIENTS WITH ANTIPHOSPHOLIPID SYNDROME INTIMA-MEDIA PP-TH-279 CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME AND OBSTETRICCOMPLICATIONS PP-TH-278 SYNDROME INANTIPHOSPHOIPID THROMBOCYTOPENIA PP-TH-277 Risk FactorsandEpidemiologyofVenous Thrombosis III 2009 THURSDAY, JULY 16, POLYMORPHISM ON ANTITHROMBIN LEVELS THROMBOSIS ANTICOAGULANT SYNDROME.CASREPORT AND REVIEWOFLITERATURE CASES ASSAY CARDIOLIPIN IN AN ELISA N TF 67 YRA TIMEPCR REAL AND MTHFRC667TBY AUT STUDY MULTI-CENTER PROSPECTIVEOBSERVATIONAL SURGERY: A SAMPLE OFP LARGENATIONWIDE FROM A ASSESSMENT OFRACE,GENDER AND MORTALITY INHERITED OR ASSAY ACTIVITY SYNDROME UEFCA VEINTHROMBOSIS(SVT) SUPERFICIAL A. I. P J. Debeij*(NL),B.vanZaane,O.M.Dekkers, J.W. A. Smit,J. A. Romijn,V. E. A. Gerdes, A. I. Coll, Tirado* (ES),E.Martínez-Sánchez, J.Souto,V. Orantes,J.Fontcuberta F D. M.Courtney*(US),R.K.Khare C. Legnani*(IT),M.Cini,Pili,G.LoManto,Frascaro,O.Boggian, Palareti Z. Cao*(US),R.Bottenus,D.Sanchez,M. P. Kuca,W. Z. Tomkowski* (PL),G.Malek,M.Dybowska,J.Burakowski,Meissner G. Malek,W. Z. Tomkowski* (PL),P. Kuca,M.Dybowska,J.Burakowski,Meissner V. O.Bitsadze*(RU),S.M.Baimuradova,D.H.Hizroeva,V. Akinshina, A. D.Makatsariya Seredavkina, L.V. Kondratieva,E.V. Ostryakova,E.L.Nasonov T. M.Reshetnyak*(RU),I.B.Shtivelband,E.N. Alexandrova, A. A. Novikov, N.V. T. K.Dib*(DZ),C. Abi-Ayad, S. Ayad, M.Gheras,S.Brixi, A. Reghis S. C.Nair*(IN),N. Arora, N.V. Patkar, S.Baidya,L.G.Mattew, P. D.Moses Ruf S. Olivieri*(IT),M. STATES V . . vanZanten,D.P. M.Brandjes,H.R.Büller, F. R.Rosendaal,S.C.Cannegieter icente, B.Sánchez-V Altintas* (TR),?.Öztürk,B. fatti OMATIZATION OFGENETIC ANALYSIS: FACTOR VLEIDEN,F2G20210A,F12C46T Antón, R. Teruel, J.Corral*(ES), A. Miñano,I.Martínez-Martínez, A. Ordóñez,V. A TIENTS ACQUIRED THROMBOPHILIC Tonello, A. Cavazzana, A. Bontadi, A. Banzato,E.Bison,V. Pengo, A. ega ADMITTED FORPULMONAR Atilla, R. Tözün, F. Pestilci T riscott AL TERA Y TIONS (TAS) INPATIENTS WITH EMBOLISM INTHEUNITED 351

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-288 COMPARISON OF THE CLINICAL HISTORY OF SYMPTOMATIC ISOLATED DISTAL DEEP-VEIN THROMBOSIS VERSUS PROXIMAL DEEP-VEIN THROMBOSIS IN 11086 PATIENTS: RESULTS FROM THE RIETE REGISTRY J. Galanaud* (FR), S. Quenet, K. Guillot, I. Quéré, J. Sanchez Munoz-Torrero, C. Tolosa, M. Monreal, A. The Riete Investigators PP-TH-289 QUANTITATIVE TRAIT LOCI INVOLVED IN THE REGULATION OF LIPOPROTEIN A (LPA) LEVELS: GENOME-WIDE LINKAGE ANALYSIS FROM THE GAIT PROJECT S. López, A. Buil, J. Souto, J. Ordoñez, J. Blangero, F. Blanco-Vaca, J. Fontcuberta, L. Almasy, J. Soria* (ES) PP-TH-290 QUANTITATIVE TRAIT NUCLEOTIDE ANALYSIS IN THE NNMT GENE: A GENETIC DETERMINANT FOR HOMOCYSTEIN LEVELS M. Sabater-Lleal, J. Martín, A. Buil, M. Chillón, J. Souto, J. Blangero, J. Fontcuberta, F. Blanco-Vaca, J. Soria* (ES), L. Almasy PP-TH-291 LIPID-LOWERING DRUGS, LIPID PARAMETERS AND VENOUS THROMBOEMBOLISM K. Lacut* (FR), J. Malecot, A. Delluc, F. Couturaud, H. Kerspern, J. Carre, D. Mottier, E. Oger PP-TH-292 CASE FATALITY RATE OF RECURRENT VENOUS THROMBOEMBOLISM AND MAJOR BLEEDING DURING AND FOLLOWING ANTICOAGULATION THERAPY M. Carrier* (CA), G. Le Gal, P. S. Wells, M. A. Rodger PP-TH-293 IS SCREENING FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN PATIENTS WITH A PREVIOUS PULMONARY EMBOLISM INDICATED N. S. Gibson* (NL), S. Surie, V. E. A. Gerdes, B. J. Bouma, B. L. F. van Eck-Smit, H. R. Buller, P. Bresser PP-TH-294 ASSOCIATION OF THE VEGF POLYMORPHISMS AND HAPLOTYPES WITH THE RISK OF OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES IN POSTMENOPAUSAL WOMEN N. Kim* (KR), Y. Chung, S. Hong, D. Shin, J. Lee PP-TH-295 DIFFERENCES IN AETIOLOGICAL AND CLINICAL MANIFESTATIONS IN UPPER AND LOWER LIMB DEEP VENOUS THROMBOSIS PATIENTS FROM INDIA N. Pai* (IN), S. Shetty, B. Kulkarni, K. Ghosh PP-TH-296 PROTHROMBOTIC TENDENCY IN PATIENTS WITH HYPERTHYROIDISM N. M. Antonijevic* (RS), B. Stojanovic, D. Mikovic, M. Kovac, S. Popovic, M. Petakov, B. Jakovljevic, A. Beletic, V. Djordjevic, B. Trbojevic, N. Radovanovic, I. Elezovic PP-TH-297 THROMBOPHILIA MARKERS IN PORTAL VEIN THROMBOSIS N. Ben Romdhane* (TN), S. Mahjoub, H. Kallel, R. Ellouze, H. Baccouche, Z. Manai PP-TH-298 THROMBOPHILIC ABNORMALITIES IN TUNISIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE N. Ben Romdhane* (TN), R. Ellouze, S. Mahjoub, H. Kallel, L. Kallel, A. Filali PP-TH-299 THROMBOPROPHYLAXIS IN HOSPITALIZED PATIENTS: CAN WE DO IT BETTER P. Marchena Yglesias* (ES), E. Pesantes, R. Rey Santos, J. Burillo Lorente, F. Castro, F. Ribó Crusat, X. Martret Redrado, C. Paytubí Garí, J. Pérez Más, A. Domènech, M. Biosca Gómez de Tejada PP-TH-300 HIGH FACTOR VIII IN EXTRA-HEPATIC PORTAL VEIN OBSTRUCTION P. Bucciarelli* (IT), I. Martinelli, M. Primignani, R. Reati, F. Fabris, T. Battaglioli, A. Dell’Era, P. M. Mannucci PP-TH-301 RELATIONSHIP BETWEEN HYPERHOMOCYSTEINEMIA AND LOW BONE MINERAL DENSITY P. Bucciarelli* (IT), G. Martini, I. Martinelli, R. Nuti, P. M. Mannucci

352 PT-0 ER IESSA OETA OREO UMNR EMBOLISM.FINDINGS SOURCEOFPULMONARY POTENTIAL HEARTDISEASES AS A PP-TH-304 STABLE RISKSTRATIFICATION PATIENTS AND OUTCOMES INHEMODYNAMICALLY PP-TH-303 VEIN ONCARDIOVASCULAR RISKINRETINAL PROSPECTIVECOHORTSTUDY PP-TH-302 POSTER PRESENTATIONS PP-TH-314 GENETICRISKFACTORS FORVENOUSTHROMBOEMBOLISM IN YOUNG WOMEN PP-TH-313 PP-TH-312 THEPREDICTIVEVALUE OFICD-9-CMCODINGFORDEEP-VENOUS THROMBOSIS PP-TH-311 DIVERSE AMERICAN PEDIATRIC INCIDENCEOFVENOUSTHROMBOTICEVENTSIN A PP-TH-310 TO CONTRIBUTE AS STRONGLY ALLELE ARE UNLIKELY COMMONSUSCEPTIBILITY PP-TH-309 FOUNDINCATHETER-RELATED FACTOR UPPER VLEIDENISMOSTCOMMONLY PP-TH-308 HOSPITAL FRENCHGENERAL OF ANTICOAGULANT USEIN A SURVEY ONE-DAY A PP-TH-307 OFTHROMBOPHILICSTATES INSLOVAK REPUBLIC REGISTRY NATIONAL PP-TH-306 PLATELET SYNDROME:ROLE OFFLOWCYTOMETRY STICKY PP-TH-305 HRDY UY1,2009 THURSDAY, JULY 16, IS FROM NORTH-WESTERNRUSSIA Brown EPVI HOBSS IDNSFO H UIAREGISTRY DEEP-VEIN THROMBOSIS.FINDINGSFROMTHETULIPA SURVEY CROSS-SECTIONAL FROM A WITHTHREEMONTHSOFFOLLOW-UP STUDY WITH OCCLUSION INFLUENCE OFGENDERONTHECLINICAL EMBOLISM(PE) (DVT) AND PULMONARY INTENSIVE CAREUNITPOPULATION GWAS AS THEFV APPROACH AND ABO LOCITO VTERISK:RESULTS FROM A EXTREMITY H. L. A. Janssen,F. W. G.Leebeek,D.C.Rijken S. Talens* (NL),J.Hoekstra,S.P. G.Dirkx,S.DarwishMurad,J.Garcia-Pagan, D.C.Valla, S. I.Kapustin*(RU),V Rabe, S.M.Schellong R. M.Bauersachs*(DE),H.Riess,V. Hach-Wunderle, H.Gerlach,Carnarius,S.Eberle,E. R. H.White*(US),M.Garcia,B.Sadeghi,D. R. Zelenika, I.Juhan-Vague, M. Alessi, L. Tiret, M.Lathrop,J.Emmerich,P. E.Morange*(FR) D. Monreal P. diMicco, A. A. Visonà* (IT),V. V. Roldan, R.Lecumberri, A. A. Tirado, A. A. Niglio,M. P Chudy P. Kubisz*(SK),I.Plamenová,J.Chudej,K.Gregorová,L.Bartos P. Kubisz*(SK),L.Bartos Perina, V. Pengo, A. Pagnan P. Prandoni*(IT),R.Pesavento,H. T. Sorensen,N.Gennaro, F. DallaValle, I.Minotto,F. Prandoni* (IT) C. Bova,R.Pesavento, A. Marchiori, A. Palla,I.Enea, V. Pengo, A. Visonà, A. Noto,P. (IT) M. BUDD-CHIARI SYNDROME . Girard*(FR),C.Christidis,J.Cosserat,N.Cathala,D.Czitrom,LeGuillou, A A. Higgerson*(US),S.Hanson,K. T T. Sartori, A. Donà,S.Piermarocchi, E.Pilotto,G.Saggiorato, A. Pagnan,P. Prandoni* regouet, S.Heath,N.Saut,C.Biron,J.Schved,G.Pernod,P O EE FAOIORTI 1ARISKFACTOR FOR THROMBOSISIN OF APOLIPOPROTEIN A1 A LOW LEVEL ’, J.Stas CT UMNR MOIM PROSPECTIVEMULTICENTRE COHORT EMBOLISM. A ACUTE PULMONARY DEEP ˇ ko VEIN THROMBOSIS;DA . A. Kobilyanskaya,N.B.Saltykova,V. M.Shmeleva,N.Blinov ˇ ová, J.Fedorová,P. Holly, J.Stas A. Lawson,L.M.Christie,B. T T ancredi, P A PRESENT FROM THERIETEREGISTR . Zrelak,P ˇ A ko TION ˇ ová, M.Dobrotová,P. . Galand,L.Drouet,D. AND DIAGNOSISOF . S.Romano T otapally, J.McArthur, A. Y A. Lebuisson 353

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-315 NATIONAL PROSPECTIVE COHORT STUDY OF VENOUS THROMBOEMBOLISM (VTE) MANAGEMENT IN THE CANADIAN OUTPATIENT SETTING: RECOVERY REGISTRY S. R. Kahn* (CA), S. Schulman, J. Martineau, N. Komari, A. McLeod, C. Strulovitch, M. Blostein, J. Faucher, G. Gamble, W. Gordon, P. Kagoma, M. Miron PP-TH-316 HOMOCYSTEINE PLASMA LEVELS AND MTHFR C677T MUTATION S. M. Ouviña* (AR), A. La Greca, C. Mardaraz, G. Araujo, F. Negro, A. Ferro PP-TH-317 LONG-TERM SURVIVAL AFTER VENOUS THROMBOEMBOLISM: A COHORT STUDY AMONG YOUNG WOMEN S. E. Reitter* (AT), C. Laczkovics, T. Waldhoer, C. Vutuc, I. Pabinger-Fasching PP-TH-318 PLASMA HOMOCYSTEINE LEVEL AND MTHFR MUTATION IN IRANIAN PATIENTS WITH THROMBOTIC EVENTS T. Shashaani* (IR), M. Faranoush, S. Hejazi, M. Jazebi, F. Ala, N. Danaie PP-TH-319 PRESENCE OF LOWER LIMB DEEP VEIN THROMBOSIS AND PROGNOSIS IN PATIENTS WITH SYMPTOMATIC PULMONARY EMBOLISM T. Yamaki* (JP), H. Sakurai, K. Soejima, T. Kono, A. Hamahata PP-TH-320 TYPE I ANTITHROMBIN DEFICIENCY IS MORE CLOSELY ASSOCIATED WITH VENOUS THROMBOEMBOLISM THAN TYPE II ANTITHROMBIN DEFICIENCY T. Sakata, S. Kameda, M. Mitsuguro, A. Okamoto, M. Sano, Y. Kokubo, Y. Tsutsumi, T. Miyata* (JP) PP-TH-321 THROMBOPHILIC RISK PROFILE IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN NORTH-WESTERN RUSSIA V. M. Shmeleva* (RU), S. I. Kapustin, M. N. Blinov PP-TH-322 THE RISK OF VENOUS THROMBOSIS, INCLUDING CEREBRAL VEIN THROMBOSIS, AMONG WOMEN WITH THROMBOPHILIA AND ORAL CONTRACEPTIVE USE: A META- ANALYSIS N. Dayan, V. Tagalakis* (CA), C. Holcroft PP-TH-323 THE EFFECT OF CASE DEFINITION ON THE APPARENT INCIDENCE OF VENOUS THROMBOEMBOLISM WITHIN A LARGE ADMINISTRATIVE HEALTH CLAIMS DATABASE IN QUÉBEC, CANADA V. Tagalakis* (CA), S. R. Kahn, Y. Moride, J. Bovin PP-TH-324 THE RELATIONSHIP BETWEEN THE A6963G EPCR POLYMORPHISM AND VENOUS THROMBOEMBOLISM IN AMERICAN WHITES AND BLACKS: THE GATE STUDY C. Destareck, C. Lally, J. Benson, D. Ellingsen, H. Austin, W. C. Hooper* (US) PP-TH-325 THE RELATIONSHIP OF TWO POLYMORPHISMS OF THE TCF7L2 GENE AND VENOUS THROMBOEMBOLISM IN AMERICAN WHITES AND BLACKS: THE GATE STUDY C. J. Bean, C. Lally, J. Benson, H. Austin, W. C. Hooper* (US) PP-TH-326 LACK OF ASSOCIATION BETWEEN THE PHE204 ALLELE OF FACTOR XIII WITH VENOUS THROMBOEMBOLISM AND MYOCARDIAL INFARCTION H. Austin, C. Lally, M. Pyle, W. C. Hooper* (US) PP-TH-327 FACTOR V LEIDEN AND VENOUS THROMBOEMBOLISM RISK AMONG IDIOPATHIC AND PROVOKED CASES IN THE GATE STUDY C. Lally, H. Austin, M. Beckman, M. Pyle, W. C. Hooper* (US) PP-TH-328 POLYMORPHISMS IN THE THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR GENE AND RISK OF VENOUS THROMBOEMBOLISM W. C. Hooper* (US), N. Dowling, C. Destaercke, C. Whitsett, C. Miller, M. Beckman, H. Austin

354 PT-3 OBNDOCREC FHRDTR PROTEINC AND PROTEINSDEFICIENCY COMBINEDOCCURRENCEOFHEREDITARY PP-TH-331 WITHRULEBASED IMPLEMENTATION OF AN ELECTRONIC RISK ASSESSMENT TOOL PP-TH-330 CONTRIBUTIONOFHIGHLEVELSFACTORS VIII,IX AND XITO THERISKOF PP-TH-329 POSTER PRESENTATIONS PP-TH-342 PP-TH-341 PP-TH-340 PP-TH-339 POLYMORPHISM OFB-FIBRINOGENGENE AND THERISKOFPREMATURE G-455A PP-TH-338 PP-TH-337 ASYMPTOMATIC MRIBRAIN ABNORMALITIES INPATIENTS WITHTHALASSEMIA PP-TH-336 SIGNIFICANCEOFPLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INTHEEARLY PP-TH-335 WITH CHINESEFAMILY OFFACTOR VGENEIN A MUTATION (G2172?C) NOVEL A PP-TH-334 RISKFACTOR FORVENOUSTHROMBOSIS AS A ABOBLOODGROUP PP-TH-333 STATE INPATIENTS INFLAMMATORY PRESENTINGWITHVENOUSTHROMBOSIS PP-TH-332 Arterial Vascular DiseasesIII 2009 THURSDAY, JULY 16, ISCHEMIC HEART DISEASE THE FIREUNDER – AN UPDATED META-ANALYSIS NONRESPONSIVENESS AND RISKOFCARDIOVASCULAR MORBIDITY CLOPIDOGREL EUTO N NOHLA PROGENITOR CELLSINOVERWEIGHT SUBJECTS REDUCTION AND ENDOTHELIAL CR STROKE INFARCTION AND ISCHAEMIC THROMBOSIS: DIFFERENCESBETWEENMYOCARDIAL IN TWOCHINESEFAMILIES WITHVENOUSTHROMBOSIS THROMBOEMBOLISM RECOMMENDA CARRIERS RECURRENT VENOUSTHROMBOSISINHETEROZYGOUSFACTOR VLEIDEN EFFECT OF GENETIC V INFARCTION MYOCARDIAL TISSUE F INTERMEDIA DEVELOPMENT OFHSCT THROMBOEMBOLISM ACTIV G. Corinaldesi*(IT), C.Corinaldesi F. Sofi*(IT),R.Marcucci, A. Gori,B.Giusti,R. Abbate, G.Gensini F B. Siegerink*(NL),F A. E.Gialeraki*(GR),L.Rallidis,M.Politou,Merkouri,D.Kremastinos, A. Undas*(PL),D.Potaczek,M.Mazur, M.Pieculewicz,P. Podolec,W. Tracz A. Taher* (LB),K.M.Musallam, W. Nasreddine, A. Beydoun Y. Han*(CN),D.Wu, A. Sun,Z.Wang, C.Ruan H. Cai,B.Hua,L.Fan,Q.W Y. P. Adamczuk* (AR),M.L.IglesiasVarela, M.E.Martinuzzo,G.S.Cerrato,R.Forastiero J. C.Kluin-Nelemans Y. I.G.V. Tichelaar* (NL),W. M.Lijfering,H.G.Niesters,N.J.Veeger, A. B.Mulder, Y. Wu* (CN),G.Xu,Q.Ding,X.Xi,Wang, H.Wang G. C.Moore,I.Clark,N.Gautam,Jeskins,Suggett,W. Lester*(UK) W . Cesari*(IT),F. Sofi,I.Corsani,N.Pucci, R. Caporale, Abbate, G.Gensini, A. Casini . M.Lijfering*(NL),S.C.Christiansen,F YPTOGENIC ISCHEMICSTROKE A TED PROTEINCRESIST ACT ARIA A OR POL PERSONALIZED PHYSICAL IN O RVNINO OPTLACQUIREDVENOUS TIONS FORPREVENTIONOFHOSPITAL TION INCOAGULATION FACTOR XIII AND THERISKOF ARTERIAL . R.Rosendaal, YMORPHISMS, TISSUEF ASH: WHICH ARE THEPREDICTORS OFRELAPSE AFTER -ASSOCIA ang, S.W ANCE A. TED THROMBOTICCOMPLICA ang, Y. Zhao*(CN) Algra ASSOCIATED WITHVENOUS . R.Rosendaal,S.C.Cannegieter ACTIVITY ACT OR LEVELS PROGRAMME ONWEIGHT AND RISKFOR TIONS A. T ravlou 355

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-343 PLATELET GLYCOPROTEIN IIB/IIIA POLYMORPHISM AND RISK OF CARDIOVASCULAR EVENTS IN ASPIRIN-TREATED PATIENTS WITH STABLE CORONARY ARTERY DISEASE I. Elalamy* (FR), T. Chakroun, F. Addad, Z. Dridi, F. Abderrazak, S. Hamdi, M. Hassine, M. Hassine, F. Betbout, G. Gerotziafas, M. Hatmi, H. Gamra PP-TH-344 A RETROSPECTIVE CASE CONTROL STUDY ON THE ROLE OF HYPERCOAGULABILITY IN LATE STENT THROMBOSIS K. Winckers* (NL), V. Poenitz, R. van Oerle, H. Spronk, T. M. Hackeng, D. W. T. Nilsen, H. ten Cate PP-TH-345 THE ACTIVITY OF THROMBOMODULIN, TISSUE FACTOR AND CIRCULATING PROCOAGULANT PHOSPHOLIPIDS AS MARKERS FOR ACUTE MYOCARDIAL INFARCTION (AMI) P. Vandreden, A. Rousseau, B. Lenormand, S. Fontaine, B. J. Woodhams, M. Vasse* (FR) PP-TH-346 GENETIC POLYMORPHISM OF THE HOMOCYSTEINE AND FOLATE METABOLIZING ENZYMES: ASSOCIATION WITH PLASMA HOMOCYSTEINE AND PERIPHERAL ARTERIAL DISEASE RISK N. A. Klenkova* (RU), S. I. Kapustin, A. A. Gyrgy, V. M. Shmeleva, L. P. Papayan, N. B. Saltykova, M. N. Blinov PP-TH-347 ASSOCIATION OF ENDOGENOUS THROMBIN POTENTIAL (ETP) WITH CORONARY ARTERY DISEASE. AN ANGIOGRAPHY-BASED STUDY N. Martinelli* (IT), O. Olivieri, N. Campostrini, A. Castagna, S. Friso, F. Pizzolo, P. Guarini, L. Annarumma, F. Busti, R. Corrocher, D. Girelli PP-TH-348 ANTITHROMBOTIC EFFECTS OF BETA2-ADRENERGIC RECEPTOR BLOCKADE ON TOP OF BETA1-RECEPTOR BLOCKADE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR HEART FAILURE; A SYSTEMATIC REVIEW O. R. de Peuter* (NL), F. Lussana, R. J. Peters, H. R. Büller, P. W. Kamphuisen PP-TH-349 ELEVATED PLASMA FIBRIN D-DIMER AS A RISK FACTOR FOR VASCULAR DEMENTIA:THE THREE-CITY COHORT STUDY L. Carcaillon, P. Gaussem* (FR), P. Ducimetière, M. Giroud, C. Tzourio, K. Ritchie, J. Dartigues, P. Scarabin PP-TH-350 PROSPECTIVE EPIDEMIOLOGICAL STUDY OF THROMBOPHILIA AND INFLAMMATION MARKERS IN YOUNG HISPANIC PATIENTS WITH ARTERIAL THROMBOSIS P. Casais* (AR), M. F. Alberto, L. Jones, G. Campregher, A. I. Woods, J. Paiva-Patiño, L. Keller, A. C. Kempfer, A. N. Blanco, S. S. Meschengieser, M. A. Lazzari PP-TH-351 CLOTTING FACTORS, INFLAMMATORY MARKERS AND GLYCEMIC CONTROL IN DIABETES: ROLE IN CLOT STRUCTURE AND FIBRINOLYSIS R. A. Ajjan* (UK), K. F. Standeven, S. Mughal, K. Hess, F. Phoenix, A. M. Carter, R. A. S. Ariens, P. J. Grant PP-TH-352 CLOSE MONITORING OF HEMOSTASIS BY THROMBOELASTOMETRY DURING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) R. Paniccia* (IT), E. Antonucci, N. Maggini, S. Bevilacqua, M. Bonacchi, G. Sani, G. Olivo, D. Prisco, R. Abbate, G. F. Gensini PP-TH-353 LOW-DOSE ASPIRIN THERAPY AFTER KIDNEY TRANSPLANTATION R. Paniccia* (IT), E. Antonucci, M. Zanazzi, N. Maggini, N. Paudice, I. Ricci, R. Marcucci, L. Mannini, G. F. Gensini, R. Abbate PP-TH-354 ACUTE ISCHEMIC CEREBROVASCULAR ACCIDENT (CVA) AFTER BEVACIZUMAB THERAPY. CASE REPORT & REVIEW OF THE LITERATURE R. M. Biswar* (US), S. J. Jubelirer, J. G. Rosencrance

356 PT-5 CHADS2SCOREPREDICTIONOFPOST-OPERATIVE STROKEINPATIENTS WITH AND PP-TH-357 PP-TH-356 THEHPA-1B (PRO33)VARIANT OFPLATELET INTEGRIN ALPHAIIB BETA3 CAN PP-TH-355 POSTER PRESENTATIONS PP-TH-366 POLYMORPHISM, PLATELET RELATION BETWEENCYTOCHROME P4502C19681G>A PP-TH-365 CHARACTERIZATION OFCANDIDATE GENETIC DETERMINERSFORMYOCARDIAL PP-TH-364 PP-TH-363 STIFFNESS NEWLINKBETWEEN ARTERIAL TISSUEFACTOR PATHWAY INHIBITOR: A PP-TH-362 PP-TH-361 PP-TH-360 VASCULAR COMPARISON OFTWODIFFERENTHEPARIN DOSESINPERIPHERAL PP-TH-359 BACKGROUNDOF ACUTE ISCHEMICSTROKEPATIENTS WITHEXTREMELY CLINICAL PP-TH-358 HRDY UY1,2009 THURSDAY, JULY 16, CHILDREN ASSOCIATED WITHVASCULAR, BUTNOTTHROMBOEMBOLIC,STROKEIN FIBRILLATION WITHOUT ATRIAL TROMBOSIS DISEASE ON ARTERIAL ANDVONWILLEBRAND SYSTEMATIC REVIEWOFTHEEFFECTSHEMOPHILIA A STATE PROTHROMBOTIC INDUCE A IKO OOAYSLRSSMOADA INFARCTION INWOMEN SCLEROSIS/MYOCARDIAL RISK OFCORONARY INTERACTION BETWEENHOMOCYSTEINE PERCUT OUTCOME AFTER ELECTIVE ANDCLINICAL RESPONSIVENESS TO ADP INF TRANSITION FROM ACUTE DECOMPENSATED TO CHRONICHEARTFAILURE INFLAMMATION AND COAGULATION MARKERSINHEARTFAILURE PATIENTS: AND THROMBINGENERATION FAILURE ACTIV GENETIC V SURGERY OFSERUMD-DIMER HIGH LEVEL Z. Bereczky*(HU),É.Katona,E.Balogh, K.Kósa,I.Czuriga,Édes,L.Muszbek C. Pouplard,E.Blicq,S.Regina, A. deLabriolle,B.Charbonnier, Y. Gruel*(FR) J. Cui,E.Randell,R.James,F. Y. Han,G.Sun,C.Butt,J.Hwa, Y. G.Xie*(CA) V. Vila* (ES),V. Martinez-Sales,I.Sanchez-Lazaro,L. Almenar, E.Reganon V V. M.Shmeleva*(RU),O.N.Semenova U. Nowak-Gottl*(DE),S. Thedieck, T. Seehafer, M.Stoll U. Schott*(SE),D.Winstedt Nohara, N. Yoshimura, T. Ohtake,K.Hirabayashi,M. Yokochi, Y. Katayama,H. Takubo T. Nagao*(JP), A. Nogami,M.Okamura, N.Umesato,M.Inoue,Komine-Kobayashi,C. S. Kaatz*(US),B.F. Gage,J.D.Douketis,R.H.White Kamphuisen S. Rafi*(NL),M.Zwiers,Peters,J.vanderMeer R. E.Scharf*(DE),V CLOPIDOGREL . Regnault*(FR), ARCTION IN A TION OFHAEMOST ANEOUS CORONAR ARIA A TION INTHEPLASMA A. Kearney-Schwartz,J.Max, GENETIC HOMOGENEOUSPOPULA . R.Stoldt ASIS INELDERL Y INTER VENTION INP GLUTATHIONE PEROXIDASE(GPX-3)GENEIS Y AND LIPOPROTEIN(A)INCREASESTHE P T. Lecompte, A. Benetos,P. Lacolley ATIENTS WITHCHRONICHEART , F. R.Rosendaal,H.Buller, P. W. A TIENTS TREATED WITH TION 357

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

Hormones, Pregnancy and Women’s Issues III

PP-TH-367 ROLE OF NATURAL PROGESTERONE IN PROPHYLAXIS OF RECURRENT PREGNANCY LOSS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME E. N. Shakhovskaya* (RU), A. D. Makatsaria PP-TH-368 MONITORING OF HAEMOCOAGULATION CHANGES DURING LONG-TERM LOW MOLECULAR WEIGHT HEPARIN PROTECTION OF PREGNANCY P. Sigutova* (CZ), Z. Hajsmanova, J. Slechtova, Z. Ulcova-Gallova PP-TH-369 VENOUS THROMBOEMBOLISM IN CZECH WOMEN IN ASSOCIATION WITH ORAL CONTRACEPTIVE USE: FREQUENCY, ETIOLOGY AND THERAPY OF BUDD-CHIARI SYNDROME P. Dulicek* (CZ), J. J. M. Maly’, T. T. F. Fejfar, R. R. M. Maly’, F. F. V. Vrbacky’ PP-TH-370 INTRAPARTUM BRIDGING THERAPY USING LOW MOLECULAR WEIGHT HEPARIN IN PREGNANT PATIENTS REQUIRING A HIGH DEGREE OF ANTICOAGULATION R. S. Chitsike* (ZA), G. Toweel, S. Moodley, H. A. Rhemtula, P. Manga, B. F. Jacobson PP-TH-371 IS DOSAGE ADJUSTMENT OF LOW MOLECULAR WEIGHT HEPARIN NECESSARY AND SAFE FOR PREGNANCIES AT GREATEST RISK OF THROMBOSIS R. S. Chitsike* (ZA), H. A. Rhemtula, P. Manga, B. F. Jacobson PP-TH-372 MODULATION OF COAGULATION FACTOR LEVELS AND THROMBIN GENERATION PARAMETERS BY A HEALTHY DIET IN PRE-MENOPAUSAL MIDDLE-AGED WOMEN WITH MODERATE CARDIOVASCULAR RISK S. Calzavarini* (IT), S. Volpato, P. Caruso, A. Passaro, R. Fellin, F. Bernardi PP-TH-373 PREVALENCE OF JAK2V617F MUTATION IN WOMEN WITH UNEXPLAINED RECURRENT MISCARRIAGE S. P. Kaandorp, M. N. Lauw, C. van der Schoot, M. Goddijn, F. van der Veen, H. R. Koene, B. J. Biemond, S. Middeldorp* (NL) PP-TH-374 PREVENTION OF VENOUS THROMBOEMBOLISM IN PREGNANT WOMEN: MANAGEMENT STRATEGY ON A LARGE HEALTH CARE AREA S. Testa* (IT), O. Paoletti, E. Ronca, A. Rigolli, A. Alatri, A. Zimmermann, A. Riccardi PP-TH-375 LOW MOLECULAR WEIGHT HEPARINS LABORATORY MONITORING: VARIABILITY IN RELATION TO CALIBRATION AND ANTITHROMBIN PLASMA LEVEL S. Testa* (IT), O. Paoletti, L. Bassi, A. Alatri, A. Zimmermann, A. Cogrossi, M. Stramezzi PP-TH-376 STRATEGY OF THROMBUS REMOVAL FOR ILIOFEMORAL DVT OF PREGNANCY S. Thakur* (US), A. J. Comerota, J. L. Martinez Trabal, R. Disalle, S. N. Kazanjian, D. M. Sepanski, Z. Assi PP-TH-377 CHANGES IN THE COAGULATION SYSTEM IN HUMANS AND MICE DURING PREGNANCY S. N. Tchaikovski* (NL), B. van Vlijmen, M. L. G. D. Thomassen, E. Castoldi, L. L. Peeters, G. Tans, J. Rosing PP-TH-378 ROLE OF THROMBOPHILIA IN PROSTHETIC VALVE THROMBOSIS DURING PREGNANCY S. V. Akinshina* (RU), A. D. Makatsariya, V. O. Bitsadze, S. M. Baimuradova PP-TH-379 PREGNANCY IN WOMEN WITH HISTORY OF STROKE: PATHOGENETIC PROPHYLAXIS IS POSSIBLE S. V. Akinshina* (RU), A. D. Makatsariya, V. O. Bitsadze, S. M. Baimuradova PP-TH-380 THROMBOPHILIC AND PROINFLAMMATORY STATES IN PREGNANT WOMEN WITH METABOLIC SYNDROME T. B. Pshenichnikova* (RU), E. B. Perederyaeva, Z. Gadaeva, A. D. Makatsariya

358 PT-8 ANTI-XaMONITORING ISREQUIREDINPREGNANTWOMENONLOWMOLECULAR PP-TH-384 MILDRESISTANCE TO THROMBOPROPHYLAXISWITHLMWHDURINGPREGNANCY PP-TH-383 INCREASEDTHROMBINGENERATION DURINGPREGNANCY PP-TH-382 CONCENTRATION ANDSCD40L MICROPARTICLES‘ PROCOAGULANT ACTIVITY PP-TH-381 POSTER PRESENTATIONS PT-9 FIAYADSFT FRVI NA CT REILBEDN OE IN BLEEDINGMODEL OFRFVIIa IN AN ACUTE ARTERIAL AND SAFETY EFFICACY PP-TH-394 THROMBOELASTOGRAPHIC RAT (TEG)EVALUATION MODEL OFHEMOSTASIS IN A PP-TH-393 AUTOTAXIN/LYSOPHOSPHATIDIC ROLEIN ACID AXIS: INVIVOEVIDENCEFOR A PP-TH-392 OFLMWHSCOMPARED TO FXA SUSTAINED ANTITHROMBOTIC ACTIVITY PP-TH-391 OFOVERSULFATED CHONDROITIN SULFATE. BIOAVAILABILITY IMMUNOLOGIC PP-TH-390 EXTENDED ADMINISTRATION OFDEFIBROTIDEINNON-IMMUNOGENICEXTENDED PP-TH-389 PP-TH-388 LOSSES PREGNANCY INVOLVEMENT OFHEPARANASE INEARLY PP-TH-387 PP-TH-386 MANAGEMENTOFPREGNANCIESWITHHIGHRISKTHROMBOSIS: A PP-TH-385 Animal andExperimentalModelsIII 2009 THURSDAY, JULY 16, HEAL OF OBSTRUCTIVESLEEP WEIGHT HEPARIN (LMWH) SYNDROME WOMEN AND WOMENWITH ANTIPHOSPHOLIPID INHEALTHY DURING PREGNANCY OBESITY INHIBIT IMPLICATIONS STUDIES INRA F PREGNANCY ENDOGENOUS THROMBINPOTENTIAL,DDIMERS MULTICENTER PROSPECTIVESTUDY P. Carteaux, T. Lecompte M. Durand*(FR), M. Othman*(CA),S.P. Gordon,S.Iscoe L. Federico*(US),S.Liu,P. Muller, G.B.Mills, A. J.Morris,S.Smyth Bakhos J. M.Walenga* (US),W. P. Jeske, E.Litinas,J.Emanuele,D.Hoppensteadt,Cunanan,M. C. Adiguzel, D.Hoppensteadt, H.Messmore,J.M.Walenga, R.Wahi, J.Fareed*(US) J. Fareed*(US),D.Hoppensteadt,Cunanan,H.Zhu,C.Echart,M.Iacobelli M. Levi E. C.Lowenberg*(NL),J.M.Meijers,H.Zhang,R.Crosby, E.S.Stroes, B.P. Monia, Y Y Trzeciak Desmurs Clavel,J.Ninet,P. Gaucherand,C.R.Rudigoz,M.Berland,F. Champion,M.C. Y. Dargaud*(FR),L.Rugeri,M.C.Vergnes, B. Arnuti, P. Miranda,C.Negrier, A. Bestion,H. V. M. A. Simpson*(UK),M.Pescott,D.Peebles,H.Cohen V. Rossetto*(IT),P. Dabrilli,L.Spiezia,F. DallaValle, E.Campello,S.Gavasso,P. Simioni Simioni V M. Celinska-Lowenhof . Nadir*(IL),I.Henig,Vlodavsky . Dargaud*(FR),S.Hierso,L.Rugeri,B.Chatard,C.Battie,P ACT . Rossetto*(IT),P. Dabrilli,L.Spiezia,M.Castelli,E.Campello,Perlati,S.Gavasso,P. OR XI THY ORS PREDISPOSITION RABBIT: A BLIND STUDY BLIND RABBIT: A ANTISENSE THERAPY TS A. Godier AND DOGS f, T. Iwaniec*(PL), A. Grzyb,J.Musial , V APNEA . Notet,M.Hacquard, O.Collignon,G.Corbonnois,F , B.Brenner REDUCES THROMBUSFORMATION INMICE AND F1+2INNORMAL . Gaucherand,C.Negrier . Plénat,J. 359

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-395 THE INFLUENCE OF STREPTOKINASE ON PLATELET LINK OF HAEMOSTATIC SYSTEM N. Burlova-Vasilieva* (UA), O. Savchuk, I. Krasnobrizha, G. Volkov PP-TH-396 METHODS TO EVALUATE THE PHARMACOKINETICS OF TAL6003, A SIMPLIFIED VERSION OF PLASMIN C. Cruz, K. Yarbrough, B. Sandy, P. Vandeberg* (US) PP-TH-397 NEW INSIGHT INTO THE FUNCTION OF VKORC1L1 P. Westhofen* (DE), M. Watzka, M. Marinova, M. Hass, J. Oldenburg PP-TH-398 PASSENGER GENE POINT MUTATION: DISCOVERY OF A SPONTANEOUS IRS1 MUTATION IN LINKAGE WITH PAI2 DEFICIENCY R. J. Westrick* (US), K. L. Mohlke, G. Zhu, S. L. Manning, D. Ginsburg PP-TH-399 EVALUATION OF ANTI HUMAN PLATELET GLYCOPROTEIN GPIIIA THERAPEUTIC CHIMERIC ANTIBODY F(AB)2 FRAGMENT IN BEAGLE DOGS S. Ji* (CN), M. Jiang, Y. Zhao, W. Fang, J. Yang, C. Ruan PP-TH-400 DEVELOPMENT AND EVALUATION OF AN IMMUNOASSAY FOR THE MONITORING OF A NEW ANTI-PLATELET DRUG CHIMERIC MONOCLONAL SZ21 F(AB)2 S. Ji* (CN), N. Wen, Z. Li, C. Ruan PP-TH-401 FUNCTIONAL ROLES OF THROMBOXANE A2 ON PREECLAMPSIA C. Pai, I. Yu, S. Lin, S. Lin* (TW) PP-TH-402 A MILD ARTERIAL DAMAGE FACILITATES DOWNSTREAM THROMBUS FORMATION BY PRIMING PLATELET ACTIVATION S. Momi* (IT), S. Giannini, P. Gresele PP-TH-403 PRECLINICAL TOXICOLOGY AND SAFETY PHARMACOLOGY OF PLASMIN (HUMAN) V. Arora* (US), G. A. Baumbach, P. Scuderi, S. R. Petteway PP-TH-404 SALICYLAMIDE DERIVATIVES AS ANTAGONISTS FOR LOW MOLECULAR WEIGHT HEPARIN AND HEPARIN-LIKE DRUGS C. Schroeder, M. Prechel, J. M. Walenga, W. P. Jeske* (US), M. Bakhos PP-TH-405 EFFICACY OF ASPIRIN ON IMPROVEMENT OF PERIPHERAL BLOOD CIRCULATION IN MICE W. K. Jeon* (KR), B. K. Yoo, B. S. Ko, J. Y. Ma PP-TH-406 TREATMENT OF VENOUS THROMBOSIS WITH THE ORAL DIRECT FACTOR Xa INHIBITOR DU-176B IN CONSCIOUS RATS Y. Morishima* (JP), Y. Honda, C. Kamisato-Matsumoto, T. Shibano

Clinical Trials III

PP-TH-407 ATTENUATED ELEVATION OF SP-SELECTIN IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION IS RELATED TO BLEEDING EVENTS DURING ANTITHROMBOTIC TREATMENT C. Christersson* (SE), J. Oldgren, L. Wallentin, A. Siegbahn PP-TH-408 GOAL-DIRECTED INTRAVENOUS HEPARIN (IVH) VERSUS SUBCUTANEOUS HEPARIN (SQH) IN PREVENTING THROMBOEMBOLISM IN POST-SURGICAL SICU PATIENTS K. E. Nordenholz* (US), C. Hamiel, S. Cheng, A. Baer, D. Matero, N. Pearlman, P. Wischmeyer PP-TH-409 CO-ADMINISTRATION OF IDRAPARINUX AND WARFARIN IN HEALTHY SUBJECTS M. Trellu* (FR), I. Paty

360 PT-1 D-DIMERTO PREDICTTHROMBOSISRECURRENCE:COMPARISON OF AGGREGATE PP-TH-412 EVALUATION OFFONDAPARINUX FORPREVENTIONOFVENOUS CLINICAL PP-TH-411 OFENOXAPARIN FORTHEPREVENTIONOFVENOUS ANDSAFETY EFFICACY PP-TH-410 POSTER PRESENTATIONS PT-2 THEEFFECTOFVITAMIN KRICHDIETONTHEINR,VITAMIN KDEPENDENT PP-TH-422 PP-TH-421 ON RISKFACTORS AND ANDSPLANCNIC VEINTHROMBOSIS:STUDY PORTAL PP-TH-420 UNFRACTIONATED HEPARIN UFHVERSUS LOW MOLECULARWEIGHTHEPARIN PP-TH-419 PP-TH-418 LACKOFEXTENDEDVENOUSTHROMBOEMBOLISMPROPHYLAXISINHIGH-RISK PP-TH-417 FRESHFROZEN DECREASEOFINTRAOPERATIVE TRANSFUSION,ESPECIALLY PP-TH-416 PP-TH-415 DURING HIGH-RISKSITUATIONS FOR MAINTENANCEOF AT ACTIVITY OPTIMAL PP-TH-414 ENOXAPARIN VERSUSDABIGATRAN ETEXILATE ORRIVAROXABAN FOR PP-TH-413 HRDY UY1,2009 THURSDAY, JULY 16, FACTORS ACTIVITY, AND D-DIMERINPATIENTS USINGWARFARIN INCREASED INPATIENTS AFTER HEARTTRANSPLANTATION PLATELET (ETC) ARE NOT AGGREGATION AND ENDOGENOUSTHROMBINCAPACITY NLN EMOA ANTICOAGULANTS ON LONGTERMORAL ORKNEEREPLACEMENTSURGERY HIP TOTAL Saggiorato, P THE POSTOPERATIVE INFECTION PATIENT META-ANALYSES DATA ANDINDIVIDUAL DATA THROMBOEMBOLISM INJAP SURGER THROMBOEMBOLISM INJAPANESE PATIENTS UNDERGOINGMAJOR ABDOMINAL TREA CONTROLLED CLINICAL LMWH FORBRIDGINGDURINGW EV PATIENTS AT DISCHARGEFROMSWISSHOSPITALS (ESSENTIAL) ELECTRONIC PATIENTS UNDERGOINGMAJORORTHOPEDICORCANCERSURGERY: PLASMA, DURINGCARDIOV POTENTIAL THROMBOSIS WITHTHEUSEOF ANTITHROMBIN (RECOMBINANT) KNEE ARTHROPLASTY OR HIP THROMBOPROPHYLAXIS AFTER P. Kessler*(CZ), M.Kusnierova,H.Poul, A. Komarek,E.Vlckova P. Staritz*(DE), A. Huth-Kühne, R.Zimmermann, T. J.Dengler, B. T. Ivandic M. O. Dabbagh*(US),M.P. Lent, S. R.Bearelly N. OstasevskiFernandez*(SI), Kalka N. Kucher*(CH),D.Spirk,K.Siebenrock,U.Metzger M. Iwade*(JP),Nomura,K.Iwade M. R.Lassen*(DK), M. J.Paidas*(US),C. Tait, J.Frieling M. V. Huisman*(NL),D.J.Quinlan,O.E.Dahl,S.Schulman C. Tait,Poli, A. Tosetto M. Marcucci*(IT), A. Iorio,J.Douketis, T. Baglin,M.Cushman,S.Eichinger, G.Palareti,D. M. Sakon*(JP), T. Kobayashi M. Sakon*(JP) ALUA T . Sartori,M.Senzolo,C.Ferronato,P. Burra,P. Boccagni,D.Gasparini,S.Gavasso,G. TMENT TION OFPERIPROCEDURAL Y IMP . Simioni*(IT) ALGORITHM ASSESSMENT OFVTEPROPHYLAXISINHIGH-RISKSURGICAL ACT OFRIV A. G. TRIALS Turpie, A. K.Kakkar, B.I.Eriksson,M.Gent RXBNO OGTR AEYOUTCOMES AFTER AROXABAN ONLONG-TERMSAFETY ASCULAR SURGER NS AINSUDRON BOIA SURGERY ANESE PATIENTS UNDERGOING ABDOMINAL A. Mavri ARF ANTICOAGULATION MANAGEMENTINPATIENTS ARIN INTERRUPTION: Y , D.Sterzing,M.Zuber, E.Mouhsine, C. LEADS T O DECREASETHERISKOF A MET AANAL YSIS OF 361

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-423 PHARMACOKINETICS AND PHARMACODYNAMICS OF EP42675, A NEW SYNTHETIC ANTICOAGULANT WITH A DUAL MECHANISM OF ACTION P. Gueret* (FR), C. Krezel, P. L. M. van Giersbergen, M. Petitou, E. Neuhart PP-TH-424 PHYSICIAN ALERTS TO PREVENT SYMPTOMATIC VENOUS THROMBOEMBOLISM IN HOSPITALIZED PATIENTS G. Piazza, E. J. Rosenbaum, W. Pendergast, J. O. Jacobson, R. C. Pendleton, G. D. McLaren, C. Elliott, S. M. Stevens, W. F. Patton, O. Dabbagh, M. D. Paterno, E. Catapane, S. Z. Goldhaber* (US) PP-TH-425 THROMBOPROPHYLAXIS WITH CERTOPARIN IN ACUTELY ILL, NON-SURGICAL PATIENTS – CERTAIN STUDY S. Schellong* (DE), S. Haas, A. Greinacher, C. Abletshauser, H. Riess PP-TH-426 TOWARDS THE REDUCTION OF THE INCIDENCE OF MAJOR BLEEDING UNDER ANTICOAGULANT DRUGS IN MAJOR ORTHOPAEDIC SURGERY. MYTH OR REALITY S. Laporte* (FR), P. Zufferey, P. Mismetti PP-TH-427 LEFT VENTRICULAR (LV) THROMBUS FORMATION IN SPITE OF INTENSIVE ANTIPLATELET TREATMENT IN PATIENTS WITH ACUTE ANTERIOR WALL ST- ELEVATION MYOCARDIAL INFARCTION (STEMI) TREATED WITH PCI S. Solheim* (NO), I. Seljeflot, K. Lunde, R. Bjørnerheim, S. Aakhus, K. Forfang, H. Arnesen PP-TH-428 COMPARISON OF TWO INFUSION RATES OF ANTITHROMBIN CONCENTRATE IN CARDIOPULMONARY BYPASS SURGERY U. Schott* (SE), T. Carlsson, P. Lund PP-TH-429 THE INFLUENCE OF GENETIC BESIDES NON GENETIC FACTORS ON WARFARIN RESPONSE IN 300 VERY ELDERLY INPATIENTS V. Siguret* (FR), C. Moreau, I. Gouin-Thibault, J. L. Golmard, I. Mahe, P. Beaune, E. Pautas, M. A. Loriot PP-TH-430 BLEEDING EVENTS IN THE EARLY PHASE OF THROMBOPROPHYLAXIS: A POOLED ANALYSIS OF FOUR RIVAROXABAN STUDIES W. D. Fisher* (CA), M. R. Lassen, A. G. G. Turpie, A. K. Kakkar, B. I. Eriksson, M. Gent PP-TH-431 THE GENETIC PREDICTORS OF BLEEDINGS DURING WARAFRIN THERAPY (THE DATA BASED ON FIVE YEAR PROSPECTIVE STUDY Y. A. Mikheeva* (RU), E. S. Kropacheva, D. A. Sichev, A. B. Dobrovolsky, E. P. Panchenko

Intravascular Devices and Interventions II

PP-TH-432 HAEMOSTATIC PARAMETERS IN PATIENTS WITH SUBCLAVIAN CATHETER- ASSOCIATED THROMBOSIS L. Petit, V. Cottenceau, F. Masson, S. Labrouche, G. Freyburger* (FR) PP-TH-433 INFLAMMATORY AND COAGULATION MARKERS IN PATIENTS WITH ATRIAL FIBRILATION TREATED WITH RF ABLATION J. Kyselovic* (SK), P. Musil, L. Urban, P. Krenek, R. Hatala PP-TH-434 COAGULATION LABORATORY SCREENING IS NOT A GOOD PREDICTOR FOR BLEEDING COMPLICATIONS IN PEDIATRIC PATIENTS REQUIRING PERIPHERALLY INSERTED CENTRAL CATHETERS J. Woodley-Cook* (CA), J. Amaral, B. Connolly, L. Brandao PP-TH-435 BIOMATERIAL SURFACE MODIFICATION WITH AN ANTITHROMBIN-HEPARIN COVALENT COMPLEX FOR IMPROVED INTRAVASCULAR DEVICES K. N. Sask* (CA), J. L. Brash, A. K. C. Chan, L. R. Berry, W. G. McClung

362 PT-3 TETETO LOEOA EPVEINTHROMBOSISINPUERPERIUMUSING DEEP TREATMENT OFILEOFEMORAL PP-TH-438 MARKERS PREDICTIVEVALUE OFCOAGULATION MARKER(D-DIMER) AND PLASMA PP-TH-437 TROMBINGENERATION AS HEMOSTASIS INDICATOR: CVVH VALIDATION IN A PP-TH-436 POSTER PRESENTATIONS PT-4 NIIINO HOBNGNRTO YRVRXBNI ENTLPLASMA RIVAROXABAN IN NEONATAL INHIBITION OFTHROMBINGENERATION BY PP-TH-448 PP-TH-447 THROMBOSISINCHILDREN OUTCOMEOFCATHETER-RELATED ARTERIAL PP-TH-446 VALUE AS PROTHROMBOTIC HIGHERENDOGENOUSTHROMBINPOTENTIAL PP-TH-445 VENOUSTHROMBOSISINCHILDREN:EVALUATION OFTHE CEREBRAL PP-TH-444 PLATELET AGGREGATES AND LEUCOCYTES INTHELUNGCAPILLARIESOFCASES PP-TH-443 COMPLIANCEOF ANTITHROMBOTIC MANAGEMENTWITHPAEDIATRIC GUIDELINES PP-TH-442 PP-TH-441 OFENOXAPARIN, CERTOPARIN, AND DALTEPARIN EFFICACY INPREVENTING PP-TH-440 MEMBRANEBIOCOMPATIBILITY INVITROEVALUATION OF ARTIFICIAL PP-TH-439 Pediatric Thrombosis III 2009 THURSDAY, JULY 16, TRANSPLANTATION INCHILDHOODBONEMARROW MARKER OFVASCULAR INJURY OFSOLUBLETHROMBOMODULIN AS A THE RATIO ACTIVITY/ANTIGENIC LEVEL Chan, R.C.H.Li, A. C.W. Lee CATHETER-DIRECTED THROMBOLYSIS FIBRILLATION ATRIAL OF MYOCARDIAL SETTING MARKER INNEWL ASSOCIATION WITHPROTHROMBOTICRISKFACTORS OF SUDDENINF EXPERIENCE OFTREA CARDIAC CATHETER THROMBOSIS: AN INVITRO APPROACH MONITORING SUPPORT MOLECULAR WEIGHTHEPARIN (LMWH)IN AN INSTITUTELACKOF ANTI-Xa Muntean M. Novak*(AT), H.Bernhard, M.Koestenberger, D. Ulrich,B.Leschnik,S.Schweintzger, W. A. Rousseau,P S. Kroiss,O.Kretschmar Hesham, U.RoshdyElsafy, M.Badr, L.Bomgaars, A. Pappo,M.Chintagumpala,J. Teruya M. Aly Aldeen Abd Elbasset Aly Mohamed*(EG),R.M.Edwards,D.Cooper, I. Tjia, M. L. R.Goncalves*(PT),M.Carvalho,Campos,Vaz, L.M.Ribeiro L. Jørgensen*(NO), F. H. Newall, J.Doan*(AU), T. Wallace, V. Ignjatovic,P. Monagle J. W U. Raaz*(DE),M.Buerke,Busshardt,L.Maegdefessel, A. Plehn,B.Hauroeder, K. Cahalan S. C.Minkin*(US),M.Benner, M.Beeler, B.Curry, P. Iakova,J.Biggerstaff, P. Cahalan,L. Solar, J.Fridrich,Vojacek R. Maly*(CZ),V. Chovanec, A. Krajina,J.Raupach,M.Lojik,P. Dulicek,L.Vodickova, M. P. Musil*(SK),J.Kyselovic,P. Krenek,L.Urban,R.Hatala J. W M. vanSchilfgaarde*(NL),H.Oudemans,vanStraaten,P erdan, Y . K. ester Y A. Schlitt ang* HongKongSpecial , A. Leyte , A. . Schneider ANT DEA AAEO UCS AEO AIFEUNYABLATION OF DAMAGE ONSUCCESSRATE OFRADIOFREQUENCY Y T. Hanssen DIAGNOSED PEDIATRIC CANCERPATIENTS , I.Forster TING PEDIA , P TH SYNDROME . vanDreden,J.P. Vannier, M.Vasse* (FR) Administrative Regionof(CN),M.L.G.W , M.Schmugge, TRIC VENOUSTHROMBOEMBOLISMWITHLOW Albisetti* (CH) . J.Molenaar, N.R.Wiertz,J.P. ong, A. K.C. 363

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-449 PROPHYLAXIS FOR SEVERE PROTEIN C DEFICIENCY: A NOVEL APPROACH M. D. Williams* (UK), D. Marshall, P. Nyatanga PP-TH-450 RECURRENT PULMONARY EMBOLISM IN A 14 YEAR OLD BOY WITH ANTIPHOSPHOLIPID SYNDROME M. Girisch* (DE), R. Rauch, G. Wiegand, M. Hofbeck PP-TH-451 CEREBRAL THROMBOEMBOLISM IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA N. Conde, N. Conde* (ES), T. Toll, R. Berrueco, A. Català, S. Rives, J. Estella PP-TH-452 OUTCOME AFTER CENTRAL VENOUS LINES RELATED VENOUS THROMBOSIS (CVL- VT) IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A SINGLE CENTRE PROSPECTIVE STUDY P. Saracco* (IT), L. L. Garbarini, N. N. Bertorello, E. E. Barisone, S. S. Longo, L. L. Artesani, L. L. Farinasso PP-TH-453 A RETROSPECTIVE AND PROSPECTIVE SINGLE CENTRE STUDY ON APPLICABILITY OF THE PROPOSED WRAIGE CLASSIFICATION FOR SUBTYPES OF ARTERIAL ISCHEMIC STROKE (AIS) IN CHILDREN P. Saracco* (IT), M. Agostini, A. Tocchet, R. Vittorini, V. Licari, C. Marinaccio, L. Pagana, B. Bobba, B. Bassi PP-TH-454 FACTORS OF EXTRACEREBRAL NON CATHETHER RELATED THROMBOSIS IN CHILDREN P. V. Svirin* (RU), V. V. Vdovin, G. A. Sukchanova, T. G. Plachuta, L. E. Larina, E. A. Shiller, E. A. Yatzenko, A. V. Ageenkova, E. K. Doniusch PP-TH-455 VALIDITY OF PAEDIATRIC THROMBOSIS DIAGNOSES IN A NATIONAL REGISTRY OF PATIENTS R. Tuckuviene* (DK), J. Helgestad, S. P. Johnsen, S. R. Kristensen PP-TH-456 INHERITED THROMBOPHILIA IN CHILDHOOD STROKE: EXPERIENCE OF A TERTIARY CARE CENTER IN LEBANON S. A. Muwakkit* (LB), M. Majdalani, R. Hourani, Z. Otrock, R. Saab, M. Abboud, M. Mikati PP-TH-457 MANAGEMENT OF VENOUS THROMBOEMBOLIC EVENTS IN PEDIATRIC ICU PATIENTS S. J. Hanson* (US), K. A. Lawson, A. Brown, L. M. Christie, B. Totapally, J. McArthur, R. A. Higgerson PP-TH-458 EFFECTIVENESS AND LONG-TERM OUTCOME OF THE USE OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (RT-PA) IN CHILDREN WITH LIFE-THREATENING THROMBOSIS S. J. Russell* (AU), G. D. Williams, J. J. Brereton, A. Numa PP-TH-459 EQUIVALENCY OF TINZAPARIN AND ENOXAPARIN CHILDREN: A SINGLE CENTRE REPORT ON EFFICACY AND SAFETY A. Al-Zahrani* (SA), P. Komwilaisak, L. Brandao, W. H. A. Kahr, A. K. C. Chan, S. Williams PP-TH-460 PROTHROMBOTIC GENETIC RISK FACTORS IN STROKE: A POSSIBLE DIFFERENT ROLE IN PEDIATRIC AND ADULT PATIENTS V. J. Djordjevic* (RS), M. Stankovic, V. Brankovic-Sreckovic, L. Rakicevic, T. Damnjanovic, N. Antonijevic, D. Radojkovic PP-TH-461 LOW MOLECULAR WEIGHT HEPARIN (LMWH) RESPONSE IN CHILDREN V. Ignjatovic* (AU), C. Cuman, R. Summerhayes, F. Newall, P. Monagle PP-TH-462 AGE-RELATED DIFFERENCES IN THE BINDING OF UNFRACTIONATED HEPARIN (UFH) TO PLASMA PROTEINS E. Straka, V. Ignjatovic* (AU), R. Summerhayes, P. Monagle

364 PT-6 HOBPII ETN COMPARATIVE STUDY TESTING- A THROMBOPHILIA PP-TH-465 PP-TH-464 SINUSVENOUSTHROMBOSISINTHESETTINGOF EXTENSIVECEREBRAL PP-TH-463 POSTER PRESENTATIONS PP-TH-476 PP-TH-475 OFPORTABLE AND ACCURACY CONTROL ASSESSMENTOFQUALITY PP-TH-474 COAGULATION ANALYZER TABLETOP OFA STUDY AND ACCURACY PRECISION PP-TH-473 PP-TH-472 VTENURSESPECIALIST LEADS A VTE PREVENTIONPROGRAMIMPLEMENTEDBY A PP-TH-471 ARECITRATED PARTIAL-DRAW POLYMER COLLECTIONTUBES ADEQUATE FOR PP-TH-470 PP-TH-469 SAMPLINGMETHODSFORMICROPARTICLES INSTORED EVALUATION OFOPTIMAL PP-TH-468 ANTI-Xa BY MONITORING OFLOWMOLECULARWEIGHTHEPARIN (LMWH)THERAPY PP-TH-467 RAREVKORC1MUTATIONS IN AFRICAN BRAZILIAN PATIENTS TAKING ORAL PP-TH-466 Health ServiceandOutcomesIII 2009 THURSDAY, JULY 16, MEASURES T HEPARIN (UFH FORMONITORING UNFRACTIONATED ASSAY AUTOMATED ANTI-FACTOR IIA HOSPIT RESULTS FROMTHEFRENCHPHARMACOVIGILANCESURVEY OF ADVERSE EFFECTSWITHFONDAPARINUX TREATMENT: 4-YEARFOLLOW-UP A CHILD HYPERTHYROIDISM IN A ANTICOAGULA ANTICOAGULANTTREATMENT IN COAGULOMETERS FORMONITORING ORAL WITH EXP INAPPROPRIATE VTEPROPHYLAXISINPATIENTS DOESNOTLEADTO AN INCREASEIN NOT AT RISK HOSPITAL REFERRAL TERTIARY IN A SIGNIFICANT IMPROVEMENTOFVENOUSTHROMBOEMBOLISM(VTE) PROPHYLAXIS MARKED AND SUSTAINED IMPROVEMENTIN APPROPRIATETO VTEPROPHYLAXIS A BASIC COAGULA TREATMENT INSWEDEN TIR -RESUL RED BLOODCELLS PERSPECTIVEUSINGHEPARIN SPECIFICSTANDARDS LABORATORY ASSAY. A ANTICOAGULANT THERAPY S. R.Hossain*(UK), M.Madhani,G.Varma, P. K.MacCallum R. Summerhayes*(AU),V. Ignjatovic,F. Newall, P. Monagle D. Prisco,R. R. Paniccia*(IT),D.Poli,E. Antonucci, M.Pagliuca,D.Lami,I.Ricci, A. Alessandrello Liotta, R. Porche-Sorbet*(US),J.Hughes,P. Barnes,G.Cutsforth,K.Whelchel,C.S.Eby R. D.Collins*(AU),H.Gibbs,J.Schluter, L. Tewhatu R. D.Collins*(AU),H.Gibbs,J.Schluter P. A. Toulon* (FR),V. Eschvege,M.Dreyfus, T. Boutekedjiret,V. Proulle P P. Davizon-Castillo*(US),J. A. Lopez, T. R.Watkins P. A. Kotsi*(GR), A. Chanos,I. Anastasopoulou, C. Tsoukala, K.Markakis, A. Karafoulidou F. A. Orsi,K.Weck, E.V. dePaula,J.Evans,M.C.Ozelo, Annichino-Bizzacchi* (BR) L. Mammo, T. Saour, A. Sheereen,J.Saour*(SA) A. Lillo-LeLouet,D.M.Smadja*(FR),C.LeBeller Brandão, S.W V . J.Svensson*(SE),V. Frykman, A. Själander, M.Rosenqvist, L.Wallentin . F. vanEimeren*(CA),L.Billinghurst,E. Yiu, R. Askalan, T. Soman, S.Laughlin,L.R. AL ANDED TESTMENU DISCHARGE TS FROMTHENA Abbate illiams, W MRV AEYOFWARFARINIZED PATIENTS FOLLOWING O IMPROVESAFETY TION CLINIC TION TESTS . H. A. Kahr INLQAIYRGSR FORANTICOAGULATION REGISTRY QUALITY TIONAL , L. T ewhatu 365

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-477 A RETROSPECTIVE REVIEW OF BRIDGING THERAPY IN A COMMUNITY BASED OUT PATIENT ANTICOAGULATION CLINIC S. Beaudoin* (US), S. C. Johnson, M. Mukon, D. Kapur, M. Dhami, D. E. Slater PP-TH-478 EVALUATION OF COMPLIANCE WITH LOW DOSE UNFRACTIONATED HEPARIN FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN MEDICALLY ILL HOSPITALIZED PATIENTS AT AN ACADEMIC MEDICAL CENTER S. H. Bhatt* (US) PP-TH-479 HEMOPHILIA IN UKRAINE:PROBLEMS AND PROSPECTS S. V. Vydyborets* (UA), G. I. Moroz, S. M. Gaydukova PP-TH-480 OUTPATIENT DVT TREATMENT – AN AUDIT OF SAFETY INDICATORS FOR PATIENTS ON ORAL ANTICOAGULANT TREATMENT S. Bacon* (UK), S. Chadwick PP-TH-481 PHARMACOGENETIC RELEVANCE OF CYP4F2 V433M POLYMORPHISM ON ACENOCOUMAROL THERAPY V. Pérez Andreu* (ES), V. Roldan, A. Anton, N. Garcia Barbera, J. Corral, V. Vicente, R. Gonzalez Conejero

Cancer and Thrombosis III

PP-TH-482 A PROSPECTIVE ANALYSIS OF PLASMA TISSUE FACTOR IN PATIENTS WITH OVARIAN TUMORS A. Amirkhosravi* (US), G. Bigsby Iv, E. Coll, H. Desai, M. Amaya, L. Robles, P. Faust, A. Drexler, F. Langer, E. Reyes, J. Francis PP-TH-483 VENOUS THROMBOEMBOLISM DURING THE COURSE OF PANCREATIC CANCER: IMPLICATION OF TISSUE FACTOR A. Delluc* (FR), A. Rousseau, C. Delluc, E. Le Moigne, G. Le Gal, K. Lacut, E. Oger, P. van Dreden, D. Mottier PP-TH-484 METASTASIS PROMOTING EFFECTS OF DIRECT THROMBIN INHIBITORS T. M. H. Niers, G. L. van Sluis* (NL), L. W. Bruggeman, R. D. Liu, H. H. Versteeg, H. R. Buller, C. J. F. van Noorden, P. H. Reitsma, C. A. Spek, D. J. Richel PP-TH-485 CANCER CELLS ACCELERATE IN VITRO THROMBIN GENERATION IN HUMAN PLASMA BUT THEIR EFFECT IS DETERMINED BY THE HISTOLOGICAL TYPE OF THE CANCER G. T. Gerotziafas* (FR), V. Galea, E. Mbemba, A. Khaterchi, F. Couppey, C. Prengel, M. Hatmi, J. Bernaudin, I. Elalamy PP-TH-486 CLINICALLY RELEVANT CONCENTRATIONS OF FONDAPARINUX EFFICIENTLY INHIBIT IN VITRO THROMBIN GENERATION TRIGGERED BY DIFFERENT HISTOLOGICAL TYPES OF CANCER CELLS G. T. Gerotziafas* (FR), V. Galea, E. Mbemba, A. Khaterchi, C. Prengel, M. Hatmi, J. Bernaudin, I. Elalamy PP-TH-487 PROCOAGULANT PHOSPHOLIPIDS IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND CANCER L. Spiezia* (IT), E. Campello, S. Gavasso, V. Rossetto, C. Abalotti, B. Woodhams, P. Simioni PP-TH-488 HYPOFIBRINOLYSIS IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND CANCER L. Spiezia* (IT), E. Campello, S. Gavasso, V. Rossetto, F. Dalla Valle, S. Barbar, B. Woodhams, P. Simioni PP-TH-489 DOSE ESCALATION OF LOW MOLECULAR WEIGHT HEPARIN TO MANAGE RECURRENT VENOUS THROMBOEMBLIC EVENTS DESPITE SYSTEMIC ANTICOAGULATION IN CANCER PATIENTS M. Carrier* (CA), G. Le Gal, R. Cho, S. Tierney, M. A. Rodger, A. Y. Lee 366 PT-9 LACKOFPROPHYLAXISPRIORTO THEONSETOF ACUTE VENOUS PP-TH-492 TUMORCELL-DERIVEDMICROPARTICLES: DOESSIZEMATTER PP-TH-491 POSSIBLEPROGNOSTICMARKEROFBREASTCANCERIN D-DIMER AS A PP-TH-490 POSTER PRESENTATIONS PT-0 ERAE VRL UVVLANDINCREASEDRISK OFTHROMBOSISIN SURVIVAL DECREASED OVERALL PP-TH-503 PP-TH-502 PP-TH-501 PP-TH-500 MICROVESICLESSUGGESTTHEIR PROCOAGULANTPROPERTIESOFMELANOMA PP-TH-499 IN THEINCIDENCEOFVENOUSTHROMBOEMBOLISM AND ITSIMPACT ONSURVIVAL PP-TH-498 STANDARDS, OPTIONS:RECOMMENDATIONS 2008PROPHYLAXIS AND TREATMENT PP-TH-497 VEINTHROMBOSIS–WHAT LIESBENEATH DEEP PP-TH-496 PP-TH-495 PROGNOSTICVALUE OFTHROMBOPATH DETERMINATION FORCHEMOTHERAPY- PP-TH-494 FORDIAGNOSISOF MAGNETICRESONANCEIMAGING:ISITUSEFUL PP-TH-493 HRDY UY1,2009 THURSDAY, JULY 16, CHILDREN WITH CANCER SIGNALING INBREASTCANCERPROGRESSION THE ROLEOFTISSUEFACTOR-FACTOR VIIa-PROTEASE ACTIVATED RECEPTOR 2 PROTEASOME INHIBITION AND APOPTOSIS INCANCERCELLS THROMBOEMBOLISM AMONG HOSPITALIZED CANCERPATIENTS RECEPTOR NEGATIVE PATIENTS HORMONAL HAEMOST HAEMOST INVOLVEMENT INCANCER-ASSOCIATED THROMBOSIS P OF CENTRAL KUNITZ TYPEINHIBIT ASSOCIATED VENOUSTHROMBOEMBOLISM LYMPHOBLASTIC LEUKAEMIA THROMBOEMBOLICEVENTSINCHILDREN WITH ACUTE ASYMPTOMATIC CEREBRAL CHRONIC MYELOIDLEUKAEMIA U. Athale* (CA),S.Siciliano,J.Cheng,L. Thabane, A. K.C.Chan T. McEachron*(US),F. Church,N.Mackman S. O. S. O. Abegunde* (NG), A. A. Famodu,O. A. Awodu, I.O. Ajayi, F. A. Ojeokun R. Q.Monteiro*(BR),Chammas,C.P R. K.Sandhu*(US),H.White, T. Wun, H.K.Chew Elalamy P. Debourdeau*(FR),D.Kassab Chahmi,E.Desruennes,M.Douard,I.Kriegel, A. Elias,I. P. Braude*(UK),B.Prathibha M. Chudzinski-T P G. Pera, P. Ferroni*(IT),F. Martini,I.Portarena,Grenga,S.Riondino, A. Spila,R.D’Alessandro,M. Arcamone, N.Santoro,D.deMattia P. Giordano*(IT),M.Grassi,V. Cecinati,G.C.DelVecchio, F. Dicuonzo,M.Palma,G. Bounameaux N. Kucher*(CH),D.Spirk,C.Kalka,L.Mazzolai,Nobel,M.Banyai,B.Frauchiger, H. M. Davila*(US), Gomes, L.M.S.Dusse, M. G.Carvalho*(BR), ACUTE LYMPHOBLASTIC LEUKAEMIA . L.De-Sá-Júnior*(BR),E.M.Reis,S. A. Barreto,E.M. Akagi, S.M.Simons,Demasi, A. A TIENTS WITHBLADDERCANCER Abegunde* (NG), , G.Legal,M.Pavic,Scroboachi,I.Quere,D.FargeBancel A. Laudisi,M.Roselli,F A A I N AMRELGCLCHANGESIN AFRICAN PATIENTS WITH TIC AND HAEMORHEOLOGICAL TIC VENOUS CA avassi AND HAEMORHEOLOGICAL A. Amirkhosravi, C.H.Baker, J.Colon,Francis A. P. Fernandes,C.P. Figueiredo,E.C.Bueno,M. A. Ribeiro,K.B. OR (RKTI)INDUCESCHANGESINGENEEXPRESSION, A. A. Famodu,O. A. Awodu, I.O. Ajayi, F. A. Ojeokun A. P THETER THROMBOSISINCANCERP . B.Batschauer AND CENTRAL . Guadagni . V icente, M. VENOUS LINE(CVL) DYSFUNCTION CHANGES IN A. Barcinski,L.G.Lima AFRICAN PATIENTS WITH ATIENTS 367

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-504 LOW INCIDENCE OF THROMBOEMBOLISM IN KOREAN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH THALIDOMIDE Y. Koh* (KR), S. Bang, J. Lee, H. Yoon, Y. Do, H. Ryoo, N. Lee, S. Kim, K. Kim, H. Kim, S. Yoon, J. Won, Y. Mun, M. Lee, K. Rhee, H. Eom, M. Kim, H. Shin

Venous Thrombosis: Diagnosis III

PP-TH-505 DIAGNOSTIC PERFORMANCE OF THE VIDAS D-DIMER IN A PROSPECTIVE STUDY OF INPATIENTS AND EMERGENCY PATIENTS EVALUATED FOR PULMONARY EMBOLISM WITH ANALYSIS OF PERCENT OBSTRUCTION D. M. Courtney* (US), N. T. Klekowski, C. D. Miller, H. A. Smithline, M. M. Hogg, J. A. Kline PP-TH-506 THROMBOPHILIC RISK FACTORS IN PATIENTS UNDERGOING MAJOR ABDOMINAL SURGERY AND THEIR RELEVANCE TO DEEP VENOUS THROMBOSIS E. A. A. Khaled* (EG), F. M. Essawy, E. M. Esmat, N. A. Hussein, S. E. Sabaie, A. S. Hassanien, N. E. Mikhail PP-TH-507 AGREEMENT OF PERFUSION SCINTIGRAPHY AND CT-ANGIOGRAPHY IN DETECTING RESIDUAL THROMBOEMBOLI AFTER PULMONARY EMBOLISM F. Dentali* (IT), M. Donadini, B. Cosmi, S. Bozzato, A. Squizzato, C. Neri, W. Ageno PP-TH-508 DIAGNOSIS OF DEEP VEIN THROMBOSIS BY COMPRESSION ULTRASONOGRAPHY DURING PREGNANCY AND THE POSTPARTUM PERIOD: A MANAGEMENT OUTCOME STUDY G. Le Gal* (FR), M. Righini, G. Kercret, L. Bressollette, P. Louis, C. Bohec, M. Labalette, D. Mottier, ANGIO-GETBO Group PP-TH-509 EVALUATION OF THE INNOVANCE® D-DIMER ASSAY ON THE SYSMEX® CA-7000 SYSTEM S. Park, H. Chi* (KR), S. Chun, S. Jang, C. Park PP-TH-510 PROSPECTIVE AUDIT OF THE MEDICAL DOCUMENTATION AND OUTCOMES OF PATIENTS EVALUATED WITH THE PULMONARY EMBOLISM RULE-OUT CRITERIA J. A. Kline* (US), C. Peterson, M. T. Steuerwald PP-TH-511 RESULTS OF A MULTICENTER, CROSS-SECTIONAL VENOUS THROMBOSIS SCREENING STUDY IN IZMIR M. Karacelik* (TR), E. Kara, I. Erdinc, A. B. Ozelci, C. S. Atalay, E. O∂uz, M. Sen, G. Albayrak, S. T. Kutlu, E. Bahtiyar, C. Sert, A. Gurbuz, T. Calkavur, Karabay PP-TH-512 ROLE OF CONGENITAL THROMBOPHILIC CONDITIONS IN THE DEVELOPMENT OF THROMBUS FLOTATION N. A. Vorobyeva* (RU), M. G. Anisimov PP-TH-513 LEVEL OF D-DIMER AND DURATION OF SYMPTOMS OF VENOUS THROMBOEMBOLISM N. M. Vorobyeva* (RU), E. P. Panchenko, A. B. Dobrovolsky, E. V. Titaeva, A. I. Kirienko PP-TH-514 FATAL PULMONARY EMBOLISM IN YOUNG PEOPLE: RISK FACTORS AND CLINICAL PRESENTATION O. V. Fesenko* (RU), A. V. Glechikov PP-TH-515 VALIDATION OF 9 DIFFERENT PROTEIN S ASSAYS IN A FAMILY COHORT WITH A PROS1 MUTATION R. Mulder* (NL), M. K. ten Kate, A. B. Mulder, H. C. Kluin-Nelemans, J. van der Meer PP-TH-516 CALIBRATED AUTOMATED THROMBOGRAPHY IN THE PRESENCE AND ABSENCE OF THROMBOMODULIN TO ASSESS THE PROTHROMBOTIC STATE R. Mulder* (NL), M. K. ten Kate, H. M. H. Spronk, R. van Oerle, H. ten Cate, A. B. Mulder, H. C. Kluin-Nelemans, J. van der Meer

368 PT-1 TLT FDDMRASYFRDANSN UMNR EMBOLISM:SINGLE FORDIAGNOSINGPULMONARY OFD-DIMER ASSAY UTILITY PP-TH-519 OF UTILITY AGE-ADJUSTEDD-DIMERCUT-OFF LEVELSINCREASETHECLINICAL PP-TH-518 COMPARISON OF4- AND 64-SLICECTSCANNINGINTHEDIAGNOSISOF PP-TH-517 POSTER PRESENTATIONS PP-TH-530 NEWRFVIII(N8)WITH VWF AND LRP THEINTERACTIONSOF A PP-TH-529 PP-TH-528 PP-TH-527 ELEVATED LEVELSOFSOLUBLEFIBRININPATIENTS WITHVENOUS PP-TH-526 PP-TH-525 PP-TH-524 RETROSPECTIVEEVALUATION AS OF AN IMMUNOTURBIDOMETRIC D-DIMER ASSAY PP-TH-523 PP-TH-522 VENOUSTHROMBOSIS(DVT)INTHEICU D-DIMERTESTFORDIAGNOSISOFDEEP PP-TH-521 NEW AUTOMATED CHEMILUMINESCENTD-DIMERIMMUNOASSAY: AND ANALYTICAL PP-TH-520 Hemophilia III 2009 THURSDAY, JULY 16, HAEMOPHILIA TWENTY SCREENELISA FVIII ANTIBODY COMMERCIAL USE OF A INSTITUTE STUDY RULING OUTPULMONAR EMBOLISM PULMONARY COAGULOP VENOUS THROMBOEMBOLICCOMPLICATIONS INPATIENTS WITHSEVERE THROMBOEMBOLISM ALERT18-SAFER ANTICOAGULATION SAFETY VTEPATIENTS, PATIENT PATICULAR REFERENCETO NATIONAL OUTCOME OF205 SCORE SCORE AND WELLS EMBOLISM:REVISEDGENEVA SUSPECTED PULMONARY INTEROBSER STAND-ALONE TESTTO EXCLUDEVENOUSTHROMBOEMBOLISM A DEVELOPMENT OF PERFORMANCEINPATIENTS SUSPECTED OFVTE CLINICAL J. Blatny*(CZ),O. Zapletal, V. Komrska I. Hilden*(DK),E.Persson A. F. Riddell*(UK),S.Brooks, T. Yee S. M.Siragusa A. Malato*(IT), A. Tagliaferri, P. Redossi,P. Solimeno,G.Saccullo,L.LoCoco, Tagariello, Y. Abe, N.Ito,K.Onishi,Nakatani, A. Uchida,K.Suzuki, M.Ito,N.Katayama, T. Nobori T. Matsumoto* (JP),H.Wada, A. Tsuji, S.Ota,N. Yamada, T. Sugiyama,K.Ohishi, A. Sudo, S. B.Bacon*(UK),Chadwick Righini, D. S. Dambrine*(FR),F. Verschuren, G.LeGal,J.Callahan,N.Delvau,C.Coroller-Bec,M. S. M.Bates*(CA),Johnston,E. S. M.Bates*(CA),Johnston,E. Ali, J.S.Ginsberg R. Moroi*(JP), A. Yaguchi, M. Takeda, M. Abe, T. Harada, T. Yamaki de Moerloose,G.Reber R. G.Barry*(US),J.F. Guasch,Z.Pascual,J.Serra,K. A. Morin,J. Arnout, M.Vanrusselt, P. R. Park*(KR), Y. Seo,S. Yoon, J.Shin, T. Choi,S.Lee,Uh, Y. Kim A. Kruip,H.Bounameaux,R.Büller, P. M.Roy R. A. Douma*(NL),G.LeGal,M.Söhne,Righini,P. W. Kamphuisen, A. Perrier, M.J.H. Lely R. A. Douma*(NL),H.M. A. Hofstee,C.Schaefer-Prokop,J.H. T. M.vanWaesberghe, R. , P . W. Kamphuisen,V. E. A. Gerdes,M.H.Kramer, H.R.Büller YEARS OFIMPROVEMENTINTHE TREATMENT OFCHILDRENWITH Aujesky A THY VER REPRODUCIBILITY IN THECZECHREPUBLIC , O.Sanchez, UNDERGOING MAJORSURGER A CLINICAL MOIMI LEL PATIENTS EMBOLISMINELDERLY Y A. Perrier, F. Thys, P. Roy U-ON O NEW AUTOMATED D-DIMER CUT-POINT FOR A Ali, J.S.Ginsberg OF CLINICAL Y PROBABILITY ASSESSMENT IN 369

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-531 DOSING AND SAFETY OF ANTITHROMBIN CONCENTRATE IN PEDIATRIC PATIENTS WHO REQUIRE HEPARIN ANTICOAGULATION M. E. Bauman* (CA), K. L. Black, A. Bruce, S. Kuhle, L. Bajzar, M. P. Massicotte PP-TH-532 SPONTANEOUS CERVICAL EPIDURAL HAEMATOMA IN HAEMOPHILIA: AN IMPORTANT DIFFERENTIAL DIAGNOSIS OF UNSPECIFIC BACK PAIN M. S. Pereira* (BR), G. C. Duarte, E. V. de Paula, F. A. Orsi, M. C. Ozelo, J. M. Annichino- Bizzachi PP-TH-533 MAGNETIC RESONANCE IMAGING (MRI) IDENTIFIES EARLIEST JOINT DAMAGE IN CLINICALLY ASYMPTOMATIC PATIENTS WITH HEMOPHILIA A, HEMOPHILIA B AND VON WILLEBRAND DISEASE DESPITE PROPHYLAXIS M. Olivieri* (DE), C. Bidlingmaier, K. Kurnik PP-TH-534 THE IMPACT OF INHIBITORS ON THE COST OF CLOTTING FACTOR REPLACEMENT THERAPY IN HEMOPHILIA A IN SOUTH OF IRAN M. Karimi* (IR), A. Ahmadkia Daliri, K. Pourmohammadi, P. Bastani PP-TH-535 QUALITY OF LIFE IN HEMOPHILIA COMPLICATED BY INHIBITORS M. Karimi* (IR), K. Pourmohamadi, P. Bastani PP-TH-536 ENHANCEMENT OF HAEMOSTATIC EFFICACY OF PLASMA-DERIVED FVIII BY FORMULATION WITH PEGYLATED LIPOSOMES M. Baru* (IL), I. Dayan, M. Robinson PP-TH-537 TRANSIENT ELASTOGRAPHY DISCLOSES IDENTICAL DISTRIBUTION OF LIVER FIBROSIS IN HAEMOPHILIACS WITH HCV-MONO- AND HCV/HIV-COINFECTION N. Vidovic* (DE), R. Lochowski, F. Grünhage, G. Goldmann, B. Niemann, S. Horneff, J. Schröder, U. Spengler, T. Sauerbruch, J. Oldenburg PP-TH-538 BONE MINERAL DENSITY IN CHILDREN WITH SEVERE HAEMOPHILIA RECEIVING REGULAR FVIII PROPHYLAXIS N. B. Heaney, A. Gibson, S. Khanna, F. Ahmed, E. Chalmers* (UK) PP-TH-539 ECONOMIC ASSESSMENT OF HOME TREATMENT VERSUS HOSPITAL TREATMENT WITH APCC IN INHIBITOR PATIENTS P. A. Holme* (NO), K. Nyhus, J. Sverre, G. Tjønnfjord PP-TH-540 DETECTION OF F8 MUTATIONS BY HIGH RESOLUTION MELTING (HRM) ANALYSIS P. A. Bignell* (UK), D. Keeling, P. Giangrande PP-TH-541 DETECTION OF DUPLICATIONS AND DELETIONS WITHIN THE FACTOR VIII GENE BY MPLA P. A. Bignell* (UK), D. Keeling, P. Giangrande PP-TH-542 INTRAMURAL URETERAL HEMORRHAGE ASSOCIATED WITH CONTRALATERAL ILIOPSOAS HEMATOMA IN A PATIENT WITH HEMOPHILIA A WITH INHIBITOR: CASE REPORT P. R. Villaca* (BR), C. L. Dinardo, L. F. Botelho, E. P. N. Sandoval, P. L. Junqueira, E. Okazaki, A. K. Zeinad, C. S. S. S. Silva, T. R. F. Rocha, D. A. F. Chamone, E. A. D’ Amico PP-TH-543 HEAMOPHILIA EPIDEMIOLOGY ASSESSMENT IN CENTRAL AND EAST EUROPEAN COUNTRIES PROVIDED BY ONLINE CLINICAL REGISTRY P. Brabec* (CZ), P. Salaj, T. Pavlík PP-TH-544 PHENOTYPE-GENOTYPE CORRELATION IN MILD HEMOPHILIA A P. Casaña* (ES), N. Cabrera, A. R. Cid, S. Haya, A. Moret, L. Abad-Franch, J. A. Aznar PP-TH-545 CURRENT PRACTICE IN MANAGEMENT OF MUSCLE HAEMATOMA IN PATIENTS WITH SEVERE HAEMOPHILIA R. Beyer* (DK), J. Ingerslev, B. Sørensen

370 PT-4 SESETO HOBNGNRTO NML AMPII WITHFACTOR A ASSESSMENTOFTHROMBINGENERATION INMILDHAEMOPHILIA PP-TH-549 PP-TH-548 PP-TH-547 ISCHEMICHEARTDISEASEINHAEMOPHILIACPATIENTS PP-TH-546 POSTER PRESENTATIONS PP-TH-560 PATIENTS – HAEMOPHILIA-SPECIFIC AQUA-TRAINING FOR HAEMOPHILIA A PP-TH-559 PATIENTS HAEMOPHILIA OFLIFEINELDERLY HEALTH-RELATED QUALITY PP-TH-558 HEMOPHILICPATIENT UNDERGOINGHIP LOW-DOSE THROMBOPROPHYLAXISIN A PP-TH-557 BRAZILIANPATIENT ABERRANTDIAGNOSTICPATTERN WITHSEVERE IN A PP-TH-556 AND FACTOR VIIIGENE MUTATIONS A INPATIENTS WITHSEVEREHEMOPHILIA PP-TH-555 AND BRAZILIAN PROGRAMOFHAEMOPHILIA SCREENINGLABORATORY PP-TH-554 PP-TH-553 PP-TH-552 PATIENT WITHMODERATE RESULTS IN A DIFFERENTONESTAGE FVIII ACTIVITY PP-TH-551 TUMORWITHPARANEOPLASTIC PULMONARY GERMCELL MALIGNANTGONADAL PP-TH-550 HRDY UY1,2009 THURSDAY, JULY 16, DEVELOPING COUNTRY EDUCATION ONPATIENTSIMPACT AND FAMILIES OFHAEMOPHILIA IN A (WAT-QOL) OFLIFESTUDY RESULTS OFTHEWATERCISE -QUALITY EOHLAAPATIENTS A HEMOPHILIA DELETION INF8 DISCREPANCY VIII ASSAY OPPORTUNITY HEMOPHILIAS WITHOUTROUTINETREATMENT AND DISCUSSIONFORCURE EVOLUTIONINCHINESECHILDREN JOINT BLEEDING AND ARTHROPATHY A PATIENT WITHHAEMOPHILIA LUPUS ANTICOAGULANT IN A SURGER HEMOPHILIA INHIBITORS FROMVENEZUELA INHIBITORS DETECTION OF101NOVEL URINAR DEPENDINGONTHETYPEOF APTT REAGENTUSED A HAEMOPHILIA A PATIENT WITH SEVEREHEMOPHILIA EMBOLISM IN A T. Zafar*(PK) S. vonMackensen*(DE), A. Wieloch,D.Zäch,B.Eifrig,J.Kalnins, W. Zeller T S. vonMackensen*(DE), A. Gringeri,S.Siboni,M.Ferretti,F. Tradati, M. Franchini, A. Ljatifi, D.Dukovski,L.Cevreska S. Stankovic*(MK), A. Stojanovic, T. Smilevska,Z.Stojanovski, T. Sotirova,S. Trajkova, A. C. Mühle,S.F. Pio,D.Zouain,G.Correa,S.M.Rezende*(BR) S. Albanez* (VE),N.deBosch, A. Boadas, A. Sáez, A. Porco S. S. Ravanbod*(IR),G.Rastegarlari,M.Rassoulzadegan,F. Ala, S.Enayat S. Cheng*(TW),C. S. V S. Struve*(DE),M.Griesshammer Jenkins R. M.Gilmore*(IE),S.Harmon,C.Gannon,Byrne,B.White,J.O’Donnell,P. V. R. Wu* (CN),N.Zhang,L. Zhao,X.Wu R. Santoro*(IT),S.Prejanò,P R. Santoro*(IT),S.Prejanò,P. Iannaccaro,G.Muleo THERAPY WITHOUT INHIBITOR DURING ACUTE JOINTBLEEDING, AND STATE OFFACTOR agliaferri, E.Santagostino,P. Mannucci A. L.Montalvão*(BR),E.V. dePaula,S. Thomas, J.M. Annichino-Bizzacchi, M.C.Ozelo . Brooks*(UK),S. Y Y XRTO F8IOPF NHMPII PATIENTS WITHOR A EXCRETION OF8-ISO-PGF2INHEMOPHILIA A XLIAL YANINT1H-RELATED INVERSION COMBINEDWITH A EXPLAINABLE BY Yc Aghighi, K.Gomez,G.Mellars,M.Mathias . Iannaccaro,G.Muleo MUT A TIONS INTHEF ACT OR 8GENEOFIRANIANS 371

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-561 PROLONGED HALF-LIFE OF RECOMBINANT FACTOR VIIa FUSION PROTEIN - SINGLE DOSE STUDY IN RABBITS U. Kronthaler* (DE), S. Schmidbauer, U. Liebing, W. Lang, H. J. Metzner, T. Weimer, S. Schulte PP-TH-562 PREVALENCE OF THE FACTOR VIII GENE INTRON 1 INVERSION IN CHINESE HAEMOPHILIAC AND ITS APPLICATION TO THE CARRIER DETECTION AND PRENATAL DIAGNOSIS Y. Lu* (CN), X. Wang, Q. Ding, J. Dai, X. Xi, H. Wang PP-TH-563 HAEMOPHILIA A IN A FEMALE WITH DE NOVEL INV22 AND SKEWED X- CHROMOSOME INACTIVATION Y. Lu* (CN), X. Wang, J. Dai, Q. Ding, X. Xi, H. Wang PP-TH-564 COMBINED HAEMOPHILIA A AND B IN A PEDIGREE WITH MOSAICISM OF THE F9 GENE MUTATION IN HB INDEX’S MATERNAL GRANDFATHER Y. Lu* (CN), X. Wang, Q. Ding, J. Dai, X. Xi, B. Xie, M. Wang, H. Wang PP-TH-565 HAEMOPHILIA A IN A FEMALE WITH INV 1 AND SKEWED X-CHROMOSOME INACTIVATION Y. Lu* (CN), X. Wang, Q. Ding, J. Dai, X. Xi, H. Wang

Hemophilia Therapy III

PP-TH-566 VISUALISING THE COAGULATION PROCESS AND HEMOPHILIA IN 3D, A UNIQUE AND VALUABLE EDUCATIONAL TOOL FOR PATIENTS AND HEALTH CARE PROFESSIONALS C. Hermans, C. Lambert* (BE) PP-TH-567 EFFECTS OF RFVIIa ANALOGUE (NN1731) ON PLATELET FUNCTION, CLOT STRUCTURE AND CLOT KINETICS IN WHOLE BLOOD FROM PATIENTS WITH HEMOPHILIA A D. F. Brophy* (US), E. J. Martin, M. E. Nolte, J. G. Kuhn, M. Ezban PP-TH-568 NO EVIDENCE FOR NEONATIGENS FORMATION IN DIFFERENTS BATCHES OF A DOUBLE-VIRUS INACTIVATED FACTOR VIII CONCENTRATE MANUFACTURED IN ARGENTINA H. A. Guglielmone* (AR), F. Farias, C. Moya, D. Navarro, M. Vitali PP-TH-569 UPDATE OF A LONG-TERM PHARMACOVIGILANCE SURVEILLANCE: REC. FVIII FOR THE TREATMENT OF HEMOPHILIA A J. Oldenburg* (DE), P. Petrini, A. Tagliaferri, A. Faradji, E. Zanon, I. Pabinger, M. Broder, C. Zacharias, H. Lenk PP-TH-570 THE NUMBER OF FACTOR VIII DOSAGE STRENGTHS OFFERED IS ASSOCIATED WITH THE NUMBER OF VIALS NEEDED TO TREAT HEMOPHILIA J. D. Epstein* (US), M. P. Luo PP-TH-571 RETROSPECTIVE ANALYSIS OF FACTOR VIII UTILIZATION IN MATCHED HEMOPHILIA A PATIENTS TREATED WITH EITHER FULL-LENGTH OR B DOMAIN-DELETED RECOMBINANT FACTOR VIII J. D. Epstein* (US), J. M. Li-McLeod PP-TH-572 IMPACT OF FVIII PRODUCT CHANGE IN SEVERE HAEMOPHILIA A PATIENTS PREVIOUSLY TREATED WITH PLASMA-DERIVED FVIII M. E. Mingot* (ES), A. I. Heiniger, M. García, J. A. Fernández PP-TH-573 INFLUENCE OF RECOMBINANT ACTIVATED FVII ON CLOT STABILITY: A THROMBOELASTOGRAPHIC STUDY IN NORMAL AND HAEMOPHILIC BLOOD M. Colucci* (IT), R. Galasso, C. Carrieri, R. Marino, F. A. Scaraggi, N. Semeraro

372 PT-7 OTATOIAINSFT SURVEILLANCE (PASS) PROGRAMOF POST-AUTHORIZATION SAFETY PP-TH-576 PP-TH-575 ACTIVATION AND COMPLEMENT ACTIVATION MARKERSOFBLOODCELL INFACTOR PP-TH-574 POSTER PRESENTATIONS PT-8 OE IPA OFPATIENT TREATMENT DISPLAY RECORDS AND ASSOCIATED BLEEDING NOVEL A PP-TH-586 IMPACT OFFACTOR VIIIHALFLIFEONPROPHYLACTIC DOSINGINCHILDREN AND PP-TH-585 PP-TH-584 PP-TH-583 POOR PATIENTS WITHINHIBITORS AND A A TREATMENT OFHAEMOPHILIA PP-TH-582 INDICATORS FOR ASSESSING EFFECTIVENESSOFTHESTATE PROGRAMONDRUG PP-TH-581 ONLONG-TERMPROPHYLAXIS ARE AS PATIENTS WITHSEVEREHAMOPHILIA PP-TH-580 PP-TH-579 ASPECTSINTHEMANAGEMENTOF ACUTE HAEMARTHROSISINHAEMOPHILIA: KEY PP-TH-578 OFLONG ACTING RFVIIa(40K FORMULATION DESIGN AND STABILITY PP-TH-577 HRDY UY1,2009 THURSDAY, JULY 16, PATTERNS FORPROPHYLAXIS REGIMENS A ADULTS WITHSEVEREHAEMOPHILIA HEMOPHILIA RH-F)FRJPNS EOHLAAPATIENTS A (RAHF-PFM) FORJAPANESE HEMOPHILIA ANTIHEMOPHILIC FACTOR (RECOMBINANT),PLASMA/ALBUMIN-FREEMETHOD PRACTICE:RESULTS OFTHEFIRST YEAR CLINICAL OFRECOMBINANTFACTOR IXINDAILY ANDEFFICACY EVALUATION OFSAFETY VIII ORVWFCONCENTRATES EFFICACY OR WILLEBRANDDISEASE MANAGEMENT OFCORONAR PROGNOSIS: ITIWITHOCT SUPPL SWEDISHPOPULATION ACTIVE AS THEGENERAL PHYSICALLY INTRA RECOMBINANT LONG ACTING FACTOR IX(40KPEG-RFIX)PRODUCT AFTER PHARMACOKINETIC (PK) EUROPEANSURVEY A GLYCOPEGYLATED FACTOR VIIa FORMULA P. Schroth* (US), L.Huang,W. Knowlton, S.Fritsch Casey, G.Spotts,B.Ewenstein P. W. Collins*(UK),K. Fischer, V. Blanchette,S. Björkman,M.Oh,P. Schroth,S. Fritsch,K. P Goudemand N. Trillot* (FR),F. Mouquet,B.Wibaut,O.Equine,Jude,E.vanBelle,S.Susen, J. N. I.Zozulya*(RU) I. Zozulya*(RU) P. A. Vorobyev, O.V. Borisenko,U. A. Zhulev, E. A. Telnova, A. A. Tonoyan, V. U.Zorenko, N. M. Khawaji*(SE),E.Berntorp Merricks, H.G.Franck,R. A. Raymer, T. C.Nichols M. Ezban*(DK),B.Hermit,P Lavigne-Lissalde, R.Perez,G.Dolan,C.Hermans M. Richards*(UK),P. deMoerloose,K.Fischer, K.Holstein,R.Klamroth, T. Lambert,G. M. B.Jensen*(DK),L.Kragelund Pass Study M. Taki* (JP),K.Fukutake,H.Hanabusa,J. Takamatsu, M.Shima, A. Shirahata,G. Advate Severin, A. Huth-Kuehne,J.Oldenburg M. W M. Brodde*(DE),B.E.Kehrel . Collins*(UK), A. Faradji,M.Morfini,MaasEnriquez,L.Schwartz estfeld* (DE),H.Pollmann,C.Niekrens,Laws,M.Girisch,S.Halimeh,Ries,K. EOS(V DIITAINT EOHLABDOGS VENOUS (IV) ADMINISTRATION TO HEMOPHILIA O AINSWT EEIAYCOAGULOPATHIES: FORPATIENTS WITHHEREDITARY Y TED RECOMBINANTF OF SECONDAR WITH AND WITHOUTTARGET JOINTS A N HRAOYAI P)POETE FANEW AND PHARMACODYNAMIC(PD)PROPERTIESOF A Y ANA PROPHYLACTIC VERSUSON-DEMANDSUCROSE- . K.Holm,L.Hansen,H.Østergaard,M. Y TE ARTER ACTOR VIIITREATMENT IN ADULTS WITHSEVERE ® Y DISEASES INP A TIENTS WITHHAEMOPHILIA T ranholm, E.P . 373

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-587 PLASMA DERIVED FACTOR VIII IN THE TREATMENT OF PATIENTS WITH HEMOPHILIA A: UPDATE OF A LONG-TERM PHARMACOVIGILANCE R. Klamroth* (DE), R. Zimmermann, B. Schütz, C. Zacharias, M. Broder, K. Kurnik PP-TH-588 STRUMECTOMY IN A PATIENT WITH HEMOPHILIA B USING A REASONABLE AMOUNT OF RECOMBINANT FACTOR IX FOR REPLACEMENT THERAPY S. Gottstein, K. Unger, R. Klamroth* (DE) PP-TH-589 PHARMACOKINETIC PROPERTIES OF A HIGH PURITY PLASMA-DERIVED FIX CONCENTRATE IN HAEMOPHILIA B ADULTS AND CHILDREN – AN OVERVIEW OF CLINICAL DATA R. Kuhelj* (CH), M. Jansen, J. Feddern PP-TH-590 TRANSCATHETER ARTERIAL EMBOLIZATION OF CONCURRENT SPONTANEOUS HEMATOMAS OF THE RECTUS AND OBLIQUE LEFT ABDOMINAL MUSCLES IN A MODERATE HAEMOPHILIA B PATIENT R. R. M. Musso* (IT), D. Cultrera, A. Basile, M. Musso, A. Cipolla PP-TH-591 LC-ESI-MS/MS ANALYSIS OF Y1680 SULFONATION IN RECOMBINANT FVIII CONCENTRATES S. Grancha* (ES), R. Navajas, A. Nardi, A. Paradela, J. P. Albar, J. I. Jorquera PP-TH-592 THE JAPANESE GUIDELINE FOR THE PRACTICAL REPLACEMENT THERAPY FOR ACUTE BLEEDING AND SURGICAL PROPHYLAXIS IN HEMOPHILIA WITHOUT INHIBITORS T. Matsushita* (JP), K. Amano, M. Taki, T. Oka, M. Sakai, A. Shirahata, N. Takata, J. Takamatsu, H. Takedani, H. Hanabusa, A. Higasa, K. Fukutake, T. Fujii, I. Tanaka, J. Mimaya, A. Yoshioka, M. Shima PP-TH-593 SECONDARY PROPHYLAXIS WITH ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES (APCC) REDUCES BLEEDING FREQUENCY IN HAEMOPHILIA A PATIENTS WITH INHIBITORS T. Lambert* (FR), C. Rothschild, J. Goudemand, C. Négrier, S. Girault, P. Moreau, M. Trossaërt PP-TH-594 EFFICACY OF A NEW RECOMBINANT FVIII (N8) IN A TAIL BLEEDING MODEL IN HEMOPHILIA A MICE T. Elm* (DK), M. Kjalke, H. Pelzer, M. Tranholm PP-TH-595 AVAILABILITY OF PERIPHERAL INSERTED CENTRAL CATHETERS IN SEVERE HEMOPHILIA PATIENTS Y. Park* (KR), J. Park

Inhibitors: Pathogenesis, Prevention and Treatment III

PP-TH-596 HOW CAN THE RIGHT FVIII DOSAGE TO NEUTRALISE LOW TITRE INHIBITOR BE CALCULATED C. Altisent* (ES), A. Cid, V. Jiménez, M. López, E. Mingot, R. Nuñez, M. Paloma, M. Prieto, C. Sedano, I. Soto PP-TH-597 SUCCESSFUL TOLERIZATION WITH HIGH VON WILLEBRAND FACTOR / FACTOR VIII CONTENT RATIO CONCENTRATE OF CHILDREN WITH SEVERE HAEMOPHILIA A AND HIGH RESPONDING INHIBITOR H. Platokouki* (GR), H. Pergantou, P. Xafaki, A. Komitopoulou, S. Aronis PP-TH-598 IMMUNE TOLERANCE INDUCTION IN CONGENITAL HEMOPHILIA A WITH HIGH TITRE INHIBITOR - CASE REPORT J. Stasko* (SK), I. Plamenová, P. Holly’, P. Kubisz

374 PT-0 OIGADEFCIEESO EOBNN VI RVI)I UGCLAND DOSING AND EFFECTIVENESSOFRECOMBINANT FVIIa(RFVIIa)INSURGICAL PP-TH-601 PP-TH-600 USINGPLASMA-DERIVED A IMMUNE-TOLERANCE INHAEMOPHILIA CASESTUDY PP-TH-599 POSTER PRESENTATIONS PT-1 NEWINSIGHTSINTO THEROLEOFHEMOSTATIC COMPONENTS(FEIBA® PP-TH-611 PP-TH-610 WITHRFVIIa AND ACTIVATED PROTHROMBINCOMPLEX THERAPY SEQUENTIAL PP-TH-609 PP-TH-608 PP-TH-607 PP-TH-606 SINGLECENTRE DERIVEDFVIIIFORIMMUNETOLERANCE: A USEOFPLASMA PP-TH-605 FORMONITORING (ROTEM®)UTILITY ROTATIONAL THROMBELASTOGRAPHY PP-TH-604 FORMONITORING (ROTEM®)UTILITY ROTATIONAL THROMBELASTOGRAPHY PP-TH-603 TO DATA (HTRS) REGISTRY ANDTHROMBOSISRESEARCHSOCIETY HEMOPHILIA PP-TH-602 HRDY UY1,2009 THURSDAY, JULY 16, INHIBITORS FOCUSINGONCOSTOUTLIERS RETROSPECTIVECLAIMSDATABASE PATIENTS WITH ANALYSISA OFHAEMOPHILIA Karafoulidou EITY(2004-2008) REGISTRY (HTRS) ANDTHROMBOSISRESEARCHSOCIETY EXPERIENCE OFTHEHEMOPHILIA WITHINHIBITORS: THE HEMOPHILIA PROCEDURESINCONGENITAL DENTAL PATIENTS WITHINHIBITORS EPISODES INHEMOPHILIA ECONOMIC COMPARISON OF APCC VSRFVIIaFORMILD-TO-MODERATE BLEEDING FACTOR VIIICONCENTRATE THREA BPATIENT WITHINHIBITOR CONCENTRATESAND LIFE (APCCS)INHAEMOPHILIA RADIOISOT TREA PATIENT WITHINHIBITORS HEMOPHILIA HEMORRHAGEIN A INTRACRANIAL RECOMBINANT ACTIVATED FACTOR VIIPROPHYLACTICTREATMENT FOR EXPERIENCE (NOVOSEVEN P ANDFACTOR VIIIINHIBITORSPATIENTS TREATED WITHFEIBA® WITHHAEMOPHILIA HEMOPHILIA OUTCOMESFORTHETREATMENT OFSPECIFICJOINTBLEEDSIN CLINICAL UNDERSTAND DIFFERENCESINRECOMBINANTFACTOR VIIa(RFVIIa)DOSING AND K. Varadi, P. Montsch,B.Keil,P. L. Turecek* (AT), H.J.Ehrlich,P. Schwarz P. O.Bonnet*(US) O. Katsarou*(GR), N. Mesli,S.BereksiReguig,Mesli*(DZ),H.Hemche,Bezzou,K. M. A. Cermelj*(AR),S.Ouviña, A. Guzmán,O. Torres, A. Ferro S. Formisano, M. Martinez*(AR), A. Costa, R.Fernandez,V. Schuttenberg,L. Alba, F. Cuello,M. Aznar, M. C.Mathias*(UK),R.Liesner Muñoz, V. Jimenez-Yuste, F. Hernandez-Navarro M. Garcia-Rodriguez*(ES), Alvarez, M.Martin-Salces,I.Fernandez,N.Butta,Rivas, Rivas, V. Jimenez-Yuste, F. Hernandez-Navarro M. Garcia-Rodriguez*(ES),Martin-Salces, L. A. Valentino* (US),D.L.Cooper L. A. Valentino* (US),D.L.Cooper J. W J. Needham*(UK), TET IHHEOHLAANDFACTOR VIIIINHIBITORS TREATEDATIENTS WITHRFVIIa WITHHAEMOPHILIA . Hay*(US),Z.Zhou,G. Young TMENT OF TENING BLEEDING OPE SYNOVECT A. Fynn,S. ȭ ) QIE AMPII WITHRECOMBINANT ACTIVATED FVII A AQUIRED HAEMOPHILIA A. Roy, S.Knight, Y. Stebbings,S.Rangarajan A. Kouraba,I. Arguello OMY , K.Khair Anastasopoulou, P. Kotsi,M.Gavalaki, K.Markakis, A. IN HAEMOPHILIA Alvarez, I.Fernandez,N.Butta,Muñoz, WITH INHIBIT ORS Taouli,Slama A. 375

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-612 PROPHYLACTIC TREATMENT WITH RECOMBINANT FACTOR VIIa IN PATIENT WITH ADVANCED HAEMOPHILIAC ARTHROPATHY P. Smejkal* (CZ), G. Chlupova, M. Matyskova, A. Bulikova, J. Kissova, M. Slechtova, M. Penka PP-TH-613 RECOMBINANT FACTOR VIIa IN TREATMENT OF BLEEDS IN HEMOPHILIACS WITH INHIBITOR IN RELATION TO TIME TO TREATMENT AND DOSE P. Smejkal* (CZ), P. Brabec, M. Matyskova, A. Bulikova, M. Slechtova, G. Chlupova, J. Kissova, T. Pavlik, M. Penka PP-TH-614 RECOMBINANT FVIIa IN THE MANAGEMENT OF PORT-A-CATH ACCESS IN A BOY WITH SEVERE HEMOPHILIA A AND HIGH-TITRE INHIBITOR:WAS IT PROPHYLAXIS S. I. Heine* (DE), T. Krenn, N. Graf PP-TH-615 MANAGEMENT OF PATIENTS WITH INTRACRANIAL BLEED IN MGUS ASSOCIATED AVWS J. Laurie, J. Chacko, J. Mainwaring, R. Scott, S. Rangarajan* (UK) PP-TH-616 TETRAMER-GUIDED ANALYSIS OF T-CELL RESPONSES IN MONOZYGOTIC TWINS WITH SEVERE HEMOPHILIA A DISPLAYING A DISCORDANT ANTIBODY RESPONSE TO FACTOR VIII S. D. van Haren* (NL), E. Herczenik, E. A. James, H. van den Berg, K. Fischer, K. Pratt, J. Voorberg PP-TH-617 USE OF RECOMBINANT FACTOR VIIa (RFVIIa) IN INDIVIDUALS WITH CONGENITAL HEMOPHILIA B COMPLICATED BY ALLOANTIBODY INHIBITORS TO FACTOR IX: ANALYSIS OF DATA CAPTURE FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY (2004-2008) S. W. Pipe* (US), D. L. Cooper PP-TH-618 PREVENTION AND TREATMENT OF INHIBITOR FORMATION IN GENE THERAPY FOR HEMOPHILIA B S. Nayak* (US), O. Cao, R. W. Herzog PP-TH-619 POLYMORPHISMS IN THE VWF GENE AND DEVELOPMENT OF FVIII INHIBITORS IN PATIENTS WITH SEVERE HEMOPHILIA A Y. Repesse* (FR), E. Farrokhi, C. Costa, A. Borel-Derlon, R. D’Oiron, J. Oldenburg, A. Pavlova, C. Rothschild, C. Vinciguerra, S. Kaveri, S. Lacroix-Desmazes PP-TH-620 INHIBITOR TITER PREDICTS THE OCCURRENCE BUT NOT THE SEVERITY OF BLEEDING IN ACQUIRED HEMOPHILIA A PATIENTS: SINGLE INSTITUTION EXPERIENCE IN TAIWAN Y. B. Yu* (TW), H. C. Hsu, J. P. Gau, C. H. Ho, W. K. Chau, C. C. Chen, J. Y. You, Y. C. Hong, C. H. Tzeng PP-TH-621 AN ELISA-BASED ASSAY FOR ALLOANTIBODIES AGAINST FACTOR VIII IN PATIENTS WITH HEMOPHILIA A Z. Yu* (CN), L. Zhang, W. Zhang, Y. Zhao, Z. Wang, X. Bai, C. Ruan

von Willebrand Disease III

PP-TH-622 INTERIM ANALYSIS OF A PROSPECTIVE OBSERVATIONAL STUDY ON ITALIAN VWD PATIENTS, MONITORING EFFICACY AND SAFETY DURING A FORMULATION SHIFT OF A PASTEURIZED FVIII/VWF CONCENTRATE M. Morfini, A. Coppola* (IT), E. Zanon, E. Boeri, R. Musso, S. Siragusa PP-TH-623 DISTRIBUTION OF VON WILLEBRAND DISEASE (VWD) TYPES IN 94 FAMILIES FROM THE FRENCH NATIONAL REFERENCE CENTER FOR VWD (CRMW) : TYPE 1 IS NOT THE MOST FREQUENT WITHIN «TRUE» VWD J. Goudemand* (FR), E. Fressinaud, P. Boisseau, C. Ternisien, C. Caron, M. Trossaert, N. Itzhar, A. Borel-Derlon, M. Dreyfus, C. Boyer-Neumann, T. Lambert, V. Proulle, C. Zawadzki, D. Meyer, A. Veyradier

376 PT-2 EORAI INWOMENWHITVONWILLEBRANDDISEASE:EXPERIENCE A MENORRHAGIA PP-TH-627 RETROSPECTIVE ANALYSIS OFDESMOPRESSINRESPONSESIN TYPE1 AND TYPE2 PP-TH-626 PP-TH-625 PERI- PATIENTAND POST-OPERATIVE HEMATOLOGIC WITH MANAGEMENTIN A PP-TH-624 POSTER PRESENTATIONS PT-3 DETECTION OFTYPE1VONWILLEBRAND DISEASEWITHINCREASEDVON PP-TH-637 PP-TH-636 PP-TH-635 PP-TH-634 PP-TH-633 PP-TH-632 VONWILLEBRANDFACTOR DONOT LEVELSOFPLASMA SUPRAPHYSIOLOGICAL PP-TH-631 MUTATIONS CAUSINGPREMATURE TERMINATION CODONSINTHEVON PP-TH-630 PP-TH-629 CANADIANCOHORTOF PHENOTYPIC AND GENOTYPICCHARACTERIZATION OF A PP-TH-628 HRDY UY1,2009 THURSDAY, JULY 16, WILLEBRAND F P MOLECULAR ANALYSIS OFTYPE2VON WILLEBRANDDISEASEINIRANIAN MULTIMERZATION NEWPARAMETERFACTOR TO DESCRIBETHEDEGREEOF MULTIMERS AND A EEEC OGNTLCOAGULOPATHIES UNITINSPAINREFERENCE CONGENITAL INSOUTH AUSTRALIA A VON WILLEBRANDDISORDER, AND HAEMOPHILIA PERFORMANCE ANDCLINICAL ANALYTICAL PRELIMINARY VWF:RCO ASSAYS:NEW AUTOMATEDVWF:AG AND CHEMILUMINESCENT VALVE REPLACEMENT TYPE IIVONWILLEBRANDSDISEASEUNDERGOINGMITRAL 1 AND TYPE2VONWILLEBRANDDISEASE (VWD) NEW WILLEBRAND DISEASESEENINTAIWAN NOVEL NOVEL COHORT STUDY 10 YEAR A DISEASE PATIENTS WITHINTERVENTIONS AND BLEEDINGEVENTSBY STANDARDISED BLEEDINGSCOREFORVONWILLIBRAND CORRELATION OF A HEMOSTASIS INVONWILLEBRANDFACTOR KNOCK-OUT MICE SUPPORT PRIMARY POSITION-DEPENDENT MRNA WILLEBRAND FACTOR GENE ARE ASSOCIATED WITH ALLELE-SPECIFIC AND DENT TYPE 3VONWILLEBRANDDISEASE(VWD)PATIENTS M. Meiring*(ZA),P. Setlaba,M.Coetzee M. HashemiSoteh*(IR),Jazebi,S. Ravanbod,G.Rastegar-Lari,F. Ala M. Piñol, M. C.Shen*(TW),B.D.Lin,H. Y. Lin,W. Tsai, J.S.Lin,F. Kuo,M.H.Hong, Y. C.Wang M. L.Udvardy*(HU),K.Szekeres-Csiki,J.Hársfalvi M. D.Creagh*(UK),R.Kalathara,S.Johns,W D. Lillicrap M. Golder*(CA),C.Pruss,Hegadorn,K.Laverty, K.Sponagle,J.Mewburn,Meens, M. Platè*(IT),S.Duga,L.Baronciani, A. B.Federici,R. Asselta M. E.Seary, L.Winter, P. Judd,M.J. Casas, A. M.Stain,D.Carcao*(CA) Blanchette, D.Lillicrap,P. James M. Bowman*(CA), A. Tuttle, M.HemostasisResearchLabMembers, A. H.C.D.C.,V. S. Aznar L. Abad-Franch* (ES), A. R.Cid,S.Haya,P. Casaña,N.Cabrera, A. Moret,J.Gilabert, J. A. K. Bavishi,E.Duncan,S.Rodgers,McRae,L.H. Tay* (AU),J.Lloyd J. J. E. A Tous, R.G.Barry, J. Arnout, M.Vanrusselt, Z.Pascual,J.Serra*(ES) TIENTS Arnason* (US),M. T. Desancho AUT AL MUT EV T DISEASE INTYPE3VONWILLEBRANDDISEASE; MTDRSOEI OATRATVT SA TO DISTINGUISHTYPE ASSAY OMATED RISTOCETIN COFACTOR ACTIVITY . Sánchez,M.Sales*(ES),Vanrusselt, J. Arnout ALUA A TION INTHEVONWILLEBRANDF ACT TION METHODFORDENSITOMETRIC CURVES OFVONWILLEBRAND OR CLEARANCE DECA Y allace ACT OR GENEOFTYPE2VON NEGLECTEDPROBLEM A 377

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-638 FUT3 GENE DETERMINING LEWIS BLOOD GROUP ANTIGEN EXPRESSION INFLUENCES VWF:AG LEVELS IN PLASMA N. Hickson* (UK), D. J. Hampshire, P. R. Winship, P. D. James, I. R. Peake, A. C. Goodeve, on behalf of the EU-VWD and ZPMCB-VWD Study Groups PP-TH-639 COMPARATIVE ANALYSIS OF VON WILLEBRAND FACTOR MULTIMERS FROM THE CANADIAN TYPE 1 VWD STUDY P. James* (CA), C. Hegadorn, J. Grabell, E. Ong, D. Rapson, Association of Hemophilia Clinic Directors of Canada, U. Budde, D. Lillicrap PP-TH-640 DEVELOPMENT OF A CONVENIENT LECTIN-BASED METHOD FOR THE DISCRIMINATION OF PLASMA-DERIVED AND RECOMBINANT VON WILLEBRAND FACTOR A. Weber, E. Minibeck, P. L. Turecek* (AT), H. J. Ehrlich, H. P. Schwarz PP-TH-641 IN VITRO CLEAVAGE OF RECOMBINANT AND PLASMA-DERIVED VWF UNDER STATIC CONDITIONS AND UNDER SHEAR STRESS H. Rottensteiner, K. Varadi, S. Vejda, J. Schreiner, H. Gritsch, P. L. Turecek* (AT), H. J. Ehrlich, H. P. Schwarz PP-TH-642 PURIFICATION AND CHARACTERIZATION OF RECOMBINANT MOUSE VON WILLEBRAND FACTOR R. Pendu* (FR), E. Westein, I. Marx, P. J. Lenting, C. V. Denis, O. D. Christophe PP-TH-643 VWF:AG AND FVIII LEVELS IN THE PATIENTS WITH VON WILLEBRAND DISEASE: A SINGLE CENTER STUDY S. T. Amanat* (PK), N. Ikram, T. Zafar PP-TH-644 MONITORING OF DIFFERENT VON WILLEBRAND PARAMETERS AFTER ADMINISTRATION OF VWF/FVIII-CONCENTRATES S. R. Alesci* (DE), K. Bickhardt, B. Llugaliu, G. Asmelash, W. Miesbach PP-TH-645 GENETIC CHARACTERISATION OF TYPE 3 VON WILLEBRAND DISEASE IN THE NORTH-WEST OF ENGLAND PATIENT POPULATION M. S. Sutherland, S. Keeney* (UK), P. H. B. Bolton-Maggs, C. R. M. Hay, A. Will, A. M. Cumming PP-TH-646 CASE REPORT: 7-YEAR OLD PATIENT WITH SEVERE VWD TYPE 3 AND INHIBITORS AGAINST FVIII AND VWF S. Halimeh* (DE), H. Rott, B. Faeser, M. Bicker, S. Eisert, W. Kreuz, H. Laws, U. Budde PP-TH-647 SUCCESFUL PROPHYLACTIC TREATMENT OF PAEDIATRIC VON WILLEBRAND DISEASE (VWD) TYPE 2 AND 3 WITH TWO DIFFERENT VON WILLEBRAND FACTOR CONCENTRATE- A CHORT STUDY S. Halimeh* (DE), H. Rott, A. Kruempel, N. Bogdanova, G. Kappert, U. Nowak-Goettl PP-TH-648 PREVALENCE OF VON WILLEBRAND DISEASE IN WOMEN WITH MENORRHAGIA N. Hossain, T. Shamsi* (PK), A. A. N. Naz, M. M. B. Borhany PP-TH-649 DETECTION AND CHARACTERIZATION OF VON WILLEBRAND DISEASE: A CRUCIAL STEP PRIOR TO MAJOR SURGERY V. Proulle* (FR), T. Boutekedjiret, J. Pottecher, C. Court, J. Missenard, M. Dreyfus PP-TH-650 WHOLE BLOOD IMPEDANCE AGGREGOMETRY: A NEW TOOL FOR VON WILLEBRAND DISEASE CHARACTERIZATION V. Proulle* (FR), V. Valarche, T. Boutekedjiret, M. Dreyfus PP-TH-651 PROSPECTIVE CRITERIA FOR SIDE EFFECTS OF DDAVP W. Miesbach* (DE), O. Dück, B. Llugaliu, G. Asmelash, S. Krekeler, J. Schüttrumpf, S. Alesci, R. Grossmann

378 PT-5 MULTICENTRIC EVALUATION OFCURRENTDOSINGPRACTICERECOMBINANT PP-TH-654 PP-TH-653 PATIENT WITH TREATMENTAGGRESSIVE PERIODONTITIS AND IN A PERIODONTAL PP-TH-652 POSTER PRESENTATIONS PT-6 FACTOR XIIIDEFICIENCY: EFFECTIVEHAEMOSTASIS DESPITE TREATMENT FORTHE PP-TH-664 HEMOSTASIS: RESULTS FROM A BRUISINGININHERITEDDISORDERS OFPRIMARY PP-TH-663 FACTOR MANAGEMENTOFTWOPATIENTS VII WITHCONGENITAL SUCCESSFUL PP-TH-662 ANDNOVEL/RECURRENT MCFD2MUTATION FROM ARGENTINA FIRSTINDEL PP-TH-661 PP-TH-660 PHENOTYPIC AND GENOTYPICCHARACTERIZATION OFFACTOR VIIDEFICIENCY PP-TH-659 PP-TH-658 REPORTEDMISSENSE AND109PREVOUSLY ANALYSIS OF8NOVEL STRUCTURAL PP-TH-657 CASEREPORT INFACTOR XIDEFICIENCY: A MONITORING OFCARDIACSURGERY PP-TH-656 THROMBINGENERATION AND FIBRINCLOTFORMATION INPATIENTS WITHSICKLE PP-TH-655 Other InheritedCoagulationDisorders III 2009 THURSDAY, JULY 16, WRONG DIAGNOSIS PROSPECTIVE STUDY WESTERN INDIA THROMBIN GENERA FIX INITALY STUDIES FAMILIAL VONWILLEBRANDDISEASEINTAIWAN: 2PATIENTSTYPE 2A REPORTWITH CASEREPORT VON WILLEBRANDDISEASE: A DEFICIENCY ETHNIC ORIGINOFNINEP BASEDONTHE SCREENINGSTRATEGY VARIATIONS INF5F8D:RESULTS OF A PHENOTYPIC P 54-YEAR-OLDMALE FACTORS (VKCFD1)DIAGNOSEDIN A OFVITAMIN K-DEPENDENTCOAGULATION INHERITED COMBINEDDEFICIENCY ON FXIDEFICIENCY MUTATIONS INTHEINTERACTIVEFXIMUTATION DATABASE REVEALSNEWINSIGHT CELL Makris N. R.Farquharson*(UK),M.Maclean, K.Hampton,S.Kitchen,J.vanVeen, M. M. Pai*(CA),G. T. Wang, Y. Liu,K.E.Webert, N. Heddle, C.P. M.Hayward M. Krause*(DE),D.Pillitteri, T. Scholz,D.Westrup, C.M.Kirchmaier K. Sittinger*(DE),M.Vega-Ostertag, R.Eisert,E.Seifried,J.Oldenburg,C.Geisen K. Ghosh*(IN),S.Shetty, L.Mota K. Ghosh*(IN),L.Mota,S.Shetty J. Windyga*(PL),M.Watzka, B.Baran,K.Owczarska,J.Oldenburg T R. E.Saunders,N.Shiltagh,K.Gomez,G.Mellars*(UK),C.Cooper, D.J.Perry, E.G. A. Siegemund*(DE),J.Oppermann,C.Kämpfert,U.Scholz Ataga, N.S.Key A. S.Wolberg* (US),C. Amin, S. Adam, A. Kutlar, B.Hulkower, L.Gray, J. Y. Chang,K.I. A. Lorio*(IT), A. Rocca,S.Pizzinelli Y W . Chen*(TW),S.Cheng,Hu, T. Huang, T. Chao uddenham, S.J.Perkins A . Miesbach*(DE),P. Eickholz,K.Himmer, S. Alesci, M.Wohlfeil TIENTS FROMWESTERNINDIA DISEASE (SCD) NEGIGTNILCOYWITHRFVIIa-NORMALIZATION OF UNDERGOING TONSILLECTOMY AND GENOTYPICDIVERSITY TION A TIENTS OF F ACT OR XDEFICIENCY FROM 379

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

PP-TH-665 RESULTS OF TREATMENT WITH LONG TERM HAEMOCOMPLETTAN IN TWO PATIENTS WITH CONGENITAL AFIBRINOGENEMIA AND MULTIPLE BONE CYSTS P. Brons* (NL), R. Thomson, B. Verbruggen, J. de Rooy, R. Veth PP-TH-666 FACTOR XIII DEFICIENCY IN A NEWBORN OF A NON CONSANGUINEOUS CAUCASIAN COUPLE P. Lê* (BE), A. Ferster, L. Leenders, A. Tarantino, T. Khalil, M. Demaegd, A. Demulder PP-TH-667 SEVERE COAGULATION FACTOR X DEFICIENCY CAUSED BY TWO DE NOVEL HETEROZYGOUS MISSENSE MUTATIONS IN FACTOR X GENE AND CONSTRUCTION OF MUTANT EXPRESSION VECTORS R. Zhou* (CN), J. Ou-Yang, D. Chang PP-TH-668 EFFECT OF CO-INHERITED THROMBOPHILIA GENES ON THE CLINICAL SEVERITY OF RARE BLEEDING DISORDERS SUCH AS FACTOR VII AND FACTOR X DEFICIENCY S. Shetty* (IN), L. Mota, K. Ghosh PP-TH-669 OCCULT BLOOD COAGULATION DISORDERS AND MASSIVE OBSTETRICAL BLEEDING V. V. Smurygina* (RU), A. D. Makatsarya PP-TH-670 CHARACTERIZATION OF THE GENETIC BASIS OF FXI DEFICIENCY IN FOURTEEN UNRELATED PATIENTS V. Rimoldi* (IT), I. Guella, S. Spena, N. Ciavarella, F. Peyvandi, R. Asselta, P. M. Mannucci, S. Duga PP-TH-671 STRUCTURAL ANALYSIS OF SIX NOVEL COAGULATION FACTOR XIII SUBUNIT A MISSENSE MUTATIONS V. Ivaskevicius* (DE), V. Schroeder, H. Kohler, H. Rott, P. Petrides, A. Biswas, R. Knoefler, J. Oldenburg

Acquired Coagulation Disorders and DIC III

PP-TH-672 ASSOCIATION BETWEEN ETIOLOGY OF CIRRHOSIS, CHILD’S CLASSIFICATION, PRESENCE OF ASCITES AND CONVENTIONAL COAGULOGRAM, AND THE IMMEDIATE PREOPERATIVE THROMBOELASTOGRAPHIC PROFILES IN PATIENTS SUBMITTED TO LIVER TRANSPLANTATION D. D. Ribeiro* (BR), T. C. A. Ferrari, A. S. Lima, P. R. S. Rocha PP-TH-673 PREDICTING FIBRINOLYISIS DURING LIVER TRANSPLANTATION BY CLINICAL AND LABORATORIAL CHARACTERISTICS OF THE RECEPTOR IMMEDIATELY BEFORE THE BEGINNING OF TRANSPLANT D. D. Ribeiro* (BR), A. S. Lima, M. D. Faria, C. Caram PP-TH-674 CLINICAL AND LABORATORIAL CHARACTERISTICS OF LIVER TRANSPLANTATION RECEPTORS AND THEIR RELATION WITH THE USE OF BLOOD PRODUCTS D. D. Ribeiro* (BR), A. S. Lima, M. D. Faria, C. Caram PP-TH-675 BENEFITS AND RISKS OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIa) IN MASSIVE BLEEDING: A SINGLE CENTRE STUDY E. Panizo, R. Lecumberri, P. Rodríguez-Otero, M. Hernández, C. Pegenaute, J. A. Páramo* (ES) PP-TH-676 MASSIVE PULMONARY EMBOLISM NECESSITATING CARDIOPULMONARY RESUSCITATION IS FREQUENTLY ASSOCIATED WITH OVERT DISSEMINATED INTRAVASCULAR COAGULATION J. M. Leitner* (AT), K. Janata, A. O. Spiel, F. Sterz, A. N. Laggner, B. Jilma

380 PT-7 AINSWT UMNR HYPERTENSIONHAVE HIGHERTHROMBIN PATIENTS WITHPULMONARY PP-TH-679 PP-TH-678 WHOLEBLOOD AGENTSONCLOTTINGTIMESIN A EFFECTOFDIFFERENTTOPICAL PP-TH-677 POSTER PRESENTATIONS PT-8 FIAYADSFT OFRECOMBINANT HUMANSOLUBLETHROMBOMODULININ ANDSAFETY EFFICACY PP-TH-689 PP-TH-688 CHANGESINTHROMBINGENERATION KINETICSFOLLOWINGSEVERE PP-TH-687 OFFACTOR VIIINPATIENTS MEASUREMENTOFTHEPROCOAGULANT ACTIVITY PP-TH-686 ACUTETRAUMATIC CHARACTERISATION COAGULOPATHY: BY FUNCTIONAL PP-TH-685 ISTHDICSCORE:INTERESTOFFIBRINRELATED MARKERSINICUPATIENTS PP-TH-684 PP-TH-683 DYNAMICCHANGESINCLOTELASTICMODULUSDURINGHEMORRHAGICSHOCK PP-TH-682 OFCIRRHOTICPATIENTS HASNOSYSTEMATIC FACTOR VARIATION VINPLASMA PP-TH-681 VONWILLEBRANDSYNDROMEWITHOUT ACQUIREDSEVEREBIOLOGICAL PP-TH-680 HRDY UY1,2009 THURSDAY, JULY 16, INTRA SEPTIC ANTITHROMBIN SUBSTITUTION-RESISTANT DISSEMINATED METASTASIS OFGASTRICCANCER INR FIBRILLATIONGENERATION INDIVIDUALSWITHTHESAME COMPARED TO ATRIAL COAGULOPATHY OFDILUTIONAL BLOOD MODEL WHOLE HEMOSTATIC AGENTS ONCLOTTINGTIMESIN A EFFECT OFTOPICAL OF ACIDOSIS MEDIATED COAGULOPATHY MODEL P HEMORRHAGE AND LRRESUSCITATION INPIGS THE BLEEDINGRISK :EVALUATION OF PROTHROMBIN ACTIVITY WITH LIVERCIRRHOSIS AND NORMAL ROT MANAGEMENT OF A MULTICENTER STUDY BETWEEN LABORATORIES: A BLEEDING: ROLEOFPLATELET VONWILLEBRANDFACTOR Y Y W S. Ayaz* (TR),N.Mengi,S.B.Guney R. A. Davenport*(UK),S. Allard, A. Coates,C. Thiemermann, J.Pasi,R.Pearse, K.Brohi C. Cauchie,M.Daune P. Cauchie*(BE),S.Ollieuz,B.Woodhams, P. Biston,K.ZouaouiBoudjeltia,N.Deschepper, P. Kanagasabapathy*(UK),H.Greensmith,D.Bevan,S. Austin N. J.White*(US),E.Martin,K.R.Ward Villamil, R.Forastiero M. E.Martinuzzo*(AR),G.Cerrato, A. Ruf,F. Cairo,C.Duboscq,S.Ouviña,L.Chavez,F. Soria, L.Drouet*(FR) M. E.Chollet,C.Caron,B.Boval,S.Bellucci,BalDitSollier, A. Hadj-Ali,M. Yakoubi, C. K. P. Hickey*(UK), A. Gatt,P. Sephton,D.G.Kiely, C. A. Elliot,P. C.Cooper, M.Makris K. K. Fuse, S.Furukawa . Seki*(JP),K.W . Eguchi*(JP), A . Z.Martini*(US),S.Colvin,M. SWINE MODEL A. Moskowitz*(US),D.Manly, N.Mackman A. Moskowitz*(US),D.Manly, N.Mackman THOLOGICAL TOA THROMBOLELASTOMETRY ATIONAL ACLRCAUAINRSLSO PILOTSTUDY VASCULAR COAGULATION:RESULTS OF A T . Saotome,K.Matsumura, Y. Tsujita, T. Hamamoto, K.Fujino,Hayafuji,I. FINDINGS OFDIC akagi ACQUIRED HAEMOPHILIA A. Dubick N M NAPATIENT WITHBONEMARROW IN A AND TMA A - A SINGLE CENTREEXPERIENCE 381

Thursday Posters POSTER PRESENTATIONS THURSDAY, JULY 16, 2009

Innovative Therapies for Hemorrhagic Disorders II

PP-TH-690 PERI-INTERVENTIONAL CONTROL OF HEMOSTASIS WITH RECOMBINANT ACTIVATED FACTOR VII IN A PATIENT WITH COMBINED COAGULATION FACTOR V- AND FACTOR VIII-DEFICIENCY AND ANAPHYLAXIS TO FRESH FROZEN PLASMA D. Lechner* (AT), R. Kotz, H. A. Wanivenhaus, P. A. Kyrle, S. Eichinger PP-TH-691 CORRECTION OF ABNORMAL CLOTTING BY A TOPICAL HEMOSTATIC AGENT IN A WHOLE BLOOD MODEL OF DRUG-INDUCED COAGULOPATHY K. A. Moskowitz* (US), D. Manly, N. Mackman PP-TH-692 LOW-DOSE RECOMBINANT FACTOR VIIa FOR LIFE-THREATENING BLEEDING IS EFFICACIOUS EVEN AT LOW FIBRINOGEN LEVELS P. Schmid, A. Mordasini, B. Laemmle, L. Alberio* (CH) PP-TH-693 COMPARATIVE STUDY OF THE HEMOSTATIC POTENCY OF THREE PREPARATIONS OF THERAPEUTIC PLASMA M. Hacquard* (FR), B. Belcour, T. Lecompte, T. Schneider PP-TH-694 SORAFENIB IS A FEASIBLE THERAPEUTIC OPTION IN HAEMOPHILIACS WITH HEPATOCELLULAR CARCINOMA M. Lapecorella* (IT), M. Napolitano, M. Tudini, G. Bruera, A. Lucchesi, A. V. Giordano, G. Mariani, E. Ricevuto PP-TH-695 BEDSIDE POINT OF CARE COAGULATION TESTING FOR INDIVIDUALIZED ANTIVITAMIN K REVERSAL IN EMERGENCY SURGERY U. Schott* (SE), D. Winstedt, P. Anveden PP-TH-696 CONSTRUCTION OF A NEW HELPER VECTOR FOR THE PRODUCTION OF HELPER- DEPENDENT ADENOVECTORS FOR THE USE IN HEMOPHILIA A GENE THERAPY Z. A. Aburubaiha* (DE), M. Srour, H. Fenchner, J. Oldenburg, R. Schwaab

382 ISTH2009

Nursing Program

383 Nursing Program

The Nursing Program at ISTH 2009 provides a forum for nurses world-wide to identify issues that directly impact their role pertaining to disorders of hemostasis and thrombosis in both pediatric and adult populations. The goal is to provide free exchange of knowledge, experience, and practice patterns needed to standardize and improve the quality of hands-on participation in the art and science of medicine focused on disorders of hemostasis and thrombosis.

384 for patientswithhemostasis andthrombosis disorders Darlene Castles(CA) Division ofWorkload Mission andFuture Sessions Maura Malone (US) Closing Remarks /EvaluationsT Fiona Newall(AU) Q&A Discussion Ruthann Kirschman(US) Menorrhagia: alter phlebitic syndr V Debi Smith(NZ) Case TBD Br Q&A Discussion Laurel Mckernan(US) in hemophiliaA Iron reduction forparoxysmal atrialfibrillation Kathy Harney(US) on warfarin Managing aninfantwithmitralvalvereplacement Jen Maahs(US) long-term implications in bleedingandclottingdisorders and A r Fiona Newall(AU) Nurse drivenresearch-nurses asPI Maura Malone(US) Welcome andIntroduction Moderators: usn omte etn Room204 AB Room204 AB Challengesin Treatment Management Populations: A 2009 MONDAY, JULY 13, Nursing CommitteeMeeting 2009 SATURDAY, JULY 11, enous stasisulcerinpediatricpatientwithpost- eak Workshop onBleeders andClotters inPediatric and Adult eview ofincidenceIntracranialHemorrhage Maura Malone(US),FionaNewall(AU) ome native tr (selected abstractfororalpresentation) eatment regimens considered opic Suggestions 12:00 PM-2:00 12:30 PM-2:15 12:35 -12:45PM 12:30 -12:35PM 12:45 -1:00PM 2:10 -2:15PM 2:05 -2:10PM 1:55 -2:05PM 1:45 -1:55PM 1:35 -1:45PM 1:25 -1:35PM 1:20 -1:25PM 1:10 -1:20PM 1:00 -1:10PM 385

Nursing Program TUESDAY, JULY 14, 2009 12:30 PM - 2:15 PM

Haemostasis and Thrombosis: Partners for Adolescent Care: Adherence and Transition Challenges Room 204 AB Moderators: Mary Bauman (IE), Anna O'Sullivan (IE) Welcome and Introduction Mary Bauman (CA) 12:30 - 12:35 PM Psycho social issues of adolescents with chronic illness (selected abstract for oral presentation) Anna O'Sullivan (IE) 12:35 - 12:45 PM Development of a Quality of Life tool in children with chronic illness Aisha Bruce (CA) 12:45 - 12:55 PM Cultural challenges in translation and application of QOL tools Cindy Wakefield (CA) 12:55 - 1:05 PM Challenges for managing the athletic adolescent clotter Marilyn Blumstein (US) 1:05 - 1:15 PM Patient education and knowledge transfer (selected abstract for oral presentation) Rebecca Goldsmith (US) 1:45 - 1:55 PM Q & A Discussion 1:25 - 1:30 PM Break 1:30 - 1:35 PM Adolescents with/or at risk for thrombosis: Transition to adult care Karina Black (US) 1:35 - 1:45 PM Hemostasis: Transition Programs Reviewed Rhonda Fritz (US) 1:45 - 1:55 PM Optimizing Adherence Regina Butler (US) 1:55 - 2:05 PM Q&A Discussion Anna O'Sullivan (IE) 2:05 - 2:10 PM Closing Remarks, Evaluations / Topic Suggestions Mary Bauman (CA) 2:10 - 2:15 PM

386 Bunis Packman(UK) admitted intohospital:Nationalstandards reviewed Standard thromboprophylaxis forallpatients Bunis Packman(UK) Welcome andIntroduction Moderators: Regina Butler(US) Closing Remarks,Evaluations /Topic Suggestions Marie Mahoney(US) Q&A Discussion Mar (selected abstractfororalpresentation) Medicines (CAM)inpatientswithcoagulopathies Don't seeRed:ComplementaryAlter Luchtman(CA) Lory this bedonepriortoinitiationoftherapy? sensitivity/r Pharmacogenomics: DeterminingCoumadin (US) Pam Bryant a lookatthepros andcons data baseforbleedingandclottingdisorders: Network (ATHN): onemodelofasecured national The AmericanThrombosis andHemostasis Jen Maahs(US) T Moderators: Break Q&A Discussion Chris A.DiPaola(US) US: JointCommission:PatientSafetyGoals otoese nTrmoi n eotssRoom204 AB Controversies in Thrombosis andHemostasis 2009 WEDNESDAY, JULY 15, oward standard diseasemanagementforhemophilia y Bauman(CA) esistance withbloodtests-should Regina Butler(US),MarieMahoney(US)) Bunis Packman(UK),KathyHarney(US) native 12:30 PM-2:15 12:45 -12:55PM 12:35 -12:45PM 12:30 -12:35PM 12:55 -1:00PM 2:10 -2:15PM 2:00 -2:10PM 1:50 -2:00PM 1:40 -1:50PM 1:30 -1:40PM 1:10 -1:30PM 1:00 -1:10PM 387

Nursing Program NOTES ISTH2009

Special Symposia

389 Special Symposia Special Symposia take place on: SUNDAY, JULY 12, 2009 12:30 PM - 2:30PM

Scienta Healthcare Education® Room 205 ABC Supported by an educational grant from Baxter Bayer HealthCare Room 253 ABC sanofi-aventis (US) Room 258 ABC

SUNDAY, JULY 12, 2009 3:15 PM - 5:15 PM

Octapharma AG (CH) Room 205 ABC Medscape LLC Supported by an educational grant Room 258 ABC from sanofi-aventis

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

Scienta Healthcare Education® Supported by Baxter Healthcare Room 205 ABC

Bayer HealthCare AG and Ortho-McNeil Pharmaceuticals Inc. Division of Ortho-McNeil Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC. Room 156 ABC

Potomac Center for Medical Education Room 258 ABC Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. CSL Behring Room 107 ABC ACCELMED® and Postgraduate Institute for Medicine® Supported by an educational grant from Room 104 ABC Daiichi Sankyo Inc. and Lilly USA, LLC Grifols International Room 160 ABC Network for Continuing Medical Education Supported by an unrestricted educational grant Room 253 ABC from Novo Nordisk Healthcare AG Stago Room 153 ABC Wyeth Pharmaceuticals Room 204 AB

390 for ClinicalPractice Risk Factors,Prediction Modeling,andImplications Update onFactorVIIIImmunogenicity: Supported byaneducationalgrantfromBaxter Chairperson andfaculty Questions andanswers Gilbert C.WhiteII(US) Concluding r Gilbert C.WhiteII(US) implications forclinicalr Improving andutilizingprediction models: Johanna G.vanderBom(NL) pr Prediction modelsforinhibitordevelopmentin Jan Astermark(SE) inhibitors Risk factorsfordevelopmentofFactorVIII Gilbert C.WhiteII(US) Welcome andintroductions Chairperson: UDY UY1,20 12:30PM-2:30PM SUNDAY, JULY 12,2009 Healthcare Education® Sponsored byScienta eviously untreated patients Gilbert C.WhiteII(US) emarks esear ch 23 M-23 MRoom205ABC 12:30 PM-2:30 and practice 12:30 -12:40PM 12:40 -1:10PM 2:15 -2:30PM 2:10 -2:15PM 1:40 -2:10PM 1:10 -1:40PM 391

Special Symposia SUNDAY, JULY 12, 2009 12:30 PM - 2:30 PM

Bayer HealthCare 12:30 PM - 2:30 PM Room 253 ABC

Hemophilic Arthropathy: New Insights into Mechanisms, Prevention, and Management Chairperson: Leonard A Valentino (US) Welcome and introduction Leonard A Valentino (US) 12:30 - 12:35 PM Biology of joint disease Leonard A Valentino (US) 12:35 - 1:00 PM Reducing joint bleeding and arthropathy in children Marilyn Manco-Johnson (US) 1:00 - 1:25 PM When medical management fails to prevent arthropathy Carlos Rodriguez-Merchan (ES) 1:25 - 1:50 PM Clinical investigations of long-acting rFVIII formulation and improved rFVIIa product Georg Lemm (DE) 1:50 - 2:00 PM Next-generation coagulation factors John Murphy (US) 2:00 - 2:10 PM Questions and discussion Panel 2:10 - 2:25 PM Concluding remarks Leonard A Valentino (US) 2:25 - 2:30 PM

sanofi-aventisUS 12:30 PM - 2:30 PM Room 258 ABC

Across the Clinical and Temporal Continuum: Defining Successful Strategies for Venous Thromboprophylaxis Chairpersons: Ajay K. Kakkar (UK) and Samuel Z. Goldhaber (US) Welcome and Introduction Samuel Z. Goldhaber (US) 12:30 - 12:35 PM Clinical presentations and mechanisms of thrombogenesis in VTE: implications for therapy Henri Bounameaux (CH) 12:35 - 12:50 PM

392 Appr Ajay K.Kakkar(UK) Thromboprophylaxis inspecialpopulations Samuel Z.Goldhaber(US) thromboprophylaxis Defining clinicalstrategiesforimproving Victor Tapson (US) fromLearning ourfailures: Lessonsfrom theregistries Sebastien Lacroix-Desmazes (FR) patients undergoing immunetolerance induction Immune monitoringofHaemophilia A Christoph Königs(DE) induction treatment? assay helpoptimizeindividual immunetolerance Can inhibitorprofile andthrombin generation Wolfhart Kreuz(DE) therapy.Still room forimprovement? After a30-yearexperiencewithimmunetolerance David Lillicrap(CA) Immune r Georges E.Rivard(CA)andDavidLillicrap Welcome andintroduction Chairpersons: Bridging LabandFieldResearch Pr Ajay K.Kakkar(UK) Concluding remarks Moderator: Panel discussion/Questionsandanswers Roger D.Yusen (UK) UDY UY1,20 3:15PM-5:15 (CH) Octapharma AG 2009 SUNDAY, JULY 12, 12:30PM-2:30 2009 SUNDAY, JULY 12, evention andEradicationofFVIIIInhibitors: oaching pharmacologicprophylaxis esponse toFVIII Ajay K.Kakkar(UK) Georges E.Rivard(CA)andDavidLillicrap :5P o51 MRoom205ABC 3:15 PMto5:15 12:50 -1:05PM 4:10 -4:25PM 3:55 -4:10PM 3:35 -3:55PM 3:20 -3:35PM 3:15 -3:20PM 2:25 -2:30PM 1:50 -2:25PM 1:35 -1:50PM 1:20 -1:35PM 1:05 -1:20PM 393

Special Symposia SUNDAY, JULY 12, 2009 3:15 PM - 5:15 PM

How I prevent and treat FVIII inhibitors in Hemophilia A patients Georges E. Rivard (CN) 4:25 - 4:45 PM Incidence of FVIII inhibitors in PUPs with hemophilia Carmen Escuriola-Ettingshausen (DE) 4:45 - 5:00 PM Concluding remarks Georges E. Rivard (CA) and David Lillicrap (CA) 5:00 - 5:05 PM Questions and answers Chairperson and Faculty 5:05 - 5:15 PM

Medscape LLC 3:15 PM - 5:15 PM Room 258 ABC Supported by an educational grant from sanofi-aventis Meeting the Challenges in Long-Term Anticoagulation: Opportunities to Improve Patient Care Chairpersons: Elaine Hylek (US) and Ander Cohen (UK) Welcome and introduction Elaine Hylek (US) 3:15 - 3:20 PM Real world, real patients: Understanding the burden of venous and arterial thromboembolic diseases Greg Lip (UK) 3:20 - 3:40 PM Recognizing the gaps: Opportunities for addressing the patient's need and improving the continuum of care Elaine Hylek (US) 3:40 - 4:00 PM Emerging treatment options in long-term anticoagulation: Gateway to the future of clinical care Ander Cohen (UK) 4:00 - 4:20 PM New and ongoing anticoagulant trials: what does the future hold? Jack Ansell (US) 4:20 - 4:40 PM Panel Discussion (Questions and answers) 4:40 - 5:00 PM Concluding remarks Ander Cohen (UK) 5:00 - 5:15 PM

394

Meeting theUnmetNeedsinAnticoagulantTherapy Chairperson: The RoleofLaboratoryAssays with HemophiliaAandInhibitors: Challenges inClinicalDecision-MakingforPatients Supported byaneducationalgrantfromBaxter Alexander G.G.Turpie (CA) Extended thr Jeffrey I.Weitz (CA) W Chairpersons: Questions andanswers Kenneth Mann(US) Novel assaysformonitoringbypassingtherapy New insightsintolaboratorymonitoring: Yesim Dargaud(FR) care ininhibitorpatients the thrombin generation:Assayforroutine clinical Validating therole ofthromboelastography and Claude Négrier(FR) for patientswithhemophiliaAandinhibitors Introduction: Challengesinclinicaldecision-making refining theapproach administered byOrtho-McNeilJanssenScientificAffairs, LLC Ortho-McNeil JanssenPharmaceuticals,Inc., Ortho-McNeil PharmaceuticalsInc.Divisionof and Bayer HealthCare AG 6:30PM-8:00 Healthcare Education Supported byScienta 2009 MONDAY, JULY 13, elcome andintroduction Claude Negrier(FR omboprophylaxis: Definingthecase, Jeffrey I.WeitzR.Büller(NL) (CA)andHarry ® :0P :0P 205ABC 6:30 PM-8:00 ) :0P :0P 156ABC 6:30 PM-8:00 6:40 -7:00PM 6:30 -6:40PM 7:45 -8:00PM 7:15 -7:45PM 6:45- 7:15PM 6:30- 6:45PM 395

Special Symposia

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

Advancing the treatment of VTE Harry R. Büller (NL) 7:00 - 7:20 PM Long-term anticoagulation in cardiovascular indications: Where do we go from here? C. Michael Gibson (US) 7:20 - 7:40 PM Panel Discussion / Questions and answers Giancarlo Agnelli (IT) 7:40 - 7:55 PM Concluding remarks Giancarlo Agnelli (IT) 7:55 - 8:00 PM

Potomac Center for Medical Education 6:30 PM - 8:00 PM 258 ABC Supported by an educational grant from Boehringer Ingelheim pharmaceuticals, Inc. Thrombosis and Thromboembolism: Emerging Therapies Chairperson: John Heit (US) Welcome and introduction Anticoagulants and antithrombotics: The current situation John Heit (US) 7:00 - 7:10 PM Therapies for stroke prevention in atrial fibrillation Giuseppe Di Pasquale (IT) 7:10 - 7:30 PM Therapies for prevention and treatment of venous thromboembolism Shannon Bates (US) 7:30 - 7:50 PM Questions and answers All faculty 7:50 - 8:00 PM

396

implications inclinicalpractice Classification ofvonWillebranddiseaseand Peter Kouides(US)andWolfhart Kreuz(DE) W Chairpersons: Disease intheNextDecade:AClinicalPerspective Diagnosis andManagementofInheritedvonWillebrand Panel discussion Questions and answers Paul A.Gurbel(US) on r Emerging antiplatelettherapies: Thepotentialimpact Gilles Montalescot(FR) Platelet functiontesting: Thefuture standard ofcare? Paul A.Gurbel(US) Antiplatelet respons variability:Areview oftheliterature Paul A.Gurbel(US) Welcome andOverview Chairperson: What istheFuture ofAntiplateletTherapy? Variability, Testing, andTreatment: and LillyUSA,LLC Supported by (US) Thomas Abshire of vonWillebranddisease:T The role ofprophylaxis inthemanagement Erik Berntorp(SE) Haemate P/Humate-P:Asystematicreview Andra James(US) state oftheart Awareness anddiagnosisofvonWillebranddisease: Augusto Federici(IT) Institute forMedicine® ACCELMED® andPostgraduate 6:30PM-8:00 CSL BehringGmbH 2009 MONDAY, JULY 13, elcome andintroduction esponse variability Paul A.Gurbel(US Peter Kouides(US)andW an educationalgrantfromDaiichiSankyo,Inc. oday andtomorrow ) :0p :0p 107ABC 6:30 pm-8:00 olfhart Kreuz(DE) :0P-:0P 104ABC 6:30 PM-8:00PM 7:40 -8:00PM 7:15 -7:40PM 6:35 -7:00PM 6:30 -6:35PM 7:40 -8:00PM 7:20 -7:40PM 7:00 -7:20PM 6:40 -7:00PM 6:30 -6:40PM 7:00- 7:15PM 397

Special Symposia

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

Grifols 6:30 PM - 8:00 PM Room 160 ABC

Managing Hemophilia B: How can we Optimize Treatment from a Laboratory and Clinical Perspective? Chairperson: Lou M. Aledort (US) Welcome and introduction Lou M. Aledort (US) 6:30 - 6:40 PM Grifols' Factor IX concentrates: New findings in biochemical characteristics and safety profiles Steve Herring (US) 6:40 - 6:55 PM New insights from Factor IX activation studies with chromogenic assays What are the implications of disparate results between different products? Trevor Barrowcliffe (UK) 6:55 - 7:10 PM Clinical challenges in hemophilia B patients undergoing surgery, when a reliable Factor IX level is required. Doris Quon (US) 7:10 - 7:30 PM Prophylaxis in hemophilia B patients: Unresolved issues and pharmacoeconomic implications. Elena Santagostino (IT) 7:30 - 7:50 PM Concluding remarks Lou M. Aledort (US) 7:50 - 7:55 PM Questions and answers 7:55 - 8:00 PM

398

with Inhibitors in theManagementofHaemophiliaPatients Applying theLatestClinicalTrial DatatoControl Bleeding Novo NordiskHealthCareAG Supported byanunrestrictededucationalgrantfrom Françoise Dignat-George (FR) Welcome andintroduction Chairperson: Is itTimetoRevisittheConcept? Thr Questions andanswers Benny Sørensen(DK) and futur Monitoring by-passingagents:achievements Guy Y for patientswithhaemophiliainhibitors Early on-demandtreatment versusprophylaxis Gili Kenet(IL) of inhibitorHaemophilia An updateofclinicalstudiesinby-passingtherapy Nigel Key(US) and dosageofby-passingagentplayar with haemophiliainhibitors:Maychoice and inflammatorystatusinpatients Clot structure/stability, histology, anatomy, Nigel Key(US) Welcome andintroduction Chairperson: Stago 6:30PM-8:00 Medical Education Network forContinuing 2009 MONDAY, JULY 13, ombosis, Inflammationand Haemostasis: oung (US) e challenges Françoise Dignat-George(FR) Nigel Key(US 6.30 PM-8:00 ) :0P :0P Room253ABC 6:30 PM-8:00 ole? Room 153ABC 6:30 -6:35PM 7:55 -8:00PM 7:35 -7:55PM 7:15 -7:35PM 6:55 -7:15PM 6:35 -6:55PM 6:30 -6:35PM 399

Special Symposia

MONDAY, JULY 13, 2009 6:30 PM - 8:00 PM

The vessel wall and its interaction Paul S. Frenette (US) 6:35 - 7:00 PM Platelets and inflammation Alan Nurden (FR) 7:00 - 7:25 PM The protein C pathway: The interface between coagulation and inflammation Charles T. Ermon (US) 7:25 - 7 :50 PM Panel discussion Moderator: Françoise Dignat-George (FR) 7:50 - 8 :00 PM

Wyeth Pharmaceuticals 6.30 PM - 8:00 PM Room 204 AB

Hemophilia Treatment: The Past, Present & Future Chairperson: Christopher Ludlam ((UK) Chairperson’s Welcome and Introduction Christopher Ludlam (UK) 6:30 - 6:35 PM An early history of hemophilia and product development Jeanne Lusher (US) 6:35 - 6:45 PM Clinical perspectives of pathogens in bleeding disorders Christopher Ludlam (UK) 6:45 - 7:05 PM Prions: Another reason for robust pharmacovigilance James Ironside (UK) 7:05 - 7:25 PM Strategies for addressing the safety of treatment in bleeding disorders Riita Lassila (FI) 7:25 - 7:40 PM Concluding Questions and answers Christopher Ludlam (UK) 7:40 - 7:55 PM Chairperson’s Summary Christopher Ludlam (UK) 7:55 - 8:00 PM

400 ISTH2009

Satellite Symposia

401 Satellite Symposia Satellite Symposia take place on:

WEDNESDAY, JULY 15, 2009 6:30 PM - 8:00 PM

Biomérieux Room 153 ABC CMEducation Resources, LLC Supported by an educational grant Room 157 ABC from BMS

CMEducation Resources, LLC Supported by an educational grant Room 160 ABC from EISAI

CSL Behring GmbH Room 104 ABC

Loyola University Chicago Room 107 ABC

Institute for Medical Studies (CME provider) Supported by an educational grant Room 205 ABC from Lundbeck Inc.

Octapharma AG (CH) Room 253 ABC

Siemens Room 156 ABC

Wyeth Pharmaceuticals Room 204 AB

402

What makesagoodD-dimerassayforVTEexclusion? Arnaud Perrier(CH) Introduction Chairperson: Thromboembolism (VTE):Current andFuture Perspectives D-dimer intheManagementofVenous Stavros Konstantinides (DE) Pr of program Welcome andIntroduction -Goalsandobjectives Chairperson: The PracticalandResear Supported byaneducationalgrantfromBMS Moderator: Questions andanswers Moderator: Discussion Marc Roger(CN) Is ther Grégoire LeGal(FR) of VTE? How shouldtheclinicianuseD-dimerindiagnosis Guido Reber(CH) the car new challengesandemerging advancesfor coronary syndrome, andatrialfibrillation- the arteriovenousriskspectrum: VTE,acute and ManagementinCancerAssociatedConditions of anticoagulanttherapyinunprovoked VTE? CMEducation Resources, LLC 6:30PM-8:00 Biomérieux 2009 WEDNESDAY, JULY 15, ophylaxis ofthromboembolism across e arole forD-dimertodeterminetheduration diovascular andthr Arnaud Perrier(CH) Arnaud Perrier(CH) John H.Alexander(US) Arnaud Perrier(CH) :0P 80 MRoom153ABC 6:30 PM-8:00 ch DimensionsofVTEPr ombosis specialist :0P :0P Room157ABC 6:30 PM-8:00 evention 6:30 -6:45PM 7:50 -8:00PM 7:40 -7:50PM 7:20 -7:40PM 7:00 -7:20PM 6:40 -7:00PM 6:30 -6:40PM 403

Satellite Symposia

WEDNESDAY, JULY 15, 2009 6:30 PM - 8:00 PM

The emerging role of factor Xa inhibition in the setting of cardiovascular disease and VTE: Novel approaches to residual risk reduction Deepak L. Bhatt (US) 6:45 - 7:10 PM Acute Coronary Syndrome (ACS) - Achieving effective prevention of thrombosis-related events: Factor Xa inhibition and the optimal balance between anti-ischemic efficacy and bleeding risk reduction John H. Alexander (US) 7:10 - 7:35 PM Challenges and new dimensions to stroke prevention in the setting of Atrial Fibrillation: Current deficiencies and future opportunities Sunil V. Rao (US) 7:35 - 7:55 PM Questions and answers: Faculty and participants debate results and implications of current trials focused on factor Xa inhibition Moderator: Stavros Konstantinides (DE) 7:55 - 8:00 PM

CMEducation Resources, LLC 6:30 PM - 8:00 PM Room 160 ABC Supported by an educational grant from EISAI The Practical and Research Dimensions of VTE Prevention and Management in Cancer and Associated Conditions: Focus on Optimal, Best Practice Strategies for DVT Management in the Inpatient and Outpatient Setting Chairperson: Craig M. Kessler (US) Welcome and introduction Clotting and cancer: Controversies and questions-critical challenges and landmark advances in venous thromboembolism (VTE)-A look at the contemporary landscape Craig M. Kessler (US) 6:30 - 6:45 PM

404

of patientswithcancerandVTE Interactive analysisofcase-basedmanagement cancer articulate,illuminateanddebatekeyissues care-focus onLMWHsandevidence-basedmedicine setting ofcanceratthefront linesofpatient Approaches tooptimizingDVTprophylaxis inthe clinical trialsguideus? A science-to-clinicalstrategyperspective-howdo Cancer, thrombosis, andthebiologyofmalignancy: Craig M.Kessler(US) about LMWHs? malignancy-What doestheresearch tellus with pharmacologicagentsinthesettingof preventing VTEandoptimizingmortalityoutcomes molecular weightheparin(LWMH) inmalignancy science, research, andfoundationrole oflow The interfaceofcancerandcoagulation:evolving Moderator: Inter Questions andanswers Edith Nutescu(US) and specialpopulations Focus oncompliance,challengingpatients, lines ofpractice: Optimizing long-termVTEpr guidelines NCCN,ASCO,andACCP) VTE prophylaxis inthecancerpatient-national Frederick Rickles(UK) ENSA,JL 5 09 6:30PM-8:00 2009 WEDNESDAY, JULY 15, national expertsinthr Craig M.Kessler(US) ombosis and evention atthefr ont 7:55 -8:00PM 7:35 -7:55PM 7:10 -7:35PM 6:45 -7:10PM 405

Satellite Symposia

WEDNESDAY, JULY 15, 2009 6:30 PM - 8:00 PM

CSL Behring GmbH 6:30 PM - 8:00 PM Room 104 ABC

Treatment of Congenital Bleeding Disorders: Future Trends in Management Chairpersons: Pier Mannucci (IT) and Donna DiMichele (US) Welcome and introduction Pier Mannucci (IT) and Donna DiMichele (US) 6:30 - 6:40 PM Visions in hemophilia care Steven Pipe (US) 6:40 - 7:00 PM Half-life extension through albumin fusion technologies Stefan Schulte (DE) 7:00 - 7:20 PM Results of international, multi-center pharmacokinetics trial in congenital fibrinogen deficiency Flora Peyvandi (IT) 7:20 - 7:40 PM Cryo: no longer the best choice for congenital Factor Deficiencies? David Bevan (UK) 7:40 - 8:00 PM

Loyola University Chicago 6:30 PM - 8:00 PM Room 107 ABC

Anticoagulant Therapy in Transition. Heparin and Oral Anticoagulants Challenged Chairpersons: Lilia Talarico (US) and Charles Francis (US) Moderator: Gary Raskob (US) Welcome and introduction Richard Kennedy (US) 6:30 - 6:40 PM Newer developments in heparin related drugs from heparin to pentasaccharides Jawed Fareed (US) 6:40 - 6:55 PM Future oral anticoagulants in the next decade Henry I. Bussey (US) 6:55 - 7:10 PM Antithrombin and anti-factor Xa drugs. Current developments Charles Francis (US) 7:10 - 7.25 PM

406

Gary Raskob(US) Gary Concluding remarks Russell Hull(CN) fromWhat dowelearn clinicaltrials? Transitions inanticoagulanttherapy. Job Harenberg(US) management ofthrombosis Newer andconventionalanticoagulantsinthe Stephan Moll(US) Concluding remarks Moderator: Discussion R. CampbellTait (UK) and efficacy Dosing strategiesofantithr Jerrold H.Levy(US) with car Acquir Michael J.Paidas(US) Clinical issuesinpatientsatrisk Stephan Moll(US) involving antithr Defining unmetpathologicandclinicalneeds Stephan Moll(US) Welcome andintroduction Chairperson: in Thromboembolic Disease Exploring theDiverseRoleofAntithrombin Deficiency Supported byaneducationalgrantfromLundbeckInc. (CME Provider) Institute forMedicalStudies 6:30PM-8:00 2009 WEDNESDAY, JULY 15, ed antithr diac surgeryandcar Stephan Moll(US) Stephan Moll(US) ombin disorders ombin deficiencyassociated ombin tooptimizesafety diopulmonary bypass :0P :0P Room205ABC 6:30 PM-8:00 7:25 -7:40PM 7:55 -8:00PM 7:40 -7:55PM 7:25 -7:40PM 7:05 -7:25PM 6:50 -7:05PM 6:35 -6:50PM 6:30 -6:35PM 7:55 -8:00PM 7:40 -7:55PM 407

Satellite Symposia

WEDNESDAY, JULY 15, 2009 6:30 PM - 8:00 PM

Octapharma AG (CH) 6:30 PM - 8:00 PM Room 253 ABC

From Human to Humans - Introducing the First Recombinant FVIII Produced From a Human Cell-Line Chairpersons: Edward G.D. Tuddenham (UK) and Johannes Oldenburg (DE) Welcome and introduction Edward G.D. Tuddenham (UK) 6:30 - 6:40 PM The human cell-line as a superior expression system - what are the benefits? Christoph Kannicht (DE) 6:40 - 7:00 PM Characterization and functional properties of the new human cell-line derived recombinant FVIII Irene Agerkvist (SE) 7:00 - 7:20 PM The clinical development of the first recombinant FVIII from a human cell-line Sigurd Knaub (DE) 7:20 - 7:35 PM First clinical experiences from a crossover pharmacokinetic study Nadezhda Zozulya (RU) 7:35 - 7:45 PM Concluding remarks Johannes Oldenburg (DE) 7:45 - 7:50 PM Questions and answers All Faculty 7:50 - 8:00 PM

Siemens 6:30 PM - 8:00 PM Room 156 ABC

Beyond the Clot - Innovations Targeting Primary and Secondary Hemostasis in Cardiovascular Disease Chairperson: Thomas Kickler (US) Welcome and introduction Thomas Kickler (US) 6:00 - 6:35 PM Targeting platelets in acute experimental stroke Bernhard Nieswandt (DE) 6:35 - 7:00 PM

408

Questions andanswers Edelgard Lindhoff-Last(DE) diagnostics? plasma expanders:Howdotheyinfluence New anticoagulants,thrombocyte antagonistsand Jeffrey Rade(US) after coronary arterybypasssurgery resistance predict earlyveingraftthrombosis Markers ofplatelethyper-reactivity andaspirin Robert Janco(US) Chairperson's Summary Robert Janco(US) Concluding QuestionsandAnswers Victor Blanchette(CA) Recombinant therapyinclinicalpractice Brian Colvin(US) Modifications infactormanufacturingprocesses Jørgen Ingerslev(DK) The historyofrecombinant therapy Robert Janco(US) Chairperson's Welcome andIntroduction Chairperson: and PurificationProcesses Recombinant TherapyandAdvancesinManufacturing Moderator: Wyeth Pharmaceuticals 6:30PM-8:00 2009 WEDNESDAY, JULY 15, Thomas Kickler(US) Robert Janco(US) :0P :0P Room204AB 6:30 PM-8:00 7:00 -7:25PM 7:55 -8:00PM 7:40 -7:55PM 7:10 -7:40PM 6:50 -7:10PM 6:35 -6:50PM 6:30 -6:35PM 7:50 -8:00PM 7:25 -7:50PM 409

Satellite Symposia NOTES ISTH2009

Technical Symposia Sessions

411 Technical Symposia

Technical Sessions take place on:

TUESDAY, JULY 14, 2009 6:30 PM - 7:30 PM

Rovi Room 104 ABC Network for Continuing Medical Education Room 107 ABC Supported by an unrestricted educational grant from Novo Nordisk Healthcare AG

412

in cancersurgery Scientific guidelinesonthromboprophylaxis Vijay Kakkar(UK) Welcome andintroduction Chairperson: Weight Heparins Latest AdvancesinCancerandLowMolecular Vijay Kakkar(UK) Concluding remarks Ana Falanga(IT) Effects oflowmolecularweightheparinincancer Paolo Prandoni(IT) in cancersurgery Prolonged thromboprophylaxis withbemiparin Vijay Kakkar(UK) USA,JL 4 09 6:30PM-7:30 Rovi 2009 TUESDAY, JULY 14, Vijay Kakkar(UK) :0P :0P Room104 ABC 6:30 PM-7:30 7:25 -7:30PM 7:15 -7:25PM 6:50 -7:15PM 6:35 -6:50PM 6:30 -6:35PM 413

Technical Symposia Sessions

TUESDAY, JULY 14, 2009 6:30 PM - 7:30 PM

Network for Continuing 6:30 PM - 7:30 PM Room 107 ABC Medical Education Supported by an unrestricted educational grant from Novo Nordisk Healthcare AG Evolving Pathogenic Threats to the Global Blood Supply: Impact an Haemophilia Treatment Chairperson: Roshni Kulkarni (US) Welcome and introduction Roshni Kulkarni (US) 6:30 - 6:35 PM Blood supply safety issues, emerging pathogens and surveillance – The US picture – The global picture Roger Y. Dodd (US) 6:35 - 6:50 PM The UK experience with variant Creutzfeldt-Jakob disease and surveillance Maura Ricketts (CN) 6:50 - 7:05 PM Current and emerging recombinant clotting factors for aemophilia with and without inhibitors Roshni Kulkarni (US) 7:05 - 7:20 PM Question and answer session and panel discussion All faculty 7:20 - 7:30 PM

414 ISTH2009

Exhibition and Sponsors

415 Sponsors ISTH 2009 would like to thank the following

PLATINUM SPONSORS

GOLD SPONSORS

416 s Sponsors ISTH 2009 would like to thank the following

SILVER SPONSORS Exhibition and Sponsor

BRONZE SPONSORS

Loyola University Medical Center

417

ISTH 2009 Partners

4 S Dawn Clinical Software Intelligent Imaging Innovations Inc. Accumetrics Inverness Medical Affinity Biologicals Invitrox Inc. American Diagnostica Inc. ISTH AstraZeneca ISTH 2011 Arteriosclerosis , Thrombosis and Journal of Thrombosis and Haemostasis Vascular Biology Kedrion Beckman Coulter Inc. Medirox AB Bio / Data Corporation MLTD & MLTD Foundation Bio Products Laboratory Multitplate Services GmbH Biocascade Inc. NHLBI-NIH Biogen Idec Hemophilia North American Thrombosis Forum Biomérieux Novo Nordisk Haemophilia Foundation Biotest AG Pentapharm DSM Nutritional Products AG Biovitrum Precision Biologic Inc. Chrono-log Corp. R2 Diagnostics Inc. Corgenix Inc. Roche Diagnostics GmbH Diapharma Group Inc. Rotem Inc. Elsevier S. Karger Publishers Inc. Enzyme Research Laboratories Inc. Saringer Life Science Technologies Inc Esoterix Inc. Schattauer GmbH Fluxion Biosciences SSC 2010 GTI Diagnostics Syntonix Subsidiary Haematologic Technologies Inc. Technoclone GmbH Haemonetics Corp. Thrombinoscope BV HPS Network Trinity Biotech PLC Hyphen Biomed SAS Vascular Disease Foundation Innovative Research Wiley Blackwell World Federation of Hemophilia

418 Thrombosis andHaemostasis. attendees willhaveacompleteoverviewofnewfindingsinthedomainVascular Medicine, areas are locatedadjacenttothebooths.Thanksexhibitorsfrom allovertheworld, An Exhibitionisheldconcurrently withtheISTH2009Congress. Thecoffee break andlunch HOSPITALITY SUITES Exhibition Area

FOOD COURT

POSTERS AREA

419 ENTRANCE TO POSTER AREA WHEN EXHIBITION REGISTRATION AREA MAIN ENTRANCE & EXIT IS CLOSED

Exhibition and Sponsors

Exhibition List

Exhibitors COMPANY NAME Exhibition Stand N° as of 4 S Dawn Clinical Software 867 June 2009 Accumetrics 917 Affinity Biologicals 915 Alexion Pharmaceuticals Inc. 711 American Diagnostica Inc. 869 Arteriosclerosis, Thrombosis and Vascular Biology 1108 Baxter Healthcare 660, 960 & 1063 Bayer HealthCare 1131 Bayer HealthCare & Ortho McNeil 1145 Beckman Coulter Inc. 517 Bio / Data Corp. 912 Bio Products Laboratory 1539 Biocascade Inc. 1173 Biogen Idec Hemophilia 611 Biomérieux 618 Biotest AG 139 Biovitrum 611 Boehringer Ingelheim 131 Chrono-log Corp. 1016 Corgenix Inc. 909 CSL Behring GmbH 345 DiaPharma Group Inc. 923 Eisai Inc. 1101 Elsevier 1011 Enzyme Research Laboratories Inc. 1008 Esoterix Inc. 1014 Fluxion Biosciences 1172 Future Event’s Knosk 1005 GlaxoSmithKline 361 Grifols International SA 315 B GTI Diagnostics 811 Haematologic Technologies Inc. 908 Haemonetics Corp. 614 HPS Network 368 Hyphen BioMed SA 1309 Innovative Research 913 Instrumentation Laboratory 315 A Intelligent Imaging Innovations Inc. 910 Inverness Medical 809 420

Exhibition List

COMPANY NAME Exhibition Stand N° Exhibitors as of Invitrox Inc. 110 ISTH 161 June 2009 ISTH 2011 360 Journal of Thrombosis and Haemostasis 1002 Kedrion 145 Laboratorios Farmaceuticos Rovi SA 123 Leo Pharma 1531 LFB 1339 Lundbeck Inc. 801 & 901 Medirox AB 515 MLDT & MLTD Foundation 267 Multiplate Services 616 NHLBI-NIH 364 North American Thrombosis Forum 362 Novo Nordisk Haemophilia Foundation 523, 622 & 624 Novo Nordisk Health Care AG 239 & 331 Octapharma AG 1345 Pentapharm DSM Nutritional Products AG 919 Pfizer 1201 Precision Biologic Inc. 124 R2 Diagnostics Inc. 1010 Roche Diagnostics GmbH 1545 Rotem Inc. 1166 S. Karger Publishers Inc. 1110 sanofi-aventis 617 & 819 Saringer Life Science Technologies Inc. 1164 Schattauer GmbH 1009 Siemens Healthcare Diagnostics Products 1551 SSC 2010 Cairo 162 Stago 151 Syntonix Subsidiary 611 Sysmex Corp. 1551 Talecris Biotherapeutics 1321 Technoclone GmbH 923 Thrombinoscope BV 1069 Trinity Biotech PLC 1019 Vascular Disease Foundation 366 Wiley Blackwell 1004 World Federation of Hemophilia 269 Wyeth Pharmaceuticals 1331 421 NOTES ISTH2009

Exhibitor and Sponsor Profiles

423 EXHIBITOR AND SPONSOR PROFILES

4S DAWN CLINICAL SOFTWARE BOOTH N°867

4 The Square Milnthorpe Cumbria LA7 7QJ California United Kingdom Website: www.4s-dawn.com 4S was founded in 1984 and has been involved in medical applications since start-up. Currently, we have 16 staff members, and over 350 clients in 17 countries worldwide. An estimated 500,000 patients are managed using our software. Our Software helps Clinicians manage patients in the following areas: Anticoagulation - Clinical Haematology - Hepatitis - Anaemia - Diabetes - Rheumatology

ACCUMETRICS BOOTH N° 917

3985 Sorrento Valley Blvd San Diego 92121 California United States Website: www.accumetrics.com Accumetrics is committed to advancing medical understanding of platelets and enhancing quality of care for patients who are at risk of cardiovascular disease by providing industry-leading diagnostic tests to assess response to antiplatelet therapy. With Accumetrics' family of VerifyNow® tests, which address every major type of antiplatelet therapy, including aspirin, P2Y12 inhibitors (Plavix®) and GP IIa/IIIb inhibitors (e.g. ReoPro® and Integrilin®), it provides physicians with a rapid, easy and valuable tool to help guide treatment decisions.

AFFINITY BIOLOGICALS BOOTH N° 915

1395 Sandhill Drive L9G 4V5 Ancaster Ontario Canada Website: www.affinitybiologicals.com Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis and haemostasis research as well as medical diagnostics. Products include an extensive line of antibodies and conjugates, immunoassay products, the VisuLize™ line of complete ELISA kits, and a full line of human plasma products including affinity-depleted factor-deficient plasmas (Factors II through XIII, PC, PS, ATIII), calibrators and controls. Affinity is registered to ISO 13485, holds license(s) with the Canadian Therapeutic Products Directorate (TPD) and is FDA QSR compliant.

ALEXION PHARMACEUTICALS INC. BOOTH N° 711

352 Knotter Drive Cheshire, CT 6410 USA Website: www.alxn.com Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life- changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, transplant, cancer, and autoimmune disorders. Soliris is Alexion's first marketed product, approved in the U.S. and Europe in 2007, and Canada and Australia in 2009.

424 EXHIBITOR AND SPONSOR PROFILES

AMERICAN DIAGNOSTICA INC. BOOTH N° 869

500 West Avenue PO Box 110215 Stamford 06911-0215 Connecticut United States Website: www.americandiagnostica.com American Diagnostica Inc. is now a member of the Sekisui Group and is a subsidiary of Sekisui Medical

Co. Ltd. in Tokyo, Japan. We are displaying our World Class products, including tests for Lupus ofiles Anticoagulants, including the first commercial dPT test and ACTICLOT® LA Complete™, combined dRVVT and dilute PT assays. Also kits for Protein S, Protein C, ATIII, D-dimer, activity and ELISA kits for vWF, PAI-1 and ADAMTS13, ELISA kits for APS, TF, TFPI, uPA, etc. We are a leader in new products such as FSAP (Factor V Activating Protease) and 12 LOX (12-Lipoxygenase), to name a few.

ARTERIOSCLEROSIS, THROMBOSIS BOOTH N° 1108 AND VASCULAR BIOLOGY

University of Rochester, Exhibitor and Sponsor Pr 10 Circle Drive, Ste 12 North Liberty 52317 United States Website: atvb.ahajournals.org The Editorial Office of Arteriosclerosis, Thrombosis and Vascular Biology, journal of the American Heart Association, is available to discuss submissions, policies, and provide additional journal information, including journals and reprints. Visit us today or online at atvb.ahajournals.org!

ASTRAZENECA SPONSOR

S-431 83 Mölndal, Sweden Telephone: 0046 317761000 Websites: www.astrazeneca.com

BAXTER HEALTHCARE BOOTH N° 660, 960 & 1063

One Baxter Way Westlake Village CA 91362 United States www.Baxter.com Baxter's BioScience business is a leading producer of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders. Baxter continues to innovate, advancing science and technology to drive better patient care.

425 EXHIBITOR AND SPONSOR PROFILES

BAYER HEALTHCARE BOOTH N° 1131 & 1145

6 West Belt Wayne 07470 6806 New Jersey United States Website: www.pharma.bayer.com About Bayer HealthCare Pharmaceuticals. Bayer HealthCare Pharmaceuticals is among the top ten specialty pharmaceutical companies worldwide. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer HealthCare Pharmaceuticals aims for leading positions in specialized markets worldwide. Using new ideas, Bayer HealthCare Pharmaceuticals aims to make a contribution to medical progress and strives to improve the quality of life.

BECKMAN COULTER, INC. BOOTH N° 517

200 S. Kraemer Blvd. Brea 92822 California United States Website: www.beckmancoulter.com Beckman Coulter offers hemostasis solutions scaled to your laboratory's needs-today and in the future. Our easy-to-use, fully automated ACL* systems offer superior performance and reliability along with the widest range of routine and specialty assays. Our instruments also offer unsurpassed service and support to help your lab increase productivity and improve patient care.*ACL is a registered trademark of Instrumentation Laboratory

BIO / DATA CORPORATION BOOTH N° 912

155 Gibraltar Road, PO Box 347 Horsham, PA 19044-0347 USA Website: www.biodatacorp.com Bio/Data Corporation is a leading manufacturer, marketer, and worldwide distributor of thrombosis, hemostasis, and platelet function products. Our Company focuses on providing high quality instruments, reagents, controls, accessories and disposables. Bio/Data Corporation also offers specialized, study specific products for clinical trials. New this year: vW Select™, Ristocetin CoFactor Assay Kit. It is the only complete test system designed to help laboratories comply with regulatory requirements for test system verification and calibration. An ISO 9001:2000, ISO 13485:2003 Registered Company.

BIO PRODUCTS LABORATORY BOOTH N° 1539

Dagger Lane Elstree WD6 3BX United Kingdom Website: www.bpl.co.uk BPL is the United Kingdom's national plasma fractionator and is a part of the National Health Service Blood and Transplant (NHSBT).BPL is committed to providing a continuous supply of high quality, safe plasma-derived products to a growing global market through investing in the latest research, technology and manufacturing methods.

426 reagents, andtestkits-Immobilized heparintestingofmedicaldevices. validation studies-Customandspecialtytestdevelopmentservices-Contractmanufacture ofproteins, heparin, andantithr research, pharmaceuticalandmedicaldevicemanufacturingsectors:-Chromogenic heparin,LMW- Biocascade, agloballeaderincoagulationtesting,provides thefollowingservicesandproducts tothe Website: www.biocascade.com United States Wisconsin Arlington 53911 P.O. Box 98 107 SkylineDrive myeloma andpsoriasis. biotherapeutics, includinginnovativemonoclonalantibodytherapiesagainst rheumatoidarthritis,multiple human plasma.Themainfocusofclinicalinvestigationisonrecent developmentsinthefield of immunoglobulin preparations, clottingfactorconcentratesandalbumins,whichallare purifiedfrom immunology andhaematology Biotest isaGermanresearch-based pharmaceuticalanddiagnosticscompany, dedicatedtotheareas of Website: www.biotest.com Germany Dreieich 63303 Landsteinerstrasse 3-5 to safelyexcludeout-patientswithsuspectedvenousthr FDA-cleared/CE-marked test foruseinconjunctionwithaclinicalPre-Test Probability assessmentmodel new, recognized more rapidversionoftheinternationally VIDAS®D-DimerExclusion™test-first car VIDAS® Emergencyrangepr bioMérieux isaworldleaderinthefieldofvitro diagnosticsforclinicalandindustrialapplications.Our W France France 69280 Chemin del'Orme IMREXBOHN 618 BOOTHN° BIOTEST AG BIOMÉRIEUX 1173 BOOTHN° BIOCASCADE INCORPORATED EXHIBITOR AND SPONSORPROFILES ebsite: www diovascular diseasesandbacterialinfection.TheupcomingVIDAS®D-DimerExclusion™IIassayisa .biomerieux.com ombotic testing-Kinetichrome Anti-XaandAnti-IIatestkits-Methoddevelopment ovides highmedicalvaluer . Biotest'splasmaprotein divisiondevelopsandmarketsvarious omboembolism (VTE). esults andauniquemenuforthediagnosisof OT °139 BOOTH N° 427

Exhibitor and Sponsor Profiles EXHIBITOR AND SPONSOR PROFILES

BIOGEN IDEC HEMOPHILIA/ SYNTONIX SUBSIDIARY & BIOVITRUM BOOTH N°611

Biogen Idec Hemophilia Biovitrum AB (publ) Syntonix Subsidiary SE-112 76 Stockholm 9 Fourth Avenue Sweden Waltham, MA 02451 Website: www.biovitrum.com United States Biogen Idec's Syntonix Subsidiary with development partner Biovitrum AB (publ) has developed several Fc fusion molecules by coupling a therapeutic agent to the Fc domain of an antibody to extend the plasma half-life of the therapeutic agent. The lead investigational compound of this collaboration, FIXFc, is a recombinant fusion molecule that combines the Fc domain of antibody to clotting factor IX. Clinical evaluation of the potentially long-acting FIX product is underway.

BOEHRINGER INGELHEIM GMBH BOOTH N° 131

Binger Strasse 173 Ingelheim 55216 Germany Website: www.boehringer-ingelheim.com The Boehringer Ingelheim Group has become one of the top 20 leading pharmaceutical companies in the world since it was founded in 1885. Headquartered in Ingelheim, Germany, with more then 40.000 employees, it operates globally with 135 affiliates in companies spread around the globe. The family- owned company is committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2008, Boehringer Ingelheim posted net sales of over 11,6 billion Euros, while spending one-fifth of net sales on research and development.

BRISTOL-MYERS SQUIBB SPONSOR

Corporate Headquarters 345 Park Avenue New York New York 10154 Website: www.bms.com Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life. Bristol-Myers Squibb employees are dedicated to discovering, developing and providing innovative medicines that help patients prevail against serious diseases.

CHRONO-LOG CORP. BOOTH N° 1016

2 West Park Road Havertown 19083 Pennsylvania United States Website: www.chronolog.com Chrono-log Corp. manufactures systems for quickly screening the anti-platelet effect of drugs such as Aspirin and Plavix. Systems with disposable impedance probes [Models 700, 591A and 592A], plus the ability to test platelets in Whole Blood, greatly reduce hands-on and significantly improve turn-around time. Systems with Disposable probes are rated CLIA-moderate and tests are reimbursable. Visit Booth No. 1016 to also learn more about Chrono-log systems with Luminescence used to detect specific platelet disorders such as Secretion and Storage Pool Disorders. See you in Boston!

428 von Willebrand Disease.Corgenixalsooffers contractR&Dandmanufacturingservices. von Willebrand assays forselectedautoimmune,vascularandliverdisorders, suchasAntiphospholipidSyndrome and The REAADSELISAproducts includethenewAspirinWorks® Test formeasuringaspirineffect, and Corgenix develops,manufactures andmarketsdiagnosticproducts fortheworldwidehealthcare market. Website: www.corgenixonline.com United States Colorado Broomfield 80020 Suite 400 11575 MainStreet generation, ADAMTS13,microparticles, andplateletfunction. applications. PleasevisitDiapharma, andseeournewestdiagnostictoolsformeasuringthrombin customer serviceandahighlytrained teamoftechnicalrepresentatives todiscussspecializedproduct bleeding disorder management,andhemostasisresearch. We prideourselvesinproviding supportive DiaPharma distributestestkitsand reagents forthrombophilia diagnosis,anticoagulationmonitoring, W United States West Chester45069 8948 BeckettRoad 07054 Parsippony, NY DaiichiSankyo,Inc. www United States 46285 Indianapolis,IN Lilly CorporateCenter networks, CSLPlasma.BehringisasubsidiaryofLimited,biopharmaceuticalcompany and inheritedemphysema.Thecompanyalsooperatesoneoftheworld'slargestplasmacollection treatment disease,otherbleedingdisorders ofimmunedeficiency disorders, hemophilia,vonWillebrand derived andrecombinant products andrelated services. Thecompany'stherapiesare usedinthe the qualityofpatients'lives,CSLBehringmanufactures andmarketsarangeofsafeeffective plasma- CSL Behringisagloballeaderintheplasmapr Website: http://www.cslbehring.com Germany Marburg 35002 P.0.Box 1230 DIAPHARMA GROUP 345 BOOTHN° DAIICHI SANKYOINCANDLILL 909 BOOTHN° CSL BEHRINGGMBH CORGENIX, INC. EXHIBITOR AND SPONSORPROFILES ebsite: www llycmUnitedStates .lilly.com .diapharma.com , INC. www T wo HiltonCourt .dsus.com Y USA,LLC otein biotherapeuticsindustry . Passionateaboutimpr BOOTH N SPONSOR ° . 923 oving 429

Exhibitor and Sponsor Profiles EXHIBITOR AND SPONSOR PROFILES

EISAI INC. BOOTH N° 1101

100 Tice Blvd. Woodcliff Lake New Jersey 07677 United States Website: www.eisai.com Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

ELSEVIER BOOTH N° 1011

1600 JFK Blvd. Suite 1800 Philadelphia 19103 Pennsylvania United States Website: www.elsevierhealth.com Elsevier is the leading international publisher of medical journals, books, and electronic products. Stop by our booth to browse our latest selections in the field of Thrombosis and Haemostasis.

ENZYME RESEARCH LABORATORIES INC. BOOTH N° 1008

1801 Commerce Drive South Bend 46628 Indiana United States Website: www.enzymeresearch.com Enzyme Research Laboratories provides coagulation and fibrinolytic proteins from human plasma, other source plasmas and platelets. Additionally, we offer monoclonal and polyclonal antibodies, immu- nodepleted plasmas and ELISA reagents. Custom purifications and contract services are also available.

ESOTERIX, INC BOOTH N° 1014

4509 Freidrich Ln Bldg. 1, Ste. 100 Austin 78744 Texas United States Website: www.esoterix.com Esoterix is a national reference laboratory and a recognized leader in coagulation testing. Through a consultative approach, Esoterix's services become a seamless extension to a client's current laboratory capabilities. Esoterix's extensive test menu and staff expertise ensure that clients have the resources to predict, diagnose, and manage even the most unusual bleeding and clotting disorders. Esoterix is a wholly owned subsidiary of Laboratory Corporation of America where its laboratories operate as Centers of Excellence for specialized services and esoteric testing.

430 derivatives totreat patients,savelivesandimprove lifeexpectancy. to makepossibleaclearandprecise diagnosiswhiletheBioscienceDivisionprovides highqualityplasma range fr therapy, enteralnutrition,diagnosticsystemsandmedicalmaterials.Inthehemostasisfield,ourproducts countries around theworld.We research, develop,manufacture andmarketplasmaderivatives,IV assays andinvivostudiestopr high throughput ionchannel screening. Ourtechnologiesbridgethegapbetweenbiochemicalscreening microfluidicFluxion's technologiesprovide simplehighthroughput livecellassaysundershearflowand Website: www.fluxionbio.com United States California SSF 94080 Suite 6 384 OysterPointBlvd GTI Diagnosticsdesigns,manufactur Website: www.gtidiagnostics.com United States W Waukesha 53186 20925 CrossroadsCircle Grifols isagr Website: www.grifols.com Spain Barcelona 8005 C/ delaMarina,16-18,Torre Mapfre,planta30 changing healthcar combination ofskillsandresources thatprovides a platformfordeliveringstrong growth intoday'srapidly GlaxoSmithKline (GSK)isaworldleadingresearch-based pharmaceuticalcompanywithapowerful Website: www.gsk.com France Marly-Le-Roi 78163Cedex 100 RoutedeVersailles interested partners. automated foruse ontheQuickStepinstrument.GTI Diagnosticsalsooffers selectOEM servicesto Blood Bank,CoagulationandHLAlaboratories. Manyofourassaysare configured formanualuseorare come visitusatourexhibitionboothifyouwouldlikefurtherinformation. thrombosis andcardiovascular diseasebyproviding arangeofinformationonitsproduct portfolio.Please to domore, feelbetterand livelonger.At theISTH,GSKwilldemonstrateitscontinuedcommitmentto T IGOTC OT °811 BOOTHN° 315B BOOTHN° GTI DIAGNOSTICS 361 BOOTHN° GRIFOLS INTERNATIONAL, S.A. 1172 BOOTHN° GLAXOSMITHKLINE FLUXION BIOSCIENCES EXHIBITOR AND SPONSORPROFILES isconsin om DiagnosticstoTherapy:theDiagnosticDivisionoffers reagents, instrumentationandsoftware oup ofhealthcar e envir onment.Our missionistoimpr ovide more powerful,predictive assaysandhigherqualityleadcompounds. e companieswhichserveshealthpr es andmarketsworldwideavariety of invitr ove thequalityofhumanlifebyenablingpeople ofessionals andpatientsinover90 o diagnosticassaysfor 431

Exhibitor and Sponsor Profiles EXHIBITOR AND SPONSOR PROFILES

HAEMATOLOGIC TECHNOLOGIES, INC. BOOTH N° 908

57 River Road Unit 1021 Essex Junction 5452 United States Website: www.haemtech.com Haematologic Technologies, Inc. (HTI) is a primary manufacturer of research reagents, specializing in the isolation and characterization of plasma proteins involved in the regulation of blood coagulation and fibrinolysis. Our product line of highly purified proteins includes zymogens, enzymes, cofactors, and inhibitors as well as monoclonal and polyclonal antibodies. Services available by contract include: custom protein purification, assay development, and contract research.

HAEMONETICS CORPORATION BOOTH N° 614

400 Wood Road Braintree 2184 Massachusetts United States Website: www.haemonetics.com Haemonetics assists you in understanding your unique blood management needs and applying the right combinations of technologies and services to help you improve patient outcomes and decrease costs. When the options seem limitless but the right ones aren't clear, you need a partner to help make the changes that are right for your hospital's blood management program.

HPS NETWORK BOOTH N° 368

One South Road Oyster Bay New York 11771-1905 United States Website: www.hpsnetwork.org

HYPHEN BIOMED SAS BOOTH N° 1309

155 Rue d'Eragny Neuville sur Oise 95000 France Website: www.hyphen-biomed.com HYPHEN BioMed is a scientific and technical company, expert in biological reagents for haemostasis, thrombosis, fibrinolysis and auto-immune disorders. It is a privileged laboratory partner for anti-thrombotic drug discovery, manufacturing processes and QC of anticoagulant drugs. Through its worldwide distribution network, and expert partner companies (Aniara Diagnostica, Biogenic, Coachrom, Diagnostica CZ, Quadratech, Nodia, Endotell and Cabru), research and IVD reagents (CE and 510(k) cleared) can be applied to all automatic platforms available, with a full service for instrument applications.

432 expectations witheverypr in theirrespective field of research andwewill continuedoourbesttoexceedyour continually strivetoprovide ourresearchers with the toolstheyneedtoachieveacompetitiveadvantage human andanimalbiologicals,coagulationproteins, antibodiesandELISAkitsremains ourgoal.We the highestqualitybiomedicalproducts andservicesavailabletoday. Ourfocusonproviding dependable For overadecade,researchers around theworld have trustedInnovativeResearch toprovide themwith Website: www.innov-research.com United States Michigan Novi 48377 Court 46430 Peary single moleculetracking,orgeneralmicr discuss highspeedandmulti-dimensionalimagingduringvasculardamage, cellularrolling andtrafficking, fluorescence, spinningdiskconfocal,and2-photonmicroscopy. Representatives willbeavailableto for avarietyofliveanimalimagingtechniquesincludingtransmitted light,multi-channelwidefield released 64-bitnativeSlideBook5.0software. ComeseeourVIVOlineofintravitalimagingsystems,ideal 3i manufactures research levellivecellandintravitalmicroscopy imagingsystemsbasedonourNEWLY Website: www.intelligent-imaging.com United States Denver 80216 5124 N.W panel offullyautomatedassays,IL Automation”; andtheACLELITEsystem.CombinedwithHemosIL®lineofreagents, acomprehensive CTS, ACLTOP700CTSandLAS-allfullyautomated,random-accessanalyzersthatdeliver“Testing Process hemostasis specialtytesting;ACLTOP®FamilyofHemostasisTesting Systems, includingACLTOP500 exhibitfeatures:IL's thenewACLAcuStar™,firstfullyautomated,chemiluminescentanalyzerfor Website: www.ilus.com United States Massachusetts Bedford 01730 180 HartwellRoad NELGN MGN NOAIN,IC OT °910 BOOTHN° INTELLIGENT IMAGINGINNOVATIONS, INC. 315A BOOTHN° 913 BOOTHN° INSTRUMENTATION LABORATORY INNOVATIVE RESEARCH EXHIBITOR AND SPONSORPROFILES ashington Street oduct. fers completediseasestatemanagementforthehemostasislab. oscopy asitpertainstoyourr esear ch. 433

Exhibitor and Sponsor Profiles EXHIBITOR AND SPONSOR PROFILES

INVERNESS MEDICAL BOOTH N° 809

3347 Investment Boulevard Hayward 94545 California United States Website: www.invernessmedicalpd.com HemoSense®, a subsidiary of Inverness Medical, develops, manufactures and sells easy-to-use, handheld blood coagulation monitoring systems for use by patients and healthcare professionals in the management of warfarin medication. Warfarin is an oral anticoagulant, or blood thinning drug given to patients to prevent potentially lethal blood clots from forming. HemoSense's INRatio® PT/INR Monitoring System consists of a small, portable monitor and disposable test strips and provides a quick and accurate measurement of a patient's blood clotting time, known as a PT/INR value.

INVITROX INC. BOOTH N° 110

104 TW Alexander Dr. Bdlg. #6 Research Triangle Park RTP 27709 United States Website: www.invitrox.com Invitrox, a diagnostic company founded in 2003, provides clinical lab services to pharmaceutical and biotechnology companies. The company has filed multiple patents for two medical instruments capable of uniquely identifying and characterizing suspended particles, e.g., microparticles, platelets, circulating tumor cells, and microbes. Invitrox's most advanced technology, a cell size and surface antigen detector - MPAD, provides an analysis capability not yet available in the market.

ISTH 2011 BOOTH N° 360

Secretariat of ISTH2011 c/o Japan Convention Services, Inc. 1-4-2 Kasumigaseki, Chiyoda-ku Tokyo Japan 100-0013 Website: www.isth2011.com

XXIIIrd Congress of the International Society on Thrombosis and Haemostasis(ISTH 2011) and 57th Annual SSC Meeting will be held in Kyoto, Japan. Kyoto is a charming city jeweled by over 2000 temples and shrines. The experience in this city which had been the capital of Japan for over eleven centuries will be precious and unforgettable. See you in two years!

JTH BOOTH N° 1002

Commonwealth Bldg, 5 th Floor, Du Cane Rd London, W12 0NN UK Website: www.journalth.com Visit the Journal of Thrombosis and Haemostasis booth to find out more about the official journal of the ISTH and one of the leading titles in the field. Now with an Impact Factor of 5.947 (2007), the Journal of Thrombosis and Haemostasis is the essential resource for all involved in thrombosis, bleeding disorders and vascular biology. Pick up your sample copy and speak to a member of the editorial team. For more information visit www.journalth.com

434 commercialization inforeign markets·otheractivities:inparticulartransferoftechnologicalknow-how. ·commer works infourbusinessareas: ·production andcommercialization ofplasma-derivedproducts plants: Bolognana,nearLucca-I-S.Antimo,NaplesGödöllQ,Budapest-Hu-Kedrion and distributionofplasma-derivedproducts. Production iscarriedoutinthree authorizedproduction Kedrion isabiopharmaceuticalcompanyspecializedinthedevelopment,production, commercialization Website: www.kedrion.com Italy Castelvecchio Pascoli-Barga55051 Loc. aiConti owned bytheLEOFoundation. tissue toproduction offinishedproduct.LEO Pharmaisanindependentpharmaceuticalcompany100% companies whichmaintainitsownintegratedmanufacturingfrom extractionofrawmaterialfrom animal Pr pulmonary embolismanddeepveinthrombosis.LEO Pharmaalsosuppliestheheparinantidote, Innohep® isoneoftheleadinglowmolecularweightheparinsusedin treatment andprevention of In 1991,LEOPharmalaunchedthelowmolecularweightheparin(LMWH), Innohep®(tinzaparinsodium). Website: leo-pharma.com Denmark Ballerup 2750 Industriparken 55 unequivocal LMWHlicensedinEUforapost-opinitiationofthr resulting from apatentedexclusivefractionationprocess.Just intimefortheprevention ofVTE:the Bemiparin, asecondgenerationLMWHBemiparinhasanuniqueandinnovativepharmacologicalprofile W Spain Madrid 28037 Julián Camarillo,35 exposed tobemiparin. effective strategy. 10yearsofpost-marketingexperience:in35countrieswith over7millionpatients more effective thanUFHinreducing thrombus sizeduringtheacutephaseofDVTandrepresents acost- orthopaedic surgeryandasef LEO PHARMA 145 BOOTHN° 123 BOOTHN° LABORATORIOS FARMACÉUTICOS ROVI,S.A. KEDRION EXHIBITOR AND SPONSORPROFILES ebsite: www otamine SulphateLEOPharma,inanumberofmarkets.LEOPharmaisone ofthefewr cialization offluvaccinesandsyntheticpharmaceuticalproducts ·plasmacollectionand .rovi.es fective andsafeasenoxaparin.Forthetr ombopr eatment ofDVTwithorwithoutPE: ophylaxis 6hoursaftergeneraland OT °1531 BOOTH N° esearch-based 435

Exhibitor and Sponsor Profiles EXHIBITOR AND SPONSOR PROFILES

LFB BOOTH N° 1339

3 Avenue des Tropiques BP 305 Les Ulis ZA Courtaboeuf Les Ulis 91958 France Website: www.lfb.fr LFB is a biopharmaceutical group that develops,manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields:Hemostasis,Immunology and Intensive Care.LFB is the leading manufacturer of plasma-derived medicinal products in France and the 6th player worldwide.It is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies.With its strong focus on innovation,LFB is developing a growth strategy expanding its business activities in international markets and offering new therapeutics.

LUNDBECK INC. BOOTH N° 801 & 901

Four Parkway North Suite 200 Deerfield, IL 60015 United States Website: www.lundbeckinc.com

Lundbeck Inc. has proven success in developing and commercializing high-need treatments. The company is committed to providing innovative therapies that fulfill unmet medical needs of people with severe, and often rare, disorders for which few, if any, effective treatments are available. More information about the company, its products and full prescribing information may be found at www.lundbeckinc.com.

MEDIROX AB BOOTH N° 515

SE 611 82 Nykoeping Nykoping SE 611 82 Sweden Website: www.medirox.se MediRox produces high quality instruments, diagnostic reagents and quality control material used in the areas of visco-elasticity and coagulation diagnostics since 1998. MediRox is constantly searching for commited distribution partners for our product portfolio. We are also OEM/ Private labelling bulk supply to well known companies including Siemens/DADE, Trinity, Teco, Helena Lab and others.Products;oCoag ControlsBasicMulti incl D-DimerMulti PLUS incl D-Dimer, Prot S&CoCoag ReagentsPT D-DimerATIII FXa APTT LR oInstrumentsAdvanced coag. Thromboelastography analysers.See www.medirox.se for more information.

436 and car function analyzersinEurope. Multiplate®isavailableforresearch useintheUSA. over500installationsinthemarketMultiplate®isamongmostwidelyappliedplatelet thrombosis. With as inadequateresponders according toMultiplateanalysisexhibiteda9.4foldincreased riskofearlystent the clinicalimpactofclopidogrel resistance (JACC2008;53(10):849-56)hasshownthatpatients,stratified prasugrel, IIb/IIIareceptor antagonistsandacquired plateletdisorders. Thelargeststudytodateevaluating The Multiplate®plateletfunctionanalyzerishighlysensitiveforthedetectionofaspirin®,clopidogrel, Website: www.multiplate.net Germany Munich 80469 Reichenbachstr. 27 translational research; 2)Clinicalresearch; 3)Prevention andeducation;4)Publicpolicy;5)Advocacy. peripheral arterialocclusivedisease,andstroke. NATF's fiveareas ofmajorfocusare: 1)Basic r car The NorthAmericanThrombosis Forum(NATF) isanonprofit agencywiththevisionofimproving patient Website: www.NATFonline.org United States Massachusetts Crossing02120-1613 Roxbury 1620 Tremont Street,Suite3022 NHLBI hasalsohadadministrativer of theheart,bloodvessels,lung,andblood;resources; andsleepdisorders. SinceOctober1997,the The NationalHeart,Lung,andBloodInstitute(NHLBI)provides leadershipforanationalprogram indiseases Website: www.nhlbi.nih.gov United States Bethesda 20892,MD Suite 9030 6701 RockledgeDrive Two RockledgeCenter and sleepdisor r clinical investigationsandtrials,observationalstudies,demonstrationeducationprojects. Research is The Instituteplans,conducts,fosters,andsupportsanintegratedcoordinated program ofbasicresearch, elated tothecauses,prevention, diagnosis,andtreatment ofheart,bloodvessel,lung,anddiseases; esear OT MRCNTRMOI OU OT °362 BOOTHN° 364 BOOTHN° NORTH AMERICANTHROMBOSISFORUM 616 BOOTHN° NHLBI-NIH MULTIPLATE GMBH SERVICES EXHIBITOR AND SPONSORPROFILES e, outcomes,andpublichealthbyutilizingamulti-disciplinaryapproach toadvancethrombosis ch andeducation.NA diovascular diseasessuchasdeepveinthr ders. TF's missionistofocusonunmetneedsandissuesrelated tothrombosis esponsibility fortheNIHW ombosis, pulmonaryembolism,myocar oman's HealthInitiative. dial infar ction, 437

Exhibitor and Sponsor Profiles EXHIBITOR AND SPONSOR PROFILES

NOVO NORDISK HAEMOPHILIA FOUNDATION BOOTH N° 523

Andreasstrasse 15 Zürich 8050 Switzerland Website: www.nnhf.org

The Novo Nordisk Haemophilia Foundation (NNHF) was created in 2005, in Zurich, Switzerland, as an independent, non-profit entity to address the significant need for improving haemophilia care in the developing world. An estimated 75% of the global haemophilia population resides in the developing world where haemophilia is not a healthcare priority and many people go undiagnosed or are inadequately treated. NNHF funds development programmes to deliver capacity building, patient education, diagnosis and registries in the developing world - aiming to bridge the gap between the developed and the developing worlds.

NOVO NORDISK HEALTH CARE AG BOOTH N° 239 & 331

Andreasstrasse 15 Zurich 8050 Switzerland Website: www.novonordisk.com Novo Nordisk is a global healthcare company with a leading position in haemostasis management, providing treatment of spontaneous and surgical bleedings in haemophilia A and B patients with inhibitors against factors VIII and IX respectively.For more information on what Novo Nordisk are doing to Change Possibilities in Haemophilia, visit us at our booth in the exhibition hall.

OCTAPHARMA AG BOOTH N° 1345

Seidenstrasse 2 Lachen 8853 Switzerland Website: www.octapharma.com Octapharma is an independent, Swiss-based biopharmaceutical company operating worldwide in 28 countries, with 3,000 employees and 5 modern, state-of-the-art production facilities in Austria, France, Germany, Sweden, and Mexico. Octapharma's overall mission is to provide safe and optimal use of human proteins to patients in need of lifesaving therapies covering coagulation disorders, immune diseases and medical emergencies. Octapharma will highlight the following products in ISTH: wilate®, octanate®, octanine F®, nanotiv®, and octaplex®, including its new recombinant factor VIII concentrate produced from a human cell line.

PENTAPHARM DSM NUTRITIONAL PRODUCTS AG BOOTH N° 919

Engelgasse 109 Basel 4002 Switzerland Website: www.pentapharm.com Pentapharm is a manufacturer of reagents for blood coagulation diagnostics:Test kits e.g. Pefakit® APC- R Factor V Leiden, PiCT® (for anti-FIIa and FXa drug monitoring), Reptilase Time, in-TDT®, FXIII functional assay, TAFI or OEM products.Reagents (from research to bulk quantities) including custom development and production: synthetic chromogenic and fluorogenic substrates, inhibitors, snake venom enzymes. Active pharmaceutical ingredients: aprotinin, peptides and snake venom derived enzymes (Batroxobin; Haemocoagulase ) and custom synthesis of peptides and small organic molecules.

438 diagnostic kits,controls and specialtyplasmashavebecomefavoritesinmanylaboratories. pr approaches tobetterhealth. We discover, develop,manufacture anddeliverquality, safeandeffective Founded in1849,Pfizeristheworld'slargestresearch-based pharmaceuticalcompanytakingnew Website: www.pfizer.com United States New York New York 10017-5755 MS 219-7-1 235 E.42ndStreet inflammatory andmetabolic disor leader invirology. Itisalsoactiveinothermajortherapeuticareas suchasautoimmune diseases, Roche istheworldleaderinin-vitro diagnosticsanddrugsforcancer andtransplantation,isamarket company theGr healthcare groups inthefieldsofpharmaceuticalsanddiagnostics. Astheworld'sbiggestbiotech About Rocheheadquarter Website: www.roche-diagnostics.com Germany Mannheim 68305 Sandhofer Strasse116 r2 Diagnostics,asistercompanytoEnzymeResear Website: www.r2diagnostics.com United States Indiana South Bend46628 1801 CommerceDrive coagulation laboratoriesar technologists, we'vedevelopedandmanufactur achieve theproductivity you need.Through yearsofextensivecollaborationwithlabmanagersand and getthemrightthefirsttime.AtPrecision BioLogic,we're committedtomakingiteasierforyou In thecoagulationlab,youwantconfidenceinresults youare reporting. You wanttodothingsquickly Website: www.precisionbiologic.com Canada Dartmouth B0J2E0 140 EileenStubbsAve assays forhemostasis. of specialtyreagents andkits,canprovide thelaboratorywithanexpandingmenuofdiagnostic purity pr S, LupusScreen andConfirm,KCT, andFibrinogenkitsmanufactured Thrombin withERL'shigh Time, specialty reagents totheclinicalcoagulationlaboratory. Ourproducts includerobust PT, APTT, Protein ROCHE DIAGNOSTICSGMBH 1201 BOOTHN° R2 DIAGNOSTICS,INC. PRECISION BIOLOGICINC. PFIZER EXHIBITOR AND SPONSORPROFILES escription medicinestotreat andhelpprevent diseaseforbothpeopleandanimals. oteins andwith“endtoend”control overmaterialsandprocesses. r2investsinthedevelopment oup contributesonabroad rangeoffronts toimproving people'shealthandqualityoflife. ed inBasel,Switzerland,Rocheisone oftheworld'sleadingresearch-focused ound theworld.Knownfortheirintegrity ders anddiseases ofthecentralnervoussystem. ed arangeofinnovativepr ch Laboratories,pr , simplicity ovides generalpurposeand oducts usedinclinical BOOTH N BOOTH N , andr OT °124 BOOTH N° elevance, our 1545 ° ° 1010 439

Exhibitor and Sponsor Profiles EXHIBITOR AND SPONSOR PROFILES

ROTEM, INC. BOOTH N° 1166

1009 Slater Road Suite 450 Durham 27703 North Carolina United States Website: www.roteminc.com ROTEM, Inc. distributes whole blood haemostasis analysis systems, consumables, and reagents for the ROTEM® Systems, based on rotation thromboelastometry®. ROTEM, Inc., newly established in the US, will provide anesthesiologists central laboratory and peri-operative bleeding management systems.

S. KARGER PUBLISHERS, INC. BOOTH N°1110

26 W. Avon Rd. P.O. Box 529 Unionville, CT 06085 United States Website: www.karger.com

Publications on display include the journals Acta Haematologica, Cardiology, Cerebrovascular Diseases, Journal of Vascular Research, and Pathophysiology of Haemostasis and Thrombosis.

SANOFI-AVENTIS BOOTH N° 617 & 819

174 Avenue de France Paris 75013 France Website: www.sanofi-aventis.com

Sanofi-aventis, a global leader in the pharmaceutical industry, researches and develops medicines and vaccines to help improve the lives of the greatest possible number of people. R&D explores a broad spectrum of innovative approaches, and develops new products in the key areas of therapeutic expertise: Thrombosis, Cardiovascular diseases, Diabetes,Vaccines, Oncology, Central Nervous System disorders and Internal Medicine. By virtue of its commitments, sanofi-aventis constantly adapts its development model to the world's emerging human and economic problems.

SARINGER LIFE SCIENCE TECHNOLOGIES INC BOOTH N° 1164

2345 Wyecroft Road Unit 2 Oakville l6l 6l8 Canada Website: www.saringer.com Venowave is a portable, non-invasive, external venous pump designed to provide improved vascular and lymphatic flow of the lower limbs using a patented wave technology.

440 new technologies,diagnostictoolsanddrugs. and vasculardevelopment;cardiovascular biologyandcellsignalling;cellularproteolysis andoncology; cellular haemostasis;plateletsandbloodcells;woundhealinginflammation/infection;endothelium clinical studiesinvascularbiologyandmedicine.Categoriesinclude:bloodcoagulation,fibrinolysis THROMBOSIS ANDHAEMOSTASIS publishesoriginalarticleswithabroad scopeinbasicresearch and Website: www.thrombosis-online.com Germany Stuttgart 70174 3 Hoelderlinstrasse take placeinCair consideration. The56thAnnualMeeting oftheScientific&Standardization CommitteeoftheISTHwill pr SSC iscomprisedof20scientificsubcommittees, registries andworkinggroups thatmeetannuallyto hemorrhagic disorders andstandards andmethodsofresearch related tothesemedicalproblems. The SSC hassupportedthecollaborationofexpertsworldwideonmatters r The Scientific&Standardization CommitteeoftheISTHisworkingarmSociety. Since1954,the W Egypt El Rodaisland P.O. Box2288 Corniche ElNile,GardenCity Grand HyattCairo V particle counting,urinalysisandlifesciences. clinical laboratorytestingdevices,reagents andsoftware forhematology, hemostasis,immuno-chemistry, manufacturerSysmex isaleadinginternational ofdiagnosticsystems,involvedinthedevelopment designed tostr systems, unmatchedmenuoffering, andITsolutions,inconjunctionwithhighlyresponsive service,is provided hemostasissolutions tolaboratoriesworldwide.Siemens'portfolioofperformance-driven Since 1995,thepartnershipbetweenSiemensHealthcar W United States New York Tarrytown 10591 511 BenedictAvenue S 00BOHN 263 BOOTHN° SSC 2010 1551 BOOTHN° 1009 BOOTHN° AND SYSMEXCORPORATION SIEMENS HEALTHCARE DIAGNOSTICS SCHATTAUER GMBH EXHIBITOR AND SPONSORPROFILES enue address: ebsite: www ebsite: www esent publicreports oftheirworkinprogress andtoaddress problems andissuesthatrequire expert www.sysmex.com .ssc2010.org .diagnostics.siemens.com eamline workflow o, Egyptfr om 22to25May , enhanceoperationalefficiency andsupportimproved patientcare. , 2010. e Diagnostics&SysmexCorporationhas elated tobloodcoagulation, 441

Exhibitor and Sponsor Profiles EXHIBITOR AND SPONSOR PROFILES

STAGO BOOTH N° 151

9 rue des Frères Chausson Asnières sur Seine 92600 France Website: www.stago.com Stago dedicates its research and innovative skills to develop and improve the accuracy of the medical diagnostic. The firm formulates, manufactures and markets worldwide, a broad range of reagents (routine & research) and fully automated systems for haemostasis & thrombosis.Thanks to its haemostasis expertise, Stago is recognized and is in position to cooperate with the scientific community worldwide. Affiliates in USA, China, UK, Australia/NZ, Canada - wide network of distributors (> 100 countries) BioCytex, a Stago group company, develops advanced research tools in field of cellular biology.

TALECRIS BIOTHERAPEUTICS BOOTH N° 1321

79 TW Alexander Drive 4101 Research Commons Research Triangle Park 27709 North Carolina United States Website: www.talecris.com Talecris Biotherapeutics is dedicated to the development and delivery of life-saving and life-enhancing protein therapies to markets throughout the world. Visit booth #1321 to learn more about our products.

TECHNOCLONE GMBH BOOTH N° 923

Brunner Str. 59/5 Vienna 1230 Austria Website: www.technoclone.com TECHNOCLONE is a world leading producer of global and special coagulation tests. Ceveron alpha offers the unique feature of fully automated thrombin generation measurement in the routine. Another innovation is the Ceveron MFU 500, a microparticle filtration unit which can identify microparticles thombogenicity in conjunction with the Technothrombin MP. Furthermore Technoclone provides a complete range of ADAMTS13 ELISAs and FXIII assays. With the new TECHNOVIEW control and calibration plasma product range we were able to expand the portfolio for anticoagulant therapy monitoring.

442 through put'DestinyMax'analyserwhichisthelatestinnovation. instruments whichare used todetectbloodcoagulationdisorders. Trinity nowlaunchesitsnewhigh partnerships globallyinover80countries.Trinity provides abroad lineofhaemostasisreagents and thrombotic andbleedingtendencies. function testofthecoagulationsystemisusedtomonitoranticoagulanttreatment andissensitivetoboth because ofitsreproducibility andcorrect calculation ofthrombin intime.Thisoverallphysiological each individualpatientpossible.TheCAT assayisthemostcommonlyusedthrombin generationassay platelet-poor plasma,andhasauniquepatentedcalibrationwhichmakesproper measurement of research purposes.Theassaycanbemeasured inplatelet-richor (CAT) assaywhichisintendedtomeasure thrombin generationfor Thrombinoscope BVoffers theCalibratedAutomatedThrombogram Website: www.thrombinoscope.com Netherlands Maastricht 6229BC Oude Maasstraat47 outcomes. Visit www.VenousDiseaseCoalition.orgoutcomes. Visit orcall888.833.4463formore information. risk for, venousdisease.Joinourefforts foracommoncampaignandmessageshelpimprove patient awareness, andpromote efforts toimprove thesurvivalratesandqualityoflifeindividualswith,orat network ofprofessional andpublicorganizationsunitedtoincrease publicandhealthprofessional A divisionoftheVascular DiseaseFoundation,theVenous DiseaseCoalition(VDC)isacollaborative Website: www.VDF.org, VenousDiseaseCoalition.org United States Colorado Lakewood 80226 1075 SY Dublin. Ithasdir laboratory andpoint-of-car Trinity Biotechdevelops,acquires, manufactures, andmarketsdiagnosticproducts fortheclinical W Ireland Bray Co.Wicklow IDA BusinessPark One SouthernCrossRoad ACLRDSAEFUDTO OT °366 BOOTHN° 1019 BOOTHN° VASCULAR DISEASEFOUNDATION 1069 BOOTHN° TRINITY BIOTECHPLC THROMBINOSCOPE BV EXHIBITOR AND SPONSORPROFILES ebsite: www ukon Street,Ste320 .trinitybiotech.com ect af filiate distributioninUK,GermanyandUSAisr e diagnosticmarket.Trinity BiotechisanIrishcompanywithheadquartersin epr esented bydistributor 443

Exhibitor and Sponsor Profiles EXHIBITOR AND SPONSOR PROFILES

WILEY BLACKWELL BOOTH N° 1004

9600 Garsington Road Oxford Business Park Oxford, OX2 4DQ UK Website: www.wiley.com Wiley-Blackwell is a leading publisher in hematology and other related areas. We publish many of the top journals in the field including; the official journal of the ISTH, the Journal of Thrombosis and Haemostasis and the British Journal of Haematology. Come and pick up your free sample copy. We also have many leading book titles - all with an exclusive 20% discount. For more information, visit: www.interscience.wiley.com

WORLD FEDERATION OF HEMOPHILIA BOOTH N° 269

1425 René Lévesque Blvd West, Suite 1010 Montreal H3G 1T7 Canada Website: www.wfh.org The World Federation of Hemophilia is the leading international organization representing the inherited bleeding disorders community. With a global network of patient organizations in 113 countries, the WFH works to provide treatment for all people with bleeding disorders through education and training, advocacy, and product donations. Visit the WFH booth for a chance to win free registration for the Hemophilia 2010 World Congress in Buenos Aires, Argentina, 10-14 July 2010.

WYETH PHARMACEUTICALS BOOTH N° 1331

500 Arcola Road Collegeville 19426 Pennsylvania United States Website: www.wyeth.com Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE)*, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

444 ISTH2009

Congress Information

445 Layout of the Congress Venue

Grand Ballroom Level Two Meeting Rooms

Level One Meeting Rooms Exibit Level

Registration Fee On-site ISTH Member $ 950 ISTH Non Member $ 1,200 Fees payable in USD only. Trainees / Students* $ 350 * For trainees and students, a letter of up to the age of 38 confirmation from the Head of Department on departmental letter- Exhibitors $ 410 head must be presented with the Accompanying Persons $ 280 registration form. Students older than 38 can request a waiver from this age SSC Meeting attendance only Free restriction by providing a brief Saturday July 11, explanation and a letter from the Sunday July 12, 2009 Head of Department confirming their student status.

446 Use oftheCongress ShuttleServicetotheOfficial Congress Hotels Scheduled Coffee Breaks Access toExhibitionArea Welcome Reception Opening Ceremony Abstract CD-ROM State oftheArtBookandCD-ROM Final Program Congress Bag Admission toallScientificSessions Delegates’ RegistrationFeeincludes: on-site r Please alsonote thatavailabilityofhotel accommodationatthe time of 3:00PM-6:00 July10,2009 Sunday Satur Friday The RegistrationDeskattheBCECwillbeopenasfollows: On-site RegistrationHours cation r fee ofUSD50perregistration willbechargedforeveryregistration modifi- For cancellationsafterMay6,2009,norefund willbeavailable.Ahandling r email). Forcancellationsreceived before May6,2009,depositswillbe All cancellationsmustbesenttoMCISuisseSAin writing (fax,letteror Modification orCancellationofRegistration Use oftheCongress ShuttleServicetotheofficial Congress Hotels Neighborhoods ofBostonExcursionTour Scheduled cof Access toExhibitionArea Welcome Reception Opening Ceremony Accompanying Persons’RegistrationFeeincludes: hrdyJl 6 09 7:30AM-6:30PM July16,2009 7:30AM-6:30PM 7:30AM -6:30PM July14,2009 July15,2009 Thursday Wednesday Tuesday Monday efunded lessUSD100foradministrativecosts. Hotel and Transportation Information Hotel andTransportation day eceived afterJune10,2009. egistration may belimited. fee br uy1,20 7:30AM-6:30 PM July 13,2009 7:00 AM-6:00PM July 12,2009 July 11,2009 eaks 7:30 AM-PM 447

Congress Information Hotel and Transportation Information

Hotels MCI Suisse SA has reserved a large number of rooms in different hotel categories and offers discounted room rates for Congress participants. Only reservations made through MCI Suisse SA will benefit from these rates. All of these hotels are located in the City Center, or near the Convention Center. Rates are in US dollars (USD) and are per room, per night. Please also note that availability of hotel accommodations at the time of on-site registration may be limited.

Boston Hotel Map Please note that hotel availability will be limited for those registering on site.

Hotel Check-in/Check-out Time Check-in time is 3:00 PM or later. If you are arriving after 6:00 PM, please notify MCI Suisse SA in advance. Check-out time is noon. 448 Changes ofHotelBooking when checkingout. expenses suchasmini-bar, laundry, etc.mustbe paiddirectly tothehotel for thefirstnightmustaccompanyhotelaccommodationform.Additional All paymentsare inUSdollars(USD).Forhotelbookings,adepositpayment Payment bypersonalcheckscannotbeaccepted. Methods ofPayment 7MdonHtl+ 67 6 001111BackBay 191 191 +1(617)2621000 CityCenter 214 CityCenter 214 321 +1(617)4261400 BackBay 321 Junior Suites,Suites etc.maybeavailableuponrequest. RatesareinUSD$. BackBay 269 Rates include12,45% CityTax andapplyforStandard rooms;otherroomtypeslike Deluxerooms, +1(617)2270800 MidTown Hotel 261 17 269 Airport 239 Courtyard BostonTremont +1(617)536 9000 15 242 Congress Center CityCenter +1(617)236 2000 281 247 Boston MarriottLongWharf 242 16 CityCenter +1(617)5681234 BackBay 281 247 20 254 247 +1(617)3384111 TheCopleySquare Hotel +1(617)2278600 14 13 254 247 SheratonBostonHotel 12 +1(617)5560006 BackBay +1(617)2361100 11 RenaissanceBostonWaterfront TheOmniParkerHouseHotel 10 248 9 CityCenter HyattHarborside 8 225 343 HiltonBostonFinancialDistrict 7 TheHiltonBostonBackBay 6 +1(617)4262000 5 343 The BostonParkPlazaHotel&Towers 4 +1(617)5747100 3 2 TheRitz-Carlton,BostonCommon 19 18 1 HOTELS INBOSTON reserve therighttochargefullstayifhotelroom cannotbere-sold. for hotelmodificationsmadeatthistime.Inthecaseofcancellations,we Registration Area. AhandlingfeeofUSD$50perhotelroom willbecharged For anychangestohotelreservations pleaseinquire attheHotelDeskin Hotel and Transportation Information Hotel andTransportation h epr oe 1804031 5 5 Congress Center 258 258 +18004403318 The W The W The SeaportHotel BackBay 394 The BackBayHotel(formerlyJurysBoston) 394 +1(617)5358888 The ColonnadeHotelBoston Boston MarriottCopleyPlace Mandarin OrientalBoston The Langham HOTELS 2* HOTELS 3* HOTELS 3*Superior HOTELS 4* HOTELS 5* si olyPaeBso 1(1)2290 8 1 BackBay 311 288 +1(617)2629600 estin BostonW estin CopleyPlaceBoston trrn 1(1)5240 7 9 Congress Center 297 275 +1(617)532 4600 aterfront +1 (617)2667200 +1 (617)4247000 +1 (617)2365800 +1 (617)4511900 Telephone NUMBER 270 BackBay 286 269 258 276 AERATE RATE SINGLE DOUBLE LOCATION 270 BackBay 269 276 Back Bay City Center 449

Congress Information Hotel and Transportation Information

Transportation There will be a shuttle bus system available ONLY from/to the hotels booked through the Congress. The Congress Organizers have worked to ensure convenient and timely transportation between the Congress Hotels and the BCEC with the following arrangements:

Departures from Hotels or Defined Pick-Up Points to the BCEC Every 10 minutes starting 7:00 AM

Departures from the BCEC to Hotels and Defined Drop-Off Points Every 10 minutes For more information, please refer to the Transportation Guide.

Following the All Congress Party Shuttle buses will transport participants back to Congress Hotels.

Transportation to the Airport The MBTA will offer direct service for the attendees from the BCEC to Logan Airport terminals with ADA accessible, luggage friendly Silver Line vehicles. A shuttle will be available for $2 per person from the BCEC to Boston’s Logan Airport on Thursday, July 16 from 2:30 PM to 6:30 PM. Inquire at the Hotel Desk in the Registration area for more information. Many hotels also offer shuttle service to and from the airport. Please check with your hotel if this is available. For any questions, kindly inquire at the Hotel Desk in the Registration area or contact: MCI Suisse SA Phone: Local Number +1 617 954 3360

Disclaimer MCI Suisse SA as the Congress Organizer, ISTH and committee members and officers of the XXII Congress of the ISTH claim no liability for the act of any supplier to this meeting, nor liability for: personal injury, the safety of any attendee while in transit to or from this event, for any loss or damage, for delays in transport by air, sea, rail, road, weather, in case of strikes, sickness, war or other causes.

450 South BostonWaterfront DrivingDirections andLocalParkingOptions “How To getthere” Local ParkingLotsandPedestrianAccesstotheBCEC Hotel and Transportation Information Hotel andTransportation From Logan International Airport International Logan From www.massconvention.com Additional informationabouttheBCEC: MA02210 Boston, 415 SummerStreet, Boston Convention&ExhibitionCenter closures visit For updatedinformationontraffic í Seaport Boulev CongressStreet, reached fromNorthern Avenue, Public parkinglotsandgarages canbe • BearleftatsplitontoEastServiceRoad. • Massachusetts • I-93NorthtoExit20 Northbound: I-93 • Gostraight ontoSeaportBoulevard. • Take leftattopoframp. • I-93SouthtoExit23 • BearleftatsplitontoEastServiceRoad Massachusetts: • Massachusetts Turnpike /I-90Eastto Western From • Gostraight ontoBStreet. • Bearleftatendoframp. • I-90 and Route 1A South: 1A Route and P I-93 Southbound: I-93 “South Boston”. Exit 25 “South Boston”. Logan Airport”. “SouthBoston”. Exit 25, Parking Lots West/Ted Williams Tunnel toExit25 Parking Lot Entrance/Exit toParking Lot Stairs toSummerStreet Pedestrian Routes Silver LineEntrance www.masspike.com ard andconnectingstreets. Turnpike/I-90 Eastto “I-90 East/ “Purchase Street”. 617.954.2000 : 451 .

Congress Information ISTH 2009 Congress Information

Abstract CD-Rom The Abstract CD-Rom is inside the Congress Bag and includes all submitted abstracts as well as the abstracts of the Plenary, State-of-the-Art and Symposia Sessions. It will also be included in the August issue of the Journal of Thrombosis and Haemostasis.

ATM (Automatic Teller Machine) There are ATM’s located at the BCEC. Please ask the Registration Desk for further information.

Badges Congress Name Badges are issued upon check in at the Congress site and must be visible and used at all times throughout the BCEC for access to the meetings and official social functions.

CME AMA PRA Credits The Congress has been reviewed by the American Medical Association and approved for a maximum of 29.75 AMA PRA Category 1 Credits™. Credit claim forms will be available in your Conference bag. In order to receive credit you must complete the claim form, pay the $35 USD processing fee ( waived for AMA members), and return the form to the AMA monitor's desk during the Congress or fax the form to AMA headquarters after the conference. A credit certificate will be emailed to physicians within 4 weeks of receipt of the claim form. Physicians should only claim credit commensurate with the extent of their participation in the activity. One credit may be claimed for each hour of participation in approved sessions. If you should have any questions about this process, you may contact the AMA directly (Mindi Daiga, mindi.daiga@ama- assn.org phone: 312.464-5196 fax: 312-464-5830). Further information can be obtained under the AMA website.

Congress Bag The Congress Bag will be distributed to registered participants at the Registration Desk.

Congress Documents The Congress documents should be collected on-site at the Registration Desk at the BCEC.

452 mi: [email protected] /Web: www.isth2009.com +41223399601 Email: Fax: +41223399587 Phone: Local Phone Switzerland 1211 Geneva13 Rue deLyon 75 MCI SuisseSA Congress Organizer Thursday, July16. highlights. Anewissuewillbedistributedeachdayfrom Monday, July13to The ISTH2009Congress willfeature anewspaperthatwillincludescientific Congress News hrdy uy1,20 10:00AM-4:00 PM July16,2009 10:00AM-5:00PM 10:00AM-5:00PM 10:00AM-5:00PM Thursday July14,2009 July15,2009 Wednesday July13,2009 Tuesday Monday Exhibition Area Schedule the BCEC. scientific societies,cateringandloungeareas willbelocatedinHallsA&B1of organizations, sponsorpharmaceuticalcompanies, media publishersand The Congr Exhibition Area Information Exhibition expressed writtenconsentoftheCongress Organizers. and video)ofsessionsincludingPosterPresentations isprohibited withoutthe Any formofduplication(r Duplicating /Recording ISTH 2009 Congress Information ISTH 2009Congress ess Exhibition,featuringcommer ecor ding, audiotaping,digitalphotography cial displaysofinternational 453

Congress Information ISTH 2009 Congress Information

Food & Beverage Coffee Breaks Coffee breaks are included in the registration fee. Coffee will be served to delegates in several locations, including the Exhibition Area, from Monday to Thursday during the session breaks. (For times, please see the Program Overview on page 26). Coffee breaks will be provided outside the meeting rooms during the SSC Annual Meeting and Education Program on Saturday and Sunday. It will also be possible to purchase coffee at various outlets throughout the BCEC.

Future Meetings A Future Meetings table is located in the Exhibition Area

Internet Wifi is provided throughout the BCEC. Please inquire at the Registration Desk for more information. Two Cyber Cafés are situated inside the Exhibition.

ISTH General Membership Assembly The ISTH Membership Meeting will take place on Tuesday July 14, from 3:00- 3:15 PM in the Grand Ballroom.

ISTH Secretariat The International Society on Thrombosis and Haemostasis Secretariat is located in Room 255 on the 2nd Floor of the BCEC.

Language English is the official Congress language, and no translation services are offered.

Lunch On Saturday, July 11 and Sunday, July 12 lunch may be purchased at the Food Court of the BCEC. From Monday, July 13 to Thursday, July 16 lunch may be purchased at the Food Court of the BCEC, as well as at various locations in the Exhibition Area.

454 in theExhibitionArea. Participants canusethemessageoptionsavailableatCyberCafélocated Messages was required forthelunchboxes.) Exhibition Area uponpresentation ofyourvoucher. (Note:Advancepurchase of yourregistration, thesemaybecollectedatdesignatedoutletsinthe For thosewhopurchased lunchboxesforMondaythrough Thursdayaspart 12:30 PMto2:15on thedayoftheirposterpr area. Theposterpresenting authorsshouldbepresent inthePosterArea from PM. Postersshouldbemountedontheassignedboard inthePosterDisplay Exhibition Area, onMonday, Wednesday andThursdayfrom 12:30PMto2:15 Poster sessionswilltakeplaceinHallB2oftheBCEC, adjacenttothe Poster Sessions Poster Area. A PosterHelpDeskwillbeavailableattheRegistration Deskaswellinthe Poster HelpDesk Please refer topage451thatshowstheplanofparkingareas. Parking A MiniProgram willbehandedouttoparticipants. Mini Program The MediaRoomislocatedin209onthesecondfloorofBCEC. Media /Press Room or refreshments from pharmaceuticalormedicaldevicecompanies. Massachusetts-licensed healthcare providers from acceptinggifts(pens,etc) Please notethatMassachusettsregulations, effective July1,2009,prohibit Massachusetts Regulations and inthePosterAr discussion. Supportstaff willbeatavailableforhelp at theRegistrationDesk ISTH 2009 Congress Information ISTH 2009Congress ea. esentation foropen 455

Congress Information ISTH 2009 Congress Information

Registration Desk The Registration Desk at the BCEC will be open as follows: Friday July 10, 2009 3:00 PM - 6:00 PM Saturday July 11, 2009 7:00 AM - 6:00 PM Sunday July 12, 2009 7:30 AM - 7:30 PM Monday July 13, 2009 7:30 AM - 6:30 PM Tuesday July 14, 2009 7:30 AM - 6:30 PM Wednesday July 15, 2009 7:30 AM - 6:30 PM Thursday July 16, 2009 7:30 AM - 6:30 PM

Rules Smoking Policy The ISTH 2009 Congress is a non-smoking event. Participants are kindly requested to refrain from smoking in the BCEC, including the Exhibition Area.

Mobile Phones Delegates are kindly requested to keep their mobile phones silenced in the rooms where scientific and educational sessions are being held, as well as during poster sessions.

Speaker’s Preview Room Speakers are asked to bring their formatted PowerPoint presentations to the Speaker’s Preview Room (Room 251) at least two hours before their session. Files from keydrives or CD-ROMs can be transferred to the Congress servers at that time. All conference rooms contain state-of-the-art technical equipment.

The Speakers’ Preview Room will be open as follows: Friday July 10, 2009 3:00 PM - 6:00 PM Saturday July 11, 2009 7:30 AM - 7:00 PM Sunday July 12, 2009 7:30 AM - 7:00 PM Monday July 13, 2009 7:30 AM - 7:00 PM Tuesday July 14, 2009 7:30 AM - 7:00 PM Wednesday July 15, 2009 7:30 AM - 7:00 PM Thursday July 16, 2009 8:00 AM - 12:00 PM

456 at theRegistrationDeskBCEC. obtained fr July 16.More informationontheschedulecanbe to participantsfr BCEC andof A complimentaryshuttleservicebetweenthe T Jour Bag. TheCD-RomwillalsobeincludedintheJulyissueof The State-of-the-ArtBookandCD-Romare insidetheCongress State-of-the-Art BookandCD-Rom ner are availableonthewebsite: www.isth2009.com Updated informationandtheon-lineitineraryplan Website ofISTH2009 lunch br and andduringmorning available toanswerquestionsSundayafternoon, a placeforinformalmeeting,relaxing andnetworking.Seniormentorswillbe Suite foralldelegatesregistered asTrainees. TheHospitalitySuitewillserveas Room 101onthe1stfloorofBCEChasbeendesignatedasaHospitality Trainee HospitalitySuite July 16. Suite.) TheSuitewillbeopenfr ransportation ISTH 2009 Congress Information ISTH 2009Congress nal ofThrombosis andHaemostasis. eaks Mondaythr om theTransportation Guide,whichishandedoutuponregistration ficial Congress Hotelswillbeavailable om Saturday, July11toThursday, ough Thursday om 8:00AMto6:00PMthr . (Aspecificscheduleispostedinthe - ough Thursday 457 ,

Congress Information Boston Information

About Boston Boston is one of America’s oldest cities and the economic and cultural hub of New England. Home to about 600,000 residents, its population is augmented by the more than 250,000 students from around the world who attend universities and colleges in the greater Boston area. Finance, health care and education are among the mainstays of the city’s economic life. Tourism is one of New England’s major industries, with 1.2 million visitors annually. While Boston over the last several decades has developed a modern skyline, it has maintained its architectural heritage with vibrant neighborhoods each with their unique personality and appeal. Boston is also home to many fine cultural institutions, some of the world’s finest hospitals, and world class professional sports organizations. For more information, please visit the Boston Information Booth at the Registration Desk and the following websites: www.cityofboston.gov www.bostontourism.com

Getting to Boston By Air: Logan Airport is located in East Boston. There are several options for getting from Logan Airport to the Boston Convention and Exhibition Center 458 walking maptohelpcommuters andvisitorsgetaround town. W information, pleasegoto:www.mbta.com. for figuringouthowtogetaround bysubway, localbus,andtrain.Formore By car: more detailedinformationpleasegoto:www.massport.com. Logan/Boston HotelShuttlevanservice,watertransportandtaxiservice.For service provided bytheMetropolitan BostonTransit Authority(MBTA), and theofficial Congress Hotels,includingrapidtransitbusandsubway www.massport.com/default.aspx www www.walkboston.org/resources/maps.htm For more information,weinviteyoutovisitthefollowing websites: Hotels ar to manyattractions,includingshoppingandhistoricsights. SeveralCongress compact downtownarea provides opportunitiestowalkfrom Congress Hotels Chances ar Getting Around www For more information,weinviteyoutovisit: South Station,witheasyconnectiontotheBCECvia MBTA’s SilverLine. hours onAcelaExpress trains,about4hoursonothertrains.Trains arriveat other pointsintheNortheastCorridor. Thetripfrom NewYork Citytakes31/2 By Train: easy connectionfrom SouthStationtotheBCEC. Island, Connecticut,andNewYork City. TheMBTA’s SilverLineprovides an offer scheduledservicefrom BostontoNewHampshire, CapeCod,Rhode Peter PanstopdowntownatSouthStation.Severalregional buscompanies By Bus(Regional): By SubwayandBus(Local): I-93 from thenorthandsouth I-95 from thenorthandsouth I-90 (MassachusettsTurnpike) from thewest Boston Information alkBoston hasdeveloped a Downtown/BackBay/SouthBostonSeaport .cityofboston.gov/visitors/gettingher .mbta.com There are 3mainroutes intoBoston: e withinwalkingdistanceof theBCEC. Amtrak hasscheduledtrainservicetoBostonfrom NewYork and e you’veheard Bostonreferred toas«thewalkingcity.» Boston’s Nationwide buscompaniesincludingGreyhound and The MBTA offers anonlinetripplanneruseful e.asp 459

Congress Information Boston Information

Driving around Boston can be difficult, and parking expensive. Most hotels have parking facilities, with rates ranging from USD $20 to USD $40. For more information, please go to: http://www.cityofboston.gov/transportation/accessboston/ parking.asp

Parking is also available at the BCEC for USD $10. A free shuttle service provides transportation from the parking lot to the BCEC entrance. For more information, please go to: http://www.massconvention.com/bcec_dir_par.html

Taxi For taxi fares, please go to: http://www.massport.com/logan/getti_typeo_taxis.html.

Food Boston has many excellent restaurants. Visitors have their choice of popular Boston restaurants in many areas of the city such as the narrow alleys of the North End and the bustling avenues of the Back Bay. The city is home to people from around the world who have enriched the local New England cuisine, providing a wide array of dining opportunities.

For restaurant information, please see the following websites: http://www.bostonusa.com/visitor/geninfo.htm http://www.yelp.com/c/boston/restaurants

Banks Only major banks exchange foreign currency. ATMs are widespread and credit cards and travelers’ checks are widely accepted. Travelers’ checks should be issued in US dollars for maximum convenience. Banking hours are Monday to Friday 9AM to 3PM. There are several ATM’s at the BCEC.

Climate Boston has a continental climate with very changeable weather patterns such as wide temperature swings in a matter of days. Summers are usually sunny, hot and humid. In July the average temperatures are a high of 82°F (28°C) and a low of 65°F (18°C).

460 Dress Code shops. All majorcredit cards are acceptedinthemajorityofhotels,restaurants and Credit Cards The USdollar(USD)istheunitofcurrency andisdividedinto100cents. Currency require anadapter, whichcanbepurchased inmostmajordeparture airports. plugs are alsowidelyused.Applianceswithoutdualvoltagecapabilitieswill 120 volts,60Hz.Plugsare mainlythetwo,flat-pintype,thoughthree-pin Electricity casual attire. Thedress codeforthemeetingsisbusinesscasual. The dress codefortheWelcome ReceptionandtheAllCongress Partyis Boston Information 461

Congress Information Boston Information

Shops Shops are generally open from 10:00 AM - 7:00 PM from Monday to Saturday. Most large stores will also open on Sunday but generally with shorter opening hours.

Taxes Massachusetts has a sales tax of 5% that is applied to the price of goods at checkout. Clothing under USD $175 and food purchased in grocery stores are exempt. There is no VAT.

Time Standard time zone: UTC/GMT -5 hours Daylight saving time: +1 hour Boston is on EDT (Eastern Daylight Time).

Tipping A 15% tip is expected by taxi drivers, bartenders, hairdressers and waiters, but don’t tip in fast- food or self-service restaurants. It is normal to tip staff in hotels. Most services are customarily tipped if the service is good.

Travel Insurance A travel insurance policy to cover theft, loss and medical problems is recommended. The Congress will not be held liable for illness, accidents or thefts suffered by participants or accompanying persons during the Congress or their stay in USA before or after the Congress.

462 guests At 6:30PMsharp,aboat willleaveforaharbortourbeforedroppingoff This functionisbyinvitation only T John F. KennedyLibrary, Boston Pr to allofficialISTH2009CongressHotels. Grand Ballr Included intheregistration fee Sunday July12,2009,6:00PM Opening Cer W 6:00 PM.At 10:00 PM,abusdeparture isscheduledbacktothe Westin uesday Social Events aterfront Hotel. esidents’ Dinner at theJohnFKennedyLibrar , July14,2009,6:00PM oom. emony andWelcome Reception From 9:00PMuntil9:30busdeparturesarescheduled . ThiseventwilltakeplaceattheBCECin . y. PleasemeetintheRegistration Area at 463

Congress Information Social Events

All Congress Party Bank of America Pavilion, 290 Northern Ave, Boston Thursday July 16, 2009, 6:30 PM A reservation fee of USD $35 must be paid in advance. While the event is an easy walk from the Convention Center, bus transfers are available from the BCEC to the Pavilion between 6:00 PM and 6:45 PM. After the event, a bus transfer back to the official Congress Hotels will be available from 9:30 PM to 12:00 PM. If you would still like to register for the All Congress Party onsite, please inquire at the Registration Desk.

Accompanying Persons’ Program/Excursions All excursions depart from and return to the BCEC, Level 0. Excursions will take place only if a minimum of participants is met (please refer to the Excursions’ counter at the Registration Desk for more information). The Neighborhoods of Boston Tour is included in the registration fee for Accompanying Persons.

Trainee Reception BCEC Saturday July 11 from 6:30 PM to 10:00 PM Included in the registration fee for Trainees. Reception, brief program and light dinner, followed by music and dancing, at the BCEC. All those who have registered as Trainees are welcome to attend.

464 Excursions

ISTH 2009 Excursion Overview

Saturday July 11 ess Information Neighborhoods of Boston 9:00 AM – 12:00 PM Congr Tall Ships 1:00 PM – 04:00 PM

Sunday July 12 Tall Ships 9:00 AM – 12:00 PM Hometown Favorites 1:00 PM – 04:00 PM Neighborhoods of Boston 1:00 PM – 04:00 PM

Monday July 13 Neighborhoods of Boston 9:00 AM – 12:00 PM Ducks, Sharks and Penguins 1:00 PM – 05:00 PM Whale of a Tail 2:30 PM – 05:30 PM

Tuesday July 14 Veni, Veidi, Vice 9:00 AM – 12:00 PM The Gilded Age of Newport 9:00 AM – 05:00 PM Ducks, Sharks and Penguins 1:00 PM – 05:00 PM

Wednesday July 15 Pleasurable Provincetown 8:30 AM – 06:00 PM JFK Legacy Tour 9:00 AM – 01:00 PM

Thursday July 16 Veni, Veidi, Vice 9:00 AM – 12:00 PM Art and Architecture 1:00 PM – 04:00 PM

Cancellation of Excursions There will be no refunds for cancellations after May 6, 2009. Full refunds will be made if an activity is cancelled due to insufficient numbers of participants. For any cancellations or more information, please address inquiries to the Registration Desk.

465 Excursions

Neighborhoods of Boston Tour of the City Saturday July 11, 2009 9:00 AM - 12:00 PM Sunday July 12, 2009 1:00 PM - 04:00 PM Monday July 13, 2009 9:00 AM - 12:00 PM 3 hours Boston is a city rich in American history, neighborhoods and education. To many, Boston is known as “Beantown,” Boston is our nation’s oldest major city with world famous medical centers, industry and finance at our fingertips, and endless faith in the beloved Red Sox. A city of seasons makes the snow- covered rooftops of Beacon Hill or the flower-filled public gardens something to see for any season. Begin your trip with the Back Bay, an area rich in Victorian architecture as well as modern marvels such as the Prudential Center and Hancock Tower. Drive by the Boston Public Library, the Trinity Church, the Boston Common and the Public Gardens on the way to Beacon Hill. Beacon Hill’s 19th Century neighborhood impresses locals and tourists alike with its charming streets, brick sidewalks lined with antique gas lamps, hidden gardens, unique doors, doorknockers, and detailed iron balconies. From Beacon Hill to the Freedom Trail, see King’s Chapel and Burying Ground, Granary Burying Ground, the Old Corner Bookstore, the Old South Meeting House, the Old State House, the site of the Boston Massacre and Faneuil Hall. From Faneuil Hall, Quincy Market and the statue of Samuel Adams, move to Boston’s North End. The area today is largely populated by those of Italian descent, whose many cafes, delis and restaurants make it one of the city’s most distinct communities! Hanover and Salem Streets are the main arteries of the area with the Old North Church at the top of Salem Street. Built in 1723, this is Boston’s oldest religious building and most famous for the part it played in Paul Revere’s midnight ride. Just south is North Square, site of the Paul Revere House. From the North End look across the harbor and view “Old Ironsides,” the USS Constitution, and the Bunker Hill Monument, which is the last stop along the Freedom Trail. The only stops where guests disembark are the North End and a harbor view of the Constitution. This Tour Includes: Round trip Motor Coach transportation - Uniformed Conventures, Inc. Guide All applicable taxes and gratuities Cost: $55.00 per person Based on a 35 person minimum per coach

466 It’s likevisitingItaly, nopassportrequired. Andiamo! get an“insider’s view”ofonethepremier foodneighborhoodsinthecountry. secrets, sampleauthenticflavorsanddiscoverMediterraneantraditionsasyou produce, andalittleliquoriinthisOldWorld community. cooking Learn authentic tastesofpastries,cured meats,cheeses,thefreshest seasonal make yourmealsmemorable.Enjoythecolorfulsights,tantalizingaromas and enoteca ,andaspiceconfectionstore thatstockstheingredients thatcan 3hours this sideofRome.You’ll discoverthepasticceria,greengrocer, thedeli,an America’s mostEuropean neighborhoodtosomeofthebestItalianmarkets traditions ofItaly. Followyourguidethrough thecobblestonepathsof Food Network’s “TheBestOf“forherknowledgeofthefoodandmarket experience. Your guideistrainedbyMicheleTopor whohasbeenfeatured on wine andallthingsItalian,youwon’t wanttomissoutonthisuniquetour 9:00AM-12:00PM Come see,tasteandconquertheNorthEnd!Ifyouhaveapassionforfood, 9:00AM-12:00PM July16,2009 Thursday July14,2009 Tuesday North EndMarketTour andTasting The Veni, Veidi, Vice Tour Based onaminimumof30 percoach Cost: $115.00 comfortable footwearandclothing. and guestsareadvisedtowear This tourdoesinvolvewalking, All applicabletaxesandgratuities Uniformed Conventures,Inc.guide North EndMarketTour andTasting Motor Coach Round T This Tour Includes: Excursions rip Transportation viaDeluxe per person 467

Congress Information Excursions

Art & Architecture The Isabella Stewart Gardner Museum, Boston Public Library and Trinity Church Thursday July 16, 2009 1:00 PM - 4:00 PM 3 hours Your first stop will be the Isabella Stewart Gardner Museum. Isabella Stewart Gardner, a Boston socialite, opened the museum on January 1st, 1903, with a musical and visual arts celebration. It now contains more than 2,500 paintings, sculptures, tapestries, furniture, manuscripts, rare books and decorative arts. The galleries house works by well-known artists, including John Singer Sargent and James McNeill Whistler. The spirit of the architecture, the personal character of the arrangements and the artistic display of the enchanting courtyard in full bloom all create an atmosphere that distinguishes the Isabella Stewart Gardner Museum as an intimate and culturally rich treasure. The next stop will be the Boston Public Library. Founded in 1848, the library was the first large free municipal library in the United States. The present Copley Square location has been its home since 1895, when architect Charles Follen McKim completed his “palace for the people.” A must see is the sumptuous Abbey Room with its luxurious beauty. The room’s dominating feature is the series of splendid and richly colored mural paintings, “The Quest of the Holy Grail“, by the American artist, Edwin Austin Abbey. The ceiling is remarkable for its heavy ornamental rafters. Across the street is Trinity Church. Ask any architect, architectural historian, or critic and they’ll tell you that Trinity is a masterpiece of American architecture. Dedicated in 1877, Trinity presented a bold, fresh new face and feeling for ecclesiastical architecture in America. The church continues to be heralded today as a celebrated example of “Richardsonian Romanesque“ design, named after its architect, H. H. Richardson. This Tour Includes: Round Trip Transportation via Deluxe Mini or Motor Coach Entrance and Tour of Gardner, Library and Church Uniformed Conventures, Inc. guide All applicable taxes and gratuities This tour does involve walking, and guests are advised to wear comfortable footwear and clothing. Cost: $80 per person Based on a minimum of 35 guests per coach

468 gratuities All applicabletaxesand guide Uniformed Conventures,Inc. England Aquarium Admission totheNew (not apublicDuckT T The FamousBostonDuck via DeluxeMotorCoach fascinating exhibits. outdoor tank–homestoalivelycolonyofharborseals-ar fr outside ofthetankandprovides close-upviewpointsoftheinteriortank contains awidearrayofmarineanimals.Acurvingwalkwayrunsar 1969, theaquarium’ The Duckwillthendrop youoff atTheNewEnglandAquarium.Designedin br 4hours more. Onceyou’veseenallofBostonbyland,you’llentertheCharlesRiverfor Center, fashionableNewburyStreet, QuincyMarket,thePrudentialTower, and Banknorth Garden, toBostonCommonandCopleySquare, Government of Firsts!From thegolden-domedStateHousetoBunkerHillandTD Cruise byalltheplacesthatmakeBostonbirthplaceofFreedom andaCity whistle soyouwillnotloseyourvoicequackingthrough thestreets ofBoston. World War IIamphibiouslandingvehicle.You willreceive asouvenirduck 1:00PM-5:00 The funbeginsassoonyouboard your“DUCK“,anauthentic,renovated 1:00PM-5:00 July14,2009 July13,2009 Tuesday Monday Duck Tour andNewEnglandAquarium Ducks, SharksandPenguins Private Duck maximum of32 utilizing1 Based onaminimumand Cost: $115.00 Round T This Tour Includes: our –Exclusivecharter om dif Excursions eathtaking viewsofBostonandCambridgefr fer rip T ent levels.Coloniesofpenguins,aT ransportation per person our) s cor e enclosesavastfour om thewater r opical FishGalleryandan -story oceantank,which e someoftheother . ound the 469

Congress Information Excursions

Hometown Favorites Fenway Park and Faneuil Hall

Sunday July 12, 2009 9:00 AM - 1:00 PM 4 hours

Visit America’s most beloved ballpark, Fenway Park, where the Boston Red Sox, 2004 and 2007 World Series Baseball Champions play ball! Though generations have come and gone, Fenway Park remains, much like it did the day it opened on April 20, 1912. The home of the Red Sox resounds with echoes of the past from some of the great players like Cy Young, Babe Ruth, Ted Williams, Carlton Fisk and Carl Yastrzemski to name a few. Soak up the rich history; hear the echoes of the past. Visit the Green Monster, imagine being one of the “Knights of the Keyboard“ as you see the view from the Press Box, visit the State Street Pavilion Club before strolling around Fenway Park. With the stories of all the legends that have played here for more than eight decades, Fenway remains an important link to baseball’s past. After the tour, enjoy a walk around the most popular tour attraction in Boston, Faneuil Hall and Quincy Market. For over 250 years, this marketplace has played an important role in the life of Boston’s residents. The marketplace has more than 100 wonderful shops and carts and 17 restaurants and pubs including Cheers! This Tour Includes: Round Trip Transportation via Deluxe Mini or Motor Coach Entrance and Tour of Fenway Park Tour of Faneuil Hall and free time Uniformed Conventures, Inc. guide All applicable taxes and gratuities This tour does involve walking, and guests are advised to wear comfortable footwear and clothing. Cost: $66 per person Based on a minimum of 35 per coach

470 ar This beautifulcampuswillenchanteveryonewithitscharmingbrick alastingtributetooneofourcountry’sGovernment, mostdedicatedleaders. landmarks intheoldyard. WhileatHarvard, passbytheJFKSchoolof guide willelaborateonthehistory, incredible architecture and famous institutions, andwalkthesamepathsJohnF. Kennedyoncetraveled.Thetour Afterwards, experienceHarvard, oneoftheworld’s mostrenowned academic the euphoriaof“Camelot”andnumbhorror oftheassassination. Office. Thecombinationofartifacts,displaysandtelevisionfootageevokeboth Excursions WhiteHouseduringtheKennedyadministrationincludingOval 4hours glass overlookingthesea.Severalrooms recreate keychambersofthe mouth oftheharbor. Itsinteriorisequallyasdramaticwitha50footwallof buildingstandssentinelonColumbiaPointnearthe white andblackmodern fromjourney thecampaigntrailthrough hispresidency. ThestrikingI.M.Pei life, leadership,andlegacyofPresident Kennedy. ExperienceKennedy’s Tour 9:00AM-1:00PM theJohnF. Kennedy Presidential LibraryandMuseum,whichportraysthe July, 15,2009 Wednesday John F. KennedyLegacyTour Based onaminimumof35percoach Cost: $66.00 All applicabletaxesandgratuities Uniformed Conventures,Inc.guide Tour University of Harvard Tour of theJohnF. andMuseum KennedyLibrary Round Trip Transportation viaDeluxeMiniCoachorMotor This T Excursions chitectur our Includes: e andelegantstyle. per person 471

Congress Information Excursions

The Majesty of the Tall Ships

Saturday July 11, 2009 1:00 PM - 4:00 PM Sunday July 12, 2009 9:00 AM - 12:00 PM 3 hours

A Tall Ship is a large rigged sailing vessel. Most of the Tall Ships are manned by a largely cadet or trainee crew who are partaking in sail training. Fifty percent of these crew members must be aged between 15 and 25 and do not have any previous sailing experience! Boston is hosting a “Tall Ships Celebration” in July of 2009. With over 50 of the world’s remaining large sailing ships in port, a very special opportunity is open to the attendees of the International Society on Thrombosis and Haemostasis Congress. A motorcoach will pick up those interested attendees at the BCEC and transfer them to and from Boston Harbor private dock areas. The group will board one of the Harbor Cruise boats reserved exclusively for them, and enjoy a magnificent water view tour of the Tall Ships in port. Your guide will tell you which country each is from, how long they are and some of their fascinating maritime history. Afterwards, you will be able to board one of the ships (without waiting in the public lines!), meet some of the crew, tour the vessel and take pictures of these great sailing ships from another era. A once in a lifetime experience!

This Tour Includes: Round Trip Transportation via Motorcoach Admission aboard a Cruise thru the Harbor Tour of a Tall Ship Uniformed Conventures, Inc. guide All applicable taxes and gratuities Cost: $124.00 per person Based on a 35 person minimum per coach

472 All applicabletaxesandgratuities Uniformed Conventures,Inc. guide Alcoholic Beveragesarenot Included Catered lunchatTheMooring Guided T houses tothelegendaryresort ofopulentstonepalaces. Newport’s subsequenttransformationfrom aquietsummer colonyofwooden mor modest housesoftheearly19thcentury. However, MarbleHousewasmuch house, or“cottage“,asNewporterscalledthemin remembrance ofthe built between1888and1892forMr Your final visitwillbethemagnificentMarbleHouse.TheHousewas various boutiquesalongthewatersedge. the localshopsandattractions,guestswillhaveaboutanhourtoperuse enchanting day. Astherestaurant iswithineasywalkingdistanceofmany finest r chowder, choiceofentree, dessertandbeverage.Oneofthewaterfront’s downtown Newport.ThemealwillincludeacupofNewEnglandclam Morris Hunt’s architecture inspired and furnishings bythe16 8hours preeminence. All70rooms covering138,000square-feet aboundwithRobert Vanderbilt builtthisestateasasymbolofthefamily’s socialandfinancial Breakers, isyourfirststop.Railroad industrialistCommodore Cornelius in thecoastalcrown ofNewEngland.ThegrandestNewportMansions,the hospitality, Newport,RhodeIslandisconsidered bymanytobeashininggem awe-inspiring architecture, athrivingwaterfront downtownandwelcoming 9:00AM-5:00PM Age spurred bytheIndustrialRevolution.Hometospectacularcoastalscenery, Experience thegrandioseNewport“cottages”builtatapexofGilded July14,2009 Tuesday The GildedAgeNewportMansionsTour Based onaminimum of35percoach Cost: $138.00 Round T This Tour Includes: on thewaterfr Afterwards, relax withlunchatTheMooringSeafoodKitchenandBarlocated extravagant indicationsoftheVanderbilt family’s fortune. Renaissance palazzos.To thisday, the Breakers remains oneofthemost Excursions e; itwasasocialandar estaurants, TheMooringistheperfectlocationforabr rip T our ofTwo NewportMansions:1) Breakers; and,2)MarbleHouse ransportation viaDeluxeMini CoachorMotor ont atSayer’ per person s Wharf,dir chitectural landmarkthatsetthepacefor . andMrs.W ectly off America’s CupAvenue in illiam K.V anderbilt, asummer th eak duringthis century Italian 473

Congress Information Excursions

A Whale of a Tail Whale Watching Excursion

Monday July 13, 2009 2:30 PM - 5:30 PM 3 hours

Venture out on the water for an exiting day of Humpback whale watching. Cruise out to sea on a comfortable high-speed catamaran that will provide you with more viewing time and less travel time. You will travel aboard a pristine vessel complete with climate-controlled cabins, three viewing decks, restrooms and a full service snack bar. You will find Humpback whales are an amazing species to watch. These whales are some of the largest mammals on Earth, and it is incredible to see these huge creatures leap many feet out of the water. Humpbacks are also known for their “singing”. On board you will enjoy a professional researcher from the Whale Center of New England to narrate your tour. A whale of a good time! This Tour Includes: Round Trip Transportation via Deluxe Motor Coach Public Whale Watching Excursion Uniformed Conventures, Inc. guide All applicable taxes and gratuities Cost: $89.00 per person Based on a minimum of 40 per coach

Pleasurable Provincetown

Wednesday July 15, 2009 8:30 AM - 6:00 PM 9.5 hours

Zoom to Provincetown in 90 minutes on the newest, most luxurious ferry from Boston. The state of the art catamaran, the Provincetown III, has ample comfortable seating and an enclosed, air-conditioned lower deck. You will be awed by the amazing sand dunes on the Provincetown Cape Cod National Seashore protected lands during this special tour. Expert guides will entertain you with their knowledge and history of these special dunes as you ride in a comfortable SUV. Enjoy dunes that stretch as far as you can see with wispy beach grass, dark green pine trees and deep red beach plums nestled

474 Provincetown ontheirown.EnjoyfindingyourownProvincetown treasures! group willhavetheopportunitytoexplore thequaintshopsandgalleriesin always newdiscoveriestobemade.Aftertheseintriguingadventures, your members’ showsusuallyaccompanythein-depthretrospectives, sothere are an acknowledgedmastersharingspacewithaless-skilledupstart.Juried four galleries.Intoday’s lesscompetitiveatmosphere, it’s notunusualtosee the countryandinternationally. PAAM averages35exhibitionsyear-round in collection nownumbers2,000works,anditsreputation isrecognized across the newsummerartcolony. TheMuseumhasflourishedovertheyears;its of regional art.PAAM wasfoundedbyartistsin1914tobethefocalpointof the premier artmuseumsinthecountry, andincludesapermanentcollection view theirphenomenalcollectionsspanningan80-yearperiod.Thisisoneof Enter theProvincetown ArtAssociationandMuseum(PAAM) where youwill relaxing stop,getready forthenextexcursion. dishes. Iffishisnotyourpreference, there are manyoptionsavailable.Afterthis connoisseurs, enjoythefresh lobsterrolls, clamroll, andvariousseafood Satisfy yourhungerwithlunchatthefamedLobsterPot.Forallyoufish lovely tourasapeacefulretreat from metropolitan Boston. such famousartistsandwritersasEugeneO’NeillHarryKemp.Enjoythis along theshoreline willenlightenyouaboutthe“duneshacks”thatinspired in hollows,whichare brought togetherbyasilhouetteofbluesky. Your journey Based onaminimumof40 percoach Cost: $210.00 Private GuidedT Round T This T All applicabletaxesandgratuities Uniformed Conventures,Inc.Guide Museum (PAAM) Admission andGuidedT Lunch attheLobsterPot Dunes viacar Excursions our Includes: rip T ransportation Boston-ProvincetownviaProvincetown III ferr per person our oftheProvincetownCapeCodNationalSeashore our oftheProvincetownArtAssociationand y 475

Congress Information NOTES ISTH2009

Authors Index

477 AUTHORS INDEX

Aakhus S., PP-TH-427 Aberson H., PP-MO-489, Adebayo A. O., PP-TH-209 Aarden L., PP-TH-153 PP-WE-839 Adelmeijer J., PP-WE-771 Aarsetøy H., PP-WE-830, Abgral R., PP-WE-510 Adeyemi A. A., PP-MO-278, PP-WE-831 Abgrall J. F., PP-TH-189 PP-WE-330 Aaspollu A., PP-MO-149 Abgrall J., PP-TH-113, Adiguzel C., OC-TH-019, Ababneh B. A., PP-WE-504 PP-MO-310 PP-MO-136, PP-MO-139, Abi-Ayad C., PP-TH-276 PP-MO-140, PP-MO-143, Abad-Franch L., PP-TH-627, PP-MO-399, PP-TH-145, PP-WE-668, PP-TH-544 Abinet I., PP-WE-532 PP-TH-166, PP-TH-390, Abalotti C., PP-TH-487, Abletshauser C., PP-MO-420, PP-WE-143, PP-WE-166, PP-WE-147 PP-TH-425 PP-WE-261, PP-WE-385, PP-WE-387, PP-WE-482 Abasolo N., PP-WE-821 Abolghasemi H., PP-TH-210 Adjali M., PP-WE-639 Abate C., PP-MO-503 Abou-Saleh R. H., PP-WE-259 Adraktas T., PP-MO-715 Abate M., PP-WE-311 Abousamra N. K., PP-WE-257 Advate Pass Study G., Abbate R., AS-TH-034, Abousamra N. K., PP-WE-257 PP-TH-576 OC-MO-010, OC-TH-047, Abrahams J. M., OC-WE-067, Afink G. B., OC-TU-055 OC-WE-031, OC-WE-032, PP-WE-848, PP-WE-849 OC-WE-102, PP-MO-013, Afrasiabi A., PP-WE-459 PP-MO-217, PP-MO-303, Abrams S. T., PP-TH-129 Agaoglu L., PP-MO-222 PP-MO-304, PP-MO-339, Abrams S., OC-TH-091 PP-MO-340, PP-MO-341, Agar C., PP-MO-262 Abriss D., AS-TH-014 PP-MO-743, PP-MO-799, Ageenkova A. V., PP-MO-688, PP-MO-800, PP-MO-801, Abshire T. C., PP-MO-596, PP-TH-454 PP-MO-802, PP-MO-803, PP-WE-613 PP-MO-804, PP-MO-805, Ageno W., OC-MO-092, Abslander G., PP-WE-712 PP-MO-818, PP-MO-836, OC-TH-011, OC-TH-014, Abulata N., PP-MO-277 PP-MO-301, PP-MO-308, Abbott D., PP-WE-636 PP-MO-309, PP-MO-462, Aburima A. A., PP-MO-023 Abbott L. S., PP-WE-447 PP-MO-463, PP-MO-659, Aburubaiha Z. A., PP-TH-696 Abboud M., PP-TH-456, PP-TH-507, PP-WE-313, PP-WE-686 Acaia B., PP-WE-691 PP-WE-340, PP-WE-403 Abd.Karim F., PP-MO-636 Acevedo M., PP-WE-121 Agerkvist I., PP-MO-574 Abdel Gader A. M., PP-WE-363 Achenbach T., PP-WE-488 Agerso H., PP-MO-569, PP-MO-570 Abdelgadir A. M., PP-MO-057, Ackermann B., PP-MO-694 Agersoe H., OC-MO-085 PP-WE-163 Acuña S., PP-WE-654 Abdelkarim R., PP-WE-281 Aghighi S., PP-MO-524, Adam F., OC-WE-043, PP-TH-551 Abdel-Razeq H. N., AS-TU-024 Aghili M., PP-WE-281 PP-MO-488, PP-WE-504 Adam M., PP-TH-185 Agic D., PP-WE-680 Abderrazak F., PP-TH-343 Adam S., PP-MO-768, Abdihakim A., PP-MO-805 PP-TH-655 Agnelli G. G. A., PP-MO-312 Abdo A. A., PP-WE-163 Adamczuk Y. P., PP-TH-333 Agnelli G., OC-MO-018, OC-MO-092, OC-TH-014, Abdul Karim F., PP-MO-651 Adamczuk Y., PP-MO-275 OC-TU-024, PP-MO-282, Abdulkadirov K. M., Adamo M., PP-TH-102 PP-MO-457, PP-MO-458, PP-MO-476, PP-WE-313 PP-MO-495 Adams G. N., OC-MO-128 Agostini M., PP-TH-453 Abdullahi Said A., PP-WE-746 Adams G., OC-TH-056 Agrawal S. G., PP-WE-377 Abe K., OC-TH-107 Adamson P. J., OC-MO-115, Abe M., PP-TH-521 PP-MO-250 Agriello E., PP-TH-060 Abe Y., PP-TH-526 Adamson U., OC-TH-079, Agterof M. J., PP-WE-317, OC-WE-104 PP-WE-318, PP-WE-475 Abegunde S. O., PP-TH-500, PP-TH-501 Ádány R., PP-WE-350 Aguilar S., PP-WE-073 Abel K., PP-MO-578 Addad F., PP-TH-343 Aharon A., OC-TU-057, OC-TU-058

478 OC-WE-114, PP-TH-351, Ahmed A., Ahmadkia Daliri A., Ahmadinejad T., Ahmadinejad M., Ahmadian L., Ahmadian H., OC-WE-063 Ahmad R.U., PP-WE-037 Ahmad F PP-WE-456 Ahluwalia J., INDEX AUTHORS Akassaglou K., Akasaka T., PP-WE-709 Akarsu S., Akar N., Akagi E.M., Ajzenberg N., Ajjan R., PP-WE-212 Ajjan R. A., PP-WE-330 Ajayi O.I., Ajayi I.O., PP-TH-501, PC-008 Ajayi I.O., Aixalá M., Aivado M., Aitken E.W., PP-MO-445 Aïtchafa Tadlaoui D., Aissaoui H., Aisina R., Aisina R.B., Aillaud M.F., Aikawa E., Aida K., PP-TH-189 Aiach M., Ahrens I., Ahmidatou H., Ahmed M., Ahmed F OC-TU-032, PP-MO-835, PP-TH-272, PP-WE-266, PP-WE-793 PC-001 ., ., PP-WE-215 AS-TH-023, PC-005, PP-TH-219 PP-MO-100 PP-MO-204 PP-TH-538 PP-MO-638, PP-MO-278, PC-008 PC-009, PP-TH-500, PP-WE-708, AS-WE-057 PP-MO-661 AS-MO-055 PP-TH-062 OC-TH-055, PP-MO-429 PP-TH-495 OC-WE-021 PP-TH-227 OC-MO-045 PP-MO-324, PP-TH-189 OC-TH-054, PP-WE-518 PP-MO-077 PC-042 PP-TH-204 AS-TU-045 PP-WE-324 PP-WE-324 PP-TH-534 PC-018, 007, PP-MO-035,PP-MO-036, PP-TH-278, PP-TH-378, PP-MO-360, PP-MO-361, Ala F. A., Al ZahraniH., Al SawatK., Al SaniaF Al NounouR., Al MohareebF PP-WE-280 Al Harthi Al Haidari A., Al Ghumlas Al Ghomlas Al DuhgyalM., PP-WE-683 Al DieriR., Akulich N.V PP-MO-653 Aksu S., Aksöyek A., Akria L., Akrami M., Åkra S., PP-TH-046, PP-WE-024 Akkerman J.W. N., OC-WE-046 Akkerman J.N., PP-MO-080 Akiyama M., PP-TH-379 Akinshina S.V., PP-TH-121, PP-WE-571 Akici F Akiba E., Akhvlediani M., PP-WE-327 Akhter M.S., OC-WE-147 Akhremitchev B.B., Akdogan M., PP-TH-121, PP-WE-571 Akcay A., PP-WE-006 Akbar H., Akay O.M., Akassoglou K., PP-MO-582, PP-TH-246, ., PP-MO-073, PP-TH-118 PC-053 PP-MO-606, A., PP-MO-539 PP-TH-054 PP-TH-095, . M., PP-MO-073, PP-MO-214 PP-MO-251, OC-MO-002 ., A. K., A. K., PP-WE-880 PP-MO-425, AS-MO-012, PP-WE-163 PC-003 PP-MO-208, PP-MO-057 PP-WE-820 PP-WE-280 ., PP-TH-062 PP-WE-163 PP-WE-163 SA-WE-001 PC-019 PP-WE-280 PC-017, OC-TU-030, PP-WE-163 PP-MO-057 PP-MO- PP-MO-496, PP-TH-374, 006, PP-MO-290,PP-MO-291, PP-MO-753, PP-TH-692, PP-MO-274, PP-TH-100, Alatri A., Alamelu J., PP-WE-377 Alam S., PP-TH-636 Ala F., PP-TH-474 Alessandrello Liotta A., PP-TH-651, PP-TH-652 Alesci S., Alesci S.R., Alemany G.V., Aleksic D., Alekseeva L. A., Aleil B., Aledort L.M., Aldeshev PP-WE-360 Alcalá PedrajasJ.N., Albrecht S., Albors M., PP-TH-446 Albisetti M., Alberts P Alberto M., PP-TH-350, PP-WE-354 Alberto M.F., Alberto F Alberti S., PP-WE-21 Alberio L., Alber M., Albayram S., Albayrak G., Albayrak D., Albar J.P., Albanyan A., Albanez S., PP-TH-193, PP-WE-506 Alban S., Alba R., Alba L., M., Al-Awadhi A. PP-TH-375, PP-WE-682 PP-TH-318, PP-TH-553, PP-TH-606 OC-MO-008 PP-WE-151 PP-MO-135, ., ., OC-TH-003, OC-TH- PP-WE-394 PP-TH-192, 1, PP-WE-717 A., PP-MO-584, PP-WE-048 PP-TH-103 PP-MO-637 PP-MO-204 PP-MO-736, PP-WE-254 PP-TH-591 PP-MO-056 PP-WE-609 PP-TH-555 PP-MO-824 OC-TU-061, PP-TH-644 PP-WE-806 PP-TH-511 PP-WE-281 OC-TU-056 PC-039 PP-MO-038, PP-WE-704 PP-WE-428 PP-WE-224 PP-WE-724 479

Authors Index AUTHORS INDEX

Alessi M. C., OC-WE-099, Alonso S., OC-TH-081, Amirizadeh N., PP-TH-210 PP-MO-774 OC-WE-099 Amirkhosravi A., PP-MO-004, Alessi M., AS-TU-024, Al-Tamimi M., OC-MO-110 PP-TH-482, PP-TH-491, OC-MO-007, OC-MO-021, Altantsetseg E. E., PP-TH-017 PP-WE-001, PP-WE-108, OC-TH-045, PP-MO-773, PP-WE-485 Althaus H., PP-TH-241 PP-TH-309, PP-WE-775 Amlie-Lefond C., PP-MO-442 Alessio A. M., PP-MO-870 Althaus K., OC-TH-024, OC-TH-102 Ammollo C. T., PP-MO-176, Alexander R. A., PP-WE-843 PP-MO-245, PP-MO-423, Altintas F., PP-TH-284 Alexandrova E. N., PP-MO- PP-WE-249 268, PP-TH-267, PP-TH-277 Altisent C., PP-MO-528, Amodeo R., PP-MO-634, PP-MO-560, PP-MO-566, PP-MO-635 Alexandru N., PP-MO-855, PP-MO-590, PP-MO-601, PP-TH-003 PP-TH-596, PP-WE-234, Amore C., AS-TU-042 Alexanyan M. G., PP-MO-218, PP-WE-237, PP-WE-761 Amuzescu M., PP-MO-855 PP-MO-668, PP-WE-170 Altomare M., PP-WE-878 Anak S., PP-MO-222 Alfahim A., PP-WE-281 Altun M., PP-WE-571 Anand S. S., PP-MO-086 Alfter K., PP-MO-253 Álvarez A., PP-WE-236 Anand S., PP-WE-800 Algra A., AS-WE-008, Alvarez C., PP-MO-413 Anastasopoulou I., PP-MO- OC-WE-036, PP-TH-339 Alvarez M., PC-048, 715, PP-TH-609, PP-TH-467 Alhenc-Gelas M., OC-TH-022, PP-MO-579, PP-TH-059, Anastasovska L., PC-028 PP-TH-189, AS-TH-001 PP-TH-603, PP-TH-604, Anastasovski S., PC-028 Ali E., PP-TH-522, PP-TH-523, PP-WE-560, PP-WE-765 Ancona E., PP-WE-248 PP-WE-520 Al-Wazzan H. J., PP-WE-724 Ande A. A., PC-008 Ali F. Y., AS-WE-052, Aly Aldeen Abd Elbasset Aly PP-TH-001 Mohamed M., PP-TH-445 Ande A. B., PP-TH-111 Ali U., PP-TH-220 Alzadjali S., PP-MO-675 Andersen A. S., PP-MO-405 Alía P., PP-WE-816 Al-Zahrani A., PP-TH-459 Andersen M. D., PP-MO-575 Al-Jafar H. A., PP-WE-724 Al-Zahrani F. M., PP-MO-052 Andersen M. R., PP-WE-383 Alkindi S., PP-MO-675 Amadio P., PP-WE-868 Andersen M., PP-WE-319, PP-WE-740 Allard S., OC-TH-067, Amanat S. T., PP-TH-643 PP-TH-685 Anderson D. A., OC-TU-011 Amann-Vesti B., PP-MO-643 Allart S., OC-MO-099, Anderson D., PP-WE-462 PP-WE-019 Amano K., PP-TH-592, PP-WE-606, PP-WE-666 Anderson F. A., OC-MO-052, Allen D. J., PP-MO-065 PP-MO-247, PP-MO-248 Amaral J., PP-TH-434 Allen K. L., OC-TU-042 Anderson F., OC-MO-054 Amato A., PP-MO-351, Allen S., PP-MO-043 PP-WE-509 Anderson P. J., AS-MO-014 Alley S., PP-WE-118 Amaya M., PP-TH-482, Andersson A., OC-TU-096 Allievi A., PP-WE-236 PP-WE-001 Andersson H. M., AS-TU-019 Allison A. C., OC-TH-060 Amelot A. A., PP-MO-237 Andjelkovic N., PP-WE-664 Al-Marwani A. O., PP-MO-075 Amengual O., PP-WE-269, Andrade M. V., PP-MO-387 PP-WE-271 Almasy L., PP-TH-289, Andre P., AS-TH-022, PP-TH-290, PP-WE-208, Amin A. N., OC-TH-016, PP-MO-045, PP-TH-027, PP-WE-209, PP-WE-243 PP-WE-465 PP-WE-801, AS-TU-026 Almeida N., OC-TH-084 Amin C., PP-MO-768, Andre S., PP-MO-588 PP-TH-655 Almenar L., PP-TH-363, André S., OC-MO-064, PP-WE-885 Amirabadi A., PP-MO-518 OC-WE-066, PP-TH-172 Almomen A. M., PP-WE-363 Amiral J. J., PP-MO-419, Andrea D., PP-MO-056 PP-MO-697, PP-MO-701 Almonte T. M., PP-WE-541 Andrei E., PP-MO-855 Amiral J., PP-WE-199 Aloisio L., PP-MO-654 Andrei-Selmer C., AS-MO-057

480 OC-TH-1 Angeloni G., OC-WE-037, OC-WE-134 AS-TU-018, OC-MO-044, Angelillo-Scherrer A., Angela D., Andziak P., Andronicos N.M., Andrews R., OC-MO-110, PP-MO-033 Andrews R.K., Andrew P. C., Andreozzi G., INDEX AUTHORS PP-MO-644, PP-WE-607 Antmen B., Antman E., Antic D., Antic D. A., Antalfi B., Ansell S.M., Annie BangK.W PP-TH-532 Annichino-Bizzachi J.M., 296, PP-WE-476,PP-WE-535 WE-294, PP-WE-295,PP-WE- PP-TH-466, PP-TH-554,PP- PP-MO-870, PP-TH-157, PP-MO-825, PP-MO-826, PP-MO-520, PP-MO-725, PC-046, PP-MO-145, Annichino-Bizzacchi J.M., PP-MO-687 Annetta S.E., PP-TH-347 Annarumma L., Ankri A., Anisimov M.G., PP-MO-521 Anicchino-Bizzacchi J.M., Angus G., Anglés-Cano E., PP-TH-039 Angles-Cano E., Angiolillo D.J., PP-TH-508 Angio-Getbo Group A., OC-WE-051, PP-MO-620 Angerer J.I., Angelosanto N., 13, PP-MO-794, PP-WE-634 PP-WE-333 PP-WE-350 PP-MO-231 PP-MO-487 PP-WE-433 OC-WE-003 PP-MO-606, PP-MO-599 AS-WE-032 PP-WE-048 PP-MO-487 AS-TH-057, OC-TU-060 PP-WE-338 OC-TU-064, AS-TU-039, PP-WE-022 PP-MO-342, PP-TH-512 PP-MO-287 AS-WE-050, OC-WE-111 ., AS-TU-020 PP-MO-020 OC-WE-104, PP-MO-374, PP-WE-794, PP-WE-797, PP-TH-101, PP-WE-757, Apitz-Castro R., Apergis G., Apeler H., Apan H., Aoun J., Aouba A., PP-WE-222 Aoki S., Anyanwu R. A., PP-TH-695 Anveden P., Antunes M.B., MO-762, PP-WE-664 Antovic J., PP-WE-114 Antovic J.P PP-MO-761 Antovic A., PP-WE-747, PP-WE-748 Antonucci E., Antonova O. A., 801, PP-WE-802 Antonino M., PP-WE-798, PP-WE-799 Antonino M.J., PP-WE-415 Antonijoan R.M., PP-WE-368 Antonijevic N., Antonijevic N.M., Antoni G., Antongiovanni M., Antonazzo P., OC-TH-120, PP-WE-764 Antón A., Anton A., PP-WE-123 PP-MO-144, PP-TH-287, I., Antón A. Antoine G., TH-026, PP-WE-043,PP-WE- PP-WE-745, PP-WE-746, 474, PP-WE-002,PP-WE-283, PP-TH-352, PP-TH-353,PP-TH- PP-MO-743, PP-MO-818, PP-MO-340, PP-MO-341, PP-MO-304, PP-MO-339, OC-WE-102, PP-MO-303, OC-WE-038, PP-WE-281 PP-TH-235 AS-TH-052, PP-TH-481 PP-WE-592 OC-WE-059 OC-MO-021 PP-MO-533, PP- OC-TH-079, AS-MO-054, ., OC-WE-063 PP-WE-314 PP-MO-258, PP-MO-771, PP- PP-MO-703, AS-TH-034, PP-MO-375 PP-TH-460, PP-WE-588 PP-MO-739, PP-TH-111 PP-MO-856 PP-TH-155 PP-WE-178, PP-TH-296 PP-MO-803 Appel B., 177, PP-TH-150,PP-TH-151 Appa R., PP-MO-122 Appa R.S., PP-WE-426 Apostolovska R., PP-TH-351, PP-WE-130, OC-MO-115, OC-TH-055, PP-WE-212, PP-WE-215 Ariens R. A. S., Aridogan A., Arias-Salgado E., Arhan M., Arguello S., PP-MO-737, PP-WE-692 Arguello A., Arepally G., Arepally G.M., Arellano Ardissino D., PP-MO-655 Ardeshiri OC-TH-090 Arderiu G., Archarit N., Arcelus J., Arcari PP-MO-304, PP-WE-283 Arcangeli C., PP-TH-493 Arcamone G., Arcaini L., Arca M., Arbuthnot C., PP-WE-209 Arbesú I., Arbasi M., Araya V., Araújo I.G., Araujo G., Arantes M.J., Aranko K., Arachiche A., PP-WE-340 Appio L., Appelbom H.I., PC-027, PC-028,PP-TH-271, A., PP-WE-246 A. R., OC-MO-058, PP-MO- OC-WE-090 PP-MO-309, OC-TH-023 Y PP-MO-876 PC-003 PP-WE-208, PP-MO-523 PP-TH-316 AS-TU-004 ., PP-TH-068 OC-TU-019 AS-WE-055, PP-MO-121, PC-052 PP-TH-606 OC-TH-020 PP-MO-526, PP-TH-178 PC-044, PP-WE-607 PP-MO-303, PP-WE-339 PP-WE-008 OC-TH-015 AS-TU-019 PP-MO-448, OC-MO-020 AS-TH-006 OC-MO-076, PP-TH-237 PC-014, PP-TH-059 481

Authors Index AUTHORS INDEX

Ariëns R. A. S., PP-MO-250, Artoni A., AS-WE-020, Atkinson H. M., PP-MO-197, PP-TH-212, PP-WE-231, OC-MO-131, PP-MO-092 PP-WE-173 PP-WE-259 Arya R., OC-MO-088, Atmaca S., PP-WE-806 Arif A., AS-TU-041 OC-MO-089, OC-TH-076 Atsumi G., PP-MO-864 Ariga T., PP-TH-229 Arza B., PP-WE-525 Atsumi T., PP-MO-842, Arikan E., PP-TH-221 Arzamendi D., OC-WE-007, PP-WE-269, PP-WE-271 Arina G. A., PC-041 PP-MO-254 Attias D., PP-WE-272 Aristizabal M., PP-MO-160 Asada R., PP-MO-704 Attilio M., PP-MO-056 Armand-Perroux A., Asada Y., PP-MO-111, Attwood S. J., PP-MO-058 PP-MO-123, PP-MO-127 OC-TH-018 Auerswald G., PP-MO-603, Armani C., OC-WE-029 Asahara M., PP-MO-439 PP-MO-647 Armero S., PP-MO-785 Asakura H., PP-TH-057, Auh H., PP-MO-389 PP-WE-278 Armstrong P. C. J., Aujesky D., SA-MO-001, PP-MO-740, PP-MO-741, Ashby D., OC-TU-002 OC-MO-041, PP-MO-299, PP-TH-001, PP-TH-002 Ashcroft B., AS-WE-019 PP-TH-524 Arnason J. E., PP-TH-624 Ashikaga T., OC-MO-003 Aung P. P., PP-WE-101 Arnaud E., PP-MO-112, Ashrani A. A., AS-TH-003, Austin H., PP-TH-324, PP-MO-766, PP-TH-183, PP-MO-284, PP-TH-220 PP-TH-325, PP-TH-326, PP-TH-235, PP-WE-164, Asidin N., PP-MO-636 PP-TH-327, PP-TH-328 PP-WE-619 Askalan R., PP-TH-463 Austin R. C., AS-MO-022 Arnaud L., OC-TU-089 Asmelash G., PP-MO-584, Austin S., PP-TH-683 Arnaud P., PP-MO-530 PP-TH-644, PP-TH-651 Austinat M., OC-WE-040 Arndt B., OC-TH-101 Asmis L. M., OC-MO-129 Averett L. E., OC-WE-147 Arnesen H., PP-MO-719, Asmis L., PP-MO-318 Averkov O., PP-TH-223 PP-TH-118, PP-TH-427, PP-WE-026, PP-WE-344 Assafim M., PP-TH-179 Averna M., OC-TU-088, PP-MO-016 Arning M., AS-MO-055 Asselta R., PP-MO-210, PP-MO-648, PP-TH-630, Avery G., PP-WE-503 Arnold M., OC-WE-034 PP-TH-670, PP-WE-657 Awodu O. A., PP-MO-276, Arnould B., PP-WE-425 Assi Z., PP-TH-376 PP-MO-278, PP-TH-111, Arnout J., PP-TH-520, PP-TH- Astermark J., OC-TH-050, PP-TH-209, PP-WE-330, 625, PP-TH-635, PP-WE-267, PP-MO-540, PP-MO-541, PP-TH-500, PP-TH-501 PP-WE-270, PP-WE-525 PP-WE-570, PP-WE-611 Ay C., OC-MO-027, Arnuti B., PP-TH-385 Astudillo O. G., PP-WE-402 OC-TU-013, OC-TU-015, OC-TU-016, PP-MO-322, Arocas V., AS-TU-024, Asvold B. O., OC-WE-013 OC-WE-070 PP-WE-663 Ataga K. I., PP-MO-768, Ay Y., PP-WE-577 Aronis S., PP-TH-597, PP-TH-655 PP-WE-440, PP-MO-619 Ayachi O., AS-MO-063 Atalar A., PP-WE-568 Arora N., PP-TH-275 Ayad A. S., PP-WE-564 Atalay C. S., PP-TH-511 Arora V., PP-TH-232, Ayad S., PP-TH-276 Atanasov B. P., PP-WE-614 PP-TH-403 Ayares D., PP-MO-070 Atanasova S., PP-TH-271, Arruda V. R., AS-TH-013, Ayats J., PP-WE-761 AS-TU-013 PP-WE-426 Ayaz Ozkul A., PP-MO-858 Arruda V., PL-TU-004, Atarodi K., PP-WE-324 AS-TH-046 Ataullakhanov F. I., Ayaz S., PP-TH-686, PP-WE-880 Arshinov A. V., PP-MO-260 PP-MO-182, PP-MO-235, PP-WE-253 Aydogan G., PP-MO-073, Arslan A. A., OC-TU-039 Athale U., PP-MO-494, PP-TH-121, PP-WE-571 Arslan F., PP-WE-709 PP-TH-503, PP-WE-507 Aydogdu S., PP-WE-577 Artesani L. L., PP-TH-452 Atilla B., PP-TH-284 Ayers D., PP-MO-247 Arthur J. F., AS-TU-039

482 OC-TH-022, PP-MO-391, Azzam N., Aznar M., PP-TH-627, PP-WE-668 Aznar J. A., Azibani F Azevedo M., Azari B.M., Ayob Y., PP-TH-162, PP-WE-434 Aygören-Pürsün E., PP-MO-130 Aygören PürsünE., INDEX AUTHORS AS-WE-055, OC-TH-090 Badimon L., Badimon J.J., Badila A., Bader M., Badenhorst P PP-MO-647 Bade A., Badalucco S., Badainh F. A., PP-TH-480 Bacon S., Bacon S.B., Bacon C.L., Backx P. H., Bäckhed F., Bäck J., Bachli E., PP-MO-748 Bachelot-Loza C., Bachar A., PP-TH-110 Bach R.R., Baccouche H., Bacci M., Baccarelli PP-WE-553 Babyn P., Babinska A., Baarslag M. A., B. JohnsenL., Azzaoui R., PP-MO-590, PP-TH-544, OC-MO-106 PP-MO-636 PP-MO-603, ., PP-WE-791 AS-WE-003, PP-TH-606 AS-MO-047 PP-MO-643 PP-MO-855 OC-TH-076, A., PP-WE-163 OC-WE-070 OC-TU-057 PP-MO-314, PP-MO-814 OC-TH-092 PP-MO-589, AS-WE-054 PP-TH-125 AS-MO-065, OC-WE-037 PP-MO-593 PP-TH-525 OC-TH-092 ., PP-MO-321 PP-MO-488 PP-MO-067 PP-MO-834 PP-MO-565 PP-TH-297 PP-WE-726 PP-WE-548 AS-TH-023, PP-MO-284 Bailey K.R., Bailey C., Baik N., Baidya S., Baiardi G., PP-TH-621, PP-WE-711 Bai X., Bai H., Bai C., PP-WE-291 Bai B., Bahtiyar E., Bahena A., Bahawdory M., Bahatyrova S., OC-MO-089 Bagot C.N., PP-WE-774 Bagoly Z., PP-WE-286, PP-WE-556 Baglin T., Baglin T Baglin C. A., PP-WE-549 Baghiu D., Bagherian M., Baghaipour M.R., PP-MO-552 Baghaiepour M.R., PP-MO-652, PP-WE-206 Baghaei F., Baggio M.S., PP-MO-580 Bagger-Sørensen A., Bagemühl J., Baer Baena J., Bækgaard N., Badr S. A., Badr M., Badoz M., OC-MO-060, PP-MO-090 Badirou I., PP-TH-412, PP-WE-133, OC-TH-004, PP-TH-240, AS-TH-005, OC-TH-002, PP-MO-854, PP-MO-859, A., PP-MO-830, AS-TU-020 PP-MO-131 PP-MO-549, . P AS-TU-020 PP-TH-408 PP-TH-445 SA-TH-001, PP-WE-761 AS-TU-002 ., PP-WE-533 PP-MO-009, PP-TH-275 AS-TH-015, PP-MO-532, AS-TH-030 PP-WE-067 PP-MO-794 PP-MO-567, PP-TH-511 PP-MO-289 OC-MO-088, AS-TH-003, PP-MO-289 AS-TH-007 OC-WE-023 AS-MO-008 PP-WE-558 AS-WE-019 PP-WE-703 PP-WE-559 PP-TH-531, PP-WE-238, PP-MO-455, PP-MO-456, 066, PP-MO-435,PP-MO-454, Baimuradova S.M., PP-WE-043 Bailon O., Bailly N., Bailley M., PP-WE-083 Bailey M., Balibrea J., Bali L., Baleja J.B., PP-MO-085 Balduini C., Balduini C.L., Balduini Baldellou M., Baldelli F., Baldacci E., Balasch J., PP-WE-253 N., Balandina A. Balakrishnan U., Balakhonova T. V., OC-WE-099 Bal DitSollierC., PP-MO-162 Bakowski-Enzian B., Bakhtiari K., Bakhsh E., PP-WE-387 Bakhos M., PP-TH-188 Baker R., Baker C.H., PP-WE-150, PP-WE-151 Baker Bakchoul T., PP-WE-450, PP-WE-452 Bajzar L., Bajetta M.T., TH-278, PP-TH-378,PP-TH-379 PP-MO-360, PP-MO-361,PP- PP-MO-018, PP-MO-046, PP-WE-412, PP-WE-810, PP-MO-421, PP-TH-680, PP-MO-074, PP-MO-175, PP-TH-391, PP-TH-404, A. H., PP-MO-773 A., PP-MO-040 PP-MO-019, OC-TH-116, OC-TU- PP-TH-067, PP-TH-026, PP-TH-073 OC-WE-087 PP-MO-425 PP-WE-371 PP-MO-399, LB-MO-002 AS-TU-004, PP-MO-067 OC-TU-076, PP-MO-287 PP-TH-491 PP-TH-159 AS-TU-035 AS-MO-052 OC-WE-131 AS-MO-065 PP-MO-067 PP-MO-235, PP-WE-834 OC-MO-011, PP-WE-526 PC-017, 483

Authors Index AUTHORS INDEX

Balkan C., PP-MO-606, Barazer I., AS-TH-032, OC-MO- Bark N., PP-TH-141, PP-WE-577 132, PP-MO-783, PP-WE-744 PP-TH-186 Balkanov T., PP-TH-271, Barbanoj M. J., PP-WE-178, Barker K., PP-WE-574 PP-WE-426 PP-WE-415 Barna L., PP-WE-549 Ball G., OC-WE-092 Barbar S., OC-MO-049, Barnard D. R., PP-WE-447 PP-TH-488, PP-WE-147 Ballard N. E., PP-MO-388 Barnard D., PP-MO-686 Barbara B., PP-MO-056 Balling K. W., PP-WE-582, Barnard J., PP-WE-101 PP-WE-589 Barbato D., PP-MO-876 Barnes C. D., PC-043 Ballon F., PP-WE-073 Barbato E., PP-WE-416 Barnes C., PP-WE-531 Balmforth A. J., AS-TH-019, Barbay V., PP-TH-144, OC-MO-115 PP-WE-859 Barnes P., PP-TH-473 Balogh E., PP-TH-366 Barberis G., PP-MO-616 Baron G., AS-WE-025, PP-MO-332, Balsara R. D., OC-WE-022 Barbic-Zagar B., PP-MO-350 Baronciani L., OC-TU-072, Baltar P., PP-MO-579 Barbieri I., PP-MO-285 PP-TH-630, PP-WE-625 Baltayiannis G., PP-WE-681 Barbieri S. S., PP-WE-050, Barone M., AS-MO-009, Baltopoulos P., OC-TH-044 PP-WE-868 PP-MO-415 Baluch S., PP-WE-324 Barbour E. M., AS-MO-027 Barouch D. H., PP-WE-151 Bambace N. M., AS-MO-032 Barbui T., AS-TU-048, Barr A., PP-TH-021 AS-TU-050, PP-MO-867 Bamford J. M., OC-WE-114 Barr J. D., OC-WE-041 Barcella S., PP-WE-050 Banaszewski M., PP-WE-795 Barr J. Y., PP-WE-389 Barcellona D., OC-MO-028, Bandi A., PP-MO-777, PP-MO-266, PP-MO-267 Barragan P., PP-MO-787, PP-MO-778 PP-MO-785 Barchitta A., PP-MO-331 Bandinelli B., PP-MO-013 Barré J., OC-MO-050 Barcinski M. A., PP-TH-499 Bandinelli S., PP-WE-311 Barreira J., PP-WE-236 Barco S., PP-MO-415 Banfi C., PP-WE-050 Barreiro E. J., PP-MO-390 Bardhan A., PP-TH-090 Bang S., PP-MO-301, Barrellier M. T., OC-TU-022 Bardin N., AS-MO-060 PP-TH-504, PP-WE-069, Barrenetxe J., OC-MO-130, PP-WE-496 Bare L. A., AS-MO-005, OC-TH-113 OC-MO-020 Banno F., PP-MO-093, Barreto S. A., PP-TH-495 PP-WE-090 Bareiss P., PP-MO-416 Barreto S., PP-WE-312 Banno M., PP-WE-872 Barendracht A., PP-TH-055 Barrett Y., PP-MO-407 Baños M., PP-MO-794 Barendrecht A., OC-TH-025 Barron N., AS-TU-059 Banov L., PP-MO-525, Barett J., OC-WE-094 Barros F. E. V., PP-MO-034 PP-MO-616 Baretton G. B., PP-MO-824 Barruet E., OC-TH-045 Banoviæ M., PP-TH-258 Barfoed A., PP-WE-383 Barry R. G., PP-TH-520, Bansal V., PP-MO-143, Bari S., PP-MO-038 PP-TH-145, PP-WE-166, PP-TH-625, PP-WE-267, PP-WE-261 Barillari G., OC-MO-121 PP-WE-270, PP-WE-768 Banti A., PP-MO-779 Barinagarrementería F., Barsegov V., PP-TH-214 PP-WE-264 Banyai M., PP-TH-492 Barsoum M. K., PP-MO-284 Baris M., PC-039 Banzato A., OC-MO-028, Barsoum M., AS-TH-003 OC-MO-113, OC-TU-040, Baris S., PC-039 Bartfeld G., PP-WE-036 PP-TH-274 Barisciano M., PP-MO-099, Bartimoccia S., PP-TH-050 Bao H., PP-MO-883 PP-TH-048 Bartorelli A., PP-WE-356 Bao J., PP-WE-857 Barisone E. E., PP-TH-452 Bartosová L., PP-TH-305, Baraj B., AS-TH-045 Barizzi G., PP-MO-736, PP-TH-306 PP-WE-717 Baran B., PP-MO-714, Bartrop R., PP-MO-410 PP-TH-658, PP-WE-660 Bark D. L., AS-MO-040

484 PP-WE-105, PP-WE-753, 379, PP-MO-380,PP-TH-050, Basili S., PP-MO-458, PP-WE-688 Basileo M., Basile A., Bashash D., Baser O., PP-TH-053, PP-WE-059 Basabe-Desmonts L., PP-MO-090 Baruch D., PP-WE-608 Baru M., Bartunek J., INDEX AUTHORS PP-TH-490 Batschauer A. P. B., PP-WE-656 Batorova A., Batlle J., Batista R., Batista I.F. C., Bates S., PP-TH-522, PP-TH-523 Bates S.M., Bates J., Bates G., OC-TU-087 Basu S., Basu 204, PP-WE-145,PP-WE-146 Bastos L. PP-TH-535 Bastani P., Basson M., Basso M., Bassler N., Bassi P PP-TH-375, PP-WE-682 Bassi L., Bassi B., Bassi A., K., Bassi A. Bass R., Basquiera Baslar Z., Basire A., PP-WE-824 A., ., PP-TH-536, OC-TU-034, PP-MO-853 PP-MO-473 PP-WE-866 PP-MO-637 PP-MO-233 PP-MO-496, PP-MO-015, PP-MO- OC-TH-030 PP-WE-520 PP-TH-453 PP-MO-233 PP-WE-478 A., PP-TH-590 PP-TH-121 AS-WE-050 PP-WE-647 A. L., PP-TH-211 PP-TH-534, OC-WE-149, PP-MO-100 PP-MO-457, PP-MO-471 PP-WE-798 PP-MO-515, PP-WE-416 PP-WE-324 PP-MO-560, PC-047, PP-MO- PP-MO-475 PP-MO-279 PP-TH-531, PP-WE-450, PP-MO-455, PP-MO-456, PP-MO-435, PP-MO-454, Beaudoin S., PP-WE-810 Beauchaton-Piallat M., Bearelly S., Bearelly S.R., Bearelly D., Bean C.J., Bdeir K., Bazzi L., Bayat B., Bavishi K., Bautista P.,Bautista A. Bauters Bautch V. L., Baumeister J., Baumbach G. A., Baumann PP-WE-238 Bauman M., PP-MO-456, PP-WE-452 Bauman M.L., PP-WE-451, PP-WE-452 Bauman M.E., Bauman J., PP-WE-655 Baulon-Thaveau E., Baujat G., PP-TH-312 Bauersachs R.M., PP-TH-019, PP-WE-886 Bauersachs J., PP-WE-684 Bauer M., Bauer K. Bauduer F., PP-MO-609, PP-WE-604 Baudo F Baud G., Battleman D., PP-WE-018 Battiston M., Battie C., PP-TH-300 Battaglioli T., ., A., A., PP-MO-273 AS-WE-027 A., PP-MO-263 AS-MO-057 PP-TH-386 OC-WE-058, A., PP-TH-087, PP-MO-748 PP-TH-626 PP-TH-325 PP-WE-762 PP-MO-464 AS-TH-027 PP-MO-074 AS-TH-027 PP-MO-464 PP-MO-435, PP-WE-421 AS-WE-051 PP-TH-008, PP-TH-477 PP-MO-694 OC-MO-081, PP-WE-465 PP-WE-428 PP-TH-419 AS-TH-024 PP-MO-454, OC-TU-066, PP-MO-005, PP-TH-403 PP-MO-509, Becerra PP-MO-312, PP-WE-313 OC-TH-014, OC-TU-024, Becattini C., Beavis J., Beaune P., Beaulieu L.M., Belfiori B., Beletic A., PP-WE-576 Belda F., Belcour B., Belcik T Belcher J., Bejaoui M., PP-MO-083 Bein G., Beillat-Lucas T., Behnisch W Behfar A., Beheshtipoor N., Behari M., Begonia A., Beglova N., Bégin L.R., Begaliyev M., Beer N., Beer J.H., Beeler M., PP-WE-251 Bedencic M., Becquemont L., OC-WE-074 Beckwith J., Beck-Peccoz P., PP-TH-327, PP-TH-328 Beckman M., Becker-Peters K., Becker R., Becker R.C., Becker J., Becker D., Beck W., PP-WE-692 Becerra J., PP-WE-782 ., A., AS-MO-052, PP-WE-841 PP-WE-575, PP-MO-578 OC-MO-123 PP-WE-638 PP-TH-220 PP-TH-439 PP-TH-086 PP-MO-208 PP-TH-296 SA-TH-004 OC-TU-020 OC-TU-052 PP-TH-429 OC-WE-087 OC-MO-043 PP-MO-737, AS-WE-018, PP-WE-455 PP-TH-693 ., AS-WE-026 PP-TH-266 PP-MO-820 AS-TU-025, OC-MO-092, PP-MO-350, PP-TH-206, AS-TH-033 PP-WE-453 PP-WE-281 PP-TH-064 PP-WE-186 AS-WE-025 PP-WE-321 PC-044 PP-MO-592 485

Authors Index AUTHORS INDEX

Belhani M., PP-WE-639, Benson J., PP-MO-596, Bermejo E., PP-MO-038 PP-TH-204 PP-TH-324, PP-TH-325, Bermot C., PP-WE-139 PP-WE-613 Belin A., PP-WE-171 Berna-Erro A., AS-TU-005, Bellia M. S., PP-WE-314 Bentley M. J., PP-WE-725 AS-TU-040 Bellido-Martin L., AS-TU-060, Benz P. M., OC-MO-068 Bernard G. R., OC-TH-069 OC-MO-108 Berber E., PP-MO-653 Bernardi F., AS-WE-039, Bello T., PP-WE-665 Berckmans R. J., OC-TU-059, OC-TH-028, PP-MO-654, Bellucci S., PP-MO-074, PP-MO-763, PP-MO-769 PP-TH-372 PP-TH-680 Berckmans R., PP-MO-022 Bernardina E., PP-MO-483 Belmont S., PP-MO-860 Berdague P., OC-MO-132, Bernardini A., PP-MO-306 Beltrame M. P., PP-MO-870 PP-MO-783 Bernaudin J., PP-TH-485, Beltrametti C., AS-MO-009, Berdagué P., AS-TH-032, PP-TH-486, PP-WE-490 PP-MO-415 PP-WE-744 Berndt M. C., AS-MO-048, Belzunce M., OC-TH-113 Bereczky Z., PP-TH-366 AS-TU-039, OC-MO-110, Bereksi Reguig S., PP-TH-608, OC-TU-046, PP-MO-080, Ben Ammar Elgaaied A., PP-MO-735 PP-MO-649, PP-MO-650 PP-WE-701 Béres B. J., PP-MO-772 Bernhard H., OC-WE-138, Ben Amor M., PP-MO-649, PP-TH-448, PP-WE-439 PP-MO-650 Beretta L., PP-MO-716 Bernlochner I., OC-MO-124 Ben Cheik J., PP-MO-281 Berfelo F. J., OC-TU-063 Berntorp E., OC-TH-050, Ben Romdhane N., PP-TH-297, Berg R., PP-WE-574 PP-MO-540, PP-MO-541, PP-TH-298, PP-WE-455 Berge N., OC-MO-011, PP-MO-604, PP-TH-580, Benavente-García O., PP-WE-810 PP-WE-570, PP-WE-597, PP-WE-611 PP-TH-096 Berger C., PP-MO-594 Benazzo M., PP-MO-684 Berny M. A., AS-WE-044, Berger J. S., AS-TH-033 PP-TH-037, PP-WE-260 Benchenni S., AS-WE-025, Berger K., AS-WE-010, Berrueco R., PP-TH-451 OC-TH-082 OC-WE-118, OC-WE-119, Bendaoud H., PC-018 PP-MO-694, PP-WE-542 Berry J. L., PP-WE-861 Bendedouche B. K., Berger M. G., PC-013 Berry L. R., OC-MO-074, PP-WE-564 PP-MO-197, PP-TH-135, Berger P. B., AS-TH-033 PP-TH-435, PP-WE-173, Bender M., AS-WE-029, Bergholt T., PP-MO-405 PP-WE-174, PP-WE-177, AS-WE-030 PP-WE-193 Bergmann F., OC-TH-101 Benedettelli S., PP-MO-802 Berta A., PP-TH-216 Bergmann J., OC-MO-054 Benedik-Dolnicar M., Bertazzi P. A., PP-MO-321 AS-MO-028 Bergmeier W., SA-TU-001, OC-TU-045, PP-WE-016 Berthaut A., PP-WE-855 Benesova K., PP-MO-583 Bergqvist D., OC-TU-019 Berthelsen J. G., PP-MO-405 Benessiano J., PP-WE-787 Bergrem A., PP-MO-288, Bertholon P., PP-MO-332 Benetos A., PP-MO-402, PP-WE-332 PP-TH-362 Bertina R. M., AS-MO-035, Berguer A. M., PP-MO-400 AS-WE-019, OC-MO-019, Benhamou Y., PP-TH-144 OC-MO-078, PL-TU-001 Bergvist D., OC-TU-021 Ben-Hasan M., PP-WE-161 Bertina R., PP-WE-497 Berkner K. L., OC-WE-078 Benhida A., PP-MO-605 Bertini D., PP-WE-247, Berkner K., OC-WE-072 Benner M., PP-TH-439 PP-WE-248 Berkouk Y., PP-TH-204 Bennett J. S., AS-MO-039 Bertling A., PP-MO-030, Berkun Y., AS-TU-052 PP-MO-031 Bennett J., SA-WE-004 Berland M., PP-TH-385 Bertomoro A., PP-WE-641 Benninga M. A., PP-MO-444 Berland Y., OC-TU-089 Bertorello N. N., PP-TH-452 Benoit M., AS-TU-009 Berman J. N., PP-WE-447 Bertrand G., AS-MO-053, Berman J., PP-MO-686 PP-MO-079

486 PP-WE-616 PP-MO-562, PP-WE-539, Bevan D., PP-TH-683 Bevan D.H., Bettini F Betbout F., Betancourt M., Bestion A., PP-WE-556 Besser M.W Beski S., Bertrand M., INDEX AUTHORS Bidar A. W.,Bidar A. Bicknell R., Bickhardt K., Bicker M., Biasucci L.M., PP-WE-599 Biasoli C., Bianchini E.P., Bianchini C., Bianchi M., Bialkowska K., PP-WE-151 Bhella D., OC-TH-094 PP-TH-022, PP-WE-012, OC-TH-098, PP-MO-106, Bhavaraju K., Bhatt S.H., Bhatt D.L., PP-TH-175 Bhakta V., Bezzou H., Beznos O., Bezieau S., PP-WE-568 Bezgal F., OC-MO-020 Bezemer I.D., Beyer R., Beyer J., Beydoun A., Bevilacqua S., Bevan S., ., OC-TU-010 PP-WE-377 PP-TH-545 PP-WE-715 PP-WE-377 PP-WE-150, PP-MO-543, PP-MO-683, PP-TH-646 PP-MO-161, PP-MO-523, PP-TH-608 PP-TH-343 PC-005 PP-TH-385 AS-TH-033 OC-TH-014 PP-WE-642 PP-TH-478 OC-MO-069 PP-MO-385 ., PP-TH-336 PP-MO-618 PP-MO-628, PP-MO-476 PP-TH-644 OC-MO-043, PP-TH-240, AS-MO-005, PP-TH-352 AS-WE-022 PP-WE-789 OC-MO-109 PP-MO-187 Bird J.E., Birch N., PP-TH-299 Biosca GómezDeTejada M., PP-MO-287 Biondo F., Biolchini F., Binevski P., Binette T., Binetruy B., Bindlingmaier C., Binder C.J., OC-WE-069 Binder B., PP-WE-842, PP-WE-843 Binder B.R., PP-TH-074 Binard S., Billinghurst L., Billiald P Billett H.H., Bilgili H., Bikas D., PP-MO-058 Bihan D., PP-WE-052 Bihan D.G., PP-WE-691 Biguzzi E., Bigsby IvG., PP-TH-541 Bignell P Biggerstaff J., Biggerstaff J.P., Bigetti L., Bieth E., PP-WE-318, PP-WE-475 Biesma D.H., Bierings R., PP-MO-769, PP-TH-373 Biemond B.J., Bielenberg W PP-WE-210, PP-WE-453 PP-MO-607, PP-TH-533, Bidlingmaier C., PP-TH-148, PP-WE-777, PP-MO-838, PP-MO-848, PP-MO-551, PP-MO-71 ., . A., PP-MO-529 OC-TU-079 PP-WE-380 PP-MO-394 PP-MO-041, PC-034 AS-TH-043, PP-WE-100 PP-MO-786 OC-TH-116 OC-TU-081, PP-MO-210, PP-MO-375, PC-005 PP-MO-285 OC-MO-067 OC-TH-045 OC-WE-101 PP-MO-852, PP-WE-777 PP-TH-540, PP-MO-189, ., PP-TH-482 PP-WE-317, PP-TH-439 AS-TU-057 OC-TU-059, PP-TH-463 AS-MO-028, PP-WE-494 OC-WE-117 1, Bishop-Bailey D., Bisbe J., Birschmann I., OC-MO-021 Biron-Andreani C., Biron C., Birdsey G., PP-TH-628, PP-WE-553 AS-WE-003, PP-MO-639, Blanchette V. S., Blair P Black K., PP-WE-451, PP-WE-452 Black K.L., Bjørngaard B., Bjørnerheim R., Bjørn S.E., PP-WE-570 Björkman S., Björkman J., Bjorkegren J., Bjorholt I., PP-MO-575 Bjelke J.R., Bizzacchi J., Bizjak B., PP-WE-294 Bittar L.F PP-TH-379 Bitsadze V. O., J., Bitonti A. Biswas T. K., PP-TH-671, PP-WE-327 Biswas Biswar R.M., Biston P., Bisson R., Biss T. T., PP-TH-274 Bison E., Bisiani G., Bisi M., OC-MO-1 PP-MO-456, PP-TH-531, PP-MO-454, PP-MO-455, PP-TH-278, PP-TH-378, PP-MO-360, PP-MO-361, ., A., OC-TH-028 PP-WE-106 13, OC-TU-040, PP-WE-360 PP-TH-309 PP-MO-435 ., OC-MO-028, PP-WE-308 AS-TH-053 PP-TH-684 PP-MO-542 PP-WE-230 PP-WE-472 PP-MO-208, PP-MO-870, OC-MO-065 PP-MO-575 OC-TU-066, PP-MO-118, OC-MO-083 PP-WE-631 PP-WE-386 PP-WE-029 PP-TH-585, PP-TH-354 PP-MO-813 AS-MO-038 PC-017, PP-WE-383 PP-TH-427 AS-TH-053, PP-WE-809 487

Authors Index AUTHORS INDEX

Blanchette V., OC-TU-068, Blumenfeld De Bosch Böhm E., PP-MO-150 PP-TH-585 N., PP-MO-737, PP-WE-692 Böhm M., PP-MO-809 Blanco A. N., PP-MO-204, Bo W., PP-MO-691 Böhm-Weigert M., PP-WE-087 PP-TH-350, PP-WE-145, Boadas A., PP-MO-526, PP-WE-146 Böing A. N., AS-WE-017, PP-MO-663, PP-MO-737, OC-TU-055, PP-MO-109 Blanco A., PC-047 PP-TH-555, PP-WE-692 Boinot C., PP-TH-189 Blanco-Vaca F., PP-TH-289, Boban A., PP-MO-519, PP-TH-290 PP-MO-630 Boisseau P., PP-MO-529, PP-TH-623, PP-WE-642 Blangero J., PP-TH-289, Bobba B., PP-TH-453 Boissier E., OC-TH-022 PP-TH-290, PP-WE-208, Boccagni P., PP-TH-420, PP-WE-209, PP-WE-243 PP-WE-424 Boisson-Vidal C., OC-TH-046, OC-TH-048 Blank E., OC-WE-059 Bock P. E., AS-TH-050, Blaszkowski A., PP-MO-868 AS-WE-044, OC-WE-082 Bokemeyer C., PP-MO-014, PP-WE-485 Blatny J., PP-TH-530, Bock S. C., PP-TH-191 Boknäs N., PP-WE-014 PP-WE-441 Bockenstedt P. L., PP-MO-596, Blavignac J., AS-TH-045 PP-WE-613 Bokuchava M., PC-019 Blazek B., PP-MO-563 Bockmeyer C. L., PP-TH-086, Bolanos-Garcia V., PP-MO-852 Bleda D., PP-MO-209 PP-TH-087, PP-WE-684 Boldrin M., PP-WE-248, PP-WE-384 Bledzka K., OC-MO-048 Boda Z., PP-MO-359 Boldueva S. A., PP-MO-431 Blesingk N., PP-MO-233 Bode C., PP-MO-100 Bolli G. B., PP-TH-069 Blest N., PP-WE-427 Bodé-Dotto E., OC-MO-029 Bodenez C., PP-MO-332 Bolli P., PP-WE-003, Blickstein D., PP-MO-749 PP-WE-745 Bodman-Smith K., PP-WE-873 Blicq E., PP-TH-365 Bolliger D., PP-MO-676, Bliden K. P., PP-MO-739, Boehlen F., OC-TU-037, PP-MO-776, PP-WE-187 PP-WE-375 PP-TH-101, PP-WE-757, Bolt G., PP-MO-565, PP-WE-794, PP-WE-797, Boehncke W. H., PP-MO-705, PP-WE-109, PP-WE-572 PP-WE-798 PP-MO-706 Bolton-Maggs P. H. B., Bliden K., PP-MO-771, Boëlle E., OC-WE-006 OC-TU-078, PP-TH-645 PP-TH-026, PP-WE-043, Boeri E., PP-TH-622, Bombardier C. G., PP-WE-255 PP-WE-799, PP-WE-801, PP-WE-567 PP-WE-802 Bomgaars L., PP-TH-445 Boettcher J. M., OC-TU-091, Blinc A., PP-MO-350 PP-MO-113 Bomke B., PP-MO-745 Blinov M. N., PP-TH-313, Boezeman J., PP-TH-260, Bomken C., PP-WE-372 PP-TH-321, PP-TH-346, PP-WE-064 PP-WE-361 Bompiani K. M., PP-WE-189 Boffa M. B., OC-TH-115, Bonacchi M., PP-TH-352 Blobel G. A., AS-TH-042 OC-WE-109, PP-WE-241 Bonafede M. M., PP-WE-466 Bloch E. M., PP-MO-066 Boffard K. D., OC-TH-069 Bonanni G., PP-WE-866 Blombäck M., PP-MO-374, Bogani P., PP-WE-356 PP-TH-141, PP-TH-186 Bonar R., PP-MO-724 Bogankova N. A., PP-TH-025 Blombery P., PP-WE-409 Boncler M., PP-MO-097, Bogatkevich G. S., PP-MO-194 Blömer L., OC-MO-126, PP-WE-034 PP-MO-809 Bogchelman D. H., PP-MO-677 Bond H., PP-WE-523 Blomstrand C., OC-WE-115, Bogdanov V., PP-MO-808 Bonduel M., OC-TU-064, PP-MO-343 Bogdanova N., PP-TH-647 PP-MO-687, PP-WE-637 Blondon M., PP-WE-375 Boggian O., PP-TH-282, Bonello L., PP-MO-785 Blostein M., PP-TH-315 PP-WE-715 Bongarzoni A. A. B., Blot-Chabaud M., AS-MO-060 Bogolyubov A. A., PP-MO-182 PP-MO-312 Blumbach K., OC-WE-076 Bogutchi T., PP-WE-312 Bonneau M., PP-WE-810 Blume C., OC-MO-068 Bohec C., PP-TH-508

488 Boonstra A., Boon-Spijker M., Bontadi A., PP-WE-597 Bonnet P. O., PP-MO-773, PP-WE-775 Bonnet J., PP-MO-478 Bonnet F., Bonnet D., PP-MO-061 Bonnefoy A., INDEX AUTHORS Bosanquet J.P Bortoletto E., PP-WE-415 Borrell M., Borovsky M., OC-MO-125 Borissoff J.I., PP-TH-581, PP-WE-561 Borisenko O.V Borhany M.B., Borgognone A., Borghi H., PP-MO-238 Borggrefe M., Borges R., Borges M. A., Borgel D., PP-WE-859 Borg J., 105, PP-MO-489,PP-WE-839 Borensztajn K.S., TH-623, PP-WE-600 PP-MO-619, PP-TH-619,PP- Borel-Derlon Bordet J., PP-WE-493 Bordet J.C., PP-WE-305 Borch K.H., Borah B., Bopp C., PP-TH-610, PP-WE-563, PP-TH-172, PP-TH-174, PP-MO-514, PP-TH-144, OC-TU-006, PP-WE-304, PP-WE-178, PP-WE-243, OC-MO-050, PP-MO-611 OC-MO-051 PP-MO-658 AS-WE-050 PP-MO-187 PP-MO-477, OC-MO-007, PP-WE-175, OC-WE-089 PP-MO-663 PP-TH-274 OC-TU-005, PP-WE-322 OC-WE-021, A., PP-MO-060, PP-MO-696, PP-WE-656 PP-WE-535 PP-MO-349 OC-TH-068, AS-WE-058, ., ., PP-MO-104 PP-MO-618, PP-MO-553, PP-WE-430 OC-MO-111 PP-TH-648 OC-WE- PP-TH-103, PP-TH-492, PP-MO-318, PP-MO-505, OC-MO-132, OC-TH-073, OC-MO-038, OC-MO-041, PP-TH-680 Boval B., Bova C., Bouvard C., OC-WE-070 Bouton M., PP-TH-649, PP-TH-650 Boutekedjiret T Bourguet N., Bourada S., PP-TH-518, PP-WE-744 Bounameaux H., PP-WE-741, PP-WE-742 Bouman H.J., PP-WE-216 Bouma B., Bouma B.N., Bouma B.J., Boulvain M., PP-MO-787 Boulay-Moine D., OC-WE-070 Boulaftali Y., OC-WE-021, OC-MO-062 Boukerche H., Bouillon R., Bouillon B., Boudreaux M.K., PP-MO-721 Bouchard B. Bouabdelli M., PP-WE-115, PP-WE-117 PP-TH-264, PP-TH-281, Bottenus R., Bottaro F., Botha E.M.D., Botelho L.F PP-WE-100 Bostwick J.S., Bosson J., Bosquet L., PP-WE-782 Bosch I., PP-MO-781, PP-MO-788, OC-MO-135, PP-MO-780, PP-TH-303 AS-WE-018, OC-MO-01 PP-WE-293 AS-TH-038, PP-MO-315 AS-TU-024, ., PP-WE-483 PP-MO-059 OC-TH-069 PP-WE-639 OC-TH-046 AS-TU-024, PP-MO-265, PP-WE-375 A., PP-MO-787 PP-TH-293 AS-TH-038 PP-TH-542 OC-MO-133, OC-WE-021, PP-MO-077 ., PP-TH-202, PP-WE-124 OC-MO-120, PP-TH-470, AS-TH-032, PP-MO-766, PP-MO-754 1, Bovin J., Bovill E., PP-WE-458 Bovill E.G., Boveda RuizD., Branco C.C., Branch D.R., PP-WE-356 Brambilla M., Brakenhielm E., Brakebusch C., Brainsky Brain T Braga J., Braester A., Braemswig K., Brady B., C., Bradshaw A. Bradna P., 469, PP-WE-470,PP-WE-471 Bradley-Kennedy C., Bradford H.N., Bracone F PP-TH-613 Brabec P., PP-MO-067 Bozzi V Bozzato S., Bozic MijovskiM., Bozic M., Bozas G., Boyle AS-TH-009 Boylan B., PP-MO-618, PP-TH-623 Boyer-Neumann C., Boyer O., OC-WE-074 Boyd D., Boxnick B., PP-TH-628 Bowman M., OC-WE-145 Bowley S.R., Bowen D.J., OC-TU-003, OC-TU-034, OC-MO-024, OC-TU-001, A. J., ., ., PP-MO-233 AS-TU-004, AS-TU-025, A., PP-TH-323 PP-MO-819 PP-WE-374 PP-WE-251 PP-MO-593 PP-WE-859 ., PP-WE-503 PP-TH-543, PP-WE-068 AS-MO-052, PP-TH-507 PP-MO-876 PP-MO-161 PP-MO-595 AS-TU-007, PC-053 AS-TU-002 OC-TU-078, OC-TU-078 OC-TU-025, PP-MO-297 OC-MO-102 OC-MO-1 OC-WE-069 AS-TH-047 AS-WE-030 PP-WE-859 PP-WE-222 PP-WE-151 PP-MO-350 PP-WE- 17, 489

Authors Index AUTHORS INDEX

Brand B., PP-MO-643 Bressollette L., OC-MO-041, Bronic A., PP-WE-442 Brandao L. R., PP-MO-426, OC-WE-113, PP-MO-500, Brons P., PP-TH-665 PP-WE-508, PP-MO-499, PP-WE-288, PP-WE-446, Bronstein M. M., OC-WE-072 PP-WE-719 PP-TH-508 Brook N., PP-MO-370 Brandão L. R., PP-TH-463 Bretherton S., PP-WE-297 Brooks J., PP-WE-546 Brandao L., PP-MO-443, Brettler D. B., PP-MO-596, PP-MO-447, PP-TH-434, PP-WE-613 Brooks M. B., PP-MO-751 PP-TH-459, PP-WE-443, Breuss J. M., PP-MO-848, Brooks S. V., PP-TH-551, PP-WE-445 PP-WE-843 PP-WE-649 Brandjes D. P. M., PP-MO-292, Breuss J., PP-MO-838 Brooks S., PP-TH-528, PP-WE- PP-MO-293, PP-TH-286 Brewer J., PP-WE-530 192, PP-WE-713 Brandl R., OC-MO-124 Breyne J., PP-MO-815, Brophy D. F., PP-TH-567 Brandolin B., OC-MO-049, PP-MO-814 Brophy T. M., OC-MO-056 PP-MO-348 Brezinova J., PC-022 Brosnihan K. B., PP-WE-854 Brandt M., PP-TH-060 Bridey F., PP-MO-619, Brotschi B., OC-TU-061 Brankovic-Sreckovic V., PP-MO-618 Brouland J. P., PP-MO-074 PP-TH-460 Brierre F., PP-TH-136 Brouland J., PP-WE-810 Brash J. L., PP-MO-428, Brill A., AS-MO-047, PP-TH-435 OC-TU-045, PP-WE-847 Brouns R., PP-MO-229, PP-MO-230 Brass L. F., AS-TU-028, PP-TH- Brinkman H. J. M., OC-WE-084 038, PP-WE-030, PP-WE-063 Brouwer J., AS-MO-002 Brioschi M., PP-WE-050 Braude P., PP-TH-496 Browett P., OC-TU-079 Brisset A. C., OC-WE-037 Braun A., AS-TU-005, Brown A. E. X., OC-WE-146 AS-TU-037, AS-TU-040 Brito D. D. V., PP-WE-814, PP-WE-815 Brown A., PP-TH-310, Bray M., OC-WE-045 PP-TH-457 Britto M., AS-TU-059 Bray P. F., OC-TH-095, OC-WE- Brown C., OC-TU-076 045, PP-MO-756, PP-WE-752, Brivio L., PP-MO-309, Brown H., OC-WE-134 AS-TH-041 PP-WE-340 Brown M., PP-WE-695 Bray S. L., AS-MO-037 Brixi S., PP-TH-276 Brox J., OC-WE-137, Breen K. A., PP-WE-615 Brkic J., OC-WE-121 OC-WE-140 Breet N. J., OC-MO-135, Brock J., OC-WE-061 Broyer V., PP-MO-645 PP-MO-788, PP-WE-741, Brodde M. F., PP-WE-734 PP-WE-742 Broze - Jr. G. J., AS-MO-021 Brodde M., PP-TH-574 Bremme K., AS-WE-024, Broze G., PP-TH-163 PP-WE-643 Broder M., PP-TH-569, PP-TH-587 Brozzetti M., PP-WE-529 Brennan M. P., PP-TH-056, Bruce A. A. K., PP-MO-435 PP-WE-813 Brodin E., OC-MO-058, PP-MO-177 Bruce A., PP-TH-531, Brennan M., PP-TH-102 Broek L., PP-WE-341 PP-WE-451 Brennecke S. P., PP-MO-381 Brogden A., PP-MO-300 Bruera G., PP-TH-694 Brenner B., OC-TU-057, Bruggeman L. W., PP-TH-484 OC-TU-058, PP-MO-313, Brohi K., OC-TH-067, PP-MO-850, PP-TH-387 PP-TH-685 Brügger-Andersen T., PP-TH- Brohmann H., PP-MO-244 131, PP-WE-126, PP-WE-829, Brenner H., PP-MO-480 PP-WE-830, PP-WE-831 Broholm R., AS-MO-008 Brereton J. J., PP-TH-458 Brummel-Ziedins K., Brescia L. P., PP-MO-448, Bröijersén A., PP-MO-761 SA-MO-004, OC-MO-003, PP-WE-878 Bröker B. M., AS-TH-007 OC-TU-003, PP-TH-196, PP-WE-358, AS-TU-023, Bresser P., OC-WE-105, Bromirski J., PP-TH-230, OC-MO-120, OC-TU-069, PP-TH-293 PP-TH-231 PP-MO-721 Brondke H., AS-WE-002 Brunaud C., PP-WE-084

490 Bryckaert M., Bruzgol T., Bruzelius M., Brusi C., Bruntz J., Brunso L., Bruns C., Brüning J.C., PP-MO-090 Bruneval P Brunette A., Brunet P., INDEX AUTHORS PP-WE-190 Buerke M., PP-WE-357 Bueno-De-Mesquita H.B., Bueno E.C., Buelens K., Buehler B., Budnik I., Budhrani C.C., PP-WE-722 Budde U., Buczma PP-TH-239 Buczko W., Buckley T., Buckley S., Buckley S.M.K., Buckley C.D., Bucklar G., PP-TH-030 Buckland R.J., Bucherini E., Buccioni A., WE-132, PP-WE-691 Bucciarelli P., Bucciarelli L.G., Bubpachart C., Bryon A., Brynda E., AS-TU-024 PP-WE-630, PP-WE-651, PP-TH-646, PP-WE-629, PP-TH-091, PP-TH-639, OC-WE-136, PP-MO-638, PP-TH-300, PP-TH-301,PP- A., AS-TH-029 PP-MO-751 OC-TH-101 PP-WE-044 OC-MO-029 PP-WE-850 OC-TU-077, ., PP-MO-053 PP-TH-213 PP-MO-338 PP-TH-440, PP-MO-410 PP-MO-025 PP-MO-234, PP-WE-329 OC-TU-076 PP-WE-660 OC-TH-1 PP-MO-402 OC-TH-048, PP-MO-803 PP-TH-490 PP-WE-403 PP-WE-643 OC-WE-043, OC-MO-081, OC-WE-076 PP-WE-076 PP-MO-446 OC-MO-012, PP-WE-428 OC-TU-088 PP-WE-150 14 PP-MO-243, PP-WE-080, PL-TU-004, PP-MO-242, PP-MO-438 Burgess J., PP-TH-280 Burakowski J., PP-WE-223 Buraczewska-Buczko A., PP-WE-169 Bura Rivière PP-MO-280, PP-MO-281 Bura A., Bungay S.D., Bunce M., Bumgarner J., PP-TH-063, PP-WE-075 Bumbea H., Bulut G., PP-WE-293 Bullorsky E., Bullinger M., Bullinger B., PP-TH-518 PP-TH-348, PP-TH-517, PP-TH-139, PP-TH-286, PP-MO-286, PP-MO-298, OC-WE-035, OC-WE-100, OC-TU-008, OC-TU-012, OC-MO-091, OC-TH-017, Büller H.R., PP-TH-484 Buller H.R., Bull A., PP-WE-596 Bulikova A., Bulhak A., Bulder I., PP-WE-248, PP-WE-384 Bulato C., PP-WE-209, PP-WE-243 Buil Buhan T. P., Buffone A., PP-TH-290, PP-WE-208, PP-TH-293, PP-TH-356, PP-MO-417, PP-MO-763, PP-MO-292, PP-MO-293, OC-WE-014, OC-WE-019, OC-TU-010, OC-WE-001, OC-MO-039, OC-MO-042, PP-TH-612, PP-TH-613, PP-MO-270, PP-MO-271, A., OC-TU-049 PP-TH-289, OC-WE-085, PP-WE-128 PP-TH-153 OC-MO-121, AS-TH-046 PP-WE-386 PP-WE-893 PP-MO-437, PP-MO-069, PP-MO-147 AS-MO-030, PP-MO-259, LB-MO-004, A., OC-WE-119 PP-WE-542 PP-WE-135, OC-WE-095 PP-WE-694 PP-TH-279, PP-MO-188, PP-TH-154, PP-TH-196, PP-TH-603, PP-TH-604, Bürki C., Burke C., Burillo LorenteJ., PP-WE-836 Burián K., Burgos G., Burghel G.J., PP-WE-560, PP-WE-765 Butta N., Butt C., Butler J., Butler J.J., PP-WE-152, PP-WE-362 Butenas S., Butcher M., PP-TH-347 Busti F., Busshardt M., PP-MO-469 Bussey SmithK.L., Bussey H.I., Bussel J., AS-TU-002 Bussel J.B., Busse Grawitz Busonera F., Buschmann A., Buschek S., PP-WE-058 Buryachkovskaya L.I., PP-MO-770, PP-WE-091 Buryachkovskaya L.I., PP-TH-069 Bury L., Burroughs Burris S.M., Burra P Burns T. L., Burns P., Burnier L., Burnett L., OC-TH-086 Burnett E., Burnand K., PP-TH-395 Burlova-V ., PP-TH-364 PP-MO-085, PP-MO-342, PP-TH-420 PC-048, PP-TH-059, OC-TU-061 AS-MO-037 PP-MO-713 asilieva N., PP-MO-757 SA-TU-004 OC-TU-051, AS-TU-018 PP-WE-703 A., OC-TH-053, OC-MO-021 AS-TU-023, PP-WE-636 PP-MO-713 PP-WE-817 PP-MO-384 PP-MO-674 PP-MO-081 AS-MO-055, PP-WE-338 PP-MO-469 OC-TU-077 PP-TH-440 PP-TH-106 A., PP-MO-556 PP-WE-519 PP-TH-299 491

Authors Index AUTHORS INDEX

Buurman W. A., PP-TH-181 Calderzzo J. C., PP-WE-089 Campetella O., PP-WE-035 Buyue Y., PP-WE-184 Cale J. M., PP-TH-252 Campiotti L., PP-MO-309 Buzby J. S., PP-MO-823, PP- Califano S., PP-MO-799 Camporese G., PP-WE-338, TH-065, PP-TH-066 Calini A., PP-WE-230 PP-WE-403 Bykowska K., PP-MO-714 Calkavur T., PP-TH-511 Campos F., PP-MO-667 Bynagari Y. B., OC-TH-098 Callahan J. B., PP-WE-207 Campos L., OC-TH-021, PP-WE-165 Bynagari Y. S., OC-TH-094 Callahan J., OC-MO-038, Byrne C., OC-WE-114 PP-TH-524 Campos M. M., PP-TH-444 Byrne M., PP-TH-549, Callas P. W., AS-TU-007, Campos M., PP-MO-667, PP-WE-685 OC-MO-024, OC-TU-003, PP-WE-374 Byrne S., PP-MO-414 PP-WE-458 Campostrini N., PP-MO-342, PP-TH-347 Byron O., OC-WE-148 Callebert J., PP-WE-408 Calori G., PP-MO-775 Campregher G., PP-TH-350, Byzova T. V., PL-TU-005 PP-WE-354 Calugareanu A., PP-WE-737 Caballero S., PP-WE-575, Canaro M., PP-MO-590 PP-WE-576 Calvaruso V., PP-TH-106 Canault M., AS-MO-047, Cabaravbic M., OC-WE-069 Calvel L., PP-MO-416 OC-TU-045 Cabello A., PP-WE-665 Calvo F., PP-WE-436 Canciani M. T., PP-WE-625 Cabral R., PP-MO-297 Calzavarini S., AS-WE-039, Candela M., PP-WE-618 PP-TH-372 Cabrera M. J., OC-WE-086 Caniato A., PP-MO-351 Camacho J., PP-WE-551 Cabrera N., PP-TH-627, Cannegieter S. C., PP-WE-668, PP-TH-544 Camargo C. A., OC-TU-004 OC-MO-079, OC-WE-013, Caferri H., PP-TH-060 Camargos E. R., PP-MO-387 OC-WE-091, PP-MO-293, PP-TH-238, PP-TH-286, Cafolla A., PP-MO-287 Cambefort P., PP-WE-510 PP-TH-329 Caglar T., PP-MO-841, Cambier N., PP-WE-762 Cano H., PP-WE-141 PP-WE-889 Cambou J. P., OC-WE-085, Canobbio I., PP-MO-018, Caglayan H., PP-MO-653 PP-MO-280, PP-MO-281 PP-MO-046 Cahalan L., PP-TH-439 Cambou J., OC-WE-017 Canpolat N., PP-MO-073 Cahalan P., PP-TH-439 Cambus J., PP-WE-412 Cantalino E., PP-MO-482 Cahillane G., OC-TH-057 Camera A., PP-MO-616 Cantor A. B., OC-WE-152 Cai H., PP-TH-334 Camera M., OC-TU-025, Cantu-Brito C., PP-WE-264 PP-WE-356 Cai W., PP-MO-159 Cao L., PP-WE-711 Cameron K. J., PP-TH-244 Cai X., PP-MO-171 Cao O., AS-TU-015, PP-TH-618 Camilleri R. S., PP-TH-088 Caiafa J., PP-WE-312 Cao P., PP-WE-823 Caille V., AS-TU-009 Camire R. M., AS-TH-013, AS-TH-046 Cao W., PP-TH-080 Cailleux N., PP-TH-144 Camire R., AS-TH-008 Cao Y., PP-TH-095 Cairo A., OC-WE-132 Camoin L., PP-MO-774 Cao Z., PP-TH-281 Cairo F., PP-TH-681 Camoin-Jau L., OC-TU-089, Capalbo A., PP-MO-799, Cajfinger F., PP-WE-483 PP-MO-785, AS-WE-050, PP-MO-800 Cakici O., PP-WE-708 OC-MO-007 Caplan A., PL-TU-005 Calabro L., PP-WE-021 Campbell J. E., AS-TU-023 Capobianco A., OC-WE-127 Calaf R., PP-WE-850 Campbell P. J., OC-TH-015 Caporale R., PP-MO-799, PP-MO-800, PP-MO-836, Calandini O., PP-WE-855 Campbell R. A., OC-MO-073 PP-TH-340, PP-WE-002 Calanni F., PP-MO-202 Campbell S., PP-TH-182 Cappucci F., PP-MO-822, Calderazzo J. C., PP-MO-610, Campello E., PP-MO-765, PP-WE-366 PP-MO-831, PP-MO-832 PP-TH-382, PP-TH-383, PP-TH- 487, PP-TH-488, PP-WE-460

492 PP-WE-587 Carcao M.D., OC-WE-017, PP-TH-349 Carcaillon L., Carazzolle M.F., Carazolle M.F Caramazza D., PP-TH-674, PP-WE-689 Caram C., Captug O., Capron C., PP-TH-169, PP-TH-170 Caprini J. A., INDEX AUTHORS PP-TH-680, PP-WE-762 Caron C., PP-WE-105, PP-WE-753 Carnevale R., Carneiro J.D. PP-TH-312 Carnarius H., Carmony A., Carmona F., Carmeliet P., Carmazzi Carmassi F., Carlsson T Carlsson S.U., Carlson K.S., PP-TH-235, PP-WE-164 Carlo A., PP-WE-610 Carlier V. A., Carlebach M., Carew J. PP-MO-364, PP-WE-815 Cardoso J.E., Cardoso G., Cardinali B., Cardigan R. Cardenas J., Cardel L.K., PP-WE-553 Card R., PP-WE-695 Card R.T 112, PP-MO-766,PP-TH-183, PP-MO-626, PP-TH-623, AS-WE-003, ., PP-MO-108, PP-MO- A., Y PP-MO-611, PP-TH-673, ., ., OC-TU-068, PP-MO-394 OC-WE-149 A., PP-TH-428 PP-WE-1 PP-MO-794 PP-WE-371 PP-MO-758 OC-WE-148 PP-MO-246 PP-MO-605, OC-WE-022 PP-MO-678 OC-MO-044 PP-WE-290 PP-MO-167, PP-MO-509, OC-TH-005, ., PP-TH-050, PP-TH-629, A., PP-WE-272 PP-WE-718 PP-MO-363, AS-TH-030 OC-WE-141 PP-MO-759 PP-MO-825 PP-MO-826 PP-WE-444 13 PP-MO-364, PP-TH-444, PP-MO-335, PP-MO-363, Casari C., Casanegra PP-TH-544 Casaña P., PP-WE-354 Casais P., PP-WE-365, PP-WE-812 Carvalho M., PP-WE-869 Carvalho M.G., Caruso V., Caruso P., Cartot-Cotton S., Cartier S., Carter T., PP-WE-231 OC-WE-1 M., Carter A. Carteaux J., Carteaux J.P., Carson P., Carrothers T Carroll V. A., PP-WE-094 Carrivale M. A., Carrillo M., PP-MO-849 Carrijo-Carvalho L.C., PP-TH-573, PP-WE-249 Carrieri C., PP-TH-489 Carrier M., Carreras M.C., Carre J., Carraro V Carr M.E., Carr C., PP-WE-668, PP-MO-589, AS-WE-022, PP-TH-292, OC-TH-012, OC-TU-011, PP-TH-044, PP-WE-093, PP-WE-310, PP-WE-364, PP-WE-226, PP-WE-227, PP-TH-490, PP-WE-092, PP-TH-217, PP-TH-218, PP-MO-816, PP-MO-871, PP-MO-698, PP-MO-699, PP-MO-346, PP-MO-349, OC-MO-123 14, PP-TH-351, PP-TH-291 ., OC-MO-067 AS-WE-039 PP-TH-350, OC-TU-020 PP-TH-372 PP-WE-522 PP-WE-498 PP-TH-627, OC-MO-087, PP-MO-598 OC-TU-086 A. I., PP-MO-176, PP-TH-156 . J., PP-WE-700 OC-TH-089, PP-MO-848 PP-MO-333, PP-TH-394 PP-MO-589 PP-MO-831, PP-MO-334, PP-WE-464 OC-WE-003 PP-WE-423 Cases Casciu L., Casazza G., Casazza F Casazza F. F. C., Casas M.J., PP-WE-499 Castoldi E., PP-WE-443, PP-WE-446 Castle D., PP-TH-096, PP-WE-033 Castillo J., Castellone D.D., Castellino F PP-MO-881 Castellino F. J., Castelli R., PP-MO-765, PP-TH-382 Castelli M., PP-WE-744 Castelli C., Castelli Castellano R., Casteels P., PP-MO-687 Castañon M., Castaño S., PP-WE-630 Castaman G., AS-WE-023, PP-MO-372 Castaman G.C., PP-TH-347 Castagna A., Cassee F. R., PP-WE-645 Casonato A., PP-MO-803, PP-TH-340 Casini A., Casey K., OC-MO-132, OC-WE-099, PP-MO-186, PP-TH-377, OC-MO-1 OC-WE-022, PP-MO-880, AS-WE-049, OC-TU-050, PP-WE-628, PP-WE-629, PP-WE-626, PP-WE-627, OC-WE-136, PP-MO-612, OC-TU-074, OC-TU-075, AS-TU-032, AS-TU-033, AS-MO-017, AS-MO-029, PP-TH-259, PP-WE-641, A., A., 19, OC-WE-097, ., PP-WE-871 PP-TH-585 PP-MO-801, PP-MO-447, PP-MO-266 PP-MO-055, AS-TH-032, PP-MO-775 PP-WE-230 OC-TU-086, ., OC-TH-014 AS-TH-024 OC-MO-005, PP-MO-160 OC-TH-010 PP-TH-629 PP-MO-342, AS-WE-039, SA-TU-007 PP-TH-122 OC-TU-064, SA-MO-007, PC-015 AS-TU-043, PP-MO-312 PP-MO-129 493

Authors Index AUTHORS INDEX

Castro F., PP-TH-299 Celi A., Chafa O., PP-MO-656 Castro Ozelo M., PP-WE-066 OC-WE-029, PP-MO-758 Chagnon I., OC-TU-011 Català A., PP-TH-451 Celik M., PP-MO-073 Chai J., OC-TH-043 Cataland S. R., OC-WE-009, Celinska-Lowenhoff M., Chaim E. E. A. C., PC-046 PP-TH-381 OC-WE-129, OC-WE-130, Chaireti R., PP-TH-018, PP-WE-729 Celkan T., AS-MO-028, PC-039 PP-WE-334 Catalfamo J. L., PP-MO-751 Cella G., OC-WE-088, Chakroun T., PP-TH-343 PP-MO-867 Catanese J. J., AS-WE-010 Chalmers E., PP-TH-538 Cellai A., PP-MO-217 Catapane E., PP-TH-424 Chambost H., OC-TU-073, Cathala N., PP-TH-307 Cellini C., PP-WE-856 PP-WE-603 Catricalà S., PP-MO-046 Cera M., PP-MO-775 Chammas R., PP-TH-499 Cattaneo M., SA-TH-005, Cerbone A. M., PP-MO-336, Chamone D. A. F., PP-MO-755, OC-TH-010, PP-MO-092 PP-WE-320, PP-WE-325 PP-TH-542, PP-WE-444, Cattaneo R., OC-TH-011 Ceresetto J. J., PP-WE-135 PP-WE-705 Cattaneo V., PP-WE-035 Ceresetto J. M., PP-WE-293 Chamouard V., PP-MO-530 Cattini M. G., PP-WE-641, Ceriani E., OC-TH-010, Champion F., PP-TH-385 PP-WE-645 PP-MO-505 Chan A. K. C., OC-MO-074, Cattini M., PP-TH-259 Cerini C., PP-WE-850 OC-TU-068, PP-MO-197, PP-MO-426, PP-TH-135, Cauchie C., PP-TH-684 Cerletti C., PP-MO-099, PP-TH-048, PP-TH-094, PP-TH-435, PP-TH-441, Cauchie P., PP-TH-684 PP-TH-248, PP-WE-048, PP-TH-459, PP-TH-503, PP-WE-246 PP-WE-173, PP-WE-174, Caughran J. D., PP-WE-103 PP-WE-177, PP-WE-193, Cavallaroni K., PP-WE-509 Cermelj M. A., PP-TH-607, PP-WE-288, PP-WE-431, PP-WE-203 PP-WE-541, AS-TH-051 Cavallo L., PP-WE-878 Cerrato G. S., PP-TH-333 Chan A. K., OC-WE-095, Cavazza S., PP-WE-509 Cerrato G., PP-MO-275, PP-WE-445, PP-WE-719 Cavazzana A., PP-TH-274 PP-TH-681 Chan A., AS-WE-003, Cavoni A., PP-MO-015 Cesari F., OC-TH-047, PP-MO-494, PP-WE-507, Cawthern K. M., PP-TH-264, PP-MO-799, PP-MO-800, PP-WE-553 PP-WE-117 PP-MO-801, PP-MO-802, Chan C. T., PP-TH-125 PP-MO-803, PP-MO-804, Cazap N., PP-WE-135 PP-MO-836, PP-TH-163, Chan C., AS-WE-060 Cazenave J. P., OC-MO-008, PP-TH-340, PP-WE-002, Chan H. H. W., PP-WE-174 OC-TH-033, OC-TH-034, PP-WE-747 Chandra D., PP-MO-623 PP-MO-416 Cesarman-Maus G. N., Chandrasekaran E. V., Cazenave J., AS-MO-058, PP-WE-264 PP-WE-893 AS-TU-047, OC-TH-035, Cetin I., PP-MO-375 OC-TU-049, OC-WE-150, Chang C., PP-MO-846, PP-WE-891 Cetin R., PP-WE-806 PP-MO-877, PP-MO-878 Cazin L., PP-TH-174 Cetkovsky P., PP-MO-583 Chang D., PP-TH-667 Cazzaniga M., PP-MO-673 Cevreska L., PP-TH-557, Chang J. Y., PP-MO-768, PP-WE-769 PP-TH-655 Cecchetti L., OC-TU-047, PP-MO-085 Cha Y., PP-MO-213 Chang L., PP-MO-010 Cecchi E., PP-MO-013 Chaabane C., PP-WE-810 Chang M. C., PP-MO-869, PP-TH-058 Cech L., PP-WE-142 Chaar G., PP-WE-281 Chang M., OC-TH-119, Cecinati V., PP-MO-448, Chabot F., PP-MO-402 PP-TH-065, PP-TH-066 PP-TH-493, PP-WE-878 Chacko J., PP-TH-615 Chang R., AS-MO-010, Ceelen W. P., PP-WE-176 Chadha S., AS-WE-045 PP-TH-225, PP-TH-225 Cefalù A. B., OC-TU-088 Chadwick S., PP-TH-480, Chang-Claude J., PP-MO-480 Celestini A., PP-WE-105 PP-TH-525

494 Charbonnier B., Charbonnel C., Chappell L., Chappell J.C., Chapman S., Chapman R.L., OC-TH-021, PP-WE-165 Chapelle C., PP-TH-653 Chao T Chantarangkul V., Chanos A., INDEX AUTHORS PP-TH-620 Chen C.C., Chen A., Chegeni R., Cheema Che NordinS., Chavez M., Chavez L., Chaunsamrit Chauleur C., OC-TU-045, PP-MO-093 Chauhan Chaudry G., Chau W. K., PP-WE-063, PP-WE-194 Chatterjee M.S., Chatellier G., PP-MO-618 Chatelanaz C., Chatelain R., Chatelain N., Chatelain B., PP-TH-386 Chatard B., PP-MO-710 Charunwatthana P., Charniot J., PC-011, PC-051 Charnaya M. A., Charlanne H., Charkviani T., Charitos C., Chari R., PP-TH-038, PP-TH-049, ., A., PP-MO-555, PP-WE-078 PP-TH-011 A. K., PP-TH-681 AS-WE-031 PP-TH-467 PP-MO-658, PP-MO-330, PP-MO-356 PP-MO-723 OC-TH-053 PP-TH-620 PP-WE-693 PP-WE-623 PP-WE-446 OC-MO-053, OC-TH-081 A., OC-TU-073 PP-MO-814 PP-MO-040 OC-WE-022 AS-TU-009 AS-TH-043 PP-WE-281 PP-MO-619, AS-WE-051 PP-MO-636 OC-TH-063, PP-WE-858 PP-MO-587 PC-010, PP-TH-365 PC-052 OC-TH-109, PP-MO-673 PP-TH-408, PP-TH-552, PP-MO-555, PP-MO-844, PP-WE-836, PP-WE-848, PP-MO-796, PP-WE-394, PP-MO-629, PP-MO-678, OC-TU-051, OC-WE-067, Chesnokova N., Chernysh I.N., Cherkasova M.V., OC-MO-060 Cherel G., Chennoukh K., Chennoukh K.W PP-TH-653 Cheng S., Cheng Q., PP-WE-079, PP-WE-429 Cheng J., AS-TU-002 Cheng G., PP-WE-706 Chen Z., PP-TH-653, PP-WE-005 Chen Chen PP-TH-095 Chen X., PP-WE-586 Chen W., Chen W Chen V. M., Chen S.W PP-MO-41 Chen Q., 139, OC-WE-121,PP-WE-060 Chen P Chen P. M., Chen M., Chen L., Chen K., PP-WE-887, AS-MO-011 Chen J., Chen H., Chen F., Chen E., Chen E.P., Chen E.I., PP-WE-849 Chen D., Y Y ., ., . C., . J., AS-TU-030, OC-MO- OC-WE-027 PP-MO-010, PP-TH-092, OC-TU-027 PP-TH-078, PP-TH-078, PP-TH-225 OC-MO-107 PP-MO-646 OC-TH-043, PP-MO-410, OC-TU-034 PP-WE-585, 1, PP-TH-126 PP-TH-503, PP-MO-555, ., AS-TH-039 AS-MO-055, AS-TH-015, AS-TU-020 PP-MO-676 PP-MO-100 AS-MO-043 PP-MO-330 PP-TH-088 PP-WE-659 AS-WE-048 PP-TH-204 PC-005 ., PP-TH-267 PP-WE-639 PP-TH-509, PP-WE-343 Chi H., PP-TH-498 Chew H.K., Chevalier Y., PP-MO-847 Cheung E. Y., 353, PP-MO-712,PP-WE-877 Choi J., Choi G., Choi E., Choi D., Chocarne P Cho R., Cho P Cho J., Cho H., PP-TH-613 Chlupova G., Chlopicki S., PP-TH-371 Chitsike R.S., Chitlur M., Chitima-Matsiga R., Chironi G., Chirivella M., OC-TU-076 Chirinian Y., L., Chiriac A. Chion C.K.W., Chion A. C.K., Chio S., PP-WE-772 Chinthammitr Y., Chintagumpala M., PP-MO-822 Chinni E., Chin-Dusting J., Chillón M., Chiles P. G., Chiesa R., Chieng YaneP., Chieffo A., PP-TH-211, PP-WE-505 Chidiac J., Chicanne G., Chi J., . W., OC-MO-002 PP-MO-727, OC-MO-057 PP-TH-489 PP-TH-149 PL-TU-005, PP-MO- PP-WE-783 PP-TH-123 PP-WE-877 PP-WE-407 OC-TU-035, PP-WE-757 PC-015 PP-TH-180 PP-MO-775 PP-MO-514, PP-TH-290 PP-WE-408 ., OC-TU-014, AS-MO-020, OC-MO-022 PP-MO-264 PP-MO-530 PP-TH-239 OC-TU-016 PP-WE-019 PP-TH-612, PP-MO-215 OC-MO-078, PP-TH-370, OC-MO-065 PP-MO-091 PP-MO-837 PP-WE-391 PP-MO-406, PP-TH-445 AS-TH-027 495

Authors Index AUTHORS INDEX

Choi M., PP-MO-727 Chuansumrit A., PP-MO-354, Cimmino G., PP-MO-834 Choi S. H., PP-TH-256 PP-MO-681, PP-WE-566 Cines D. B., OC-WE-112, Choi T., PP-TH-519 Chudej J., PP-TH-306 AS-TU-001 Choi W., PP-MO-301 Chudy’P.,PP-TH-306, Cines D., AS-TH-008 PP-WE-220 Chojnowski K., PP-MO-692, Cini M., PP-MO-351, PP-MO-752 Chudzinski-Tavassi A. M., PP-MO-503, PP-MO-504, PP-MO-475, PP-MO-849, PP-TH-282, PP-WE-351, Cholera S., PP-MO-054 PP-WE-160, PP-WE-167, PP-WE-509, PP-WE-715 Chollet M. E., PP-MO-074, PP-TH-495, PP-WE-098 Ciocea A., PL-TU-005 PP-TH-680 Chumakova E. L., PP-WE-224 Ciorascu M., PP-MO-069 Chopard P., PP-MO-318 Chun S., PP-TH-509 Cipolla A., PP-TH-590, Chovanec V., PP-TH-438 Chung C., PP-MO-840, PP-WE-870 Chow C., PP-WE-004 PP-MO-846, PP-MO-878 Cipolla L., PP-MO-046 Chow T. Y., PP-MO-820 Chung D. W., PP-TH-092 Cirillo F., PP-WE-321 Chowdary P., PP-MO-524, Chung D., AS-MO-011 Ciuti G., OC-WE-102, PP-WE-192, PP-WE-649, Chung J., PP-WE-501, PP-MO-303, PP-MO-304, PP-WE-713 PP-WE-569 PP-MO-339, PP-MO-341, Chrast R., OC-WE-037 Chung K., PP-WE-783 PP-WE-283 Chretien J., OC-TH-018 Chung M., PP-WE-844 Clabon M., PP-MO-112 Chrisitian G., AS-TU-047 Chung Y., PP-TH-294 Claesson-Welsh L., SA-TH-007 Christ G., PP-MO-107 Chunharas A., PP-MO-354 Claeyssens S., PP-MO-567 Christadoss P., OC-TU-038 Church F. C., PP-WE-189 Clappers N., PP-MO-780 Christensen E. I., PP-MO-121, Church F., PP-TH-502, Clark D. S., AS-TH-053 PP-MO-122 PP-WE-290 Clark I., PP-TH-330 Christersson C., PP-MO-408, Ciabattoni G., OC-TU-088, Clark N. P., PP-MO-462, PP-TH-407 PP-MO-015, PP-MO-016, PP-MO-463 Christiansen K., PP-MO-386, PP-WE-738 Clark N., PP-MO-308 PP-WE-658, PP-WE-677 Cianchetti S., OC-WE-029 Clarke B. J., OC-MO-059 Christiansen M. L. S., Ciancia M., PP-WE-824 PP-WE-590, PP-WE-591 Clase C. M., OC-TH-009 Ciavarella N., PP-TH-670, Claus R. A., PP-TH-086, Christiansen M. S., PP-WE-657 PP-WE-589 PP-TH-087, PP-WE-684 Cichon S., OC-TH-059 Christiansen S. C., Claustres M., PP-MO-656 OC-WE-013, PP-TH-329 Cicin I., PP-MO-841, Clavert J., PP-MO-611 PP-WE-889 Christidis C., PP-TH-307 Clayessens S., PP-MO-530 Cid A. R., PP-MO-589, Christie L. M., PP-TH-310, PP-TH-544, PP-MO-566, Clemens A., PP-MO-167, PP-TH-457 PP-MO-601, PP-TH-596, PP-TH-167, PP-TH-169, Christophe O. D., AS-TH-015, PP-TH-627, PP-WE-668 PP-WE-204, PP-WE-205, PP-WE-469 OC-MO-060, OC-WE-042, Ciepluch K., PP-MO-216 PP-TH-642 Clemente J. L., PP-WE-479 Cierniewski C. S., PP-MO-839, Christopherson P. A., AS-MO- PP-MO-843, PP-MO-861 Clemetson K., AS-MO-050 017, OC-TU-071, OC-WE-133 Ciesla-Dul M., PP-MO-216 Clemmons W., OC-TU-048 Christopoulou-Cokkinou V., Clerici M., PP-MO-673 PP-MO-707 Cifuni S., AS-MO-047 Cleuren A. C. A., PP-MO-236 Chromov I. S., PP-TH-158 Cillo U., PP-WE-424 Clifford J., PP-MO-713 Chrostek A., AS-WE-030 Ciminello A. A. C., AS-WE-023 Cluitmans F., OC-TH-008 Chrzanowska-Wodnicka M., Ciminno E., PP-WE-325 AS-MO-064 Cimino E., PP-MO-336, Coates A., PP-TH-685 Chu S. G., AS-TH-033 PP-WE-320 Cochery-Nouvellon E., OC-TH-081

496 Cohen A. J., Cohen A. Cohan N., Cogulu O., PP-WE-682 Cogrossi Coetzee M., PP-WE-442 Coen HerakD., PP-WE-347, PP-WE-814 Coelho F Coe D.J., Codaccioni J., INDEX AUTHORS PP-TH-585 Collins P. W., Collins P. B., Collignon O., PP-WE-837, PP-WE-840 Collier M.E.W., Colliec-Jouault S., Colli S., Colletta G., Collet J.P., PP-WE-082 Coller B.S., PP-WE-175 Coll I., PP-WE-108 Coll E., Coletti V Coletta W., Colby E. A., PP-WE-502 Colavecchia G., OC-TU-035 PP-WE-366, PP-WE-367, Colaizzo D., Cokkinos D., PP-MO-298 Cohn D.M., Cohen S., Cohen M.J., PP-TH-384 Cohen H., Cohen H.W., PP-MO-427 Cohen PP-MO-481, PP-TH-248, PP-WE-275, PP-WE-435, PP-MO-323, PP-TH-285, A., PP-TH-482, ., PP-WE-050 . F., A., PC-030 OC-TH-043 PP-MO-710 OC-MO-054, PP-TH-263, PC-044, PP-MO-655 PP-WE-577 PP-TH-048 PP-WE-870 OC-MO-008 AS-MO-030, PP-TH-637 PP-WE-299 AS-MO-027, PP-MO-822, PP-WE-127 PP-MO-346, PP-TH-375, OC-TH-067 PP-TH-034 PP-MO-707 OC-WE-101 OC-TU-078, PP-TH-394 PP-MO-833 PP-MO-223, PP-MO-202, PP-MO-479, OC-TH-048 PP-MO-604, PP-MO-609, PP-WE-776 Connor D.E., Connonly B., Connolly G.C., Connolly B., Connell S.D., Conlon S.J., Conley R.B., AS-TU-026 Conley P., PP-MO-045, PP-TH-027 Conley P Cong Y.L., Conely P Condez PP-TH-451 Conde N., PP-WE-316 Conard J., Conant C.G., Compes M., Comerota PP-MO-783 Combescure C., Com O., Colwell C., Colvin S., Coluccia PP-TH-573, PP-WE-249 Colucci M., PP-WE-717 Colucci G., Colovic M., Colov N.P., Colon K., Colon J., Colomina M., Colombo G., Colombo D., Colombo A., Collins R., PP-TH-472 Collins R.D., PP-TH-584, PP-WE-604 Collins P., PP-MO-245, PP-MO-423, A., PP-MO-785 . B., ., A., PP-TH-491 PP-WE-065 PP-TH-687 A. J., AS-TH-022, PP-TH-451, OC-WE-058, PP-WE-801 AS-MO-003, PP-WE-409 PP-MO-247 PP-MO-731 PP-WE-649 PP-MO-753, PP-MO-176, PP-MO-327 PP-WE-383 PP-MO-128 PC-034 PP-TH-434 PP-MO-775 OC-MO-069 OC-TU-025 OC-TH-107, OC-TU-014 PP-WE-446 PP-TH-471, OC-MO-123 PP-WE-234 PP-WE-860 PP-MO-747, PP-WE-259 OC-TU-018 PP-TH-376 PP-MO-505, PP-TH-679, PP-WE-144, Contant G., Constans J., Consoli Conri C., Conradi F., Connor N., Cordisco A., PP-TH-028, PP-WE-258 Cordell P. A., Cordazzo C., Corbonnois G., Corbella E., PP-TH-069, PP-WE-823 Corazzi T PP-WE-797 Coppolecchia R., PP-WE-599, PP-WE-325 Coppola A., PP-WE-302 Cooper P. C., Cooper N., Cooper M., Cooper D., PP-WE-601, PP-WE-602 Cooper D.L., Cooper D.K.C., Cooper C., Cooney M.T PP-WE-134 Cooley B.C., Cook D.J., Conway E., Conway E.M., Contreras T., PP-MO-193 Contreras M.T PP-WE-359 Conti E., PP-MO-753 Conte T PP-MO-098, PP-MO-881, PP-TH-602, PP-TH-617, PP-MO-600, PP-TH-601, PP-MO-545, PP-MO-598, PP-WE-320, PP-WE-567, PP-MO-525, PP-TH-622, OC-TU-075, PP-MO-336, ., A., AS-TH-029, ., PP-MO-196 PP-MO-736, PP-MO-085, AS-TU-003 PP-TH-445 PP-TH-657 OC-MO-033 PP-TH-087 AS-TU-015 PP-MO-016 PP-WE-429 PP-MO-819 PP-MO-766 AS-TU-032, PP-WE-816 ., AS-TH-034 PP-MO-196 PP-MO-758 PP-WE-885 OC-WE-125, AS-MO-024, PP-MO-199, PP-MO-535, PP-TH-034 ., PL-TU-006 PP-TH-394 PP-MO-192, PP-MO-070 PP-TH-101, 497

Authors Index AUTHORS INDEX

Corinaldesi C., PC-016, Cosmi B., AS-TH-029, Cranswick N., PP-WE-438 PC-054, PP-MO-807, OC-TH-003, OC-TH-006, Craven S. J., PP-MO-017 PP-MO-866, PP-TH-342, PP-MO-290, PP-MO-291, PP-WE-790, PP-WE-807 PP-TH-507, PP-WE-351, Crawford R., PP-WE-021 Corinaldesi G., PC-016, PP-WE-715 Crawford S., PP-WE-021 PC-054, PP-MO-807, Cosserat J., PP-TH-307 Crawley J. T. B., AS-TU-019, PP-MO-866, PP-TH-342, Costa C., PP-MO-529, AS-WE-012, PP-MO-089, PP-WE-790, PP-WE-807 PP-TH-619, PP-WE-600 PP-TH-089, PP-TH-090 Coriolano E. O., PP-MO-390 Costa H., PP-WE-402 Crea F., PP-WE-789 Cork W., PP-TH-182 Costa M. A., PP-TH-606 Creagh M. D., PP-TH-632, PP-WE-522, PP-WE-523 Cornacchini S., PP-MO-266 Costa Pinto Prego De Faria Cornet Y., PP-MO-040 M., PP-MO-637 Creary M., PP-MO-596, PP-WE-613 Coroller-Bec C., OC-MO-038, Costamagna G., PP-WE-647 PP-TH-524 Crescente M., PP-MO-099, Costantino G., OC-TH-010 PP-TH-048, PP-TH-094, Corrada E., PP-WE-791 Costanzo S., PP-MO-876 PP-WE-246 Corradini S., PP-MO-285 Cotellese R., PP-WE-856 Crichton I., AS-TU-028 Corral J., AS-MO-054, Cottenceau V., PP-TH-432 Crikis S., AS-TH-025, AS-TH-052, OC-TH-027, OC-MO-127 OC-TU-080, OC-TU-082, Coughlin P. B., OC-TU-084, OC-WE-107, PP-MO-134, PP-TH-224 Crippa L., PP-MO-261 PP-MO-144, PP-TH-247, Coughlin P., OC-TU-079 Criqui M. H., AS-TU-007, PP-TH-287, PP-TH-481, PP-WE-458 PP-WE-123, PP-WE-141 Coughlin S. R., AS-MO-043 Crisby M., PP-MO-845 Corrales F. J., OC-TU-080 Couppey F., PP-TH-485 Crispin A., OC-WE-119 Corrales I., PP-MO-528 Cournoyer D., PP-MO-820 Crist R. A., PP-WE-306 Correa G., PP-TH-556 Court C., PP-TH-649 Cristiano M., OC-TH-018 Correcher P., PP-WE-436 Courtney D. M., OC-TU-007, PP-MO-512, PP-TH-283, Cristofalo C., PP-MO-716 Corrente J. E., PP-MO-311 PP-TH-505, PP-WE-414, Croce M. A., OC-TH-069 Corrocher R., OC-TH-028, PP-WE-467 Cromwell C., PP-WE-704 OC-TH-030, PP-MO-342, Couturaud F., AS-TU-009, PP-TH-347 PP-MO-310, PP-WE-510, Cronin K. R., PP-WE-113 Corsani I., PP-TH-340 PP-MO-508, PP-TH-291 Croockewit S., PP-TH-260 Corseaux D., PP-MO-814, Cowan P., AS-TH-025, Crosby J. R., OC-TH-108, PP-MO-815, PP-WE-858 OC-MO-101, OC-MO-127 PP-TH-388 Corte T. J., PP-WE-805 Cox D., OC-WE-047, Crowe B. R., PP-MO-081 PP-MO-051, PP-MO-738, Cortes M., PP-MO-160 PP-TH-056, PP-TH-102, Crowther M. A., OC-TH-009, Cortez P., OC-WE-006, PP-WE-813 PP-MO-306, PP-MO-462, PP-MO-463 PP-MO-418 Cozza G., PP-WE-384 Cortina B., PP-WE-096 Crowther M., SA-TH-010, Cozzi E., PP-WE-248, OC-MO-051, OC-TU-020, Cortina E., PP-MO-345, PP-WE-384 PP-MO-308, PP-MO-309, PP-MO-362 Cozzi F., OC-WE-088 Cruz C., PP-TH-396 Cortina V., PP-MO-590 Cozzi G., PP-WE-625 Cruz E., PP-MO-667 Cosemans J. M. E. M., Cozzi M. R., PP-WE-018 AS-TU-029, OC-MO-044, Cruz N. G., PP-WE-347, OC-WE-123, PP-WE-260 Cozzi M., PP-TH-008 PP-WE-814 Cosgrave J., PP-MO-775 Crain E. J., PP-TH-171 Csák É., PP-MO-228 Cosin R., PP-MO-215 Cramer-Borde E., OC-WE-149 Csanadi A., OC-TU-051, PP-WE-836 Cranenburg E. C. M., PP-WE-808 Csapó A., PP-MO-205 Cuccaro C., PP-WE-325

498 Cuisset T., Cui Z., Cui J., Cugno M., Cueto C., Cuello F., Cuddy K.K., PP-WE-549 Cucuianu Cuccurullo F., Cucchini U., INDEX AUTHORS Cutler J. A., Custodio S., PP-WE-151 Custers J., Cushner F., PP-WE-458 PP-TH-412, PP-WE-286, OC-TH-004, OC-WE-103, OC-MO-006, OC-TH-002, AS-TU-007, Cushman M., Curtis K., Curry B., Curnow J., Curnow J.L., Cupanik V., Cunningham Cunha-Melo J.R., Cunha A., PP-WE-482 PP-WE-261, PP-WE-387, PP-TH-389, PP-TH-391, PP-TH-142, PP-TH-166, PP-MO-140, PP-MO-399, OC-TH-103, PP-MO-139, Cunanan J., Cummins P Cumming T., PP-TH-645 M., Cumming A. Cuman C., PP-WE-870 Cultrera D., Cullinan D.B., Culakova E., PP-WE-775 PP-MO-773, PP-MO-774, PP-TH-364 OC-WE-057 PP-TH-439 PP-MO-265 PP-TH-606 PP-WE-479 A., PP-WE-374 PP-WE-230 PP-TH-461 OC-MO-007, ., PP-WE-547 PP-WE-150, AS-WE-009, PP-WE-656 PP-TH-590, PP-MO-247 PP-WE-635 OC-TH-019, OC-TH-075 PP-WE-476 AS-TU-059 PP-MO-534 OC-TU-018 OC-TH-106 A., PP-MO-532, AS-TH-005, PP-WE-221 PP-WE-311 PP-TH-159 OC-TU-078, OC-WE-047 PP-MO-387 PP-TH-419, PP-TH-424, PP-TH-249, PP-WE-246, PP-MO-481, PP-TH-248, OC-WE-141 Dahlbäck B., PP-WE-140 Dahlback B., PP-WE-204, PP-WE-205 Dahl O.E., Dahan K., PP-MO-312 D’Agostino C.D. A., OC-MO-125 Daemen M., Dadkhahi S., Daddona J.L., D’Adamo P Dadaian M., PP-WE-008 Dachary-Prigent J., PP-TH-383, PP-WE-147 Dabrilli P., PP-WE-430 Dabbagh O., Dabar G., Daalhuisen J., D’Apice A., D´atri L.P D. SteenstrupT., AndreaG., D’ PP-TH-542, PP-WE-705 AmicoE. A., D’ Czwalinna A., Czuriga I., Czitrom D., Cziffer A., Cymbalista F., Cwikla J., Cvejic A., Cutsforth G., Cutsforth G. PP-WE-502 Cutrone A., PP-TH-152 Cutler J., PP-TH-170, PP-TH-413, OC-TH-078, OC-TU-096, OC-MO-097, OC-MO-098, PP-MO-628, ., AS-MO-037 PP-WE-281 PP-MO-608 PP-WE-532 PP-WE-495 PP-TH-382, PP-TH-366 ., PP-TH-169, PP-WE-042 OC-MO-101 PP-TH-307 PP-MO-202, AS-WE-058, PP-MO-574 PP-MO-085 A., AS-TH-027, OC-MO-096, OC-MO-063, PP-MO-827 PP-TH-473 PP-WE-367 PP-MO-693 PP-MO-723 OC-WE-105 PP-TH-1 PP-MO-755, PP-MO-467 PP-MO-565 17 PP-TH-383, PP-TH-488,PP- PP-WE-641, PP-WE-645 Daidone V., Dai L., PP-WE-770, PP-MO-646 Dai J., Dahou M., PP-MO-261, PP-MO-415 D’Angelo A., Dangelmaier C., PP-TH-040 Dangelmaier C.D., OC-TH-040, PP-MO-028 Dangelmaier C. Danesh J., Dandekar T., Dandachli F PP-TH-318 Danaie N., Dampier C., Damoiseaux J., Damnjanovic T., PP-MO-034 D’Amico E. A., Damian G., PP-WE-631 Damian G.B., PP-TH-524 Dambrine S., Daly M., PP-MO-075 Daly M.E., PP-WE-417 Dalsgaard NielsenJ., Dalsgaard J., WE-247 Dalla Valle F., Dali-Ali F., OC-WE-038, PP-WE-222 D’Alessandro-Gabazza C.N., D’Alessandro R., Daleskog M., D’Alecy L., PP-TH-188 Dale B., PP-TH-565, PP-WE-536, PP-TH-563, PP-TH-564, OC-TH-041, PP-MO-052, PP-MO-510, PP-TH-562, PP-WE-616 PP-MO-148, PP-MO-076 OC-TH-084 OC-TH-005 PP-TH-124, SA-WE-007 OC-MO-131, OC-MO-128 PP-MO-520 ., PP-TH-259, PP-WE-894 AS-MO-038 OC-TH-083, AS-WE-024 OC-WE-007 OC-MO-038, PP-WE-319 PP-TH-304, PP-MO-521, PP-WE-444, A., PP-MO-670 OC-WE-122 PP-TH-460 PP-TH-494 499

Authors Index AUTHORS INDEX

Daniel J. J. D., PP-TH-040 David T. H., AS-MO-043 De Craen T. J. M., OC-WE-116 Daniel J. L., OC-TH-040, David-Dufilho M., PP-MO-837 De Craen T., OC-WE-033 OC-WE-122, PP-MO-028, Davidoff A. M., AS-TU-011 De Cristofaro R., AS-MO-013, PP-TH-011 Davidova O., PP-WE-155 AS-TU-049, PP-MO-092, Daniel J., AS-TH-058 PP-MO-328, PP-TH-085, Davidovic L., PP-MO-599 Daniele F., PP-MO-572 PP-WE-647, PP-WE-738 Davidson B. L., AS-TH-028 Danielsen B., OC-MO-080 De Curtis A., PP-TH-248, Davidson S. J., PP-MO-120, PP-TH-249, PP-WE-246, Dantona G., PP-MO-634, PP-TH-115, PP-TH-187, PP-MO-876, PP-TH-048 PP-MO-635 PP-WE-232, PP-WE-805 De Deyn P., PP-MO-229, Dao V. V. D., PP-WE-500 Davila M., PP-TH-491, PP-MO-230 Daoxin M., PP-MO-691 PP-WE-001 De Feudis L., PP-MO-015 D’Apice A., AS-TH-025, Davis R. J., OC-WE-043 De Filippis V., AS-MO-013, OC-MO-127 Davis-Harrison R. L., OC-MO-113, OC-WE-081, Dardik R., PP-MO-749 OC-TU-091, PP-WE-256 PP-TH-085 Dargaud Y., OC-MO-062, Davizon-Castillo P., PP-TH-468 De Gaetano G., PP-MO-099, PP-MO-202, PP-MO-481, OC-WE-021, PP-MO-658, Davoodabadi A., PP-MO-517 PP-TH-385, PP-TH-386, PP-MO-876, PP-TH-048, PP-WE-133 Davydova O. N., PP-MO-882 PP-TH-094, PP-TH-248, PP-TH-249, PP-WE-048, Dawood B. B., OC-MO-131, Darlington D. N., PP-WE-399 PP-WE-246, PP-WE-498, OC-TH-041, PP-MO-076 D’Armini A. M., AS-MO-009 PP-WE-502 Dawson D., PP-MO-142 Darnige L., PP-WE-263 De Goede-Bolder A., Dawson G., OC-WE-024 PP-MO-633 Dartigues J., PP-TH-349 Daxecker H., PP-MO-043, De Gregorio A. M., PP-MO- Darwish Murad S., PP-TH-314 PP-MO-044 336, PP-WE-320, PP-WE-325 Das M., OC-MO-047 Day Y., PP-MO-877 De Groot P. G., AS-TH-035, Das R., PP-MO-324, Dayan I., PP-TH-536, AS-TH-038, AS-TU-017, PP-WE-456 PP-WE-608 AS-WE-008, AS-WE-037, OC-MO-030, OC-MO-123, Dasgupta S., OC-WE-066, Dayan N., PP-TH-322 PP-MO-588 OC-TH-064, OC-TU-001, De Agostini A. I., PP-MO-165 OC-TU-030, OC-TU-072, Dash C. H., PP-MO-568 OC-WE-016, PP-MO-126, De Amici M., PP-MO-415 Dash D., OC-WE-139, PP-MO- PP-MO-262, PP-MO-352, 791, PP-MO-792, PP-MO-793 De Angelis G., OC-TU-062 PP-TH-037, PP-TH-046, PP-TH-055, PP-WE-887, De Angelis V., OC-MO-121 Dashnyam P., PP-TH-029 PP-WE-355 De Biasio A., PP-TH-266 Dasi M. A., PP-MO-027, De Groot P., OC-MO-111, PP-MO-589 De Boer A., OC-WE-014, OC-MO-112, OC-MO-114 OC-WE-035 Dastot F., PP-MO-529 De Groot R., PP-TH-089, Daugherty A., OC-TH-077 De Boer H. C., AS-WE-040 PP-TH-090 Daune M., PP-TH-684 De Boer H., PP-WE-851 De Haan T. R., OC-TU-063 Dauphin C., PC-021 De Boer T., PP-WE-735 De Haas F., PP-WE-061 Daurés J., OC-TH-081 De Bon E., PP-WE-866 De Jaegere P. P. T., AS-TH-024 Dauzat M., OC-TH-081 De Bono B., AS-MO-037 De Jouvencel T., PP-TH-039 Davenport A., PP-WE-713 De Bosch N., AS-WE-018, De Kock A., PP-WE-650 PP-MO-526, PP-MO-663, De Kok J., PP-WE-128 Davenport R. A., PP-TH-685 PP-TH-555, PP-WE-782 De Kruif M., PP-TH-153 Davi G., PP-MO-015, De Bruijn R., PP-WE-336 PP-MO-016, PP-WE-738 De La Morena M. E., De Caterina R., OC-WE-071, PP-MO-144 Davì G., AS-TU-049, PP-MO-828, PP-WE-856 OC-TU-088, PP-TH-082 De La Peña A., PP-MO-794, De Conti G., PP-WE-527 Davì V., OC-TU-088 PP-MO-865, PP-WE-874 De Cos C., PP-WE-141

500 PP-MO-332, OC-TH-082, PP-MO-507, PP-WE-303, PP-MO-088, PP-TH-091, PP-TH-554, PP-WE-294, PP-TH-157, PP-TH-532, PP-MO-725, PP-MO-870, PP-WE-295, PP-WE-535, PP-MO-521, PP-TH-466, OC-MO-1 PP-WE-267, PP-WE-270, PP-TH-578, PP-WE-213, PP-TH-189, PP-TH-520, PP-MO-206, PP-MO-645, OC-MO-132, OC-TU-037, De MaeyerM., De MaeyerB., OC-TU-034 De MaatM.P. M., De LeonardisF., PP-WE-236 De LarrañagaG.F., De Labriolle TU-039 De LaatB., INDEX AUTHORS PP-WE-341, PP-WE-512 De Roos De RooijM.F PP-TH-074 De ProstD., De PoliF., PP-TH-348 De PeuterO.R., PP-WE-476 De PaulaE.V., De NegriF PP-MO-395, PP-WE-396 De NanteuilG., PP-WE-744, PP-WE-375 De MoerlooseP., De MicheliV., PP-WE-013, PP-WE-084 De MeyerS.F., De MetrioM., De MeisE., PP-TH-493, PP-WE-878 De MattiaD., PP-TH-008 De MarcoL., OC-MO-029 De MaistreE., OC-TH-029, PP-WE-355, OC-MO-078, PP-MO-847, PP-MO-781, PP-WE-346, 11, OC-MO-112, OC- A., ., OC-MO-008 AS-WE-013, PP-MO-483 PP-MO-246 AS-TU-010, AS-WE-025, A., . M., PP-WE-018, PP-MO-448, OC-TU-025 OC-TH-075 AS-TH-043, PP-MO-088 PP-MO-094 PP-MO-520, OC-WE-040, PP-MO-382, PP-TH-365 OC-WE-035, PP-MO-448 AS-TH-032, OC-MO-133, PP-WE-339 Deev A., Décousus H., OC-TH-021, PP-WE-165 Decousus H., PP-MO-219, PP-MO-225 Declerck P. J., PP-WE-260, PP-WE-726 Deckmyn H., PP-MO-826 C., Deckmann A. Deckers M., Deckers J.W., Decker K.P., PP-WE-483 Debourdeau P., Debili N., Debergh I.M.C., PP-TH-286 Debeij J., Debbas V., Debastos M., Deangelis J.P., Deangelis G., De Wee E.M., PP-MO-174, PP-WE-188 De Waele M., De Vriese A., De Vries L.S., De V De Vos A. F., PL-TU-001, PP-TH-139 OC-MO-004, OC-MO-019, De Visser M.C.H., De StefanoV., AS-WE-023, PP-MO-372 De StefanoV. V. D.S., De SmedtE., PP-WE-534 De Schepper De SaintMartinL., De RossiG., De RooyJ., PP-WE-084, PP-WE-085, PP-WE-013, PP-WE-056, PP-MO-094, PP-TH-091, PP-MO-050, PP-MO-088, OC-WE-040, PP-MO-049, PP-MO-293, PP-TH-238, os R., PP-WE-335 AS-WE-030 OC-WE-013, PP-WE-041 PP-MO-034 PP-TH-665 PP-WE-128 PC-030 PP-WE-407 AS-MO-037, PP-WE-541 PL-TU-006 A. M. A., PP-MO-173, PP-TH-107 PP-WE-312 PP-WE-410 OC-MO-052, PP-WE-756 PP-MO-633 PP-WE-366 OC-TU-063 OC-TH-114, OC-TH-029 PP-TH-497, PP-WE-289 PP-MO-825, PP-WE-176 OC-WE-1 13 PP-TH-238, PP-TH-286, PP-MO-292, PP-MO-293, Degen J., OC-TH-063, OC-WE-121 Degen J.L., Defoort C., Defilippis V., PP-MO-332 Defay F., PP-MO-588 Delignat S., Delhaye C., PP-MO-128 Delev D., Delestre M., Delavenne X., Delavaux P PP-MO-463 Delate T Delaney S.M., Delahousse B., OC-WE-030, PP-WE-888 Dela CadenaR. A., PP-TH-493 Del Vecchio G.C., PP-WE-874 Del Valle L., Del Toro L., Del PinoM., Del Fiorentino A., PP-WE-888 Del Carpio-CanoF PP-WE-512 Dekkers O.M., Dekker F. W., PP-TH-271, PP-WE-426 Dejanova V., Deitelzweig S., Deitchman D., PP-TH-177 Deinum J., Dehgani M., Dehbozorgian J., Deguzman F., Deguzman F Deguchi H., PP-MO-633 Degenaar-Dujardin M.E.L., ., AS-WE-025, AS-WE-004, PP-MO-462, AS-WE-058 ., PP-TH-176, OC-TU-087 PP-WE-858 OC-WE-066, PP-WE-525 PP-MO-813 . R., AS-TU-045, PP-MO-865, PP-WE-459 PP-MO-814 PP-WE-408 PP-MO-095 PC-028, OC-TU-040 PP-MO-316 AS-TH-022 OC-MO-050 PP-WE-489 PP-MO-045 OC-WE-013, OC-WE-018 PP-MO-664 OC-TH-107 PC-044 OC-WE-029 . E., PP-MO-448, 501

Authors Index AUTHORS INDEX

Delitto D., PP-MO-627 Denis C. V., AS-TH-015, Deveber G., PP-WE-528 Della Corte A., PP-TH-048 OC-MO-060, OC-WE-042, Devecioglu O., PP-MO-222, PP-MO-090, PP-TH-642 Della Valle P., PP-MO-261 PP-MO-440 Denis C., SA-MO-008, Deveeska M., PP-WE-447 Dell’Era A., PP-MO-673, OC-TH-034 PP-TH-300 Devera M. E., OC-MO-031 Denisov I. G., PP-WE-119 Delluc A., OC-WE-113, Devlin J. J., AS-WE-010, PP-MO-500, PP-TH-483, Denney W. S., OC-TH-109 OC-MO-020 PP-WE-508, PP-MO-499, Dennis A., PP-MO-233 Devreese K. M. J., PP-WE-268 PP-TH-291 Dentali F., OC-MO-092, Devriendt K., PP-MO-059 Delluc C., PP-TH-483 PP-MO-308, PP-MO-309, Devries J. H., PP-MO-298 Delmar M., AS-TU-018 PP-MO-463, PP-MO-659, PP-TH-507, PP-WE-313, Dewald G., PP-MO-130 Delpero N., PP-MO-496 PP-WE-340 Dewar L. L., PP-MO-017 Del-Rio-Navarro B., Deoisares R., PP-TH-245 PP-WE-217 Deygas B., OC-WE-002 Depasse F., PP-WE-198, Deltour I., PP-MO-405 PP-WE-199 Dezamis E., PP-WE-592 Delvaeye M., PL-TU-006 Deprez D., PP-WE-655 Dezfouli S., AS-TH-025, OC-MO-101, OC-MO-127 Delvau N., PP-TH-524 Derksen R. H. W. M., Dhadwar S. S., AS-TH-012 Delvecchio M., PP-WE-878 OC-MO-030 Dhami M., PP-TH-477 Demaegd M., PP-TH-666 Derksen R., OC-MO-111, OC-MO-114 Dhanakshmi B., PP-MO-811 Demarmels Biasiutti F., PP-WE-211 Derosa L., PP-MO-437, Dhanalakshmi B., OC-TH-118, PP-MO-438 PP-MO-812 Demasi M., PP-TH-495 Deruelle P., PP-MO-376 Dhanasekaran D., AS-TH-044, Dementieva I. I., PC-011, PP-MO-078 PC-051 Desai H., PP-TH-482, PP-WE-001 Dhanjal T. S., PP-WE-076 Demers C., AS-WE-003, PP-WE-553 De-Sá-Júnior P. L., PP-TH-495, Dhanji A. A., AS-WE-052, PP-MO-475 PP-MO-740, PP-MO-741 Demir M., PP-MO-841, PP-TH-221, PP-TH-222, Desancho M. T., PP-TH-624, D’Hertog W., PP-WE-041 PP-WE-718 PP-WE-876, PP-WE-889 Dhouib N., PP-WE-455 Desch K. C., PP-WE-640 Demir V., PP-MO-841, Dhungana S., PP-WE-302 PP-WE-889 Deschepper N., PP-TH-684 Di Bari F., PP-MO-085 Demirkol D., PP-MO-440 Deshpande C. S., PP-TH-108 Di Capua M., PP-MO-336, Demler C., PP-MO-025 Desmurs Clavel H., PP-MO-525, PP-WE-320, Dempfle C. H., OC-TH-068, PP-WE-483, PP-TH-385 PP-WE-325 PP-MO-238 Despoix N., AS-MO-060 Di Castelnuovo A., Demulder A. C., PP-MO-617 Desposit G., SA-TH-011 PP-MO-876, PP-TH-248, PP-WE-246, PP-WE-498 Demulder A., PP-MO-441, Desprez D., PP-MO-611 PP-TH-666 Di Cera E., OC-WE-083 Desruennes E., PP-TH-497 Demyanets S., PP-MO-829 Di Cesare Merlone A., Destaercke C., PP-TH-328 AS-TU-004 Den Heijer M., PL-TU-001 Destareck C., PP-TH-324 Di Cocco P., PP-MO-654 Den Hertog H. M., OC-MO-078 Destors J., OC-WE-006 Di Fulvio P., PP-MO-016 Den Uijl I. E. M., OC-TU-070, PP-WE-534 Desuremain M., OC-MO-021 Di Gennaro L., OC-MO-094 Denas G., OC-MO-015, Detzler G., PP-MO-518 Di Giuseppe R., PP-MO-876 OC-MO-028, OC-TH-075 D’Eustacchio A., PP-MO-085 Di Iorio A., PP-WE-311 Denenberg J. O., AS-TU-007, Deutsch V. R., PP-TH-070 Di Marzio I., PP-TH-082 PP-WE-458 Deutschinoff G., LB-MO-003 Di Micco P., PP-TH-308 Dengler T. J., PP-TH-421 Deutschmann A., PP-WE-439 Di Michele M., PP-WE-041

502 PP-MO-525, PP-WE-320, PP-MO-525, PP-WE-598 Di PernaC., Di PaulaE., Di PaoloD., PP-WE-613, PP-WE-636 Di PaolaJ., PP-WE-311 Di NisioM., PP-WE-321, PP-WE-325 Di MinnoM.N.D., PP-WE-321, PP-WE-325 Di MinnoG., INDEX AUTHORS Diehl J.L., Dicuonzo F Dickey L., Dicker P Dickemann D., Dickele M.C., Dick A., PP-WE-794, PP-TH-026 Dichiara J., Dib T. K., PP-MO-053, PP-WE-871 Diaz-Ricart M., PP-MO-400 Diaz J. A., PP-WE-1 Diaz D., Diani E., PP-WE-194, PP-TH-049 Diamond S.L., PP-WE-472, PP-WE-473 OC-WE-005, PP-MO-468, Diamantopoulos Diamant M., Diamandis M., Di StasioE., Di SommaC., PP-WE-105, PP-WE-753 Di SantoS., Di Santo A., Di RenzoL., Di PietrantonioD., PP-WE-030, PP-WE-063, OC-WE-053, PP-TH-038, OC-TH-109, OC-WE-049, AS-TU-028, PP-MO-336, PP-WE-320, ., PP-TH-264, PP-WE-039 17 PP-MO-482 PP-TH-276 PP-MO-735 PP-MO-686 PP-MO-388, ., PP-MO-090 AS-TU-038, PP-MO-739, PP-MO-596, OC-WE-014, PP-WE-631 AS-TU-042 PP-TH-050, PP-TH-060 PP-MO-769 PP-MO-523, PP-WE-789 PP-MO-328 PP-TH-493 OC-TU-075, PP-WE-321 OC-MO-008 AS-TH-045 AS-TH-018, PP-MO-373 SA-MO-005, A., PP-MO-336, PP-MO-104 PP-WE-770, PP-MO-646, PP-TH-565, PP-WE-536, PP-TH-563, PP-TH-564, PP-TH-331, PP-TH-562, PP-TH-127, PP-TH-203, Ditta S., Distelmaier P., Distasio K., Discher D.E., Disalle R., Dirven R.J., Dirkx S.P Diquattro M., PP-WE-355 Dippel D.W. J., PP-WE-588 Diniz M., Diniz D., Ding Z., PP-TH-126, PP-MO-531 Ding Q., D’Incà M., Dinardo C.L., Dimsits J., Dimitrovski K., Dimitrov J.D., Dimichele D.M., Dima R., Dima L., Dilks J.R., Dikici F., PP-WE-785 Dignat-George F., PP-WE-576 Diez J.M., Dietze T., PP-WE-448, PP-WE-449 OC-WE-092, OC-WE-096, Dietrich K., Dienava I., PP-WE-169 Diemert V., PP-WE-352 Dielis A. W. J.H., Dielis A. J.W. H., OC-TU-089, PP-MO-785, PP-MO-833, AS-MO-060, PP-MO-486, PP-WE-850, OC-TU-087, OC-WE-089, PP-TH-022 PP-MO-750 PP-MO-203, PP-WE-737 PP-WE-365 PP-TH-214 PP-WE-568 PP-MO-591, . G., PP-MO-347 PP-MO-523 PP-TH-376 PP-WE-575, OC-MO-111 OC-TH-069 PP-WE-106 PP-MO-188, AS-TU-054, PP-WE-207 AS-WE-040 PP-MO-750 OC-WE-146 PP-TH-314 PP-TH-542 PP-WE-614 PP-TH-077 PP-TH-271 OC-TH-029, OC-WE-077 PP-MO-337, OC-TH-001 AS-WE-050, OC-WE-015, OC-WE-016, OC-MO-023, OC-TU-001, AS-TH-002, OC-MO-004, Djanguidze M.V., Djafari N., Diz-Kucukkaya R., OC-TH-048, PP-MO-391 Dizier B., Dix D., Dittrich M., PP-WE-214, PP-WE-215 Dolan G., Dojcinoski A., PP-WE-597 D’Oiron R., Doi T Doh H., Dogru O., Dogné J.M., PP-MO-316, PP-MO-352 Doggen C.J.M., OC-WE-1 Doeuvre L., Doerffler J., Doepke S., Dodt J., Dodig S., PP-WE-557 Dockal M., PP-TH-513, PP-WE-526 B., Dobrovolsky A. Dobrotová M., Dobler D., Doan J., Do Y., Do K., Dlott J.S., Djurdjevic P Djunic I.S., Djukic S.M., Djukic A., Djoric P., PP-WE-379 Djordjevic V., Djordjevic V. J., Djokic D., PP-TH-619, PP-MO-527, PP-TH-296, PP-WE-368, ., PP-TH-504 OC-TU-01 OC-TH-088 PP-WE-447 PP-WE-783 PP-WE-841 PP-TH-442 1 PP-MO-599 OC-TH-046, PP-WE-435 PP-TH-578, 1 PP-WE-664 PC-039 PP-WE-254 AS-TH-043 PP-MO-696 PP-WE-274 PP-MO-150, AS-MO-038 PP-WE-644 PP-MO-604, ., PP-WE-634 PP-TH-039, PP-MO-318 PP-MO-040 PP-WE-664 PP-WE-664 PP-MO-327, PC-028 PP-TH-306 PP-TH-460 1 AS-MO-005, PC-017 PP-TH-270 PP-TH-431, 503

Authors Index AUTHORS INDEX

Dolgushina N. V., PP-WE-381 Douma R., OC-TH-014 Duboscq C., PP-TH-681, Dolling S., PP-WE-212 Dovlatova N. E., PP-WE-091 PP-WE-293 Domagala T. B., PP-MO-355, Dovlatova N., PP-WE-045 Dubuis E., PP-TH-197 PP-WE-883, PP-WE-884 Dowal L., PP-WE-106 Duca P., OC-TH-010 Domènech A., PP-TH-299 Dowd M., PP-MO-463 Ducasse C., OC-MO-062 Domenico C., PP-MO-056 Dowling N., PP-TH-328 Duchemin J., PP-MO-310 Domenico P., PP-MO-290 Downey C., PP-TH-129, Ducimetière P., PP-TH-349 Donà A., PP-MO-424, PP-WE-116 Dück O., PP-TH-651 PP-TH-302 Downey H., AS-TH-013, Duckers C., OC-MO-119 Donadini M., PP-TH-507 AS-TH-046 Ducroq G., OC-WE-007 Donahue D. L., OC-TU-050 Dowsey C., OC-TH-091 Ducros E., PP-WE-139 Donati M. B., PP-MO-099, Doyle M., OC-TH-117, Dudbridge F., AS-MO-037 PP-MO-202, PP-MO-481, PP-WE-207 Duerschmied D., AS-MO-047 PP-TH-048, PP-TH-248, Dragani A., AS-TU-032, PP-TH-249, PP-WE-048, AS-TU-049, PP-TH-082 Duffull S. B., PP-MO-249 PP-WE-246, PP-WE-498, PP-WE-502 Dragovic R., OC-TU-056 Duga S., PP-MO-210, PP-MO-648, PP-TH-630, Donati M., PP-MO-876 Drejka M., PP-WE-127 PP-TH-670, PP-WE-657 Dondorp A. M., PP-MO-710 Drexler A., PP-TH-482 Dukovski D., PP-TH-557, Dong C., PP-TH-220 Dreyfus M., AS-WE-025, PP-WE-769 PP-TH-189, PP-TH-470, DulíčEk P., PP-WE-524 Dong J. F., PP-MO-767, PP-TH-623, PP-TH-649, PP-WE-752 PP-TH-650 Dulicek P., PP-MO-682, Dong L., PP-WE-667 PP-TH-369, PP-TH-438, Dridi Z., PP-TH-343 PP-WE-068 Dong N., PP-TH-093, Driggers J., PP-MO-596, Dumas M., AS-TH-023 PP-WE-088, PP-WE-099 PP-WE-613 Dumont B., PP-MO-077 Doniusch E. K., PP-TH-454 Drilhole D., PP-MO-112 Doria A. S., PP-MO-518 Duncan A., PP-MO-068, Dropinski J., PP-MO-784, PP-MO-137, PP-WE-672 Dorling A., SA-MO-010, PP-WE-883 Duncan E. M., PP-MO-148 OC-TH-043, OC-WE-067, Drouet L., OC-MO-011, PP-MO-070, PP-WE-848, OC-MO-021, OC-WE-099, Duncan E., PP-TH-188, PP-WE-849 PP-MO-074, PP-MO-175, PP-TH-626, PP-WE-544 Dors N., PP-MO-720 PP-MO-421, PP-MO-514, Duncan S., PP-WE-450 Dorsam R., PP-WE-012 PP-TH-211, PP-TH-309, PP-TH-680, PP-WE-412, Dunkerley A., PP-WE-623 Doti C., PP-WE-135, PP-WE-810 Dunkler D., OC-TU-013, PP-WE-293 Du H., PP-TH-022 OC-TU-015, OC-TU-016, Dotsenko O., PP-WE-852 PP-MO-322 Du V. X., PP-TH-055 Dotto P., OC-MO-029 Dunkley S., PP-WE-171, Du V., PP-MO-042 PP-WE-547 Dou L., PP-WE-850 Du W., OC-WE-068, Dunn A. L., PP-MO-587, Douard M., PP-TH-497 PP-WE-706, PP-WE-707 PP-MO-596, PP-WE-613 Douketis J. D., OC-TU-009, Du X., AS-TU-027, PP-WE-004 Dunne E., AS-MO-048 PP-TH-357, PP-WE-429 Duarte G. C., PP-TH-532 Dunois-Larde C., OC-WE-149, Douketis J., AS-TH-005, PP-MO-090 OC-MO-013, OC-TH-002, Dubart A., OC-TH-018 OC-TH-004, PP-MO-515, Dubick M. A., PP-TH-687, Dunoyer-Geindre S., PP-TH-412, PP-WE-286 PP-WE-399 OC-TU-037, OC-WE-110 Douma R. A., OC-MO-039, Dubois C., AS-TH-015, Duong J. P., OC-TH-048 OC-MO-042, OC-MO-091, PP-MO-485, PP-MO-486 Duran A., PP-WE-473 OC-TU-008, PP-TH-517, Dubois M., OC-TU-023 PP-TH-518 Durán N., PP-MO-145 Duboscq C. L., PP-WE-135

504 Dusse L.M.S., Dusek L., Duru F., Durmaz B., Durieux P., Duranti M., Duranovic V., PP-WE-700 Durand M., INDEX AUTHORS Eckhardt C.L., Echeverri G., PP-MO-737, PP-WE-692 Echenagucia M., PP-TH-389 Echart C., Eby C.S., Eberspaecher B., PP-TH-312 Eberle S., PP-MO-647 Eberl W., Earnshaw P., D., Earhart A. E DeBraccoM., Dzyadzko PP-MO-329, PP-MO-355 Dziedzina S., Dyr J.E., PP-TH-280, PP-WE-433 Dybowska M., OC-MO-127 Dwyer K., Duval OC-WE-074 Dutton R., Dutton R.P., Dutt T., Dutour Dutheil J., Dusseaux M., PP-MO-334, PP-TH-218 Dusse L.S., PP-WE-869 PP-WE-310, PP-WE-364, PP-TH-490, PP-WE-092, PP-MO-871, PP-TH-217, PP-MO-363, PP-MO-364, A., A., PP-TH-197, PP-WE-116 PP-WE-806 AS-TH-055, PP-MO-862 PP-TH-213 PP-MO-259 AS-TH-025, A. M., PP-MO-509, PP-TH-473 OC-WE-108, AS-TU-025, OC-TU-022 PP-MO-774 OC-TH-018 OC-TH-014 PP-TH-394, PP-WE-577 PP-MO-333, OC-TH-069 PP-MO-166 PP-MO-270, PP-MO-070 PP-WE-435 PP-TH-097 PP-MO-079 PP-TH-279, PP-MO-597 PP-MO-063, PP-TH-234 PP-WE-618 PP-MO-663, PP-MO-660 PP-TH-690, PP-WE-286, PP-MO-422, PP-TH-412, OC-TH-002, OC-TH-004, AS-MO-004, PP-TH-611, PP-TH-640, OC-WE-063, PP-MO-640, Eikenboom J., OC-TU-077, PL-TU-001 AS-TH-035, Eikenboom J.C.J., PP-MO-633 AS-MO-035, AS-WE-040, Eikenboom H.C.J., PP-WE-800 Eikelboom J., Eikelboom J.W., PP-MO-086 Eikelboom J.W., PP-WE-594 Eifrig B., Eickholz P., Eichman A., PP-WE-309 Eichinger S., Ehrlich Ehrlich H., PP-TH-641, PP-WE-619 Ehrlich H.J., Ehnholm C., Ehm M., Eheberg D., Eguchi Y., Egorina E., Egberg N., Egan K., PP-WE-484 Efraimidou S., Efira Eeckhoudt S., Edwards R.M., Edwards R.J., Édes I., Edelbusch C., Ectors F PP-WE-019, PP-WE-891 Eckly A., OC-TH-035, OC-WE-150, OC-TH-033, OC-TH-034, PP-TH-559, PP-WE-485, A., Y PP-TH-366 . G., PP-MO-617 PP-TH-241 . H., PP-MO-735 AS-WE-030, PP-MO-014, PP-TH-689 OC-WE-065 PP-MO-762 PP-MO-808 PP-TH-652 AS-TH-005, OC-WE-118 SA-WE-010 PP-MO-605 OC-TU-096 SA-TH-002, OC-TH-092 OC-TH-054, PP-MO-019, PP-MO-220 PP-WE-756 PP-MO-305, PP-MO-612 PP-MO-044 PP-TH-445 AS-TH-033 PP-WE-490, PP-WE-768, PP-TH-485, PP-TH-486, PP-MO-778, PP-MO-779, PP-MO-478, PP-MO-777, Eisenhardt S.U., Eisenberger A., PP-WE-309 Eischer L., Eimon Eilertsen K., L., Eilertsen A. Elf J.L., PP-WE-634, PP-WE-867 Elezovic I., Eldin N., Eldemeri Eldemeri Elbers C.C., Elbaz S., PP-WE-853 Elbaz O., Elashry M.S., PP-MO-707 Elalamy I., PP-TH-497 Elalamy I., Elagroudi A., El SherifM., El QacemiV., El MouelhiM., El KheirD. Y., El Khattouti A., El GhannudiS., Ekser B., Ekmekci O.B., Ekmekci H., PP-WE-611 Ekman M., Ekman C., Ekert J., O., Ejele A. Eisert S., PP-WE-670, PP-WE-763 Eisert R., Eisen-Schuchan I., PP-MO-599, PP-TH-296, A., PP-WE-514 PP-WE-531 AS-TU-054 AS-TH-043 A. M., A. M.H., PC-035, PC-038, PP-TH-646 PP-MO-070 PP-TH-661, PP-WE-236 OC-TH-078 PP-MO-477, PP-TH-343, PP-MO-541, AS-MO-004, PP-MO-327, PP-MO-276 PP-MO-222 PP-MO-425 PP-MO-795 OC-MO-024 PC-035 PP-TH-235 OC-TU-010 PP-WE-853 PP-WE-022 AS-TH-004 PP-MO-222 PP-MO-001 PP-WE-853 PP-MO-427 PP-MO-416 PP-MO-100 PC-038 PP-MO-685 505

Authors Index AUTHORS INDEX

Elg M., PP-MO-385, Emerson M., PP-MO-026, Eriksson U. G., PP-WE-172 PP-TH-176, PP-TH-177, PP-MO-062 Eriksson U., PP-WE-200, PP-TH-186, PP-WE-172, Emmerechts J., PP-MO-398 PP-WE-201 PP-WE-185 Emmerich J., AS-TH-035, Erman T., PP-MO-644 Elgue G., OC-MO-106 OC-MO-021, OC-TH-005, Ermantas N., PP-TH-222 Elias A., PP-TH-497 OC-TH-048, OC-WE-017, Eroglu H., PP-MO-744 Elias E., PP-MO-224, PP-MO-391, PP-TH-189, PP-WE-281 PP-TH-309, PP-WE-263, Erol D., PP-WE-708 AS-TH-001 Eligini S., PP-WE-050 Ershov A. A., PP-WE-422 Emmi V., AS-MO-009 Elit L., OC-MO-017 Ersoy M., PP-WE-890 Emsley J., OC-MO-103, Elkharrat D., PP-MO-514 OC-TU-043, PP-MO-089, Erten N., PP-MO-744 Ellingsen D., PP-MO-596, PP-TH-045 Ertl H., AS-TU-015 PP-TH-324, PP-WE-613 Enayat M. S., PP-MO-614 Escalante C. P., PP-WE-489 Elliot C. A., PP-TH-679 Enayat S., OC-WE-134, Escalante V., PP-WE-395 PP-MO-539, PP-TH-553, Elliott C., PP-TH-424 Eschmann E., PP-WE-329 PP-TH-636 Elliott D., PP-WE-760 Eschvege V., PP-TH-470 Enden T. R., AS-MO-007 Elliott M. A., PP-MO-487, Escolar G., AS-TH-018, Endres G., PP-MO-561 PP-WE-723 PP-MO-053, PP-TH-047, Ellis M. H., PP-WE-036 Endresz V., OC-TU-051, PP-WE-237, PP-WE-871 PP-WE-836 Ellis P., OC-TU-029, Escoll J., PP-WE-761 Enea I., PP-TH-303 OC-WE-126 Escuriola Ettinghausen C., Ellis S. G., AS-WE-010 Enever D., PP-WE-021 OC-WE-117 Ellis V., PP-MO-853 Engel R., OC-MO-076, Escuriola-Ettinghausen C., PP-WE-130 PP-MO-592 Ellison S., AS-WE-033, PP-TH-021 Engelmann B., AS-TU-021 Eshghi P., PP-TH-210 Ellouze R., PP-TH-297, Engelsberger I., PP-WE-453 Eskola M., PP-TH-068 PP-TH-298, PP-WE-455 Engelsen J., PP-WE-417 Esmat E. M., PP-TH-506 Elm T., OC-MO-084, Enger S., PP-WE-026 Esmerian M., PP-MO-135 OC-WE-056, PP-TH-594 Englyst N. A., OC-WE-114 Esmon C. T., OC-TH-062, Elmahmoudi H., PP-MO-649, OC-TH-063, OC-TH-065, PP-MO-650 Engström M., PP-MO-258, PP-WE-721 OC-TH-066, OC-WE-019, Elmas E., OC-TH-068, OC-WE-144, PL-TU-006 Enjolras N., OC-MO-062 PP-MO-238 Esmon N. L., OC-TH-063, Elreda L., PP-WE-127 Ennis D., OC-TH-007 OC-TU-033, PL-TU-006 Elsenberg E. H. A. M., PP-WE- Eom H., PP-TH-504 Espana F., PP-MO-192, 742 Epinat M., PP-TH-076 PP-MO-193 Elshaarawy S. M., PP-WE-257 Epstein J. D., PP-MO-576, PP- España F., OC-TH-027, PP-MO-215 Elvers M., AS-TU-037, TH-570, PP-TH-571, PP-WE- AS-WE-029, AS-WE-030, 537, PP-WE-538 Esposito B., PP-TH-009 OC-TH-039 Equine O., PP-TH-583 Essawy F. M., PP-TH-506 Elvevoll E., PP-MO-795 Erba N., OC-TH-075 Esserman D., PP-MO-768 Emal C., PP-TH-252 Erdinc I., PP-TH-511 Estella J., PP-TH-451 Emanuele J., PP-TH-201, Erdogan A., OC-WE-128 Estelle S., PP-TH-180 PP-TH-391 Eriksson A. C., PP-MO-047 Estelles A., PP-MO-193, Emanuele R., PP-MO-461 Eriksson B. I., OC-WE-004, PP-MO-215 Emanuelsson B. M., PP-MO-167, PP-TH-167, Estellés A., OC-TH-027, PP-MO-095 PP-TH-169, PP-TH-170, PP-MO-192 Emanuylov V. I., PP-MO-260 PP-TH-415, PP-TH-430, PP-WE-204, PP-WE-205, Estrada D., PP-WE-495 PP-WE-404, PP-WE-421 506 OC-MO-132, PP-MO-783, PP-WE-782 Evans J., Evans C.E., Evangelisti L., AS-TU-042, OC-WE-127 Evangelista V., PP-WE-042 Etulain J., PP-WE-837, PP-WE-840 Ettelaie C., PP-WE-841 Etscheid M., Etches W., INDEX AUTHORS Faienza M.F., Fahs S., Fagnou C., M., Fager A. Faeser B., PP-WE-080 Fadin M., Facskó Facchini M., Facchin M.F., Fabris F Fabre O., PC-033, PP-WE-699 Fabra S., Fabiani J., Faber E. Fabbro-Péray P., PP-WE-744 Fabbro-Peray P., Fabbriciani G., Ezzelarab M., PP-WE-591 Ezban M., PP-WE-776, PP-WE-786 Exner T., PP-MO-604 Ewing N., PP-WE-597, PP-WE-617 Ewenstein B., Everse S.J., PP-TH-585, PP-WE-574, PP-WE-154, PP-WE-589, PP-TH-567, PP-TH-579, PP-MO-570, PP-MO-580, OC-WE-061, PP-MO-564, A., ., PP-TH-128 A., PP-MO-671, PC-031, PC-032, PP-MO-242, PP-TH-300 PP-WE-858 PP-TH-466, PP-MO-586, OC-WE-056, PP-WE-035, PP-TH-646 PP-MO-835 PP-TH-216 PP-WE-448 AS-TH-043 PP-MO-479, PP-WE-495 OC-TU-092 PP-TH-060 PP-MO-384 OC-TH-110, OC-TU-092 PP-MO-070 PP-WE-878 PP-MO-602, PP-MO-802 AS-TH-059, PP-WE-529 AS-TH-032, OC-TH-081 OC-TH-026 PP-TH-584, PP-WE-655, PP-WE-098 Faria F PP-WE-483 Farge BancelD., PP-TH-389, PP-TH-390,PP Fareed J., Faraudo S., PP-TH-318 Faranoush M., Faraizah KarimK., Faraizah Karim PP-MO-61 Faradji A., Farac J., Fang W., OC-TH-097 Fang J., Fang C.C., Fan L., Fan H., Famulari PC-009, PP-TH-500,PP-TH-501 A., Famodu A. PP-WE-836 Faludi I., Fallon J.T., Fallah M., Falk E., Falet H., Falco A., PP-WE-823 Falcinelli E., PP-WE-499 Falanga Faioni E.M., Faille D., PP-TH-209, PP-WE-330, PP-TH-145, PP-TH-166, PP-TH-138, PP-TH-142, PP-MO-857, PP-TH-137, PP-MO-412, PP-MO-703, PP-MO-154, PP-MO-396, PP-MO-152, PP-MO-153, PP-MO-140, PP-MO-143, PP-MO-136, PP-MO-139, OC-WE-108, PP-MO-072, OC-TH-103, OC-WE-088, PP-MO-482, PP-MO-867, AS-TU-050, PP-MO-476, ., PP-MO-642, PP-TH-334 OC-TU-046 PP-WE-810 A., AS-TH-009, PP-MO-475, AS-WE-026 OC-TU-051, PP-MO-128 AS-TU-049 A., PP-TH-399 PP-WE-775 1 AS-TH-057 OC-TH-019, PP-TH-569, AS-TU-048, PP-MO-158 PP-MO-808 PP-WE-768 PP-MO-654 PP-MO-085, PP-WE-136 PP-MO-278, PP-TH-124, A., PP-TH-497, PP-MO-367 PP-MO-366 Farndale R.W., Farkas K., Farinasso L.L., Farias F., Faria S., PP-TH-674, PP-WE-689 Faria M.D., PP-WE-633, PP-WE-653 Feddern J., Febbraio M., Fazavana J., Fazakas F., PP-MO-358 Fay W Fay P PP-MO-157, PP-WE-289 Fay P PP-TH-018 Faxälv L., PP-WE-367, OC-TU-035 Favuzzi G., Favretto P Favre G., PP-MO-368, PP-MO-369 Favier R., PP-WE-359 Favaretto E., PP-MO-724 Favaloro E.J., Faust P., Faure A., Faucher J., Faucher A., Fattorini A., PP-WE-003 Fatini C., Farrugia R., Farrokhi E., Farris D.M., Farren T., Farrell D.H., PP-TH-664, PP-WE-766 Farquharson N.R., Farndale R., PP-WE-052, PP-MO-852 PP-MO-503, PP-WE-351, PP-MO-058, PP-WE-028, PP-MO-041, PP-MO-048, ., . J., . P., AS-WE-045 PP-WE-374 PP-TH-482 PP-MO-805, PP-MO-155, PP-WE-169 PP-TH-568 PP-TH-199 OC-TH-076 AS-TU-024, . P AS-MO-062, PP-MO-430, PP-MO-359 PP-WE-366, PP-WE-774 PP-TH-315 PP-TH-589, PP-TH-673, PP-MO-188 PP-TH-619 PP-MO-261 OC-WE-126 . F., OC-MO-124 PP-MO-388 OC-MO-107 PP-MO-187 PP-MO-239 PP-MO-351, OC-WE-134, OC-WE-048, PP-TH-452 PP-MO-312 507

Authors Index AUTHORS INDEX

Federici A. B., AS-WE-020, Fernandez I., PC-048, Feys H. B., AS-MO-014, OC-MO-131, OC-TU-072, PP-MO-022, PP-TH-059, PP-MO-088, PP-MO-094, PP-TH-630, PP-WE-625 PP-TH-603, PP-TH-604, PP-WE-086 Federici A., PP-WE-647 PP-WE-560, PP-WE-765 Feys H., PP-WE-339 Federico L., AS-TH-059, Fernández J. A., AS-TU-043, Fiamoli V., PP-WE-441 PP-TH-392 PP-MO-880, PP-MO-881, PP-TH-572, PP-WE-551 Fichelson S., OC-WE-149 Fedi S., OC-WE-032, Fidalgo T., PP-WE-730 PP-MO-217, PP-MO-339, Fernandez J., PP-MO-813 PP-MO-801, PP-TH-163 Fernandez R., PP-TH-606 Fiebig A., PP-MO-307 Fedorová J., PP-TH-305 Fernandez-G J., PP-MO-865, Figini F., PP-MO-775 Feijge M. A. H., AS-TU-029, PP-WE-874 Figler R., OC-TU-027 AS-TU-037, PP-MO-670, Ferrando F., PP-MO-192, Figueiredo C. P., PP-TH-490 PP-TH-007, PP-WE-260 PP-MO-193 Figueiredo J., AS-WE-057 Fejfar T. T. F., PP-TH-369 Ferrante E., OC-TU-088, Figueiredo L., PP-TH-240 Feldman B. M., AS-WE-003 PP-TH-082, PP-WE-738 Ferraresi P., PP-MO-654 Figueiredo-Pontes L. L., Feldman B., PP-WE-553 OC-WE-023 Ferrari T. C. A., PP-TH-672 Feldman D., PP-WE-587 Fijnheer R., AS-WE-013, Felicissimo P., OC-TU-019 Ferrario C. M., PP-WE-854 AS-WE-037 Felippo M., PP-WE-618 Ferrazzi P., AS-WE-007 Fijnvandraat K., AS-TH-054, Ferré N., PP-MO-530 PP-MO-560, PP-MO-597, Feliu-Torres A., PP-WE-637 PP-MO-633 Ferreira C. N., PP-MO-816, Feliú-Torres A., OC-TU-064, Filali A., PP-TH-298 PP-MO-687 PP-WE-227 Filipescu D. C., PP-WE-737 Fellin R., PP-TH-372 Ferrel J. P., AS-MO-024 Filippini M., AS-TH-029, Felsburg P., PP-MO-754 Ferrer J., PP-MO-226, PP-MO-227 PP-MO-351 Felten M., PP-WE-182 Ferrer-Marin F., PP-WE-083 Filippucci E., OC-TH-011, Fem L. L., PP-WE-198 PP-MO-282, PP-MO-457, Ferrero S., PP-WE-136 Fenchner H., PP-TH-696 PP-MO-458 Ferretti M., PP-TH-558 Feng Y., PP-TH-132 Fimbel B., PP-MO-527 Ferri V. V. F., OC-TH-026 Fenger-Eriksen C., PP-WE-698 Fimmers R., AS-WE-004 Ferris S., PP-MO-562 Fenu L., PP-MO-267 Finazzi G., AS-TU-048 Ferro A. M., PP-WE-203 Feola G., PP-WE-567 Findling O., OC-WE-034 Ferro A., PP-TH-316, Fink H., PP-MO-430 Fernandes A. B., PP-WE-226 PP-TH-607 Finn J. D., AS-TU-013 Fernandes A. P., PP-MO-333, Ferro M., PP-WE-870 PP-MO-334, PP-MO-335, Finn J., PL-TU-004 Ferronato C., PP-TH-420, PP-MO-346, PP-MO-816, Fioritoni F., AS-TU-049 PP-TH-490, PP-WE-227, PP-WE-424 PP-WE-310, PP-WE-347, Ferroni P., PP-MO-379, Firbas C., OC-WE-011, PP-WE-364, PP-WE-814, PP-MO-380, PP-TH-494, PP-MO-622, PP-MO-718 PP-WE-815 PP-WE-824 Fischer A. M., OC-TH-046, Fernandes A., PP-MO-349, Ferrucci L., PP-WE-311 OC-TH-048, PP-MO-862 PP-MO-363, PP-MO-364, Ferster A., PP-MO-441, Fischer A., PP-MO-165, PP-WE-365 PP-TH-666 PP-WE-263 Fernandes N. L., OC-MO-055 Fesenko O. V., PP-TH-514 Fischer B., PP-TH-241 Fernandes R. A., PP-MO-483 Feudtner C., AS-TU-055 Fischer D., PP-MO-660 Fernandez C. V., PP-WE-447 Feuring M., PP-TH-167, Fischer H., PP-MO-845 Fernandez C., PP-MO-209 PP-TH-169, PP-TH-170, Fischer K., OC-TU-070, Fernández C., PP-WE-234 PP-WE-205 PP-MO-585, PP-TH-578, PP-TH-585, PP-TH-616, PP-WE-534

508 Fitzgerald D.J., Fitzgerald C., Fitridge R., Fisseau C., Fisher W Fisher P Fish R., Fisgin T., PP-MO-827 Fischer S., PP-MO-513 Fischer R., INDEX AUTHORS PP-WE-874 Flores M., Flores M.P., Flores D., Florean M., Floras J.S., Flood V. H., Flondell D., Flliser D., Fliser D., Flisberg P OC-WE-015 Flinterman L.E., Flinck A., Fliers E., Flierl U., OC-TH-063, OC-WE-121 Flick M.J., Flevaris P., Fleury R., Fletcher J., PP-WE-300, PP-WE-301 Fletcher J.P., Flesch B., Flem L.L., Fleisher S., Flege S., Flaumenhaft R., Flaujac C., Fiusa M.M., Fitzpatrick P., OC-MO-052, PP-MO-247 Fitzgerald G., . B., PP-WE-213 . D., PP-TH-019 OC-WE-106 PP-MO-292 PP-MO-809 PP-WE-806 ., PP-WE-206 OC-MO-126 PP-MO-567 PP-MO-064 PP-MO-865, PP-MO-307 PP-WE-199 PP-WE-316 AS-TU-045, OC-TH-023, PP-MO-083, PP-WE-004 PP-WE-427 PP-MO-258 OC-MO-121 PP-WE-409 PP-WE-624 PP-WE-712 OC-TH-078 OC-TU-071 PP-TH-125 OC-WE-021 PP-WE-476 PP-WE-160 PP-TH-430 PP-WE-447 AS-TU-059 SA-TH-013, PP-MO-326, AS-WE-035 PP-WE-106 OC-MO-079, PP-MO-783, PP-TH-103, AS-TU-018, OC-MO-132, Fourn E., Fouassier M., Fort J.G., Forster I., PP-MO-468 Forster F., Foroni M., Fornage M., Formoso G., Formisano S., Forfang K., Forestier M., OC-WE-116 Ford I., PP-TH-681 Forastiero R., Forastiero R.R., Fontes P. A., OC-TH-082 Fontenay M., PP-WE-415 Fontcuberta J., PP-WE-744 Fontana P., Fontana G., Fontaine S., Fonseca R.J.C., Fong T. S., Fong K., AS-TU-038 Fong K.P., Fondu P., Fondacone C., Folsom Foley J.H., Foley D., Foley D.P., Fogarty P., PP-WE-704 Fogarty P. F., Fobker M., PP-WE-209, PP-WE-243, PP-WE-178, PP-WE-208, PP-TH-290, PP-WE-175, PP-TH-285, PP-TH-289, PP-MO-323, PP-MO-413, OC-WE-033, A. R., PP-WE-030 PP-MO-738 OC-WE-113 PP-WE-013 PP-TH-446 PP-WE-803 PP-MO-306 OC-WE-005, AS-TU-002 PP-WE-528 OC-MO-077 AS-TU-028, AS-TH-032, PP-TH-427 PP-MO-735 OC-TU-069 PP-WE-136 AS-WE-009 PP-TH-345 PP-MO-016 OC-MO-031 OC-TU-052 PP-WE-316, PP-MO-066, PP-WE-819 PP-WE-642 PP-MO-275, PP-TH-606 PP-MO-423 OC-TH-027, PP-TH-333 PP-TH-178 PP-TH-558, PP-WE-140, PP-MO-540, PP-MO-541, PP-MO-020, PP-WE-060, OC-MO-139, OC-WE-121, PP-WE-886 Fraccarollo D., PP-WE-045, PP-WE-755 Fox S.C., Fox P Fox J.E.B., Fox D., Frei C., PP-MO-065 Freedman J., Freedman J.E., 106, OC-WE-079,PP-MO-428 Fredenburgh J.C., Fraysse B., Frauchiger B., Frattani F Frattani F Frasson R., PP-WE-715 Frascaro M., Franque S., Franklin P., Franklin M. A., Franke K., Frangov M., PP-MO-364, PP-WE-365 Franco R.M., Franco J., PP-TH-579 Franck H.G., Francisci D., PP-WE-001, PP-WE-108 Francis J., Francis J.L., PP-TH-170 Francis C., PP-MO-492 Francis C.W., PP-WE-598 Franchini M., PP-WE-691 Franchi F., Fraga C. PP-TH-482, PP-TH-491, . L., PP-MO-790 PP-MO-469 A. M., . S., . F AS-TU-041 OC-MO-100, PP-WE-446 PP-TH-215 PP-MO-375, PP-MO-004, PP-TH-169, . S., PP-MO-248 PP-MO-332 OC-WE-081 PP-MO-383 PC-028 OC-MO-109 PP-TH-282, OC-WE-087 AS-TU-030, PP-WE-485 OC-MO-097, PP-MO-570, PP-MO-390 PP-MO-363, OC-TU-018, PP-TH-492 PP-MO-283 PP-MO-005, PP-MO-390 PP-TH-179 PP-TH-064 OC-TH- 509

Authors Index AUTHORS INDEX

Freire C., PP-WE-371 Froesner G., PP-WE-578 Fukutake K., PP-MO-546, Freitas V. M., PP-MO-063 Frölich L., PP-WE-182 PP-MO-577, PP-TH-576, PP-TH-592, PP-WE-516, Fremeaux-Bacchi V., Frölich M., PP-MO-782 PP-WE-579, PP-WE-606, OC-WE-012 Frontoni R., OC-TH-075 PP-WE-666 French D. L., PP-WE-082, Frontroth J. P., OC-WE-134, Funaro D., PC-030 PP-WE-174 PP-WE-637 Funes C., PP-MO-536 Frengen E., PP-TH-165 Frontroth J., OC-TU-064, Funk K., PP-TH-095, Frenkel E., PP-MO-757 PP-MO-687 PP-WE-006 Frere C., OC-MO-007, Frost C. E., PP-MO-407 Funk R. T., OC-TH-104 PP-MO-773, PP-MO-774, Fruhwald M., OC-WE-106 PP-WE-775 Furby D., PP-WE-609 Fruth K., PP-WE-488 Freson K., PP-MO-059, Furenes E. B., PP-WE-344 PP-WE-041, PP-WE-085 Fryer H. J. L., PP-MO-296, Furie B. C., AS-MO-043, PP-MO-319, PP-MO-502, AS-TU-022, OC-MO-057, Fressinaud E., PP-MO-626, PP-MO-709 PP-TH-623 OC-MO-108, OC-WE-072 Frykman V., PP-TH-469 Fretigny M., OC-TU-073, Furie B., AS-MO-043, PP-MO-645, PP-TH-144, Fu J., PP-MO-830 AS-TU-022, OC-MO-057, OC-MO-108, OC-WE-072 PP-WE-533 Fu Q., PP-MO-510 Furlan-Freguia C., AS-TU-043 Freund M., AS-TU-047, Fu X., PP-TH-092, AS-MO-011 OC-TH-033, OC-TH-034, Fürle T., PP-MO-112 Fu Y., PP-WE-674 OC-TH-035, OC-TU-049, Fürll B., AS-TH-007, OC-WE-150 Fuchs B., PP-WE-624 OC-TH-023 Freyburger G. F., PP-MO-196 Fuentes P., PP-WE-175 Furmedge J., PP-WE-531 Freyburger G., PP-MO-195, Fuerll B., OC-TH-024 Furtmüller M., OC-TU-081, PP-TH-432, PP-WE-673 Fuhr U., PP-WE-183 PP-MO-189 Freyssinet J., PP-WE-787 Fujieda Y., PP-WE-269, Furugohri T., PP-TH-195 Fridrich J., PP-TH-438 PP-WE-271 Furukawa S., PP-TH-689, Friedman K. D., AS-WE-038, Fujii T., PP-TH-592, PP-WE-025 OC-TU-071 PP-WE-606 Furukoji E., PP-MO-111, Friedman R. J., PP-MO-167 Fujii W., PP-MO-084 PP-MO-127 Friedman R., PP-MO-247, Fujimori Y., PP-MO-138, Fuse I., PP-TH-689 PP-TH-167 PP-TH-081, PP-WE-671 Fusegawa K., PP-WE-348 Friedman S., PP-TH-087 Fujimoto D. E., PP-MO-521 Fuset M. P., PP-WE-796 Friedrich W., PP-MO-029 Fujimoto H., OC-WE-038 Fuster V., PP-MO-834 Frieling J., PP-TH-414, Fujimoto T., PP-TH-168, Fynn A., PP-TH-606 PP-WE-405 PP-WE-398, PP-WE-400 Gaarder C., OC-TH-067 Fries D. M., PP-MO-034 Fujimura Y., OC-WE-008, PP-MO-717 Gabazza E. C., OC-WE-038, Fries M., PP-WE-557 PP-WE-222 Fujino K., PP-TH-689 Friese K., PP-WE-784 Gabbeta J., PP-TH-200 Fujioka M., PP-WE-090 Frijling B., PP-WE-475 Gaborit B., PP-MO-773, Friso S., OC-TH-030, Fujiwara A., OC-WE-038 PP-MO-774 PP-MO-342, PP-TH-347 Fujiwara H., PP-MO-511, Gachet C., AS-MO-058, Frith D., OC-TH-067 PP-WE-011 AS-WE-030, OC-MO-008, Fritsch S., PP-TH-585, Fujiwara M., PP-WE-090 OC-MO-124, OC-TH-033, OC-TH-034, OC-TH-035, PP-TH-586 Fukasawa I., PP-MO-734 OC-TU-049, OC-WE-150, Fritsche I., PP-MO-357 Fukuda T., PP-MO-864 PP-MO-033, PP-MO-416, Fritsma G. A., PP-MO-102, Fukushima H., PP-WE-090 PP-TH-010, PP-WE-891, PP-WE-235 AS-TH-021 Gadaeva Z., PP-TH-380

510 PP-MO-334, PP-MO-335, PP-MO-634, PP-MO-635, Gahunia H., Gahl W. A., Gagnon F., PP-MO-750 Gagliano F Gage B.F Gafsou B., J., Gafou A. Gadisseur PP-MO-346, PP-WE-360 Gadelha T., INDEX AUTHORS Galmes B., OC-TU-010 S., Gallus A. Gallo U., Gallo R., PP-WE-641, PP-WE-645 Gallinaro L., Galligan A., Galleguillos T., Galimanis A., PP-TH-486, PP-WE-490 Galea V PP-TH-573, PP-WE-249 Galasso R., Galassi N., PP-WE-491, PP-WE-492 Galar M., Galanter W., Galand P., PP-TH-288 Galanaud J., Galanakis D.K., Galan P., PP-TH-047, PP-WE-237 Galan Galajda P., PP-WE-574, PP-WE-617 Gajek H., Gajeck H., PP-WE-576 Gajardo R., PP-TH-037 OC-MO-104, PL-TU-003, AS-TH-039, OC-MO-103, Gailani D., A. M., ., OC-MO-015 PP-MO-061 PP-TH-485, OC-MO-021 PP-MO-868, ., PP-MO-567, ., PP-TH-309 A. P. A., PC-043 SA-WE-013, PP-WE-220 OC-TH-046 OC-MO-021 PP-WE-618 PP-TH-357 AS-WE-034 PP-MO-590 PP-MO-333, PP-WE-575, PP-MO-176, PP-TH-255 PP-WE-314 PP-MO-518 PC-015, PP-MO-053, PP-TH-259, PP-MO-464 LB-MO-005, OC-TH-081, OC-WE-034 OC-WE-090 PP-MO-211 PP-MO-383 OC-TU-032, PP-TH-189, Garcia D., PP-MO-463 Garcia D. A., García CandelF Garcia CandelF Garcia C., Garcia BarberaN., Garcia A., B., Garcia A. OC-WE-023 A., Garcia A. Garbiero S., Garbarini L.L., Garbaraviciene J., Garaulet M., PP-WE-241 Garand M., Garai B., PP-MO-092 Garagiola I., Gao W Gao J., Gao D., Gao C., Gansevoort R., Gansevoort R.T., PP-WE-685 Gannon C., OC-TH-082 Gandrille S., PP-WE-687 Gando S., Ganci A., Gan E., Gamra H., Gamble G., Gambert S., Gambaryan S., PP-MO-684 Gamba G., OC-TH-048, PP-MO-862 Galy-Fauroux I., PP-MO-668, PP-WE-170 Galstyan G.M., ., PP-MO-686 AS-TH-009 PP-MO-713 OC-TH-108 PP-MO-464 PP-MO-228 PP-MO-016 AS-MO-036 PP-MO-669, PP-MO-308 OC-MO-099 PP-TH-343 AS-TU-032, OC-WE-109, PP-TH-315 PP-TH-549, PP-WE-043 AS-TH-018 PP-TH-060 OC-WE-132, OC-TH-022, OC-MO-004, PP-MO-462, OC-WE-023 PP-WE-077 PP-TH-452 OC-MO-001 ., ., PP-MO-218, OC-TH-046, PP-MO-536 PP-MO-601 OC-MO-082 PP-MO-705 PP-TH-481 Garcia M., García J.J., Garcia IglesiasL., García- EstañJ., PP-WE-822 AS-TU-060, PP-WE-821, Garcia DeFrutosP., Gascoigne E.W., Gasbarrini A., Garwood C.L., PP-WE-051 Gartner T. K., Garrido C., PP-WE-165 Garraud O., Garofalo J., OC-TH-093 Garner S.F., Garmer S.F Gårdsvoll H., Gardsvoll H., Gardiner E., OC-MO-1 Gardiner E.E., Gardiner C., Garcin I., Garcia-Talavera J., PP-TH-603, PP-TH-604 Garcia-Rodriguez M., PP-WE-497 Garcia-Rodrigues P., Garcia-Pagán J., Garcia-Pagan J., García-Mouriz A., García-Latorre E., García-Dabrio C., Garcia-Candel F., Garcia V., AS-MO-035, AS-WE-019 Garcia RodriguezP., PP-WE-436 Garcia R., PP-WE-822 Garcia N., PP-WE-551 García M., PP-WE-560, PP-WE-765 10 PP-WE-008 AS-WE-010 PP-MO-227, PP-WE-821, PP-TH-31 PP-TH-572, PP-MO-526 ., PP-MO-464 OC-TH-021, AS-WE-032 PP-MO-279 PP-TH-263 AS-MO-037, AS-WE-047 PP-WE-585 PP-WE-225 PP-MO-082, PP-MO-328 AS-TU-039, PP-WE-479 PP-MO-224 PP-TH-314 PP-TH-003 PP-MO-568 AS-MO-003 PP-MO-566 PP-MO-472 PP-WE-264 PP-MO-637 PP-WE-665 1, PC-048, 511

Authors Index AUTHORS INDEX

Gasparini D., PP-TH-420, Geetha N. M., PP-MO-848 Gerhardt H., AS-MO-061 PP-WE-424 Geetha N., PP-WE-842 Gerlach H. E., PP-MO-509 Gastineau D. A., PP-MO-487 Geierova V., PP-MO-583, Gerlach H., PP-TH-312 Gasto C., PP-TH-047 PP-TH-083 Gerlofs-Nijland M. E., Gatenholm P., PP-MO-430 Geiger M., OC-TU-081, PP-TH-122 Gatt A., PP-MO-524, PP-MO-189 Germani A., PP-WE-688 PP-TH-106, PP-TH-679, Geisel J., OC-MO-126 Gerometta M., OC-TU-009 PP-WE-192, PP-WE-649 Geisen C., OC-WE-076, Gerotziafas G. T., PP-MO-477, Gattis J., PP-WE-065 OC-WE-077, PP-MO-128, PP-MO-478, PP-MO-777, Gatzoulis M., PP-WE-805 PP-TH-661, PP-WE-210 PP-MO-778, PP-MO-779, Gau J. P., PP-MO-330, Geissen C., AS-TU-054 PP-TH-485, PP-TH-486, PP-TH-620 Geiter S., PP-MO-711, PP-WE-490 Gaucherand P., PP-TH-385, PP-TH-148, PP-WE-777 Gerotziafas G., PP-TH-343 PP-TH-386 Gelderman M. P., PP-TH-016 Gerrits A. J., PP-MO-007, Gaussem P., AS-TH-023, Gemmati D., AS-WE-039, PP-WE-024 AS-TH-035, OC-TH-022, PP-WE-657 Gersh K. C., OC-WE-112 OC-TU-032, OC-TU-090, Genc S., PP-MO-744 Gersh K., OC-TH-055, OC-WE-089, PP-MO-835, PP-WE-212 PP-TH-349, PP-WE-263 Gennaro N., PP-TH-304 Gensbittel M., PP-MO-530 Gershkovich K., PP-TH-219, Gautam N., PP-TH-330 PP-TH-227 Gautier P., PP-WE-600 Gensini G. F., OC-WE-102, PP-MO-340, PP-MO-341, Gertler F. B., OC-MO-068 Gavalaki M., PP-TH-609, PP-MO-743, PP-MO-818, Gertow K., OC-TU-025 PP-MO-679 PP-TH-352, PP-TH-353, Gertz M. A., PP-MO-487, Gavasso S. S. G., OC-TH-026 PP-WE-745, PP-WE-746, PP-WE-723 PP-WE-747, PP-WE-748 Gavasso S., OC-MO-005, Gesell-Salazar M., OC-TU-026 OC-MO-119, OC-MO-121, Gensini G., AS-TH-034, PL-TU-004, PP-MO-242, OC-MO-010, OC-TH-047, Gesheff M., PP-WE-797 PP-MO-243, PP-MO-348, OC-WE-031, OC-WE-032, Gesheff T., PP-WE-798 PP-MO-765, PP-TH-382, PP-MO-013, PP-MO-217, PP-TH-383, PP-TH-420, PP-MO-303, PP-MO-304, Geskus R. B., PP-MO-597 PP-TH-487, PP-TH-488, PP-MO-339, PP-MO-799, Gessner C. R., OC-TU-095 PP-WE-080, PP-WE-248, PP-MO-800, PP-MO-801, Gessner J. E., AS-TU-005 PP-WE-384 PP-MO-802, PP-MO-803, Getz T. M., PP-TH-040 Gavish D., PP-MO-338 PP-MO-804, PP-MO-805, PP-MO-836, PP-TH-163, Getz T., OC-TH-098 Gavrylyuk S. P., PP-MO-401 PP-TH-340, PP-TH-341, Geyer M., PP-MO-244 Gay S., PP-WE-787 PP-WE-002, PP-WE-003 Ghanayem N. S., OC-TU-065 Gaydukova S. M., PP-TH-479 Gent M., OC-WE-004, PP-TH-415, PP-TH-430, Ghenu O., PP-WE-737 Gayen-Betal S., PP-WE-894 PP-WE-404, PP-WE-421 Gheras M., PP-TH-276 Gayol S., PP-MO-416 George J. N., OC-WE-009, Ghirarduzzi A., OC-MO-013, Gazikalovic S., PP-WE-867 PP-TH-079, PP-WE-729 OC-TH-003, OC-TH-006, Ge J., PP-TH-078, PP-WE-706, Georgescu A., PP-MO-855 OC-TH-011, PP-MO-285, PP-WE-707 Georgiou G., PP-MO-679 PP-MO-290, PP-MO-291, PP-WE-403 Gear A. R. L., OC-TU-027 Gerard-Blanluet M., PP-TH-074 Ghiselli L., PP-MO-802 Gebbink M. F. B. G., Gerdes C., OC-TH-058 AS-TH-038, PP-WE-216 Ghomchi H., PP-WE-737 Gerdes N., PP-WE-890 Gebbink M., OC-MO-112 Ghorbani R., PP-TH-124 Gerdes V. E. A., OC-TU-010, Gebhard S., OC-TU-026 PP-MO-221, PP-MO-292, Ghosh K., PP-TH-295, Gebuis E. P. A., LB-MO-001 PP-MO-293, PP-TH-286, PP-TH-659, PP-TH-660, PP-TH-293, PP-TH-517, PP-TH-668 Geerts W., PL-MO-002 PP-WE-336, OC-MO-039, Giacomelli M., PP-MO-611 PP-MO-659 512 PP-WE-627, PP-WE-628, OC-WE-136, PP-WE-626, Giannarelli C., PP-TH-541, PP-WE-542 Giangrande P., PP-WE-246 Gianfagna F., Gianellini S., OC-WE-032, PP-MO-217 Giambene B., Gialeraki PP-WE-629, PP-WE-630 Giacomelli S., INDEX AUTHORS PP-MO-215 Gilabert-Estelles J., PP-MO-215 Gilabert J., Gil BernabeP., Gijsen S., Giglioli C., Giessen P., Giesen P. L. A., Giese C., Giermasz A., Gierczak R.F PP-WE-039, PP-WE-542 Giebl OC-TU-010, PP-TH-293 Gibson N.S., Gibson A., PP-TH-472 Gibbs J., PP-TH-472, PP-WE-409 Gibbs H., PP-WE-809 Gibbins J.M., Giaya K., PP-WE-659 PP-MO-656, PP-MO-657, Giansily-Blaizot M., PP-TH-402 Giannini S., OC-WE-101 Giannattasio E.R., PP-TH-031, PP-WE-040, PP-MO-032, PP-TH-014, OC-TH-093, OC-TH-100, OC-WE-087, PP-MO-085, OC-WE-119, PP-TH-540, A., OC-WE-1 A. E., PP-TH-471, PP-MO-420 PP-WE-782 PP-TH-471, PP-MO-621 PP-MO-013 PP-TH-538 PP-TH-627, OC-TH-057 OC-TH-032, ., PP-WE-868 PP-MO-066 PP-TH-249, OC-MO-039, OC-WE-031, OC-TH-037, OC-TU-074, PP-MO-834 PP-TH-175 AS-MO-028, PP-TH-338 PP-WE-222 OC-WE-060 19, PP-MO-131, PP-TH-159, PP-TH-398, PP-WE-047, OC-WE-039, OC-WE-072, AS-TU-058, OC-TH-061, PP-MO-515, PP-TH-522, OC-WE-01 PP-TH-493, PP-WE-878 Giordano P PP-TH-248 Giordano L., Giordano G., V.,Giordano A. Giolo E., PP-WE-640 Ginsburg D., Ginsberg M., Ginsberg J., PP-TH-523 Ginsberg J.S., Ginsberg J.S., PP-MO-590 Gimenez F., PP-MO-219, PP-MO-225 Gils A., Gilmour L., PP-MO-593 Gilmore R., PP-WE-685 Gilmore R.M., Gilmore G., PP-WE-610 Gilles J.G., Gillanders K.R., Gill N., PP-WE-553 Gill K., PP-WE-601 Gill J.C., PP-WE-260 Gilio K., Gilet H., Gil-Campos I., Gilbert J., PP-MO-622 Gilbert J.C., PP-WE-153, PP-WE-674 Gilbert G.E., OC-TU-071, PP-MO-600, OC-WE-123, PP-TH-007, AS-WE-003, OC-MO-033 OC-TH-114, AS-TU-037, PP-WE-425 PP-WE-460 AS-WE-038, 1, OC-WE-129, OC-WE-007 ., PP-WE-472 AS-MO-028, PP-MO-019 PP-MO-605, PP-MO-566, PP-MO-310 PP-MO-448, AS-WE-014, PP-TH-048, SA-TU-008, AS-MO-046 PP-WE-823 OC-TU-095, PP-WE-563 PP-TH-549, OC-TU-009, PP-TH-694 PP-MO-568 PP-MO-086 OC-TU-003, PP-TH-196, Girelli D., Girault S., Girard P., Giraldo R., Giptner A., OC-MO-092 Giorgi PierfranceschiM., Goffin V., PP-TH-208 Goerlinger K., Goekoop R.J., PP-TH-218, PP-WE-869 Godoi L.C., Godino C., PP-MO-835, PP-TH-394 Godier A., Goddijn M., Glover S., PP-WE-396 Gloanec P., Glennane T Gleiter C., Glechikov Glazer S., Glatz J.F PC-01 Gladysheva V. G., PP-WE-003 OC-MO-010, PP-TH-341, Giusti B., Giuseppe C., Giugliano R., Giuffrida A., Giubilato S., Gitz E., Githanga J.W PP-WE-358, PP-WE-362 Gissel M., Giroud M., Girodon E., PP-MO-809 Girndt M., PP-TH-575 Girisch M., PP-TH-347 OC-TH-030, PP-MO-342, 1, PC-051 PP-MO-007 ., AS-TH-034, PP-MO-022 PP-TH-307 OC-TH-028, OC-TH-057 OC-MO-126, OC-MO-003, OC-TH-020 A. V PP-TH-593 PP-WE-183 PP-MO-391, PP-TH-012 PP-TH-349 ., PP-MO-775 OC-TU-082 PP-MO-083 PP-TH-450, PP-MO-382, PP-MO-529 PP-TH-373 AS-TU-032 PP-MO-871, PP-WE-789 PP-WE-409 PP-WE-866 OC-WE-003 ., ., PP-TH-207, OC-MO-037 PP-MO-452 PP-TH-514 PC-010, 513

Authors Index AUTHORS INDEX

Goico F. J., PC-050 Gonzalez M., PP-MO-766 Gottsäter A., OC-TH-078, Goker H., PP-MO-394 González O., OC-TH-036 PP-WE-328 Golanski J., PP-TH-099 González-Conejero R., Gottstein S., PP-MO-357, PP-TH-588, PP-WE-620 Goldenberg N. A., PP-TH-265, AS-MO-054, AS-TH-052, PP-WE-255, AS-TU-051 OC-TH-027, PP-MO-144, Gouault-Heilman M., PP-WE-123 PP-TH-189 Goldenberg N., OC-WE-117 González-Manchón C., Goudemand J., OC-TU-073, Golder M., AS-MO-018, AS- PP-WE-764 PP-MO-530, PP-MO-618, MO-020, PP-TH-631 Goodall A. H., AS-MO-037, PP-MO-626, PP-TH-583, Goldford M. D., PP-WE-195 OC-TH-093, OC-TU-029, PP-TH-593, PP-TH-623 Goldhaber S. Z., OC-TU-004, OC-WE-126 Goudsmit J., PP-WE-150, PP-TH-424 Goodeve A. C., AS-MO-019, PP-WE-151 Goldhaber S., SA-MO-002, OC-TU-077, OC-WE-135, Gouider E., PP-MO-649, OC-MO-054 PP-TH-638 PP-MO-650 Goldmann G., PP-TH-537 Goodeve A., PP-MO-199, Gouin-Thibault I., PP-WE-412, PP-MO-534 PP-TH-429 Goldsmith R. E., PP-WE-431, PP-WE-541 Goodwin C., OC-WE-024 Gourhant L., PP-WE-186 Goli N., PP-TH-161 Goossens M., PP-MO-529, Goussetis E., OC-TH-044 PP-WE-600 Golmard J. L., PP-TH-429 Goux D., OC-WE-111 Gorbacheva L. R., PP-MO-882 Golmard J., PP-WE-412 Govaert P., OC-TU-063 Gorbacheva L., OC-WE-143, Golubeva M., PP-MO-256 Govers-Riemslag J. W. P., PP-WE-155 AS-TH-038, OC-TU-085, Gomes K. B., PP-MO-335, Gorbatenko A. S., PP-MO-182 OC-WE-036, PP-MO-433, PP-MO-346, PP-MO-363, Gorczyca M., AS-WE-014 PP-TH-122, PP-TH-131, PP-MO-364, PP-MO-816, PP-WE-126, PP-WE-219, PP-TH-490, PP-WE-310, Gordon B., PP-WE-215 PP-WE-352 PP-WE-347, PP-WE-364, PP-WE-365, PP-WE-814, Gordon S. P., PP-TH-393 Goyal A., PP-TH-231, PP-WE-815 Gordon W., PP-TH-315 PP-TH-232 Gomez K., PP-TH-551, Gori A. M., PP-MO-743, Goyal P., PP-MO-008 PP-TH-657 PP-WE-745, PP-WE-747, Grabell J., PP-TH-639 PP-WE-748 Gómez N., PP-MO-144 Gräber S., PP-MO-809 Gomez P., AS-TH-018 Gori A., AS-TH-034, OC-MO-010, OC-TH-047, Grabhorn E., PP-TH-215 Gomez-Lechon M., PP-MO-215 PP-MO-799, PP-MO-800, Grace J., PP-WE-474 Gomez-Vidales V., PP-MO-865 PP-MO-801, PP-MO-802, Graf M., PP-MO-711, PP-MO-803, PP-MO-836, PP-TH-148, PP-WE-777 Gomis R., AS-TH-018 PP-TH-341, PP-WE-002, Gomperts E. D., OC-MO-086 PP-WE-003 Graf N., PP-TH-614, PP-WE-648 Gomperts E., PP-WE-597 Gorkun O. V., OC-WE-147 Graham I. G., PP-TH-034 Gonçalves E., PP-WE-730 Görlinger K., PP-WE-697 Graham R. M., OC-TU-054 Goncalves L. R., PP-TH-444 Gorodetsky V. M., PP-MO-218, PP-MO-668, PP-WE-170 Grailly S. Y., PP-WE-610 Gonczol E., OC-TU-051, PP-WE-836 Gorog D., PP-TH-061, Grainger J. D., PP-MO-690 PP-WE-751 Gonen R., PP-WE-272 Gram J., PP-MO-164, Gorska M., PP-WE-433 PP-WE-282, PP-WE-515 Gong H., PP-WE-004 Gosens I., PP-TH-122 Grancha S., PP-TH-591 Gonidec M., PP-MO-112, PP-TH-183 Gosic V., PC-028 Grandchamp B., PP-MO-077 Gonsalves C., PP-MO-460 Goslings C., OC-TH-067 Grandi A. M., PP-MO-309 Gonzalez Conejero R., Goto S., PP-MO-111, Grandone E. E. G., OC-TH-120, PP-TH-481 PP-TH-004 AS-WE-023, PP-MO-372 Gonzalez G., PP-MO-865 Gottenberg J., PP-WE-787

514 OC-TH-024, OC-TH-102, AS-TH-007, OC-TH-023, PP-TH-351, PP-WE-231, PP-MO-250, PP-TH-028, OC-WE-114, OC-WE-125, OC-TH-089, OC-TU-054, OC-MO-115, OC-TH-055, Grassi M., PP-WE-258, PP-WE-259 Grant P Granier D., Granier C., Grange C., OC-TU-035 Grandone E., INDEX AUTHORS Grenegård M., OC-TH-022, PP-MO-748 Grelac F., OC-TU-026, PP-TH-425 Greinacher Greig J. A., Gregory G.D., Gregorová K., PP-WE-531 Greenway L., Greenway A. Greensmith H., PP-MO-709 Greenfield R.S., Green S., Green S.P Green M., Green K., PP-WE-530 Green D., Greco L., Greaves P Gray L., Gray J.T Gray E., PP-TH-137, PP-WE-481 Gray PP-MO-227, PP-WE-436 Grau E., PP-WE-019 Gratacap M., PP-TH-493, PP-WE-878 PP-MO-319, PP-MO-502, PP-WE-366, PP-WE-367, A., . J., PP-TH-655 PP-WE-133 PP-MO-136, PP-MO-226, ., PP-WE-367 PP-MO-550 AS-WE-060, AS-TH-023, PP-WE-782 ., OC-WE-003 ., AS-TU-01 A., PP-MO-448, PP-WE-483 PP-MO-079 PP-TH-172 AS-TH-019, A., PP-WE-150 PP-MO-680 PP-WE-298 OC-MO-099, PP-MO-822, PP-MO-437, PP-TH-306 PP-MO-021 AS-TH-042 PL-WE-001, PP-TH-683 PP-MO-438 PP-MO-296, 1 PP-TH-094, PP-TH-402, PP-TH-008, PP-TH-069, OC-WE-087, PP-MO-085, OC-TH-032, OC-TU-047, PP-WE-534 Grobbee D.E., Gritsenko P. G., PP-TH-641 Gritsch H., Grisaru D., PP-MO-783 Gris J., Gris J.C., Grion A., PP-WE-597 Gringeri A., Grimaux M., Grilli P., Grigorov A., PP-WE-397 Grigorjeva M., Grigoriev S.V Grifoni S., PP-MO-341, PP-WE-283 Grifoni E., Griffiths Griffith M., Griffioen A., PP-MO-880, PP-MO-881 Griffin J.H., Griest A., Griesshammer M., Gridelli B., Gribkova I.V., Grgurevich S., PP-WE-801 Gretler D., Gretener S., PP-WE-823 Gresele P., PP-MO-809 Grenner Y., Grenga I., PP-TH-558, PP-WE-542, PP-MO-591, PP-MO-604, PP-MO-585, PP-MO-586, OC-WE-1 PP-MO-339, PP-MO-340, PP-MO-303, PP-MO-304, OC-TH-081, PP-MO-457 A. E., 19, PP-MO-560, OC-MO-015 PP-MO-522 PP-TH-494 OC-WE-099 OC-TH-014 OC-WE-102, PP-TH-027, OC-MO-086 PP-MO-070 OC-MO-028, PP-MO-640, PP-TH-070 OC-MO-126, OC-MO-034, AS-TU-043, PP-WE-211 PP-WE-192 PP-MO-514 PP-MO-551 ., PP-MO-182 PP-MO-155 PP-MO-256, PP-MO-054 OC-TU-070, PP-TH-250 PP-MO-212 PP-TH-550 PP-MO-664, PP-TH-172, OC-TU-073, PP-MO-527, Groot E., PP-MO-489 P.,Groot A. Gröning A., PP-MO-557 Gröner A., Groenendaal F., Gu X., Gu J., Gu H., PP-WE-707 PP-TH-078, PP-WE-706, Gu D., Gu C., M., Grzywacz A. Grzyb Gruzdev A., Gruppo R. Grunzke M.L., Grünhage F PP-WE-655 Grunebaum L., PP-WE-831 Grundt H., Gruhler A., PP-TH-365 Gruel Y., PP-TH-232 Gruber T PP-TH-237, PP-WE-110 Gruber F. X., PP-WE-097 Gruber A., Grove E.L., PP-MO-613 Grosso S., Grosso S.H., Grossmann R., Grosser M., OC-TH-060, PP-TH-009 Gross P Groschup M., Grosbrois S., OC-TU-072, PP-MO-091 OC-MO-104, PP-TH-037, PP-WE-829, PP-WE-830, PP-TH-131, PP-WE-126, A., PP-MO-810, PP-WE-009 PP-WE-009 PP-MO-810, PP-WE-009 OC-WE-068, OC-MO-013, PC-043 . L., ., OC-TH-022, AS-WE-037, PP-TH-381 PP-TH-231, AS-TH-039, A., PP-MO-556, PP-MO-433, PP-MO-204, PP-MO-558 ., OC-WE-105, AS-WE-042, OC-TH-101 PP-MO-824 PP-WE-743 PP-WE-788 PP-MO-808, PP-TH-537 PP-TH-172 PC-047 PP-MO-556 OC-WE-012 PP-WE-255 PP-MO-611, PP-TH-651 OC-TU-063 PP-WE-307 515

Authors Index AUTHORS INDEX

Guadagni F., PP-MO-379, Guimaraes A. H., PP-MO-224 Gutierrez M. J., PP-MO-590 PP-MO-380, PP-TH-494, Guimarães D. A. M., Gutiérrez-Gallego R., PP-WE-824 PP-MO-363, PP-MO-364, OC-TU-082 Guarini P., OC-TH-030, PP-WE-364, PP-WE-365 Gutte H., OC-MO-040 PP-MO-342, PP-TH-347 Guimarães D. A., PP-WE-092, Gutti R. K., PP-TH-067, Guasch J. F., PP-TH-520, PP-WE-310, PP-WE-347 PP-WE-083 PP-WE-270 Guinet C., PP-WE-198, Gutti R., PP-TH-073 Guazzaloca G., AS-TH-029, PP-WE-199 Guy C., PP-TH-076 OC-TH-075, PP-MO-503, Guinto E. R., PP-MO-709 PP-WE-359 Guzmán A., PP-TH-607 Guinto E., PP-MO-296, Gubensek M., PP-MO-404 PP-MO-319 Gyenes M., AS-TH-060, PP-MO-001, PP-WE-862 Guechi Z., PC-018, PP-MO-445 Guizzardi G., PP-MO-015 Gyrgy A. A., PP-TH-346 Gueguen P., AS-TH-015, Guldiken S., PP-TH-221, OC-MO-060 PP-TH-222, PP-WE-876 Gyulkhandanyan A. V., PP-MO-065 Guella I., PP-MO-648, Guler S., PP-MO-537, PP-TH-670, PP-WE-657 PP-MO-538 H.C.D.C. A., PP-TH-628, PP-TH-639 Gueret P., PP-TH-423 Gulin D., PC-005, PP-TH-227 Ha J. R., PP-WE-238 Guerin V., PP-MO-645 Gumustekin C., PP-MO-797 Ha Noh J., PP-MO-567 Guerrero F., PP-MO-188, Guney B., PP-MO-858 PP-WE-169 Haahr K., PP-WE-383 Guney S. B., PP-TH-686, Guerrero J. A., PP-MO-082, PP-WE-880 Haaning J., OC-WE-057, PP-MO-134 OC-WE-059 Gunja N., PP-MO-326 Guerrero J., PP-WE-033 Haas S., PP-TH-425 Gunnarsson M., PP-MO-540 Guest J. F., PP-WE-676 Habas R., AS-WE-035 Günther A., AS-TH-037 Guglielmini G., OC-WE-087, Haberichter S. L., AS-MO-017, PP-MO-085, PP-TH-008 Guo C., OC-MO-136, AS-WE-038, OC-WE-133, OC-MO-137 Guglielmone H. A., PP-MO- PP-TH-128 547, PP-TH-568, PP-WE-511 Guo L. J., OC-MO-096 Haberstock-Debic H., Gui T., AS-WE-042 Guo Z., PP-TH-078 PP-MO-045, PP-TH-027 Guida A., PP-MO-336, Gupalo E. M., PP-WE-058 Habib A., PP-WE-738 PP-WE-320, PP-WE-325 Gupta S., PP-WE-523 Hachelaf M., OC-TH-018 Guidetti G. F., PP-MO-018 Guralnik J., PP-WE-311 Hachem A., PP-MO-012 Guidi G. C., OC-MO-096 Gurbel P. A., PP-MO-739, Hach-Wunderle V., Guidi G., OC-MO-097, PP-MO-771, PP-TH-026, PP-MO-509, PP-TH-312 OC-TH-030, PP-MO-540, PP-TH-101, PP-WE-043, Hackeng C. M., OC-MO-133, PP-MO-541, PP-WE-140 PP-WE-757, PP-WE-794, OC-MO-135, PP-MO-780, PP-WE-797, PP-WE-798, Guido G., PP-WE-870 PP-MO-781, PP-MO-788, PP-WE-799, PP-WE-801, PP-WE-741, PP-WE-742 Guido R., PP-MO-634, PP-WE-802, PP-WE-803 PP-MO-635 Hackeng T. M., OC-MO-005, Gurbel P., PP-WE-797 PP-MO-186, PP-TH-344 Guil M., PP-MO-226 Gurbuz A., PP-TH-511 Hackeng T., SA-TH-016 Guillaizeau F., OC-TH-018 Gurewich V., AS-WE-050 Hacquard M., PP-TH-394, Guillet B., OC-TU-073, Gurgey A., OC-WE-132 PP-TH-693, PP-WE-700 PP-TH-172, PP-MO-833 Gurney D. A., PP-MO-166 Hadadeh O., OC-TH-045 Guilliatt A. M., PP-MO-614, PP-MO-623 Gurniak C., AS-WE-029 Haderer C., PP-MO-615 Guillo P., PP-MO-508, Gussoni G., OC-MO-018 Hadj-Ali A., PP-TH-680 PP-WE-510 Gustafsson T., PP-MO-845 Hadonou M., PP-MO-628, Guillot K., OC-WE-017, Gut R., PP-WE-602 PP-WE-635 PP-TH-288 Guthold M., PP-WE-861 Hadzi-Pecova L. B., PP-WE-769

516 Haidl H., Haider S., Hahnfeld S., PP-WE-418 Hagiwara N., PP-WE-348 Hagihara K., Haggag S., Hagemeyer C.E., AS-TU-040, AS-WE-030 Hagedorn I., Hafez F. M., INDEX AUTHORS Hammarström P., Hammamy B., OC-WE-044 Hamilton J.R., Hamiel C., Hamers S., PP-WE-043 Hamed M., Hamed M.S., Hamed F., Hamdi S., PP-WE-605 Hamamoto T., PP-MO-058, PP-MO-852 Hamaia S.W., PP-TH-319, PP-WE-463 Hamahata Hamaguchi Y., Hallam S., Hall K.J., Hall PP-WE-756 Halimeh S., Halaris PP-WE-070 Hajsmanova Z., Hajjar K., AS-WE-046 Hajjar K. A., Hajduk B., Haiko J., PP-WE-669, PP-WE-670, PP-WE-633, PP-WE-653, PP-TH-647, PP-WE-370, PP-TH-575, PP-TH-646, PP-MO-377, PP-MO-607, A. J., A., PP-WE-439 OC-TH-064 OC-MO-026 PP-WE-161 OC-WE-123 PP-TH-343 PP-WE-382 PP-WE-043 A., PP-MO-680 AS-TH-028 PP-TH-408 PP-MO-857 PP-TH-026, AS-MO-030 PP-WE-281 OC-WE-117, PP-WE-202 PP-WE-264, AS-TH-040, LB-MO-003 PP-MO-096, PP-WE-342, PP-WE-798 PP-MO-516, PP-TH-689, PP-MO-041, PP-MO-664 PP-MO-119 OC-MO-110, PP-TH-368, AS-TH-038 PP-MO-100 PP-TH-181, PP-WE-017, PP-MO-337, PP-TH-007, PP-TH-237, PP-WE-110, OC-WE-140, PP-MO-808, OC-TU-006, OC-WE-137, OC-WE-100, PP-MO-670, OC-MO-125, OC-TH-001, OC-TU-077, OC-WE-135, Hansen K.J., PP-WE-304, PP-WE-305 Hansen J., Hansen J.J., PP-MO-177, PP-MO-813 Hansen J.B., Hansen A., Hannah M.J., Hann A., Hanley J., Hanley J.P., Hankey G., A., Hanke A. Hang M.X., Hancer V., Hanazawa S., Hanau D., PP-TH-592, PP-WE-606 Hanabusa H., Han Z., Han Y., Han K., Han H., Han F PP-WE-352, PP-WE-457 Hamulyák K., PP-WE-219 Hamulyak K., Hamsten A., PP-TH-664, PP-WE-766 Hampton K.K., PP-TH-638 Hampshire D.J., Hammond G.C., Hammerstrom J., Hammerstingl C., OC-TH-059 Hammerschmidt S., Hammer D., Hammelburger J., . Y., PP-TH-335, PP-WE-773 OC-WE-068 PP-WE-112 PP-WE-844 PP-MO-397 PP-TH-364 PP-WE-891 PP-WE-298 PP-TH-270 OC-TU-005, PP-MO-014 PP-MO-019 PP-WE-553 PP-WE-030 PP-MO-108 PP-WE-697 PP-WE-372 PP-WE-572 AS-WE-058, PP-MO-286, PP-WE-854 OC-MO-058, PP-TH-576, PP-TH-229 OC-MO-067 PP-MO-199, PP-WE-537 AS-MO-019, OC-WE-013 PP-MO-409 PP-WE-115 PP-MO-343 Hanson E., Hanslik A., Hansen T PP-TH-151, PP-TH-579 Hansen L., OC-TU-056, PP-MO-759 Harrison P., Harris S., Harris G. A., Harrington L.S., Harries C., Harper P Harper P PP-WE-020 Harper M.T., Harper J., Harper OC-TH-085 Harpell L., PP-WE-685 Harmon S., Harhouri K., PP-WE-182, PP-WE-183 Harenberg J., Hardwardt M., Harbrecht U., Haratian Z., Harashima M., Haramura G., Harada T Harada A., Hara H., Hanzu F., PP-WE-703, PP-WE-861 Hantgan R.R., Hantel S., Hansson M., Hansson G., Hansson G.K., Hanssen T., Hanson S., Hanson S.R., PP-TH-457 Hanson S.J., PP-MO-575, PP-TH-150, OC-MO-045, OC-WE-123, A. G.S., ., . L., PP-MO-070 ., . B., AS-TH-018 PP-WE-530 PP-WE-204 PP-MO-493 PP-WE-116 PP-TH-521 AS-TU-014, PP-MO-127 PP-WE-805 OC-MO-085, PP-MO-436 OC-WE-115, PP-TH-310 PP-TH-549, PC-049 OC-MO-009, PP-TH-443 AS-MO-060 OC-TH-112 OC-TU-079 SA-WE-008 PP-MO-762 AS-WE-035, PC-042 PP-WE-210 PP-MO-205 OC-TU-065, PP-MO-420, PP-WE-097 PP-MO-185 PP-TH-229 PP-TH-105, PP-WE-890 PP-MO-003 AS-WE-052 517

Authors Index AUTHORS INDEX

Harsfalvi J., PP-WE-049 Hathaway H. A., PP-WE-255 Hazen S., SA-TU-010 Hársfalvi J., PP-TH-633 Hathaway W. E., PP-WE-255 Hazenberg B. P. C., AS-TH-038 Hart D. P., PP-MO-708 Hatmi M., PP-TH-343, Hazenoot T. A., PP-WE-322 Hart E., PP-WE-239 PP-TH-485, PP-TH-486, Haznedaroglu I. C., PC-003, PP-WE-490 Hart G., PP-TH-197 PP-MO-394 Hato T., PP-MO-511, He C., OC-WE-098 Hartman D., OC-MO-100 PP-WE-011 Hartmann R., PP-WE-557 He S., PP-TH-141, PP-TH-186, Hattori K., PP-MO-123, PP-WE-846, PP-TH-146, Hartwell E., PP-MO-767 PP-MO-127 PP-TH-114 Hartwig J. H., PL-TU-002, Hau C. M., AS-WE-017, He X., PP-WE-846, PP-TH-146, PP-WE-077, AS-WE-026 PP-MO-109 PP-TH-114 Harustiakova D., PP-MO-259 Haubelt H., OC-WE-077 He Y., PP-MO-854, PP-WE-732 Harvey E. J., PP-MO-820 Haubold K., PP-MO-603, Head M. W., OC-MO-032 PP-MO-647 Harvey S., AS-MO-049 Heaney N. B., PP-TH-538 Hauer A., OC-WE-046, Harwardt M., PP-MO-184 PP-WE-439 Heath S., OC-MO-021, PP-TH-309 Hasan I., PP-MO-638 Haumer M., PP-MO-436 Heath V. L., OC-MO-069 Hasebe Y., PP-TH-229 Hauroeder B., PP-TH-440, Hasegawa M., PP-MO-096, PP-WE-190 Heath V., PP-WE-638 PP-TH-054 Hauschner H., OC-TH-042 Hebbagodi S., PP-MO-811, PP-MO-812, PP-WE-828 Haselböck J., PP-WE-663 Hauser C. J., OC-TH-069 Haselboeck J., OC-TU-013 Hechler B., AS-MO-058, Haushner H., PP-TH-084 OC-TH-033, OC-TH-034, Hashemi A., PP-TH-210 Hausl C., OC-TH-054 OC-TH-035, OC-TU-049 Hashemi Soteh M., PP-TH-636, Havens P. L., OC-TU-065 Hecking C., PP-MO-501 PP-WE-558 Hawley A. E., OC-TU-060, Hedayatiasl A., PP-TH-124 Hashiguchi T., PP-MO-884 PP-MO-388, PP-MO-400 Heddle N., PP-TH-663 Hashimoto M., PP-MO-096 Hay C. R. M., OC-TU-078, Hedner U., OC-WE-061, Hass M., PP-TH-397, PP-TH-645 PP-WE-237 PP-WE-159 Hay J. W., PP-TH-600, Hedstrom L., PP-WE-218 Hassairi N., PP-MO-280 PP-WE-612 Heeb M. J., OC-MO-055 Hassan M. U., PP-MO-710 Haya S., PP-MO-589, PP-MO-590, PP-TH-544, Heegaard C. W., PP-MO-131 Hassanien A. S., PP-TH-506 PP-TH-627, PP-WE-668 Heemskerk J. W. M., Hassanzadeh G. H., Hayafuji K., PP-TH-689 AS-TU-029, AS-TU-037, OC-TH-114 AS-WE-044, OC-MO-044, Hayakawa K., PP-WE-090 Hasse M., AS-TH-060, OC-WE-123, PL-TU-003, PP-WE-862 Hayakawa M., PP-WE-687 PP-MO-670, PP-TH-007, PP-TH-012, PP-WE-260 Hassenpflug W. A., PP-TH-215 Hayashi A., OC-TH-088, OC-TU-041, PP-MO-232 Heemskerk J., PP-TH-104 Hassine M., PP-TH-343, PP-TH-343 Hayashi H., PP-TH-051 Heeneman S., AS-WE-058, OC-MO-125 Hasslacher M., AS-WE-015, Hayashi T., OC-WE-054, PP-MO-087, PP-MO-150 PP-TH-143, PP-WE-032, Hegadorn C., AS-MO-018, PP-WE-882, PP-TH-057, AS-MO-020, AS-TU-014, Hasstedt S. J., OC-MO-024, PP-WE-278 OC-TH-085, OC-TH-086, OC-TU-001 Hayashida Y., PP-WE-411 PP-TH-631, PP-TH-639 Hasumi K., PP-TH-226 Haynes R., PP-WE-429 Heidinger K. S., PP-MO-083 Hatala R., PP-TH-433, Heidinger K., PP-MO-513 PP-TH-437 Hayun Y., PP-WE-847 Heijnen H. F. G., PP-MO-042, Hatemi A., PP-MO-858 Hayward C. P. M., AS-TH-045, OC-MO-134, PP-TH-663, PP-TH-055, PP-WE-061 Hatfield M. L., PP-MO-004 AS-TH-031 Heilmann C., PP-MO-030

518 Heit J. Heistinger M., Heisel-Kurth M. PP-WE-551 Heiniger I., Heiniger A. PP-WE-648 Heine S.I., PP-MO-809 Heine G.H., Heim V., INDEX AUTHORS PP-MO-388 Henke P. K., Henk J., Henig I., Hendriks H.G.D., PP-MO-230 Hendriks D., Hendriks D.F Hendrickx B., Members M., Hemostasis ResearchLab Hemmeryckx B., Hemker P. W., PP-WE-683 Hemker H.C., PP-TH-176, PP-TH-177 Hemker C., Hemker C.H., PP-WE-701 Hemche H., Hemapriya K., Helmerhorst F. M., Hellweg A., PP-MO-862 Helley D., PP-WE-210, PP-WE-434 Heller C., PP-TH-099 Helinska M., Helgestad J., Helal O., PP-TH-318 Hejazi S., PP-WE-292 PP-MO-678, PP-MO-760, PP-MO-284, PP-MO-629, PP-MO-582, PP-TH-246, A., OC-MO-051 PP-WE-891 PP-TH-387 A., OC-TU-087 PP-MO-592, PP-MO-539, AS-TH-003, OC-TH-046, PP-TH-614, PP-TH-107, AS-WE-053 PP-TH-608, PP-WE-550, OC-MO-126, OC-TU-060, PP-TH-098, PP-MO-229, PP-TH-628 ., PP-TH-455 PP-TH-572 OC-TU-008 PP-MO-251 PP-MO-251, PP-TH-155 OC-WE-077 OC-TH-118 PP-MO-327 A., PP-MO-819 PP-WE-771 AS-TH-002 PP-MO-586 PP-MO-575, PP-TH-579, PP-MO-560, PP-TH-566, PP-MO-101, PP-WE-045, PP-MO-881 Hernandez I., PP-WE-560, PP-WE-765 Hernandez F., Hernan N., PP-WE-154 Hermit M.B., Hermida J., PP-TH-578, PP-WE-532 Hermans C., PP-MO-234 Hermanowicz J.M., Hermann D., Hermann C., Hermanides J., Herman J.H., Herman Herlea O., OC-TH-104 Hergenroeder G.W., Herczenik E., Herbiniaux U., Herbert S., Herbert J.M.J., Herbel P., Herault J., Heras M., PP-WE-755 Heptinstall S., PP-MO-687 Hepner M., Hepner M.D., PP-WE-739 Hentrich J., Henskens Y. M.C., Henschler R., Henry H., PP-MO-374 Henriksson P Henriet C., Hennessy E.M., Henneke I., Henley K.J., Henkens I.R., A., PP-MO-686 PP-MO-254 PP-TH-120 OC-TH-065 PP-WE-388 PP-MO-618 PP-WE-665 PP-WE-522 OC-TU-064, AS-TH-037 PP-MO-338 PP-MO-178 PP-MO-700, PP-MO-220, OC-MO-100 OC-WE-063 AS-WE-032 ., PP-MO-1 PP-MO-880, PP-TH-616 PP-MO-029 PP-WE-637 PP-MO-756 PP-TH-059, PP-WE-322 OC-MO-100, AS-WE-002 OC-WE-104, PP-MO-298 OC-MO-069 OC-TU-002 PP-WE-017 18, OC-TH-120 Hernandez RomeroD., Hernández R., Hernández M., PP-WE-692 Hernandez M., Hernandez J., PP-TH-457 Higgerson R. A., PP-WE-025 Higashihara M., Higasa S., Higasa PP-WE-284 Hiestand B., Hierso S., PP-WE-393 Hiebert L.M., PP-MO-860 Hidalgo P PP-TH-638 Hickson N., Hickey K., PP-TH-679, PP-WE-144 Hickey K.P., Heyndrickxs G., PP-MO-230, PP-MO-327 Heylen E., Hewlett L., Hessner M.J., Hess K., Hess K. A., Hesham M., Herzog W., PP-WE-802 Herzog R.W., Hertfelder H.J., Hersi A., Hersemeyer K., Hers I., Herrera M., B., Herr A. PC-048, PP-TH-603,PP-TH-604 Hernandez-Navarro F., OC-WE-107 Hernández-Espinosa D., OC-TH-049, PP-WE-798, AS-TU-015, PP-TH-618, A., PP-WE-007 PP-TH-351 PP-WE-163 ., PP-TH-386 PP-WE-606 PP-WE-302 PP-MO-229, PP-TH-592 OC-WE-048 OC-MO-067 OC-WE-086, PP-WE-802 AS-TH-019 PP-WE-665 AS-MO-019, PP-TH-445 PP-MO-470, PP-MO-199, PP-WE-392, SA-TU-013, PP-WE-284 OC-TH-036 PP-MO-880 PP-TH-675 PP-MO-737, AS-TH-058 PP-MO-084, PP-MO-253 PP-WE-416 PP-TH-310, 519

Authors Index AUTHORS INDEX

Higgins J. R., PP-MO-381 Hlusˇí A., PP-WE-378 Holbrook L., OC-TH-037 Higgins-Gruber S. L., Ho C. H., PP-TH-620 Holcomb J. B., OC-TH-069, OC-WE-075 Ho D., OC-MO-025 PP-MO-767 High K. A., AS-TU-015 Hobbs H., PL-MO-001 Holcroft C., PP-TH-322 Hijjawi S. B., PP-WE-504 Hobbs W., PP-WE-887 Hollenbach S. J., OC-TH-107 Hilbig A., LB-MO-003 Hochstrasser D., OC-TH-073 Hollenbach S., AS-TH-022 Hildebrand R. B., OC-WE-046 Hocini H., PP-WE-483 Hollestelle M. J., PP-WE-339, PP-WE-355 Hilden I., OC-MO-058, Hockin M. F., OC-TU-003 PP-MO-177, PP-TH-529, Holliday B. A., OC-MO-117 Hockings P. D., PP-MO-385 PP-WE-589 Holloway D., PP-WE-623 Hill C. E., OC-WE-109 Hoebbel-Schnell T., PP-MO-693, PP-WE-644 Holly’P.,PP-TH-305, Hill F. G. H., OC-MO-032, PP-TH-598, PP-WE-220 OC-MO-033 Hoecke C. J., PP-MO-296, PP-MO-319, PP-MO-502, Holm P. K., PP-MO-118, Hill G., PP-MO-090 PP-MO-709 PP-MO-575, PP-MO-578, PP-TH-579 Hill M., PP-MO-534, Hoefer I., OC-TH-031 PP-WE-214, PP-WE-215 Holmberg H. L., OC-WE-056 Hoefman S., AS-TH-024 Hill S. N., PP-MO-054, Holmberg M., PP-WE-200, PP-TH-097 Hoeg T. S., PP-WE-586 PP-WE-201 Hillarp A., OC-TH-050, Höehr N. F., PP-MO-145 Holme P. A., PP-MO-581, PP-MO-258, PP-MO-615, Hoekstra J. B. L., PP-MO-298 PP-TH-539 PP-WE-758 Hoekstra J., PP-MO-224, Holme P., PP-MO-560 Hillege H., OC-MO-001 PP-TH-314 Holmes C. E., AS-MO-032, Hills J., PP-TH-263 Hoelscherman H., OC-WE-128 AS-MO-033, AS-MO-034 Himmer K., PP-TH-652 Hoes A. W., OC-TH-017, Holmström M., AS-TU-034, Hinckley J., PP-WE-636 OC-TU-012 PP-MO-533, PP-WE-643 Hinrichs A., PP-WE-620 Hofbeck M., PP-TH-450 Holstein K., PP-TH-578 Hintenberger R., PP-MO-829 Hoffman B. E., AS-TU-015 Höltje H. D., PP-TH-094 Hirabayashi K., PP-TH-358 Hoffman M., OC-WE-061, Holy E. W., OC-TU-052 PP-MO-300, PP-TH-205 Hiramoto J., PP-WE-562 Holz J., AS-TH-024, Hoffman S., OC-MO-134 PP-WE-416 Hirata K., PP-MO-429 Hoffmann T., PP-MO-745 Hölzenbein T., PP-MO-561 Hirmerova J., PP-WE-287 Hoffmeister M., PP-MO-480 Holzhauer S., OC-TU-062, Hiroe K., PP-MO-201, OC-WE-117, PP-MO-607 PP-TH-168, PP-WE-400 Hofman T., PP-WE-128 Homann J., PP-MO-253 Hirsch A. M., PP-WE-462 Hofstee H. M. A., PP-TH-517 Homer-Vanniasinkam S., Hirsch J., AS-TH-008 Hofstra J. H., PP-MO-190 PP-MO-024 Hitchen C., PP-TH-224 Hofstra J. J. H., PP-MO-191 Homma S., AS-WE-006 Hitos K., PP-MO-326, Hogan W. J., PP-MO-487 Honauer G., PP-WE-519 PP-WE-300, PP-WE-301 Hogg M. M., OC-TU-007, Honda S., PP-TH-015 Hiura H., OC-WE-008 PP-TH-505, PP-WE-414 Honda Y., PP-TH-406 Hizroeva D. H., PP-TH-278 Hogg P. J., OC-MO-056 Hong B., PP-WE-783 Hjemdahl P., AS-WE-024, Hogg P., PL-TU-000 Hong H., PP-WE-535 PP-WE-890 Hogwood J., PP-WE-133 Hong M. H., PP-TH-634 Hjortdal V., PP-WE-677 Hoibraaten E., AS-TH-004 Hla T., AS-WE-056 Hong S., PP-TH-294, Hoit B., OC-MO-128 PP-WE-783 Hlawaty M., PP-WE-107 Holada K., PP-TH-016 Hong W., AS-TH-042, Hlusi A., PC-022, PP-MO-689, Holbrook J. B., PP-WE-854 OC-TH-095 PP-WE-142, PP-WE-273

520 PP-WE-239 Hoover-Plow J.L., Hoots W. K., Hoots K., PP-TH-327, PP-TH-328 Hooper W Hooper N.M., PP-WE-613 Hooper C., Hoogerwerf J., PP-TH-620 Hong Y.C., INDEX AUTHORS Hoskins P PP-WE-031 Hoshino H., Hoshi A., Horvathova D., OC-TU-084 Horvath J., Horvath A. AS-TU-012 Hortelano G., Horneff S., Horne M.K., Horiuchi H., PP-WE-269, PP-WE-271 Horita T Horio T., Horie S., PP-WE-412 Horellou M., Horchani R., PP-MO-473, PP-WE-466 Horblyuk R.V., Hoque G., PP-TH-391, PP-WE-143 PP-TH-389, PP-TH-390, PP-TH-166, PP-TH-201, PP-TH-142, PP-TH-145, PP-TH-137, PP-TH-138, PP-MO-703, PP-MO-857, PP-MO-396, PP-MO-399, PP-MO-153, PP-MO-154, PP-MO-143, PP-MO-152, PP-MO-139, PP-MO-140, OC-TH-103, PP-MO-136, Hoppensteadt D., Hopkins B.J., PP-TH-325, PP-TH-326, ., A., PP-WE-872 PP-TH-051 PP-MO-842, PP-WE-501 . C., PP-MO-586 ., PP-MO-710 PP-TH-537 PP-MO-596, PP-MO-330, OC-MO-017 OC-TU-079, PP-WE-015, PP-MO-789 PP-WE-316, PP-TH-225 PP-WE-610 PP-MO-650 AS-TH-012, AS-TH-019 PP-TH-224 PP-TH-324, PP-MO-702 PP-TH-153 PP-MO-283, PP-WE-656 OC-TH-019, OC-TU-036, OC-MO-137, PP-MO-695, PP-TH-334 Hua B., Hu Z., Hu Y., Hu S., Hu L., PP-TH-1 Hu J., Hu H., Hu G., Hu C. PP-TH-620 Hsu H.C., Hsu C., Hsiao S., Hron G., Hrncir Z., PP-TH-083 Hrachovinova I., Hrachovinová I.V Hrachovinova I.V., PP-MO-819 Hoylaerts M.F., Howes J., G., Howard A. PP-WE-851 Hovens M.C., Hovatta O., PL-TU-001 Houwing-Duistermaat J.J., Houweling A., Houska M., Hourani R., K., Houng A. OC-TH-085, OC-TH-086 Hough C., PP-WE-731 Hou M., Hou J., Hostetler K., Hosseini KhahZ., Hossain S.R., PP-WE-382 Hossain N., PP-MO-398, PP-MO-795, OC-WE-043, OC-TH-057, PP-WE-085, PP-WE-268, Y PP-WE-101 PP-WE-732, PP-WE-846, PP-WE-083 PP-TH-022 PP-MO-555, PP-TH-653 PP-MO-105, PP-WE-818 OC-WE-064 ., PP-WE-674 PP-MO-642, PP-MO-879 14 OC-MO-136, AS-MO-004 PP-MO-180 AS-WE-032 PP-WE-068 PP-WE-028 AS-TU-014, PP-MO-330, PP-MO-374 PP-TH-213 PP-TH-456 PP-TH-648, PP-WE-672 PP-WE-218 PP-WE-819 PP-WE-462 PP-TH-476 OC-MO-044, PP-MO-551, PP-MO-782, ., PP-WE-558 PP-WE-345 PP-MO-583 PP-WE-838 Huang J., Huang F Huang D., Huang D.C.S., Huang C., Hua M., Hunter R.W., PP-TH-231 Hunt J., PP-MO-371, PP-WE-727 Hunt B.J., Humphries J., Humphries J.E., Hulot J., Hull R.D., PP-TH-655 Hulkower B., Huisman M., PP-WE-851 Huisman M.V., Huijgen R., Hughes J., OC-TU-062 Huge A., Hug M., Huber S., Huber K., Hubel E., Hubbuch Huang Z., Huang Huang X., PP-WE-895 Huang T., PP-WE-225 Huang M., Huang L., Huang L.H., PP-WE-513, PP-WE-521, PP-WE-341, PP-WE-512, PP-TH-413, PP-WE-322, PP-MO-507, PP-MO-782, OC-TH-008, PP-MO-506, AS-TU-010, OC-MO-037, PP-TH-653, PP-WE-895, PP-MO-878, PP-MO-879, PP-MO-844, PP-MO-846, Y., AS-WE-032 ., OC-TU-061 PP-TH-230, OC-MO-007 AS-TU-053, A., PP-TH-070 OC-TH-117 AS-TU-055 PP-WE-217 PP-MO-829 PP-MO-840, OC-MO-070, PP-MO-105 PP-TH-586 PP-WE-857 PP-MO-646 PP-WE-079 AS-WE-047, OC-TU-021 OC-TU-039, PP-TH-473 PP-MO-298 PP-WE-519 SA-MO-003 PP-MO-768, PP-WE-007 PP-MO-384 AS-MO-035, PP-MO-159 AS-WE-032 OC-TH-031 521

Authors Index AUTHORS INDEX

Hunter R., PP-WE-065 Hyllner M., PP-MO-652, Ilic V., PP-WE-634 Huntington J. A., AS-MO-025, PP-WE-206 Iliceto S., OC-TH-075 AS-TH-049, OC-WE-081, Hynes E., PP-WE-298, Iliescu V., PP-WE-737 OC-WE-098 PP-WE-372 Iliuta L., PP-WE-737 Huntington J., SA-TH-017 Hyseni A. A., PP-WE-355 Ilonczai P., PP-MO-359 Huo M., PP-MO-247 Hyun J., PP-TH-149 Imaeda Y., PP-MO-201, Hurbin F., PP-WE-388 Iaboni S., PP-MO-457, PP-TH-168, PP-WE-398, Hurevich H. L., PP-MO-873, PP-MO-458 PP-WE-400 PP-MO-874, PP-WE-863, Iacobelli M., OC-WE-108, Imai M., PP-WE-149 PP-WE-864 PP-TH-389 Imamura T., PP-MO-111 Hurst S., PP-WE-097 Iacobellis N., PL-TU-004 Imanishi D., PP-WE-666 Hursting M. J., OC-TH-104 Iacoviello L., PP-MO-481, Imanishi T., PP-MO-429 Hurtado B., PP-WE-821, PP-MO-876, PP-TH-048, PP-WE-822 PP-TH-248, PP-TH-249, Imbergamo S., PP-WE-866 PP-WE-246, PP-WE-498 Hurtado J., PP-MO-732 Imberti D., OC-MO-092, Iakova P., PP-TH-439 OC-TH-011, PP-WE-403 Hurtaud-Roux M., PP-TH-074 Iannaccaro P., PP-MO-432, Imfeld K. L., PP-MO-823, Hurwitz J., PP-MO-722 PP-TH-546, PP-TH-547 PP-TH-065 Husain M. F., PP-MO-057 Iannaccone A., PP-WE-367 Immenschuh S., OC-MO-072 Husova L., PP-WE-596 Iannuzzi F., PP-MO-673 Inaba H., PP-MO-546, Hussain M., PP-MO-030 Iasella M., PC-034 PP-WE-666 Hussein A. H., PP-MO-037, Iatmanen S., OC-WE-070 Inagaki M., AS-TH-022, PP-WE-067 OC-TH-107 Iba T., PP-TH-198 Hussein M. A., OC-TH-016 Inami N., PP-WE-781, Ibarra A., OC-TU-038 Hussein M., PP-WE-465 PP-WE-827 Ibghi D., PP-WE-423 Hussein N. A., PP-TH-506 Inbal A., PP-MO-749 Ibrahim B., PP-WE-691 Hutabarat R. M., PP-WE-569 Incampo F., PP-WE-249 Ichikawa H., AS-WE-045 Hutabarat R., AS-WE-014, Ingalls R., PP-TH-064 PP-MO-622 Ichinose A., OC-WE-073 Ingerslev J., AS-MO-028, Hutchaleelaha A., OC-TH-107, Ido M., PP-WE-032 OC-MO-036, PP-MO-386, PP-WE-801 Ieko M., PP-MO-842 PP-MO-543, PP-TH-545, PP-WE-658, PP-WE-677, Huth - Kühne A., PP-MO-513 Iglesias Varela M. L., PP-WE-698, PP-WE-702, Huth-Kuehne A., PP-MO-662, PP-TH-333 PP-WE-740 PP-TH-575 Iglesias Varela M., PP-MO-275 Ingle A., PP-MO-068, Huth-Kuhne A., PP-MO-609, Ignjatovic V., OC-WE-093, PP-WE-672 PP-WE-604 PP-MO-381, PP-MO-437, Ingram A. J., OC-TH-009 PP-MO-438, PP-MO-449, Huth-Kühne A., OC-WE-058, Ingratti M., PC-047 PP-TH-421 PP-MO-450, PP-MO-451, PP-MO-674, PP-TH-442, Innocenti M., PP-MO-542 Hutspardol S., PC-052, PP-TH-461, PP-TH-462, Innocenti P., PP-WE-856 PP-WE-710 PP-TH-475, PP-WE-437, Huyck J., PP-TH-256 PP-WE-438, PP-WE-480, Inoue H., PP-WE-196 PP-WE-531 Hvas A., PP-MO-386, Inoue M., PP-TH-358 PP-WE-788 Iijima K., PP-TH-143 Inoue O., OC-TH-099, Hvitfeldt Poulsen L., Ikeda R., PP-TH-173 PP-TH-005 OC-MO-036 Ikeda T., PP-MO-789 Inoue Y., PP-WE-005 Hwa J., PP-TH-364 Ikeda Y., SA-WE-016 Interthal C., PP-MO-373 Hwang S., PP-TH-190 Ikenaga H., PP-WE-348 Inwards D. J., PP-MO-487 Hylek E. M., PP-MO-462, Ikram N., PP-TH-643 Inzitari D., OC-TH-047 PP-MO-463

522 PP-WE-286, PP-WE-529, PP-TH-412, PP-TH-654, PP-MO-458, PP-MO-542, PP-MO-282, PP-MO-457, OC-TH-004, OC-TU-075, OC-MO-035, OC-TH-002, AS-TU-032, AS-TU-033, Iotti M., Iorio M., PP-WE-688 Iorio Ionita H., Ionescu-Zanetti C., Iommi P., INDEX AUTHORS Isma N., Iskas M.S., PP-MO-875, PP-MO-882 Ishiwata S., PP-TH-054 Ishiwata A., Ishii M., PP-MO-252 Ishii H., Ishihara C., Ishida N., Ishida H., Ishibashi T., AS-TH-048, AS-WE-053 Isermann B., PP-MO-050 Iserbyt B.F., Iscoe S., Isbister G., Isbister G.K., Isarria S., Isaev V. A., Ironside J., Ironside J.W., Irigoyen M.B., PP-WE-866 Iqbal O., Ippolito L., PP-WE-387, PP-WE-482, PP-WE-143, PP-WE-261, PP-TH-138, PP-TH-166, PP-MO-857, PP-TH-137, PP-MO-143, PP-MO-154, PP-MO-136, PP-MO-140, OC-WE-088, PP-MO-072, A., PP-MO-285 PP-TH-061, AS-TH-005, PP-WE-025 PP-MO-758 PP-WE-328 OC-TH-019, PP-TH-393 PP-WE-549 PP-TH-060 PP-TH-051 PP-TH-004 PP-MO-227 PP-WE-598 PP-WE-118 PP-WE-422 OC-MO-033 OC-TH-088 PP-WE-131 OC-WE-143, OC-TH-051, PP-WE-875 PP-MO-049, AS-MO-059, PP-MO-249 OC-MO-032 PP-WE-618 PP-WE-860 OC-MO-134, OC-TU-068, PP-TH-381, PP-WE-651, PP-MO-271, PP-MO-329, PP-MO-269, PP-MO-270, PP-TH-165, PP-WE-191, J. HansenJ., PP-WE-048 Izzi B., PP-MO-362 Izaguirre R. Iyu D., Iwata H., Iwasaka T., PP-WE-883, PP-WE-884 Iwaniec T., Iwaki T Iwai T., Iwahashi H., Iwade M., Iwade K., PP-WE-487 Iversen P. O., PP-WE-487 Iversen N., Ivaskevicius V., Ivandic B.T OC-TH-112, AS-TH-046 Ivanciu L., Itzhar N., Ittah M., Itoh H., Ito Y., Ito T., PP-WE-411 Ito N., Ito M., Ito H., Ithychanda S., Itani M., Italiano J., PP-WE-077 Italiano J.E., Italiano -JrJ., PP-WE-553 Israels S., Israels S.J., Israel-Biet D., Isonishi A., PP-MO-884 PP-TH-081, PP-TH-229 PP-MO-717, PP-TH-526, PP-TH-041, PP-TH-042 PP-TH-526 ., PP-MO-101 PP-MO-059, PP-WE-005 PP-WE-349 PP-WE-281 PP-WE-787 OC-TU-050 OC-WE-073 PP-TH-623 PP-TH-416 PP-TH-416 AS-WE-003, AS-TH-013, SA-MO-006 PP-MO-206, PP-TH-164, PP-WE-781 ., OC-WE-008 A., PP-WE-411 PP-TH-032 PP-TH-421 PL-TU-002, PP-MO-565 PP-WE-486, OC-TU-090 OC-MO-047 PP-MO-345, AS-WE-026 PP-TH-671 PP-WE-695 Jackson S.C., PP-WE-813 Jackson C.L., Jackson C.J., Jablonska E., Jaax M.E., PP-WE-369 Jakovljevic B., Jakobsson L., Jakiela B., Jaïs X., AS-MO-031 Jain S., Jain M.K., Jaimovich R., Jahangiri M., Jahan R., Jager D., Jagannathan I., PP-TH-156 OC-TH-105, OC-WE-052, Jagadeeswaran P Jaenisch R., Jadhav M. A., Jadaon M.M., PP-WE-614 Jacquemin M., PP-WE-153, PP-WE-610 Jacquemin M.G., Jacquemin L., Jacobson L.J., Jacobson J.O., PP-TH-371 Jacobson B.F Jacobsen E.M., Jacobsen C., Jacobsen B., PP-WE-332 F.,Jacobsen A. Jacobs G., Jacobi P. M., Jackson S., PP-WE-391 Jackson S.P OC-WE-122, OC-WE-124, OC-MO-1 PP-MO-376 OC-WE-020, 10, OC-WE-044, OC-TH-109 PP-TH-232 PP-MO-784 OC-TU-042 OC-MO-128 OC-TH-023 PL-WE-002 ., PL-TH-002 AS-WE-038 PP-WE-852 PP-MO-122 PP-WE-225 AS-TH-037 PP-WE-156 ., OC-WE-086 AS-WE-032, PP-WE-724 AS-MO-061 AS-TH-017 OC-MO-008 OC-TU-054, PP-WE-546, OC-TH-057, PP-TH-296, PP-MO-288, AS-WE-045 PP-WE-255 PP-TH-370, PP-TH-424 PP-MO-288 ., PP-MO-605, 523

Authors Index AUTHORS INDEX

Jakovljevic G., PP-WE-442 Javela K., PP-MO-742, Jeske W., PP-MO-140, Jakubowski J. A., OC-MO-012, PP-WE-279 PP-MO-396, PP-WE-143, PP-MO-096, PP-MO-733, Javier R., PC-050 PP-WE-385, PP-WE-481 PP-MO-787, PP-TH-030 Jawien A., PP-WE-433 Jeskins G., PP-TH-330 Jalagadugula G. S., Jayachandran M., PP-WE-780 Jespersen J., OC-MO-090, AS-TH-044, PP-MO-078 PP-MO-164, PP-WE-515 Jayakodi D., PP-WE-171 Jallad S. G., PP-WE-504 Jessen G., PP-TH-094 Jayo A., PP-WE-764 Jallu V., AS-MO-053, Jessen S., AS-MO-050 PP-MO-079 Jazebi M., PP-TH-124, PP-TH-318, PP-TH-636 Jevtic D. M., PP-WE-867 Jambor C., PP-WE-038 Jeandriens A., PP-MO-617 Ji Q., PP-WE-818 Jámbor L., PP-MO-359 Jeanpierre E., PP-MO-814, Ji S., PP-TH-399, PP-TH-400, James A. H., PP-TH-206 PP-MO-815, PP-WE-762 PP-WE-099 James E. A., PP-TH-616 Jelicic Z. D., PP-WE-369 Ji X., OC-MO-136 James P. D., AS-MO-017, Jenei A., PP-WE-049 Ji Y., PP-MO-358 AS-MO-019, AS-TH-053, Jia F., OC-WE-124 OC-WE-133, PP-MO-639, Jeng J. H., PP-MO-869, PP-TH-638 PP-TH-058 Jia J., AS-TU-041 James P., PP-TH-628, Jenkins P. V., PP-TH-549 Jia S., PP-MO-880 PP-TH-639 Jenkins V., PP-MO-593 Jiang H., AS-TU-028, James R., PP-MO-852, Jenkinson H. F., OC-WE-047, OC-WE-059, PP-WE-030, PP-TH-364 PP-MO-051 OC-WE-057 Jamrozek-Jedlinska M. M., Jennersjö C., PP-WE-334 Jiang M., PP-MO-859, PP-WE-307 PP-MO-883, PP-TH-399 Jennings I., PP-MO-116, Janata K., PP-TH-676 PP-MO-320, PP-MO-534, Jiang N., OC-WE-109 Janco R., PP-MO-541 PP-WE-716, PP-MO-115 Jilma B., AS-WE-014, OC-TH-068, OC-WE-011, Jandrot Perrus M., PP-WE-018 Jennings L. K., PP-MO-054, PP-TH-097, PP-WE-103 PP-MO-622, PP-MO-718, Jandrot-Perrus M., AS-TU-024, PP-TH-676, PP-WE-675 Jenny N. S., AS-WE-060, OC-WE-070, PP-MO-077, Jilma P., AS-WE-014 PP-MO-786, PP-TH-119 OC-TH-117, OC-WE-103 Jilwan F., PP-MO-376 Janes J., PP-MO-238 Jensen A. L., PP-WE-401 Jiménez D., PP-MO-299 Jang M., PP-MO-301 Jensen C. V., OC-MO-040 Jensen E., PP-WE-172 Jimenez V., PP-MO-566, Jang S., PP-MO-727, PP-MO-579, PP-WE-560, PP-TH-509, PP-WE-343 Jensen M. B., PP-TH-577 PP-WE-765 Jankovicova D., PP-WE-656 Jensen O. E., PC-042 Jiménez V., PP-TH-596 Jansen M., PP-MO-163, Jensen T. J., OC-TH-057 Jiménez Yuste V., PP-MO-601 PP-TH-589 Jeon W. K., PP-TH-405 Jimenez-Yuste V., PC-048, Janssen H. L. A., PP-TH-314 Jeppsson A., PP-MO-652, PP-MO-590, PP-TH-059, Janssen H. L., PP-MO-224 PP-WE-206 PP-TH-603, PP-TH-604 Januszek R., PP-MO-355, Jepsen T., PP-WE-585 Jin J., OC-TH-040, PP-MO-106, PP-WE-883, PP-WE-884 PP-TH-022, PP-WE-012 Jerczynska H., PP-WE-879 Jarchau T., AS-MO-038 Jin M., OC-WE-129, Jerling J. C., PP-WE-228 Jarchum G., PP-MO-547, OC-WE-130 PP-WE-511 Jern C., OC-WE-115, Jin S., AS-MO-015, PP-TH-080 PP-MO-343 Jardín I., PP-TH-003 Jin Y., OC-TH-095, OC-WE-045 Jeschke U., PP-WE-784 Jarvis G. E., PP-MO-041, Jinca C., PP-MO-532, PP-MO-048 Jeske W. P., PP-MO-399, PP-WE-552 PP-TH-201, PP-TH-391, Jasuja R., AS-TU-022 PP-TH-404, PP-WE-262 Jindal K. K., OC-TH-009 Jauhiainen M., OC-TU-096 Jing D., PP-MO-531 Javela K. M., AS-TH-010 Jing H., OC-TH-109

524 PP-MO-450, PP-MO-451, John S., John E., Johansson P. I., Joglekar M., PP-MO-174, PP-WE-188 Jochmans K., Joch C., Jobe S.M., Jlizi Jirouskova M., Jirgård L., INDEX AUTHORS Jonhsson H., Jong G., Jones S., Jones R., PP-TH-242, PP-WE-240 Jones N., Jones M.L., PP-WE-354 Jones L., Jones K.L., OC-TH-100, PP-WE-040 Jones C.I., Joimel U., PP-WE-1 Johnston M., PP-WE-437, PP-WE-438 Johnston L., Johnson S.C., Johnson G.J., OC-WE-081, OC-WE-098 Johnson D.J.D., PP-WE-466 Johnson B.H., J., Johnson A. OC-WE-140 Johnsen S., PP-WE-315 Johnsen S.P., Johnsen J., Johns S., PP-MO-647 Johne J., PP-WE-828 OC-TH-037, OC-TH-093, PP-TH-522, PP-TH-523, PP-MO-793, PP-MO-811, PP-MO-791, PP-MO-792, A., PP-MO-649 15, PP-WE-520 OC-WE-139, PP-WE-662 PP-WE-697 OC-TH-119, PC-037 PP-MO-603, PP-TH-350, PP-MO-026 PP-TH-632 PP-MO-199 PP-MO-561, PP-TH-174 PP-WE-758 OC-TU-048 AS-MO-037, AS-TU-058 OC-WE-137, OC-TH-037 OC-MO-045 PP-WE-051 PP-MO-449, PP-MO-200, PP-TH-141 PP-MO-173, PP-TH-455, PP-WE-045 PP-MO-314 PP-WE-082 PP-TH-477 OC-WE-018, OC-TH-067 AS-TH-049, Jung H., Jun P., OC-MO-017, PP-WE-489 Julian J., Julian J. A., Julian D., Jukema W., Jukema J.W., PP-WE-775 Juhan-V Juhan V Jugder B., TH-030 Judge H.M., PP-WE-762, PP-WE-858 Jude B., Judd P., PP-TH-354 Jubelirer S.J., Jozwiak M., Jovic M., Jover S., PP-WE-565 Jovanoski I.J., PP-WE-565 Jovanoska V. V., PP-MO-170 Joutsi-Korhonen L., Jourde-Chiche N., Joshua D., Joshi S.S., PP-WE-776 Joseph J.E., Josefsson E.C., PP-WE-575, PP-WE-576 Jorquera J.I., OC-WE-104 Jörneskog G., PP-WE-383 Jørgensen M., Jørgensen L., Jordanova K., Joore M., PP-MO-343 Jood K., Jonj B.B., OC-TH-045, PP-TH-309, 815, PP-TH-189,PP-TH-583, PP-MO-691 ague I., ague I., PP-TH-629 PP-MO-814, PP-MO- OC-WE-115, PP-WE-800 PP-WE-665 PP-WE-254 OC-MO-016, OC-TH-017 OC-MO-017 PP-TH-029 PP-MO-147 PP-WE-171 PP-TH-108 OC-TH-110 PP-TH-128 PP-MO-515 OC-MO-012, PP- PP-MO-747, PP-TH-443 PP-TH-591, AS-MO-063 PP-WE-346 OC-TH-079, AS-MO-008, PP-MO-661, OC-WE-099 OC-MO-021, AS-WE-032 PC-029, PC-029, PP-WE-850 OC-TU-028, OC-WE-121, PP-TH-542, PP-WE-705 Junqueira P. L., PP-MO-698, PP-MO-699 Junqueira D.R.G., Jungel A., PP-TH-036 Jung S.M., Kahraman R., Kahr W. H., PP-TH-459, PP-TH-463 Kahr W OC-TU-01 Kahn S.R., Kahn M.L., Kagoma P., Kaech A., PP-WE-278 Kadohira Y., Kadir R. Kadioglu PP-WE-739 Kaden T., Kadar J., PP-MO-128 Kadar J.G., Kaczor M., Kaci Z., PP-MO-512 Kabrhel C., Kaatz S., Kaatz S.S., Kaandorp S.P., K. KlausenN., Juutistenaho S., PP-MO-815 Juthier F., Just S., Just B., PP-WE-734 Jurk K., Jurisic D., PP-WE-801 Jurek M., Jurak Begonja Jünschke A., PP-WE-461, PP-WE-462, PP-TH-315, PP-TH-323, . H. A., AS-MO-008 PP-TH-204 PP-MO-128 PP-MO-029, A., PP-TH-357 1, A., PP-WE-633 PP-TH-027, PP-MO-700, OC-MO-129 PP-MO-814, PP-WE-787 PP-WE-369 PP-MO-355 OC-TU-004, AS-TU-006 PP-TH-035, AS-TU-038 OC-TH-060 OC-TH-084, PP-TH-315 AS-MO-026 OC-TU-009 OC-WE-077, PP-TH-057, OC-WE-047 PP-TH-120 PP-TH-270 AS-WE-028, PP-MO-565 A., PP-TH-373 PP-MO-755, PP-TH-068 PP-WE-077 525

Authors Index AUTHORS INDEX

Kaida M., PP-WE-025 Kamphuisen P. W., Kaprinis I., PP-MO-777, Kaider A., AS-MO-003, AS-MO-030, OC-MO-042, PP-MO-778, PP-MO-779 PP-MO-422 OC-MO-091, OC-TU-008, Kapur D., PP-TH-477 OC-WE-014, OC-WE-035, Kaiser W. J., OC-TH-093, PP-MO-298, PP-MO-597, Kapustin S. I., PP-TH-313, PP-TH-014, PP-TH-031, PP-MO-720, PP-TH-348, PP-TH-321, PP-TH-346, PP-WE-040 PP-TH-356, PP-TH-517, PP-WE-361 Kajiura T., PP-WE-781 PP-TH-518, PP-WE-548 Kara E., PP-TH-511 Kakkar A. K., OC-WE-004, Kamphuisen P., OC-TH-014, Kara M., PP-WE-709 PP-MO-763 OC-WE-024, PP-TH-415, Karabay, PP-TH-511 PP-TH-430, PP-WE-404, Kamps M. P., AS-TU-020 PP-WE-421 Karabocuoglu M., PP-MO-440 Kanagasabapathy P., Kakkar A., OC-MO-054 PP-TH-683 Karacelik M., PP-TH-511 Kakkar V. V., AS-WE-059, Kanai S., PP-MO-864 Karafoulidou A., PP-MO-585, LB-MO-002, OC-TH-118, PP-MO-715, PP-TH-609, OC-WE-139, PP-MO-791, Kanakura Y., PP-MO-080 PP-WE-693, PP-MO-679, PP-MO-792, PP-MO-793, Kanayama N., OC-TH-111 PP-TH-467 PP-MO-811, PP-MO-812, Kane J. P., AS-WE-010 Karagun B. S., PP-MO-644 PP-MO-817, PP-WE-828, PP-WE-832, PP-WE-833, Kane W. H., PP-TH-261 Karakas Z., PP-MO-222 PP-WE-834 Kaneko C., PP-MO-704 Karaman I., PP-MO-683 Kakkar V., OC-TU-051, Kanellopoulou G., PP-MO-679, Karami-Djurabi R., PP-MO-506 PP-MO-796, PP-WE-836 PP-MO-715 Karapetian H., PP-MO-436 Kaku S., PP-TH-184 Kang C., PP-WE-810 Karatas A., PP-MO-222 Kala P., PP-WE-804 Kang H., PP-WE-759 Karatela R. A., PP-WE-825, Kalantar G., PP-WE-855 Kang J., AS-WE-060 PP-WE-826 Kalashnyk O. M., PP-MO-872 Kang S. Y., PP-WE-595 Karavokiros I., PP-MO-715 Kalathara R., PP-TH-632 Kang S., PP-WE-783 Karbovskyy V. L., PP-TH-160 Kalia N., AS-WE-033 Kannan M., PP-MO-638, Kardkasam P., PP-MO-354 Kalish Y., AS-TU-058 PP-WE-037 Karimi M., PC-044, Kalka C., PP-TH-417, Kannicht C., PP-MO-574, PP-MO-655, PP-TH-534, PP-TH-492 PP-WE-624 PP-TH-535, PP-WE-459, PP-WE-518 Kallel H., PP-TH-297, PP-TH- Kanse S. M., AS-TH-058, 298, PP-WE-455 OC-TH-070, OC-TH-110 Karimi N., PP-WE-545 Kallel L., PP-TH-298 Kanse S., OC-WE-128 Karimi S., PP-WE-518 Kallner A., PP-WE-114 Kansiz E., PP-MO-858 Karimipoor M., PP-WE-545 Kalnins J., PP-TH-559 Kanz R., OC-TU-013 Karlman M., PP-WE-646 Kalpodimou C., PP-MO-707 Kao C. Y., PP-MO-158 Karlsson J., PP-MO-565 Kalus U., PP-MO-240 Kapelak B., PP-MO-798 Karlsson M., PP-MO-652, PP-WE-206 Kam A. W., PP-TH-225 Kapiotis S., PP-WE-200, PP-WE-201 Karovitch A., PP-MO-460 Kameda S., PP-TH-320 Kaplan C., AS-MO-053, Karpf D. M., PP-MO-569, Kamide K., PP-WE-872 PP-MO-079 PP-MO-570, PP-WE-154 Kaminska M., PP-MO-071 Kappas N. C., AS-WE-051 Karpova I. S., PP-MO-873, PP-MO-874 Kamisato-Matsumoto C., Kappel A., PP-MO-107 PP-TH-195, PP-TH-406 Karst A., PP-MO-162 Kappelmayer J., PP-MO-009, Kamocka M., PP-WE-394 PP-MO-359, PP-WE-774 Kartsios H., PP-MO-305 Kamp S., OC-TU-033 Kappert G., PP-MO-377, Karumanchi A., AS-WE-021 Kampf L., PP-WE-570 PP-TH-647, PP-WE-370, Kase M. T., PP-MO-719 PP-WE-669 Kämpfert C., PP-TH-656 Kashanian M., PP-WE-074

526 Kasthuri R., Kasthuri R.S., Kastelein J.P., Kastelan D., Kassak P., Kassab ChahmiD., PP-TH-054 Kashiwakura Y., PP-TH-081 Kashiwagi H., AS-WE-053 Kashif M., INDEX AUTHORS PP-MO-078 Kaur G., Kaun C., Kauling M., Kauke T., Kaufmann V Kaufmann R., OC-WE-062 Kaufman R.J., Katzenell S., Katz B., Katsutani S., Katsuhiko H., Katsman PP-MO-778 Katsiki N., PP-TH-609, PP-WE-693 Katsarou O., Katsaros K., Katsamouris PP-TH-366 Katona É., Kato S., PP-WE-271 Kato M., Katerchi A., Katayama Y., Katayama N., PP-WE-269, PP-WE-271 Kataoka H., Katabami K., Kaszuba M., Kastrissios H., Kastrikina I., PP-MO-228, PP-TH-216, PP-TH-070 OC-WE-008 AS-TH-044, PP-WE-269, PP-MO-829 Y PP-WE-039 AS-MO-059, ., PP-MO-777, OC-MO-125 PP-MO-205, PP-MO-476 ., PP-MO-842, PP-WE-768 OC-MO-102 OC-TU-017 PP-MO-519 PP-WE-884 PP-MO-829 OC-TU-058 PP-MO-715, PP-WE-062 A., PP-MO-050 PP-WE-687 PP-TH-358 PP-TH-526 PP-WE-777 PP-WE-398 PP-MO-705 PP-MO-080, OC-TH-020 AS-WE-043, OC-WE-003 OC-TH-051, PP-MO-778 PP-MO-022 PP-TH-497 Keeling D.M., Keegan M.B., Kebir A., PP-WE-462, SA-TH-003 Kearon C., PP-TH-362 Kearney-Schwartz Kearney M.T., Kearney E., Keane G., PP-MO-051 Keane C., Kazui M., Kazlauskas A., Kazi M., Kazazian H.H., Kazantzidou E., Kazanjian S.N., Kay S., PP-WE-420 Kawasugi K., PP-TH-042 Kawasaki T., Kawano Y., Kawanami D., PP-WE-400 PP-TH-168, PP-WE-398, Kawamura M., Kawajiri H., Kawai Y., Kawai T., Kawahara K., PP-MO-588, PP-TH-619 Kaveri S., PP-WE-614 Kaveri S.V Kavas Kavanagh M., Kavanagh G.F PP-WE-577 Kavakli K., Kautzner J., Kauskot A., Kaushansky K., PP-WE-240 Kaur J., PP-MO-310, PP-MO-515, ˇ E., PP-TH-070 PP-TH-242, PP-WE-522 AS-MO-060 PP-WE-349 PP-WE-196 PP-WE-348 PP-WE-308 OC-WE-047, OC-WE-066, PP-WE-685 ., PP-MO-282, PP-MO-606, PP-WE-872 PP-TH-194 PP-WE-474 OC-WE-043 PP-WE-345 OC-MO-064, PP-TH-041, PP-MO-669, PP-MO-884 PP-WE-615 OC-TU-042 OC-MO-032 PP-WE-430 ., OC-TH-055 PP-MO-201, AS-TU-038 AS-TU-013 PP-MO-302 SA-WE-017 PP-TH-376 PP-MO-735 A., PP-TH-574, PP-WE-734 Kehrel B.E., PP-TH-645 Keeney S., PP-WE-716 Keeling D., PP-WE-059 Kenny D., Kenny D.J., Kennedy R., PP-WE-274 Kennedy M., Kennedy D.R., PP-WE-036 Kenet G., Kempton C.L., PP-WE-094, PP-WE-402 PP-WE-089, PP-WE-093, PP-TH-044, PP-TH-350, PP-MO-831, PP-MO-832, Kempfer Kemp B., OC-WE-077 Kemkes-Matthes B., PP-MO-513 Kemkes -MatthesB., Kelly N., Kelly L. A., Kelly I., Kelley J., PP-MO-753 Keller P PP-MO-241 Keller M.K., PP-WE-093 Keller L., Keller G., Keleidari B., PP-TH-068 Kekomäki R., Kekilli M., Keil B., Kehrel B., PP-MO-434, PP-MO-685, OC-WE-106, OC-WE-117, PP-TH-541, PP-WE-638, PP-TH-052, PP-TH-053, OC-TH-095, PP-MO-735, PP-MO-030, PP-MO-031, PP-TH-350, PP-WE-089, PP-MO-831, PP-MO-832, ., PP-TH-611 PP-WE-615 PP-WE-474 A. C., PP-MO-736, PP-MO-610, AS-WE-009 OC-MO-101 AS-TU-052, PP-WE-082 AS-TU-039, PC-003, PP-MO-394 AS-MO-050 OC-TU-078, PP-WE-373 PP-TH-540, AS-MO-048 PP-MO-240, PP-MO-396 PP-MO-517 PP-WE-082, PP-MO-029, AS-TH-010, PP-MO-610, PP-MO-587 OC-MO-057 527

Authors Index AUTHORS INDEX

Kent N., PP-TH-052, Khare R. K., PP-TH-283, Kim N., PP-MO-353, PP-WE-059 PP-WE-467 PP-TH-294, PP-WE-877 Kentner T. A., PP-WE-177 Khaterchi A., PP-TH-485, Kim O., PP-MO-353 Kentouche K., PP-TH-086, PP-TH-486, PP-WE-490 Kim P. Y., OC-MO-061, PP-TH-087, PP-WE-651 Khawaji M. M., PP-TH-580 OC-MO-095, OC-TU-067 Kerachian M. A., PP-MO-820 Khazanov N. A., AS-MO-027 Kim S. N., PP-WE-595 Kerbiriou-Nabias D., Kheirabadi B. S., PP-WE-399 Kim S., OC-MO-043, PP-WE-008 Khizroeva J., PP-WE-265 OC-TH-094, OC-TH-098, Kercret G., PP-TH-508 OC-WE-052, OC-WE-122, Khoo L. T., PP-WE-547 PP-MO-106, PP-TH-011, Kerdelo S., PP-TH-113 Khorana A. A., OC-TU-018, PP-TH-156, PP-TH-504 Kerdélo S., PP-MO-112, PP-MO-492 Kim T., PP-WE-844 PP-TH-183 Khoury A., PP-WE-281 Kim Y., AS-TU-034, Keresztes Z., PP-MO-851 Kieffer N., PP-WE-013 PP-MO-301, PP-TH-519, Kern A., OC-WE-051 PP-WE-419, PP-WE-496, Kiely D. G., PP-TH-679 PP-WE-844 Kerrigan S. W., OC-WE-047, Kienast A., PP-WE-453 PP-MO-051 Kimura Y., PP-WE-793 Kierzek G., PP-MO-514, Kinasewitz G. T., OC-TH-112 Kerrigan S., PP-TH-056 PP-TH-211 Kindler S., PP-TH-254 Kerschen E. J., PP-MO-880, Kijac A. Z., OC-TU-091 PP-MO-881 King S. M., PP-WE-071, Kijlstra A., PP-TH-246 Kershaw G. W., PP-WE-171, PP-WE-218 PP-WE-547 Kiklevich V., PP-MO-754 Kini R. M., OC-TH-105 Kerspern H., PP-TH-291 Kikukawa Y., PP-WE-516 Kini R., PP-MO-172 Kervran D., AS-MO-053 Kile B. T., AS-WE-032, Kink-Eiband M., PP-MO-347, PP-WE-258 Kessel C., PP-MO-592 PP-WE-181, PP-WE-390 Kile B., SA-TH-014 Kessler C. M., PP-MO-598, Kinoshita A., PP-MO-439 PP-MO-600, PP-WE-601 Kilicaslan I., PC-039 Kinoshita T., PP-TH-015 Kessler P., PP-TH-422 Kilicoglu O., PP-WE-568 Kirby D., OC-WE-114 Keßler W., AS-TH-007 Kilic-Okman T., PP-TH-221, Kirby R., PP-MO-370 PP-WE-876 Kesteven P., PP-WE-298, Kirchgesner T., PP-MO-416 PP-WE-372 Kilinc E., PP-TH-122 Kirchheiner J., PP-WE-183 Key N. S., OC-TU-017, Kilinc Y., PP-MO-644, PP-MO-768, PP-TH-262, PP-WE-607 Kirchhofer D., AS-MO-044 PP-TH-655, PP-WE-299, Kim B., PP-WE-069, Kirchmaier C. M., PP-MO-179, PP-WE-785 PP-WE-069 PP-MO-746, PP-TH-662, PP-WE-763 Key N., OC-TH-020 Kim H. C., PP-TH-190 Khair K., PP-TH-605 Kirienko A. I., PP-TH-513, Kim H. J., PP-TH-190 PP-WE-526 Khalafallah A. A., PP-MO-233 Kim H., PP-MO-213, Kirwan G., PP-WE-813 Khaled E. A. A., PP-MO-037, PP-TH-149, PP-TH-190, PP-TH-506, PP-WE-067 PP-TH-504, PP-WE-069, Kiseleva E. V., PP-MO-882 PP-WE-112, PP-WE-496, Kishi K., PP-MO-119 Khalfi K., PP-WE-505 PP-WE-759 Kishta S. A., PP-MO-037 Khalil T., PP-TH-666 Kim I., PP-WE-027, PP-WE-069 Khan A., AS-TH-050 Kiskinis D., PP-MO-777, Kim J., OC-WE-059, PP-MO-778, PP-MO-779 Khan M. I., PP-WE-817 PP-TH-149, PP-WE-027, Kiss L. N., PP-MO-378 Khan N., PP-WE-382 PP-WE-027, PP-WE-112, PP-WE-496, PP-WE-783 Kiss R., PP-MO-772 Khanbhai M., OC-TH-055 Kim K., PP-TH-504, Kissova J., PP-TH-612, Khandoga A. L., PP-MO-008 PP-WE-112, PP-WE-463 PP-TH-613 Khanna S., PP-TH-538 Kim M., PP-TH-504 Kitabata H., PP-MO-429

528 PP-WE-593, PP-WE-594, PP-TH-587, PP-TH-588, PP-MO-746, PP-TH-578, PP-MO-357, PP-MO-591, Kitpoka P., Kitonyi G.W., Kitjakornpa S., PP-WE-144, PP-WE-716 Kitchen S., PP-WE-716 Kitchen D.P., PP-MO-127 Kitazawa T., Kitamura K., INDEX AUTHORS OC-WE-040 Kleinschnitz C., Kleinridders Kleinow M.E., Kleinjan A., Kleine BuddeI., OC-TU-083 Klein GebbinckJ.W Klein E., Kleber F., Klausen N.K., Klare M.O.G., PP-WE-620 Klamroth R., Klajnbard A., OC-WE-132, PP-WE-553 Klaassen R., PP-WE-589, PP-WE-591 Kjalke M., PP-WE-572 Kjaergaard K., Kjærgaard J., Kjær B., Kjær A., Kiyak A., Kitzmüller E., PP-MO-446 Kittikalayawong Y., PP-MO-534, PP-TH-664, PP-MO-199, PP-MO-320, PP-MO-1 PP-MO-116, PP-MO-320, PP-WE-581, PP-WE-582, PP-TH-594, PP-WE-401, PP-MO-570, PP-MO-580, PP-MO-565, PP-MO-569, 15, PP-MO-1 OC-MO-040 PP-MO-118 PP-MO-313 PP-MO-073 OC-MO-053 PP-MO-558, PP-MO-681 PP-MO-110, PP-MO-763 PP-MO-123, A., PP-MO-111 AS-WE-003, OC-WE-077, PP-WE-383 PP-MO-436 PP-MO-115, OC-MO-040 PP-MO-452 PP-WE-479 PP-MO-580 PP-MO-565, PC-024 PP-MO-681 OC-WE-076 AS-TH-040, PP-MO-571 . T. M., 16, Knoebl P. N., Knoche J., PP-MO-622 Knöbl P Knobl P., Knirsch W., Knipe L., PP-TH-599 Knight S., Knetsch M.L., Knapp S., PP-WE-372 Knaggs K., Klungel O.H., PP-MO-608, PP-WE-722 Klukowska PP-TH-332 Kluin-Nelemans J.C., AS-MO-002 Kluin-Nelemans H., PP-TH-516 OC-WE-098, PP-TH-515, Kluin-Nelemans H.C., Kluft C., Kløw N.E., Klose G., Klompas PP-WE-512, PP-WE-513 Klok F. A., PP-WE-491, PP-WE-492 Kloczko J., Klinzing S., PP-WE-611 Klintman J., PP-WE-434 Klingebiel T., PP-WE-414 Kline J. Kliem P., Klich K., PP-WE-361 Klenkova N. A., PP-TH-505 Klekowski N.T., PP-MO-507, PP-WE-341, OC-MO-037, PP-MO-506, PP-WE-284, PP-WE-323, PP-TH-505, PP-TH-510, PP-MO-470, PP-MO-512, ., A., OC-MO-090 PP-MO-592 PP-TH-254 A., OC-WE-01 PP-MO-609 OC-MO-067 PP-MO-141 PP-TH-148 PP-MO-272, AS-TU-010, PP-MO-066 OC-TU-007, AS-MO-007 A., PP-WE-298, PP-MO-868, PP-WE-684 OC-TU-061 OC-TH-050, PP-WE-238 PP-TH-077 PP-TH-162, OC-WE-035 PP-MO-163, PL-TU-003 PP-TH-346, OC-TU-007, 1, PP-TH-265, PP-WE-613 Knoll C., Knol H.M., PP-TH-671 Knoefler R., PP-WE-604 Knoebl P., Koide T., Koide H., Köhler H., Kohler H., Kohler H.P Koh PP-MO-172 Koh C. PP-TH-042 Koga Y., Kofiady I., Koestenberger M., Koenig W., Koenen R.R., Koene H.R., Koenderman J.S., Koeleman B.P. C., PP-WE-024 Koekman C. Koehler-Vajta K., PP-TH-273 Koder S., Kodali L., Koch G.G., PP-TH-268, PP-TH-313 Kobilyanskaya V. A., PP-WE-793 Kobayashi T., Kobayashi K., Kobayashi E., Kobayashi A., Kobalava Z., Ko B.S., PP-WE-401 Knudsen T., Knowlton W., OC-TU-085, PP-WE-219 Knottnerus I.L.H., OC-WE-058, PP-MO-666, OC-TU-015, PP-TH-077, Y., Y PP-TH-504 ., PP-TH-041, PP-MO-596, PP-TH-194 PP-TH-405 PP-TH-226 OC-MO-027, PP-TH-180 OC-TH-105, AS-WE-014, OC-MO-126 PP-TH-671 PP-WE-335 ., OC-TU-034 PP-MO-677 PP-WE-299 AS-TH-055, PP-TH-116, A., OC-WE-034 PP-TH-223 PP-TH-373 PP-TH-586 PP-TH-411, PP-WE-892 OC-TH-051 PP-WE-418 PP-MO-842 PP-MO-007, PP-WE-578 PP-TH-448 OC-WE-091 OC-MO-024 529

Authors Index AUTHORS INDEX

Koike T., PP-MO-842, Kondratieva L. V., PP-TH-277 Koster S., AS-WE-028 PP-WE-269, PP-WE-271 Kondratyeva L. V., PP-MO-268 Kostovska S., PC-014, Kojima H., PP-MO-080, Konetschny C., PP-MO-150 PP-WE-426 PP-TH-071 Kongtim P., PP-MO-406 Kotev S., PP-MO-771, Kojima T., PP-MO-138, PP-WE-797 Königs C., PP-MO-592 PP-WE-671 Kotha J., PP-MO-054 Konings J., PP-TH-131 Kok M. G. M., OC-MO-091 Kotsi P. A., PP-MO-679, Kokabee L., PP-WE-545 Konishi N., PP-MO-201, PP-TH-467 PP-TH-168, PP-WE-398, Kokame K., AS-MO-012, PP-WE-400 Kotsi P., PP-MO-715, OC-WE-008, PP-MO-093, PP-TH-609, PP-WE-693 Konkle B., AS-TH-033 PP-MO-393, PP-WE-090 Kottke-Marchant K., Kokoviadou K., PP-WE-484 Kono T., PP-MO-516, PP-WE-101 PP-TH-071, PP-TH-319 Kokubo Y., PP-MO-726, Kotula-Horowitz K., PP-TH-320 Konopatskaya O., OC-WE-123 PP-WE-883, PP-WE-884 Kolaitis N. I., PP-MO-657, Konrad S., AS-TU-005 Kotz R., PP-TH-690 PP-WE-681 Konstantinides S., OC-TH-014 Kotze R. C. M., PP-WE-228 Kolck U. W., PP-MO-253 Konstantinova E. E., PP-WE- Kouchakji B., PP-MO-514 863, PP-WE-864 Kolesnikova I. N., PP-MO-212 Koudstaal P. J., OC-MO-078 Koo J., PP-MO-211 Kolev K., OC-MO-075, Koumarianou A., PP-WE-693 PP-MO-851, PP-WE-229 Koo Y., PP-WE-027 Kouraba A., PP-TH-609, Koliakos G., PP-MO-257, Kooiman J., PP-MO-506, PP-WE-693 PP-TH-006 PP-WE-513 Kouramba A., PP-MO-679 Koliou P., PP-MO-657 Koolwijk P., PP-MO-847 Koutsas C., PP-WE-129 Kolset S. O., PP-WE-487 Kopferschmitt J., PP-MO-416 Ková D., PP-WE-524 Kolte D., PP-TH-133 Kopylov K. G., PP-MO-553, PP-WE-561 Kovac M., PP-TH-296, Komada Y., PP-WE-032 PP-WE-368, PP-WE-379 Komarek A., PP-TH-422 Korantzis I., PP-MO-305, PP-WE-484 Kovacs E., PP-TH-063, Komari N., PP-TH-315 PP-WE-075 Koren A., PP-TH-084 Komarov A. L., PP-WE-335 Kovács G., PP-MO-359 Koren G., OC-TH-084 Komatsu N., OC-TH-088 Kovacs M. J., PP-MO-403, Koretsune Y., PP-WE-196 Kombrinck K. W., AS-TU-045 PP-WE-462, OC-TU-011 Korfi K., PP-TH-244 Komine-Kobayashi M., Kovacs M., PP-WE-517 PP-TH-358 Korhonen T. K., OC-TH-064 Kowalska M. A., AS-TH-008, Komisarenko S. V., Korkmaz G., PP-MO-537, PP- AS-WE-027, OC-WE-151 PP-MO-212 MO-538 Koyama T., PP-MO-546, Komissarova S. M., Kornecki E., OC-TH-092 PP-MO-827, PP-WE-501 PP-WE-337 Körner I., PP-WE-733 Kozak M., PP-MO-350 Komitopoulou A., Kornø H. T., PC-042 Kozasa T., PP-WE-004 PP-TH-597, PP-WE-440 Korporaal S. J. A., OC-WE-046 Kozuma Y., PP-TH-071 Komorowicz E., PP-MO-851 Kósa K., PP-TH-366 Kragelund L., PP-TH-577 Komorowski P., PP-WE-879 Kosar A., PP-MO-394 Kraiss L. W., AS-WE-028 Komrska V., PP-TH-530 Kosch M., PP-WE-593 Krajaèiæ - Karas G., Komukai K., PP-MO-429 PP-TH-258 Koschinsky M. L., OC-WE-109, Komwilaisak P., PP-TH-459 PP-WE-241 Krajina A., PP-TH-438 Kondakova O. A., PP-MO-182 Koskinen S., AS-TH-010 Krajnc O., PP-MO-453 Kondkar A., OC-WE-045 Kost O., PC-005 Kramaric A., OC-TH-013 Kondo K., PP-MO-439 Kosˇtál M., PP-WE-524 Kramer M. H. H., PP-TH-517

530 PP-MO-662, PP-MO-746, Krauel K., Kraszula £., Krasnobrysha I., Krasnobrizha I., Krapiec F Kranz A., Kranenburg O., Kramp B.K., Kramor R., PP-TH-239 Kramkowski K., Kramer M.S., INDEX AUTHORS PP-TH-423 Krezel C., PP-WE-594 PP-TH-646, PP-WE-434, PP-MO-592, PP-TH-162, Kreuz W., Kretz C. A., PP-TH-446 Kretschmar O., PP-WE-648 Krenn T PP-TH-437 Krenek P., PP-MO-714 Kremer HovingaJ., PP-TH-079, PP-TH-080 Kremer HovingaJ. Kremastinos D., Krell S., PP-TH-651 Krekeler S., PP-MO-668, PP-WE-170 V.,Krechetova A. PP-WE-273 PP-MO-689, PP-WE-142, Krcova V OC-MO-104 Kravtsov D.V Kravos A., Kraut E.H., Krause S., PP-TH-662, PP-WE-763 Krause M., Kraus P. S., Kraus J., OC-TH-023 ., OC-TH-101 ., ., PP-TH-614, OC-WE-138 PP-MO-422 PP-MO-130, PP-MO-175, AS-TH-007, PP-TH-433, PC-022, PP-TH-086 PP-MO-350 PP-WE-190 PP-MO-179, PP-TH-219 OC-TH-106 OC-WE-009 OC-TH-074 PP-MO-584, PP-TH-099 PP-WE-892 ., OC-TH-084 OC-MO-103, OC-TU-061, PP-WE-216 PP-MO-234, PP-TH-395 PP-TH-338 PP-MO-146 PP-MO-218, A., PP-WE-152 Krudysz-Amblo J., PP-WE-046 PC-026, PP-TH-023, Kruchynsky N.G., Kruchinsky N.G., Krougliak V Kropacheva E.S., PP-WE-216 Kroon-Batenburg L.M.J., PP-TH-561, PP-WE-652 Kronthaler U., Kronmal R., PP-MO-706, PP-WE-714 Kroll H., PP-TH-446 Kroiss S., Kroiss R., AS-WE-030 Krohne G., OC-WE-082 Kroh H.K., PP-MO-575 Krogh T. N., PP-MO-507, PP-WE-512 Kroft L.J.M., Kriukov A., OC-MO-040 Kristoffersen U.S., PP-WE-315 PP-TH-140, PP-TH-455, Kristensen S.R., Kristensen S.D., PP-WE-572 Kristensen C., PP-WE-401 T.,Kristensen A. OC-TU-096 Krisinger M.J., OC-WE-080 Krishnaswamy S., Krishnan U., Krishnan S., PP-MO-675 Krishnamoorthi R., Krishna R., Kriegel I., OC-WE-120, PP-TH-130, AS-TH-047, PP-MO-705, PP-TH-497 OC-TU-061, PP-WE-380 AS-WE-029, AS-TH-050, ., AS-TH-050, PP-WE-574 PP-MO-199 PP-MO-118, OC-TH-117 PP-WE-894 OC-WE-126 PP-TH-200 AS-TU-010, AS-TH-040, PP-WE-109, OC-MO-096, PP-TH-116, PP-MO-134, PP-WE-788 PP-WE-820 PP-TH-431 AS-TH-008, PC-025, AS-TU-023, PP-TH-306, PP-TH-598, Kruip M.J., PP-WE-548 Kruip M.J.H. Krugluger W Kruger T Kruempel A., Krueger T., AS-TU-037, PP-TH-012 Kuijpers M.J.E., Kuhn T., Kuhn J.G., PP-WE-450 Kuhle S., PP-WE-624 Kuhelj R., PP-WE-304, PP-WE-305 OC-TU-005, OC-TU-006, Kufaas-Braekkan S., Kueter T Kudryk B., PP-MO-492 Kuderer N.M., PP-WE-329 Kucher N., PP-TH-280, PP-WE-433 Kuca P., Kubota N., PP-WE-400 Kubo K., PP-WE-220 Kubisz P Kubicek C., PP-MO-722 Ku D.N., Krystofiak E.S., Krych M., Krusche C., PP-WE-821, PP-WE-822 Krupinski J., Krümpel A., Krumpel A., OC-WE-1 Kruithof E.K.O., PP-MO-781 Kruit PP-TH-168, PP-WE-398, PP-MO-454, PP-TH-531, PP-TH-417, PP-TH-492, A., . J., ., ., PP-TH-279, OC-MO-133, PP-MO-563 10 PP-MO-201, AS-MO-040, OC-TU-066, PP-MO-694 AS-WE-045 PP-TH-589, PP-TH-305, PP-WE-687 PP-MO-211 PP-MO-318, OC-TU-053 PP-TH-567 OC-MO-078 PP-MO-357 PP-TH-086 PP-WE-453 OC-WE-094 ., PP-TH-097 AS-MO-065, PP-TH-647 A., PP-MO-141 OC-TU-018, PP-MO-039 PP-TH-518, AS-TU-029, OC-TU-037, 531

Authors Index AUTHORS INDEX

Kuint J., PP-MO-434, PP-MO- Kurth A., PP-TH-169, Labro S., OC-WE-085 685 PP-TH-170 Labrouche S., PP-MO-195, Kuiper J., OC-WE-046 Kurtoglu M., PP-WE-197 PP-MO-196, PP-TH-432, Kuivenhoven J. A., Kurz J. C., PP-WE-168, PP-WE-673 OC-WE-046 PP-WE-569 Labruyere C., PP-MO-783 Kulharia M., PP-WE-157 Kushimoto S., PP-MO-669 Lacatusu A., PP-MO-532, Kulkarni B., PP-TH-295 Kusnierova M., PP-TH-422 PP-WE-549, PP-WE-552 Kulkarni V., OC-WE-052, Kusumoto E., PP-WE-605 Lacerda S. H., PP-TH-016 PP-TH-156 Kutlar A., PP-MO-768, Lacerda-Alves J., PP-WE-098 Kulman J. D., PP-TH-092 PP-TH-655 Lacolley P., PP-TH-362 Kulsum S., PP-WE-014 Kutlu S. T., PP-TH-511 Lacreta F., PP-MO-407 Kumanogoh A., PP-WE-030 Kuttler B., OC-TU-026 Lacroix R., AS-WE-050, Kumanongoh A., AS-TU-028 Kuwahara G., PP-WE-411 PP-MO-486, PP-WE-785 Kumar K., PP-MO-817 Kuwatjanakul P., PP-MO-446 Lacroix-Desmazes S., OC-MO-064, OC-WE-066, Kumar S. K., PP-MO-487 Kuziej J., PP-MO-396, PP-MO-588, PP-TH-172, Kumar S., OC-TH-105, PP-WE-262 PP-TH-619, PP-WE-614 PP-WE-327 Kuzmanovic M., PP-TH-269 Lacut K., PP-MO-500, Kunapuli S. P., OC-TH-040, Kuznetsov Y. V., PP-MO-182 PP-TH-483, PP-WE-508, PP-MO-508, PP-TH-291, OC-TH-098, OC-WE-030, Kwak B. R., AS-TU-018 OC-WE-122, PP-MO-028, PP-WE-186 PP-TH-011, PP-TH-022, Kwon H., PP-WE-783 Laczkovics C., PP-TH-317, PP-WE-888, PP-WE-896 Kwon J. H., PP-MO-576 PP-WE-663 Kunapuli S. S. P. K., Kwon S., PP-WE-543 Ladislau R., PP-WE-552 PP-TH-040 Kwong L. M., PP-WE-478 Ladurner G., OC-WE-138 Kunapuli S., OC-TH-094, PP-MO-106, PP-WE-012 Kwong L., PP-MO-247, Laemmle B., PP-MO-711, PP-WE-473 PP-TH-692, PP-WE-211, Kung C., PP-MO-548, PP-WE-717 PP-TH-200 Kyndt X., OC-WE-017 Laferriere N., AS-WE-003, Kyriakidis D. A., PP-WE-131 Kunishima S., PP-MO-084, PP-WE-553 PP-TH-081 Kyrle P. A., AS-MO-004, Laffan M. A., OC-MO-065, PP-MO-422, PP-TH-690, Kunitada S., PP-MO-198 PP-MO-231, PP-MO-397 PP-WE-309 Kuo S. F., PP-TH-634 Laffan M., PP-WE-635 Kyselovic J., PP-TH-433, Kuo S., PP-MO-877, PP-TH-437 Lages G. F. G., PP-MO-349 PP-TH-123 L. Nørby P., PP-MO-565 Lages G. G., PP-MO-333 Kuperman A., PC-053 La Farina F., PP-MO-379, Lages P., OC-WE-077, Kupesiz A., PP-MO-606 PP-MO-380 PP-MO-662 Kurata A., PP-MO-864 La Greca A., PP-TH-316 Laggner A. N., PP-TH-676 Kurihara A., PP-MO-096, La Heij E. C., PP-TH-246 Laguna P., PP-MO-163, PP-WE-348 PP-MO-608 La Marca S., PP-WE-625 Kuritsch I., PP-MO-347, Lahav J., PP-MO-749, La Rosa L., OC-TH-075 PP-WE-181, PP-WE-390 PP-WE-010 Labalette M., PP-TH-508 Kurnik K., OC-WE-117, Lahood B. D., PP-MO-113 PP-MO-607, PP-TH-533, Labar B., PP-MO-630 PP-TH-587, PP-WE-453 Lairon D., OC-TU-087 Labarere J., PP-MO-315 Kurosaki H., OC-TH-088 Lak M., PP-MO-552 Labarthe B., PP-MO-060, PP- Lakhani P., PP-WE-012 Kurt M., PC-003, PP-MO-394 MO-061 Lakoski S. G., OC-WE-103 Kurt O. K., PP-MO-394 Labat V., PP-MO-664 Lally C., PP-TH-324, PP-TH- Kurth A. A., PP-MO-167, Labelle A., OC-TH-085, 325, PP-TH-326, PP-TH-327 PP-WE-204, PP-WE-205 OC-TH-086

532 PP-MO-591, PP-TH-578, PP-MO-091, PP-TH-089, AS-WE-012, PP-MO-089, PP-MO-450, PP-MO-451, PP-MO-328, PP-TH-085, PP-TH-474, PP-WE-745 Lami D., Lame M.W., Lambrechts D., PP-TH-593, PP-TH-623 Lambert T OC-WE-151 Lambert M.P., PP-TH-566, PP-WE-532 Lambert C., Lam S., Lalouschek W., INDEX AUTHORS Langford C., PP-WE-485 Langer F., Langer C., PP-TH-561 Lang W OC-WE-121, PP-WE-060 Lang S., Lang L. A., Lang J., PP-WE-437, PP-WE-438 Lane G., PP-TH-090 Lane D. Lands L.T., Landowska J., PP-MO-328, PP-WE-647 Landolfi R., PP-WE-403 Landini F., Landgraf H., Landford C., OC-TH-042, PP-TH-075 Landau M., PP-WE-647 Lancellotti S., Lancé M.D., Lance M.D., Lamy E., PP-TH-080 Lämmle B., PP-TH-482, PP-WE-001, ., PP-WE-004 A., AS-MO-003 AS-TU-030, PP-MO-217, PP-MO-449, AS-WE-050 OC-WE-120, ., PP-MO-014, PP-MO-285, PP-WE-528 AS-WE-009 AS-TU-019, OC-MO-105, OC-TU-073, PP-TH-079, OC-MO-094, PP-WE-103 PP-MO-220, PP-MO-389 PP-MO-357 PP-MO-670 PP-WE-017 OC-WE-126 OC-TU-029 AS-MO-013, AS-WE-027, PP-WE-474 AS-WE-010 PL-TU-006 PP-MO-525, PP-MO-654, PP-MO-416, PP-TH-010, OC-WE-150, PP-MO-033, OC-TH-035, OC-TU-049, OC-TH-033, OC-TH-034, Lassila R., Lass-Flörl C., PP-WE-454 Lassen M.R., PP-MO-077, PP-MO-748 Lasne D., OC-MO-128 Larusch G., Larson J., Larsen S., Larsen S.B., Larsen O.H., PP-WE-589 Larsen L.F., Larsen K.S., Larsen A., PP-WE-555 Laros-V Larina L.E., Laranjeira C., PP-TH-076, PP-TH-426 OC-MO-053, OC-WE-002, Laporte S., PP-WE-745 Lapini I., PP-TH-694 Lapecorella M., Lapalud P Lapadatescu M., Lap P., Lanzi P., PP-WE-891 Lanza F., Lanois I., Lannoy N., PP-WE-649 Lanning L., Lanir N., Lanier R., Langlet S., Langlet P., PP-WE-404, PP-WE-421, PP-TH-415, PP-TH-430, OC-WE-004, PP-MO-405, PP-TH-260 angorkom B., AS-MO-028 PP-MO-850 PP-MO-801, AS-TU-047, AS-MO-058 ., OC-TH-022, PP-WE-414 PP-WE-292 OC-TH-061 PP-MO-433 PP-MO-224 PP-MO-170 PP-WE-619 PP-WE-532 OC-MO-050, PP-TH-172 PP-WE-192, OC-TH-056, PP-TH-454 PP-MO-580, AS-TH-049 PP-WE-788 PP-WE-702 PP-MO-031 PP-WE-374 LB-MO-005, AS-TU-032, OC-TH-061 Latinne D., Latif L., Latib A., PP-TH-309 Lathrop M., Latella M., Latal B., PP-TH-575, PP-TH-646 Laws H., PP-WE-125 S., Lawrie A. Lawrence D., PP-TH-252 Lawrence D. PP-WE-797 Lawal L., PP-TH-172, PP-TH-578 AS-TH-054, PP-MO-527, Lavigne-Lissalde G., OC-WE-099 Lavigne LissaldeG., AS-MO-020, PP-TH-631 Laverty K., Lauzon M., Lauwereys M., Lauw M.N., Lauro R., Lauritzen B., Laurie J., Laurie A., Lauricella Laurent M., Laurén A., Launay J., Laughlin S., Laufs U., Laudisi A., Lau J.T. Y., Lau C., PP-WE-738 Lattanzio S., Latour C.L., PP-WE-096 Latorre PP-TH-026, PP-WE-794, PP-MO-015, PP-MO-016, PP-MO-325, PP-MO-759, PP-MO-667 A., PP-WE-045 OC-TU-061 PP-MO-775 PP-MO-595, PP-MO-809 PP-MO-771, PP-MO-016 PP-TH-615 PP-MO-631 A., PP-MO-481 OC-WE-055 PP-WE-408 PP-MO-027, PP-TH-494 AS-MO-018, PP-MO-220 PP-WE-1 PP-TH-174 PP-WE-893 OC-MO-021, PP-TH-373 PP-TH-463 AS-TU-049, A., OC-TU-056, PP-MO-564 SA-WE-002 PP-WE-210 AS-TH-024 PP-MO-594 PP-MO-244, 15 533

Authors Index AUTHORS INDEX

Lawson K. A., PP-TH-310, Leal S., OC-WE-045 Leebeek F. W. G., OC-MO-042, PP-TH-457 Lebel B., OC-TU-022 OC-MO-133, OC-TH-029, Layman R., OC-MO-031 PP-MO-633, PP-MO-781, Leblebisatan G., PP-MO-644, PP-TH-314, PP-WE-346, Lazarski E. A., PP-MO-502 PP-WE-607 PP-WE-355 Lazarus A., SA-TU-005 Lebra E., PP-MO-112, Leebeek F. W., PP-MO-224 PP-TH-235 Lazo-Langner A., PP-MO-403, Leenders L., PP-TH-666 PP-WE-517 Lebret M., PP-MO-074 Leenders P., AS-WE-058, Lazzari M. A., PP-MO-038, Lebuisson A., PP-TH-307 PP-TH-181 PP-MO-274, PP-MO-613, Lecam-Duchez V., PP-TH-174 PP-MO-831, PP-MO-832, Lees M., OC-WE-005, PP-TH-044, PP-TH-100, Lecchi A., AS-WE-020 PP-MO-468, PP-WE-472, PP-WE-473 PP-TH-350, PP-WE-089, Lecher B., OC-TH-059 PP-WE-093, PP-WE-094, Lefrançois A., PP-WE-642 Lechner D., PP-MO-666, PP-WE-145, PP-WE-146, Lefrandt J. D., PP-WE-554 PP-WE-354, PP-WE-402, PP-TH-690 PP-WE-498 Lechner K., PP-WE-621 Legal G., PP-TH-497 Lazzari M., PC-047, Lecompte T., OC-MO-029, Legall C., OC-TH-018 PP-MO-204, PP-MO-610 PP-MO-402, PP-TH-362, Legge L., PP-MO-435 Lazzeri C., PP-MO-013 PP-TH-394, PP-TH-693, PP-WE-133, PP-WE-700 Leggo J., OC-WE-134 Lazzerini G., PP-MO-828 Lecumberri R. R., PP-TH-308 Legnani C. C. L., PP-MO-372 Le Beller C., PP-TH-464 Lecumberri R., PP-MO-472, Legnani C., AS-TH-029, Le Bonniec B. F., PP-MO-237 PP-TH-675, PP-WE-141 OC-MO-028, OC-TH-003, OC-TH-006, PP-MO-290, Le Bonniec B., PP-MO-391, Lee A. C. W., PP-TH-441 PP-MO-291, PP-MO-351, PP-MO-837 Lee A. Y., OC-MO-016, PP-MO-503, PP-MO-504, Le Cam-Duchez V., PP-TH-144 OC-MO-017, PP-TH-489 PP-TH-282, PP-WE-351, Le Cessie S., AS-MO-005 PP-WE-359, PP-WE-509, Lee B., PP-WE-783 PP-WE-715 Le D. T., OC-MO-025 Lee C., PP-TH-266 Leguet P., PP-WE-425 Le Duc-Pennec A., Lee D., PP-WE-030, PP-MO-508, PP-WE-510 Lehmann-Kopydlowska A., PP-WE-069 PP-MO-216 Le Flem L., PP-WE-073 Lee E. K., AS-TU-028 Lehmeyer S., PP-MO-501 Le Gal G., OC-MO-038, Lee H., OC-WE-044, Lei Y., PP-MO-691 OC-MO-041, OC-TH-073, PP-TH-190, PP-WE-844 PP-MO-500, PP-MO-505, Leiber F., OC-TU-052 Lee J., PP-MO-353, PP-TH-292, PP-TH-483, Leibovitz E., PP-MO-338 PP-TH-489, PP-TH-524, PP-MO-731, PP-TH-294, PP-WE-508, PP-WE-510, PP-TH-504, PP-WE-069, Leibson C. L., AS-TH-003, OC-MO-087, OC-TH-012, PP-WE-242, PP-WE-496, PP-MO-284 PP-WE-877 OC-TU-011, PP-MO-499, Leikauf M., OC-MO-129 PP-TH-508, PP-TH-518, Lee K., PP-MO-712, PP-MO-508 PP-WE-496 Lein V. C., PP-WE-498 Le Grand B., AS-TH-023 Lee L. P., PP-WE-059 Leis L. A., PP-MO-314 Le Guillou J., PP-TH-307 Lee M., OC-MO-086, Leissinger C., PP-MO-625, PP-WE-597 Le Guludec D., PP-MO-786 PP-TH-504, PP-WE-543 Leitges M., OC-WE-123 Le J., PP-WE-887 Lee N., PP-TH-504, PP-WE-595 Leitner J. M., PP-TH-676 Le Moigne E., PP-TH-483 Lee S., PP-MO-213, PP-MO-353, PP-MO-493, Leitner J., PP-MO-718 Lê P., PP-MO-441, PP-TH-666 PP-TH-519, PP-WE-573 Leizorovicz A., PP-WE-410 Le Querrec A., OC-TH-082, Lee T. K., PP-TH-109 AS-WE-025 Leker R., PP-WE-847 Lee T. S., PP-MO-330 Le Sache F., PP-MO-391 Lely R., PP-TH-517 Lee T., PP-MO-301 Le Tourneau T., PP-MO-815, Lemesle G., PP-WE-858 PP-WE-858 Lee Y., PP-WE-759

534 Lenting P Lenti M., Lent M.P., Lenormand B., Lennon D., Lennemann K., PP-WE-594 Lenk H., PP-WE-442 Lenicek KrlezaJ., Leng B., INDEX AUTHORS Levenkova N., Levels J.H.M., Levashov M. Y., Letourneau S., Letley L., PP-WE-591 Lethagen S., Letellier T Lester W Lester W AS-TU-049 Lessiani G., Leslie B. A., PP-TH-448, PP-WE-439 Leschnik B., Lesavre N., PP-WE-510, PP-MO-508 Leroyer C., Lerolle N., Lereun C., K., Leppaniemi A. Leporace A., Leontyev D., PP-TH-094 Leone M., Leone B., OC-WE-150 Léon C., Leon Leo A., PP-WE-887 Lenting P., AS-MO-016 PP-WE-339, PP-WE-355, PP-MO-091, PP-TH-642, OC-TU-072, OC-WE-042, PP-WE-589, PP-WE-590, A., PP-WE-789 ., . PP-TH-569, PP-WE-665 OC-MO-008, PP-TH-191 PP-WE-823 . J., ., OC-TU-002 A., PP-MO-380 OC-WE-087, PP-TH-330 PP-MO-090 OC-WE-005 PP-TH-419 PP-WE-056, PL-TU-005 PP-WE-008 PP-MO-310, OC-TU-087 AS-TH-029, OC-WE-079 OC-WE-138, OC-MO-036, OC-MO-102 PP-MO-210 OC-MO-131 AS-WE-037, AS-MO-027 PP-MO-529 PP-TH-345 PP-MO-693 PP-MO-262 PP-TH-219 OC-TH-069 PP-WE-435, OC-TH-066, OC-WE-144, PP-WE-674 Li W., Li ThiaoT Li T Li S., PP-TH-045 Li R., Li R.C.H., PP-WE-890, PP-TH-146 Li N., Li L., Li J., Li H., Li G.L., Li D., PP-WE-060 Li C., Leytin V PP-WE-778, PP-WE-779 Leyte A., Leymarie V., Lewis H., Lewis D. Lewandrowski U., Levy-Shraga Y., Levy R. A., Levy P. J., Levy M., PP-WE-187 Levy J.H., Levy C., Levis J.E., Levine R.L., OC-MO-017 Levine M., Levine M.N., PP-TH-388, PP-WE-407 Levi M., PP-MO-190, PP-MO-191 Levi M.M., OC-WE-058 Levesque H., PP-WE-604, PP-WE-483, PP-TH-144, PP-TH-172, OC-TH-031, PP-MO-710, OC-MO-107, OC-WE-074, ., PP-WE-536, PP-WE-540 PP-WE-640 OC-WE-121, PP-TH-112 AS-TU-030, PP-TH-230, PP-TH-252 OC-TU-043, OC-TU-046, PP-MO-105, PP-WE-818, PP-TH-174, PP-WE-674 SA-WE-01 AS-MO-025, AS-TU-025, ., SA-TH-012, PP-WE-412 OC-WE-089 A., PP-TH-436, PP-WE-111 PP-MO-065 e V., PP-WE-854 OC-MO-016, PP-MO-776, PP-TH-441 PP-MO-159 OC-TH-062, PP-MO-483 AS-MO-032 OC-MO-002 AS-TH-043 OC-TH-104 PP-WE-489 PP-MO-609, PP-MO-125 1, AS-WE-031 PP-MO-685 AS-MO-038 PP-MO-286, PP-TH-329, Liang N., Liang H.P., Liakopulu M., Li Z., Li Y.G., PP-WE-005 Li X., PP-MO-819, OC-WE-122 Lijnen H.R., OC-MO-082, PP-WE-326 Lijfering W PP-TH-332, PP-WE-554 Lijfering W PP-WE-552 Lighezan D., Lievens D., PP-TH-605 Liesner R., PP-WE-489 Liebman H., Liebing U., Lieberman J., Liebe V., PP-MO-174, PP-WE-188 Liebaers I., Licht C., Lichman I., Licastro G., Licari V Librè L., Libraire J., Liberman C., Libby P., Liaw W., PP-WE-245 Liaw P. C., Liaw P. C. Y., Liao W., Liao M., Liao C., Liang Y., Liang X., PP-MO-219, PP-TH-039, PP-TH-400 PP-TH-147, ., PP-MO-877 PP-MO-733 PP-MO-665 OC-WE-068 AS-WE-007 OC-TU-028 PP-MO-665 AS-WE-057 PP-MO-238 PP-MO-642 PP-TH-453 PP-TH-261 OC-MO-022 ., . M., PP-MO-490, PP-MO-237 PP-TH-561 PP-TH-088, PP-MO-338 PP-MO-173, AS-MO-047 PC-015 AS-MO-002, OC-TU-017, OC-TH-065, PP-MO-532, AS-MO-022 OC-WE-090 PP-WE-129 PP-MO-248 OC-MO-056 OC-WE-100, 535

Authors Index AUTHORS INDEX

Lillicrap D., AS-MO-017, Lindahl T. L., PP-MO-021, PP-TH-391, PP-WE-166, AS-MO-018, AS-MO-020, PP-MO-133, PP-MO-430, PP-WE-262, PP-WE-385 AS-TH-053, AS-TU-012, PP-TH-018, PP-WE-014, Littenberg B., AS-MO-033 AS-TU-013, AS-TU-014, PP-WE-334 AS-WE-003, OC-TH-053, Litvinov R. I., AS-MO-039, Lindblad B., OC-TH-078, OC-WE-146, PP-TH-214 OC-TH-085, OC-TH-086, PP-WE-328 OC-TU-068, OC-TU-076, Litzow M. R., PP-MO-487 OC-WE-133, OC-WE-134, Linde T., PP-WE-190 Liu C. Y., PP-MO-330 OC-WE-135, PP-MO-639, Linden J., OC-TU-027 PP-TH-628, PP-TH-631, Liu C., PP-MO-010 PP-TH-639, PP-WE-553, Linder H., OC-TU-081 Liu F., OC-MO-070 SA-MO-009 Lindgren P., PP-MO-606 Liu J., AS-TH-013, PP-WE-857, Lillo-Le Louet A., PP-TH-464 Lindhoff-Last E., OC-WE-077, AS-TH-046 Lim Y., PP-WE-844 PP-MO-295, PP-MO-307, PP-MO-501, PP-MO-705, Liu K., AS-WE-060 Lima A. S., PP-TH-672, PP-MO-706, PP-MO-730, Liu M., OC-WE-068 PP-TH-673, PP-TH-674, PP-WE-376, PP-WE-714, PP-WE-689 PP-WE-792 Liu P., OC-WE-068 Lima E. M., PP-WE-092 Lindner J. R., OC-MO-123 Liu R. D., PP-TH-484 Lima L. G., PP-TH-499 Lindsey D. A., PP-WE-232 Liu S., PP-TH-392 Lima L. M., PP-MO-390, Lindstrom K., PP-WE-749, Liu T., OC-WE-057, PP-WE-226, PP-WE-812 PP-WE-750 OC-WE-059 Lima L., PP-WE-374 Lindvall K., PP-WE-570 Liu W., PP-WE-711 Limaye S., PP-WE-676 Ling M., PP-TH-092 Liu X. X. L., PP-MO-159 Li-Mcleod J. M., PP-TH-571, Linhardt R. J., PP-MO-165 Liu X., PP-WE-394 PP-WE-537, PP-WE-538 Link A., PP-MO-238 Liu Y., PP-TH-663 Limonov E., PP-WE-091 Linnemann B., PP-MO-295, Liu Z., PP-TH-067, PP-TH-073, Lin B. D., PP-TH-634 PP-MO-730, PP-WE-376, PP-WE-083 Lin C. N., PP-MO-158 PP-WE-792 Ljatifi A., PP-TH-557, PP-WE-769 Lin C., PP-MO-070, PP-WE-079 Lins P., OC-TH-079, OC-WE-104 Ljung R., OC-WE-119, Lin E., PP-TH-064 Liotier J., OC-MO-053 PP-WE-542, PP-WE-570 Lin H. Y., PP-TH-634 Lip G. Y. H., PP-WE-172, Llanto L., PP-TH-180 Lin H., PP-WE-207 PP-WE-345 Llobet D., PP-WE-175 Lin J. C., PP-MO-156 Lipets E. N., PP-WE-253 Llop E., OC-TU-082 Lin J. H., PP-WE-241 Lippi G., OC-MO-096, Lloyd J. V., PP-MO-148 Lin J. S., PP-TH-634 OC-MO-097, PP-MO-540, Lloyd J., PP-TH-626, PP-MO-541, PP-WE-140 Lin J., OC-WE-018, PP-WE-544, PP-WE-662 PP-MO-465, PP-MO-466, Lisboa T. A., PP-MO-387 Lloyd N. S., PP-WE-429 PP-TH-123, PP-WE-465, Lischetzki G. R., PP-MO-544 PP-WE-661 Llugaliu B., PP-MO-584, Lisman T., OC-TU-001, PP-TH-644, PP-TH-651 Lin K., PP-MO-840 OC-WE-016, PP-MO-126, Lo Coco L., AS-TH-030, Lin L., PP-WE-225 PP-MO-352, PP-WE-771 PP-TH-527 Lin S. R., PP-MO-158 Lison S., PP-WE-039 Lo H., PP-WE-845 Lin S. W., PP-MO-158 Lissalde-Lavigne G., Lo Manto G., PP-TH-282 Lin S., OC-WE-009, OC-TH-081 Lobo J., PP-MO-299 OC-WE-130, PP-MO-877, Lissens W., PP-MO-173, PP-TH-401, PP-TH-401 PP-MO-174, PP-WE-188 Lochowski R., PP-TH-537 Linares A., PP-MO-160 Litinas E., PP-MO-072, Lockwood C., PP-WE-382 Lincoln B., PP-WE-059 PP-MO-139, PP-MO-140, Lodder J., OC-TU-085, PP-MO-396, PP-MO-857, PP-WE-219 Lincz L. F., PP-WE-118 PP-TH-145, PP-TH-201,

536 PP-WE-308 Lokar L., OC-TH-048, OC-TU-032 Lokajczyk A., Lojik M., Lohmann C., Lofthus C.M., Löfgren E., Loffredo M., PP-WE-753 Loffredo L., Lodigiani C., INDEX AUTHORS López S., Lopez S., López M., Lopez M.F., PP-TH-092 Lopez J. A., PP-MO-601 López FernándezF., PP-MO-637 Lopez FernandezF Lopez E., Lopes R., Lopes L., Lopatina E., PP-TH-260 Loof A., Longstreth W OC-MO-116, PP-WE-229 Longstaff C., Longo S.S., Long C., PP-MO-486 Lombardo D., AS-WE-011 Lombardi R., PP-WE-598 Lombardi M., Lombardi G., Lomakin N.V., Lollar P., Loktionova S. A., Lokhorst H.M., AS-MO-01 PP-WE-056, PP-WE-887, PP-TH-468, PP-WE-023, OC-TH-052, PP-MO-070 PP-TH-438 AS-TU-016 PP-MO-453, 1, PP-TH-045, PP-MO-034 PP-TH-289 PP-WE-209 PP-MO-656 PP-WE-374 PP-TH-596 PP-MO-021 PP-WE-105, PP-MO-002, PP-MO-590 OC-MO-036 PP-WE-325 PP-TH-452 AS-WE-007 OC-TU-052 . T OC-MO-075, PP-MO-092, PP-WE-321 PP-MO-294, OC-TH-046, PP-MO-485, AS-TH-004 PP-WE-743 ., AS-TH-038 AS-WE-009 PP-MO-856 ., PP-TH-248, PP-TH-249, PP-MO-481, PP-TH-048, PP-TH-388, PP-WE-407 Lowenberg E.C., Lowe R., OC-WE-033, PP-WE-353 Lowe G., Lowe G.D.O., Lovis C., Lovegrove J., Lovegrove J. A., Lova P Louzada M.L., PP-WE-484 Loukidhs K., Louis P., D., Loughney A. Louedec L., Loubele S.T. B.G., AS-WE-011 Lotta L. Lothrop -JrC.D., Lospalluti M., PP-TH-087, PP-WE-684 Losche W., Lorut C., Loriot M. A., Loreth R.M., PP-WE-246, PP-WE-502 Lorenzet R., OC-WE-145 Lord S.T., Lorand-Metze I., PP-TH-047, PP-WE-237 Lopez-Vilchez I., PP-MO-178 Lopez-Sagaseta J., Lopez-Miranda J., PP-MO-585 López-Fernández M., PP-MO-560 Lopez-Fernández M., PP-MO-566 López-Fernandez M., PP-MO-591 Lopez-Fernàndez FM., Lopez-Alonso A., ., A., PP-MO-018 PP-TH-508 AS-TU-009 PP-MO-674 OC-TH-080, PP-MO-318 OC-MO-117, OC-WE-132, PP-TH-086, PP-MO-786 PP-MO-202, PP-TH-429 PP-MO-305, PP-MO-141 PC-015 OC-TU-087 OC-WE-1 PP-WE-500 PP-WE-372 PP-MO-870 PP-MO-032 PP-MO-053, PP-TH-053 PP-MO-710, OC-TU-087 OC-TH-087 PP-TH-181 16 Lozier J.N., PP-WE-764 PP-TH-096, PP-WE-033, PP-MO-055, PP-MO-732, Lozano M., Lozano M.L., PP-MO-786 Loyau S., PP-TH-193 Lühn S., Lugovskoy E.V., Lugovskaya N.E., Luetjohann D., PP-MO-706 Ludwig R.J., Ludwig A., PP-WE-824 Ludovici G., PP-WE-133, PP-WE-556 Luddington R., J., Lucking A. Luciani M., Luchian M., Lucchesi B.R., PP-TH-694 Lucchesi Lucas-Junior F Lucas S.B., Lucas R.C., Lucarini L., Lubkowski J., Lubetzky A., Lubetsky A., Luan P PP-MO-531 Lu Y., PP-MO-817, PP-WE-836 Lu X., Lu T., Lu S., PP-WE-153 Lu J., Lu G., Lu B., PP-TH-225 PP-MO-551, PP-TH-240, PP-WE-770, PP-MO-646, PP-TH-564, PP-TH-565, PP-MO-307 AS-TU-027, PP-MO-131, PP-TH-562, PP-TH-563, OC-TU-051, PP-MO-796, OC-WE-068 OC-TU-084, PP-TH-224 OC-TH-107 ., OC-TH-107 PP-TH-192, A., AS-TU-024, OC-MO-110 AS-TH-052, PC-030 PP-MO-818 PP-WE-737 AS-MO-010, PP-WE-727 PP-MO-380, PP-WE-156 PP-WE-036 PP-MO-654, PP-MO-434 PP-MO-705, AS-MO-054 PP-TH-212 PP-WE-065 ., PP-WE-159 PP-MO-289, PP-MO-400 PP-MO-063 PP-MO-212 PP-MO-212 537

Authors Index AUTHORS INDEX

Luke K., AS-WE-003, Ma H., PP-WE-728 Maclean R. M., PP-MO-199, PP-WE-553 Ma J. Y., PP-TH-405 PP-TH-664 Luke M. M., AS-WE-010 Ma T., OC-TH-119, PC-037 Maclean R. N., PP-WE-766 Luken B. M., AS-TU-019, Ma Y. Q., OC-MO-048 Maclean R., PP-MO-110 AS-WE-012, PP-MO-089 Ma Y. T., PP-TH-112 Macleod A. R., OC-TH-108 Luksza E., PP-WE-492 Ma Z., PP-TH-093, PP-WE-088 Madan B., PP-MO-166, Lunacsek O. E., PP-MO-283 PP-WE-623, PP-WE-635 Maek G., AS-TH-028 Lunardi J., PP-MO-748 Maddox B. D., PP-MO-048 Maas C., AS-TH-038, Lund P., PP-TH-428 AS-TU-017, OC-MO-112, Madeira C. L., OC-MO-031 Lunde K., PP-TH-427 PP-WE-216 Madeira H. S., PP-MO-871, Lundin B., OC-MO-034 Maas Enriquez M., PP-TH-584 PP-TH-218, PP-WE-869 Lunghi B., OC-TH-028 Maayan-Metzger A., Mäder G., PP-TH-079 Luo J., PP-MO-733 PP-MO-685 Madhani M., PP-MO-680, PP-TH-476 Luo M. P., PP-TH-570 Macaulay I. C., AS-MO-037, AS-WE-035 Madoiwa S., OC-TH-051, Luo R., PP-WE-179 Maccallum P. K., OC-TU-002, PP-MO-669, PP-TH-054 Luo Y., OC-MO-021 PP-TH-476, PP-WE-377 Madon J., OC-MO-129 Lupu C., AS-MO-045, Macchi S., PP-MO-523 Madonna R., OC-WE-071, OC-TH-065, OC-TH-112, PP-MO-828, PP-WE-856 OC-WE-028 Maccraith B. D., PP-WE-059 Madronio E. B., PP-WE-428 Lupu F., AS-MO-045, Macdonald V., PP-MO-708 OC-TH-065, OC-TH-112, Macey M. G., PP-WE-377 Maeda Y., PP-TH-015 OC-WE-028 Mach E. S., PP-MO-268 Maegdefessel L., PP-TH-440, PP-WE-190 Luque A., AS-MO-065, Mach F., AS-TH-032, PP-MO-526 OC-MO-132, PP-WE-744 Maegele M., OC-TH-067 Lüscher T. F., OC-TU-052, Machado A. B. C., PP-MO-311 Maekawa M., PP-TH-057, PP-WE-329 PP-WE-278 Machado T. F. G. S., Lusher J. M., PP-TH-180 PP-MO-725 Maes P., PP-MO-619 Lussana F., PP-TH-348 Machado T. M., PP-TH-157 Maffei F. H. A., PP-MO-311 Lütjohann D., PP-MO-809 Machherndl-Spandl S., Magari Y., PP-TH-233 Luu H., PP-MO-602, PP-MO-666 Mager J., PP-WE-777 PP-WE-574 Machin S. J., OC-MO-138, Maggini N., PP-MO-743, Luxembourg B., OC-WE-077, PP-MO-325, PP-MO-708, PP-MO-818, PP-TH-352, PP-MO-295, PP-MO-307, PP-MO-759, PP-TH-088, PP-TH-353, PP-WE-745, PP-MO-501, PP-WE-376, PP-TH-263, PP-WE-125 PP-WE-746, PP-WE-747, PP-WE-714 Machlus K. R., PP-TH-119, PP-WE-748 Luzak B., PP-MO-097 PP-WE-299 Magic Z., PP-WE-368 Lv B., OC-WE-027 Machovich R., PP-MO-851 Magnenat S., OC-TH-033, Lwaleed B. A., PP-MO-871, Mack G., PP-WE-451 OC-TH-034 PP-TH-217, PP-TH-218, Mackie I. J., OC-MO-138, Maguire P. B., AS-WE-035 PP-WE-869 PP-MO-325, PP-MO-759, Maguy A., PP-MO-060, Lyapina L. A., PC-012 PP-TH-088, PP-WE-125 PP-MO-061 Lyman G. H., OC-TU-018, Mackinnon B., PP-MO-515 Mah C., OC-TH-049 PP-MO-492 Mackman N., SA-TU-009, Mahaldar A., PP-MO-757 Lyutova L. V., PP-WE-422 AS-MO-042, AS-MO-043, Mahan C. E., OC-TH-016 M. Petersen J., PP-MO-565 AS-MO-044, AS-TU-044, OC-TH-020, OC-TU-017, Mahdi F., OC-MO-128, Ma A. C., OC-TU-067 PL-TU-003, PP-MO-768, PP-TH-133 Ma D. D. F., PP-WE-776 PP-TH-119, PP-TH-502, Mahe I., PP-TH-429, PP-TH-677, PP-TH-678, PP-WE-483 Ma D., PP-WE-731 PP-TH-691

538 PP-TH-278, PP-TH-378, PP-MO-360, PP-MO-361, Maier H., Mahmoodi B., OC-MO-001, OC-MO-082 Mahmoodi B.K., PP-MO-471 Mahlangu J.N., PP-WE-757, PP-WE-799 Mahla E., PP-TH-298, PP-WE-455 Mahjoub S., PP-MO-273 Mahfouz R., Mahé I., INDEX AUTHORS PP-TH-006, PP-WE-129 Makris M.P., Makkonen P., Makita K., PP-WE-330 Makinde Y.O., Makhoul B., PP-MO-286 Mäkelburg D., Makatsarya A. PP-TH-379, PP-TH-380 D., Makatsariya A. PP-WE-381 Makatsaria PP-TH-367 D., Makatsaria A. PP-WE-265 D., A. Makatsaria A. Majeed H., Majeed H.M., Majeed Majdalani M., Majdalani M.M., Majcen Vivod B., Majado M., Maj R., Maître B., PP-MO-793 Maitra A., Mairuhu R., Maiorana A., Mainwaring J., PP-MO-791, PP-MO-792, OC-WE-128 A., PP-WE-412 PP-WE-519 PP-TH-101, OC-WE-139, PP-WE-891 PP-MO-138 AS-TU-034 A. B.U., OC-TH-012 A., PP-MO-536 PP-WE-106 PP-MO-135, PP-MO-313 PP-TH-297, PP-MO-635 PP-MO-257, PP-TH-456 PP-WE-276 PP-WE-326 PP-MO-474, PP-MO-278, PP-TH-615 PP-MO-471, PP-WE-686 PP-WE-500 AS-MO-002, PP-WE-308 PP-MO-378, PP-TH-669 PC-017, PP-TH-006, PP-WE-129, OC-MO-092, PP-MO-308, Maly Maly Maly J., Maly Malovichko M.V., Maloney S., AS-TU-038, OC-WE-049 Maloney S.F., PP-WE-586 Malmstrom J., Malloy M.J., Mallouli F., Mallouk N., Mallik A., PP-WE-240 Mallett S., Mallela J., Malinin N., Malincarne L., Malhotra P., Malhotra J.D., PP-WE-228 Malfliet J.J., PP-WE-213 Malendowicz-Portala L., Maleki PP-TH-280, PP-WE-433 Malek G., Malecot J., PP-MO-561 Male C., Malcorra J.J., Malaver E., PP-TH-527 Malato A., Malara A., Malan E., Makris P., PP-WE-131 Makris P PP-WE-766 Makris M., PP-WE-252, PP-WE-302, PP-TH-664, PP-TH-679, PP-MO-076, PP-MO-199, R.M., ’ J., ’ J.M., ’ A., PP-WE-524 PP-WE-068 . E., PP-MO-436, PP-WE-718 PP-MO-713 PP-TH-279, PP-WE-252 PP-MO-214 AS-TH-030, PP-TH-242, PP-MO-067 PP-MO-885 PP-MO-075, PL-TU-005 PP-WE-455 PP-TH-291 PP-WE-042 PP-MO-783 PP-WE-030 PP-MO-324 PP-MO-257, AS-WE-010 PP-MO-224, PP-TH-369 PP-TH-369 AS-TU-028, OC-WE-087 PP-MO-590 PP-WE-585, AS-WE-043 PP-WE-158 Manai Z., PP-TH-465, PP-WE-285 Mammo L., PP-MO-267 Mameli A., PP-WE-068 Maly R., PP-TH-691 Manly D., PP-TH-119 Manly D. PP-TH-237, PP-WE-110 Manjunath G.B., Manithody C., Manion C.V Manina G., PP-WE-792 Mani H., PP-MO-812 Mani Mangolini F. G., PP-WE-891 Mangin P Mangieri E., PP-TH-371 Manga P., Manfredi E., PP-MO-056 A., Manfredi A. Mandic V., AS-WE-025 Mandelbrot L., Mandalà M., PP-WE-567 Mancuso M., OC-TU-075, PP-WE-555 Mancuso M.E., PP-WE-567, PP-WE-599 Mancuso G., PP-WE-255, PP-WE-613 PP-MO-596, PP-TH-265, Manco-Johnson M.J., Manavifar L., AS-TU-042 Manarini S., Manakov M. Y., OC-WE-122, PP-TH-010, PP-TH-677, PP-TH-678, OC-TU-074, PP-MO-542, OC-TU-075, PP-MO-750, A., PP-TH-438, OC-TH-1 PP-MO-730, ., A., PP-TH-297 AS-MO-044, PP-TH-370, AS-TU-047, PP-WE-379 PP-MO-266, OC-TU-024 PP-MO-425, ., AS-TH-059, PP-WE-105 OC-TU-017, OC-TH-011 PP-MO-476 AS-TU-032, AS-WE-020, PP-WE-632 PP-WE-267 OC-TU-093 OC-TH-082, OC-WE-127, PP-MO-182 AS-WE-005, OC-WE-023 18, PP-MO-808, 539

Authors Index AUTHORS INDEX

Mann K. G., AS-TU-023, Manyak S., PP-TH-231 PP-TH-341, PP-TH-353, OC-MO-003, OC-MO-006, Manzato F., OC-TH-028 PP-WE-002, PP-WE-003, OC-TU-003, PP-TH-154, PP-WE-747, PP-WE-748 Manzino A., PP-MO-641 PP-TH-196, PP-WE-152, Marcus M. A. E., PP-WE-017 PP-WE-358, PP-WE-362 Mao G., AS-TH-044, Marcus M. A., PP-MO-670 Mann K., PP-MO-244 PP-MO-078 Mardaraz C., PP-TH-316 Manner D., OC-TU-062, Mao Y., PP-MO-106, OC-WE-117, PP-MO-607 PP-WE-896 Marder V. J., PP-TH-231, PP-TH-232 Mannhalter C., AS-WE-010, Maraèiè I., PP-WE-308 PP-MO-322, PP-MO-821, Marathe D. D., PP-WE-893 Maréchaux S., PP-MO-815 PP-WE-621 Maraveyas A., PP-MO-479, Marek G., PP-WE-107 Manning R. A., PP-MO-397 PP-WE-503 Marenzi G., OC-TU-025 Manning S. L., OC-WE-039, Marbet G. A., PP-TH-199 Marés P., OC-TH-081 PP-TH-398 Marcato P. D., PP-MO-145 Marfisi R., OC-MO-094 Mannini L., OC-WE-031, OC-WE-102, PP-MO-013, March L., AS-TH-017 Margaglione M., AS-WE-005, PP-MO-340, PP-MO-341, Marchena Yglesias P., OC-TU-075, PP-MO-822, PP-MO-802, PP-MO-803, PP-TH-299 PP-WE-366, PP-WE-367, PP-MO-804, PP-TH-353 OC-TU-035, AS-WE-023, Marcher C., AS-MO-055 PP-MO-372 Manns J. M., OC-WE-030 Marchese P., OC-TU-044 Margeli A., OC-TH-044 Manns K., OC-MO-138, Marchesi M., PP-WE-688 PP-TH-088 Margue C., PP-WE-013 Marchesini E., OC-MO-035, Mannucci P. M., AS-TU-033, Mari D., AS-WE-007 PP-WE-688 OC-MO-034, OC-MO-081, Maria Annichino-Bizzacchi J., PP-MO-321, PP-MO-648, Marchetti G., OC-TH-028 PP-WE-066 PP-MO-673, PP-TH-300, Marchetti M., AS-TU-048, Mariani G., PP-MO-654, PP-TH-301, PP-TH-670, AS-TU-050, AS-WE-058, PP-TH-694, PP-WE-658 PP-WE-132, PP-WE-230, PP-MO-476, PP-MO-482, PP-WE-339, PP-WE-625, PP-MO-867, PP-WE-499 Mariani M., AS-WE-011 PP-WE-657 Marchetti P., PP-WE-858 Marie J., PP-WE-855 Mannucci P., AS-WE-005, Mariette X., PP-WE-787 AS-WE-020, OC-MO-035, Marchick M. R., PP-MO-512, OC-TU-074, OC-TU-075, PP-WE-323 Marin C., OC-TU-087 PP-MO-375, PP-MO-542, Marchie T. T., PC-009 Marín F., OC-TH-027, PP-MO-716, PP-TH-085, OC-TH-120, PP-MO-732 PP-TH-558, PP-WE-691, Marchioli R., OC-MO-094 AS-WE-011 Marchiori A., PP-TH-303 Marin S., PP-WE-737 Manolopoulos P., PP-WE-045 Marco P., PP-MO-609, Marinaccio C., PP-TH-453 Manotti C., PP-MO-461 PP-WE-604 Marinaki A., PP-MO-715 Mansmann U., PP-MO-660 Marcone S., PP-TH-048 Maringhini A., PC-015 Mansour A. H., PP-MO-488 Marconi M., PP-WE-791 Marino P., PP-MO-616 Mansour W., PP-TH-084 Marcoux L., PP-MO-611 Marino R., PP-TH-573 Mansouri Taleghani B., Marcucci M., AS-TH-005, Marinova M., PP-TH-397, OC-WE-077 OC-MO-035, OC-TH-002, PP-WE-159 OC-TH-004, PP-MO-282, Markakis K., PP-MO-715, Mansouritorghabeh H., PP-TH-412, PP-WE-286, PP-MO-552, PP-WE-632 PP-TH-609, PP-WE-693, PP-WE-529 PP-MO-679, PP-TH-467 Mantovani L. G., OC-MO-034 Marcucci R., AS-TH-034, Markart P., AS-TH-037 Mantovani L., OC-WE-119, OC-MO-010, OC-TH-047, PP-WE-542 OC-WE-031, OC-WE-032, Marks M., PP-MO-460 OC-WE-102, PP-MO-013, Marmur J. D., OC-TH-092 Manuel M., PP-WE-360 PP-MO-217, PP-MO-303, Manuel R., OC-MO-061 PP-MO-304, PP-MO-339, Maroney S. A., AS-MO-024 PP-MO-340, PP-MO-341, Manwani D., PP-MO-180 Marongiu F., OC-MO-028, PP-MO-743, PP-MO-801, PP-MO-266, PP-MO-267

540 PP-MO-321, PP-TH-300, Marro M., PP-MO-478 Marret E., Marrero C., Marquès-Verdier A., Marques-V Marqués M., Marques D., Marquart J. Marotta H., Marosi C., Marosi A., INDEX AUTHORS Martínez Á., Martinez Martinelli P., PP-TH-347 Martinelli N., PP-TH-301, PP-WE-132 Martinelli I., Martineau N., Martineau J., PP-WE-019 Martin V Martin T PP-WE-765 Martin M., PP-WE-782 Martin K.J., Martín J., PP-MO-421 Martin J., PP-TH-682 Martin E.J., Martí E., Marti E., Marti D., Martelli N., Martageix C., Marshall D., OC-MO-089 Marsh M.S., Marsh J.J., Marsden P. A., Marsden K., Marschall T., OC-TH-030, PP-MO-342, outain I., ., PP-MO-323 PP-MO-413 PP-MO-299 A., PP-TH-290 OC-TU-002, OC-MO-099, PP-WE-022 PP-MO-477, PP-TH-059, erdier A., PP-WE-774 PP-MO-322 AS-TH-059 OC-WE-088 PP-WE-665 A., OC-MO-022 OC-MO-081, PP-WE-768 PP-WE-243 PP-TH-449 AS-WE-018, PP-TH-567, PP-MO-724 PP-WE-730 PP-WE-367 PP-MO-472 OC-MO-088, OC-TH-028, OC-TH-023 PP-TH-315 AS-MO-053 PP-WE-619 AS-TU-056 PP-MO-262 PP-WE-333 PC-013 PC-021 PP-MO-063 Martins-Filho O. PP-WE-560 PP-TH-603, PP-TH-604, Martin-Salces M., Martins P., Martins N., Martinoli J., Martinod E., Martino L., PP-WE-399 Martini W. Z., Martini G., PP-TH-494, PP-WE-824 Martini F Martinho P., PP-MO-323, PP-TH-285 Martínez-Sánchez E., Martínez-Sales V., Martinez-Sales V., PP-WE-434 PP-MO-130, PP-TH-162, Martinez-Saguer I., PP-TH-287, PP-WE-141 PP-MO-144, PP-TH-247, OC-WE-107, PP-MO-134, OC-TU-080, OC-TU-082, Martínez-Martínez I., PP-WE-178, PP-WE-415 LB-MO-002, OC-MO-130, Martinez-Gonzalez J., PP-WE-415 Martinez-Colomer J., PP-TH-376 Martinez Trabal J.L., Martinez S., PP-TH-060 Martinez P., Martinez M., Martinez M. A., OC-WE-017 Martinez I., OC-MO-130 Martinez DeLizarrondoS., PP-WE-141, PP-WE-764 Martínez C., PP-TH-247, PP-WE-033, PP-MO-732, PP-TH-096, PP-MO-055, PP-MO-134, AS-TH-052, OC-TU-082, ., PP-MO-379, PP-TH-301 PP-MO-387 OC-TH-018 PP-WE-730 OC-TH-005, PP-TH-060, PP-WE-198 PP-WE-699 AS-MO-054, PP-WE-730 PP-TH-606 PP-MO-723 PP-TH-687, PP-WE-371 A., PC-048, PP-WE-885 PP-TH-363 Martret RedradoX., Martorell T., PP-WE-761 Martorell M., Martorana A., PP-TH-333, PP-TH-681 Martinuzzo M.E., Matevosyan K., Matero D., Materazzi M., PP-WE-175 Mateo J., OC-MO-104 Matafonov A., Masurat S., Masuda Y., E., Mast A. Massons J., Masson F., Massicotte P., Massicotte M., PP-WE-452 PP-WE-450, PP-WE-451, PP-MO-456, PP-TH-531, PP-MO-454, PP-MO-455, Massicotte M.P PP-WE-613 Massey G., Massberg S., OC-WE-090, PP-MO-860 Massardo T., PP-TH-138, PP-TH-142 Masood S., Mason K.D., PP-MO-775 Maseri Marzolo M., Marzec U.M., Marzac C., PP-MO-221, PP-WE-336 Marx P. F., PP-MO-395, PP-TH-642 Marx I., PP-WE-684 Marx G., Maruyama I., Maruff P PP-TH-299 A., OC-WE-042, ., PP-TH-086, PP-MO-413, OC-WE-129 OC-WE-127, OC-TH-064, PP-TH-408 PP-WE-855 AS-MO-024 PP-TH-432 PP-MO-252 PP-MO-596, PP-TH-137, PP-MO-603 PP-WE-338 PP-MO-254 PP-WE-234 PP-MO-528, AS-WE-032 OC-WE-086, PP-MO-884 PP-WE-688 PP-MO-005 PP-MO-634 PP-WE-097 AS-TH-039, PP-WE-238 PP-MO-435 ., PP-MO-757 OC-TU-066, PP-MO-275, 541

Authors Index AUTHORS INDEX

Matheron J., PP-MO-862 Matus V., OC-WE-026, Mazzucato M., PP-TH-008, Mathias M. C., PP-TH-605 PP-MO-064, PP-TH-024, PP-WE-018 PP-TH-043, PP-WE-057, Mazzucconi G., AS-TU-032 Mathias M., PP-TH-551 PP-WE-121, PP-WE-654 Mathiesen E., OC-TU-005, Mazzucconi M., AS-TU-033, Matyja-Bednarczyk A., PP-MO-210, PP-MO-287, OC-TU-006, OC-WE-137, PP-MO-270, PP-MO-271 OC-WE-140, PP-MO-813, PP-MO-542 PP-WE-304, PP-WE-305 Matysiak M., PP-MO-608 Mbemba E., PP-TH-485, Matijevic N., PP-MO-767, Matyskova M., PP-TH-612, PP-TH-486 PP-WE-819 PP-TH-613 Mbemba M., PP-WE-490 Matisic D., PP-WE-275 Maude R. J., PP-MO-710 Mcalindon M., PP-WE-766 Matos R., PP-MO-667 Mauer A. C., AS-MO-027 Mcallister E., PP-TH-201 Matsubara Y., Maufus M., PP-MO-499, Mcardle W. L., OC-TU-034 PP-MO-500 PP-TH-072, PP-WE-015, Mcarthur J., PP-TH-310, PP-WE-031, PP-WE-349 Mauge L., OC-TU-090, PP-TH-457 OC-WE-089 Matsuda J., PP-MO-864, Mcbride E., PP-MO-686 PP-TH-051 Maugeri N., OC-WE-127, Mccall M., PP-MO-738 Matsuda K., PP-WE-400 PP-MO-056 Mccallum P., PP-MO-680 Matsuda S., PP-MO-111, Maurer G., PP-MO-829 PP-MO-123 Maurer M. C., PP-MO-250, Mccarty O. J. T., PP-TH-037 Matsui H., AS-TU-012, AS-TU- PP-WE-156, PP-WE-158 Mccarty O. J., AS-WE-044 014, OC-TH-085, OC-TH-086 Maurissen L. F., OC-MO-005 Mccarty O., OC-MO-123 Matsui T., OC-TH-088, Maurizi F., PP-WE-527 Mcclintock R. A., OC-TH-096 OC-TU-041 Mauser-Bunschoten E. P., Mcclung W. G., PP-TH-435 Matsumoto A., PP-WE-501 PP-MO-571, PP-MO-633 Mcclure L. A., OC-WE-103 Matsumoto K., PP-WE-015 Mavri A., OC-TH-013, Mccool K. H., PP-MO-463 Matsumoto M., OC-WE-008, PP-MO-404, PP-TH-418 PP-MO-717, PP-WE-196 Mavrogiorgos N., PP-TH-064 Mccool K., PP-MO-308 Matsumoto S., OC-TH-088, Max J., PP-MO-402, PP-TH-362 Mccorkell S., PP-MO-562 OC-TU-041 May F., OC-TH-039 Mccourt S., PP-WE-372 Matsumoto T., PP-TH-526, May J. A., OC-MO-100, Mccrae K. R., OC-TU-042 PP-MO-497 PP-WE-755 Mcdonald H., OC-MO-051, Matsumura K., PP-TH-689 Mayanglambam A., OC-TU-020, OC-WE-005, Matsuo M., PP-MO-704 PP-MO-028 PP-MO-468 Matsuo T., PP-MO-704 Mayer B., AS-MO-055 Mcdonald V., OC-MO-138 Matsushima H., PP-MO-704 Mayer G., AS-TH-048, Mceachron T., PP-TH-502 Matsushita T., PP-TH-592, PP-WE-180 Mcewan P. A., OC-MO-103, PP-WE-606, PP-WE-671 Mayne P., PP-TH-034 OC-TU-043, PP-TH-045 Matsuura E., PP-MO-842 Mazgajska-Barczyk K., Mcewen B., PP-MO-411 Matta K. L., PP-WE-893 PP-WE-491 Mcewen N., PP-WE-520 Matta M. A. P., PP-WE-535 Mazharian A., AS-WE-033, Mcfarland R., PP-MO-300 PP-WE-076 Matter C. M., OC-TU-052 Mcgarrigle S. A., PP-TH-034 Mazoyer E., PP-MO-723, Mcgeehan E., PP-MO-396 Mattew L. G., PP-TH-275 OC-WE-099 Mcginness K., PP-WE-569 Matthews A., OC-MO-001 Mazur M., PP-TH-337 Mcglasson D. L., PP-MO-102, Matthews S., PP-WE-547 Mazurov A. V., PP-MO-856 PP-MO-103, PP-WE-235 Matthijsen R. A., PP-TH-181 Mazzarelli L., PP-WE-367 Mcgrath J., PP-MO-200, Mattle H. P., OC-WE-034 Mazzolai L., PP-TH-492 PP-MO-494 Mattoscio D., AS-TU-049, Mazzotta C., PP-MO-654 Mcinerney M., PP-WE-474 PP-TH-082

542 Mcmahon C., PP-WE-553 Mclimont M., Mcleod A., Mclean M. OC-WE-059 Mclean K., Mclaren G.D., PP-MO-231 Mckinnon T Mckinley S., Mcjunkin B., INDEX AUTHORS Mehta H., Mehrvar A., Megens R., Meens J., PP-WE-327 Meena Meeks S.L., PP-MO-193 Medina P PP-MO-649 Meddeb B., Mechurová A., S., Mecawi A. Meade G., Meade G.R., Mead J.R., Md. PP-WE-849 Mcvey J.H., PP-WE-523 Mcsorley PP-TH-626, PP-WE-544 Mcrae S., PP-WE-427 Mcrae S.J., PP-WE-218 Mcnamee R. A., Mcnamara H., Mcmurray M., Mcmonagle J., PP-TH-032 Mcmillan-Ward E.M., Mcmichael M., Mcmanus A., PP-WE-151, PP-WE-848, OC-WE-067, PP-WE-150, Afandi F., A., ., A., OC-TU-010, PP-WE-071 PP-TH-631 PP-MO-208, PP-TH-052 A., PP-MO-192, OC-WE-057, PP-TH-315 . A. J., . A. PP-WE-662 PP-TH-104 AS-TU-002, PP-TH-124 PP-TH-188, PP-MO-410 PP-MO-587 OC-TH-043, PP-WE-522, PP-MO-661 AS-WE-003, PP-WE-059 OC-TH-076 PP-WE-615 PP-WE-1 PP-TH-178 AS-TU-014 PP-MO-636 OC-TH-084 PP-TH-424 PP-TH-255 PP-WE-378 OC-TU-087 PP-WE-071, OC-MO-065, 19 Mende M., OC-WE-032, PP-MO-217 Menchini U., Menchen H., Menashku S., Menahem M., OC-WE-016, PP-MO-352 Meltzer M.E., Melton L.J., Melton IiiL.J., Melot C., Melo T Mellors G., Mello T PP-TH-657 Mellars G., Melinyshyn A., PP-WE-240 Melikian C., Melenovsk Melchior C., Melazzini F Melamed E., Melado M., Meixner S.C., PP-TH-280 Meissner M., PP-WE-650, PP-WE-726 Meiring M., Meijers J.C., PP-WE-407 Meijers J.C.M., PP-MO-168 Meijer P., PP-WE-554 Meijer K., OC-WE-084 Meijer Meier N., Mehta Z., PP-MO-677, PP-WE-419, PP-TH-388, PP-WE-336, PP-MO-710, PP-TH-139, PP-MO-298, PP-MO-352, PP-MO-262, PP-MO-293, OC-WE-016, PP-MO-221, OC-TH-064, OC-TU-059, AS-TU-035, OC-MO-030, . M., A. B., . B.T PP-MO-498 OC-WE-034 OC-MO-134, OC-MO-009 PP-MO-633, AS-WE-004 y ., ’ PP-WE-295 PP-TH-551, PP-WE-234 PP-MO-624 PP-TH-637, ., PP-TH-242, PP-WE-013 AS-TU-004 OC-TU-083, OC-TU-057 V., PP-MO-284 OC-WE-031, OC-WE-022 PP-TH-279, OC-TH-031 AS-TU-008 PP-WE-296 AS-TU-052 OC-TU-001, OC-MO-118 AS-TH-003 OC-TH-007 PP-WE-345 AS-TU-017, OC-MO-1 Mendolicchio G.L., Menditto L. A., Mendelsohn M.E., PP-MO-198, PP-WE-179 Mendell J., PP-WE-049 Mendelboum RavivS., Messano L., OC-WE-066, PP-MO-588 Meslier Y., PP-WE-701, PP-TH-608 Mesli N., Mesli M.N., PP-WE-146, PP-WE-354 Meschengieser S., PP-MO-613, PP-TH-350 Meschengieser S.S., Mesa M., OC-WE-084 Mertens K., Merriman E.G., OC-MO-108, OC-WE-072 AS-TU-022, OC-MO-057, Merrill-Skoloff G., Merrill J.T., PP-TH-579 Merricks E.P., Merlini P., Merli G.J., Merkouri E., PP-MO-012 Merhi Y., Mercier E., Meola A., Mensi N., Mennecier P., Menke L. A., Mengi N., Mengatti J., Meneveau N., Meneguzzi A., PP-MO-210 Menegatti M., Mendolicchio L., PP-WE-791 PP-TH-100, PP-WE-145, PP-MO-204, PP-MO-274, 12, OC-TU-083, OC-WE-007, PP-TH-608, PP-WE-665 PP-WE-321 OC-TH-073 PP-TH-686 PP-WE-339 OC-MO-064, OC-TH-081 PP-WE-465 OC-WE-003, OC-MO-111, PP-WE-564 OC-TU-033 PP-WE-535 PP-WE-048 PP-TH-338 PP-MO-597 AS-MO-028, PP-MO-382 AS-TU-009 PP-MO-015 PP-MO-570, PP-MO-283 PP-MO-631 PP-MO-775 AS-MO-043, AS-TH-016 PC-047, 543

Authors Index AUTHORS INDEX

Messina M., OC-TU-075 Michel J., PP-MO-786 Miller C., PP-TH-328 Messmore H., PP-MO-143, Michel-Behnke I., PP-MO-436 Miller E., PP-MO-518 PP-TH-390, PP-WE-385 Michell B., OC-MO-101 Miller J. L., PP-WE-029 Mesters R., OC-TU-062 Michielsen P., PP-MO-383 Miller R., PP-WE-292 Mesterton J., PP-MO-606 Michno A., PP-MO-024 Miller V. M., PP-WE-780 Metassan S., PP-TH-212 Micic D., PP-TH-269 Milli B., PP-MO-294 Metelin V., PP-MO-729, Micucci J. A., AS-TH-047 Mills G. B., PP-TH-392 PP-WE-062 Miculschi G., PP-WE-552 Mills N. L., PP-TH-212 Metin A., OC-WE-132 Miczák A., OC-TU-051, Mills S., AS-TH-022, Metjian A., OC-MO-002 PP-WE-836 PP-MO-045 Metzger K. E., PP-WE-640 Middeldorp S., AS-MO-030, Milos M., PP-MO-223, Metzger U., PP-TH-417 OC-WE-100, PP-MO-286, PP-WE-275, PP-WE-435 Metzner H. J., OC-WE-120, PP-TH-139, PP-TH-373, Milosevic Jovcic N., PP-TH-561 AS-MO-001 PP-WE-634 Metzner H., PP-TH-130 Miesbach W., AS-MO-003, Milyutina D. A., PP-WE-863, PP-MO-584, PP-TH-644, PP-WE-864 Meulemans A., PP-MO-786 PP-TH-651, PP-TH-652, Meurs I., OC-WE-046 PP-WE-210 Mimaya J., PP-TH-592, PP-WE-606 Mewburn J., PP-TH-631 Mihailov D., PP-WE-549 Mimikakou G. E., PP-WE-131 Mewhort-Buist T. A., Mihailov M., PP-MO-532, OC-MO-074, PP-WE-173 PP-WE-552 Mimuro J., OC-TH-051, PP-TH-054 Meyer B., PP-MO-332 Mihaly J., PP-MO-838, PP-MO-848, PP-WE-842 Min P., PP-WE-783 Meyer D., PP-TH-623 Mijares M., PP-MO-663 Min S., PP-MO-727, Meyer G., AS-TU-009, PP-WE-343 OC-MO-041, OC-TH-018, Mikati M., PP-TH-456 Minagawa Y., PC-040 PP-MO-376, PP-WE-483 Mikhail N. E., PP-TH-506 Meyer J. P., PP-TH-103 Miñano A., OC-TH-027, Mikhalovska L. I., PP-MO-872 OC-TU-080, OC-WE-107, Meyer J., PP-MO-004 Mikhalovsky S. V., PP-MO-872 PP-MO-134, PP-MO-144, Meyer M., PP-TH-215 Mikheeva Y. A., PP-TH-431 PP-TH-247, PP-TH-287, PP-WE-141 Meyer S. C., PP-TH-079, Mikovic D., AS-TU-033, PP-TH-080 PP-MO-533, PP-TH-296, Minaudo M., AS-WE-007 Meyer T., PP-MO-004, PP-WE-379 Ming H., PP-MO-691 PP-WE-001 Mikovic Z., PP-WE-379 Mingot E., PP-MO-566, Mezzano D., AS-MO-054, Mikulenkova D., PP-TH-083 PP-MO-601, PP-TH-596 AS-TH-052, OC-WE-026, Milanov P., AS-TH-014 Mingot M. E., PP-TH-572, OC-WE-086, PP-MO-064, PP-WE-550, PP-WE-551 PP-MO-860, PP-TH-024, Miles L. A., AS-TU-020 Minhas N., AS-TH-017 PP-TH-043, PP-WE-057, Milio G., AS-TH-030 PP-WE-121, PP-WE-123, Miniati M., PP-MO-303, PP-WE-654, AS-MO-041 Miljic P. S., PP-MO-327 PP-MO-304, PP-WE-283 Mezzasoma A., PP-MO-085 Miljic P., PP-MO-599 Minibeck E., PP-TH-640 Mialhe A., AS-WE-050 Millar C. M., OC-MO-032, Minkin S. C., PP-TH-439 PP-MO-624 Miao C. H., OC-WE-062 Minoldo S., PP-MO-547, Millar C., OC-MO-033 Miao H. Z., OC-WE-062, PP-WE-511 PP-WE-153 Miller C. D., OC-TU-007, Minotto I., PP-TH-304, PP-TH-505, PP-WE-414 Miao H., AS-WE-043 PP-WE-527 Miller C. H., PP-MO-596, Minou A. F., PP-TH-234 Miccio A., AS-TH-042 PP-WE-613, PP-WE-749, Miccoli R., PP-MO-016 PP-WE-750 Minuk L., PP-WE-517 Miceli-Richard C., PP-WE-787 Miller C. M., OC-TH-077 Minuz P., PP-MO-015

544 OC-WE-092, OC-WE-096, PP-TH-21 PP-TH-174, PP-TH-185, PP-WE-139, PP-WE-505, Mirshahi M., PP-WE-864 Mironova E.V., Miron M., Mirault T Miras F., Miranda P., PP-MO-743, PP-WE-748 Miranda M., Miranda C.G., Miranda A., Miqueo C., INDEX AUTHORS Mitsopoulou K., Mitri Z., Mitragorti S., PP-WE-369, PP-WE-379 Mitic G., PP-TH-152, PP-WE-616 Mitchell M., PP-WE-635 Mitchell M.J., OC-WE-106 Mitchell L., PP-WE-448, PP-WE-449 Mitchell L.G., Mitchell J., PP-MO-740, PP-MO-741 Mitchell J. Mitchell B., PP-MO-207 Miszalski-Jamka T., Missenard J., Misquith R., PP-WE-483 Mismetti P., Mishra G., Mishima K., PP-WE-505 Mirshahi S., Mirshahi P., PP-WE-855 PP-TH-426, PP-WE-165, PC-023, PP-TH-076, OC-TU-022, OC-WE-002, OC-MO-053, OC-TH-021, PP-MO-135 ., PP-WE-368, PP-MO-637 1, PP-WE-139, PP-TH-315 PP-MO-748 A., PP-MO-233 OC-TU-080 PP-WE-539 OC-WE-094, PP-TH-385 PP-WE-078 PP-WE-167 PP-MO-562, OC-MO-050, PP-WE-855 PP-MO-667, PP-WE-090 PP-MO-514, PP-MO-675 PP-MO-214, AS-MO-049 AS-WE-052, PP-TH-649 AS-TU-054, PP-MO-628, PP-MO-346 PP-WE-863, PP-MO-302 OC-WE-104, PP-MO-374, PP-MO-053, PP-WE-871 Molina P., PP-WE-778 Molenaar P. J., Mole J.P Molderings G.J., Molad Y., Mohseni R., Mohlke K.L., Mohler E.R., PP-TH-239 Mogielnicki A., PP-WE-507 Moghrabi A., OC-TH-049 Moghimi B., Mogami H., Moffat K. A., Moessmer G., Moeller F., PP-MO-761, PP-MO-762 Mobarrez F Mobalegh Moazed B., Mo X., Mizukoshi M., Miyazawa Y., Miyazaki Y., Miyazaki K., Miyazaki H., PP-WE-671 Miyawaki Y., PP-WE-090, PP-WE-872 Miyata T PP-WE-720 Miyata S., Miyata K., Miyashita K., Miyamoto S., PP-WE-271 Miyamoto E., Miyajima Mitterer A., Mitsuguro M., PP-TH-015, PP-TH-320, PP-MO-393, PP-MO-726, OC-WE-008, PP-MO-093, OC-TU-046, PP-TH-045 ., ., Y., PP-MO-749 AS-MO-012, AS-TH-018, A., PP-MO-093, PP-TH-184 PP-WE-655 PP-MO-573 ., PP-MO-150 PP-WE-393 OC-WE-054 PP-WE-666 PP-TH-081 PP-WE-558 AS-TU-015, PP-MO-084 PP-WE-605 PP-MO-138, OC-TH-079, OC-MO-134 PP-WE-420 PP-MO-494, AS-TH-033 PP-MO-704 PP-MO-393 PP-WE-269, PP-WE-632 PP-TH-398 PP-TH-320 PP-MO-429 PP-MO-132 PP-TH-436, PP-MO-234, PP-MO-253 Molins B., Molino-Lova R., PP-MO-676, PP-TH-136 Molinaro R.J., PP-MO-616 C., Molinari A. Molina R., Monteagudo E., Montavão S. A. L., Montano N., Montani N., Montalvo A., PP-TH-157, PP-TH-554 PP-MO-145, PP-MO-521, Montalvão S. A. L., Montalescot G., PP-TH-205 Monroe D.M., PP-WE-415 Monreal M., Monreal M.M., Mono M., Monkman K., PP-TH-388 Monia B.P., Mongiat M., Mondorf W Monavari Monatte T., Monassier J.P OC-TH-087, OC-WE-064 Monahan P. E., PP-WE-531 Monagle P., Monagle P. T., PP-TH-094, PP-TH-402 Momi S., Møller B., Mollah S. A., Moll F. L., Molkentin J.D., PP-TH-288, PP-WE-178, PP-WE-438, PP-WE-480, PP-TH-475, PP-WE-437, PP-TH-461, PP-TH-462, PP-MO-451, PP-TH-442, PP-MO-449, PP-MO-450, PP-MO-381, PP-MO-437, OC-WE-061, PP-MO-392, OC-TH-032, A., OC-WE-034 PP-WE-740 OC-TU-030 AS-MO-049 PP-MO-227 ., PP-TH-076 PP-MO-684 OC-WE-093, PP-WE-527 PP-MO-299, OC-TH-108, OC-TH-010 PP-WE-593 AS-MO-027 PL-TU-002 PP-TH-034 PP-MO-403 PP-MO-438 AS-WE-042, ., PP-MO-525, PP-MO-137, PP-TH-308 AS-WE-042, OC-WE-123 PP-WE-311 PP-WE-436 OC-MO-008 OC-MO-008 PP-WE-296 545

Authors Index AUTHORS INDEX

Monteagudo J., PP-MO-254, Morange P., OC-MO-007, Morozov Y. A., PC-010, PP-WE-371 OC-MO-021, PP-MO-773, PC-011, PC-051 Montebello E., PP-MO-828 PP-WE-165, PP-WE-775 Morrell C. N., PP-MO-011 Monteiro R. Q., PP-TH-499 Morateck P. A., OC-TU-071 Morris A. J., PP-TH-392 Monteiro R. R. Q., PP-TH-179 Morcillo S., PP-WE-768 Morris T. A., OC-MO-022, Montero F., PC-050 Mor-Cohen R., PP-TH-013 OC-TU-009 Montes R., PP-MO-178 Mordasini A., PP-TH-692 Morrissey J. H., AS-WE-034, Moreau C., PP-TH-429 OC-TU-091, PP-MO-113, Montgomery For Canadian - PP-TH-255, PP-TH-256, Vicenza - And Zpmcb-Vwd Moreau P., PP-TH-593 PP-WE-120 Study Groups R. R., Moreira L., PP-WE-374 AS-MO-017 Morrrissey J. H., PP-WE-256 Morel O., PP-MO-416 Montgomery For The Morse M., PP-MO-233 Canadian Type 1 Vwd And Morel-Kopp M. C., PP-MO-410, Morser J., OC-WE-038, Zpmcb-Vwd Study R. R., PP-MO-411, PP-WE-221 PP-WE-222 OC-WE-133 Morel-Kopp M., PP-WE-547 Mortensen J., OC-MO-040 Montgomery R. R., Morenghi E., AS-WE-007 Mortensen S. B., PP-WE-788 AS-WE-038, OC-TU-071, PP-TH-128 Moreno M., PP-MO-536 Mos I. C. M., OC-MO-037, Moreno N., OC-WE-086 PP-WE-341, PP-WE-512, Montiel-Manzano G., PP-WE-513 OC-MO-026 Moret A., PP-MO-589, Moscardo A., PP-MO-027, Montsch P., PP-TH-611 PP-MO-590, PP-TH-544, PP-TH-627, PP-WE-668 PP-WE-096 Moodley S., PP-TH-370 Morfini M., PP-MO-542, Moscardó A., PP-WE-796 Moons K. G. M., OC-TH-017 PP-TH-584, PP-TH-622, Moses P. D., PP-TH-275 PP-WE-599 Moons K. M. G., OC-TU-012 Moshou M., PP-MO-257, Moore C. L., PP-MO-512 Mörgelin M., PP-MO-221 PP-TH-006 Moore C., PP-MO-062 Morgret M. L., PP-WE-120 Mosialos L., PP-MO-777, Moore G. C., PP-TH-330 Mori F., PP-MO-246 PP-MO-778, PP-MO-779 Moore G. W., PP-MO-166 Moriarty R., PP-MO-043 Moskowitz K. A., PP-TH-677, PP-TH-678, PP-TH-691 Moore G., PP-MO-543 Moride Y., PP-TH-323 Mosnier I., PP-MO-332 Moore L. C., PP-WE-854 Moriguchi-Goto S., PP-MO-123, PP-MO-127 Mosnier L. O., AS-TU-043, Moores L., PP-MO-299 OC-WE-142, PP-MO-880, Morikawa C., PP-TH-173 Moorthi C., PP-MO-603, PP-MO-881 PP-MO-647 Morimoto M., PP-MO-439 Møss J., OC-WE-055 Mor Cohen R., PP-WE-010 Morin K. A., PP-TH-520, Mostafa . Z., PP-MO-277 PP-WE-267, PP-WE-270 Moraes L. A., OC-TH-093, Mota L., PP-TH-659, OC-TH-100, PP-WE-040, Morishige N., PP-WE-411 PP-TH-660, PP-TH-668 PP-WE-809 Morishima Y., PP-TH-195, Mota R., OC-WE-107 Morag I., PP-MO-434 PP-TH-406 Mota-Vieira L., PP-MO-297 Morais S., PP-MO-667, Morishita E., PP-TH-057, PP-WE-374 PP-WE-278 Mothabeng S. M., PP-WE-650 Moraleda J., PP-MO-536 Morissey J., SA-TH-018 Motta G., PP-MO-124 Morales A., PP-MO-536 Morita T., PP-WE-150 Motte S., PP-MO-498 Morales J., PP-WE-065 Moritani Y., PP-TH-041, Motterlini R., PP-TH-239 PP-TH-042 Moran N., PP-MO-043, Mottier D., PP-MO-310, PP-MO-044, PP-TH-034 Moroi M., PP-MO-080, PP-MO-500, PP-TH-483, PP-TH-035, PP-TH-036 PP-WE-186, PP-WE-508, Morange P. E., OC-WE-099, PP-WE-510, PP-TH-291, PP-MO-774, PP-TH-309 Moroi R., PP-TH-521 PP-TH-508, PP-MO-508 Moroz G. I., PP-TH-479

546 OC-WE-063, PP-MO-150, Mourão P. A. S., PP-MO-012 Mourad W., PP-WE-858 Mouquet F Moulin N., Moulard M., Mouhsine E., Moubarik C., Möttönen S., PP-MO-090, PP-WE-389 Motto D.G., INDEX AUTHORS PP-TH-515, PP-TH-516 Mulder R., PP-TH-516 B., Mulder A. Muladzanov A., Mukon M., Mukhopadhyay R., PP-WE-811 Mukherjee M.S., Mukhametova L., Mukhametova L.I., Mukai H. Mühle C., OC-TH-1 Muhl L., Mughal S., Muenzel T., Mueller-Esterl W., Mueller M., Mueller F., Muehlberger E., PP-MO-640, PP-WE-557 Muchitsch E.M., Much E.S., Mucci L., Mu J., Mt-Isa S., Moyna N., Moya C., Mowinckel M., Mowinckel M.C., Mousavi H., PP-TH-332, PP-TH-515, PP-WE-394 10 AS-TH-058, Y PP-TH-568 PP-TH-082 OC-TU-002 PP-TH-556 ., ., AS-TU-059 PP-TH-076 AS-WE-034 OC-WE-098, PP-TH-477 PP-TH-351 PP-WE-519 OC-MO-068 OC-WE-007, PP-TH-267 PP-TH-583, PP-TH-071 PP-MO-787 PC-049 OC-WE-041, PP-TH-068 PP-MO-833 OC-WE-098, PP-TH-417 PP-WE-486 PP-WE-462 OC-TH-070 PP-TH-178 OC-TH-054, PP-TH-108, AS-TH-004 PP-TH-227 OC-TH-059 AS-TU-041 PC-005 OC-MO-044, OC-WE-123, PP-TH-072, PP-WE-015, Murphy A., Murayama S., Murate T., PP-WE-031, PP-WE-349 Murata M., Murat E., Murasaki K., Murasaki K.M., Murakami Murad S.D., PP-TH-448, PP-WE-439 Muntean W., PP-WE-282 B., Münster A. PP-MO-1 Munroe S., PP-WE-822 Muñoz X., Muñoz S., PP-WE-765 PP-TH-604, PP-WE-560, Muñoz I., PP-TH-012 Munnix I.C. A., Munier A., PP-MO-817 Mundkur L. OC-TH-041 Mundell S.J., PP-WE-023, PP-WE-056 D., Munday A. Mun Y., Mun H., Mumford A., OC-TH-041 Mumford OC-TH-063 Mullins E.S., Mullier F Müller-Reible C., Müller S., Muller P., PP-WE-180 Müller J., PP-TH-546, PP-TH-547 Muleo G., PP-TH-504 PP-WE-783 ., 16 A. D., PP-MO-858 PC-048, PP-TH-603, AS-TH-048, PP-TH-392 OC-TH-023 PP-MO-432, PP-MO-040 PP-MO-138 Y PP-WE-821, PP-WE-236 PP-MO-723 PP-MO-717, AS-TU-059 PP-MO-115, ., A., PP-MO-076 PP-MO-224 OC-WE-138, PP-WE-342 PP-WE-875 AS-TU-045, OC-MO-131, PP-MO-119 PP-MO-002, PP-MO-164, OC-TH-1 OC-MO-131, AS-WE-044, PP-WE-418 OC-WE-076 18, PP-TH-622, PP-WE-567, OC-TU-075, PP-MO-577, Murphy R.P Murphy M., Murphy K.K., OC-WE-059 Murphy J.E., PP-TH-033 Murphy D., PP-WE-686 Muwakkit S. A., OC-WE-075 Mutucumarana V. P., PP-TH-042 Mutoh S., PP-WE-562 Muto S., Mutlu Muthny F., Muth A., PP-WE-130 Mutch N.J., AS-WE-034 Mutch MuellerN.J., PP-WE-350, PP-WE-774 Muszbek L., PP-WE-276, PP-WE-279 Mustonen P., Mussoni L., PP-WE-579, PP-WE-870 Musso R., Musso R.M., PP-WE-870 Musso M., PP-TH-437 Musil P PP-WE-270 Musial J., Musallem K.M., Musallam K.M., Murugesan G., Murugappan S., Murray-Segal L., Murray J., Murray H., PP-TH-216, PP-TH-366, PP-MO-205, PP-MO-228, PP-TH-381, PP-WE-267, PP-MO-329, PP-MO-784, PP-MO-270, PP-MO-271, A., ., PP-MO-439, PP-TH-241 PP-TH-433, PP-MO-065 PP-TH-041, PP-MO-269, AS-TU-032, PP-WE-636 PP-TH-590, PP-MO-459 OC-WE-033 PP-MO-044, OC-TU-056 ., PP-WE-050 OC-MO-076, PP-MO-009, PP-MO-742, AS-TU-059 OC-WE-057, PP-WE-306 PP-WE-101 PP-TH-456, PP-TH-590 PP-TH-01 PP-WE-686 PP-TH-336 OC-MO-127 1 547

Authors Index AUTHORS INDEX

Muyldermans S., OC-TH-114 Nair S. C., PP-TH-275 Nasirikenari M., PP-WE-893 Muzard J., PP-MO-786 Naito S., PP-WE-148 Näslin D., PP-WE-643 Muzykantov V., OC-WE-112 Najid S., OC-WE-093 Nasonov E. L., PP-MO-268, Mwanda W. O., PP-MO-452 Nakadate H., PP-WE-025 PP-TH-267, PP-TH-277 Myers B., PP-MO-370, Nakagaki T., OC-WE-073, Nasreddine W., PP-TH-336 PP-WE-760 PP-WE-605 Natesha B. K., AS-WE-059, Myers H. R., AS-MO-063 Nakagawa H., PP-MO-842 PP-WE-832, PP-WE-833, PP-WE-834 Myers Jr D. D., OC-TU-060, Nakagawa P. A., PP-TH-065, PP-MO-388, PP-MO-400 PP-TH-066 Nathwani A. C., AS-TU-011 Myers L., PP-MO-136 Nakajima Y., PP-MO-704 Natorska J., PP-WE-107 Mykhaylov S., PP-MO-065 Nakajo Y., PP-MO-393 Navajas R., PP-TH-591 Myklebust C. F., PP-TH-164 Nakamura H., PP-WE-005 Navalon F., PP-MO-053, PP-TH-047, PP-WE-871 Myojin K., PP-WE-720 Nakamura N., PP-MO-429 Navaneetham D., PP-MO-181 Mysliwiec M., PP-MO-114, Nakanishi K., PP-WE-032 PP-WE-223 Navarrete A., OC-WE-066, Nakao S., PP-TH-057, PP-MO-588 N. Krogh T., PP-MO-565 PP-WE-278 Navarro D., PP-TH-568 Nadal-Wollbold F., AS-TH-023 Nakashima H., PP-TH-229 Navarro F., PP-MO-579 Nadir Y., PP-TH-387 Nakashima T., PP-WE-605 Navarro M., PP-WE-816 Næsgaard P., PP-MO-433 Nakatani K., PP-TH-526 Navarro N., AS-MO-054 Naess I., OC-WE-013 Nakatomi Y., PP-WE-605 Navarro S., PP-MO-192, Nagae C., PP-MO-439, Nakaya S. M., PP-MO-156 PP-MO-193 PP-WE-562 Nakic M., PP-WE-442 Navarro-Fernández J., Nagai R., OC-TH-009 Nakkinkun Y., PP-WE-772 OC-TU-082 Nagalla S., OC-WE-045, Nanba T., PP-WE-348 Navarro-Núñez L., AS-MO-054, PP-MO-756, PP-WE-752 AS-TH-052, PP-MO-055, Nandurkar H., AS-TH-025, Nagam N., AS-TH-027 PP-MO-732, PP-TH-096, OC-MO-101, OC-MO-127 PP-WE-033, PP-WE-764 Nagao T., PP-TH-358 Nanna C., AS-TH-034 Navis G., OC-MO-001, Nagaraj S., PP-MO-792, Nanni L., PP-WE-246 PP-WE-326 PP-MO-793 Naparstek E., PP-TH-070 Nawroth P. P., AS-MO-059, Nagaswami C., AS-WE-048 AS-WE-053 Napoleone E., PP-MO-202, Nagaya H., PP-MO-119 PP-MO-481, PP-TH-248, Nayak S., AS-TU-015, Nagpal S., PP-WE-495 PP-TH-249, PP-WE-246, OC-TH-049, PP-TH-618 Nagy - Jr B., OC-MO-043 PP-WE-502 Nayiager T., PP-MO-494 Nagy B., OC-TH-094, Napoleone M., OC-WE-051, Nayiger T., PP-WE-507 PP-MO-620 OC-TH-098, PP-MO-009 Nayir A., PP-MO-440 Nagy J., PP-WE-049 Napolitano M., PP-MO-654, PP-TH-694 Naz A. A. N., PP-TH-648 Nahal A., PP-MO-820 Narasaki R., PP-TH-226 Neceva V., PC-014, PC-027, Nahrendorf M., AS-WE-057 PC-028, PP-TH-271, Nardi A., PP-TH-591 PP-WE-426 Naidu S., OC-MO-072 Nardi M., PP-WE-338 Needham J., PP-MO-272, Naik M. U., OC-MO-046, PP-TH-599, PP-WE-111 OC-MO-071, OC-TH-038, Nardini I., PP-MO-246 PP-WE-053 Naseem K. M., PP-MO-023, Neelamegham S., OC-WE-050, PP-WE-893 Naik U. P., OC-MO-046, PP-MO-024, PP-TH-020 OC-MO-071, OC-TH-038, Naseem K., OC-TH-055 Neerman-Arbez M., PP-MO-206, PP-WE-213 PP-WE-053 Naseem S., PP-TH-272, Naina H. V. K., PP-MO-487, PP-WE-266, PP-WE-456 Neeves K. B., AS-TU-028, PP-TH-220, PP-WE-723 AS-TU-038, OC-WE-053

548 OC-MO-062, PP-MO-604, PP-WE-533, OC-WE-021, PP-WE-133, PP-WE-493, PP-TH-385, PP-TH-386, PP-MO-645, PP-MO-658, PP-MO-567, PP-MO-586, PP-MO-263, PP-MO-264, OC-TH-072, OC-TU-067, OC-MO-095, OC-TH-071, PP-TH-593, AS-TH-011 Negrier C., PP-WE-487 Negaard H.F. S., PP-WE-613 T.,Neff A. Neeves K., INDEX AUTHORS PP-WE-438 PP-TH-442, PP-WE-437, PP-MO-450, PP-MO-451, Newall F. H., Nevière R., Neuhaus D., PP-TH-423 Neuhart E., PP-MO-600 Neufeld E.J., Neubert U., OC-TU-069 Nesheim M.E., Nesbitt W Nerlich C., Neri T., Neri C., Nergiz-Ünal R., Nergiz-Unal R., Nepal S., Nendaz M., Nendaz M.R., Nencini P., PP-WE-542, PP-WE-604 OC-WE-119, PP-MO-609, Nemes L., Nemery B., Nemekh A., Nemecz M., Nelli P. J., Nekkal S., Neiva T. J.C., Negrotto S., Negro F PP-MO-758 ., PP-TH-507 PP-TH-316 PP-MO-407 . S., PP-MO-596, PP-WE-861 OC-WE-058, PP-WE-639 PP-TH-130 OC-TH-047 OC-TU-073, PP-WE-030 PP-WE-858 PP-WE-375 PP-MO-398 PP-MO-175, PP-WE-755 PP-TH-029 PP-MO-855 PP-WE-042 OC-TU-061 PP-MO-449, PP-MO-535, OC-WE-124 PP-MO-034 PP-MO-318 AS-TU-029 OC-MO-061, PP-TH-012 PP-WE-486, PP-MO-437, PP-MO-438, PP-MO-031, PP-WE-734 Niemann S., Niemann B., Nieman M., Nieman M.T Nielsen M., Nielsen H.M., PP-WE-585, PP-WE-586 Nielsen Nieland Niekrens C., PP-TH-063 Nicolescu A., Nicole O., Nicolaes G. A. F., PP-WE-151 Nicklin S. Nickerson D. PP-MO-678 Nichols W. L., Nichols T., PP-MO-570, PP-TH-579 Nichols T. C., Nicham F Ni R., PP-WE-060 Ni H., OC-WE-151 Nguyen Y., OC-WE-002 Nguyen P., PP-TH-045 Nguyen N.X., Ngo M., Ngo J., Newton Newman P., AS-TH-009 Newman P Newman D., Newman D.K., Newell J.L., Newby D.E., PP-TH-461, PP-TH-475 Newall F., OC-MO-139, OC-WE-121, AS-TU-030, PP-TH-009 AS-WE-041 A. D., A. S., A., PP-TH-133 ., A., OC-WE-093, OC-WE-111 . J., OC-MO-086 PP-MO-766 AS-WE-027, OC-MO-050, OC-TH-076 PP-MO-1 OC-MO-128 AS-MO-057 ., SA-TU-002 PP-MO-030, PP-MO-157 PP-TH-537 PP-TH-575 PP-TH-212 PP-WE-150, A., AS-TU-013, PP-MO-069, OC-TH-056 PP-MO-435 PP-MO-559, OC-TU-046, PP-MO-629, PP-MO-121 AS-MO-052, AS-TH-009 AS-WE-009 AS-WE-042, PP-WE-157 18 PC-028, PP-TH-271, Nieswandt B., Niesters H.G.M., Niessen F., PP-TH-484 Niers T. M.H., W.,Nienhuis A. Nishio K., Nishino Y., Nishimura S., Nishimi M., Nishihira K., Ninomiya H., Ninet J., PP-MO-343 Nilsson S., Nilsson EkdahlK., Nilsson B., Nilsen D., PP-WE-830, PP-WE-831 Nilsen D.W. T., Niladri S., Nikookhesal E., Nikolskaya I., PP-WE-426 Nikoloska I., PP-MO-506 Nijkeuter M., Nijhuis S., Niitsu Y., PP-MO-380 Nigro C., A., Niglio A. PP-MO-843 Niewiarowska J., Niewiadomska E., PP-WE-784 Nieuwland R., J., Nieuwkoop A. Nieuwdorp M., OC-TH-039, OC-WE-040 PP-MO-763, PP-MO-769, PP-MO-022, PP-MO-109, OC-TU-055, OC-TU-059, AS-WE-029, AS-WE-030, AS-TU-037, AS-TU-040, AS-TH-040, PP-WE-072, PP-WE-126, PP-TH-131, PP-TH-344, PP-TH-385 PP-MO-096 PP-MO-379, PP-WE-829 PP-WE-090 PP-WE-833 PP-TH-155 PP-TH-014 OC-WE-115, AS-TU-043 OC-MO-106 AS-TU-005, PP-WE-411 PP-TH-308 PP-MO-111 PC-014, PC-027, AS-MO-035, PP-TH-071 PC-005 PP-WE-605 AS-WE-017, SA-WE-005, OC-WE-019, PP-MO-221 PP-MO-433, AS-TU-011 PP-TH-104 OC-TU-091 PP-MO-839, PP-TH-332 PP-WE-722 OC-MO-106 549

Authors Index AUTHORS INDEX

Nishio M., PP-MO-827, Noris P., PP-MO-085, Nowakowski G. S., PP-MO-487 PP-WE-501 AS-TU-004 Noya G., OC-TU-024 Nishiya K., PP-MO-255, Normann S., PP-WE-528 Nozaki M., PP-WE-463 PP-WE-250, PP-WE-516 Norris J. W., PP-MO-389 Nuchsongsin F., PP-MO-710 Nitti C., OC-MO-092, Norris L. A., PP-WE-373 OC-TH-014 Nugent D. J., PP-MO-823, Norstrom E. A., OC-MO-098 PP-TH-065, PP-TH-066 Nixon B., PP-WE-636 North P., OC-TH-097 Nugent D., PP-MO-625 Nixon J., PP-TH-230 Notet V., PP-TH-394 Numa A., PP-TH-458 Njerve I. U., PP-MO-719 Notheaux Micheli J., Nuñez R. J., PP-WE-767 Njolstad I., OC-TU-005, PP-MO-125 OC-TU-006, PP-WE-304, Nuñez R., PP-MO-566, PP-WE-305 Notley C., AS-MO-020, PP-MO-601, PP-TH-596 OC-TU-076, OC-WE-134 Njølstad I., OC-WE-137, Nur E., PP-MO-292 OC-WE-140 Noto A., PP-TH-303 Nurden A. T., OC-TH-097 Nkujani T., PP-MO-471 Noto D., OC-TU-088 Nurden A., SA-MO-013, Noack H., PP-MO-167, Noubouossié D., PP-MO-617 AS-TH-043, PP-TH-074 PP-TH-167, PP-TH-169, Nougier C., PP-MO-263, Nurden P., AS-TH-043, PP-TH-170, PP-WE-205 PP-MO-264 OC-TH-097 Nobel D., PP-TH-492 Nourani Khojaste H., Nutescu E. A., PP-MO-464 Nobori T., PP-TH-526, PP-WE-459 Nutescu E., PP-WE-406 PP-MO-497 Novak M., OC-WE-138, Nuti R., PP-TH-301 Nogami A., PP-TH-358 PP-TH-448, PP-WE-439 Nyatanga P., PP-TH-449 Nogami K., PP-MO-255, Novakov Mikic A., PP-WE-368 Nyhus K., PP-TH-539 PP-WE-250, PP-WE-516 Nováková I. R. O., PP-MO-571 Nylander M., PP-MO-021 Nohara C., PP-TH-358 Novakova I., PP-TH-260, Nokes T., OC-TH-076 PP-WE-735 Nylander S., PP-TH-018 Nolan B., PP-MO-593, Nováková I., PP-MO-633 O Neill S., PP-TH-033, PP-TH-034 PP-WE-615 Novakovic V. A., PP-TH-159 O’Donnell J., PP-TH-053 Nolli S., AS-TH-032, Noveck R. J., PP-WE-179 OC-MO-132, PP-WE-744 O’Beirne J., PP-WE-649 Noventa F., OC-MO-015 Nolte M. E., PP-TH-567 Öberg K. V., PP-WE-014 Novikov A. A., PP-MO-268, Nomikou E., PP-WE-314 PP-TH-267, PP-TH-277 Obergan T., PC-012, PP-WE-397 Nomura M., PP-TH-416 Novokhatny V., PP-TH-230, Nomura S., PP-WE-781, PP-TH-231 Oberkanins C., PP-MO-141 PP-WE-827, AS-WE-016 Nowak A. A., PP-MO-231 Oborna I., PC-022 Nonne C., OC-TH-034 Nowak G., PP-MO-700, O’Brien M. C., PP-WE-489 Noordermeer K., PP-WE-072 PP-WE-739 O’Brien S., PP-TH-052, Norberg E., PP-MO-703 Nowak Göttl And U., PP-WE-059 PP-TH-074 Nord E., PP-WE-643 Obser T., OC-WE-136, Nowak Gottl U., AS-TU-054 PP-MO-638, PP-WE-629, Norda R., PP-MO-672 PP-WE-630 Nowak-Goettl U., OC-WE-117, Nordenholz K. E., PP-MO-512, PP-TH-647 Ocak G., PP-MO-316 PP-TH-408 Nowak-Gottl U., AS-TU-053, Ockelford P. A., PP-MO-493 Nordstrom S. M., OC-MO-077 OC-WE-094, OC-WE-106, Ockelford P., OC-TU-079 Norenberg C., PP-MO-577, PP-MO-607, PP-TH-360, PP-WE-579 PP-WE-528, PP-WE-756 O’Connor M. N., AS-MO-037 Norengaard L., PP-WE-658 Nowak-Göttl U., OC-TU-062, Odone-Filho V., PP-WE-444 Noris M., PL-TU-006 PP-WE-453, PP-WE-633, O’Donnell C. J., OC-TU-034 PP-WE-653

550 PP-TH-483, PP-WE-508, Ogawa S., Oganova E.G., Ofosu F. A., Offenberg H., Oettle H., PP-MO-573, PP-MO-578 Oestergaard H., Oelenberg S., O O’Donnell J., PP-WE-685 O’Donnell J.S., INDEX AUTHORS Oka T., PP-TH-501 Ojeokun F. A., Oishi K., Oikonomou A., Oikawa Y., PP-MO-177 Øie C., Ohtake T., PP-WE-148 Ohsugi T., PP-TH-054 Ohmori T., Ohlmann P PP-MO-864 Ohkura N., PP-WE-162 Ohkubo Ohkita Y., Ohishi K., Ohayon T., PP-WE-580 Ohashi K., Oh M., Oh H.J., PP-MO-353, PP-WE-877 Oh D., O’Gorman D., PP-WE-250 Ogiwara K., PP-MO-508, PP-TH-291 Oger E., Ogbata O.U., Ogawa T., ∂ uz E., PP-MO-301, PP-TH-585 OC-MO-058, PP-TH-592, PP-WE-606 Y PP-MO-500, PP-TH-511 PP-TH-051 PP-WE-595 . Z., LB-MO-003 PP-WE-720 PP-MO-096 PP-TH-526 PP-TH-358 PP-TH-228, PP-WE-196 ., PP-WE-349 OC-TH-051, PP-WE-244, PP-TH-051, PP-TH-070 PP-MO-017 PP-MO-255, PP-MO-416 PP-MO-593 PP-MO-578 OC-TU-094, PP-WE-127 AS-TU-059 OC-TU-053 PP-TH-500, PP-WE-681 PP-WE-337 PP-TH-549, OC-MO-084, PP-WE-574, PP-WE-594, PP-WE-159, PP-WE-210, PP-TH-671, PP-TH-696, PP-TH-658, PP-TH-661, PP-TH-575, PP-TH-619, PP-TH-537, PP-TH-569, PP-MO-513, PP-TH-397, PP-MO-128, PP-MO-253, OC-WE-076, OC-WE-077, AS-WE-002, PP-WE-167 Oliveira D.G.L., OC-WE-090, PP-MO-860 Olivares P., Oliva A., Olié V., Olie V Olesen J.B., Oleksiuk J., O’Leary M. A., O’Leary J.J., PP-TH-407 Oldgren J., PP-WE-660 Oldenburg J., Oláh Z., Okuyama Y., PP-TH-229 Okumura N., Okuda T Okuda M., Okuchi K., PP-WE-271 Oku K., Okazaki O., Okazaki H., PP-TH-542, PP-WE-705 Okazaki E., PP-WE-580 Okano T., PP-MO-726 Okamura T Okamura M., PP-WE-882 Okamoto T Okamoto K., Okamoto Okada Y., Okada H., ., PP-WE-316 OC-TH-005 PP-WE-269, ., PP-MO-359 PP-WE-665 A., OC-MO-128 PP-MO-393 PP-WE-244, PP-MO-726 PP-MO-119 ., ., PP-WE-090 PP-MO-408, PP-MO-755, OC-WE-086, PP-WE-736 PP-WE-348 AS-WE-004, PP-WE-492 PP-TH-143, PP-MO-669, PP-TH-320 PP-TH-143 PP-MO-669 OC-WE-145, PP-TH-358 PP-MO-386 PP-WE-373 AS-TH-048, PP-WE-118 PP-MO-475, OC-TH-030, PP-MO-342, PP-MO-607, PP-TH-533, Oliveira V PP-TH-178 Oliveira S.M.C.G., Oliveira F., Oliveira DuarteV., PP-WE-631 Oliveira DiMigueliC., Onimaru M., Ong S., Ong E., C., Ong A. Oney S., Study ., On BehalfOfTheEclaxir PP-MO-409 Omran H., PP-WE-827 Omoto S., PP-WE-418 Omori H., PP-WE-330 Omolade O. Omnes S., Omer B., O’Meara E., Omar S.Z., Olteanu G., Olszynski P., Olsson B., Olson J., PP-MO-795 Olsen J., Olsen J.O., Olorunju S., PP-MO-077, PP-TH-119 Ollivier V., Ollieuz S., Olivo G., PP-TH-274 Olivieri S., PP-TH-347 Olivieri O., PP-WE-453 Olivieri M., PP-WE-122 Oliver J. PP-MO-442 PP-TH-639 A., PP-WE-189 PP-TH-352 PP-MO-744 OC-WE-025, ., OC-TH-082 OC-WE-134 PP-WE-342, PP-WE-781, AS-TU-024, PP-MO-029, PP-TH-684 PP-MO-075 AS-WE-025 OC-MO-113, PP-WE-172 OC-TH-028, AS-TH-055, PP-WE-374 PP-MO-034 PP-MO-367 PP-MO-532 AS-WE-009 PP-MO-039, OC-MO-025 A., PP-WE-124 PP-WE-875 PP-WE-704 PP-MO-278, PP-WE-066 551

Authors Index AUTHORS INDEX

Onisai M., PP-MO-069, Osanto S., AS-MO-035, Oude Egbrink M. G. A., PP-WE-075 AS-WE-019, PP-WE-497 AS-TU-029 Onishi K., PP-TH-526 Oschatz C., OC-TH-059 Oude Egbrink M., PP-TH-104 Ono A., AS-WE-032, O’Shaughnessy D., Oudega R., OC-TH-017, OC-WE-044 OC-TH-076 OC-TU-012 Ono M., PP-TH-072 Oshea S., PP-MO-414 Oudemans - Van Straaten H. Ono N., PP-MO-232 Oshimura M., OC-TH-088 M., PP-TH-436 Ooe E., PP-TH-194 Oslakovic C., OC-TU-096 Ouvina S. M., PP-WE-203 Oosterkamp T. H., AS-WE-019 Osman A., PP-MO-133 Ouviña S. M., PP-TH-316 Opitz B., LB-MO-003 Ostapchenko L. I., PP-MO-401 Ouviña S., PP-TH-607, PP-TH-681 Oppermann J., PP-TH-656 Ostasevski Fernandez N., OC-TH-013, PP-TH-418 Ouwehand W. H., AS-MO-037, Opstad T. B., PP-TH-118 OC-TH-037, OC-TH-093, Orantes V., PP-TH-285 Østenstad B., PP-WE-486, OC-TU-029, OC-WE-126 PP-WE-487 Orbe J., OC-MO-130, Ouwehand W., SA-TU-016 Oster K., OC-MO-126 OC-TH-113 Ou-Yang J., PP-TH-667 Orden A., PP-WE-236 Ostergaard H., OC-MO-085, PP-MO-118, PP-WE-590 Ovali F., PP-MO-683 Ordóñez A., OC-TH-027, Østergaard H., PP-MO-575, Ovanesov M. V., PP-TH-109, OC-TU-080, OC-TU-082, PP-WE-253 OC-WE-107, PP-MO-134, PP-TH-579 PP-MO-144, PP-TH-247, Östergren-Ludén G., Overberg D., PP-MO-603, PP-TH-287, PP-WE-141 AS-WE-054 PP-MO-647 Ordoñez J., PP-TH-289 Ostermann H., PP-MO-694 Overmyer K. A., OC-MO-073 Orebaugh C., PP-WE-703 Osterud B., OC-WE-025 Overvad K., PP-WE-315 O’Reilly L. A., AS-WE-032 Østerud B., OC-MO-025, Oviedo-Orta E., PP-WE-873 Orel E. B., PP-MO-218, PP-MO-795, PP-MO-808, Øvlisen K., PP-WE-581 PP-MO-668 PP-TH-237, PP-WE-110 Owaidah T. M., PP-TH-062, Orfeo T., AS-TU-023, Osthaus A., PP-TH-207, PP-WE-280 OC-MO-003, OC-TU-003, PP-TH-208 Owczarska K., PP-TH-658 PP-TH-196 Osto E., OC-WE-088 Owen B. A., PP-MO-760 Orford N., OC-TH-015 Ostryakova E. V., PP-MO-268, Owen W. G., PP-TH-161, Orje J. N., AS-MO-049 PP-TH-277 PP-WE-292, PP-WE-780 Orlando C., PP-MO-173, Ota S., PP-TH-526 Oyen F., PP-MO-638, PP-MO-174, PP-WE-188 Otegui M., PP-WE-575, PP-WE-722 Orlemans E., PP-WE-803 PP-WE-576 Ozaki Y., SA-TU-003, Orlovic M., PP-MO-357 Otero R., PP-MO-299 OC-TH-099, PP-MO-734, PP-TH-005, PP-WE-793 Orosz Z. Z., PP-TH-216 Otgontaij S. B., PP-TH-017 Ozdemir N., PC-039 Orset C., OC-TH-113 Othman M., OC-TH-053, OC-TU-076, OC-WE-134, Ozdemir O., PP-MO-394 Orsi F. A., PP-TH-466, PP-MO-632, PP-TH-393 PP-TH-532, PP-WE-295, Ozdenkaya Y., PP-WE-197 PP-WE-476 Otomo K., PP-WE-269, Ozel Demiralp D. F., PP-WE-271 Orsi F. L. A., PP-MO-870, PP-MO-797 PP-WE-294 Otrock Z., PP-TH-456 Ozelci A. B., PP-TH-511 Orsi F., PP-MO-725 Ott J., OC-WE-098 Ozelo M. C., AS-TU-013, Ortel T. L., OC-MO-002, Otten J. M. M. B., OC-MO-014, AS-TU-014, OC-WE-134, PP-MO-492 PP-MO-484 PP-MO-520, PP-MO-521, Otzen D. E., PP-TH-140 PP-TH-157, PP-TH-466, Ortner E., OC-WE-034 PP-TH-532, PP-TH-554, Osakue J., PC-008, PC-009 Ouarhlent Y., PC-045 PP-WE-295, PP-WE-535 Ouchchane L., PC-021

552 PP-TH-663, PP-WE-429, PP-TH-304, PP-WE-527, PP-TH-259, PP-TH-302, OC-TU-086, PP-MO-424, Pabinger I., Ozyurek E., Ozulker T Öztürk Ozturk G., PP-WE-889 Ozturk E., Ozkilic H., PP-WE-631 Ozelo M., INDEX AUTHORS Paidas M., PP-WE-405 Paidas M.J., Pai N., PP-WE-553 Pai M., Pai C., Pagnano R.G., PP-WE-641, PP-WE-645 Pagnan Pagliuca M., Pagella F Page M.J., Paganelli F Pagana L., Padrini R., PP-WE-141 Padilla J., Padickakudi J., Padeh S., OC-MO-028 Padayattil S., Pacouret G., Packard R.R., Pacheco P. R., Paccamiccio E., PP-TH-317, PP-WE-621 Pabinger-Fasching I., PP-WE-663 PP-TH-569, PP-WE-594, PP-MO-322, PP-TH-273, OC-TU-015, OC-TU-016, OC-MO-027, OC-TU-013, PP-TH-295 PP-TH-401 AS-WE-003, Y ’ A., ., ., ., OC-TH-085, AS-TU-052 PP-TH-284 PP-MO-144, PP-MO-841, PP-MO-222 PP-WE-577 PP-MO-684 ., PP-WE-382 PP-WE-641 PP-TH-453 PP-WE-571 OC-MO-049, OC-WE-083 AS-MO-003, PP-WE-806 PP-MO-785 PP-TH-474 AS-TU-009 PP-TH-414, OC-MO-015, PP-MO-835 PP-MO-297 PP-WE-535 PP-WE-813 PP-MO-458 PP-MO-716, PP-TH-085, OC-WE-131, OC-WE-132, PP-WE-359, PP-WE-509, PP-WE-286, PP-WE-351, PP-TH-282, PP-TH-412, PP-MO-503, PP-MO-504, PP-MO-291, PP-MO-351, PP-MO-282, PP-MO-290, OC-TH-004, OC-TH-006, OC-TH-002, OC-TH-003, AS-TH-005, AS-TH-029, Pamuklar Z., PP-WE-889 Pamuk G.E., Pampuch A., Palumbo V., OC-TH-063 Palumbo J.S., PP-WE-871 Palomo M., PP-WE-551 Palomo A., PP-MO-601, PP-TH-596 Paloma M., Paloma M.J., PP-MO-380, PP-WE-824 Palmirotta R., Palmieri V., Palma M., PP-WE-586 Palm L., PP-MO-860 Pallavicini J., PP-WE-339, Palla R., Palla A., Palekar S., PP-WE-715 Palareti G., PP-MO-372 Palareti G.P Pakola S., Pak Paixão D.S.P., Paiva-Patiño J., Paiva-Palomino J., PP-WE-364 Paiva S.G., PP-TH-044, PP-WE-402 PP-MO-831, PP-MO-832, Paiva PalominoJ.H., Y ., AS-TH-022, PP-MO-045 PP-WE-585, AS-MO-028, PP-TH-303 PP-TH-493 OC-TH-057 PP-MO-427 PP-WE-550, AS-MO-003, AS-TH-018, PP-MO-566, PP-WE-321 AS-WE-011 PP-MO-364, OC-TH-047 AS-TH-059 PP-WE-048 PP-MO-841, OC-WE-086, PP-MO-590 PP-MO-379, AS-TU-045, ., PP-WE-296 PP-TH-350 AS-WE-023, PP-MO-610 PP-WE-057, PP-WE-121, PP-TH-024, PP-TH-043, OC-WE-090, PP-MO-064, OC-WE-026, OC-WE-086, Panchenko E., PP-TH-513, PP-WE-526 Panchenko E.P., PP-WE-693 Panagiotakopoulos V., OC-WE-059 Pan J., PP-WE-682 Paoletti O., PP-TH-273 Panzer S., Pantziarela E., PP-WE-881 Pantovic S.M., PP-WE-253 Panteleev M. A., Pantazatos D., Pansini V AS-TU-050 Panova-Noeva M., Panova M., Pannell R., Pankiv S., Panizzi P., Panizzi P. R., PP-MO-472, PP-TH-675 Panizo E., PP-MO-485, PP-MO-486 Panicot-Dubois L., PP-WE-747, PP-WE-748 Paniccia R., Panholzer E., Pang J., PP-WE-654, AS-MO-041 Panes O., Paneesha S., Panduro L., Pandey A., Pancotti S., Panchenko V. M., PP-TH-374, PP-TH-375, PP-WE-745, PP-WE-746, PP-WE-002, PP-WE-003, PP-TH-353, PP-TH-474, PP-MO-818, PP-TH-352, PP-MO-013, PP-MO-743, OC-WE-057, PP-TH-037 ., AS-MO-054, AS-TH-050 PP-TH-237 OC-MO-027, PC-030 AS-TH-022 AS-WE-050 PP-MO-496, PP-MO-867 PC-030 AS-MO-008 AS-TH-034, AS-WE-057 OC-TH-076 PP-WE-557 PP-MO-302 OC-TU-095 PP-WE-335 PC-002, PP-MO-235, PP-TH-431, PP-WE-422 AS-TU-048, AS-TH-015, 553

Authors Index AUTHORS INDEX

Paoloski G. B., PP-WE-203 Park G., PP-MO-213 Passlow C., OC-TH-015 Papadakis E., PP-MO-305, Park J., PP-TH-595, Pasta G., PP-MO-542 PP-WE-484 PP-WE-069, PP-WE-573, Pasterkamp G., OC-TH-031 PP-WE-805 Papageorgiou C., PP-MO-477, Pastor F., PP-MO-732 PP-MO-478 Park R., PP-MO-213, Pastorova V., PC-012 Papageorgiou P. C., PP-MO-712, PP-TH-519 PP-TH-125 Park S., PP-MO-213, Patel B., OC-MO-067 Papajik T., PP-MO-689 PP-MO-727, PP-TH-149, Patel H., PP-MO-548 PP-TH-509, PP-WE-027, Papalardo E., OC-MO-026, PP-WE-027, PP-WE-069, Patel Hett S., PP-WE-077 OC-MO-114, OC-TU-038 PP-WE-343 Patel K. P., PP-WE-468 Paparella D., PP-MO-423 Park Y., PP-WE-573, Patel K. V., PP-TH-014 PP-TH-595 Papassotiriou I., OC-TH-044 Patel R. K., OC-MO-088, Papayan L. P., PP-MO-431, Parker A. L., PP-WE-150, OC-MO-089 PP-WE-151 PP-MO-495, PP-TH-268, Patel S. R., PL-TU-002 PP-TH-346, PP-WE-361 Parker J. L., PP-WE-569 Patel Y. M., PP-TH-014 Papi R. M., PP-WE-131 Parker W. A., PP-WE-430 Patel-Hett S., AS-WE-026 Papiewska-Pajak I., Parmar K., OC-TU-039 PP-MO-861 Paterno M. D., PP-TH-424 Parmer R. J., AS-TU-020 Pappo A., PP-TH-445 Paterson A., AS-TH-045 Parpia S., OC-MO-016, Paterson C., PP-MO-412 Para A. N., AS-MO-040, OC-MO-017, PP-MO-515 PP-MO-722 Pathak A. S., PP-MO-790 Parr M. J. A., OC-TH-069 Paraboschi E. M., PP-MO-648, Pathak A., PP-TH-243 PP-WE-657 Parra R., PP-MO-528, PP-MO-590, PP-WE-234, Pathare A. V., PP-MO-675 Paradela A., PP-TH-591 PP-WE-761 Pati S., PP-MO-767 Paradis A. K., PP-MO-721 Parry C., PP-MO-514 Patil S. B. G., OC-MO-012 Parahuleva M., OC-WE-128 Parsi K., PP-MO-671, Patino G., PP-MO-103 Paramo J. A., OC-MO-130, PP-WE-786 Patkar N. V., PP-TH-275 OC-TH-113 Parthasarathi L., PP-MO-043 Patnaik M. M., PP-TH-220 Páramo J. A., PP-MO-472, Pascale S., PP-TH-082 PP-TH-675 Patno T., PP-TH-182 Paschke M., OC-TH-059 Parent F., AS-TU-009, Patrizia R., PP-MO-056 Pascual M., OC-WE-058 PP-MO-376 Patrono C., SA-TH-006, Pareyn I., PP-MO-049, Pascual T., PP-WE-360 PP-MO-015, PP-MO-016, PP-MO-050, PP-MO-094, Pascual Z., PP-TH-520, PP-WE-738 PP-WE-013 PP-TH-625 Patsialas K., PP-WE-129 Parfitt L. A., PP-WE-805 Pasdelou M., PP-WE-388 Pattacini C., PP-MO-461, Pargalava N., PC-019 Pasetto L., PP-MO-424 PP-MO-523 Parhami-Seren B., PP-TH-154 Pasha S. M., OC-MO-037, Pattarini E., PP-MO-261 Parienti J., OC-TU-022 PP-MO-782 Patton J. M., PP-WE-071 Parisi Q., PP-WE-048 Pasi J., PP-TH-685 Patton W. F., PP-TH-424 Parizkova E., PP-MO-682 Pasic S., PP-TH-269 Pattyn P., PP-WE-176 Parizzi L. P., PP-MO-825, Paskavitz J., OC-WE-129 Paty I., OC-WE-006, PP-MO-826 Pasowicz M., PP-MO-207 PP-MO-418, PP-TH-409, PP-WE-413, PP-WE-423 Park C., PP-MO-727, Pasquier E., OC-WE-113 Paudice N., PP-TH-353 PP-TH-509, PP-WE-343 Passamonti F., AS-TU-004 Paul P., OC-TU-089 Park D., PP-WE-496 Passamonti S., OC-MO-081, Park E., PP-MO-213, PP-WE-132 Paula G. M. M., PP-MO-063 PP-WE-027 Passaro A., PP-TH-372 Paulsson M., OC-WE-076

554 PP-MO-513, PP-TH-619, OC-MO-131, OC-TU-077, Pavlova A., Pavlík T Pavlik T., PP-MO-753 Pavicic M., Pavic M., Pauzner R., PP-WE-412 Pautas E., PP-MO-125 Pautard MuchembleB., Pautard B., INDEX AUTHORS Peden A., Pecka M., PP-MO-067 Pecci A., Pecce R., PP-TH-028, PP-WE-258 OC-TU-054, OC-WE-125, Pease R.J., Pearson D., Pearse R., Pearse R.M., Pearlman N., OC-WE-135, PP-TH-638 Peake I.R., Peace A., Peace Pazzini C., Paz B., Paytubí GaríC., Paysant J., PP-WE-019 Payrastre B., Payne C.D., Pawlowska Z., PL-TU-003 Pawlinski R., Pawlik C., PP-WE-223 Pawlak K., PP-MO-234, PP-WE-223 Pawlak D., Pavord S., PP-WE-660 AS-MO-044, A. J., PP-MO-850 ., AS-TU-004, PP-TH-543 PP-TH-613 PP-TH-497 AS-TH-059 PP-MO-738 OC-MO-032 PP-WE-068 PP-MO-441 PP-TH-429, PP-TH-685 PP-WE-760 PP-MO-145 PP-MO-1 PP-MO-114, PP-MO-736, PP-MO-395 AS-WE-004, AS-MO-019, PP-MO-125 OC-TH-102 AS-TU-044, PP-MO-075 PP-MO-735 OC-MO-115, PP-MO-733 PP-TH-408 AS-MO-042, OC-MO-099, OC-TH-067 PP-WE-879 PP-TH-299 14, PP-MO-609, PP-WE-041, Pendleton R.C., Pendergast W., Penaloza A., Peña M., OC-TH-090, PP-MO-209 Peña E., Pen P Pelzer U., 570, PP-TH-594,PP-WE-154 Pelzer H., Pellequer J.L., Pellegrini V Pellechia D., PP-WE-571 Pekun F., Pekcelen Pejovic E., Pejovic E.M., Peiretti F Pehrsson S., Pegoraro V., PP-TH-675 Pegenaute C., PP-MO-862 Peffault DeLatourR., PP-MO-373, PP-WE-488 Peetz D., PP-WE-176 Peeters M., Peeters L.L., Peeters K., PP-MO-129 Peerschke E.I.B., Peerlink K., PP-WE-086, PP-WE-268 Peerlinck K., Peel S. A. F., Peebles D., PP-MO-758 Pedrinelli R., Pedrazzi P., PP-TH-140 Pedersen S., Pedersen J., PP-MO-575 A., Pedersen A. PP-MO-537, PP-MO-538, ., PP-TH-1 AS-WE-055, ., PP-MO-794 PP-MO-317, Y PP-MO-344, LB-MO-003 PP-MO-569, PP-MO- OC-TH-045 ., PP-WE-881 . D., PP-WE-085 PP-MO-225, PP-TH-384 AS-MO-028 PP-MO-523 PP-MO-653 PP-MO-321 PP-MO-498 PP-WE-533 PP-MO-565 PP-MO-518 OC-WE-058, PP-MO-134, OC-WE-029, PP-MO-385 PP-TH-377 PC-002 PP-MO-472, 12 PP-WE-659 PP-TH-424 PP-MO-248 PP-MO-118, PP-TH-424 PP-WE-121, PP-WE-123, PP-TH-043, PP-WE-057, PP-MO-860, PP-TH-024, OC-WE-090, PP-MO-064, OC-WE-026, OC-WE-086, PP-WE-731 Peng J., PP-TH-642 Pendu R., PP-WE-284 Pendleton R., PP-WE-476 Pereira M.S., PP-WE-654 Pereira J., Pereira G.J.C., PP-MO-826 Pereira G. A. G., Pereira F. G., PP-TH-380 Perederyaeva E.B., Pereboom I.T. A., Percic I., Perchuc Perchuc Perarnau J., Pera M.G., PP-WE-839 Peppelenbosch M., OC-WE-105, PP-MO-489 Peppelenbosch M.P., Pepler L., Peoc’H K., Penz S., Pennings M., PP-WE-056 Penkala R. A., PP-WE-596, PP-WE-804 Penka M., PP-TH-303, PP-TH-304 Pengo V OC-MO-060, OC-WE-042, PP-TH-612, PP-TH-613, PP-MO-331, PP-TH-274, PP-MO-290, PP-MO-291, OC-TU-040, PP-MO-282, OC-TH-006, OC-TH-075, OC-MO-113, OC-TH-003, OC-MO-015, OC-MO-028, OC-MO-137, PP-MO-695, PP-TH-157, PP-TH-532, ., OC-MO-136, OC-MO-124 A., A. M., PP-WE-680 OC-MO-013, PP-WE-245 AS-TH-015, PP-MO-259, AS-MO-054, PP-WE-408 PP-TH-494 PP-WE-039 PP-MO-664 PP-MO-870 OC-MO-1 PP-MO-725, PP-MO-470, PP-MO-002, PP-MO-025 PP-MO-31 PP-MO-825, PP-WE-771 14 1 555

Authors Index AUTHORS INDEX

Pereira M., PP-WE-374 Persson E., PP-MO-117, Petros S., PP-TH-253, Pereirinha T., PP-MO-297 PP-TH-529, PP-WE-589 PP-TH-254 Perés Wingeyer S., Peruhype-Magalhães V., Petrov V. Y., PP-MO-688 PP-WE-236 PP-MO-063 Petruk O. A., PP-WE-337 Pérez Andreu V., OC-TH-120, Perutelli P., PP-MO-616 Pettersen A., PP-MO-719, PP-TH-481 Perveen R., PP-TH-095, PP-TH-118 Perez Bianco R., PP-WE-618 PP-WE-006 Petterson T. M., AS-TH-003, Perez Cuadra A., PP-MO-362 Perzborn E., PP-MO-162, PP-MO-284, PP-WE-292 PP-MO-183, PP-MO-184, Pettersson F., PP-TH-018 Pérez Más J., PP-TH-299 PP-MO-185, PP-WE-198, Perez R., PP-MO-590, PP-WE-199 Petteway - Jr S. R., PP-TH-231 PP-TH-578 Pesantes E., PP-TH-299 Perez-Casal M., PP-TH-197 Petteway S. R., PP-TH-230, Pesavento R., PP-TH-303, PP-TH-403 Perez-Garrido R., PP-WE-767 PP-TH-304, PP-WE-527 Pettinella C., OC-TU-088, Pérez-Lara Á., OC-TU-082 Pescott M., PP-TH-384 PP-MO-015, PP-WE-738 Perez-Ontiveros J., Pessina A. C., PP-MO-331 Peutz-Kootstra C. J., PP-WE-217 Pestilci F., PP-TH-284 PP-TH-181 Pergantou H., AS-MO-028, PP- Petakov M., PP-TH-296 Peynaud-Debayle E., TH-597, PP-WE-440 Peter K., PP-MO-100, AS-WE-025, OC-TH-082 Perina F., PP-TH-304 PP-WE-211 Peyrafitte M., PP-MO-419 Perini E., PP-MO-698, Peternel P., PP-WE-251 Peyvandi F., AS-MO-028, PP-MO-699 Peters A., OC-TU-034 AS-TU-033, OC-WE-131, Perkins S. J., PP-TH-657 OC-WE-132, PP-MO-092, Peters J., OC-TU-026 PP-MO-648, PP-MO-716, Perkmann T., PP-WE-777 Peters M. P., PP-MO-036 PP-TH-085, PP-TH-670, Perlati M. M. P., OC-TH-026 PP-WE-086, PP-WE-339, Peters M., PP-MO-597, PP-WE-657, AS-WE-011 Perlati M., OC-MO-049, PP-TH-356, PP-WE-548 PP-MO-242, PP-TH-382, Pezzullo S., PP-WE-321 Peters R. J., PP-TH-348 PP-WE-247 Pfaffenberger S., PP-MO-829 Peters R. T., OC-MO-083 Perlingeiro Beltrame M., Pfammatter T., PP-MO-643 PP-WE-066 Petersen C. L., OC-MO-040 Pfannkuche H., PP-WE-022 Perneby C., AS-WE-024 Petersen H., PP-MO-051 Pfeiff M., PP-TH-241 Perneger T., OC-TH-073, Petersen J. M., PP-MO-118, PP-MO-505 PP-MO-575 Pfenniger A., AS-TU-018 Pernod G., OC-MO-021, Petersen K., PP-MO-244 Pfrang J., PP-WE-886 PP-MO-315, PP-TH-309 Petersen L. C., PP-MO-575, Philippe P., PC-021 Perret C., OC-MO-021 PP-TH-116, PP-TH-237, Philippou H., OC-MO-076, Perret-Guillaume C., PP-WE-154 OC-MO-115, PP-MO-250, OC-MO-029 Peterse-Stienissen I., PP-WE-130, PP-WE-231, PP-WE-259 Perrier A., AS-TU-009, PP-MO-169 OC-MO-038, OC-MO-041, Peterson C., OC-TH-116, Phillips D. R., OC-TH-107, OC-TH-018, OC-TH-073, PP-TH-510 PP-MO-045, PP-TH-027, AS-TU-026 PP-MO-505, PP-TH-518, Petit L., PP-TH-432 PP-TH-524, PP-WE-375, Phillips D., AS-TH-022 OC-TU-011 Petitou M., PP-MO-175, PP-TH-423 Phillips J. K., PP-WE-297 Perry D. J., PP-MO-534, PP-TH-657, PP-WE-690 Petkovic M., PP-WE-369 Phillott A., PP-WE-609 Persdotter Eberg K., Petrera N. S., OC-WE-079 Philpot M. A., PP-WE-430 PP-MO-374 Petrides P., PP-TH-671 Phng L., AS-MO-061 Persichillo M., PP-MO-876 Petrini P., PP-TH-569 Phoenix F. P., PP-WE-212

556 Pieculewicz M., Pickard PP-TH-208 Pichlmaier M., Piccoli Piccioli A., Picardi N., Picard V., Piazza G., Piacente L., PP-TH-351 Phoenix F., INDEX AUTHORS Pineda J., Pilz G., PP-TH-302 Pilotto E., Pilon D., Pillot J., PP-WE-763 Pillitteri D., Pilka R., Pili C., Pilgrimm Piletz J., Pileri P Pijoan J., Pijl H., Pignoloni P., PP-WE-105, PP-WE-753 Pignatelli P., Piga M., Pietrangelo L., Pieters M., PP-MO-687, PP-WE-637 Pieroni G., PP-TH-302 Piermarocchi S., PP-MO-833 Piercecchi-Marti M., OC-WE-059 Pierce G.F., OC-MO-114, OC-TU-038 Pierangeli S.S., PP-TH-208 Piepenbrock S., Pieczanski P., PP-MO-746, PP-TH-662, ., PP-TH-282, PP-WE-359 PP-MO-782 A., OC-WE-138 A., PP-MO-266 PP-MO-375 PP-WE-673 PP-WE-378 OC-TU-023 PP-MO-857 A., PP-WE-371 PP-MO-187 PP-MO-424, OC-TH-027 PP-TH-424 AS-TH-059 PP-WE-856 PP-WE-228 OC-TU-064, OC-MO-013 PP-MO-545 PP-MO-179, OC-TH-055, PP-WE-878 OC-WE-057, PP-MO-746 PP-TH-050, PP-MO-287 PP-TH-100 PP-TH-207, PP-WE-738 PP-TH-337 PP-TH-207, OC-MO-026, PP-MO-424, OC-WE-062, PP-TH-617, Pizzuti M., PP-MO-342, PP-TH-347 Pizzolo F., Pizzo G., Pizzinelli S., Pittet M., Pittens C. Pitocco D., Piseddu G., Piscitelli L., Pisano P., Pisani F., PP-WE-366, OC-TU-035 Pisanelli D., Pirck M., Piran S., PP-WE-153 Pipe S.W., OC-TU-010, PP-MO-415 Piovella F., Piovella C., PP-WE-165 Piot M., Pio S.F., Pinzon E., Pintó X., Pinto B.L., Pinto A., Pintão M.C., OC-MO-019, OC-WE-023 Pintao M.C., OC-TH-028, PP-MO-654 Pinotti M., Piñol M., Pino M., Pink R., Pinho N., PP-WE-347 Pinheiro P. S., Ping T., PP-MO-466 Pineo G., OC-MO-053 Pineo G.F., PP-WE-155 Pinelis V., PP-WE-392 OC-TH-021, PP-WE-150 PP-TH-047 AS-TU-030 AS-TH-030 PP-WE-816 AS-WE-057 PP-TH-635 PP-WE-617 AS-TH-030 PP-TH-556 PP-MO-654 PP-MO-667 PP-MO-465, A. C., OC-WE-143, PP-MO-833 AS-WE-039, PP-MO-865 OC-TH-030, PP-MO-716 AS-WE-043, AS-MO-009, PP-WE-789 OC-TH-074 PP-MO-415 LB-MO-005, PP-WE-567 PP-MO-503 PP-MO-822, PP-TH-654 PP-TH-139 OC-MO-004, PP-MO-816, PP-MO-788 Planchetka J., PP-TH-598 Plamenová I., PP-MO-087 Plaimauer B., PP-TH-454 Plachuta T. G., Plyushch O.P Plyuchsh O.P., OC-TU-028 Pluthero F. G., Plumhoff E., PP-WE-470, PP-WE-471 Plumb J.M., Plug I., Plu-Bureau G., Plow E., OC-MO-048 Plow E.F PP-WE-225 Ploug M., OC-WE-022 Ploplis V Plompen E.P. C., Plessier Plesch W., Plénat F AS-WE-029, AS-WE-030 Pleines I., Plehn A., Plebani A., OC-WE-111, PP-TH-039 Plawinski L., Platzer C., Platt S.J., Platt R., PP-WE-440, PP-MO-619 Platokouki H., PP-TH-630 Platè M., Plat E., Plasenzotti R., Plantier J., Plantier J.L., Plantavid M., Planken E.V Plançon S., OC-TU-070 PP-MO-500 ., OC-TH-084 A., . PL-TU-005 PP-MO-210, ., PP-TH-440 PP-TH-394 A., AS-WE-047, AS-TH-040, PP-WE-613 OC-TH-101 OC-MO-047, PP-TH-120 OC-MO-062 PP-TH-050 PP-MO-224 PP-WE-013 ., OC-MO-134 PP-WE-469, AS-WE-050, OC-TU-050, PP-WE-019 OC-WE-021 AS-WE-015, ., PP-TH-306, OC-TH-008 PP-TH-597, PP-WE-803 OC-TH-060, PP-WE-675 PP-MO-688, PP-WE-316 OC-MO-036 PC-041 OC-TH-008 557

Authors Index AUTHORS INDEX

Plyushch O., PP-WE-608 Pomin V. H., PP-TH-178 Porte R. J., PP-WE-771 Pock K., PP-MO-615 Pompili M., PP-MO-328, Pos W., AS-WE-012, Podda G., OC-TH-010 PP-WE-823 AS-WE-013, PP-TH-080 Podolak-Dawidziak M., Poncelet P., PP-MO-766, Post M., PP-WE-193 PP-MO-692 PP-WE-785 Post Marketing Study Group ., Podolec P., PP-TH-337 Poncz M., AS-TH-008, PP-MO-618, PP-MO-619 AS-TH-042, AS-WE-027, Postma S., PP-WE-742 Podorolskaya L. V., OC-WE-151, SA-TU-006 PP-TH-158, PP-TH-257, Postmus P. E., PP-WE-322 Pongrácz E., PP-WE-350 PP-WE-224 Potaczek D., PP-TH-337 Poniewierski M. S., Podrez E., PL-TU-005, Potapova G. N., PP-MO-806 SA-TH-015 PP-MO-492 Potgieter J. J., PP-WE-124 Poenaru D., PP-WE-549 Pönitz V., PP-MO-433, PP-TH-131, PP-WE-126, Pötschke C., AS-TH-007 Poenitz V., PP-TH-344, PP-WE-829 PP-WE-072 Pottecher J., PP-TH-649 Ponniahpillai Subramanian H., Poettler M., OC-WE-069 PP-MO-821 Potthoff C. M., PP-MO-595 Poggi M., PP-MO-503, Pons D., OC-TH-110 Pötzsch B., AS-TH-048, PP-WE-715 PP-MO-409, PP-WE-180 Pontara E., PP-TH-259, Poggio R., OC-TH-014 PP-WE-641, PP-WE-645 Poul H., PP-TH-422 Pohar-Perme M., PP-MO-350 Pool R., PP-WE-124 Poulhazan E., PP-WE-186 Pohl S., PP-MO-030 Poole A. W., OC-MO-045, Pounder E., PP-TH-265 Pohlreichova V., PP-MO-583 OC-WE-123, PP-WE-020 Pouplard C., OC-TH-022, Poole A., AS-WE-035 PP-MO-527, PP-TH-365, Polack B., PP-TH-172 AS-TH-043 Poon M. C., AS-WE-003 Polanowska-Grabowska R. K., Pourfathollah A., PP-MO-214 OC-TU-027 Poon M., OC-TU-068, Pourmohamadi K., PP-TH-535 Polanski S., PP-WE-884 PP-WE-546, PP-WE-553, PP-WE-695 Pourmohammadi K., Poldermans D. D., OC-TH-029 Pop L., PP-MO-532, PP-TH-534 Polenewen R., PP-WE-735 PP-WE-549, PP-WE-552 Povazan L., PP-WE-368, Poli D., AS-TH-005, Popescu N. I., AS-MO-045, PP-WE-369 OC-TH-002, OC-TH-003, OC-TH-065, OC-WE-028 Powazniak Y. P., PP-MO-831, OC-TH-004, OC-WE-102, Poplavsky J. L., PP-WE-655 PP-MO-832, PP-TH-044, PP-MO-290, PP-MO-291, PP-WE-089, PP-WE-094 PP-MO-303, PP-MO-304, Popov D., PP-MO-855, PP-MO-339, PP-MO-340, PP-TH-003 Powell L., PP-WE-873 PP-MO-341, PP-TH-412, Popov V. I., PP-WE-075 Powell S., AS-TU-014, PP-TH-474, PP-WE-283, OC-TH-085 PP-WE-286 Popov V., PP-TH-063 Poyet R., PP-MO-773 Poli G., PP-MO-540 Popovic S., PP-TH-296, Pozgaj R., OC-TH-039 Polipoli D., OC-TH-006 PP-WE-680 Pozner R., PP-WE-042 Politou M., PP-TH-338 Porcar L., OC-WE-050 Porcher R., PP-MO-862 Pozzi N., AS-MO-013, Polkinghorne V., OC-TH-089 OC-MO-113, OC-TU-040, Pollack C. V., PP-WE-284 Porche-Sorbet R., PP-TH-473 OC-WE-081, PP-TH-085 Pollmann H., OC-WE-077, Porco A., PP-TH-555 Pracucci G., OC-TH-047 PP-MO-459, PP-TH-575, Pordes G., OC-TH-054 Pradella P., OC-MO-121 PP-WE-593, PP-WE-594, Poredos P., PP-MO-350 PP-WE-670 Pradier O., PP-WE-013 Porntrasertsud N., PP-MO-354 Pollola J. A., PP-WE-203 Prager G. W., OC-WE-069, Porreca E., OC-WE-014, PP-MO-838, PP-MO-848, Poloczek M., PP-WE-804 PP-WE-311 PP-WE-843 Pombo M., PP-MO-389 Portarena I., PP-TH-494

558 PP-WE-410, PP-WE-460, PP-TH-304, PP-WE-403, PP-TH-302, PP-TH-303, OC-MO-049, PP-MO-424, OC-MO-013, OC-MO-015, OC-TH-070, OC-TH-110, AS-TH-058, OC-TH-023, Pratt K.P., Praticò D., Prathibha B., PP-MO-805, PP-MO-836 Pratesi G., PP-MO-805, PP-MO-836 Pratesi C., PP-WE-527 Prandoni P., INDEX AUTHORS PP-MO-673, PP-TH-300 Primignani M., Primiani L., PP-TH-596 Prieto M., Priepke H., PP-WE-553 Price V Price L., Prezoto B.C., Prezoti A., Prévost C., Preudhomme C., Prestidge T., PP-WE-678 Presnyakova M.V., OC-WE-002, PP-TH-076 Presles E., Presbitero P., PP-TH-486, PP-WE-490 Prengel C., PP-TH-546, PP-TH-547 Prejanò S., PP-MO-827 Preissner K.T., Preiss J.R., Préda I., PP-TH-404, PP-WE-395 Prechel M., Pratt K., PP-MO-686, PP-WE-447, PP-MO-590, PP-MO-601, ., AS-WE-003, PP-TH-616 OC-MO-002 PP-MO-772 PP-MO-566, PP-WE-631 PP-MO-804, OC-WE-046 PP-MO-804, PP-MO-156 OC-MO-050, PP-WE-390 PP-MO-432, OC-WE-021 PP-TH-485, PP-MO-703, PP-WE-618 PP-WE-569 LB-MO-002, PP-MO-493 PP-TH-496 PP-WE-791 PP-MO-124 PP-MO-224, AS-TH-037, PP-WE-762 PP-WE-425, PP-WE-457, PP-WE-317, PP-WE-318, PP-MO-286, PP-MO-337, OC-TU-012, OC-WE-100, OC-TH-001, OC-TH-017, PP-TH-380 Pshenichnikova T. B., Psaty B., Psaty B.M., Przyklenk K., Pryzdial E.L.G., PP-MO-629, PP-MO-678 Pruthi R.K., AS-MO-020, PP-TH-631 Pruss C.M., Pruss A., Provaznikova D., PP-TH-074 Proulle V Protonotariou E., Prorok M., PP-WE-824 Proietti M., Profumo A., Prock A., Prochnow S., Procházková J., PP-WE-273 Prochazkova J., Procházka M., Privalov D., Pritchard D., Prisyazhnaya N., PP-WE-748 Prisco D., Prinsloo A., PP-WE-352 Prins M., PP-WE-475 Prins M.H., PP-TH-650, PP-WE-787, PP-TH-623, PP-TH-649, PP-WE-746, PP-WE-747, PP-TH-474, PP-WE-283, PP-MO-743, PP-TH-352, PP-MO-340, PP-MO-341, PP-MO-304, PP-MO-339, PP-MO-291, PP-MO-303, OC-WE-102, PP-MO-217, OC-WE-031, OC-WE-032, OC-TH-006, OC-TH-075, ., OC-MO-016, SA-TU-017 AS-TU-057 PP-MO-240 OC-TH-003, PP-TH-470, AS-WE-049 PP-MO-379, PP-WE-743 LB-MO-004, PP-WE-124 OC-WE-148 OC-TH-117 AS-MO-018, PP-MO-487, PP-MO-433 PP-WE-102 PP-MO-730 PP-WE-378 PP-WE-378 PP-WE-142, OC-MO-118 PP-TH-227 PP-TH-083 PP-MO-302 Pugh N., Puehringer H., Puck M., Puchta A., PP-MO-800, PP-TH-340 Pucci N., Ptoszkova H., Qing P Qin P Qin L., OC-MO-048 Qin J., Qi Qi G., PP-WE-449 Qayyum S., Qadura M., PP-TH-327 Pyle M., Puy C., Puurunen M., Puttarajappa C., PP-WE-063 Purvis J.E., Purroy N., Purihit P. K., Pure E., Punzo M., Punzalan R.C., Puntes M., Pullinger C.R., PP-MO-805, PP-MO-836 Pulli R., Pullenayegum E., Pullen G., Pullan S., Pulizzi N., PP-WE-789 Pulcinelli F. M., Pulanic R., Pulanic D., PP-WE-505 Pujade-Lauraine E., PP-WE-270 Puig J., PP-WE-052 OC-WE-096, PP-WE-448, Y ., ., OC-MO-123 OC-TU-051, PP-WE-836 ., PP-MO-695 OC-MO-047, PP-WE-222 PP-MO-178 PP-WE-267, OC-MO-136 PP-MO-804, AS-TU-028 PP-TH-326, PP-WE-028, PP-WE-329 PP-MO-799, PP-WE-416 PP-MO-756 OC-TU-072 PP-MO-016 PP-WE-761 OC-MO-059 PP-WE-178 PP-MO-630 PP-MO-630 OC-TH-053 OC-WE-092, PP-TH-049, OC-WE-146 PP-WE-276 PP-MO-563 PP-MO-141 AS-WE-010 PP-MO-104, OC-TU-065 PP-WE-495 PP-WE-553 559

Authors Index AUTHORS INDEX

Qing Y., PP-MO-691 Rachmilewitz E., PP-MO-338 Raman S. V., PP-WE-729 Qiu Y., PP-WE-857 Radaelli T., PP-WE-691 Ramasamy S. M., PP-WE-503 Quehe P., PP-MO-500, Radesi S., PP-MO-069, Rambaldi A., AS-TU-048, PP-WE-508, PP-MO-499 PP-TH-063 AS-TU-050 Quehenberger P., OC-MO-027, Radhakrishnan R., PP-WE-063 Ramirez A. E., PP-MO-345 OC-TU-016, PP-MO-422, Radojkovic D., PP-TH-460, Ramirez L. M., PP-WE-489 PP-TH-077, PP-TH-273, PP-WE-379 PP-WE-663 Ramirez L., PP-MO-528 Radossi P., PP-MO-542 Queijo I. M. I., PP-MO-641 Ramon L. A., PP-MO-215 Radovanovic N., PP-TH-296 Quenet S., PP-TH-288 Ramos C. D., PP-WE-535 Radu C., OC-MO-005, Ramos O. H., PP-WE-160 Quentin G., PP-MO-112, OC-MO-119, OC-MO-121, PP-TH-235 OC-TU-086, PL-TU-004, Ramos-Nino M. E., AS-MO-033 Quere G., PP-MO-310 PP-MO-242, PP-MO-243, Rampini M. R., PP-MO-380 Quere I., PP-TH-497 PP-MO-765, PP-WE-080, PP-WE-081, PP-WE-247, Rampini M., PP-MO-379 Quéré I., OC-TH-081, PP-WE-248, PP-WE-384 Ramroop N., PP-TH-090 PP-TH-288 Radulovic V., PP-MO-652 Ramström M., PP-MO-574 Querellou S., PP-WE-510, PP-MO-508 Rafailovich M., PP-MO-211 Ramstrom S., PP-TH-053 Quero F., PC-050 Raffini L. J., AS-TU-055 Ramström S., PP-WE-014 Quesnel B., PP-MO-814 Rafi S., OC-WE-014, Ramzi M., PP-WE-459 PP-TH-356, PP-WE-548 Quijada A., PP-MO-737, Rancan E., PP-MO-659 Rafiee Khoshnood E., PP-WE-692 Rand J. H., OC-TU-039, PP-WE-074 Quilici J., PP-WE-775, PP-WE-468 Rafii A., PP-WE-855 PP-MO-773 Rand M. L., AS-TH-053, Quinart A., PP-WE-673 Rafii S., SA-TH-008 OC-TH-060, PP-MO-020, PP-MO-639, PP-TH-009 Quinlan D. J., PP-TH-413 Ragab M. ., PP-WE-202 Randell E., PP-TH-364 Quinn-Allen M., PP-TH-261 Ragni M. V., OC-MO-031, PP-MO-627 Randolph G., SA-TU-011 Quintana J. C., OC-WE-086 Rago L., PP-MO-876 Rangarajan S., PP-MO-272, Quintana M., PC-031, PC-032, Ragoonanan V., PP-WE-432 PP-MO-371, PP-MO-543, PC-033, PP-MO-579, PP-MO-562, PP-TH-014, PP-MO-590, PP-WE-699 Rahayu P., OC-MO-072 PP-TH-599, PP-TH-615, Quintanar L., PP-WE-874 Rahe-Meyer N., PP-TH-207, PP-WE-111, PP-WE-539, PP-WE-609, PP-WE-616 Quintavalla R., PP-MO-294 PP-TH-208 Rahman S., PP-TH-014 Ranjan R., PP-MO-208, Quintavalle G., PP-MO-336 PP-WE-327 Rahmani M., PP-TH-124 Quintella F. F., PP-MO-483 Rank A., PP-WE-784 Rajab J. A., PP-MO-452 Quiroga T., AS-MO-054, Rankin A., OC-TH-093 AS-TH-052, PP-WE-123 Rajic N. V., PP-WE-680, Rannou O., AS-TH-058 Qureshi S. H., OC-TU-093 PP-WE-680 Rans D., PP-MO-617 Raab M., PP-MO-043, Rajnavölgyi É., PP-MO-359 PP-MO-044 Rajpurkar M., PP-TH-180 Rao A. K., AS-TH-044, PP-MO-078 Raaz U., PP-TH-440, Rajpurohit S., PP-TH-156 Rao A., PP-WE-894 PP-WE-190 Raju N. C., PP-WE-800 Rao V. S., AS-WE-059, Rabe E., PP-MO-509, Rakicevic L., PP-TH-460, PP-TH-312 OC-TH-118, OC-WE-139, PP-WE-379 PP-MO-791, PP-MO-792, Rabelink T. J., PP-WE-851 Ralevic V., PP-WE-045 PP-MO-793, PP-MO-811, Rabinovich O., PP-WE-135, Rallidis L., PP-TH-338 PP-MO-812, PP-WE-828, PP-WE-293 PP-WE-832, PP-WE-833, Ramacciotti E., OC-TU-060, PP-WE-834 Rachman A., OC-MO-072 PP-MO-388

560 Rassoulzadegan M., Rasmussen L.H., Rasmussen J.T., Rasmussen J.K., Raskob G.E., Rasheed N., Rapson D., OC-WE-074 Rapoport T., PP-MO-380, PP-WE-824 Raparelli V., Rapaccini G., INDEX AUTHORS Razzari C., Razzaq T., Rázsó K., PP-TH-579 Raymer R. A., Ray P Ray M.J., Ray L., Rawlins P PP-MO-385 Ravnefjord A., PP-MO-685 Ravid B., Ravi KumarV Ravenhill L., PP-TH-553, PP-TH-636 Ravanbod S., OC-TH-034, PP-MO-033 Ravanat C., Raval S.R., Raupach J., Rauova L., Rauh M., Rauch R., Raubal B., Ratignier C., Rathnam V., Rathgen K., Rateri D.L., Rasul F., Rastegar-Lari G., PP-TH-553 Rastegarlari G., PP-MO-539, PP-TH-553 . S., PP-WE-450 OC-WE-005 PP-MO-544 PP-MO-434, ., AS-TU-041 PP-MO-359 PP-TH-450 PP-WE-021 OC-WE-024 PP-MO-561 AS-TH-008 PP-WE-136 PP-TH-206 PP-TH-639 OC-MO-124, PP-WE-195 PP-TH-134 OC-TH-077 PP-TH-438 PP-MO-379, PP-TH-117 AS-TU-025, PP-TH-062 PP-MO-530 PP-MO-853 ., PP-MO-539, PP-MO-328 LB-MO-005 PP-MO-570, PP-MO-095, OC-TH-1 PP-MO-539, PP-TH-636 PP-MO-131 PP-MO-580 PP-WE-172 18 PP-WE-055 Reiff E., Reid R., Reiber J.H.C., PP-WE-060 Reheman A., Rehberg S., Rego E.M., PP-TH-362 Regnault V., PP-TH-365 Regina S., Reghis PP-WE-885 Reganon E., Regan I., Reekers J. A., Reed M., PP-WE-218 Reed G.L., Redzic D., Redou P Redossi P., Redondo M., Redfors P., Reddy C.D., Rector W. G., Recknagel P., Recke P. V. D., Recher C., Receveur N., PP-WE-738 Recchiuti A., Rebrikov D., PP-WE-449 Rebeyka I., PP-WE-270 Reber G., Reaves Reati R., Reale D., Reakatanan W Rea C., Rea C.J., PP-MO-402, PP-WE-133, PP-TH-520, PP-WE-267, A., PP-WE-623 A., ., AS-TH-060, PP-WE-462 PP-TH-300 OC-TH-015 PP-WE-615 PP-MO-104 OC-TU-037, PP-TH-1 PP-MO-371 PP-WE-254 PP-MO-527, PP-TH-276 OC-MO-099 PP-MO-471 OC-WE-115 OC-WE-096, PP-WE-071, PP-TH-527 OC-WE-023 PP-MO-556 OC-MO-029, PP-TH-363, PP-WE-335 PP-MO-028 AS-TU-049, AS-WE-042, PP-MO-71 PP-TH-010 PP-MO-463 PP-TH-087 ., OC-TH-031 OC-MO-040 PP-WE-303 PP-MO-354 13 1 OC-MO-124, OC-WE-051, PP-MO-588, PP-TH-619, PP-MO-620 Reininger Reinhart K., Reinhardt C., P.,Reiner A. Rein C.M., Reshetnyak T., PP-TH-267, PP-TH-277 Reshetnyak T. M., Resh M., PP-WE-600 Repesse PP-WE-744 Reny J., OC-TU-032, PP-MO-783 Reny J.L., Renneville OC-TH-059, PL-TU-003 Renné T., Renna F., PP-WE-408 Rendu F., Renaudin J., Remuzzi G., Remones V Remandet B., Reizig P., PP-WE-621 Reitter S.E., PP-TH-484 Reitsma P. H., Reiter M., Reiss U., PP-WE-155 Reiser G., PP-TH-495 Reis E.M., Reis D., Reipert B., OC-WE-063, OC-WE-065 Reipert B.M., AS-WE-034, OC-MO-068, AS-TH-037, PP-MO-764, PP-TH-139, OC-MO-020, PP-MO-236, OC-MO-004, OC-MO-019, AS-MO-063, AS-WE-040, PP-WE-310 AS-TH-032, Y., PP-WE-326 AS-TU-011 LB-MO-003 SA-WE-014, PP-WE-856 PP-MO-837, PP-MO-150 A. J., OC-WE-143, A., SA-TU-014 OC-MO-132, PP-MO-475, ., PP-MO-239 AS-TH-039, OC-WE-066, PP-WE-684 PL-TU-006 AS-WE-009 OC-TH-005 PP-TH-317, PP-WE-483 AS-WE-054 PP-WE-388 OC-TH-054, AS-MO-005, PP-WE-762 PP-WE-062 AS-TH-057, PP-MO-268, 561

Authors Index AUTHORS INDEX

Rettig R., OC-TU-026 Riccardi F., PP-MO-523, Rijken D. C., PP-MO-224, Reuken P., PP-TH-086, PP-WE-598 PP-TH-314, PP-WE-228 PP-WE-684 Ricci I., PP-TH-353, PP-TH-474 Rijnders A. J. M., OC-TU-008 Reusser M., PP-MO-736 Riccioni M., PP-WE-647 Rim D., PP-MO-353 Reutelingsperger C. P., Ricco A. J., PP-TH-052, Rim S., PP-WE-783 OC-TU-053 PP-TH-053, PP-WE-059 Rimm E., OC-TU-004 Reuwer A. Q., PP-MO-022 Riccò M., PP-MO-294 Rimoldi V., PP-TH-670 Revel A., PP-WE-696 Rice A., PP-WE-749, Riondino S., PP-MO-379, Revel P., PP-WE-673 PP-WE-750 PP-TH-494, PP-WE-789, Revel-Vilk S., AS-TU-008, Ricevuto E., PP-TH-694 PP-WE-824 PP-WE-696 Richard V., PP-WE-859 Rios D. R. A., PP-MO-363, Reverter J. C., OC-MO-130, Richards M., AS-TH-054, PP-MO-364, PP-TH-217, PP-MO-254, PP-WE-371 PP-MO-560, PP-TH-578 PP-WE-092, PP-WE-310 Rey I., PC-047 Richardson J. L., PL-TU-002 Rios M., PP-WE-665 Rey Santos R., PP-TH-299 Richardson J., PP-WE-168 Riou B., PC-023 Reyes C., PP-MO-663, Richardson P. G., OC-WE-108 Ris C., OC-TU-055 PP-MO-737, PP-WE-692 Richel D. J., OC-WE-019, Risberg B., PP-MO-430 Reyes E., OC-MO-134, PP-TH-484 Rischel C., PP-MO-559 PP-TH-482, PP-WE-264 Richter E. K., OC-TU-052 Risco L., OC-WE-090 Reynaud J. J. R., PP-MO-594 Ricker L. J. A. G., PP-TH-246 Riserus U., OC-TU-087 Reynaud J., PP-WE-165 Rickles F., OC-MO-016 Rishavy M. A., OC-WE-078 Rezaie A. R., OC-TU-093 Rico M. C., OC-WE-030, Rishavy M., OC-WE-072 Rezende S. M., AS-TU-019, PP-WE-888 Risse F., PP-MO-385 PP-TH-556 Rico S., PP-WE-178, Ritchie K., PP-TH-349 Rezende S., PP-WE-312 PP-WE-415 Ritli L., PP-MO-532, Rezende-Neto J. B., Riddell A. F., PP-MO-524, PP-WE-549 PP-MO-387 PP-MO-624, PP-TH-106, PP-TH-528, PP-WE-713 Rittich S., PP-MO-583, Rezzonico F., OC-TU-072, PP-TH-083 PP-WE-625 Riddell A., PP-TH-242, PP-WE-192, PP-WE-240 Rivard G. E., AS-TH-045, Rhee K., PP-TH-504 AS-WE-003, OC-TU-069, Rhemtula H. A., PP-TH-370, Ridker P., SA-WE-009 PP-WE-553 PP-TH-371 Riedel T., PP-TH-213 Rivard G., OC-TU-068 Rhomdhane M., AS-WE-030 Rieke M., PP-MO-693, Rivas I., PC-048, PP-TH-603, Rib L., PP-WE-209, PP-WE-243 PP-WE-644 PP-TH-604, PP-WE-560, Riba R., PP-MO-023, Rienstra C. M., OC-TU-091, PP-WE-765 PP-TH-020 PP-MO-113 Rivera J., AS-MO-054, Ribeiro D. D., PP-MO-333, Riera A., PP-MO-226 AS-TH-052, PP-MO-055, PP-MO-334, PP-MO-335, Ries M., PP-TH-575 PP-MO-732, PP-TH-096, PP-WE-033, PP-WE-764 PP-MO-387, PP-TH-672, Riess H. B., LB-MO-003, PP-TH-673, PP-TH-674, PP-MO-509 Rivera L., OC-TH-036 PP-WE-364, PP-WE-689 Riess H., PP-TH-312, Rives S., PP-TH-451 Ribeiro L. M., PP-TH-444 PP-TH-425 Rivolta G. F., PP-MO-525 Ribeiro M. A., PP-TH-490 Riewald M., AS-TH-020 Rivolta G., PP-MO-523, Ribeiro M., PP-WE-730 Righini M., OC-MO-038, PP-WE-567, PP-WE-598 Ribó Crusat F., PP-TH-299 OC-MO-041, OC-TH-073, Rivron-Guillot K., PP-WE-165 Ricafort R., PP-MO-180 PP-MO-505, PP-TH-518, Rizoli S. B., PP-MO-387 PP-TH-524, PP-WE-375, Riccardi A., PP-TH-374 OC-TU-011, PP-TH-508 Rizza V., PP-MO-654 Rigolli A., PP-TH-374 Robert F., PP-WE-768

562 PP-TH-542, PP-WE-444, Robertson J.D., Robertson I., PP-TH-020 Roberts W., OC-MO-089 Roberts L., OC-TU-044 Roberts J.R., Roberts H.R., Roberts PP-WE-785, OC-TU-089 Robert S., INDEX AUTHORS PP-WE-629, PP-WE-630 Rodeghiero F OC-TU-075, PP-MO-591 Rocino Rochon J., Roche H., PP-MO-034 Rocha T. R.F., Rocha P. R.S., Rocha M.M., Rocco M., Rocci A., Rocchetti L., PP-WE-738 Rocca B., Rocca A., OC-MO-127 Robson S., Robles-Carillo L., 001 Robles L., OC-TU-023 Robinson-Cohen C., OC-TU-068, PP-WE-553 Robinson S., PP-WE-608 Robinson M., Robier A., OC-WE-116 Robertson M., PP-WE-443 PP-TH-082, PP-TH-085, OC-TU-087, PP-MO-040, PP-WE-627, PP-WE-628, PP-MO-612, PP-WE-626, OC-TU-074, OC-WE-136, A., A. W., PP-MO-294 AS-TU-049, PP-TH-654 OC-TU-087 AS-WE-050, PP-MO-332 OC-WE-148 PP-TH-482, PP-WE- AS-WE-005, PP-MO-295 AS-TH-025, OC-MO-088, PP-MO-024, PP-WE-688 ., AS-WE-003, PP-MO-233 PP-MO-124 PP-TH-536, OC-TH-096, OC-WE-061 OC-WE-033, AS-WE-032 PP-MO-124, AS-MO-029, PP-TH-672 PP-MO-639, PP-MO-004 OC-TH-012, OC-TU-011, PP-MO-523, PP-MO-542, PP-WE-123, PP-WE-764 Roldán V., PP-TH-481 Roldan V Roldan V. V., Rojnuckarin P Rojas M., Roheghiero F., Rohatagi S., PP-MO-809 Rogacev K.S., PP-WE-357 Roest M., Roessle M., Roemisch J., PP-MO-190, PP-MO-191 Roelofs J.T PP-MO-472, PP-TH-675 Rodríguez-Otero P., PP-TH-100 Rodriguez MoncalvoJ., Rodriguez J., OC-TH-1 Rodriguez J. A., Rodriguez C., Rodriguez Rodrigues V., OC-WE-091 Rodrigues PereiraR., PP-WE-347 Rodrigues K.F Rodrigues C. A., PP-WE-509 Rodorigo G., PP-TH-626, PP-WE-544 Rodgers S., PP-WE-725 Rodgers G.M., PP-MO-460 Rodger M., PP-TH-489, PP-WE-462 OC-MO-037, PP-TH-292, Rodger M. Rodewald L., Roden R.C., OC-TH-025, PP-TH-055, OC-TH-027, PP-MO-732, 13 ., PP-MO-790 AS-WE-008, AS-TH-052, OC-TH-120, A., A., OC-MO-087, OC-WE-148 PP-TH-188, OC-WE-003 PP-TH-308 PP-WE-016 AS-TH-029, PP-WE-697 PP-MO-615 PP-MO-209 ., PP-TH-217 AS-WE-022, PC-047 . H., OC-MO-130 ., AS-MO-017 OC-MO-126, PP-WE-306, PP-TH-245 OC-MO-130, PP-MO-816, PP-MO-862 Romaniuk M. Romanenko O., PP-MO-805 Romagnuolo I., Rolli V., PP-MO-373 Rolfes E., Rosenbaum E.J., Rosen H., PP-WE-394 Rosen E.D., Roselli M., Rose P Rose K., Rose H., Rosario P. W., Rosano C., Rosado J. A., Rosa J., Roque M., Roos Roodt J., Rondelli F., Roncon L.R., Ronca E., Rommens J., PP-TH-286 Romijn J. A., Romijn F PP-MO-656 Romey-Chatelain M.C., Romero J., Romeih S., OC-MO-1 Romay-Penabad Z., OC-MO-026 Romay- PenabadZ., Romanov Y. A., N., Romanov A. Romano P. S., Romano M., PP-WE-747 Romano E., PP-WE-042 PP-WE-745, PP-WE-746, Y ., . B.W. E., OC-MO-062 OC-TH-076 OC-WE-043 ., 14, OC-TU-038 PP-WE-022 PP-WE-468 AS-TH-024 PP-MO-317, AS-TU-043 PP-TH-374 PP-WE-497 PP-MO-254 PP-TH-494 PP-MO-579 PP-MO-507 OC-WE-148 OC-TU-024 PP-MO-818, AS-TU-049 OC-TU-031, PP-TH-238, AS-TH-045 A., PP-TH-003 PP-MO-349 PP-TH-311 PP-MO-856 PP-MO-743, PP-WE-010 PP-MO-182 PP-MO-312 PP-WE-035, AS-TU-035 PP-TH-424 563

Authors Index AUTHORS INDEX

Rosenberg N., OC-MO-105, Rossi L., PP-MO-818, Roy P., AS-TU-009, OC-TH-042, PP-TH-013, PP-WE-746 OC-MO-038, OC-MO-041, PP-TH-075, PP-WE-010 Rossi M., PP-WE-791 OC-TH-018, PC-023, PP-TH-524 Rosenbreg N., PP-TH-084 Rossi V., PP-MO-572 Royer B., AS-TH-043 Rosencher N., OC-MO-050, Rosso F., PP-WE-338 OC-WE-002, PP-TH-167, Rozalski M., PP-TH-098, PP-TH-169, PP-TH-170, Rosso M., PP-WE-870 PP-TH-099 PP-WE-204, PP-WE-205 Rota L. L., AS-WE-007 Ruan C., PP-MO-830, Rosencrance J. G., PP-TH-354 Rota L., PP-WE-791 PP-MO-854, PP-MO-859, PP-MO-883, PP-TH-093, Rosendaal F. R., AS-MO-003, Roth I., AS-TU-018 AS-MO-005, AS-MO-034, PP-TH-399, PP-TH-400, AS-TH-002, AS-TH-035, Rother R. P., OC-WE-012 PP-TH-621, PP-WE-088, PP-WE-099, PP-WE-711, AS-WE-008, LB-MO-001, Rothschild C., PP-MO-077, PP-TH-335, PP-WE-773 OC-MO-003, OC-MO-004, PP-MO-530, PP-TH-593, OC-MO-020, OC-MO-023, PP-TH-619, PP-WE-592 Ruan J., PP-MO-883 OC-MO-024, OC-MO-079, Rothwell P., OC-MO-009 Ruano M., PP-WE-796 OC-TH-025, OC-TU-001, OC-TU-070, OC-WE-013, Rotilio D., PP-TH-048, Rubal B. J., PP-MO-103 OC-WE-015, OC-WE-016, PP-TH-248 Rubbi F., OC-TH-011 OC-WE-036, OC-WE-091, Rotmans J. I., OC-TH-031 PP-MO-289, PP-MO-316, PP Rubboli A. A. R., PP-MO-312 Rotschild C., PP-TH-172 Rosendaal F., SA-TU-018 Rubets I., PP-WE-179 Rott H., PP-MO-377, Rubichek O., PP-MO-313 Rosenkranz A., PP-WE-439 PP-TH-646, PP-TH-647, Rosenqvist M., PP-TH-469 PP-TH-671, PP-WE-370, Rubin M. S., PP-MO-825, PP-WE-669, PP-WE-670 PP-MO-826 Rosenstein R., PP-MO-038 Rottensteiner H., PP-MO-640, Rubini V., PP-WE-625 Rosenthal C., PP-MO-240, PP-TH-641, PP-WE-619 PP-MO-241 Ruchutrakool T., PP-MO-406, Rough J. J., OC-WE-030, PP-WE-772 Rosenthal E., PP-MO-749 PP-WE-888 Rudd C. E., PP-MO-041 Roshani S., AS-MO-030, Rouhl R. P. W., OC-TU-085, PP-TH-139 Rudd-Scott L., OC-TH-007 PP-WE-219 Roshdy Elsafy U., PP-TH-445 Rudez G., OC-MO-133 Roullet S., PP-WE-673 Rosholm A., OC-WE-055 Rudezˇ G., PP-MO-781 Roumenina L. T., PP-WE-614 Rosing J., OC-MO-005, Rudigoz C. R., PP-TH-385 Roumeque L., PP-TH-060 OC-MO-119, OC-WE-097, Rudzki Z., PP-WE-544 PP-MO-186, PP-MO-337, Rouse J., PP-WE-703 Ruf A., PP-TH-681 PP-TH-377, PP-WE-157, Rousseau A., PP-MO-368, PP-WE-352, PP-WE-499 PP-MO-369, PP-MO-491, Ruf W., SA-MO-011, AS-MO-063, AS-TU-043, Roskell N. S., PP-WE-469, PP-TH-345, PP-TH-447, AS-WE-054, OC-MO-129, PP-WE-470, PP-WE-471 PP-TH-483, PP-WE-508 OC-TH-110 Ross D. A., AS-WE-010 Roussel B., PP-MO-125 Ruffatti A., OC-MO-028, Ross D., OC-WE-096, Roussel-Robert V., OC-MO-113, OC-TU-040, PP-WE-449 PP-WE-533, AS-TH-043 PP-TH-274 Rossetti G., AS-TU-032 Routledge M. N., PP-TH-212 Rugeri L., PP-MO-645, Rossetto V., OC-TU-086, Rovere-Querini P., OC-WE-127 PP-MO-658, PP-TH-385, PP-TH-386 PP-MO-348, PP-TH-382, Roveri R. G., PP-WE-535 PP-TH-383, PP-TH-487, Ruggeri Z. M., AS-MO-049, PP-TH-488, PP-WE-147, Rovin B. H., PP-WE-729 OC-TH-096, OC-TU-044, PP-WE-247 Rovira N., AS-MO-065 PP-WE-018, PP-WE-791, AS-WE-036 Rossi E. E. R., PP-MO-372 Rowland C. M., AS-WE-010 Ruggeri Z., AS-TU-030, Rossi E., PP-WE-366 Roy A., PP-TH-599, PP-MO-775, PP-WE-060 Rossi J., PP-WE-694 PP-WE-111, PP-WE-609 Ruggiero L., OC-TU-025 Roy P. M., PP-TH-518

564 OC-WE-033, OC-WE-116, PP-WE-353 Rumley A., PP-WE-692 Ruiz-Saez Ruiz NodarJ., PP-WE-270 Ruiz N., Ruivard M., PP-MO-169 Ruinemans-Koerts J., Rugin A., INDEX AUTHORS Ryser R., Ryoo H., PP-WE-125 Ryland J.K., PP-WE-034 Rychlik B., Rychli K., Rybaltowski M., Rybakova L.P., Ryan K., Ryan F., Ryan C., Ruzza L., PP-MO-781 Ruven H.J.T., Rutella S., Russolillo PP-MO-476, PP-WE-499 Russo L., Russo A., Russmüller G., Russin M.P., PP-MO-082, AS-MO-031 Russell S., Russell S.J., PP-TH-162, PP-WE-434 Rusicke E., Rusconi A., Rusanova Rupwate M., PP-MO-395, PP-WE-396 Rupin A., Rundgren M., Rumph B., PP-MO-663, PP-MO-737, PP-WE-267, PP-MO-414 PP-WE-802 PP-WE-443 PP-TH-504 PP-MO-331 PP-MO-279 PP-MO-382, OC-TU-057 AS-TU-050, PP-MO-829 PP-WE-653 A., A., A., PP-TH-085 PP-MO-776 OC-WE-020, PP-TH-098, OC-TH-080, PP-MO-130, PC-013, PC-021 OC-TH-010 PP-MO-200 PP-MO-325, PP-WE-704 PP-TH-458 PP-MO-526, PP-MO-336 PP-MO-875 PP-WE-721 OC-TH-120 OC-MO-133, PP-MO-718 PP-WE-835 OC-WE-054 PP-MO-346, PP-MO-363, PP-MO-334, PP-MO-335, OC-TU-087, PP-MO-833, Sage S.O., Saftoiu C., PP-WE-888 Safadi F Safa O., PP-TH-043, PP-WE-057 Sáez C.G., Sáez A., Saenz D., PP-WE-107 Sadowski J., Sadler J., Sadler J.E., Sadler E., Sadeghi B., Saczewicz I., Sack B., Sachs U., Sachs U.J.H., Sachdev S., Sacewicz I., PP-TH-527 Saccullo G., Sabrina G., Sabovic M., Sabo T PP-WE-364, PP-WE-815 P.,Sabino A. Sabatino D.E., PP-WE-850 Sabatier F., PP-WE-208, PP-WE-209 Sabater-Lleal M., Sabaie S.E., PP-WE-686 Saab R., Sa Q., S. SenH., Rzeszutko M., PP-WE-034 Rywaniak J., Ryttberg L., Rysz J., OC-WE-090, PP-MO-860, OC-TU-036 . M., . F PP-MO-200 PP-MO-097 PP-TH-555 OC-TH-049 PP-TH-456, PP-MO-038 PL-TH-001 PP-MO-083 ., OC-MO-070 PP-TH-121 PP-TH-063 PP-WE-158 OC-WE-086, AS-WE-050, PP-MO-003 PP-WE-147 OC-MO-043, PP-TH-31 PP-MO-350 PP-WE-472 PP-MO-839 PP-MO-427 AS-MO-014 AS-TH-030, PP-MO-333, PP-TH-506 PP-MO-097, PP-MO-798, PP-MO-843 PP-MO-355 AS-MO-050 AS-TU-013 PP-TH-290, 1 Sahuquillo J., Sahlab S., Sahin T., Saggioro F PP-WE-866 Saggiorato G., PP-WE-179 Salazar D., Salazar D.E., PP-MO-508 Salaun P., Salatic I., Salameh P., PP-TH-083, PP-TH-543 Salaj P., PP-WE-822 Sala N., Sakurai Y., PP-TH-319, PP-WE-463 Sakurai H., Saksena R., Saksela K., PP-TH-411 Sakon M., Sakellaridis T PP-TH-054 Sakata Y., PP-TH-320 Sakata T., PP-TH-042 Sakata C., Sakariassen K.S., PP-WE-606 Sakai M., Saka B., Saito J., PP-TH-081, PP-WE-671 Saito H., PP-WE-614 Saint-Remy J., PP-WE-610 Saint-Remy J.R., PP-WE-826 Sainani G., Saillant D., Said J.M., PP-TH-302, PP-TH-420, PP-WE-821, PP-MO-583, PP-WE-148 PP-MO-744 PP-MO-138, PP-WE-571 PP-TH-592, PP-WE-368 PP-MO-726, OC-TH-051, PP-WE-510, PP-TH-410, PP-MO-277 PP-TH-041, . P., PP-MO-381 PP-WE-244 AS-MO-053 OC-WE-003, PP-WE-825, PP-MO-516, AS-TU-038 PP-WE-281 PP-MO-180 ., PP-MO-733 PP-MO-226 OC-WE-023 OC-WE-088, OC-TH-057, PP-WE-693 PP-MO-605, PP-TH-103 565

Authors Index AUTHORS INDEX

Salcioglu Z., PP-MO-073, Samonte M., PP-WE-277 Sandset P., PP-TH-164, PP-TH-121, PP-WE-571 Samoylenko V., PP-MO-863, PP-TH-165, PP-WE-191 Saleh M. N., AS-MO-055, PP-TH-236, PP-WE-138 Sandy B., PP-TH-396 AS-TU-002 Samudra A., OC-MO-101 Sane D. C., PP-WE-861 Salem H. H., AS-WE-032, Samulski R. J., OC-TH-087 Sanguigni V., PP-TH-050 OC-WE-044 Sanabria P., PP-WE-065 Sani G., PP-TH-352 Salem H., PP-WE-391 Sanak M., PP-MO-270, Sanjay A., PP-TH-011, Salerno F., PP-MO-673 PP-MO-329, PP-MO-784 PP-WE-012 Sales M., PP-TH-635, Sanchez C., OC-WE-099 Sanna S., OC-TU-074 PP-WE-525 Sánchez Casado M., PC-031, Sannappa P. R., OC-WE-139, Salgado V., PP-WE-874 PC-032, PC-033, PP-WE-699 PP-MO-791, PP-MO-792, Salguero M., PP-MO-279 Sanchez D., PP-MO-265, PP-MO-793 Salhi N., PP-MO-611 PP-TH-281 Sano M., PP-TH-320, Salido E., PP-MO-536 Sanchez J., OC-MO-106, PP-WE-671 Salido G. M., PP-TH-003 OC-TH-073, PP-MO-227 Santacroce R., PP-WE-366 Salifu M. O., OC-TH-092 Sanchez Luceros A., PC-047, Santagostino E., AS-TU-032, PP-MO-204, PP-MO-274 AS-WE-005, AS-WE-020, Saller F., OC-WE-037 Sánchez Luceros A., OC-TU-074, OC-TU-075, Salles I. I., AS-MO-037, PP-WE-089, PP-WE-093, PP-MO-542, PP-TH-558, PP-WE-084, PP-WE-085 PP-WE-094, PP-WE-402 PP-WE-555, PP-WE-599 Salles I. S., PP-MO-049 Sanchez Munoz-Torrero J., Santamaria A., PP-MO-413 Sallmon H., PP-TH-067, PP-TH-288 Santamaría A., PP-MO-323 PP-TH-073 Sanchez O., AS-TU-009, Santamaria M., PP-WE-048 Salmela B., PP-MO-170 OC-MO-041, OC-TU-090, Santana Sorensen A., PP-MO-376, PP-TH-524 Salmoiraghi S., AS-TU-050 PP-TH-103 Sanchez R., PP-MO-226 Salomon R., PP-MO-748 Santana-Lemos B. A. A., Sánchez T., PP-TH-635, OC-WE-023 Saltykova N. B., PP-TH-313, PP-WE-525 PP-TH-346 Santesson P., OC-WE-104 Sanchez-Lazaro I., PP-TH-363 Salvado R., PP-WE-730 Santilli F., AS-TU-049, Sánchez-Lázaro I., PP-WE-885 OC-TU-088, PP-MO-015, Salvadori M., PP-WE-002 Sanchez-Luceros A., PP-MO-016, PP-WE-738 Salvagno G., OC-MO-096, PP-MO-610, PP-MO-613 Santoro C., PP-MO-210, OC-MO-097, PP-MO-540, PP-MO-525, PP-MO-542, PP-MO-541, PP-WE-140 Sánchez-Vega B., AS-TH-052, PP-TH-247, PP-TH-287 PP-MO-572, PP-WE-567 Salvaris E., OC-MO-127 Sanclemente C., PP-WE-360 Santoro M. L., PP-MO-034 Salvi A., OC-MO-092, Sanda N., PP-MO-138 Santoro N., PP-MO-448, OC-TH-014 PP-TH-493 Sandberg H., PP-MO-574 Salzer-Muhar U., PP-MO-436 Santoro R., AS-TU-032, Samama C. M., PP-MO-391 Sander M., PP-MO-240 PP-MO-432, PP-MO-525, PP-TH-546, PP-TH-547 Samama C., OC-WE-002, Sanderink G., OC-WE-006, PC-023 PP-WE-423 Santos A. O., PP-WE-535 Samama M. M., PP-MO-185, Sandhu M., PP-MO-427 Santos A. V., PP-TH-217 PP-WE-198, PP-WE-199 Sandhu R. K., PP-TH-498 Santos A., PP-MO-520, Sambo A. L. A., PP-WE-535 Sandoval E. P. N., PP-TH-542 PP-MO-521, PP-WE-066, PP-WE-588, PP-WE-631 Sambrook P. N., AS-TH-017 Sandoval-Cooper M. J., Santos C. G. M., PP-MO-335 Samel M., PP-MO-149 OC-TU-050, OC-WE-022 Santos E. C., PP-WE-428 Samis J. A., OC-TH-071, Sandset P. M., AS-MO-007, OC-TH-072 AS-TH-004, PP-MO-288, Santos G. A. S., OC-WE-023 PP-WE-332, PP-WE-486, Samkova A., PP-MO-682 PP-WE-487 Santos I. R., PP-WE-347, PP-WE-814

566 OC-TH-082, PP-TH-074, Saour J., Saotome T., Sanz-Rosa D., OC-MO-072, PP-MO-083 Santoso S., PP-WE-436 Santos M., PP-WE-096, PP-WE-796 Santos M.T PP-WE-365 Santos M.S., INDEX AUTHORS PP-MO-644, PP-WE-607 Sasmaz I., Sask K.N., PP-WE-566 Sasanakul W., Sasamata M., Sartori R., PP-MO-351, PP-WE-359 Sartori M., PP-WE-424 Sartori M.T PP-WE-641, PP-WE-645 Sartorello F., Sarper N., Sarode R., Sarmiento I., Sarlon G., Sarig G., Sargent I., Sarda-Mantel L., Saraniti J., PP-WE-751 Saraf S., PP-MO-818 Saracini C., PP-TH-452 Saracco P., Sarabi A., OC-TU-032, PP-TH-189 Saposnik B., PP-WE-285 Saour T., PP-TH-465, PP-WE-285 PP-TH-302, PP-TH-420, AS-MO-052, AS-MO-057, PP-MO-364, PP-WE-364, PP-MO-334, PP-MO-363, PP-TH-061, PP-MO-313 PP-TH-465, PP-MO-425, PP-WE-892 OC-TH-048 PP-WE-571 PP-MO-542 AS-TH-029, OC-TU-056 PP-MO-606, PP-MO-757 PP-MO-227, PP-WE-239 ., PP-TH-435 ., PP-TH-453, AS-MO-050, AS-TH-034, PP-TH-689 AS-TH-043, PP-MO-424, PP-TH-259, PP-MO-160 PP-MO-027, PP-MO-333, PP-TH-184 PP-MO-026 PC-052, PP-MO-786 PP-WE-599 Scaraggi F Scaraggi A., AS-TH-001 Scarabin P Scannapieco G., Sbraccia P Sazonova I. Y., Sayer R., PP-WE-327 Saxena R., Sawamura A., Sawada K., PC-006, PC-007 Savushkin PP-WE-075 Savopol T., PP-WE-824 Savonarola A., Savoia A., PP-WE-049 Savion N., Savinkova I., Savic I., Savic A., Savchuk O., PP-MO-401 Savchuk O.M., N., Savchuk A. Sautet A., PP-TH-309 Saut N., Saunders R.E., Saunders B., Sauls D.L., Sauerbruch T., Saucedo J.F., OC-WE-1 Sattar N., Satta N., Satoh K., Satoh D., Sato Sato K., Satake M., PP-MO-638, PP-WE-037, OC-WE-017, PP-TH-349, Y., PP-MO-123 OC-MO-021, PP-WE-793 PP-WE-680 16 OC-TU-037 PP-WE-680 PP-MO-708 PP-MO-734 PP-WE-781 OC-WE-033, PC-023 ., . A., ., PP-MO-085 PP-WE-044, PP-WE-736 A. V., PP-MO-208, PP-TH-063, PP-TH-229 PP-MO-300 PP-MO-016 OC-TH-005, PP-TH-395 PP-MO-542 OC-WE-143 PP-MO-471 PP-WE-687 PP-WE-794 PP-TH-573, PP-TH-537 PP-WE-218 PP-MO-380, PP-TH-160 PP-MO-146, PP-TH-657 PC-004, OC-TH-011 PP-MO-087, PP-MO-150, PP-MO-022 Schaap M.C.L., Scepansky E., Scekic M., Scarvelis D., Scarno A., Scaraggi F., Schenk W. A., Schellongowski P., Schellong S., PP-MO-509, PP-TH-312 Schellong S.M., Schejter-Dinur Y., PP-WE-557 Scheiflinger F Scheffler B., Scheele J.S., Schaub R., PP-WE-569 Schaub R.G., PP-WE-035, PP-WE-042 Schattner M., PP-WE-633, PP-WE-653 Scharrer I., PP-WE-865 Scharf R.E., Schapira M., PP-MO-307 Schambeck C.M., Schaffner F., PP-MO-557 Schäfer W., Schäfer H., PP-TH-517 Schaefer-Prokop C., PP-TH-019, PP-WE-886 Schaefer A., PP-WE-488 Schadmand-Fischer S., Schadinger S., Schadinger S.L., PP-WE-095 E., Schade A. PP-MO-063 Schachnik N.C.C., PP-WE-055, PP-WE-862, PP-TH-355, PP-WE-054, PP-MO-001, PP-MO-745, PP-WE-369 PP-WE-824 OC-WE-007 PP-TH-215 PP-WE-087, PP-MO-556, OC-TU-075 PP-MO-005, PP-TH-120 AS-TH-060, OC-WE-037 AS-WE-054 PP-MO-504 ., PP-TH-425 PP-MO-006, PP-MO-029 AS-WE-034 PP-WE-168, PP-MO-632 PP-WE-241 AS-WE-015, OC-TU-010, OC-TU-059, OC-TH-115 PP-WE-696 PP-MO-295, PP-TH-077 567

Authors Index AUTHORS INDEX

Schenka A. A. A. S., PC-046 Schneider M. F., AS-TH-057, Schroeder C., PP-TH-404 Scherer M. R., PP-WE-399 OC-WE-051, PP-MO-620 Schroeder V., OC-TH-089, Scheucher P. S., OC-WE-023 Schneider P., PP-MO-491, OC-WE-034, PP-TH-671 PP-TH-447 Schiavon F., OC-TU-086 Schroth P., PP-TH-585, Schneider T., PP-TH-253, PP-TH-586 Schiavone D., OC-WE-071 PP-TH-693 Schuemann M., OC-TH-070 Schiavoni M., PC-034 Schneiter S., PP-WE-717 Schuepbach R. A., AS-TH-020 Schiavulli M., PP-WE-599 Schneppenheim R., Schuerholz T., PP-WE-684 Schiemann S., PP-WE-506 OC-TU-077, OC-WE-136, PP-MO-638, PP-TH-215, Schuettrumpf J., AS-TH-014 Schiff E., PP-WE-272 PP-WE-629, PP-WE-630, Schuh K., OC-MO-068 Schifferdecker T., PP-MO-030 PP-WE-651, PP-WE-722 Schuhler S., PP-MO-033 Schiks B., AS-TH-038 Schobess R., OC-WE-106 Schulman K. L., OC-WE-018 Schimanski S., PP-MO-295 Schoenefeld H., PP-MO-240 Schulman S., AS-TU-025, Schinco P., OC-TU-075, Schoenfisch M. H., AS-TU-034, OC-TH-007, PP-MO-525 OC-WE-147 OC-WE-074, PP-MO-515, Schindewolf M., PP-MO-501, Schoenwaelder S. M., PP-TH-315, PP-TH-413, PP-MO-705, PP-MO-706, AS-WE-032 PP-WE-419 PP-WE-376, PP-WE-714 Schols S. E. M., AS-WE-044, Schulte A., PP-MO-030 Schinzel H., PP-MO-317, PP-MO-670, PP-WE-260 Schulte S., OC-WE-120, PP-MO-373, PP-WE-488 Scholz T., PP-MO-179, PP-TH-130, PP-TH-561 Schiviz A., PP-WE-557 PP-MO-746, PP-TH-662, Schulte-Merker S., OC-TU-030 PP-WE-763 Schlachterman A., AS-TH-013 Schultz M. J., PP-MO-190, Scholz U., PP-MO-365, Schlegel N., AS-TH-043, PP-MO-191 PP-TH-656, PP-WE-233, PP-TH-074 PP-WE-622, PP-WE-733 Schulz A. S., PP-MO-029 Schliamser L., PP-WE-272 Schoolmeester A., AS-TH-024 Schulz C., PP-MO-005 Schlitt A., OC-MO-126, Schosser R., PP-MO-660 Schulze H., PP-MO-029, PP-TH-440, PP-WE-190 PP-WE-077 Schott U., PP-MO-258, Schluckebier L., PP-MO-483 PP-MO-672, PP-TH-359, Schumacher M., OC-TH-058 Schluter J., PP-TH-471, PP-TH-428, PP-TH-695, Schumacher W. A., PP-TH-472 PP-WE-721, PP-WE-758 PP-TH-202, PP-WE-100 Schmaier A. A., AS-TU-038 Schouten J., PP-MO-383 Schuman J., PP-MO-156 Schmaier A. H., OC-MO-128, Schouten M., OC-TH-062, Schunemann H. J., OC-TH-056, AS-TH-036 OC-TH-066, OC-WE-144 PP-MO-876, PP-WE-429 Schmid J., OC-TU-081 Schramm W., OC-WE-118, Schurgers L. J., OC-MO-044, Schmid M. L., PP-MO-550 OC-WE-119, PP-MO-532, OC-TU-053, PP-WE-808 PP-WE-542, PP-WE-549, Schuster M., OC-WE-063, Schmid P., PP-TH-692 PP-WE-552, PP-WE-594 PP-MO-241 Schmid R., PP-MO-422 Schranz S., OC-WE-011, Schutgens R. E. G., PP-MO-622 Schmidbauer S., PP-TH-130, OC-TU-010, PP-MO-036, PP-TH-561 Schreiber S., PP-MO-307 PP-WE-317, PP-WE-318, Schmidt J., OC-TH-018 Schreibner D., PP-MO-470, PP-WE-475 Schmidt M., PP-MO-087 PP-MO-470 Schuttenberg V., PP-TH-606 Schmidt-Woell T., OC-TH-070 Schreiner J., PP-TH-641 Schüttrumpf J., PP-TH-651 Schmugge M., OC-TU-061, Schreiner P. J., AS-WE-060 Schütz B., PP-TH-587 PP-TH-446 Schrenk G., PP-WE-619 Schützer K., PP-WE-200, Schnee J. M., PP-MO-167, Schreyer B., PP-MO-141 PP-WE-201 PP-WE-204 Schrieber D., PP-WE-284 Schved J., AS-TH-032, Schneider D., OC-WE-059 OC-MO-021, OC-MO-132, Schröder J., PP-TH-537 PP-MO-657, PP-TH-172, PP-TH-309, PP-WE-744 568 Schwarz H., PP-TH-641, PP-WE-619 Schwarz H.P., Schwartz M., Schwartz M. A., Schwartz L., Schwartz K. A., Schwartz J., Schwartz D., PP-TH-696 Schwaab R., INDEX AUTHORS Seaton D., PP-WE-587 Seary M.E., Searle E.J., PP-TH-088 Scully M., Scully M.F Scully M. A., PP-TH-231, PP-TH-403 Scuderi P., Scroyen I., Scroboachi M., Scriven N., Scrascia G., Scott R., Scott P., Scott J. A., Scott D.M., Scorizello B. Scoazec J. Y., PP-MO-687, PP-WE-637 Sciuccati G., N., Scianname’ PP-MO-730, PP-WE-792 Schwonberg J., Schwertz H., Schweintzger S., L., Schwarzman A. PP-WE-594 Schwarz T., Schwarz N., Schwarz M., OC-WE-063 PP-TH-61 OC-WE-065, PP-MO-640, OC-TH-116 1, PP-TH-640, PP-TH-615 PP-MO-708, ., PP-MO-233 PP-TH-230, PP-MO-219 PP-TH-212 OC-TH-076 OC-WE-040, OC-TH-043 PP-WE-714 OC-MO-090, PP-TH-629, PP-MO-690 OC-WE-024 PP-MO-100 PP-MO-423 PP-MO-321 PP-TH-584 AS-WE-004, OC-MO-138 AS-WE-028 PP-WE-495 A., OC-TU-064, PP-WE-860 PP-WE-493 OC-TH-054, OC-TU-035 PP-TH-497 PP-WE-495 AS-TH-056 PP-MO-501, OC-WE-101 PP-TH-448 PP-TH-025 PP-WE-026, PP-WE-344 Seljeflot I., Selime A., Selim T. S., PP-TH-084 Seligsohn U., Selfa S., Seldon M., OC-TU-020 Selby R., OC-MO-101 Selan C., Seksarn P PP-TH-688 Seki Y., Seki T., PP-MO-367 Sekaran M., Seitz R., PP-TH-661, PP-WE-210 Seifried E., Seifert S., Seidlerova J., Seidel H., Seibt S., Séguin C., Segers O., PP-WE-590, PP-WE-591 Segel S., Segbefia C.I., Segal H., PP-MO-121, PP-MO-122 Seested JohansenT Seehaus S., Seehafer T., See B.H., Sedlmeier R., Sedding D., Sedding D.G., PP-TH-596 Sedano C., Sebastian S., PP-TH-118, PP-TH-427, PP-MO-128, PP-MO-295, OC-WE-076, OC-WE-077, PP-MO-590, PP-MO-601, OC-TH-102, PP-TH-013, OC-MO-105, OC-TH-042, PP-TH-229 PP-MO-669, PP-WE-841 PP-MO-227 PP-WE-620 PP-WE-589, AS-TH-025, OC-MO-009 OC-MO-051, ., PP-MO-253 OC-MO-068 PP-MO-172 PP-MO-858 PP-MO-820 OC-WE-097 PP-WE-118 PP-MO-719, AS-TH-014, PP-MO-566, PP-WE-257 PP-MO-446 AS-TH-058 PP-MO-366, PP-TH-360 AS-MO-059 AS-WE-037 SA-WE-015, OC-TH-059 PP-WE-287 PP-MO-443 AS-TU-057 ., PP-MO-245, PP-MO-423, Semberova J., Selton-Suty C., Sellink E., Selleng K., Sellborn A., Sellam J., PP-TH-625, PP-WE-267 Serra J., Seroski W. M., Sermon Serino M., Serin K., Serhan C., Seredkina N., PP-TH-267, PP-TH-277 Seredavkina N.V., PP-TH-158, PP-TH-257 Serebryakova T Serebruany V. L., Serbic O., Serbic O.M., PP-WE-549, PP-WE-552 Serban M., Serafimidou O., Sequeria Sephton P., Sepanski D.M., Seo Y., PP-WE-424 Senzolo M., Senis Y., PP-TH-021, AS-MO-036 Senis Sengupta R., PP-WE-478 Sengupta N., Sen M., PP-WE-571 Sen H., PP-TH-573, PP-WE-249 Semeraro N., PP-WE-249 Semeraro F., Semenova O.N., PP-MO-245, PP-MO-423, PP-MO-532, PP-WE-542, Y . PP-TH-519 PP-MO-073, PP-TH-511 A. M., A., PP-TH-520, AS-TU-036 PP-WE-197 A., PP-WE-787 PP-WE-254 OC-WE-084 PP-MO-523 SA-MO-016 OC-WE-119, OC-TH-102 AS-WE-033, PP-TH-679 PP-TH-420, PP-MO-430 PP-WE-757 PP-MO-176, AS-TU-012 PP-TH-269 PP-WE-473, PP-MO-176, PP-MO-808 PP-MO-1 PP-WE-431 PP-TH-016 . N., OC-MO-029 PP-TH-376 PP-MO-302 PP-TH-361 PP-WE-022 10 569

Authors Index AUTHORS INDEX

Serrano R., OC-TH-113 Sharifian R. A., PP-MO-552 Shi G. Y., PP-MO-158 Serre A. F., PC-013 Sharkova T. S., PP-TH-158, Shi J., PP-MO-131, PP-WE-674 Sert C., PP-TH-511 PP-TH-257 Shi M., PP-MO-198, Sessa W., SA-MO-017 Sharma A., OC-MO-101, PP- PP-WE-179 WE-327 Setlaba P., PP-TH-637 Shi Q., PP-TH-128 Sharma S., PP-WE-751, Setty Y. B. N., PP-WE-894 Shi Y., OC-MO-136, PP-TH-061 OC-MO-137 Setty Y. B., PP-TH-262 Sharp A., PP-MO-775 Shibamiya A., OC-TH-070 Sevde U., PP-MO-858 Sharpless N., PP-WE-290 Shibano T., PP-TH-072, Severin K., PP-TH-575 Sharrack B., PP-WE-302 PP-TH-195, PP-TH-406, Severin S., PP-WE-019 Sharrett R., PP-WE-819 PP-WE-015 Severinsen M. T., PP-WE-315 Shashaani T., PP-TH-124, Shibeko A. M., PP-MO-235 Sevestre M., PP-MO-315 PP-TH-318 Shibhu J., OC-TH-118 Sevilla J., PC-033 Shattil S., SA-WE-006 Shibu J., AS-WE-059, PP-WE-832, PP-WE-833 Sevivas T., PP-MO-144, Shaughnessy S. G., PP-WE-730 PP-WE-817 Shick E., PP-MO-006, PP-WE-095 Seyed Mortaz L., PP-WE-324 Shaw C., OC-WE-045 Shida Y., PP-WE-090 Shah A. D., PP-MO-103 Shaw M. A., AS-TU-045 Shidham G. B., PP-WE-729 Shah A., PP-WE-755 Sheehan J. P., PP-WE-184 Shigenaga T., PP-TH-042 Shahidi M., PP-WE-873 Sheereen A., PP-TH-465, PP-WE-285 Shikata K., PP-TH-051 Shahrour N., PP-WE-281 Sheffield W. P., OC-MO-059, Shilagard T., OC-MO-026, Shahzad K., AS-MO-059, PP-MO-161, PP-TH-175 OC-MO-114 AS-WE-053 Shemirani A. H., PP-WE-350 Shiller E. A., PP-TH-454 Shakhmatova O., PP-WE-335 Shen F., PP-MO-854 Shiltagh N., PP-TH-657 Shakhovskaya E. N., PP-TH-367 Shen M. C., PP-TH-634 Shim S., PP-WE-877 Shams Eldin A., PP-MO-277 Shen M., PP-TH-123 Shima M., PP-MO-255, PP-TH-576, PP-TH-592, Shamsi T., PP-TH-648, Shen X., PP-WE-846, PP-TH-114, PP-TH-146 PP-WE-244, PP-WE-250, PP-WE-382 PP-WE-516, PP-WE-580, Shan N., PP-MO-695 Shen Y., AS-TU-039, PP-WE-606 PP-MO-757 Shang X., PP-WE-006 Shimada A., PP-WE-349 Sheng Y., PP-WE-540 Shanker J., OC-TH-118, Shimazu C., PP-WE-420 Shenkman B., OC-TH-102, OC-WE-139, PP-MO-791, Shimazu T., PP-WE-781 PP-MO-792, PP-MO-793, PP-WE-044, PP-WE-049 PP-MO-811, PP-MO-812, Shentu W., OC-MO-123 Shimokawa T., PP-WE-720 PP-WE-828 Shepherd J., OC-WE-116 Shin D. J., PP-WE-595 Shanley C., PP-WE-135, Shin D., PP-TH-294 PP-WE-293 Sheptovitsky V., PP-WE-010 Shin H., PP-TH-504 Shapiro A. D., PP-MO-596, Sheridan D., PP-MO-550 PP-WE-613 Shermock K. M., OC-TH-074 Shin J., PP-TH-519 Shapiro A., PP-MO-522, Sherwood R., OC-MO-088, Shin S., PP-WE-877 PP-WE-636 OC-MO-089 Shinhmar S. K., PP-TH-002 Shapiro S., PP-WE-462 Sheth S., PP-TH-243 Shinozawa E., PP-MO-201, Shaposhnikov S. A., Shetty K. R., PP-TH-108, PP-WE-400 PP-TH-251 PP-WE-811 Shinozawa K., PP-MO-546, Sharathkumar A. A., Shetty S., PP-TH-295, PP-WE-516, PP-WE-666 PP-MO-522 PP-TH-659, PP-TH-660, Shipolini A., AS-WE-052 Shariat-Madar Z., OC-MO-128, PP-TH-668 Shirafuji N., PP-WE-420 PP-TH-133, PP-MO-885

570 Shmeleva V Shlaen R., Shlaen M., Shivadasani R., PP-TH-015 Shirotani-Ikejima H., Shirokova T. E., Shirasaki R., Shiraishi H., PP-TH-592, PP-WE-606 Shirahata A., INDEX AUTHORS Siciliano S., Sichev D. A., Siboni S., AS-TU-033 Siboni S.M., PP-MO-812, PP-WE-828 Sibi K., Siami E., Shworak N.W., Shustova O.N., Shurin S., Shuman H., Shuldiner A., Shubina T PP-TH-277 Shtivelband I.B., Shrivastava S., Shrier I., Shpilberg O., Shoya Y., PP-WE-827 Shouzu Shoukri M., PP-MO-473, PP-WE-466 F.,Shorr A. Shorbagi A., Shomer E., Shokunbi W. A., PP-WE-562 Shoji T Shofuda K., Shmirev I.I., PP-WE-361, PP-WE-835 PP-TH-346, PP-TH-361, PP-TH-313, PP-TH-321, PP-MO-495, PP-TH-268, ., OC-TH-1 A., PP-MO-439, PP-WE-462 PP-WE-558 PP-TH-194 ., PP-TH-558 PL-TU-005 PP-MO-694 PP-WE-542 PP-WE-781, . M., OC-TU-058 PP-MO-283, PC-012 PP-WE-285 AS-MO-039 PP-WE-400 PP-TH-503 PP-TH-226 PP-MO-394 AS-MO-028, PP-MO-235 PP-WE-420 PP-TH-431 PP-TH-576, PP-WE-802 PP-MO-749 OC-TH-043 PP-MO-165 18, SA-MO-014 PP-MO-856 PP-MO-770 PP-MO-431, PP-MO-276 PP-MO-268, PP-MO-164, PP-WE-282, PP-MO-034 Silva C.S.S., Silva C.L. A., Silva A. C.S., Siller-Matula J., Siller-Matula J.M., Siller J., OC-WE-028 Silasi-Mansat R., Sijpkens Y. W. J., Siigur J., Siigur E., Sigutova P PP-WE-412 Siguret V PP-WE-653 Sigl-Kraetzig M., Sigaud M., PP-MO-008 Siess W., Siemieniak D., Siemieniak D.R., PP-WE-593, PP-WE-670 Siegmund B., OC-WE-036, PP-TH-339 Siegerink B., PP-WE-622 PP-WE-133, PP-WE-233, PP-TH-253, PP-TH-254, Siegemund T., PP-TH-254 Siegemund R., PP-WE-622, PP-WE-733 Siegemund A., PP-TH-407 Siegbahn A., Sieber M.W., Siebenrock K., PP-WE-169 Sié P N., Sidorkina A. Sidorkin V. G., PP-WE-515 Sidelmann J.J., Siddiqui A., PP-WE-133, PP-WE-233, PP-MO-365, PP-TH-656, PP-TH-542, PP-WE-444, PP-MO-188, PP-MO-618, ., OC-MO-099, AS-WE-014 ., PP-MO-149 PP-MO-149 OC-MO-124, ., PP-TH-429, PP-WE-642 PP-MO-845 PP-TH-368 AS-WE-008, PP-MO-408, PP-TH-087 OC-WE-023 PP-MO-459, PP-WE-092 PP-MO-365, PP-WE-678 PP-WE-640 PP-MO-128, PP-TH-253, PP-TH-417 PP-MO-718 PP-WE-678 OC-MO-090, PP-MO-124, PP-WE-453, OC-TH-112, OC-WE-039 PP-WE-513 PP-WE-675 OC-TU-016, PP-MO-322, Silveira J.R., Silveira Silvani C., Silva PintoC., Silva M., Silva J.B.J., Simpson H., Simpson PP-WE-422 Simowchenko G.S., PP-MO-475 Simons S.M., Simonneau G., Simon Z., Simon J., Simon A., PP-TH-217 Simões ESilva A. C., PP-WE-384, PP-WE-460 Simioni P., OC-TH-026, PP-MO-372 Simioni P Simionescu M., Simionecu M., S Simchen M., PP-TH-074 Simansour M., PP-WE-663 Simanek R., Simakova O., Simak J., OC-WE-059 Sim D., Silverstrim C., Silverstein R., Silver R.M., Silver L., PP-WE-247, PP-WE-248, PP-WE-081, PP-WE-147, PP-TH-488, PP-WE-080, PP-TH-420, PP-TH-487, PP-TH-382, PP-TH-383, PP-MO-348, PP-MO-765, PP-MO-242, PP-MO-243, PL-TU-004, PP-MO-186, OC-MO-121, OC-TU-086, OC-MO-049, OC-MO-119, ˇ imetka O., OC-WE-057, A., PP-WE-229 . P A. M.C., OC-MO-009 PP-TH-016 OC-TH-036 PP-MO-009 PP-WE-408 PP-WE-688 OC-MO-005, PP-MO-108 . S., PP-WE-378 OC-TU-015, PP-MO-194 PP-MO-658 AS-TU-052 PP-WE-535 OC-MO-066 PP-TH-016 PP-TH-495, OC-MO-107 PP-WE-730 PP-TH-003 PP-MO-502 OC-TH-082, PP-MO-376 PP-MO-855 AS-WE-023, PP-MO-058 571

Authors Index AUTHORS INDEX

Simpson V. M. A., PP-TH-384 Skalicky S., AS-WE-015, Smejkal P., PP-TH-612, Sinauridze E. I., PP-MO-182, PP-MO-087 PP-TH-613, PP-WE-804 PP-WE-170 Skalka V. N., PP-TH-160 Smethurst P., OC-MO-124 Sinclair G. D., OC-TU-068 Skeith L. A., PP-WE-546 Smid M., OC-TH-080, Singh A., PP-MO-326 Skenderi K., OC-TH-044 PP-MO-337, PP-WE-352, PP-WE-353 Singh I., OC-WE-050 Skjeldestad F. E., PP-MO-288, PP-WE-332 Smilevska T., PP-TH-557, Singh P. R., PP-WE-811 PP-WE-769 Skoda R., AS-TU-047 Singh P., PP-MO-756 Smirnov M., PP-MO-200, Singh S., PP-TH-272, Skok M. V., PP-MO-872 PP-MO-709 PP-WE-266, PP-WE-456 Skotnicki A. B., PP-WE-651 Smirnova O. A., PP-MO-431, Singhi P., PP-WE-456 Skotnicki A., PP-MO-206 PP-TH-268, PP-WE-361 Singla A., PP-MO-739, Skouby S. O., OC-MO-090 Smit A. J., PP-WE-554 PP-MO-771, PP-TH-026, Skouri H., PP-MO-135 Smit J. W. A., PP-TH-238, PP-WE-043, PP-WE-794, PP-TH-286 PP-WE-797, PP-WE-801 Skrahina A. M., PP-WE-863 Smith A., PP-MO-384 Singleton E. E., PP-MO-593 Skretting G., PP-TH-164, PP-TH-165, PP-WE-191 Smith E. L., PP-MO-250, Sinha D., PP-MO-181 PP-WE-259 Skrtic S., PP-WE-206 Sinha U., OC-TH-107, Smith H., OC-WE-134, AS-TU-026 Skubiszak A., PP-MO-216 PP-MO-632 Sinkov S. V., PP-TH-250, Skutnitskaya L., PP-TH-223 Smith J. M., PP-MO-110 PP-TH-251 Slagboom P. E., PL-TU-001 Smith J., AS-MO-049 Sion M., PP-WE-484 Slagsvold C. E., AS-MO-007 Smith K. A., OC-MO-115 Sionis A., PP-MO-254 Slama A., PP-TH-608 Smith K. J., PP-MO-627 Sipos T., PP-MO-359 Slater B. C. S., PP-TH-110 Smith L., PP-MO-233 Siqueira L. H. S., PP-WE-296 Slater D. E., PP-TH-477 Smith M., PP-MO-631 Siqueira L. H., PP-MO-520, Slattery D., PP-MO-470, Smith N. L., OC-TU-034 PP-MO-521, PP-WE-066, PP-WE-284 PP-WE-294 Smith P. L., PP-WE-100 Slavik L., PC-022, PP-WE-142, Siqueira L., PP-WE-631 PP-WE-273 Smith S. A., PP-TH-255, PP-TH-256 Sirachainan N., PC-052, Slavík L., PP-WE-378 PP-MO-354 Smith T. S., PP-MO-549, PP- Slayton W., PP-WE-083 Siragusa S. M., AS-TH-030, WE-291 OC-MO-093, PP-TH-527 Slechtova J., PC-020, Smithline H. A., OC-TU-007, PP-TH-368, PP-WE-070 Siragusa S., OC-MO-037, PP-TH-505, PP-WE-414 OC-MO-092, PP-MO-308, Slechtova M., PP-TH-612, Smock K. J., PP-WE-306 PP-TH-613 PP-TH-622, PP-WE-403 Smolewski P., PP-MO-752 Sletten M., PP-TH-165 Siregar B., OC-MO-112 Smrtka M. P., PP-TH-206 Slevin M., AS-MO-065 Siripattanapong P., Smurygina V. V., PP-TH-669 PP-WE-710 Slichter S. J., AS-MO-051 Smyth S. S., AS-TH-059, Sirisena T., PP-WE-021 Sligar S. G., OC-TU-091, PP-TH-392 PP-WE-119 Sirotkina O. V., PP-TH-025 Smyth S., SA-MO-018 Sloane D. D., PP-MO-086 Sisler I., AS-TH-039 Snijder R. J., PP-WE-318 Slowik A., PP-WE-358 Sittinger K., OC-WE-077, Snir A., PP-MO-850 PP-TH-661, PP-WE-210 Smadja D. M., OC-TU-090, Snoep J. D., AS-MO-034, Siu G., OC-TH-107 OC-WE-089, PP-MO-835, PP-TH-464, PP-WE-263 AS-TH-035, OC-MO-037, Siwkowski A., OC-TH-108 OC-TH-025, PP-MO-782, Small D. S., PP-MO-733 Själander A., PP-TH-469 PP-WE-851 Smedsrød B., OC-MO-058, Snyder M. L., PP-TH-136 PP-MO-177

572 Sodi A., Socoliuc C., Socié G., Sobreira M.L., Soboleva E.L., Sobol PP-MO-086 Sobieraj-Teague M., PP-MO-264 Sobas F Soares A., Snyder M., INDEX AUTHORS S Solimeno P Solimeno L., Solimando M., Solheim S., Soldati M., PP-WE-083 Sola-V Sola-Visner M.C., Solar M., PP-WE-491 Sokolowski J., PP-MO-189 Sokolikova B., Soisamrong Sohrabi N., Söhne M., OC-MO-042 Sohne M., PP-TH-224 Sofian T PP-WE-746 Sofi F., Soep J., PP-TH-319, PP-WE-463 Soejima K., PP-WE-250 Soeda T., OC-WE-032, PP-MO-217 PP-WE-002, PP-WE-003, PP-TH-340, PP-TH-341, PP-MO-836, PP-TH-163, PP-MO-804, PP-MO-805, PP-MO-802, PP-MO-803, PP-MO-800, PP-MO-801, OC-WE-032, PP-MO-799, OC-TH-047, OC-WE-031, ˇ olman L., A., isner M., OC-MO-010, ., ., OC-WE-031, PP-TH-265 PP-TH-438 PP-MO-862 PP-MO-071 PP-MO-127, PP-MO-263, OC-TU-084, PP-TH-518 OC-MO-039, PP-MO-349 PC-030 ., PP-MO-453 PP-WE-477 PP-WE-074 PP-MO-516, PP-TH-427 A., PP-WE-075 PP-TH-527 PP-MO-542 OC-TU-072 OC-TU-081, PP-MO-868, PP-MO-311 PP-MO-806 PP-TH-073, PC-052 PP-TH-067 PP-WE-209, PP-WE-243, PP-TH-290, PP-WE-208, PP-TH-211, PP-TH-289, PP-TH-174, PP-TH-185, Sosnovik D.E., Soskov G.I., Sos B.C., Soroka S.D., Soria N., PP-WE-505, PP-WE-855 Soria J., Soria J.M., PP-WE-505, PP-WE-855 Soria C., Sorensen H.T., Sørensen C., PP-WE-740 Sørensen B., PP-WE-698 Sorensen B., PP-WE-589 Sørensen B.B., PP-WE-591 Sorensen B.B., Sooriyakumar T., Soonsawad S., Sonnek M., Song Y., Song M., PP-WE-242 Song J., Sonesson E., OC-WE-059 Sommer J.M., Sommer C., Somma J., Soman T Somaini S., PP-WE-489 Solymoss S., PP-TH-208 Solomon C., B., Solomon A. PP-TH-211, PP-TH-680, PP-TH-174, PP-TH-185, PP-WE-677, PP-WE-702, PP-WE-539, PP-WE-658, PP-MO-581, PP-TH-545, PP-MO-543, PP-MO-562, ., PP-MO-017 PP-MO-712, PP-MO-514, PP-MO-279 PP-MO-514, PP-WE-844 PP-TH-463 OC-MO-077 PP-WE-468 PP-MO-467 OC-TH-027 OC-WE-108 PP-MO-578 PP-TH-207, PP-MO-688 PP-MO-386, PP-WE-616, PP-MO-405 OC-TH-009 OC-TU-011, OC-TH-057 OC-WE-057, PP-WE-710 PP-MO-026 PP-TH-304 AS-WE-057 PP-TH-1 PP-WE-590, PP-WE-297 16, PP-WE-814, PP-WE-815, PP-WE-365, PP-WE-812, PP-WE-227, PP-WE-347, PP-MO-816, PP-WE-226, PP-MO-349, PP-MO-363, Sottilotta G., PP-TH-596 Soto I., PP-WE-769 Sotirova T., Sosothikul D., Spengler U., Spencer F Spena S., Speletas M., PP-TH-484 Spek C. A., PP-MO-489, PP-WE-839 Spek PP-TH-181 Spek PP-WE-103 Speich H.E., PP-WE-485 Spath B., PP-WE-038, PP-WE-039 Spannagl M., Spalton J.C., Spada C., PP-TH-237, PP-WE-110 Sovershaev M., Souza R. OC-WE-035 Souverein P. C., Souto L.R.S., PP-WE-243 Souto J., Souto J.C., Soutari N.M.H., PP-WE-816 Sousa M.O., Souri M., Soukup T., Soucie M., PP-WE-613 Soucie J.M., PP-MO-590, PP-MO-601, PP-WE-208, PP-WE-209, PP-TH-289, PP-TH-290, PP-MO-307, PP-MO-620, A., A. C., PP-MO-566, OC-WE-105, A., PP-TH-285, OC-WE-073 PP-MO-014, . PP-TH-670 PP-WE-647 PP-MO-522 A., PP-WE-068 AS-MO-063, OC-WE-019, PP-TH-557, PP-MO-413 PP-WE-092 PP-WE-484 PP-TH-537 AS-TU-033 PP-MO-335, PP-MO-596, PP-TH-097, OC-WE-077, OC-TH-041 PP-WE-429 PP-MO-446 PP-MO-808, OC-WE-014, PP-WE-1 PC-046 14 573

Authors Index AUTHORS INDEX

Sperandio O., PP-WE-157 Spyropoulos A. C., Stankovic S., PP-TH-557, Speroni J., PP-MO-204 OC-MO-052, OC-TH-016, PP-WE-769 PP-MO-248, PP-WE-406 Spiel A. O., PP-MO-718, Stanley R. G., PP-TH-031 PP-TH-676 Spyrou A., PP-MO-305 Stanssens P., AS-TH-024 Spiel A., AS-WE-014 Squizzato A., PP-MO-292, Stanworth S., OC-TH-067 PP-MO-293, PP-MO-309, Spies C., PP-MO-240, PP-MO-659, PP-TH-507, Stare J., PP-MO-350 PP-MO-241 PP-WE-340 Staritz P., PP-MO-513, Spiezia L., AS-TU-032, Squizzqato A., OC-MO-039 PP-MO-662, PP-TH-421 OC-MO-005, OC-MO-119, ˇ Starostova L., PP-MO-689 OC-MO-121, OC-TU-086, Srámek A., PP-WE-303 PL-TU-004, PP-MO-242, Sreeram G., PP-MO-676 Stashenko G., OC-MO-002 PP-MO-243, PP-MO-348, Sridhara H., AS-WE-059, Stasiak M., PP-MO-071 PP-MO-765, PP-TH-382, OC-TH-118, PP-MO-791, PP-TH-383, PP-TH-487, Stasko J., PP-TH-598, PP-MO-792, PP-MO-793, PP-WE-220 PP-TH-488, PP-WE-080, PP-WE-832, PP-WE-833 PP-WE-147, PP-WE-247, Stasˇ ko J., PP-TH-305, PP-WE-248, PP-WE-384, Srivastava A., AS-WE-001 PP-TH-306 PP-WE-460 Srour M., PP-TH-696 Stassen J., OC-TH-057 Spila A., PP-TH-494 Staals J., OC-TU-085, Staubitz A., OC-WE-128 Spinar J., PP-WE-804 PP-WE-219 Stavenuiter F., OC-WE-084 Spira J., PP-WE-608 Stadler M., PP-MO-615 Stavik B., PP-TH-164, Spirk D., PP-MO-318, Staelens S., PP-MO-049, PP-TH-165 PP-TH-417, PP-TH-492, PP-MO-050 Stebbings Y., PP-TH-599 PP-WE-329 Staels B., PP-MO-814 Steele B. M., AS-WE-035 Spiropoulos A., OC-TH-044 Stafford A. R., OC-TH-106, Steele M., AS-WE-003, Spitzer C., PP-WE-695 OC-WE-079, PP-MO-428 PP-WE-553 Spohn G., OC-WE-076, Stafford D. W., AS-WE-042, Steen Carlsson K., PP-WE-570 OC-WE-077 OC-WE-075 Steenstrup T. D., PP-MO-569, Sponagle K., AS-MO-018, Stahle M. C., PP-TH-105, PP-WE-109, PP-WE-572, AS-MO-020, PP-TH-631 PP-WE-703 PP-WE-589 Spotti E., PP-MO-496 Stain A. M., PP-TH-629, PP-WE-587 Stefanini L., PP-WE-016 Spotts G., PP-MO-602, Stefanska-Windyga E., PP-TH-585, PP-WE-574, Staines H., PP-TH-131, PP-MO-714 PP-WE-617 PP-WE-829 Stegnar M., PP-MO-350, Spreafico M., AS-MO-028, Stalker T. J., AS-TU-028, PP-WE-251 OC-WE-131, PP-MO-716 PP-TH-038, PP-WE-030 Stegner D., AS-TU-005, Spring C. M., OC-WE-121 Stalls C., PP-WE-694 AS-TU-037 Springer T. A., PP-WE-013 Stambolsky D., PP-WE-335 Stehle S., PP-WE-183 Spronk H. M. H., OC-TH-001, Stamos T., PP-MO-464 Stehouwer A., AS-MO-030 OC-TH-080, OC-TU-085, Stancu P., PP-MO-532, OC-WE-060, PL-TU-003, PP-WE-549 Steil L., OC-TU-026 PP-MO-337, PP-MO-484, Stanczyk L., PP-MO-097 Stein S. F., PP-WE-749, PP-TH-122, PP-TH-181, PP-WE-750 PP-TH-516, PP-WE-219, Standeven K. F., AS-TH-019, PP-WE-352, PP-WE-353 OC-TH-055, OC-TH-089, Steiner T., AS-TU-031 Spronk H. M., PP-WE-779 PP-TH-351, PP-WE-212, Steinitz K. N., OC-WE-065 PP-WE-231, PP-WE-259 Spronk H., AS-TU-048, Steinseifer U., PP-WE-190 Stanford T., PP-TH-188 AS-WE-058, OC-MO-125, Stemkowski S., PP-WE-465 PP-TH-344 Stang L., PP-WE-448 Stemmelin G., PP-WE-135, Spyridon M., PP-WE-040, Stangier J., PP-TH-134 PP-WE-293 PP-WE-809 Stankovic M., PP-TH-460 Stemple D. L., AS-MO-037

574 Stephan F., PP-MO-332, OC-TH-082 Stepanian A., Stensballe A., Steno B., Stennicke H., Stennicke H.R., Stenlund P., PP-WE-1 Sten-Linder M., PP-WE-383 Stender S., INDEX AUTHORS Stokol T Stojanovski Z., PP-TH-271 Stojanovska-Trajkovska L., Stojanovska Z., Stojanovic B., Stojanovic OC-TH-017, OC-TU-012 Stoffers H.E.J.H., PP-WE-652 Stockschlaeder M., Stieltjes N., Stieler J., PP-MO-818, PP-WE-003 Sticchi E., OC-TH-072 Stewart K. A., Stewart Steward M., Stevic I., Stevens S.M., Steuerwald M.T Sterzing D., Sterz F., PP-MO-466 Stern L., Sterkers O., Stepinska J., PP-MO-207, PP-MO-798 Stepien E., PP-WE-801 Stephens G., PP-MO-602, PP-WE-574 Stephens D., Stephan J.L.S., ., A. B., 14 PP-TH-676 PP-MO-465, PP-WE-177 PP-WE-656 PP-TH-1 LB-MO-003 PP-MO-805, A., PP-MO-206, PP-WE-319, PP-TH-153 PP-WE-533 PP-TH-417 AS-MO-037 PP-MO-332 PP-MO-574 PP-MO-567, PP-TH-027, PP-WE-795 AS-TH-049 AS-WE-025, OC-TH-071, PP-TH-202 PP-TH-140 PP-TH-557 PP-TH-296 PP-TH-424 PP-TH-557 PP-MO-703, ., PC-027 PP-TH-116 PP-TH-510 17 PP-MO-594 OC-TU-049, OC-WE-150, PP-WE-054, PP-WE-055, PP-MO-001, PP-TH-355, Strobel U., Strike K.L., Strickland S., Streva A., Strengers P. F. W., Streiter D., Streiff M.B., Streif W Strawn W. B., PP-MO-434, PP-MO-685 Strauss T., Strauch M., Strater R., PP-MO-033 Strassel C., Strassberger V., PP-WE-758, PP-WE-514 Strandberg K., PP-WE-682 Stramezzi M., Straka E., Straight D.L., Strahler J.R., Strachan D., PP-WE-694 Stouffer G., PP-WE-838 Stouffer G. A., Stott D., Stott D.J., Storti S., Storrie B., PP-WE-305 Stormer J., OC-MO-012, PP-TH-030 Storey R.F., Stone N.L., Stoll P OC-TU-062, PP-TH-360 Stoll M., OC-WE-040 Stoll G., PP-WE-862, PP-WE-865 Stoldt V. R., OC-TU-006, PP-WE-304, ., ., PP-MO-100 AS-TH-040, AS-TU-053, OC-WE-033 PP-WE-498 AS-TH-055 PP-TH-462 PP-MO-521 PP-MO-082 PP-WE-528 AS-TU-052, OC-WE-116 OC-TH-024 OC-MO-100 OC-TU-005, LB-MO-003 AS-TU-047, PP-MO-790, AS-MO-055 AS-TH-060, PP-WE-541 OC-TU-034 OC-TH-074 PP-TH-375, SA-WE-003 PP-WE-854 OC-TU-060 OC-WE-075 PP-TH-243, PP-MO-258, AS-MO-038 PP-MO-571 Strukova S.M., Stroobants Ström J., Strogolov V Stroes E.S., Stroes E.S.G., PP-MO-127 Sugita C., Sugimura H., Sugimoto M., Sugimoto K., PP-MO-787, PP-TH-030 Sugidachi Suggett N., Sugano M., Sugamele R., Sueishi K., Sudo PP-TH-526 Sudo A., Sucker C., Subrt I., PP-MO-466 Subrahmanian T Subbi J., Subbarayal B., PP-WE-801 Suarez T., PP-WE-757, PP-WE-798 Suarez T. A., Su H., Su E.J., S PP-MO-109, PP-MO-769 Sturk A., Sturgeon S., Sturgeon S. A., Stuart-Smith S., Stuart M., Stuart M.J., PP-TH-550 Struve S., Strulovitch C., PP-MO-875, PP-WE-155 Strukova S., OC-TU-055, OC-TU-059, ˇ turm D., Y., PP-MO-467 PP-WE-287 PP-TH-051 PP-MO-244 PP-MO-497, AS-WE-017, PP-MO-149 PP-WE-586 PP-TH-258 PP-WE-894 PP-MO-123, OC-WE-077, PP-TH-026, A., PP-WE-210 PP-WE-875 A. K., ., PP-TH-330 PP-WE-687 PP-TH-262 OC-WE-143, PP-TH-388 PP-MO-739, PP-WE-391 PP-WE-122 PP-MO-252 PP-MO-111 AS-TU-018 PP-WE-090 PP-MO-096, PP-TH-315 PP-MO-821 OC-WE-044 PP-MO-882 OC-TH-031 ., OC-TU-039 PP-MO-720 PP-MO-465, 575

Authors Index AUTHORS INDEX

Sugita M., PP-MO-717 Suslov V., PP-MO-863, Szczeklik A., PP-MO-355, Sugiyama T., PP-TH-526 PP-TH-236, PP-WE-137, PP-MO-784, PP-WE-883, PP-WE-138 PP-WE-884 Sukchanova G. A., PP-TH-454 Sussman I. I., PP-WE-468 Szecsi P. B., PP-WE-383 Sukhu K., PP-WE-638 Sutherland J. S., PP-TH-175 Szekeres-Csiki K., PP-TH-633, Sˇulc P., PP-WE-345 Sutherland M. S., OC-TU-078, PP-WE-049 Sulimov V. B., PP-MO-182 PP-TH-645 Szlam F., PP-MO-676, Sullenger B. A., PP-WE-189 Suttnar J., PP-TH-213 PP-MO-776, PP-WE-187 Sullivan K., PP-WE-116 Suvajac N., OC-TH-068, Sztark F., PP-WE-673 Sulpice E., OC-WE-043 PP-MO-238 Sztukowska M., PP-WE-645 Sultan E., PP-MO-418 Suwanawiboon B., Szucs G., PP-MO-205 PP-MO-406, PP-WE-772 Sultanaliev T., PP-WE-281 Szymanski J., PP-MO-071 Suzan F., AS-MO-028, Tabares A. H., PP-MO-279, Sulzer I., PP-TH-079, PP-MO-530 PP-WE-717 PP-WE-464 Suzuki A., PP-MO-497, Tabatabaii M., PP-WE-324 Sumarokov A. A. B., PP-MO-138, PP-WE-671 PP-WE-058 Tabbers M. M., PP-MO-444 Suzuki H., PP-WE-005 Sumarokov A. B., PP-MO-770, Taberna M., PC-031, PC-032 PP-WE-091 Suzuki K., PP-TH-143, PP-TH-184, PP-TH-526, Tablin F., PP-MO-389 Sumathipala R. N., PP-TH-014 PP-WE-032, PP-WE-882 Tabrizian M., PP-MO-012 Sumi H., PP-TH-228, Suzuki N., PP-WE-015, Tacheuchi K., PP-WE-411 PP-WE-148, PP-WE-149 PP-WE-031 Tachibana M., PP-MO-198 Sumi T., PP-MO-111 Suzuki T., PP-WE-666 Tadokoro K., PP-WE-736 Sumida E., PP-TH-228 Suzuki Y., OC-TH-111, Summerhayes R., OC-WE-093, OC-WE-054 Tadokoro S., PP-TH-015 PP-MO-437, PP-MO-438, Suzuki-Inoue K., OC-TH-099, Tagalakis V., OC-TU-023, PP-MO-449, PP-MO-450, PP-TH-005 PP-TH-322, PP-TH-323 PP-MO-451, PP-MO-674, Suzumiya J., PP-TH-081 Tagariello G., PP-MO-542, PP-TH-461, PP-TH-462, PP-TH-527 PP-TH-475, PP-WE-438, Svennevig K., PP-WE-487 PP-WE-480, PP-WE-531 Tagliaferri A., AS-TU-032, Svensson P. J., AS-MO-003, AS-WE-005, OC-TU-075, Sun A., PP-TH-335, PP-TH-469, PP-WE-328, PP-MO-523, PP-MO-525, PP-WE-773 PP-WE-514 PP-TH-527, PP-TH-558, Sun G., PP-TH-364 Sverre J., PP-TH-539 PP-TH-569, PP-WE-567, PP-WE-598, PP-WE-599 Sun H., OC-TH-061, Svirin P. V., PP-MO-688, OC-WE-072, PP-MO-011 PP-TH-454 Taguchi O., OC-WE-038, PP-WE-222 Sun J., OC-MO-136, Swadzba J., PP-MO-269, OC-MO-137, OC-TH-087, PP-MO-270, PP-MO-271 Tagzirt M., PP-MO-237 OC-WE-064, PP-MO-203, Swaim A., PP-MO-011 Taher A., PP-MO-135, PP-MO-554, PP-TH-203, PP-MO-273, PP-TH-336, PP-WE-800 Swaminathan K., OC-TH-105 PP-WE-281 Sun M., AS-TH-039, Swanson K., PP-TH-255 Tait C., AS-TH-005, OC-TH-002, OC-MO-103, OC-MO-104 Swanson P. L., OC-TH-116, OC-TH-004, PP-TH-412, Sun Y., OC-MO-098 PP-WE-238 PP-TH-414, PP-WE-286, Sunder-Plassmann R., Swirski F. K., AS-WE-057 PP-WE-405 PP-WE-621 Swystun L. L., PP-MO-490 Tait R. C., PP-WE-214 Supina D., PP-WE-478 Syed A., OC-MO-009 Tajkhorshid E., OC-TU-094, PP-WE-162 Suri D., PP-TH-272, Syed S. N., AS-TU-005 PP-WE-266 Takada K., PP-MO-252 Synder M. L., PP-MO-137 Surie S., PP-TH-293 Takagi A., PP-MO-138, Szabó L., OC-MO-075 Susen S., PP-MO-814, PP-WE-671 PP-TH-583, PP-WE-858 Szarvas M., PP-MO-359 576 PP-WE-341, PP-WE-513, Takano K., T Takami E., T PP-TH-592, PP-WE-606 T Takaki A., PP-MO-127 Takahashi M., PP-WE-222 Takagi T., Takagi J., INDEX AUTHORS Tan F., Tamura S., Tamura N., PP-WE-851 Tamsma J.T., PP-WE-246 T T T PP-WE-298 Talks K.L., Talens S., Talbot K., Talalaeva I.N., T PP-WE-562, PP-WE-606 Taki M., PP-WE-250 Takeyama M., OC-TU-041, PP-MO-232 T PP-WE-222 Takei Y., PP-WE-606 Takedani H., T Takeda M., Takayama S., PP-WE-606 Takata N., PP-TH-042 Takasaki J., Takarada S., PP-TH-576, PP-TH-592, PP-TH-048, PP-WE-048, akamura F., akamatsu akamatsu J., amburrelli C., am B.H.L., almage K.E., akubo H., akeya H., akeda S., PP-WE-047 PP-MO-439, OC-WE-038, OC-WE-038, AS-MO-012 OC-MO-118 PP-WE-605 PP-TH-314 PP-TH-592, AS-MO-012 PP-WE-605 OC-TH-088, PP-WE-793 PP-TH-358 PP-TH-521 PP-MO-127 PP-TH-004 Y., PP-MO-550, PP-TH-041, PP-TH-592, PP-MO-429 PP-TH-041 PP-WE-445 PP-MO-439 PP-MO-255, PP-MO-782, PP-MO-123, PP-TH-081 PP-TH-576, AS-TU-045 PP-MO-378 PP-MO-099, PP-WE-043, PP-WE-801, PP-WE-797, PP-WE-798, PP-WE-757, PP-WE-794, PP-TH-026, PP-TH-101, Tarantino M.D., Tarantino A., OC-MO-054 T PP-MO-656 Tapon-Bretaudière J., Tapaneya-Olarn, T PP-WE-701 Taouli K., Tao M.H., Tanzilli G., PP-WE-802 T PP-WE-799 Tantry U.S., T Tanner F. C., Tankere F., T Taniguchi T., T Tani Y., T PP-MO-681 Tangnararatchakit K., Tange J.I., Tang Y., Tang W., T Tang H., Tancredi D., Tanck M.W., Tanaka Y., PP-TH-208 Tanaka K., PP-MO-776, PP-WE-187 Tanaka K. A., PP-WE-606 Tanaka I., PP-MO-429, PP-WE-666 Tanaka A., Tan M., apson V., aouli T antry U., ans G., animoto T aniguchi R., anguay J.F ang M., . K., PP-WE-736 PP-WE-521 OC-WE-027 OC-TH-065 PP-TH-377 PP-WE-677 OC-TU-034 PP-TH-608, PP-TH-592, PP-MO-771, PP-MO-158 PP-TH-143 OC-TH-111, OC-MO-052, ., PP-WE-105 PP-TH-207, PP-MO-332 PP-MO-629 PP-WE-564 PP-TH-311 ., PP-MO-429 PP-MO-739, OC-TU-052 PP-TH-139 PP-MO-119 PP-TH-666 PP-MO-676, PP-MO-789 OC-WE-007 AS-TU-003 PP-MO-354 OC-TH-021, PP-TH-189, T PP-WE-165 T PP-WE-165 Tardy B., PP-WE-613 Tarantino M., Tello Montoliu A., Telega D., PP-WE-889 Tekgunduz E., PP-MO-364, PP-WE-365 T T T OC-WE-104 T PP-MO-738 TedescoF., A. Tebbe U., Teague M., Tea M.M., PP-WE-277 T T T T OC-TH-072 Taylor -JrF. B., PP-WE-544 Tay L.H., T Taveras M., T T PP-WE-580 T Tateno C., PP-WE-371 Tassies D., PP-WE-876 Taskiran B., Tashiro T., Tashiro H., Taser O., PP-MO-744 TascıOglu C., as P ardy- PoncetB., eixeira G.S., eitel J., eigelkamp S., ehrani S., cherniantchouk O., chaikovski S.N., aylor S.M., aylor F avoosi N., aubman M.B., aubert D., atsumi K., ., AS-MO-038 . B., PP-WE-597 AS-TU-009, PP-WE-568 PP-TH-626, PP-MO-420 PP-MO-442 PP-WE-380 PP-WE-580 PP-WE-411 OC-TH-079, PP-WE-800 PP-WE-420 OC-MO-135 PP-MO-254, PP-WE-256 PP-WE-244, PC-050 OC-TH-1 PP-TH-221, AS-WE-051 PP-MO-596, PP-MO-363, PP-MO-735, PP-MO-841, PP-TH-241 OC-TH-077 OC-TH-071, OC-TH-021, OC-TH-120 PP-TH-377 12 577

Authors Index AUTHORS INDEX

Telnova E. A., PP-MO-553, Tewhatu L., PP-TH-471, Thom K., PP-MO-436, PP-TH-581, PP-WE-561 PP-TH-472 PP-MO-561 Ten Berg J. M., PP-WE-741, Teyssandier M., OC-MO-064, Thomas C., PP-WE-642 OC-MO-133, OC-MO-135, OC-WE-066, PP-MO-588 Thomas D. H., OC-TH-040 PP-MO-780, PP-MO-781, Thabane L., PP-TH-503, PP-MO-788, PP-WE-742 Thomas D., OC-WE-085, PP-WE-429, PP-WE-507 PP-MO-028 Ten Cate H., AS-TH-038, Thachil J., OC-TH-091, Thomas G. M., PP-MO-485, AS-TU-048, AS-TU-050, PP-TH-129, PP-WE-116 AS-WE-058, OC-MO-125, PP-MO-486 OC-TH-001, OC-TH-080, Thai Trung King M., Thomas K., OC-TU-033 OC-WE-036, OC-WE-097, PP-TH-056, PP-TH-102 Thomas S., PP-MO-521, PL-TU-003, PP-MO-337, Thakur S., PP-TH-376 PP-MO-433, PP-MO-482, PP-TH-554, PP-WE-754 PP-MO-484, PP-MO-670, Thaler C., PP-WE-784 Thomas W. E., PP-MO-002 PP-TH-122, PP-TH-131, Thaler J., OC-TU-015 Thomas W., PP-WE-056 PP-TH-181, PP-TH-344, Thames B. H., PP-TH-206 PP-TH-516, PP-WE-072, Thomas-Dewing R. R., PP-WE-126, PP-WE-352 Thapa B., PP-WE-456 PP-WE-727 Ten Cate-Hoek A. J., Thati M., AS-MO-059, Thomassen M. L. G. D., OC-TH-001, OC-TH-017, AS-WE-053 PP-TH-377 OC-TU-012, PP-WE-457, The Riete Investigators A., Thompson N., PP-WE-215 PP-WE-683 PP-TH-288 Thompson P., OC-TH-085, Ten Kate M. K., OC-WE-098, Thedieck S., AS-TU-053, OC-TH-086 PP-TH-515, PP-TH-516 OC-TU-062, PP-TH-360, Thomsen M., PP-TH-140 Ten Kate M., AS-MO-002 PP-WE-756 Thomson G., PP-MO-543 Ten Wolde M., OC-TU-008 Theill C., PP-TH-150, PP-TH-151 Thomson R., PP-TH-665 Tengborn L., OC-WE-058, PP-MO-609, PP-WE-604 Thelwell C., OC-MO-116, Thon J. N., PL-TU-002 PP-WE-229 Tenias J., PP-MO-226, Thon J., AS-WE-026 PP-MO-227, PP-WE-436 Themistou E., OC-WE-050 Thong B., PP-MO-197 Tentsova I., OC-MO-036 Theodoridis T., PP-MO-707 Thongtanyong N., PP-WE-772 Teplyakov A., PC-025, PC-026 Theodosiadis G., PP-WE-314 Thornton S., OC-TH-063 Terada C., PP-WE-736 Theophilus B. D. M., Thouvenin S. S. T., PP-MO-594 PP-MO-614 Ternisien C., PP-MO-626, Thuerlemann C., PP-MO-753 PP-TH-189, PP-TH-623, Theophilus B. D., PP-MO-623 Thuillez C., PP-WE-859 PP-WE-642 Théorêt J. F., OC-WE-007, Ternström L., PP-MO-652, PP-MO-012 Thul J., PP-TH-180 PP-WE-206 Theroux P., PP-MO-060, Thuraisingham R., PP-WE-377 Terpstra W. E., PP-WE-778, PP-MO-061 Thys C., PP-WE-041 PP-WE-779 Theunissen H. M. S., Thys F., PP-TH-524 Teruel R., AS-MO-054, PP-WE-017 Thys J., PP-WE-084 PP-MO-134, PP-TH-247, Thieme F., PP-MO-307 PP-TH-287, PP-WE-141 Tichelaar Y. I. G. V., PP-TH-332 Thiemermann C., OC-TH-067, Tiede A., PP-WE-670 Teruya J., PP-TH-445 PP-TH-685 Tieken C., PP-TH-139 Tesic R., PP-WE-369 Thijs T., PP-WE-084 Tien L., OC-TH-119, PC-037 Tesselaar M. E. T., AS-MO-035, Thim L., PP-MO-565, PP-WE-497 PP-MO-570 Tierney S., OC-TH-012, PP-TH-489 Testa S., OC-MO-028, Thim T., PP-WE-810 OC-TH-003, OC-TH-006, Tigchelaar Gutter W., Thiruchelvam A., PP-MO-366, OC-TH-075, PP-MO-290, OC-WE-019 PP-MO-496, PP-TH-374, PP-MO-367 Tillmanns H., AS-TU-057, PP-TH-375, PP-WE-682 Thom J., PP-MO-019 OC-WE-128

578 PL-TU-004, PP-MO-243, Tiscia G.L., T PP-TH-285, PP-WE-175 Tirado I., T Tipton H., Tinot T., Tinel H., Tincani E., Timur C., PP-WE-232 Tillyer L., INDEX AUTHORS Tomin D., Tomer A., Tomaiuolo M., Toltl L.J., T T Toll T., OC-TU-012 T T T Toh C., PP-WE-116 Toh C.H., PP-MO-348, PP-WE-080 Tognin G., Tofler G., Toennes S.W., Todo K., T Todd T., T Tocchet A., T Tobin E., Tjønnfjord G., Tjia I., Tjeldhorn L., Tizzano E., Titaeva E.V., Tisseau J., Tiscia G., oll D.B., olenaar D., oledo V odesco S., oda M., oby G., olosa C., olley N., iret L., A., irado A. PP-TH-445 PP-TH-451 OC-TH-091, PP-TH-197 PP-TH-309 PP-WE-690 . P. C., PP-MO-125 PP-MO-183 PP-MO-080 OC-MO-083 OC-WE-038 PP-MO-857 PP-MO-323, PP-MO-410 PP-WE-571 OC-TU-047 PP-MO-120, PP-MO-822 PP-WE-634 PP-WE-712 OC-TH-017, AS-MO-022 OC-WE-022 PP-TH-129, PP-TH-288 OC-MO-121, PP-MO-306 PP-TH-113 PP-MO-536 PP-TH-453 OC-TU-086 OC-TU-035 PP-MO-567 PP-TH-308 PP-WE-191 PP-TH-513 PP-TH-539 PP-MO-822 PP-WE-792 PP-WE-226 PP-TH-279, PP-TH-280, PP-MO-046 Torti M., Tortella B.J., PP-WE-217 Torres-Alcantara S., Torres O., Torres I., T T T T Tornai I., PP-WE-247, PP-WE-460 T Toril J., T Torchet M., T T Topalidou M., PP-TH-581, PP-WE-561 Tonoyan A.A., Tonnesen E., T Tonismagi K., OC-MO-020 Tong C.H., PP-TH-274 Tonello M., T Tomonaga M., Tomokiyo K., Tomoike H., Tomlinson S., OC-MO-069, PP-TH-021 Tomlinson M.G., Tomlin M.E., PP-WE-433 Tomkowski W. Z., PP-TH-015, PP-TH-081 Tomiyama Y., Tomita A., PP-MO-372, PP-WE-147, PP-MO-186, PP-MO-242, OC-TH-026, PL-TU-004, OC-MO-005, OC-MO-049, orres E., orres orpier G., ornvall J., ormene D., ordoir J., opor-Madry R., opf H., onn T ona F., ., A., PP-WE-360 PP-MO-544 AS-TH-014 OC-WE-088 PP-MO-018, PP-MO-228 PP-MO-865 PP-TH-043 PP-MO-663 PP-TH-607 PP-MO-232 PP-WE-457 PP-MO-814 OC-TU-040, AS-WE-010, PP-MO-095 PP-WE-592 PP-WE-720 AS-WE-023, PP-MO-733 PP-WE-698 PP-WE-605 OC-TH-069 PP-MO-080, PP-MO-305 PP-MO-149 OC-TH-015 PP-WE-666 PP-MO-553, PP-MO-207 AS-WE-033, AS-TH-028, PP-TH-412, PP-WE-286 Tosetto A., PP-MO-372 TosettoT.,A. A. Tosato F., Tran S., PP-WE-030 Tran A., PP-WE-769 T Traisci G., T T PP-WE-107 T OC-TH-1 Tracy R.P., OC-MO-120, OC-TU-092 T Traby L., T Tözün R., T PP-WE-217 Toussaint-Martinez DeCastro., Tous J., Tournoij E., Toulon P., PP-WE-333 Toulon P. A., PP-MO-445 T PP-WE-787 Toti F., Tóth-Zsámboki E., PP-WE-774 Tóth J., Toth B., PP-TH-457 Totapally B., OC-WE-127 Totani L., AS-TH-046 Toso R., T PP-MO-291, PP-MO-612, OC-TH-003, OC-TH-004, AS-TH-005, OC-TH-002, PP-MO-216, PP-TH-337, oweel G., ouchrift C., osi M., rajkova S., radler T., radati F., racz W racy P rabattoni D., OC-WE-111, . B., ., PP-MO-359, AS-TU-028, OC-MO-063 17 PP-WE-784 PL-TU-005 PP-TH-625 AS-TH-013, PP-MO-422 PP-MO-207, AS-TH-059, PP-TH-284 PP-MO-331 PP-TH-558 PP-MO-504 OC-TH-059 PP-MO-015 PP-TH-370 AS-MO-029, AS-WE-060, OC-MO-066, OC-TU-030 PP-TH-557, PC-018, PP-TH-310, PP-TH-470, PP-WE-356 AS-WE-023, PP-MO-772 579

Authors Index AUTHORS INDEX

Tran T. H., PP-TH-199 Tromp E. A. M., PP-WE-317, Tugcu D., PP-MO-073, Tranholm M., OC-MO-084, PP-WE-318 PP-MO-222, PP-TH-121, OC-MO-085, OC-WE-056, Trossaert M., PP-TH-172, PP-WE-571 PP-MO-564, PP-MO-573, PP-TH-623 Tugrul A., PP-TH-221, PP-MO-575, PP-MO-578, Trossaërt M., PP-TH-593, PP-TH-222 PP-TH-579, PP-TH-594, PP-WE-642 Tuischer J., PP-WE-593 PP-WE-401, PP-WE-581 Trujillo M., PP-WE-665 Tuma R. F., PP-WE-896 Trappenburg M. C., PP-WE-778, PP-WE-779 Trummal K., PP-MO-149 Turck N., OC-TH-073 Travlou A., PP-TH-338 Truss N. J., PP-MO-740, Turecek P. L., PP-MO-640, PP-TH-001, PP-TH-002 PP-TH-611, PP-TH-640, Trawinski B., PP-MO-522 Trzeciak M. C., PP-TH-385 PP-TH-641, PP-WE-619 Trawnicek L., PP-WE-624 Tsai H., PP-MO-665, Turenhout E. A. M., Trbic A., OC-TH-054 OC-WE-010 AS-WE-013 Trbojevic B., PP-TH-296 Tsai W., PP-TH-634 Turgut B., PP-TH-221 Trebicka J., PP-MO-224 Tsatsaris V., AS-WE-025 Turhan N., PC-003 Treepongkarune S., Tseng C., PP-MO-877, Turkkan E., PP-MO-344, PP-MO-354 PP-WE-079 PP-MO-537, PP-MO-538, PP-WE-571 Tregouet D., OC-MO-021, Tseu I., PP-WE-193 PP-TH-309 Turner N., PP-MO-120 Tsevrenis V., PP-WE-314 Treish I. M., PP-MO-488 Turoczi T., AS-TH-008 Tsianos E. V., PP-WE-681 Trelinski J., PP-MO-752 Turpie A. G. G., OC-WE-004, Tsikopoulou F., PP-MO-302 Trellu M., OC-WE-006, PP-TH-415, PP-TH-430, PP-MO-418, PP-TH-409, Tsimerman G., OC-TU-057 PP-WE-404, PP-WE-421 PP-WE-388, PP-WE-413, Tsironi M., OC-TH-044 Turpie A. G., PP-MO-248 PP-WE-423 Tsoukala C., PP-TH-467 Turu M. M., AS-MO-065, Tremoli E., OC-TU-025, PP-MO-834 Tsuji A., PP-TH-526 PP-WE-050, PP-WE-356, Tusell J., PP-WE-237 PP-WE-868 Tsuji M., PP-WE-605 Tushuizen J. M., PP-MO-769 Trenchfield S., PP-MO-543 Tsujita Y., PP-TH-689 Tuttle A., PP-TH-628 Treumann A., PP-MO-044 Tsukada Y., PP-WE-349 Tutun U., PP-WE-880 Tribulatti M. V., PP-WE-035 Tsutsumi Y., PP-TH-320 Tveit A., PP-WE-026, Triche E., PP-WE-382 Tsuyoshi H., PP-MO-669 PP-WE-172 Trichet C., AS-TH-043 Tsygankov A. Y., OC-TH-040 Twickler M. T. H. B., Trifiro’ E., PP-MO-104, Tu A., PP-WE-056 PP-MO-292 PP-WE-789 Tucker A. T., PP-MO-740, Twickler M., PP-MO-022 Trillot N., PP-TH-583, PP-MO-741 Tybura M., PP-MO-752 PP-WE-762 Tucker E. I., AS-TH-039, Tychinsky V., PP-MO-729 Trinchero A., PP-MO-684 OC-MO-104, PP-TH-037, Tylko G., PP-MO-798 Trinquart L., AS-TU-009 PP-WE-097 Tymvios C., PP-MO-062 Tripodi A., OC-TH-003, Tuckuviene R., PP-TH-455 OC-TH-006, PP-MO-290, Tuddenham E. G. D., Tzeng C. H., PP-MO-330, PP-MO-291, PP-MO-673 PP-MO-642, AS-TU-011 PP-TH-620 Triscott M. X., PP-TH-264, Tuddenham E. G., PP-TH-106, Tzourio C., PP-TH-349 PP-WE-117 PP-TH-657 Uchida A., PP-TH-526 Triscott M., PP-MO-200, Tudini M., PP-TH-694 Uchitel I. A., PP-MO-770, PP-MO-265, PP-MO-548, Tufano A., PP-MO-336, PP-WE-091 PP-TH-200, PP-TH-281, PP-WE-320, PP-WE-325 PP-WE-115, PP-WE-207 Uchiyama S., PP-WE-196 Tuganbekova S., PP-WE-281 Trobo R., PP-WE-236 Uchiyama T., PP-MO-669

580 Uh S., Ueyama T PP-WE-418 Uetsuka Y., PP-TH-042 Uemura T., Uekötter A., Ueba T., Udvardy M., Udvardy M.L., PP-MO-681 Udomchaisakun R., INDEX AUTHORS Urbanus R., PP-TH-037 Urbanus R.T., PP-TH-437 Urban L., OC-WE-054 Urano T Uprichard J., PP-MO-440 Unuvar A., Unterthurner S., Unseld M., Unger K., PP-WE-362 Undas A., Unadkat S., Umesato N., Umeda M., Ulus T. A., Ulrichts H., Ulrich D., Ulrich C., Ulrich C.K., Uljanov Ulimoen S., Úlehlová J., PP-WE-142, PP-WE-273 Ulehlova J., Ulcova-Gallova Z., OC-MO-076, PP-WE-231 Uitte DeWillige S., PP-WE-213, PP-WE-358, PP-TH-337, PP-WE-107, PP-MO-798, PP-TH-154, PP-MO-207, PP-MO-216, AS-WE-008, OC-MO-030, PP-TH-519 ., A., PP-WE-827 OC-TH-1 ., PP-TH-433, PP-TH-448 OC-MO-126 PP-TH-588 PP-MO-206, PP-WE-880 PP-MO-222, PP-MO-838 PP-WE-005 PP-TH-041, PC-012 PP-WE-090 AS-TH-024 PP-WE-342, PP-WE-649 PP-WE-026 PP-WE-378 PC-022, PP-MO-031 OC-MO-114 PP-MO-359 PP-MO-809 PP-TH-358 PP-MO-397 AS-TU-017, PP-TH-633 OC-WE-063 11, PP-TH-368 PP-TH-602, PP-WE-583, Vali Zadeh F., Valéra M., V PP-WE-584 Valentino L. A., V Valentin N., Valentijn K.M., Valente S., V PP-WE-874 V V PP-WE-509, PP-WE-567 Valdrè L., L., Valdre’ Valdre L., V Valdés M., Valarche V., V Vaillant H., V Vagg M., V Vafafar A., OC-TU-089 Vacher CoponatH., Uvaraj P., Uthman I., PP-WE-709 Ustundag B., Usluer S., Uslu O., Useini S., PP-WE-737 Uscatescu V Usami PP-WE-549, PP-WE-552 Ursu E., Urosevic I., PP-MO-453, PP-WE-308 Urlep S Uresandi F., alenzuela G., alentin S., alente E., alente B., ale Lopez aldre L.V ainchenker W ahter M., agdatli E., ˇ A., alinoviæ V., AS-TH-058 PP-MO-532, OC-TH-015 OC-TH-105 PP-WE-351 PP-MO-523, PC-027, PP-WE-426 PP-MO-1 PP-MO-653 OC-MO-099 AS-WE-024 PP-WE-359 PP-MO-273 PP-MO-732 PP-MO-655 PP-MO-013 PP-WE-374 PC-021 PP-MO-794, A., PP-MO-302 PP-WE-680 PP-WE-585 OC-TH-097 PP-TH-650 ., PP-MO-299 ., PP-WE-708, PP-WE-558 PP-WE-549, PP-MO-637 OC-WE-026 AS-WE-023 ., AS-WE-040 PP-TH-601, SA-WE-018 19 Valls SerónM., PP-MO-395, PP-WE-396 Vallez M.O., PP-WE-096, PP-WE-796 Valles J., PP-TH-314 Valla D.C., PP-MO-633 OC-TH-025, OC-TU-070, AS-MO-034, AS-TH-035, Van Der BomJ.G., Van DerBijlN., AS-MO-063, PP-MO-764 Van DenHengelL.G., PP-MO-769 Van DenGoorJ.M., PP-MO-720 V Van DenBornB., PP-MO-190, PP-MO-191 V Van DenBlinkB., OC-TU-083 Van DenBiggelaarM., AS-MO-063 V van denBergM., V van deW PP-MO-049 van deWalle G.R., PP-WE-741 Van DeWal R.M. A., van deCraenB., van DammeN., V PP-WE-475 Van BladelE.R., OC-WE-046 van BerkelT Van BerkelM., PP-TH-583, PP-WE-858 van BelleE., PP-MO-769 Van BeersE.J., Valsecchi L., AS-WE-011 Valsecchi C., V Vallvé C., an DenDoolE.J., an DenBoogaardF an DenBerg an DenBergH., an BuulM.C., alsami S., ater N., PP-MO-027, PP-WE-175 PP-MO-224, OC-MO-129 . J.C., PP-MO-382, PP-MO-814, OC-TH-083 OC-WE-131, Y OC-MO-112 . W OC-TH-064 AS-TU-010 PP-WE-176 OC-TU-059, OC-TU-079 PP-MO-219 PP-WE-318, SA-TU-015 PP-TH-616 PP-MO-710 OC-WE-105 ., PP-WE-317 . E., 581

Authors Index AUTHORS INDEX

Van Der Griend R., PP-WE-475 van Dreden P., PP-MO-369, OC-WE-097, PP-MO-337, Van Der Kley-Corssmit N.P.M., PP-TH-447, PP-TH-483, PP-MO-433, PP-MO-484, PP-TH-238 PP-WE-508 PP-TH-122, PP-TH-344, van Dyke M., PP-WE-703 PP-TH-516, PP-WE-017, van der Lee J. H., PP-MO-597 PP-WE-072, PP-WE-219, van der Linden I. K., van Eck M., OC-WE-046 PP-WE-352, PP-WE-353 PP-MO-236 Van Eck-Smit B. L. F., Van Ommen C. H., PP-MO-444, Van Der Linden I., PP-WE-497 PP-TH-293 PP-MO-597 Van Der Linden P. W. G., Van Eimeren V. F., PP-TH-463 Van Ommen C., OC-TU-063 PP-MO-571 van Geet C., PP-MO-059, Van Oostenbrugge R. J., van der Linden P., PP-MO-617 PP-MO-094, PP-WE-041, PP-WE-219 PP-WE-085, SA-MO-015 Van Der Meer F. J. M., Van Oostenbrugge R., LB-MO-001, OC-TH-008, Van Geffen M., OC-TH-052, OC-TU-085 PP-WE-555 PP-MO-571 Van Os G. M. A., OC-MO-030 Van Geloven N., AS-TU-035 Van Der Meer J., AS-MO-002, Van Pampus E. C. M., OC-MO-001, OC-MO-082, Van Giersbergen P. L. M., PP-MO-670 OC-WE-098, OC-WE-100, PP-TH-423 Van Rooden C. J., PP-WE-521 PP-MO-286, PP-MO-677, Van Giezen J. J. J., PP-TH-356, PP-TH-515, PP-MO-095, PP-TH-104 van Rooijen N., PP-WE-151 PP-TH-516, PP-WE-326, van Russelt M., PP-WE-267 PP-WE-554 Van Haren B., PP-MO-621 Van Haren S. D., PP-TH-616 Van Ryn J., PP-MO-347, Van Der Meijden P. E. J., PP-TH-134, PP-WE-181, AS-TU-037, PP-TH-007 Van Heerde W. L., PP-TH-260, PP-WE-190, PP-WE-390 PP-WE-064, PP-WE-555 Van Der Meijden P. J. E., Van Schie M. C., OC-TH-029, AS-TU-029 Van Heerde W., OC-TH-052 PP-WE-355 Van Der Neut E., PP-MO-720 Van Helden P. M., OC-WE-063, Van Schilfgaarde M., van der Planken M., OC-WE-065 PP-TH-436, PP-WE-778, PP-MO-383 van Hoorelbeke K., PP-WE-779 van der Poll T., OC-TH-062, PP-WE-726 Van Schouwenburg I. M., OC-TH-066, OC-WE-144, Van Hylckama Vlieg A., OC-MO-082, OC-WE-098 PP-MO-190, PP-MO-191, AS-TH-002, OC-MO-023, Van Sluis G. L., OC-MO-042, PP-TH-153, PP-WE-407 OC-MO-079, OC-WE-015, OC-WE-019, PP-MO-484, Van Der Post J. M., PP-MO-289 PP-TH-484 AS-MO-030 Van Kraaij M., PP-TH-260 van Staden B., PP-WE-726 Van Der Schoot C., PP-TH-373 Van Kruchten R., AS-TU-037 Van Stralen K. J., PP-MO-316 van der Sluijs K., OC-TH-066 Van Langevelde K., Van ‘T Veer C., PP-MO-190, Van Der Steege G., PP-WE-303 PP-MO-191, OC-TH-062, OC-WE-098 Van Leeuwen Y., OC-TH-066, OC-WE-144 Van Der Veen F., PP-TH-373 LB-MO-001, PP-WE-771 van Thiel D., PP-TH-142 Van Der Velde E., OC-TH-017, Van Loon J. E., OC-TH-029, Van Tiel C. M., PP-MO-022 PP-WE-346 OC-TU-012 Van Veen J. J., PP-MO-702, Van Der Voort R. G. J., Van Marion V., PL-TU-001 PP-TH-664, PP-WE-766 OC-MO-023 Van Minkelen R., OC-MO-019, Van Veen J., PP-MO-199 PL-TU-001 Van Der Wal D. E., PP-MO-035, Van Velzen J., PP-WE-064 PP-MO-036, PP-TH-046 Van Nispen Tot Pannerden H. E., PP-MO-042, PP-WE-061 van Vlijmen B. J. M., Van Der Zee A. G. J., PP-MO-236 PP-MO-677 Van Noorden C. J. F., Van Vlijmen B., PP-TH-377 Van Dijk S. M., PP-MO-042 OC-WE-019, PP-TH-484 Van Oerle R., AS-WE-058, Van Waesberghe J. H. T. M., Van Doormaal F. F., PP-TH-517 OC-MO-014, OC-TU-059, OC-MO-125, PP-MO-763, PP-MO-769 OC-TH-001, OC-TH-080, van Walderveen M. C., OC-TU-085, OC-WE-060, PP-TH-135

582 PP-TH-611, PP-TH-641, PP-WE-013, PP-WE-084, PP-MO-094, PP-TH-091, PP-MO-050, PP-MO-088, OC-WE-040, PP-MO-049, PP-TH-286, PP-MO-659 Van ZaaneB., PP-MO-151 Van Wijngaarden A., PP-WE-407 V PP-WE-742 PP-MO-788, PP-WE-741, PP-MO-780, PP-MO-781, OC-MO-133, OC-MO-135, V Van Weert H., Van Weert H.C., INDEX AUTHORS Varfaj F., V Vardosanidze R., PP-WE-619 Varadi K., PP-TH-625, PP-TH-635 V VannucchiM., A. Vannini M., V Vannier J.P., V PP-WE-086 Vanhoorelbeke K., Vangenechten I., PP-MO-491, PP-TH-345 V V PP-WE-086 Vandeputte N., AS-TH-002 Vandenbroucke J.P., Vandeberg P., Vandahl B., Vandahl B.S., PP-MO-094 Vancraenenbroeck R., V Van Zonneveld A., Van Zanten A. P., PP-MO-293, PP-TH-238, an W an Werkum J.W., anrusselt M., annier J., anni S., andreden P anderelst L. anacore R., arela L., esterloo D.J., PP-WE-289 OC-TH-014 PP-MO-641 PP-MO-640, PP-MO-491 PP-MO-267 PP-MO-558 ., PP-MO-758 PP-TH-447 A., OC-TU-012 PP-MO-368, PP-TH-396 PP-MO-292, PP-MO-565 PP-TH-520, PP-MO-050, OC-TH-017 PP-MO-605 AS-TU-046 PP-MO-383 PP-WE-281 PP-TH-286 PP-WE-851 AS-MO-014, PP-WE-062, PP-WE-137, PP-MO-863, PP-TH-236, Vdovin V. V., Vazzana N., Vaz R., Vaysse N., PP-MO-193 Vayá A., Vavilova T. V., Vauthier C., PP-TH-345, PP-TH-447 Vasse M., PP-MO-778, PP-MO-779 V Vassallo J.V., PP-WE-1 Vasquez J., PP-MO-668, PP-WE-170 V PP-WE-138 V Vasileiadou D., V V Vasco B., Vaschuk I., Varughese J.I., PP-WE-681 V Varraso R., V Varon D., Varma S., PP-WE-456 Varma N., Varma M., Varma G., PP-WE-505, PP-WE-855 V Vargová K., Varga-Szabó D., OC-TH-039 Varga-Szabo D., OC-MO-1 Vargas G., PP-TH-227 Varfolomeyev S., PP-TH-174, PP-TH-211, assara C., asiliev S. asilenko I., asheghani asey S., artholomatos G., arpio L., arin R., PP-TH-444 17 PP-MO-192, 14 PP-MO-514, AS-MO-055 PP-WE-847 PP-MO-226 PP-MO-460 PP-MO-491, PP-MO-324 PP-MO-324, PP-TH-476 PP-MO-817 A., OC-MO-026, OC-WE-085 PP-MO-863 OC-TU-004 PP-MO-777, PP-MO-265, PP-MO-772 OC-TU-088 A., PP-MO-112 PP-MO-729, PP-TH-454 PP-MO-218, PP-TH-025 PP-MO-257 PP-WE-281 PP-MO-427 AS-TU-040 AS-TU-005, PC-046 PP-TH-219, PP-MO-657, PP-TH-665, PP-WE-555, PP-MO-621, PP-TH-260, PP-MO-168, PP-MO-169, V Vedantham S., PP-WE-367 Vecchione G., PP-MO-458 Vecchioli M., Vecchio V., Verghese L., Vergeer M., Veréb Z., V Vercruysse K., V PP-WE-735 V PP-MO-395, PP-WE-396 Verbeuren T. J., V Verbeek K., PP-MO-849 V Venter C.S., Venisse L., V PP-WE-521 Velthuis S.I., Vellicce A., PP-WE-867 V Veldman A., PP-WE-141 V Velasco F., PP-TH-641 Vejda S., Veiga M., Vegting I.L., PP-WE-210 Vega-Ostertag M., OC-MO-001, PP-WE-326 Veeger N., PP-TH-332 V PP-WE-313 082, OC-WE-100,PP-MO-286, edovati M.C., erduijn M., ercauteren E., erbruggen B., erberne L.M., entura J.S., ely F eljkovic D., elázquez L., eeger N.J.G.M., ., AS-MO-060 PP-MO-640, PP-MO-359 PP-MO-521 AS-MO-002, PP-MO-566 AS-TU-024 PP-TH-044 PP-MO-802 OC-WE-046 PP-TH-260 PP-MO-316 PP-MO-660 PP-TH-269, PP-WE-228 PP-WE-377 PP-MO-444 PP-MO-457, PP-MO-506, PP-MO-134, PP-MO-475, PP-MO-822, AS-TH-026 PP-WE-416 OC-TH-014, OC-TH-052, OC-MO-091 PP-MO-225 PP-MO-382, PP-TH-661, OC-MO- 583

Authors Index AUTHORS INDEX

Vergnes C., PP-MO-195, PP-TH-096, PP-TH-247, Vinnikov I., AS-MO-059 PP-MO-196, PP-TH-189 PP-TH-287, PP-TH-481, Vinther K., PP-MO-118 Vergnes M. C., PP-TH-385 PP-WE-033, PP-WE-123, PP-WE-141, PP-WE-764 Violi F., PP-TH-050, Vergnes M., OC-WE-017 PP-WE-105, PP-WE-753 Vickars L., OC-TU-011, Vergouwen M. D. I., AS-TU-035 OC-TU-068 Vishenskaya T., PP-MO-729 Vergura P., PP-MO-822, Vickerman M., PP-MO-051 Vishnevskaya S., PP-TH-023, PP-WE-367 PP-WE-046 Vickers M. R., OC-TU-002 Verhagen H. J. M., OC-TH-031 Visonà A. A., PP-TH-308 Vidal F., PP-MO-528 Verhamme P., OC-TH-057 Visonà A., PP-TH-303 Vidovic A., PP-WE-634 Verheugt F. W. A., PP-WE-741 Vissac A. M., PP-MO-419, Vidovic N., PP-TH-537 Verhoef S., PP-MO-035, PP-MO-697, PP-MO-701 PP-MO-036 Vidwan P., PP-TH-243, Visser M. M., OC-MO-082 PP-WE-694 Verkleij C. J. N., PP-MO-221, Visseren F. L., PP-MO-007 Vielpeau C. H., OC-TU-022 PP-WE-336 Visvikis-Siest S., OC-MO-021 Vielpeau C., OC-WE-002 Verlato F., PP-WE-338 Viswanathan S., PP-WE-729 Viertel A., PP-MO-317 Verlato G., PP-WE-338 Vitale J., OC-MO-092 Viesti U., PP-MO-616 Vermeer C., OC-TU-053, Vitali M., PP-TH-568 PP-WE-808 Viganò M., AS-MO-009 Vittorini R., PP-TH-453 Vermeulen M., AS-TU-035 Vigh T., PP-WE-087 Vitzthum F., OC-MO-090 Vermylen C., PP-WE-532 Vigneron C., PP-MO-530 Viuff D., PP-WE-589, Vernois J., PP-MO-530 Vignoli A., AS-TU-050, PP-WE-590, PP-WE-591 Verro P., PP-MO-356 PP-MO-476, PP-MO-867, PP-WE-499 Vivien D., OC-TH-113 Verschuren F., AS-TU-009, Vija H., PP-MO-149 Vladareanu A., PP-MO-069, OC-TH-073, PP-TH-524 PP-TH-063, PP-WE-075 Verschurren F., OC-MO-041 Vik A., OC-WE-137, OC-WE-140 Vladareanu R., PP-MO-069 Verso M., OC-MO-018 Vila K., PP-WE-065 Vlahovic G., PP-TH-269 Versteeg H. H., AS-MO-063, Vlaisavljevic N., PP-WE-680 PP-MO-764, PP-TH-484 Vila V., PP-TH-363, PP-WE-885 Villa D., PP-WE-356 Vlasova E., PP-MO-863, Verstuyft C., PP-WE-186 PP-TH-236, PP-WE-137, Verzijlbergen J. F., PP-WE-317 Villa R., PP-WE-264 PP-WE-138 Veselova S. P., PP-MO-806 Villaca P. R., PP-MO-755, Vlckova E., PP-TH-422 PP-TH-542, PP-WE-705 Vestrini A., AS-TH-034, Vliegen H. W., PP-WE-322 Villalta S., PP-WE-460 PP-WE-748 Vlodavsky I., PP-TH-387 Villamil F., PP-TH-681 Veth J., OC-MO-019 Vodickova L., PP-TH-438 Villanueva C., PP-MO-413 Veth R., PP-TH-665 Vohnout B., PP-TH-249, Vetr H., PP-MO-711, Villaume K., PP-WE-493 PP-WE-246 PP-TH-148, PP-WE-777 Villaverde C. A., PP-MO-209 Voican I., PP-MO-069 Veyradier A., PP-MO-626, Villoutreix B. O., PP-WE-157 Voisin S., PP-MO-188, PP-TH-623 Vincent J. L., OC-TH-069 PP-WE-169 Vianello F., OC-WE-088, PP- Vincent L., PP-WE-855 Vojacek J., PP-TH-438 MO-867 Vincentelli A., PP-MO-815 Völker U., OC-TU-026 Vicente C. P., PP-TH-499 Vincenzi D., PP-MO-523 Volkmann N., OC-WE-148 Vicente V., AS-MO-054, AS-TH-052, OC-TH-027, Vinciguerra C., OC-TU-073, Volkov G. L., PP-MO-146, OC-TH-120, OC-TU-080, PP-MO-645, PP-TH-619, PP-MO-401, PP-TH-160 OC-TU-082, OC-WE-107, PP-WE-533 Volkov G., PP-TH-395 PP-MO-055, PP-MO-134, Vinícius De Paula E., Volovyk Z., PP-TH-205 PP-MO-144, PP-MO-732, PP-WE-066

584 OC-MO-024, PP-MO-316, PP-TH-080, PP-TH-616, AS-WE-013, OC-MO-111, Von MackensenS., Von KügelgenI., PP-MO-241 Von HeymannC., PP-MO-307 V V OC-WE-105 Von DerThusenJ., PP-WE-633, PP-WE-644 V Von DepkaM., Volpato S., INDEX AUTHORS V Vossough P., PP-MO-480 Vossen C. Y., Vosmaer A., PP-MO-256 V PP-MO-151 Vos H.L., V Vorpahl F., PP-WE-526 Vorobyeva N.M., PP-WE-679 Vorobyeva N. A., PP-TH-581, PP-WE-561 Vorobyev P. A., Vorobiova E., Vorobev A., PP-MO-322, PP-TH-273 V PP-WE-157 V PP-WE-322 V Vondrakova J., Von PapeK., PP-WE-542, PP-WE-563 PP-TH-558, PP-TH-559, OC-MO-034, OC-WE-119, OC-MO-122, PL-TU-001, OC-MO-019, OC-MO-078, OC-TU-013, OC-TU-016, owles J., on Eller-EbersteinH., on EiffC., on DepkaProndzinskiM., oscresenskaya O., orster H.H., ormittag R., oorberg J., onk Noordegraaf A., AS-TH-035, PP-MO-550 PP-MO-592 PP-TH-372 PP-MO-031 PP-MO-474 OC-WE-091 AS-WE-012, PP-WE-038 AS-MO-003, PP-TH-124 OC-MO-027, PP-WE-228 PC-019 PP-MO-693 PP-MO-689 PP-MO-553, PP-MO-253 PP-TH-512, PP-TH-513, PP-MO-240, PP-MO-669, PP-MO-717, PP-WE-289 Wakabayashi H., Wajima T., Wajih N., W W PP-MO-189 Wahlmüller F., PP-WE-185 Wåhlander K., PP-WE-201 Wahlander K., W PP-MO-402 W PP-TH-390 Wahi R., W Wagstaff L., W Wagner O., W PP-MO-093 Wagner D.D., W Wagenvoord R., PP-TH-177 Wagenvoord R.J., Wågberg F., Waelkens E., Wadoodi A., PP-WE-150, PP-WE-151 Waddington S.N., Wada T., PP-TH-526 Wada H., Vydyborets S.V., V Vukovich T., Vujic D., Vuilleumier N., Vucemilo T., Vrbacky PP-WE-004 Voyno-Yasenetskaya T., PP-MO-153, PP-MO-154, OC-TH-063, OC-TU-045, utuc C., aite C., ain G.V ahl M., ahl D., aha R., agner T agner L., agner B., F. F. V., ’ OC-MO-029, PP-MO-152, PP-WE-867 PP-WE-687 PP-MO-244 ., AS-MO-028 PP-WE-861 PP-WE-547 PP-MO-497, ., PP-TH-317 PP-MO-249 PP-WE-380 PP-MO-551 PP-WE-300 PP-MO-075 OC-TU-015 PP-WE-185 PP-MO-853 PP-MO-384 OC-TU-013 PP-TH-258 PP-WE-041 AS-MO-047, PP-WE-200, PP-WE-172, OC-TU-081, OC-TH-073 PP-TH-369 PP-TH-107 PP-MO-155, PP-TH-479 OC-TU-076, PP-TH-176, PP-MO-374, PP-MO-761, PP-MO-140, PP-WE-143, Waldhoer T., PP-MO-388, AS-MO-006 W W W Waked E. A., Wakagi K., PP-MO-406, PP-WE-772 Wanachiwanawin W., Waltham M., W PP-WE-077 W Walter L., PP-WE-352 Waltenberger J., W W Walsh C.E., PP-TH-407, PP-TH-469 Wallentin L., Wallen N., PP-MO-762, PP-TH-186 Wallén H., Wallen H., Wallace T., Wallace S., Wallace K., PP-WE-879 W Walker S.P., Walker M.B., PP-WE-541 Walker I., PP-WE-716 Walker I.D., W PP-WE-385 Walenga J., PP-WE-481 W PP-WE-387, PP-WE-395, PP-TH-404, PP-WE-262, PP-TH-390, PP-TH-391, PP-MO-139, PP-MO-399, PP-MO-116, PP-MO-534, akefield T. W., akefield C.D., aked M., alters D., alter U., alsh P alsh M.T alkowiak B., alker A., alenga J.M., . N., PP-MO-115, PP-MO-317 AS-MO-038, AS-MO-037 OC-TH-079 OC-WE-104, PP-TH-141 ., PP-WE-281 PP-TH-688 PP-TH-442 PP-WE-021 PP-TH-632 OC-TU-027 OC-TH-103, PP-MO-181 OC-TU-045 PP-MO-320, PP-WE-584 PP-MO-384 PP-MO-408, PP-TH-317 PP-MO-381 PP-WE-067 PP-MO-469 PP-MO-071, OC-TH-019, OC-TU-060, AS-TH-053 PP-MO-337, 585

Authors Index AUTHORS INDEX

Wanaka K., PP-MO-704 Ward K. R., PP-TH-682 Webert K. E., PP-TH-663 Wang A., PP-TH-093 Ward V. A., OC-TU-067 Weck K., PP-TH-466 Wang C., PP-MO-695 Wardrop J., PP-MO-754 Weeterings C., AS-TU-017, Wang D., PP-WE-707 Ware J., AS-TU-030, PP-MO-126 Wang G. T., PP-TH-663 OC-WE-020, PP-MO-082, Wegrzyn W., PP-MO-784 PP-WE-051, PP-WE-060, Wei Z., AS-MO-023 Wang G., OC-TH-091, AS-MO-031 PP-TH-129, PP-TH-197 Weickardt S., AS-TH-055 Warner T. D., AS-WE-052, Wang H., AS-MO-059, PP-MO-740, PP-MO-741, Weidow B. L., PP-WE-494 OC-TH-060, OC-WE-027, PP-TH-001, PP-TH-002 Weijers E. M., PP-MO-847 PP-MO-020, PP-MO-203, PP-MO-510, PP-TH-127, Warnock M., PP-MO-244, Weiler H., SA-MO-012, PP-TH-203, PP-TH-331, PP-TH-252 AS-TH-008, AS-TU-043, PP-TH-562, PP-TH-563, Warwick D., PP-MO-248 AS-WE-058, OC-TH-068, PP-MO-880, PP-MO-881 PP-TH-564, PP-TH-565, Waschke J., OC-MO-068 PP-WE-770, PP-WE-846, Weilitz J., PP-MO-095 PP-MO-531, PP-TH-114, Washington A., OC-TH-036, PP-MO-646 PP-WE-065 Weimer T., OC-WE-120, PP-TH-130, PP-TH-561 Wang J. W., AS-WE-040 Wasserman B., PP-WE-819 Weinberger J., PP-MO-615 Wang J., AS-MO-044, Watala C., PP-MO-097, OC-TU-017, PP-MO-510, PP-TH-098, PP-TH-099, Weingärtner O., PP-MO-809 PP-TH-119 PP-WE-034 Weinspach S., PP-MO-595 Wang K., PP-WE-636 Watanabe G., PP-TH-229, Weinstein B., SA-WE-012 PP-WE-015 Wang L., OC-MO-136, Weintraub M., AS-TU-008 OC-TH-077, PP-WE-478, Waterman P., AS-WE-057 Weise-Kelly L., PP-WE-489 PP-WE-009 Waters B., OC-TH-053 Weisel J. W., AS-MO-039, Wang M., AS-WE-049, Waters E. K., PP-WE-168, AS-WE-048, OC-TH-055, PP-TH-265, PP-TH-564 PP-WE-569 OC-WE-112, OC-WE-146, Wang Q., PP-TH-334, Watkins N. A., AS-MO-037, PP-TH-214, PP-WE-212 PP-WE-101, PP-WE-857 OC-TH-037, OC-TU-029, Weiss A., AS-WE-033, Wang R., PP-TH-112 OC-WE-126 PP-TH-021 Wang S., PP-TH-334 Watkins T. R., PP-TH-468 Weiss C., PP-MO-420, Wang W., PP-WE-819 Watson C. A., PP-TH-171 PP-WE-182, PP-WE-183 Wang X., PP-MO-203, Watson C. C., PP-MO-702 Weiss D., PP-WE-210 PP-MO-510, PP-MO-554, Watson H. G., PP-WE-676 Weiss E. J., OC-MO-077 PP-TH-127, PP-TH-203, Weiss R., PP-MO-518 PP-TH-331, PP-TH-562, Watson S. P., AS-WE-033, PP-TH-563, PP-TH-564, OC-MO-069, OC-MO-131, Weiss T., PP-WE-344 OC-TH-041, PP-TH-021, PP-TH-565, PP-WE-536, Weisser H., PP-WE-038 PP-WE-770, PP-MO-531, PP-WE-076, AS-TU-036 PP-WE-667, PP-MO-646, Watson S., PP-MO-076 Weissleder R., AS-WE-057 PP-TH-126 Wattanatittan S., PP-WE-710 Weissman P., PP-WE-172 Wang Y. C., PP-TH-634 Watzka M., OC-WE-076, Weitz J. I., OC-TH-106, Wang Y., AS-TH-042, OC-WE-077, PP-TH-397, OC-WE-079, PP-MO-428, AS-WE-027, PP-TH-092 PP-TH-658, PP-WE-159 PP-TH-009 Wang Z., PP-TH-335, Waye J. S., AS-TH-045 Weitz J. J. I., PP-MO-086 PP-WE-773 Webb I. G., PP-TH-014 Weksler B. B., PP-WE-868 Wanivenhaus H. A., PP-TH-690 Weber A., PP-MO-640, Welland M. E., PP-MO-058 Wannemacher K. M., PP-TH-640 Wells P., OC-MO-051, PP-WE-030 Weber C., SA-TU-012, OC-TU-020, OC-WE-005, Ward C. M., PP-MO-410, PP-WE-892 PP-MO-460, PP-MO-468, PP-MO-411, PP-WE-221 PP-WE-500, OC-TH-012, Weber G. J., OC-TU-030 OC-TU-011, OC-MO-021, PP-TH-292, PP-WE-462

586 PP-MO-746, PP-TH-662, Werth S., W PP-WE-190 Werdan K., PP-TH-1 Wen Z., Wen Z.B., Wen N., Wen J., Wen B.Z., OC-WE-1 Welsh P., INDEX AUTHORS White -MdJ.G., Whiss P. A., Whinna H., Whinna H.C., OC-MO-006 Whelihan M.F., Whelchel K., Wheeler R.B., Wheeler M., Wheatcroft S.B., OC-TU-047 S., Weyrich A. Wetzel K., PP-WE-763 W PP-TH-398 Westrick R.J., Westrick L.G., W PP-WE-159 W PP-WE-593, PP-WE-594 Westfeld M., Westerlund E., Westerga J., Westerbeek R.E., W Westenfeld R., OC-WE-1 Westendorp R., 507 Westenberg J.M., PP-TH-642 Westein E., erstuck G.H., estrup D., estrich G., esthofen P ester J.P AS-TH-012, AS-TU-012 14 PP-WE-846, PP-TH-400 16 16 AS-MO-057 OC-WE-033, PP-TH-134 PP-TH-146 PP-TH-112 . J., PP-WE-290 PP-TH-440, OC-WE-124, PP-MO-179, PP-MO-713 PP-MO-047 ., PP-TH-575, PP-MO-248 PP-MO-484 PP-TH-473 PP-TH-397, PP-MO-392 AS-WE-028, PP-TH-152 OC-WE-039, OC-TU-053 PP-MO-374 PP-WE-122 PP-TH-436 AS-TU-023, OC-WE-033, PP-WE-817 PP-MO-081 AS-TH-019 PP-WE-521 PP-MO- PP-TH-134, PP-WE-181, W OC-TH-097 Wilcox D. A., PP-MO-843 Wiktorska M., W W W Wiesel M.L., Wiertz N.R., Wierdak J., W PP-WE-390 Wienen W., Wieloch A., Wielders S., Wieland K., Wiegand G., W PP-WE-613 W W Wichterle D., Wichers I.M., Wice S.M., Wibaut B., Whyte K., PP-WE-479 Whittaker P Whitsett C., Whiteheart S., OC-MO-089 Whitehead M., White-Adams T. C., OC-TU-011 White R.H., White N.J., White M.M., White M.J., White J., PP-TH-549, PP-WE-685 White B., E., White A. PP-TH-357, PP-TH-498, PP-MO-356, PP-TH-311, OC-TU-009, OC-TU-014, ilde J., iklund B., ijmenga C., ijeyeratne Y.D., iens L., iedebusch S., icklund B.M., ickert T PP-MO-076 ., PP-MO-057 PP-MO-593, PP-MO-551 OC-TU-002 PP-TH-583 PP-TH-120 ., PP-WE-392 PP-MO-347, PP-MO-420 PP-TH-559 OC-WE-152 PP-TH-682 PP-MO-761 AS-WE-032 PP-WE-045 PP-TH-328 OC-MO-080, PP-WE-157 PP-TH-450 PP-TH-097 PP-TH-436 PP-WE-102, AS-TH-009, PP-MO-416 PP-WE-345 OC-WE-098 PP-TH-139 PP-MO-839, OC-WE-045 OC-MO-088, PP-MO-459 PP-MO-596, PP-WE-045 PP-TH-037 PP-MO-714, PP-TH-658, W PP-MO-600 Wilke C.T., Wilk R., PL-TU-003 Wilhelm S., Wildes M.T., PP-WE-672 W PP-TH-136 W Winkens M., PP-WE-660 W Winder A., PP-WE-072 W Wiman B., W PP-WE-725 R., Wilson A. PP-WE-305 Wilsgaard T., Wilmer M., Williams Z., PP-WE-446, PP-WE-719 Williams S., PP-TH-065 Williams S. A., PP-WE-215 Williams M., PP-TH-449 Williams M.D., Williams H., Williams G.D., PP-MO-230 Willemse J., W Willcox A., Will A., W OC-WE-140, PP-WE-304, OC-TU-006, OC-WE-137, PP-WE-443, PP-WE-445, PP-TH-463, PP-WE-288, PP-MO-447, PP-TH-459, PP-MO-426, PP-MO-443, PP-MO-614, PP-MO-623, ilkieson T. J., inkler inkler indyga J., inckers K., ilson D.W illemse J.L., M., ill A. OC-TU-078, PP-TH-645 A., A. M., PP-MO-097 PP-MO-690 PP-WE-646 PP-MO-338 AS-WE-032 PP-WE-519 PP-MO-068, PP-MO-545, OC-MO-068, ., OC-TU-068 PP-MO-692, OC-MO-116, OC-TU-054 PP-WE-214, PP-MO-229, PP-MO-337 PP-MO-722 PP-TH-344, PP-WE-306, OC-TU-005, PP-MO-389 PP-MO-137, PP-MO-823, PP-MO-327 PP-TH-458 OC-TH-041, OC-TH-009 587

Authors Index AUTHORS INDEX

Winkler S., PP-WE-892 Wood J. P., OC-MO-066, Wu J., AS-MO-062, Winkler U., OC-MO-090 OC-MO-120 OC-WE-059, PP-MO-171, PP-MO-203, PP-MO-504, Winn L. Y. N., PP-MO-089 Woodhams B. J., OC-TU-033, PP-MO-108, PP-MO-112, PP-MO-554, PP-TH-038, Winship P. R., AS-MO-019, PP-MO-368, PP-MO-369, PP-TH-203, PP-WE-536, OC-WE-135, PP-MO-052, PP-MO-491, PP-MO-514, PP-WE-540 PP-TH-244, PP-TH-638, PP-MO-533, PP-MO-766, Wu K. K., PP-WE-819 PP-WE-161 PP-TH-115, PP-TH-183, Wu M., PP-WE-845 Winstedt D., PP-TH-359, PP-TH-185, PP-TH-211, PP-TH-695 PP-TH-235, PP-TH-345, Wu R., PP-TH-548, PP-WE-728 PP-WE-164, PP-WE-232, Winter L., PP-TH-629 Wu W., PP-WE-183, PP-WE-505 PP-WE-845 Winters K. J., PP-MO-733 Woodhams B., PP-MO-348, Wu X., PP-TH-548, AS-WE-030, Wipfler P., OC-WE-138 PP-TH-487, OC-TU-039 PP-TH-488, PP-TH-684 Wischmeyer P., PP-TH-408 Wu Y. P., PP-TH-046 Woodley-Cook J., PP-TH-434 With Notø A., PP-MO-813 Wu Y., PP-TH-331, PP-WE-216 Woods A. I., PP-MO-610, Witke W., AS-WE-029 PP-MO-613, PP-TH-350, Wulf S., PP-TH-095 Witkoff L., OC-WE-009, PP-WE-089 Wulffen B., PP-WE-180 OC-WE-129 Woods D., PP-WE-118 Wun T., OC-TU-014, PP-TH-498 Witmer C., AS-TU-055 Woods T. A. L., PP-MO-320, Wunderlich F. T., OC-WE-076 Witt - D., PP-MO-308 PP-WE-716 Wurtz V., PP-MO-033, Witt D. M., PP-MO-462, Woods T., PP-MO-115, PP-TH-010 PP-MO-463 PP-MO-116 Wuttke W., PP-WE-373 Witteman J. C. M., OC-TU-034 Woods V. L., OC-MO-022, Wygrecka M., AS-TH-037 Wittig I., PP-MO-365 OC-TU-095 Wysocki T., PP-MO-839, Woodward M., OC-TH-080, Wizowski L., PP-WE-431 PP-MO-843 PP-WE-353 Wlian L., PP-MO-849 Xafaki P., PP-TH-597, Woollard K. J., PP-WE-391 Woda M., AS-WE-018 PP-WE-440 Worms B., PP-MO-530 Wohlfeil M., PP-TH-652 Xhaja K. J., AS-WE-018 Wort S. J., PP-WE-805 Wohner N., PP-MO-851 Xi X., PP-TH-331, PP-TH-562, Woulfe D. S., AS-WE-031 PP-TH-563, PP-TH-564, Wojta J., PP-MO-829 Woulfe D., OC-TH-094, PP-TH-565, PP-WE-770 Wolberg A. S., OC-MO-073, OC-TH-095 Xia J., PP-MO-548 PP-TH-119, PP-TH-655, PP-WE-299 Wright B., PP-MO-032, Xia M., OC-TU-051, PP-WE-836 PP-TH-031 Wolf H., AS-MO-030 Xiao Q., PP-WE-852 Wright J. R., OC-TU-029, Xiao X., OC-WE-027 Wolf M., PP-MO-376, OC-WE-126 PP-MO-626 Xie A., OC-MO-123 Wright M. J., PP-WE-541 Wolfsegger M., AS-WE-015, Xie B., PP-TH-564 OC-WE-065 Wrobleski S. K., OC-TU-060, PP-MO-388, PP-MO-400 Xie X., PP-MO-830 Wolowacz S. E., PP-WE-469, PP-WE-470, PP-WE-471 Wu C., PP-MO-665 Xie Y. G., PP-TH-364 Wolter M., PP-MO-706 Wu D., PP-TH-335, PP-WE-773 Ximenes B., PP-WE-870 Wolzt M., PP-WE-200, Wu H. L., PP-MO-158 Xin B., PP-TH-202 PP-WE-201 Wu H. M., OC-WE-009, Xing W., OC-WE-068 Won J., PP-TH-504 OC-WE-129, OC-WE-130, Xiong S., PP-WE-857 PC-036, PP-WE-729 Wong A., PP-TH-188 Xu G., PP-MO-646, PP-TH-331 Wu J. K. M., AS-WE-003, Wong I., AS-TH-045 OC-TU-068, PP-WE-553 Xu J., OC-WE-068, PP-WE-707 Wong M. L. G., PP-TH-441 Wu J. R., PP-MO-319, Xu L., PC-036 Wong P. C., PP-TH-171, PP-MO-549, PP-WE-291, Xu Q., PP-WE-852 PP-TH-202 PP-WE-299 588 PP-TH-319, PP-TH-521, Yadav S., PP-WE-037 Yadav B.K., Yada H., Yacoub D., Xue M., Xue J., Xue F Xue Xu Z., Xu Y., Xu X., INDEX AUTHORS PP-WE-278 Yamazaki M., Yamauchi T., Yamashita T., PP-MO-439, PP-WE-562 PP-MO-123, PP-MO-127, Yamashita A., PP-WE-011 Y Y PP-WE-720 Y PP-WE-463 Yamaki T., Y Yamaguchi T., PP-WE-671 Yamada T., PP-WE-720, PP-MO-497 Yamada N., Y PP-WE-571 Y PP-WE-01 Yakushijin Y., OC-TU-041 Y Yakoubi M., PP-WE-864 Yahorava N.V., Y Yaguchi A., PP-TH-173 Yago H., PP-WE-798 PP-MO-874, PP-WE-863, amamoto J., amamoto H., amaji K., amada K., alcin akura ahalom V., amanouchi J., A., ., OC-TH-061 PP-WE-394 AS-WE-047 Atay D., PP-WE-707 PP-WE-893 Y PP-WE-292 AS-TH-017 ., PP-WE-516 PP-MO-497, 1 PP-WE-794, OC-TH-088, PP-WE-031 PP-MO-516, PP-MO-012 PP-MO-138, PP-TH-526, PP-WE-781 PP-TH-521 PP-TH-680 PP-WE-036 PP-MO-208, OC-TH-051 PP-TH-057, PP-WE-196 PP-MO-511, PP-TH-061 PP-MO-111, PP-MO-393, PP-WE-196 PP-MO-344, PP-MO-873, PP-MO-51 1, PP-TH-203, PP-WE-706, PP-MO-554, PP-TH-078, OC-WE-068, OC-WE-130, Yc C., Yazihan N., PP-WE-078 Yazdani-Abyaneh M., PP-WE-459, PP-WE-518 Y Y Y Y Yates IiiJ.R., Y PP-WE-01 Yasukawa M., Y PP-WE-269, PP-WE-271 Yasuda S., OC-MO-036 Y Y PP-WE-538 YarlasS., A. Yarbrough K., Yao Y., Yanni D., Y PC-036, PP-TH-123 Yang S., PP-WE-707 Yang R., Yang M., Yang L., PP-WE-099 Yang J., PP-TH-441, PP-WE-288 Yang J. Y. K., Yang H., Y Yanamoto H., Yanagisawa Y., Yan Y., Yan J., Yamori Y., PP-WE-562 Yamazaki S., PP-MO-885, PP-TH-399, avarian M., au J.W., atzenko E. A., atuv R., atagai C., asui astrubinetskaya O., asaka M., ang W anar H., Y PP-TH-552 AS-WE-032 AS-MO-023 ., PP-WE-732 ., PP-MO-093, OC-TU-093 OC-WE-009, AS-TU-054 PP-MO-203, OC-WE-121 PP-TH-147 PP-WE-732 PP-MO-440 PP-WE-608 PP-WE-197 1 PP-MO-428 PP-TH-061 PP-MO-842, PP-WE-148 PP-WE-196 PP-MO-797 PP-WE-537, PP-MO-655, PP-MO-439, PP-MO-426, PP-MO-393 AS-TU-020 PP-MO-511, PP-TH-396 PP-WE-149 PP-TH-454 PP-TH-519, PP-WE-027, PP-WE-719 Y Y Y Y Yee A., Ye X., PP-WE-661 Young J., PP-TH-600, PP-WE-597 Young G., PP-WE-602 Young G. A., PP-TH-620 You J. Y., Y PP-WE-606 Y Y Y Y PP-WE-069 Y Yoon H., Y Yoo K. Y., Yoo H., Yoo B.K., Y Y PP-WE-349 Yokoyama K., Yokochi M., Yoder M., PP-MO-478 Ynineb Y., Yiu E., Yin H., Yin F., Yilmaz E., PP-WE-577 Yilmaz D., Yildirmak Y., Yhap M., Yesilipek A., Y oshizato K., oshioka oshimura N., oshida K., oon oon S., oo K., ong J., oksan S., enson P. R., ee T., ee T. T., ee C.K., eo E.L., Y PP-TH-132 AS-WE-042 ., PP-TH-463 AS-TU-027 PP-MO-567, PP-TH-528 PP-WE-047 PP-TH-190 PP-WE-844 PP-WE-783 PP-MO-577 PP-TH-504, PP-TH-504 PP-WE-447 PP-MO-624 A., PP-MO-330, PP-WE-579, SA-TH-009 PP-TH-125 PP-WE-543 PP-WE-817 PC-001 PP-MO-604, PP-TH-405 PP-MO-606, PP-MO-477, PP-MO-681 PP-TH-143 PP-TH-358 PP-MO-606 PP-WE-571 PP-TH-592, PP-MO-545, PP-WE-580 PP-MO-639, PP-WE-015, PP-TH-358 589

Authors Index AUTHORS INDEX

Young L., OC-TU-079, Zain Z. N. M., PP-MO-740 Zecca M., AS-TU-004 PP-MO-493 Zaitsev S., OC-WE-112 Zecevic Z., PP-WE-867 Younis K. A., PP-WE-067 Zajicek J., AS-WE-049 Zeerleder S., PP-TH-153 Ypma P., PP-MO-571 Zakai N. A., AS-WE-009 Zeinad A. K., PP-MO-755, Yu I. S., PP-MO-158 Zakarija A., PP-WE-530 PP-TH-542, PP-WE-705 Yu I., PP-TH-401 Zakernia M., PP-WE-459 Zeinali S., PP-WE-545 Yu M., PP-MO-554 Zaki Zadeh R., PP-WE-558 Zekas E., OC-WE-080 Yu P., OC-TH-039 Zaman A., OC-MO-033 Zelenika D., OC-MO-021, PP-TH-309 Yu T., PP-MO-510, PP-TH-127, Zamboni W., PP-MO-099, PP-WE-770, PP-MO-646 PP-WE-502 Zeller W., PP-TH-559 Yu X., OC-MO-128, PP-TH-022 Zamfir C., PP-MO-855 Zemani F., OC-TH-048 Yu Y. B., PP-MO-330, Zampolli A., OC-TH-096, Zemanova M., PP-WE-345 PP-TH-620 OC-TU-044 Zemljic E., PP-WE-251 Yu Z., PP-TH-621 Zanardelli S., PP-MO-091 Zeng F., PP-WE-857 Yuan Y., AS-WE-032 Zanazzi M., PP-TH-353, Zeng G., AS-WE-051 Yuana Y., AS-WE-019 PP-WE-002 Zeravica B., PP-WE-680 Yuce H., PP-WE-708, Zanon E., AS-TU-032, Zerbinati P., PP-MO-243, PP-WE-709 AS-TU-033, OC-TU-075, PP-WE-248 Yuldasheva N. Y., AS-TH-019 PP-MO-525, PP-TH-569, PP-TH-622, PP-WE-567 Zerr Fouineau M., OC-TH-035 Yun Y., PP-WE-844 Zapata V. A., PP-MO-832, Zerr-Fouineau M., AS-MO-058 Yun-Choi H., PP-WE-027 PP-TH-044, PP-WE-093, Zgheib N., PP-MO-135 PP-WE-094, PP-WE-402 Yunus E. B., PP-MO-710 Zgouras D., PP-MO-501 Zapfl C., PP-MO-615 Yusen R. D., OC-TU-009, Zhai Z., OC-WE-121 OC-TU-021 Zapletal O., PP-TH-530 Zhang H., OC-TH-108, Yusen R., PP-MO-299 Zappelli C., OC-MO-112 PP-TH-388 Yves-Line D., PP-WE-507 Zarifis J., PP-MO-777, Zhang J., PP-TH-093, Z Omar S., PP-MO-366 PP-MO-778, PP-MO-779 PP-WE-088, PP-WE-731 Za T., PP-WE-366 Zarpellon A., OC-TH-096 Zhang L., PL-TU-005, Zaatari G., PP-MO-135 Zaucke F., OC-WE-076 PP-MO-165, PP-MO-859, PP-TH-621, PP-WE-101, Zabolotskikh I. B., PP-TH-250, Zavalloni D., PP-WE-791 PP-WE-706, OC-WE-068 PP-TH-251 Zavazava N., PP-WE-594 Zhang M., PP-WE-896 Zacchi E., PP-WE-868 Zavrelova J., PP-MO-259, Zhang N., PP-TH-548 Zäch D., PP-TH-559 PP-WE-596, PP-WE-804 Zhang S., PP-TH-022 Zacharias C., PP-TH-569, Zawadzki C., OC-TU-073, PP-TH-587 PP-MO-814, PP-MO-815, Zhang T., PP-MO-854 PP-TH-623 Zachoval R., PP-WE-578 Zhang W., OC-WE-073, Zawilska K. M., PP-WE-307 PP-TH-621 Zachrisson H., PP-WE-386 Zawilska K., PP-MO-216, Zhang X., AS-TH-025, Zadro R., PP-MO-223, PP-WE-213 OC-MO-101, OC-MO-127, PP-WE-275, PP-WE-435, OC-MO-136, OC-MO-137, PP-WE-442 Zawilska On Behalf Of OC-WE-057, OC-WE-059, Haemostasis Group Of Phit K. Zaehringer M., OC-MO-008 PP-MO-203, PP-TH-203, M., PP-MO-692 PP-WE-674 Zafar T., PP-TH-560, Zbikowski P., PP-MO-608 PP-TH-643 Zhang Y., OC-MO-109, Zborilova R., PP-MO-689 PP-TH-022, PP-WE-732, Zafiri C., PP-WE-314 Zdziarska J., PP-MO-206, PP-MO-810 Zafreen L., OC-WE-052 PP-MO-692, PP-WE-651 Zhao C., OC-TH-108 Zaidat O. O., PP-MO-442 Zeadin M. G., PP-WE-817 Zhao H., PP-TH-078, PP-WE-706, PP-WE-707

590 OC-TH-063, OC-TU-043, Zheng X.L., Zheng L., PP-WE-536 Zheng C., PP-WE-076, PP-WE-732 Zhao Y., OC-WE-059 Zhao X., Zhao L., INDEX AUTHORS Zhu W., OC-WE-017 Zhu T Zhu M., PP-WE-818 Zhu L., Zhu J., PP-TH-389 Zhu H., PP-TH-398, PP-WE-060 Zhu G., Zhu D., PP-TH-600, PP-WE-612 Zhou Z., OC-TH-056 Zhou Y., Zhou W., AS-TU-015 Zhou S., Zhou R., Zhou M., Zhou J., Zhou B., Zhou A., Zhong D., Zhong A., Zhmurov PP-WE-674 Zheng Y., PP-TH-045 Zheng X., PP-MO-153, PP-MO-154, OC-WE-028, PP-MO-152, OC-MO-139, OC-WE-039, PP-TH-399, PP-TH-621, PP-TH-203, PP-TH-334, PP-MO-642, PP-MO-854, PP-MO-203, PP-MO-554, OC-MO-123, PP-MO-105, PP-MO-105, PP-WE-030, ., OC-TH-005, AS-WE-033, PP-TH-021 AS-TU-028, OC-TH-103, OC-WE-059 AS-TU-030, PP-MO-859 PP-MO-171 AS-WE-033, OC-MO-128, PP-WE-674 PP-TH-548 PP-TH-078, AS-TU-013, OC-WE-057, AS-MO-023 PP-TH-667 OC-WE-068 PP-TH-147 OC-WE-010 A., PP-WE-006, PP-WE-857 AS-MO-015, PP-MO-171, PP-MO-518 PP-TH-112 PP-TH-080 PP-TH-214 PP-TH-684 Zouaoui Boudjeltia K., Zouain D., Zou Z., Zorio E., Zorenko V Zonzin P. P. Z., Zon L.I., Zomer C. A., Zolotukhina S.F Zolfaghari S., Zoghlami C., PP-MO-881 Zogg M., Zocco M., PP-MO-434 Zivelin A., Zito F Zipfel P. F., PP-TH-179 Zingali R.B., PP-WE-594 Zimmermann R., PP-WE-682 Zimmermann Zimmerman G. A., Zilberberg M.D., PP-MO-322 Zielinski C., PP-MO-838 Zielinski C.C., PP-MO-128, PP-WE-210 Zieger B., Ziegelin M., PP-TH-204 Zidani N., Zidane M., Ziaja K., PP-TH-581, PP-WE-561 Zhulev U. A., PP-MO-872 I., Zhukova A. PP-MO-695, PP-WE-731 Zhu X., PP-TH-421, PP-TH-587, PP-MO-513, PP-MO-662, OC-TU-015, OC-TU-016, PP-TH-374, PP-TH-375, ., PP-MO-876 AS-TU-038 OC-MO-136, PP-WE-433 OC-TH-027 PP-MO-880, OC-TU-030 . U., PP-WE-639, PP-MO-029, PP-MO-328 OC-MO-105, PP-TH-556 OC-TH-008 OC-TU-028 OC-MO-126 OC-TU-013, PP-WE-741 PP-TH-273 PP-MO-553, PP-MO-390, A., PP-WE-324 PP-MO-146, PP-TH-581 OC-WE-069, PP-MO-312 ., PP-MO-496, OC-WE-077, PP-MO-473 PP-WE-337 AS-WE-028 PP-TH-248, PP-TH-249, Zu J., Zrinski Topic R., Zrelak P., Zozulya N., PP-TH-582, PP-WE-561 Zozulya N.I., Zybin K.D. PP-WE-554 Zwiers M. Zwiauer K. Zwaginga J. Zwaginga J. PP-WE-246 Zurlo F Zupancic-Salek S. Zupancic SalekS. PP-WE-568 Zulfikar B., Zuily S., PP-TH-426 Zufferey P Zucker M., Zubova N.V., Zuber M., PP-MO-553, PP-TH-581, PP-WE-732 ., PP-MO-481, OC-MO-029 , PP-TH-356, PP-TH-311 PP-TH-417 ., , PP-MO-561 , PP-TH-250 OC-MO-105 PP-MO-683, PP-WE-608 OC-MO-050, , AS-MO-037 PC-041, PP-MO-260 , AS-TH-035 PP-WE-435 , PP-MO-630 , PP-MO-519 591

Authors Index